PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chen, QP; Bates, SR; Fisher, AB				Chen, QP; Bates, SR; Fisher, AB			Secretagogues increase the expression of surfactant protein A receptors on lung type II cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY SURFACTANT; PHORBOL ESTER; HIGH-AFFINITY; BINDING; PHOSPHATIDYLCHOLINE; SECRETION; INTERNALIZATION; PNEUMOCYTES	Since secretagogues have been shown to increase the internalization of surfactant phospholipid and protein by lung cells, we postulated that their action occurred through a mechanism involving increased surfactant protein A (SP-A) receptor density, Therefore, we evaluated the influence of secretagogues on the binding of iodinated SP-A to alveolar type II cells, Type II cells were isolated from rat lung and maintained in primary culture for 18 h on Transwell membranes. Upon exposure to 8-bromo-cyclic AMP (cAMP, 0.1 mM), phorbol 12-myristate 13-acetate (PMA, 10 nM), terbutaline (0.1 mM), or ATP (1 mM), the binding of SP-A increased 1.5-2-fold. This stimulation was cell substrate-dependent since type II cells plated on plastic dishes did not show this effect, A time course of the stimulation of SP-A binding due to secretagogues showed that both cAMP and PMA increased SP A binding by a-fold after 20 min, With cAMP, binding remained elevated for 2 h, while binding in the presence of PMA had returned to control values, The effects of submaximal concentrations of cAMP and PMA on binding were additive, Inhibition of cellular protein synthesis with cycloheximide did not alter the increase of SP-A binding stimulated by the secretagogues, Type II cells pretreated with PMA responded to subsequent treatment with cAMP by increasing SP-A binding, while these cells were refractory to subsequent treatment with PMA, Both constitutive and regulated binding of SP-A to type II cells were sensitive to trypsin, The binding of SP-A to type TI cells showed saturation at a concentration of 1 mu g/ml SP-A under control and secretagogue-stimulated conditions, with both total and calcium-dependent binding showing a a-fold increase upon secretagogue exposure, The data are consistent with the hypothesis that secretagogues stimulate surfactant uptake, at least in part, through recruitment of SP-A receptors to the type II cell surface, resulting in an increase in the number of SP-A binding sites.	UNIV PENN,SCH MED,INST ENVIRONM MED,PHILADELPHIA,PA 19104	University of Pennsylvania					NHLBI NIH HHS [HL-19737] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019737] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bates SR, 1996, AM J PHYSIOL-LUNG C, V271, pL258, DOI 10.1152/ajplung.1996.271.2.L258; BATES SR, 1994, AM J PHYSIOL-LUNG C, V267, pL753, DOI 10.1152/ajplung.1994.267.6.L753; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDER A, 1995, AM J PHYSIOL-LUNG C, V268, pL108, DOI 10.1152/ajplung.1995.268.1.L108; CHINOY MR, 1993, AM J PHYSIOL, V264, pL300, DOI 10.1152/ajplung.1993.264.3.L300; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; DUBROVIN LC, 1992, AM J PHYSIOL, V263, pL42, DOI 10.1152/ajplung.1992.263.1.L42; DwyerNield LD, 1996, AM J PHYSIOL-LUNG C, V270, pL526, DOI 10.1152/ajplung.1996.270.4.L526; FALLON RJ, 1986, J BIOL CHEM, V261, P5081; FISHER AB, 1985, J APPL PHYSIOL, V59, P743, DOI 10.1152/jappl.1985.59.3.743; FISHER AB, 1991, AM J PHYSIOL, V260, pL226, DOI 10.1152/ajplung.1991.260.4.L226; FISHER AB, 1989, AM J PHYSIOL, V257, pL284; GRIESE M, 1993, BIOCHIM BIOPHYS ACTA, V1167, P85, DOI 10.1016/0005-2760(93)90221-T; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; HU KQ, 1990, J BIOL CHEM, V265, P13864; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROSE L, 1992, MOL CELL BIOCHEM, V115, P203, DOI 10.1007/BF00230332; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURATA Y, 1993, BIOCHEM J, V291, P71, DOI 10.1042/bj2910071; PETTENAZZO A, 1988, J APPL PHYSIOL, V64, P120, DOI 10.1152/jappl.1988.64.1.120; PHILLIPS MA, 1983, J BIOL CHEM, V258, P2875; ROSS GF, 1986, J BIOL CHEM, V261, P14283; SOLANKI V, 1981, P NATL ACAD SCI-BIOL, V78, P1722, DOI 10.1073/pnas.78.3.1722; STEVENS PA, 1995, BIOCHEM J, V308, P77, DOI 10.1042/bj3080077; Strayer DS, 1996, EXP CELL RES, V226, P90, DOI 10.1006/excr.1996.0206; STRAYER DS, 1993, J BIOL CHEM, V268, P18679; SUWABE A, 1991, AM J RESP CELL MOL, V4, P264, DOI 10.1165/ajrcmb/4.3.264; TSUZUKI A, 1993, AM J PHYSIOL, V265, pL193, DOI 10.1152/ajplung.1993.265.2.L193; VATICOVSKI L, 1988, BIOCHEMISTRY-US, V27, P3682; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410; ZACHARIAS U, 1995, EXP CELL RES, V216, P371, DOI 10.1006/excr.1995.1047	34	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25277	25283		10.1074/jbc.271.41.25277	http://dx.doi.org/10.1074/jbc.271.41.25277			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810290	hybrid			2022-12-27	WOS:A1996VL69300034
J	Rajamohan, F; Hussain, SRA; Cotrill, JA; Gould, F; Dean, DH				Rajamohan, F; Hussain, SRA; Cotrill, JA; Gould, F; Dean, DH			Mutations at domain II, loop 3, of Bacillus thuringiensis CryIAa and CryIAb delta-endotoxins suggest loop 3 is involved in initial binding to lepidopteran midguts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; BUTTERFLY PIERIS-BRASSICAE; IRREVERSIBLE BINDING; CRYSTAL-STRUCTURE; BOMBYX-MORI; SPECIFICITY; RESISTANCE; TOXINS; TOXICITY; INHIBITION	Alanine substitutions of loop 3 residues, (438)SGF-SNS443, Of CryIAb toxin were constructed to study the functional role of these residues in receptor binding and toxicity to Manduca sexta and Heliothis virescens. Experiments with trypsin and insect gut juice enzyme digestions of mutant toxins showed that these mutations did not produce any gross structural changes to the toxin molecule. Bioassay data showed that mutant G439A (alanine substitution of residue Gly(439)) and F440A significantly reduced toxicity toward M. sexta and H. virescens. In contrast, mutants S438A, S441A, N442A, and S443A were similar or only marginally less toxic (2-3 times) to the insects compared to the wild-type toxin. Binding studies with brush border membrane vesicles prepared from M. sexta and H. virescens midgut membranes revealed that the loss of toxicity of mutants G439A and F440A was attributable to substantially reduced initial binding. Consistent with the initial binding, mutants G349A and F440A showed 3.5 times less binding to M. sexta and H. virescens brush border membrane vesicles, although the off-rate of bound toxins was not affected. The role of hydrophobic residue, Phe(440), is distinctly different from our previous observation that alanine substitution of Phe(371) at loop 2 of CryIAb did not affect initial binding but reduced irreversible association of the toxin to the receptor or membrane toward M. sexta (Rajamohan, F., Alcantara, E., Lee, M. K., Chen, X. J., and Dean, D. H. (1995) J. Bacteriol. 177, 2276-2282). Likewise, deletion of relatively hydrophobic CryIAa loop 3 residues, (440)AAGA(443) (D3a), resulted in reduced toxicity to Bombyx mori (>62 times less) and M. sexta (28 times less). The loss of toxicity was correlated with reduced initial binding to midgut vesicles prepared from these insects. However, alanine substitution of residues (437)LSQ(439) (A3a), contiguous to loop 3, altered neither toxicity nor receptor binding toward B. mori or M. sexta. These results suggest that the loop 3 residues of CryIAb and CryIAa toxins establish hydrophobic interactions with the receptor molecule, and mutations at these hydrophobic residues affect initial binding.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,MOL CELLULAR & DEV BIOL PROGRAM,COLUMBUS,OH 43210; N CAROLINA STATE UNIV,DEPT ENTOMOL,RALEIGH,NC 27695	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of North Carolina; North Carolina State University					PHS HHS [R01 29092] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOSCH D, 1994, BIO-TECHNOL, V12, P915, DOI 10.1038/nbt0994-915; CHEN XJ, 1993, P NATL ACAD SCI USA, V90, P9041, DOI 10.1073/pnas.90.19.9041; CHEN XJ, 1995, J BIOL CHEM, V270, P6412, DOI 10.1074/jbc.270.11.6412; FEITELSON JS, 1992, BIO-TECHNOL, V10, P271, DOI 10.1038/nbt0392-271; FERRE J, 1991, P NATL ACAD SCI USA, V88, P5119, DOI 10.1073/pnas.88.12.5119; GE AZ, 1989, P NATL ACAD SCI USA, V86, P17954; GOULD F, 1995, J ECON ENTOMOL, V88, P1545, DOI 10.1093/jee/88.6.1545; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; HARVEY WR, 1990, METHOD ENZYMOL, V192, P599; HOFMANN C, 1988, EUR J BIOCHEM, V173, P85, DOI 10.1111/j.1432-1033.1988.tb13970.x; KNOWLES BH, 1987, BIOCHIM BIOPHYS ACTA, V924, P509, DOI 10.1016/0304-4165(87)90167-X; KWAK IS, 1995, MEM I OSWALDO CRUZ, V90, P75, DOI 10.1590/S0074-02761995000100017; Lee MK, 1996, BIOCHEM BIOPH RES CO, V220, P575, DOI 10.1006/bbrc.1996.0445; LEE MK, 1995, BIOCHEM BIOPH RES CO, V216, P306, DOI 10.1006/bbrc.1995.2625; LEE MK, 1992, J BIOL CHEM, V267, P3115; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; LIANG YZ, 1995, J BIOL CHEM, V270, P24719, DOI 10.1074/jbc.270.42.24719; LU H, 1994, J BACTERIOL, V176, P5554, DOI 10.1128/JB.176.17.5554-5559.1994; MASSON L, 1994, MOL MICROBIOL, V14, P851, DOI 10.1111/j.1365-2958.1994.tb01321.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NISHIMOTO T, 1994, FEBS LETT, V348, P249, DOI 10.1016/0014-5793(94)00604-0; Rajamohan F, 1996, J BIOL CHEM, V271, P2390, DOI 10.1074/jbc.271.5.2390; RAJAMOHAN F, 1995, J BACTERIOL, V177, P2276, DOI 10.1128/jb.177.9.2276-2282.1995; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Raymond M., 1985, Cahiers O.R.S.T.O.M., Serie Entomologie Medicale et Parasitologie, V23, P117; SANGADALA S, 1994, J BIOL CHEM, V269, P10088; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEPF HE, 1990, J BIOL CHEM, V265, P20923; SCHWARTZ JL, 1991, BIOCHIM BIOPHYS ACTA, V1065, P250, DOI 10.1016/0005-2736(91)90237-3; VADLAMUDI RK, 1993, J BIOL CHEM, V268, P12334; VANRIE J, 1990, SCIENCE, V247, P72, DOI 10.1126/science.2294593; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; WOLFERSBERGER MG, 1989, ARCH INSECT BIOCHEM, V12, P267, DOI 10.1002/arch.940120406; WU D, 1992, J BIOL CHEM, V267, P2311; Wu SJ, 1996, J MOL BIOL, V255, P628, DOI 10.1006/jmbi.1996.0052; Yamamoto T., 1993, ADV ENG PESTICIDES, P3	36	63	73	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25220	25226		10.1074/jbc.271.41.25220	http://dx.doi.org/10.1074/jbc.271.41.25220			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810282	hybrid			2022-12-27	WOS:A1996VL69300026
J	Chiang, SY; Welch, JJ; Rauscher, FJ; Beerman, TA				Chiang, SY; Welch, JJ; Rauscher, FJ; Beerman, TA			Effect of DNA-binding drugs on early growth response factor-1 and TATA box-binding protein complex formation with the herpes simplex virus latency promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLURAMYCIN ANTITUMOR ANTIBIOTICS; MINOR-GROOVE; TRANSCRIPTION INITIATION; SEQUENCE SELECTIVITY; CHROMOMYCIN; DISTAMYCIN; MITHRAMYCIN; NOGALAMYCIN; SPECIFICITY; ACTIVATION	Adjacent binding sites for early growth response factor-1 (EGR1) and TATA box-binding protein (TBP) were identified on the herpes simplex virus latency promoter in previous work. The binding of EGR1 to the GC-rich region prevented TBP binding to the AT-rich region. With the simultaneous addition of both EGR1 and TBP, the intercalator nogalamycin prevented EGR1 complex formation, resulting in a dose-dependent increase of the TBP DNA complex. The minor groove binder chromomycin A(3) inhibited EGR1 complex formation but resulted in a smaller increase of the TBP complex. In contrast, an alkylating intercalator hedamycin strongly inhibited binding of both proteins. The ability of these GC-binding drugs to prevent EGR1 DNA complex formation was in the following order: hedamycin > nogalamycin > chro momycin A(3), and the specificity was nogalamycin > chromomycin A(3) > hedamycin, With transcription factor IIA (TFIIA) in the assay, TBP was able to bind the promoter whereas formation of the EGR1 DNA complex was reduced. An AT minor groove-binding drug, distamycin A(3) disrupted the TBP TFIIA DNA complex and restored the EGR1 DNA complex. We conclude that the binding motif and sequence preference of DNA-interactive drugs are manifested in their ability to inhibit the transcription factor-DNA complexes.	ROSWELL PK CANC INST,DEPT EXPT THERAPEUT,BUFFALO,NY 14263; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	Roswell Park Cancer Institute; The Wistar Institute					NATIONAL CANCER INSTITUTE [P30CA010815, P30CA016056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK049210] Funding Source: NIH RePORTER; NCI NIH HHS [CA16056, CA10815] Funding Source: Medline; NIDDK NIH HHS [DK49210] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEERMAN TA, 1991, DNA TOPOISOMERASES C, P172; BENNETT GN, 1982, NUCLEIC ACIDS RES, V10, P4581, DOI 10.1093/nar/10.15.4581; BROGGINI M, 1989, NUCLEIC ACIDS RES, V17, P1051, DOI 10.1093/nar/17.3.1051; BRUZIK JP, 1987, BIOCHEMISTRY-US, V26, P950, DOI 10.1021/bi00377a040; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHIANG SY, 1994, BIOCHEMISTRY-US, V33, P7033, DOI 10.1021/bi00189a003; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DORN A, 1992, EMBO J, V11, P279, DOI 10.1002/j.1460-2075.1992.tb05050.x; FOX KR, 1985, NUCLEIC ACIDS RES, V13, P8695, DOI 10.1093/nar/13.24.8695; GAO XL, 1990, BIOCHEMISTRY-US, V29, P10940, DOI 10.1021/bi00501a012; GAO XL, 1989, BIOCHEMISTRY-US, V28, P751, DOI 10.1021/bi00428a051; HANSEN M, 1995, J AM CHEM SOC, V117, P2421, DOI 10.1021/ja00114a006; JERNIGAN HM, 1978, BIOCHEMISTRY-US, V17, P4232, DOI 10.1021/bi00613a019; KOPKA ML, 1985, P NATL ACAD SCI USA, V82, P1376, DOI 10.1073/pnas.82.5.1376; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LIU CD, 1994, BIOCHEMISTRY-US, V33, P1419, DOI 10.1021/bi00172a019; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MCHUGH MM, 1989, BIOCHEM PHARMACOL, V38, P2323, DOI 10.1016/0006-2952(89)90472-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MORTENSEN UH, 1990, NUCLEIC ACIDS RES, V18, P1983, DOI 10.1093/nar/18.8.1983; PORTUGAL J, 1987, EUR J BIOCHEM, V167, P281, DOI 10.1111/j.1432-1033.1987.tb13334.x; PRAKASH AS, 1995, CHEM-BIOL INTERACT, V95, P17, DOI 10.1016/0009-2797(94)03341-2; RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110; SEARLE MS, 1988, BIOCHEMISTRY-US, V27, P4340, DOI 10.1021/bi00412a022; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; STORL K, 1993, FEBS LETT, V317, P157, DOI 10.1016/0014-5793(93)81513-Y; STRANEY DC, 1987, BIOCHEMISTRY-US, V26, P1987, DOI 10.1021/bi00381a031; SUN DY, 1993, BIOCHEMISTRY-US, V32, P8068, DOI 10.1021/bi00083a003; SUN DY, 1995, CHEM BIOL, V2, P457, DOI 10.1016/1074-5521(95)90263-5; SYNDER R C, 1991, Biochemistry, V30, P4290; VANDYKE MW, 1983, BIOCHEMISTRY-US, V22, P2373, DOI 10.1021/bi00279a011; WARING MJ, 1981, ANNU REV BIOCHEM, V50, P159, DOI 10.1146/annurev.bi.50.070181.001111; WELCH JJ, 1994, J BIOL CHEM, V269, P31051; WICKMAN G, 1995, FEBS LETT, V360, P231, DOI 10.1016/0014-5793(95)00110-U; WILLIAMS LD, 1990, P NATL ACAD SCI USA, V87, P2225, DOI 10.1073/pnas.87.6.2225; WOYNAROWAKI JM, 1988, MOL PHARMACOL, V35, P177	36	32	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23999	24004		10.1074/jbc.271.39.23999	http://dx.doi.org/10.1074/jbc.271.39.23999			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798634	hybrid			2022-12-27	WOS:A1996VJ44200063
J	Murata, T; Yamato, I; Igarashi, K; Kakinuma, Y				Murata, T; Yamato, I; Igarashi, K; Kakinuma, Y			Intracellular Na+ regulates transcription of the ntp operon encoding a vacuolar-type Na+ translocating ATPase in Enterococcus hirae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM PROTON ANTIPORTER; STREPTOCOCCUS-FAECALIS; ESCHERICHIA-COLI; CYTOPLASMIC PH; ALKALINE PH; GENE; NHAA; AMPLIFICATION; PROTEINS; CLONING	The Gram-positive bacterium Enterococcus hirae has a vacuolar-type Na+-translocating ATPase that is encoded by the ntp operon (ntpFIKECGABDHJ) (Takase, K., Kakinuma, S., Yamato, I., Konishi, K., Igarashi, K., and Kakinuma, Y. (1994) J, Biol, Chem, 269, 11037-11044). Primer extension experiments identified the start site of transcription of this operon upstream of the ntpF gene, In parallel with the increases of both Na+-pumping activity in whole cells and Na+-stimulated ATPase activity in the membranes, the amounts of the two major subunits (A and B) of this enzyme increased remarkably in cells grown on medium containing high concentrations of NaCl but not on medium containing KCl or sorbitol, Chloramphenicol completely abolished the increases of the enzyme activity and the amounts of A and B subunits, suggesting that the Na+-ATPase level increased by de novo synthesis of the enzyme with the stimulation of high concentrations of the external sodium ions. Finally, Western blot and Northern blot experiments revealed that the increase in the Na+-ATPase level with the external Na+ was further accelerated by addition of an ionophore, such as monensin, which rendered the cell membrane permeable to Na+. These results suggest that the transcription of the Na+-ATPase operon is regulated by the intracellular concentration of sodium ions.	SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,NODA,CHIBA 278,JAPAN; CHIBA UNIV,FAC PHARMACEUT SCI,CHIBA 263,JAPAN	Tokyo University of Science; Chiba University			Murata, Takeshi/J-6181-2017; Murata, Takeshi/F-6114-2011	Murata, Takeshi/0000-0002-5748-4670; Igarashi, Kazuei/0000-0003-3751-3187				ABRAMS A, 1985, ENZYMES BIOL MEMBR, V4, P177; Ausubel FM., 1988, CURRENT PROTOCOLS MO; CARMEL O, 1994, EMBO J, V13, P1981, DOI 10.1002/j.1460-2075.1994.tb06467.x; FUJII S, 1981, BIOCHIM BIOPHYS ACTA, V661, P342, DOI 10.1016/0005-2744(81)90023-1; HEEFNER DL, 1982, P NATL ACAD SCI-BIOL, V79, P2798, DOI 10.1073/pnas.79.9.2798; KAKINUMA Y, 1987, J BACTERIOL, V169, P4403, DOI 10.1128/jb.169.9.4403-4405.1987; KAKINUMA Y, 1990, FEBS LETT, V261, P135, DOI 10.1016/0014-5793(90)80654-2; KAKINUMA Y, 1990, J BACTERIOL, V172, P1732, DOI 10.1128/jb.172.4.1732-1735.1990; KAKINUMA Y, 1989, J BIOENERG BIOMEMBR, V21, P679, DOI 10.1007/BF00762686; KAKINUMA Y, 1987, J BACTERIOL, V169, P3886, DOI 10.1128/jb.169.9.3886-3890.1987; KAKINUMA Y, 1985, J BIOL CHEM, V260, P2086; KAKINUMA Y, 1994, J BIOCHEM-TOKYO, V116, P1302, DOI 10.1093/oxfordjournals.jbchem.a124679; KAKINUMA Y, 1990, FEBS LETT, V271, P97, DOI 10.1016/0014-5793(90)80381-R; KAKINUMA Y, 1990, FEBS LETT, V271, P102, DOI 10.1016/0014-5793(90)80382-S; KAKINUMA Y, 1993, BIOCHEM BIOPH RES CO, V195, P1063, DOI 10.1006/bbrc.1993.2152; KANE PM, 1995, J BIOL CHEM, V270, P17025; KARPEL R, 1991, J BIOL CHEM, V266, P21753; KINOSHITA N, 1984, J BACTERIOL, V158, P844, DOI 10.1128/JB.158.3.844-848.1984; KOBAYASHI H, 1984, J BACTERIOL, V158, P1157, DOI 10.1128/JB.158.3.1157-1160.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Murata T, 1996, J BIOL CHEM, V271, P10042, DOI 10.1074/jbc.271.17.10042; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; PADAN E, 1993, ALKALI CATION TRANSP, P3; RAHAVMANOR O, 1992, J BIOL CHEM, V267, P10433; ROSEN BP, 1986, ANNU REV MICROBIOL, V40, P263, DOI 10.1146/annurev.mi.40.100186.001403; Sambrook J., 2002, MOL CLONING LAB MANU; SKULACHEV VP, 1988, MEMBRANE BIOENERGETI, P293; SOLIOZ M, 1994, J BIOL CHEM, V269, P9453; STRAUSAK D, 1994, EBEC SHORT REP, V8, P77; TAKASE K, 1993, J BIOL CHEM, V268, P11610; TAKASE K, 1994, J BIOL CHEM, V269, P11037; WASER M, 1992, J BIOL CHEM, V267, P5396; Yamato I., 1993, ALKALI CATION TRANSP, P53	34	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23661	23666		10.1074/jbc.271.39.23661	http://dx.doi.org/10.1074/jbc.271.39.23661			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798587	hybrid			2022-12-27	WOS:A1996VJ44200016
J	Jideama, NM; Noland, TA; Raynor, RL; Blobe, GC; Fabbro, D; Kazanietz, MG; Blumberg, PM; Hannun, YA; Kuo, JF				Jideama, NM; Noland, TA; Raynor, RL; Blobe, GC; Fabbro, D; Kazanietz, MG; Blumberg, PM; Hannun, YA; Kuo, JF			Phosphorylation specificities of protein kinase C isozymes for bovine cardiac troponin I and troponin T and sites within these proteins and regulation of myofilament properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTOMYOSIN MGATPASE ACTIVITY; MUSCLE-CONTRACTION; CA2+-STIMULATED MGATPASE; RECONSTITUTED ACTOMYOSIN; HEAVY-MEROMYOSIN; MYOCARDIAL-CELLS; RAT-HEART; ACTIN; TROPOMYOSIN; EXPRESSION	Protein kinase C (PKC) isozymes alpha, delta, epsilon, and zeta, shown to be expressed in adult rat cardiomyocytes, displayed distinct substrate specificities in phosphorylating troponin I and troponin T subunits in the bovine cardiac troponin complex, Thus, because they have different substrate affinities, PKC-alpha, -delta, and -epsilon phosphorylated troponin I more than troponin T, but PKC-zeta conversely phosphorylated the latter more than the former, Furthermore, PKC isozymes exhibited discrete specificities in phosphorylating distinct sites in these proteins as free subunits or in the troponin complex, Unlike other isozymes, PKC-delta was uniquely able to phosphorylate Ser-23/Ser-24 in troponin I, the bona fide phosphorylation sites for protein kinase A (PKA); and consequently, like PKA, it reduced Ca2+ sensitivity of Ca2+-stimulated MgATPase of reconstituted actomyosin S-1. In addition, PKC-delta, like PKC-alpha, readily phosphorylated Ser-43/Ser-45 (sites common for all PKC isozymes) and reduced maximal activity of MgATPase, In this respect, PKC-delta functioned as a hybrid of PKC-alpha and PKA. In contrast to PKC-alpha, -delta, and -epsilon, PKC-zeta exclusively phosphorylated two previously unknown sites in troponin T. Phosphorylation of troponin T by PKC-alpha resulted in decreases in both Ca2+ sensitivity and maximal activity, whereas phosphorylation by PKC-zeta resulted in a slight increase of the Ca2+ sensitivity without affecting the maximal activity of MgATPase, Most of the in vitro phosphorylation sites in troponin I and troponin T were confirmed in situ in adult rat cardiomyocytes. The present study has demonstrated for the first time distinct specificities of PKC isozymes for phosphorylation of two physiological substrates in the myocardium, with functional consequences.	EMORY UNIV, SCH MED, DEPT PHARMACOL, ATLANTA, GA 30322 USA; DUKE UNIV, MED CTR, DEPT MED HEMATOL ONCOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; CIBA GEIGY LTD, DEPT PHARMACEUT RES, ONCOL K125, CH-4002 BASEL, SWITZERLAND; NCI, MOL MECHANISMS TUMOR PROMOT SECT, CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB, NIH, BETHESDA, MD 20892 USA	Emory University; Duke University; Duke University; Novartis; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707, R37HL015696, R01HL015696] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-15696, HL-43707] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOBE GC, 1993, J BIOL CHEM, V268, P658; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; CHALOVICH JM, 1986, J BIOL CHEM, V261, P5088; DAHIYA R, 1994, J BIOL CHEM, V269, P29457; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; ELSALEH SC, 1985, J BIOL CHEM, V260, P4775; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FISHER D, 1995, J BIOL CHEM, V270, P25455, DOI 10.1074/jbc.270.43.25455; GRABAREK Z, 1986, J BIOL CHEM, V261, P608; Haselgrove J. C., 1972, COLD SPRING HARB SYM, V37, P341; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; KATOH N, 1983, BIOCHEMISTRY-US, V209, P289; KUO JF, 1970, BIOCHIM BIOPHYS ACTA, V212, P79, DOI 10.1016/0005-2744(70)90180-4; LEAVIS PC, 1984, CRC CRIT REV BIOCH, V16, P233; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NOLAND TA, 1993, J MOL CELL CARDIOL, V25, P53, DOI 10.1006/jmcc.1993.1007; NOLAND TA, 1995, J BIOL CHEM, V270, P25445, DOI 10.1074/jbc.270.43.25445; NOLAND TA, 1989, J BIOL CHEM, V264, P20778; NOLAND TA, 1991, J BIOL CHEM, V266, P4974; NOLAND TA, 1992, BIOCHEM J, V288, P123, DOI 10.1042/bj2880123; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; POTTER JD, 1982, METHOD ENZYMOL, V85, P234; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; RAY KP, 1976, FEBS LETT, V70, P11, DOI 10.1016/0014-5793(76)80716-8; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SOLARO RJ, 1986, PROTEIN PHOSPHORYLAT; STABEL S, 1991, METHOD ENZYMOL, V200, P670; STULL JT, 1977, J BIOL CHEM, V252, P851; SWIDEREK K, 1990, EUR J BIOCHEM, V190, P575, DOI 10.1111/j.1432-1033.1990.tb15612.x; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; VENEMA RC, 1993, J BIOL CHEM, V268, P2705; VENEMA RC, 1993, BIOCHEM J, V294, P401, DOI 10.1042/bj2940401; VENTURA C, 1995, J BIOL CHEM, V270, P30115; WATTANAPERMPOOL J, 1995, J MOL CELL CARDIOL, V27, P1383, DOI 10.1006/jmcc.1995.0131; Zhang R, 1995, J BIOL CHEM, V270, P30773, DOI 10.1074/jbc.270.51.30773; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	42	152	157	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23277	23283		10.1074/jbc.271.38.23277	http://dx.doi.org/10.1074/jbc.271.38.23277			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798526	hybrid			2022-12-27	WOS:A1996VH76800052
J	Menz, RI; Day, DA				Menz, RI; Day, DA			Purification and characterization of a 43-kDa rotenone-insensitive NADH dehydrogenase from plant mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD(P)H DEHYDROGENASES; ARUM-MACULATUM; INNER SURFACE; SUBMITOCHONDRIAL LOCALIZATION; SACCHAROMYCES-CEREVISIAE; MEMBRANE; OXIDOREDUCTASES	A 43-kDa NAD(P)H dehydrogenase was purified from red beetroot mitochondria. An antibody against this dehydrogenase was used in conjunction with the membrane-impermeable protein cross-linker 3,3'-dithio-bis(sulfosuccinimidylpropionate) to localize the dehydrogenase on the matrix side of the inner membrane. Immunoblotting showed that the dehydrogenase was found in mitochondria isolated from several plant species but not from rat livers. Antibodies against the purified dehydrogenase partially inhibited rotenone insensitive internal NADH oxidation by inside-out submitochondrial particles. The level of rotenone-insensitive respiration with NAB-linked substrates correlated with the amount of 43-kDa NAD(P)H dehydrogenase present in mitochondria isolated from different soybean tissues. Based on these results, we conclude that the 43-kDa NAD(P)H dehydrogenase is responsible for rotenone-insensitive internal NADH oxidation in plant mitochondria.	AUSTRALIAN NATL UNIV,DIV BIOCHEM & MOL BIOL,CANBERRA,ACT 0200,AUSTRALIA; AUSTRALIAN NATL UNIV,COOPERAT RES CTR PLANT SCI,CANBERRA,ACT 0200,AUSTRALIA	Australian National University; Australian National University			Day, David/F-6325-2011	Day, David/0000-0001-7967-2173				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNTON CJ, 1973, EUR J BIOCHEM, V39, P283, DOI 10.1111/j.1432-1033.1973.tb03125.x; BRYCE JH, 1990, PHYSIOL PLANTARUM, V78, P105, DOI 10.1034/j.1399-3054.1990.780117.x; CHAUVEAU M, 1990, PLANT PHYSL BETHESDA, V95, P934; COOK ND, 1984, EUR J BIOCHEM, V141, P573, DOI 10.1111/j.1432-1033.1984.tb08231.x; COOK ND, 1985, BIOCHIM BIOPHYS ACTA, V827, P30, DOI 10.1016/0167-4838(85)90097-4; COTTINGHAM IR, 1984, BIOCHEM J, V224, P171, DOI 10.1042/bj2240171; DAY DA, 1986, PROTOPLASMA, V134, P121, DOI 10.1007/BF01275710; DEVRIES S, 1988, EUR J BIOCHEM, V176, P377; Harlow E., 1988, ANTIBODIES LAB MANUA; JAMES AT, 1989, J MATH BIOL, V27, P29, DOI 10.1007/BF00276079; KLEIN RR, 1984, PLANT PHYSIOL, V76, P436, DOI 10.1104/pp.76.2.436; KNUDTEN AF, 1994, PLANT PHYSIOL, V106, P1115, DOI 10.1104/pp.106.3.1115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIDEN AC, 1993, PHYSIOL PLANTARUM, V87, P134, DOI 10.1111/j.1399-3054.1993.tb00135.x; LUETHY MH, 1991, PLANT PHYSIOL, V97, P1317, DOI 10.1104/pp.97.4.1317; LUETHY MH, 1995, PLANT PHYSIOL, V107, P443, DOI 10.1016/S0176-1617(11)81768-2; MARRES CAM, 1991, EUR J BIOCHEM, V195, P857, DOI 10.1111/j.1432-1033.1991.tb15775.x; MATSUSHITA K, 1987, BIOCHEMISTRY-US, V26, P7732, DOI 10.1021/bi00398a029; MENZ RI, 1992, EUR J BIOCHEM, V208, P481, DOI 10.1111/j.1432-1033.1992.tb17211.x; MENZ RI, 1995, THESIS AUSTR NATL U; MOLLER IM, 1982, PHYSIOL PLANTARUM, V54, P267, DOI 10.1111/j.1399-3054.1982.tb00258.x; RASMUSSON AG, 1991, PHYSIOL PLANTARUM, V83, P357, DOI 10.1111/j.1399-3054.1991.tb00106.x; RASMUSSON AG, 1993, BIOCHIM BIOPHYS ACTA, V1141, P107, DOI 10.1016/0005-2728(93)90196-M; SIEGEL LM, 1978, METHOD ENZYMOL, V50, P419; SOOLE KL, 1995, J BIOENERG BIOMEMBR, V27, P397, DOI 10.1007/BF02110002; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P225; YAGI T, 1991, J BIOENERG BIOMEMBR, V23, P211, DOI 10.1007/BF00762218	28	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23117	23120		10.1074/jbc.271.38.23117	http://dx.doi.org/10.1074/jbc.271.38.23117			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798503	hybrid			2022-12-27	WOS:A1996VH76800029
J	Swierczynski, SL; Blackshear, PJ				Swierczynski, SL; Blackshear, PJ			Myristoylation-dependent and electrostatic interactions exert independent effects on the membrane association of the myristoylated alanine-rich protein kinase C substrate protein in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMINENT CELLULAR SUBSTRATE; MARCKS-RELATED PROTEIN; PLASMA-MEMBRANE; MOLECULAR-CLONING; CALMODULIN-BINDING; PHOSPHORYLATION; IDENTIFICATION; PEPTIDES; RECEPTOR; 80-KDA	The myristoylated alanine-rich protein kinase C substrate (MARCKS) is a widely expressed, prominent substrate for protein kinase C. MARCKS is largely associated with membranes in cells, and hydrophobic interactions involving the amino-terminal myristoyl moiety are thought to play a role in anchoring MARCKS to cellular membranes. In addition, experiments in cell-free systems have suggested that electrostatic interactions between the positively charged phosphorylation site/calmodulin binding domain (PSD) of MARCKS and negatively charged membrane lipids are also involved in this association. Although it has been inferred from phosphorylation experiments, the electrostatic nature of the interaction between the PSD and membranes has not been demonstrated directly in intact cells. We expressed human MARCKS mutated in the myristoylation site and the PSD in REF52 cells; the cells were then fractionated by ultracentrifugation. Both nonmyristoylatable MARCKS and MARCKS in which the four serines in the PSD were mutated to aspartic acids, mimicking phosphorylation, exhibited decreased membrane affinity when compared to the fully myristoylated, wild-type, tetra-Ser protein or a myristoylated, tetra Asn mutant. A double mutant, nonmyristoylatable protein in which the four serines in the PSD were mutated to aspartic acids exhibited negligible membrane association. Similar results were obtained in 293 cells that stably expressed chicken MARCKS mutated in the same domains. The double mutant, nonmyristoylatable tetra-Asp chicken protein exhibited little membrane association as determined by both subcellular fractionation and immunoelectron microscopy. These results indicate that myristoylation and electrostatic interactions involving the PSD exert independent, essentially additive effects on the membrane association of MARCKS in intact cells.	DUKE UNIV, MED CTR,HOWARD HUGHES MED INST, DIV ENDOCRINOL METAB & NUTR,DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, SARAH W STEDMAN CTR NUTR STUDIES, DURHAM, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; AMESS B, 1992, FEBS LETT, V297, P285; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLACKSHEAR PJ, 1992, GENOMICS, V14, P168, DOI 10.1016/S0888-7543(05)80300-3; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; BYERS DM, 1993, J NEUROCHEM, V60, P1414, DOI 10.1111/j.1471-4159.1993.tb03303.x; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; FEDER D, 1991, J BIOL CHEM, V266, P19040; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HINRICHSEN RD, 1993, P NATL ACAD SCI USA, V90, P1585, DOI 10.1073/pnas.90.4.1585; HORNBECK P, 1989, MOL CELL BIOL, V9, P3727, DOI 10.1128/MCB.9.9.3727; JAMES G, 1989, J BIOL CHEM, V264, P20998; JOSHI R, 1990, J BIOL CHEM, V265, P13130; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LINSTEDT AD, 1992, J CELL BIOL, V117, P1077, DOI 10.1083/jcb.117.5.1077; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; NAKAOKA T, 1995, J BIOL CHEM, V270, P12147, DOI 10.1074/jbc.270.20.12147; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIGAL CT, 1993, MOL CELL BIOL, V13, P3084, DOI 10.1128/MCB.13.5.3084; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SWEENEY HL, 1994, P NATL ACAD SCI USA, V91, P1490, DOI 10.1073/pnas.91.4.1490; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; SWIERCZYNSKI SL, 1996, IN PRESS DEV BIOL; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253	50	65	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23424	23430		10.1074/jbc.271.38.23424	http://dx.doi.org/10.1074/jbc.271.38.23424			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798548	hybrid			2022-12-27	WOS:A1996VH76800074
J	Latour, S; Chow, LML; Veillette, A				Latour, S; Chow, LML; Veillette, A			Differential intrinsic enzymatic activity of Syk and Zap-70 protein-tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; B-CELL DEVELOPMENT; ANTIGEN RECEPTOR; ACTIVATION; PHOSPHORYLATION; BINDING; FAMILY; P56LCK; AUTOPHOSPHORYLATION; SELECTION	Syk and Zap-70 are related protein-tyrosine kinases implicated in antigen and Fc receptor signaling. While Zap-70 is restricted to T-cells and natural killer cells, Syk accumulates in B-cells, mast cells, platelets, and immature T-cells. In addition, we found that an isoform of Syk (SykB), which carries a 23-amino acid deletion in the ''linker'' region, is prominently expressed in bone marrow. To better understand the relative impact of Syk, SykB, and Zap-70 on signal transduction, we compared their intrinsic enzymatic properties in transiently transfected COS-1 cells and in hemopoietic cells. Using modified versions of these enzymes bearing a common Myc epitope at the amino terminus, we determined that the ability of Syk and SykB to undergo autophosphorylation and to phosphorylate erythrocyte band 3 in immune complex kinase reactions was at least 100-fold greater than that of Zap-70. Similarly, Syk and SykB, but not Zap-70, caused prominent tyrosine phosphorylation of p120(c-cbl) in COS-l cells. A similar pattern of activity was also noted for endogenous Syk and Zap-70 from hemopoietic cells. To understand the structural basis for these characteristics, we also created and analyzed a series of chimeras between Syk and Zap-70. These studies indicated that the catalytic domain of Syk and Zap-70, but not their SH2 domains, linker region or carboxyl-terminal tail, was responsible for their respective activity. Taken together, these data demonstrated that the intrinsic enzymatic activity of Syk and SykB is superior to that of Zap-70 and that such a distinction relates to structural variations in the catalytic domain.	MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA; MONTREAL GEN HOSP,DEPT MED,MONTREAL,PQ H3G 1A4,CANADA; MONTREAL GEN HOSP,DEPT ONCOL,MONTREAL,PQ H3G 1A4,CANADA	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University			; Latour, Sylvain/H-3652-2017	Chow, Lionel/0000-0001-8447-063X; Latour, Sylvain/0000-0001-8238-4391				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CHOW LML, 1992, MOL CELL BIOL, V12, P1226, DOI 10.1128/MCB.12.3.1226; COLIGNA JE, 1994, CURRENT PROTOCOLS IM; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FLUCK M, 1995, BIOCHEM BIOPH RES CO, V213, P273, DOI 10.1006/bbrc.1995.2126; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Greenberg S, 1996, P NATL ACAD SCI USA, V93, P1103, DOI 10.1073/pnas.93.3.1103; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KIM KJ, 1979, J IMMUNOL, V122, P549; Kimura T, 1996, MOL CELL BIOL, V16, P1471; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KONG GH, 1995, IMMUNITY, V2, P485, DOI 10.1016/1074-7613(95)90029-2; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Law CL, 1996, MOL CELL BIOL, V16, P1305; LOW PS, 1987, J BIOL CHEM, V262, P4592; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Qian DP, 1996, J EXP MED, V183, P611, DOI 10.1084/jem.183.2.611; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; Richards JD, 1996, J BIOL CHEM, V271, P6458, DOI 10.1074/jbc.271.11.6458; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; ROWLEY RB, 1995, J BIOL CHEM, V270, P12659, DOI 10.1074/jbc.270.21.12659; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TAYLOR JA, 1995, MOL CELL BIOL, V15, P4149; TIMSONGAUEN LK, 1994, MOL CELL BIOL, V14, P3729; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; van Oers N S, 1995, Semin Immunol, V7, P227, DOI 10.1006/smim.1995.0027; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WEIL R, 1995, J BIOL CHEM, V270, P2791, DOI 10.1074/jbc.270.6.2791; YAGI S, 1994, BIOCHEM BIOPH RES CO, V200, P28, DOI 10.1006/bbrc.1994.1409	43	133	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22782	22790		10.1074/jbc.271.37.22782	http://dx.doi.org/10.1074/jbc.271.37.22782			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798454	hybrid			2022-12-27	WOS:A1996VG67200073
J	Rowles, J; Scherer, SW; Xi, T; Majer, M; Nickle, DC; Rommens, JM; Popov, KM; Harris, RA; Riebow, NL; Xia, J; Tsui, LC; Bogardus, C; Prochazka, M				Rowles, J; Scherer, SW; Xi, T; Majer, M; Nickle, DC; Rommens, JM; Popov, KM; Harris, RA; Riebow, NL; Xia, J; Tsui, LC; Bogardus, C; Prochazka, M			Cloning and characterization of PDK4 on 7q21.3 encoding a fourth pyruvate dehydrogenase kinase isoenzyme in human	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; PIMA-INDIANS; INSULIN-RESISTANCE; MOLECULAR-CLONING; PROTEIN-KINASES; LINKAGE; GENE; EXPRESSION; MARKERS; ASSOCIATION	Different isoenzymes of pyruvate dehydrogenase kinase (PDK) inhibit the mitochondrial pyruvate dehydrogenase complex by phosphorylation of the E1 alpha subunit, thus contributing to the regulation of glucose metabolism. By positional cloning in the 7q21.3-q22.1 region linked with insulin resistance and non-insulin-dependent diabetes mellitus in the Pima Indians, Fee identified a gene encoding an additional human PDR isoform, as evidenced by its amino acid sequence identity (>65%) with other mammalian PDKs, and confirmed by biochemical analyses of the recombinant protein. We performed detailed comparative analyses of the gene, termed PDK4, in insulin-resistant and insulin-sensitive Pima Indians, and detected five DNA variants with comparable frequencies in both subject groups. Using quantitative reverse transcription polymerase chain reaction, we found that the variants identified in the promoter and 5'-untranslated region did not correlate with differences in mRNA level in skeletal muscle and adipose tissue. We conclude that alterations in PDK4 are unlikely to be the molecular basis underlying the observed linkage at 7q21.3-q22.1 in the Pima Indians. Information about the genomic organization and promoter sequences of PDK4 will be useful in studies of other members of this family of mitochondrial protein kinases that are important for the regulation of glucose metabolism.	NIDDK,CLIN DIABET & NUTR SECT,PHOENIX EPIDEMIOL & CLIN RES BRANCH,NIH,PHOENIX,AZ 85016; HOSP SICK CHILDREN,DEPT GENET,TORONTO,ON M5G 1X8,CANADA; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Indiana University System; Indiana University-Purdue University Indianapolis			Tsui, Lap-chee/A-1081-2010; Scherer, Stephen W./B-3785-2013; Nickle, David/ABF-2727-2020; Rommens, Johanna/AAT-7465-2021	Scherer, Stephen W./0000-0002-8326-1999; 	NIDDK NIH HHS [DK 47844] Funding Source: Medline; NIGMS NIH HHS [GM 51262] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047844] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051262, R01GM051262] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT PH, 1971, LANCET, V2, P125; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; KNOWLER WC, 1978, AM J EPIDEMIOL, V108, P497, DOI 10.1093/oxfordjournals.aje.a112648; LILLIOJA S, 1986, METABOLISM, V35, P505, DOI 10.1016/0026-0495(86)90006-5; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; LOCKER J, 1990, J DNA SEQUENCING MAP, V1, P3; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; Majer M, 1996, DIABETOLOGIA, V39, P314; MCCONLOGUE L, 1988, NUCLEIC ACIDS RES, V16, P9869, DOI 10.1093/nar/16.20.9869; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; POMP D, 1991, BIOTECHNIQUES, V10, P58; Popov K M, 1991, Protein Expr Purif, V2, P278, DOI 10.1016/1046-5928(91)90084-V; POPOV KM, 1992, J BIOL CHEM, V267, P13127; POPOV KM, 1993, J BIOL CHEM, V268, P26602; POPOV KM, 1994, J BIOL CHEM, V269, P29720; PROCHAZKA M, 1989, DIABETES, V38, P1446, DOI 10.2337/diabetes.38.11.1446; PROCHAZKA M, 1995, DIABETOLOGIA, V38, P461, DOI 10.1007/s001250050306; PROCHAZKA M, 1993, DIABETES, V42, P514, DOI 10.2337/diabetes.42.4.514; PROCHAZKA M, 1995, DIABETES, V44, pA42; PROCHAZKA M, 1995, CYTOGENET CELL GENET, V71, P30; RANDLE PJ, 1994, J CELL BIOCHEM, V55, P1, DOI 10.1002/jcb.240550002; ROMMENS JM, 1994, IDENTIFICATION OF TRANSCRIBED SEQUENCES, P65; SCHERER SW, 1994, HUM MOL GENET, V3, P1345; SCHERER SW, 1992, MAMM GENOME, V3, P179, DOI 10.1007/BF00352464; SCHERER SW, 1995, CYTOGENET CELL GENET, V71, P22; TURNER RC, 1995, DIABETES, V44, P1, DOI 10.2337/diabetes.44.1.1; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YOUNG AA, 1988, AM J PHYSIOL, V254, pE231, DOI 10.1152/ajpendo.1988.254.2.E231	32	148	188	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22376	22382		10.1074/jbc.271.37.22376	http://dx.doi.org/10.1074/jbc.271.37.22376			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798399	hybrid			2022-12-27	WOS:A1996VG67200018
J	Himanen, JP; Mirza, UA; Chait, BT; Bookchin, RM; Manning, JM				Himanen, JP; Mirza, UA; Chait, BT; Bookchin, RM; Manning, JM			A recombinant sickle hemoglobin triple mutant with independent inhibitory effects on polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; YEAST; SITE; CYANATE; LYSINE	As part of a comprehensive effort to map the most important regions of sickle hemoglobin that are involved in polymerization, we have determined whether two sites previously shown to be involved, Leu-88(beta) and Lys-95(beta), had additive effects when substituted. The former site is part of the hydrophobic pocket that binds Val-6(beta), the natural mutation of HbS, and the latter site is a prominent part of the hemoglobin exterior. A sickle hemoglobin triple mutant with three amino acid substitutions on the beta-chain, E6V/L88A/K95I, has been expressed in yeast and characterized extensively. Its oxygen binding curve, cooperativity, response to allosteric effecters, and the alkaline Bohr effect showed that it was completely functional. The polymer solubility of the deoxy triple mutant, measured by a new micromethod requiring reduced amounts of hemoglobin, was identical to that of the E6V(beta)/K95I(beta) mutant, i.e. when the K95I(beta) substitution was present on the same tetramer together with the naturally occurring E6V(beta) substitution, the L88A(beta) replacement had no additive effect on polymer inhibition. The results suggest that Lys-95(beta) on the surface of the tetramer and its complementary binding region on the adjoining tetramer are potential targets for the design of an effective antisickling agent.	NORTHEASTERN UNIV, DEPT BIOL, BOSTON, MA 02115 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; ALBERT EINSTEIN COLL MED, BRONX, NY 10461 USA	Northeastern University; Rockefeller University; Yeshiva University; Albert Einstein College of Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL018819, R01HL028018, R37HL018819] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28018, HL-18819] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1993, J BIOL CHEM, V268, P21650; BAUDINCHICH V, 1990, P NATL ACAD SCI USA, V87, P1545; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P233, DOI 10.1002/rcm.1290030708; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BOOKCHIN RM, 1994, BLOOD, V86, pA473; BOOKCHIN RM, 1974, CLIN RES, V22, pA384; CERAMI A, 1971, P NATL ACAD SCI USA, V68, P1180, DOI 10.1073/pnas.68.6.1180; DELLANO JJM, 1993, J BIOL CHEM, V268, P27004; DELLANO JJM, 1993, P NATL ACAD SCI USA, V90, P918, DOI 10.1073/pnas.90.3.918; DELLANO JJM, 1994, PROTEIN SCI, V3, P1206, DOI 10.1002/pro.5560030806; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P133; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; Eaton William A., 1994, P53; EDELSTEIN SJ, 1979, J MOL BIOL, V134, P851, DOI 10.1016/0022-2836(79)90491-1; FORSEN S, 1995, TRENDS BIOCHEM SCI, V20, P495, DOI 10.1016/S0968-0004(00)89115-X; HERNAN RA, 1995, J BIOL CHEM, V270, P26257, DOI 10.1074/jbc.270.44.26257; HIMANEN JP, 1995, J BIOL CHEM, V270, P13885, DOI 10.1074/jbc.270.23.13885; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Liao D, 1996, BIOPHYS J, V70, P2442, DOI 10.1016/S0006-3495(96)79815-6; Manning J M, 1981, Methods Enzymol, V76, P159; MANNING JM, 1991, ADV ENZYMOL RAMB, V64, P55; Manning LR, 1996, PROTEIN SCI, V5, P775; Nagel R. L., 1978, BIOCH CLIN ASPECTS H, P195; NAGEL RL, 1974, SICKLE CELL ANEMIA O, P51; NJIKAM N, 1973, J BIOL CHEM, V248, P8052; PADLAN EA, 1985, J BIOL CHEM, V260, P8280; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; ROSS PD, 1978, BIOCH CLIN ASPECTS H, P629; TRUDEL M, 1991, EMBO J, V10, P3157, DOI 10.1002/j.1460-2075.1991.tb04877.x; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WATOWICH SJ, 1989, J MOL BIOL, V209, P821, DOI 10.1016/0022-2836(89)90610-4; YANASE H, 1994, PROTEIN SCI, V3, P1213, DOI 10.1002/pro.5560030807	34	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25152	25156		10.1074/jbc.271.41.25152	http://dx.doi.org/10.1074/jbc.271.41.25152			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810271	hybrid, Green Submitted			2022-12-27	WOS:A1996VL69300015
J	Minnick, DT; Astatke, M; Joyce, CM; Kunkel, TA				Minnick, DT; Astatke, M; Joyce, CM; Kunkel, TA			A thumb subdomain mutant of the large fragment of Escherichia coli DNA polymerase I with reduced DNA binding affinity, processivity, and frameshift fidelity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; CRYSTAL-STRUCTURE; KLENOW FRAGMENT; TEMPLATE-PRIMER; BETA; MISALIGNMENT; MECHANISM; IDENTIFICATION; TERMINATION; REPLICATION	In Klenow fragment DNA polymerase, a flexible 50-amino acid subdomain at the tip of the thumb which includes two alpha helices has been suggested to interact with the duplex template-primer (Beese, L.S., Derbyshire, V. and Steitz, T.A. (1993) Science 260, 352-355). The present study investigates the properties of Klenow polymerase containing a 24-amino acid deletion (residues 590-613) that removes a portion of the tip of the thumb. The mutant polymerase has relatively normal dNTP binding and catalytic rate. However, its DNA binding affinity is reduced by more than 100-fold relative to the intact polymerase and its ability to conduct processive synthesis is also reduced, Although the mutant polymerase has relatively normal base substitution fidelity, it has strongly reduced frameshift fidelity, being especially error-prone for single nucleotide addition errors in homopolymeric runs. The addition error rateincreases as the length of the reiterated sequence increases, indicative of errors initiated by template-primer strand slippage. These observations suggest a role for the tip of the thumb of Klenow polymerase in determining DNA binding, processivity and frameshift fidelity, perhaps by tracking the minor groove of the duplex DNA. The results are discussed in light of remarkably similar observations with T7 DNA polymerase in the presence or absence of thioredoxin, an accessory subunit that affects these same properties.	NIEHS,MOL GENET LAB,NIH,RES TRIANGLE PK,NC 27709; YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Yale University			Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028550] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-28550] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; ALLEN DJ, 1989, BIOCHEMISTRY-US, V28, P4601, DOI 10.1021/bi00437a014; ARNOLD E, 1995, CURR OPIN STRUC BIOL, V5, P27, DOI 10.1016/0959-440X(95)80006-M; ASTATKE M, 1995, J BIOL CHEM, V269, P28091; BEARD WA, 1994, J BIOL CHEM, V269, P28091; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; BEBENEK K, 1989, J BIOL CHEM, V264, P16498; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P813; CATALANO CE, 1990, BIOCHEMISTRY-US, V29, P3612, DOI 10.1021/bi00467a004; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; ECKERT KA, 1993, J BIOL CHEM, V268, P13462; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; GUEST CR, 1991, BIOCHEMISTRY-US, V30, P8759, DOI 10.1021/bi00100a007; HIMAWAN JS, 1992, P NATL ACAD SCI USA, V89, P9774, DOI 10.1073/pnas.89.20.9774; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Joyce CM, 1995, METHOD ENZYMOL, V262, P3; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; JOYCE CM, 1995, P NATL ACAD SCI USA, V262, P3; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; Kroutil LC, 1996, BIOCHEMISTRY-US, V35, P1046, DOI 10.1021/bi952178h; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1992, BIOESSAYS, V14, P303, DOI 10.1002/bies.950140503; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OLLIS DL, 1985, NATURE, V313, P818, DOI 10.1038/313818a0; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SOUSA R, 1994, NATURE, V264, P593; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014	45	71	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24954	24961		10.1074/jbc.271.40.24954	http://dx.doi.org/10.1074/jbc.271.40.24954			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798775	hybrid			2022-12-27	WOS:A1996VM67400098
J	Yamazaki, H; Bujo, H; Kusunoki, J; Seimiya, K; Kanaki, T; Morisaki, N; Schneider, WJ; Saito, Y				Yamazaki, H; Bujo, H; Kusunoki, J; Seimiya, K; Kanaki, T; Morisaki, N; Schneider, WJ; Saito, Y			Elements of neural adhesion molecules and a yeast vacuolar protein sorting receptor are present in a novel mammalian low density lipoprotein receptor family member	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; CHICKEN OOCYTE RECEPTOR; EPIDERMAL GROWTH-FACTOR; AMINO-ACID SEQUENCE; LDL-RECEPTOR; CELL-ADHESION; CYTOPLASMIC DOMAIN; MEMBRANE-PROTEIN; INTERNALIZATION SIGNAL; APOLIPOPROTEIN-E	Normal cell development depends to a large part on multifunctional proteins that have evolved by recombination of proven modular elements. We now have discovered and characterized in rabbit such a multi-domain protein, and classify it as novel member of the low density lipoprotein (LDL) receptor gene family. The extracellular portion of the similar to-250-kDa membrane protein, termed LR11, contains a cluster of 11 LDL receptor ligand binding repeats, a group of 5 LDL receptor ''YWTD'' repeats, a large hexarepeat domain of structural elements found in neural cell adhesion molecules, and a domain with similarity to a yeast receptor for vacuolar protein sorting, VPS10. The cytoplasmic domain exhibits features typical of endocytosis-competent coated-pit receptors. The mosaic, and presumably multifunctional, receptor is expressed abundantly in brain, in particular the hippocampus, dentate gyrus, and cerebral cortex, and is present at significant levels in liver, adrenal glands, and testis. Western blotting of tissues and ligand blotting of LR11-transfected cells demonstrated that the novel protein binds apolipoprotein E-containing lipoproteins. In contrast to the LDL receptor, hepatic expression of LR11 is unaffected by hyperlipidemia. The identification of this highly conserved and superbly complex protein offers the opportunity to gain new insights into the emergence of multifunctional mosaic proteins akin to the ever expanding LDL receptor gene family.	KOWA CO LTD,KOWA RES INST,HIGASHIMURAYAMA,TOKYO 189,JAPAN; UNIV VIENNA,A-1030 VIENNA,AUSTRIA; BIOCTR,DEPT MOL GENET,A-1030 VIENNA,AUSTRIA	Kowa Company, Ltd.; University of Vienna	Yamazaki, H (corresponding author), CHIBA UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,1-8-1 INOHANA,CHIBA 260,JAPAN.							BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BARTHELS D, 1987, EMBO J, V6, P907, DOI 10.1002/j.1460-2075.1987.tb04837.x; BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUJO H, 1995, P NATL ACAD SCI USA, V92, P9905, DOI 10.1073/pnas.92.21.9905; BUJO H, 1995, J BIOL CHEM, V270, P23546, DOI 10.1074/jbc.270.40.23546; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; Goding J., 1986, MONOCLONAL ANTIBODIE, P108; Goridis C, 1992, Semin Cell Biol, V3, P189; HAEFLIGER JA, 1987, BIOCHEMISTRY-US, V26, P3551, DOI 10.1021/bi00386a045; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; HORAZDOVSKY BF, 1995, CURR OPIN CELL BIOL, V7, P544, DOI 10.1016/0955-0674(95)80012-3; HUETTINGER M, 1984, P NATL ACAD SCI-BIOL, V81, P7599, DOI 10.1073/pnas.81.23.7599; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRIEG PA, 1989, NUCLEIC ACIDS RES, V17, P10321, DOI 10.1093/nar/17.24.10321; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACLACHLAN I, 1994, J BIOL CHEM, V269, P24127; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; NORTON PA, 1990, CELL, V61, P15, DOI 10.1016/0092-8674(90)90209-W; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PITAS RE, 1987, J BIOL CHEM, V262, P14352; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Ruppert M, 1995, J CELL BIOL, V131, P1881, DOI 10.1083/jcb.131.6.1881; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; Sambrook J., 2002, MOL CLONING LAB MANU; Schneider Wolfgang J., 1993, Current Opinion in Lipidology, V4, P205, DOI 10.1097/00041433-199306000-00005; Schneider Wolfgang J., 1995, Current Opinion in Lipidology, V6, P92, DOI 10.1097/00041433-199504000-00006; SCHONBAUM CP, 1995, P NATL ACAD SCI USA, V92, P1485, DOI 10.1073/pnas.92.5.1485; SPEELMAN BA, 1995, J BIOL CHEM, V270, P1583, DOI 10.1074/jbc.270.4.1583; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; SUZUKI T, 1993, J BIOL CHEM, V268, P13548; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TENSEN CP, 1994, P NATL ACAD SCI USA, V91, P4816, DOI 10.1073/pnas.91.11.4816; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WESSEL GM, 1995, DEV BIOL, V167, P388, DOI 10.1006/dbio.1995.1033; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YOCHEM J, 1993, P NATL ACAD SCI USA, V90, P4572, DOI 10.1073/pnas.90.10.4572	75	177	186	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24761	24768		10.1074/jbc.271.40.24761	http://dx.doi.org/10.1074/jbc.271.40.24761			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798746	hybrid			2022-12-27	WOS:A1996VM67400068
J	Jaiswal, RK; Weissinger, E; Kolch, W; Landreth, GE				Jaiswal, RK; Weissinger, E; Kolch, W; Landreth, GE			Nerve growth factor-mediated activation of the mitogen-activated protein (MAP) kinase cascade involves a signaling complex containing B-Raf and HSP90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; HEAT-SHOCK PROTEIN; PC12 CELLS; IDENTIFICATION; TRANSFORMATION; ASSOCIATION; DROSOPHILA; MEMBRANE; MEK-1; HETEROCOMPLEX	The nerve growth factor (NGF)-mediated activation of the mitogen-activated protein (MAP) kinase cascade is an obligatory step in the morphological differentiation of PC12 cells, Signal transduction through the MAP kinase cascade is dependent upon activation of p21(ras) which binds directly to Raf family protein kinases, mediating their association with the membrane and activation. PC12 cells express two Raf isoforms, c-Raf and B-Raf. The activation of the MAP kinase cascade in response to NGF is due principally to the action of B-Raf. NGF treatment of PC12 cells resulted in the enhanced phosphorylation of B-Raf and c-Raf, and both exhibit reduced electrophoretic mobilities following stimulation of the cells. The NGF-stimulated phosphorylation of B-Raf was correlated with its enzymatic activation as measured by the phosphorylation of its substrate MEK. However, c-Raf does not exhibit significant levels of activity, B-Raf was present as a component of a high molecular mass complex, which included the molecular chaperone, heat shock protein 90 (HSP90). Importantly, c-Raf did not participate in the formation of such complexes, The B-Raf containing HSP90 complexes were normally present in PC12 cells, and their assembly was not dependent upon NGF stimulation, These data suggest that the ability of B-Raf to activate the MAP kinase cascade is due to its association with a large signaling complex, which is likely to impart signaling pathway specificity.	CASE WESTERN RESERVE UNIV, SCH MED, ALZHEIMERS RES LAB, DEPT NEUROL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, ALZHEIMERS RES LAB, DEPT NEUROSCI, CLEVELAND, OH 44106 USA; GSF MUNICH, INST KLIN MOL BIOL & TUMORGENET, HAEMATOLOGIKUM, D-81377 MUNICH, GERMANY; GSF MUNICH, INST KLIN HAEMATOL, HAEMATOLOGIKUM, D-81377 MUNICH, GERMANY	Case Western Reserve University; Case Western Reserve University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health			Kolch, Walter/ABF-2102-2021; Admin, SBI/HGB-2738-2022	Kolch, Walter/0000-0001-5777-5016	NINDS NIH HHS [NS31987] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031987] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; BOHLEN S, 1995, SCIENCE, V268, P1301; BRUGGE J, 1996, CURR TOP MICROBIOL I, V123, P1; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOI KY, 1994, CELL, V78, P499; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DOYLE HJ, 1993, GENE DEV, V7, P633, DOI 10.1101/gad.7.4.633; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JAISWAL RK, 1993, J BIOL CHEM, V268, P7055; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTS RL, 1989, J BIOL CHEM, V264, P15542; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; PAPIN C, 1995, ONCOGENE, V10, P1647; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; STANCATO LF, 1994, J BIOL CHEM, V269, P22157; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P133, DOI 10.1016/0304-419X(93)90002-T; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031	45	72	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23626	23629		10.1074/jbc.271.39.23626	http://dx.doi.org/10.1074/jbc.271.39.23626			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798578	hybrid			2022-12-27	WOS:A1996VJ44200007
J	Yenush, L; Makati, KJ; SmithHall, J; Ishibashi, O; Myers, MG; White, MF				Yenush, L; Makati, KJ; SmithHall, J; Ishibashi, O; Myers, MG; White, MF			The pleckstrin homology domain is the principle link between insulin receptor and IRS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-DEPENDENT INTERACTION; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; NPEY MOTIF; SUBSTRATE-1; BINDING; SHC; PROTEINS; PATHWAYS	Interaction domains located in the NH2 terminus of IRS-1 mediate its recognition by the insulin receptor. Alignment of IRS-1 and IRS-S reveals two homology regions: the IH1(PH) contains a pleckstrin homology (PH) domain, and the IH2(PTB) contains a phosphotyrosine binding (PTB) domain. A third region in IRS-1 called SAIN was proposed to contain another functional PTB domain. Peptide competition experiments demonstrated that the IH2(PTB) in IRS-2, like the corresponding domain in IRS-1, binds directly to peptides containing NPXY motifs. In contrast, these peptides do not bind to IH1(PH) or the SAIN regions. In 32D cells the IH1(PH) was essential for insulin-stimulated tyrosine phosphorylation of IRS-1 and insulin-stimulated phosphatidylinositol 3-kinase activity and p70(s6k) phosphorylation. In contrast, the IH2(PTB) and the SAIN regions were not required for these insulin actions; however, the IH2(PTB) improved the coupling between IRS-1 and the insulin receptor. Overexpression of the insulin receptor in 32D(IR) cells increased IRS-1 tyrosine phosphorylation and mediated insulin-stimulated DNA synthesis. The sensitivity of these responses was partially reduced by deletion of either the IH1(PH) or the IH2(PTB) and significantly reduced when both regions were deleted together. Thus, the PH and PTB domains equally couple IRS-1 to high levels of insulin receptor normally expressed in most cells, whereas at low levels of insulin receptors the PTB domain is inefficient and the PH domain is essential for a productive interaction.	JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,PROGRAM BIOL & BIOMED SCI,BOSTON,MA 02215	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Yenush, Lynne/J-8815-2014	Yenush, Lynne/0000-0001-8589-7002	NIDDK NIH HHS [DK43808] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043808] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BRISCOE J, 1994, CURR BIOL, V4, P1033, DOI 10.1016/S0960-9822(00)00236-0; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHEN DI, 1995, MOL CELL BIOL, V15, P4711; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FEENER EP, 1993, J BIOL CHEM, V268, P11256; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; WANG LM, 1995, BLOOD, V86, P4218, DOI 10.1182/blood.V86.11.4218.bloodjournal86114218; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1991, METHOD ENZYMOL, V201, P65; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yenush L, 1996, MOL CELL BIOL, V16, P2509; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	41	136	137	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24300	24306		10.1074/jbc.271.39.24300	http://dx.doi.org/10.1074/jbc.271.39.24300			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798677	hybrid			2022-12-27	WOS:A1996VJ44200106
J	Adler, V; Pincus, MR; Polotskaya, A; Montano, X; Friedman, FK; Ronai, Z				Adler, V; Pincus, MR; Polotskaya, A; Montano, X; Friedman, FK; Ronai, Z			Activation of c-Jun-NH2-kinase by UV irradiation is dependent on p21(ras)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN KINASE; PROTEIN-KINASE; IONIZING-RADIATION; AP-1 ACTIVITY; CELLS; RAS; EXPRESSION; PHOSPHORYLATION; INDUCTION; PATHWAYS	We have demonstrated previously that Jun-NH2-kinase (JNK) activation in vitro is potentiated by association with the p21(ras) protein. To determine if in vivo activation of JNK also depends on p21(ras), we have used M1311 cells that carry the cDNA for the neutralizing antibody to p21(ras), Y13-259, under a dexamethasone-inducible promoter. The ability of UV to activate JNK gradually decreased over a 4-day period of cell growth in dexamethasone. This decrease coincides with weaker transcriptional activation measured via gel shift and chloramphenicol acetyltransferase assays. Peptides corresponding to amino acids 96-110 on p21(ras), which were shown to block Ras-JNK association, inhibited UV-mediated JNK activation in mouse fibroblast 3T3-4A cells as well as in M1311 cells, further supporting the role of p21(ras) in UV-mediated JNK activation. Overall, the present studies provide in vivo confirmation of the role p21(ras) plays in JNK activation by UV irradiation.	AMER HLTH FDN,MOL CARCINOGENESIS PROGRAM,VALHALLA,NY 10595; VET AFFAIRS MED CTR,DEPT PATHOL & LAB MED,BROOKLYN,NY 11209; SUNY HLTH SCI CTR,BROOKLYN,NY 11203; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; NCI,MOL CARCINOGENESIS LAB,NIH,BETHESDA,MD 20892	American Health Foundation; US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Cancer Research UK; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Friedman, Fred K/D-4208-2016; Friedman, Fred/O-6173-2019	Friedman, Fred/0000-0002-0284-7067; RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA51995, CA42500] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042500, R29CA051995, R01CA051995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; Adler V, 1996, CARCINOGENESIS, V17, P2073, DOI 10.1093/carcin/17.9.2073; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COFFER PJ, 1995, ONCOGENE, V11, P561; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DYKES DC, 1992, MED SCI RES, V20, P809; FUCHS SY, 1996, ONCOGENE, V13, P1529; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; LIBOI E, 1984, VIROLOGY, V135, P440, DOI 10.1016/0042-6822(84)90199-5; LIWO A, 1994, J PROTEIN CHEM, V13, P237, DOI 10.1007/BF01891982; LOLYED AC, 1989, EMBO J, V8, P1099; MCNEIL PL, 1984, J CELL BIOL, V98, P1556, DOI 10.1083/jcb.98.4.1556; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MONACO R, 1995, J PROTEIN CHEM, V14, P457, DOI 10.1007/BF01888140; Monaco R, 1995, J PROTEIN CHEM, V14, P721, DOI 10.1007/BF01886911; MONTANO X, 1995, CELL GROWTH DIFFER, V6, P597; MOODIE SA, 1993, SCIENCE, V260, P1588; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHAFMAN TD, 1995, CANCER RES, V55, P3242; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; YANG YM, 1993, CELL GROWTH DIFFER, V4, P595	30	76	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23304	23309		10.1074/jbc.271.38.23304	http://dx.doi.org/10.1074/jbc.271.38.23304			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798530	hybrid			2022-12-27	WOS:A1996VH76800056
J	Berger, SA; Rowan, K; Morrison, HD; Ziltener, HJ				Berger, SA; Rowan, K; Morrison, HD; Ziltener, HJ			Identification of a bacterial inhibitor of protein kinases - Mechanism and role in host cell invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI EPEC; SALMONELLA-TYPHIMURIUM; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; VIRULENCE DETERMINANT; ADENOSINE RELEASE; MAMMALIAN-CELLS; HEP-2 CELLS; MUTANTS	We show that Escherichia coli produce a factor that inhibits the activity of tyrosine and serine/threonine protein kinases. The factor is a protein found in the periplasmic compartment and is also secreted into the culture medium. Using a particle concentration fluorescence immunoassay specific for tyrosine kinase activity and inhibition of the tyrosine kinase p56(lck), we purified this factor to apparent homogeneity. Analysis of trypsin-digested fragments by mass spectrometry identified the inhibitor as the bacterial periplasmic protein UDP-sugar hydrolase, an enzyme with potent and nonspecific 5'-nucleotidase activity. Overexpression of the enzyme in bacteria leads to coordinate increases in both 5'-nucleotidase and p56(lck) inhibitory activity, confirming the identity of the inhibitor. The kinase inhibitory activity appears to be due to the formation of adenosine, which we show is inhibitory for p56(lck), cAMP-dependent protein kinase, and casein kinase. Overexpression of UDP-sugar hydrolase leads to an increase in the recovery of enteropathogenic E. coli following infection of HeLa cell monolayers and corresponding alterations in tyrosine-phosphorylated host proteins. These results suggest that UDP-sugar hydrolase may be an important factor affecting host cell function following intracellular bacterial infection.	UNIV TORONTO, DEPT IMMUNOL, TORONTO, ON M5S 1X8, CANADA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER, BC V6T 123, CANADA; UNIV BRITISH COLUMBIA, DEPT PATHOL & LAB MED, VANCOUVER, BC V6T 123, CANADA	University of Toronto; University of British Columbia; University of British Columbia	Berger, SA (corresponding author), WELLESLEY HOSP, RES INST, 160 WELLESLEY ST, TORONTO, ON M4Y 1J3, CANADA.							BABCOOK J, 1991, ANAL BIOCHEM, V196, P245, DOI 10.1016/0003-2697(91)90461-2; BETTS J, 1992, CAN J MICROBIOL, V38, P852, DOI 10.1139/m92-138; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; BLISKA JB, 1993, TRENDS GENET, V9, P85, DOI 10.1016/0168-9525(93)90229-B; BURNS DM, 1986, NUCLEIC ACIDS RES, V14, P4325, DOI 10.1093/nar/14.10.4325; CRONSTEIN BN, 1993, J CLIN INVEST, V92, P2675, DOI 10.1172/JCI116884; CRONSTEIN BN, 1991, P NATL ACAD SCI USA, V88, P2441, DOI 10.1073/pnas.88.6.2441; CRONSTEIN BN, 1990, J CLIN INVEST, V85, P1150, DOI 10.1172/JCI114547; DONNENBERG MS, 1990, INFECT IMMUN, V58, P1565, DOI 10.1128/IAI.58.6.1565-1571.1990; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; Finlay BB, 1990, CURR OPIN CELL BIOL, V2, P815, DOI 10.1016/0955-0674(90)90078-S; FINLAY BB, 1989, MICROBIOL REV, V53, P210, DOI 10.1128/MMBR.53.2.210-230.1989; FIRESTEIN GS, 1995, J IMMUNOL, V154, P326; FOUBISTER V, 1994, J EXP MED, V179, P993, DOI 10.1084/jem.179.3.993; GALAN JE, 1992, NATURE, V357, P588, DOI 10.1038/357588a0; GLASER L, 1967, J BIOL CHEM, V242, P1944; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; Gunther G R, 1991, Ann Vasc Surg, V5, P325, DOI 10.1007/BF02015292; HESS D, 1993, PROTEIN SCI, V2, P1342, DOI 10.1002/pro.5560020817; HIRSCHHORN R, 1990, Immunodeficiency Reviews, V2, P175; HSIA RC, 1993, J BACTERIOL, V175, P4817, DOI 10.1128/JB.175.15.4817-4823.1993; KELLY SM, 1992, INFECT IMMUN, V60, P4881, DOI 10.1128/IAI.60.11.4881-4890.1992; KITAKAZE M, 1993, CARDIOVASC RES, V27, P18, DOI 10.1093/cvr/27.1.18; LEE CA, 1990, P NATL ACAD SCI USA, V87, P4304, DOI 10.1073/pnas.87.11.4304; LEUNG KY, 1991, P NATL ACAD SCI USA, V88, P11470, DOI 10.1073/pnas.88.24.11470; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; NEU HC, 1967, J BIOL CHEM, V242, P3896; NNALUE NA, 1990, J MED MICROBIOL, V31, P225, DOI 10.1099/00222615-31-4-225; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; ROSENSHINE I, 1992, EMBO J, V11, P3551, DOI 10.1002/j.1460-2075.1992.tb05438.x; ROSENSHINE I, 1992, INFECT IMMUN, V60, P2211, DOI 10.1128/IAI.60.6.2211-2217.1992; RUSCHKOWSKI S, 1992, FEMS MICROBIOL LETT, V95, P121; SAITO S, 1994, INFECT IMMUN, V62, P1551, DOI 10.1128/IAI.62.5.1551-1556.1994; SCHWAN WR, 1994, P NATL ACAD SCI USA, V91, P6428, DOI 10.1073/pnas.91.14.6428; SMAIL EH, 1992, J IMMUNOL, V148, P3588; WATTS JD, 1992, J BIOL CHEM, V267, P901; WICK MJ, 1991, CELL, V67, P651; YAMAMOTO K, 1990, J BIOL CHEM, V265, P22086	39	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23431	23437		10.1074/jbc.271.38.23431	http://dx.doi.org/10.1074/jbc.271.38.23431			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798549	hybrid			2022-12-27	WOS:A1996VH76800075
J	Grindstaff, KK; Bianco, G; Mercer, RW				Grindstaff, KK; Bianco, G; Mercer, RW			Translational regulation of Na,K-ATPase alpha 1 and beta 1 polypeptide expression in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT MESSENGER-RNAS; TISSUE-SPECIFIC EXPRESSION; 3' UNTRANSLATED REGION; AMINO-ACID-SEQUENCE; NA-K-ATPASE; VACCINIA VIRUS; SARCOPLASMIC-RETICULUM; CELLULAR-DISTRIBUTION; MOLECULAR-CLONING; TRANSPORT ATPASES	To investigate the regulation of the Na,K-ATPase, we have studied the expression of the Na,K-ATPase polypeptides in several mammalian cell lines using the vaccinia virus/T7 RNA polymerase expression system, Infection of several fibroblast-like cell lines with viral recombinants containing the Na,K-ATPase alpha and beta isoforms, the glucose transporters, GLUT 1 and GLUT 4, or the capsid protein of the Sindbis virus all result in the production of the appropriate protein products, However, all epithelial cell lines tested fail to synthesize the Na,K-ATPase viral recombinants, yet they efficiently express the other virally directed polypeptides. While Madin-Darby canine kidney (MDCK) epithelial cells infected with the Na,K-ATPase alpha 1 or beta 1 recombinant viruses produce both mRNAs, the messages are inefficiently translated. Furthermore, the RNA from infected MDCK cells does not direct the in vitro synthesis of the beta 1 polypeptide, whereas the message from infected fibroblast-like BSC 40 cells is efficiently translated both in vivo and in vitro, Moreover, the synthesis of the H,K-ATPase alpha subunit is also limited in MDCK cells, although the H,K-ATPase beta subunit is efficiently expressed, Expression of chimeras constructed between the Na+ pump beta 1 isoform and the H,K-ATPase beta subunit indicates that sequences in the 5' coding region of the beta 1 message have an inhibitory effect; however, the stringent translational regulation of the beta 1 isoform in MDCK cells requires the 5' and 3' regions of the coding sequence, The ability of the polarized cell lines to limit the synthesis of the Na+ pump polypeptides while expressing other vaccinia recombinants at high levels suggests that the polarized cells possess a stringent mechanism for the specific translational regulation of a select set of messages.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Mercer, Robert/F-5918-2012		NIGMS NIH HHS [GM 39746] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039746, R29GM039746] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOSTROM K, 1990, J BIOL CHEM, V265, P22446; BOWEN JW, 1987, AM J PHYSIOL, V252, pC179, DOI 10.1152/ajpcell.1987.252.2.C179; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; CAPLAN MJ, 1986, CELL, V46, P623, DOI 10.1016/0092-8674(86)90888-3; CHEN XL, 1993, J BIOL CHEM, V268, P21007; DETOMASO AW, 1991, SODIUM PUMP RECENT D, V46, P69; DEVARAJAN P, 1992, J BIOL CHEM, V267, P22435; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GALLOWAY CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3334, DOI 10.1073/pnas.80.11.3334; GHOSH S, 1990, J BIOL CHEM, V265, P2935; GICK GG, 1988, J BIOL CHEM, V263, P16610; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GOOD PJ, 1990, P NATL ACAD SCI USA, V87, P9088, DOI 10.1073/pnas.87.23.9088; Grindstaff KK, 1995, EPITHELIAL CELL BIOL, V4, P17; GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HENSLEY CB, 1992, AM J PHYSIOL, V262, pC484, DOI 10.1152/ajpcell.1992.262.2.C484; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; HSU YM, 1991, J BIOL CHEM, V266, P427; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LYTTON J, 1985, J BIOL CHEM, V260, P1177; LYTTON J, 1985, J BIOL CHEM, V260, P75; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MCGILL DL, 1991, J BIOL CHEM, V266, P15824; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; MERION M, 1983, P NATL ACAD SCI-BIOL, V80, P5315, DOI 10.1073/pnas.80.17.5315; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; POLLACK LR, 1981, AM J PHYSIOL, V241, pC173, DOI 10.1152/ajpcell.1981.241.5.C173; RODRIGUEZ D, 1991, J VIROL, V65, P494, DOI 10.1128/JVI.65.1.494-498.1991; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHNEIDER JW, 1988, P NATL ACAD SCI USA, V85, P284, DOI 10.1073/pnas.85.1.284; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TAKEYASU K, 1989, CURR TOP MEMBR TRANS, V34, P143; WATSON AJ, 1990, DEV GENET, V11, P41, DOI 10.1002/dvg.1020110106; WATSON AJ, 1988, DEV BIOL, V126, P80, DOI 10.1016/0012-1606(88)90241-2; XIE ZJ, 1989, ANAL BIOCHEM, V183, P215, DOI 10.1016/0003-2697(89)90470-3	58	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23211	23221		10.1074/jbc.271.38.23211	http://dx.doi.org/10.1074/jbc.271.38.23211			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798517	hybrid			2022-12-27	WOS:A1996VH76800043
J	Wajcman, H; Kister, J; Galacteros, F; Spielvogel, A; Lin, MJ; Vidugiris, GJA; Hirsch, RE; Friedman, JM; Nagel, RL				Wajcman, H; Kister, J; Galacteros, F; Spielvogel, A; Lin, MJ; Vidugiris, GJA; Hirsch, RE; Friedman, JM; Nagel, RL			Hb Montefiore (alpha 126(H9)Asp->Tyr) - High oxygen affinity and loss of cooperativity secondary to C-terminal disruption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; HYBRID HEMOGLOBINS; REACTIVITY; DYNAMICS	Hb Montefiore was found, in the heterozygous state, in a Puerto Rican female who had a slightly elevated total Hb level, Structural analysis revealed that Asp-alpha 126 was replaced by Tyr, Hb Montefiore migrates close to HbF (at pH 8.6) and accounts for 20.3% of the hemolysate. Oxygen binding of red blood cells revealed a 40% decrease in the P-50 (pH 7.4) and a low n value of 1.6 (normal: 2.6), Depletion of red blood cell 2,3-DPG did not change the results, Stripped Hb Montefiore at pH 7.2 showed an 8-fold reduction in P-50 (0.6 versus 4.6 mm Hg) and very low cooperativity (n = 1.2 versus 2.9 for the control), Heterotopic effecters, as 2,3-diphosphoglycerate and inositol hexaphosphate had a normal effect and in addition, they increased cooperativity, The chloride ion effect and the Bohr effect were moderately reduced, A bezafibrate derivative (L345), known to bind alpha 126, increases the P-50 of HbA by 9-fold, but only by 1.5-fold that of Hb Montefiore. Combining these functional studies with intrinsic fluorescence and Resonance Raman spectroscopy, we interpret the very low n value and the high oxygen affinity for Hb Montefiore as a result of both a destabilized T state that switches to R upon ligand binding and a deoxy T state that binds ligands with higher affinity than that of deoxy HbA. Hb Montefiore still binds ligands cooperatively, but the difference in ligand binding properties of the two quaternary states has been drastically reduced.	HOP HENRI MONDOR, INSERM, U91, F-94010 CRETEIL, FRANCE; HOP BICETRE, INSERM, U299, F-94275 PARIS, FRANCE; ALBERT EINSTEIN COLL MED, MONTEFIORE MED CTR, DEPT MED, DIV HEMATOL, BRONX, NY 10461 USA; ALBERT EINSTEIN COLL MED, MONTEFIORE MED CTR, DEPT ANAT & STRUCT BIOL, BRONX, NY 10461 USA; ALBERT EINSTEIN COLL MED, MONTEFIORE MED CTR, DEPT PHYSIOL & BIOPHYS, BRONX, NY 10461 USA	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL051084, P60HL038655] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01(HL51084), HL-38655] Funding Source: Medline; NIGMS NIH HHS [GM-44343] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGADE PV, 1984, J AM CHEM SOC, V106, P6593, DOI 10.1021/ja00334a024; BALWIN JM, 1976, BR MED B, V32, P213; EISINGER J, 1969, BIOCHEMISTRY-US, V8, P3902, DOI 10.1021/bi00838a004; FINDSEN EW, 1985, SCIENCE, V229, P661, DOI 10.1126/science.4023704; FRIEDMAN JM, 1982, BIOCHEMISTRY-US, V21, P2022, DOI 10.1021/bi00538a008; FRIEDMAN JM, 1994, METHOD ENZYMOL, V232, P205; FRIEDMAN JM, 1982, SCIENCE, V218, P1244, DOI 10.1126/science.7146910; FRIEDMAN JM, 1985, SCIENCE, V228, P1273, DOI 10.1126/science.4001941; FUJII M, 1993, J BIOL CHEM, V268, P15386; HIRSCH RE, 1994, METHOD ENZYMOL, V232, P231; JAYARAMAN V, 1995, SCIENCE, V269, P1843, DOI 10.1126/science.7569921; KISTER J, 1987, J BIOL CHEM, V262, P12085; LACOMBE C, 1987, ACTA HAEMATOL-BASEL, V78, P119, DOI 10.1159/000205858; LALEZARI I, 1990, BIOCHEMISTRY-US, V29, P1515, DOI 10.1021/bi00458a024; MATSUKAWA S, 1985, J AM CHEM SOC, V107, P1108, DOI 10.1021/ja00291a004; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAGAI K, 1980, P NATL ACAD SCI-BIOL, V77, P2033, DOI 10.1073/pnas.77.4.2033; ONDRIAS MR, 1982, J BIOL CHEM, V257, P8766; PERUTZ MF, 1994, J MOL BIOL, V239, P555, DOI 10.1006/jmbi.1994.1394; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PULSINELLI PD, 1973, J MOL BIOL, V74, P57, DOI 10.1016/0022-2836(73)90354-9; RADOLA BJ, 1973, ANN NY ACAD SCI, V209, P127, DOI 10.1111/j.1749-6632.1973.tb47523.x; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; SCHNEIDER RG, 1986, CRC HDB SERIES, V4, P125; SCHROEDER WA, 1980, CLIN BIOCH ANAL, V9; SCOTT TW, 1984, J AM CHEM SOC, V106, P5677, DOI 10.1021/ja00331a044; STAVROV SS, 1993, BIOPHYS J, V65, P1942, DOI 10.1016/S0006-3495(93)81265-7; WAJCMAN H, 1993, ANN BIOL CLIN-PARIS, V51, P867	28	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22990	22998		10.1074/jbc.271.38.22990	http://dx.doi.org/10.1074/jbc.271.38.22990			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798486	hybrid			2022-12-27	WOS:A1996VH76800012
J	Debinski, W; Miner, R; Leland, P; Obiri, NI; Puri, RK				Debinski, W; Miner, R; Leland, P; Obiri, NI; Puri, RK			Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS EXOTOXIN-A; SIGNAL-TRANSDUCTION; PROTEIN; AERUGINOSA; TOXIN; IMMUNOTOXIN; EXPRESSION; COMPONENT; THERAPY; MICE	Recently, we have demonstrated that human (h) glioma cell Lines express large number of receptors (R) for interleukin 13 (IL13) (Debinski, W., Obiri, N. I., Powers, S. K., Pastan, L., and Purl, R. K. (1995) Clin. Cancer Res. 1, 1253-1258). These cells are extremely sensitive to a chimeric protein composed of hIL13 and a derivative of Pseudomonas exotoxin (PE), PE38QQR. We have found that the cytotoxicity of hIL13-PE38QQR was blocked by hIL13 but not by hIL4 on the U-251 MG and U-373 MG cells, contrary to what was observed on several adenocarcinoma cell lines. In the present study, we further explored interactions between receptor for IL13 and IL4 on glioma cells. Established human glioma cell lines, such as DBTRG MG, Hs 683, U-87 MG, SNB-19, and A-172, are very susceptible to hIL13-PE38QQR, and the action of the chimeric toxin is not blocked by hIL4 on all these cells either. Also, hIL4 is not a competitor for I-125-hIL13 binding sites on glioma cells. Of interest, a corresponding hIL4-based chimeric toxin, hIL4-PE38QQR, is poorly active or not active on all the tested glioma cell lines. When active, however, hIL4 toxin action was blocked by hIL13. hIL13 is a competitor for I-125-hIL14 binding in a competitive binding assay on glioma cells. hIL13 and hIL4 did not affect the growth of the tested glioma cell lines. Human glioblastoma multiforme explant cells exhibited similar responses to the chimeric toxins and interleukins when compared with that found in established glioma cultures. Our results suggest that the hIL13R on glioma cells is expressed in one predominant form, the form that does not interact with IL4. Thus, this type of hIL13R is apparently different from the one demonstrated previously on several adenocarcinoma cell lines.	US FDA,LAB MOL TUMOR BIOL,DIV CELLULAR & GENE THERAPIES,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892	US Food & Drug Administration (FDA)	Debinski, W (corresponding author), PENN STATE UNIV,MILTON S HERSHEY MED CTR,DEPT SURG,DIV NEUROSURG,500 UNIV DR,HERSHEY,PA 17033, USA.							ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; DEBINSKI W, 1993, J BIOL CHEM, V268, P14065; DEBINSKI W, 1992, J CLIN INVEST, V90, P405, DOI 10.1172/JCI115875; Debinski W, 1995, CLIN CANCER RES, V1, P1253; DEBINSKI W, 1994, INT J CANCER, V58, P744, DOI 10.1002/ijc.2910580520; DEBINSKI W, 1994, BIOCONJUGATE CHEM, V5, P40, DOI 10.1021/bc00025a006; DEBRINSKI W, 1995, J BIOL CHEM, V270, P16775; Frankel AE, 1996, CANCER RES, V56, P926; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; HARADA N, 1992, J BIOL CHEM, V267, P22752; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; INOCENCIO NM, 1994, J BIOL CHEM, V269, P31831; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; OBIRI NI, 1996, IN PRESS CLIN CANC R; OGATA M, 1990, J BIOL CHEM, V265, P20678; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; PHILLIPS PC, 1994, CANCER RES, V54, P1008; PURI RK, 1993, CANCER INVEST, V11, P473, DOI 10.3109/07357909309018879; Puri RK, 1996, BLOOD, V87, P4333, DOI 10.1182/blood.V87.10.4333.bloodjournal87104333; PURI RK, 1994, INT J CANCER, V58, P574, DOI 10.1002/ijc.2910580421; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TONY HP, 1994, EUR J BIOCHEM, V225, P659, DOI 10.1111/j.1432-1033.1994.00659.x; VITA N, 1995, J BIOL CHEM, V270, P3512, DOI 10.1074/jbc.270.8.3512; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	28	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22428	22433		10.1074/jbc.271.37.22428	http://dx.doi.org/10.1074/jbc.271.37.22428			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798406	hybrid			2022-12-27	WOS:A1996VG67200025
J	Hou, XH; Dietrich, J; Odum, N; Geisler, C				Hou, XH; Dietrich, J; Odum, N; Geisler, C			The cytoplasmic tail of Fc gamma RIIIA alpha is involved in signaling by the low affinity receptor for immunoglobulin G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; NATURAL-KILLER-CELLS; PROTEIN-TYROSINE KINASE; EPSILON-RI-GAMMA; T-CELL; ZETA-CHAIN; PHOSPHATASE CD45; CD3-GAMMA CHAIN; MAST-CELLS; IGG FC	The low affinity receptor for IgG, Fc gamma RIIIA, is a multimeric receptor composed of the ligand binding subunit Fc gamma RIIIA alpha (CD16) in association with the signal-transducing subunits zeta or gamma. Previous studies suggested that the cytoplasmic tail of Fc gamma RIIIA alpha was not required for Fc gamma RIIIA alpha-zeta association or signaling by Fc gamma RIIIA. However, in these studies,the truncated Fc gamma RIIIA alpha chains still expressed the four most membrane-proximal amino acids of the cytoplasmic tail (amino acids 230-233). By successive truncations from the C terminus of Fc gamma RIIIA alpha, we have studied the role played by the membrane-proximal amino acids of the cytoplasmic tail of Fc gamma RIIIA alpha in (i) Fc gamma RIIIA expression, (ii) Fc gamma RIIIA alpha-zeta association, and (iii) signal transduction. We provide evidence that this region is not required for Fc gamma RIIIA expression or Fc gamma RIIIA alpha-zeta association. However, signaling by Fc gamma RIIIA is strictly dependent on the membrane-proximal amino acids in the cytoplasmic tail of Fc gamma RIIIA alpha. Thus, total deletion of the cytoplasmic tail of Fc gamma RIIIA alpha results in a severely impaired tyrosine phosphorylation of phospholipase C-gamma 1, zap, and syk and rise in intracellular free Ca2+ following receptor ligation with specific anti-CD16 monoclonal antibody or Ig-anti-Ig complexes, suggesting that Fc gamma RIIIA alpha-zeta association per se is not sufficient to establish the signal function of Fc gamma RIIIA. In conclusion, the present findings demonstrate that the most membrane-proximal amino acids of the Fc gamma RIIIA alpha cytoplasmic tail play a critical role in ligand-induced signal transduction by the Fc gamma RIIIA alpha-zeta complex.	UNIV COPENHAGEN,PANUM INST,INST MED MICROBIOL & IMMUNOL,DK-2200 COPENHAGEN,DENMARK; NIAID,MOL STRUCT LAB,NIH,ROCKVILLE,MD 20892	University of Copenhagen; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Geisler, Carsten/A-7056-2012	Geisler, Carsten/0000-0002-8472-0771				ALTIN JG, 1994, IMMUNOL CELL BIOL, V72, P87, DOI 10.1038/icb.1994.13; ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BONNEROT C, 1992, EMBO J, V11, P2747, DOI 10.1002/j.1460-2075.1992.tb05340.x; CASSATELLA MA, 1989, J EXP MED, V169, P549, DOI 10.1084/jem.169.2.549; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHOQUET D, 1994, J BIOL CHEM, V269, P6491; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; DAERON M, 1994, J IMMUNOL, V152, P783; Dietrich J, 1996, J CELL BIOL, V132, P299, DOI 10.1083/jcb.132.3.299; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; GEISLER C, 1992, J IMMUNOL, V148, P2437; GEISLER C, 1988, SCAND J IMMUNOL, V27, P685, DOI 10.1111/j.1365-3083.1988.tb02402.x; GEISLER C, 1992, J IMMUNOL, V148, P3469; HAHN WC, 1993, GENE, V127, P267, DOI 10.1016/0378-1119(93)90731-H; HOU XH, 1994, EUR J IMMUNOL, V24, P1228, DOI 10.1002/eji.1830240534; HOWARD FD, 1990, P NATL ACAD SCI USA, V87, P7015, DOI 10.1073/pnas.87.18.7015; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JUSTEMENT LB, 1994, IMMUNOL TODAY, V15, P399, DOI 10.1016/0167-5699(94)90268-2; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KOYASU S, 1992, J EXP MED, V175, P203, DOI 10.1084/jem.175.1.203; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; LANIER LL, 1991, J IMMUNOL, V146, P1571; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; PLEIMAN CM, 1994, J IMMUNOL, V152, P2837; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SCALLON BJ, 1989, P NATL ACAD SCI USA, V86, P5079, DOI 10.1073/pnas.86.13.5079; STAHLS A, 1994, EUR J IMMUNOL, V24, P2491, DOI 10.1002/eji.1830241035; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; TING AT, 1992, J EXP MED, V176, P1751, DOI 10.1084/jem.176.6.1751; VANOERS NSC, 1993, MOL CELL BIOL, V13, P5771, DOI 10.1128/MCB.13.9.5771; VIVIER E, 1993, EUR J IMMUNOL, V23, P1872, DOI 10.1002/eji.1830230821; VIVIER E, 1991, J IMMUNOL, V147, P4263; WEGENER AMK, 1995, J BIOL CHEM, V270, P4675, DOI 10.1074/jbc.270.9.4675; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISSMAN AM, 1989, EMBO J, V8, P3651, DOI 10.1002/j.1460-2075.1989.tb08539.x; WIRTHMUELLER U, 1992, J EXP MED, V175, P1381, DOI 10.1084/jem.175.5.1381	51	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22815	22822		10.1074/jbc.271.37.22815	http://dx.doi.org/10.1074/jbc.271.37.22815			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798459	hybrid			2022-12-27	WOS:A1996VG67200078
J	Klockner, U; Mikala, G; Schwartz, A; Varadi, G				Klockner, U; Mikala, G; Schwartz, A; Varadi, G			Molecular studies of the asymmetric pore structure of the human cardiac voltage-dependent Ca2+ channel - Conserved residue, GLU-1086, regulates proton-dependent ion permeation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CURRENT FLUCTUATIONS; CALCIUM CHANNELS; MUSCLE-CELLS; SELECTIVITY; DETERMINANTS; ALPHA-1-SUBUNIT; CONDUCTANCE; EXPRESSION; BINDING; SITES	Proton transfer to calcium channels results in rapid fluctuations between two non-zero conductance levels when the current is carried by monovalent cations. A combination of site-directed mutagenesis and single-channel recording techniques were used to identify the unique proton acceptor site as Glu-1086, a conserved glutamate residue located in the S5-S6 linker of motif III of calcium channels. Glu-1086 is part of an array of four glutamate residues in the pore-lining region of the channel conferring the high selectivity of calcium channels. Titration of Glu-1086 yielded a pK(alpha) value of 7.91 which is different from that expected for a free glutamic acid side-chain carboxyl. Proposed electrostatic interactions between charged nearby residues can account only in part for this phenomenon since individual elimination of the other three glutamate residues only slightly decreased the pK(alpha) of Glu-1086. These data, in addition to identifying the proton acceptor site, provide evidence for the influence of the microenvironment in forming the asymmetry of the conducting pathway of calcium channels.	UNIV CINCINNATI,COLL MED,INST MOL PHARMACOL & BIOPHYS,CINCINNATI,OH 45267; UNIV COLOGNE,DEPT PHYSIOL,D-50931 COLOGNE,GERMANY	University of Cincinnati; University of Cologne					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL043231, P01HL022619] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22619-17, HL43231-07] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASH H, 1992, CHEM ACID DERIV 1 SB, V2, P1; Chen X.-H., 1996, Biophysical Journal, V70, pA78; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 1992, IONIC CHANNELS EXCIT; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; KLOCKNER U, 1994, J GEN PHYSIOL, V103, P665, DOI 10.1085/jgp.103.4.665; KLOCKNER U, 1995, J BIOL CHEM, V270, P17306, DOI 10.1074/jbc.270.29.17306; KUO CC, 1993, J PHYSIOL-LONDON, V466, P657; MATTHEW JB, 1985, ANNU REV BIOPHYS BIO, V14, P387; MIKALA G, 1993, FEBS LETT, V335, P265, DOI 10.1016/0014-5793(93)80743-E; PETERSON BZ, 1995, J BIOL CHEM, V270, P18201, DOI 10.1074/jbc.270.31.18201; PIETROBON D, 1989, J GEN PHYSIOL, V94, P1, DOI 10.1085/jgp.94.1.1; PIETROBON D, 1988, NATURE, V333, P373, DOI 10.1038/333373a0; PRODHOM B, 1989, J GEN PHYSIOL, V94, P23, DOI 10.1085/jgp.94.1.23; PRODHOM B, 1987, NATURE, V329, P243, DOI 10.1038/329243a0; ROOT MJ, 1994, SCIENCE, V265, P1852, DOI 10.1126/science.7522344; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; TANG SQ, 1993, J BIOL CHEM, V268, P13026; URRY DW, 1992, J AM CHEM SOC, V114, P8717; VARADI G, 1995, TRENDS PHARMACOL SCI, V16, P43, DOI 10.1016/S0165-6147(00)88977-4; WENDTGALLITELLI MF, 1989, AM J PHYSIOL, V256, pH574, DOI 10.1152/ajpheart.1989.256.2.H574; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; YATANI A, 1994, CIRC RES, V75, P315, DOI 10.1161/01.RES.75.2.315; ZALEWSKI RI, 1992, CHEM FUNCTIONAL G SB, V2, P305	27	27	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22293	22296						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798385				2022-12-27	WOS:A1996VG67200004
J	Laflamme, L; deGasparo, M; Gallo, JM; Payet, MD; GalloPayet, N				Laflamme, L; deGasparo, M; Gallo, JM; Payet, MD; GalloPayet, N			Angiotensin II induction of neurite outgrowth by AT(2) receptors in NG108-15, cells - Effect counteracted by the AT(1) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; RAT PHEOCHROMOCYTOMA CELLS; GLIOMA HYBRID-CELLS; NERVE GROWTH-FACTOR; PHOSPHATASE INHIBITION; TYPE-2 RECEPTOR; PC12 CELLS; BRAIN; SUBTYPES; TAU	In the present study, 3-day treatment of nondifferentiated NG108-15 cells with 100 nM angiotensin II (Ang II) induces morphological differentiation of neuronal cells characterized by the outgrowth of neurites. These mor morphological changes are correlated with an increase in the level of polymerized tubulin and in the level of the microtubule-associated protein, MAP2c. Mediation by the AT(2) receptor may be inferred since: (a) these cells contain only AT(2) receptors; (b) the effects are mimicked by CGP 42112 (an AT(2) receptor agonist); (c) they are not suppressed by the addition of DUP 753 (an AT(1) receptor antagonist); and (d) are abolished by co-incubation with PD 123319 (an AT(2) receptor antagonist). Application of Ang II in dibutyryl cAMP-differentiated cells (which contain both types of receptors) induces neurite retraction, an effect mediated by the AT(1) receptor. These results indicate that the AT(2) receptor of Ang II induces neuronal differentiation, which is initiated through an increase in the levels of MAP2c associated with tubulin. Moreover, our results demonstrate that the AT(1) receptor inhibit the process of differentiation induced by dibutyryl cAMP, whereas the AT(2) receptors potentiate this effect, illustrating negative cross-talk interaction between the two types of Ang II receptors.	UNIV SHERBROOKE, FAC MED, SERV ENDOCRINOL, SHERBROOKE, PQ J1H 5N4, CANADA; UNIV SHERBROOKE, FAC MED, DEPT PHYSIOL & BIOPHYS, SHERBROOKE, PQ J1H 5N4, CANADA; CIBA GEIGY LTD, DIV PHARMACEUT, DEPT CARDIOVASC RES, BASEL, SWITZERLAND; INST PSYCHIAT, DEPT NEUROL, LONDON SE5 8AF, ENGLAND; UNIV LONDON KINGS COLL, SCH MED & DENT, LONDON SE5 8AF, ENGLAND	University of Sherbrooke; University of Sherbrooke; Novartis; University of London; King's College London; University of London; King's College London				Gallo, Jean-Marc/0000-0003-0214-4545				BARNES JM, 1993, EUR J PHARMACOL, V230, P251, DOI 10.1016/0014-2999(93)90558-Y; BEAMANHALL CM, 1993, J NEUROBIOL, V24, P1500, DOI 10.1002/neu.480241105; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BOTTARI SP, 1993, FRONT NEUROENDOCRIN, V14, P123, DOI 10.1006/frne.1993.1005; BRECHLER V, 1994, RECEPTOR CHANNEL, V2, P89; BUISSON B, 1992, FEBS LETT, V309, P161, DOI 10.1016/0014-5793(92)81086-2; BUISSON B, 1995, J BIOL CHEM, V270, P1670, DOI 10.1074/jbc.270.4.1670; CACERES A, 1992, NEURON, V9, P607, DOI 10.1016/0896-6273(92)90025-9; CACERES A, 1990, NATURE, V343, P461, DOI 10.1038/343461a0; CARRITHERS MD, 1992, NEUROSCI LETT, V135, P45, DOI 10.1016/0304-3940(92)90132-Q; CHIOU JY, 1992, J NEUROCHEM, V59, P1963, DOI 10.1111/j.1471-4159.1992.tb11034.x; DEGASPARO M, 1995, REGUL PEPTIDES, V59, P303, DOI 10.1016/0167-0115(95)00085-P; DOLL T, 1993, J CELL SCI, V106, P633; FERREIRA A, 1991, J NEUROSCI, V11, P392; GEHLERT DR, 1991, NEUROSCIENCE, V44, P501, DOI 10.1016/0306-4522(91)90073-W; GROVE KL, 1993, BIOCHEM PHARMACOL, V46, P1653, DOI 10.1016/0006-2952(93)90335-T; GUILLON G, 1988, BIOCHEM J, V253, P765, DOI 10.1042/bj2530765; HAMPRECHT B, 1985, METHOD ENZYMOL, V109, P316; Hamprecht B, 1977, Int Rev Cytol, V49, P99; HAYASHIDA W, 1995, CIRCULATION, V92, P826; HEEMSKERK FMJ, 1993, NEUROREPORT, V4, P103, DOI 10.1097/00001756-199301000-00027; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KANG J, 1994, AM J PHYSIOL-CELL PH, V267, pC1389, DOI 10.1152/ajpcell.1994.267.5.C1389; KATER SB, 1991, J NEUROSCI, V11, P891; LAFLAMME L, 1994, ANN ENDOCRINOL, V55, P6; LANKFORD KL, 1988, P NATL ACAD SCI USA, V85, P4567, DOI 10.1073/pnas.85.12.4567-a; LEUNG KH, 1992, EUR J PHARM-MOLEC PH, V227, P63, DOI 10.1016/0922-4106(92)90143-J; MARRERO MB, 1995, CARDIOVASC RES, V30, P530, DOI 10.1016/0008-6363(95)00094-1; MATUS A, 1981, P NATL ACAD SCI-BIOL, V78, P3010, DOI 10.1073/pnas.78.5.3010; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; MILLAN MA, 1991, P NATL ACAD SCI USA, V88, P11440, DOI 10.1073/pnas.88.24.11440; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; NAKAJIMA M, 1995, P NATL ACAD SCI USA, V92, P10663, DOI 10.1073/pnas.92.23.10663; OBERMULLER N, 1991, NEUROSCI LETT, V132, P11, DOI 10.1016/0304-3940(91)90420-X; SHEA TB, 1992, J NEUROSCI RES, V32, P363, DOI 10.1002/jnr.490320308; SOLOMON F, 1986, METHOD ENZYMOL, V134, P139; SPETH R C, 1989, Peptide Research, V2, P232; SPITZER NC, 1991, J NEUROBIOL, V22, P659, DOI 10.1002/neu.480220702; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; SWARZENSKI BC, 1994, P NATL ACAD SCI USA, V91, P649, DOI 10.1073/pnas.91.2.649; TAKAHASI K, 1994, BIOCHEM BIOPH RES CO, V198, P60, DOI 10.1006/bbrc.1994.1009; TALLANT EA, 1991, HYPERTENSION, V17, P1135, DOI 10.1161/01.HYP.17.6.1135; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TSUSUMI K, 1991, ENDOCRINOLOGY, V129, P1075; TSUTSUMI K, 1992, MOL PHARMACOL, V41, P290; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; ULLIAN ME, 1989, J CLIN INVEST, V84, P840, DOI 10.1172/JCI114244; WEBB ML, 1992, PEPTIDES, V13, P499, DOI 10.1016/0196-9781(92)90081-D; WEISSHAAR B, 1992, DEVELOPMENT, V116, P1151; WU YY, 1993, J CELL BIOL, V121, P409, DOI 10.1083/jcb.121.2.409; XIONG H, 1994, NEUROSCIENCE, V62, P163, DOI 10.1016/0306-4522(94)90322-0; YAMAMOTO H, 1988, J NEUROCHEM, V50, P1614, DOI 10.1111/j.1471-4159.1988.tb03051.x; YAMAMOTO H, 1985, J NEUROCHEM, V44, P759, DOI 10.1111/j.1471-4159.1985.tb12880.x	54	166	167	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22729	22735		10.1074/jbc.271.37.22729	http://dx.doi.org/10.1074/jbc.271.37.22729			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798447	hybrid			2022-12-27	WOS:A1996VG67200066
J	McConkey, DJ				McConkey, DJ			Calcium-dependent, interleukin 1 beta-converting enzyme inhibitor-insensitive degradation of lamin B-1 and DNA fragmentation in isolated thymocyte nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; FAS-MEDIATED APOPTOSIS; INTERLEUKIN-1-BETA-CONVERTING ENZYME; ENDONUCLEASE ACTIVATION; CHROMATIN CONDENSATION; MULTIPLE PROTEASES; ICE/CED-3 PROTEASE; SERINE PROTEASE; LIVER NUCLEI; INDUCTION	Recent work suggests that the proteolytic degradation of the nuclear lamins is a common event in apoptosis, although the nature of the proteases involved is still not clear, Our previous work showed that the degradation of lamin B-1 in glucocorticoid-treated thymocytes occurs via a Ca2+-sensitive mechanism and that exogenous Ca2+ promotes lamin degradation in isolated thymocyte nuclei from untreated cells, Here we demonstrate that peptide-based inhibitors of the interleukin 1 beta-converting enzyme family of cysteine proteases (Tyr-Val-Ala-Asp fluoromethyl ketone) and of the nuclear scaffold multicatalytic proteinase (Ala-Pro-Phe chloromethyl ketone) block the degradation of lamin B-1 to a 21-kDa fragment in thymocytes treated with glucocorticoid, the Ca2+-mobilizing agent thapsigargin, or antibodies to the T cell receptor, However, among a panel of inhibitors specific for several different proteases implicated in apoptosis, only tosylphenylalanyl chloromethyl ketone and the nuclear scaffold protease inhibitor block lamin degradation, histone H1 cleavage, and DNA fragmentation in isolated thymocyte nuclei incubated with Ca2+. Overexpression of human BCL-2 in nuclei by stable transfection resulted in an inhibition of Ca2+-stimulated lamin degradation and DNA fragmentation, suggesting that endogenous nuclear BCL-2 regulates activation of the nuclear scaffold protease, The results demonstrate the existence of an alternative pathway of lamin degradation and DNA fragmentation mediated by a resident Ca2+-stimulated nuclear protease that is not directly dependent upon activation of the interleukin 1 beta-converting enzyme family of cell death regulators.			McConkey, DJ (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL 173,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							ASHWELL JD, 1987, SCIENCE, V237, P61, DOI 10.1126/science.3037698; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; CLAWSON GA, 1993, CELL GROWTH DIFFER, V4, P589; CLAWSON GA, 1992, CELL GROWTH DIFFER, V3, P827; COHEN GM, 1994, J IMMUNOL, V153, P507; COHEN JJ, 1984, J IMMUNOL, V132, P38; DEJONG D, 1994, CANCER RES, V54, P256; DELIC J, 1993, MOL CELL BIOL, V13, P4875, DOI 10.1128/MCB.13.8.4875; DOWD DR, 1991, J BIOL CHEM, V266, P18423; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; ENOMOTO K, 1987, CARCINOGENESIS, V8, P1933, DOI 10.1093/carcin/8.12.1933; FEARNHEAD HO, 1995, FEBS LETT, V357, P242, DOI 10.1016/0014-5793(94)01367-A; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; FERNANDEZ A, 1995, ONCOGENE, V10, P769; FILIPSKI J, 1990, EMBO J, V9, P1319, DOI 10.1002/j.1460-2075.1990.tb08241.x; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HEWISH DR, 1973, BIOCHEM BIOPH RES CO, V52, P504, DOI 10.1016/0006-291X(73)90740-7; Huang P, 1995, CLIN CANCER RES, V1, P1005; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JONES DP, 1989, J BIOL CHEM, V264, P6398; KANEKO A, 1986, JNCI-J NATL CANCER I, V77, P121; KAUFMANN SH, 1989, CANCER RES, V49, P5870; Khodarev NN, 1996, J IMMUNOL, V156, P922; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MADSEN KR, 1990, EXP CELL RES, V187, P343, DOI 10.1016/0014-4827(90)90103-H; MARTIN MC, 1996, ONCOGENE, V12, P2259; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MCCONKEY DJ, 1994, IMMUNOL REV, V142, P343, DOI 10.1111/j.1600-065X.1994.tb00896.x; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; STAROSELSKY AH, 1991, CANCER RES, V51, P6292; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; SUN DY, 1994, J EXP MED, V179, P559, DOI 10.1084/jem.179.2.559; SUN XM, 1994, J BIOL CHEM, V269, P14857; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TWIGG J, 1988, NATURE, V332, P366, DOI 10.1038/332366a0; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; VANDERBILT JN, 1982, J BIOL CHEM, V257, P3009; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Wyllie A H, 1992, Semin Immunol, V4, P389; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHIVOTOVSKY B, 1994, FEBS LETT, V351, P150, DOI 10.1016/0014-5793(94)00827-2; ZHIVOTOVSKY B, 1995, EXP CELL RES, V221, P404, DOI 10.1006/excr.1995.1391	60	57	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22398	22406		10.1074/jbc.271.37.22398	http://dx.doi.org/10.1074/jbc.271.37.22398			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798402	hybrid			2022-12-27	WOS:A1996VG67200021
J	Brosh, RM; Matson, SW				Brosh, RM; Matson, SW			A partially functional DNA helicase II mutant defective in forming stable binary complexes with ATP and DNA - A role for helicase motif III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 DEOXYRIBONUCLEIC-ACID; INDUCED CONFORMATIONAL-CHANGES; ESCHERICHIA-COLI REP; SINGLE-STRANDED-DNA; UVRD GENE-PRODUCT; MISMATCH CORRECTION; PROTEIN ABOLISHES; BINDING MOTIF; POLYMERASE-I; RNA HELICASE	To address the functional significance of motif III in Escherichia coli DNA helicase II, the conserved aspartic acid at position 248 was changed to asparagine. UvrDD248N failed to form stable binary complexes with either DNA or ATP. However, UvrDD248N was capable of forming an active ternary complex when both ATP and single-stranded DNA were present. The DNA-stimulated ATPase activity of UvrDD248N was reduced relative to that of wild-type UvrD with no significant change in the apparent K-m for ATP. The mutant protein also demonstrated a reduced DNA unwinding activity. The requirement for high concentrations of UvrDD248N to achieve unwinding of long duplex substrates Likely reflects the reduced stability of various binary and ternary complexes that must exist in the catalytic cycle of a helicase. The data suggest that motif m may act as an interface between the ATP binding and DNA binding domains of a helicase. The uvrDD248N allele was also characterized in genetic assays. The D248N protein complemented the UV-sensitive phenotype of a uvrD deletion strain to levels nearly equivalent to wild-type helicase II. In contrast, the mutant protein only partially complemented the mutator phenotype. A correlation between the level of genetic complementation and the helicase activity of UvrDD248N is discussed.	UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULUM GEN & MOL BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033476] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33476] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMONEM M, 1977, EUR J BIOCHEM, V79, P39, DOI 10.1111/j.1432-1033.1977.tb11781.x; ABOUSSEKHRA A, 1989, NUCLEIC ACIDS RES, V17, P7211, DOI 10.1093/nar/17.18.7211; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; CHAO KL, 1990, J BIOL CHEM, V265, P1067; FOURY F, 1987, EMBO J, V6, P1441, DOI 10.1002/j.1460-2075.1987.tb02385.x; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1988, FEBS LETT, V235, P16, DOI 10.1016/0014-5793(88)81226-2; GRILLEY M, 1990, MUTAT RES, V236, P253, DOI 10.1016/0921-8777(90)90009-T; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; JINDAL HK, 1994, J BIOL CHEM, V269, P3283; KUHN B, 1979, J BIOL CHEM, V254, P1343; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MARTINEZ R, 1992, J VIROL, V66, P6735, DOI 10.1128/JVI.66.11.6735-6746.1992; MATSON SW, 1985, J BIOL CHEM, V260, P2281; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MATSON SW, 1986, J BIOL CHEM, V261, P169; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; Miller J. H., 1972, EXPT MOL GENETICS, P431; MODRICH P, 1989, J BIOL CHEM, V264, P6597; ORREN DK, 1992, J BIOL CHEM, V267, P780; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; PLUMPTON M, 1994, EMBO J, V13, P879, DOI 10.1002/j.1460-2075.1994.tb06331.x; RAY BK, 1985, J BIOL CHEM, V260, P7651; RICHET E, 1976, J BIOL CHEM, V251, P808; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; RUNYON GT, 1990, P NATL ACAD SCI USA, V87, P6383, DOI 10.1073/pnas.87.16.6383; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P4128, DOI 10.1021/bi00066a039; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SHARPLES GJ, 1994, NUCLEIC ACIDS RES, V22, P308, DOI 10.1093/nar/22.3.308; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TANHAUSER SM, 1992, GENE, V117, P113, DOI 10.1016/0378-1119(92)90498-E; THOMMES P, 1992, CHROMOSOMA, V101, P467, DOI 10.1007/BF00352468; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WASHBURN BK, 1993, J BACTERIOL, V175, P341, DOI 10.1128/JB.175.2.341-350.1993; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; WESSEL R, 1990, EUR J BIOCHEM, V192, P695, DOI 10.1111/j.1432-1033.1990.tb19278.x; WONG I, 1993, J BIOL CHEM, V268, P20386; WOOD ER, 1989, J BIOL CHEM, V264, P8297; YONG YQ, 1995, J BIOL CHEM, V270, P24509, DOI 10.1074/jbc.270.41.24509; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933; ZHU L, 1992, J VIROL, V66, P469, DOI 10.1128/JVI.66.1.469-479.1992; ZOLLER MJ, 1991, RECOMBINANT DNA METH, P537	58	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25360	25368		10.1074/jbc.271.41.25360	http://dx.doi.org/10.1074/jbc.271.41.25360			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810301	hybrid			2022-12-27	WOS:A1996VL69300045
J	Faull, RJ; Wang, JA; Leavesley, DI; Puzon, W; Russ, GR; Vestweber, D; Takada, Y				Faull, RJ; Wang, JA; Leavesley, DI; Puzon, W; Russ, GR; Vestweber, D; Takada, Y			A novel activating anti-beta 1 integrin monoclonal antibody binds to the cysteine-rich repeats in the beta 1 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; STIMULATED HUMAN-PLATELETS; LIGAND-BINDING; CELL-ADHESION; T-CELLS; GLANZMANN THROMBASTHENIA; FIBRONECTIN RECEPTOR; ELECTRON-MICROSCOPY; AFFINITY MODULATION; FIBRINOGEN BINDING	The functional status of an integrin depends on the conformation of its extracellular domain, which is controlled by the cell expressing that receptor. The transmission of regulatory signals from within the cell is considered to be via propagated conformational changes from the receptor's cytoplasmic tails to the extracellular ligand binding ''pocket.'' The end result is increased accessibility of the ligand binding pocket in the high affinity (''active'') form of integrins. We report a novel monoclonal antibody (QE.2E5) that binds within the cysteine-rich repeats in the integrin beta 1 chain and induces high affinity binding of fibronectin to the integrin alpha 5 beta 1. The QE.2E5 epitope is located approximately 200 residues both from the predicted binding site for fibronectin and from the epitopes recognized by other activating anti-beta 1 monoclonal antibodies. It is also expressed on beta 1 integrins from a number of nonhuman species, Although they have the same functional effects, the binding of QE.2E5 and another activating antibody (8A2) to the receptor have contrasting effects on the expression of an activation-dependent epitope in the beta 1 chain. We propose that the cysteine-rich repeats contain a regulatory region that is distinct from those previously described in the integrin beta 1 chain.	ST GEORGE HOSP, DEPT RENAL MED, KOGARAH, NSW 2217, AUSTRALIA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; QUEEN ELIZABETH HOSP, RENAL UNIT, WOODVILLE, SA 5011, AUSTRALIA; ZENTRUM MOL BIOL ENTZUNDUNG TECHNOL HOF, INST CELL BIOL, D-48149 MUNSTER, GERMANY	St George Hospital; Scripps Research Institute	Faull, RJ (corresponding author), ROYAL ADELAIDE HOSP, RENAL UNIT, N TERRACE, ADELAIDE, SA 5000, AUSTRALIA.		Leavesley, David/C-9532-2009	Leavesley, David/0000-0002-1033-5459; Vestweber, Dietmar/0000-0002-3517-732X; takada, yoshikazu/0000-0001-5481-9589				AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ARNAOUT MA, 1990, J CLIN INVEST, V85, P977, DOI 10.1172/JCI114529; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; ARROYO AG, 1993, J BIOL CHEM, V268, P9863; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BECKER GJ, 1981, PATHOLOGY, V13, P669, DOI 10.3109/00313028109086640; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23328; BUCK CA, 1986, J CELL BIOL, V103, P2421, DOI 10.1083/jcb.103.6.2421; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHEN AB, 1977, BIOCHIM BIOPHYS ACTA, V493, P310, DOI 10.1016/0005-2795(77)90187-8; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; COLLER BS, 1986, J CELL BIOL, V103, P451, DOI 10.1083/jcb.103.2.451; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1993, J BIOL CHEM, V268, P23087; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; GROUX H, 1989, NATURE, V339, P152, DOI 10.1038/339152a0; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; LAM SCT, 1987, J BIOL CHEM, V262, P947; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PLOW EF, 1981, J BIOL CHEM, V256, P9477; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHIH DT, 1993, J CELL BIOL, V122, P1361, DOI 10.1083/jcb.122.6.1361; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; TICCHIONI M, 1993, J IMMUNOL, V151, P119; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; WEISELJW, 1992, J BIOL CHEM, V2657, P16637	58	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25099	25106		10.1074/jbc.271.41.25099	http://dx.doi.org/10.1074/jbc.271.41.25099			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810264	hybrid			2022-12-27	WOS:A1996VL69300008
J	Hering, S; Aczel, S; Grabner, M; Doring, F; Berjukow, S; Mitterdorfer, J; Sinnegger, MJ; Striessnig, J; Degtiar, VE; Wang, ZY; Glossmann, H				Hering, S; Aczel, S; Grabner, M; Doring, F; Berjukow, S; Mitterdorfer, J; Sinnegger, MJ; Striessnig, J; Degtiar, VE; Wang, ZY; Glossmann, H			Transfer of high sensitivity for benzothiazepines from L-type to class A (BI) calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR DETERMINANTS; FUNCTIONAL EXPRESSION; LOCAL-ANESTHETICS; SKELETAL-MUSCLE; CA2+ CHANNELS; BLOCK; INACTIVATION; DILTIAZEM; VERAPAMIL; NEURONS	To investigate the molecular basis of the calcium channel block by diltiazem, we transferred amino acids of the highly sensitive and stereoselective L-type (alpha(1S) or alpha(1C)) to a weakly sensitive, nonstereoselective class A (alpha(1A)) calcium channel. Transfer of three amino acids of transmembrane segment IVSG of L-type alpha into the alpha(1A) subunit (I1804Y, S1808A, and M1811I) was sufficient to support a use-dependent block by diltiazem and by the phenylalkylamine (-) gallopamil after expression in Xenopus oocytes, An additional mutation F1805M increased the sensitivity for (-)-gallopamil but not for diltiazem, Our data suggest that the receptor domains for diltiazem and gallopamil have common but not identical molecular determinants in transmembrane segment IVS6. These mutations also identified single amino acid residues in segment IVS6 that are important for class A channel inactivation.			Hering, S (corresponding author), UNIV INNSBRUCK, INST BIOCHEM PHARMAKOL, PETER MAYR STR 1, A-6020 INNSBRUCK, AUSTRIA.		Striessnig, Joerg/S-9334-2017; Glossmann, Hartmut/AAL-9790-2020; Tuluc, Petronel/C-2527-2011	Striessnig, Joerg/0000-0002-9406-7120; glossmann, hartmut h./0000-0002-7392-3266; Brauns, Martina/0000-0002-0547-2731; Doring, Frank/0000-0003-1017-1498				BEZPROZVANNY L, 1995, MOL PHARMACOL, V48, P540; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GLOSSMANN H, 1990, REV PHYSIOL BIOCH P, V114, P1; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; HILLE B, 1977, J GEN PHYSIOL, V69, P497, DOI 10.1085/jgp.69.4.497; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; ISHIBASHI H, 1995, BRAIN RES, V695, P88, DOI 10.1016/0006-8993(95)00815-8; LEE KS, 1983, NATURE, V302, P790, DOI 10.1038/302790a0; MCPHEE JC, 1994, P NATL ACAD SCI USA, V91, P12346, DOI 10.1073/pnas.91.25.12346; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; QU YS, 1995, P NATL ACAD SCI USA, V92, P11839, DOI 10.1073/pnas.92.25.11839; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; STARMER CF, 1985, MOL PHARMACOL, V28, P348; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0	28	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24471	24475		10.1074/jbc.271.40.24471	http://dx.doi.org/10.1074/jbc.271.40.24471			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798706	hybrid			2022-12-27	WOS:A1996VM67400028
J	Ishimi, Y; Ichinose, S; Omori, A; Sato, K; Kimura, H				Ishimi, Y; Ichinose, S; Omori, A; Sato, K; Kimura, H			Binding of human minichromosome maintenance proteins with histone H3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; BIDIRECTIONAL DNA-REPLICATION; YEAST SWI/SNF COMPLEX; S-PHASE PROTEINS; MODEL SYSTEM; SACCHAROMYCES-CEREVISIAE; NUCLEAR-LOCALIZATION; MAMMALIAN-CELLS; MCM-PROTEINS; P1 PROTEIN	Minichromosome maintenance (MCM) proteins play essential roles in eukaryotic DNA replication, but their biochemical properties remain to be determined. We detected in HeLa cell extracts six proteins, CDC47, CDC46/MCM5, Cdc21, P1/MCM3, Mis5, and BM28/MCM2, by their binding to a specific antibody and by partial sequencing. The human homologs of the MCM2 (BM28), Mis5, Cdc21, and CDC47 proteins were tightly bound to a histone-Sepharose column and purified to near homogeneity, whereas the P1/MCM3 and CDC46/MCM5 proteins passed through. Among the four core histones, the human BM28/MCM2, Mis5, Cdc21, and CDC47 proteins had high affinity for histone H3. Immunoprecipitation with anti-Cdc21 antibody revealed that these four MCM proteins form complexes. These results are consistent with the findings that MCM proteins bind with chromatin in vivo.	HOKKAIDO UNIV,RES CTR MOL GENET,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University	Ishimi, Y (corresponding author), MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN.		Kimura, Hiroshi/B-9524-2015	Kimura, Hiroshi/0000-0003-0854-083X				BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BENBOW RM, 1992, BIOESSAYS, V14, P661, DOI 10.1002/bies.950141004; BLOW JJ, 1988, NATURE, V357, P128; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; BURTON D, 1987, NUCLEIC ACIDS RES, V5, P3643; CAMERINIOTERO RD, 1976, CELL, V8, P833; CARROLL SM, 1993, MOL CELL BIOL, V13, P2971, DOI 10.1128/MCB.13.5.2971; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; COXON A, 1992, NUCLEIC ACIDS RES, V20, P5571, DOI 10.1093/nar/20.21.5571; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; DIJKWEL PA, 1992, MOL CELL BIOL, V12, P3715, DOI 10.1128/MCB.12.9.3715; FEGER G, 1995, EMBO J, V14, P5387, DOI 10.1002/j.1460-2075.1995.tb00223.x; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; HAMLIN JL, 1992, BIOESSAYS, V14, P651, DOI 10.1002/bies.950141002; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HELD PG, 1992, BIOCHIM BIOPHYS ACTA, V1130, P235, DOI 10.1016/0167-4781(92)90435-3; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; ISHIMI Y, 1994, BIOCHEMISTRY-US, V33, P2733, DOI 10.1021/bi00175a049; ISHIMI Y, 1993, P NATL ACAD SCI USA, V90, P5399, DOI 10.1073/pnas.90.12.5399; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; ISHIMI Y, 1994, MOL CELL BIOL, V14, P6489, DOI 10.1128/MCB.14.10.6489; KEARSEY SE, 1996, BIOESSAYS, V18, P188; KELLY RE, 1995, MOL CELL BIOL, V15, P4136; KIMURA H, 1995, NUCLEIC ACIDS RES, V23, P2097, DOI 10.1093/nar/23.12.2097; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KIMURA K, 1994, J BIOL CHEM, V269, P24523; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; KRUDE T, 1994, J BIOL CHEM, V269, P21021; Krude T, 1996, J CELL SCI, V109, P309; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MADINE MA, 1995, CURR BIOL, V5, P1270, DOI 10.1016/S0960-9822(95)00253-3; MATSUMOTO K, 1994, MOL CELL BIOL, V14, P4624, DOI 10.1128/MCB.14.7.4624; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MILLER KG, 1981, J BIOL CHEM, V256, P9334; MIYAKE S, 1993, MOL BIOL CELL, V4, P1003, DOI 10.1091/mbc.4.10.1003; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; SCHULTE D, 1995, J CELL SCI, V108, P1381; Schulte D, 1996, EUR J BIOCHEM, V235, P144, DOI 10.1111/j.1432-1033.1996.00144.x; SHINOMIYA T, 1994, MOL CELL BIOL, V14, P7394, DOI 10.1128/MCB.14.11.7394; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SOMEYA A, 1995, BIOCHEM BIOPH RES CO, V209, P823, DOI 10.1006/bbrc.1995.1574; STARBORG M, 1995, J CELL SCI, V108, P927; Su TT, 1996, MOL BIOL CELL, V7, P319, DOI 10.1091/mbc.7.2.319; SYKES DE, 1995, GENE, V163, P243, DOI 10.1016/0378-1119(95)00297-J; TAKAHASHI K, 1994, MOL BIOL CELL, V5, P1145, DOI 10.1091/mbc.5.10.1145; Takizawa N, 1995, GENE, V167, P343, DOI 10.1016/0378-1119(95)00713-X; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; TODOROV IT, 1994, J CELL SCI, V107, P253; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; TREISMAN JE, 1995, GENE DEV, V9, P1709, DOI 10.1101/gad.9.14.1709; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; UMEK RM, 1990, P NATL ACAD SCI USA, V87, P2486, DOI 10.1073/pnas.87.7.2486; VanHolde K. E., 1988, CHROMATIN, P219; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	72	106	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24115	24122		10.1074/jbc.271.39.24115	http://dx.doi.org/10.1074/jbc.271.39.24115			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798650	hybrid			2022-12-27	WOS:A1996VJ44200079
J	Seoane, J; GomezFoix, AM; ODoherty, RM; GomezAra, C; Newgard, CB; Guinovart, JJ				Seoane, J; GomezFoix, AM; ODoherty, RM; GomezAra, C; Newgard, CB; Guinovart, JJ			Glucose 6-phosphate produced by glucokinase, but not hexokinase I, promotes the activation of hepatic glycogen synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOCYTES; PHOSPHORYLASE; LIVER; TRANSLOCATION; INACTIVATION; INSULIN; BINDING; GLUCOSE-6-PHOSPHATE; PREREQUISITE; QUANTITIES	In a previous study (O'Doherty, R. Ri., Lehman, D. L., Seoane, J., Gomez-Foix, A. M., Guinovart, J. J., and New-gard, C.B. (1996) J. Biol. Chem. 271, 20524-20530), we demonstrated that adenovirus-mediated overexpression of glucokinase but not hexokinase I has a potent enhancing effect on glycogen synthesis in primary hepatocytes. In an effort to understand the underlying mechanism of this differential effect of the two hexokinase isoforms, we have investigated changes in key intracellular metabolites and the activation state of glycogen synthase in cells treated with recombinant adenoviruses expressing the liver isoform of glucokinase (AdCMV-GKL) or hexokinase I (AdCMV-HKI). Glucose 6-phosphate (Glu-6-P) levels are elevated from approximately 1.5 nmol/mg protein Do 8-10 nmol/mg protein in both AdCMV-GKL- and AdCMV-HKI-treated hepatocytes as glucose is raised from 1 to 5 mM, levels four times higher than those in untreated cells. In AdCMV-GKL-treated cells, Glu-6-P continues to accumulate at glucose levels greater than 5 mM, reaching a maximum of 120 nmol/mg protein in cells incubated at 25 mM glucose, a value 10 and 50 times greater than the maximal levels achieved in AdCMV-HKI-treated and untreated cells, respectively. In parallel with the changes observed in Glu-6-P levels, increases in UDP-Glc in AdCMV-HKI- and AdCMV-GKL-treated cells were most pronounced at low (1-5 mM) and high (25 mM) glucose levels, respectively. Despite the significant increases in Glu-6-P and UDP-Glc achieved in AdCMV-HKI-treated cells, only AdCMV-GKL-treated cells exhibited increases in glycogen synthase activity ratio and translocation of the enzyme from a soluble to a particulate form relative to untreated control cells. We conclude that Glu-6-P produced by overexpressed glucokinase is glycogenic because it effectively promotes activation of glycogen synthase. Glu-6-P produced by overexpressed hexokinase, in contrast, appears to be unable to exert the same regulatory effects, probably due to the different subcellular distribution of the two glucose-phosphorylating enzymes.	UNIV BARCELONA, FAC QUIM, DEPT BIOQUIM & BIOL MOL, E-08028 BARCELONA, SPAIN; UNIV TEXAS, SW MED CTR, GIFFORD LABS DIABET RES, DEPT INTERNAL MED, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, GIFFORD LABS DIABET RES, DEPT BIOCHEM, DALLAS, TX 75235 USA	University of Barcelona; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Seoane, Joan/AAG-9173-2019	Seoane, Joan/0000-0002-6541-5974	PHS HHS [1P50H2598801] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGIUS L, 1993, BIOCHEM J, V296, P785, DOI 10.1042/bj2960785; AGIUS L, 1994, BIOCHEM J, V298, P237, DOI 10.1042/bj2980237; AGIUS L, 1994, BIOCHEM J, V303, P841, DOI 10.1042/bj3030841; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAHILL GF, 1958, J BIOL CHEM, V230, P125; CARABAZA A, 1992, FEBS LETT, V296, P211, DOI 10.1016/0014-5793(92)80381-P; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; CIUDAD CJ, 1988, ARCH BIOCHEM BIOPHYS, V264, P30, DOI 10.1016/0003-9861(88)90566-8; CIUDAD CJ, 1979, FEBS LETT, V99, P321, DOI 10.1016/0014-5793(79)80982-5; CIUDAD CJ, 1986, BIOCHEM BIOPH RES CO, V141, P1195, DOI 10.1016/S0006-291X(86)80171-1; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V281, P443, DOI 10.1042/bj2810443; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V288, P497, DOI 10.1042/bj2880497; FernandezNovell JM, 1996, EUR J BIOCHEM, V238, P570, DOI 10.1111/j.1432-1033.1996.0570z.x; Gutmann I., 1974, METHODS ENZYMATIC AN, P1464; KEPPLER D, 1974, METHOD ENZYMAT AN, V3, P524; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; LANG G, 1974, METHOD ENZYMAT AN, V3, P1238; MASSAGUE J, 1977, FEBS LETT, V82, P317, DOI 10.1016/0014-5793(77)80610-8; MASSILLON D, 1995, J BIOL CHEM, V270, P19351, DOI 10.1074/jbc.270.33.19351; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; Roach P. J., 1986, ENZYMES, VXVII, P499; STALMANS W, 1974, EUR J BIOCHEM, V41, P127, DOI 10.1111/j.1432-1033.1974.tb03252.x; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; VANDEWERVE G, 1984, AM J PHYSIOL, V247, pE271, DOI 10.1152/ajpendo.1984.247.2.E271; VILLARPALASI C, 1991, BIOCHIM BIOPHYS ACTA, V1244, P203; WEINHOUSE S, 1976, CURR TOP CELL REGUL, V11, P1; WILSON JE, 1984, REGULATION CARBOHYDR, P45	30	97	100	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23756	23760		10.1074/jbc.271.39.23756	http://dx.doi.org/10.1074/jbc.271.39.23756			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798601	hybrid			2022-12-27	WOS:A1996VJ44200030
J	Stenmark, H; Aasland, R; Toh, BH; DArrigo, A				Stenmark, H; Aasland, R; Toh, BH; DArrigo, A			Endosomal localization of the autoantigen EEA1 is mediated by a zinc-binding FYVE finger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; SMALL GTPASE RAB5; SACCHAROMYCES-CEREVISIAE; ENDOCYTIC PATHWAY; SIGNALING PROTEINS; MEMBRANE-FUSION; RING FINGER; PH DOMAIN; VACUOLAR; MOTIF	EEA1, a 162-kDa autoantigen associated with subacute cutaneous systemic lupus erythematosus, is a coiled-coil protein localized to early endosomes and cytosol. At its C terminus, the protein contains a cysteine rich motif, which is shared with Vps27, Fab1, and Vac1, yeast proteins implicated in membrane traffic (Mu, F. T., Callaghan, J. M., Steele-Mortimer, O., Stenmark, H., Parton, R. G., Campbell, P. L., McCluskey, J., Yeo, J. P., Tock, E. P., and Toh, B. H. (1995) J. Biol. Chem. 270, 13503-13511). Here we show that this motif constitutes a genuine zinc binding domain, which we term the FYVE finger (based on the first letters of four proteins containing this motif). Profile based data base searches identified the FYVE finger in 11 distinct proteins. The FYVE finger containing C terminus of EEA1 was found to bind 2 mol equivalents of Zn2+. Mutations of conserved histidine and cysteine residues in the FYVE motif independently reduced zinc binding to 1 mol equivalent. Confocal immunofluorescence microscopy of transfected HEp2 cells revealed that the C-terminal part (residues 1277-1411) of EEA1 colocalizes extensively with a GTPase deficient mutant of the early endosomal GTPase Rab5, while deletion of the FYVE finger or mutations that interfere with zinc binding cause a cytosolic localization. These results implicate the FYVE finger in the specific localization of EEA1 to endosomes.	HIB, BIOTECHNOL LAB, N-5020 BERGEN, NORWAY; MONASH UNIV, SCH MED, DEPT PATHOL & IMMUNOL, PRAHRAN, VIC 3181, AUSTRALIA	Monash University	Stenmark, H (corresponding author), NORWEGIAN RADIUM HOSP, DEPT BIOCHEM, N-0310 OSLO, NORWAY.		Stenmark, Harald/B-8868-2008					AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Aballay A, 1995, BIOCHEM J, V312, P919, DOI 10.1042/bj3120919; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; DEHOOP MJ, 1994, NEURON, V13, P11, DOI 10.1016/0896-6273(94)90456-1; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PASTERIS NG, 1994, CELL, V79, P669; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; PRESTON RA, 1991, MOL CELL BIOL, V11, P5801, DOI 10.1128/MCB.11.12.5801; ROBINSON JS, 1991, MOL CELL BIOL, V11, P5813, DOI 10.1128/MCB.11.12.5813; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; Sonnhammer ELL, 1995, GENE, V167, pGC1, DOI 10.1016/0378-1119(95)00714-8; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STENMARK H, 1995, METHOD ENZYMOL, V257, P155; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WEBSTER LC, 1991, P NATL ACAD SCI USA, V88, P9989, DOI 10.1073/pnas.88.22.9989; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; YU HT, 1995, BIOCHEMISTRY-US, V34, P9103, DOI 10.1021/bi00028a020; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	45	377	385	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24048	24054		10.1074/jbc.271.39.24048	http://dx.doi.org/10.1074/jbc.271.39.24048			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798641	hybrid			2022-12-27	WOS:A1996VJ44200070
J	Lee, LC; Hunter, JJ; Mujeeb, A; Turck, C; Parslow, TG				Lee, LC; Hunter, JJ; Mujeeb, A; Turck, C; Parslow, TG			Evidence for alpha-helical conformation of an essential N-terminal region in the human Bcl2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; SECONDARY STRUCTURE; CONSERVED DOMAINS; HOMOLOG BAK; APOPTOSIS; GENE; PEPTIDES; HETERODIMERIZATION; PREDICTION; INDUCTION	A region occupying approximately 24 amino acids near the N terminus of human Bcl2 is essential for this cytoplasmic membrane protein's ability to inhibit apoptosis. Systematic mutagenesis of this N-terminal region indicates that only five hydrophobic and aromatic residues within it are specifically required for function. Computerized secondary structure prediction, together with circular dichroism spectroscopy of synthetic peptides, indicates that the region encompassing these five residues has the propensity to take on an alpha-helical conformation in the presence of SDS micelles, which presumably mimic the hydrophobic surfaces of cellular membranes or polypeptides. The five critical residues are predicted to be clustered on one face of this putative helix, where they might serve to mediate protein protein contacts involved in the multimerization of Bcl2 or in the interaction of Bcl2 with other, as yet unidentified components of the apoptotic pathway. Apparent structural homologues of this helical motif are also present in at least some other anti-apoptotic proteins from the Bcl2 family but not in those family members that tend to potentiate, rather than inhibit, apoptosis.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco				Hunter, John/0000-0001-8262-4404	NIAID NIH HHS [AI29313, AI36636] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036636, R01AI029313] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACKLUND BM, 1994, BBA-BIOMEMBRANES, V1190, P337, DOI 10.1016/0005-2736(94)90092-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KILLIAN JA, 1994, FEBS LETT, V348, P161, DOI 10.1016/0014-5793(94)00594-X; LIN EY, 1993, J IMMUNOL, V151, P1979; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PERVUSHIN K V, 1991, Journal of Biomolecular NMR, V1, P313, DOI 10.1007/BF02192857; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RIZO J, 1993, BIOCHEMISTRY-US, V32, P4881, DOI 10.1021/bi00069a025; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; WATERSTON RH, 1984, J MOL BIOL, V180, P473, DOI 10.1016/0022-2836(84)90023-8; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395	28	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23284	23288		10.1074/jbc.271.38.23284	http://dx.doi.org/10.1074/jbc.271.38.23284			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798527	hybrid			2022-12-27	WOS:A1996VH76800053
J	Tai, GH; Huckerby, TN; Nieduszynski, IA				Tai, GH; Huckerby, TN; Nieduszynski, IA			Multiple non-reducing chain termini isolated from bovine corneal keratan sulfates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLNEURAMINIC ACID; ANION-EXCHANGE CHROMATOGRAPHY; ARTICULAR-CARTILAGE; II DIGESTION; H-1-NMR SPECTROSCOPY; STRUCTURAL-ANALYSIS; CUPROMERONIC BLUE; LINKAGE-REGION; CORE PROTEIN; PROTEOGLYCAN	Keratan sulfate-containing proteoglycans were isolated from bovine cornea (15-month old to 3-year-old animals) and digested with the enzyme, keratanase II. The released oligosaccharides, which included non-reducing termini and repeat region oligosaccharides but not linkage regions, were reduced with alkaline borohydride and fractionated on a Spherisorb column, These oligosaccharides were examined by 600-MHz H-1 NMR spectroscopy using one- and two-dimensional methods and, in addition to some oligosaccharide alditols previously recovered from skeletal keratan sulfate, the following new capping structures were identified: NeuAc alpha 2-6Gal beta 1-4GlcNAc(S)-ol, NeuAc alpha 2-3Gal(S)beta 1-4-GlcNAc(S)beta 1-3Gal beta 1-4GlcNAc(S)-ol, NeuGc alpha 2-6Gal beta 1-4GlcNAc(S)beta 1-3Gal beta 1-4GlcNAc(S)-ol, NeuGc alpha 2-3Gal beta 1-4GlcNAc(S)beta 1-3Gal beta 1-4GlcNAc(S)-ol, NeuGc alpha 2-3Gal-(S)beta 1-4GlcNAc(S)beta 1-3Gal beta 1-4GlcNAc(S)-ol, NeuGc alpha 2-3Gal-(S)beta 1-4GlcNAc(S)beta 1-3Gal(S)beta 1-4GlcNAc(S)-ol, Gal alpha 1-3Gal beta 1-4GlcNAc(S)beta 1-3Gal beta 1-4GlcNAc(S)-ol,Gal alpha 1-3Gal beta 1-4GlcNAc(S)beta 1-3Gal(S)beta 1-4GlcNAc(S)-ol, GlcNAc(S)beta 1-3Gal(S)beta 1-4GlcNAc(S)-ol, and GalNAc(S)-beta 1-3Gal(S)beta 1-4GlcNAc(S)-ol. These structures represent seven families of capping residues, whose relative molar proportions are given in parentheses: NeuAc alpha(2-3)- (12%), NeuAc alpha(2-6)- (41%), NeuGc alpha(2-3)- and NeuGc alpha(2-6)- families (12%), Gal alpha(1-3)- (26%), GalNAc(S)beta(1-3)- (5%), and GlcNAc(S)beta(1-3)(4%), It is not clear, at present, where each of these structures occurs on the bi-antennary N-linked corneal keratan sulfate chains, which themselves occur within three keratan sulfate proteoglycan species. However, examination of the relative proportions of the capping to the repeat structures and knowledge of the average molecular size suggests that the sum of these non-reducing termini represents the caps of two antennae.	UNIV LANCASTER,INST ENVIRONM & BIOL SCI,DIV BIOL SCI,LANCASTER LA1 4YQ,ENGLAND; UNIV LANCASTER,CTR POLYMER,SCH PHYS & CHEM,LANCASTER LA1 4YA,ENGLAND	Lancaster University; Lancaster University					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERMAN ER, 1991, BIOCH EYE, P89; BHAVANANDAN VP, 1968, J BIOL CHEM, V243, P1052; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P347; BRAY BA, 1967, J BIOL CHEM, V242, P3373; BROWN GM, 1992, BIOCHEM J, V286, P235, DOI 10.1042/bj2860235; BROWN GM, 1994, EUR J BIOCHEM, V224, P281, DOI 10.1111/j.1432-1033.1994.00281.x; BROWN GM, 1994, BIOCHEMISTRY-US, V33, P4836, DOI 10.1021/bi00182a012; BROWN GM, 1995, GLYCOBIOLOGY, V5, P311, DOI 10.1093/glycob/5.3.311; CHOI HU, 1975, BIOCHEM J, V151, P543, DOI 10.1042/bj1510543; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DICKENSON JM, 1990, ANAL BIOCHEM, V190, P271, DOI 10.1016/0003-2697(90)90192-C; DICKENSON JM, 1990, BIOCHEM J, V269, P55, DOI 10.1042/bj2690055; DICKENSON JM, 1992, BIOCHEM J, V282, P267, DOI 10.1042/bj2820267; DICKENSON JM, 1991, BIOCHEM J, V278, P779, DOI 10.1042/bj2780779; DORLAND L, 1984, BIOCHEM BIOPH RES CO, V122, P859, DOI 10.1016/S0006-291X(84)80113-8; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FUNDERBURGH JL, 1991, J BIOL CHEM, V266, P14226; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HOPWOOD JJ, 1974, BIOCHEM J, V141, P517, DOI 10.1042/bj1410517; HOUNSELL EF, 1986, EUR J BIOCHEM, V157, P375, DOI 10.1111/j.1432-1033.1986.tb09679.x; HUCKERBY TN, 1990, MAGN RESON CHEM, V28, P786, DOI 10.1002/mrc.1260280910; HUCKERBY TN, 1993, MAGN RESON CHEM, V31, P394, DOI 10.1002/mrc.1260310416; HUCKERBY TN, 1991, GLYCOCONJUGATE J, V8, P39, DOI 10.1007/BF00731641; HUCKERBY TN, 1992, MAGN RESON CHEM, V30, pS134, DOI 10.1002/mrc.1260301322; KANNAGI R, 1982, J BIOL CHEM, V257, P4438; KRUSIUS T, 1987, BIOCHEM J, V245, P229, DOI 10.1042/bj2450229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI W, 1992, ARCH BIOCHEM BIOPHYS, V296, P190, DOI 10.1016/0003-9861(92)90562-B; MEYER K, 1953, J BIOL CHEM, V205, P611; MEYER K, 1970, CHEM MOL BIOL INTERC, V1, P15; Nakazawa K., 1989, KERATAN SULPHATE CHE, P99; NIEDUSZYNSKI IA, 1990, BIOCHEM J, V271, P243, DOI 10.1042/bj2710243; NILSSON B, 1983, J BIOL CHEM, V258, P6056; OEBEN M, 1987, BIOCHEM J, V248, P85, DOI 10.1042/bj2480085; SAVAGE AV, 1986, EUR J BIOCHEM, V160, P123, DOI 10.1111/j.1432-1033.1986.tb09948.x; SCOTT JE, 1988, BIOCHEM J, V253, P607, DOI 10.1042/bj2530607; SCOTT JE, 1992, J ANAT, V180, P155; SENO N, 1965, J BIOL CHEM, V240, P1005; TAI GH, 1991, BIOCHEM J, V273, P307, DOI 10.1042/bj2730307; TAI GH, 1992, BIOCHEM J, V286, P231, DOI 10.1042/bj2860231; THORNTON DJ, 1989, BIOCHEM J, V260, P277, DOI 10.1042/bj2600277; TODA N, 1970, BIOCHIM BIOPHYS ACTA, V208, P227, DOI 10.1016/0304-4165(70)90241-2; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WELTI D, 1979, EUR J BIOCHEM, V94, P505, DOI 10.1111/j.1432-1033.1979.tb12919.x	48	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23535	23546		10.1074/jbc.271.38.23535	http://dx.doi.org/10.1074/jbc.271.38.23535			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798563	hybrid			2022-12-27	WOS:A1996VH76800089
J	Ueda, Y; Hirai, S; Osada, S; Suzuki, A; Mizuno, K; Ohno, S				Ueda, Y; Hirai, S; Osada, S; Suzuki, A; Mizuno, K; Ohno, S			Protein kinase C delta activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; BETA-GAMMA-SUBUNITS; MAP KINASE; PHORBOL ESTERS; REGULATORY DOMAIN; GROWTH-FACTORS; TRANSCRIPTIONAL ACTIVATION; RESPONSE ELEMENT; NPKC-EPSILON; IN-VITRO	Although the involvement of protein kinase C (PKC) in the activation of the mitogen-activated protein (MAP) kinase pathway has been implicated through experiments using 12-O-tetradecanoylphorbol-13-acetate (TPA), there has been no direct demonstration that PKC activates the MAP kinase pathway, A Raf-dependent intact cell assay system for monitoring the activation of MAPK/ERK kinase (MEK) and extracellular signal-related kinase (ERK) permitted us to evaluate the role of PRC isotypes in MAP kinase activation. Treatment of cells with TPA or epidermal growth factor resulted in the activation of MEK and ERK. The activation of the MAP kinase pathway triggered by epidermal growth factor was completely inhibited by dominant-negative Ras (RasN17), whereas the activation triggered by TPA was not, consistent with previous observations. The introduction of an activated point mutant of PKC delta, but not PKC alpha or PKC epsilon, resulted in the activation of the MAP kinase pathway. The activation of MEK and ERK by an activated form of PKC delta requires the presence of c-Raf and is independent of RasN17. These results demonstrate that activation of PKC delta is sufficient for the activation of MER and ERK and that the pathway operates in a manner dependent on c-Raf and independent of Ras.	YOKOHAMA CITY UNIV,SCH MED,DEPT MOL BIOL,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN	Yokohama City University			Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269; Osada, Shin-Ichi/0000-0001-5387-085X				AHMED S, 1993, J BIOL CHEM, V268, P10709; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; AKITA Y, 1994, J BIOL CHEM, V269, P4653; BISHOP R, 1983, BIOCHEM BIOPH RES CO, V115, P536, DOI 10.1016/S0006-291X(83)80178-8; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GENOT EM, 1995, J BIOL CHEM, V270, P9838; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; HATA A, 1989, FEBS LETT, V252, P144, DOI 10.1016/0014-5793(89)80907-X; HATA A, 1993, J BIOL CHEM, V268, P9122; HIRAI S, 1994, EMBO J, V13, P2231; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; INOUE M, 1977, J BIOL CHEM, V252, P7610; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MARQUARDT B, 1992, GENE, V120, P297, DOI 10.1016/0378-1119(92)90109-3; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MITRA G, 1993, CELL MOL BIOL RES, V39, P517; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; MURAMATSU M, 1992, FEBS LETT, V311, P75, DOI 10.1016/0014-5793(92)81371-R; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; OHNO S, 1990, J BIOL CHEM, V265, P6296; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEARS C, 1991, BIOCHEM J, V276, P257, DOI 10.1042/bj2760257; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; RAPP UR, 1991, ONCOGENE, V6, P495; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SOZERI O, 1992, ONCOGENE, V7, P2259; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANRENTERGHEM B, 1994, J BIOL CHEM, V269, P24666; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	65	498	506	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23512	23519		10.1074/jbc.271.38.23512	http://dx.doi.org/10.1074/jbc.271.38.23512			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798560	hybrid			2022-12-27	WOS:A1996VH76800086
J	Choi, YH; Matsuzaki, R; Suzuki, S; Tanizawa, K				Choi, YH; Matsuzaki, R; Suzuki, S; Tanizawa, K			Role of conserved Asn-Tyr-Asp-Tyr sequence in bacterial copper/2,4,5-trihydroxyphenylalanyl quinone-containing histamine oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER AMINE OXIDASE; TOPA QUINONE; ACTIVE-SITE; ARTHROBACTER-GLOBIFORMIS; MONOAMINE-OXIDASE; ESCHERICHIA-COLI; COFACTOR; CLONING; GENERATION; MECHANISM	Copper amine oxidase contains a covalently bound quinonoid cofactor, 2,4,5-trihydroxyphenylalanyl quinone (TPQ), which is synthesized by post-translational modification of a specific tyrosyl residue occurring in the highly conserved sequence, Asn-Tyr-(Asp/Glu)-Tyr. To elucidate the role(s) of the conserved sequence in the biogenesis of TPQ, each of the corresponding residues at positions 401-404 in the recombinant histamine oxidase from Arthrobacter globiformis has been replaced with other amino acids by site-directed mutagenesis. When Asn 401 was changed to Asp or Gln, the rate of TPQ formation by copper-dependent self-processing was 10(3)- to 10(4)-fold slower than in the wild-type enzyme. When Tyr-402 was replaced by Phe, TPQ was not formed at all, showing that Tyr-402 is essential as the precursor to TPQ. In contrast, Asp-403 could be replaced by Glu without changes in the rate of TPQ formation, whereas its replacement by Asn led to a marked decrease. Furthermore, when Tyr-404 was changed to Phe, TPQ was formed swiftly on incubation with copper ions, but the TPQ enzyme exhibited very low activity with altered substrate specificity. These results collectively indicate that a very rigorous structural motif is required for efficient formation of TPQ and for the catalytic activity in the active site of copper amine oxidases.	OSAKA UNIV,INST SCI & IND RES,DIV BIOL SCI,IBARAKI,OSAKA 567,JAPAN; OSAKA UNIV,FAC SCI,DEPT CHEM,TOYONAKA,OSAKA 560,JAPAN	Osaka University; Osaka University								AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; CAI DY, 1994, J BIOL CHEM, V269, P32039; CAI DY, 1994, BIOCHEMISTRY-US, V33, P7647, DOI 10.1021/bi00190a019; CHOI YH, 1995, J BIOL CHEM, V270, P4712, DOI 10.1074/jbc.270.9.4712; COLEMAN AA, 1991, J BIOL CHEM, V266, P6795; FARNUM M, 1986, BIOCHEMISTRY-US, V25, P1898, DOI 10.1021/bi00356a010; JANES SM, 1991, BIOCHEMISTRY-US, V30, P4599, DOI 10.1021/bi00232a034; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; KNOWLES PF, 1994, MET IONS BIOL SYST, V30, P361; MATSUZAKI R, 1994, FEBS LETT, V351, P360, DOI 10.1016/0014-5793(94)00884-1; MATSUZAKI R, 1995, BIOCHEMISTRY-US, V34, P4524, DOI 10.1021/bi00014a004; McIntire W. S., 1993, COPPER CONTAINING AM, P97; MU D, 1992, J BIOL CHEM, V267, P7979; Nakamura N, 1996, J BIOL CHEM, V271, P4718; PARSONS MR, 1995, STRUCTURE, V3, P1171, DOI 10.1016/S0969-2126(01)00253-2; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; TANIZAWA K, 1994, BIOCHEM BIOPH RES CO, V199, P1096, DOI 10.1006/bbrc.1994.1343; TIPPING AJ, 1995, J BIOL CHEM, V270, P16939, DOI 10.1074/jbc.270.28.16939; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	22	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22598	22603		10.1074/jbc.271.37.22598	http://dx.doi.org/10.1074/jbc.271.37.22598			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798429	hybrid			2022-12-27	WOS:A1996VG67200048
J	Hartsough, MT; Frey, RS; Zipfel, PA; Buard, A; Cook, SJ; McCormick, F; Mulder, KM				Hartsough, MT; Frey, RS; Zipfel, PA; Buard, A; Cook, SJ; McCormick, F; Mulder, KM			Altered transforming growth factor beta signaling in epithelial cells when Ras activation is blocked	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON-CARCINOMA CELLS; TGF-BETA; CYCLE ARREST; C-MYC; DEPENDENT KINASE; PROTEIN-KINASES; HUMAN KERATINOCYTES; REGULATED KINASE-2; DOWN-REGULATION; MAP KINASE	We have previously demonstrated that growth inhibition of untransformed intestinal epithelial cells by transforming growth factor beta(1) (TGF beta) and TGF beta(2) was associated with a rapid activation of both Ras and extracellular signal-regulated kinase 1 (Erk1) (Mulder, K. M., and Morris, S. L. (1992) J. Biol. Chem. 267, 5029-5031; Hartsough, M. T., and Mulder, K. M. (1995) J. Biol. Chem. 270, 7117-7124). In order to determine whether Ras was required for TGF beta regulation of both Erk1 and down-stream components associated with TGF beta-mediated growth inhibition, the intestinal epithelial cell (IEC) line IEC 4-1 was transfected with a vector containing a dominant-negative mutant of Ras (RasN17) under the control of an inducible metallothionein promoter, Using two different RasN17-transfected clones treated with ZnCl2, we demonstrate here that induction of Ras expression by at least 4-fold completely abrogated the TGF beta-mediated activation of Erk1. Moreover, the RasN17-mediated reversal of the TGF beta effect on Erk1 was dependent upon the level of expression of the dominant-negative protein. ZnCl2 treatment of control cells transfected with the empty vector did not alter Ras expression or the activation of Erk1 by TGF beta. In order to determine whether the activation of Ras by TGF beta was required for the growth inhibitory effect of TGF beta, we examined TGF beta(2) effects on Cdk2-associated histone H1 kinase activity, cyclin A protein expression levels, and DNA synthesis in two intestinal epithelial cell clones transfected with RasN17. In cells expressing RasN17, we observed a 50% reversal of the inhibition of Cdk2 activity, a 78% reversal of the down-regulation of cyclin A protein expression, and a 21% reversal of the inhibition of DNA synthesis by TGF beta. Collectively, these results indicate that Ras activation is obligatory for TGF beta-mediated activation of Erk1, whereas it is partially required for the growth inhibitory effect of TGF beta.	PENN STATE UNIV,COLL MED,DEPT PHARMACOL,HERSHEY,PA 17033; ONYX PHARMACEUT,RICHMOND,CA 94806	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NCI NIH HHS [CA68444, CA51452, CA54816] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054816, R01CA068444, R29CA051452, R01CA051452] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; BHUSHAN A, 1994, MOL CELL BIOL, V14, P4280, DOI 10.1128/MCB.14.6.4280; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; BRONZERT DA, 1990, MOL ENDOCRINOL, V4, P981, DOI 10.1210/mend-4-7-981; Buard A, 1996, INT J CANCER, V67, P539, DOI 10.1002/(SICI)1097-0215(19960807)67:4<539::AID-IJC13>3.0.CO;2-2; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EBLEN ST, 1994, CELL GROWTH DIFFER, V5, P109; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FAUTSCH MP, 1995, J CELL BIOCHEM, V58, P517, DOI 10.1002/jcb.240580415; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRUPPUSO PA, 1991, J BIOL CHEM, V266, P3444; HALSTEAD J, 1995, J BIOL CHEM, V270, P13600, DOI 10.1074/jbc.270.23.13600; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KO TC, 1995, ONCOGENE, V10, P177; KO TC, 1994, AM J SURG, V167, P14, DOI 10.1016/0002-9610(94)90048-5; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOIKE M, 1994, BIOCHEM BIOPH RES CO, V201, P673, DOI 10.1006/bbrc.1994.1753; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LONGSTREET M, 1992, ONCOGENE, V7, P1549; MASSAGUE J, 1992, CANCER SURV, V12, P81; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULDER KM, 1993, J CELL PHYSIOL, V154, P162, DOI 10.1002/jcp.1041540120; MULDER KM, 1988, CANCER RES, V48, P7120; MULDER KM, 1992, J BIOL CHEM, V267, P5029; MULDER KM, 1990, J CELL PHYSIOL, V145, P501, DOI 10.1002/jcp.1041450316; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; ONG G, 1991, ONCOGENE, V6, P761; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; SATOH T, 1992, J BIOL CHEM, V267, P24149; SATTERWHITE DJ, 1994, CELL GROWTH DIFFER, V5, P789; SIMON KE, 1995, CELL GROWTH DIFFER, V6, P1261; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU SP, 1993, CELL GROWTH DIFFER, V4, P115; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; YAN ZF, 1994, J BIOL CHEM, V269, P13231; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952; ZIPFEL PA, 1993, CELL GROWTH DIFFER, V4, P637	69	114	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22368	22375		10.1074/jbc.271.37.22368	http://dx.doi.org/10.1074/jbc.271.37.22368			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798398	hybrid			2022-12-27	WOS:A1996VG67200017
J	Wang, HS; Cao, HJ; Winn, VD; Rezanka, LJ; Frobert, Y; Evans, CH; Sciaky, D; Young, DA; Smith, TJ				Wang, HS; Cao, HJ; Winn, VD; Rezanka, LJ; Frobert, Y; Evans, CH; Sciaky, D; Young, DA; Smith, TJ			Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts - An in vitro model for connective tissue inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DERMAL FIBROBLASTS; HUMAN-SKIN FIBROBLASTS; NF-KAPPA-B; CYCLIC ADENOSINE-MONOPHOSPHATE; VESICULAR GLAND MICROSOMES; CULTURED HUMAN-FIBROBLASTS; DENOVO PROTEIN-SYNTHESIS; CELL-DERIVED CYTOKINE; GRAVES OPHTHALMOPATHY; INTERFERON-GAMMA	Several proinflammatory cytokines can increase prostaglandin E(2) (PGE(2)) synthesis in a variety of cell types, constituting an important component of the inflammatory response. We demonstrate here that leukoregulin, a 50-kDa product of activated T lymphocytes, dramatically increases PGE, synthesis in cultured human orbital fibroblasts. This up-regulation is mediated through an induction of prostaglandin-endoperoxide H synthase-2 (PGHS-2), the inflammatory cyclooxygenase. Steady-state levels of PGHS-2 mRNA are increased within 1.5 h of leukoregulin addition and are near maximal. by 6 h, when they are 50-fold or higher above basal levels, The increase in PGHS-2 mRNA levels is partially blocked by cycloheximide, suggesting de novo synthesis of an intermediate protein may be required for a maximal leukoregulin response. Nuclear run-on studies indicate PGHS-2 gene transcription is up-regulated by leukoregulin a-fold after 2 and 6 h. PGHS-2 protein, as assessed by Western blotting and two-dimensional protein gel analysis, is increased dramatically in orbital fibroblasts, This lymphokine-dependent expression of PGHS-2 is blocked by dexamethasone, and the increase in PGE, and cAMP levels following leukoregulin treatment is also blocked by indomethacin and by SC 58125, a newly developed PGHS-2-selective cyclooxygenase inhibitor. The dramatic increase in cAMP levels causes marked alteration in orbital fibroblast morphology. PGHS-2 expression in dermal fibroblasts is also increased by leukoregulin; however, the response is considerably less robust, and these cells do not undergo a change in morphology. Both orbital and dermal fibroblasts express high levels of PGHS-1 mRNA and protein, the other abundant form of cyclooxygenase. In contrast to its effects on PGHS-2 expression, leukoregulin fails to alter PGHS-1 levels in either orbital or dermal fibroblasts, suggesting that PGHS-1 is not involved in cytokine-dependent prostanoid production in human fibroblasts. The increased PGHS-2 expression elicited by leukoregulin in orbital fibroblasts may be a consequence of both transcriptional and post-transcriptional effects. These observations help clarify the pathogenic mechanism relevant to the intense inflammation associated with Graves' ophthalmopathy. Lymphocytes trafficked to orbital tissues have a putative role, through the cytokines they release, in the activation of fibroblasts in this autoimmune disease.	ALBANY MED COLL,DEPT MED,DIV MOL & CELLULAR MED,ALBANY,NY 12208; ALBANY MED COLL,DEPT BIOCHEM & MOL BIOL,ALBANY,NY 12208; SAMUEL S STRATTON VET AFFAIRS MED CTR,ALBANY,NY 12208; UNIV ROCHESTER,SCH MED & DENT,DEPT MED,DIV ENDOCRINOL & METAB,E HENRY KEUTMANN LABS,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; NCI,BIOL LAB,BETHESDA,MD 20892; CEA SACLAY,SERV PHARMACOL & IMMUNOL,F-91191 GIF SUR YVETTE,FRANCE	Albany Medical College; Albany Medical College; University of Rochester; University of Rochester; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); CEA; UDICE-French Research Universities; Universite Paris Saclay			Smith, Terry/ABG-1360-2020	Winn, Virginia/0000-0003-1136-2907; Smith, Terry/0000-0002-6279-9685	NATIONAL EYE INSTITUTE [R01EY008976] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016177] Funding Source: NIH RePORTER; NEI NIH HHS [EY 08976] Funding Source: Medline; NIDDK NIH HHS [DK 16177] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNETT SC, 1988, CLIN EXP IMMUNOL, V73, P505; BARNETT SC, 1986, CANCER RES, V46, P2686; BASTIEN L, 1994, J BIOL CHEM, V269, P11873; BENRENSON CS, 1995, J CLIN ENDOCR METAB, V80, P2668; BETZ M, 1991, J IMMUNOL, V146, P108; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P333, DOI 10.1016/0005-2760(94)00196-6; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P341, DOI 10.1016/0005-2760(94)00197-7; DECARLI M, 1993, J CLIN ENDOCR METAB, V77, P1120, DOI 10.1210/jc.77.5.1120; DIAZ A, 1992, J BIOL CHEM, V267, P10816; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; EHRETSMANN CP, 1995, MOL CELL ENDOCRINOL, V110, P185, DOI 10.1016/0303-7207(95)03531-B; EVANS CH, 1989, ANAL BIOCHEM, V177, P358, DOI 10.1016/0003-2697(89)90066-3; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; FOX BS, 1993, IMMUNOMETHODS, V2, P255; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; GOTO M, 1987, J CLIN INVEST, V80, P786, DOI 10.1172/JCI113135; GRUBECKLOEBENSTEIN B, 1994, J CLIN INVEST, V93, P2738, DOI 10.1172/JCI117289; GRUOL DJ, 1993, MOL ENDOCRINOL, V7, P104, DOI 10.1210/me.7.1.104; HABIB A, 1993, J BIOL CHEM, V268, P23448; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; HIGGINS PJ, 1993, BIOCHIM BIOPHYS ACTA, V1181, P23, DOI 10.1016/0925-4439(93)90085-F; Hla T, 1996, PROSTAG OTH LIPID M, V51, P81, DOI 10.1016/0090-6980(95)00158-1; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOGG MG, 1995, AM J PHYSIOL-CELL PH, V269, pC359, DOI 10.1152/ajpcell.1995.269.2.C359; HU ZQ, 1995, J IMMUNOL, V155, P2134; HUFNAGEL TJ, 1984, OPHTHALMOLOGY, V91, P1411; JAUME JC, 1994, J CLIN ENDOCR METAB, V78, P348, DOI 10.1210/jc.78.2.348; JONES DA, 1993, J BIOL CHEM, V268, P9049; JUMBLATT MM, 1991, INVEST OPHTH VIS SCI, V32, P360; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LEVENSON RM, 1986, ANAL BIOCHEM, V158, P294, DOI 10.1016/0003-2697(86)90553-1; MASFERRER JL, 1992, P NATL ACAD SCI USA, V89, P3917, DOI 10.1073/pnas.89.9.3917; MAUVIEL A, 1992, J CELL BIOCHEM, V50, P53, DOI 10.1002/jcb.240500110; MAUVIEL A, 1991, J CELL BIOL, V113, P1455, DOI 10.1083/jcb.113.6.1455; MAUVIEL A, 1992, J IMMUNOL, V149, P2969; MAUVIEL A, 1992, J BIOL CHEM, V267, P5644; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; Moore DD, 1995, GLOB MOB SURV; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OBANION MK, 1991, J BIOL CHEM, V266, P23261; OHKI S, 1979, J BIOL CHEM, V254, P829; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; PRITCHARD KA, 1994, J BIOL CHEM, V269, P8504; PRUMMEL MF, 1989, NEW ENGL J MED, V321, P1353, DOI 10.1056/NEJM198911163212002; RANSOM JH, 1985, CANCER RES, V45, P851; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; REGAN JW, 1994, MOL PHARMACOL, V46, P213; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; ROPER RL, 1990, J IMMUNOL, V145, P2644; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SEBALDT RJ, 1990, P NATL ACAD SCI USA, V87, P6974, DOI 10.1073/pnas.87.18.6974; SMITH TJ, 1989, ENDOCR REV, V10, P366, DOI 10.1210/edrv-10-3-366; SMITH TJ, 1995, AM J PHYSIOL-CELL PH, V268, pC382, DOI 10.1152/ajpcell.1995.268.2.C382; SMITH TJ, 1989, J CLIN ENDOCR METAB, V69, P1019, DOI 10.1210/jcem-69-5-1019; SMITH TJ, 1992, AM J PHYSIOL, V263, pC24, DOI 10.1152/ajpcell.1992.263.1.C24; SMITH TJ, 1994, P NATL ACAD SCI USA, V91, P5094, DOI 10.1073/pnas.91.11.5094; SMITH TJ, 1993, AM J PHYSIOL, V265, pC138, DOI 10.1152/ajpcell.1993.265.1.C138; SMITH TJ, 1993, J INVEST DERMATOL, V100, P288, DOI 10.1111/1523-1747.ep12469828; SMITH TJ, 1987, J CLIN INVEST, V79, P1493, DOI 10.1172/JCI112979; SMITH TJ, 1995, J CLIN ENDOCR METAB, V80, P2620, DOI 10.1210/jc.80.9.2620; SMITH TJ, 1984, J CLIN INVEST, V74, P2157, DOI 10.1172/JCI111642; SMITH TJ, 1991, J CLIN ENDOCR METAB, V72, P1169, DOI 10.1210/jcem-72-5-1169; SMITH TJ, 1993, BIOCHIM BIOPHYS ACTA, V1181, P300, DOI 10.1016/0925-4439(93)90036-Z; SMITH TJ, 1988, METABOLISM, V37, P179, DOI 10.1016/S0026-0495(98)90015-4; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VORIS BP, 1980, ANAL BIOCHEM, V104, P478, DOI 10.1016/0003-2697(80)90103-7; WANG HS, 1995, J CLIN ENDOCR METAB, V80, P3553, DOI 10.1210/jc.80.12.3553; WINN VD, 1993, J LIPID MEDIATOR, V6, P101; XIE WL, 1993, ARCH BIOCHEM BIOPHYS, V300, P247, DOI 10.1006/abbi.1993.1034; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YANG X, 1995, U20548 GENBANK; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; YOUNG DA, 1983, METHOD ENZYMOL, V91, P190; [No title captured]	81	88	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22718	22728		10.1074/jbc.271.37.22718	http://dx.doi.org/10.1074/jbc.271.37.22718			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798446	hybrid			2022-12-27	WOS:A1996VG67200065
J	Abrams, CS; Zhang, J; Downes, CP; Tang, XW; Zhao, W; Rittenhouse, SE				Abrams, CS; Zhang, J; Downes, CP; Tang, XW; Zhao, W; Rittenhouse, SE			Phosphopleckstrin inhibits G beta gamma-activable platelet phosphatidylinositol-4,5-bisphosphate 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; ADRENERGIC-RECEPTOR KINASE; PHOSPHOINOSITIDE-3 KINASE; THROMBIN; 4,5-BISPHOSPHATE; ACTIVATION; BINDING; RHO; PHOSPHATIDYLINOSITOL(3,4,5)-TRISPHOSPHATE; PHOSPHORYLATION	Pleckstrin, the prototypic protein containing two copies of the pleckstrin homology domain, is a prominent substrate of protein kinase C in platelets and neutrophils. Both cell types have p85 subunit-containing phosphoinositide 3-kinase (p85/PI3K) and non-p85-containing PI3K (PI3K gamma) that is activated by beta gamma subunits of heterotrimeric GTP-binding proteins. We have shown that a PI3K product, phosphatidylinositol (PI) 3,4,5-trisphosphate, promotes pleckstrin phosphorylation in platelets. Since pleckstrin homology domains are thought to interact with G beta gamma heterodimers and/or PI(4,5)P-2, we have examined the effects of recombinant pleckstrins on platelet PI3K gamma and p85/PI3K activities. Depending upon its phosphorylation/charged state, pleckstrin inhibits PI3K gamma, but not p85/PI3K. Pleckstrin-mediated inhibition of PI3K gamma is overcome by excess G beta gamma and is restricted to PI(4,5)P-2 as substrate, i.e. pleckstrin does not inhibit phosphorylation of PI(4)P or PI. Consistent with this, activation of protein kinase C by exposure of platelets to beta-phorbol diester (to increase endogenous pleckstrin phosphorylation) prior to platelet lysis causes inhibition of G beta gamma-stimulatable PI3K activity only with respect to PI(4,5)P-2 substrate. This phosphopleckstrin-mediated inhibition is overcome by increasing concentrations of G beta gamma. We propose that phosphorylation of pleckstrin may constitute an important inhibitory mechanism for PI3K gamma-mediated cell signaling.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,KIMMEL CANC INST,DEPT MOL PHARMACOL & BIOCHEM,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,CARDEZA FDN HEMATOL RES,PHILADELPHIA,PA 19107; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104; UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	Jefferson University; Jefferson University; University of Pennsylvania; University of Dundee				tang, xiuwen/0000-0002-6601-1234	NHLBI NIH HHS [R29 HL53545, HL 38622] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038622, R29HL053545] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1995, J BIOL CHEM, V270, P23317, DOI 10.1074/jbc.270.40.23317; ABRAMS CS, 1995, J BIOL CHEM, V270, P14485, DOI 10.1074/jbc.270.24.14485; CARTER AN, 1994, BIOCHEM J, V301, P415, DOI 10.1042/bj3010415; FRY MJ, 1993, PHILOS T ROY SOC B, V340, P337, DOI 10.1098/rstb.1993.0076; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RITTENHOUSE SE, 1995, METHOD ENZYMOL, V256, P241; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589; ZHANG J, 1995, J BIOL CHEM, V270, P22807, DOI 10.1074/jbc.270.39.22807; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHANG J, 1993, J BIOL CHEM, V268, P22251	24	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25192	25197		10.1074/jbc.271.41.25192	http://dx.doi.org/10.1074/jbc.271.41.25192			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810277	hybrid			2022-12-27	WOS:A1996VL69300021
J	Mahe, Y; Lemoine, Y; Kuchler, K				Mahe, Y; Lemoine, Y; Kuchler, K			The ATP binding cassette transporters Pdr5 and Snq5 of Saccharomyces cerevisiae can mediate transport of steroids in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; PLASMA-MEMBRANE; GENE-PRODUCT; DRUG-RESISTANCE; MDR-GENE; ENCODES; PHOSPHATIDYLCHOLINE; TRANSCRIPTION; DEXAMETHASONE	Multiple or pleiotropic drug resistance in the yeast Saccharomyces cerevisiae can arise from overexpression of the Pdr5 and Snq2 ATP binding cassette multidrug transporters. Expression of Pdr5 and Snq2 is regulated by the two transcription factors Pdr1 and Pdr3, as multidrug-resistant pdr1 and pdr3 gain-of-function mutants overexpress both drug efflux pumps. One such pdr1 mutant allele was previously cloned in a genetic screen by its ability to suppress the squelching toxicity mediated by an estradiol-inducible chimeric VP16-human estrogen receptor (VEO) expressed in yeast (Gilbert, D. M., Heery, D. M., Lesson, R., Chambon, P., and Lemoine, Y. (1993) Mol. Cell. Biol. 13, 462-472). In this study, we demonstrate that relief of estradiol toxicity in yeast cells expressing VEO requires functional PDR5 and SNQ2 genes, since a Delta pdr5 Delta snq2 double deletion leads to an increased estradiol toxicity. Furthermore, using URA3 as an estradiol-inducible reporter gene, we show that Pdr5 and Snq2, when overexpressed from high-copy plasmids, can reduce the intracellular concentration of estradiol. In contrast, a Delta pdr5 Delta snq2 double deletion mutant accumulates almost 30-fold more intracellular estradiol than the isogenic wild type, Indirect immunofluorescence showed that a pdr1-3 mutant massively overexpresses Pdr5 at the plasma membrane, suggesting that estradiol efflux from the cells occurs across the plasma membrane. Our data demonstrate that Pdr5 and Snq2 can transport steroid substrates in vivo and suggest that steroids and/or related membrane lipids could represent physiological substrates for certain yeast ABC transporters, which are otherwise involved in the development of pleiotropic drug resistance.	UNIV VIENNA, BIOCTR, DEPT MOL GENET, A-1030 VIENNA, AUSTRIA; UNIV STRASBOURG 1, ECOLE SUPER BIOTECHNOL STRASBOURG, F-67400 STRASBOURG, FRANCE	University of Vienna; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			kuchler, karl/AAL-6937-2020	kuchler, karl/0000-0003-2719-5955				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P2206; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; BORST P, 1993, PHARMACOL THERAPEUT, V60, P289, DOI 10.1016/0163-7258(93)90011-2; BOURGEOIS S, 1993, MOL ENDOCRINOL, V7, P840, DOI 10.1210/me.7.7.840; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; EGNER R, 1995, MOL CELL BIOL, V15, P5879; EGNER R, 1995, MEM PROT TR, V2, P57; GILBERT DM, 1993, MOL CELL BIOL, V13, P462, DOI 10.1128/MCB.13.1.462; GROSS SR, 1970, J CELL BIOL, V44, P103, DOI 10.1083/jcb.44.1.103; HAASE E, 1992, CURR GENET, V21, P319, DOI 10.1007/BF00351689; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; KANE SE, 1996, ADV DRUG RES, V2, P181; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; Kralli A, 1996, J BIOL CHEM, V271, P17152, DOI 10.1074/jbc.271.29.17152; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; KUCHLER K, 1992, COLD SPRING HARB SYM, V57, P579, DOI 10.1101/SQB.1992.057.01.064; LEPPERT G, 1990, GENETICS, V125, P13; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; Metherall JE, 1996, J BIOL CHEM, V271, P2627, DOI 10.1074/jbc.271.5.2627; Metherall JE, 1996, J BIOL CHEM, V271, P2634, DOI 10.1074/jbc.271.5.2634; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; PIERRAT B, 1992, GENE, V119, P237, DOI 10.1016/0378-1119(92)90277-V; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; ROTHMAN JH, 1986, P NATL ACAD SCI USA, V83, P3248, DOI 10.1073/pnas.83.10.3248; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SATHE GM, 1991, NUCLEIC ACIDS RES, V19, P4775, DOI 10.1093/nar/19.17.4775; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SIKORSKI RS, 1989, GENETICS, V122, P19; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; SUBIK J, 1986, CURR GENET, V10, P665, DOI 10.1007/BF00410914; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA K, 1992, J BIOL CHEM, V267, P24248; VANDERBLIEK AM, 1987, EMBO J, V6, P3325, DOI 10.1002/j.1460-2075.1987.tb02653.x; VANKALKEN CK, 1993, BRIT J CANCER, V67, P284, DOI 10.1038/bjc.1993.54; VIEIRA A, 1994, CELL BIOL LAB HDB, V2, P314; WOLF DC, 1992, INT J CANCER, V52, P141, DOI 10.1002/ijc.2910520125; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; ZINSER E, 1993, J BACTERIOL, V175, P2853, DOI 10.1128/JB.175.10.2853-2858.1993	46	126	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25167	25172		10.1074/jbc.271.41.25167	http://dx.doi.org/10.1074/jbc.271.41.25167			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810273	hybrid			2022-12-27	WOS:A1996VL69300017
J	Watabe, Y; Kuramochi, H; Furuya, Y; Inagaki, N; Seino, S; Kimura, S; Shimazaki, J				Watabe, Y; Kuramochi, H; Furuya, Y; Inagaki, N; Seino, S; Kimura, S; Shimazaki, J			Identification of histone H2A.X as a growth factor secreted by an androgen-independent subline of mouse mammary carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHIONOGI CARCINOMA; BREAST-CANCER; PROTEIN; TUMOR; GENE; DNA; TESTOSTERONE; LOCALIZATION; PROGRESSION; EXPRESSION	Shionogi carcinoma 115 (SC 115) cells and Chiba subline 2 (CS 2) cells are clones of an androgen-responsive mouse tumor cell line and its autonomous subline, respectively, We have shown previously that CS 2 cells produce a heparin-binding growth factor that stimulates the growth of SC 115 cells as well as the growth of themselves. In this study, a growth factor was purified from serum-free conditioned media of CS 2 cells cultured without testosterone. A heparin-binding fr action showed growth- promoting activity on SC 115 cells and BALB/3T3 cells. The amino acid sequence analysis revealed that the components were identical to histones H2A.1 and H2A.X. Since histone H2A purified from bovine thymus had almost no growth-promoting activity on SC115 cells, histone H2A.X was assumed to be a growth factor. cDNA of histone H2A.X was cloned from a library of CS 2 cells, and its sequence was confirmed. The expressed product of histone H2A.X cDNA in Escherichia coli showed remarkable stimulatory effects on growth of SC 115 cells cultured in the absence of testesterone, These results indicate that histone H2A.X is secreted from CS 2 cells cultured without testosterone and plays a role as a growth factor.	CHIBA UNIV,SCH MED,CTR BIOMED SCI,DEPT UROL,CHUO KU,CHIBA 260,JAPAN; CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV MOL MED,CHUO KU,CHIBA 260,JAPAN; CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV CARDIOVASC BIOL,CHUO KU,CHIBA 260,JAPAN	Chiba University; Chiba University; Chiba University				Kimura, Sadao/0000-0001-6768-7474; Inagaki, Nobuya/0000-0001-8261-2593				ATEN RF, 1989, J BIOL CHEM, V264, P11065; BONNER WM, 1993, MOL CELL BIOL, V13, P984, DOI 10.1128/MCB.13.2.984; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOE J, 1982, P NATL ACAD SCI-BIOL, V79, P1484, DOI 10.1073/pnas.79.5.1484; DICKSON RB, 1986, ENDOCRINOLOGY, V118, P138, DOI 10.1210/endo-118-1-138; DICKSON RB, 1990, J STEROID BIOCHEM, V37, P305, DOI 10.1016/0960-0760(90)90479-5; FURUYA Y, 1990, CANCER RES, V50, P4979; FUSE H, 1983, ENDOCRINOL JAPON, V30, P189; GRUBER A, 1990, GENE, V95, P303, DOI 10.1016/0378-1119(90)90377-4; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HUFF KK, 1988, MOL ENDOCRINOL, V2, P200, DOI 10.1210/mend-2-3-200; ICHIKAWA T, 1989, CANCER RES, V49, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANNIRONI C, 1989, NUCLEIC ACIDS RES, V17, P9113, DOI 10.1093/nar/17.22.9113; MAY GS, 1987, GENE, V58, P59, DOI 10.1016/0378-1119(87)90029-1; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MINESITA T, 1965, CANCER RES, V25, P1168; NAGATA T, 1991, NUCLEIC ACIDS RES, V19, P2441, DOI 10.1093/nar/19.9.2441; NAKAMURA H, 1994, J BIOL CHEM, V269, P25143; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; REICHHART R, 1985, P NATL ACAD SCI USA, V82, P4871, DOI 10.1073/pnas.82.15.4871; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO N, 1993, JPN J CANCER RES, V84, P1300, DOI 10.1111/j.1349-7006.1993.tb02838.x; SONODA H, 1992, BIOCHEM BIOPH RES CO, V185, P103, DOI 10.1016/S0006-291X(05)80961-1; SUZUKI N, 1983, ENDOCRINOL JAPON, V30, P657; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WEISBROD S, 1982, NATURE, V297, P289, DOI 10.1038/297289a0; WEST MHP, 1980, BIOCHEMISTRY-US, V19, P3238, DOI 10.1021/bi00555a022; WEST MHP, 1983, COMP BIOCHEM PHYS B, V76, P455, DOI 10.1016/0305-0491(83)90275-4; YE RD, 1988, J BIOL CHEM, V263, P4869; ZAMA S, 1987, ENDOCRINOL JAPON, V34, P279; ZUCK B, 1992, J STEROID BIOCHEM, V41, P659, DOI 10.1016/0960-0760(92)90400-D	33	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25126	25130		10.1074/jbc.271.41.25126	http://dx.doi.org/10.1074/jbc.271.41.25126			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810267	hybrid			2022-12-27	WOS:A1996VL69300011
J	Bonnet, H; Filhol, O; Truchet, I; Brethenou, P; Cochet, C; Amalric, F; Bouche, G				Bonnet, H; Filhol, O; Truchet, I; Brethenou, P; Cochet, C; Amalric, F; Bouche, G			Fibroblast growth factor-2 binds to the regulatory beta subunit of CK2 and directly stimulates CK2 activity toward nucleolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; PROTEIN-KINASE; CELL-CYCLE; MITOGENIC ACTIVITY; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; CATALYTIC ACTIVITY; ENDOTHELIAL-CELLS; MOLECULAR-COMPLEX; PHOSPHORYLATION	The presence of fibroblast growth factor-2 (FGF-2) in the nucleus has now been reported both in vitro and in vivo, but its nuclear functions are unknown. Here, we show that FGF-2 added to nuclear extract binds to protein kinase CK2 and nucleolin, a CK2 natural substrate. Added to baculovirus-infected cell extracts overexpressing CK2 or its isolated subunits, FGF-2 binds to the enzyme through its regulatory beta subunit. Using purified proteins, FGF-2 is shown to directly interact with CK2 and to stimulate CK2 activity toward nucleolin. Furthermore, a mitogenic-deficient FGF-2 mutant protein has an impaired ability to interact with CK2 and to stimulate CK2 activity using nucleolin as substrate. We propose that in growing cells, one function of nuclear FGF-2 is to modulate CK2 activity through binding to its regulatory beta subunit.	CNRS, LAB BIOL MOL EUCARYOTE, F-31062 TOULOUSE, FRANCE; CEA, BIOCHIM REGULAT CELLULAIRES ENDOCRINES, INSERM, U244, F-38054 GRENOBLE 9, FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)			Filhol-Cochet, Odile/I-3962-2016	Filhol, Odile/0000-0003-1964-7958; Cochet, Claude/0000-0002-1772-4270				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BALDIN V, 1990, THESIS U P SABATIER; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BURWEN SJ, 1987, TRENDS BIOCHEM SCI, V12, P159, DOI 10.1016/0968-0004(87)90074-0; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; COCHET C, 1983, J BIOL CHEM, V258, P1403; DARBON JM, 1986, J BIOL CHEM, V261, P8002; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONO R, 1994, DEV BIOL, V163, P316, DOI 10.1006/dbio.1994.1151; FILHOL O, 1991, BIOCHEMISTRY-US, V30, P11133, DOI 10.1021/bi00110a016; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FILHOL O, 1990, BIOCHEMISTRY-US, V29, P9928, DOI 10.1021/bi00494a025; FILHOL O, 1991, BIOCHEM BIOPH RES CO, V180, P945, DOI 10.1016/S0006-291X(05)81157-X; GABRIEL B, 1992, THESIS U P SABATIER; GAUTHIERROUVIERE C, 1991, EMBO J, V10, P2921, DOI 10.1002/j.1460-2075.1991.tb07842.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; ISACCHI A, 1991, P NATL ACAD SCI USA, V88, P2628, DOI 10.1073/pnas.88.7.2628; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LEROY D, 1995, J BIOL CHEM, V270, P17400, DOI 10.1074/jbc.270.29.17400; LIN WJ, 1991, J BIOL CHEM, V266, P5664; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LORENZ P, 1993, J BIOL CHEM, V268, P2733; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OLSON MOJ, 1990, EUKARYOTIC NUCLEUS M, V2, P520; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; SACKS DB, 1992, ARCH BIOCHEM BIOPHYS, V299, P275, DOI 10.1016/0003-9861(92)90275-2; SONG JW, 1994, MECH DEVELOP, V48, P141, DOI 10.1016/0925-4773(94)90055-8; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLOA L, 1993, EMBO J, V12, P1633, DOI 10.1002/j.1460-2075.1993.tb05808.x; VALERO E, 1995, J BIOL CHEM, V270, P8345, DOI 10.1074/jbc.270.14.8345; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6	49	122	124	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24781	24787		10.1074/jbc.271.40.24781	http://dx.doi.org/10.1074/jbc.271.40.24781			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798749	hybrid			2022-12-27	WOS:A1996VM67400071
J	Borset, M; Lien, E; Espevik, T; Helseth, E; Waage, A; Sundan, A				Borset, M; Lien, E; Espevik, T; Helseth, E; Waage, A; Sundan, A			Concomitant expression of hepatocyte growth factor scatter factor and the receptor c-MET in human myeloma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; SEQUENCE-ANALYSIS; MULTIPLE-MYELOMA; CARCINOMA-CELLS; SERINE-PROTEASE; PROTOONCOGENE; TUMORIGENICITY; ACTIVATION; BLOOD; BETA	Myeloma cell line supernatants were screened for their ability to inhibit the activity of transforming growth factor-beta (TGF beta) in the mink lung cell (Mv-1-Lu) bioassay. Supernatant from the human myeloma cell line JJN-3 contained potent TGF beta antagonistic activity. This activity was isolated and found to be associated with a 72-78-kDa glycoprotein. Specific polyclonal and monoclonal antibodies were generated toward the 72-78-kDa protein, and these antibodies precipitated the TGF beta inhibitory activity from JJN-3 supernatant. Upon amino acid sequencing the protein appeared to be identical to hepatocyte growth factor (HGF), and some of the generated antibodies directly blocked the action of recombinant HGF in various assays. By HGF-specific polymerase chain reaction we demonstrated that HGF mRNA was expressed in five out of five tested myeloma cell lines. The level of HGF protein in supernatants showed great variation from >500 ng/ml in JJN-3 supernatant to a few ng/ml in the supernatants from other myeloma cell lines. The same five cell lines were also screened for expression the HGF receptor c-MET. Four of them expressed the receptor as shown by reverse transcriptase-polymerase chain reaction and Western blot. The receptor was shown to be constitutively phosphorylated in the human myeloma cell line JJN-3. This receptor could be dephosphorylated by anti-HGF antibodies, indicating the existence of an autocrine HGF loop in this cell line. We propose that HGF/c-MET may play a role in multiple myeloma.			Borset, M (corresponding author), NORWEGIAN UNIV TECHNOL & SCI,INST CANC RES & MOL BIOL,MED TEKN SENTER,N-7005 TRONDHEIM,NORWAY.		Waage, Anders/D-7705-2013; Helseth, Eirik/AAH-2466-2020; Borset, Magne/AAY-1713-2021	Borset, Magne/0000-0001-5179-2835				BATAILLE R, 1989, J CLIN ONCOL, V7, P1909, DOI 10.1200/JCO.1989.7.12.1909; BATAILLE R, 1990, CANCER-AM CANCER SOC, V66, P167, DOI 10.1002/1097-0142(19900701)66:1<167::AID-CNCR2820660130>3.0.CO;2-9; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BORSET M, 1994, EUR J HAEMATOL, V53, P31; Borset M, 1996, J IMMUNOL METHODS, V189, P59, DOI 10.1016/0022-1759(95)00228-6; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CLARK MR, 1981, METHOD ENZYMOL, V73, P12; Comoglio P M, 1993, EXS, V65, P131; EBERT M, 1994, CANCER RES, V54, P5775; ESHHAR Z, 1986, HYBRIDOMA TECHNOLOGY, P1; ESPEVIK T, 1990, CELL IMMUNOL, V126, P47, DOI 10.1016/0008-8749(90)90299-7; FERRACINI R, 1995, ONCOGENE, V10, P739; FULLER K, 1995, BIOCHEM BIOPH RES CO, V212, P334, DOI 10.1006/bbrc.1995.1974; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HOFMANN R, 1992, BIOCHIM BIOPHYS ACTA, V1120, P343, DOI 10.1016/0167-4838(92)90258-F; HOWE PH, 1993, J BIOL CHEM, V268, P21448; JACKSON N, 1989, CLIN EXP IMMUNOL, V75, P93; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MIZUNO K, 1992, BIOCHEM BIOPH RES CO, V189, P1631, DOI 10.1016/0006-291X(92)90264-L; MIZUNO K, 1994, BIOCHEM BIOPH RES CO, V198, P1161, DOI 10.1006/bbrc.1994.1164; MOORE GE, 1968, NEW YORK STATE J MED, V68, P2054; MUNDY GR, 1990, ANN NY ACAD SCI, V593, P91, DOI 10.1111/j.1749-6632.1990.tb16102.x; NAKAMURA S, 1994, BRIT J HAEMATOL, V87, P640, DOI 10.1111/j.1365-2141.1994.tb08330.x; NAKAMURA S, 1994, CYTOKINE, V6, P285, DOI 10.1016/1043-4666(94)90025-6; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NILSSON K, 1970, CLIN EXP IMMUNOL, V7, P477; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P163; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Sambrook J., 2002, MOL CLONING LAB MANU; SATO T, 1995, J CELL PHYSIOL, V164, P197, DOI 10.1002/jcp.1041640124; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Taipale J, 1996, J BIOL CHEM, V271, P4342; TSAO MS, 1993, CELL GROWTH DIFFER, V4, P571; TSARFATY L, 1994, SCIENCE, V263, P98; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	48	119	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24655	24661		10.1074/jbc.271.40.24655	http://dx.doi.org/10.1074/jbc.271.40.24655			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798732	hybrid			2022-12-27	WOS:A1996VM67400054
J	Krell, T; Horsburgh, MJ; Cooper, A; Kelly, SM; Coggins, JR				Krell, T; Horsburgh, MJ; Cooper, A; Kelly, SM; Coggins, JR			Localization of the active site of type II dehydroquinases - Identification of a common arginine-containing motif in the two classes of dehydroquinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROSPRAY MASS-SPECTROMETRY; ASPERGILLUS-NIDULANS; ESCHERICHIA-COLI; MYCOBACTERIUM-TUBERCULOSIS; CATABOLIC 3-DEHYDROQUINASE; SUBSTRATE-BINDING; QUTE GENE; PURIFICATION; RESIDUE; CRYSTALLIZATION	A novel method based on electrospray mass spectrometry (Krell, T., Pitt, A. R., and Coggins, J. R. (1995) FEES Lett, 360, 93-96) has been used to localize active site residues in the type I and type II dehydroquinases. Both enzymes have essential hyper-reactive arginine residues, and the type II enzymes have an essential tyrosine residue. The essential hyper-reactive Arg-23 of the Streptomyces coelicolor type II enzyme has been replaced by lysine, glutamine, and alanine residues. The mutant enzymes were purified and shown by CD spectroscopy to be structurally similar to the wild-type enzyme, All three mutant enzymes were much less active, for example the k(cat) of the R23A mutant was 30,000-fold reduced. The mutants all had reduced K-m values, indicating stronger substrate binding, which was confirmed by isothermal titration calorimetry experiments, A role for Arg-23 in the stabilization of a carbanion intermediate is proposed, Comparison of the amino acid sequence around the hyper-reactive arginine residues of the two classes of enzymes indicates that there is a conserved structural motif that might reflect a common substrate binding fold at the active center of these two classes of enzyme.	UNIV GLASGOW, DIV BIOCHEM & MOL BIOL, INST BIOMED & LIFE SCI, GLASGOW G12 8QQ, LANARK, SCOTLAND; UNIV GLASGOW, DEPT CHEM, GLASGOW G12 8QQ, LANARK, SCOTLAND; UNIV STIRLING, DEPT BIOL & MOL SCI, STIRLING FK9 4LA, SCOTLAND	University of Glasgow; University of Glasgow; University of Stirling			Horsburgh, Malcolm J/H-9657-2013; Kelly, Sharon/K-4611-2013; Krell, Tino/G-7296-2015; Cooper, Alan/F-7813-2011	Krell, Tino/0000-0002-9040-3166; Cooper, Alan/0000-0001-6709-7343; Kelly, Sharon/0000-0002-3516-1387				BERI RK, 1990, BIOCHEM J, V265, P337, DOI 10.1042/bj2650337; BOYS CWG, 1992, J MOL BIOL, V227, P352, DOI 10.1016/0022-2836(92)90704-N; CHAUDHURI S, 1991, BIOCHEM J, V275, P1; CHAUDHURI S, 1986, BIOCHEM J, V239, P699, DOI 10.1042/bj2390699; Cooper A, 1994, Methods Mol Biol, V22, P137; DASILVA AJF, 1986, BIOCHEM J, V240, P481, DOI 10.1042/bj2400481; DEKA RK, 1994, FEBS LETT, V349, P397, DOI 10.1016/0014-5793(94)00710-1; DEKA RK, 1992, J BIOL CHEM, V267, P22237; DUNCAN K, 1986, BIOCHEM J, V238, P475, DOI 10.1042/bj2380475; EUVERINK GJW, 1992, J GEN MICROBIOL, V138, P2449, DOI 10.1099/00221287-138-11-2449; FERRIGE AG, 1992, RAPID COMMUN MASS SP, V6, P707, DOI 10.1002/rcm.1290061115; GARBE T, 1991, MOL GEN GENET, V228, P385, DOI 10.1007/BF00260631; GILES NH, 1985, MICROBIOL REV, V49, P338, DOI 10.1128/MMBR.49.3.338-358.1985; GILL CS, 1989, ANAL BIOCHEM, V64, P2090; GOURLEY DG, 1994, J MOL BIOL, V241, P488, DOI 10.1006/jmbi.1994.1524; HARRIS J, 1993, J CHEM SOC CHEM COMM, P1080, DOI 10.1039/c39930001080; Haslam E., 1974, SHIKIMATE PATHWAY; HAWKINS AR, 1982, BIOCHEM GENET, V20, P271, DOI 10.1007/BF00484424; HAWKINS AR, 1987, CURR GENET, V11, P491, DOI 10.1007/BF00384611; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KLEANTHOUS C, 1990, J BIOL CHEM, V265, P10935; KLEANTHOUS C, 1992, BIOCHEM J, V282, P687, DOI 10.1042/bj2820687; KRELL T, 1995, FEBS LETT, V360, P93, DOI 10.1016/0014-5793(95)00083-L; LEECH AP, 1995, J BIOL CHEM, V270, P25827, DOI 10.1074/jbc.270.43.25827; PAGE MI, 1987, ENZYME MECH, P140; PATTHY L, 1980, EUR J BIOCHEM, V105, P387, DOI 10.1111/j.1432-1033.1980.tb04512.x; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RIORDAN JF, 1979, MOL CELL BIOCHEM, V26, P71; RUTTER WJ, 1964, FED PROC, V23, P1248; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHNEIER A, 1991, J AM CHEM SOC, V113, P9416, DOI 10.1021/ja00024a085; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3582, DOI 10.1021/bi00875a029; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAGUCHI H, 1994, J BIOCHEM-TOKYO, V115, P930, DOI 10.1093/oxfordjournals.jbchem.a124441; VANBERKEL W, 1992, EUR J BIOCHEM, V210, P411; WHITE PJ, 1990, BIOCHEM J, V265, P735, DOI 10.1042/bj2650735; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	37	53	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24492	24497		10.1074/jbc.271.40.24492	http://dx.doi.org/10.1074/jbc.271.40.24492			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798709	hybrid			2022-12-27	WOS:A1996VM67400031
J	LeeFruman, KK; Collins, TL; Burakoff, SJ				LeeFruman, KK; Collins, TL; Burakoff, SJ			Role of the Lck Src homology 2 and 3 domains in protein tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; CROSS-LINKING; KINASE P56LCK; LYMPHOCYTES-T; ZETA-CHAIN; CD4 RECEPTOR; SH3 DOMAINS; ACTIVATION	Many protein tyrosine phosphorylation events that occur as a result of T cell receptor (TCR) stimulation are enhanced when CD4 is co-cross-linked with the TCR, and this increased phosphorylation is thought to be a mechanism by which T cell functions are augmented by CD4. Such enhanced tyrosine phosphorylation was originally attributed to the kinase activity of the CD4-associated tyrosine kinase Lck. However, it has been shown that CD4-associated Lck lacking the catalytic domain can enhance T cell functions, suggesting that the noncatalytic domains of Lck are also important in CD4 signaling. Using T cells expressing various CD4-Lck chimeric molecules, we assessed the role of different Lck domains in early T cell signaling, Following TCR-CD4 co-cross-linking, cells expressing a CD4-Lck full-length chimera showed enhanced tyrosine phosphorylation of many cellular proteins in a CD4-dependent manner. Surprisingly, cells expressing a CD4 Lck chimera lacking the catalytic domain (termed CD4-N32) also showed enhanced phosphorylation. This enhancement of phosphorylation required both the Src homology 2 (SH2) and SH3 domains of Lck, Lck has been postulated to dimerize through the SH2 and SH3 domains. In this way CD4-N32 may interact with endogenous Lck, and although it lacks intrinsic kinase activity, it may be capable of enhancing phosphorylation through the associated full-length Lck. Consistent with this model, when CD4-Lck chimeric molecules were expressed in J.CaM1.6 cells lacking endogenous Lck, CD4-N32 failed to enhance tyrosine phosphorylation. Moreover, a Lck SH2 and SH3 domain fragment expressed as a glutathione S-transferase fusion protein associated with Lck when incubated with activated Jurkat T cell lysates, suggesting that the SH2 and SH3 domains of Lck can associate with endogenous full-length Lck upon activation, Thus, our data suggest that dimerization is an important mechanism of Lck function in T cell activation.	HARVARD UNIV,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02215; HARVARD UNIV,DIV MED SCI,COMM IMMUNOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02215	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard University; Harvard Medical School					NIAID NIH HHS [AI17258] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017258] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AMREIN KE, 1993, P NATL ACAD SCI USA, V90, P10285, DOI 10.1073/pnas.90.21.10285; ANDERSON P, 1987, J IMMUNOL, V139, P678; BUDAY L, 1994, J BIOL CHEM, V269, P9019; COLLINS TL, 1992, J IMMUNOL, V148, P2159; COLLINS TL, 1993, P NATL ACAD SCI USA, V90, P11885, DOI 10.1073/pnas.90.24.11885; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DASILVA AJ, 1993, J EXP MED, V178, P2107, DOI 10.1084/jem.178.6.2107; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EICHMANN K, 1987, EUR J IMMUNOL, V17, P643, DOI 10.1002/eji.1830170510; EMMRICH F, 1987, EUR J IMMUNOL, V17, P529, DOI 10.1002/eji.1830170415; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HSI ED, 1989, J BIOL CHEM, V264, P10836; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OWENS T, 1987, P NATL ACAD SCI USA, V84, P9209, DOI 10.1073/pnas.84.24.9209; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAVICHANDRAN KS, 1994, J EXP MED, V179, P727, DOI 10.1084/jem.179.2.727; Ribon V, 1996, MOL CELL BIOL, V16, P45; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANOERS NSC, 1994, J IMMUNOL METHODS, V170, P261, DOI 10.1016/0022-1759(94)90401-4; VEILLETTE A, 1990, EUR J IMMUNOL, V20, P1397, DOI 10.1002/eji.1830200628; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WALKER C, 1987, EUR J IMMUNOL, V17, P873, DOI 10.1002/eji.1830170622; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISSMAN AM, 1988, J IMMUNOL, V141, P3532; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	57	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					25003	25010		10.1074/jbc.271.40.25003	http://dx.doi.org/10.1074/jbc.271.40.25003			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798782	hybrid			2022-12-27	WOS:A1996VM67400105
J	Savenkova, MI; Newmyer, SL; deMontellano, PRO				Savenkova, MI; Newmyer, SL; deMontellano, PRO			Rescue of His-42->Ala horseradish peroxidase by a Phe-41->His mutation - Engineering of a surrogate catalytic histidine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; HEME-LINKED IONIZATION; CRYSTAL-STRUCTURE; PROSTHETIC HEME; HYDROGEN-PEROXIDE; COMPOUND-I; RESOLUTION; TRYPTOPHAN-51; SULFOXIDATION; REACTIVITY	Formation of the ferryl (Fe-IV=O) porphyrin radical cation known as Compound I in the reaction of horseradish peroxidase (HRP) with H2O2 is catalyzed by His-42, a residue that facilitates the binding of H2O2 to the iron and subsequent rupture of the dioxygen bond, An H42A mutation was shown earlier to decrease the rate of Compound I formation by a factor of similar to 10(6) and of guaiacol oxidation by a factor of similar to 10(4), In contrast, an F41A mutation has little effect on peroxidative catalysis (Newmyer, S. L., and Ortiz de Montellano, P. R. (1995) J. Biol. Chem. 270, 19430-19438). We report here construction, expression, and characterization of the F41H/H42A double mutant. The pH profile for guaiacol oxidation by this double mutant has a broad maximum at similar to pH 6.3. Addition of H2O2 produces a Compound I species (lambda(max) = 406 nm) that is reduced by 1 eq of K4Fe(CN)(6) to the ferric state (lambda(max) = 407 nm) without the detectable formation of Compound II. A fraction of the heme chromophore is lost in the process, The rate of Compound I formation for the F41H/H42A double mutant is 3.0 x 10(4) M(-1) s(-1). This is to be compared with 0.9 x 10(7) M(-1) s(-1) for wild-type HRP and 19 M(-1) s(-1) for the H42A mutant, The k(cat) values for guaiacol oxidation by wild-type, H42A, and F41H/H42A HRP are 300, 0.015, and 1.8 s(-1). The corresponding k(cat) values for ABTS oxidation are 4900, 0.41, and 100 s(-1), respectively. These results show that a histidine at position 41 substitutes, albeit imperfectly, for His-42 in peroxidative turnover of the enzyme, The F41H/H42A double mutant has peroxidative properties intermediate between those of the native enzyme and the H42A mutant. The F41H/H42A double mutant, however, is a considerably better thioanisole sulfoxidation and styrene epoxidation catalyst than native or H42A HRP, The surrogate catalytic residue introduced by the F41H mutation thus partially compensates for the H42A substitution used to increase access to the ferryl oxygen.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco			Savenkova, Marina/AAN-9927-2021	Newmyer, Sherri/0000-0003-1039-5416	NIGMS NIH HHS [GM32488] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATOR MA, 1987, J BIOL CHEM, V262, P14954; ATOR MA, 1987, J BIOL CHEM, V262, P1542; DEMONTELLANO PRO, 1987, ACCOUNTS CHEM RES, V20, P289; DEMONTELLANO PRO, 1995, BIOCHEM SOC T, V23, P223, DOI 10.1042/bst0230223; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FISHEL LA, 1987, BIOCHEMISTRY-US, V26, P351, DOI 10.1021/bi00376a004; Gilfoyle DJ, 1996, EUR J BIOCHEM, V236, P714, DOI 10.1111/j.1432-1033.1996.00714.x; GOODIN DB, 1991, BIOCHEMISTRY-US, V30, P4953, DOI 10.1021/bi00234a017; HARRIS RZ, 1993, J BIOL CHEM, V268, P1637; HASHIMOTO S, 1986, P NATL ACAD SCI USA, V83, P2417, DOI 10.1073/pnas.83.8.2417; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; MILLER VP, 1992, J BIOL CHEM, V267, P8936; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; NEWMYER SL, 1995, J BIOL CHEM, V270, P19430, DOI 10.1074/jbc.270.33.19430; OZAKI S, 1995, J AM CHEM SOC, V117, P7056, DOI 10.1021/ja00132a003; OZAKI SI, 1994, J AM CHEM SOC, V116, P4487, DOI 10.1021/ja00089a052; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4331, DOI 10.1021/bi00013a023; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1993, J BIOL CHEM, V268, P4429; RODRIGUEZLOPEZ JN, 1996, IN PRESS J BIOINORG; Schuller DJ, 1996, STRUCTURE, V4, P311, DOI 10.1016/S0969-2126(96)00035-4; SITTER AJ, 1985, J BIOL CHEM, V260, P7515; SMITH AT, 1992, EUR J BIOCHEM, V207, P507, DOI 10.1111/j.1432-1033.1992.tb17077.x; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; WELINDER KG, 1985, EUR J BIOCHEM, V151, P497, DOI 10.1111/j.1432-1033.1985.tb09129.x; Welinder KG., 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [10.1016/0959-440x(92)90230-5, DOI 10.1016/0959-440X(92)90230-5]	29	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24598	24603		10.1074/jbc.271.40.24598	http://dx.doi.org/10.1074/jbc.271.40.24598			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798724	hybrid			2022-12-27	WOS:A1996VM67400046
J	Bolhuis, H; vanVeen, HW; Brands, JR; Putman, M; Poolman, B; Driessen, AJM; Konings, WN				Bolhuis, H; vanVeen, HW; Brands, JR; Putman, M; Poolman, B; Driessen, AJM; Konings, WN			Energetics and mechanism of drug transport mediated by the lactococcal multidrug transporter LmrP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACILLUS-SUBTILIS; P-GLYCOPROTEIN; LACTIC STREPTOCOCCI; RESISTANCE PROTEIN; ACTIVE EFFLUX; GENE; SYSTEMS; CELLS; TETRACYCLINE	The gene encoding the secondary multidrug transporter LmrP of Lactococcus lactis was heterologously expressed in Escherichia coli. The energetics and mechanism of drug extrusion mediated by LmrP were studied in membrane vesicles of E. coli, LmrP-mediated extrusion of tetraphenyl phosphonium (TPP+) from right-side-out membrane vesicles and uptake of the fluorescent membrane probe 1-[4-(trimethylamino)phenyl]-6-phenylhexa-1,3,5-triene (TMA-DPH) into inside-out membrane vesicles are driven by the membrane potential (Delta psi) and the transmembrane proton gradient (Delta pH), pointing to an electrogenic drug/proton antiport mechanism, Ethidium bromide, a substrate for LmrP, inhibited the LmrP-mediated TPP+ extrusion from right-side-out membrane vesicles, showing that LmrP is capable of transporting structurally unrelated drugs. Kinetic analysis of LmrP-mediated TMA-DPH transport revealed a direct relation between the transport rate and the amount of TMA-DPH associated with the cytoplasmic leaflet of the lipid bilayer. This observation indicates that drugs are extruded from the inner leaflet of the cytoplasmic membrane into the external medium. This is the first report that shows that drug extrusion by a secondary multidrug resistance (MDR) transporter occurs by a ''hydrophobic vacuum cleaner'' mechanism in a similar way as was proposed for the primary lactococcal MDR transporter, LmrA.	UNIV GRONINGEN, DEPT MICROBIOL, GRONINGEN BIOMOL SCI & BIOTECHNOL INST, NL-9751 NN HAREN, NETHERLANDS	University of Groningen			Driessen, Arnold J.M./D-1876-2012; van Veen, Hendrik W./A-4162-2008; Bolhuis, Henk/H-8535-2014; Bolhuis, Henk/A-4308-2008; Bolhuis, Henk/M-6677-2019; Bolhuis, Henk/S-2986-2019; Konings, Wilhelmus N./C-7063-2013	van Veen, Hendrik W./0000-0002-9658-8077; Bolhuis, Henk/0000-0002-4772-1898; Bolhuis, Henk/0000-0002-4772-1898; Driessen, Arnold J.M./0000-0001-9258-9104				AHMED M, 1993, J BIOL CHEM, V268, P11086; AMBUDKAR SV, 1984, J BIOL CHEM, V259, P6142; BARABAS K, 1992, J BIOL CHEM, V267, P9437; BIELICKI JK, 1991, BIOCHIM BIOPHYS ACTA, V1085, P7, DOI 10.1016/0005-2760(91)90225-7; BOLHUIS H, 1994, J BACTERIOL, V176, P6957, DOI 10.1128/JB.176.22.6957-6964.1994; BOLHUIS H, 1995, J BIOL CHEM, V270, P26092, DOI 10.1074/jbc.270.44.26092; BOLHUIS H, 1996, IN PRESS EMBO J; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; GASSON MJ, 1983, J BACTERIOL, V154, P1; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRINIUS LL, 1994, J BIOL CHEM, V269, P29998; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; Kaback H R, 1974, Methods Enzymol, V31, P698; KOK J, 1984, APPL ENVIRON MICROB, V48, P726, DOI 10.1128/AEM.48.4.726-731.1984; KUHRY JG, 1985, BIOCHIM BIOPHYS ACTA, V845, P60, DOI 10.1016/0167-4889(85)90055-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6; LOMOVSKAYA O, 1992, P NATL ACAD SCI USA, V89, P8938, DOI 10.1073/pnas.89.19.8938; MA D, 1995, MOL MICROBIOL, V16, P45, DOI 10.1111/j.1365-2958.1995.tb02390.x; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; MOLENAAR D, 1992, J BACTERIOL, V174, P3118, DOI 10.1128/jb.174.10.3118-3124.1992; MULDER HS, 1993, EUR J BIOCHEM, V218, P871, DOI 10.1111/j.1432-1033.1993.tb18443.x; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; PAULSEN IT, 1993, GENE, V124, P1, DOI 10.1016/0378-1119(93)90755-R; PRENDERGAST FG, 1981, BIOCHEMISTRY-US, V20, P7333, DOI 10.1021/bi00529a002; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SAIER MH, 1994, MOL MICROBIOL, V11, P841, DOI 10.1111/j.1365-2958.1994.tb00362.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; SHINBO T, 1978, ARCH BIOCHEM BIOPHYS, V187, P414, DOI 10.1016/0003-9861(78)90052-8; SIKKEMA J, 1995, MICROBIOL REV, V59, P201, DOI 10.1128/MMBR.59.2.201-222.1995; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; STEIN WD, 1994, MOL PHARMACOL, V45, P763; VANSCHIE BJ, 1985, J BACTERIOL, V163, P493, DOI 10.1128/JB.163.2.493-499.1985; VANVEEN HW, 1986, HDB BIOL PHYSICS, V2; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; YOSHIDA H, 1990, J BACTERIOL, V172, P6942, DOI 10.1128/jb.172.12.6942-6949.1990	47	97	99	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24123	24128		10.1074/jbc.271.39.24123	http://dx.doi.org/10.1074/jbc.271.39.24123			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798651	Green Published, hybrid			2022-12-27	WOS:A1996VJ44200080
J	Ward, NE; Gravitt, KR; OBrian, CA				Ward, NE; Gravitt, KR; OBrian, CA			Covalent modification of protein kinase C isozymes by the inactivating peptide substrate analog N-biotinyl-Arg-Arg-Arg-Cys-Leu-Arg-Arg-Leu - Evidence that the biotinylated peptide is an active-site affinity label	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; RAT FIBROBLASTS; GROWTH-CONTROL; BINDING-SITE; S-THIOLATION; EXPRESSION; INHIBITION; EPSILON; DOMAIN; OVEREXPRESSION	We recently reported that the peptide substrate analog Arg-Lys-Arg-Cys-Leu-Arg-Arg-Leu (RKRCLRRL) irreversibly inactivates the protein kinase C (PKC) isozymes alpha, beta, and gamma in a dithiothreitol-sensitive manner by an active site-directed mechanism. We hypothesized that the inactivation mechanism entailed covalent complex formation between the PKC isozyme and the inactivator peptide. In this report, N-biotinylated analogs of RKRCLRRL that inactivate Ca2+-dependent PKC activity were designed and tested for their ability to covalently label PKC isozymes. A purified PKC isozyme mixture (alpha, beta, gamma, epsilon, zeta) was incubated with the N-biotinylated peptides and then subjected to denaturing gel electrophoresis, transferred to nitrocellulose, and probed for avidin-reactive species. The Ca2+-dependent PKC subfamily members PKC-alpha, -beta, and -gamma comigrated at 82 kDa and were distinguished by isozyme-specific immunoprecipitation. N-Biotinyl-RRRCLRRL covalently labeled all of the isozymes examined. When the isozymes were denatured prior to incubation with the N-biotinylated peptides, no labeling was observed, Inactivation of the Ca2+-dependent PKC subfamily by the N-biotinylated peptides was associated with covalent labeling of the 82-kDa PKC subspecies. The concentration dependence curves observed with N-biotinyl-RRRCLRRL were similar for inactivation and covalent labeling. The rank order of potency of three N-biotinylated peptides was the same for the inactivation and covalent labeling. Both the inactivation and covalent labeling were dithiothreitol-sensitive, and they were each subject to protection by MgATP and a peptide substrate analog. The covalent label was mapped to the catalytic domain of PKC by limited proteolysis of the modified enzyme. These results provide evidence that the N-biotinylated inactivator peptides are active-site affinity labels of PKC. The inactivator peptides most likely function by S-thiolating the active site Cys residue conserved in PKC. This is the first report to demonstrate covalent labeling of PKC by a peptide substrate analog.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CELL BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			reddy, indra p/C-5363-2011		NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASU A, 1993, PHARMACOL THERAPEUT, V59, P257, DOI 10.1016/0163-7258(93)90070-T; BLOBE GC, 1993, J BIOL CHEM, V268, P658; BOTTEGA R, 1992, BIOCHEMISTRY-US, V31, P9025, DOI 10.1021/bi00152a045; BRAMSON HN, 1982, J BIOL CHEM, V257, P575; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; CACACE AM, 1993, ONCOGENE, V8, P2095; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; GESCHER A, 1992, BRIT J CANCER, V66, P10, DOI 10.1038/bjc.1992.209; GOPALAKRISHNA R, 1991, ARCH BIOCHEM BIOPHYS, V285, P382, DOI 10.1016/0003-9861(91)90377-U; GRAVITT KR, 1994, BIOCHEM PHARMACOL, V47, P425, DOI 10.1016/0006-2952(94)90037-X; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; Gupta KP, 1996, J BIOL CHEM, V271, P2102, DOI 10.1074/jbc.271.4.2102; HAGIWARA M, 1990, CANCER RES, V50, P5515; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOIDE H, 1992, P NATL ACAD SCI USA, V89, P1149, DOI 10.1073/pnas.89.4.1149; KRAUSS RS, 1989, ONCOGENE, V4, P991; KUO JF, 1994, PROTEIN KINASE; MILLER WT, 1988, P NATL ACAD SCI USA, V85, P5429, DOI 10.1073/pnas.85.15.5429; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OBRIAN CA, 1990, BIOCHEMISTRY-US, V29, P4278, DOI 10.1021/bi00470a003; OBRIAN CA, 1989, MOL PHARMACOL, V36, P355; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; SALERNO A, 1993, J BIOL CHEM, V268, P13043; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; WARD NE, 1993, BIOCHEMISTRY-US, V32, P11903, DOI 10.1021/bi00095a020; WARD NE, 1995, J BIOL CHEM, V270, P8056, DOI 10.1074/jbc.270.14.8056; WEINSTEIN IB, 1990, ADV SEC MESS PHOSPH, V24, P307; WILCHEK M, 1990, METHOD ENZYMOL, V184, P14; WU JC, 1989, J BIOL CHEM, V264, P7989; ZOLLER MJ, 1979, J BIOL CHEM, V254, P8363	39	12	12	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24193	24200		10.1074/jbc.271.39.24193	http://dx.doi.org/10.1074/jbc.271.39.24193			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798661				2022-12-27	WOS:A1996VJ44200090
J	Wood, WM; Dowding, JM; Bright, TM; McDermott, MT; Haugen, BR; Gordon, DF; Ridgway, EC				Wood, WM; Dowding, JM; Bright, TM; McDermott, MT; Haugen, BR; Gordon, DF; Ridgway, EC			Thyroid hormone receptor beta 2 promoter activity in pituitary cells is regulated by Pit-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PIT-1; RAT PROLACTIN PROMOTER; ALPHA-SUBUNIT GENE; GROWTH-HORMONE; EXPRESSION; THYROTROPES; PROTEIN; IDENTIFICATION; BINDING; DOMAIN	There are three known thyroid hormone receptor (TR) isoforms that arise from two distinct alpha and beta gene loci. TR alpha 1 and TR beta 1 mRNAs are found in many tissues, whereas mRNA for the N-terminal TR beta 2 variant derived from the beta locus is readily detectable only in the pituitary gland and derived cell sources such as GH3 somatotropes and TtT-97 thyrotropes. We previously isolated the genomic region governing expression of the TR beta 2 isoform in thyrotropes and showed that transcription arose from multiple origins within a 400-base pair (bp) region. We now report that the region extending 500 bp upstream of the putative AUG codon (A is +1) contains six areas of interaction with the pituitary-specific transcription factor Pit-1. In addition there are separate areas that bind other factors present in thyrotrope cells. Promoter deletions revealed that removal of regions containing the Pit-1 sites at -456 to -432, -149 to -127, and -124 to -102 progressively decreased TR beta 2 promoter activity in thyrotropes. A more proximal foot printed area from -65 to -19, which accounted for the remaining promoter activity, contained sites that interacted with recombinant Pit-1; however, extracts of TtT-97 thyrotropes, which express Pit-1, footprinted this proximal region with a pattern of protection that differed from that produced by Pit-1. A comparative deletional analysis demonstrated that a shorter region extending only 204 bp from the AUG was sufficient to support TR beta 2 promoter activity in GH3 somatotropes. The more proximal Pit-1 sites, including the area from -53 to -19, whose pattern differed from Pit-1 in thyrotrope extracts, showed protection patterns with GH3 extracts that were indistinguishable from recombinant Pit-1. Site-directed mutagenesis that abrogated binding of both recombinant Pit-1 and Pit-1-containing nuclear extracts revealed that the two Pit-1 sites between -149 and -102 were important for TR beta 2 promoter activity with the more proximal being most critical. Finally, we showed that TR beta 2 promoter activity in alpha-TSH cells, which do not transcribe the endogenous TR beta 2 locus or produce Pit-1 protein, could be reconstituted to a level approaching that seen in expressing TtT-97 thyrotropes by cotransfecting a Pit-1 expression vector. Activation by Pit-1 was dependent on the same Pit-1 sites shown to be important for basal TR beta 2 promoter activity in thyrotropes as constructs lacking them by deletion or mutation were not stimulated by Pit-1.			Wood, WM (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT MED ENDOCRINOL B151,DIV ENDOCRINOL,4200 E 9TH AVE,DENVER,CO 80262, USA.				NATIONAL CANCER INSTITUTE [R01CA047411] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47411] Funding Source: Medline; NIDDK NIH HHS [DK-36842] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKERBLOM IE, 1990, MOL ENDOCRINOL, V4, P589, DOI 10.1210/mend-4-4-589; ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; AYLWIN SJB, 1995, J MOL ENDOCRINOL, V15, P221, DOI 10.1677/jme.0.0150221; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; CASTRILLO JL, 1989, SCIENCE, V243, P814, DOI 10.1126/science.2563596; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CHILDS GV, 1991, ENDOCRINOLOGY, V129, P2767, DOI 10.1210/endo-129-5-2767; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; EISHOLTZ HP, 1991, GENE DEV, V4, P43; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GORDON DF, 1993, MOL CELL ENDOCRINOL, V96, P75, DOI 10.1016/0303-7207(93)90097-4; HAUGEN BR, 1994, MOL ENDOCRINOL, V8, P1574, DOI 10.1210/me.8.11.1574; Haugen BR, 1996, J BIOL CHEM, V271, P385, DOI 10.1074/jbc.271.1.385; HAUGEN BR, 1993, J BIOL CHEM, V268, P20818; HODIN RA, 1990, J CLIN INVEST, V85, P101, DOI 10.1172/JCI114398; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; HOLLOWAY JM, 1995, GENE DEV, V9, P1992, DOI 10.1101/gad.9.16.1992; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; LIN CJ, 1992, NATURE, V360, P765, DOI 10.1038/360765a0; LIN SC, 1994, DEVELOPMENT, V120, P515; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MCCORMICK A, 1988, CELL, V55, P379, DOI 10.1016/0092-8674(88)90061-X; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; OCRAN KW, 1990, MOL ENDOCRINOL, V4, P766, DOI 10.1210/mend-4-5-766; RAJNARAYAN S, 1995, MOL ENDOCRINOL, V9, P502, DOI 10.1210/me.9.4.502; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; SARAPURA VD, 1992, THYROID, V2, P31, DOI 10.1089/thy.1992.2.31; SCHWARTZ HL, 1994, J BIOL CHEM, V269, P24777; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SMITH KP, 1995, J BIOL CHEM, V270, P4484, DOI 10.1074/jbc.270.9.4484; STEINFELDER HJ, 1992, P NATL ACAD SCI USA, V89, P5942, DOI 10.1073/pnas.89.13.5942; SUN JD, 1993, J BIOL CHEM, V268, P1505; SUZUKI S, 1995, MOL ENDOCRINOL, V9, P1288, DOI 10.1210/me.9.10.1288; TANSEY WP, 1991, J BIOL CHEM, V266, P9805; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; VOSS JW, 1992, CELL, V70, P527, DOI 10.1016/0092-8674(92)90422-9; WOOD WM, 1994, MOL ENDOCRINOL, V8, P1605, DOI 10.1210/me.8.12.1605; WOOD WM, 1991, MOL ENDOCRINOL, V5, P1049, DOI 10.1210/mend-5-8-1049; WOOD WM, 1990, MOL ENDOCRINOL, V4, P1897, DOI 10.1210/mend-4-12-1897; WOOD WM, 1989, J BIOL CHEM, V264, P14840; ZHANG DE, 1994, J BIOL CHEM, V269, P11425	51	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24213	24220		10.1074/jbc.271.39.24213	http://dx.doi.org/10.1074/jbc.271.39.24213			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798664				2022-12-27	WOS:A1996VJ44200093
J	Parekh, AB				Parekh, AB			Nonhydrolyzable analogues of GTP activate a new Na+ current in a rat mast cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; CALCIUM INFLUX; SODIUM-CHANNEL; PROTEINS	Whole cell patch clamp experiments were performed to examine the effects of the nonhydrolyzable GTP analogue, guanosine 5'-3-O-(thio)triphosphate, on membrane currents in rat basophilic leukemia cells, Guanosine 5'-3-O-(thio)triphosphate activated an inward sodium current, This current had a new permeability sequence to monovalent cations and a different pharmacological profile to that of other characterized Na+ channels. Long hyperpolarizing steps revealed that the current declined during the pulse, and the decline was voltage-dependent. Activation of the current required Mg2+ and ATP. The nonhydrolyzable ATP analogues, adenosine 5'-O-(thio)triphosphate and adenosine 5'-(beta,gamma-imino)triphosphate, could not substitute for ATP, Soluble second messengers like cAMP, cGMP, inositol polyphosphates, and Ca2+ did not activate the Na+ current, These results suggest that nonhydrolyzable GTP analogues activate a Na+ current in rat basophilic leukemia cells that is new in terms of its selectivity, pharmacology, and activation mechanism. It may be the prototype for a new family of Na+ channels expressed in certain nonexcitable cells.	MAX PLANCK INST BIOPHYS CHEM,D-37077 GOTTINGEN,GERMANY	Max Planck Society								Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; BUBIEN JK, 1993, AM J PHYSIOL, V265, pC1175, DOI 10.1152/ajpcell.1993.265.4.C1175; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; EISENMAN G, 1962, Biophys J, V2, P259; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLE B, 1972, J GEN PHYSIOL, V59, P637, DOI 10.1085/jgp.59.6.637; Hille B., 1992, IONIC CHANNELS EXCIT; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; KAHN RA, 1991, J BIOL CHEM, V266, P15595; LEDERER WJ, 1990, SCIENCE, V248, P376; Mandel G, 1993, Curr Opin Neurobiol, V3, P278, DOI 10.1016/0959-4388(93)90118-I; MCCLOSKEY MA, 1990, J GEN PHYSIOL, V95, P205, DOI 10.1085/jgp.95.2.205; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	21	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23161	23168		10.1074/jbc.271.38.23161	http://dx.doi.org/10.1074/jbc.271.38.23161			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798510	hybrid			2022-12-27	WOS:A1996VH76800036
J	Pio, F; Kodandapani, R; Ni, CZ; Shepard, W; Klemsz, M; McKercher, SR; Maki, RA; Ely, KR				Pio, F; Kodandapani, R; Ni, CZ; Shepard, W; Klemsz, M; McKercher, SR; Maki, RA; Ely, KR			New insights on DNA recognition by ets proteins from the crystal structure of the PU.1 ETS domain DNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; BINDING DOMAIN; V-ETS; ONCOGENE; MOTIF; RESOLUTION; C-ETS-1; FAMILY; HELIX; ELK-1	Transcription factors belonging to the ets family regulate gene expression and share a conserved ETS DNA-binding domain that binds to the core sequence 5'-(C/ A)GGA(A/T)-3'. The domain is similar to alpha+beta (''winged'') helix-turn-helix DNA-binding proteins. The crystal structure of the PU.1 ETS domain complexed to a 16-base pair oligonucleotide revealed a pattern for DNA recognition from a novel loop-helix-loop architecture (Kodandapani, R., Pio, F., Ni, C.-Z., Piccialli, G., Klemsz, M., McKercher, S., Maki, R. A., and Ely, K. R. (1996) Nature 380, 456-460). Correlation of this model with mutational analyses and chemical shift data on other ets proteins confirms this complex as a paradigm for ets DNA recognition. The second helix in the helix-turn-helix motif lies deep in the major groove with specific contacts with bases in both strands in the core sequence made by conserved residues in alpha 3. On either side of this helix, two loops contact the phosphate backbone. The DNA is bent (8 degrees) but uniformly curved without distinct kinks. ETS domains bind DNA as a monomer yet make extensive DNA contacts over 30 Angstrom. DNA bending likely results from phosphate neutralization of the phosphate backbone in the minor groove by both loops in the loop-helix-loop motif. Contacts from these loops stabilize DNA bending and may mediate specific base interactions by inducing a bend toward the protein.	BURNHAM INST,LA JOLLA CANC RES CTR,LA JOLLA,CA 92037; UNIV PARIS 11,LURE,F-91405 ORSAY,FRANCE; NEUROCRINE BIOSCI,SAN DIEGO,CA 92121	Sanford Burnham Prebys Medical Discovery Institute; UDICE-French Research Universities; Universite Paris Saclay; Neurocrine Biosciences				pio, frederic/0000-0003-2050-847X; Shepard, William/0000-0002-5724-1193	NATIONAL CANCER INSTITUTE [R01CA063489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020194] Funding Source: NIH RePORTER; NCI NIH HHS [CA63489] Funding Source: Medline; NIAID NIH HHS [AI20194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABCOCK MS, 1994, J MOL BIOL, V237, P98, DOI 10.1006/jmbi.1994.1212; BEAMER LJ, 1992, J MOL BIOL, V227, P177, DOI 10.1016/0022-2836(92)90690-L; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BRENNAN R, 1992, CURR OPIN STRUC BIOL, V2, P100; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CROTHERS DM, 1994, SCIENCE, V266, P18; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; JANKNECHT R, 1994, ONCOGENE, V9, P1273; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE A, 1994, MOSFLM USER GUIDE MO; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MAVROTHALASSITIS G, 1994, ONCOGENE, V9, P425; MONDRAGON A, 1991, J MOL BIOL, V219, P321, DOI 10.1016/0022-2836(91)90568-Q; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PIO F, 1995, J BIOL CHEM, V270, P24258, DOI 10.1074/jbc.270.41.24258; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHORE P, 1995, J BIOL CHEM, V270, P5805, DOI 10.1074/jbc.270.11.5805; SOUDANT N, 1994, NUCLEIC ACIDS RES, V22, P3871, DOI 10.1093/nar/22.19.3871; STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; 1994, ACTA CRYSTALLOGR, V50, P760	48	77	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23329	23337		10.1074/jbc.271.38.23329	http://dx.doi.org/10.1074/jbc.271.38.23329			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798534	hybrid			2022-12-27	WOS:A1996VH76800060
J	Thaler, CD; Cardullo, RA				Thaler, CD; Cardullo, RA			The initial molecular interaction between mouse sperm and the zona pellucida is a complex binding event	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED OLIGOSACCHARIDES; ALPHA-D-MANNOSIDASE; ACROSOME REACTION; SURFACE GALACTOSYLTRANSFERASE; RECEPTOR ACTIVITY; PLASMA-MEMBRANE; EGG BINDING; GLYCOPROTEIN ZP3; TYROSINE KINASE; FERTILIZATION	Prior to fertilization, mammalian sperm must first bind to the zona pellucida (ZP), a glycoprotein matrix surrounding the egg. Sperm specifically bind to ZP3, an 83-kDa glycoprotein which functions as both an adhesion molecule and as a secretagogue for acrosomal exocytosis (Litscher, E. S., and Wassarman, P. M. (1993) Trends Glycosci. Glycotechnol. 5, 369-388). We used acid solubilized, I-125-labeled ZPs to quantify the initial binding event on mouse spermatozoa. Live sperm could not be used since solubilized ZPs rapidly initiated exocytosis. Instead, acrosome intact mouse sperm were briefly fixed in 1% glutaraldehyde for binding studies using a standard filtration assay. The fixed sperm are suitable for sperm-zona binding assays based on two experiments: 1) incubating either live or fixed sperm in low concentrations of I-125-Zps not sufficient to induce acrosomal exocytosis revealed no differences in binding up to 15 min and 2) solubilized, unlabeled ZPs competed for I-125-ZPs with K-I of approximately 3.78 nM. Sperm-I-125-Zp binding reached equilibrium with a tau(1/2) of similar to 22 min at 37 degrees C. Affinity parameters were calculated using the well substantiated assumption that only ZP3 binds intact mouse sperm. The on-rate constant for association of I-125-Zp binding to the mouse sperm surface was calculated to be 3.2 x 10(6) hr(-1) min(-1). The saturation binding isotherm revealed that there are approximately 30,000 binding sites, ascribed to ZP3, with an EC(50) of 1.29 nM. Further analysis indicated that this binding is complex (Hill coefficient = 1.72), suggesting involvement of multiple receptors on the sperm surface and/or multiple ligand moieties, High and low affinity ZP binding sites on the sperm surface were confirmed by dissociation experiments. I-125-Zp dissociation was clearly biphasic, and kinetic off-rate constants of 0.161 min(-1) and 0.0023 min(-1) were calculated for the low and high affinity sites, respectively. Apparent affinities (K-d values) of 50 nM for the low affinity and 0.72 nM for the high affinity interaction were calculated from the rate constants. These data demonstrate that the initial adhesion event between mouse sperm and the zona pellucida is a high affinity event which is sufficient to tether a sperm to the extracellular matrix prior to the induction of acrosomal exocytosis.	UNIV CALIF RIVERSIDE,DEPT BIOL,RIVERSIDE,CA 92521	University of California System; University of California Riverside			Cardullo, Richard/GVT-2950-2022		NICHD NIH HHS [HD27244] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027244, R55HD027244] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BALTZ JM, 1989, GAMETE RES, V24, P1, DOI 10.1002/mrd.1120240103; BALTZ JM, 1988, BIOPHYS J, V54, P643, DOI 10.1016/S0006-3495(88)83000-5; BENAU DA, 1987, BIOL REPROD, V36, P282, DOI 10.1095/biolreprod36.2.282; BLEIL JD, 1980, DEV BIOL, V76, P185, DOI 10.1016/0012-1606(80)90371-1; BLEIL JD, 1988, DEV BIOL, V128, P376, DOI 10.1016/0012-1606(88)90299-0; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BLEIL JD, 1988, P NATL ACAD SCI USA, V85, P6778, DOI 10.1073/pnas.85.18.6778; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; BLEIL JD, 1986, J CELL BIOL, V102, P1363, DOI 10.1083/jcb.102.4.1363; BLEIL JD, 1983, DEV BIOL, V95, P317, DOI 10.1016/0012-1606(83)90032-5; CARDULLO RA, 1989, BIOCHEMISTRY-US, V28, P1611, DOI 10.1021/bi00430a028; CARDULLO RA, 1995, BIOCHEMISTRY-US, V34, P10027, DOI 10.1021/bi00031a026; CHAMBERLIN ME, 1990, P NATL ACAD SCI USA, V87, P6014, DOI 10.1073/pnas.87.16.6014; Chen Q., 1994, Molecular Biology of the Cell, V5, p224A; CHENG A, 1994, J CELL BIOL, V125, P867, DOI 10.1083/jcb.125.4.867; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; CORNWALL GA, 1991, BIOL REPROD, V44, P913, DOI 10.1095/biolreprod44.5.913; ENDO Y, 1987, DEV BIOL, V119, P210, DOI 10.1016/0012-1606(87)90222-3; ENDO Y, 1988, DEV BIOL, V129, P199; FLORMAN HM, 1984, DEV BIOL, V106, P243, DOI 10.1016/0012-1606(84)90079-4; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; FLORMAN HM, 1981, J EXP ZOOL, V216, P159, DOI 10.1002/jez.1402160117; FLORMAN HM, 1982, DEV BIOL, V91, P121, DOI 10.1016/0012-1606(82)90015-X; GWATKIN RBL, 1977, J REPROD FERTIL, V49, P55, DOI 10.1530/jrf.0.0490055; HULME EC, 1992, RECEPTOR LIGAND INTE, P177; INOUE M, 1975, BIOL REPROD, V13, P340, DOI 10.1095/biolreprod13.3.340; KALAB P, 1994, J BIOL CHEM, V269, P3810; Lauffenburger D, 1993, RECEPTORS MODELS BIN, P9; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LEYTON L, 1992, P NATL ACAD SCI USA, V89, P11692, DOI 10.1073/pnas.89.24.11692; LIPKIN EW, 1986, J BIOL CHEM, V261, P1702; Litscher ES, 1996, BIOCHEMISTRY-US, V35, P3980, DOI 10.1021/bi952722m; LITSCHER ES, 1995, BIOCHEMISTRY-US, V34, P4662, DOI 10.1021/bi00014a020; LITSCHER ES, 1993, TRENDS GLYCOSCI GLYC, V5, P369; LOPEZ LC, 1985, J CELL BIOL, V101, P1501, DOI 10.1083/jcb.101.4.1501; MATTHEWS JC, 1993, FUNDAMENTALS RECEPTO, P49; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; MORTILLO S, 1991, DEVELOPMENT, V113, P141; PRUZANSKY JJ, 1986, IMMUNOLOGY, V58, P287; SALING PM, 1979, J EXP ZOOL, V209, P229, DOI 10.1002/jez.1402090205; SALING PM, 1978, DEV BIOL, V65, P515, DOI 10.1016/0012-1606(78)90046-5; SALING PM, 1981, P NATL ACAD SCI-BIOL, V78, P6231, DOI 10.1073/pnas.78.10.6231; SCHRODER H, 1990, BRAIN RES, V514, P249, DOI 10.1016/0006-8993(90)91420-L; SHAGLI R, 1991, MOL REPROD DEV, V29, P365; SHUR BD, 1982, J CELL BIOL, V95, P574, DOI 10.1083/jcb.95.2.574; SHUR BD, 1988, J BIOL CHEM, V263, P17706; SHUR BD, 1982, J CELL BIOL, V95, P567, DOI 10.1083/jcb.95.2.567; Smith K, 1979, MOL BASIS IMMUNE CEL, P223; TANPHAICHITR N, 1993, DEV BIOL, V156, P164, DOI 10.1006/dbio.1993.1067; Thaler C. D., 1994, Molecular Biology of the Cell, V5, p224A; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; TULSIANI DRP, 1989, J CELL BIOL, V109, P1257, DOI 10.1083/jcb.109.3.1257; VANMAURIK P, 1985, EUR J CELL BIOL, V36, P209; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Wells J. W., 1992, RECEPTOR LIGAND INTE, P289; WHITTINGHAM DG, 1971, J REPROD FERTIL, V17, P399; ZIDOVETZKI R, 1991, BIOCHEMISTRY-US, V30, P6162, DOI 10.1021/bi00239a012	59	90	93	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23289	23297		10.1074/jbc.271.38.23289	http://dx.doi.org/10.1074/jbc.271.38.23289			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798528	hybrid			2022-12-27	WOS:A1996VH76800054
J	Abramochkin, G; Shrader, TE				Abramochkin, G; Shrader, TE			Aminoacyl-tRNA recognition by the leucyl/phenylalanyl-tRNA-protein transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; PHENYLALANINE TRANSFER-RNA; ESCHERICHIA-COLI; BIOSYNTHESIS; CONTAINS; IDENTITY; CLONING	We employ mutant and mischarged aminoacyl-tRNAs to characterize aminoacyl-tRNA recognition by the leucyl/phenylalanyl-tRNA-protein transferase (L/F-transferase). Wild type Met-tRNA(Metm) (CAU anticodon) and mischarged Met-tRNA(Val-1) (CAU anticodon) are substrates for the L/F-transferase during the NH2-terminal aminoacylation of alpha-casein, whereas Val-tRNA(Val-1) (UAC), Val-tRNA(Metm) (UAC), and Arg-tRNA(Metm) (CCG, A20) are not. Mutations in the anticodon and extra arm of tRNA(Leu-1) do not measurably effect its ability to serve as a substrate for the L/F-transferase, and the dissociation constants of the complexes between L/F-transferase and either wild type Leu-tRNA(Leu-4) (UAA) or mutant Leu-tRNA(Leu-4) (CUA) are each 0.4 +/- 0.2 mu M. The dissociation constants for the complexes between the L/F-transferase and uncharged tRNA, leucine methyl ester, and puromycin are all 10-1,000-fold greater than that of the Leu-tRNA L/F-transferase complex. Dissociation of the Leu-tRNA L/F-transferase complex is slow, relative to the rate calculated assuming that association is diffusion controlled, Finally, deoxyoligonucleotide aminoacyl-tRNA hybrids (dO . AA-tRNAs) are employed to characterize the determinants of the Leu-tRNA(Leu-4) acceptor stem recognized by the L/F-transferase. A dO . AA-tRNA completely lacking acceptor stem base pairs remains a substrate for the L/F-transferase, whereas a dO . AA-tRNA containing a a-base pair single-stranded region, at its 3' terminus, does not.	ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DEPT ANAT & STRUCT BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NIGMS NIH HHS [GM52440] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052440] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOCHKIN G, 1995, J BIOL CHEM, V270, P20621, DOI 10.1074/jbc.270.35.20621; ASHHARA H, 1993, J MOL BIOL, V231, P219; BILGIN N, 1995, BIOCHEMISTRY-US, V34, P715, DOI 10.1021/bi00003a001; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; FRANCKLYN CS, 1990, CHEM REV, V90, P1327, DOI 10.1021/cr00105a013; HORINISHI H, 1975, BIOCHEM BIOPH RES CO, V67, P1136, DOI 10.1016/0006-291X(75)90792-5; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; KAJI A, 1965, J BIOL CHEM, V240, P1185; KIM SH, 1973, SCIENCE, V179, P285, DOI 10.1126/science.179.4070.285; LEIBOWITZ MJ, 1971, J BIOL CHEM, V246, P4431; LIEBOWITZ MJ, 1971, J BIOL CHEM, V246, P5207; LIPMANN F, 1971, SCIENCE, V173, P875, DOI 10.1126/science.173.4000.875; LOUIE A, 1984, J BIOL CHEM, V259, P5010; Macinga DR, 1996, MOL MICROBIOL, V19, P511, DOI 10.1046/j.1365-2958.1996.385912.x; MATSUHASHI M, 1965, P NATL ACAD SCI USA, V54, P587, DOI 10.1073/pnas.54.2.587; POOLE RK, 1993, MOL MICROBIOL, V10, P421, DOI 10.1111/j.1365-2958.1993.tb02673.x; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; RAO PM, 1974, FEBS LETT, V43, P199, DOI 10.1016/0014-5793(74)80999-3; SAKS ME, 1994, SCIENCE, V263, P191, DOI 10.1126/science.7506844; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCARPULLA RC, 1976, BIOCHEM BIOPH RES CO, V71, P584, DOI 10.1016/0006-291X(76)90827-5; SCHULMAN LH, 1989, SCIENCE, V246, P1595, DOI 10.1126/science.2688091; SHRADER TE, 1993, J BACTERIOL, V175, P4364, DOI 10.1128/JB.175.14.4364-4374.1993; SIEGELE DA, 1993, GENE DEV, V7, P2629, DOI 10.1101/gad.7.12b.2629; SOFFER RL, 1974, ADV ENZYMOL RAMB, V40, P91; SOFFER RL, 1973, J BIOL CHEM, V248, P8424; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WRIGHT GD, 1992, ACCOUNTS CHEM RES, V25, P468, DOI 10.1021/ar00022a006	31	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22901	22907		10.1074/jbc.271.37.22901	http://dx.doi.org/10.1074/jbc.271.37.22901			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798470	hybrid			2022-12-27	WOS:A1996VG67200089
J	Beaulieu, M; Levesque, E; Hum, DW; Belanger, A				Beaulieu, M; Levesque, E; Hum, DW; Belanger, A			Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C-19 steroids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LNCAP CELL-LINE; HUMAN-LIVER; 3-ALPHA-ANDROSTANEDIOL GLUCURONIDE; ANDROGEN METABOLISM; PROSTATIC-CANCER; EXPRESSION; CLONING; PLASMA; MEN; IDENTIFICATION	To isolate cDNA clones encoding novel UGT2B enzymes, human prostate and LNCaP cell cDNA libraries were screened using a pool of steroid-specific UGT2B cDNA probes, In approximately 10(6) recombinants, we isolated 3 cDNA clones of 2.1 kilobases that encode a novel UGT2B enzyme, UGT2B17 is 95% identical with UGT2B15 and 91% identical with UGT2B8. Primary structure analysis of UGT2B17 based on the nucleotide sequence revealed a putative amino-terminal membrane insertion signal peptide, a carboxyl-terminal membrane-spanning region, and three potential asparagine-linked glycosylation sites. UGT2B17 cloned in the pBK-CMV expression vector was transfected into HK293 cells to obtain a stable clonal cell line expressing a high level of the active 53-kDa UGT2B17 enzyme. Of the over 60 endogenous and exogenous substances tested, 25 compounds revealed reactivity, The major substrates are eugenol > 4-methylumbelliferone > dihydrotestosterone > androstane-3 alpha,17 beta-diol (3 alpha-diol) > testosterone > androsterone (ADT). The apparent K-m values obtained with tritiated steroids in intact cells were 0.4 mu M for ADT, 0.7 mu M for dihydrotestosterone, 1.0 mu M for 3 alpha-diol, and 3.4 mu M for testosterone, Southern blot analysis of reverse transcription-polymerase chain reaction products revealed expression of UGT2B17 mRNA in various tissues including the liver, kidney, testis, uterus, placenta, mammary gland, adrenal gland, skin, and prostate, UGT2B17 is the first human uridine diphosphoglucuronosyltransferase enzyme expressed in extrahepatic tissues to have a specificity for ADT as well as testosterone, dihydrotestosterone, and 3 alpha-diol.	CHU LAVAL, RES CTR, MRC, GRP MOL ENDOCRINOL, QUEBEC CITY, PQ G1V 4G2, CANADA	Laval University								ADAMS JB, 1989, J STEROID BIOCHEM, V33, P1023, DOI 10.1016/0022-4731(89)90256-2; BELANGER A, 1991, J STEROID BIOCHEM, V40, P593, DOI 10.1016/0960-0760(91)90281-9; BELANGER A, 1990, EUR J CANCER, V26, P277, DOI 10.1016/0277-5379(90)90222-F; BELANGER A, 1994, J CLIN ENDOCR METAB, V79, P1086; BELANGER A, 1990, ANN NY ACAD SCI, V595, P251, DOI 10.1111/j.1749-6632.1990.tb34299.x; BELANGER A, 1986, J CLIN ENDOCR METAB, V62, P812, DOI 10.1210/jcem-62-5-812; BELANGER G, 1995, MOL CELL ENDOCRINOL, V113, P165, DOI 10.1016/0303-7207(95)03627-J; BURCHELL B, 1994, HEPATOLOGY, V20, P1622, DOI 10.1002/hep.1840200636; BURCHELL B, 1991, DNA CELL BIOL, V10, P487, DOI 10.1089/dna.1991.10.487; BURCHELL B, 1989, PHARMACOL THERAPEUT, V43, P261, DOI 10.1016/0163-7258(89)90122-8; CARMINA E, 1993, J CLIN ENDOCR METAB, V76, P1111, DOI 10.1210/jc.76.5.1111; CHEN F, 1993, BIOCHEMISTRY-US, V32, P10648, DOI 10.1021/bi00091a015; CLARKE DJ, 1994, HDB EXPT PHARM, V112, P3; COFFMAN BL, 1990, ARCH BIOCHEM BIOPHYS, V281, P170, DOI 10.1016/0003-9861(90)90428-2; Dutton G.F., 1980, GLUCURONIDATION DRUG; ELO JP, 1995, HORMONES CANC, P76; FISZERSZAFARZ B, 1981, ANAL BIOCHEM, V110, P165, DOI 10.1016/0003-2697(81)90130-5; GREEN MD, 1994, DRUG METAB DISPOS, V22, P799; Guillemette C, 1995, J STEROID BIOCHEM, V55, P355, DOI 10.1016/0960-0760(95)00183-2; Guillemette C, 1996, ENDOCRINOLOGY, V137, P2872, DOI 10.1210/en.137.7.2872; GUILLEMETTE C, 1995, MOL CELL ENDOCRINOL, V107, P131, DOI 10.1016/0303-7207(94)03434-U; HENTTU P, 1992, ENDOCRINOLOGY, V130, P766, DOI 10.1210/en.130.2.766; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; JACKSON MR, 1987, BIOCHEM J, V242, P581, DOI 10.1042/bj2420581; JIN CJ, 1993, BIOCHEM BIOPH RES CO, V194, P496, DOI 10.1006/bbrc.1993.1847; LABRIE F, 1991, MOL CELL ENDOCRINOL, V78, pC113, DOI 10.1016/0303-7207(91)90116-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARD D, 1990, BIOCHEMISTRY-US, V29, P7433, DOI 10.1021/bi00484a012; LAZARD D, 1991, NATURE, V349, P790, DOI 10.1038/349790a0; LOBO RA, 1987, J CLIN ENDOCR METAB, V65, P711, DOI 10.1210/jcem-65-4-711; LOOKINGBILL DP, 1988, J CLIN ENDOCR METAB, V67, P986, DOI 10.1210/jcem-67-5-986; MACKENZIE PI, 1990, J BIOL CHEM, V265, P3432; MACKENZIE PI, 1986, J BIOL CHEM, V261, P14112; MONAGHAN G, 1994, GENOMICS, V23, P496, DOI 10.1006/geno.1994.1531; MULDER GJ, 1992, ANNU REV PHARMACOL, V32, P25; NEGRICESI P, 1994, J STEROID BIOCHEM, V51, P89, DOI 10.1016/0960-0760(94)90119-8; Prevost J, 1987, Gynecol Endocrinol, V1, P331, DOI 10.3109/09513598709082705; RAO PN, 1987, J STEROID BIOCHEM, V28, P565, DOI 10.1016/0022-4731(87)90516-4; RHEAUME E, 1991, NUCLEIC ACIDS RES, V19, P6060, DOI 10.1093/nar/19.21.6060; RITTER JK, 1992, BIOCHEMISTRY-US, V31, P3409, DOI 10.1021/bi00128a015; RITTER JK, 1990, J BIOL CHEM, V265, P7900; RITTMASTER RS, 1993, J CLIN ENDOCR METAB, V76, P977, DOI 10.1210/jc.76.4.977; ROSE JK, 1980, P NATL ACAD SCI-BIOL, V77, P3884, DOI 10.1073/pnas.77.7.3884; SAMBROOK J, 1982, MOL CLONING LAB MANU, pB14; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SONNENSCHEIN C, 1989, CANCER RES, V49, P3474; TEPHLY TR, 1990, TRENDS PHARMACOL SCI, V11, P276, DOI 10.1016/0165-6147(90)90008-V; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; VIANI A, 1990, HUM EXP TOXICOL, V9, P65, DOI 10.1177/096032719000900201; VISSER TJ, 1993, FEBS LETT, V315, P65, DOI 10.1016/0014-5793(93)81134-L; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145	51	162	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22855	22862		10.1074/jbc.271.37.22855	http://dx.doi.org/10.1074/jbc.271.37.22855			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798464	hybrid			2022-12-27	WOS:A1996VG67200083
J	Fanjul, AN; Delia, D; Pierotti, MA; Rideout, D; Qiu, J; Pfahl, M				Fanjul, AN; Delia, D; Pierotti, MA; Rideout, D; Qiu, J; Pfahl, M			4-hydroxyphenyl retinamide is a highly selective activator of retinoid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; ACID RECEPTORS; FENRETINIDE 4-HPR; N-(4-HYDROXYPHENYL)RETINAMIDE; APOPTOSIS; PROLIFERATION; AP-1; RAT; TRANSACTIVATION; SUPPRESSION	Retinoids have shown promise as anti cancer and cancer preventative agents. All-trans-N-(4-hydroxyphenyl)retinamide (4HPR) belongs to a new group of retinoids that not only inhibit the proliferation of cancer cells but also can induce apoptosis in certain cancer cells. Because of its increased efficacy against cancer cells and its low toxicity it has been entered into a number of clinical trials. However, its mechanism of action is not known, and it had been assumed that it is not a true retinoid. Here we analyze its ability to function as an activator of nuclear retinoid receptors (RARs and RXRs). We observe that, in transactivation assays, 4HPR is a potent transactivator with RAR gamma and a moderate activator with RAR beta but is not an activator with RAR alpha and RXR alpha. Furthermore, RAR gamma-selective transactivation by 4HPR is enhanced on some response elements and reduced on others when compared to natural retinoids. In contrast to transactivation, 4HPR in transrepression assays functions mostly with RAR alpha, RAR beta, and RXR alpha. Optimal receptor activation is seen at 4HPR concentrations at which it is a potent growth inhibitor and inducer of apoptosis. We conclude that 4HPR is a highly selective activator of retinoid receptors. We propose that this selective activation of the nuclear receptors is likely to be the basis for its specific biological activities and its favorable pharmaceutical properties.	SIDNEY KIMMEL CANC CTR, LA JOLLA, CA 92037 USA; IST NAZL STUDIO & CURA TUMORI, DIV EXPT ONCOL A, I-20133 MILAN, ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan			Pierotti, Marco Alessandro/AAC-4728-2022	Pierotti, Marco Alessandro/0000-0002-7431-8332				BHATNAGAR R, 1991, BIOCHEM PHARMACOL, V41, P1471, DOI 10.1016/0006-2952(91)90563-K; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHIESA F, 1992, ORAL ONCOL, V28B, P97; DECENSI A, 1992, J CELL BIOCHEM, P139; DELIA D, 1993, CANCER RES, V53, P6036; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; DEPALO G, 1995, J NATL CANCER I, V87, P146, DOI 10.1093/jnci/87.2.146; DILLEHAY DL, 1991, INT J IMMUNOPHARMACO, V13, P1043, DOI 10.1016/0192-0561(91)90060-K; DOWLATSHAHI K, 1989, CANCER LETT, V47, P187, DOI 10.1016/0304-3835(89)90089-X; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FANJUL AN, 1995, IN PRESS CANC RES; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; KALEMKERIAN G, 1995, P AM ASS CANC RES AA; Kelloff G J, 1994, J Cell Biochem Suppl, V20, P176; LaVistaPicard N, 1996, MOL CELL BIOL, V16, P4137; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MANGELSDORF DJ, 1994, RETINOIDS BIOL CHEM; MODIANO MR, 1990, INVEST NEW DRUG, V8, P317; MOON RC, 1992, ANTICANCER RES, V12, P1147; MORRISKAY G, 1992, RETINODS NORMAL DEV; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; PELLEGRINI R, 1995, CELL GROWTH DIFFER, V6, P863; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PFAHL M, 1994, VITAM HORM, V49, P327; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Pfahl Magnus, 1994, Seminars in Cell Biology, V5, P95, DOI 10.1006/scel.1994.1013; PIENTA KJ, 1993, CANCER RES, V53, P224; POLLARD M, 1991, CANCER LETT, V59, P159, DOI 10.1016/0304-3835(91)90181-G; PONZONI M, 1995, CANCER RES, V55, P853; REICHERT U, 1993, MOL BIOL THERAPEUTIC, V5, P117; RIAZULHAQ, 1991, P NATL ACAD SCI USA, V88, P8272, DOI 10.1073/pnas.88.18.8272; ROTMENSZ N, 1991, EUR J CANCER, V27, P1127, DOI 10.1016/0277-5379(91)90309-2; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SANI BP, 1993, RETINOIDS PROGR RES, P237; SCHAEFER H, 1990, NOUV DERMATOL, V9, P3; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SHAO ZM, 1995, ONCOGENE, V11, P493; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Sporn M.B., 1994, RETINOIDS BIOL CHEM; TRADATI N, 1994, CANCER LETT, V76, P109, DOI 10.1016/0304-3835(94)90385-9; VILLA ML, 1993, BRIT J CANCER, V68, P845, DOI 10.1038/bjc.1993.443; WIDSCHWENDTER M, 1995, CANCER RES, V55, P2135; WILLE JJ, 1986, P AM ASSOC CANC RES, V27, P146; YANGYEN HF, 1991, NEW BIOL, V3, P1206; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	49	185	187	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22441	22446		10.1074/jbc.271.37.22441	http://dx.doi.org/10.1074/jbc.271.37.22441			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798408				2022-12-27	WOS:A1996VG67200027
J	Wiech, H; Geier, BM; Paschke, T; Spang, A; Grein, K; Steinkotter, J; Melkonian, M; Schiebel, E				Wiech, H; Geier, BM; Paschke, T; Spang, A; Grein, K; Steinkotter, J; Melkonian, M; Schiebel, E			Characterization of green alga, yeast, and human centrins - Specific subdomain features determine functional diversity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE POLE BODY; CA-2+-MODULATED CONTRACTILE PROTEIN; SACCHAROMYCES-CEREVISIAE; CHLAMYDOMONAS-REINHARDTII; FLAGELLAR APPARATUS; MOLECULAR-CLONING; NMR-SPECTROSCOPY; GAMMA-TUBULIN; CALMODULIN; CALCIUM	Centrins are a subfamily within the superfamily of Ca2+-modulated proteins that play a fundamental role in centrosome duplication and contraction of centrin-based fiber systems. We examined the individual molecular properties of yeast, green alga, and human centrins. Circular dichroism spectroscopy revealed a divergent influence of Ca2+ binding on the cu-helical content of these proteins. Ca2+-free centrins were elongated in shape as determined by size exclusion chromatography. The presence of Ca2+ and binding peptide resulted in more spherical shaped centrins. In contrast to yeast calmodulin, centrins formed multimers in the Ca2+-bound state. This oligomerization was significantly reduced in the absence of Ca2+ and in the presence of binding peptide. The Ca2+-dependent polymerization of the green alga Scherffelia dubia centrin (SdCen) resulted in a filamentous network. This molecular property was mainly dependent on the amino-terminal subdomain and the peptide-binding site of SdCen. Finally, we analyzed whether SdCen and Cdc31p-SdCen hybrid proteins functionally substitute for the Saccharomyces cerevisiae centrin Cdc31p. Only hybrid proteins containing the amino-terminal subdomain or the third EF-hand of SdCen and the other subdomains from Cdc31p were functional in vivo.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY; UNIV COLOGNE,INST BOT,D-50931 COLOGNE,GERMANY	Max Planck Society; University of Cologne			Spang, Anne/A-7029-2008; Spang, Anne/M-7223-2019	Spang, Anne/0000-0002-2387-6203; Spang, Anne/0000-0002-2387-6203				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BARON AT, 1988, J CELL BIOL, V107, P2669, DOI 10.1083/jcb.107.6.2669; BARON AT, 1995, METHOD CELL BIOL, V47, P341, DOI 10.1016/S0091-679X(08)60828-6; BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; BHATTACHARYA D, 1993, PLANT MOL BIOL, V23, P1243, DOI 10.1007/BF00042357; BIGGINS S, 1994, J CELL BIOL, V125, P843, DOI 10.1083/jcb.125.4.843; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BWARON AT, 1992, CENTROSOME, P167; Byers B, 1981, MOL BIOL YEAST SACCH, P59; BYERS B, 1981, A BENZON S, V16, P119; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DAVIS TN, 1989, P NATL ACAD SCI USA, V86, P7909, DOI 10.1073/pnas.86.20.7909; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P127; ERRABOLU R, 1994, J CELL SCI, V107, P9; GEISER JR, 1993, MOL CELL BIOL, V13, P7913, DOI 10.1128/MCB.13.12.7913; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; HUANG B, 1988, J CELL BIOL, V107, P121, DOI 10.1083/jcb.107.1.121; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Kalt Astrid, 1993, Trends in Cell Biology, V3, P118, DOI 10.1016/0962-8924(93)90174-Y; KAWASAKI H, 1995, PROTEIN PROFILE, V2, P297; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; LEE VD, 1993, P NATL ACAD SCI USA, V90, P11039, DOI 10.1073/pnas.90.23.11039; LEE VD, 1990, CALCIUM INTRACELLULA, P245; MCFADDEN GI, 1987, J CELL BIOL, V105, P903, DOI 10.1083/jcb.105.2.903; Melkonian M., 1992, P179; MONERIEF ND, 1990, J MOL EVOL, V30, P522; MOSER MJ, 1995, J BIOL CHEM, V270, P20643, DOI 10.1074/jbc.270.35.20643; MOUNTAIN HA, 1991, YEAST, V7, P781, DOI 10.1002/yea.320070804; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; OHYA Y, 1987, EUR J BIOCHEM, V168, P13, DOI 10.1111/j.1432-1033.1987.tb13380.x; PAINTRAND M, 1992, J STRUCT BIOL, V108, P107, DOI 10.1016/1047-8477(92)90011-X; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; SALISBURY JL, 1989, J PHYCOL, V25, P201; SALISBURY JL, 1983, J SUBMICR CYTOL PATH, V15, P105; SALISBURY JL, 1984, J CELL BIOL, V99, P962, DOI 10.1083/jcb.99.3.962; SALISBURY JL, 1995, CURR OPIN CELL BIOL, V7, P39; SALISBURY JL, 1987, J CELL BIOL, V105, P1799, DOI 10.1083/jcb.105.4.1799; Sambrook J., 2002, MOL CLONING LAB MANU; SANDERMANN H, 1972, J BIOL CHEM, V247, P5123; SANDERS MA, 1994, J CELL BIOL, V124, P795, DOI 10.1083/jcb.124.5.795; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIEBEL E, 1995, TRENDS CELL BIOL, V5, P197, DOI 10.1016/S0962-8924(00)88999-0; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULZE D, 1987, EUR J CELL BIOL, V45, P51; SPANG A, 1993, J CELL BIOL, V123, P405, DOI 10.1083/jcb.123.2.405; SPANG A, 1995, J CELL BIOL, V128, P868; SPANG A, 1996, IN PRESS J CELL SCI; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STIRLING DA, 1994, EMBO J, V13, P4329, DOI 10.1002/j.1460-2075.1994.tb06753.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TRAVE G, 1995, EMBO J, V14, P4922, DOI 10.1002/j.1460-2075.1995.tb00175.x; VALLEN EA, 1994, GENETICS, V137, P407; VOGEL HJ, 1994, BIOCHEM CELL BIOL, V72, P357, DOI 10.1139/o94-049; WEBER C, 1994, J BIOL CHEM, V269, P15795; WRIGHT RL, 1985, J CELL BIOL, V101, P1903, DOI 10.1083/jcb.101.5.1903; ZHU JK, 1992, PLANT PHYSIOL, V99, P1734, DOI 10.1104/pp.99.4.1734	60	79	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22453	22461		10.1074/jbc.271.37.22453	http://dx.doi.org/10.1074/jbc.271.37.22453			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798410	hybrid			2022-12-27	WOS:A1996VG67200029
J	Elliott, S; Lorenzini, T; Yanagihara, D; Chang, D; Elliott, G				Elliott, S; Lorenzini, T; Yanagihara, D; Chang, D; Elliott, G			Activation of the erythropoietin (EPO) receptor by bivalent anti-EPO receptor antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID PROGENITOR CELLS; HUMAN GROWTH-HORMONE; TYROSINE PHOSPHORYLATION; ERYTHROLEUKEMIA-CELLS; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; CLONING; SUPERFAMILY; EXPRESSION; COMPLEX	Oligomerization of cytokine receptors including the erythropoietin (EPO) receptor has been advanced as a model for activation. If homodimerization of the EPO receptor activates it, then bivalent antibodies raised to the extracellular domain of the EPO receptor should also homodimerize and activate. Mouse monoclonal antibodies (IgG) raised to the soluble, extracellular domain of the human EPO receptor (EPOR) were found that would stimulate thymidine uptake of an human EPO-dependent cell line, UT-7/EPO. Dose response curves showed bell shapes where activity was low at low and high concentrations. Monovalent (Fab) fragments bound to the receptor but did not stimulate thymidine uptake, which indicates that two antibody binding sites are required for activation. The anti-EPOR antibodies stimulated the formation of burst forming unit erythroid colonies from human CD34(+) cells purified from peripheral blood. This indicates that homodimerization of the EPO receptor by anti-EPOR antibodies is sufficient for both proliferation and differentiation of erythroid progenitor cells and that the constraints on dimerization necessary for activation are rather loose.			Elliott, S (corresponding author), AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320, USA.							BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BROUDY VC, 1988, P NATL ACAD SCI USA, V85, P6513, DOI 10.1073/pnas.85.17.6513; CAMPBELL AM, 1984, LAB TECHNIQUES BIOCH, V13, P160; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAMEN JE, 1993, BLOOD, V81, P3204; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DONG YJ, 1993, EXP HEMATOL, V21, P483; Elliott S, 1996, BLOOD, V87, P2714, DOI 10.1182/blood.V87.7.2714.bloodjournal8772714; Fagerstam L G, 1990, J Mol Recognit, V3, P208, DOI 10.1002/jmr.300030507; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; IHLE JN, 1981, J IMMUNOL, V126, P2184; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JONES SS, 1990, BLOOD, V76, P31; KLINGMUELLER U, 1995, CELL, V80, P7629; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOMATSU N, 1993, BLOOD, V82, P456; KOMATSU N, 1991, CANCER RES, V51, P341; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; LONGMORE GD, 1994, MOL CELL BIOL, V14, P2266, DOI 10.1128/MCB.14.4.2266; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MAYEUX P, 1990, EUR J BIOCHEM, V194, P271, DOI 10.1111/j.1432-1033.1990.tb19453.x; MAYEUX P, 1991, J BIOL CHEM, V266, P23380; MCDONALD JD, 1986, MOL CELL BIOL, V6, P842, DOI 10.1128/MCB.6.3.842; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1993, ARCH BIOCHEM BIOPHYS, V306, P200, DOI 10.1006/abbi.1993.1501; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; PONTING ILO, 1994, EXP HEMATOL, V22, P496; SAWYER ST, 1989, J BIOL CHEM, V264, P13343; SAWYER ST, 1987, P NATL ACAD SCI USA, V84, P3690, DOI 10.1073/pnas.84.11.3690; SHOEMAKER CB, 1986, MOL CELL BIOL, V6, P849, DOI 10.1128/MCB.6.3.849; SPIVAK JL, 1991, BLOOD, V77, P1228; TORTI M, 1992, J BIOL CHEM, V267, P8293; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WINKELMANN JC, 1990, BLOOD, V76, P24; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	46	64	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24691	24697		10.1074/jbc.271.40.24691	http://dx.doi.org/10.1074/jbc.271.40.24691			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798737	hybrid			2022-12-27	WOS:A1996VM67400059
J	Fan, G; Merritt, SE; Kortenjann, M; Shaw, PE; Holzman, LB				Fan, G; Merritt, SE; Kortenjann, M; Shaw, PE; Holzman, LB			Dual leucine zipper-bearing kinase (DLK) activates p46(SAPK) and p38(mapk) but not ERK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; C-FOS EXPRESSION; PROTEIN-KINASE; MAMMALIAN-CELLS; V-RAF; IDENTIFICATION; ELK-1; CDC42; JNK; PHOSPHORYLATION	Because the catalytic domain of dual leucine zipper-bearing kinase (DLK) bears sequence similarity to members of the mitogen-activated protein (MAP) kinase kinase kinase subfamily, this protein kinase was investigated for its ability to activate MAP kinase pathways. When transiently transfected and overexpressed in either COS 7 cells or NIH3T3 cells, wild type DLK potently activated p46(SAPK) (SAPK/JNK) but had no detectable effect in activating p42/44(MAPK). DLK also activated p38(mapk) when overexpressed in NIH3T3 cells. A catalytically inactive point mutant of DLK had no effect in these experiments. Consistent with its specificity in activating SAPK, DLK activated Elk-1 but not Sapla-mediated transcription. In NIH3T3 cells, activation of SAPK by v-Src was markedly attenuated by coexpression of K185A, a catalytically inactive mutant of DLK, suggesting that this mutant could function in a dominant negative fashion in a pathway that leads from v-Src to SAPKs. In a series of co-transfection experiments, activation of p46(SAPK) by DLK was not inhibited by dominant negative mutants of Rad and Cdc42Hs, PAK65-R, or PAK65-A, but was attenuated by MEKK1(K432M). DLK(K185A) did not inhibit the ability of constitutively active MEKK1 to activate SAPK. Moreover, K185A significantly inhibited the activation of SAPK by constitutively active V-12 Rad and V-12 Cdc42Hs. These results suggest that DLK lies distal to Rac1 and/or Cdc42Hs but proximal to MEKK1 in a pathway leading from v-Src to SAPKs activation.	UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,DIV NEPHROL,ANN ARBOR,MI 48109; DEPT VET AFFAIRS,ANN ARBOR,MI 48105; MAX PLANCK INST IMMUNBIOL,SPEMANN LABS,D-79108 FREIBURG,GERMANY	University of Michigan System; University of Michigan; Max Planck Society				Holzman, Lawrence/0000-0002-8961-234X; SHAW, Peter/0000-0002-2598-4283				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Gille H, 1996, MOL CELL BIOL, V16, P1094; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; JANKNECHT R, 1995, ONCOGENE, V10, P1209; Kamano H, 1995, ONCOGENE, V11, P2575; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kortenjann M, 1995, CRIT REV ONCOGENESIS, V6, P99; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1995, ANN NY ACAD SCI, V766, P303, DOI 10.1111/j.1749-6632.1995.tb26683.x; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Mata M, 1996, J BIOL CHEM, V271, P16888, DOI 10.1074/jbc.271.28.16888; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SMITH EJ, 1995, MOL CELL BIOL, V15, P338, DOI 10.1128/MCB.15.1.338; STRAHL T, 1996, IN PRESS P NATL ACAD; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	52	116	131	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24788	24793		10.1074/jbc.271.40.24788	http://dx.doi.org/10.1074/jbc.271.40.24788			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798750	hybrid			2022-12-27	WOS:A1996VM67400072
J	Kwiatkowski, AV; Shapleigh, JP				Kwiatkowski, AV; Shapleigh, JP			Requirement of nitric oxide for induction of genes whose products are involved in nitric oxide metabolism in Rhodobacter sphaeroides 2.4.3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-STUTZERI; CONTINUOUS CULTURE; FNR FAMILY; DENITRIFICATION; ACTIVATION; REDUCTION; ENZYMES; PROTEIN; CELLS; EXPRESSION	During denitrification, freely diffusible nitric oxide (NO) is generated for use as a terminal electron acceptor. NO is produced by nitrite reductase (Nir) and reduced to nitrous oxide by nitric oxide reductase (Nor). Using Nir and Nor-deficient mutants of Rhodobacter sphaeroides 2.4.3, we have shown that the endogenous production of NO or the addition of exogenous NO induces transcription of certain genes encoding Nir and Nor. A Nor-deficient strain was found to be capable of expressing wild type levels of nirK-lacZ and norB-lacZ fusions in medium unamended with nitrogen oxides, When this experiment is performed in the presence of hemoglobin, fusion expression is eliminated. NO and the NO generator, sodium nitroprusside, can induce expression of both fusions in a strain lacking Nir and the consequent ability to produce NO. Sodium nitroprusside cannot induce expression of nirK-lacZ in a strain lacking the transcriptional activator NnrR (nitrite and nitric oxide reductase regulator). Addition of the cyclic nucleotides cAMP and 8-bromoguanosine-cGMP does not result in expression of either fusion. These results demonstrate that denitrifying bacteria produce NO as a signal molecule to activate expression of the genes encoding proteins required for NO metabolism.	CORNELL UNIV,DEPT MICROBIOL,ITHACA,NY 14853	Cornell University								ARAI H, 1995, FEBS LETT, V371, P73, DOI 10.1016/0014-5793(95)00885-D; BATES JN, 1991, BIOCHEM PHARMACOL, V42, pS157, DOI 10.1016/0006-2952(91)90406-U; COYNE MS, 1990, FEMS MICROBIOL ECOL, V73, P263, DOI 10.1016/0378-1097(90)90738-C; DIODATI JG, 1993, J CARDIOVASC PHARM, V22, P287, DOI 10.1097/00005344-199308000-00018; FERGUSON SJ, 1994, ANTON LEEUW INT J G, V66, P89, DOI 10.1007/BF00871634; GARBERS DL, 1992, CELL, V74, P1; GORETSKI J, 1988, J BIOL CHEM, V263, P2316; GORETSKI J, 1990, J BIOL CHEM, V265, P11535; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; HOCHSTEIN LI, 1988, ANNU REV MICROBIOL, V42, P231, DOI 10.1146/annurev.mi.42.100188.001311; IGNARRO LJ, 1990, PHARMACOL TOXICOL, V67, P1, DOI 10.1111/j.1600-0773.1990.tb00772.x; JAFFREY SR, 1994, P NATL ACAD SCI USA, V91, P12994, DOI 10.1073/pnas.91.26.12994; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KHARITONOV VG, 1994, J BIOL CHEM, V269, P5881; KOIKE I, 1975, J GEN MICROBIOL, V88, P11, DOI 10.1099/00221287-88-1-11; KOKOTEK W, 1989, GENE, V84, P467, DOI 10.1016/0378-1119(89)90522-2; KORNER H, 1989, APPL ENVIRON MICROB, V55, P1670; LAZZAZERA BA, 1996, J BIOL CHEM, V271, P2762; LEPOIVRE M, 1992, J BIOL CHEM, V267, P22994; LEUKING DR, 1978, J BIOL CHEM, V253, P451; Maniatis T., 1982, MOL CLONING; MARAGOS CM, 1993, CANCER RES, V53, P564; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MICHALSKI WP, 1988, FEMS MICROBIOL LETT, V52, P239; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1995, CURR OPIN IMMUNOL, V3, P65; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; PARIENTE F, 1996, IN PRESS ANAL CHEM; PAYNE WJ, 1981, DENITRIFICATION, P79; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; Sellers VM, 1996, BIOCHEMISTRY-US, V35, P2699, DOI 10.1021/bi952631p; SHARMA VS, 1978, J BIOL CHEM, V253, P6467; SPIRO S, 1994, ANTON LEEUW INT J G, V66, P23, DOI 10.1007/BF00871630; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STEWART V, 1994, ANTON LEEUW INT J G, V66, P37, DOI 10.1007/BF00871631; Tosques IE, 1996, J BACTERIOL, V178, P4958, DOI 10.1128/jb.178.16.4958-4964.1996; VANSPANNING RJM, 1995, FEBS LETT, V360, P151, DOI 10.1016/0014-5793(95)00091-M; YAU KW, 1994, P NATL ACAD SCI USA, V91, P1267; YE RW, 1992, J BACTERIOL, V174, P2560, DOI 10.1128/jb.174.8.2560-2564.1992; ZUMFT WG, 1993, ARCH MICROBIOL, V160, P253, DOI 10.1007/BF00292074; ZUMFT WG, 1994, EUR J BIOCHEM, V219, P481, DOI 10.1111/j.1432-1033.1994.tb19962.x	44	71	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24382	24388		10.1074/jbc.271.40.24382	http://dx.doi.org/10.1074/jbc.271.40.24382			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798693	hybrid			2022-12-27	WOS:A1996VM67400015
J	Kyriakis, JM; Avruch, J				Kyriakis, JM; Avruch, J			Sounding the alarm: Protein kinase cascades activated by stress and inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SIGNAL-TRANSDUCTION PATHWAY; AMINO-TERMINAL KINASES; HEAT-SHOCK PROTEINS; C-JUN; MAPKAP KINASE-2; PHOSPHORYLATION; IDENTIFICATION; THREONINE; YEAST; JNK	Eukaryotic cells respond to extracellular stimuli by recruiting signal transduction pathways, many of which employ protein Ser/Thr kinases of the ERK(1) family. The ubiquity of ERKs and their upstream activators, the MEKs, in signal transduction was first appreciated from studies of yeast (1, 2). Although a 54-kDa rat liver c-Jun kinase (SAPK-p54 alpha 1) with properties similar to the Ras-regulated MAPKs had been characterized (3-5), the physiologic roles and regulation of this and related mammalian enzymes have emerged only recently. Molecular cloning of the SAPKs and p38s, together with the paradigms derived from the ''classical'' MAPKs and work in lower eukaryotes has enabled rapid elucidation of the regulation and cellular functions of these newer mammalian ERK pathways. Although architecturally homologous to the Ras/MAPK pathway, the SAPK and p38 pathways are not activated primarily by mitogens but by cellular stresses and inflammatory cytokines, which stimuli result in growth arrest, apoptosis, or activation of immune and reticuloendothelial cells.	MASSACHUSETTS GEN HOSP, DIABET RES LABS, MED SERV, DIABET UNIT, CHARLESTOWN, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, CHARLESTOWN, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University								ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HATZ P, 1994, J BIOL CHEM, V269, P16802; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hirai S, 1996, ONCOGENE, V12, P641; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORI K, 1993, CELL, V74, P743; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHAFMAN TD, 1995, CANCER RES, V55, P3242; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHOU G, J BIOL CHEM, V270, P12665; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	78	980	1014	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24313	24316		10.1074/jbc.271.40.24313	http://dx.doi.org/10.1074/jbc.271.40.24313			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798679	Green Published, hybrid			2022-12-27	WOS:A1996VM67400001
J	Ornatsky, OI; McDermott, JC				Ornatsky, OI; McDermott, JC			MEF2 protein expression, DNA binding specificity and complex composition, and transcriptional activity in muscle and non-muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; C-JUN PROMOTER; SKELETAL-MUSCLE; REGULATORY ELEMENTS; POSITIVE AUTOREGULATION; MYOGENIC LINEAGE; SERUM INDUCTION; MRF4 PROMOTER; TATA ELEMENT; MINOR GROOVE	Tissue-specific gene expression can be mediated by complex transcriptional regulatory mechanisms. Based on the dichotomy of the ubiquitous distribution of the myocyte enhancer factor 2 (MEF2) gene mRNAs compared to their cell type-restricted activity, we investigated the basis for their tissue specificity. Electrophoretic mobility shift assays using the muscle creatine kinase MEF2 DNA binding site as a probe showed that HeLa, Schneider, L6E9 muscle, and C2C12 muscle cells have a functional MEF2 binding activity that is indistinguishable based on competition analysis. Interestingly, chloramphenicol acetyltransferase reporter assays showed MEF2 site-dependent trans-activation in myogenic C2C12 cells but no trans-activation by the endogenous MEF2 proteins in HeLa cells. By immunofluorescence, we detected abundant nuclear localized MEF2A and MEF2D protein expression in HeLa cells and C2C12 muscle cells. Using immuno-gel shift analysis and also co-immunoprecipitation studies, we show that the predominant MEF2 DNA binding complex bound to MEF2 sites from either the muscle creatine kinase or c-jun regulatory regions in C2C12 muscle cells is comprised of a MEF2A homodimer, whereas in HeLa cells, it is a MEF2A:MEF2D heterodimer. Thus, the presence of MEF2 DNA binding complexes is not necessarily coupled with trans-activation of target genes. The ability of the MEF2 proteins to activate transcription in vivo correlates with the specific dimer composition of the DNA binding complex and the cellular context.	YORK UNIV,FAC PURE & APPL SCI,DEPT KINESIOL,TORONTO,ON M3J 1P3,CANADA; YORK UNIV,FAC PURE & APPL SCI,DEPT BIOL,TORONTO,ON M3J 1P3,CANADA	York University - Canada; York University - Canada								ANDRES V, 1995, J BIOL CHEM, V270, P23246, DOI 10.1074/jbc.270.40.23246; BLACK BL, 1995, J BIOL CHEM, V270, P2889, DOI 10.1074/jbc.270.7.2889; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; BRAUN T, 1989, MOL CELL BIOL, V9, P2513, DOI 10.1128/MCB.9.6.2513; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BUCHBERGER A, 1994, J BIOL CHEM, V269, P17289; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; DECHESNE CA, 1994, MOL CELL BIOL, V14, P5474, DOI 10.1128/MCB.14.8.5474; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Fickett JW, 1996, MOL CELL BIOL, V16, P437; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GRAYSON J, 1995, MOL CELL BIOL, V15, P1870; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; HIDAKA K, 1993, MOL CELL BIOL, V13, P6469, DOI 10.1128/MCB.13.10.6469; HORLICK RA, 1990, MOL CELL BIOL, V10, P4826, DOI 10.1128/MCB.10.9.4826; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LEE DK, 1991, CELL, V67, P1241, DOI 10.1016/0092-8674(91)90300-N; LEE KJ, 1992, J BIOL CHEM, V267, P15875; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LIU ML, 1994, J BIOL CHEM, V269, P28514; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; MORISAKI T, 1993, MOL CELL BIOL, V13, P5854, DOI 10.1128/MCB.13.9.5854; MUSCAT GE, 1988, MOL CELL BIOL, V8, P4120, DOI 10.1128/MCB.8.10.4120; Muscat George E. O., 1992, Gene Expression, V2, P111; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; NAKATSUJI Y, 1992, MOL CELL BIOL, V12, P4384, DOI 10.1128/MCB.12.10.4384; NURRISH SJ, 1995, MOL CELL BIOL, V15, P4076; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; SHARROCKS AD, 1993, NUCLEIC ACIDS RES, V21, P215, DOI 10.1093/nar/21.2.215; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; SUZUKI E, 1995, MOL CELL BIOL, V15, P3415; WANG GS, 1994, J BIOL CHEM, V269, P30595; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; ZHU H, 1993, MOL CELL BIOL, V13, P4432, DOI 10.1128/MCB.13.7.4432	50	76	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24927	24933		10.1074/jbc.271.40.24927	http://dx.doi.org/10.1074/jbc.271.40.24927			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798771	hybrid			2022-12-27	WOS:A1996VM67400094
J	Sonveaux, N; Shapiro, AB; Goormaghtigh, E; Ling, V; Ruysschaert, JM				Sonveaux, N; Shapiro, AB; Goormaghtigh, E; Ling, V; Ruysschaert, JM			Secondary and tertiary structure changes of reconstituted P-glycoprotein - A Fourier transform attenuated total reflection infrared spectroscopy analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT PROTEINS; MULTIDRUG-RESISTANCE GENE; MEMBRANE H+-ATPASE; PLASMA-MEMBRANE; CONFORMATIONAL-CHANGES; CYSTIC-FIBROSIS; DRUG TRANSPORT; CELLS; EXPRESSION; HOMOLOGY	The structure of purified P-glycoprotein functionally reconstituted into liposomes was investigated by attenuated total reflection Fourier transform infrared spectroscopy. A quantitative evaluation of the secondary structure and a kinetic of H-2/H exchange of the P-glycoprotein were performed both in the presence and in the absence of MgATP, MgATP-verapamil, and MgADP. This approach was previously shown to be a useful tool to detect tertiary structure changes resulting from the interaction between a protein and its specific ligands, as established for the Neurospora crassa H+-ATPase. H-2/H exchange measurements provided evidence that a large fraction of the P-glycoprotein is poorly accessible to the aqueous medium. Addition of MgATP induced an increased accessibility to the solvent of a population of amino acids, while addition of MgATP-verapamil resulted in a subtraction of a part of the protein from access to the aqueous solvent. No significant changes were observed upon addition of MgADP or verapamil alone. The secondary structure of P-glycoprotein was not affected by addition of ligands. The variations observed in the H-2/H exchange rate when P-glycoprotein interacted with the above ligands therefore represented tertiary structure changes. Fluorescence quenching experiments confirmed that MgATP-induced changes are to be found in the tertiary structure of the enzyme.	BRITISH COLUMBIA CANC RES CTR,VANCOUVER,BC V5Z 1L3,CANADA	British Columbia Cancer Agency	Sonveaux, N (corresponding author), FREE UNIV BRUSSELS,CHIM PHYS MACROMOL INTERFACES LAB,CP 206-2,BD TRIOMPHE,B-1050 BRUSSELS,BELGIUM.			Goormaghtigh, Erik/0000-0002-2071-2262				ADDISON R, 1982, J BIOL CHEM, V257, P421; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; BECK WT, 1992, BIOCHEM PHARMACOL, V43, P89, DOI 10.1016/0006-2952(92)90665-6; CABIAUX V, 1989, J BIOL CHEM, V264, P4928; CHALLOU N, 1994, BIOCHEMISTRY-US, V33, P6902, DOI 10.1021/bi00188a020; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CHIN KV, 1993, ADV CANCER RES, V60, P157; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DEJONGH HHJ, 1995, BIOCHEMISTRY-US, V34, P172, DOI 10.1021/bi00001a021; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GOORMAGHTIGH E, 1993, BIOCHEMISTRY-US, V32, P6104, DOI 10.1021/bi00074a023; GOORMAGHTIGH E, 1994, SPECTROCHIM ACTA A, V50, P2137; GOORMAGHTIGH E, 1994, J BIOL CHEM, V269, P27409; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GOORMAGHTIGH E, 1990, MOL DESCRIPTION BIOL, P285; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V195, P421; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; Harrick N.J., 1967, INTERNAL REFLECTION; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.med.42.1.277; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SKACH WR, 1993, J BIOL CHEM, V268, P6903; SONVEAUX N, 1994, J BIOL CHEM, V269, P25637; TSURUO T, 1982, CANCER RES, V42, P4730; TSURUO T, 1981, CANCER RES, V41, P1967; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; VIGNERON L, 1995, J BIOL CHEM, V270, P17685, DOI 10.1074/jbc.270.30.17685; YUSA K, 1989, CANCER RES, V49, P5002; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	43	102	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24617	24624		10.1074/jbc.271.40.24617	http://dx.doi.org/10.1074/jbc.271.40.24617			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798727	hybrid			2022-12-27	WOS:A1996VM67400049
J	Tamami, M; Lindholm, PF; Brady, JN				Tamami, M; Lindholm, PF; Brady, JN			The retinoblastoma gene product (Rb) induces binding of a conformationally inactive nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIB; SUSCEPTIBILITY GENE; FACTOR E2F; LARGE-T; PROTEIN; ACTIVATION; TRANSACTIVATION; PHOSPHORYLATION; DOMAIN; P50	Nuclear factor-kappa B (NF-KB) regulates expression of several viral and cellular genes including the human immunodeficiency virus long terminal repeat, major histocompatibility complex class I, and interleukin 2R alpha cytokine genes. Here we report that the retinoblastoma gene product (Rb) stimulates binding of the NF-kappa B p50 homodimer. The addition of Rb protein to an in vitro gel shift binding assay stimulated p50 binding greater than 10-fold. Interestingly, by analyzing NF-kappa B-dependent transcription activity in vitro, we demonstrate that Rb suppresses transcriptional activity of p50. Chymotrypsin analysis suggests that Rb induces a conformational change in the NF-kappa B-DNA complex, resulting in binding of a transcriptionally inactive complex, Finally, we demonstrate by coimmunoprecipitation analysis that the Rb-p50 complex is present in Jurkat cell extracts. Our results suggest that Rb may play an important role in regulation of NF-kappa B transcriptional activity.	NCI,MOL VIROL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Bohan Cindy A., 1992, Gene Expression, V2, P391; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733	39	17	17	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24551	24556		10.1074/jbc.271.40.24551	http://dx.doi.org/10.1074/jbc.271.40.24551			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798717	hybrid			2022-12-27	WOS:A1996VM67400039
J	Bauer, MW; Bylina, EJ; Swanson, RV; Kelly, RM				Bauer, MW; Bylina, EJ; Swanson, RV; Kelly, RM			Comparison of a beta-glucosidase and a beta-mannosidase from the hyperthermophilic archaeon Pyrococcus furiosus - Purification, characterization, gene cloning, and sequence analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTASE-PHLORIZIN HYDROLASE; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; SULFOLOBUS-SOLFATARICUS; CLOSTRIDIUM-THERMOCELLUM; BACILLUS-POLYMYXA; ENZYME MYROSINASE; ALPHA-AMYLASE; BGL OPERON	Two distinct exo-acting, beta-specific glycosyl hydrolases were purified to homogeneity from crude cell extracts of the hyperthermophilic archaeon Pyrococcus furiosus: a beta-glucosidase, corresponding to the one previously purified by Kengen et al. (Kengen, S. W. M., Luesink, E. J., Stams, A. J. M., and Zehnder, A. J. B. (1993) fur. J. Biochem. 213, 305-312), and a beta-mannosidase. The beta-mannosidase and beta-glucosidase genes were isolated from a genomic library by expression screening. The nucleotide sequences predicted polypeptides with 510 and 472 amino acids corresponding to calculated molecular masses of 59.0 and 54.6 kDa for the beta-mannosidase and the beta-glucosidase, respectively. The beta-glucosidase gene was identical to that reported by Voorhorst ct al. (Voorhorst, W. G. B., Eggen, R. I. L., Luesink, E. J., and deVos, W. M. (1995) J. Bacteriol. 177, 7105-7111; GenBank accession no. U37557). The deduced amino acid sequences showed homology both with each other (46.5% identical) and with several other glycosyl hydrolases, including the beta-glycosidases from Sulfolobus solfataricus, Thermo-toga maritima, and Caldocellum saccharolyticum. Based on these sequence similarities, the beta-mannosidase and the beta-glucosidase can both be classified as family 1 glycosyl hydrolases. In addition, the beta-mannosidase and beta-glucosidase from P. furiosus both contained the conserved active site residues found in all family 1 enzymes. The beta-mannosidase showed optimal activity at pH 7.4 and 105 degrees C. Although the enzyme had a half-life of greater than 60 h at 90 degrees C, it is much less thermostable than the beta-glucosidase, which had a reported half-life of 85 h at 100 degrees C. K-m and V-max values for the beta-mannosidase were determined to be 0.79 mM and 31.1 mu mol para-nitrophenol released/min/mg with p-nitrophenyl-beta-D-mannopyranoside as substrate. The catalytic efficiency of the beta-mannosidase was significantly lower than that reported for the P. furiosus beta-glucosidase (5.3 versus 4, 500 s(-1) mM(-1) with p-nitrophenyl-beta-D-glucopyranoside as substrate). The kinetic differences between the two enzymes suggest that, unlike the beta-glucosidase, the primary role of the beta-mannosidase may not be disaccharide hydrolysis. Other possible roles for this enzyme are discussed.	N CAROLINA STATE UNIV,DEPT CHEM ENGN,RALEIGH,NC 27695; RECOMBINANT BIOCATALYSIS INC,SHARON HILL,PA 19079	University of North Carolina; North Carolina State University				Swanson, Ronald/0000-0002-6486-2676; Kelly, Robert/0000-0002-0639-3592				ADAMS MWW, 1995, ARCHAEA LAB MANUAL; AIT N, 1979, BIOCHEM BIOPH RES CO, V90, P537, DOI 10.1016/0006-291X(79)91269-5; AKINO T, 1988, AGR BIOL CHEM TOKYO, V52, P1459; BELAICH A, 1992, J BACTERIOL, V174, P4677, DOI 10.1128/JB.174.14.4677-4682.1992; BOUQUELET S, 1978, BIOCHIM BIOPHYS ACTA, V522, P521, DOI 10.1016/0005-2744(78)90084-0; BREIDT F, 1987, APPL ENVIRON MICROB, V53, P969, DOI 10.1128/AEM.53.5.969-973.1987; BROWN SH, 1993, APPL ENVIRON MICROB, V59, P2614, DOI 10.1128/AEM.59.8.2614-2621.1993; BROWN SH, 1990, APPL ENVIRON MICROB, V56, P1985, DOI 10.1128/AEM.56.7.1985-1991.1990; BRYAN L, 1990, BIOCHEM BIOPH RES CO, V173, P491, DOI 10.1016/S0006-291X(05)80060-9; BRYANT FO, 1989, J BIOL CHEM, V264, P5070; CHEN H, 1995, J BIOL CHEM, V270, P3841, DOI 10.1074/jbc.270.8.4088; COOPER A, 1986, NEW ENGL J MED, V315, P1231; COOPER A, 1988, J INHERIT METAB DIS, V11, P17, DOI 10.1007/BF01800054; COSTANTINO HR, 1990, J BACTERIOL, V172, P3654, DOI 10.1128/jb.172.7.3654-3660.1990; CUBELLIS MV, 1990, GENE, V94, P89, DOI 10.1016/0378-1119(90)90472-4; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DEVOS WM, 1989, J GEN MICROBIOL, V135, P1833; ELHASSOUNI M, 1992, J BACTERIOL, V174, P765, DOI 10.1128/jb.174.3.765-777.1992; EVANS RW, 1980, BIOCHIM BIOPHYS ACTA, V619, P533, DOI 10.1016/0005-2760(80)90105-8; FALK A, 1992, PLANT SCI, V83, P181, DOI 10.1016/0168-9452(92)90077-Y; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; FISCHER L, 1995, BIOTECHNOLOGY, V14, P88; GABELSBERGER J, 1993, FEMS MICROBIOL LETT, V109, P131, DOI 10.1016/0378-1097(93)90009-Q; GAMBACORTA A, 1994, SYST APPL MICROBIOL, V16, P518; GONZALEZCANDELAS L, 1990, GENE, V95, P31, DOI 10.1016/0378-1119(90)90410-S; GRABNITZ F, 1991, EUR J BIOCHEM, V200, P301, DOI 10.1111/j.1432-1033.1991.tb16186.x; GRABNITZ F, 1989, MOL GEN GENET, V217, P70, DOI 10.1007/BF00330944; GROGAN DW, 1991, APPL ENVIRON MICROB, V57, P1644, DOI 10.1128/AEM.57.6.1644-1649.1991; HALL BG, 1992, MOL BIOL EVOL, V9, P688; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; IWASAKI Y, 1989, J BIOCHEM-TOKYO, V106, P331, DOI 10.1093/oxfordjournals.jbchem.a122853; JANECEK S, 1993, J PROTEIN CHEM, V12, P509, DOI 10.1007/BF01025115; JENKINS J, 1995, FEBS LETT, V362, P281, DOI 10.1016/0014-5793(95)00252-5; JONES MZ, 1981, J BIOL CHEM, V256, P5185; Kate M., 1993, BIOCH ARCHAEA ARCHAE, V26, P261, DOI DOI 10.1016/S0167-7306(08)60258-6; KENGEN SWM, 1994, J BIOL CHEM, V269, P17537; KENGEN SWM, 1993, EUR J BIOCHEM, V213, P305, DOI 10.1111/j.1432-1033.1993.tb17763.x; KUSHWAHA SC, 1982, BIOCHIM BIOPHYS ACTA, V711, P19, DOI 10.1016/0005-2760(82)90004-2; LADERMAN KA, 1993, J BIOL CHEM, V268, P24402; LADERMAN KA, 1993, J BIOL CHEM, V268, P24394; LANZOTTI V, 1988, FEMS MICROBIOL LETT, V55, P223, DOI 10.1111/j.1574-6968.1988.tb13938.x; LEE KS, 1992, J BACTERIOL, V174, P2501, DOI 10.1128/jb.174.8.2501-2510.1992; LITTLE S, 1989, NUCLEIC ACIDS RES, V17, P7980, DOI 10.1093/nar/17.19.7980; LOVE DR, 1988, MOL GEN GENET, V213, P84, DOI 10.1007/BF00333402; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MARTINS LO, 1995, APPL ENVIRON MICROB, V61, P3299, DOI 10.1128/AEM.61.9.3299-3303.1995; MASTROMEI G, 1995, X74291 GENB; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NEUSTROEV KN, 1992, BIOCHEMISTRY-US, V56, P982; NUNES OC, 1995, APPL ENVIRON MICROB, V61, P2351, DOI 10.1128/AEM.61.6.2351-2357.1995; ODA Y, 1993, FOOD MICROBIOL, V10, P353, DOI 10.1006/fmic.1993.1041; OXTOBY E, 1991, PLANT MOL BIOL, V17, P209, DOI 10.1007/BF00039495; PAAVILAINEN S, 1993, APPL ENVIRON MICROB, V59, P927, DOI 10.1128/AEM.59.3.927-932.1993; PAINBENI E, 1992, J BACTERIOL, V174, P3087, DOI 10.1128/JB.174.9.3087-3091.1992; PEARL LH, 1993, J MOL BIOL, V229, P561, DOI 10.1006/jmbi.1993.1057; PISANI AM, 1990, EUR J BIOCHEM, V287, P321; PLANT AR, 1988, ARCH BIOCHEM BIOPHYS, V262, P181, DOI 10.1016/0003-9861(88)90180-4; PORTER EV, 1988, GENE, V62, P263; RUDIGER A, 1995, APPL ENVIRON MICROB, V61, P567; RUTTERSMITH LD, 1993, BIOCHIM BIOPHYS ACTA, V1156, P167, DOI 10.1016/0304-4165(93)90132-R; Sambrook J., 2002, MOL CLONING LAB MANU; SANZAPARICIO J, 1994, J MOL BIOL, V240, P267, DOI 10.1006/jmbi.1994.1441; SCHAFER T, 1994, FEMS MICROBIOL LETT, V121, P107, DOI 10.1016/0378-1097(94)90153-8; SCHNETZ K, 1987, J BACTERIOL, V169, P2579, DOI 10.1128/jb.169.6.2579-2590.1987; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SMALLBONE BW, 1981, BIOCHIM BIOPHYS ACTA, V665, P551, DOI 10.1016/0005-2760(81)90270-8; SOPHER BL, 1993, BIOCHEM J, V289, P343, DOI 10.1042/bj2890343; SOPHER BL, 1992, J BIOL CHEM, V267, P6178; TORREBLANCA M, 1986, SYST APPL MICROBIOL, V8, P89, DOI 10.1016/S0723-2020(86)80155-2; TRINCONE A, 1990, J GEN MICROBIOL, V136, P2327, DOI 10.1099/00221287-136-11-2327; TRINCONE A, 1995, BIOTECHNOL LETT, V17, P45, DOI 10.1007/BF00134194; TRINCONE A, 1992, SYST APPL MICROBIOL, V15, P11, DOI 10.1016/S0723-2020(11)80130-X; TULL D, 1991, J BIOL CHEM, V266, P15621; VOORHORST WGB, 1995, J BACTERIOL, V177, P7105, DOI 10.1128/JB.177.24.7105-7111.1995; WAKARCHUK WW, 1988, J BACTERIOL, V170, P301, DOI 10.1128/jb.170.1.301-307.1988; WENGER DA, 1986, NEW ENGL J MED, V315, P1201, DOI 10.1056/NEJM198611063151906; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; XUE JP, 1992, PLANT MOL BIOL, V18, P387, DOI 10.1007/BF00034965	78	102	106	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23749	23755		10.1074/jbc.271.39.23749	http://dx.doi.org/10.1074/jbc.271.39.23749			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798600	hybrid			2022-12-27	WOS:A1996VJ44200029
J	Chen, G; Branton, PE; Yang, E; Korsmeyer, SJ; Shore, GC				Chen, G; Branton, PE; Yang, E; Korsmeyer, SJ; Shore, GC			Adenovirus E1B 19-kDa death suppressor protein interacts with Bax but not with Bad	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; BCL-2 HOMOLOG BAK; INDUCE APOPTOSIS; MEMBRANE; DOMAIN; P53; INHIBITION; CYTOLYSIS; DNA	Adenovirus E1B 19-kDa protein (19K) is a member of the Bcl-2 family of suppressors of apoptosis. The suppressors function through heterodimerization with the death promoters, Bax and related proteins, thus establishing a set point within the cell that determines whether or not apoptosis is executed in response to a death signal. Sequence similarities between 19K and Bcl-2 are largely restricted to short Bcl-2 homology (BH) domains that mediate interaction with Bax. The BH1 sequence in 19K is degenerate but nevertheless contains a conserved glycine residue found in all family members that when mutated to alanine in Bcl-2 results in loss of Bcl-2 function and ability to dimerize with Bax (Yin, X.-M., Oltvai, Z. N., and Korsmeyer, S. J. (1994) Nature 369, 321-323). Here, we show that the analogous mutation in BH1 of 19K also abrogates the anti-apoptotic properties of 19K and its ability to interact with Bax, thus establishing the critical importance of this residue within BH1 and the likely similarity of Bcl-2 and 19K function. In distinct contrast to Bcl-2, however, 19K interaction was not detected with Bad, a Bcl-2/Bcl-X(L) dimerizing protein that can potentially regulate a Bax-Bcl-2/Bcl-X(L) survival set point and reinstate susceptibility to a death signal. Furthermore, the anti-apoptotic function of 19K was not overcome by enforced expression of Bad in transfected cells. This feature of 19K may provide adenovirus with a selective advantage in evading premature induction of apoptosis by the host cell.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	McGill University; McGill University; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)								BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Boulakia CA, 1996, ONCOGENE, V12, P529; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; CHEN G, 1995, EXP CELL RES, V221, P55, DOI 10.1006/excr.1995.1351; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Clem RJ, 1996, CELL DEATH DIFFER, V3, P9; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GINGERAS TR, 1982, J BIOL CHEM, V257, P13475; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KOCHI SK, 1993, EXP CELL RES, V208, P296, DOI 10.1006/excr.1993.1249; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Subramanian T, 1995, ONCOGENE, V11, P2403; TEODORO JG, 1995, ONCOGENE, V11, P467; TEODORO JG, 1994, J VIROL, V68, P776, DOI 10.1128/JVI.68.2.776-786.1994; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHYTE M, 1995, NATURE, V376, P17, DOI 10.1038/376017a0; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1995, CURR OPIN CELL BIOL, V7, P211, DOI 10.1016/0955-0674(95)80030-1	39	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24221	24225		10.1074/jbc.271.39.24221	http://dx.doi.org/10.1074/jbc.271.39.24221			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798665	hybrid			2022-12-27	WOS:A1996VJ44200094
J	Couture, C; Deckert, M; Williams, S; Russo, FO; Altman, A; Mustelin, T				Couture, C; Deckert, M; Williams, S; Russo, FO; Altman, A; Mustelin, T			Identification of the site in the Syk protein tyrosine kinase that binds the SH2 domain of Lck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ANTIGEN RECEPTOR; JURKAT T-CELLS; NATURAL-KILLER-CELLS; FC-EPSILON-RI; ZAP-70 KINASE; ZETA-CHAIN; PHOSPHORYLATION; ACTIVATION; P72(SYK); STIMULATION	The Syk protein tyrosine kinase (PTK) is expressed in many hematopoietic cells and is involved in signaling from various receptors for antigen and Fc portions of IgG and IgE. Upon cross-linking of these receptors, Syk is rapidly phosphorylated on tyrosine residues and enzymatically activated. We and others have found that the Lck kinase, a member of the Src family of PTKs, binds through its Src homology (SH) 2 domain to tyrosine phosphorylated Syk and to the related Zap kinase. Here we report that this interaction is direct and identify the two tandem tyrosines at the autophosphorylation site of Syk, Tyr(518), and Tyr(519), as the binding site for the SH2 domain of Lck. Mutation of either or both tyrosines to phenylalanines abrogated binding, while mutation of a second repetition of the motif at Tyr(539) and Tyr(540), or of the three tyrosines in the C terminus of Syk, did not. The SH2 domain of Lck bound the autophosphorylation site only when both Tyr(518) and Tyr(519) were phosphorylated. In intact cells the binding of the SH2 domain of Lck correlated with the ability of Syk to induce tyrosine phosphorylation of cellular proteins.	LA JOLLA INST ALLERGY & IMMUNOL, DIV CELL BIOL, SAN DIEGO, CA 92121 USA	La Jolla Institute for Immunology			Deckert, Marcel/M-4998-2016; Deckert, Marcel/T-3566-2019	Deckert, Marcel/0000-0003-2094-559X; Mustelin, Tomas/0000-0001-5912-8840	NCI NIH HHS [CA35299] Funding Source: Medline; NIAID NIH HHS [AI35603] Funding Source: Medline; NIGMS NIH HHS [GM48960] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048960] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; ASAHI M, 1993, J BIOL CHEM, V268, P23334; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BRUNATI AM, 1995, FEBS LETT, V367, P149, DOI 10.1016/0014-5793(95)00555-N; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; DARBY C, 1994, J IMMUNOL, V152, P5429; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; HARPER JW, 1993, CELL, V75, P805; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KONG GH, 1995, IMMUNITY, V2, P485, DOI 10.1016/1074-7613(95)90029-2; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; Law CL, 1996, MOL CELL BIOL, V16, P1305; LUO K, 1990, ONCOGENE, V5, P921; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; MUSTELIN T, 1995, EUR J IMMUNOL, V25, P942, DOI 10.1002/eji.1830250413; MUSTELIN T, 1994, SRC FAMILY TYROSINE, P1; OETKEN C, 1994, ONCOGENE, V9, P1625; OETKEN C, 1994, MOL IMMUNOL, V31, P1295, DOI 10.1016/0161-5890(94)90047-7; PINCUS SH, 1989, J IMMUNOL, V142, P3070; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SILLMAN AL, 1995, J BIOL CHEM, V270, P11806, DOI 10.1074/jbc.270.20.11806; STAHLS A, 1994, EUR J IMMUNOL, V24, P2491, DOI 10.1002/eji.1830241035; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; THOME M, 1995, J EXP MED, V181, P1997, DOI 10.1084/jem.181.6.1997; VIVIER E, 1993, EUR J IMMUNOL, V23, P1872, DOI 10.1002/eji.1830230821; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WATTS JD, 1994, J BIOL CHEM, V269, P29520; YAMADA T, 1991, BIOCHEM BIOPH RES CO, V180, P1325, DOI 10.1016/S0006-291X(05)81340-3; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	51	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24294	24299		10.1074/jbc.271.39.24294	http://dx.doi.org/10.1074/jbc.271.39.24294			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798676	hybrid			2022-12-27	WOS:A1996VJ44200105
J	Marchand, P; Volkmann, M; Bond, JS				Marchand, P; Volkmann, M; Bond, JS			Cysteine mutations in the MAM domain result in monomeric meprin and alter stability and activity of the proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY; ALPHA-SUBUNIT; BETA-SUBUNIT; MEMBRANE; PURIFICATION; ENZYME; METALLOENDOPEPTIDASES; ENDOPEPTIDASE-2; EXPRESSION; HYDROLYSIS	Meprins are oligomeric, glycosylated cell surface or secreted metalloendopeptidases that are composed of multidomain disulfide-linked subunits. To investigate whether subunit oligomerization is critical for intracellular transport or for the enzymatic and/or physical properties of the proteinase, specific cysteine residues were mutated, and the mutants were expressed in 293 cells. Mutation of mouse meprin alpha Cys-320 to Ala in the MAM domain (an extracellular domain found in meprin, (A) under bar-5 protein, and receptor protein-tyrosine phosphatase <(mu)under bar>) resulted in expression of a monomeric form of meprin, as determined by SDS-polyacrylamide gel electrophoresis and nondenaturing gel electrophoresis. The monomeric subunits were considerably more vulnerable to proteolytic degradation and heat inactivation in vitro compared with the oligomeric form of the enzyme. Proteolytic activity of the monomeric meprin using a bradykinin analog or aminobenzoyl-Ala-Ala Phe-p-nitroanilide as substrate was similar to that of disulfide-linked oligomeric meprin; however, activity against azocasein was markedly decreased. Mutation of another cysteine residue in the MAM domain (C289A), predicted to be involved in intrasubunit disulfide bridging, resulted in disulfide-linked oligomers and monomers. These results indicated that this mutant was capable of forming intersubunit disulfide bonds but less efficiently than wild-type meprin subunits. Mutant C289A also retained activity toward peptides but not the protein substrate and was more vulnerable to proteolytic degradation and heat inactivation compared with the wild-type enzyme. Both Cys mutants were expressed and secreted into the medium at levels comparable with the wild type and had slightly altered glycosylation. This work indicates that 1) Cys-320 of mouse meprin alpha is most likely responsible for the covalent interactions of the subunits; 2) covalent dimerization of subunits is not essential for efficient biosynthesis, trafficking, or posttranslational processing of the secreted protease; and 3) mutations in the MAM domain affect noncovalent interactions of the subunits and the stability and activity of the protease domain, indicating that domain-domain interactions are critical for structure and function of the enzyme.	PENN STATE UNIV,DEPT BIOCHEM & MOL BIOL,COLL MED,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK019691, R01DK019691, R37DK019691] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19691] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKUSJARVI G, 1987, MOL CELL BIOL, V7, P549, DOI 10.1128/MCB.7.1.549; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BONIFACINO JS, 1991, CIRR BIOL, V113, P997; CHOUDRY Y, 1991, BIOCHEM J, V280, P57, DOI 10.1042/bj2800057; COTTON RGH, 1978, EUR J BIOCHEM, V83, P319, DOI 10.1111/j.1432-1033.1978.tb12097.x; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DERYNCK R, 1987, ONCOGENES GENE GROWT, P136; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FOWLER SD, 1995, FEBS LETT, V366, P72, DOI 10.1016/0014-5793(95)00501-Y; GORBEA CM, 1993, J BIOL CHEM, V268, P21035; GORBEA CM, 1991, ARCH BIOCHEM BIOPHYS, V290, P549, DOI 10.1016/0003-9861(91)90580-C; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; JIANG W, 1996, ZINC METALLOPROTEASE, P23; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JOHNSON GD, 1992, J BIOL CHEM, V267, P13505; KAUSHAL GP, 1994, J CELL BIOL, V126, P1319, DOI 10.1083/jcb.126.5.1319; KENNY AJ, 1987, BIOCHEM J, V245, P515, DOI 10.1042/bj2450515; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17350; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; MARCHAND P, 1994, J BIOL CHEM, V269, P15388; MARCHAND P, 1995, J BIOL CHEM, V270, P5449, DOI 10.1074/jbc.270.10.5449; STEPHENSON SL, 1988, BIOCHEM J, V255, P45, DOI 10.1042/bj2550045; STERCHI EE, 1988, ARCH BIOCHEM BIOPHYS, V265, P105, DOI 10.1016/0003-9861(88)90376-1; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; WOLZ RL, 1995, METHOD ENZYMOL, V248, P325; YAMAGUCHI T, 1991, EUR J BIOCHEM, V200, P563, DOI 10.1111/j.1432-1033.1991.tb16219.x; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	32	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24236	24241		10.1074/jbc.271.39.24236	http://dx.doi.org/10.1074/jbc.271.39.24236			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798668	hybrid			2022-12-27	WOS:A1996VJ44200097
J	Shimohigashi, Y; Hatano, R; Fujita, T; Nakashima, R; Nose, T; Sujaku, T; Saigo, A; Shinjo, K; Nagahisa, A				Shimohigashi, Y; Hatano, R; Fujita, T; Nakashima, R; Nose, T; Sujaku, T; Saigo, A; Shinjo, K; Nagahisa, A			Sensitivity of opioid receptor-like receptor ORL1 for chemical modification on nociceptin, a naturally occurring nociceptive peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIATE RECEPTOR; GENE FAMILY; DYNORPHIN; CLONING; MEMBER; LOCALIZATION; LIGANDS; DELTA	Nociceptin or orphanin FQ is a novel neuropeptide that activates an opioid-like G protein-coupled receptor ORL1. This heptadecapeptide FGGFTGARKSARKLANQ resembles kappa-opioid peptide dynorphin A but exhibits an opposite effect to make animals hyperreactive to nociceptive stimulations (Meunier, J.-C., Mollereau, C., Toll, L., Suaudeau, C., Moisand, C., Alvinerie, P., Butour, J.-L., Guillemot, J.-C., Ferrara, P., Monsarrat, B., Mazarguil, H., Vassart, G., Parmentier, M., and Costentin, J. (1995) Nature 377, 532-535; Reinscheid, R.K., Nothacker, H.-P., Bourson, A., Ardati, A., Henningsen, R.A., Bunzow, J.R., Grandy, D.K., Langen, H., Monsma, F.J., Jr., and Civelli, O. (1995) Science 270, 792-794). In the present study, it was found that guinea pig brain contains receptors to which nociceptin binds much more strongly than to ORL1 receptors expressed in human 293 cells. Although the Tyr(1) --> Phe substitution for dynorphin A eliminates almost completely an ability to bind to opioid receptors, the Phe(1) --> Tyr substitution in nociceptin was found to retain almost fully both receptor binding affinity and in vivo hyperalgesic activity in tail-flick assay. Nociceptin was extremely weak to bind to opioid receptors, while Tyr(1)-nociceptin exhibited 10-40 times increased affinity, especially for mu receptors, due to its N-terminal sequential identity to opioid peptides. Shortened analogs of dynorphin A are known to retain receptor binding ability and analgesic activity, whereas the removal of C-terminal hexa- or decapeptide from nociceptin totally abolished the affinity for the ORL1 receptor. These results indicated that the mode of interaction between nociceptin and ORL1 receptor is quite different from that between dynorphin and opioid receptor and that the C-terminal portion of nociceptin is crucial for receptor recognition.	PFIZER PHARMACEUT INC,CENT RES,AICHI 47023,JAPAN	Pfizer	Shimohigashi, Y (corresponding author), KYUSHU UNIV,BIOCHEM LAB,DEPT CHEM,FAC SCI,FUKUOKA 81281,JAPAN.			Nose, Takeru/0000-0001-9771-7267				CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHAVKIN C, 1981, P NATL ACAD SCI-BIOL, V78, P6543, DOI 10.1073/pnas.78.10.6543; CHEN Y, 1994, FEBS LETT, V347, P279, DOI 10.1016/0014-5793(94)00560-5; CORBETT AD, 1982, NATURE, V299, P79, DOI 10.1038/299079a0; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; GOLDSTEIN A, 1981, P NATL ACAD SCI-BIOL, V78, P7219, DOI 10.1073/pnas.78.11.7219; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; MOSBERG HI, 1987, MOL PHARMACOL, V31, P599; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; SHIMOHIGASHI Y, 1982, BIOCHEM BIOPH RES CO, V104, P583, DOI 10.1016/0006-291X(82)90677-5; Shimohigashi Y, 1986, NIDA Res Monogr, V69, P65; TACHIBANA S, 1982, NATURE, V295, P339, DOI 10.1038/295339a0; WANG JB, 1994, FEBS LETT, V348, P75, DOI 10.1016/0014-5793(94)00557-5; WEBER E, 1982, NATURE, V299, P77, DOI 10.1038/299077a0; ZHANG SW, 1995, J BIOL CHEM, V270, P22772, DOI 10.1074/jbc.270.39.22772	16	66	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23642	23645		10.1074/jbc.271.39.23642	http://dx.doi.org/10.1074/jbc.271.39.23642			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798582	hybrid			2022-12-27	WOS:A1996VJ44200011
J	Mimnaugh, EG; Chavany, C; Neckers, L				Mimnaugh, EG; Chavany, C; Neckers, L			Polyubiquitination and proteasomal degradation of the p185(c-erbB-2) receptor protein-tyrosine kinase induced by geldanamycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT P185; HERBIMYCIN-A; BENZOQUINOID ANSAMYCINS; HETEROPROTEIN COMPLEX; STRESS PROTEINS; UBIQUITIN; PATHWAY; INHIBITION; TRANSFORMATION; AMPLIFICATION	Treatment of SKBr3 human breast carcinoma cells with the benzoquinoid ansamycin, geldanamycin, rapidly depletes p185(c-erbB-2) protein-tyrosine kinase. Loss of p185(c-erbB-2) is initiated by disruption of a heteromeric complex between p185(c-erbB-2) and the 94-kDa glucose-regulated protein, GRP94, to which geldanamycin binds avidly. Here we report that within minutes of exposure to geldanamycin, mature p185(c-erb-2) becomes polyubiquitinated. Treatment of cells with the specific proteasome proteolytic inhibitor, lactacystin, blocked geldanamycin-induced degradation of p185(c-erbB-2) and enhanced the accumulation of polyubiquitinated p185(c-erbB-2). Following geldanamycin and lactacystin treatment, a higher molecular weight form of p185(c-erbB-2), which likely represents ubiquitin-p185(c-erbB-2) conjugates, was detected by anti-p185(c-erbB-2) immunoblotting. Nascent p185(c-erbB-2) synthesized in the presence of geldanamycin is incompletely glycosylated and remains sequestered in the endoplasmic reticulum. While this immature form of the protein is not ubiquitinated in the presence of geldanamycin, its marked, drug-induced instability is nonetheless antagonized by lactacystin. Thus, the rapid depletion of mature p185(c-erbB-2) caused by geldanamycin and the marked, drug-stimulated decrease in half-life of the newly synthesized protein are both mediated by the proteasome, although only the former phenomenon involves polyubiquitination.			Mimnaugh, EG (corresponding author), NCI,CLIN PHARMACOL BRANCH,NIH,BLDG 10,ROOM 12N226,BETHESDA,MD 20892, USA.							BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X; Chavany C, 1996, J BIOL CHEM, V271, P4974; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CIECHANOVER A, 1984, J CELL BIOCHEM, V24, P137; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; GUARINO LA, 1995, CELL, V80, P301, DOI 10.1016/0092-8674(95)90413-1; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER P, 1994, CANCER RES, V54, P2724; MILLER P, 1994, BIOCHEM BIOPH RES CO, V201, P1313, DOI 10.1006/bbrc.1994.1847; MIMNAUGH EG, 1995, J BIOL CHEM, V270, P28654, DOI 10.1074/jbc.270.48.28654; MORI S, 1995, BIOCHEM BIOPH RES CO, V213, P32, DOI 10.1006/bbrc.1995.2094; MORI S, 1993, J BIOL CHEM, V268, P577; MURAKAMI Y, 1994, BIOCHEM J, V301, P63, DOI 10.1042/bj3010063; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	32	397	407	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22796	22801		10.1074/jbc.271.37.22796	http://dx.doi.org/10.1074/jbc.271.37.22796			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798456	hybrid			2022-12-27	WOS:A1996VG67200075
J	Matsuoka, Y; Hughes, CA; Bennett, V				Matsuoka, Y; Hughes, CA; Bennett, V			Adducin regulation - Definition of the calmodulin-binding domain and sites of phosphorylation by protein kinase A and C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-ADDUCIN; ERYTHROCYTE-MEMBRANE; BETA-ADDUCIN; SUBSTRATE-SPECIFICITY; PLASMA-MEMBRANE; BASIC RESIDUES; IDENTIFICATION; FAMILY; MARCKS; PURIFICATION	Adducin promotes association of spectrin with actin and caps the fast growing end of actin filaments. Adducin contains N-terminal core, neck, and C-terminal tail domains, is a substrate for protein kinases A (PKA) and C (PKC), and binds to Ca2+/calmodulin. Ser-726 and Ser-713 in the C-terminal MARCKS-related domains of alpha- and beta-adducin, respectively, were identified as the major phosphorylation sites common for PKA and PKC, PKA, in addition, phosphorylated alpha-adducin at Ser-408, -436, and -481 in the neck domain, Phosphorylation by PKA,but not PKC, reduced the affinity of adducin for spectrin-F-actin complexes as well as the activity of adducin in promoting binding of spectrin to F-actin. The myristoylated alanine-rich protein kinase C substrate-related domain of beta-adducin was identified as the dominant Ca2+-dependent calmodulin-binding site. Calmodulin-binding was inhibited by phosphorylation of beta-adducin and of a MARCKS-related domain peptide by PRA and PRC. Calmodulin in turn inhibited the rate, but not the extent, of phosphorylation of beta-adducin, but not alpha-adducin, by PKA and that of each subunit by PKC. These findings suggest a complex reciprocal relationship between regulation of adducin function by calmodulin binding and phosphorylation by PKA and PKC.	DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University; Duke University	Matsuoka, Y (corresponding author), DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA.							ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; Beavo J A, 1974, Methods Enzymol, V38, P299; BENNETT V, 1988, J BIOL CHEM, V263, P5860; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLUMENTHAL DK, 1978, J BIOL CHEM, V253, P334; BYLUND DB, 1975, J BIOL CHEM, V250, P6355; DERICK LH, 1992, EUR J CELL BIOL, V57, P317; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; GARDNER K, 1986, J BIOL CHEM, V261, P1339; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUGHES CA, 1995, J BIOL CHEM, V270, P18990, DOI 10.1074/jbc.270.32.18990; INAGAKI M, 1985, J BIOL CHEM, V260, P2922; JOHNSON JD, 1983, BIOCHEM J, V211, P473, DOI 10.1042/bj2110473; JOSHI R, 1990, J BIOL CHEM, V265, P13130; JOSHI R, 1991, J CELL BIOL, V115, P665, DOI 10.1083/jcb.115.3.665; KAISER HW, 1989, J CELL BIOL, V109, P557, DOI 10.1083/jcb.109.2.557; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Kuhlman PA, 1996, J BIOL CHEM, V271, P7986, DOI 10.1074/jbc.271.14.7986; KUSUBATA M, 1993, BIOCHEM BIOPH RES CO, V190, P927, DOI 10.1006/bbrc.1993.1138; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XL, 1996, J BIOL CHEM, V271, P15695, DOI 10.1074/jbc.271.26.15695; LIN BY, 1995, GENOMICS, V25, P93, DOI 10.1016/0888-7543(95)80113-Z; LING E, 1986, J BIOL CHEM, V261, P13875; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; MATSUOKA Y, 1992, EMBO J, V11, P2895, DOI 10.1002/j.1460-2075.1992.tb05358.x; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MIYAZAKI M, 1994, BIOCHEM BIOPH RES CO, V205, P460, DOI 10.1006/bbrc.1994.2688; NEHLS V, 1991, BLOOD, V78, P1692; NISHIKAWA M, 1985, J BIOL CHEM, V260, P8978; PALFREY HC, 1985, J BIOL CHEM, V260, P6021; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; ROSENMUND C, 1993, J PHYSIOL-LONDON, V470, P705, DOI 10.1113/jphysiol.1993.sp019884; SCARAMUZZINO DA, 1993, P NATL ACAD SCI USA, V90, P3398, DOI 10.1073/pnas.90.8.3398; Schengrund CL, 1996, J NEUROCHEM, V66, P2556; SEIDEL B, 1995, BRAIN RES, V700, P13, DOI 10.1016/0006-8993(95)00962-P; SINARD JH, 1995, MOL BIOL CELL, V6, P1562; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STULL JT, 1993, MOL CELL BIOCHEM, V128, P229, DOI 10.1007/BF01076774; TRIPODI G, 1991, BIOCHEM BIOPH RES CO, V177, P939, DOI 10.1016/0006-291X(91)90629-L; WANG KKW, 1991, J BIOL CHEM, V266, P9078; WOODGETT JR, 1994, PROTEIN KINASES, P30	51	142	154	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25157	25166		10.1074/jbc.271.41.25157	http://dx.doi.org/10.1074/jbc.271.41.25157			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810272	hybrid			2022-12-27	WOS:A1996VL69300016
J	Ramjaun, AR; McPherson, PS				Ramjaun, AR; McPherson, PS			Tissue-specific alternative splicing generates two synaptojanin isoforms with differential membrane binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL-POLYPHOSPHATE 5-PHOSPHATASE; NERVE-TERMINALS; SH3 DOMAINS; DYNAMIN; PROTEIN; FORMS; DROSOPHILA; ENDOCYTOSIS; MOLECULES; VESICLES	Synaptojanin is an Src homology 3 domain-binding inositol 5-phosphatase that is thought to function in synaptic vesicle endocytosis. It is encoded by a cDNA with two open reading frames separated by an in-frame stop codon. The first open reading frame encodes a 145-kDa form of the protein, whereas a 170-kDa isoform appears to be composed of both open reading frames and contains additional Src homology 3 domain-binding consensus sequences. Here, we demonstrate that the two synaptojanin isoforms are generated by the alternative use of an exon containing the stop codon. Whereas the 145-kDa isoform is highly enriched in adult brain, the 170-kDa isoform is excluded from this tissue and has a widespread distribution in non-neuronal cells. Unlike the 145-kDa isoform, which can be removed from membranes by a low salt wash, the 170-kDa isoform remains membrane-associated, even in the presence of 1 M salt. Further, the 170-kDa form, but not the 145-kDa form, can be isolated from membranes as part of a large molecular weight complex. These properties may allow the 170-kDa isoform of synaptojanin to play a unique and perhaps more general role in endocytosis as compared with the 145-kDa isoform.	MCGILL UNIV,MONTREAL NEUROL INST,CBET GRP,DEPT NEUROL & NEUROSURG,MONTREAL,PQ H3A 2B4,CANADA	McGill University								ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BARKER PA, 1993, J BIOL CHEM, V268, P15150; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Bauerfeind R, 1995, COLD SPRING HARB SYM, V60, P397; CATTANEO R, 1991, ANNU REV GENET, V25, P71, DOI 10.1146/annurev.ge.25.120191.000443; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; HINSHAW JE, 1995, NATURE, V374, P1905; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; MCPHERSON PS, 1996, NATURE, V379, P535; MCPHERSON PS, 1994, SEMIN NEUROSCI, V6, P137; MORRIS SA, 1995, CURR BIOL, V5, P1; MOUNT SM, 1996, NATURE, V271, P1690; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; NAKATA T, 1993, J CELL SCI, V105, P1; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; SZABO G, 1994, MOL CELL BIOL, V14, P7535, DOI 10.1128/MCB.14.11.7535; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TUMA PL, 1994, J BIOL CHEM, V269, P30842; TUMA PL, 1995, J BIOL CHEM, V270, P26707, DOI 10.1074/jbc.270.44.26707; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	41	71	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24856	24861		10.1074/jbc.271.40.24856	http://dx.doi.org/10.1074/jbc.271.40.24856			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798761	hybrid			2022-12-27	WOS:A1996VM67400083
J	Reddy, SG; McIlheran, SM; Cochran, BJ; Worth, LL; Bishop, LA; Brown, PJ; Knutson, VP; Haddox, MK				Reddy, SG; McIlheran, SM; Cochran, BJ; Worth, LL; Bishop, LA; Brown, PJ; Knutson, VP; Haddox, MK			Multisite phosphorylation of ornithine decarboxylase in transformed macrophages results in increased intracellular enzyme stability and catalytic efficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; MULTIPLE IONIC FORMS; AMINO-ACID SEQUENCE; MOUSE KIDNEY; CELL-LINE; POLYAMINE METABOLISM; NUCLEOTIDE-SEQUENCE; ACTIVE-SITE; RAT-HEART; ANTIZYME	Ornithine decarboxylase (ODC) is the initial inducible enzyme in the polyamine biosynthetic pathway, In the transformed macrophage-derived RAW264 cell line, ODC was overproduced and existed in both unphosphorylated and phosphorylated forms, To date, the only protein kinase known to phosphorylate mammalian ODC is casein kinase II (CKII), ODC was phosphorylated in vitro by CKII and subjected to exhaustive sequential proteolysis with trypsin and V8 protease. Two-dimensional peptide mapping showed only a single phosphopeptide; two dimensional phosphoamino acid analysis of the phosphopeptide revealed only P-32-labeled serine. ODC was metabolically radiolabeled with P-32(i) in RAW264 cells and also subjected to proteolysis, two-dimensional peptide mapping, and phosphoamino acid analysis. Two phosphopeptides were generated from the metabolically radiolabeled ODC, including one that migrated similarly to the peptide phosphorylated by CKII in vitro, Each of the in situ radiolabeled ODC peptides contained both P-32-labeled serine and threonine residues. Thus, in RAW264 cells, ODC is phosphorylated on at least one serine residue in addition to that phospho rylated by CKII and on at least two threonine residues. Phosphorylated ODC had an increased stability to intracellular proteolysis compared with unphosphorylated ODC, their half-lives being 49.2 +/- 3.78 and 23.9 +/- 2.6 min (p = 0.001), respectively. The phosphorylated and unphosphorylated forms of ODC were independently purified to homogeneity. Kinetic analysis revealed that the catalytic efficiency of the phosphorylated form of ODC was 50% greater than that of the unphosphorylated form; the unphosphorylated ODC had a V-max of 20.54 +/- 1.65 mu mol/min/mg, whereas the phosphorylated form had a V-max of 30.61 +/- 2.6 mu mol/min/mg (p = 0.005). Phosphorylation of ODC by CKII has no effect on enzyme activity. Taken together, these findings demonstrate that regulation of ODC activity is governed by as yet unidentified protein kinases.	UNIV TEXAS, SCH MED, DEPT PHARMACOL, HOUSTON, TX 77225 USA	University of Texas System					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044331] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44331] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERCOVICH Z, 1993, EUR J BIOCHEM, V213, P205, DOI 10.1111/j.1432-1033.1993.tb17749.x; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLEMAN CS, 1993, J BIOL CHEM, V268, P24572; COLEMAN CS, 1994, J BIOL CHEM, V269, P3155; DAHMUS ME, 1981, J BIOL CHEM, V256, P3319; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; FLAMIGNI F, 1984, BIOCHIM BIOPHYS ACTA, V802, P245, DOI 10.1016/0304-4165(84)90168-5; FLAMIGNI F, 1990, BIOCHIM BIOPHYS ACTA, V1052, P345, DOI 10.1016/0167-4889(90)90232-3; GREENFIELD ARL, 1986, CELL TISSUE RES, V243, P33; HADDOX MK, 1981, BIOCHEMISTRY-US, V20, P6721, DOI 10.1021/bi00526a030; HICKOK NJ, 1987, DNA-J MOLEC CELL BIO, V6, P179, DOI 10.1089/dna.1987.6.179; KAHANA C, 1985, P NATL ACAD SCI USA, V82, P1673, DOI 10.1073/pnas.82.6.1673; KAMEJI T, 1993, BIOCHEM J, V289, P581, DOI 10.1042/bj2890581; KAMEJI T, 1982, BIOCHIM BIOPHYS ACTA, V705, P405, DOI 10.1016/0167-4838(82)90263-1; KANAMOTO R, 1993, J BIOL CHEM, V268, P9393; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAITINEN SI, 1985, BIOCHEM INT, V10, P559; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LUO R, 1960, ONCOGENE, V5, P921; MADHUBALA R, 1988, BIOCHEM J, V254, P45, DOI 10.1042/bj2540045; MEGGIO F, 1987, BIOCHIM BIOPHYS ACTA, V929, P114, DOI 10.1016/0167-4889(87)90246-1; MEGGIO F, 1984, BIOCHEM BIOPH RES CO, V122, P997, DOI 10.1016/0006-291X(84)91190-2; MITCHELL JLA, 1991, ARCH BIOCHEM BIOPHYS, V290, P143, DOI 10.1016/0003-9861(91)90600-N; MITCHELL JLA, 1982, BIOCHEM BIOPH RES CO, V105, P1189, DOI 10.1016/0006-291X(82)91095-6; MITCHELL JLA, 1988, ARCH BIOCHEM BIOPHYS, V260, P585, DOI 10.1016/0003-9861(88)90485-7; MITCHELL JLA, 1985, BIOCHIM BIOPHYS ACTA, V840, P309, DOI 10.1016/0304-4165(85)90210-7; MURAKAMI Y, 1985, BIOCHEM J, V225, P689, DOI 10.1042/bj2250689; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; MURAKAMI Y, 1989, EUR J BIOCHEM, V180, P181, DOI 10.1111/j.1432-1033.1989.tb14630.x; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OBRIEN TG, 1986, P NATL ACAD SCI USA, V83, P9448, DOI 10.1073/pnas.83.24.9448; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; PENG T, 1988, BIOCHEM BIOPH RES CO, V153, P135, DOI 10.1016/S0006-291X(88)81199-9; PEREIRA MA, 1983, BIOCHEM PHARMACOL, V32, P2511, DOI 10.1016/0006-2952(83)90011-4; PERSSON L, 1984, BIOCHEMISTRY-US, V23, P3777, DOI 10.1021/bi00311a033; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; REDDY SG, 1994, ANAL BIOCHEM, V218, P149, DOI 10.1006/abio.1994.1154; REICH DJ, 1985, J CELL BIOL, V101, pA935; RICHARDS JF, 1981, BIOCHEM BIOPH RES CO, V99, P1461, DOI 10.1016/0006-291X(81)90783-X; RICHARDS JF, 1993, ARCH BIOCHEM BIOPHYS, V300, P80, DOI 10.1006/abbi.1993.1012; ROSENBERGHASSON Y, 1991, EUR J BIOCHEM, V197, P419, DOI 10.1111/j.1432-1033.1991.tb15927.x; RUSSELL DH, 1969, MOL PHARMACOL, V5, P253; SEELY JE, 1983, METHOD ENZYMOL, V94, P158; SUMIYOSHI H, 1991, CANCER RES, V51, P2069; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TAFFET SM, 1985, J CELL PHYSIOL, V122, P215, DOI 10.1002/jcp.1041220209; TIPNIS UR, 1990, CELL MOL BIOL, V36, P275; TOBIAS KE, 1993, BIOCHEMISTRY-US, V32, P5842, DOI 10.1021/bi00073a017; TSIRKA S, 1992, J BIOL CHEM, V267, P23057; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P124; VANKRANEN HJ, 1987, GENE, V60, P145, DOI 10.1016/0378-1119(87)90222-8; WORTH LL, 1994, CANCER RES, V54, P3967; WORTH LL, 1989, J CELL BIOL, V107, pA855; ZANDOMENI R, 1988, FEBS LETT, V235, P247, DOI 10.1016/0014-5793(88)81272-9	58	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24945	24953		10.1074/jbc.271.40.24945	http://dx.doi.org/10.1074/jbc.271.40.24945			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798774	hybrid			2022-12-27	WOS:A1996VM67400097
J	Zhu, SH; Sobolev, AY; Wek, RC				Zhu, SH; Sobolev, AY; Wek, RC			Histidyl-tRNA synthetase-related sequences in GCN2 protein kinase regulate in vitro phosphorylation of eIF-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; SACCHAROMYCES-CEREVISIAE; TRANSLATIONAL CONTROL; MALIGNANT TRANSFORMATION; EIF-2-ALPHA KINASE; INITIATION; YEAST; GENE; ACTIVATION; PURIFICATION	In yeast, starvation for amino acids stimulates GCN2 phosphorylation of the cu subunit of eukaryotic initiation factor-2 (eIF-2). Phosphorylation of eIF-2 alpha induces the translational expression of GCN4, a transcriptional activator of the general amino acid control pathway. It has been proposed that GCN2 sequences containing homology to histidyl-tRNA synthetases (HisRS) bind uncharged tRNA that accumulate during amino acid limitation and stimulate the activity of GCN2 kinase. In this report we address whether the HisRS-related sequences are required for GCN2 phosphorylation of eIF-2 alpha in an in vitro assay. To measure the activity of GCN2 kinase in cellular extracts, we expressed and purified a truncated form of yeast eIF-2 alpha. Phosphorylation of the recombinant eIF-2 alpha substrate was dependent on both GCN2 kinase activity and the eIF-2 alpha phosphorylation site, serine 51. Mutations in the HisRS-related domain of GCN2, which have been shown to block phosphorylation of eIF-2 alpha in vivo and the subsequent stimulation of the general control pathway, also greatly reduced eIF-2 alpha phosphorylation in the in. vitro assay. These results indicate that the HisRS-related sequences are required for activation of GCN2 kinase function.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM049164, R01GM049164] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49164] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; ARNEZ JG, 1995, EMBO J, V14, P4143, DOI 10.1002/j.1460-2075.1995.tb00088.x; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BOSTEIN D, 1979, GENE, V8, P17; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; FENG L, 1994, MOL CELL BIOL, V14, P5139, DOI 10.1128/MCB.14.8.5139; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; ICELY PL, 1991, J BIOL CHEM, V266, P16073; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; KAISER C, 1994, METHODS YEAST GENETI, P208; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MORAS D, 1992, TRENDS BIOCHEM SCI, V17, P159, DOI 10.1016/0968-0004(92)90326-5; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; PROUD CG, 1995, BRENDS BIOCH SCI, V20, P217; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; VANDENHEUVEL J, 1995, BBA-GENE STRUCT EXPR, V1261, P337, DOI 10.1016/0167-4781(95)00026-D; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK RC, 1990, MOL CELL BIOL, V10, P2820, DOI 10.1128/MCB.10.6.2820; WEK SA, 1995, MOL CELL BIOL, V15, P4497; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	31	91	94	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24989	24994		10.1074/jbc.271.40.24989	http://dx.doi.org/10.1074/jbc.271.40.24989			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798780	hybrid			2022-12-27	WOS:A1996VM67400103
J	Muckel, E; Soll, J				Muckel, E; Soll, J			A protein import receptor of chloroplasts is inserted into the outer envelope membrane by a novel pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEINS; TRANSLOCATION; MACHINERY; ATP; TOPOGENESIS; TRANSPORT; COMPONENT; APPARATUS; BINDING	The outer envelope protein OEP86 functions as a receptor for precursor proteins in the chloroplastic import machinery, In contrast to most other organellar outer membrane proteins it is synthesized as a precursor polypeptide (preOEP86) in the cytosol and is posttranslationally targeted to the organelles. PreOEP86 is targeted to and productively inserted into the chloroplastic outer envelope mediated by a bipartite signal consisting of the presequence and the COOH terminus of the precursor protein. The cleavable presequence alone does not seem to contain sufficient information to target preOEP86 without the COOH terminus or a hybrid protein consisting of the presequence of preOEP86 and the mature form of the small subunit of ribulose bisphosphate carboxylase to intact chloroplasts. The presequence seems to be required to maintain pre OEP86 in an integration competent state, whereas interaction of preOEP86 with chloroplasts is accomplished by a short sequence of amino acids in the COOH-terminal portion of the mature protein. The COOH-terminal portion of preOEP86 contains enough information to also direct mature OEP86 into the outer envelope membrane of pea chloroplasts. However, mature OEP86 enters the productive folding pathway much less efficiently than preOEP86. The COOH terminus of preOEP86 not only serves as a membrane anchor but seems to be required for a productive translocation through an interaction with other outer envelope proteins. Although the binding was ATP-dependent, productive folding was not, PreOEP86 seems to follow a unique road into the chloroplastic outer envelope.	CHRISTIAN ALBRECHTS UNIV KIEL, INST BOT, D-24118 KIEL, GERMANY	University of Kiel								ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; FISCHER K, 1994, PLANT MOL BIOL, V25, P167, DOI 10.1007/BF00023235; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GRAY JC, 1995, TRENDS CELL BIOL, V5, P243, DOI 10.1016/S0962-8924(00)89018-2; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HM, 1991, PLANT CELL, V3, P709, DOI 10.1105/tpc.3.7.709; LUBBEN TH, 1986, P NATL ACAD SCI USA, V83, P5502, DOI 10.1073/pnas.83.15.5502; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDLER C, 1987, Z NATURFORSCH C, V42, P103; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; SOLL J, 1995, BOT ACTA, V108, P277, DOI 10.1111/j.1438-8677.1995.tb00495.x; SOLL J, 1992, MEMBRANE BIOGENESIS, P299; THEG SM, 1989, J BIOL CHEM, V264, P6730; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x; WAEGEMANN K, 1991, PLANT J, V1, P149, DOI 10.1111/j.1365-313X.1991.00149.x; WAEGEMANN K, 1992, PLANTA, V187, P89, DOI 10.1007/BF00201628; Waegemann K, 1996, J BIOL CHEM, V271, P6545, DOI 10.1074/jbc.271.11.6545; Waegemann K, 1995, METHOD CELL BIOL, V50, P255, DOI 10.1016/S0091-679X(08)61035-3; WAEGEMANN K, 1993, NATO ASI SERIES H, V74, P101; WIRTZ W, 1980, PLANT PHYSIOL, V66, P187, DOI 10.1104/pp.66.1.187; WU CB, 1994, J BIOL CHEM, V269, P32264	29	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23846	23852		10.1074/jbc.271.39.23846	http://dx.doi.org/10.1074/jbc.271.39.23846			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798615	hybrid			2022-12-27	WOS:A1996VJ44200044
J	Stevens, BR; Kakuda, DK; Yu, K; Waters, M; Vo, CB; Raizada, MK				Stevens, BR; Kakuda, DK; Yu, K; Waters, M; Vo, CB; Raizada, MK			Induced nitric oxide synthesis is dependent on induced alternatively spliced CAT-2 encoding L-arginine transport in brain astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-II RECEPTOR; GLIAL-CELLS; MOLECULAR-CLONING; RAT-BRAIN; SYNTHASE; EXPRESSION; MACROPHAGES; INHIBITORS; CYTOKINES; CULTURES	The inducible isoform II of nitric-oxide synthase (iNOS) was recently cloned from brain and identified in astroglial cells. Induced nitric oxide biosynthesis occurs in brain cells only if extracellular cerebrospinal fluid contains L-arginine. This study demonstrates for the first time that induced iNOS activity is strictly dependent on concomitant induction of an alternatively spliced transcript of the cat-2 gene encoding high affinity L-arginine transporter System y(+) in cultured rat astrocytes, Inhibition profiles of radiolabeled L-arginine and L-leucine uptake identified the dominance of Na+-independent transport System y(+) serving cationic amino acids, with insignificant activities of Systems y(+)L, b(o,+), or B-o,B-+. A reverse transcription-polymerase chain reaction/sequencing/cloning strategy was used to identify a single 123-base nucleotide sequence coding the high affinity domain of alternatively spliced CAT-2 (not CAT-2a) in astrocytes activated by lipopolysaccharide/interferon-gamma. Using this sequence as a cDNA probe, it was determined that CAT-2 mRNA, iNOS mRNA, and System y(+) activity were concomitantly and strongly induced in astrocytes. Constitutive CAT-1 mRNA was weakly present in neurons and astrocytes, was not inducible in either cell type, and contributed <3% to total System y(+) activity. Although astroglial iNOS K-m similar to 10 mu M L-arginine for intracellular substrate, hyperbolic kinetics of inducible iNOS activity measured as a function of extracellular L-arginine concentration gave K-m similar to 50 mu M L-arginine with intact cells. The same K-m similar to 50 mu M was obtained for induced membrane transport System y(+) activity, iNOS activity was reduced to zero in the absence of extracellular L-arginine uptake via System y(+). These findings expand the current understanding of NO biosynthesis modulation and implicate a coordinated regulation of intracellular iNOS enzyme activity with membrane L-arginine transport in brain.	UNIV CALIF SAN DIEGO,DEPT MED,CANC CTR CANC GENET PROGRAM,LA JOLLA,CA 92093	University of California System; University of California San Diego	Stevens, BR (corresponding author), UNIV FLORIDA,COLL MED,DEPT PHYSIOL,GAINESVILLE,FL 32610, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030464] Funding Source: NIH RePORTER; NCI NIH HHS [CA09290] Funding Source: Medline; NIAID NIH HHS [R01-AI30464] Funding Source: Medline; NIGMS NIH HHS [GM07752] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANSO E, 1991, NEUROCHEM RES, V16, P787; BAYDOUN AR, 1994, BIOCHEM BIOPH RES CO, V200, P726, DOI 10.1006/bbrc.1994.1511; BOGLE RG, 1992, BIOCHEM J, V284, P15, DOI 10.1042/bj2840015; BROSNAN CF, 1994, DEV NEUROSCI-BASEL, V16, P152, DOI 10.1159/000112102; Buniatian HC, 1971, HDB NEUROCHEMISTRY A, P235; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; DING AH, 1988, J IMMUNOL, V141, P2407; FEINSTEIN DL, 1994, ANN NY ACAD SCI, V738, P325; FINLEY KD, 1995, P NATL ACAD SCI USA, V92, P9378, DOI 10.1073/pnas.92.20.9378; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; FREDRICK M, 1992, SHORT PROTOCOLS MOL; GALEA E, 1994, J NEUROSCI RES, V37, P406, DOI 10.1002/jnr.490370313; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; Kakuda DK, 1993, TRANSGENE, V1, P91; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; LERMA J, 1986, BRAIN RES, V384, P145, DOI 10.1016/0006-8993(86)91230-8; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MACLEOD C, 1994, J EXP BIOL, V19, P109; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; PAN M, 1995, AM J PHYSIOL, V268, pG669; PARK SK, 1994, NEUROPHARMACOLOGY, V33, P1419, DOI 10.1016/0028-3908(94)90044-2; RAIZADA MK, 1987, P NATL ACAD SCI USA, V84, P4655, DOI 10.1073/pnas.84.13.4655; RAO RL, 1995, NEUROCHEMISTRY, V65, P677; REIZER J, 1993, PROTEIN SCI, V2, P20, DOI 10.1002/pro.5560020103; SCHMIDLIN A, 1994, GLIA, V11, P262, DOI 10.1002/glia.440110307; SCHMIDLIN A, 1995, NEUROCHEMISTRY, V65, P590; SIMMONS ML, 1993, EUR J NEUROSCI, V5, P825, DOI 10.1111/j.1460-9568.1993.tb00934.x; SIMMONS ML, 1993, NEUROCHEMISTRY, V59, P897; SUMNERS C, 1991, P NATL ACAD SCI USA, V88, P7567, DOI 10.1073/pnas.88.17.7567; TRAVIS J, 1994, SCIENCE, V266, P970, DOI 10.1126/science.7973679; VANWINKLE LJ, 1995, BBA-BIOMEMBRANES, V1233, P213, DOI 10.1016/0005-2736(94)00303-7; WOOD JH, 1982, HDB NEUROCHEMISTRY, V1, P415	33	101	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24017	24022		10.1074/jbc.271.39.24017	http://dx.doi.org/10.1074/jbc.271.39.24017			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798637	hybrid			2022-12-27	WOS:A1996VJ44200066
J	Worby, CA; Vega, QC; Zhao, Y; Chao, HHJ; Seasholtz, AF; Dixon, JE				Worby, CA; Vega, QC; Zhao, Y; Chao, HHJ; Seasholtz, AF; Dixon, JE			Glial cell line-derived neurotrophic factor signals through the RET receptor and activates mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; CHLORAMPHENICOL ACETYLTRANSFERASE; TRANSCRIPTIONAL ACTIVATION; TERMINAL PHOSPHORYLATION; TRANSFORMING GENE; REPORTER GENE; PROTOONCOGENE; MUTATIONS; DISEASE; NEURONS	Glial cell line-derived neurotrophic factor (GDNF), a member of the transforming growth factor-beta family of growth factors, was first identified by its ability to promote the survival of midbrain dopaminergic neurons in culture. We demonstrate that GDNF treatment of several neuroblastoma cell lines leads to dose-dependent tyrosine phosphorylation of the RET receptor and that other transforming growth factor-beta family members are not able to activate the RET receptor. GDNF treatment of neuroblastoma cells also results in increased transcription of an Elk luciferase reporter gene, suggesting that GDNF activates the mitogen-activated protein kinase signal transduction pathway.	UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan					PHS HHS [18849] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANGRIST M, 1993, NAT GENET, V4, P351, DOI 10.1038/ng0893-351; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CRABB DW, 1989, METHOD ENZYMOL, V168, P690; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LIN LFH, 1994, J NEUROCHEM, V63, P758; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; VEGA QC, 1996, IN PRESS P NATL ACAD; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	34	139	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23619	23622		10.1074/jbc.271.39.23619	http://dx.doi.org/10.1074/jbc.271.39.23619			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798576	hybrid			2022-12-27	WOS:A1996VJ44200005
J	Chan, DC; Leder, P				Chan, DC; Leder, P			Genetic evidence that formins function within the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMB DEFORMITY GENE; MOUSE; TRANSCRIPTS; DROSOPHILA; ISOFORMS; ALLELES; EMBRYO; REGION; LOCUS; BUD	The murine limb deformity (ld) locus encodes a set of proteins, termed formins, that are required for embryonic limb and kidney development. Previous studies had indicated that these proteins are located in the nucleus and cytoplasm and have biochemical properties consistent with an action within the nucleus. To test the notion that nuclear localization is crucial for formin function, we carried out molecular and biochemical studies on three ld alleles. We show that two transgene induced alleles, ld(TgHd) and ld(TgBri), generate similar COOH truncated formins that lack the terminal 110 amino acids, while a third allele, ld(In2), generates a less extensively truncated formin that lacks the terminal 42 amino acids. Using subcellular fractionation analysis, we find that wild-type formin is detected in both nuclear and cytosolic fractions; in contrast, the truncated formins encoded by ld(TgHd) and ld(TgBri) are strictly cytosolic. The less extensively truncated ld(In2) formin shows a similar, but less complete, localization defect. Consistent with this weaker cellular phenotype, hind limbs from ld(In2) mice have milder skeletal defects than those of ld(TgBri) mice. These observations define a small region in the carboxyl terminus that is required for nuclear localization and suggest that nuclear localization plays a role in formin action.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute								CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; CHAN DC, 1995, DEVELOPMENT, V121, P3151; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Harlow E., 1988, ANTIBODIES LAB MANUA; JACKSONGRUSBY L, 1992, GENE DEV, V6, P29, DOI 10.1101/gad.6.1.29; KLEINEBRECHT J, 1982, ANAT ANZEIGER, V152, P313; MAAS R, 1994, DEV DYNAM, V199, P214, DOI 10.1002/aja.1001990306; MAAS RL, 1990, NATURE, V346, P853, DOI 10.1038/346853a0; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; Messing A, 1990, Mouse Genome, V87, P107; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRUMPP A, 1992, GENE DEV, V6, P14, DOI 10.1101/gad.6.1.14; VOGT TF, 1993, P NATL ACAD SCI USA, V90, P5554, DOI 10.1073/pnas.90.12.5554; VOGT TF, 1992, MAMM GENOME, V3, P431, DOI 10.1007/BF00356152; WOYCHIK RP, 1990, P NATL ACAD SCI USA, V87, P2588, DOI 10.1073/pnas.87.7.2588; WOYCHIK RP, 1985, NATURE, V318, P36, DOI 10.1038/318036a0; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; ZELLER R, 1989, GENE DEV, V3, P1481, DOI 10.1101/gad.3.10.1481	23	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23472	23477		10.1074/jbc.271.38.23472	http://dx.doi.org/10.1074/jbc.271.38.23472			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798555	hybrid			2022-12-27	WOS:A1996VH76800081
J	McGaughey, KM; Wheeler, LJ; Moore, JT; Maley, GF; Maley, F; Mathews, CK				McGaughey, KM; Wheeler, LJ; Moore, JT; Maley, GF; Maley, F; Mathews, CK			Protein-protein interactions involving T4 phage-coded deoxycytidylate deaminase and thymidylate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACTERIOPHAGE-T4 PROTEINS; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; HYDROXYMETHYLASE; EXPRESSION; SEQUENCE; BINDING; GENE; COMPLEX	The enzymes deoxycytidylate deaminase (EC 3.5.4.12) and thymidylate synthase (EC 2.1.1.45) are functionally associated with one another, since they catalyze sequential reactions, In T4 coliphage infection the two enzymes are found in dNTP synthetase, a multienzyme complex for deoxyribonucleotide biosynthesis, Protein-protein interactions involving the phage-coded forms of these two enzymes have been explored in three experiments that use the respective purified protein as an affinity ligand. First, an extract of radiolabeled T4 proteins was passed through a column of immobilized enzyme (either dTMP synthase or dCMP deaminase), and the specifically bound proteins were identified, Second, two mutant form of dCMP deaminase (H90N and H94N), altered in presumed zinc-binding sites, were analyzed similarly, with the results suggesting that some, but not all, interactions require normal structure near the catalytic site, Third, affinity chromatography using either enzyme as the immobilized ligand, revealed interactions between the two purified enzymes in the absence of other proteins, In these experiments we noted a significant effect of dCTP, an allosteric modifier of dCMP deaminase, upon the interactions.	NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,ALBANY,NY 12201	State University of New York (SUNY) System; Wadsworth Center	McGaughey, KM (corresponding author), OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331, USA.				NATIONAL CANCER INSTITUTE [R35CA044355] Funding Source: NIH RePORTER; NCI NIH HHS [CA44355] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; CHU FK, 1984, P NATL ACAD SCI-BIOL, V81, P3049, DOI 10.1073/pnas.81.10.3049; FINERMOORE JS, 1994, BIOCHEMISTRY-US, V33, P15459, DOI 10.1021/bi00255a028; FLEMING WH, 1965, J BIOL CHEM, V242, P363; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; JI JP, 1991, MOL GEN GENET, V226, P257, DOI 10.1007/BF00273611; MALEY GF, 1982, BIOCHEMISTRY-US, V21, P3780, DOI 10.1021/bi00259a009; MALEY GF, 1988, J BIOL CHEM, V263, P7620; MALEY GF, 1967, J BIOL CHEM, V242, P3517; MALEY GF, 1990, J BIOL CHEM, V265, P47; MALEY GF, 1972, J BIOL CHEM, V247, P940; MATHEWS CK, 1972, J BIOL CHEM, V247, P7430; MATHEWS CK, 1993, PROG NUCLEIC ACID RE, V44, P167, DOI 10.1016/S0079-6603(08)60220-2; Moen L K, 1988, J Mol Recognit, V1, P48, DOI 10.1002/jmr.300010109; MONTFORT WR, 1990, BIOCHEMISTRY-US, V29, P6964, DOI 10.1021/bi00482a004; MOORE JT, 1993, PROTEIN EXPRES PURIF, V4, P160, DOI 10.1006/prep.1993.1022; MOORE JT, 1993, J BIOL CHEM, V268, P2288; MOORE JT, 1994, BIOCHEMISTRY-US, V33, P2104, DOI 10.1021/bi00174a017; REIZER J, 1994, PROTEIN SCI, V3, P853; RICHEY B, 1987, J BIOL CHEM, V262, P7157; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; WEINER KXB, 1993, J BIOL CHEM, V268, P12983; WHEELER L, 1992, J BIOL CHEM, V267, P7664; YOUNG JP, 1992, J BIOL CHEM, V267, P10786	26	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23037	23042		10.1074/jbc.271.38.23037	http://dx.doi.org/10.1074/jbc.271.38.23037			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798492	hybrid			2022-12-27	WOS:A1996VH76800018
J	Senechal, K; Halpern, J; Sawyers, CL				Senechal, K; Halpern, J; Sawyers, CL			The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; GUANINE-NUCLEOTIDE EXCHANGE; CHRONIC MYELOID-LEUKEMIA; GROWTH-FACTOR RECEPTOR; SIGNALING GENE SEM-5; TYROSINE KINASE; PHILADELPHIA-CHROMOSOME; SH3 DOMAINS; HEMATOPOIETIC-CELLS; V-CRK	The CRKL adaptor protein was recently identified as a substrate for the BCR-ABL tyrosine kinase in patients with chronic myelogenous leukemia, but its function is unknown. Here we report that CRKL is phosphorylated when overexpressed, activates RAS and JUN kinase signaling pathways, and transforms fibroblasts in a RAS-dependent fashion. We examined the potential role of CRKL in BCR-ABL function by deleting the CRKL binding site in BCR-ABL. This mutant BCR-ABL protein shows a 50% reduction in fibroblast transforming activity. The GRB2 adaptor protein has previously been implicated in this pathway, presumably linking BCR-ABL to RAS. To address the relative roles of CRKL and GRB2 in this system, we compared BCR-ABL mutants with defects in binding to one or both adaptors. Whereas each single mutant showed a 2-3-fold loss in transforming activity, the double mutant showed a 15-fold reduction, suggesting that GRB2 and CRKL both contribute to BCR-ABL transformation. These results demonstrate the oncogenic potential of CRKL and provide functional evidence that CRKL plays a role in fibroblast transformation by BCR-ABL in conjunction with other adaptor proteins.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Senechal, K (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,INST MOL BIOL,11-934 FACTOR BLDG,10833 LE CONTE AVE,LOS ANGELES,CA 90095, USA.		Sawyers, Charles/G-5327-2016		NCI NIH HHS [P01 CA32737-13A1] Funding Source: Medline; NIGMS NIH HHS [GM07185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA032737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEJONG R, 1995, ONCOGENE, V11, P1469; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; FREED E, 1992, MOL CELL BIOL, V12, P1312, DOI 10.1128/MCB.12.3.1312; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Ribon V, 1996, MOL CELL BIOL, V16, P45; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; Sabe H, 1995, J BIOL CHEM, V270, P31219, DOI 10.1074/jbc.270.52.31219; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TSUCHIE H, 1989, ONCOGENE, V4, P1281; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247	65	114	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23255	23261		10.1074/jbc.271.38.23255	http://dx.doi.org/10.1074/jbc.271.38.23255			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798523	hybrid			2022-12-27	WOS:A1996VH76800049
J	Lewis, AL; Guicherit, OM; Datta, SK; Hanten, GR; Kellems, RE				Lewis, AL; Guicherit, OM; Datta, SK; Hanten, GR; Kellems, RE			Structure and expression of the murine muscle adenylosuccinate synthetase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; MOLECULAR-CLONING; BETA-ENOLASE; MOUSE; TRANSCRIPTION; MYOGENESIS; ELEMENTS; PROMOTER; CELLS; DEAMINASE	A muscle-specific isoform of adenylosuccinate synthetase (AdSS1, EC 6.3.4.4) is one of three enzymes that constitute the purine nucleotide cycle, a muscle-specific metabolic cycle. Previously, we showed that the muscle Adss1 gene was highly expressed in both skeletal muscle and heart of the adult mouse. Here we have shown that the Adss1 gene is initially activated early in embryonic development in skeletal muscle and heart precursors and is subsequently up regulated perinatally. The earliest detectable gene expression corresponds with the establishment of the first myogenic and cardiac lineages. To allow identification of the genetic signals controlling this developmental pattern of expression, the Adss1 gene was cloned and its structure determined. Transgenic analysis has shown that 1.9 kilobase pairs of 5' flank can activate expression in skeletal muscle progenitors and direct enhanced expression to adult cardiac muscle. Sequence analysis of the promoter and 5' flanking region revealed the presence of numerous potential muscle-specific cis-regulatory elements.	BAYLOR COLL MED, DEPT MOL & HUMAN GENET, HOUSTON, TX 77030 USA; BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042436] Funding Source: NIH RePORTER; NICHD NIH HHS [2 P30 HD24064] Funding Source: Medline; NIGMS NIH HHS [GM42436] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1989, MOL CELL BIOL, V9, P2513, DOI 10.1128/MCB.9.6.2513; BUCKINGHAM ME, 1992, CIBA F SYMP, V165, P111; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; GILBERT SF, 1988, DEV BIOL, P214; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; GUICHERIT OM, 1994, J BIOL CHEM, V269, P4488; GUICHERIT OM, 1991, J BIOL CHEM, V266, P22582; JAVEHERY R, 1994, MOL CELL BIOL, V14, P116; JOH K, 1990, PROG CLIN BIOL RES, V344, P53; KELLER A, 1992, MECH DEVELOP, V38, P41, DOI 10.1016/0925-4773(92)90037-K; LI SSL, 1990, PROG CLIN BIOL RES, V344, P75; LI ZL, 1993, J BIOL CHEM, V268, P10403; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LOWENSTEIN JM, 1990, INT J SPORTS MED, V11, pS36; LYONS GE, 1991, DEVELOPMENT, V113, P1017; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; NAKAZAWA A, 1990, PROG CLIN BIOL RES, V344, P495; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; ORDAHL C, 1992, CURR TOP DEV BIOL, V26, P146; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; SABINA RL, 1989, MOL CELL BIOL, V9, P2244, DOI 10.1128/MCB.9.5.2244; SALMINEN M, 1994, MOL CELL BIOL, V14, P6797, DOI 10.1128/MCB.14.10.6797; Sambrook J., 2002, MOL CLONING LAB MANU; SARTORELLI V, 1993, CIRC RES, V72, P925, DOI 10.1161/01.RES.72.5.925; SCHWEIGHOFFER F, 1986, J BIOL CHEM, V261, P271; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; SUTHERLAND CJ, 1991, DEV BIOL, V146, P167, DOI 10.1016/0012-1606(91)90457-E; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; TAYLOR JM, 1995, J BIOL CHEM, V270, P2535, DOI 10.1074/jbc.270.6.2535; VANDENBERGHE G, 1992, PROG NEUROBIOL, V39, P547, DOI 10.1016/0301-0082(92)90006-Z; WASSARMAN PM, 1993, GUIDE TECHNIQUES MOU, P434; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P1; WINSTON JH, 1992, J BIOL CHEM, V267, P13472; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277	43	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22647	22656		10.1074/jbc.271.37.22647	http://dx.doi.org/10.1074/jbc.271.37.22647			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798436	hybrid			2022-12-27	WOS:A1996VG67200055
J	Viguera, E; Hernandez, P; Krimer, DB; Boistov, AS; Lurz, R; Alonso, JC; Schvartzman, JB				Viguera, E; Hernandez, P; Krimer, DB; Boistov, AS; Lurz, R; Alonso, JC; Schvartzman, JB			The ColE1 unidirectional origin acts as a polar replication fork pausing site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA GENES; SV40 DNA-REPLICATION; INTERTWINED CATENATED DIMERS; AGAROSE-GEL ELECTROPHORESIS; PAPILLOMAVIRUS TYPE-1 DNA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; PLASMID REPLICATION; POTENTIAL ORIGINS; BACILLUS-SUBTILIS	Co-orientation of replication origins is the most common organization found in nature for multimeric plasmids, Streptococcus pyogenes broad-host-range plasmid pSM19035 and Escherichia coli pPI21 are among the exceptions. pPI21, which is a derivative of pSM19035 and pBR322, has two long inverted repeats, each one containing a potentially active ColE1 unidirectional origin. Analysis of pPI21 replication intermediates (RIs) by two-dimensional agarose gel electrophoresis and electron microscopy revealed the accumulation of a specific RI containing a single internal bubble. The data obtained demonstrated that initiation of DNA replication occurred at a single origin in pPI21. Progression of the replicating fork initiated at either of the two potential origins was transiently stalled at the other inversely oriented silent ColE1 origin of the plasmid, The accumulated RIs, containing an internal bubble, occurred as a series of stereoisomers with different numbers of knots in their replicated portion. These observations provide one of the first functional explanations for the disadvantage of head-to-head plasmid multimers with respect to head-to-tail ones.	CSIC, CTR INVEST BIOL, DEPT BIOL CELULAR & DESARROLLO, E-28006 MADRID, SPAIN; ST PETERSBURG STATE TECH UNIV, DEPT BIOPHYS, ST PETERSBURG, RUSSIA; MAX PLANCK INST MOL GENET, D-1000 BERLIN, GERMANY; CSIC, CTR NACL BIOTECNOL, E-28049 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Peter the Great St. Petersburg Polytechnic University; Max Planck Society; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)			Krimer, Dora/J-9176-2014; Alonso, Juan Carlos/D-2595-2009; Mínguez, Enrique Viguera/H-4416-2015; Schvartzman, Jorge B/J-9171-2014	Krimer, Dora/0000-0001-9972-3994; Alonso, Juan Carlos/0000-0002-5178-7179; Mínguez, Enrique Viguera/0000-0001-5475-3807; Pablo, Hernandez/0000-0002-8113-1277				ALONSO JC, 1995, J BIOL CHEM, V270, P2938, DOI 10.1074/jbc.270.7.2938; BAKER TA, 1995, CELL, V80, P521, DOI 10.1016/0092-8674(95)90504-9; BAUER WR, 1980, SCI AM, V243, P118; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1994, P NATL ACAD SCI USA, V91, P3418, DOI 10.1073/pnas.91.8.3418; BREWER BJ, 1988, CELL, V53, P679, DOI 10.1016/0092-8674(88)90086-4; BREWER BJ, 1993, SCIENCE, V262, P1728, DOI 10.1126/science.8259517; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; CEGLOWSKI P, 1994, GENE, V145, P33, DOI 10.1016/0378-1119(94)90319-0; CEGLOWSKI P, 1993, FEMS MICROBIOL LETT, V109, P145, DOI 10.1016/0378-1097(93)90011-P; CHERNY DI, 1993, J MOL BIOL, V230, P379, DOI 10.1006/jmbi.1993.1154; COLLINS J, 1980, COLD SPRING HARB SYM, V45, P409, DOI 10.1101/SQB.1981.045.01.055; DASGUPTA S, 1987, CELL, V51, P1113, DOI 10.1016/0092-8674(87)90597-6; DEAN FB, 1985, J BIOL CHEM, V260, P4975; DHAR V, 1991, MOL CELL BIOL, V11, P6268, DOI 10.1128/MCB.11.12.6268; DROGE P, 1992, METHOD ENZYMOL, V212, P120; DUBEY DD, 1994, EMBO J, V13, P3638, DOI 10.1002/j.1460-2075.1994.tb06671.x; Friedman KL, 1995, METHOD ENZYMOL, V262, P613; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; GREENFEDER SA, 1992, MOL CELL BIOL, V12, P4056, DOI 10.1128/MCB.12.9.4056; HERNANDEZ P, 1993, EMBO J, V12, P1475, DOI 10.1002/j.1460-2075.1993.tb05791.x; HYRIEN O, 1992, NUCLEIC ACIDS RES, V20, P1463, DOI 10.1093/nar/20.7.1463; HYRIEN O, 1993, EMBO J, V12, P4511, DOI 10.1002/j.1460-2075.1993.tb06140.x; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KOBAYASHI T, 1992, MOL GEN GENET, V233, P355, DOI 10.1007/BF00265431; KREUZER KN, 1980, CELL, V20, P245, DOI 10.1016/0092-8674(80)90252-4; KUBOTA Y, 1993, GENE, V126, P9; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LITTLE RD, 1995, MOL CELL BIOL, V15, P2893; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; LIU Y, 1990, J VIROL, V64, P5903, DOI 10.1128/JVI.64.12.5903-5911.1990; LOPEZESTRANO C, 1996, CHROMOSOMES TODAY, V12, P149; LUCCHINI R, 1994, MOL CELL BIOL, V14, P318, DOI 10.1128/MCB.14.1.318; LUCCHINI R, 1995, NATURE, V374, P276, DOI 10.1038/374276a0; LYAMICHEV VI, 1986, J BIOMOL STRUCT DYN, V3, P667, DOI 10.1080/07391102.1986.10508454; MAHBUBANI HM, 1992, NUCLEIC ACIDS RES, V20, P1457, DOI 10.1093/nar/20.7.1457; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARTINPARRAS L, 1992, J BIOL CHEM, V267, P22496; MARTINPARRAS L, 1991, J MOL BIOL, V220, P843, DOI 10.1016/0022-2836(91)90357-C; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MIZUUCHI K, 1982, J MOL BIOL, V156, P229, DOI 10.1016/0022-2836(82)90325-4; NAKASU S, 1992, P NATL ACAD SCI USA, V89, P10139, DOI 10.1073/pnas.89.21.10139; NAWOTKA KA, 1988, MOL CELL BIOL, V8, P1408, DOI 10.1128/MCB.8.4.1408; PELEG M, 1995, NUCLEIC ACIDS RES, V23, P1292, DOI 10.1093/nar/23.8.1292; RAO BS, 1994, GENE, V140, P3233; SCHVARTZMAN JB, 1993, NUCLEIC ACIDS RES, V21, P5474, DOI 10.1093/nar/21.23.5474; SCHVARTZMAN JB, 1990, MOL CELL BIOL, V10, P3078, DOI 10.1128/MCB.10.6.3078; SEUFERT W, 1988, J BIOL CHEM, V263, P2719; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; VOLOSHIN ON, 1988, NATURE, V333, P475, DOI 10.1038/333475a0; WALDECK W, 1984, EMBO J, V3, P2173, DOI 10.1002/j.1460-2075.1984.tb02109.x; WALMSLEY RM, 1984, MOL GEN GENET, V195, P260, DOI 10.1007/BF00332757; WASSERMAN SA, 1986, SCIENCE, V232, P951, DOI 10.1126/science.3010458; WEAVER DT, 1985, CELL, V41, P565, DOI 10.1016/S0092-8674(85)80029-5; WHITE JH, 1987, J MOL BIOL, V197, P585, DOI 10.1016/0022-2836(87)90566-3; WHITE JH, 1984, P NATL ACAD SCI-BIOL, V81, P3322, DOI 10.1073/pnas.81.11.3322; WIESENDANGER B, 1994, NUCLEIC ACIDS RES, V22, P5038, DOI 10.1093/nar/22.23.5038	61	45	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22414	22421		10.1074/jbc.271.37.22414	http://dx.doi.org/10.1074/jbc.271.37.22414			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798404	Green Published			2022-12-27	WOS:A1996VG67200023
J	Bessman, MJ; Frick, DN; OHandley, SF				Bessman, MJ; Frick, DN; OHandley, SF			The MutT proteins or ''nudix'' hydrolases, a family of versatile, widely distributed, ''housecleaning'' enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ESCHERICHIA-COLI MUTT; NUCLEOSIDE TRIPHOSPHATE PYROPHOSPHOHYDROLASE; MOLECULAR-CLONING; CATALYTIC DOMAIN; DNA-SYNTHESIS; STREPTOCOCCUS-PNEUMONIAE; MUTAGENIC SUBSTRATE; GENE-PRODUCT; RUVC GENE; PURIFICATION		JOHNS HOPKINS UNIV, MCCOLLUM PRATT INST, BALTIMORE, MD 21218 USA	Johns Hopkins University	Bessman, MJ (corresponding author), JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA.			O'Handley, Suzanne/0000-0001-8373-0065; Frick, David/0000-0002-2434-7223	NIGMS NIH HHS [GM18649, 5-T32-GM07231] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007231] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEYGUNAWARDANA C, 1995, BIOCHEMISTRY-US, V34, P14997, DOI 10.1021/bi00046a006; AKIYAMA M, 1987, MOL GEN GENET, V206, P9, DOI 10.1007/BF00326530; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AOYAMA K, 1994, MOL BIOL EVOL, V11, P829; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BAXI MD, 1995, J PHARMACOL TOX MET, V33, P121, DOI 10.1016/1056-8719(94)00127-P; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BULLIONS LC, 1993, FASEB J, V7, pA1290; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; FRICK DN, 1995, J BIOL CHEM, V270, P1529, DOI 10.1074/jbc.270.4.1529; FRICK DN, 1995, J BIOL CHEM, V270, P1; GLASER L, 1965, BIOCHIM BIOPHYS ACTA, V101, P6, DOI 10.1016/0926-6534(65)90025-4; HAGEGE J, 1993, MOL MICROBIOL, V10, P799, DOI 10.1111/j.1365-2958.1993.tb00950.x; HURTADO C, 1987, J BACTERIOL, V169, P1718, DOI 10.1128/jb.169.4.1718-1723.1987; *INT UN BIOCH, 1964, ENZ NOM, P362; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KAMATH AV, 1993, GENE, V134, P99, DOI 10.1016/0378-1119(93)90180-B; KAMIYA H, 1995, J BIOL CHEM, V270, P19446, DOI 10.1074/jbc.270.33.19446; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P4847, DOI 10.1093/nar/21.20.4847; LAZEWSKA D, 1993, PROTEIN EXPRES PURIF, V4, P45, DOI 10.1006/prep.1993.1007; Lin J, 1996, BIOCHEMISTRY-US, V35, P6715, DOI 10.1021/bi953071x; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; MECHULAM Y, 1985, J BACTERIOL, V164, P63, DOI 10.1128/JB.164.1.63-69.1985; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; MITCHELL SJ, 1995, INFECT IMMUN, V63, P1552, DOI 10.1128/IAI.63.4.1552-1562.1995; MURPHY PR, 1994, MOL ENDOCRINOL, V8, P852, DOI 10.1210/me.8.7.852; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; PETSKO GA, 1993, TRENDS BIOCHEM SCI, V18, P372, DOI 10.1016/0968-0004(93)90091-Z; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SCHAAPER RM, 1987, J BIOL CHEM, V262, P16267; SHARPLES GJ, 1991, J BACTERIOL, V173, P7711, DOI 10.1128/jb.173.23.7711-7715.1991; SILLERO MAG, 1977, EUR J BIOCHEM, V76, P331; SONNINO S, 1966, J BIOL CHEM, V241, P1009; SONNINO S, 1966, ARCH BIOCHEM BIOPHYS, V116, P26, DOI 10.1016/0003-9861(66)90007-5; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; Tercero JA, 1996, J BIOL CHEM, V271, P1579, DOI 10.1074/jbc.271.3.1579; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; VOLK R, 1989, EMBO J, V8, P2983, DOI 10.1002/j.1460-2075.1989.tb08448.x; WEBER DJ, 1992, J BIOL CHEM, V267, P16939; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274; ZAMECNIK PC, 1966, BIOCHEM BIOPH RES CO, V24, P91, DOI 10.1016/0006-291X(66)90415-3	47	578	595	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25059	25062		10.1074/jbc.271.41.25059	http://dx.doi.org/10.1074/jbc.271.41.25059			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810257	hybrid			2022-12-27	WOS:A1996VL69300001
J	Romoser, V; Ball, R; Smrcka, AV				Romoser, V; Ball, R; Smrcka, AV			Phospholipase C beta 2 association with phospholipid interfaces assessed by fluorescence resonance energy transfer - G protein beta gamma subunit-mediated translocation is not required for enzyme activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; ALPHA-SUBUNITS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; KINASE PATHWAY; GROWTH-FACTOR; HIGH-AFFINITY; BOVINE BRAIN; RECEPTOR; CELLS; STIMULATION	Phospholipase C beta 2 (PLC beta 2) is activated by G protein beta gamma subunits and calcium. The enzyme is soluble and its substrate, phosphatidylinositol 4,5-bisphosphate (PIP2), is present in phospholipid membranes. A potential mechanism for regulation of this enzyme is through influencing the equilibrium association of the enzyme with membrane surfaces. In this paper we describe a fluorescence resonance energy transfer (FRET) method for measuring the association of PLC beta 2 with phospholipid bilayers. The method allows equilibrium measurements to be made under a variety of conditions, including those that support enzymatic activity and ability to be regulated by G proteins. Using this method it was found that PLC beta 2 bound to vesicles containing anionic lipids and demonstrated a selective and unique interaction with PIP2 containing vesicles. The FRET data were corroborated with a centrifugation based method for estimating the affinity of PLC beta 2 for vesicles. Apparently different modes of association of PLC beta 2 with vesicles of different composition can be distinguished based on alterations in resonance energy transfer efficiency. Association of PLC beta 2 with PLP(2) vesicles requires an intact lipid bilayer, is blocked by neomycin, and is not affected by D-myo-inositol 1,4,5-trisphosphate (D-IP3). G protein beta gamma subunits do not alter the affinity of PLC beta 2 for lipid bilayers and at the PIP2 concentrations used to measure beta gamma-dependent stimulation of PLC activity, the majority of the PLC beta 2 is already associated with the vesicle surface. Furthermore, under conditions where beta gamma subunits strongly activate PLC activity, the extent of association with vesicles is unaffected by beta gamma subunits or calcium. These results indicate that activation of PLC beta 2 by G protein py subunits or Ca2+ in vitro does not involve translocation to the vesicle surface.	UNIV ROCHESTER,SCH MED & DENT,DEPT PHARMACOL,ROCHESTER,NY 14642; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75231	University of Rochester; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BOYER JL, 1989, TRENDS PHARMACOL SCI, V10, P360, DOI 10.1016/0165-6147(89)90008-4; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAGA K, 1992, J BIOL CHEM, V267, P2222; HEITHIER H, 1992, EUR J BIOCHEM, V204, P1169, DOI 10.1111/j.1432-1033.1992.tb16744.x; JAMES SR, 1995, J BIOL CHEM, V270, P11872, DOI 10.1074/jbc.270.20.11872; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KWON G, 1993, BIOCHEMISTRY-US, V32, P2401, DOI 10.1021/bi00060a035; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; PARK DG, 1993, J BIOL CHEM, V268, P4573; PARKER PJ, 1994, TRENDS BIOCHEM SCI, V19, P54, DOI 10.1016/0968-0004(94)90031-0; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SCHACHT J, 1978, J LIPID RES, V19, P1063; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; VAZIRI C, 1992, J BIOL CHEM, V267, P22973; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3	35	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25071	25078		10.1074/jbc.271.41.25071	http://dx.doi.org/10.1074/jbc.271.41.25071			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810260	hybrid			2022-12-27	WOS:A1996VL69300004
J	Salgia, R; Pisick, E; Sattler, M; Li, JAL; Uemura, N; Wong, WK; Burky, SA; Hirai, H; Chen, LP; Griffin, JD				Salgia, R; Pisick, E; Sattler, M; Li, JAL; Uemura, N; Wong, WK; Burky, SA; Hirai, H; Chen, LP; Griffin, JD			p130(CAS) forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ACTIN-BINDING DOMAINS; TYROSINE PHOSPHORYLATION; V-CRK; SH3 DOMAINS; MOLECULAR-CLONING; C-ABL; ADHESION; KINASE; IDENTIFICATION	The Philadelphia chromosome (Ph) translocation generates a chimeric tyrosine kinase oncogene, BCR/ABL, which causes chronic myelogenous leukemia (CML) and a type of acute lymphoblastic leukemia (ALL). In primary samples from virtually all patients with CML or Ph(+)ALL, the CRKL adapter protein is tyrosine phosphorylated and physically associated with p210(BCR/ABL). CRKL has one SH2 domain and two SH3 domains and is structurally related to c-CRK-II (CRK) and the v-Crk oncoprotein. We have previously shown that CRKL, but not the related adapter protein c-CRK, is tyrosine phosphorylated in cell lines transformed by BCR/ABL, and that CRKL binds to BCR/ABL through the CRKL-SH3 domains. Furthermore, the CRKL-SH2 domain has been shown to bind one or more cellular proteins, one of which is p120(CBL). Here we demonstrate that another cellular protein linked to BCR/ABL through the CRKL-SH2 domain is p130(CAS). p130(CAS) was found to be tyrosine phosphorylated and associated with CRKL in BCR/ABL expressing cell lines and in samples obtained from CML and ALL patients, but not in samples from controls. In both normal and BCR/ABL transformed cells, p130(CAS) was detected in focal adhesion-like structures, as was BCR/ABL. In normal cells, the focal adhesion proteins tensin, p125(FAK), and paxillin constitutively associated with p130(CAS). However, in BCR/ABL transformed cells, the interaction between p130(CAS) and tensin was disrupted, while the associations between p130(CAS), p125(FAK) and paxillin were unaffected. These results suggest that the BCR/ABL oncogene could alter the function of p130(CAS) in at least three ways: tyrosine phosphorylation, inducing constitutive binding of CRKL to a domain in p130(CAS) containing Tyr-X-X-Pro moths (substrate domain), and disrupting the normal interaction of p130(CAS) with the focal adhesion protein tensin. These alterations in the structure of signaling proteins in focal adhesion Like structures could contribute to the known adhesion abnormalities in CML cells.	DANA FARBER CANC INST, DIV HEMATOL MALIGNANCIES, BOSTON, MA 02115 USA; DANA FARBER CANC INST, DIV CELLULAR & MOL BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV TOKYO, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of Tokyo			Li, Jian-Liang/AAE-9315-2019	Li, Jian-Liang/0000-0002-6487-081X	NATIONAL CANCER INSTITUTE [K08CA060821, R37CA036167, R01CA036167] Funding Source: NIH RePORTER; NCI NIH HHS [CA36167, CA60821] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1995, ONCOGENE, V10, P1465; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; Law SF, 1996, MOL CELL BIOL, V16, P3327; LO SH, 1994, J BIOL CHEM, V269, P22310; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUDA M, 1992, J VIROL, V66, P115, DOI 10.1128/JVI.66.1.115-121.1992; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NICHOLS GL, 1994, BLOOD, V84, P2912; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; ODA T, 1994, J BIOL CHEM, V269, P22925; PATCH LA, 1995, J CELL SCI, V108, P1371; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Ribon V, 1996, MOL CELL BIOL, V16, P45; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, ONCOGENE, V11, P1149; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sattler M, 1996, ONCOGENE, V12, P839; SATTLER M, 1995, EXP HEMATOL, V23, P1040; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259	45	111	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25198	25203		10.1074/jbc.271.41.25198	http://dx.doi.org/10.1074/jbc.271.41.25198			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810278	hybrid			2022-12-27	WOS:A1996VL69300022
J	Fan, CY; Pan, J; Chu, RY; Lee, D; Kluckman, KD; Usuda, N; Singh, I; Yeldandi, AV; Rao, MS; Maeda, N; Reddy, JK				Fan, CY; Pan, J; Chu, RY; Lee, D; Kluckman, KD; Usuda, N; Singh, I; Yeldandi, AV; Rao, MS; Maeda, N; Reddy, JK			Hepatocellular and hepatic peroxisomal alterations in mice with a disrupted peroxisomal fatty acyl-coenzyme A oxidase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; ACID OMEGA-HYDROXYLASE; COA OXIDASE; ZELLWEGER SYNDROME; LIPID-METABOLISM; MEMBRANE-PROTEIN; CLOFIBRIC ACID; RENAL SYNDROME; RAT-LIVER; ADRENOLEUKODYSTROPHY	Peroxisomal genetic disorders, such as Zellweger syndrome, are characterized by defects in one or more enzymes involved in the peroxisomal beta-oxidation of very long chain fatty acids and are associated with defective peroxisomal biogenesis. The biologic role of peroxisomal beta-oxidation system, which consists of three enzymes: fatty acyl-CoA oxidase (ACOX), enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase (HD), and thiolase, has been examined in mice by disrupting ACOX gene, which encodes the first and rate-limiting enzyme of this system, Homozygous (ACOX -/-) mice lacked the expression of ACOX protein and accumulate very long chain fatty acids in blood. However, these homozygous mice are viable, but growth-retarded and infertile. During the first 3-4 months of age, the livers of ACOX -/- mice reveal severe microvesicular fatty metamorphosis of hepatocytes. In such steatotic cells, peroxisome assembly is markedly defective; as a result, they contain few or no peroxisomes. Few hepatocytes in 1-3-month-old ACOX -/- mice contain numerous peroxisomes, and these peroxisome-rich hepatocytes show no fatty change. At this stage, the basal mRNA levels of HD, thiolase, and other peroxisome proliferator-induced target genes were elevated in ACOX -/- mouse liver, but these mice, when treated with a peroxisome proliferator, showed no increases in the number of hepatic peroxisomes and in the mRNAs levels of these target genes. Between 4 and 5 months of age, severe steatosis resulted in scattered cell death, steatohepatitis, formation of lipogranulomas, and focal hepatocellular regeneration. In 6-7-month-old animals, the newly emerging hepatocytes, which progressively replaced steatotic cells, revealed spontaneous peroxisome proliferation. These livers showed marked increases in the mRNA levels of the remaining two genes of the beta-oxidation system, suggesting that ACOX gene disruption leads to increased endogenous ligand-mediated transcription levels. These observations demonstrate links among peroxisomal beta-oxidation, development of severe microvesicular fatty liver, peroxisome assembly, cell death, and cell proliferation in liver.	NORTHWESTERN UNIV,DEPT PATHOL,CHICAGO,IL 60611; UNIV N CAROLINA,DEPT PATHOL,SCH MED,CHAPEL HILL,NC 27599; MED UNIV S CAROLINA,DEPT PEDIAT,CHARLESTON,SC 29464	Northwestern University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Medical University of South Carolina					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042630, R37HL042630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42630] Funding Source: Medline; NIGMS NIH HHS [R37 GM23750] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN T, 1991, J HEPATOL, V12, P224, DOI 10.1016/0168-8278(91)90942-5; AOYAMA T, 1990, J LIPID RES, V31, P1477; ASHBY J, 1994, HUM EXP TOXICOL, V13, pS1, DOI 10.1177/096032719401300201; AUBOURG P, 1994, CURR OPIN GENET DEV, V4, P407, DOI 10.1016/0959-437X(94)90029-9; Ausubel F, 1990, CURRENT PROTOCOLS MO, V1; CHU RY, 1995, J BIOL CHEM, V270, P29636; CHU RY, 1995, J BIOL CHEM, V270, P4908, DOI 10.1074/jbc.270.9.4908; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; Dianzani M.U., 1991, HEPATOTOXICOLOGY, P327; ESPEEL M, 1995, HEPATOLOGY, V22, P497, DOI 10.1016/0270-9139(95)90571-5; FEIL R, 1991, AM J HUM GENET, V49, P1361; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FOURNIER B, 1994, J CLIN INVEST, V94, P526, DOI 10.1172/JCI117365; GOLDFISCHER S, 1973, SCIENCE, V182, P62, DOI 10.1126/science.182.4107.62; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; HASHIMOTO T, 1982, ANN NY ACAD SCI, V386, P5, DOI 10.1111/j.1749-6632.1982.tb21403.x; HO JK, 1995, J CLIN INVEST, V96, P1455, DOI 10.1172/JCI118182; HUANG Q, 1995, INT J ONCOL, V6, P307; IMAOKA S, 1993, DNA CELL BIOL, V12, P893, DOI 10.1089/dna.1993.12.893; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Lazarow P B, 1981, Methods Enzymol, V72, P315; Lazarow P. B., 1995, METABOLIC MOL BASES, P2287; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LEE SST, 1995, MOL CELL BIOL, V15, P3012; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MOODY DE, 1992, DRUG METAB DISPOS, V20, P779; MOSER AE, 1984, NEW ENGL J MED, V310, P1141, DOI 10.1056/NEJM198405033101802; MOSER HW, 1995, METABOLIC BASIS INHE, P2025; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NEMALI MR, 1989, TOXICOL APPL PHARM, V97, P72, DOI 10.1016/0041-008X(89)90056-2; NOVIKOFF AB, 1969, J HISTOCHEM CYTOCHEM, V17, P675, DOI 10.1177/17.10.675; OSUMI T, 1987, J BIOL CHEM, V262, P8138; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; POWERS JM, 1974, AM J PATHOL, V76, P481; PURDUE PE, 1994, J BIOL CHEM, V269, P30065; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; RAO MS, 1987, CARCINOGENESIS, V8, P631; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; REDDY JK, 1985, HDB CARCINOGEN TESTI, P482; REDDY JK, 1992, MECHANISM CARCINOGEN, P225; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; SINGH I, 1984, P NATL ACAD SCI-BIOL, V81, P4203, DOI 10.1073/pnas.81.13.4203; SUZUKI Y, 1994, AM J HUM GENET, V54, P36; Teli MR, 1995, HEPATOLOGY, V22, P1714, DOI 10.1002/hep.1840220616; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; USUDA N, 1988, LAB INVEST, V58, P100; Usuda N, 1996, J HISTOCHEM CYTOCHEM, V44, P13, DOI 10.1177/44.1.8543776; VARANASI U, 1994, P NATL ACAD SCI USA, V91, P3107, DOI 10.1073/pnas.91.8.3107; WANDERS RJA, 1995, J NEUROPATH EXP NEUR, V54, P726, DOI 10.1097/00005072-199509000-00016; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	63	210	220	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24698	24710		10.1074/jbc.271.40.24698	http://dx.doi.org/10.1074/jbc.271.40.24698			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798738	hybrid			2022-12-27	WOS:A1996VM67400060
J	Nichols, AF; Ong, P; Linn, S				Nichols, AF; Ong, P; Linn, S			Mutations specific to the xeroderma pigmentosum group E Ddb(-) phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; DAMAGE RECOGNITION PROTEIN; COMPLEMENTATION GROUP-E; HELA-CELLS RESISTANT; CIS-DIAMMINEDICHLOROPLATINUM(II); RNA	The activity of a damage-specific DNA-binding protein (DDB) is absent from a subset, Ddb(-), of cell strains from patients with xeroderma pigmentosum group E (XP-E). DDB is a heterodimer of 127-kDa and 48-kDa subunits. We have now identified single-base mutations in the gene of the 48-kDa subunit in cells from the three known Ddb(-) individuals, but not in XP-E strains that have the activity. An A --> G transition causes a K244E change in XP82TO and a G --> A transition causes an R273H change in XP2RO and XP3RO. No mutations were found in the cDNA of the 127-kDa subunit. Overexpression of p48 in insect cells greatly increases DDB activity in the cells, especially if p127 is jointly overexpressed. These results demonstrate that p48 is required for DNA binding activity, but at the same time necessitate further definition of the genetic basis of XP group E.	UNIV CALIF BERKELEY,DIV BIOCHEM & MOL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley								BIRNBOIM HC, 1988, NUCLEIC ACIDS RES, V16, P1487, DOI 10.1093/nar/16.4.1487; CHAO CCK, 1991, CANCER RES, V51, P601; CHAO CCK, 1991, BIOCHEM J, V277, P875, DOI 10.1042/bj2770875; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; CHU G, 1990, P NATL ACAD SCI USA, V87, P3324, DOI 10.1073/pnas.87.9.3324; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; de Weerd-Kastelein E A, 1974, Mutat Res, V22, P87, DOI 10.1016/0165-1218(74)90056-1; DUALAN R, 1995, GENOMICS, V29, P62, DOI 10.1006/geno.1995.1215; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; HIRSCHFELD S, 1990, MOL CELL BIOL, V10, P2041, DOI 10.1128/MCB.10.5.2041; Hwang BJ, 1996, MUTAT RES-DNA REPAIR, V362, P105, DOI 10.1016/0921-8777(95)00040-2; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; KATAOKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139, DOI 10.1016/0006-291X(91)91684-5; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC, P89; Kazantsev A, 1996, P NATL ACAD SCI USA, V93, P5014, DOI 10.1073/pnas.93.10.5014; KEENEY S, 1994, P NATL ACAD SCI USA, V91, P4053, DOI 10.1073/pnas.91.9.4053; KEENEY S, 1993, J BIOL CHEM, V268, P21293; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; KONDO S, 1989, PHOTODERMATOLOGY, V6, P89; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Sambrook J., 2002, MOL CLONING LAB MANU; TAKAO M, 1993, NUCLEIC ACIDS RES, V21, P4111, DOI 10.1093/nar/21.17.4111; VAISMAN A, 1995, BIOCHEMISTRY-US, V34, P105, DOI 10.1021/bi00001a013; Vaisman A, 1996, ONCOL RES, V8, P7	25	130	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24317	24320		10.1074/jbc.271.40.24317	http://dx.doi.org/10.1074/jbc.271.40.24317			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798680	hybrid			2022-12-27	WOS:A1996VM67400002
J	Wang, P; Raynoschek, C; Svensson, K; Ljunggren, HG				Wang, P; Raynoschek, C; Svensson, K; Ljunggren, HG			Binding of H-2K(b)-specific peptides to TAP and major histocompatibility complex class I in microsomes from wild-type, TAP1, and beta(2)-microglobulin mutant mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; BETA-2-MICROGLOBULIN TRANSLATED INVITRO; HEAVY-CHAINS; ENDOPLASMIC-RETICULUM; ANTIGEN PRESENTATION; INTACT-CELLS; T-CELLS; MOLECULES; TRANSPORTERS; TRANSLOCATION	Major histocompatibility complex (MHC) class I molecules are trimolecular complexes consisting of a heavy chain (HC), beta(2)-microglobulin (beta 2m), and a short peptide. Assembly of MHC class I molecules is thought to take place early during biosynthesis. Deficiency in either beta 2m or the transporter associated with antigen processing (TAP) results in accumulation of class I molecules in the endoplasmic reticulum (ER). In this study, we have assessed peptide binding to TAP and MHC class I in purified microsomes derived from wild-type, TAP1(-/-), beta 2m(-/-), and TAP1/beta 2m(-/-) mice using a cross-linkable H-2K(b)-binding peptide. This enabled us to study the influence of an intact TAP complex and beta 2m on peptide binding to MHC class I and to analyze the stepwise interaction of peptide with TAP and MHC class I molecules. Peptide bound both immature and mature (terminally glycosylated) class I molecules in intact as well as permeabilized microsomes from wild-type mice. Efficient peptide binding to immature class I molecules was also detected in permeabilized microsomes from TAP1(-/-) mice. In contrast, no peptide binding to beta 2m-free HC was detected in permeabilized microsomes from beta 2m(-/-) and TAP1/beta 2m(-/-) mice. However, the addition of exogenous beta 2m allowed peptide binding to class I in permeabilized beta 2m(-/-) and TAP1/beta 2m(-/-) microsomes. These results demonstrate that a preformed class I HC .beta 2m heterodimer is necessary for efficient peptide binding under physiological conditions. The observed peptide binding to class I in permeabilized TAP1(-/-) microsomes further suggests that TAP1 is not required for peptide binding to class I in the ER. Finally, kinetic studies allowed the demonstration of a stepwise binding of peptide to TAP, subsequent translocation across the ER membrane, a step that required ATP hydrolysis, and binding of peptide to preformed class I HC .beta 2m heterodimers.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet	Wang, P (corresponding author), LUDWIG INST CANC RES,STOCKHOLM BRANCH,BOX 240,S-10401 STOCKHOLM,SWEDEN.							ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; BIJLMAKERS MJ, 1993, CURR OPIN IMMUNOL, V5, P21, DOI 10.1016/0952-7915(93)90076-5; BIJLMAKERS MJE, 1993, EUR J IMMUNOL, V23, P1305, DOI 10.1002/eji.1830230618; BIX M, 1992, J EXP MED, V176, P829, DOI 10.1084/jem.176.3.829; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; DAY PM, 1995, IMMUNITY, V2, P137, DOI 10.1016/S1074-7613(95)80014-X; ELLIOTT T, 1991, IMMUNOL TODAY, V12, P386; ELLIOTT T, 1991, NATURE, V351, P402, DOI 10.1038/351402a0; GLAS R, 1992, P NATL ACAD SCI USA, V89, P11381, DOI 10.1073/pnas.89.23.11381; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HEEMELS MT, 1993, SCIENCE, V262, P2059, DOI 10.1126/science.8266106; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HOWARD JC, 1995, CURR OPIN IMMUNOL, V7, P69, DOI 10.1016/0952-7915(95)80031-X; KALTOFT MB, 1992, HYBRIDOMA, V11, P507, DOI 10.1089/hyb.1992.11.507; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KOPPELMAN B, 1992, P NATL ACAD SCI USA, V89, P3908, DOI 10.1073/pnas.89.9.3908; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; LEVY F, 1991, J CELL BIOL, V115, P959, DOI 10.1083/jcb.115.4.959; LJUNGGREN HG, 1995, INT IMMUNOL, V7, P975, DOI 10.1093/intimm/7.6.975; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MACHOLD RP, 1995, J EXP MED, V181, P1111, DOI 10.1084/jem.181.3.1111; MOMBURG F, 1994, J EXP MED, V179, P1613, DOI 10.1084/jem.179.5.1613; MOMBURG F, 1994, CURR OPIN IMMUNOL, V6, P32, DOI 10.1016/0952-7915(94)90030-2; Momburg F, 1996, J IMMUNOL, V156, P1756; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; NEEFJES JJ, 1993, J EXP MED, V178, P1971, DOI 10.1084/jem.178.6.1971; Nijenhuis M, 1996, J IMMUNOL, V156, P2186; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; RAMMENSEE HG, 1995, CURR OPIN IMMUNOL, V7, P85, DOI 10.1016/0952-7915(95)80033-6; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHUMACHER TNM, 1994, J EXP MED, V179, P533, DOI 10.1084/jem.179.2.533; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SUCH WK, 1994, SCIENCE, V264, P1322; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; VANENDERT PM, 1995, J EXP MED, V182, P1883, DOI 10.1084/jem.182.6.1883; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; WILLIAMS DB, 1995, CURR OPIN IMMUNOL, V7, P77, DOI 10.1016/0952-7915(95)80032-8; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5	46	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24830	24835		10.1074/jbc.271.40.24830	http://dx.doi.org/10.1074/jbc.271.40.24830			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798757	hybrid			2022-12-27	WOS:A1996VM67400079
J	Colandene, JD; Garrett, RH				Colandene, JD; Garrett, RH			Functional dissection and site-directed mutagenesis of the structural gene for NAD(P)H-nitrite reductase in Neurospora crassa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINACH NITRITE REDUCTASE; ESCHERICHIA-COLI; NITRATE ASSIMILATION; SULFITE REDUCTASE; NUCLEOTIDE-SEQUENCE; REGIONS	Neurospora crassa NAD(P)H-nitrite reductase, coded by the nit-6 gene, is a soluble, alpha(2)-type modimeric protein composed of 127-kDa polypeptide subunits. This multicenter oxidation-reduction enzyme utilizes either NADH or NADPH as electron donor and possesses as prosthetic groups two iron-sulfur (Fe4S4) clusters, two siroheme groups, and two FAD molecules. The native activity of the enzyme is the NAD(P)H-dependent reduction of nitrite to ammonia. In addition, N. crassa nitrite reductase displays several partial activities in vitro, including a siroheme-independent NAD(P)H-cytochrome c reductase activity and an FAD-independent dithionite-nitrite reductase activity. These partial activities are presumed to be manifestations of discrete functional domains within the protein. A full-length nit-6 cDNA was constructed and used in developing an expression system within E. coli capable of yielding high levels of NADPH-nitrite reductase activity. Maximal expression was obtained in nirB(-) E. coli cells grown anaerobically at 22 +/- 1 degrees C, in conjunction with co-expression of a plasmid-borne cysG gene (encoding the rate-limiting enzyme in siroheme synthesis) and cotransformation with plasmid pGroESL (encoding bacterial chaperonins GroES and GroEL). Dissection of gene segments encoding putative functional domains within the nit-6 gene was performed. Expression of a partial cDNA construct encoding the FAD-/NAD-binding domain yielded extracts with NADPH-cytochrome c reductase activity but no NADPH-nitrite reductase activity or dithionite-nitrite reductase activity. Expression of a cDNA construct encoding the (Fe4S4)-siroheme-binding domain resulted in extracts possessing dithionite-nitrite reductase activity but no NADPH-nitrite reductase or NADPH-cytochrome c reductase activity. Analysis of site-directed mutations altering amino acid residues Cys-331 within the FAD-/NAD-binding domain and Ser-755 within the (Fe4S4)-siroheme-binding domain of the nitrite reductase demonstrated that these residues were not essential for native or partial enzyme activity. Cys-757 within the (Fe4S4)-siroheme-binding domain was essential for native enzyme activity.	UNIV VIRGINIA,DEPT BIOL,CHARLOTTESVILLE,VA 22903	University of Virginia								BACK E, 1988, MOL GEN GENET, V212, P20, DOI 10.1007/BF00322440; CAMPBELL WH, 1990, TRENDS BIOCHEM SCI, V15, P315, DOI 10.1016/0968-0004(90)90021-3; CLACKSON T, 1991, PCR PRACTICAL APPROA, P187; CRANE BR, 1995, SCIENCE, V270, P59, DOI 10.1126/science.270.5233.59; CRAWFORD NM, 1990, PLANT CELL, V2, P829; CRAWFORD NM, 1995, PLANT CELL, V7, P859, DOI 10.1105/tpc.7.7.859; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; DUNNCOLEMAN NS, 1984, INT REV CYTOL, V92, P1; EXLEY GE, 1993, J BACTERIOL, V175, P2379, DOI 10.1128/JB.175.8.2379-2392.1993; FRIEMANN A, 1992, MOL GEN GENET, V231, P411, DOI 10.1007/BF00292710; Garrett R H, 1978, Adv Microb Physiol, V18, P1; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HURLBURT BK, 1988, MOL GEN GENET, V211, P35, DOI 10.1007/BF00338390; JOHNSTONE IL, 1990, GENE, V90, P181, DOI 10.1016/0378-1119(90)90178-T; Kinghorn J. R., 1989, Molecular and genetic aspects of nitrate assimilation., P385; LAFFERTY MA, 1974, J BIOL CHEM, V249, P7555; LAHNERS K, 1988, PLANT PHYSIOL, V88, P741, DOI 10.1104/pp.88.3.741; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15726; PEAKMAN T, 1990, EUR J BIOCHEM, V191, P315, DOI 10.1111/j.1432-1033.1990.tb19125.x; PRODOUZ KN, 1981, J BIOL CHEM, V256, P9711; Sambrook J., 2002, MOL CLONING LAB MANU; Siegal L. M., 1989, Molecular and genetic aspects of nitrate assimilation., P263; VEGA JM, 1976, ARCH MICROBIOL, V109, P237, DOI 10.1007/BF00446634; VEGA JM, 1975, P 6 C SPAN SOC BIOCH, P108; WU JY, 1991, J BACTERIOL, V173, P325, DOI 10.1128/jb.173.1.325-333.1991	25	6	6	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24096	24104		10.1074/jbc.271.39.24096	http://dx.doi.org/10.1074/jbc.271.39.24096			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798648	hybrid			2022-12-27	WOS:A1996VJ44200077
J	Fischer, BE; Schlokat, U; Mitterer, A; SavidisDacho, H; Grillberger, L; Reiter, M; Mundt, W; Dorner, F; Eibl, J				Fischer, BE; Schlokat, U; Mitterer, A; SavidisDacho, H; Grillberger, L; Reiter, M; Mundt, W; Dorner, F; Eibl, J			Rational design, recombinant preparation, and in vitro and in vivo characterization of human prothrombin-derived hirudin antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-THROMBIN; IDENTIFICATION; ANTICOAGULANT; COAGULATION; EXPRESSION; COMPLEX	A mutant derivative of human prothrombin in which active site aspartate at position 419 is replaced by an asparagine (D419N-prothrombin) has been designed, expressed in recombinant Chinese hamster ovary cells, and purified to homogeneity, D419N-prothrombin was converted to the related molecules D419N-meizothrombin and D419N-thrombin by limited proteolysis by Echis carinatus and Oxyuranus scutellatus venom protease, respectively, and affinity-purified using an immobilized modified C-terminal hirudin-derived peptide, Neither D419N-thrombin nor D419N-meizothrombin exhibited thrombin activity, Titration resulted in no detection of the active site, but binding to the most specific thrombin inhibitor, hirudin, was conserved in both proteins, In vitro examinations showed that D419N-thrombin and D419N-meizothrombin bind to immobilized hirudin, neutralize hirudin in human blood plasma as well as in the purified system, and reactivate the thrombin-hirudin complex, Animal model studies confirmed that D419N-thrombin and D419N-meizothrombin act as hirudin antagonist in blood circulation without detectable effects on the coagulation system, Thus, both D419N-thrombin and D419N-meizothrombin combine for the first time hirudin-neutralizing properties with the advantages of recombinant production of human coagulation factors.			Fischer, BE (corresponding author), IMMUNO AG, BIOMED RES CTR, UFERSTR 15, A-2304 ORTH DANAU, AUSTRIA.							BECKER RC, 1994, THROMB THROMBOLYSIS, V1, P7; BICHLER J, 1991, ANN HEMATOL, V63, P67, DOI 10.1007/BF01707275; DOYLE MF, 1993, METHOD ENZYMOL, V222, P299; FALKNER FG, 1992, THROMB HAEMOSTASIS, V68, P119; FAREED J, 1991, SEMIN THROMB HEMOST, V17, P137, DOI 10.1055/s-2007-1002602; FISCHER B, 1994, FEBS LETT, V351, P345, DOI 10.1016/0014-5793(94)00861-2; FISCHER B, 1995, J BIOTECHNOL, V38, P129, DOI 10.1016/0168-1656(94)00124-U; Fischer BE, 1996, THROMB RES, V81, P157, DOI 10.1016/0049-3848(95)00224-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; JOHNSON PH, 1994, ANNU REV MED, V45, P165, DOI 10.1146/annurev.med.45.1.165; KAISER B, 1991, SEMIN THROMB HEMOST, V17, P130, DOI 10.1055/s-2007-1002601; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOVITS J, 1994, CIRCULATION, V90, P1522, DOI 10.1161/01.CIR.90.3.1522; LUNDBLAD RL, 1977, CHEM BIOL HEPARIN; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2356; MARAGANORE JM, 1993, ADV EXP MED BIOL, V340, P227; MARKWARDT F, 1991, HAEMOSTASIS, V21, P11; MARKWARDT F, 1991, THROMB HAEMOSTASIS, V66, P141; MARKWARDT F, 1958, H-S Z PHYSIOL CHEM, V312, P85, DOI 10.1515/bchm2.1958.312.1.85; MARKWARDT F, 1994, THROMB RES, V74, P1, DOI 10.1016/0049-3848(94)90032-9; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216	26	2	3	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23737	23742		10.1074/jbc.271.39.23737	http://dx.doi.org/10.1074/jbc.271.39.23737			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798598	hybrid			2022-12-27	WOS:A1996VJ44200027
J	Green, SA; Spasoff, AP; Coleman, RA; Johnson, M; Liggett, SB				Green, SA; Spasoff, AP; Coleman, RA; Johnson, M; Liggett, SB			Sustained activation of a G protein-coupled receptor via ''anchored'' agonist binding - Molecular localization of the salmeterol exosite within the beta(2)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTORS; ADRENOCEPTOR AGONISTS; MODEL; ACID; CDNA	An inherent therapeutic limitation of many G protein-coupled receptor agonists is a short duration of action due to rapid dissociation from receptors. Salmeterol is a modified beta-adrenergic receptor (beta AR) agonist that has a long duration of action at the beta(2)AR (but not the beta(1)AR) both in vitro and in vivo and that is persistent despite extensive washout of the agonist. It has been proposed that salmeterol binds not only to the active site of the beta(2)AR (localized to receptor transmembrane spanning domains (TMDs) 3 and 5) but also to another site (termed the ''exosite'') that anchors it to the receptor and provides for repetitive active-site binding events. To identify the location of this exosite, we used site-directed mutagenesis to replace beta(2)AR amino acids 149-173 (within TMD4) with beta(1)AR sequence. The resulting constructs were then expressed in COS-7 cells for radioligand binding studies. Using this approach, when this domain was replaced with the analogous beta(1)AR sequence, the ability of salmeterol to persist at the receptor under washout conditions was reduced by 67%. The results from more selective mutants (S-(149-166), S-(164-173), and S-(149-158)) indicated that a limited 10-amino acid region (beta(2)AR residues 149-158), localized at the interface of the cytoplasm and the transmembrane domain, contains a critical determinant for exosite binding. Whereas CHW cells stably expressing wild-type beta(2)AR displayed persistent salmeterol-promoted cAMP accumulation despite agonist washout, substitution of beta(2)AR residues 149-158 with beta(1)AR sequence resulted in a 56% attenuation of salmeterol-promoted cAMP accumulation under identical washout conditions. A reverse chimera was also studied, which consisted of a substitution of beta(2)AR residues 152-156 into the beta(1)AR. This substitution was found to confer exosite binding to the beta(1)AR. None of these mutations decreased the affinity of salmeterol for the receptor at the active site as assessed in competition binding studies. Anchored binding to this motif thus represents a novel mechanism by which agonists like salmeterol can repetitively activate receptors. Conceivably, with other G protein-coupled receptors that have similar motifs, anchored ligands can be designed to provide for long durations of action by this mechanism.	UNIV CINCINNATI,COLL MED,DEPT PHARMACOL & MOL GENET,CINCINNATI,OH 45267; GLAXO WELLCOME LTD,UXBRIDGE UB11 1BT,MIDDX,ENGLAND	University of Cincinnati; GlaxoSmithKline	Green, SA (corresponding author), UNIV CINCINNATI,COLL MED,DEPT PULM MED,231 BETHESDA AVE,BOX 670564,CINCINNATI,OH 45267, USA.		liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [HL03346, HL45967] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045967, K08HL003346, R37HL045967, R56HL045967] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON GP, 1994, EUR RESPIR J, V7, P569, DOI 10.1183/09031936.94.07030569; BALL DI, 1991, BRIT J PHARMACOL, V104, P665, DOI 10.1111/j.1476-5381.1991.tb12486.x; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Clark RB, 1996, MOL PHARMACOL, V49, P182; CRONET P, 1993, PROTEIN ENG, V6, P59, DOI 10.1093/protein/6.1.59; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1980, J BIOL CHEM, V255, P7108; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; GREEN SA, 1993, J BIOL CHEM, V268, P23116; GREEN SA, 1994, J BIOL CHEM, V269, P26215; GREEN SA, 1992, MOL PHARMACOL, V41, P889; JACK D, 1991, BRIT J CLIN PHARMACO, V31, P501, DOI 10.1111/j.1365-2125.1991.tb05571.x; JOHNSON M, 1995, MED RES REV, V15, P225, DOI 10.1002/med.2610150303; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lewell X Q, 1992, Drug Des Discov, V9, P29; LIGGETT SB, 1989, MOL PHARMACOL, V36, P641; NIALS AT, 1993, BRIT J PHARMACOL, V108, P507, DOI 10.1111/j.1476-5381.1993.tb12833.x; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; RHODES DG, 1992, MOL PHARMACOL, V42, P596; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRADER CD, 1991, J BIOL CHEM, V266, P5; STRADER CD, 1988, J BIOL CHEM, V263, P10267; STRADER CD, 1989, J BIOL CHEM, V264, P13572; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V	27	127	132	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24029	24035		10.1074/jbc.271.39.24029	http://dx.doi.org/10.1074/jbc.271.39.24029			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798639	hybrid			2022-12-27	WOS:A1996VJ44200068
J	Hunt, JG; Kasinsky, HE; Elsey, RM; Wright, CL; Rice, P; Bell, JE; Sharp, DJ; Kiss, AJ; Hunt, DF; Arnott, DP; Russ, MM; Shabanowitz, J; Ausio, J				Hunt, JG; Kasinsky, HE; Elsey, RM; Wright, CL; Rice, P; Bell, JE; Sharp, DJ; Kiss, AJ; Hunt, DF; Arnott, DP; Russ, MM; Shabanowitz, J; Ausio, J			Protamines of reptiles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H1-LIKE PROTEIN; AMINO-ACID-SEQUENCE; SPERM BASIC-PROTEINS; MYTILUS-CALIFORNIANUS; P1 GENES; EVOLUTION; CDNA; EXPRESSION; GENUS; BOAR	We have characterized for the first time the complete primary structure of the main protamine components of the sperm from four reptiles: Chrysemys picta (turtle), Elaphe obsoleta (snake), Anolis carolinensis (lizard), and Alligator mississipiensis (crocodilian). These species were chosen to represent one of each of the main phylogenetic branches of this taxonomic group. Comparison of these protamine sequences with those already available from other vertebrate groups allows us to define properly the chemical consensus composition of protamines and provides a unique insight into their molecular evolution and classification.	UNIV VICTORIA, DEPT BIOCHEM & MICROBIOL, VICTORIA, BC V8W 3P6, CANADA; UNIV BRITISH COLUMBIA, DEPT ZOOL, VANCOUVER, BC V6T 1Z4, CANADA; DEPT WILDLIFE & FISHERIES, ROCKEFELLER WILDLIFE REFUGE, FUR & REFUGE DIV, GRAND CHENIER, LA 70643 USA; UNIV VIRGINIA, DEPT CHEM, CHARLOTTESVILLE, VA 22901 USA	University of Victoria; University of British Columbia; University of Virginia			Kiss, Andor J/E-9863-2016; Hunt, Donald F/I-6936-2012	Kiss, Andor J/0000-0002-7508-0485; Hunt, Donald F/0000-0003-2815-6368	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-37537] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIYOSHI N, 1994, MOL REPROD DEV, V37, P363, DOI 10.1002/mrd.1080370402; AUSIO J, 1988, J BIOL CHEM, V263, P10141; AUSIO J, 1989, EUR J BIOCHEM, V182, P569, DOI 10.1111/j.1432-1033.1989.tb14865.x; AUSIO J, 1986, COMP BIOCHEM PHYS B, V85, P439, DOI 10.1016/0305-0491(86)90025-8; AUSIO J, 1995, ADV SPERMATOZOAL TAX, V166, P447; Ausio J., 1995, ADV SPERMATOZOAL TAX, V166, P501; Bloch D.P., 1976, P139; BLOCH DP, 1969, GENETICS, V61, P93; CARLOS S, 1993, J BIOL CHEM, V268, P185; Carroll RL, 1988, VERTEBRATE PALEONTOL; CHAO H, 1992, FEBS LETT, V299, P166, DOI 10.1016/0014-5793(92)80239-D; CHIVA M, 1989, J EXP ZOOL, V249, P329, DOI 10.1002/jez.1402490312; COLE RD, 1989, METHOD ENZYMOL, V170, P524; DABAN M, 1995, J MOL EVOL, V40, P663, DOI 10.1007/BF00160515; Dixon GH, 1985, CHROMOSOMAL PROTEINS, P287; Doolittle R. F., 1986, URFS ORFS PRIMER ANA; Hecht NB, 1989, HISTONES OTHER BASIC, P347; Hickman C. P., 1993, ZOOLOGIA PRINCIPIOS; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HIYOSHI H, 1991, EXP CELL RES, V194, P95, DOI 10.1016/0014-4827(91)90135-H; Hoffmann J A, 1990, Protein Expr Purif, V1, P127, DOI 10.1016/1046-5928(90)90005-J; HUNT DF, 1991, TECHNIQUES PROTEIN C, V2, P441; JUTGLAR L, 1991, J BIOL CHEM, V266, P8184; Kasinsky H. E., 1989, HISTONES OTHER BASIC, P73; KASINSKY HE, 1987, J EXP ZOOL, V243, P137, DOI 10.1002/jez.1402430116; KOSSEL A, 1896, SB KGL PREUSS AKAD W, V18, P403; Kossel A., 1896, HOPPE SEYLERS Z PHYS, V22, P176; LEE C, 1991, MOL REPROD DEV, V30, P154, DOI 10.1002/mrd.1080300212; MAIER WM, 1990, NUCLEIC ACIDS RES, V18, P1249, DOI 10.1093/nar/18.5.1249; MANN M, 1982, J EXP ZOOL, V222, P173, DOI 10.1002/jez.1402220209; Miescher F., 1874, Z F R ANALYTISCHE CH, V7, P376, DOI [10.1002/cber.187400701119, DOI 10.1002/CBER.187400701119, DOI 10.1007/BF01302341]; Mita K, 1995, BBA-GEN SUBJECTS, V1245, P430, DOI 10.1016/0304-4165(95)00124-7; NAKANO M, 1976, INT J PEPT PROT RES, V8, P565; OLIVA R, 1991, PROG NUCLEIC ACID RE, V40, P25; OLIVA R, 1986, BIOCHEMISTRY-US, V25, P6508, DOI 10.1021/bi00369a025; OLIVA R, 1989, J BIOL CHEM, V264, P12472; OLIVA R, 1989, J BIOL CHEM, V264, P17627; Oliva R, 1995, ADV SPERMATOZOAL TAX, V166, P537; RETIEF JD, 1993, EUR J BIOCHEM, V214, P609, DOI 10.1111/j.1432-1033.1993.tb17960.x; RETIEF JD, 1995, MOL BIOL EVOL, V12, P708; RETIEF JD, 1993, EUR J BIOCHEM, V218, P457, DOI 10.1111/j.1432-1033.1993.tb18396.x; RETIEF JD, 1995, P ROY SOC B-BIOL SCI, V259, P7, DOI 10.1098/rspb.1995.0002; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; STEWART CB, 1993, NATURE, V361, P603, DOI 10.1038/361603a0; SUBIRANA JA, 1983, P 4 INT S SPERM, P197; TAKAMUNE K, 1991, EUR J BIOCHEM, V196, P401, DOI 10.1111/j.1432-1033.1991.tb15830.x; TOBITA T, 1983, BIOCHIM BIOPHYS ACTA, V744, P141, DOI 10.1016/0167-4838(83)90083-3; WINKFEIN RJ, 1993, EUR J BIOCHEM, V215, P63, DOI 10.1111/j.1432-1033.1993.tb18007.x; ZUG GR, 1993, HERPETOLOGY; [No title captured]	50	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23547	23557		10.1074/jbc.271.38.23547	http://dx.doi.org/10.1074/jbc.271.38.23547			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798564	hybrid			2022-12-27	WOS:A1996VH76800090
J	Shyjan, AM; Heldin, P; Butcher, EC; Yoshino, T; Briskin, MJ				Shyjan, AM; Heldin, P; Butcher, EC; Yoshino, T; Briskin, MJ			Functional cloning of the cDNA for a human hyaluronan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; ACID SYNTHESIS; MOLECULAR CHARACTERIZATION; ADHESION MOLECULE-1; CELLS; FIBROBLASTS; GROWTH; LOCALIZATION; SYNTHETASE; RECEPTOR	Hyaluronan is a constituent of the extracellular matrix of connective tissue and is actively synthesized during wound healing and tissue repair to provide a framework for ingrowth of blood vessels and fibroblasts. Changes in the serum concentration of hyaluronan are associated with inflammatory and degenerative arthropathies such as rheumatoid arthritis. In addition, hyaluronan has been implicated as an important substrate for migration of adhesion of leukocytes during inflammation. A human hyaluronan synthase (HuHAS1) cDNA was isolated by a functional expression cloning approach. Transfection of CHO cells conferred hyaluronidase-sensitive adhesiveness of a mucosal T cell line via the lymphocyte hyaluronan receptor, CD44, as well as increased hyaluronan levels in the cultures of transfected cells. The HuHAS1 amino acid sequence shows considerable homology to the hasA gene product of Streptococcus pyogenes, a glycosaminoglycan synthetase from Xenopus laevis (DG42), and is the human homolog of a recently described murine hyaluronan synthase.	LEUKOSITE INC, CAMBRIDGE, MA 02142 USA; STANFORD UNIV, SCH MED, DEPT PATHOL, LAB IMMUNOL & VASC BIOL, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, CTR DIGEST DIS, STANFORD, CA 94305 USA; VET ADM MED CTR, CTR MOL BIOL & MED, PALO ALTO, CA 94304 USA; UNIV UPPSALA, CTR BIOMED, DEPT MED & PHYSIOL CHEM, S-75123 UPPSALA, SWEDEN	Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Uppsala University								ANDREW DP, 1994, J IMMUNOL, V153, P3847; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BRECHT M, 1986, BIOCHEM J, V239, P445, DOI 10.1042/bj2390445; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BUTCHER EC, 1980, EUR J IMMUNOL, V10, P556, DOI 10.1002/eji.1830100713; CRATER DL, 1995, J BIOL CHEM, V270, P18452, DOI 10.1074/jbc.270.31.18452; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1994, BIOCHEM BIOPH RES CO, V199, P1, DOI 10.1006/bbrc.1994.1184; DOUGHERTY BA, 1994, J BIOL CHEM, V269, P169; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; EDELSTAM GAB, 1991, J HISTOCHEM CYTOCHEM, V39, P1131, DOI 10.1177/39.8.1856461; GRABER N, 1990, J IMMUNOL, V145, P819; Gunthert U, 1993, Curr Top Microbiol Immunol, V184, P47; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; HELDIN P, 1989, BIOCHEM J, V258, P919, DOI 10.1042/bj2580919; HRONOWSKI L, 1980, J BIOL CHEM, V255, P9210; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; KLEWES L, 1994, J CELL PHYSIOL, V160, P539, DOI 10.1002/jcp.1041600317; KLEWES L, 1993, BIOCHEM J, V290, P791, DOI 10.1042/bj2900791; LANSING M, 1993, BIOCHEM J, V289, P179, DOI 10.1042/bj2890179; LAURENT C, 1991, CELL TISSUE RES, V263, P201, DOI 10.1007/BF00318761; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAURENT TC, 1986, CIBA F SYMP, V124, P9; LAURENT TC, 1996, IN PRESS ANN MED, V28; MATUOKA K, 1987, J CELL BIOL, V104, P1105, DOI 10.1083/jcb.104.4.1105; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; MIAN N, 1986, BIOCHEM J, V237, P333, DOI 10.1042/bj2370333; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; OREGAN M, 1994, INT J BIOL MACROMOL, V16, P283, DOI 10.1016/0141-8130(94)90056-6; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; PREHM P, 1984, BIOCHEM J, V220, P597, DOI 10.1042/bj2200597; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; Semino CE, 1996, P NATL ACAD SCI USA, V93, P4548, DOI 10.1073/pnas.93.10.4548; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; Shyjan AM, 1996, J IMMUNOL, V156, P2851; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; SUZUKI M, 1995, BIOCHEM J, V307, P817, DOI 10.1042/bj3070817; TOMIDA M, 1975, J CELL PHYSIOL, V86, P121, DOI 10.1002/jcp.1040860114; TOOLE BP, 1984, HYALURONATE CELL INT, P43; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; TURLEY EA, 1992, CANCER METAST REV, V11, P1233; Varki A, 1996, P NATL ACAD SCI USA, V93, P4523, DOI 10.1073/pnas.93.10.4523; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x	50	143	156	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23395	23399		10.1074/jbc.271.38.23395	http://dx.doi.org/10.1074/jbc.271.38.23395			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798544	hybrid			2022-12-27	WOS:A1996VH76800070
J	Warnock, DE; Hinshaw, JE; Schmid, SL				Warnock, DE; Hinshaw, JE; Schmid, SL			Dynamin self-assembly stimulates its GTPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED-VESICLE FORMATION; TEMPERATURE-SENSITIVE MUTANT; DROSOPHILA-MELANOGASTER; ENDOCYTOSIS; MICROTUBULES; ACTIVATION; BLOCKAGE; DOMAINS	GTP hydrolysis by dynamin is required to drive coated vesicle budding at the plasma membrane, A diverse set of molecules including microtubules, grb2, and acidic phospholipids stimulate dynamin GTPase activity in vitro, although the physiological relevance of these effecters remains to be determined. Dynamin has been shown to assemble around microtubules, the most potent stimulatory molecule, into structures indistinguishable by electron microscopy from collars captured in vivo at the necks of endocytic coated pits. Under low ionic strength conditions purified dynamin self-assembles into rings and helical stacks of rings, Here we show that dynamin self-assembly stimulates its GTPase activity as much as 10-fold. Thus, we identify dynamin, itself, as the first effector of dynamin GTPase activity known to be physiologically relevant. Assembled dynamin's stimulated GTPase activity is not dependent on the direct interaction of high affinity GTP binding sites since a mutant defective in GTP binding and hydrolysis can coassemble with and stimulate GTP hydrolysis by wild-type dynamin. Finally, we find that GTP destabilizes assembled dynamin structures, suggesting that the activated rates of GTP hydrolysis reflect a continuing cycle of assembly, GTP hydrolysis, and disassembly.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				Schmid, Sandra/0000-0002-1690-7024	NIGMS NIH HHS [GM42455] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042455] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baba T, 1995, COLD SPRING HARB SYM, V60, P235, DOI 10.1101/SQB.1995.060.01.027; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; LIU JP, 1995, ENDOCR REV, V16, P590, DOI 10.1210/er.16.5.590; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; RAMASWAMI M, 1993, J NEUROGENET, V9, P73, DOI 10.3109/01677069309083451; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TSURUHARA T, 1990, CELL TISSUE RES, V259, P199, DOI 10.1007/BF00318441; TUMA PL, 1994, J BIOL CHEM, V269, P30842; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x	20	201	206	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22310	22314		10.1074/jbc.271.37.22310	http://dx.doi.org/10.1074/jbc.271.37.22310			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798389	hybrid			2022-12-27	WOS:A1996VG67200008
J	Mizushima, T; Sasaki, S; Ohishi, H; Kobayashi, M; Katayama, T; Miki, T; Maeda, M; Sekimizu, K				Mizushima, T; Sasaki, S; Ohishi, H; Kobayashi, M; Katayama, T; Miki, T; Maeda, M; Sekimizu, K			Molecular design of inhibitors of in vitro oriC DNA replication based on the potential to block the ATP binding of DnaA protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; INITIATION PROTEIN; ORIGIN	DnaA protein, the initiation factor for chromosomal DNA replication in Escherichia coli, is activated by binding to ATP. We earlier reported that 3-acetoxy-2,2'-bi-1H-indol inhibited the ATP binding to DnaA protein (Sasaki, S., Mizushima, T., Hashimoto, T., Maeda, M., and Sekimizu, K. (1994) Bioorg. Med. Chem. Lett. 4, 1771-1774), In the present study, derivatives of 3-acetoxy-2,2'-bi-1H-indol with different lengths of aliphatic chains at the 3-O position were synthesized, and their potential to inhibit the ATP binding to DnaA protein was examined. Elongation of the aliphatic chain resulted in inhibition of the ATP binding to DnaA protein at lower concentrations. Among the derivatives, 3-[N-(11-carboxyundecyl)] carbamoylmethoxy-2,2'-bi-1H-indol (structure 7 (3-CUCM-BI)) exhibited the most potent inhibition with an IC50 value of 7 mu M. The mode of the inhibition was competitive. We further demonstrated that structure 7 (3-CUCM-BI) inhibited DNA replication of the oriC plasmid in a system reconstituted from purified proteins. This inhibition was specific for the initiation of DNA replication rather than for the elongation. The inhibition was overcome by preincubation of DnaA protein with ATP. Furthermore, structure 7 (3-CUCM-BI) showed little inhibition on DNA synthesis in the ABC primosome system. We propose that structure 7 (3-CUCM-BI) functions in the in vitro oriC DNA replication by inhibiting the ATP binding to DnaA protein.	KYUSHU UNIV, FAC PHARMACEUT SCI, HIGASHI KU, FUKUOKA 81282, JAPAN	Kyushu University				Katayama, Tsutomu/0000-0001-9994-1684				CASTUMA CE, 1993, J BIOL CHEM, V268, P24665; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; Katayama T, 1995, MOL MICROBIOL, V18, P813, DOI 10.1111/j.1365-2958.1995.18050813.x; KATAYAMA T, 1994, J BIOL CHEM, V269, P22075; KATAYAMA T, 1995, J BIOL CHEM, V270, P9265, DOI 10.1074/jbc.270.16.9265; Kornberg A., 1992, DNA REPLICATION; MASAI H, 1990, J BIOL CHEM, V265, P15134; MIKI T, 1978, P NATL ACAD SCI USA, V75, P5099, DOI 10.1073/pnas.75.10.5099; Mizushima T, 1996, J BIOL CHEM, V271, P3633; SASAKI S, 1994, BIOORG MED CHEM LETT, V4, P1771, DOI 10.1016/S0960-894X(00)80378-9; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7124; TRINKS U, 1994, J MED CHEM, V37, P1015, DOI 10.1021/jm00033a019; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202	17	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25178	25183		10.1074/jbc.271.41.25178	http://dx.doi.org/10.1074/jbc.271.41.25178			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810275	hybrid			2022-12-27	WOS:A1996VL69300019
J	Arzumanov, AA; Semizarov, DG; Victorova, LS; Dyatkina, NB; Krayevsky, AA				Arzumanov, AA; Semizarov, DG; Victorova, LS; Dyatkina, NB; Krayevsky, AA			gamma-phosphate-substituted 2'-deoxynucleoside 5'-triphosphates as substrates for DNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOSIDE 5'-TRIPHOSPHATES; ANALOGS; TRIPHOSPHATE; ALPHA; ROUTE; ACID	Several 2'-deoxythymidine 5'-triphosphate and 3'-azido-2',3'-dideoxythymidine 5'-triphosphate analogs containing a hydrophobic phosphonate group instead of the gamma-phosphate were synthesized and evaluated as substrates for human immunodeficiency virus (HIV) and avian myeloblastosis virus reverse transcriptases, human placental DNA polymerases alpha and beta, and calf thymus terminal deoxynucleotidyl transferase. They were efficiently incorporated into the DNA chain by the retroviral enzymes but were not utilized by the mammalian ones. Also, some gamma-ester and gamma-amide derivatives of dTTP and 3'-azido-2',3'-dideoxythymidine 5'-triphosphate (AZTTP) were synthesized and studied. They proved to be substrates for both the retroviral and mammalian enzymes under study. The K-m values for incorporation of the dTTP derivatives into the DNA chain were close to those for dTTP and AZTTP. The K-m for the AZTTP derivatives were one order of magnitude greater than those for dTTP and AZTTP. The results obtained indicate that HIV and avian myeloblastosis virus reverse transcriptases have no sterical obstacles for binding the triphosphate fragment bearing a bulky substituent at the gamma-position. Modification of the gamma-phosphate in AZTTP increased the selectivity of HIV reverse transcriptase inhibition versus DNA polymerase alpha. gamma-Methylphosphonate and gamma-phenylphosphonate were dephosphorylated in human serum much less rapidly than AZTTP. Besides, they were shown to be markedly more hydrophobic than AZTTP. Thus, replacement of the gamma-phosphate in AZTTP with gamma-phosphonate markedly alters its substrate properties toward some cellular DNA polymerases and blood dephosphorylating enzymes but does not change its substrate activity with respect to HIV reverse transcriptase.	RUSSIAN ACAD SCI,INST MOL BIOL,MOSCOW 117984,RUSSIA	Russian Academy of Sciences								ARMSTRONG VW, 1976, EUR J BIOCHEM, V70, P33, DOI 10.1111/j.1432-1033.1976.tb10952.x; ARZUMANOV AA, 1994, NUCLEOS NUCLEOT, V13, P1031, DOI 10.1080/15257779408011876; ATRAZHEV AM, 1987, BIOORG KHIM+, V13, P1045; BABKINA GT, 1975, BIOORG KHIM+, V1, P611; BUNEVA NV, 1983, DOKL AKAD NAUK SSSR, V268, P243; BUNEVA NV, 1980, MOL BIOL RUSSIAN, V14, P1080; BURGERS PMJ, 1979, J BIOL CHEM, V254, P6889; CHAMBERS RD, 1990, J CHEM SOC CHEM COMM, P1053, DOI 10.1039/c39900001053; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DORONIN SV, 1987, FEBS LETT, V216, P221, DOI 10.1016/0014-5793(87)80693-2; DYATKINA N, 1995, NUCLEOS NUCLEOT, V14, P91, DOI 10.1080/15257779508014655; EGLUND PT, 1969, J BIOL CHEM, V244, P3038; FERRIN LJ, 1986, BIOCHEMISTRY-US, V25, P5131, DOI 10.1021/bi00366a023; KILESSO TY, 1990, BIOORG KHIM, V16, P530; KNORRE DG, 1988, BIOCHIMIE, V70, P655, DOI 10.1016/0300-9084(88)90250-7; Kolocheva T. I., 1993, Molekulyarnaya Biologiya (Moscow), V27, P1368; KRAEV A S, 1988, Molekulyarnaya Biologiya (Moscow), V22, P1164; KRAUT J, 1961, ACTA CRYSTALLOGR, V14, P1146, DOI 10.1107/S0365110X61003363; LUDWIG J, 1981, ACTA BIOCHIM BIOPHYS, V16, P131; Mozzherin D. Yu., 1992, Molekulyarnaya Biologiya (Moscow), V26, P999; OKAYA Y, 1966, ACTA CRYSTALLOGR, V20, P7122; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PERRIER WG, 1962, ACTA CRYSTALLOGR, V15, P616; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; ROSOVSKAYA TA, 1993, MOL BIOL RUSSIAN, V27, P1051; ROSOVSKAYA TA, 1992, MOL BIOL RUSSIAN, V27, P618; Sambrook J., 2002, MOL CLONING LAB MANU; SEMIZAROV DG, 1993, FEBS LETT, V327, P45, DOI 10.1016/0014-5793(93)81036-Y; SLOAN DL, 1975, J BIOL CHEM, V250, P8913; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; VICTOROVA LS, 1992, NUCLEIC ACIDS RES, V20, P783, DOI 10.1093/nar/20.4.783	32	44	59	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24389	24394		10.1074/jbc.271.40.24389	http://dx.doi.org/10.1074/jbc.271.40.24389			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798694	hybrid			2022-12-27	WOS:A1996VM67400016
J	Geck, RK; Larimer, FW; Hartman, FC				Geck, RK; Larimer, FW; Hartman, FC			Identification of residues of spinach thioredoxin f that influence interactions with target enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; CHLOROPLAST FRUCTOSE-1,6-BISPHOSPHATASE; FRUCTOSE 1,6-BISPHOSPHATASE; MALATE-DEHYDROGENASE; REDUCTIVE ACTIVATION; C-4 PHOTOSYNTHESIS; CRYSTAL-STRUCTURE; PURIFICATION; RESOLUTION; MECHANISM	The necessity for two types of thioredoxins (Trx f and m) within chloroplasts of higher plants that mediate the same redox chemistry with various target enzymes is not well understood. To approach this complex issue, we have applied site-directed mutagenesis to the identification of residues of Trx f that affect its binding to and selectivity for target enzymes. Based upon amino acid sequence alignments and the three-dimensional structure of Escherichia coli thioredoxin, putative key residues of Trx f were replaced with residues found at corresponding positions of Trx m to generate the mutants K58E, Q75D, N74D, and deletion mutants Delta Asn-74 and Delta Asn-77. Kinetics of activation of oxidized recombinant sorghum leaf NADP-dependent malate dehydrogenase and oxidized spinach chloroplastic fructose-1,6-bisphosphatase by wild-type Trx f, wild-type Trx m, and Trx f mutants were compared. All of the mutants are less efficient than wild-type Trx f in the activation of fructose-1,6-bisphosphatase and are altered in both S-0.5 and V-max. In contrast to literature reports, the activation of NADP-dependent malate dehydrogenase does not display rate saturation kinetics with respect to the concentration of Trx f, thereby signifying very weak interactions between the two proteins. The mutants of Trx f likewise interact only weakly with NADP-dependent malate dehydrogenase, but the apparent second-order rate constants for activation are increased compared to that with wild-type Trx f. Thus, Lys-58, Asn-74, Gln-75, and Asn-77 of Trx f contribute to its interaction with target enzymes and influence target protein selectivity.	OAK RIDGE NATL LAB,DIV BIOL,PROT ENGN PROGRAM,OAK RIDGE,TN 37831; OAK RIDGE NATL LAB,OAK RIDGE GRAD SCH BIOMED SCI,OAK RIDGE,TN 37831	United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville								AGUILAR F, 1992, PLANT MOL BIOL, V20, P301, DOI 10.1007/BF00014497; BRANDES HK, 1993, J BIOL CHEM, V268, P18411; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; BUCHANAN BB, 1994, ARCH BIOCHEM BIOPHYS, V314, P257, DOI 10.1006/abbi.1994.1439; Buchanan Bob B., 1992, P171; CLANCEY CJ, 1987, J BIOL CHEM, V262, P13545; CRAWFORD NA, 1986, ARCH BIOCHEM BIOPHYS, V244, P1, DOI 10.1016/0003-9861(86)90088-3; DELAMOTTEGUERY F, 1991, EUR J BIOCHEM, V196, P287; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4129, DOI 10.1021/bi00469a016; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; GLEASON FK, 1992, J BACTERIOL, V174, P2592, DOI 10.1128/jb.174.8.2592-2598.1992; HABERLEIN I, 1995, BBA-PROTEIN STRUCT M, V1253, P169, DOI 10.1016/0167-4838(95)00153-1; HODGES M, 1994, PLANT MOL BIOL, V26, P225, DOI 10.1007/BF00039534; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Holmgren A., 1986, THIOREDOXIN GLUTARED; JACQUOT JP, 1993, FEBS LETT, V96, P243; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARCUS F, 1987, BIOCHEMISTRY-US, V26, P7029, DOI 10.1021/bi00396a026; NISHIZAWA AN, 1981, J BIOL CHEM, V256, P6119; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; SAARINEN M, 1995, STRUCTURE, V3, P1097, DOI 10.1016/S0969-2126(01)00245-3; SALAMON Z, 1995, BBA-BIOENERGETICS, V1230, P114, DOI 10.1016/0005-2728(95)00042-H; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEIBE R, 1986, BIOCHIM BIOPHYS ACTA, V870, P191, DOI 10.1016/0167-4838(86)90221-9; SCHEIBE R, 1981, BIOCHIM BIOPHYS ACTA, V636, P58, DOI 10.1016/0005-2728(81)90075-X; SCHURMANN P, 1981, EUR J BIOCHEM, V116, P37, DOI 10.1111/j.1432-1033.1981.tb05297.x; TSUGITA A, 1983, BIOCHEM BIOPH RES CO, V115, P1, DOI 10.1016/0006-291X(83)90960-9; WEDEL N, 1992, PLANT MOL BIOL, V18, P527, DOI 10.1007/BF00040668; WOLOSIUK RA, 1979, J BIOL CHEM, V254, P1627; XIA TH, 1992, PROTEIN SCI, V1, P310; ZIMMERMANN G, 1976, EUR J BIOCHEM, V70, P361, DOI 10.1111/j.1432-1033.1976.tb11025.x	36	65	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24736	24740		10.1074/jbc.271.40.24736	http://dx.doi.org/10.1074/jbc.271.40.24736			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798742	hybrid			2022-12-27	WOS:A1996VM67400064
J	OHandley, SF; Frick, DN; Bullions, LC; Mildvan, AS; Bessman, MJ				OHandley, SF; Frick, DN; Bullions, LC; Mildvan, AS; Bessman, MJ			Escherichia coli orf17 codes for a nucleoside triphosphate pyrophosphohydrolase member of the MutT family of proteins - Cloning, purification, and characterization of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE; CATALYTIC DOMAIN; STREPTOCOCCUS-PNEUMONIAE; RUVC GENE; SEQUENCE; EXCHANGE; K-12; PYROPHOSPHATASE; IDENTIFICATION; SUBSTRATE	The product of the Escherichia coli orf17 gene is a novel nucleoside triphosphate pyrophosphohydrolase with a preference for dATP over the other canonical (deoxy)nucleoside triphosphates, and it catalyzes the hydrolysis of dATP through a nucleophilic attack at the beta-phosphorus to produce dAMP and inorganic pyrophosphate. It has a pH optimum between 8.5 and 9.0, a divalent metal ion requirement with optimal activity at 5 mm Mg2+, a K-m of 0.8 mm and a k(cat) of 5.2 s(-1) at 37 degrees C for dATP. dAMP is a weak competitive inhibitor with a K-i of approximately 4 mw, while PPi is a much stronger inhibitor with an apparent K-i of approximately 20 mu M. The enzyme contains the highly conserved signature sequence GXVEX(2)ETX(6)REVXEEX(2)I designating the MutT family of proteins. However, unlike the other nucleoside triphosphate pyrophosphohydrolases with this conserved sequence, the Orf17 protein does not complement the mutT(-) mutator phenotype, and thus must serve a different biological role in the cell.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, MCCOLLUM PRATT INST, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				O'Handley, Suzanne/0000-0001-8373-0065; Frick, David/0000-0002-2434-7223	NIDDK NIH HHS [DK-28616] Funding Source: Medline; NIGMS NIH HHS [GM-18649] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028616, R37DK028616] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEYGUNAWARDANA C, 1995, BIOCHEMISTRY-US, V34, P14997, DOI 10.1021/bi00046a006; ABEYGUNAWARDANA C, 1993, BIOCHEMISTRY-US, V32, P13071, DOI 10.1021/bi00211a017; AKIYAMA M, 1987, MOL GEN GENET, V206, P9, DOI 10.1007/BF00326530; AMES BN, 1960, J BIOL CHEM, V235, P769; AOYAMA K, 1994, MOL BIOL EVOL, V11, P829; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; Cleland W W, 1979, Methods Enzymol, V63, P103; COHN M, 1978, P NATL ACAD SCI USA, V75, P200, DOI 10.1073/pnas.75.1.200; DESIRAJU V, 1991, THESIS U MARYLAND BA; Fiske CH, 1925, J BIOL CHEM, V66, P375; FRICK DN, 1994, J BIOL CHEM, V269, P1794; FRICK DN, 1995, J BIOL CHEM, V270, P1529, DOI 10.1074/jbc.270.4.1529; FRICK DN, 1995, J BIOL CHEM, V270, P24086, DOI 10.1074/jbc.270.41.24086; FRICK DN, 1995, THESIS J HOPKINS U B, P49; GEORGE DG, 1990, METHOD ENZYMOL, V183, P333; JOSSE J, 1966, J BIOL CHEM, V241, P1948; JOSSE J, 1966, J BIOL CHEM, V241, P1938; KAMATH AV, 1993, GENE, V134, P99, DOI 10.1016/0378-1119(93)90180-B; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P4847, DOI 10.1093/nar/21.20.4847; KUHKO E, 1986, EUR J BIOCHEM, V127, P347; KUKKOKALSKE E, 1989, J BACTERIOL, V171, P4498, DOI 10.1128/JB.171.8.4498-4500.1989; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LOWE G, 1978, J CHEM SOC CHEM COMM, P783, DOI 10.1039/c39780000783; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAY U, 1979, MOL GEN GENET, V171, P215, DOI 10.1007/BF00270007; REYNOLDS MA, 1983, J AM CHEM SOC, V105, P6663, DOI 10.1021/ja00360a020; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SHARPLES GJ, 1991, J BACTERIOL, V173, P7711, DOI 10.1128/jb.173.23.7711-7715.1991; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; WALSH C, 1979, ENZYMATIC REACTION M, P259; WEBER DJ, 1992, J BIOL CHEM, V267, P16939	38	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24649	24654		10.1074/jbc.271.40.24649	http://dx.doi.org/10.1074/jbc.271.40.24649			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798731	hybrid			2022-12-27	WOS:A1996VM67400053
J	Roy, S; Sun, A; Redman, C				Roy, S; Sun, A; Redman, C			In vitro assembly of the component chains of fibrinogen requires endoplasmic reticulum factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN FIBRINOGEN; PROTEIN DISULFIDE-ISOMERASE; SECRETORY PROTEINS; ALPHA-SUBUNIT; BETA-SUBUNIT; CALNEXIN; ASSOCIATION; MOLECULES; BONDS; BIOSYNTHESIS	Human fibrinogen (340 kDa) is a dimer, with each identical half-molecule composed of three different polypeptides (A alpha, 66 kDa; B beta, 55 kDa; and gamma, 48 kDa). To understand the mechanisms of chain assembly, a coupled in vitro transcription translation system capable of assembling fibrinogen chains was developed, Fibrinogen chain assembly was assayed in an expression system coupled to rabbit reticulocyte lysate in the presence or absence of dog pancreas microsomal membranes, Fibrinogen chain assembly required microsomal membranes and oxidized glutathione. Co-expression of two of the chains, B beta and gamma or A alpha and gamma, yielded free chains and two-chain complexes, Unlike combinations of A alpha with gamma and B beta with gamma, co expression of A alpha and B beta did not form a single two-chain complex but produced a mixture of two-chain complexes. Co-expression of all three chains yielded free chains, two-chain complexes, and higher molecular weight complexes that corresponded to a half-molecule and to fully formed fibrinogen. Upon treatment of this mixture with thrombin and factor XIIIa, a gamma .gamma dimer, similar to that obtained from crosslinked human fibrin, was produced, indicating that properly folded fibrinogen was formed in vitro. Molecular chaperones may participate in fibrinogen assembly, since antibodies to resident proteins of the endoplasmic reticulum (BiP, Hsp90, protein disulfide isomerase, and calnexin) co-precipitated the chaperones together with nascent fibrinogen chains and complexes.			Roy, S (corresponding author), NEW YORK BLOOD CTR,LINDSLEY F KIMBALL RES INST,310 E 67 ST,NEW YORK,NY 10021, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037457] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37457] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BILJMAKERS MJE, 1993, EUR J IMMUNOL, V23, P1305; BINNIE CG, 1993, BIOCHEMISTRY-US, V32, P107, DOI 10.1021/bi00052a015; BLOMBACK B, 1972, ANN NY ACAD SCI, V202, P77, DOI 10.1111/j.1749-6632.1972.tb16323.x; BLOMBACK B, 1968, NATURE, V218, P130, DOI 10.1038/218130a0; BLOMBACK B, 1976, THROMB RES, V8, P639, DOI 10.1016/0049-3848(76)90245-0; BOUMA H, 1978, THROMB RES, V13, P557, DOI 10.1016/0049-3848(78)90142-1; CARRENO BM, 1995, J IMMUNOL, V154, P5173; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FU YP, 1992, BIOCHEMISTRY-US, V31, P11968, DOI 10.1021/bi00163a002; FU YP, 1994, P NATL ACAD SCI USA, V91, P2625, DOI 10.1073/pnas.91.7.2625; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HANTGAN RR, 1994, HEMOSTASIS THROMBOSI, P277; HARTWIG R, 1991, J BIOL CHEM, V266, P6578; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HENSCHEN A, 1964, ARK KEMI, V22, P355; Herbert Daniel N., 1995, Cell, V81, P425; HOEPRICH PD, 1983, BIOCHEMISTRY-US, V22, P2049, DOI 10.1021/bi00278a003; HUANG SM, 1993, J BIOL CHEM, V268, P8919; HUANG SM, 1993, BIOCHEM BIOPH RES CO, V190, P488, DOI 10.1006/bbrc.1993.1074; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; IWANAGA S, 1967, BIOCHIM BIOPHYS ACTA, V147, P606, DOI 10.1016/0005-2795(67)90025-6; JOHN DCA, 1993, EMBO J, V12, P1587, DOI 10.1002/j.1460-2075.1993.tb05803.x; KIM P, 1995, J CELL BIOL, V12, P29; KUDRYK B, 1982, EUR J BIOCHEM, V125, P673, DOI 10.1111/j.1432-1033.1982.tb06735.x; LOO TW, 1994, J BIOL CHEM, V269, P28683; MOSESSON M W, 1992, Seminars in Hematology, V29, P177; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; ROY S, 1992, J BIOL CHEM, V267, P23151; ROY SN, 1995, J BIOL CHEM, V270, P23761, DOI 10.1074/jbc.270.40.23761; ROY SN, 1991, J BIOL CHEM, V266, P4758; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SONDERFELDFRESKO S, 1988, J BIOL CHEM, V263, P13463; YU S, 1984, J BIOL CHEM, V259, P574; YU S, 1983, J BIOL CHEM, V258, P3407; YU S, 1986, SCHEME INTRACELLULAR, P665; ZHANG JZ, 1994, J BIOL CHEM, V269, P652; Zhang JZ, 1996, J BIOL CHEM, V271, P12674, DOI 10.1074/jbc.271.21.12674	47	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24544	24550		10.1074/jbc.271.40.24544	http://dx.doi.org/10.1074/jbc.271.40.24544			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798716	hybrid			2022-12-27	WOS:A1996VM67400038
J	Wang, ZY; Qiu, QQ; Seufert, W; Taguchi, T; Testa, JR; Whitmore, A; Callen, DF; Welsh, D; Shenk, T; Deuel, TF				Wang, ZY; Qiu, QQ; Seufert, W; Taguchi, T; Testa, JR; Whitmore, A; Callen, DF; Welsh, D; Shenk, T; Deuel, TF			Molecular cloning of the cDNA and chromosome localization of the gene for human ubiquitin-conjugating enzyme 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE INSITU HYBRIDIZATION; TUMOR SUPPRESSOR GENE; WILMS-TUMOR; PROTEASOME PATHWAY; PROMOTER ACTIVITY; WT1; PRODUCT; PROTEIN; TRANSCRIPTION; DEGRADATION	We report a novel human gene whose product specifically associates with the negative regulatory domain of the Wilms' tumor gene product (WT1) in a yeast two-hybrid screen and with WT1 in immunoprecipitation and glutathione S-transferase (GST) capture assays. The gene encodes a 17-kDa protein that has 56% amino acid sequence identity with yeast ubiquitin-conjugating enzyme (yUBC) 9, a protein required for cell cycle progression in yeast, and significant identity with other subfamilies of ubiquitin-conjugating enzymes. The human gene fully complements yeast that have a temperature-sensitive yUBC9 gene mutation to fully restore normal growth, indicating that we have cloned a functionally conserved human (h) homolog of yUBC9. Transcripts of hUBC9 of 4.4 kilobases (kb), 2.8 kb, and 1.3 kb were found in all human tissues tested. A single copy of the hUBC9 gene was found and localized to human chromosome 16p13.3. We conclude that hUBC9 retains striking structural and functional conservation with yUBC9 and suggest a possible link of the ubiquitin/proteosome proteolytic pathway and the WT1 transcriptional repressor system.	BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215; PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08560; UNIV MUNICH,INST GENET & MIKROBIOL,D-80638 MUNICH,GERMANY; FOX CHASE CANC CTR,DEPT MED ONCOL,PHILADELPHIA,PA 19111; WOMENS & CHILDRENS HOSP,DEPT CYTOGENET & MOL GENET,ADELAIDE,SA 5006,AUSTRALIA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Princeton University; University of Munich; Fox Chase Cancer Center; Womens & Childrens Hospital Australia			Callen, David F/G-1975-2012; Seufert, Wolfgang/F-7136-2019	Seufert, Wolfgang/0000-0001-8938-9064; Callen, David/0000-0002-6189-9991				CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CALLEN DF, 1995, GENOMICS, V29, P503, DOI 10.1006/geno.1995.9005; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; Maniatis T., 1982, MOL CLONING; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; TESTA JR, 1992, CYTOGENET CELL GENET, V60, P247, DOI 10.1159/000133350; WANG ZY, 1995, ONCOGENE, V10, P415; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1995, ONCOGENE, V10, P1243; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828	28	71	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24811	24816		10.1074/jbc.271.40.24811	http://dx.doi.org/10.1074/jbc.271.40.24811			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798754	hybrid			2022-12-27	WOS:A1996VM67400076
J	Weaver, AM; McCabe, M; Kim, I; Allietta, MM; Gonias, SL				Weaver, AM; McCabe, M; Kim, I; Allietta, MM; Gonias, SL			Epidermal growth factor and platelet-derived growth factor-BB induce a stable increase in the activity of low density lipoprotein receptor-related protein in vascular smooth muscle cells by altering receptor distribution and recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; TRANSFERRIN RECEPTORS; ALPHA(2)-MACROGLOBULIN RECEPTOR; ACTIVATED ALPHA-2-MACROGLOBULIN; PLASMINOGEN-ACTIVATOR; MEDIATED ENDOCYTOSIS; PLASMA-MEMBRANE; RAT ADIPOCYTES; BINDING DOMAIN; RATE-CONSTANT	Low density lipoprotein receptor-related protein (LRP) is a multifunctional receptor, expressed by vascular smooth muscle cells (VSMCs) in normal arteries and in atherosclerotic lesions. In this investigation, we demonstrate a novel mechanism for the regulation of LRP activity in cultured rat aortic VSMCs. Cells that were treated with platelet-derived growth factor-BB (PDGF-BB) or epidermal growth factor (EGF) for 24 h bound increased amounts of the LRP ligand, activated alpha(2)-macroglobulin (alpha(2)M), at 4 degrees C. The B-max for activated alpha(2)M was increased from 56 +/- 5 to 178 +/- 24 and 143 +/- 11 fmol/mg cell protein by PDGF-BB and EGF, respectively, while the K-D was unchanged. Northern and Western blot analyses demonstrated that neither PDGF-BB nor EGF increase LRP mRNA or protein levels. Instead, LRP was redistributed to the cell surface and remained localized primarily in coated pits, as determined by surface protein biotinylation, affinity labeling, and immunoelectron microscopy studies. The increase in cell-surface LRP was partially explained by a 50% decrease in receptor endocytosis rate; however, at 37 degrees C, PDGF-BB- and EGF-treated VSMCs still bound/internalized increased amounts of activated alpha(2)M and subsequently released increased amounts of trichloroacetic acid-soluble radioactivity. The cytokine-induced shifts in LRP subcellular distribution were stable when VSMCs were challenged with a saturating concentration of ligand and then incubated, in the absence of cytokine, for 2.5 h at 37 degrees C. Regulation of LRP distribution and activity may be an important aspect of the VSMC response to the atherogenic cytokines, PDGF-BB and EGF.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53462] Funding Source: Medline; NIGMS NIH HHS [GM07267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAMPBELL JH, 1985, ARTERIOSCLEROSIS, V5, P318, DOI 10.1161/01.ATV.5.4.318; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; CZECH MP, 1993, J BIOL CHEM, V268, P9187; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; DAVIS RJ, 1986, EMBO J, V5, P653, DOI 10.1002/j.1460-2075.1986.tb04263.x; DAVIS RJ, 1987, J BIOL CHEM, V262, P13126; DESCAMPS O, 1993, J BIOL CHEM, V268, P974; DICKSON RB, 1981, J CELL BIOL, V89, P29, DOI 10.1083/jcb.89.1.29; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GROBMYER SR, 1993, J BIOL CHEM, V268, P13291; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HERZ J, 1990, J BIOL CHEM, V265, P21355; Hussaini IM, 1996, J LEUKOCYTE BIOL, V59, P733, DOI 10.1002/jlb.59.5.733; HUSSAINI IM, 1990, J BIOL CHEM, V265, P19441; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KAPLAN J, 1980, CELL, V19, P197, DOI 10.1016/0092-8674(80)90401-8; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KUTT H, 1989, BIOCHIM BIOPHYS ACTA, V1009, P229, DOI 10.1016/0167-4781(89)90107-3; LAMARRE J, 1993, J CLIN INVEST, V91, P1219, DOI 10.1172/JCI116283; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; LUOMA J, 1994, J CLIN INVEST, V93, P2014, DOI 10.1172/JCI117195; LUPU F, 1994, ARTERIOSCLER THROMB, V14, P1438, DOI 10.1161/01.ATV.14.9.1438; LUSIAK JJ, 1995, J BIOL CHEM, V270, P21919; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MISRA UK, 1994, J BIOL CHEM, V269, P12541; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; MOSSE PRL, 1985, LAB INVEST, V53, P556; SALVESEN G, 1992, FEBS LETT, V313, P198, DOI 10.1016/0014-5793(92)81443-P; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; STOUFFER GA, 1993, J BIOL CHEM, V268, P18340; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TANNER LI, 1987, J BIOL CHEM, V262, P8975; THYBERG J, 1983, DIFFERENTIATION, V25, P156; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; TYCKO B, 1982, CELL, V28, P643, DOI 10.1016/0092-8674(82)90219-7; VANLEUVEN F, 1980, CELL, V20, P37, DOI 10.1016/0092-8674(80)90232-9; WARDZALA LJ, 1984, J BIOL CHEM, V259, P8378; WATANABE Y, 1994, ARTERIOSCLER THROMB, V14, P1000, DOI 10.1161/01.ATV.14.6.1000; Weaver AM, 1995, J BIOL CHEM, V270, P30741, DOI 10.1074/jbc.270.51.30741; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILEY HS, 1984, P NATL ACAD SCI-BIOL, V81, P7456, DOI 10.1073/pnas.81.23.7456	50	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24894	24900		10.1074/jbc.271.40.24894	http://dx.doi.org/10.1074/jbc.271.40.24894			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798766	hybrid			2022-12-27	WOS:A1996VM67400089
J	DSouza, SE; ByersWard, VJ; Gardiner, EE; Wang, HW; Sung, SS				DSouza, SE; ByersWard, VJ; Gardiner, EE; Wang, HW; Sung, SS			Identification of an active sequence within the first immunoglobulin domain of intercellular cell adhesion molecule-1 (ICAM-1) that interacts with fibrinogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-ENDOTHELIUM INTERACTION; GLYCOPROTEIN-IIB-IIIA; GAMMA-CHAIN; RECOGNITION SPECIFICITY; INFLAMMATORY RESPONSES; PLATELET RECEPTOR; HUMAN RHINOVIRUS; LIGAND-BINDING; PEPTIDE; MAC-1	Monocytic cells bind fibrinogen (fg) through integrin alpha(M) beta(2). fg-bound monocytic cells demonstrate an enhanced adhesion to endothelial cells, which is dependent on intercellular adhesion molecule-1 (ICAM-1). Our studies differentiate fg interactions with stimulated and resting endothelial cells, which are ICAM-1 dependent and independent, respectively. This report documents a direct interaction between fg and intact ICAM-1 and with a two-Ig domain form of ICAM-1. A small region within the first Ig domain of ICAM-1, ICAM-1-(8-21) (KVILPRGGSVLVTC), was identified to interact with fg in a specific and selective manner. ICAM-1-(8-21) bound to plasmin-derived fg fragments X, D100, and D80 but not to fragment E. Consistent with this finding, fg gamma-chain peptide, fg-gamma-117-133, blocked fg interaction with ICAM-1-(8-21). ICAM-1-(8-21) peptide and antibodies directed against ICAM-1-(8-21) also blocked the adhesion and binding of ICAM-1-bearing Raji cells with fg. ICAM-1-(8-21) and fg-gamma-117-133 are likely to be one of the contact pairs mediating fg-ICAM-1 interactions.			DSouza, SE (corresponding author), CLEVELAND CLIN FDN, JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL, DEPT MOL CARDIOL, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.		Gardiner, Elizabeth/P-8716-2019; Gardiner, Elizabeth/E-7774-2011	Gardiner, Elizabeth/0000-0001-9453-9688; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043721, R01HL043721] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 43721] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1995, J BIOL CHEM, V270, P696, DOI 10.1074/jbc.270.2.696; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BERNSTEIN FC, 1977, EUR J BIOCHEM, V80, P319, DOI 10.1111/j.1432-1033.1977.tb11885.x; BUDZYNSK.AZ, 1974, J BIOL CHEM, V249, P2294; CHARO IF, 1987, J BIOL CHEM, V262, P9935; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; COBB RR, 1992, BIOCHEM BIOPH RES CO, V185, P1022, DOI 10.1016/0006-291X(92)91729-A; DEFOUGEROLLES AR, 1994, J EXP MED, V179, P619, DOI 10.1084/jem.179.2.619; DEJANA E, 1985, J CLIN INVEST, V75, P11, DOI 10.1172/JCI111661; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DOOLITTLE RF, 1967, ARCH BIOCHEM BIOPHYS, V118, P456, DOI 10.1016/0003-9861(67)90374-8; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FAULL RJ, 1989, TRANSPLANTATION, V48, P226, DOI 10.1097/00007890-198908000-00009; FECONDO JV, 1991, P NATL ACAD SCI USA, V88, P2879, DOI 10.1073/pnas.88.7.2879; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GARVEY JS, 1977, METHODS IMMUNOL, V1, P273; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GIRANDA VL, 1990, PROTEINS, V7, P227, DOI 10.1002/prot.340070304; Hicks RCJ, 1996, NATURE, V379, P818, DOI 10.1038/379818a0; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; KLOCZEWIAK M, 1983, THROMB RES, V29, P249, DOI 10.1016/0049-3848(83)90147-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGUINO LR, 1989, BLOOD, V73, P734; LANGUINO LR, 1995, P NATL ACAD SCI USA, V92, P1505, DOI 10.1073/pnas.92.5.1505; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; LEVESQUE JP, 1990, J BIOL CHEM, V265, P328; LEVESQUE JP, 1986, P NATL ACAD SCI USA, V83, P6494, DOI 10.1073/pnas.83.17.6494; LI R, 1993, J BIOL CHEM, V268, P17513; LI R, 1993, J BIOL CHEM, V268, P21474; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MARGUERIE GA, 1982, J BIOL CHEM, V101, P372; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; OCKENHOUSE CF, 1992, CELL, V68, P63, DOI 10.1016/0092-8674(92)90206-R; PEERSCHKE EIB, 1985, SEMIN HEMATOL, V22, P241; ROSS L, 1992, J BIOL CHEM, V267, P8537; SHANKAR R, 1994, J BIOL CHEM, V269, P13936; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TANG LP, 1993, J EXP MED, V178, P2147, DOI 10.1084/jem.178.6.2147; TANG LP, 1995, AM J CLIN PATHOL, V103, P466; TRANQUI L, 1989, J CELL BIOL, V108, P2519, DOI 10.1083/jcb.108.6.2519; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; XU H, 1994, J EXP MED, V180, P95, DOI 10.1084/jem.180.1.95	54	27	28	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24270	24277		10.1074/jbc.271.39.24270	http://dx.doi.org/10.1074/jbc.271.39.24270			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798673	hybrid			2022-12-27	WOS:A1996VJ44200102
J	Schwalbe, RA; Wang, ZG; Bianchi, L; Brown, AM				Schwalbe, RA; Wang, ZG; Bianchi, L; Brown, AM			Novel sites of N-glycosylation in ROMK1 reveal the putative pore-forming segment H5 as extracellular	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER K+ CHANNEL; ASPARAGINE-LINKED OLIGOSACCHARIDES; POTASSIUM CHANNEL; TRANSMEMBRANE TOPOLOGY; RECEPTOR; RECTIFICATION; TERMINUS; GLYCOPROTEINS; MUTAGENESIS; EXPRESSION	Inwardly rectifying K+ channels (IRKs) maintain resting membrane potential, excitability, and K+ exchange. The proposed topological model of IRKs consists of intracellular amino and carboxyl termini and two transmembrane segments (M1 and M2) linked by a pore-forming segment (H5). Structure-function studies have identified critical pore determinants in M2 and the carboxyl terminus but not as expected by analogy with voltage-dependent K+ channels, in H5. We investigated the topology of the IRK ROMK1 by substituting novel N-glycosylation sites which act as markers for extracellular segments. N-Glycosylation, before and after an N-glycosylation inhibitor, tunicamycin, was measured directly by gel shift assays and changes in membrane currents. Tunicamycin produced gel shifts and changes in membrane currents that correlated exactly. N-Glycosylation sites substituted into the amino and carboxyl termini and the M1 segment gave results consistent with the proposed model. N-Glycosylation sites were distributed throughout H5 and its flanking regions indicating that H5 is mainly extracellular. Thus, the linker between M1 and M2 has little or no intramembranous component.	CASE WESTERN RESERVE UNIV,METROHEALTH CAMPUS,RAMMELKAMP CTR EDUC & RES,CLEVELAND,OH 44109	Case Western Reserve University; MetroHealth System			Wang, Zhiguo/GRS-4339-2022	Wang, Zhiguo/0000-0002-0811-2045				BAMBERG K, 1994, J BIOL CHEM, V269, P16909; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; ELBEIN AD, 1981, TRENDS BIOCHEM SCI, V6, P219, DOI 10.1016/0968-0004(81)90080-3; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; PESSIA M, 1995, NEURON, V14, P1039, DOI 10.1016/0896-6273(95)90342-9; Possee RD., 1992, BACULOVIRUS EXPRESSI; SAMBROOK J, 1992, MOL CLONING LAB MANU; SCHWALBE RA, 1995, J BIOL CHEM, V270, P15336, DOI 10.1074/jbc.270.25.15336; TAGLIALATELA M, 1995, EMBO J, V14, P5532, DOI 10.1002/j.1460-2075.1995.tb00240.x; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; TAGLIALATELA M, 1994, NEWS PHYSIOL SCI, V9, P169; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; WO ZG, 1994, P NATL ACAD SCI USA, V91, P7154, DOI 10.1073/pnas.91.15.7154; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494	33	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24201	24206		10.1074/jbc.271.39.24201	http://dx.doi.org/10.1074/jbc.271.39.24201			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798662	hybrid			2022-12-27	WOS:A1996VJ44200091
J	Tseng, A; Inglis, AS; Scott, KF				Tseng, A; Inglis, AS; Scott, KF			Native peptide inhibition - Specific inhibition of type II phospholipases A(2) by synthetic peptides derived from the primary sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNOVIAL-FLUID PHOSPHOLIPASE-A2; PANCREATIC PHOSPHOLIPASE-A2; CYTOSOLIC PHOSPHOLIPASE-A2; CONFORMATIONAL-CHANGES; CRYSTAL-STRUCTURE; FUNCTIONAL ROLES; ACTIVE-SITE; N-TERMINUS; BINDING; NMR	The binding of low molecular weight type II phospholipase A(2) (EC 3.1.1.4) to membrane surfaces and hydrolysis of phospholipid are thought to involve the formation of a hydrophobic channel into which a single substrate molecule diffuses before cleavage, The floor and right side of the channel are provided by hydrophobic residues 2, 5, and 9 of an amphipathic amino-terminal helix, The channel is postulated to form via a conformational change in this helix and inward movement of a hydrophobic flap (residue 69 side chain). We show that the amino-terminal tryptic peptide of human type II phospholipase A(2) forms a noncovalent complex with the tryptic peptide from residues 70-74 of the enzyme, Further, the 70-74-peptide sequence (FLSYK) dose-dependently inhibits phospholipid hydrolysis in a mixed micelle assay. This native peptide inhibition also occurred with type II enzymes from Crotalus durissus and Crotalus atrox, which have different amino acid sequences at the amino terminus as well as different 70-74 regions of the molecules. Despite significant conservation of tertiary structure among the enzymes, inhibition by each peptide is specific to the enzyme from which the peptide sequence is derived, We propose that these native peptides inhibit enzyme activity via a sequence-specific, noncovalent interaction with the amino-terminal residues of the enzyme, thereby preventing the conformational change on binding to the micelle interface, These experiments demonstrate a new method for specific inhibition of phospholipase A(2) which, in principle, would be applicable to other biologically active polypeptides and proteins.	ST VINCENTS HOSP, UNIV NEW S WALES, DEPT MED, DARLINGHURST, NSW 2010, AUSTRALIA; ST VINCENTS HOSP, UNIV NEW S WALES, GARVAN INST MED RES, DARLINGHURST, NSW 2010, AUSTRALIA	St Vincents Hospital Sydney; University of New South Wales Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney				Scott, Kieran/0000-0002-6012-4107				BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BRUNIE S, 1985, J BIOL CHEM, V260, P9742; Darbre A., 1986, PRACTICAL PROTEIN CH; DEKKER N, 1991, EUR J BIOCHEM, V199, P601, DOI 10.1111/j.1432-1033.1991.tb16160.x; DIJKSTRA BW, 1984, BIOCHEMISTRY-US, V23, P2759, DOI 10.1021/bi00307a035; DIJKSTRA BW, 1981, J MOL BIOL, V147, P97, DOI 10.1016/0022-2836(81)90081-4; DIJKSTRA BW, 1981, NATURE, V289, P604, DOI 10.1038/289604a0; DIJKSTRA BW, 1982, J MOL BIOL, V1981, P97; DIMARCO S, 1992, J BIOCHEM-TOKYO, V112, P350; DUPUREUR CM, 1992, BIOCHEMISTRY-US, V31, P6402, DOI 10.1021/bi00143a007; ELSBACH P, 1991, METHOD ENZYMOL, V197, P24; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GREEN JA, 1991, INFLAMMATION, V15, P355, DOI 10.1007/BF00917352; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; INGLIS AS, 1988, J BIOCHEM BIOPH METH, V15, P249, DOI 10.1016/0165-022X(88)90012-7; JAIN MK, 1986, BIOCHIM BIOPHYS ACTA, V860, P448, DOI 10.1016/0005-2736(86)90542-0; JORGENSEN WL, 1991, SCIENCE, V254, P954, DOI 10.1126/science.1719636; KILBY PM, 1995, BIOCHEM J, V305, P935, DOI 10.1042/bj3050935; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LIU XH, 1995, BIOCHEMISTRY-US, V34, P7322, DOI 10.1021/bi00022a005; MALIWAL BP, 1994, BIOCHEMISTRY-US, V33, P4509, DOI 10.1021/bi00181a010; MARKI F, 1993, AGENTS ACTIONS, V38, P202, DOI 10.1007/BF01976212; MARKI F, 1993, J BIOCHEM-TOKYO, V113, P734; NEVALAINEN TJ, 1993, INFLAMMATION, V17, P453, DOI 10.1007/BF00916585; ONO T, 1988, J BIOL CHEM, V263, P5732; PETERS AR, 1992, BIOCHEMISTRY-US, V31, P10024, DOI 10.1021/bi00156a023; RANDOLPH A, 1980, PHOSPHOLIPASE A2 STR; RENETSEDER R, 1985, J BIOL CHEM, V260, P1627; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SMITH GM, 1992, BRIT J RHEUMATOL, V31, P175; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; Tseng A, 1991, Protein Expr Purif, V2, P127, DOI 10.1016/1046-5928(91)90061-M; VANDENBERG B, 1995, NAT STRUCT BIOL, V2, P402, DOI 10.1038/nsb0595-402; Waite M, 1987, HDB LIPID RES, V5, P155; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; YANG CC, 1988, TOXICON, V26, P721, DOI 10.1016/0041-0101(88)90279-6	38	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23992	23998		10.1074/jbc.271.39.23992	http://dx.doi.org/10.1074/jbc.271.39.23992			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798633	hybrid			2022-12-27	WOS:A1996VJ44200062
J	Auger, KR; Zhou, SY; Lo, SH; Roberts, TM; Chen, LB				Auger, KR; Zhou, SY; Lo, SH; Roberts, TM; Chen, LB			Platelet-derived growth factor-induced formation of tensin and phosphoinositide 3-kinase complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; EXTRACELLULAR-MATRIX; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE-C; BINDING-SITE; ASSOCIATION; DOMAINS; ACTIN	Tensin is an SH2 domain-containing cytoskeletal protein that binds to and caps actin filaments. Investigation of signal transduction mechanisms associated with tensin revealed the presence of phosphoinositide 3-kinase (PI 3-kinase) activity in tensin immunoprecipitates from platelet derived growth factor-treated cells. Association of PI 3-kinase activity with tensin was transitory, and the amount of activity was approximately 1% of the total PI 3-kinase activity found in anti-phosphotyrosine (anti-pY) immunoprecipitates. In vitro, PI 3-kinase activity associated with the SH2 domain of tensin in a platelet-derived growth factor-dependent manner. The optimal phosphopeptide binding specificity of the SH2 domain of tensin was determined to be phospho-Y (E or D), N, (I, V, or F). Synthetic phosphopeptides containing the sequence YENI could specifically block the association of PI 3-kinase activity with tensin in a dose dependent manner. These results suggest that PI 3-kinase interacts with the cytoskeleton via the SH2 domain of tensin and may play an important role in platelet-derived growth factor-induced cytoskeletal reorganization that is concomitant with cell migration and proliferation.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02111 USA	Harvard University; Harvard Medical School; Tufts University; Harvard University; Beth Israel Deaconess Medical Center	Auger, KR (corresponding author), DANA FARBER CANC INST, DIV CELL & MOL BIOL, 44 BINNEY ST, BOSTON, MA 02115 USA.				NCI NIH HHS [CA30002] Funding Source: Medline; NIGMS NIH HHS [GM22427] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030002, R37CA030002] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Auger K. R., 1990, METHODS INOSITIDE RE, P159; AUGER KR, 1991, CANCER CELL-MON REV, V3, P263; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BALDWIN GS, 1993, TRENDS BIOCHEM SCI, V18, P378, DOI 10.1016/0968-0004(93)90093-3; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BERRIDGE M, 1994, BIOCHEM J, V222, P195; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1989, BIOESSAYS, V10, P104, DOI 10.1002/bies.950100403; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LO SH, 1994, J BIOL CHEM, V269, P22310; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEVERINSSON L, 1990, MOL CELL BIOL, V10, P801, DOI 10.1128/MCB.10.2.801; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	49	49	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23452	23457		10.1074/jbc.271.38.23452	http://dx.doi.org/10.1074/jbc.271.38.23452			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798552	hybrid			2022-12-27	WOS:A1996VH76800078
J	Brunke, M; Dierks, T; Schlotterhose, P; Escher, A; Schmidt, B; Szalay, AA; Lechte, M; Sandholzer, U; Zimmermann, R				Brunke, M; Dierks, T; Schlotterhose, P; Escher, A; Schmidt, B; Szalay, AA; Lechte, M; Sandholzer, U; Zimmermann, R			Luciferase assembly after transport into mammalian microsomes involves molecular chaperones and peptidyl-prolyl cis/trans-isomerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; BACTERIAL LUCIFERASE; CYCLOSPORINE-A; PROTEIN TRANSLOCATION; PRESECRETORY PROTEINS; TRIPLE-HELIX; CYCLOPHILIN; INVIVO; MEMBRANE; LUMEN	The assembly of a heterodimeric luciferase was studied after de novo synthesis of corresponding precursor proteins in reticulocyte lysate and concomitant transport into dog pancreas microsomes. This cytosolic luciferase from a prokaryotic organism (Vibrio harveyi) was specifically used as a model protein to investigate (i) whether the eukaryotic cytosol and the microsomal lumen have similar folding capabilities and (ii) whether the requirements of a polypeptide for certain molecular chaperones and folding catalysts are determined by the polypeptide or the intracellular compartment, The two luciferase subunits were fused to the preprolactin signal peptide, Data indicate that efficient assembly of luciferase occurs in the mammalian microsomes, Furthermore, it was observed that luciferase assembly can be separated in time from synthesis and membrane transport, depends on ATP hydrolysis, is partially sensitive to cyclosporin A and FK506, and in the absence of lumenal proteins is less efficient as compared with the presence of lumenal proteins, Thus, heterodimeric luciferase depends on functionally related molecular chaperones and folding catalysts during its assembly in either the eukaryotic cytosol or the microsomal lumen.	UNIV SAARLAND,D-66421 HOMBURG,GERMANY; UNIV GOTTINGEN,INST BIOCHEM & MOL ZELLBIOL,D-37073 GOTTINGEN,GERMANY; UNIV ALBERTA,DEPT PLANT SCI,PLANT MOL GENET LAB,EDMONTON,AB T6G 2P5,CANADA	Saarland University; University of Gottingen; University of Alberta			Dierks, Thomas/A-3596-2012	Dierks, Thomas/0000-0001-6426-1339				BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BOSE S, 1994, BIOCHEM J, V300, P871, DOI 10.1042/bj3000871; BOSE S, 1994, BIOCHEM J, V300, P865, DOI 10.1042/bj3000865; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; COSTE J, 1990, TETRAHEDRON LETT, V31, P205, DOI 10.1016/S0040-4039(00)94371-5; DAVIS JM, 1989, J BIOL CHEM, V264, P8956; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ESCHER A, 1993, MOL GEN GENET, V238, P65, DOI 10.1007/BF00279532; ESCHER A, 1989, P NATL ACAD SCI USA, V86, P6528, DOI 10.1073/pnas.86.17.6528; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FLYNN GC, 1993, P NATL ACAD SCI USA, V90, P10826, DOI 10.1073/pnas.90.22.10826; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HELENIUS A, 1994, TRENDS BIOCHEM SCI, V19, P227; Higuchi R., 1989, PCR TECHNOLOGY, P61; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KLAPPA P, 1991, EMBO J, V10, P2795, DOI 10.1002/j.1460-2075.1991.tb07828.x; KRUSE M, 1995, J BIOL CHEM, V270, P2588, DOI 10.1074/jbc.270.6.2588; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LODISH HF, 1991, J BIOL CHEM, V266, P14835; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; OLSSON O, 1988, MOL GEN GENET, V215, P1, DOI 10.1007/BF00331295; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; Sambrook J., 2002, MOL CLONING LAB MANU; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLENSTEDT G, 1990, J BIOL CHEM, V265, P13960; SCHLENSTEDT G, 1992, J BIOL CHEM, V267, P24328; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; WADDLE JJ, 1987, BIOCHEMISTRY-US, V26, P4917, DOI 10.1021/bi00390a004; WATTS C, 1983, P NATL ACAD SCI-BIOL, V80, P2809, DOI 10.1073/pnas.80.10.2809; ZIEGLER MM, 1993, J BIOL CHEM, V268, P10760; [No title captured]	40	9	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23487	23494		10.1074/jbc.271.38.23487	http://dx.doi.org/10.1074/jbc.271.38.23487			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798557	hybrid			2022-12-27	WOS:A1996VH76800083
J	Charng, MJ; Kinnunen, P; Hawker, J; Brand, T; Schneider, MD				Charng, MJ; Kinnunen, P; Hawker, J; Brand, T; Schneider, MD			FKBP-12 recognition is dispensable for signal generation by type I transforming growth factor-beta receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; TGF-BETA; MESODERM INDUCTION; COMPLEX; EXPRESSION; CLONING; ACTIVIN; REQUIRES; DOMAINS; CELLS	The FK506-binding protein, FKBP12, is a putative target of type I receptors for transforming growth factor-beta (T beta R-I). As the FK506 motif that competes with T beta R-I for FKBP12 resembles an invariant Leu-Pro dipeptide in T beta R-I, we replaced Leu(193) and Pro(194) with Ala, along with mutations across the Gly/Ser box. L193A, P194A, and L193A/P194A do not alter T beta R-I function; T204D partially activates, independent of ligand; L193A/P194A/T204D was an even more potent constitutive mutation, Association with FKBP12 in a yeast two-hybrid assay was disrupted by P194A, L193A/P194A, and L193A/P194A/T204D, but not L193A or T204D alone. Thus, FKBP12 recognition is dispensable for TGF beta signaling.	BAYLOR COLL MED,MOL CARDIOL UNIT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PHYSIOL & MOL BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine			Brand, Thomas/AAR-7545-2020	Brand, Thomas/0000-0001-7090-5356	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047567, P01HL049953, R01HL052555] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL47567, P01 HL49953, R01 HL52555] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BRAND T, 1995, J BIOL CHEM, V270, P8274, DOI 10.1074/jbc.270.14.8274; BRAND T, 1993, J BIOL CHEM, V268, P11500; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CLARDY J, 1995, P NATL ACAD SCI USA, V92, P56, DOI 10.1073/pnas.92.1.56; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LABONNE C, 1994, DEVELOPMENT, V120, P463; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; STONE JM, 1994, SCIENCE, V266, P793, DOI 10.1126/science.7973632; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	26	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22941	22944		10.1074/jbc.271.38.22941	http://dx.doi.org/10.1074/jbc.271.38.22941			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798476				2022-12-27	WOS:A1996VH76800002
J	Orpiszewski, J; Aswad, DW				Orpiszewski, J; Aswad, DW			High mass methyl-accepting protein (HMAP), a highly effective endogenous substrate for protein L-isoaspartyl methyltransferase in mammalian brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTYL RESIDUES; CARBOXYL METHYLTRANSFERASE; O-METHYLTRANSFERASE; REPAIR; PEPTIDES; DEAMIDATION; POLYPEPTIDES; ERYTHROCYTE; RECOGNITION; CONVERSION	A previously unidentified endogenous substrate for protein L-isoaspartyl methyltransferase in mammalian brain has been characterized and partially purified. This high mass methyl-accepting protein (HMAP) is concentrated in rat brain cytosol and is not detectable in rat liver, heart, lung, kidney, or skeletal muscle, HMAP is acidic and heterogeneous in size, with an average mass, as judged by size exclusion high performance liquid chromatography, greater than 700 kDa, After partial purification from cow brain by anion-exchange chromatography, ammonium sulfate fractionation, and gel filtration, HMAP could accept 12.1 nmol of methyl groups per mg of protein, suggesting that it contains a level of isoaspartate at least 50 times greater than that of the average protein in brain cytosol. Partially purified HMAP is degraded by trypsin, verifying that it is composed, at least in part, of protein. Additional studies on this unusual macromolecule may shed important new light on mechanisms of isoaspartate formation in cells and the molecular pathology of brain aging.	UNIV CALIF IRVINE,DEPT BIOCHEM & MOL BIOL,IRVINE,CA 92697	University of California System; University of California Irvine					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017269] Funding Source: NIH RePORTER; NINDS NIH HHS [NS17269] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRENNAN TV, 1994, J BIOL CHEM, V269, P24586; BRENNAN TV, 1995, DEAMIDATION ISOASPAR, P65; DAVID CL, 1995, PROTEIN EXPRES PURIF, V6, P312, DOI 10.1006/prep.1995.1041; DILIBERTO EJ, 1976, J NEUROCHEM, V26, P1159, DOI 10.1111/j.1471-4159.1976.tb07001.x; FAIRBANKS G, 1972, Journal of Supramolecular Structure, V1, P66, DOI 10.1002/jss.400010110; GALLETTI P, 1995, BIOCHEM J, V306, P313, DOI 10.1042/bj3060313; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; GEIGER T, 1987, J BIOL CHEM, V262, P785; JOHNSON BA, 1991, BIOCHEM INT, V24, P841; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1993, NEUROCHEM RES, V18, P87, DOI 10.1007/BF00966926; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1991, ANAL BIOCHEM, V192, P384, DOI 10.1016/0003-2697(91)90553-6; JOHNSON BA, 1995, DEAMIDATION ISOASPAR, P91; JONES AJ, 1983, BIOCHEM J, V211, P499, DOI 10.1042/bj2110499; KIM S, 1971, BIOCHIM BIOPHYS ACTA, V252, P526, DOI 10.1016/0304-4165(71)90155-3; LADINO CA, 1992, J CELL PHYSIOL, V153, P297, DOI 10.1002/jcp.1041530209; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; Najbauer J, 1996, BIOCHEMISTRY-US, V35, P5183, DOI 10.1021/bi953063g; OCONNOR CM, 1985, BIOCHEM BIOPH RES CO, V132, P1144, DOI 10.1016/0006-291X(85)91926-6; PARANANDI MV, 1994, J BIOL CHEM, V269, P243; Robinson A B, 1974, Curr Top Cell Regul, V8, P247; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072	26	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22965	22968		10.1074/jbc.271.38.22965	http://dx.doi.org/10.1074/jbc.271.38.22965			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798482	hybrid			2022-12-27	WOS:A1996VH76800008
J	Raussens, V; Narayanaswami, V; Goormaghtigh, E; Ryan, RO; Ruysschaert, JM				Raussens, V; Narayanaswami, V; Goormaghtigh, E; Ryan, RO; Ruysschaert, JM			Hydrogen/deuterium exchange kinetics of apolipophorin-III in lipid-free and phospholipid-bound states - An analysis by Fourier transform infrared spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-EXCHANGE; CYTOCHROME-C; MANDUCA-SEXTA; LOCUSTA-MIGRATORIA; INTEGRAL-EQUATIONS; ALPHA-HELICES; APOLIPOPROTEIN; BINDING; STABILITY; PROTEINS	Attenuated total reflection Fourier transform infrared spectroscopy was used to probe the kinetics of hydrogen/deuterium exchange in Manduca sexta apolipophorin-III (apoLp-III), ApoLp-III is an exchangeable apolipoprotein that is made up of five elongated amphipathic alpha-helices in a helical bundle conformation in the monomeric lipid-free form, Upon interaction with phospholipids, it is postulated to undergo a large con formational change whereby the hydrophobic interior is exposed, facilitating binding to the lipid surfaces, We have used the lipid-free and dimyristoylphosphatidylcholine-bound apoLp-III to study the dynamically variable domains in the two forms, Three populations of amide protons varying in their hydrogen/deuterium exchange rates were found to exist: slow, intermediate, and fast exchanging, which could correspond to completely buried, partially buried, and solvent-exposed domains on the protein in both the states. In lipid free apoLp-III, 36, 12, and 52% of the total residues contributed to the slow, intermediate, and fast exchanging populations, respectively, In the dimyristoylphosphatidylcholine-bound form, the corresponding distribution was 20, 16, and 64%, representing a 12% increase in the number of exposed residues. The results are discussed in terms of increased solvent accessibility due to gross tertiary structural reorganization.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2S2,CANADA	University of Alberta	Raussens, V (corresponding author), FREE UNIV BRUSSELS,CHIM PHYS MACROMOL INTERFACES LAB,CP 206-2,B-1050 BRUSSELS,BELGIUM.			Goormaghtigh, Erik/0000-0002-2071-2262; Narayanaswami, Vasanthy/0000-0001-7088-4057				AMELOOT M, 1992, METHOD ENZYMOL, V210, P279; BLACKLOCK BJ, 1994, INSECT BIOCHEM MOLEC, V24, P855, DOI 10.1016/0965-1748(94)90015-9; BLUNDELL T, 1983, NATURE, V306, P281, DOI 10.1038/306281a0; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; COLE KD, 1987, J BIOL CHEM, V262, P11794; DEJONGH HHJ, 1995, BIOCHEMISTRY-US, V34, P172, DOI 10.1021/bi00001a021; DEJONGH HHJ, 1992, BIOCHEMISTRY-US, V31, P1636, DOI 10.1021/bi00121a008; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; GOORMAGHTIGH E, 1994, SPECTROCHIM ACTA A, V50, P2137; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GOORMAGHTIGH E, 1990, MOL DESCRIPTION BIOL, P285; GREGORY RB, 1985, BIOPOLYMERS, V24, P301, DOI 10.1002/bip.360240203; HALVORSON HR, 1992, METHOD ENZYMOL, V210, P54; Harrick N.J., 1967, INTERNAL REFLECTION; HEIMBURG T, 1993, BIOPHYS J, V65, P2408, DOI 10.1016/S0006-3495(93)81299-2; HOLDEN HM, 1988, J BIOL CHEM, V263, P3960; KAWOOYA JK, 1986, J BIOL CHEM, V261, P3588; KIM KS, 1993, BIOCHEMISTRY-US, V32, P9600, DOI 10.1021/bi00088a012; Kim P S, 1986, Methods Enzymol, V131, P136; KNOX DG, 1980, BIOPOLYMERS, V19, P1049, DOI 10.1002/bip.1980.360190509; LUMRY R, 1995, PROTEIN SOLVENT INTE, P1; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; NARAYANASWAMI V, 1994, BIOCHEMISTRY-US, V33, P13312, DOI 10.1021/bi00249a018; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PROVENCHER SW, 1976, BIOPHYS J, V16, P27, DOI 10.1016/S0006-3495(76)85660-3; PROVENCHER SW, 1979, J BIOCHEM BIOPH METH, V1, P313, DOI 10.1016/0165-022X(79)90021-6; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; RAUSSENS V, 1995, J BIOL CHEM, V270, P12542, DOI 10.1074/jbc.270.21.12542; RIFICI VA, 1985, BIOCHIM BIOPHYS ACTA, V834, P205, DOI 10.1016/0005-2760(85)90157-2; RYAN RO, 1993, J BIOL CHEM, V268, P1525; SPOONER PJR, 1991, BIOCHEMISTRY-US, V30, P3871, DOI 10.1021/bi00230a010; SWANEY JB, 1980, J BIOL CHEM, V255, P877; WEERS PMM, 1994, BIOCHEMISTRY-US, V33, P3617, DOI 10.1021/bi00178a019; WELLS MA, 1985, INSECT BIOCHEM, V15, P565, DOI 10.1016/0020-1790(85)90116-7; WIENTZEK M, 1994, J BIOL CHEM, V269, P4605; ZHOU NE, 1992, J AM CHEM SOC, V114, P4320, DOI 10.1021/ja00037a042	36	55	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23089	23095		10.1074/jbc.271.38.23089	http://dx.doi.org/10.1074/jbc.271.38.23089			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798499	hybrid			2022-12-27	WOS:A1996VH76800025
J	Zhu, XR; Lamango, NS; Lindberg, I				Zhu, XR; Lamango, NS; Lindberg, I			Involvement of a polyproline helix-like structure in the interaction of 7B2 with prohormone convertase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH PEPTIDES; SH3 DOMAINS; NEUROENDOCRINE CHAPERONE; TYROSINE KINASE; BINDING; PC2; POLYPEPTIDE; PROTEINS; FAMILY; CELLS	The neuroendocrine protein 7B2 is known to be involved in the biosynthesis and activity of prohormone convertase 2 (PC2). Previous studies have demonstrated that while the carboxyl-terminal portion of 7B2 (residues 155-186) regulates the enzymatic activity of PC2, the amino terminus of the molecule (residues 1-151) is required for maturation of proPC2. In this study we employed four different experimental approaches (co-immunoprecipitation with proPC2, facilitation of proPC2 maturation, acquisition of enzymatic activity, and thermal protection assays) to identify structural elements of 7B2 important for bioactivity. Inspection of the sequence of 7B2 indicated potential involvement of a polyproline helix-like (PPII) structure, with similarities to those present within SH3 domain ligands, in the interaction of 7B2 with proPC2. Site-directed point mutagenesis of this proline-rich region confirmed the involvement of this area. Replacement of prolines in positions critical to helix formation (Pro(90), Pro(91), Pro(93), and Pro(95)) either severely impaired or totally abolished 7B2 bioactivity, as gauged by the four assays described. In addition, constructs longer than residues 1-121 were still functional, whereas those shorter than residues 1-109 were not. Computer-assisted analysis predicts the presence of an alpha-helix structure between residues 107 and 123. We conclude that both the proline-rich region and the alpha-helix contribute to 7B2 activity. Polyproline-containing peptides have been shown to be involved in cytoplasmic protein-protein interactions; our results suggest that the polyproline helix motif may also be used to mediate protein-protein interactions within the secretory pathway.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM & MOL BIOL, NEW ORLEANS, LA 70112 USA	Louisiana State University System			Lindberg, Iris/Q-3825-2019; Lamango, Nazarius/W-8459-2019		NIDA NIH HHS [DA05084, R56 DA005084] Funding Source: Medline; NIDDK NIH HHS [R01 DK049703] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005084, R56DA005084] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; AYOUBI TAY, 1990, J BIOL CHEM, V265, P15644; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BRAKS JAM, 1995, FEBS LETT, V371, P154, DOI 10.1016/0014-5793(95)00915-V; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; CEDERGRENZEPPEZ.ES, 1994, EMBO J, V13, P2341; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HSI KL, 1982, FEBS LETT, V147, P261, DOI 10.1016/0014-5793(82)81055-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Lamango NS, 1996, ARCH BIOCHEM BIOPHYS, V330, P238, DOI 10.1006/abbi.1996.0249; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SHEN FS, 1993, J BIOL CHEM, V268, P24910; VANHORSSEN AM, 1995, J BIOL CHEM, V270, P14292; WALDBIESER GC, 1991, ENDOCRINOLOGY, V128, P3228, DOI 10.1210/endo-128-6-3228; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU A, 1994, J BIOL CHEM, V269, P17440; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	30	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23582	23587		10.1074/jbc.271.38.23582	http://dx.doi.org/10.1074/jbc.271.38.23582			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798569	hybrid			2022-12-27	WOS:A1996VH76800095
J	Gregoire, CJ; Loret, EP				Gregoire, CJ; Loret, EP			Conformational heterogeneity in two regions of TAT results in structural variations of this protein as a function of HIV-1 isolates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 TAT; CIRCULAR-DICHROISM; TRANS-ACTIVATOR; SECONDARY STRUCTURE; RNA RECOGNITION; BINDING; TRANSACTIVATION; INVITRO; COMPLEX; INDUCTION	TAT protein is an essential regulatory protein of the human immunodeficiency virus type 1 (HIV-1). Inhibition of TAT activity blocks the virus cycle, and a drug that blocks TAT is one of the possibilities to cure AIDS. Circular dichroism (CD) was measured for TAT peptides covering the TAT sequence with overlaps. The CD spectrum of each peptide was measured in different solvents to evaluate the ability of each TAT region to form different secondary structures, The most variation or conformational heterogeneity is observed with the two regions adjacent to the TAT basic region. CD data show that the basic region can adopt an extended structure in a full TAT protein, which is not the case for the isolated peptide, TAT sequences from the different HIV-1 isolates were analyzed, and the results showed that the sequences could be gathered into six groups. Molecular modeling was done on the various isolates based on a TAT structure from two-dimensional NMR. After minimization and dynamic steps, the modeled three dimensional structures were compared. The results showed structural variations of the TAT protein as a function of the HIV-1 isolates, These structural variations were mainly in the two regions adjacent to the basic region, confirming the conformational heterogeneity indicated by the CD measurements. Furthermore, Chou-Fasman analysis shows significant changes in propensities for each secondary structure only for regions III and V, This conformational heterogeneity should be essential for TAT activity and points out that regions III and V are a poor potential target to design a TAT ligand. We propose a target involving TAT structurally conserved regions, accessible whatever the size of the TAT C terminus.	CNRS,UPR 9027,LAB INGN & DYNAM SYST MEMBRANAIRES,INST BIOL STRUCT & MICROBIOL,F-13402 MARSEILLE 20,FRANCE	Centre National de la Recherche Scientifique (CNRS)								ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BAYER P, 1995, J MOL BIOL, V247, P529, DOI 10.1016/S0022-2836(05)80133-0; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN JB, 1991, GENE DEV, V5, P210; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CORPET F, 1989, NUCLEIC ACIDS RES, V22, P10881; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; HOWCROFT TK, 1993, SCIENCE, V260, P1320, DOI 10.1126/science.8493575; JOHNSON WC, 1985, METHOD BIOCHEM ANAL, V31, P61, DOI 10.1002/9780470110522.ch2; JONES AK, 1994, ANNREV BIOCH, V63, P717; KAMINE J, 1991, VIROLOGY, V182, P570, DOI 10.1016/0042-6822(91)90598-6; KOKEN SEC, 1994, J BIOL CHEM, V269, P8366; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LORET EP, 1991, BIOCHEMISTRY-US, V30, P6013, DOI 10.1021/bi00238a027; LORET EP, 1992, P NATL ACAD SCI USA, V89, P9734, DOI 10.1073/pnas.89.20.9734; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MATHEWS CK, 1990, BIOCHEMISTRY-US, P176; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; MUJEEB A, 1994, P NATL ACAD SCI USA, V91, P8248, DOI 10.1073/pnas.91.17.8248; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; RAPPAPORT J, 1989, New Biologist, V1, P101; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; SANGER F, 1963, BIOCHIM BIOPHYS ACTA, V71, P468, DOI 10.1016/0006-3002(63)91108-9; WATERHOUS DV, 1994, BIOCHEMISTRY-US, V33, P2121, DOI 10.1021/bi00174a019; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x	40	30	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22641	22646		10.1074/jbc.271.37.22641	http://dx.doi.org/10.1074/jbc.271.37.22641			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798435	hybrid			2022-12-27	WOS:A1996VG67200054
J	Hill, JR; Corbett, JA; Kwon, G; Marshall, CA; McDaniel, ML				Hill, JR; Corbett, JA; Kwon, G; Marshall, CA; McDaniel, ML			Nitric oxide regulates interleukin 1 bioactivity released from murine macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR ANTAGONIST; IL-1-BETA; INHIBITION; BINDING; ALPHA; IDENTIFICATION; THIOREDOXIN; IL-1-ALPHA; SUPEROXIDE; APOPTOSIS	The bioactivity of interleukin-1 (IL-1), a major proinflammatory cytokine, can be modulated by a variety of factors including inhibitors of IL-1 production and release and receptor blockade by IL-1 receptor antagonist and by binding to nonsignaling soluble receptors. This study demonstrates that the free radical nitric oxide (NO) is also a regulator of IL-1 bioactivity. Lipopolysaccharide-activated murine macrophage RAW264.7 cells, and lipopolysaccharide plus interferon-gamma-activated murine peritoneal macrophages release IL-1 bioactivity, which is increased 10-fold over control levels by 24 h. N-G-Monomethyl L-arginine (NMMA), a nitric oxide synthase (NOS) inhibitor, almost completely inhibits the release of IL-1 bioactivity from activated macrophages in a time- and concentration-dependent manner with an IC50 of 50 mu M. IL-1 activity was determined by thymocyte proliferation bioassay and by a new spectrophotometric bioassay based on TL-1-specific induction of NOS and NO production by an insulinoma cell Line, RnNm5F. Neither NO nor NOS inhibitors present in the macrophage supernatant interfere with the bioassays. Aminoguanidine and iodonium diphenyl, mechanistically unrelated NOS inhibitors, also prevent the release of IL-1 activity hom RAW 264.7 cells. The addition of the NO donor S-nitrosoacetylpenicillamine reconstituted the release of IL-1 bioactivity inhibited by NMMA in a concentration-dependent manner. NO appears to increase the amount of IL-1 protein released by activated macrophages as determined by enzyme-linked immunosorbent assay, but not by mechanisms involving cell death nor modification of IL-1 precursor processing. A cGMP donor, 8-bromo-cGMP, dose-dependently reverses NMMA inhibition of bioactive IL-1 release, suggesting that NO regulates IL-1 release by a cGMP-dependent mechanism, These observations suggest that NO stimulation of the activity of IL-1, a key mediator of the immune response, may be a potentially important mechanism for control of IL-1 activity in vivo.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; ST LOUIS UNIV,DEPT BIOCHEM,ST LOUIS,MO 63104	Washington University (WUSTL); Saint Louis University					NIDDK NIH HHS [F32 DK-08748, DK-06181] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008748, R56DK006181, R01DK006181] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGGARD E, 1994, LANCET, V343, P1199, DOI 10.1016/S0140-6736(94)92405-8; AREND WP, 1994, J IMMUNOL, V153, P4766; AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065-2776(08)60535-0; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BORTH W, 1990, J IMMUNOL, V145, P3747; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; DINARELLO CA, 1993, TRENDS PHARMACOL SCI, V14, P155, DOI 10.1016/0165-6147(93)90200-4; ESTRADA C, 1992, BIOCHEM BIOPH RES CO, V186, P475, DOI 10.1016/S0006-291X(05)80832-0; Ferreira S H, 1993, Drugs, V46 Suppl 1, P1; GEARING AJH, 1985, J IMMUNOL METHODS, V83, P1, DOI 10.1016/0022-1759(85)90053-5; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hill JR, 1996, ANAL BIOCHEM, V236, P14, DOI 10.1006/abio.1996.0125; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; JESSOP JJ, 1993, LYMPHOKINE CYTOK RES, V12, P51; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; LANCASTER JR, 1992, AM SCI, V80, P248; MICHETTIM, 1995, BIOCHEM BIOPH RES CO, V207, P1009; MILLER DK, 1993, ANN NY ACAD SCI, V696, P133; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUEGGE K, 1991, MEASUREMENT SOLUBLE, V1; Murad F, 1994, Adv Pharmacol, V26, P19, DOI 10.1016/S1054-3589(08)60049-6; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; REMVIG L, 1993, DAN MED BULL, V40, P255; RUBARTELLI A, 1991, BIOCHEM SOC T, V19, P255, DOI 10.1042/bst0190255; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SHEFFLER LA, 1995, J IMMUNOL, V155, P886; SIDERS WM, 1993, J BIOL CHEM, V268, P22170; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; TEODORESCU M, 1991, MOL IMMUNOL, V28, P323, DOI 10.1016/0161-5890(91)90144-9; WILLIAMS DLH, 1985, CHEM SOC REV, V14, P171, DOI 10.1039/cs9851400171; ZYCHLINSKY A, 1994, J CLIN INVEST, V94, P1328, DOI 10.1172/JCI117452	39	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22672	22678		10.1074/jbc.271.37.22672	http://dx.doi.org/10.1074/jbc.271.37.22672			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798439	hybrid			2022-12-27	WOS:A1996VG67200058
J	Lenting, PJ; Christophe, OD; terMaat, H; Rees, DJG; Mertens, K				Lenting, PJ; Christophe, OD; terMaat, H; Rees, DJG; Mertens, K			Ca2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-LIKE DOMAIN; PLASMA THROMBOPLASTIN ANTECEDENT; GAMMA-CARBOXYGLUTAMIC ACID; FACTOR-LIKE MODULES; BOVINE FACTOR-IX; FACTOR-X; CALCIUM-BINDING; CHRISTMAS FACTOR; MARFAN-SYNDROME; CA-2+ BINDING	Ca2+ binding to the first epidermal growth factor (EGF)-like domain of factor IX is known to be required for biological activity, but the mechanism by which Ca2+ contributes to factor IX function has remained unclear, We have studied recombinant factor IX mutants which lack Ca2+ binding to the first EGF-like domain, due to a replacement of Asp(64) by Glu, Lys, or Val, The purified mutants (factors IX D64E, D64K, and D64V), were compared to plasma-derived and recombinant wild-type factor IX with regard to a number of metal-ion dependent functional parameters, In the presence of Mg2+, the activated mutants were indistinguishable from normal factor IXa in hydrolyzing the synthetic substrate CH3-SO2-Leu-Gly-Arg-p-nitroanilide. Replacing Mg2+ by Ca2+ further stimulated the activity of normal factor IXa but not of mutant factor IXa, In factor Vm-independent factor X activation, factor IXa D64K and D64E displayed reduced catalytic activity compared to normal factor IXa (apparent k(cat)/K-m approximate to 1, 2, and 4 x 10(3) M(-1) s(-1), respectively), In the presence of factor VIIIa, factor X activation rates by normal and mutant factor IXa were stimulated by factor VIIIa to a different extent (approximate to 700- and 200-fold, respectively), indicating that Asp(64) replacements affect the interaction with factor VIIIa, This possibility was addressed in inhibition studies employing synthetic peptides comprising the factor IXa-binding motifs of factor VIII heavy or light chains, Whereas the heavy chain peptide (Ser(558)-Gln(565)) inhibited factor VIII-dependent factor X activation by normal and mutant factor IXa with similar efficiency, the light chain peptide (Lys(1804)-Lys(1818)) inhibited normal factor 1Xa 2-3-fold more efficiently than did mutant factor VIIIa, This indicates that the reduced response to factor VIIIa may be due to impaired binding of mutant factor IXa to the factor VIII light chain. This was further explored in direct binding studies, In the presence of Mg2+, normal and mutant factor IXa were similar in binding to the factor VIII light chain. However, in the presence of Ca2+, factor IXa mutants were less efficient than normal factor IXa, which was illustrated by a 4-5-fold lower affinity than normal factor IXa for factor VIII light chain, Collectively, our data demonstrate that a number of factor IXa functions, including enzymatic activity and assembly into the factor IXa-factor VIIIa complex, are dependent on Ca2+ binding to the first EGF-like domain of factor IX.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CENT LAB, DEPT PLASMA PROT TECHNOL, NL-1066 CX AMSTERDAM, NETHERLANDS; UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, OXFORD OX1 3RE, ENGLAND	University of Oxford			Lenting, Peter/AAH-5663-2019; Lenting, Peter/F-8269-2013; Rees, Jasper/D-9672-2011; christophe, olivier/W-4268-2017	Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429; Rees, Jasper/0000-0003-3321-1325; christophe, olivier/0000-0002-9080-6336				AHMAD SS, 1992, J BIOL CHEM, V267, P8571; AHMAD SS, 1990, J BIOL CHEM, V265, P20907; AMPLETT GW, 1981, ARCH BIOCHEM BIOPHYS, V208, P576; ANSON DS, 1984, EMBO J, V3, P1053, DOI 10.1002/j.1460-2075.1984.tb01926.x; ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; ASTERMARK J, 1994, J BIOL CHEM, V269, P3690; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BAJAJ SP, 1982, J BIOL CHEM, V257, P4127; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRNE R, 1980, J BIOL CHEM, V255, P5336; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; DISCIPIO RG, 1979, BIOCHEMISTRY-US, V18, P899, DOI 10.1021/bi00572a026; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DONATH MJSH, 1995, J BIOL CHEM, V270, P3648, DOI 10.1074/jbc.270.8.3648; FAY PJ, 1994, J BIOL CHEM, V269, P20522; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GIANNELLI F, 1994, NUCLEIC ACIDS RES, V22, P3534, DOI 10.1093/nar/22.17.3534; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HEWETT DR, 1993, HUM MOL GENET, V2, P475, DOI 10.1093/hmg/2.4.475; HUGHES PE, 1994, PROTEIN ENG, V7, P1121, DOI 10.1093/protein/7.9.1121; HUGHES PE, 1993, J BIOL CHEM, V268, P17727; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; LENTING PJ, 1995, J BIOL CHEM, V270, P14884, DOI 10.1074/jbc.270.25.14884; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LENTING PJ, 1996, J BIOL CHEM, V271, P1835; LIN SW, 1990, J BIOL CHEM, V265, P144; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; MANN KG, 1990, BLOOD, V76, P1; MERTENS K, 1982, THROMB HAEMOSTASIS, V47, P96; MERTENS K, 1980, BIOCHEM J, V185, P647, DOI 10.1042/bj1850647; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1084, DOI 10.1177/22.12.1084; OBRIEN DP, 1994, BIOCHEMISTRY-US, V33, P14162, DOI 10.1021/bi00251a027; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; REES DJG, 1986, THESIS U OXFORD; ROBERTS HR, 1993, THROMB HAEMOSTASIS, V70, P1; SADLER JE, 1987, MOL BASIS BLOOD DISE, P575; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; STENFLO J, 1991, BLOOD, V78, P1637; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VELTKAMP JJ, 1968, THROMB DIATH HAEMOST, V19, P279, DOI 10.1055/s-0038-1651206	48	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25332	25337		10.1074/jbc.271.41.25332	http://dx.doi.org/10.1074/jbc.271.41.25332			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810297	hybrid			2022-12-27	WOS:A1996VL69300041
J	MacDonald, NJ; Freije, JMP; Stracke, ML; Manrow, RE; Steeg, PS				MacDonald, NJ; Freije, JMP; Stracke, ML; Manrow, RE; Steeg, PS			Site-directed mutagenesis of nm23-H1 - Mutation of proline 96 or serine 120 abrogates its motility inhibitory activity upon transfection into human breast carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE-DIPHOSPHATE KINASE; X-RAY STRUCTURE; MYXOCOCCUS-XANTHUS; CRYSTAL-STRUCTURE; TUMOR-METASTASIS; HEPATOCELLULAR-CARCINOMA; PROTEIN EXPRESSION; DICTYOSTELIUM-DISCOIDEUM; DROSOPHILA DEVELOPMENT; STIMULATING PROTEIN	We report the first correlation of Nm23 sequence and its tumor metastasis-suppressive capacity using site-directed mutagenesis and an in vitro tumor cell motility assay. MDA-MB-435 human breast carcinoma cells were transfected with a control expression vector (pCMVB-amneo), the vector containing the wild type nm23-H1, or the nm23-H1 vector encoding mutations at the following amino acids: serine 44, a phosphorylation site; proline 96, the k-pn mutation in the Drosophila nm23 homolog that causes developmental defects; histidine 118, involved in Nm23's nucleoside diphosphate kinase activity; and serine 120, a site of mutation in human neuroblastomas and phosphorylation. The wild type nm23-H1 transfectants were 44-98% less motile to serum and 86-99% less motile to autotaxin than control vector transfectants. The proline 96 k-pn, serine 120 to glycine, and to a lesser extent serine 120 to alanine mutant nm23-H1-transfected cell lines exhibited motility levels at or above the control transfectants, indicating that these mutations can abrogate the motility-suppressive phenotype of nm23-H1. No effect was observed on cellular proliferation, nor were the serine 44 to alanine nm23-H1 mutant transfectants motile, demonstrating the specificity of the data. The data identify the first structural motifs of nm23-H1 that influence its metastasis suppressive effect and suggest complex biochemical associations or activities in the Nm23 suppressive pathway.	NCI,WOMENS CANC SECT,PATHOL LAB,DIV CLIN SCI,NIH,BETHESDA,MD 20892; NCI,TUMOR INVAS & METASTASIS SECT,PATHOL LAB,DIV CLIN SCI,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Freije, José M.P./A-6535-2008	Freije, José M.P./0000-0002-4688-8266				BABA H, 1995, CANCER RES, V55, P1977; BARNES R, 1991, AM J PATHOL, V139, P245; BERG P, 1953, NATURE, V172, P1008, DOI 10.1038/1721008a0; BERGER SL, 1993, ANAL BIOCHEM, V214, P571, DOI 10.1006/abio.1993.1540; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOIX L, 1994, GASTROENTEROLOGY, V107, P486, DOI 10.1016/0016-5085(94)90175-9; BOMINAAR AA, 1994, FEBS LETT, V353, P5, DOI 10.1016/0014-5793(94)00997-X; Boyden S, 1962, J EXP MED, V115, P435; CALIGO MA, 1992, ANTICANCER RES, V12, P969; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; CHERFILS J, 1994, BIOCHEMISTRY-US, V33, P9062, DOI 10.1021/bi00197a006; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; CROPP CS, 1994, JNCI-J NATL CANCER I, V86, P1167, DOI 10.1093/jnci/86.15.1167; DEAROLF CR, 1988, DEV BIOL, V129, P169, DOI 10.1016/0012-1606(88)90171-6; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; FLORENES VA, 1992, CANCER RES, V52, P6088; FREIJE JMP, 1996, ATTEMPTS UNDERSTAND, P215; Fukuda M, 1996, INT J CANCER, V65, P531, DOI 10.1002/(SICI)1097-0215(19960208)65:4<531::AID-IJC23>3.0.CO;2-B; GOLDEN A, 1993, NUCLEOSIDE DIPHOSPHA; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4580, DOI 10.1021/bi00134a007; HENNESSY C, 1991, J NATL CANCER I, V83, P281, DOI 10.1093/jnci/83.4.281; HILDEBRANDT M, 1995, NUCLEIC ACIDS RES, V23, P3858, DOI 10.1093/nar/23.19.3858; HIRAYAMA R, 1991, J NATL CANCER I, V83, P1249, DOI 10.1093/jnci/83.17.1249; HOWLETT AR, 1994, J NATL CANCER I, V86, P1838, DOI 10.1093/jnci/86.24.1838; ILIJAS M, 1994, INT J ONCOL, V5, P1455; KANTOR JD, 1993, CANCER RES, V53, P1971; KAPITANOVIC S, 1995, ANTICANCER RES, V15, P587; KIMURA N, 1990, J BIOL CHEM, V265, P15744; KODERA Y, 1994, CANCER, V73, P259, DOI 10.1002/1097-0142(19940115)73:2<259::AID-CNCR2820730205>3.0.CO;2-V; KREBS HA, 1953, BIOCHIM BIOPHYS ACTA, V12, P172, DOI 10.1016/0006-3002(53)90136-X; LAKSHMI MS, 1993, ANTICANCER RES, V13, P299; LASCU I, 1993, J BIOL CHEM, V268, P20268; LASCU I, 1992, J BIOL CHEM, V267, P12775; Lee HY, 1996, BIOCHEM BIOPH RES CO, V218, P714, DOI 10.1006/bbrc.1996.0127; LEONE A, 1993, ONCOGENE, V8, P2325; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MANDAI M, 1995, CANCER, V75, P2523, DOI 10.1002/1097-0142(19950515)75:10<2523::AID-CNCR2820751019>3.0.CO;2-L; MANDAI M, 1994, CANCER RES, V54, P1825; MUNOZDORADO J, 1993, J BACTERIOL, V175, P1176; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2707; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; MURATA J, 1994, J BIOL CHEM, V269, P30479; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; PARHAR RS, 1995, INT J CANCER, V60, P204; PARKS RE, 1973, NUCLEOSIDE DIPHOSPHO; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; PRICE JE, 1990, CANCER RES, V50, P717; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; ROYDS JA, 1993, J NATL CANCER I, V85, P727, DOI 10.1093/jnci/85.9.727; Scambia G, 1996, J CLIN ONCOL, V14, P334, DOI 10.1200/JCO.1996.14.2.334; SHANKAR S, 1995, J BIOL CHEM, V270, P28246; SHIMADA N, 1993, J BIOL CHEM, V268, P2583; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; STRELKOV SV, 1995, J MOL BIOL, V249, P665, DOI 10.1006/jmbi.1995.0327; SU ZZ, 1993, ONCOGENE, V8, P1211; TEPPER AD, 1994, J BIOL CHEM, V269, P32175; TOKUNAGA Y, 1993, INT J CANCER, V55, P66, DOI 10.1002/ijc.2910550113; TROLL H, 1993, J BIOL CHEM, V268, P25469; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; WEBB PA, 1995, J MOL BIOL, V251, P574, DOI 10.1006/jmbi.1995.0457; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673; XU J, 1996, IN PRESS DEV BIOL; YAMAGUCHI A, 1994, CANCER, V73, P2280, DOI 10.1002/1097-0142(19940501)73:9<2280::AID-CNCR2820730908>3.0.CO;2-3	75	115	119	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25107	25116		10.1074/jbc.271.41.25107	http://dx.doi.org/10.1074/jbc.271.41.25107			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810265	hybrid			2022-12-27	WOS:A1996VL69300009
J	Amillet, JM; Buisson, N; LabbeBois, R				Amillet, JM; Buisson, N; LabbeBois, R			Characterization of an upstream activation sequence and two Rox1p-responsive sites controlling the induction of the yeast HEM13 gene by oxygen and heme deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; COPROPORPHYRINOGEN OXIDASE; HYPOXIC GENES; DNA-BINDING; TRANSCRIPTIONAL REGULATION; EXPRESSION; ELEMENTS; REPRESSOR; ROX1	The Saccharomyces cerevisiae HEM13 gene codes for coproporphyrinogen oxidase, an oxygen-requiring enzyme catalyzing the sixth step of heme biosynthesis, Its transcription has been shown to be induced 40-50-fold in response to oxygen or heme deficiency, in part through relief of repression exerted by Rox1p and in part by activation mediated by an upstream activation sequence (UAS), This report describes an analysis of HEM13 UAS and of the Rox1p-responsive sites by electrophoretic mobility shift assays, DNase I footprinting, and mutational mapping, HEM13 UAS is composed of two subelements: a 16-base pair sequence binding a constitutive factor acting as a transcriptional activator, and a 5'-flanking 20-base pair GC-rich region. Both subelements were required additively for transcription, but each element alone was sufficient for almost normal control by oxygen/heme deficiency, Mutations in both elements decreased the induction ratio 3-4-fold. HEM13 UAS conferred a 2-4-fold oxygen/heme control on a heterologous reporter gene, Two Rox1p-responsive sites, R1 and R3, were identified, which accounted for the 6-7-fold repression by Rox1p, A factor bound to a sequence close to site R3, This DNA-binding activity was only detected in protein extracts of aerobic heme-sufficient ROX1 TUP1 cells, suggesting a possible role in site R3 function.	UNIV PARIS 07,INST JACQUES MONOD,LAB BIOCHIM PORPHYRINES,F-75251 PARIS,FRANCE	UDICE-French Research Universities; Universite Paris Cite								AMILLET JM, 1995, CURR GENET, V28, P503, DOI 10.1007/BF00518161; ARCANGIOLI B, 1985, EMBO J, V4, P2627, DOI 10.1002/j.1460-2075.1985.tb03980.x; BALASUBRAMANIAN B, 1993, MOL CELL BIOL, V13, P6071, DOI 10.1128/MCB.13.10.6071; BRUKNER I, 1994, J MOL BIOL, V236, P26, DOI 10.1006/jmbi.1994.1115; CHOW CS, 1994, BIOCHEMISTRY-US, V33, P15124, DOI 10.1021/bi00254a023; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; DECKERT J, 1995, MOL CELL BIOL, V15, P6109; DECKERT J, 1995, GENETICS, V139, P1149; Donzeau M, 1996, MOL MICROBIOL, V20, P449, DOI 10.1111/j.1365-2958.1996.tb02631.x; FYTLOVICH S, 1993, EMBO J, V12, P1209, DOI 10.1002/j.1460-2075.1993.tb05762.x; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GILLESGONZALEZ MA, 1995, BIOCHEMISTRY-US, V34, P232, DOI 10.1021/bi00001a027; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; GUEST JR, 1992, J GEN MICROBIOL, V138, P2253, DOI 10.1099/00221287-138-11-2253; HODGE MR, 1990, MOL CELL BIOL, V10, P5510, DOI 10.1128/MCB.10.10.5510; HODGE MR, 1989, MOL CELL BIOL, V9, P1958, DOI 10.1128/MCB.9.5.1958; IUCHI S, 1993, J BIOL CHEM, V268, P23972; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; KENG T, 1992, MOL CELL BIOL, V12, P2616, DOI 10.1128/MCB.12.6.2616; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; Labbe-Bois R, 1990, BIOSYNTHESIS HEME CH, P235; LAMBERT JR, 1994, P NATL ACAD SCI USA, V91, P7345, DOI 10.1073/pnas.91.15.7345; LIN ECC, 1991, ANNU REV GENET, V25, P361, DOI 10.1146/annurev.ge.25.120191.002045; LOWRY CV, 1990, MOL CELL BIOL, V10, P5921, DOI 10.1128/MCB.10.11.5921; MALININA L, 1994, J MOL BIOL, V243, P484, DOI 10.1006/jmbi.1994.1674; MEHTA KD, 1989, J BIOL CHEM, V264, P8670; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; PFEIFER K, 1987, CELL, V49, P9, DOI 10.1016/0092-8674(87)90750-1; Pinkham Jennifer L., 1994, V11, P455; Rose MD., 1990, METHODS YEAST GENETI; SABOVA L, 1993, EUR J BIOCHEM, V213, P547, DOI 10.1111/j.1432-1033.1993.tb17793.x; Sambrook J., 2002, MOL CLONING LAB MANU; Svetlov VV, 1995, YEAST, V11, P1439, DOI 10.1002/yea.320111502; TRAWICK JD, 1992, MOL CELL BIOL, V12, P2302, DOI 10.1128/MCB.12.5.2302; TURI TG, 1992, J BIOL CHEM, V267, P2046; USHINSKY SC, 1994, GENETICS, V136, P819; VERDIERE J, 1991, MOL GEN GENET, V228, P300; VINCENT O, 1995, CURR GENET, V27, P387, DOI 10.1007/BF00352109; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WRIGHT RM, 1995, BIOCHEM BIOPH RES CO, V216, P458, DOI 10.1006/bbrc.1995.2645; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; ZAGOREC M, 1986, J BIOL CHEM, V261, P2506; ZAGOREC M, 1988, J BIOL CHEM, V263, P9718; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	44	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24425	24432		10.1074/jbc.271.40.24425	http://dx.doi.org/10.1074/jbc.271.40.24425			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798700	hybrid			2022-12-27	WOS:A1996VM67400022
J	Couture, C; Zhou, SY; Jascur, T; Williams, S; Tailor, P; Cantley, LC; Mustelin, T				Couture, C; Zhou, SY; Jascur, T; Williams, S; Tailor, P; Cantley, LC; Mustelin, T			Regulation of the Lck SH2 domain by tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; PROTEIN-KINASE; EFFICIENT EXPRESSION; T-CELLS; P56(LCK); ACTIVATION; RECOGNITION; SPECIFICITY; STIMULATION	Src homology 2 (SH2) domains bind to phosphotyrosine (Tyr(P)) residues in specific sequence contexts in other proteins and thereby mediate tyrosine phosphorylationdependent protein-protein interactions. The SH2 domain of the Src family kinase Lck is phosphorylated at tyrosine 192 in T cells upon T cell antigen receptor triggering. We have studied the consequences of this phosphorylation on the properties of the SH2 domain and on the function of Lck in T cell activation. We report that phosphorylation at Tyr(192) reduced the capacity of the isolated SH2 domain to bind a high affinity peptide ligand and Tyr(P)-containing cellular proteins. This effect was mimicked by mutation of Tyr(192) to an acidic residue. In intact T cells, where Lck participates in T cell antigen receptor signal transduction in an SH2 domain dependent manner, phosphorylation of Tyr(192) correlated with reduced downstream signaling. Our results indicate that tyrosine phosphorylation of the SH2 domain of Lck terminates its high affinity binding to ligands, thereby negatively regulating its participation in T cell antigen receptor signaling. This represents a novel mechanism for the regulation of the function of SH2 domains.	LA JOLLA INST ALLERGY & IMMUNOL, DIV CELL BIOL, LA JOLLA, CA 92037 USA; HARVARD UNIV, SCH MED, DIV SIGNAL TRANSDUCT, BOSTON, MA 02115 USA	La Jolla Institute for Immunology; Harvard University; Harvard Medical School			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Mustelin, Tomas/0000-0001-5912-8840	NIAID NIH HHS [AI35603] Funding Source: Medline; NIGMS NIH HHS [GM48960] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048960] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAIER G, 1994, BIOTECHNIQUES, V17, P94; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FRORATH B, 1992, BIOTECHNIQUES, V12, P558; HURLEY TR, 1989, ONCOGENE, V4, P265; IZQUIERDO M, 1994, J EXP MED, V180, P401, DOI 10.1084/jem.180.1.401; LUO K, 1990, ONCOGENE, V5, P921; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; MUSTELIN T, 1994, SRC FAMILY TYROSINE, P1; OETKEN C, 1992, EXP CELL RES, V202, P370, DOI 10.1016/0014-4827(92)90087-O; OETKEN C, 1994, MOL IMMUNOL, V31, P1295, DOI 10.1016/0161-5890(94)90047-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PINCUS SH, 1989, J IMMUNOL, V142, P3070; REYNOLDS PJ, 1992, ONCOGENE, V7, P1949; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SOULA M, 1993, J BIOL CHEM, V268, P27420; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; VONBONIN A, 1994, J BIOL CHEM, V269, P33035; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WATTS JD, 1993, J BIOL CHEM, V268, P23275; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WATTS JD, 1993, J IMMUNOL, V151, P6862; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	32	73	74	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24880	24884		10.1074/jbc.271.40.24880	http://dx.doi.org/10.1074/jbc.271.40.24880			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798764	hybrid			2022-12-27	WOS:A1996VM67400087
J	Gao, B; Esnouf, MP				Gao, B; Esnouf, MP			Elucidation of the core residues of an epitope using membrane-based combinatorial peptide libraries	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-XII; HAGEMAN-FACTOR; IDENTIFICATION; DISCOVERY; SEQUENCE; LIGANDS; GENE	Combinatorial peptide libraries have proved to be a valuable tool for the study of the interaction of a functional protein with its ligand. Here, the epitope for a monoclonal antibody 201/9, raised against beta-factor XIIa, has been identified with a two-step approach using peptide libraries attached to a polymer (polyvinylidene difluoride) membrane. First, the octapeptide libraries with two amino acids defined at position 2 and 4, represented by the formula X-O-2-X-O-4-X-X-X-X, were synthesized on a sheet of polymer membrane in which X represents a mixture of all the natural L-amino acids except cysteine, while O-2 and O-4 each represent a single amino acid, The libraries were probed with the antibody 201/9, and the bound antibody was detected with a sensitive chemiluminescent method, In the first cycle, the peptide mixtures X-Phe-X-Gln-X-X-X-X showed the strongest signal development. In the second cycle Phe and Gin were incorporated into new libraries consisting of sequences O-1-Phe-X-Gln-X-X-X-X, X-Phe-O-3-Gln-X-X-X-X, X-Phe-X-Gln-O-5-X-X-X, X-Phe-X-Gln-X-O-6-X-X, X-Phe-X-Gln-X-X-O-7-X, and X-Phe-X-Gln-X-X-X-O-8. After probing these new peptides, the residues representing the core sequence of the epitope for monoclonal antibody 201/9 were elucidated, The sequence Ser-Phe-Leu-Gln Glu-Asn, identified as the immunodominant epitope, correlates well with the sequence Ser-Phe-Leu-Gln-Glu-Ala previously identified (Gao, B., and Esnouf, M. P. (1996) J. Immunol, 157, 183-188) in a scan of overlapping peptides based on the sequence of human beta-factor XIIa.	UNIV OXFORD, RADCLIFFE INFIRM, DEPT CLIN BIOCHEM, OXFORD OX2 6HE, ENGLAND	Radcliffe Infirmary; University of Oxford								COOL DE, 1987, J BIOL CHEM, V262, P13662; DEKOSTER HS, 1995, J IMMUNOL METHODS, V187, P179, DOI 10.1016/0022-1759(95)00182-A; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EICHLER J, 1994, PEPTIDE RES, V7, P300; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FUJIKAWA K, 1983, J BIOL CHEM, V258, P924; FUJIKAWA K, 1981, METHOD ENZYMOL, V80, P198; Gao B, 1996, J IMMUNOL, V157, P183; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HOUGHTEN RA, 1994, CURR BIOL, V4, P564, DOI 10.1016/S0960-9822(00)00127-5; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; PINILLA C, 1994, BIOCHEM J, V301, P847, DOI 10.1042/bj3010847; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SEMBA U, 1992, BIOCHIM BIOPHYS ACTA, V1159, P113, DOI 10.1016/0167-4838(92)90014-5; SHIBUYA Y, 1994, BBA-PROTEIN STRUCT M, V1206, P63, DOI 10.1016/0167-4838(94)90073-6; WANG LF, 1995, J IMMUNOL METHODS, V178, P1, DOI 10.1016/0022-1759(94)00235-O; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	19	7	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24634	24638		10.1074/jbc.271.40.24634	http://dx.doi.org/10.1074/jbc.271.40.24634			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798729	hybrid			2022-12-27	WOS:A1996VM67400051
J	Ito, T; Tyler, JK; Bulger, M; Kobayashi, R; Kadonaga, JT				Ito, T; Tyler, JK; Bulger, M; Kobayashi, R; Kadonaga, JT			ATP-facilitated chromatin assembly with a nucleoplasmin-like protein from Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; NUCLEAR-LOCALIZATION SIGNALS; HISTONE-BINDING PROTEIN; DNA-REPLICATION INVITRO; AMINO-ACID SEQUENCE; SPERM DECONDENSATION; EGG EXTRACTS; PURIFICATION; NUCLEOSOMES; CLONING	To gain a better understanding of the factors that can mediate chromatin assembly, we have purified and cloned a core histone-binding protein from Drosophila melanogaster embryos. This protein resembles Xenopus laevis nucleoplasmin, and it has therefore been termed dNLP, for Drosophila nucleoplasmin-like protein. dNLP is a nuclear protein that is present throughout development. Both purified native and recombinant dNLP bind to core histones and can function in the assembly of approximately regularly spaced nucleosomal arrays in a reaction that additionally requires DNA, purified core histones, ATP, and a partially purified fraction (containing at least one other assembly activity). We also analyzed the properties of an N-terminally truncated version of dNLP, termed dNLP-S, and found that the deletion of the N-terminal 31 residues of dNLP results in a loss of the specificity of the interaction of dNLP with core histones. We then compared the abilities of dNLP and Drosophila nucleosome assembly protein-1 (dNAP-1) to promote the decondensation of Xenopus sperm chromatin, a process that can be mediated by nucleoplasmin. We observed that dNAP-1, but not dNLP, was able to promote the decondensation of sperm chromatin. These and other data collectively suggest that dNLP may participate in parallel with other histone-binding proteins such as dNAP-1 in the assembly of chromatin.	UNIV CALIF SAN DIEGO, DEPT BIOL, SAN DIEGO, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR GENET MOL, SAN DIEGO, CA 92093 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Cold Spring Harbor Laboratory				Tyler, Jessica/0000-0001-9765-1659	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046995] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 46995] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE S, 1990, MOL CELL BIOL, V10, P2863, DOI 10.1128/MCB.10.6.2863; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; Bulger M., 1994, METH MOL G, V5, P241; BURGLIN TR, 1987, GENE DEV, V1, P97, DOI 10.1101/gad.1.1.97; COTTEN M, 1986, BIOCHEMISTRY-US, V25, P5063, DOI 10.1021/bi00366a014; COTTEN M, 1987, EMBO J, V6, P3945, DOI 10.1002/j.1460-2075.1987.tb02736.x; CREVEL G, 1995, EMBO J, V14, P1711, DOI 10.1002/j.1460-2075.1995.tb07160.x; DILWORTH SM, 1988, BIOESSAYS, V9, P44, DOI 10.1002/bies.950090203; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; DREYER C, 1983, DEV BIOL, V100, P412, DOI 10.1016/0012-1606(83)90235-X; EARNSHAW WC, 1980, CELL, V21, P373, DOI 10.1016/0092-8674(80)90474-2; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GRUSS C, 1992, BIOESSAYS, V14, P1, DOI 10.1002/bies.950140102; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; Ito T, 1996, MOL CELL BIOL, V16, P3112; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kamakaka RT, 1996, MOL CELL BIOL, V16, P810; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KAUFMAN PD, 1994, CURR OPIN GENET DEV, V4, P229, DOI 10.1016/S0959-437X(05)80049-8; KAWASAKI K, 1994, J BIOL CHEM, V269, P10169; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; KLEINSCHMIDT JA, 1982, CELL, V29, P799, DOI 10.1016/0092-8674(82)90442-1; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KROHNE G, 1980, P NATL ACAD SCI-BIOL, V77, P1034, DOI 10.1073/pnas.77.2.1034; KROHNE G, 1980, EXP CELL RES, V129, P167, DOI 10.1016/0014-4827(80)90341-9; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; MILLS AD, 1980, J MOL BIOL, V139, P561, DOI 10.1016/0022-2836(80)90148-5; OHSUMI K, 1991, DEV BIOL, V148, P295, DOI 10.1016/0012-1606(91)90338-4; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; PHILPOTT A, 1991, CELL, V65, P569, DOI 10.1016/0092-8674(91)90089-H; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SEALY L, 1986, BIOCHEMISTRY-US, V25, P3064, DOI 10.1021/bi00358a049; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; van Holde KE., 1989, SPRINGER SERIES MOL; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WEDLICH D, 1988, CELL TISSUE RES, V254, P295; Wolffe A., 1995, CHROMATIN STRUCTURE	49	79	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					25041	25048		10.1074/jbc.271.40.25041	http://dx.doi.org/10.1074/jbc.271.40.25041			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798787	hybrid			2022-12-27	WOS:A1996VM67400110
J	Reddy, LR; Reddy, KS; Surrey, S; Adachi, K				Reddy, LR; Reddy, KS; Surrey, S; Adachi, K			Role of hydrophobic amino acids at beta 85 and beta 88 in stabilizing F helix conformation of hemoglobin S	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCEPTOR POCKET; PHENYLALANINE BETA-85; VALINE BETA-6; POLYMERIZATION; YEAST	Three Hb S variants containing Glu substitutions at Phe-beta 85 and/or Leu-beta 88 were expressed in yeast in an effort to evaluate the role of hydrophobic amino acids at these sites in stabilizing F helix conformation of Hb S. Helix stability of tetrameric Hb beta F8E, beta L88E was measured by CD and compared with those of Hb S beta F85E, Hb S beta L88E, Hb A, and Hb S, The CD spectra of these Hb S variants were similar to those of Hb S and Hb A at 10 degrees C, However, changes in ellipticity at 222 nm for Hb S beta F85E in the CO form at 60 degrees C were about 15-fold greater than that of Hb S, while those for Hb S beta L88E and Hb S beta F85E, beta L88E were similar and about 30-fold greater than Hb S, Thermal stability measured by continuous scanning of spectral changes revealed the three Hb S variants were much more unstable than Hb S, and stability of Hb S beta F85E, beta L88E was similar to that of Hb S beta L88E rather than Hb S beta F85E. These results suggest that Glu insertion at both beta 85 and beta 88 makes heme insertion into the heme pocket more difficult; however, once inserted, stability of Hb S beta F85E, beta L88E is similar to Hb S beta L88E rather than Hb S beta F85E, Furthermore, these results suggest that both Phe-beta 85 and Leu-beta 88 are critical for F helix stabilization and that Glu insertion at beta 88 leads to more destabilization than insertion at beta 85.	UNIV PENN,SCH MED,CHILDRENS HOSP PHILADELPHIA,DIV HEMATOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania					NHLBI NIH HHS [HL38632] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038632] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1993, J BIOL CHEM, V268, P21650; ADACHI K, 1995, PROTEIN SCI, V4, P1272, DOI 10.1002/pro.5560040703; ADACHI K, 1992, PROTEIN ENG, V5, P807, DOI 10.1093/protein/5.8.807; ADACHI K, 1994, J BIOL CHEM, V269, P31563; ADACHI K, 1994, J BIOL CHEM, V269, P17477; DELANO JJM, 1994, PROTEIN SCI, V3, P1206; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P125; HOFMANN OM, 1994, PROTEIN ENG, V7, P281; PERUTZ MF, 1968, NATURE, V219, P131, DOI 10.1038/219131a0; Shackleton CHL, 1994, MASS SPECTROMETRY CL, V2, P135; TRIFILLIS P, 1991, BLOOD, V78, P3298; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WAKS M, 1973, J BIOL CHEM, V248, P6462; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; YIP YK, 1972, J BIOL CHEM, V247, P7237	15	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24564	24568		10.1074/jbc.271.40.24564	http://dx.doi.org/10.1074/jbc.271.40.24564			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798719	hybrid			2022-12-27	WOS:A1996VM67400041
J	Strayer, DS				Strayer, DS			SV40 as an effective gene transfer vector in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOASSOCIATED VIRUS; SIMIAN VIRUS-40; DNA-REPLICATION; TUMOR-ANTIGEN; CELLS; CONSTRUCTION; INTEGRATION; EXPRESSION	SV40 was used to transduce gene expression in vitro and in vivo. Using cloned SV40 genome, we replaced large T antigen gene (Tag) with a polylinker, and inserted firefly luciferase, controlled by SV40 early promoter. Transfection into Tag-expressing cells yielded Tag-deficient virus, SVluc. SVluc was Tag-deficient and therefore replication-deficient in cells that did not supply Tag. SVluc transduced functional luciferase expression in vitro. BALB/c mice were inoculated with SVluc, and their tissues were assayed 3-21 days post-inoculation (dpi) for luciferase protein production and enzyme activity. Luciferase protein was detected by immunohistochemistry throughout the experiment, from 3 to 21 dpi. There was no inflammatory reaction against SVluc-infected cells at any time, in any tissue studied. Luciferase activity was first detected by luminometry 14 dpi, and remained level through day 21. Thus, replication-deficient recombinant SV40 can mediate gene transfer in vitro and in vivo.			Strayer, DS (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL ANAT & CELL BIOL,1020 LOCUST ST,PHILADELPHIA,PA 19107, USA.				NATIONAL CANCER INSTITUTE [R01CA044800] Funding Source: NIH RePORTER; NCI NIH HHS [CA44800] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akkina RK, 1996, J VIROL, V70, P2581, DOI 10.1128/JVI.70.4.2581-2585.1996; ANDERSON WF, 1995, J NATL CANCER I, V87, P406; ASANO M, 1985, NUCLEIC ACIDS RES, V13, P8573, DOI 10.1093/nar/13.23.8573; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BUTEL JS, 1986, BIOCHIM BIOPHYS ACTA, V865, P171, DOI 10.1016/0304-419X(86)90027-2; CARBONE M, 1994, ONCOGENE, V9, P1781; CHIA W, 1981, P NATL ACAD SCI-BIOL, V78, P6638, DOI 10.1073/pnas.78.11.6638; DAI YF, 1995, P NATL ACAD SCI USA, V92, P1401, DOI 10.1073/pnas.92.5.1401; FLOTTE TR, 1994, AM J RESP CELL MOL, V11, P517, DOI 10.1165/ajrcmb.11.5.7946381; GETHING MJ, 1981, NATURE, V293, P620, DOI 10.1038/293620a0; GIRAUD C, 1994, P NATL ACAD SCI USA, V91, P10039, DOI 10.1073/pnas.91.21.10039; GLORIOSO JC, 1994, DEV BIOL STAND, V82, P79; GOODING LR, 1977, J IMMUNOL, V118, P920; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; LEHN H, 1986, J GEN VIROL, V67, P1581, DOI 10.1099/0022-1317-67-8-1581; Miller AD, 1996, J VIROL, V70, P1804, DOI 10.1128/JVI.70.3.1804-1809.1996; MORTIMER EA, 1981, NEW ENGL J MED, V305, P1517, DOI 10.1056/NEJM198112173052507; MUZYCZKA N, 1994, J CLIN INVEST, V94, P1351, DOI 10.1172/JCI117468; MYERS RM, 1980, P NATL ACAD SCI-BIOL, V77, P6491, DOI 10.1073/pnas.77.11.6491; OHE Y, 1995, HUM GENE THER, V6, P325, DOI 10.1089/hum.1995.6.3-325; Purcell DFJ, 1996, J VIROL, V70, P887, DOI 10.1128/JVI.70.2.887-897.1996; ROSENBERG BH, 1981, J VIROL METHODS, V3, P167, DOI 10.1016/0166-0934(81)90051-3; ROSENFELD MA, 1993, PATHOL BIOL, V41, P677; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; Smith C, 1992, J Hematother, V1, P155, DOI 10.1089/scd.1.1992.1.155; TORNOW J, 1985, J VIROL, V53, P415, DOI 10.1128/JVI.53.2.415-424.1985; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564	30	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24741	24746						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798743				2022-12-27	WOS:A1996VM67400065
J	Lokeshwar, VB; Iida, N; Bourguignon, LYW				Lokeshwar, VB; Iida, N; Bourguignon, LYW			The cell adhesion molecule, GP116, is a new CD44 variant (ex14/v10) involved in hyaluronic acid binding and endothelial cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOMA TRANSMEMBRANE GLYCOPROTEIN; HOMING RECEPTOR CD44; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; CANCER-CELLS; PROTEIN; EXPRESSION; ANKYRIN; GP85; RAT	In this study we have found that endothelial cells from different origins all contain a CD44-related transmembrane glycoprotein, named GP116. Using a bovine aortic endothelial cell line and a standard pulse-chase protocol, we show that GP116 is synthesized as a 52-kDa nascent polypeptide precursor (p52) which is processed to GP116 as follows, p52 --> p63/65 --> p82 --> p100 --> GP116. GP116 contains approximate to 8 N- and approximate to 11 O-linked oligosaccharide chains (but lacks glycosaminoglycans) and interacts directly with the cytoskeletal protein, ankyrin, both in vitro (K-d approximate to 1.2 nM) and in vivo. The results of GP116 amino acid composition, reverse transcriptase polymerase chain reaction, Southern blot, Northern blot, cloning, and sequence analyses indicate that endothelial cells express this new CD44 variant that contains an exon having significant homology with human CD44 exon 14 (ex14/v10). GP116, designated as CD44 (ex14/v10), has been shown to be a major hyaluronic acid (HA) receptor (K-d approximate to 0.5-0.8 nM) responsible for cell adhesion. Most importantly, we have found that the interaction between CD44(ex14/v10) and HA or a small fragment of HA (10-15 disaccharide units) induces a mitogenic response in endothelial cells, These findings suggest that this CD44 variant plays an important role in regulating endothelial cell proliferation.	UNIV MIAMI, SCH MED, DEPT CELL BIOL & ANAT R124, MIAMI, FL 33101 USA	University of Miami					NCI NIH HHS [1F32CA06047, CA 66163] Funding Source: Medline; NIGMS NIH HHS [GM 36353] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036353] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; BANERJEE SD, 1992, J CELL BIOL, V119, P643, DOI 10.1083/jcb.119.3.643; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BOSWORTH BT, 1991, MOL IMMUNOL, V28, P1131, DOI 10.1016/0161-5890(91)90028-I; BOURGUIGNON LYW, 1986, J CELL BIOL, V102, P2115, DOI 10.1083/jcb.102.6.2115; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; BOURGUIGNON LYW, 1992, MOL CELL BIOL, V12, P4464, DOI 10.1128/MCB.12.10.4464; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; Bourguignon LYW, 1995, J NEURO-ONCOL, V26, P201, DOI 10.1007/BF01052623; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CARTER WG, 1988, J BIOL CHEM, V263, P4193; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; FAASSEN AE, 1992, J CELL BIOL, V116, P521, DOI 10.1083/jcb.116.2.521; FOX SB, 1993, LANCET, V342, P548, DOI 10.1016/0140-6736(93)91670-H; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HULL SR, 1989, J CELL BIOCHEM, V40, P67, DOI 10.1002/jcb.240400108; HYMAN R, 1991, IMMUNOGENETICS, V33, P392, DOI 10.1007/BF00216699; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; JALKANEN S, 1988, J IMMUNOL, V141, P1615; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KALOMIRIS EL, 1988, J CELL BIOL, V106, P319, DOI 10.1083/jcb.106.2.319; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KUAN SF, 1989, J BIOL CHEM, V264, P19271; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P22073; LOKESHWAR VB, 1989, J BIOL CHEM, V264, P19318; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; LOKESHWAR VB, 1991, J BIOL CHEM, V266, P17983; MORITA H, 1990, BIOCHEM J, V265, P61, DOI 10.1042/bj2650061; NUOVO GJ, 1994, BIOCHEMICA, V11, P4; OMARY MB, 1988, IMMUNOGENETICS, V27, P460, DOI 10.1007/BF00364434; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; RUDY W, 1993, CANCER RES, V53, P1262; SCREATON GR, 1993, J BIOL CHEM, V268, P12235; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; STJOHN T, 1990, CELL, V60, P45, DOI 10.1016/0092-8674(90)90714-P; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; UNDERHILL C, 1992, J CELL SCI, V103, P293; WELSH CF, 1995, J CELL PHYSIOL, V164, P605, DOI 10.1002/jcp.1041640319; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; WEST DC, 1989, CIBA F SYMP, V143, P187; YANNARIELLOBROWN J, 1992, J BIOL CHEM, V267, P20451	53	106	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23853	23864		10.1074/jbc.271.39.23853	http://dx.doi.org/10.1074/jbc.271.39.23853			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798616	hybrid			2022-12-27	WOS:A1996VJ44200045
J	Mamoun, CB; Beckerich, JM; Gaillardin, C				Mamoun, CB; Beckerich, JM; Gaillardin, C			The TSR1 gene of Yarrowia lipolytica is involved in the signal recognition particle-dependent translocation pathway of secretory proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE EXTRACELLULAR PROTEASE; ENDOPLASMIC-RETICULUM MEMBRANE; COLI 4.5S RNA; ESCHERICHIA-COLI; SCHIZOSACCHAROMYCES-POMBE; ELONGATION ARREST; 7SL RNA; RIBONUCLEOPROTEIN; TRANSFORMATION	We have isolated suppressors (tsr1 to tsr5) of the thermosensitive growth of the scr2.II-13 mutation, which affects the stability of the signal recognition particle. The growth of these mutants is largely affected in the SCR2 context at 34 degrees C. We have studied the synthesis and secretion of an alkaline extracellular protease (AEP) in both wild-type and tsr1-1(SCR2(+)) thermosensitive mutant strains. Pulse-chase labeling and immunoprecipitation of this protein showed that the level of AEP precursors in the tsr1-1(SCR2(+)) strain is 70% less than in the wild-type strain under conditions where the global protein synthesis is practically unaffected. This defect was observed as early as 10 min after the shift to nonpermissive temperature. In neither strain was there any effect on the kinetics of secretion, and no cytoplasmic accumulation was detected, We have cloned the TSR1 gene by complementing the thermosensitive phenotype of a tsr1-1(SCR2(+)) mutant. Analysis of the TSR1 DNA sequence revealed an open reading frame of 1383 base pairs, encoding a serine-rich protein of 461 amino acids with an amino-terminal signal peptide, and a membrane-spanning domain of 20 amino acids that could act as a stop transfer signal to ensure membrane localization of Tsr1p. Two homologues of the TSR1 gene were identified in Saccharomyces cerevisiae (YHC8) and Hansenula polymorpha (YLU2). Disruption of the TSR1 gene revealed that it is an essential single-copy gene. The TSR1 gene encodes a single mRNA of 1.5 kilobase pairs. The study of the synthesis and secretion of AEP in the complemented tsr1-1(SCR2(+),TSR1(+)) strain revealed that the TSR1 gene ensures complete recovery of the synthesis defect and thus could encode an important component of the endoplasmic reticulum membrane involved in the early steps of the signal recognition particle-dependent translocation pathway.			Mamoun, CB (corresponding author), INRA PARIS GRIGNON,CTR BIOTECHNOL AGROIND,CNRS,LAB GENET MOL & CELLULAIRE,F-78850 THIVERVAL GRIGNON,FRANCE.							AGAPHONOV MO, 1994, YEAST, V10, P509, DOI 10.1002/yea.320100410; ALMASSY RJ, 1983, J MOL BIOL, V170, P497, DOI 10.1016/S0022-2836(83)80159-4; BARTH G, 1996, IN PRESS GENETICS BI; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; DAVIDOW LS, 1985, CURR GENET, V10, P39, DOI 10.1007/BF00418492; FONTECILLACAMPS JC, 1981, TRENDS BIOCHEM SCI, V6, P291, DOI 10.1016/0968-0004(81)90105-5; Gibson TJ, 1984, THESIS CAMBRIDGE U; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HANN BC, 1992, NATURE, V356, P532, DOI 10.1038/356532a0; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HE F, 1990, CURR GENET, V17, P289, DOI 10.1007/BF00314874; HE F, 1992, J BIOL CHEM, V267, P1932; HE F, 1988, CURR GENET, V16, P347; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MANIATIS T, 1982, MOL CLONING, pCH1; MATOBA S, 1988, MOL CELL BIOL, V8, P4904, DOI 10.1128/MCB.8.11.4904; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; NICAUD JM, 1989, CURR GENET, V16, P253, DOI 10.1007/BF00422111; PORITZ MA, 1988, P NATL ACAD SCI USA, V85, P4315, DOI 10.1073/pnas.85.12.4315; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RIBES V, 1988, EMBO J, V7, P231, DOI 10.1002/j.1460-2075.1988.tb02804.x; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; RISLER JL, 1988, J MOL BIOL, V204, P1019, DOI 10.1016/0022-2836(88)90058-7; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WOLIN SL, 1989, J CELL BIOL, V109, P2617, DOI 10.1083/jcb.109.6.2617; XUAN JW, 1988, CURR GENET, V14, P15, DOI 10.1007/BF00405848; YAVER DS, 1992, J CELL BIOL, V116, P605, DOI 10.1083/jcb.116.3.605	32	1	2	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23895	23901		10.1074/jbc.271.39.23895	http://dx.doi.org/10.1074/jbc.271.39.23895			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798620	Green Published, hybrid			2022-12-27	WOS:A1996VJ44200049
J	Rossi, F; Forne, T; Antoine, E; Tazi, J; Brunel, C; Cathala, G				Rossi, F; Forne, T; Antoine, E; Tazi, J; Brunel, C; Cathala, G			Involvement of U1 small nuclear ribonucleoproteins (snRNP) in 5' splice site-U1 snRNP interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; PREMESSENGER RNA; SR PROTEINS; 5'-SPLICE-SITE RECOGNITION; BINDING PROTEINS; U5; STEPS; U2; SPECIFICITY; ASSOCIATION	U1 small nuclear ribonucleoprotein (snRNP) is an important ribonucleoprotein involved early in the spliceosome formation to commit pre-mRNAs to the splicing pathway. We have determined the association and dissociation kinetics of the 5' splice site-U1 snRNP interaction using purified U1 snRNP and a short RNA oligonucleotide comprising the 5' splice site (5'-SS) consensus sequence of pre-mRNAs (5'-SS RNA oligo). The association is rapid, does not require ATP, and is almost irreversible. Surprisingly, oligonucleotide-directed cleavage of the U1 small nuclear RNA (snRNA) 5' end sequence with RNase H has no significant effect on the rate of association of the 5'-SS RNA oligo, but it does lead to rapid dissociation, This provides evidence that U1-specific snRNP proteins are critical for the 5' splice site recognition while base pairing ensures the stability of the interaction. The recognition of the 5' splice site by U1 snRNP does not result from the individual action of one or more proteins but rather from their organization around U1 snRNA. A consequence of this organization is that the U1-C protein makes direct contacts with the site, as it becomes cross-linked to the RNA oligo upon exposition of the reactions to shortwave UV light.	UNIV MONTPELLIER 2,INST MOL GENET,UMR CNRS 5535,F-34033 MONTPELLIER 1,FRANCE	Universite de Montpellier			Forne, Thierry/D-3718-2013	Forne, Thierry/0000-0002-9179-1551; Tazi, Jamal/0000-0002-1949-8748				BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BRINGMANN P, 1986, EMBO J, V5, P3509, DOI 10.1002/j.1460-2075.1986.tb04676.x; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CORTES JJ, 1993, EMBO J, V12, P5181, DOI 10.1002/j.1460-2075.1993.tb06213.x; CRISPINO JD, 1994, SCIENCE, V265, P1866, DOI 10.1126/science.8091213; DAUGERON MC, 1992, NUCLEIC ACIDS RES, V20, P3625, DOI 10.1093/nar/20.14.3625; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EPERON IC, 1993, EMBO J, V12, P3607, DOI 10.1002/j.1460-2075.1993.tb06034.x; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; Gunnewiek JMTK, 1995, NUCLEIC ACIDS RES, V23, P4864; HALL KB, 1992, P NATL ACAD SCI USA, V89, P10969, DOI 10.1073/pnas.89.22.10969; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONFORTI BB, 1993, CELL, V75, P863, DOI 10.1016/0092-8674(93)90531-T; KONFORTI BB, 1995, RNA, V1, P815; KONFORTI BB, 1994, GENE DEV, V8, P1962, DOI 10.1101/gad.8.16.1962; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; Moore M., 1993, RNA WORLD, P303; NELISSEN RLH, 1994, EMBO J, V13, P4113, DOI 10.1002/j.1460-2075.1994.tb06729.x; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; ROGERS J, 1980, P NATL ACAD SCI-BIOL, V77, P1877, DOI 10.1073/pnas.77.4.1877; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; TARN WY, 1994, GENE DEV, V8, P2704, DOI 10.1101/gad.8.22.2704; TARN WY, 1995, P NATL ACAD SCI USA, V92, P2504, DOI 10.1073/pnas.92.7.2504; TAZI J, 1992, J BIOL CHEM, V267, P4322; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WILL CL, 1993, MOL BIOL REP, V18, P121, DOI 10.1007/BF00986766; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	40	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23985	23991		10.1074/jbc.271.39.23985	http://dx.doi.org/10.1074/jbc.271.39.23985			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798632	Green Published, hybrid			2022-12-27	WOS:A1996VJ44200061
J	Blase, M; Bruntner, C; Tshisuaka, B; Fetzner, S; Lingens, F				Blase, M; Bruntner, C; Tshisuaka, B; Fetzner, S; Lingens, F			Cloning, expression, and sequence analysis of the three genes encoding quinoline 2-oxidoreductase, a molybdenum-containing hydroxylase from Pseudomonas putida 86	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BROAD HOST RANGE; CARBON-MONOXIDE DEHYDROGENASE; LIVER XANTHINE DEHYDROGENASE; GRAM-NEGATIVE BACTERIA; RHODOCOCCUS-SPEC B1; MICROBIAL-METABOLISM; DROSOPHILA-MELANOGASTER; MOLECULAR-CLONING; ALDEHYDE OXIDOREDUCTASE	The three genes coding for quinoline a-oxidoreductase (Qor) of Pseudomonas putida 86 were cloned and sequenced. The qor genes are clustered in the transcriptional order medium (M) small (S), large (L) and code for three subunits of 288 (QorM), 168 (QorS), and 788 (QorL) amino acids, respectively. Formation of active quinoline 2-oxidoreductase and degradation of quinoline occurred in a recombinant P. putida KT2440 clone. The amino acid sequences of Qor show significant homology to various prokaryotic molybdenum containing hydroxylases and to eukaryotic xanthine dehydrogenases. QorS contains two conserved motifs for [2Fe-2S] clusters. The binding motif for the N-terminal [2Fe-2S] cluster corresponds to the binding site of bacterial and chloroplast-type [2Fe-2S] ferredoxins, whereas the amino acid pattern of the internal [2Fe-2S] center apparently is a distinct feature of molybdenum-containing hydroxylases, showing no homology to any other described [2Fe-2S] binding motif. The medium subunit QorM presumably contains the FAD, but no conserved sequence areas or described motifs of FAD, NAD, NADP, or ATP binding were detected. Putative binding sites of the molybdopterin cytosine dinucleotide cofactor were detected in QorL by comparison with ''contacting segments'' recently described in aldehyde oxidoreductase from Desulfovibrio gigas (Romao, M. J., Archer, M., Moura, I., Moura, J. J. G., LeGall, J., Engh, R., Schneider, M., Hof, P., and Huber, R. (1995) Science 270, 1170-1176).	UNIV HOHENHEIM,INST MIKROBIOL 250,D-70593 STUTTGART,GERMANY	University Hohenheim				Fetzner, Susanne/0000-0002-7228-1871				AMAYA Y, 1990, J BIOL CHEM, V265, P14170; BAGDASARIAN M, 1981, GENE, V16, P237, DOI 10.1016/0378-1119(81)90080-9; BATES PF, 1983, GENE, V26, P137, DOI 10.1016/0378-1119(83)90183-X; BAUDER R, 1990, BIOL CHEM H-S, V371, P1137, DOI 10.1515/bchm3.1990.371.2.1137; BENEN JAE, 1989, J GEN MICROBIOL, V135, P1787; BORCK K, 1976, MOL GEN GENET, V146, P199, DOI 10.1007/BF00268089; BRAY RC, 1991, BIOCHEM J, V280, P817, DOI 10.1042/bj2800817; Bray RC, 1975, ENZYMES 12, P303; Brenner DJ, 1984, BERGEYS MANUAL SYSTE, P408; CLEWELL DB, 1969, P NATL ACAD SCI USA, V62, P1159, DOI 10.1073/pnas.62.4.1159; DAVIS RW, 1980, ADV BACTERIAL GENET, P120; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V0005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; EGGINK G, 1990, J MOL BIOL, V212, P135, DOI 10.1016/0022-2836(90)90310-I; FETZNER S, 1989, BIOCHEM BIOPH RES CO, V161, P700, DOI 10.1016/0006-291X(89)92656-9; FETZNER S, 1993, BIOL CHEM H-S, V374, P363, DOI 10.1515/bchm3.1993.374.1-6.363; Frantz B., 1986, BACTERIA, V10, P295; GLATIGNY A, 1995, J BIOL CHEM, V270, P3534, DOI 10.1074/jbc.270.8.3534; GRETHERBECK S, 1994, MOL MICROBIOL, V13, P929, DOI 10.1111/j.1365-2958.1994.tb00484.x; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HAMES BD, 1990, GEL ELECTROPHORESIS, P36; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; HETTRICH D, 1991, BIOL CHEM H-S, V372, P513, DOI 10.1515/bchm3.1991.372.2.513; HOUDE M, 1989, GENE, V85, P391, DOI 10.1016/0378-1119(89)90432-0; HUGHES RK, 1992, BIOCHEM J, V285, P507, DOI 10.1042/bj2850507; HUGHES RK, 1992, BIOCHEMISTRY-US, V33, P3070; ICHIDA K, 1993, GENE, V133, P279; JEENES DJ, 1986, MOL GEN GENET, V203, P421, DOI 10.1007/BF00422066; KEITH TP, 1987, GENETICS, V116, P67; KIESER T, 1984, PLASMID, V12, P19, DOI 10.1016/0147-619X(84)90063-5; LEE CS, 1987, GENETICS, V116, P55; LEHMANN M, 1994, J BIOL CHEM, V269, P11254; LEHMANN M, 1995, J BIOL CHEM, V270, P14420, DOI 10.1074/jbc.270.24.14420; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; Miller J.H., 1972, EXPT MOL GENETICS; MURRAY NE, 1977, MOL GEN GENET, V150, P53, DOI 10.1007/BF02425325; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; Palleroni N., 1984, BERGEYS MANUAL SYSTE, VVolume 1, P141; PEARSON DM, 1994, BBA-BIOENERGETICS, V1188, P432, DOI 10.1016/0005-2728(94)90066-3; PESCHKE B, 1991, BIOL CHEM H-S, V372, P1081, DOI 10.1515/bchm3.1991.372.2.1081; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; RICE DW, 1984, J MOL BIOL, V174, P483, DOI 10.1016/0022-2836(84)90332-2; RILEY MA, 1989, MOL BIOL EVOL, V6, P33; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUBEL U, 1995, J BACTERIOL, V177, P2197, DOI 10.1128/jb.177.8.2197-2203.1995; SCHWARZ G, 1988, SYST APPL MICROBIOL, V10, P185, DOI 10.1016/S0723-2020(88)80035-3; SCHWARZ G, 1989, BIOL CHEM H-S, V370, P1183, DOI 10.1515/bchm3.1989.370.2.1183; SHUKLA OP, 1989, MICROBIOS, V59, P47; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SOLDATI L, 1987, FEMS MICROBIOL LETT, V42, P163; TAMAKI T, 1989, J BIOCHEM-TOKYO, V106, P541, DOI 10.1093/oxfordjournals.jbchem.a122889; TAUTZ D, 1983, ANAL BIOCHEM, V132, P14, DOI 10.1016/0003-2697(83)90419-0; TAYLOR WR, 1986, J THEOR BIOL, V119, P205, DOI 10.1016/S0022-5193(86)80075-3; TERAO M, 1992, BIOCHEM J, V283, P863, DOI 10.1042/bj2830863; THOENES U, 1994, EUR J BIOCHEM, V220, P901, DOI 10.1111/j.1432-1033.1994.tb18693.x; TSHISUAKA B, 1993, BIOCHEMISTRY-US, V32, P12938; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8	63	35	39	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23068	23079						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798497				2022-12-27	WOS:A1996VH76800023
J	Cattaneo, E; DeFraja, C; Conti, L; Reinach, B; Bolis, L; Govoni, S; Liboi, E				Cattaneo, E; DeFraja, C; Conti, L; Reinach, B; Bolis, L; Govoni, S; Liboi, E			Activation of the JAK/STAT pathway leads to proliferation of ST14A central nervous system progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASE; NEURONAL DIFFERENTIATION; ERYTHROPOIETIN RECEPTOR; HEMATOPOIETIC-CELLS; NEUROTROPHIC FACTOR; INTERLEUKIN-3; EXPRESSION; BRAIN; SIGNALS	We were interested in whether central nervous system progenitor cells possess the signal transduction machinery necessary to mediate cytokine functions and whether this machinery can become activated upon stable expression of a particular cytokine receptor. For this purpose we utilized a previously obtained conditionally immortalized striatum-derived nestin-positive cell. line (ST14A). We found that ST14A cells express Jak2, but not Jak1 or Tyk2. An identical pattern of expression was found in embryonic striatal tissue. To evaluate the susceptibility of these cytokine specific cytoplasmic transducers to activation, ST14A cells were stably transfected with the alpha and beta (AIC2A) chains of the murine interleukin-3 receptor. Four independent lines expressing both the alpha and beta receptor subunits were obtained. We found that cells from each of these lines were induced to proliferate upon exposure to interleukin-3. Dose response curve, antibody blocking experiments and binding studies revealed that the response was mediated by the reconstituted high affinity interleukin-3 receptor. Immunoprecipitation studies on these cells showed that Jak2 and Stat5 were being phosphorylated after stimulation of the reconstituted receptor. These results indicate that members of the JAK/STAT family of proteins are expressed in central nervous system progenitor cells and are susceptible to activation through stimulation of an exogenously expressed cytokine receptor, ultimately leading to cell proliferation.	UNIV VERONA,INST BIOL CHEM,I-37100 VERONA,ITALY; UNIV PAVIA,INST PHARMACOL,I-27100 PAVIA,ITALY	University of Verona; University of Pavia	Cattaneo, E (corresponding author), UNIV MILAN,INST PHARMACOL SCI,VIA BALZARETTI 9,I-20133 MILAN,ITALY.		Govoni, Stefano/K-2965-2015; Conti, Luciano/H-4184-2012	Govoni, Stefano/0000-0002-7243-6837; Conti, Luciano/0000-0002-2050-9846; CATTANEO, ELENA/0000-0002-0755-4917				ANDERSON DJ, 1989, NEURON, V3, P1, DOI 10.1016/0896-6273(89)90110-4; CATTANEO E, 1994, DEV BRAIN RES, V83, P197, DOI 10.1016/0165-3806(94)00137-5; CATTANEO E, 1993, SOC NEUR ABSTR, V107, P6; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; FARRAR WL, 1989, BLOOD, V73, P137; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.neuro.18.1.159; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; KAMEGAI M, 1990, NEURON, V2, P429; KONISHI Y, 1994, NEUROSCI LETT, V182, P271, DOI 10.1016/0304-3940(94)90814-1; KONISHI Y, 1995, J NEUROSCI RES, V41, P572, DOI 10.1002/jnr.490410503; KUSHIMA Y, 1992, NEUROSCI RES, V13, P267, DOI 10.1016/0168-0102(92)90039-F; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LIBOI E, 1992, BLOOD, V80, P1183; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; LUNDBERG C, 1994, SOC NEUR ABSTR, V205, P2; MASUDA S, 1993, J BIOL CHEM, V268, P11208; MCKAY RDG, 1989, CELL, V58, P815, DOI 10.1016/0092-8674(89)90934-3; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAJIMA A, 1993, BLOOD, V82, P1960; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NICOLA NA, 1986, J CELL PHYSIOL, V128, P180, DOI 10.1002/jcp.1041280207; POUSSET F, 1994, DEV BRAIN RES, V81, P143, DOI 10.1016/0165-3806(94)90078-7; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; VANDERHEYDEN J, 1991, J IMMUNOL, V147, P3413; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YANG XJ, 1993, J NEUROSCI, V13, P3006; ZHOU J, 1994, P NATL ACAD SCI USA, V91, P3824, DOI 10.1073/pnas.91.9.3824	31	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23374	23379		10.1074/jbc.271.38.23374	http://dx.doi.org/10.1074/jbc.271.38.23374			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798541	Green Published, hybrid			2022-12-27	WOS:A1996VH76800067
J	Dvir, A; Conaway, RC; Conaway, JW				Dvir, A; Conaway, RC; Conaway, JW			Promoter escape by RNA polymerase II - A role for an ATP cofactor in suppression of arrest by polymerase at promoter-proximal sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-DELTA; MAJOR LATE PROMOTER; ABORTIVE INITIATION; ELONGATION COMPLEXES; RUNOFF TRANSCRIPTS; FACTOR-EPSILON; BASAL FACTORS; RAT-LIVER; REQUIREMENT; INVITRO	It is well established that TFIIH-dependent transcription by RNA polymerase II requires a hydrolyzable ATP cofactor for synthesis of the first phosphodiester bond of nascent transcripts. Whether an ATP cofactor is also required after initiation for escape of RNA polymerase II from the promoter has, however, been controversial. We have now addressed this question directly by investigating the ability of RNA polymerase II transcription complexes containing short, similar to 5-8-nucleotide transcripts synthesized in the presence of limiting nucleotides to escape the promoter in the absence of an ATP cofactor in a basal transcription system reconstituted with purified RNA polymerase II and general initiation factors. Depletion of ATP had a profound effect on the ability of initiated complexes to progress into the elongation phase: whereas in the presence of ATP, the majority of transcription complexes could be chased away from the promoter proximal region, most complexes deprived of ATP catalyzed synthesis of only a few phosphodiester bonds and then ceased elongation after synthesizing transcripts less than 10-14 nucleotides in length. A significant fraction of these transcripts could be extended following addition of ATP, indicating that they were contained in arrested, but potentially active elongation complexes. Like the ATP-requiring step in initiation, ATP-dependent suppression of arrest by RNA polymerase II at promoter proximal sites is inhibited by adenosine 5'-O-(thio)triphosphate. Transcription complexes containing transcripts longer than 9-10 nucleotides are insensitive to inhibition by ATP gamma S, indicating that susceptibility to ATP sensitive arrest is a property of very early elongation complexes. Taken together, our findings reveal a novel role for an ATP cofactor in transcription by RNA polymerase II.	OKLAHOMA MED RES FDN,PROGRAM MOL & CELL BIOL,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation				Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS JA, 1989, J BIOL CHEM, V264, P3223; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CAI H, 1987, J BIOL CHEM, V262, P298; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; ERNST H, 1983, MOL CELL BIOL, V3, P2172, DOI 10.1128/MCB.3.12.2172; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JACOB GA, 1991, J BIOL CHEM, V266, P22537; JIANG Y, 1995, J BIOL CHEM, V270, P27332, DOI 10.1074/jbc.270.45.27332; JIANG Y, 1993, J BIOL CHEM, V268, P6535; LUSE DS, 1987, J BIOL CHEM, V262, P14990; LUSE DS, 1987, J BIOL CHEM, V262, P289; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1991, NATURE, V354, P369; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; TAN SY, 1994, BIOTECHNIQUES, V16, P824; TANTIN D, 1994, J BIOL CHEM, V269, P17397; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361	29	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23352	23356		10.1074/jbc.271.38.23352	http://dx.doi.org/10.1074/jbc.271.38.23352			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798537	hybrid			2022-12-27	WOS:A1996VH76800063
J	GopalSrivastava, R; Cvekl, A; Piatigorsky, J				GopalSrivastava, R; Cvekl, A; Piatigorsky, J			Pax-6 and alpha B-crystallin/small heat shock protein gene regulation in the murine lens - Interaction with the lens-specific regions, LSR1 and LSR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX-CONTAINING GENE; RETINOIC ACID RECEPTOR; PAIRED DOMAIN; EYELESS GENE; EXPRESSION; IDENTIFICATION; DNA; FAMILY; MUTATIONS; ENHANCER	We have demonstrated previously that a transgene comprising the -164/+44 fragment of the murine alpha B-crystallin gene fused to the bacterial chloramphenicol acetyltransferase (cat) gene is lens-specific in transgenic mice. The -147 to -118 sequence was identified as a lens-specific regulatory region and is called here LSR1 for lens-specific region 1. In the present experiments, a -115/+44-cat transgene was also lens specific in transgenic mice, although the average activity was 30 times lower than that derived from the -164/+44-cat transgene. The -115/+44 alpha B-crystallin fragment contains a highly conserved region (-78 to -46) termed here LSR2. A -68/+44-cat transgene, in which LSR2 is truncated, was inactive in transgenic mice. DNase I footprinting indicated that LSR1 and LSR2 bind partially purified nuclear proteins from either alpha TN4-1 lens cells or the mouse lens as well as the purified paired domain of Pax-6. Site-specific mutation of LSR1 eliminated both Pax-6 binding and promoter activity of the -164/+44-cat transgene in transgenic mice. Finally antibody/electrophoretic mobility shift assays and cotransfection experiments indicated that Pax-6 can activate the alpha B-crystallin promoter via LSR1 and LSR2. Our data strengthen the idea that Pax-6 has had a major role in recruiting genes for high expression in the lens.	NEI, MOL & DEV BIOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)			Cvekl, Ales/B-2427-2013					BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BLOEMENDAL H, 1991, PROG NUCLEIC ACID RE, V41, P259; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CHALEPAKIS G, 1994, NUCLEIC ACIDS RES, V22, P3131, DOI 10.1093/nar/22.15.3131; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; CVEKL A, 1995, MOL CELL BIOL, V15, P653; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; CVEKL A, 1995, P NATL ACAD SCI USA, V92, P4681, DOI 10.1073/pnas.92.10.4681; CVEKL A, 1991, GENE, V103, P253, DOI 10.1016/0378-1119(91)90282-G; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DENNY P, 1992, NUCLEIC ACIDS RES, V20, P2887, DOI 10.1093/nar/20.11.2887; DUBIN RA, 1991, MOL CELL BIOL, V11, P4340, DOI 10.1128/MCB.11.9.4340; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; Earle WR, 1943, J NATL CANCER I, V4, P165; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GLASER T, 1992, NAT GENET, V8, P463; GOPALSRIVASTAVA R, 1994, NUCLEIC ACIDS RES, V22, P1281, DOI 10.1093/nar/22.7.1281; GOPALSRIVASTAVA R, 1993, MOL CELL BIOL, V13, P7144, DOI 10.1128/MCB.13.11.7144; GOPALSRIVASTAVA R, 1995, MOL CELL BIOL, V15, P7081; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HALDER G, 1995, CURR OPIN GENET DEV, V5, P602, DOI 10.1016/0959-437X(95)80029-8; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HANSON IM, 1994, NAT GENET, V6, P168, DOI 10.1038/ng0294-168; HAYNES JI, 1996, IN PRESS DEV DYNAMIC; HENRY JJ, 1990, DEV BIOL, V141, P149, DOI 10.1016/0012-1606(90)90110-5; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOGAN B, 1986, MANIPULATING MOUSE E, P174; KAMACHI Y, 1995, EMBO J, V14, P3510, DOI 10.1002/j.1460-2075.1995.tb07357.x; KEL OV, 1995, NUCLEIC ACIDS RES, V23, P4097, DOI 10.1093/nar/23.20.4097; Maniatis T, 1989, MOL CLONING; MARTHA A, 1994, AM J HUM GENET, V54, P801; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; REDDAN JR, 1986, DIFFERENTIATION, V33, P168, DOI 10.1111/j.1432-0436.1986.tb00422.x; RICHARDSON J, 1995, P NATL ACAD SCI USA, V92, P4676, DOI 10.1073/pnas.92.10.4676; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TYNDALL C, 1981, NUCLEIC ACIDS RES, V9, P6231, DOI 10.1093/nar/9.23.6231; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WISTOW G, 1995, BBA-GENE STRUCT EXPR, V1263, P105, DOI 10.1016/0167-4781(95)00087-W; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; WRIGHT EM, 1993, NUCLEIC ACIDS RES, V21, P744, DOI 10.1093/nar/21.3.744; YAMADA T, 1990, CURR EYE RES, V9, P31, DOI 10.3109/02713689009000052	52	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23029	23036		10.1074/jbc.271.38.23029	http://dx.doi.org/10.1074/jbc.271.38.23029			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798491	hybrid			2022-12-27	WOS:A1996VH76800017
J	Lengyel, E; Wang, H; Stepp, E; Juarez, J; Wang, Y; Doe, W; Pfarr, CM; Boyd, D				Lengyel, E; Wang, H; Stepp, E; Juarez, J; Wang, Y; Doe, W; Pfarr, CM; Boyd, D			Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; HUMAN-COLON CARCINOMA; GROWTH-FACTOR; MESSENGER-RNA; C-JUN; TRANSCRIPTIONAL ACTIVATION; LAMININ DEGRADATION; SIGNAL-TRANSDUCTION; FIBROBLAST GROWTH; PROMOTER ACTIVITY	The urokinase-type plasminogen activator receptor (u-PAR) facilitates extracellular matrix proteolysis by accelerating plasmin formation at the cell surface, The present study was undertaken to identify elements in the u-PAR promoter required for the elevated expression of this binding site, Toward this end, we used two cultured colon cancer cell lines; one (RKO) has a transcriptionally activated u-PAR gene, and the other (GEO) overexpresses the receptor only after phorbol ester treatment. A chloramphenicol acetyltransferase (CAT) reporter driven by 398 nucleotides of 5' regulatory sequence of the u-PAR gene was strongly activated in the RKO cells, which displays approximately 3 x 10(5) receptors/cell. A region of this promoter between -197 and -8 was required for optimal expression, as indicated using a CAT reporter driven by 5' deleted fragments. DNase I footprinting revealed three protected regions (I, -190 to -171; II, -148 to -124; and III, -99 to -70) in this part of the promoter, Mutation of an AP-1 binding site at -184 within region I reduced activation of the promoter by 85%. Deletion of either region II or III also reduced promoter activity by over 60%. An oligonucleotide spanning the AP-1 motif at -184 bound, specifically, nuclear factors from RKO cells, and antibodies specific for Jun-D, c-Jun, or Fra-1 proteins supershifted the complex indicating the presence of these proteins. The amount of these factors was reduced in GEO cells in which the u-PAR gene is only weakly transcriptionally activated, Expression of a vector encoding a wild-type Jun-D cDNA increased u-PAR promoter activity in GEO cells, Conversely, transfection of RKO cells with a transactivation domain-lacking Jun-D expression construct resulted in a dose-dependent decrease in u-PAR promoter activity, Treatment of GEO cells with phorbol ester increased u-PAR mRNA and the activity of a CAT reporter driven by the wild-type but not the AP-1 (-184)mutated u-PAR promoter, and this was associated with a strong induction in the amount of Jun-D, c-Jun, and c-Fos. Methylation interference studies using a fragment of the u-PAR promoter (spanning -201 to -150) bound with nuclear extracted proteins from RKO cells, and phorbol 12-myristate 13 acetate-treated and -untreated GEO cells showed that the contact points corresponded 60 the AP-1 binding site at -184, Thus, the elevated expression of u-PAR in RKO cells, which constitutively produces this binding site, as well as in phorbol 12-myristate 13-acetate stimulated GEO cells requires an AP-1 motif located 184 bp upstream of the transcriptional start site.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; TECH UNIV MUNICH,DEPT OBSTET & GYNECOL,D-81675 MUNICH,GERMANY; AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,MUCOSAL INFLAMMAT & CANC GRP,DIV MOL MED,CANBERRA,ACT 2601,AUSTRALIA; INST PASTEUR,DEPT BIOTECHNOL,UNITE VIRUS ONCOGENES,F-75724 PARIS 15,FRANCE	University of Texas System; UTMD Anderson Cancer Center; Technical University of Munich; Australian National University; John Curtin School of Medical Research; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Lengyel, Ernst/D-9220-2014; Pfarr, Curt/HHD-1410-2022	Lengyel, Ernst/0000-0001-8624-1507; 	NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58311] Funding Source: Medline; NIDCR NIH HHS [R01DE10845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGARWAL S, 1995, ONCOGENE, V11, P427; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BOYD D, 1989, CANCER RES, V49, P816; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; CASEY JR, 1994, BLOOD, V84, P1151; CHANTRET I, 1988, CANCER RES, V48, P1936; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLIS V, 1991, J BIOL CHEM, V266, P12752; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; HOLLAS W, 1991, CANCER RES, V51, P3690; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KARIKO K, 1993, CANCER RES, V53, P3109; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; LUND LR, 1992, FEBS LETT, V298, P177, DOI 10.1016/0014-5793(92)80050-Q; LUND LR, 1991, EMBO J, V10, P3399, DOI 10.1002/j.1460-2075.1991.tb04904.x; LUND LR, 1991, J BIOL CHEM, V266, P5177; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; Maxam A M, 1980, Methods Enzymol, V65, P499; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; Moffat GJ, 1996, J BIOL CHEM, V271, P1054, DOI 10.1074/jbc.271.2.1054; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PYKE C, 1993, FEBS LETT, V326, P69, DOI 10.1016/0014-5793(93)81763-P; QUATTRONE A, 1995, CANCER RES, V55, P90; ROBBINS KC, 1967, J BIOL CHEM, V242, P2333; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHLECHTE W, 1989, CANCER RES, V49, P6064; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; Suzuki T, 1996, J BIOL CHEM, V271, P1626, DOI 10.1074/jbc.271.3.1626; SUZUKI T, 1992, NUCLEIC ACIDS RES, P5537; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; VAGNARELLI P, 1992, CYTOGENET CELL GENET, V60, P197, DOI 10.1159/000133335; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WANG H, 1994, INT J CANCER, V58, P650, DOI 10.1002/ijc.2910580506; WANG Y, 1995, EUR J BIOCHEM, V227, P116, DOI 10.1111/j.1432-1033.1995.tb20366.x; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; YOON JK, 1994, MOL CELL BIOL, V14, P7731, DOI 10.1128/MCB.14.12.7731	62	84	85	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23176	23184		10.1074/jbc.271.38.23176	http://dx.doi.org/10.1074/jbc.271.38.23176			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798512	hybrid			2022-12-27	WOS:A1996VH76800038
J	Ruocco, MR; Chen, XE; Ambrosino, C; Dragonetti, E; Liu, WM; Mallardo, M; DeFalco, G; Palmieri, C; Franzoso, G; Quinto, I; Venuta, S; Scala, G				Ruocco, MR; Chen, XE; Ambrosino, C; Dragonetti, E; Liu, WM; Mallardo, M; DeFalco, G; Palmieri, C; Franzoso, G; Quinto, I; Venuta, S; Scala, G			Regulation of HIV-1 long terminal repeats by interaction of C/EBP(NF-IL6) and NF-kappa B/Rel transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LOOP-HELIX PROTEINS; C/EBP FAMILY; DNA-BINDING; INTERLEUKIN-8 GENE; NUCLEAR FACTOR; P50 SUBUNIT; EXPRESSION; TYPE-1; INFECTION	We report the characterization of a CAAT enhancer-binding protein (C/EBP) (NF-IL6) element encompassing the region from -174 to -166 of the U3 long terminal repeat (LTR) region of HIV-1. This C/EBP cis sequence was found to bind to C/EBP beta and C/EBP delta factors in DNA band shift assay. Transfection of NTera-2 cells with a HIV-1-LTR CAT construct (pC15CAT), together with C/EBP beta or C/EBP delta expression plasmids showed that C/EBP proteins strongly activated the HIV-1 promoter. Deletions encompassing the C/EBP-binding site resulted in the enhancement of the LTR activation mediated by C/EBP proteins, suggesting that other sequences located 3' to -170 were indeed the target for C/EBP factors, This possibility was confirmed by using the pCD54E9CAT plasmid, in which the NF-kappa B enhancer was inserted 5' to the HIV-1 LTR TATA box. A NF-kappa B1(p50) expression plasmid was also utilized to test for functional co-operation between NF-kappa B and C/EBP factors. We observed that p50 . C/EBP beta and p50 . C/EBP delta complexes were generated in tested cells and strongly activated the HIV-1 LTR by binding to the NF-kappa B sequences, The physical association of NF-kappa B1(p50) with C/EBP factors was assayed by direct interaction of in vitro translated p50 proteins with C/EBP beta or C/EBP delta produced as glutathione S-transferase fusion proteins. Moreover, p50 . C/EBP beta complexes were observed in vivo by using DNA affinity studies with biotinylated NF-kappa B oligonucleotides. By using mutant forms of p50 or C/EBP beta proteins we found that the transactivation of HIV-1 LTR by p50 . C/EBP beta complexes required the DNA-binding domain of p50 and the transcription activation domain of C/EBP beta.	UNIV REGGIO CALABRIA,SCH MED,INST CLIN & EXPT MED,I-88100 CATANZARO,ITALY; UNIV NAPLES FEDERICO II,SCH MED,DEPT BIOCHEM & BIOMED TECHNOL,I-80131 NAPLES,ITALY; NIAID,IMMUNOREGULAT LAB,NIH,BETHESDA,MD 20892	Universita Mediterranea di Reggio Calabria; University of Naples Federico II; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			SCALA, GIUSEPPE/A-3280-2009; Franzoso, Guido/GRR-8628-2022; Palmieri, Camillo/A-3195-2009	Palmieri, Camillo/0000-0001-6707-4723; QUINTO, Ileana/0000-0001-8212-8515; Franzoso, Guido/0000-0002-0778-988X; MALLARDO, Massimo/0000-0002-4001-3856				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, RES IMMUNOL, V143, P734, DOI 10.1016/0923-2494(92)80012-A; AVITAHL N, 1994, J BIOL CHEM, V269, P23553; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DIFAGAGNA FD, 1995, J VIROL, V69, P2765, DOI 10.1128/JVI.69.5.2765-2775.1995; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FAUCI AS, 1984, ANN INTERN MED, V100, P92, DOI 10.7326/0003-4819-100-1-92; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KIM JYH, 1993, J VIROL, V67, P1658, DOI 10.1128/JVI.67.3.1658-1662.1993; KUNSCH C, 1994, J IMMUNOL, V153, P153; LAPSIA MF, 1989, CELL, V59, P283; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LEVINE AM, 1992, BLOOD, V80, P8; LI XX, 1991, J BIOL CHEM, V266, P15192; LU YC, 1990, J VIROL, V64, P5226, DOI 10.1128/JVI.64.10.5226-5229.1990; LU YC, 1989, J VIROL, V63, P4115, DOI 10.1128/JVI.63.9.4115-4119.1989; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V88, P966; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MICHAEL NL, 1994, J VIROL, V68, P3163, DOI 10.1128/JVI.68.5.3163-3174.1994; MICHAEL NL, 1994, J VIROL, V68, P979, DOI 10.1128/JVI.68.2.979-987.1994; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MULLER CR, 1990, CELL, V61, P279; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P8202; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PAUL WE, 1995, CELL, V82, P177, DOI 10.1016/0092-8674(95)90304-6; POMERANTZ RJ, 1990, J EXP MED, V172, P253, DOI 10.1084/jem.172.1.253; RAY A, 1995, J BIOL CHEM, V270, P7365, DOI 10.1074/jbc.270.13.7365; RICE AP, 1988, NATURE, V332, P551, DOI 10.1038/332551a0; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553; Sambrook J., 2002, MOL CLONING LAB MANU; SCALA G, 1993, J VIROL, V67, P2853, DOI 10.1128/JVI.67.5.2853-2861.1993; SCALA G, 1990, J EXP MED, V172, P61, DOI 10.1084/jem.172.1.61; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; WEY X, 1995, NATURE, V373, P117; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG YH, 1995, J CLIN INVEST, V95, P2324, DOI 10.1172/JCI117924	63	90	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22479	22486		10.1074/jbc.271.37.22479	http://dx.doi.org/10.1074/jbc.271.37.22479			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798413	hybrid			2022-12-27	WOS:A1996VG67200032
J	Sibbesen, O; DeVoss, JJ; deMontellano, PRO				Sibbesen, O; DeVoss, JJ; deMontellano, PRO			Putidaredoxin reductase-putidaredoxin-cytochrome P450(cam) triple fusion protein - Construction of a self-sufficient Escherichia coli catalytic system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NADPH-P450 REDUCTASE; CRYSTAL-STRUCTURE; ELECTRON-TRANSFER; FUSED ENZYME; PSEUDOMONAS-PUTIDA; NADPH-CYTOCHROME-P450 REDUCTASE; AMINO-ACID; EXPRESSION; P-450CAM	Fusion proteins of cytochrome P450(cam) with putidaredoxin (Pd) and putidaredoxin reductase (PdR), the two proteins required to transfer electrons from NADH to P450(cam), were constructed by fusing cDNAs encoding the three proteins in the expression vector pCWori(+). Several fusion proteins, in which the order of the three protein domains and the linkers between them were varied, were expressed in Escherichia coli, purified, and characterized, The highest activity (k(cat) = 30 min(-1)) was obtained with a PdR-Pd-P450(cam) construct in which the peptides TDGTASS and PLEL were used, respectively, to Link the PdR to the Pd and the Pd to the P450(cam) domains, Oxygen and NADH consumption is tightly coupled to substrate oxidation in the fusion proteins, The rate-limiting step in the catalytic turnover of these fusion proteins is electron transfer from Pd to P450(cam). This is indicated by high rates of electron transfer from the PdR and Pd domains to exogenous electron accepters, by an increase in the activity of the P450(cam) domain upon addition of exogenous Pd, and by the high activity of wild-type P450(cam) when incubated with a PdR-Pd fusion protein. E. cold cells expressing the PdR-Pd-P450(cam) fusion protein efficiently oxidize camphor to 5-exo-hydroxycamphor and 5-oxocamphor. E. coli cells expressing the triple fusion protein thus constitute the first heterologous self-sufficient catalytic system for the oxidation of camphor and other substrates by P450(cam).	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NIGMS NIH HHS [GM-25515] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025515, R37GM025515] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINS WM, 1988, J BIOL CHEM, V263, P18842; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BLACK SM, 1994, P NATL ACAD SCI USA, V91, P7247, DOI 10.1073/pnas.91.15.7247; COLLINS JR, 1988, J BIOL CHEM, V263, P3164; CUPPVICKERY JR, 1995, STRUCT BIOL, V2, P144; DAVIES MD, 1990, J AM CHEM SOC, V112, P7396, DOI 10.1021/ja00176a050; DESJARLAIS RL, 1988, J MED CHEM, V31, P722, DOI 10.1021/jm00399a006; DEVOSS JJ, 1995, J AM CHEM SOC, V117, P4185, DOI 10.1021/ja00119a041; FISHER CW, 1992, P NATL ACAD SCI USA, V89, P10817, DOI 10.1073/pnas.89.22.10817; FRUETEL J, 1994, J AM CHEM SOC, V116, P11643, DOI 10.1021/ja00105a003; FRUETEL JA, 1992, J AM CHEM SOC, V114, P6987, DOI 10.1021/ja00044a006; GELB MH, 1982, BIOCHEM BIOPH RES CO, V104, P853, DOI 10.1016/0006-291X(82)91327-4; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; GUENGERICH FP, 1987, MAMMALIAN CYTOCHROME, P1; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; JONES JP, 1993, J AM CHEM SOC, V115, P381, DOI 10.1021/ja00055a002; KADKHODAYAN S, 1995, J BIOL CHEM, V270, P28042; KATAGIRI M, 1968, J BIOL CHEM, V243, P3543; KOGA H, 1985, BIOCHEM BIOPH RES CO, V130, P412, DOI 10.1016/0006-291X(85)90432-2; KOGA H, 1993, FEBS LETT, V331, P109, DOI 10.1016/0014-5793(93)80307-G; LI SY, 1993, BIOCHEMISTRY-US, V32, P9355, DOI 10.1021/bi00087a014; LOIDA PJ, 1995, J BIOL CHEM, V270, P5326, DOI 10.1074/jbc.270.10.5326; Mueller Ernest J., 1995, P83; MURAKAMI H, 1987, DNA-J MOLEC CELL BIO, V6, P189, DOI 10.1089/dna.1987.6.189; NAKAMURA K, 1994, BBA-PROTEIN STRUCT M, V1207, P40, DOI 10.1016/0167-4838(94)90049-3; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; PETERSON JA, 1990, J BIOL CHEM, V265, P6066; POCHAPSKY TC, 1994, BIOCHEMISTRY-US, V33, P6424, DOI 10.1021/bi00187a006; POULOS TL, 1987, BIOCHEMISTRY-US, V26, P8165, DOI 10.1021/bi00399a022; POULOS TL, 1982, J BIOL CHEM, V257, P427; RAAG R, 1990, BIOCHEMISTRY-US, V29, P8119, DOI 10.1021/bi00487a019; RAAG R, 1993, BIOCHEMISTRY-US, V32, P4571, DOI 10.1021/bi00068a013; RAAG R, 1991, BIOCHEMISTRY-US, V30, P2674, DOI 10.1021/bi00224a016; RAAG R, 1989, BIOCHEMISTRY-US, V28, P7586, DOI 10.1021/bi00445a013; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; SAKAKI T, 1990, DNA CELL BIOL, V9, P603, DOI 10.1089/dna.1990.9.603; SAKAKI T, 1994, BIOCHEMISTRY-US, V33, P4933, DOI 10.1021/bi00182a023; SHET MS, 1993, P NATL ACAD SCI USA, V90, P11748, DOI 10.1073/pnas.90.24.11748; SHET MS, 1995, ARCH BIOCHEM BIOPHYS, V318, P314, DOI 10.1006/abbi.1995.1235; SHET MS, 1994, ARCH BIOCHEM BIOPHYS, V311, P402, DOI 10.1006/abbi.1994.1255; SHIBATA M, 1990, DNA CELL BIOL, V9, P27, DOI 10.1089/dna.1990.9.27; SHIOTA N, 1994, PLANT PHYSIOL, V106, P17, DOI 10.1104/pp.106.1.17; STAYTON PS, 1990, BIOCHEMISTRY-US, V29, P7381, DOI 10.1021/bi00484a005; STAYTON PS, 1991, BIOCHEMISTRY-US, V30, P1845, DOI 10.1021/bi00221a017; TRUDGILL PW, 1966, J BIOL CHEM, V241, P1194; UNGER BP, 1986, J BIOL CHEM, V261, P1158; WADA A, 1991, ARCH BIOCHEM BIOPHYS, V290, P376, DOI 10.1016/0003-9861(91)90554-V; YABUSAKI Y, 1988, DNA-J MOLEC CELL BIO, V7, P701, DOI 10.1089/dna.1988.7.701; YAMAZAKI S, 1993, J BIOCHEM-TOKYO, V114, P652, DOI 10.1093/oxfordjournals.jbchem.a124232	51	96	96	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22462	22469		10.1074/jbc.271.37.22462	http://dx.doi.org/10.1074/jbc.271.37.22462			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798411	hybrid			2022-12-27	WOS:A1996VG67200030
J	Tobimatsu, T; Azuma, M; Matsubara, H; Takatori, H; Niida, T; Nishimoto, K; Satoh, H; Hayashi, R; Toraya, T				Tobimatsu, T; Azuma, M; Matsubara, H; Takatori, H; Niida, T; Nishimoto, K; Satoh, H; Hayashi, R; Toraya, T			Cloning, sequencing, and high level expression of the genes encoding adenosylcobalamin-dependent glycerol dehydrase of Klebsiella pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIOL DEHYDRASE; ESCHERICHIA-COLI; DHA REGULON; COENZYME; PROTEIN; DNA	The gld genes encoding adenosylcobalamin-dependent glycerol dehydrase of Klebsiella pneumoniae were cloned by cross-hybridization with a DNA fragment of Klebsiella oxytoca diol dehydrase genes. Since the Escherichia coli clones isolated did not show appreciable enzyme activity, plasmids for high level expression of cloned genes were constructed. The enzyme expressed in E. coli was indistinguishable from the wild-type glycerol dehydrase of K. pneumoniae by the criteria of polyacrylamide gel electrophoretic, immunochemical, and catalytic properties, It was also shown that the recombinant functional enzyme consists of M(r) 61,000, 22,000, and 16,000 subunits. Sequence analysis of the genes revealed four open reading frames separated by 2-12 bases. The sequential three open reading frames from the first to the third (gldA, gldB, and gldC genes) encoded polypeptides of 555, 194, and 141 amino acid residues with predicted molecular weights of 60,659(alpha), 21,355(beta), and 16,104(gamma), respectively. High level expression of these three genes in E. coli produced more than 14-fold higher level of fully active apoenzyme than that in a pneumoniae. It was thus concluded that these are the genes encoding the subunits of glycerol dehydrase. The deduced amino acid sequences of the three subunits were 71, 58, and 54% identical with those of the alpha, beta, and gamma subunits of diol dehydrase, respectively, but failed to show any apparent homology with other proteins.	OKAYAMA UNIV,FAC ENGN,DEPT BIOSCI & BIOTECHNOL,OKAYAMA 700,JAPAN	Okayama University			TOBIMATSU, Takamasa/B-2646-2011					CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DANIEL R, 1992, FEMS MICROBIOL LETT, V100, P281, DOI 10.1016/0378-1097(92)90222-A; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HA, 1963, J BIOL CHEM, V238, P2367; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POZNANSKAJA AA, 1979, ARCH BIOCHEM BIOPHYS, V194, P379, DOI 10.1016/0003-9861(79)90630-1; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER Z, 1966, B ACAD POL SCI BIOL, V14, P7; STROINSKI A, 1974, ARCH BIOCHEM BIOPHYS, V162, P321, DOI 10.1016/0003-9861(74)90189-1; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOBIMATSU T, 1995, J BIOL CHEM, V270, P7142, DOI 10.1074/jbc.270.13.7142; TONG IT, 1991, APPL ENVIRON MICROB, V57, P3541, DOI 10.1128/AEM.57.12.3541-3546.1991; TORAYA T, 1994, MET IONS BIOL SYST, V30, P217; TORAYA T, 1977, J BIOL CHEM, V252, P963; TORAYA T, 1976, BIOCHEM BIOPH RES CO, V69, P475, DOI 10.1016/0006-291X(76)90546-5; TORAYA T, 1977, EUR J BIOCHEM, V76, P285, DOI 10.1111/j.1432-1033.1977.tb11594.x; TORAYA T, 1980, J BACTERIOL, V141, P1439, DOI 10.1128/JB.141.3.1439-1442.1980; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	27	65	88	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22352	22357		10.1074/jbc.271.37.22352	http://dx.doi.org/10.1074/jbc.271.37.22352			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798396	hybrid			2022-12-27	WOS:A1996VG67200015
J	vanderDrift, KMGM; Spaink, HP; Bloemberg, GV; vanBrussel, AAN; Lugtenberg, BJJ; Haverkamp, J; ThomasOates, JE				vanderDrift, KMGM; Spaink, HP; Bloemberg, GV; vanBrussel, AAN; Lugtenberg, BJJ; Haverkamp, J; ThomasOates, JE			Rhizobium leguminosarum bv trifolii produces lipo-chitin oligosaccharides with nodE-dependent highly unsaturated fatty acyl moieties - An electrospray ionization and collision-induced dissociation tandem mass spectrometric study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-SPECIFICITY; NODULATION FACTORS; SIGNAL MOLECULES; ACID MOIETY; MELILOTI; BIOSYNTHESIS; GENES	The lipo-chitin oligosaccharides (LCO) or nodulation factors synthesized by Rhizobium leguminosarum bv. trifolii were analyzed using positive mode fast atom bombardment and positive and negative mode electrospray ionization mass spectrometry. From their mass spectrometric behavior it is clearly possible to distinguish between the [M + Na](+) pseudomolecular ion of the nodE-independent molecule IV(C18:1,Ac) and the [M + H](+) pseudomolecular ion of the nodE-dependent molecule IV(C20:4,Ac), although they both have the same mass value. The results unequivocally show that the bacterial strain investigated produces nodE-dependent LCOs with highly unsaturated fatty acyl moieties. We further demonstrate that the interpretation of the mass spectrometric data by Philip-Hollingsworth et al. (Philip-Hollingsworth, S., Orgambide, G. G., Bradford, J. J., Smith, D. K., Hollingsworth, R. I., and Dazzo, F. B. (1995) J. Biol. Chem. 270, 20968) is incorrect and that their data do not contradict our hypothesis that the nodE gene determines the host specificity of R. leguminosarum bv. trifolii.	LEIDEN UNIV,CLUSIUS LAB,INST MOL PLANT SCI,NL-2333 AL LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC	vanderDrift, KMGM (corresponding author), UNIV UTRECHT,DEPT MASS SPECTROMETRY,FAFC WENT GEBOUW,SORBONNELAAN 16,NL-3584 CA UTRECHT,NETHERLANDS.		Spaink, Herman P./S-3586-2017; Bloemberg, Guido/AAC-4914-2020	Spaink, Herman P./0000-0003-4128-9501; 				CARLSON RW, 1994, MOL PLANT MICROBE IN, V7, P684, DOI 10.1094/MPMI-7-0684; CARROLL JA, 1995, ANAL CHIM ACTA, V307, P431, DOI 10.1016/0003-2670(94)00514-M; CERNY RL, 1986, ORG MASS SPECTROM, V21, P655, DOI 10.1002/oms.1210211009; DEMONT N, 1993, J BIOL CHEM, V268, P20134; DEMONT N, 1994, EMBO J, V13, P2139, DOI 10.1002/j.1460-2075.1994.tb06490.x; FISHER RF, 1993, J MOL BIOL, V233, P336, DOI 10.1006/jmbi.1993.1515; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; ORLANDO R, 1990, BIOMED ENVIRON MASS, V19, P747, DOI 10.1002/bms.1200191202; PHILIPHOLLINGSWORTH S, 1995, J BIOL CHEM, V270, P20968, DOI 10.1074/jbc.270.36.20968; RELIC B, 1993, MOL PLANT MICROBE IN, V6, P764, DOI 10.1094/MPMI-6-764; Ritsema T, 1996, MOL GEN GENET, V251, P44; SCHLAMAN HRM, 1992, J BACTERIOL, V174, P5177, DOI 10.1128/JB.174.16.5177-5182.1992; SCHULTZE M, 1995, INT REV CYTOL, V156, P1; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; SPAINK HP, 1995, MOL PLANT MICROBE IN, V8, P155, DOI 10.1094/MPMI-8-0155; SPAINK HP, 1994, PLANT MOL BIOL, V26, P1413, DOI 10.1007/BF00016482; VERDUYN R, 1992, RECL TRAV CHIM PAY B, V111, P367; ZHOU ZR, 1990, J ORG CHEM, V55, P5444, DOI 10.1021/jo00307a011	18	20	20	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22563	22569		10.1074/jbc.271.37.22563	http://dx.doi.org/10.1074/jbc.271.37.22563			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798424	Green Published, hybrid			2022-12-27	WOS:A1996VG67200043
J	Stoltz, M; Rassow, J; Buckmann, AF; Brandsch, R				Stoltz, M; Rassow, J; Buckmann, AF; Brandsch, R			Covalent attachment of FAD derivatives to a fusion protein consisting of 6-hydroxy-D-nicotine oxidase and a mitochondrial presequence - Folding, enzyme activity, and import of the modified protein into yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEMBRANE SPACE; DEHYDROGENASE; TRANSLOCATION; BINDING; MATRIX; FLAVINYLATION; MUTAGENESIS; CYTOCHROME; APOENZYME	Autoflavinylation of 6-hydroxy-D-nicotine oxidase (6-HDNO) was successfully employed to modify the protein covalently with FAD derivatives, The model compounds N-6-(2-aminoethyl)-FAD and N-6-(6-carboxyhexyl)-FAD were spontaneously bound to a fusion protein consisting of the mitochondrial targeting sequence of Neurospora crassa F-0-ATPase subunit 9 (Su9) attached to 6-HDNO. When translated in the rabbit reticulocyte lysate, Su9-6-HDNO was in the trypsin-sensitive apoenzyme form; when translated in the presence of flavins it adopted a trypsin-resistant conformation characteristic of the 6-HDNO holoenzyme. With flavin derivatives, Su9-6-HDNO exhibited approximately 50% of the 6-HDNO activity observed with FAD. The covalently modified Su9-6-HDNO was imported into Saccharomyces cerevisiae mitochondria with an efficiency equal to that of the apoenzyme, Apparently the increase in size and charge of the FAD moiety did not hamper translocation across the mitochondrial membranes. Yeast mutant ssc1-2 mitochondria deficient in mtHsp70 unfoldase activity imported the flavinylated Su9-6-HDNO protein. in mutant ssc1-3 mitochondria deficient in both mtHsp70 unfoldase and translocase activity Su9-6-HDNO was trapped as translocation intermediate; the Su9 presequence was passed to the matrix where it was proteolytically cleaved by the mitochondrial processing peptidase; (MPP); the translocation-arrested 6-HDNO moiety adopted a trypsin-sensitive conformation, Our results indicate that unfolding of the FAD-stabilized flavin-binding domain of 6-HDNO in passage through the mitochondrial general insertion pore does not require the activity of mtHsp70.	INST BIOCHEM & MOL BIOL,D-79104 FREIBURG,GERMANY; GESELL BIOTECHNOL FORSCH MBH,D-38124 BRAUNSCHWEIG,GERMANY	Gesellschaft fur Biotechnologische Forschung mbH								BRANDSCH R, 1989, BIOCHEM J, V258, P187, DOI 10.1042/bj2580187; BRANDSCH R, 1991, J BIOL CHEM, V266, P19056; BUCKMANN AF, 1993, FLAVINS FLAVOPROTEIN, P597; DAUM G, 1982, J BIOL CHEM, V257, P3028; DECKER K, 1991, BIOFACTORS, V3, P69; GAMBILL D, 1993, J CELL BIOL, V12, P3288; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KIM JH, 1994, J BACTERIOL, V176, P6349, DOI 10.1128/jb.176.20.6349-6361.1994; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; MAUCH L, 1989, FEBS LETT, V257, P86, DOI 10.1016/0014-5793(89)81792-2; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MOHLER H, 1972, EUR J BIOCHEM, V29, P152, DOI 10.1111/j.1432-1033.1972.tb01969.x; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; SCRUTTON NS, 1994, J BIOL CHEM, V269, P13942; STOLTZ M, 1995, J BIOL CHEM, V270, P8016, DOI 10.1074/jbc.270.14.8016; VOOS, 1996, EMBO J, V15, P2668; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119; ZARA V, 1992, J BIOL CHEM, V267, P12077; ZHOU BP, 1995, BIOCHEMISTRY-US, V34, P9526, DOI 10.1021/bi00029a029	23	6	6	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25208	25212		10.1074/jbc.271.41.25208	http://dx.doi.org/10.1074/jbc.271.41.25208			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810280	hybrid			2022-12-27	WOS:A1996VL69300024
J	Bradford, AP; Conrad, KE; Tran, PH; Ostrowski, MC; GutierrezHartmann, A				Bradford, AP; Conrad, KE; Tran, PH; Ostrowski, MC; GutierrezHartmann, A			GHF-1/Pit-1 functions as a cell-specific integrator of Ras signaling by targeting the ras pathway to a composite Ets-1/GHF-1 response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLACTIN PROMOTER ACTIVITY; DEPENDENT PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; ETS DOMAIN PROTEIN; GENE-EXPRESSION; TRANSCRIPTION FACTOR; C-FOS; TRANSDUCTION PATHWAYS; ACTIVATION DOMAIN; CARCINOMA-CELLS	Activation of the rat prolactin (rPRL) promoter by Ras is a prototypical example of tissue-specific transcriptional regulation in a highly differentiated cell type. Using a series of site specific mutations and deletions of the proximal rPRL promoter we have mapped the major Ras/Raf response element (RRE) to a composite Ets-1/GHF-1 binding site located between positions -217 and -190. Mutation of either the Ets-1 or GHF-1 binding sites inhibits Ras and Raf activation of the rPRL promoter, and insertion of this RRE into the rat growth hormone promoter confers Ras responsiveness. We show that Ets-1 is expressed in GH(4) cells and, consistent with their functional synergistic interaction, both Ets-1 and GHF-1 are able to bind specifically to this bipartite RRE. We confirm that Ets-1 or a related Ets factor is the nuclear target of the Ras pathway leading to activation of the rPRL promoter and demonstrate that Elk-1 and Net do not mediate the Ras response, Thus, the pituitary-specific POU homeodomain transcription factor, GHF-1, serves as a cell-specific signal integrator by functionally interacting with an Ets-1-like factor, at uniquely juxtaposed binding sites, thereby targeting an otherwise ubiquitous Ras signaling pathway to a select subset of cell-specific GHF-1-dependent genes.	UNIV COLORADO, HLTH SCI CTR, DEPT BIOCHEM BIOPHYS & GENET, PROGRAM MOL BIOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, COLORADO CANC CTR, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT MED, PROGRAM MOL BIOL, DENVER, CO 80262 USA; OHIO STATE UNIV, DEPT MOL GENET, COLUMBUS, OH 43210 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University System of Ohio; Ohio State University			Gutierrez-Hartmann, Arthur/F-1295-2011; Ostrowski, Michael/H-3108-2011	Ostrowski, Michael/0000-0003-2948-6297	NIDDK NIH HHS [DK 46868, N43-DK-2-2214] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046868, N43DK022214, R01DK046868] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERWAER M, 1993, MOL CELL ENDOCRINOL, V92, P1, DOI 10.1016/0303-7207(93)90068-U; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; CONRAD KE, 1992, ONCOGENE, V7, P1279; DAY RN, 1990, MOL ENDOCRINOL, V4, P1964, DOI 10.1210/mend-4-12-1964; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; ELSHOLTZ HP, 1992, SEMIN REPROD ENDOCR, V10, P183, DOI 10.1055/s-2007-1018875; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FLEISCHMAN LF, 1995, MOL CELL BIOL, V15, P925; GALANG CK, 1994, ONCOGENE, V9, P2913; GALIEN R, 1991, ONCOGENE, V6, P849; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GRUENEBERG DA, 1995, MOL CELL BIOL, V15, P3318; GUTIERREZHARTMANN A, 1994, MOL ENDOCRINOL, V8, P1447, DOI 10.1210/me.8.11.1447; GUTIERREZHARTMANN A, 1987, P NATL ACAD SCI USA, V84, P5211, DOI 10.1073/pnas.84.15.5211; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; JACOB KK, 1994, J BIOL CHEM, V269, P25515; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KEDAR PS, 1990, MOL CELL BIOL, V10, P3852, DOI 10.1128/MCB.10.7.3852; KEECH CA, 1991, MOL CELL ENDOCRINOL, V78, P55, DOI 10.1016/0303-7207(91)90185-U; KEECH CA, 1989, MOL ENDOCRINOL, V3, P832, DOI 10.1210/mend-3-5-832; KIM MK, 1993, J BIOL CHEM, V268, P23366; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LACAL JC, 1990, MOL CELL BIOL, V10, P2983, DOI 10.1128/MCB.10.6.2983; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; OBERWETTER JM, 1993, MOL ENDOCRINOL, V7, P915, DOI 10.1210/me.7.7.915; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; OWEN RD, 1990, P NATL ACAD SCI USA, V87, P3866, DOI 10.1073/pnas.87.10.3866; OWEN RD, 1990, MOL CELL BIOL, V10, P1; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PEERS B, 1991, J BIOL CHEM, V266, P18127; PEERS B, 1992, EUR J BIOCHEM, V210, P53, DOI 10.1111/j.1432-1033.1992.tb17389.x; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; PICKETT CA, 1995, MOL CELL BIOL, V15, P6777; RAJNARAYAN S, 1995, MOL ENDOCRINOL, V9, P502, DOI 10.1210/me.9.4.502; REDDY MA, 1992, MOL ENDOCRINOL, V6, P1051, DOI 10.1210/me.6.7.1051; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHEPARD AR, 1994, J BIOL CHEM, V269, P1804; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WERNERT N, 1992, AM J PATHOL, V140, P119; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670; Yang BS, 1996, MOL CELL BIOL, V16, P538	72	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24639	24648		10.1074/jbc.271.40.24639	http://dx.doi.org/10.1074/jbc.271.40.24639			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798730	hybrid			2022-12-27	WOS:A1996VM67400052
J	Cui, L; Yu, WP; DeAizpurua, HJ; Schmidli, RS; Pallen, CJ				Cui, L; Yu, WP; DeAizpurua, HJ; Schmidli, RS; Pallen, CJ			Cloning and characterization of islet cell antigen-related protein-tyrosine phosphatase (PTP), a novel receptor-like PTP and autoantigen in insulin-dependent diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMIC-ACID DECARBOXYLASE; VIRULENCE DETERMINANT; TRYPTIC FRAGMENTS; ANTIBODIES; DISTINCT; EXPRESSION; IDDM; SEQUENCE; IA-2; IDENTIFICATION	Cloning of the cDNA encoding a novel human protein-tyrosine phosphatase (PTP) called islet cell antigen-related PTP (IAR) predicts a receptor-like molecule with an extracellular domain of 614 amino acids containing a hydrophobic signal peptide, one potential N-glycosylation site, and an RGDS peptide which is a possible adhesive recognition sequence. The 376-amino acid intracellular region contains a single catalytic domain. Recombinant IAR polypeptide has phosphatase activity. Northern blot analysis shows tissue-specific expression of two IAR transcripts of 5.5 and 3.7 kilobases, which are most abundant in brain and pancreas. The IAR PTP is homologous in its intracellular region to IA-2, a putative PTP that is an insulin-dependent diabetes mellitus (IDDM) autoantigen. IAR is also reactive with IDDM patient sera. IAR and IA-2 may distinguish different populations of IDDM autoantibodies since they identify overlapping but nonidentical sets of IDDM patients. Thus IAR is likely to be an islet cell antigen useful in the preclinical screening of individuals for risk of IDDM.	NATL UNIV SINGAPORE, INST MOL & CELL BIOL, CELL REGULAT LAB, SINGAPORE 117548, SINGAPORE; WALTER & ELIZA HALL INST MED RES, BURNET CLIN RES UNIT, PARKVILLE, VIC 3032, AUSTRALIA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Walter & Eliza Hall Institute				Pallen, Catherine/0000-0002-3576-5295				ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BINGLEY PJ, 1994, DIABETES, V43, P1304, DOI 10.2337/diabetes.43.11.1304; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BONIFACIO E, 1990, LANCET, V335, P147, DOI 10.1016/0140-6736(90)90013-U; BOTTAZZO GF, 1974, LANCET, V2, P1279, DOI 10.1016/S0140-6736(74)90140-8; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHRISTIE MR, 1993, J CLIN INVEST, V92, P240, DOI 10.1172/JCI116556; CHRISTIE MR, 1990, J EXP MED, V172, P789, DOI 10.1084/jem.172.3.789; CHRISTIE MR, 1994, DIABETES, V43, P1254, DOI 10.2337/diabetes.43.10.1254; CHRISTIE MR, 1992, DIABETES, V41, P782, DOI 10.2337/diabetes.41.7.782; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GENOVESE S, 1994, LANCET, V344, P756, DOI 10.1016/S0140-6736(94)92248-9; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HAKES DJ, 1993, P NATL ACAD SCI USA, V90, P4017, DOI 10.1073/pnas.90.9.4017; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; KAMBAYASHI Y, 1995, BIOCHEM J, V306, P331, DOI 10.1042/bj3060331; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAN MS, 1994, DNA CELL BIOL, V13, P505, DOI 10.1089/dna.1994.13.505; LU J, 1994, BIOCHEM BIOPH RES CO, V204, P930, DOI 10.1006/bbrc.1994.2549; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; PALMER JP, 1983, SCIENCE, V222, P1337, DOI 10.1126/science.6362005; PASSINI N, 1995, P NATL ACAD SCI USA, V92, P9412, DOI 10.1073/pnas.92.20.9412; PAYTON MA, 1995, J CLIN INVEST, V96, P1506, DOI 10.1172/JCI118188; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RABIN DU, 1994, J IMMUNOL, V152, P3183; SCHMIDLI RS, 1994, J AUTOIMMUN, V7, P55, DOI 10.1006/jaut.1994.1005; Schultz Leonard D., 1993, Cell, V73, P1445; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TABITI K, 1995, CANCER LETT, V93, P239, DOI 10.1016/0304-3835(95)03816-F; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALKER PA, 1994, BIO-TECHNOL, V12, P601, DOI 10.1038/nbt0694-601; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	40	53	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24817	24823		10.1074/jbc.271.40.24817	http://dx.doi.org/10.1074/jbc.271.40.24817			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798755	hybrid			2022-12-27	WOS:A1996VM67400077
J	Flodby, P; Barlow, C; Kylefjord, H; Ahrlund-Richter, L; Xanthopoulos, KG				Flodby, P; Barlow, C; Kylefjord, H; Ahrlund-Richter, L; Xanthopoulos, KG			Increased hepatic cell proliferation and lung abnormalities in mice deficient in CCAAT/enhancer binding protein alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-ALBUMIN GENE; C/EBP-ALPHA; TRANSCRIPTION FACTORS; ADIPOCYTE DIFFERENTIATION; 3T3-L1 PREADIPOCYTES; HEPATOCELLULAR-CARCINOMA; LEUCINE ZIPPER; STEM-CELLS; RAT-LIVER; C-MYC	CCAAT/enhancer binding protein alpha (C/EBP alpha) is a transcription factor that has been implicated in the regulation of cell-specific gene expression mainly in hepatocytes and adipocytes but also in several other terminally differentiated cells. It has been previously demonstrated that the C/EBP alpha protein is functionally indispensable, as inactivation of the C/EBP alpha gene by homologous recombination in mice results in the death of animals homozygous for the mutation shortly after birth (Wang, N., Finegold, M. J., Bradley, A., Ou, C. N., Abdelsayed, S. V., Wilde, M. D., Taylor, L. R., Wilson, D. R., and Darlington, G. J. (1995) Science 269, 1108-1112). Here we show that C/EBP alpha-1-mice have defects in the control of hepatic growth and lung development. The liver architecture is disturbed, with acinar formation, in a pattern suggestive of either regenerating liver or pseudoglandular hepatocellular carcinoma. Pulmonary histology shows hyperproliferation of type II pneumocytes and disturbed alveolar architecture. At the molecular level, accumulation of glycogen and lipids in the liver and adipose tissues is impaired, and the mutant animals are severely hypoglycemic. Levels of c-myc and c-jun RNA are specifically induced by several fold in the livers of the C/EBP alpha -/- animals, indicating an active proliferative stage. Furthermore, immunohistologic detection with an antibody to proliferating cell nuclear antigen/cyclin shows a 5-10 times higher frequency of positively stained hepatocytes in C/EBP alpha -/- liver. These results suggest a critical role for C/EBP alpha in vivo for the acquisition of terminally differentiated functions in liver including the maintenance of physiologic energy homeostasis.	KAROLINSKA INST, NOVUM, DEPT BIOSCI, S-14157 HUDDINGE, SWEDEN; CGTB, NATL CTR HUMAN GENOME RES, NIH, BETHESDA, MD 20892 USA	Karolinska Institutet; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)			Ahrlund-Richter, Lars/C-6226-2012					ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; ANTONSON P, 1995, EUR J BIOCHEM, V232, P397, DOI 10.1111/j.1432-1033.1995.tb20824.x; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; FLODBY P, 1995, MOL CARCINOGEN, V12, P103, DOI 10.1002/mc.2940120207; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GRAYSON DR, 1988, SCIENCE, V239, P786, DOI 10.1126/science.3257586; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KUO CF, 1990, DEVELOPMENT, V109, P473; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEGRAVEREND C, 1993, NUCLEIC ACIDS RES, V21, P1735, DOI 10.1093/nar/21.8.1735; LI F, 1995, AM J PHYSIOL, V13, P241; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; MAEDA T, 1995, J SURG ONCOL, V60, P75, DOI 10.1002/jso.2930600202; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8224; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; PIONTKEWITZ Y, 1993, ENDOCRINOLOGY, V133, P2327, DOI 10.1210/en.133.5.2327; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; SCOTT LM, 1992, BLOOD, V80, P1725; SMITH CI, 1995, AM J PHYSIOL-LUNG C, V269, pL603, DOI 10.1152/ajplung.1995.269.5.L603; TAE HJ, 1994, J BIOL CHEM, V269, P10475; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; TONJES RR, 1992, EMBO J, V11, P127, DOI 10.1002/j.1460-2075.1992.tb05035.x; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VALLET V, 1995, EXP CELL RES, V216, P363, DOI 10.1006/excr.1995.1046; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; XANTHOPOULOS KG, 1992, EUR J BIOCHEM, V208, P501, DOI 10.1111/j.1432-1033.1992.tb17214.x; XANTHOPOULOS KG, 1989, P NATL ACAD SCI USA, V86, P4117, DOI 10.1073/pnas.86.11.4117; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x; YUBERO P, 1994, BIOCHEM BIOPH RES CO, V198, P653, DOI 10.1006/bbrc.1994.1095	60	250	255	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24753	24760		10.1074/jbc.271.40.24753	http://dx.doi.org/10.1074/jbc.271.40.24753			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798745	hybrid			2022-12-27	WOS:A1996VM67400067
J	Mackay, F; Majeau, GR; Hochman, PS; Browning, JL				Mackay, F; Majeau, GR; Hochman, PS; Browning, JL			Lymphotoxin beta receptor triggering induces activation of the nuclear factor beta B transcription factor in some cell types	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; HUMAN IMMUNODEFICIENCY VIRUS; FACTOR-ALPHA; HETEROMERIC COMPLEX; ENDOTHELIAL-CELLS; MICE DEFICIENT; GROWTH-FACTORS; CROSS-LINKING; TNF RECEPTOR	NF kappa B is a pleiotropic transcription factor capable of activating the expression of a great variety of genes critical for the immunoinflammatory response. Tumor necrosis factor alpha (TNF alpha) and lymphotoxin alpha (LT alpha, originally TNF beta) are potent nuclear factor kappa B (NF kappa B) activators in various cell types. The LT alpha molecule, in addition to being secreted as a soluble trimer, can also form membrane-anchored heterotrimers with the LT beta chain, another member of the TNF family. The LT alpha 1 beta 2 heterotrimer binds a specific receptor, called the LT beta receptor (LT beta-R), which is also a member of the TNF receptor family. Here, we show that engagement of LT beta-R with a soluble form of LT alpha 1 beta 2 or with a specific anti-LT beta-R agonistic monoclonal antibody CBE11 quickly induces activation of NF kappa B in HT-29 and WiDr human adenocarcinomas. LT beta-R triggering activates NF kappa B and induces proliferation in WI-38 human lung fibroblasts. No NF kappa B activation is observed in human umbilical vein endothelial cells, correlating with the inability of LT beta-R activation to induce expression of NF kappa B-dependent cell surface adhesion molecules. Thus, like several other members of the TNF receptor family, the LT beta-R can activate NF kappa B following receptor ligation in some but not all LT beta-R-positive cells.			Mackay, F (corresponding author), BIOGEN INC,DEPT CELL BIOL,14 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		Mackay, Fabienne/B-7440-2008	Mackay, Fabienne/0000-0002-6074-2693; Browning, Jeffrey/0000-0001-9168-5233				AGGARWAL BB, 1995, EXP CELL RES, V218, P381, DOI 10.1006/excr.1995.1169; ALDERSON MR, 1994, INT IMMUNOL, V6, P1799, DOI 10.1093/intimm/6.11.1799; ANDROLEWICZ MJ, 1992, J BIOL CHEM, V267, P2542; BANKS TA, 1995, J IMMUNOL, V155, P1685; BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; Bazzoni F, 1995, J INFLAMM, V45, P221; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BISWAS P, 1995, IMMUNITY, V2, P587; Browning JL, 1996, J BIOL CHEM, V271, P8618, DOI 10.1074/jbc.271.15.8618; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; BROWNING JL, 1995, J IMMUNOL, V154, P33; BROWNING MJ, 1993, P NATL ACAD SCI USA, V90, P2842, DOI 10.1073/pnas.90.7.2842; CHATURVEDI MM, 1994, LYMPHOKINE CYTOK RES, V13, P309; CROWE PD, 1994, J IMMUNOL METHODS, V168, P79, DOI 10.1016/0022-1759(94)90212-7; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; DIGMAN JD, 1983, NUCLEIC ACIDS RES, V11, P1475; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FAJARDO LF, 1992, AM J PATHOL, V140, P539; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FRANCIS CA, 1994, J PROD AGRIC, V7, P151, DOI 10.2134/jpa1994.0151; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; HESS S, 1995, J IMMUNOL, V155, P4588; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; ISRAEL N, 1989, J IMMUNOL, V143, P3956; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LEONARDO M, 1987, SCIENCE, V236, P1573; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; MCDONALD PP, 1995, EUR J IMMUNOL, V25, P2870, DOI 10.1002/eji.1830251024; MICHIHIKO S, 1989, LANCET, V1, P1206; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; RENSINGEHL A, 1995, J INFLAMM, V45, P161; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SCHUTZE S, 1995, IMMUNOBIOLOGY, V193, P193, DOI 10.1016/S0171-2985(11)80543-7; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIMADA Y, 1990, J CELL PHYSIOL, V142, P31, DOI 10.1002/jcp.1041420105; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; TOTPAL K, 1994, J IMMUNOL, V153, P2248; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175	55	65	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24934	24938		10.1074/jbc.271.40.24934	http://dx.doi.org/10.1074/jbc.271.40.24934			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798772	hybrid			2022-12-27	WOS:A1996VM67400095
J	Ryan, SE; Demers, CN; Chew, JP; Baenziger, JE				Ryan, SE; Demers, CN; Chew, JP; Baenziger, JE			Structural effects of neutral and anionic lipids on the nicotinic acetylcholine receptor - An infrared difference spectroscopy study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; RECONSTITUTED MEMBRANES; POSTSYNAPTIC MEMBRANES; CHOLINERGIC RECEPTOR; TORPEDO-CALIFORNICA; ION-CHANNEL; CHOLESTEROL; BINDING; BACTERIORHODOPSIN; PHOSPHOLIPIDS	The effects of both neutral and anionic lipids on the structure of the nicotinic acetylcholine receptor (nAChR) have been probed using infrared difference spectroscopy, The difference between infrared spectra of the nAChR recorded using the attenuated total reflectance technique in the presence and absence of the neu rotransmitter analog, carbamylcholine, exhibits a complex pattern of positive and negative bands that provides a spectral map of the structural changes that occur in the nAChR upon ligand binding and subsequent desensitization. This spectral map is essentially identical in difference spectra recorded from native, native alkaline-extracted, and affinity purified nAChR reconstituted into either soybean asolectin or egg phosphatidylcholine membranes containing both neutral and anionic lipids, This result suggests both a similar structure of the nAChR and a similar resting to desensitized conformational change in each membrane environment. In contrast, difference spectra recorded from the nAChR reconstituted into egg phosphatidylcholine membranes lacking neutral and/or anionic lipids all exhibit an essentially identical pattern of band intensity variations, which is similar to the pattern of variations observed in difference spectra recorded in the continuous presence of the desensitizing local anesthetic, dibucaine, The difference spectra suggest that the main effect of both neutral and anionic lipids in a reconstituted egg phosphatidylcholine membrane is to help stabilize the nAChR in a resting conformation, In the absence of neutral and/or anionic lipids, the nAChR is converted into an alternate conformation that appears to be analogous to the local anesthetic-induced desensitized state, Significantly, the proportion of receptors found in the resting versus the putative desensitized state appears to be dependent upon the final lipid composition of the reconstituted membrane, A lipid-dependent modulation of the equilibrium between a channel-active resting and channel-inactive desensitized state may account for the modulations of nAChR activity that are observed in different lipid membranes.	UNIV OTTAWA,DEPT BIOCHEM,OTTAWA,ON K1H 8M5,CANADA	University of Ottawa				Baenziger, John/0000-0002-2888-5328				AUGER M, 1990, J AM CHEM SOC, V112, P1373, DOI 10.1021/ja00160a013; Baenziger J. E., 1995, Biophysical Journal, V68, pA377; BAENZIGER JE, 1992, BIOPHYS J, V61, P983, DOI 10.1016/S0006-3495(92)81905-7; BAENZIGER JE, 1992, BIOPHYS J, V62, P64, DOI 10.1016/S0006-3495(92)81780-0; BAENZIGER JE, 1993, BIOCHEMISTRY-US, V32, P5448, DOI 10.1021/bi00071a022; BHUSHAN A, 1993, BIOPHYS J, V64, P716, DOI 10.1016/S0006-3495(93)81431-0; BLANCHARD SG, 1979, BIOCHEMISTRY-US, V18, P5880, DOI 10.1021/bi00593a019; BOYD ND, 1980, BIOCHEMISTRY-US, V19, P5344, DOI 10.1021/bi00564a031; BRAIMAN MS, 1994, BIOCHEMISTRY-US, V33, P1629, DOI 10.1021/bi00173a003; BRAIMAN MS, 1988, ANNU REV BIOPHYS BIO, V17, P541; BRASWELL LM, 1984, BRIT J PHARMACOL, V83, P305, DOI 10.1111/j.1476-5381.1984.tb10147.x; BUTLER DH, 1993, BIOCHIM BIOPHYS ACTA, V1150, P17, DOI 10.1016/0005-2736(93)90116-H; CRIADO M, 1984, J BIOL CHEM, V259, P9188; ELLENA JF, 1983, BIOCHEMISTRY-US, V22, P5523, DOI 10.1021/bi00293a012; FERNANDEZBALLESTER G, 1994, BIOCHEMISTRY-US, V33, P4065, DOI 10.1021/bi00179a035; FONG TM, 1987, BIOCHEMISTRY-US, V26, P3871, DOI 10.1021/bi00387a020; FONG TM, 1986, BIOCHEMISTRY-US, V25, P830, DOI 10.1021/bi00352a015; GREGORIOU VG, 1995, BIOCHEMISTRY-US, V34, P6876, DOI 10.1021/bi00020a035; HIENERWADEL R, 1995, BIOCHEMISTRY-US, V34, P2832, DOI 10.1021/bi00009a013; HORVATH LI, 1988, BIOCHEMISTRY-US, V27, P46, DOI 10.1021/bi00401a009; JONES OT, 1988, BIOCHEMISTRY-US, V27, P2364, DOI 10.1021/bi00407a018; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KRODEL EK, 1979, MOL PHARMACOL, V15, P294; LUDLAM CFC, 1995, BIOCHEMISTRY-US, V34, P2, DOI 10.1021/bi00001a001; MARCELJA S, 1974, BIOCHIM BIOPHYS ACTA, V367, P165, DOI 10.1016/0005-2736(74)90040-6; Marsh D., 1982, LIPID PROTEIN INTERA, V2, P53; MCCARTHY MP, 1992, J BIOL CHEM, V267, P7655; McNamee M., 1988, LIPID DOMAINS RELATI, P43; METHOT N, 1995, BIOCHEMISTRY-US, V34, P15142, DOI 10.1021/bi00046a021; METHOT N, 1994, BIOCHEMISTRY-US, V33, P7709, DOI 10.1021/bi00190a026; MOORE MA, 1994, BBA-BIOMEMBRANES, V1190, P457, DOI 10.1016/0005-2736(94)90108-2; OCHOA ELM, 1983, BIOCHIM BIOPHYS ACTA, V727, P151, DOI 10.1016/0005-2736(83)90379-6; RAINES DE, 1993, BIOPHYS J, V64, P32; Reid SE, 1996, SPECTROCHIM ACTA A, V52, P1347, DOI 10.1016/0584-8539(96)01718-7; ROTHSCHILD KJ, 1992, J BIOENERG BIOMEMBR, V24, P147, DOI 10.1007/BF00762674; SALMON A, 1987, J AM CHEM SOC, V109, P2600, DOI 10.1021/ja00243a010; SUNSHINE C, 1992, BIOCHIM BIOPHYS ACTA, V1108, P240, DOI 10.1016/0005-2736(92)90031-G; SUNSHINE C, 1994, BBA-BIOMEMBRANES, V1191, P59, DOI 10.1016/0005-2736(94)90233-X; WEILAND G, 1977, J BIOL CHEM, V252, P7648	39	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24590	24597		10.1074/jbc.271.40.24590	http://dx.doi.org/10.1074/jbc.271.40.24590			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798723	hybrid			2022-12-27	WOS:A1996VM67400045
J	Takashima, S; Klagsbrun, M				Takashima, S; Klagsbrun, M			Inhibition of endothelial cell growth by macrophage-like U-937 cell-derived oncostatin M, leukemia inhibitory factor, and transforming growth factor beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR; MOLECULAR-CLONING; SIGNAL TRANSDUCER; FORMATION INVITRO; EXPRESSION; ANGIOGENESIS; RECEPTOR; NEOVASCULARIZATION; PROLIFERATION; GP130	Conditioned media were collected from phorbol ester-treated human macrophage-like U-937 cells and analyzed for the presence of inhibitors of endothelial cell (EC) proliferation. By a combination of ion exchange and reverse-phase liquid chromatography, three inhibitors were purified to homogeneity as ascertained by microsequencing of 14-17 N-terminal amino acids. These inhibitors were identified as oncostatin M (OSM), leukemia inhibitory factor (LIF), and transforming growth factor beta 1 (TGF-beta 1). The identities of the three EC growth inhibitors were confirmed by demonstrating that recombinant human OSM, LIF, and TGF-beta 1 were inhibitory in the same concentration range. Inhibition of EC proliferation by OSM was a newly described property of this cytokine. OSM was the most potent inhibitor with a half-maximal inhibition by recombinant material of 0.15-.2 ng/ml compared with 0.6-0.9 and 0.9-1.0 ng/ml for LIF and TGF-beta 1, respectively. The three factors inhibited basal, vascular endothelial cell growth factor-stimulated, and fibroblast growth factor 2-stimulated EC proliferation. Interleukin-6 and ciliary neurotrophic factor, two cytokines related structurally to OSM and LIF, were not active as EC growth inhibitors. It was concluded that macrophage-like cells secrete a variety of potent EC growth inhibitors and that one of these, OSM, is among the most potent EC growth inhibitors yet reported.	CHILDRENS HOSP, DEPT SURG, BOSTON, MA 02115 USA; CHILDRENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School					NCI NIH HHS [P01 CA45548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANZANO MA, 1986, J CELL PHYSIOL, V126, P312, DOI 10.1002/jcp.1041260223; BAIRD A, 1986, BIOCHEM BIOPH RES CO, V138, P476, DOI 10.1016/0006-291X(86)90305-0; BAIRD A, 1985, BIOCHEM BIOPH RES CO, V126, P358, DOI 10.1016/0006-291X(85)90614-X; BARGER AC, 1984, NEW ENGL J MED, V310, P175, DOI 10.1056/NEJM198401193100307; BAUMANN H, 1989, J IMMUNOL, V143, P1163; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BESNER GE, 1991, MICROVASC RES, V42, P187, DOI 10.1016/0026-2862(91)90086-Q; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DODGE AB, 1993, J CELL BIOCHEM, V53, P21, DOI 10.1002/jcb.240530104; FERRARA N, 1992, P NATL ACAD SCI USA, V89, P698, DOI 10.1073/pnas.89.2.698; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIESEL R, 1987, J CELL BIOL, V104, P689, DOI 10.1083/jcb.104.3.689; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GROVE RI, 1993, P NATL ACAD SCI USA, V90, P823, DOI 10.1073/pnas.90.3.823; GUPTA SK, 1994, J CELL BIOL, V127, P1121, DOI 10.1083/jcb.127.4.1121; HARRIS PE, 1985, CANCER RES, V45, P9; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOCH AE, 1986, J LEUKOCYTE BIOL, V39, P233, DOI 10.1002/jlb.39.2.233; LAEMMLI UK, 1980, NATURE, V277, P680; LOWE DG, 1989, DNA-J MOLEC CELL BIO, V8, P351, DOI 10.1089/dna.1.1989.8.351; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; MAJEWSKI S, 1985, ARCH DERMATOL, V121, P1018, DOI 10.1001/archderm.121.8.1018; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MALIK N, 1995, MOL CELL BIOL, V15, P2349; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MORNEX JF, 1986, J CLIN INVEST, V78, P61, DOI 10.1172/JCI112574; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; NGUYEN M, 1992, J BIOL CHEM, V267, P26157; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; POLVERINI PJ, 1984, LAB INVEST, V51, P635; REID IR, 1990, ENDOCRINOLOGY, V126, P1416, DOI 10.1210/endo-126-3-1416; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; SCHWEIGERER L, 1987, BIOCHEM BIOPH RES CO, V143, P997, DOI 10.1016/0006-291X(87)90350-0; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAYLOR S, 1982, NATURE, V297, P307, DOI 10.1038/297307a0; THOMA B, 1994, J BIOL CHEM, V269, P6215; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; VANOBBERGHENSCHILLING E, 1987, MOL ENDOCRINOL, V1, P693, DOI 10.1210/mend-1-10-693; YIN TG, 1994, J BIOL CHEM, V269, P3731; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	55	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24901	24906		10.1074/jbc.271.40.24901	http://dx.doi.org/10.1074/jbc.271.40.24901			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798767	hybrid			2022-12-27	WOS:A1996VM67400090
J	Florio, SK; Prusti, RK; Beavo, JA				Florio, SK; Prusti, RK; Beavo, JA			Solubilization of membrane-bound rod phosphodiesterase by the rod phosphodiesterase recombinant delta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTORECEPTOR CGMP PHOSPHODIESTERASE; CYCLIC-GMP PHOSPHODIESTERASE; ACID-BINDING PROTEIN; SEQUENCING PLASMID DNA; OUTER SEGMENTS; SMALL GTPASES; BETA-SUBUNIT; RETINAL RODS; CHICK RETINA; RAB GTPASES	Retinal rod and cone phosphodiesterases are oligomeric enzymes that consist of a dimeric catalytic core (alpha'(2) in cones and alpha beta in rods) with inhibitory subunits (gamma) that regulate their activity. In addition, a 17-kDa protein referred to as the delta subunit co-purifies with the rod soluble phosphodiesterase and the cone phosphodiesterase. We report here partial protein sequencing of the rod delta subunit and isolation of a cDNA clone encoding it. The predicted amino acid sequence is unrelated to any other known protein. Of eight bovine tissue mRNA preparations examined by Northern analysis, the strongest delta subunit-specific signal was present in the retina. A less intense signal was seen in the brain and adrenal mRNA. In bovine retinal sections, rod delta subunit anti peptide antibodies label rod but not cone outer segments, delta sub unit, added back to washed outer segment membranes, solubilizes a large fraction of the membrane-bound phosphodiesterase, indicating that this subunit binds to the classical membrane associated phosphodiesterase. The subunit forms a tight complex with native, but not trypsin-released phosphodiesterase, suggesting that the isoprenylated carboxyl termini of the catalytic subunits may be involved in binding of the delta subunit to the phosphodiesterase holoenzyme.	UNIV WASHINGTON,SCH MED,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NEI NIH HHS [EY 08197] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008197] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANANT JS, 1992, J BIOL CHEM, V267, P687; ANDERSEN AS, 1992, BIOTECHNIQUES, V13, P678; ANDREWS PC, 1987, ANAL BIOCHEM, V161, P524, DOI 10.1016/0003-2697(87)90484-2; Ausubel F.M, 1992, CURRENT PROTOCOLS MO, V1; BEAVO JA, 1970, J BIOL CHEM, V245, P5649; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARCAMO B, 1995, J NEUROCHEM, V65, P1085; CATTY P, 1992, J BIOL CHEM, V267, P19489; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS C, 1992, GENOMICS, V13, P698, DOI 10.1016/0888-7543(92)90144-H; DUMKE CL, 1994, J GEN PHYSIOL, V103, P1071, DOI 10.1085/jgp.103.6.1071; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; GILLESPIE PG, 1989, J BIOL CHEM, V264, P12187; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GODBOUT R, 1995, EXP EYE RES, V60, P645, DOI 10.1016/S0014-4835(05)80006-5; HAMILTON SE, 1993, FEBS LETT, V318, P157, DOI 10.1016/0014-5793(93)80012-J; HAMILTON SE, 1990, J BIOL CHEM, V265, P11259; Harlow E., 1988, ANTIBODIES LAB MANUA; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HURWITZ RL, 1984, J BIOL CHEM, V259, P8612; HURWITZ RL, 1985, J BIOL CHEM, V260, P568; KITTS PA, 1993, BIOTECHNIQUES, V14, P810; KONG HM, 1993, J BIOL CHEM, V268, P1965; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; MALITSCHEK B, 1991, BIOTECHNIQUES, V11, P177; MYERS TW, 1991, BIOCHEMISTRY-US, V30, P7661, DOI 10.1021/bi00245a001; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; ONG OC, 1989, P NATL ACAD SCI USA, V86, P9238, DOI 10.1073/pnas.86.23.9238; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; QIN N, 1992, J BIOL CHEM, V267, P8458; QIN N, 1994, J BIOL CHEM, V269, P3265; REED L. J., 1938, AMER JOUR HYG, V27, P493; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEARS LE, 1992, BIOTECHNIQUES, V13, P626; SELLNER P, 1994, DEV DYNAM, V200, P333, DOI 10.1002/aja.1002000408; SELLNER P, 1994, INVEST OPHTH VIS SCI, V35, P443; SHIVELY JE, 1986, METHODS PROTEIN MICR; STRYER L, 1991, J BIOL CHEM, V266, P10711; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; SWANSON RJ, 1983, J BIOL CHEM, V258, P599; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKAI Y, 1993, CIBA F SYMP, V176, P128; TRONG HL, 1990, BIOCHEMISTRY-US, V29, P10280, DOI 10.1021/bi00496a018; UHL R, 1987, J BIOCHEM BIOPH METH, V14, P127, DOI 10.1016/0165-022X(87)90015-7; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	59	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24036	24047		10.1074/jbc.271.39.24036	http://dx.doi.org/10.1074/jbc.271.39.24036			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798640	hybrid			2022-12-27	WOS:A1996VJ44200069
J	Park, YK; Li, H; Kemper, B				Park, YK; Li, H; Kemper, B			Phenobarbital induction mediated by a distal CYP2B2 sequence in rat liver transiently transfected in situ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; PROTEIN-BINDING; MESSENGER-RNAS; REPORTER GENE; 2B2 GENE; DNA; CYTOCHROME-P-450; PROMOTER	The promoter activities of the genes for cytochrome P450 2B1 (CYP2B1) and cytochrome P450 2C1 (CYP2C1) have been assayed by direct injection of promoter-luciferase chimeric genes into rat liver, Activities of minimal promoters for CYP2C1 and CYP2B1 were detectable in untreated animals but were not increased by treatment of the animals with phenobarbital. After insertion to the 5' side of the minimal promoters of one to three copies of the CYP2B2 sequence from -2318 to -2155, a phenobarbital-responsive element in primary hepatocyte cultures (Trottier, E., Belzil, A., Stoltz, C., and Anderson, A. (1995) Gene (Amst.) 158, 263-268), phenobarbital treatment induced the activity of the CYP2C1 promoter by 5-15-fold and the CYP2B1 promoter by 2.5-5-fold. Mutation of a basal transcription element-like motif and a CCAAT/enhancer binding protein element in the CYP2B1 proximal promoter region reduced expression, but 3-4-fold induction by phenobarbital was retained. Mutation of the ''Barbie box,'' a putative phenobarbital-responsive element (He, J.-S., and Fulco, A. J. (1991) J. Biol. Chem. 266, 7864-7869) in the CYP2B1 proximal promoter did not reduce the relative response to phenobarbital. These results demonstrate that direct injection of DNA into rat liver may be used to assay phenobarbital responsiveness of cytochrome P450 genes. In this system, a distal CYP2B2 element mediates a response to phenobarbital, and proximal elements, including the Barbie box, are not required for the induction.	COLL MED URBANA CHAMPAIGN,DEPT MOL & INTEGRAT PHYS,URBANA,IL 61801; COLL MED URBANA CHAMPAIGN,DEPT CELL & STRUCT BIOL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039360] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADESNIK M, 1981, J BIOL CHEM, V256, P340; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHEN D, 1994, DNA CELL BIOL, V13, P771, DOI 10.1089/dna.1994.13.771; FOURNIER T, 1994, J BIOL CHEM, V269, P27175; GONZALEZ FJ, 1982, J BIOL CHEM, V257, P5962; HAHN CN, 1991, J BIOL CHEM, V266, P17031; HE JS, 1991, J BIOL CHEM, V266, P7864; Hoffmann Marcel, 1992, Gene Expression, V2, P353; Honkakoski P, 1996, J BIOL CHEM, V271, P9746, DOI 10.1074/jbc.271.16.9746; LIANG QW, 1995, J BIOL CHEM, V270, P4438, DOI 10.1074/jbc.270.9.4438; LUBET RA, 1992, BIOCHEM PHARMACOL, V43, P1067, DOI 10.1016/0006-2952(92)90614-O; Luc PV, 1996, BIOCHEM PHARMACOL, V51, P345, DOI 10.1016/0006-2952(95)02190-6; MALONE RW, 1994, J BIOL CHEM, V269, P29903; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; OMIECINSKI CJ, 1986, NUCLEIC ACIDS RES, V14, P1525, DOI 10.1093/nar/14.3.1525; Park Y, 1996, DNA CELL BIOL, V15, P693, DOI 10.1089/dna.1996.15.693; PHILLIPS IR, 1983, GENE, V24, P41; PRABHU L, 1995, P NATL ACAD SCI USA, V92, P9628, DOI 10.1073/pnas.92.21.9628; RAM N, 1995, ARCH BIOCHEM BIOPHYS, V317, P39, DOI 10.1006/abbi.1995.1133; RAMSDEN R, 1993, J BIOL CHEM, V268, P21722; RANGARAJAN PN, 1989, P NATL ACAD SCI USA, V86, P3963, DOI 10.1073/pnas.86.11.3963; RAO MV, 1990, J BIOL CHEM, V265, P5617; REMMER H, 1958, NATURWISSENSCHAFTEN, V45, P189, DOI 10.1007/BF00621338; SHEPHARD EA, 1994, DNA CELL BIOL, V13, P793, DOI 10.1089/dna.1994.13.793; TROTTIER E, 1995, GENE, V158, P263, DOI 10.1016/0378-1119(94)00916-G; UPADHYA P, 1992, NUCLEIC ACIDS RES, V20, P557, DOI 10.1093/nar/20.3.557; VENEPALLY P, 1992, J BIOL CHEM, V267, P17333; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577	30	92	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23725	23728		10.1074/jbc.271.39.23725	http://dx.doi.org/10.1074/jbc.271.39.23725			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798596				2022-12-27	WOS:A1996VJ44200025
J	Roy, K; Mitsugi, K; Sirotnak, FM				Roy, K; Mitsugi, K; Sirotnak, FM			Organization and alternate splicing of the murine folylpolyglutamate synthetase gene - Different splice variants in L1210 cells encode mitochondrial or cytosolic forms of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; TUMOR-CELLS; EXPRESSION; PURIFICATION; SEQUENCES; ANALOGS; MOUSE; DNA	The organization of the murine folylpolyglutamate synthetase (FPGS) gene has been determined by sequence analysis that also revealed an interesting complexity in the case of exon 1, The entire nucleotide sequence of the L1210 FPGS cDNA, the 3'- and 5'-untranslated regions, the mitochondrial leader sequence, and the coding region were found to be distributed on 15 exons with an overall length of 10.358 kilobases, Two splice variants of exon 1 were identified by screening of an L1210 cell cDNA library, Variant I (exons 1a + 1b plus 2-15) incorporates all of the sequence homologous to the recently reported (Taylor, S. M., Freemantle, S. J., and Moran, R. G. (1995) Cancer Res. 55, 6030-6034) human exon 1, including two ATG start codons at positions +1 and +126, and encodes both mitochondrial and cytosolic form of FPGS. The most prevalent variant, Variant II (exons Ib plus 2 to 15), incorporates only a portion (92 nucleotides at the 3' end) of this sequence, incorporates only one ATG start codon at position +126, and encodes only cytosolic FPGS, The existence of this variant is consistent with the identification of an appropriately situated internal donor/acceptor site in what was believed to be exon 1, A third related variant (Variant III) with a novel 5' termini was originally identified by screening of a mouse liver cDNA library, This variant, which occurs at moderately low frequency in the L1210 cell cDNA library, incorporates an alternate to exon 1a (exon 1c) spliced to exon Ib plus exons 2-15 and encodes a different mitochondrial leader peptide than Variant I. The identification of these variants suggests another possible mechanism, i.e. at the level. of precursor mRNA splicing, for regulating synthesis of mitochondrial versus cytosolic forms of FPGS in the cell, Exon 1c is positioned in the gene upstream of exon 1a separated by an intron of 56 nucleotides within a region of DNA sequence that like the homologous human sequence is distinctly promoter-like, However, the sequence of this region differs from the human sequence in terms of the number, position, and type of putative regulatory elements, particularly in regard to the number of SP-1 binding sites and the position of multiple transcription start sites as determined by enzymatic primer extension.	MEM SLOAN KETTERING CANC CTR, LAB MOL THERAPEUT, PROGRAM MOL PHARMACOL & THERAPEUT, NEW YORK, NY 10021 USA; CORNELL UNIV, GRAD SCH MED SCI, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University					NATIONAL CANCER INSTITUTE [P30CA008748, R35CA056517] Funding Source: NIH RePORTER; NCI NIH HHS [CA56517, CA08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BARREDO J, 1992, MOL PHARMACOL, V42, P687; BARRUECO JR, 1992, J BIOL CHEM, V267, P15356; Chen L, 1996, J BIOL CHEM, V271, P13077, DOI 10.1074/jbc.271.22.13077; EGAN MG, 1995, J BIOL CHEM, V270, P5462, DOI 10.1074/jbc.270.10.5462; FABRE I, 1984, CANCER RES, V44, P3190; FREEMANTLE SJ, 1995, J BIOL CHEM, V270, P9579, DOI 10.1074/jbc.270.16.9579; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HENDRICK SM, 1984, NATURE, V308, P149; JACKSON RC, 1984, FOLATE ANTAGONISTS T, V1, P290; KISLIUK RL, 1981, MOL CELL BIOCHEM, V39, P331, DOI 10.1007/BF00232583; KISLIUK RL, 1984, FOLATE ANTAGONISTS T, V1, P2; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCGUIRE JJ, 1980, J BIOL CHEM, V255, P5776; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; MORAN RG, 1985, MOL PHARMACOL, V27, P156; MORAN RG, 1984, BIOCHEMISTRY-US, V23, P4580, DOI 10.1021/bi00315a011; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; ROY K, 1995, J BIOL CHEM, V270, P26918, DOI 10.1074/jbc.270.45.26918; RUMBERGER BG, 1990, CANCER RES, V50, P4639; SAMUELS LL, 1985, CANCER RES, V45, P1488; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHANE B, 1989, VITAM HORM, V45, P263; SIROTNAK FM, 1988, BIOCHEM PHARMACOL, V37, P4239, DOI 10.1016/0006-2952(88)90122-0; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SIROTNAK FM, 1984, FOLATE ANTAGONISTS T, V2, P43; TAYLOR SM, 1995, CANCER RES, V55, P6030; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x	31	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23820	23827		10.1074/jbc.271.39.23820	http://dx.doi.org/10.1074/jbc.271.39.23820			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798611	hybrid			2022-12-27	WOS:A1996VJ44200040
J	Schneikert, J; Peterziel, H; Defossez, PA; Klocker, H; deLaunoit, Y; Cato, ACB				Schneikert, J; Peterziel, H; Defossez, PA; Klocker, H; deLaunoit, Y; Cato, ACB			Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTORS; MOLECULAR-CLONING; COLLAGENASE GENE; MESSENGER-RNA; C-JUN; STROMELYSIN PROMOTER; HUMAN ENDOMETRIUM; AP-1 SITE	Matrix metalloproteinases belong to a family of structurally related enzymes that plays important role in tissue morphogenesis, differentiation, and wound healing. Their expression is negatively regulated by several members of the steroid hormone receptor family. This is thought to occur through interaction of the steroid receptors with the transcription factor AP-1 that is otherwise required for positive regulation. Here, we demonstrate that AP-1 is not always a target for downregulation of expression of matrix metalloproteinases by steroid receptors, Androgen receptor negatively regulates matrix metalloproteinase-1 expression not through AP-1 but through a family of Ets-related transcription factors that are also required for positive regulation. This negative regulation is specific for the androgen receptor. It does not require the DNA binding activity but needs amino terminal sequences of the receptor. These results identify a novel regulatory pathway for negative regulation utilized by a member of the steroid hormone receptor family for down-regulating the expression of matrix metalloproteinases.	FORSCHUNGSZENTRUM KARLSRUHE, INST GENET, D-76021 KARLSRUHE, GERMANY; INST PASTEUR, CNRS, URA 1160, UNITE ONCOL MOL, F-59019 LILLE, FRANCE; UNIV INNSBRUCK, DEPT UROL, A-6020 INNSBRUCK, AUSTRIA	Helmholtz Association; Karlsruhe Institute of Technology; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of Innsbruck			Klocker, Helmut/AAI-7130-2020; Cato, Andrew C. B./H-2071-2013	Cato, Andrew C. B./0000-0001-8508-3834; Defossez, Pierre-Antoine/0000-0002-6463-9263				AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; AUER HP, 1995, THESIS U KARLSRUHE K; BEITEL LK, 1994, HUM MOL GENET, V3, P21, DOI 10.1093/hmg/3.1.21; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; BRUNER KL, 1995, P NATL ACAD SCI USA, V92, P7362, DOI 10.1073/pnas.92.16.7362; CHATTERJEE B, 1987, J BIOL CHEM, V262, P822; CLAY CM, 1993, J BIOL CHEM, V268, P13556; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Crepieux Pascale, 1993, Gene Expression, V3, P215; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GACK S, 1994, J BIOL CHEM, V269, P10363; GAST A, 1995, MOL CELL ENDOCRINOL, V111, P93, DOI 10.1016/0303-7207(95)03554-K; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAHN SL, 1994, ONCOGENE, V9, P2499; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HENTTU P, 1992, ENDOCRINOLOGY, V130, P766, DOI 10.1210/en.130.2.766; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KASPAR F, 1993, MOL CELL BIOL, V13, P7850, DOI 10.1128/MCB.13.12.7850; Knox JD, 1996, MOL CARCINOGEN, V15, P57; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Laget MP, 1996, ONCOGENE, V12, P1325; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; MARBAIX E, 1992, P NATL ACAD SCI USA, V89, P11789, DOI 10.1073/pnas.89.24.11789; MARCELLI M, 1991, J CLIN INVEST, V87, P1123, DOI 10.1172/JCI115076; MARIOTTI A, 1981, ENDOCRINOLOGY, V109, P837, DOI 10.1210/endo-109-3-837; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MCDONNELL S, 1994, BIOCHEM SOC T, V22, P58, DOI 10.1042/bst0220058; METSIS M, 1992, GENE, V121, P247, DOI 10.1016/0378-1119(92)90128-C; MONTE D, 1994, ONCOGENE, V9, P1397; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MUNTZING J, 1980, Prostate, V1, P71, DOI 10.1002/pros.2990010110; NAGEL RB, 1994, J CELL BIOCHEM, V19, P232; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; NEBL G, 1994, J BIOL CHEM, V269, P7371; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; OIKARINEN A, 1993, J INVEST DERMATOL, V101, P205, DOI 10.1111/1523-1747.ep12363823; OSTEEN KG, 1994, P NATL ACAD SCI USA, V91, P10129, DOI 10.1073/pnas.91.21.10129; PAJOUH MS, 1991, J CANCER RES CLIN, V117, P144, DOI 10.1007/BF01613138; PERSSON H, 1990, SCIENCE, V247, P704, DOI 10.1126/science.2154035; SCHNEIKERT J, 1991, THESIS L PASTEUR U S; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; STAUBER C, 1992, NEW BIOL, V4, P527; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WILSON MJ, 1991, BIOL REPROD, V44, P776, DOI 10.1095/biolreprod44.5.776; WILSON MJ, 1992, BIOL REPROD, V47, P683, DOI 10.1095/biolreprod47.5.683; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	62	136	138	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23907	23913		10.1074/jbc.271.39.23907	http://dx.doi.org/10.1074/jbc.271.39.23907			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798622	hybrid			2022-12-27	WOS:A1996VJ44200051
J	Bajzar, L; Kalafatis, M; Simioni, P; Tracy, PB				Bajzar, L; Kalafatis, M; Simioni, P; Tracy, PB			An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V-Leiden	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; INACTIVATION; FIBRINOLYSIS; RESISTANCE	Factor Va is the essential cofactor in prothrombinase-dependent activation of prothrombin. Resistance of Factor Va(Leiden) to inactivation by activated protein C (APC) contributes to thrombotic tendencies in subjects with the variant due, in part, to the inability to terminate thrombin production which increases both fibrin accretion and the frequency of thrombus formation, A reduced ability to inhibit thrombin generation, however, may lead to the stabilization of a clot through the activation of thrombin activatable fibrinolysis inhibitor (TAFI). This hypothesis was tested by determining the profibrinolytic effect of APC on lysis time using clots formed with plasma from either homozygous normal (n = 4) or homozygous factor V-Leiden (n = 4) subjects, Clots were formed in the presence of tissue-type plasminogen activator, thrombin, phosphatidylcholine/phosphatidylserine vesicles, Ca2+, and various concentrations of APC, Approximately 10-fold more APC was required to reduce lysis time from 140 to 50 min in clots containing factor V-Leiden compared to normal factor V. This effect was specific to the form of factor V present in plasma since identical results were obtained in an appropriately reconstituted purified system, which included both TAFI and either form of factor V purified from pooled plasma, In the absence of TAFI, APC did not affect clot lysis in experiments with either normal factor V or factor V-Leiden. During the various lysis assays performed with purified components, clots were solubilized and the proteolytic alterations in factor V/Va were assessed by Western blotting using a specific factor Va heavy chain monoclonal antibody, The heavy chain of factor Va(Leiden) persisted for as long as 60 min, in the presence of 6.3 nM APC indicating sustained activity of factor Va(Leiden) during the lysis assay, In contrast, no factor Va heavy chain was present after the first 5.0 min in clots formed in the presence of normal factor V and 6.3 nM APC. These combined data indicate that factor Va(Leiden) specifically attenuates the profibrinolytic effect of APC, Thus, an impaired TAFI-dependent profibrinolytic response to APC in APC-resistant individuals appears to be an additional factor contributing to the prothrombotic tendencies in subjects with factor V-Leiden.	UNIV VERMONT,COLL MED,DEPT BIOCHEM,BURLINGTON,VT 05405; UNIV PADUA,IST SEMEIOT MED,I-35100 PADUA,ITALY	University of Vermont; University of Padua			Simioni, Paolo/AAC-5416-2022; SIMIONI, PAOLO/AAC-5438-2022	SIMIONI, PAOLO/0000-0002-6744-383X	NHLBI NIH HHS [HL P01-46703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; EATON DL, 1991, J BIOL CHEM, V266, P21833; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; HEEB MJ, 1995, BLOOD, V85, P3405, DOI 10.1182/blood.V85.12.3405.bloodjournal85123405; Kalafatis M, 1996, BLOOD, V87, P4695, DOI 10.1182/blood.V87.11.4695.bloodjournal87114695; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CD, 1989, BLOOD, V73, P185; Mann K G, 1981, Ann N Y Acad Sci, V370, P378, DOI 10.1111/j.1749-6632.1981.tb29750.x; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; von dem Borne PA, 1995, BLOOD, V86, P3035	16	86	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22949	22952		10.1074/jbc.271.38.22949	http://dx.doi.org/10.1074/jbc.271.38.22949			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798478	hybrid			2022-12-27	WOS:A1996VH76800004
J	Voshol, H; vanZuylen, WEM; Orberger, G; Vliegenthart, JFG; Schachner, M				Voshol, H; vanZuylen, WEM; Orberger, G; Vliegenthart, JFG; Schachner, M			Structure of the HNK-1 carbohydrate epitope on bovine peripheral myelin glycoprotein P0	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED OLIGOSACCHARIDE STRUCTURES; SULFATED GLUCURONYL GLYCOLIPIDS; MAGNETIC-RESONANCE SPECTROSCOPY; MONOCLONAL-ANTIBODY HNK-1; L2/HNK-1 CARBOHYDRATE; NERVOUS-SYSTEM; CELL-ADHESION; L-SELECTIN; NEUROPATHY; PROTEIN	The HNK-1 carbohydrate epitope, expressed by many neural recognition molecules, is involved in cell interactions that control cell type-specific neurite outgrowth and regeneration, It is also the target for autoimmune IgM antibodies in demyelinating neuropathies of the peripheral nervous system in humans, Despite its acknowledged importance in cell interactions, the HNK-1 carbohydrate-structure, when expressed on glycoproteins, is still unknown, Here, we describe the structure of one of the predominant HNK-1-bearing glycans of bovine P0. The epitope consists of the sulfated trisaccharide SO4-3GlcA beta 1-3Gal beta 1-4GlcNAc, attached to the alpha 1-6 arm of a diantennary core with a bisecting N-acetylglucosamine. It is the first example of a terminal 3-sulfated glucuronic acid on an asparagine-linked carbohydrate, Because the similarity between the glycoprotein derived structure and the glycosphingolipids carrying HNK-1 is restricted to the terminal sulfated trisaccharide, we conclude that this element is sufficient for HNK-1 immunoreactivity. Knowledge of the HNK-1 structure on proteins is an important prerequisite for the elucidation of its functional role in development and disease.	ETH ZURICH,DEPT NEUROBIOL,CH-8093 ZURICH,SWITZERLAND; UNIV UTRECHT,BIJVOET CTR BIOMOL RES,DEPT BIOORGAN CHEM,NL-3508 TB UTRECHT,NETHERLANDS	Swiss Federal Institutes of Technology Domain; ETH Zurich; Utrecht University								ABO T, 1981, J IMMUNOL, V127, P1024; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BRUNDEN KR, 1992, J NEUROCHEM, V58, P1659, DOI 10.1111/j.1471-4159.1992.tb10038.x; BURGER D, 1992, J NEUROCHEM, V58, P845, DOI 10.1111/j.1471-4159.1992.tb09334.x; BURGER D, 1992, J NEUROCHEM, V58, P854, DOI 10.1111/j.1471-4159.1992.tb09335.x; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; FIELD MC, 1992, J NEUROCHEM, V58, P993, DOI 10.1111/j.1471-4159.1992.tb09353.x; FILBIN MT, 1991, NEURON, V7, P845, DOI 10.1016/0896-6273(91)90286-9; FILBIN MT, 1993, J CELL BIOL, V122, P451, DOI 10.1083/jcb.122.2.451; GIESE KP, 1992, CELL, V71, P565, DOI 10.1016/0092-8674(92)90591-Y; GREY AA, 1982, CAN J BIOCHEM CELL B, V60, P1123, DOI 10.1139/o82-144; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GRIFFITH LS, 1992, J NEUROSCI RES, V33, P639, DOI 10.1002/jnr.490330417; HALL H, 1993, EUR J NEUROSCI, V5, P34, DOI 10.1111/j.1460-9568.1993.tb00202.x; HARD K, 1992, EUR J BIOCHEM, V205, P785; HARDY MR, 1994, METHOD ENZYMOL, V230, P208; ILYAS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1225, DOI 10.1073/pnas.81.4.1225; KANDA T, 1995, P NATL ACAD SCI USA, V92, P7897, DOI 10.1073/pnas.92.17.7897; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; LOW K, 1994, EUR J NEUROSCI, V6, P1773, DOI 10.1111/j.1460-9568.1994.tb00570.x; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MARTINI R, 1992, EUR J NEUROSCI, V4, P628, DOI 10.1111/j.1460-9568.1992.tb00171.x; NEEDHAM LK, 1993, J CELL BIOL, V121, P397, DOI 10.1083/jcb.121.2.397; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; OKA S, 1992, J BIOL CHEM, V267, P22711; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCHMITZ B, 1994, GLYCOCONJUGATE J, V11, P345, DOI 10.1007/BF00731208; SHY ME, 1986, J NEUROIMMUNOL, V12, P291, DOI 10.1016/0165-5728(86)90035-4; TATUM AH, 1993, ANN NEUROL, V33, P502, DOI 10.1002/ana.410330514; UYEMURA K, 1991, COMP BIOCHEM PHYS C, V98, P63; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1	33	143	147	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22957	22960		10.1074/jbc.271.38.22957	http://dx.doi.org/10.1074/jbc.271.38.22957			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798480	Green Published, hybrid			2022-12-27	WOS:A1996VH76800006
J	Behrendt, N; Ronne, E; Dano, K				Behrendt, N; Ronne, E; Dano, K			Domain interplay in the urokinase receptor - Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE RECEPTOR; LINKED-IMMUNOSORBENT-ASSAY; HUMAN TISSUE FACTOR; PLASMINOGEN-ACTIVATOR; GLYCOSYL-PHOSPHATIDYLINOSITOL; EXTRACELLULAR DOMAIN; NH2-TERMINAL DOMAIN; MONOCLONAL-ANTIBODY; PROTEIN-STRUCTURE; CRYSTAL-STRUCTURE	The urokinase plasminogen activator receptor (uPAR) is a membrane protein comprised of three extracellular domains. In order to study the importance of this domain organization in the ligand-binding process of the receptor we subjected a recombinant, soluble uPAR (suPAR) to specific proteolytic cleavages leading to liberation of single domains. Treatment of the receptor with pepsin resulted in cleavage between residues 183 and 184, thus separating the third domain (D3) from the rest of the molecule, which was left as an intact fragment (D(1 + 2)), D(1 + 2) proved capable of ligand binding as shown by chemical cross-linking, but quantitative binding/competition studies showed that the apparent ligand affinity was 100- to 1000-fold lower than that of the intact suPAR. This loss of affinity was comparable with the loss found after cleavage between the first domain (D1) and D(2 + 3), using chymotrypsin. This result shows that in addition to D1, which has an established function in ligand binding (Behrendt, N., Ploug, M., Patthy, L., Houen, G., Blasi, F., and Dana, K. (1991) J. Biol. Chem. 266, 7842-7847), D3 has an important role in governing a high affinity in the intact receptor. Real-time biomolecular interaction analysis revealed that the decrease in affinity was caused mostly by an increased dissociation rate of the ligand complex of D(1 + 2), Zero length cross-linking, using carbodiimide-induced, direct condensation, was used to identify regions within suPAR engaged in molecular ligand contact. The purified suPAR was cross-linked to the radiolabeled aminoterminal fragment (ATF) of urokinase, followed by cleavage with chymotrypsin, In accordance with the cleavage pattern found for the uncomplexed receptor, this treatment led to cleavage between D1 and D(2 + 3), Analysis of the radiolabeled fragments revealed the expected ligand labeling of D1 but a clear labeling of D(2 + 3) was also found, indicating that this part of the molecule is also situated in close contact with ATF in the receptor-ligand complex, The latter contact site may contribute to the role of molecular regions outside D1 in high affinity binding.			Behrendt, N (corresponding author), RIGSHOSP,FINSEN LAB,STRANDBOULEVARDEN 49,BLDG 72,DK-2100 COPENHAGEN 0,DENMARK.			Behrendt, Niels/0000-0003-1833-3922				APPELLA E, 1987, J BIOL CHEM, V262, P4437; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; BEHRENDT N, 1993, METHOD ENZYMOL, V223, P207; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BEHRENDT N, 1993, J BIOL CHEM, V268, P5985; BEHRENDT N, 1995, BIOL CHEM H-S, V376, P269; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; GOODSON RJ, 1994, P NATL ACAD SCI USA, V91, P7129, DOI 10.1073/pnas.91.15.7129; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; HIGASHI S, 1994, J BIOL CHEM, V269, P18891; HOYERHANSEN G, 1992, J BIOL CHEM, V267, P18224; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KARLSSON R, 1995, ANAL BIOCHEM, V228, P274, DOI 10.1006/abio.1995.1350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MINAMI Y, 1993, J BIOL CHEM, V268, P9604; MOLLER LB, 1992, EUR J BIOCHEM, V208, P493, DOI 10.1111/j.1432-1033.1992.tb17213.x; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; ONISHI H, 1992, BIOCHEMISTRY-US, V31, P1201, DOI 10.1021/bi00119a033; *PHARM BIOS, 1995, BIAEV 2 1 SOFTW HDB; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; PLOUG M, 1995, BIOCHEMISTRY-US, V34, P12524, DOI 10.1021/bi00039a006; PLOUG M, 1993, J BIOL CHEM, V268, P17539; PLOUG M, 1991, J BIOL CHEM, V266, P1926; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; RONNE E, 1994, J IMMUNOL METHODS, V167, P91, DOI 10.1016/0022-1759(94)90078-7; RONNE E, 1995, BREAST CANCER RES TR, V33, P199, DOI 10.1007/BF00665944; ROSSI V, 1995, BIOCHEMISTRY-US, V34, P7311, DOI 10.1021/bi00022a004; RUF W, 1994, BIOCHEMISTRY-US, V33, P1565, DOI 10.1021/bi00172a037; STANLEY P, 1994, EMBO J, V13, P1790, DOI 10.1002/j.1460-2075.1994.tb06447.x; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WACHTFOGEL YT, 1994, J BIOL CHEM, V269, P19307; YONEZAWA N, 1991, J BIOL CHEM, V266, P10485	43	94	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22885	22894		10.1074/jbc.271.37.22885	http://dx.doi.org/10.1074/jbc.271.37.22885			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798468	hybrid			2022-12-27	WOS:A1996VG67200087
J	Chan, CL; Gill, GN				Chan, CL; Gill, GN			Mutational analysis of the nucleotide binding site of the epidermal growth factor receptor and v-Src protein-tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CATALYTIC SUBUNIT; PEPTIDE INHIBITOR; DOMAIN; SPECIFICITY; EXPRESSION; ADENOSINE; PHOSPHORYLATION; ANTIBODIES; TRANSIENT	Tyrosine kinases differ from serine/threonine kinases in sequences located at the active site where ATP and substrate bind. In the structure of cyclic AMP-dependent protein kinase, the catalytic loop contains the sequence Lys-Pro-Glu where the Lys residue contacts the gamma-phosphate of ATP and the Glu residue contacts a basic residue located in the peptide substrate. In tyrosine kinases, the analogous sequence is Ala-Ala-Arg in the receptor tyrosine kinase subfamily and Arg-Ala-Ala in the Src tyrosine kinase subfamily. To deduce the role of these residues in tyrosine kinase function, site-directed mutations were prepared in the epidermal growth factor receptor (EGFR) and in v-Src and effects on ATP binding and kinase activity were determined. Changing Arg to either Lys or Ala dramatically reduced activity of both tyrosine kinases and this correlated with loss of ATP binding. Changing the orientation of this sequence impaired activity of EGFR to a greater extent than that of v-Src but did not change substrate specificity of the two enzymes. These results support the hypothesis that Arg functions to coordinate the gamma-phosphate of ATP. Analysis of sequence inversions in the catalytic loop indicate that the active site of v-Src exhibits greater flexibility than that of EGFR.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NIDDK NIH HHS [DK13149] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013149, R01DK013149] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BUHROW SA, 1985, METHOD ENZYMOL, V109, P816; CACHIANES G, 1993, BIOTECHNIQUES, V15, P255; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HERBST R, 1991, J BIOL CHEM, V266, P19908; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LEE TR, 1995, J BIOL CHEM, V270, P5375, DOI 10.1074/jbc.270.10.5375; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; PABORSKY LR, 1990, PROTEIN ENG, V3, P547, DOI 10.1093/protein/3.6.547; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RIGAUDY P, 1994, DNA CELL BIOL, V13, P585, DOI 10.1089/dna.1994.13.585; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1994, P NATL ACAD SCI USA, V91, P12803, DOI 10.1073/pnas.91.26.12803; WEBER W, 1984, J BIOL CHEM, V259, P4631; WEDEGAERTNER PB, 1992, ARCH BIOCHEM BIOPHYS, V292, P273, DOI 10.1016/0003-9861(92)90079-C; WEDEGAERTNER PB, 1989, J BIOL CHEM, V264, P11346; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	33	7	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22619	22623		10.1074/jbc.271.37.22619	http://dx.doi.org/10.1074/jbc.271.37.22619			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798432	hybrid, Green Published			2022-12-27	WOS:A1996VG67200051
J	Garrow, TA				Garrow, TA			Purification, kinetic properties, and cDNA cloning of mammalian betaine-homocysteine methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE METABOLISM; RAT-LIVER; ASSAY; N,N-DIMETHYLGLYCINE; CHROMATOGRAPHY; COBALAMIN; PROTEINS; SYNTHASE; TISSUES; ACID	Porcine liver betaine-homocysteine methyltransferase (BHMT; EC 2.1.1.5) was purified to homogeneity, and the Michaelis constants for betaine, dimethylacetothetin, and L-homocysteine are 23, 155, and 32 mu M, respectively. The maximum rate of catalysis is 47-fold greater using dimethylacetothetin as a methyl donor compared with betaine. Partial amino acid sequence of porcine BHMT was obtained, and inosine containing redundant oligonucleotide primers were used to amplify an 815-base pair sequence of the porcine cDNA by polymerase chain reaction (PCR). Nondegenerate oligonucleotide primers based on the porcine cDNA were synthesized and used to isolate a 463-base pair fragment of the human cDNA by PCR. The human PCR DNA product was then used to screen a cDNA library by plaque hybridization, and cDNAs encoding human BHMT were isolated. The primary structure of the human cDNA is reported here, and the open reading frame encodes a 406-residue protein of M(r) 44,969. The deduced amino acid sequence of human BHMT shows limited homology to bacterial vitamin B-12-dependent methionine synthases (EC 2.1.1.13). A plasmid containing the human BHMT cDNA fused in frame to the N terminus of beta-galactosidase was transformed into Escherichia coli, and transformants expressed BHMT activity, an activity that is absent from wild type E. coli.	UNIV ILLINOIS,DIV NUTR SCI,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	Garrow, TA (corresponding author), UNIV ILLINOIS,DEPT FOOD SCI & HUMAN NUTR,445 BEVIER HALL,905 S GOODWIN AVE,URBANA,IL 61801, USA.							ALLEN RH, 1993, METABOLISM, V42, P1448, DOI 10.1016/0026-0495(93)90198-W; BARAK AJ, 1979, LIPIDS, V14, P860, DOI 10.1007/BF02534129; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DRUMMOND JT, 1993, BIOCHEMISTRY-US, V32, P9290, DOI 10.1021/bi00087a005; DUBNOFF JW, 1948, J BIOL CHEM, V176, P789; Dudman NPB, 1996, J NUTR, V126, pS1295, DOI 10.1093/jn/126.suppl_4.1295S; DUERRE JA, 1966, ANAL BIOCHEM, V17, P310, DOI 10.1016/0003-2697(66)90209-0; DURELL J, 1957, BIOCHIM BIOPHYS ACTA, V26, P270, DOI 10.1016/0006-3002(57)90005-7; ERICSON LE, 1960, ACTA CHEM SCAND, V14, P2113, DOI 10.3891/acta.chem.scand.14-2113; ERICSON LE, 1960, ACTA CHEM SCAND, V14, P2127, DOI 10.3891/acta.chem.scand.14-2127; ERICSON LE, 1960, ACTA CHEM SCAND, V14, P2101; FINKELSTEIN JD, 1967, J BIOL CHEM, V242, P873; FINKELSTEIN JD, 1972, ARCH BIOCHEM BIOPHYS, V153, P320, DOI 10.1016/0003-9861(72)90451-1; FINKELSTEIN JD, 1971, ARCH BIOCHEM BIOPHYS, V146, P84, DOI 10.1016/S0003-9861(71)80044-9; FINKELSTEIN JD, 1983, J NUTR, V113, P519, DOI 10.1093/jn/113.3.519; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; FINKELSTEIN JD, 1984, BIOCHEM BIOPH RES CO, V118, P14, DOI 10.1016/0006-291X(84)91060-X; FINKELSTEIN JD, 1974, ARCH BIOCHEM BIOPHYS, V165, P774, DOI 10.1016/0003-9861(74)90306-3; FINKELSTEIN JD, 1982, ARCH BIOCHEM BIOPHYS, V218, P169, DOI 10.1016/0003-9861(82)90332-0; FINKELSTEIN JD, 1982, BIOCHEM BIOPH RES CO, V108, P344, DOI 10.1016/0006-291X(82)91872-1; FROMM HJ, 1959, ARCH BIOCHEM BIOPHYS, V81, P363, DOI 10.1016/0003-9861(59)90214-0; GOEGER DE, 1993, ARCH BIOCHEM BIOPHYS, V302, P222, DOI 10.1006/abbi.1993.1203; Hanes CS, 1932, BIOCHEM J, V26, P1406, DOI 10.1042/bj0261406; HAUBRICH DR, 1981, BIOCHEM PHARMACOL, V30, P2993, DOI 10.1016/0006-2952(81)90265-3; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARYEA MD, 1994, CLIN CHIM ACTA, V230, P169, DOI 10.1016/0009-8981(94)90269-0; LEE KH, 1992, ARCH BIOCHEM BIOPHYS, V292, P77, DOI 10.1016/0003-9861(92)90053-Y; MAR MH, 1995, J NUTR BIOCHEM, V6, P392, DOI 10.1016/0955-2863(95)80008-Z; MARTIN JJ, 1981, ANAL BIOCHEM, V111, P72, DOI 10.1016/0003-2697(81)90230-X; MAW GA, 1956, BIOCHEM J, V63, P116, DOI 10.1042/bj0630116; MAW GA, 1959, BIOCHEM J, V72, P602, DOI 10.1042/bj0720602; MAW GA, 1948, J BIOL CHEM, V176, P1037; MAW GA, 1953, BIOCHEM J, V55, P42, DOI 10.1042/bj0550042; MCKEEVER MP, 1991, CLIN SCI, V81, P551, DOI 10.1042/cs0810551; Motulsky AG, 1996, AM J HUM GENET, V58, P17; NELSON LD, 1985, J CHROMATOGR, V324, P203, DOI 10.1016/S0021-9673(01)81320-0; RHODES D, 1993, ANNU REV PLANT PHYS, V44, P357, DOI 10.1146/annurev.pp.44.060193.002041; ROBERTS DL, 1994, J BACTERIOL, V176, P6127, DOI 10.1128/jb.176.19.6127-6130.1994; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIDRANSKY H, 1960, ARCH BIOCHEM BIOPHYS, V87, P129, DOI 10.1016/0003-9861(60)90133-8; SKIBA WE, 1982, J BIOL CHEM, V257, P4944; SPEED D, 1968, J CHROMATOGR, V35, P497, DOI 10.1016/S0021-9673(01)82415-8; STEELE RD, 1978, J BIOL CHEM, V253, P7844; UELAND PM, 1984, J BIOL CHEM, V259, P2360; UELAND PM, 1992, ATHEROSCLEROTIC CARD; WANG J, 1991, CLIN CHIM ACTA, V204, P239, DOI 10.1016/0009-8981(91)90235-5; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585; WHITFIELD CD, 1970, J BIOL CHEM, V245, P390	49	197	204	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22831	22838		10.1074/jbc.271.37.22831	http://dx.doi.org/10.1074/jbc.271.37.22831			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798461	hybrid			2022-12-27	WOS:A1996VG67200080
J	Powell, W; Bartholomew, B; Reines, D				Powell, W; Bartholomew, B; Reines, D			Elongation factor SII contacts the 3'-end of RNA in the RNA polymerase II elongation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACILITATED TRANSCRIPT CLEAVAGE; INITIATION FACTOR-ALPHA; ESCHERICHIA-COLI; ACTIVE-SITE; TERNARY COMPLEXES; TFIIS	Elongation factor SII (also known as TFIIS) is an RNA polymerase II binding protein that allows bypass of template arrest sites by activating a nascent RNA cleavage reaction. Here we show that SII contacts the 3'-end of nascent RNA within an RNA polymerase II elongation complex as detected by photoaffinity labeling, Photocross-linking was dependent upon the presence of SII, incorporation of 4-thio-UMP into RNA, and irradiation and was sensitive to treatment by RNase and proteinase. A transcriptionally active mutant of SII lacking the first 130 amino acids was also cross-linked to the nascent RNA, but SII from Saccharomyces cerevisiae, which is inactive in concert with mammalian RNA polymerase II, failed to become photoaffinity labeled, SII-RNA contact was not detected after a labeled oligoribonucleotide was released from the complex by nascent RNA cleavage, demonstrating that this interaction takes place between elongation complex-associated but not free RNA. This shows that the 3'-end of RNA is near the SII binding site on RNA polymerase II and suggests that SII may activate the intrinsic RNA hydrolysis activity by positioning the transcript in the enzyme's active site.	EMORY UNIV,SCH MED,GRAD PROGRAM BIOCHEM & MOL BIOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; SO ILLINOIS UNIV,DEPT BIOCHEM MED,CARBONDALE,IL 62901	Emory University; Emory University; Southern Illinois University System; Southern Illinois University			excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243; Powell, Wade H./0000-0002-3727-2822	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046331, GM46331] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CIPRESPALACIN G, 1994, P NATL ACAD SCI USA, V91, P8087, DOI 10.1073/pnas.91.17.8087; CONAWAY RC, 1996, IN PRESS METHODS ENZ, V273; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; GU W, 1993, J BIOL CHEM, V268, P18762; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; GU WG, 1993, J BIOL CHEM, V268, P25604; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; Powell W, 1996, J BIOL CHEM, V271, P6866, DOI 10.1074/jbc.271.12.6866; REINES D, 1991, J BIOL CHEM, V266, P10510; REINES D, 1994, TRANSCRIPTION MECHAN, P263; RIVA M, 1990, J BIOL CHEM, V265, P16498; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SHENG NJ, 1993, BIOCHEMISTRY-US, V32, P2248, DOI 10.1021/bi00060a017; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; TREICH I, 1992, NUCLEIC ACIDS RES, V20, P4721, DOI 10.1093/nar/20.18.4721; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; WU J, 1996, IN PRESS P NATL ACAD, V93	27	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22301	22304		10.1074/jbc.271.37.22301	http://dx.doi.org/10.1074/jbc.271.37.22301			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798387	Green Accepted, hybrid			2022-12-27	WOS:A1996VG67200006
J	Tezuka, KI; Denhardt, DT; Rodan, GA; Harada, SI				Tezuka, KI; Denhardt, DT; Rodan, GA; Harada, SI			Stimulation of mouse osteopontin promoter by v-Src is mediated by a CCAAT box-binding factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; SECRETED PHOSPHOPROTEIN; NEOPLASTIC TRANSFORMATION; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; DNA-BINDING; 3T3 CELLS; RNA; IDENTIFICATION; REQUIREMENT	Osteopontin is an arginine-glycine-aspartic acid containing cell adhesion protein, which is frequently expressed in transformed cells and is thought to play a role in tumorigenesis. v-Src is a transforming viral oncogene product encoded by Rous sarcoma virus (RSV). We report that v-Src expression in HT1080 fibrosarcoma cells significantly stimulates mouse osteopontin promoter activity. We also determined the v-Src response element in the osteopontin promoter as an inverted CCAAT box located at -53 to -49 from the transcription start site. Mutations of the CCAAT box disrupts protein-DNA interaction and diminishes both v-Src stimulation and basal promoter activity. A CCAAT box-containing fragment corresponding to -155 to -122 of RSV long terminal repeat competed with the -72 to -38 fragment of mouse osteopontin promoter for specific protein binding in the gel shift assay. A polyclonal antibody against CEF, a CCAAT box-binding factor, supershifted in gel shift assays the protein-DNA complex formed by nuclear extract of HT1080 with either the RSV CCAAT box fragment or with the osteopontin -72 to -38 fragment. Moreover, both osteopontin mRNA levels and enhancer activity of CCAAT box-containing -72 to -38 fragment were significantly elevated in v-src-transformed NIH 3T3 cells relative to parental cells. These findings suggest that the elevated osteopontin expression in transformed cells could be due, at least in part, to v-Src stimulation of the osteopontin promoter and that this effect is mediated by a CBF-like factor.	MERCK RES LABS, DEPT BONE BIOL & OSTEOPOROSIS RES, West Point, PA 19486 USA; RUTGERS STATE UNIV, DEPT BIOL SCI, PISCATAWAY, NJ 08855 USA	Merck & Company; Rutgers State University New Brunswick			Tezuka, Ken-ichi/B-3836-2012					APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; Ausbel FM, 1994, CURRENT PROTOCOLS MO; BEHREND EI, 1994, CANCER RES, V54, P832; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BLOBEL GA, 1991, P NATL ACAD SCI USA, V88, P1162, DOI 10.1073/pnas.88.4.1162; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Chackalaparampil I, 1996, ONCOGENE, V12, P1457; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIG AM, 1988, BIOCHEM BIOPH RES CO, V157, P166, DOI 10.1016/S0006-291X(88)80028-7; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; CZERNILOFSKY AP, 1980, NATURE, V287, P198, DOI 10.1038/287198a0; CZERNILOFSKY AP, 1983, NATURE, V301, P736, DOI 10.1038/301736b0; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DUTTA A, 1990, GENE DEV, V4, P243, DOI 10.1101/gad.4.2.243; FABER M, 1990, J BIOL CHEM, V265, P22243; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GARDNER HAR, 1994, ONCOGENE, V9, P2321; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; IKEDA T, 1992, J HISTOCHEM CYTOCHEM, V40, P1079, DOI 10.1177/40.8.1619274; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LAVERDURE GR, 1987, FEBS LETT, V222, P261, DOI 10.1016/0014-5793(87)80382-4; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAITY SN, 1992, J BIOL CHEM, V267, P8286; NODA M, 1988, J BIOL CHEM, V263, P13916; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; SATO H, 1993, J BIOL CHEM, V268, P23460; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SENGER DR, 1983, NATURE, V302, P714, DOI 10.1038/302714a0; SENGER DR, 1980, NATURE, V286, P619, DOI 10.1038/286619a0; SENGER DR, 1989, ANTICANCER RES, V9, P1291; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STACEY DW, 1991, ONCOGENE, V6, P2297; SU LC, 1995, ONCOGENE, V10, P2163; TAKESHITA S, 1988, GENE, V71, P9, DOI 10.1016/0378-1119(88)90072-8; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; TEZUKA K, 1990, BIOCHEM BIOPH RES CO, V173, P246, DOI 10.1016/S0006-291X(05)81048-4; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; TUCK AB, 1991, J NATL CANCER I, V83, P485	46	43	44	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22713	22717		10.1074/jbc.271.37.22713	http://dx.doi.org/10.1074/jbc.271.37.22713			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798445				2022-12-27	WOS:A1996VG67200064
J	Boorer, KJ; Loo, DDF; Frommer, WB; Wright, EM				Boorer, KJ; Loo, DDF; Frommer, WB; Wright, EM			Transport mechanism of the cloned potato H+/sucrose cotransporter StSUT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; BETA-VULGARIS L; NA+ GLUCOSE COTRANSPORTER; SUCROSE-H+ SYMPORTER; ELECTROGENIC PROPERTIES; ARABIDOPSIS-THALIANA; XENOPUS-OOCYTES; VOLTAGE-CLAMP; LEAF TISSUES; PHLOEM	The transport mechanism of the potato StSUT1 H+/sucrose cotransporter expressed in Xenopus oocytes was investigated using the 2-electrode voltage clamp and radiotracer flux methods. Sucrose induced inward currents through the transporter that were dependent on the extracellular sucrose and H+ concentrations and the membrane voltage. The activation of StSUT1 by H+ and sucrose displayed Michaelis-Menten-type kinetics suggestive of a 1:1 H+:sucrose stoichiometry. This was confirmed by simultaneously measuring inward currents and sucrose flux in voltage-clamped oocytes. The apparent affinities K-0.5 for H+ and sucrose were voltage-dependent, At -150 mV K-0.5(suc) was 0.5 +/- 0.07 mM at 10 mu M H-o(+) and K-0.5(H) was 0.1 +/- 0.05 mu M at 20 mM sucrose(o). StSUT1 exhibited presteady-state transient currents, which relaxed with time constants between <1 and 4 ms and fitted to the Boltzmann equation: maximum charge transfer Q(max) approximate to 1.8 nanocoulombs; apparent valence z approximate to 1; potential for 50% charge transfer V-0.5 approximate to -15 mV at 0.032 mu M H-o(+) and -45 mV at 10 mu M H-o(+). The steady state data were used to formulate a kinetic model for sucrose transport, and computer simulations were performed to obtain rate constants for the partial reaction steps. Our model is consistent with protons binding to StSUT1 before sucrose with both ligands transported simultaneously across the membrane.	UNIV TUBINGEN, INST BOT, D-72076 TUBINGEN, GERMANY	Eberhard Karls University of Tubingen	Boorer, KJ (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT PHYSIOL, 10833 LE CONTE AVE, LOS ANGELES, CA 90095 USA.		Frommer, Wolf B/K-5042-2017; Frommer, Wolf B/A-8256-2008	Frommer, Wolf B/0000-0001-6465-0115; Frommer, Wolf B/0000-0001-6465-0115	NIDDK NIH HHS [DK 19567] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019567] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOORER KJ, 1994, J BIOL CHEM, V269, P20417; Boorer KJ, 1996, J BIOL CHEM, V271, P2213, DOI 10.1074/jbc.271.4.2213; BUCKHOUT TJ, 1989, PLANTA, V178, P393, DOI 10.1007/BF00391867; BUCKHOUT TJ, 1994, PLANT PHYSIOL, V106, P991, DOI 10.1104/pp.106.3.991; BUSH DR, 1990, PLANT PHYSIOL, V93, P1590, DOI 10.1104/pp.93.4.1590; BUSH DR, 1993, ANNU REV PLANT PHYS, V44, P513, DOI 10.1146/annurev.pp.44.060193.002501; BUSH DR, 1989, PLANT PHYSIOL, V89, P1318, DOI 10.1104/pp.89.4.1318; DELROT S, 1981, PLANT PHYSIOL, V67, P560, DOI 10.1104/pp.67.3.560; DELROT S, 1981, PLANT PHYSIOL, V68, P706, DOI 10.1104/pp.68.3.706; FROMM J, 1989, PLANT PHYSIOL BIOCH, V27, P577; GAHRTZ M, 1994, PLANT J, V6, P697, DOI 10.1046/j.1365-313X.1994.6050697.x; GALLI A, 1995, J EXP BIOL, V198, P2197; GRIGNON C, 1991, ANNU REV PLANT PHYS, V42, P103, DOI 10.1146/annurev.pp.42.060191.000535; JAUCH P, 1986, J MEMBRANE BIOL, V94, P117, DOI 10.1007/BF01871192; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; MAYNARD JW, 1982, PLANT PHYSIOL, V70, P1436, DOI 10.1104/pp.70.5.1436; MAYNARD JW, 1982, PLANT PHYSIOL, V69, P734, DOI 10.1104/pp.69.3.734; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; RIESMEIER JW, 1994, EMBO J, V13, P1; RIESMEIER JW, 1992, EMBO J, V11, P4705, DOI 10.1002/j.1460-2075.1992.tb05575.x; RIESMEIER JW, 1993, PLANT CELL, V5, P1591, DOI 10.1105/tpc.5.11.1591; SAUER N, 1994, PLANT J, V6, P67, DOI 10.1046/j.1365-313X.1994.6010067.x; SLONE JH, 1991, PLANTA, V183, P584, DOI 10.1007/BF00194280; STADLER R, 1995, PLANT CELL, V7, P1545, DOI 10.1105/tpc.7.10.1545; TAGLIALATELA M, 1992, BIOPHYS J, V61, P78, DOI 10.1016/S0006-3495(92)81817-9; VANBEL AJE, 1994, PLANTA, V192, P165, DOI 10.1007/BF01089031; WILLIAMS LE, 1992, PLANTA, V186, P541, DOI 10.1007/BF00198034; WILLIAMS LE, 1990, PLANTA, V182, P532, DOI 10.1007/BF02341028	30	103	110	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25139	25144		10.1074/jbc.271.41.25139	http://dx.doi.org/10.1074/jbc.271.41.25139			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810269	hybrid			2022-12-27	WOS:A1996VL69300013
J	Corroyer, S; Maitre, B; Cazals, V; Clement, A				Corroyer, S; Maitre, B; Cazals, V; Clement, A			Altered regulation of G(1) cyclins in oxidant-induced growth arrest of lung alveolar epithelial cells - Accumulation of inactive cyclin E-CDK2 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATION-RELATED GENES; PULMONARY OXYGEN-TOXICITY; DEPENDENT KINASE; POSTTRANSCRIPTIONAL REGULATION; FUNCTIONAL INTERACTIONS; RETINOBLASTOMA PROTEIN; DNA-DAMAGE; TGF-BETA; EXPRESSION; G1	The alveolar surface of the lung is a major target for oxidant injury, and its repair following injury is dependent on the ability of its stem cells, the type 2 cells, to initiate proliferation. From previous studies it is likely that events located before the entry into the S phase of the cell cycle and involving several components of the insulin-like growth factor system as well as of transforming growth factor-beta (TGF-beta) play a key role in growth regulation of oxidant-exposed type 2 epithelial cells. To gain further insights into these mechanisms, we explored the effects of O-2 exposure on G(1) cyclins and their cyclin-dependent kinases (CDKs). We documented an increased expression of these genes in O-2-treated type 2 cells. However, despite this induction, a dramatic decrease in cyclin E-CDK2 activity, but not in cyclin D-CDK4 activity, was found. The concomitant induction of CDK inhibitory proteins (CKIs), mainly p21(CIP1), suggests that accumulation of inactive cyclin E-CDK2 activity is due to CKI binding. We also provided evidence that the mechanisms regulating this process involved TGF-beta as anti-TGF-beta antibody treatment was able to reduce the oxidant-induced inhibition of cyclin E-CDK2 activity, Taken together, these results suggest that oxidants may block entry into S phase by acting on a subset of late G(1) events whose alterations are sufficient to impair the activation of cyclin E-CDK2 complexes.	UNIV PARIS,ST ANTOINE MED SCH,TROUSSEAU HOSP,DEPT PHYSIOL,F-75012 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite				Maitre, Bernard/0000-0002-8061-1252				ADAMSON IYR, 1974, LAB INVEST, V30, P15; AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; BRENNA P, 1983, BIOCHIM BIOPHYS ACTA, V74, pS14; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAZALS V, 1994, J BIOL CHEM, V269, P14111; CHEN X, 1985, CANCER RES, V55, P4257; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEMENT A, 1991, EXP CELL RES, V196, P198, DOI 10.1016/0014-4827(91)90251-O; CLEMENT A, 1990, P NATL ACAD SCI USA, V87, P318, DOI 10.1073/pnas.87.1.318; CLEMENT A, 1992, J CLIN INVEST, V90, P1812, DOI 10.1172/JCI116056; CRAPO JD, 1986, ANNU REV PHYSIOL, V48, P721; DEFFIE A, 1995, MOL CELL BIOL, V15, P3926; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FARBER JL, 1990, LAB INVEST, V62, P670; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; HALLIWELL B, 1991, AM J MED S3C, V91, P14, DOI DOI 10.1016/0002-9343(91)90279-7; HARRIS JB, 1991, AM J RESP CELL MOL, V4, P115, DOI 10.1165/ajrcmb/4.2.115; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HSU YS, 1995, J BIOL CHEM, V270, P6966, DOI 10.1074/jbc.270.12.6966; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; JACKSON RM, 1985, CHEST, V88, P900, DOI 10.1378/chest.88.6.900; JACOBS T, 1992, DEV BIOL, V153, P1, DOI 10.1016/0012-1606(92)90087-W; JANSSEN YMW, 1993, LAB INVEST, V69, P261; KAPANCI Y, 1969, LAB INVEST, V20, P101; KARP JE, 1995, NAT MED, V1, P309, DOI 10.1038/nm0495-309; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LI C, 1995, J BIOL CHEM, V270, P4941; LI Y, 1992, J BIOL CHEM, V267, P19097; LOYER P, 1994, J BIOL CHEM, V269, P2491; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MICHIELI P, 1994, CANCER RES, V54, P3391; MILLER BE, 1990, ENVIRON HEALTH PERSP, V85, P15, DOI 10.2307/3430661; MOUHIEDDINE OB, 1994, ENDOCRINOLOGY, V135, P83, DOI 10.1210/en.135.1.83; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; THET LA, 1986, EXP LUNG RES, V11, P209, DOI 10.3109/01902148609064297; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WITSCHI H, 1990, ENVIRON HEALTH PERSP, V85, P5, DOI 10.2307/3430660; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMAGOE S, 1991, MOL CELL BIOL, V11, P3522, DOI 10.1128/MCB.11.7.3522; ZHANGW, 1995, CANCER RES, V55, P668	64	74	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25117	25125		10.1074/jbc.271.41.25117	http://dx.doi.org/10.1074/jbc.271.41.25117			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810266	hybrid			2022-12-27	WOS:A1996VL69300010
J	Li, JX; Liu, SS; Rosen, BP				Li, JX; Liu, SS; Rosen, BP			Interaction of ATP binding sites in the ArsA ATPase, the catalytic subunit of the Ars pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-TRANSLOCATING ATPASE; ESCHERICHIA-COLI; H+-ATPASE; BETA-SUBUNIT; MUTAGENESIS; RESISTANCE; ARSENATE; ARSENITE; DOMAINS; SEQUENCE	The ArsA ATPase is the catalytic subunit of the Ars pump that catalyzes arsenical extrusion in Escherichia coli, thus providing resistance, The active form of ArsA is a homodimer with four nucleotide binding sites, two from each monomer, The codons for Gly-15 in the N-terminal consensus nucleotide binding sequence and Gly-334 in the C-terminal sequence were individually mutated to cysteine codons, Cells expressing an arsA(G334C) mutation retained arsenite resistance, while an arsA(G15C) mutation resulted in substantial reductions in arsenite resistance, transport, and ATPase activity. Selection for suppression of the G15C mutation that restored arsenite resistance yielded an A344V substitution, Ala-344 is located adjacent to the C-terminal nucleotide binding sequence, The second site mutation did not suppress the loss of resistance resulting from G18D, G20S, or T22I substitutions in the N-terminal nucleotide binding site, Cells expressing the G15C/A344V double mutant regained arsenite extrusion, These results suggest a spatial proximity of Gly-15 and Ala-344 and support a model for interaction of the nucleotide binding sites in ArsA.	WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,DETROIT,MI 48201; ACAD SINICA,INST ZOOL,STATE KEY LAB BIOMEMBRANE & MEMBRANE BIOTECHNOL,BEIJING 100080,PEOPLES R CHINA	Wayne State University; Chinese Academy of Sciences; Institute of Zoology, CAS				Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019793] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19793] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BHATTACHARJEE H, 1995, J BIOL CHEM, V270, P11245, DOI 10.1074/jbc.270.19.11245; CHEN CM, 1986, J BIOL CHEM, V261, P5030; DEY S, 1995, J BACTERIOL, V177, P385, DOI 10.1128/jb.177.2.385-389.1995; DEY S, 1994, ARCH BIOCHEM BIOPHYS, V311, P418, DOI 10.1006/abbi.1994.1256; DEY S, 1995, DRUG TRANSPORT ANTIM, P103; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; HSU CM, 1989, J BIOL CHEM, V264, P17349; HUMPHREYS GO, 1976, MOL GEN GENET, V145, P101, DOI 10.1007/BF00331564; IWAMOTO A, 1993, J BIOL CHEM, V268, P3156; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KAUR P, 1993, J BACTERIOL, V175, P351, DOI 10.1128/JB.175.2.351-357.1993; KAUR P, 1994, J BIOL CHEM, V269, P9698; KAUR P, 1992, J BIOL CHEM, V267, P19272; KAUR P, 1994, BIOCHEMISTRY-US, V33, P6456, DOI 10.1021/bi00187a010; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEI-HSU C, 1991, Journal of Biological Chemistry, V266, P2327; MOBLEY HLT, 1982, P NATL ACAD SCI-BIOL, V79, P6119, DOI 10.1073/pnas.79.20.6119; OMOTE H, 1994, J BIOL CHEM, V269, P10265; REAY PF, 1977, ANAL BIOCHEM, V78, P557, DOI 10.1016/0003-2697(77)90117-8; ROSEN BP, 1995, J BIOENERG BIOMEMBR, V27, P85, DOI 10.1007/BF02110335; ROSEN BP, 1984, BIOCHEM BIOPH RES CO, V124, P760, DOI 10.1016/0006-291X(84)91023-4; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVER S, 1981, J BACTERIOL, V146, P983, DOI 10.1128/JB.146.3.983-996.1981; TAKEYAMA M, 1990, J BIOL CHEM, V265, P21279; VOGEL G, 1976, BIOCHEMISTRY-US, V16, P208; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; ZHOU TQ, 1995, BIOCHEMISTRY-US, V34, P13622, DOI 10.1021/bi00041a042	31	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25247	25252		10.1074/jbc.271.41.25247	http://dx.doi.org/10.1074/jbc.271.41.25247			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810286	hybrid			2022-12-27	WOS:A1996VL69300030
J	Zhao, XJ; Raitt, D; Burke, PV; Clewell, AS; Kwast, KE; Poyton, RO				Zhao, XJ; Raitt, D; Burke, PV; Clewell, AS; Kwast, KE; Poyton, RO			Function and expression of flavohemoglobin in Saccharomyces cerevisiae - Evidence for a role in the oxidative stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; HEMOGLOBIN-LIKE PROTEIN; ESCHERICHIA-COLI; BACTERIAL HEMOGLOBIN; PHYSIOLOGICAL-FUNCTION; ALCALIGENES-EUTROPHUS; SUPEROXIDE-DISMUTASE; YEAST HEMOGLOBIN; PRIMARY SEQUENCE; GENE-EXPRESSION	We have studied the function and expression of the flavohemoglobin (YHb) in the yeast Saccharomyces cerevisiae. This protein is a member of a family of flavohemoproteins, which contain both heme and flavin binding domains and which are capable of transferring electrons from NADPH to heme iron. Normally, actively respiring yeast cells have very low levels of the flavohemoglobin. However, its intracellular levels are greatly increased in cells in which the mitochondrial electron transport chain has been compromised by either mutation or inhibitors of respiration. The expression of the flavohemoglobin gene, YHB1, of S. cerevisiae is sensitive to oxygen. Expression is optimal in hyperoxic conditions or in air and is reduced under hypoxic and anaerobic conditions. The expression of YHB1 in aerobic cells is enhanced in the presence of antimycin A, in thiol oxidants, or in strains that lack superoxide dismutase. All three conditions lead to the accumulation of reactive oxygen species and promote oxidative stress. To study the function of flavohemoglobin in vivo, we created a null mutation in the chromosomal copy of YHB1. The deletion of the flavohemoglobin gene in these cells does not affect growth in either rho(o) or rho(+) genetic backgrounds. In addition, a rho(+) strain carrying a yhb1(-) deletion has normal levels of both cyanide-sensitive and cyanide insensitive respiration, indicating that the flavohemoglobin does not function as a terminal oxidase and is not required for the function or expression of the alternative oxidase system in S. cerevisiae. Cells that carry a yhb1(-) deletion are sensitive to conditions that promote oxidative stress. This finding is consistent with the observation that conditions that promote oxidative stress also enhance expression of YHB1. Together, these findings suggest that YHb plays a role in the oxidative stress response in yeast.	UNIV COLORADO, DEPT MOL CELLULAR & DEV BIOL, BOULDER, CO 80309 USA	University of Colorado System; University of Colorado Boulder					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030228, R01GM039324] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30228, GM39324] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; BOERMAN SJ, 1982, J GEN APPL MICROBIOL, V28, P35, DOI 10.2323/jgam.28.35; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; Boveris A., 1977, TISSUE HYPOXIA ISCHE, P67; BOYLAND E, 1967, BIOCHEM J, V104, P95, DOI 10.1042/bj1040095; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CRAMM R, 1994, J BIOL CHEM, V269, P7349; CRAWFORD MJ, 1995, J BIOL CHEM, V270, P6991, DOI 10.1074/jbc.270.12.6991; CUMSKY MG, 1985, P NATL ACAD SCI USA, V82, P2235, DOI 10.1073/pnas.82.8.2235; DIKSHIT RP, 1992, ARCH BIOCHEM BIOPHYS, V293, P241, DOI 10.1016/0003-9861(92)90391-9; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; GUIDOT DM, 1993, J BIOL CHEM, V268, P26699; IOANNIDIS N, 1992, BIOCHEM J, V288, P649, DOI 10.1042/bj2880649; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IWAASA H, 1992, J MOL BIOL, V227, P948, DOI 10.1016/0022-2836(92)90236-D; KARPLUS PA, 1994, J BIOENERG BIOMEMBR, V26, P89, DOI 10.1007/BF00763221; KEILIN D, 1953, NATURE, V172, P390, DOI 10.1038/172390a0; KHOSLA C, 1988, NATURE, V331, P633, DOI 10.1038/331633a0; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; LIU XF, 1992, J BIOL CHEM, V267, P18298; MCEWEN JE, 1985, J BACTERIOL, V161, P831, DOI 10.1128/JB.161.3.831-835.1985; MEISTER A, 1988, J BIOL CHEM, V263, P17205; OSHINO R, 1973, EUR J BIOCHEM, V35, P23, DOI 10.1111/j.1432-1033.1973.tb02805.x; PERUTZ MF, 1986, NATURE, V322, P405, DOI 10.1038/322405a0; PLUMMER JL, 1981, METHOD ENZYMOL, V77, P30; POOLE RK, 1994, P ROY SOC B-BIOL SCI, V255, P251, DOI 10.1098/rspb.1994.0036; POOLE RK, 1994, ANTON LEEUW INT J G, V65, P289, DOI 10.1007/BF00872215; POYTON RO, 1988, ANN NY ACAD SCI, V550, P289, DOI 10.1111/j.1749-6632.1988.tb35344.x; POYTON RO, 1992, BIOCHIM BIOPHYS ACTA, V1101, P252, DOI 10.1016/S0005-2728(05)80033-7; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; PROBST I, 1979, BIOCHIM BIOPHYS ACTA, V576, P471, DOI 10.1016/0005-2795(79)90422-7; RIGGS AF, 1991, AM ZOOL, V31, P535; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sies H., 1985, OXIDATIVE STRESS, V1, P73, DOI DOI 10.1016/B978-0-12-642760-8.50008-9; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; TAKAGI T, 1993, CURR OPIN STRUC BIOL, V3, P413, DOI 10.1016/S0959-440X(05)80115-0; TSANG SS, 1993, BIOTECHNIQUES, V14, P380; VASUDEVAN SG, 1991, MOL GEN GENET, V226, P49, DOI 10.1007/BF00273586; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; WATERLAND RA, 1991, J BIOL CHEM, V266, P4180; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; YCAS M, 1956, EXP CELL RES, V11, P1; Yu B.P., 1993, FREE RADICALS AGING, P57; ZEIGLER DM, 1987, OXYGEN FREE RADICALS, P730; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015; ZHU H, 1994, FASEB J, V8, pA1421; ZHU H, 1995, THESIS U TEXAS AUSTI; ZITOMER RS, 1992, MICROBIOL REV, V56, P1; [No title captured]	59	71	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25131	25138		10.1074/jbc.271.41.25131	http://dx.doi.org/10.1074/jbc.271.41.25131			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810268	hybrid			2022-12-27	WOS:A1996VL69300012
J	Zhao, YW; Sparks, DL; Marcel, YL				Zhao, YW; Sparks, DL; Marcel, YL			Specific phospholipid association with apolipoprotein A-I stimulates cholesterol efflux from human fibroblasts - Studies with reconstituted sonicated lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CELL-DERIVED CHOLESTEROL; SMOOTH-MUSCLE CELLS; ACYLTRANSFERASE ACTIVITY; DISCOIDAL LIPOPROTEINS; PLASMA-LIPOPROTEINS; GEL-ELECTROPHORESIS; ELEVATED LEVELS; PARTICLE-SIZE; LIPID EFFLUX	To understand how the lipid composition of high density lipoprotein mediates the efflux of cellular cholesterol, we have characterized the effects of variations in the lipid composition of well defined model sonicated apolipoprotein A-I (apoA-I)-containing lipoprotein (LpA-I) particle on cholesterol efflux from cultured human skin fibroblasts. LpA-I particles with varying content of phosphatidylcholine (POPC), phosphatidylinositol, sphingomyelin, cholesterol ester, and triolein were prepared by co-sonication. Association of as little as 5 mol of phosphatidylcholine with apoA-I is sufficient to transform lipid-free apoA-I into a distinct lipoprotein-like particle that is a significantly better acceptor of cellular cholesterol, Increasing the ratio of POPC/apoA-I from 5/1 to 35.5/1 in the sonicated LpA-I is associated with a significant increase in the release of cellular cholesterol, At low POPC/apoA-I ratios, native gradient gel electrophoresis of the LpA-I shows these lipoproteins to be small complexes (around 5-6 nm), with only 1 molecule of apoA-I (Lp1A-I). At a POPC/apoA-I ratio above 11/1, LpA-I form well defined complexes that contain 2 molecules of apoA-I (Lp2A-I) and range in size from 7.6 to 7.7 nm. Inclusion of sphingomyelin into an Lp1A-I further stimulates cholesterol efflux significantly. In contrast, inclusion of either sphingomyelin or phosphatidylinositol into a sonicated Lp2A-I has no effect on cholesterol efflux, Incorporation of cholesterol ester and/or triolein into an Lp2A-I particle is associated with a small reduction in cholesterol efflux to these lipoproteins. Therefore, cholesterol efflux from human fibroblasts is directly proportional to the amount and type of phospholipid in a sonicated LpA-I particle. Changes in the conformation and charge of apoA-I that result from changes in the lipid composition of a sonicated LpA-I particle appear to directly affect the ability of the lipoprotein to bind and retain cholesterol molecules. These data therefore suggest that the adsorption/desorption of cholesterol molecules to/from a sonicated LpA-I complex may be less sensitive to interfacial lipid-lipid interactions, but may depend on a conformation-dependent ability of apoA-I to bind cholesterol.	UNIV OTTAWA,INST HEART,LIPOPROT & ATHEROSCLEROSIS GRP,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,DEPT PATHOL & LAB MED,OTTAWA,ON K1Y 4E9,CANADA; UNIV OTTAWA,DEPT BIOCHEM,OTTAWA,ON K1Y 4E9,CANADA	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa								AGNANI G, 1993, BIOCHEMISTRY-US, V32, P2643, DOI 10.1021/bi00061a024; BANERJEE D, 1983, J CELL BIOL, V96, P651, DOI 10.1083/jcb.96.3.651; BANKA CL, 1991, J BIOL CHEM, V266, P23886; BERGERON J, 1995, J BIOL CHEM, V270, P27429, DOI 10.1074/jbc.270.46.27429; BIELICKI JK, 1992, J LIPID RES, V33, P1699; BIELICKI JK, 1991, BIOCHIM BIOPHYS ACTA, V1085, P7, DOI 10.1016/0005-2760(91)90225-7; BREWER HB, 1986, METHOD ENZYMOL, V128, P223; CASTLE CK, 1991, J LIPID RES, V32, P439; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; COLLET X, 1991, J BIOL CHEM, V266, P9145; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; EISENBERG S, 1984, J LIPID RES, V25, P1017; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING PE, 1994, BIOCHEMISTRY-US, V33, P6981, DOI 10.1021/bi00188a030; FORTE TM, 1993, J LIPID RES, V34, P317; FRANCONE OL, 1990, EUR HEART J, V11, P218, DOI 10.1093/eurheartj/11.suppl_E.218; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; FUGLER L, 1985, J BIOL CHEM, V260, P4098; HARA H, 1992, BIOCHEMISTRY-US, V31, P2040, DOI 10.1021/bi00122a021; HARA H, 1991, J BIOL CHEM, V266, P3080; HIRZ R, 1970, BIOCHIM BIOPHYS ACTA, V207, P364, DOI 10.1016/0005-2795(70)90029-2; HUSSAIN MM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P90; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; JOHNSON WJ, 1991, J LIPID RES, V32, P1993; JONAS A, 1989, J BIOL CHEM, V264, P4818; JONAS A, 1994, J LIPID RES, V35, P860; KAN CC, 1991, BIOCHEMISTRY-US, V30, P7759, DOI 10.1021/bi00245a013; KUNITAKE ST, 1985, J LIPID RES, V26, P549; LI QQ, 1993, BIOCHEMISTRY-US, V32, P4597, DOI 10.1021/bi00068a016; LI QQ, 1995, J BIOL CHEM, V270, P26216, DOI 10.1074/jbc.270.44.26216; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDKATZ S, 1988, BIOCHEMISTRY-US, V27, P3416, DOI 10.1021/bi00409a044; MCCALL MR, 1988, J LIPID RES, V29, P1127; MCCALL MR, 1989, J LIPID RES, V30, P1579; MIIDA T, 1992, BIOCHEMISTRY-US, V31, P11112, DOI 10.1021/bi00160a022; MIIDA T, 1990, BIOCHEMISTRY-US, V29, P10469, DOI 10.1021/bi00498a007; NEARY RH, 1987, CLIN CHEM, V33, P1163; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; NUNEZ JF, 1984, J BIOL CHEM, V259, P9141; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SPARKS DL, 1995, J BIOL CHEM, V270, P26910, DOI 10.1074/jbc.270.45.26910; SPARKS DL, 1992, J LIPID RES, V33, P123; SPARKS DL, 1995, J BIOL CHEM, V270, P5151, DOI 10.1074/jbc.270.10.5151; SPARKS DL, 1993, J BIOL CHEM, V268, P23250; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; STEIN O, 1988, BIOCHIM BIOPHYS ACTA, V960, P322, DOI 10.1016/0005-2760(88)90040-9; STEIN O, 1973, BIOCHIM BIOPHYS ACTA, V326, P232, DOI 10.1016/0005-2760(73)90249-X; Sviridov D, 1996, BIOCHEMISTRY-US, V35, P189, DOI 10.1021/bi9507544; SWANEY JB, 1986, METHOD ENZYMOL, V128, P613; THRIFT RN, 1986, J LIPID RES, V27, P236; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021; YEAGLE PL, 1986, J BIOL CHEM, V261, P8175; Zhao YW, 1996, BIOCHEMISTRY-US, V35, P7174, DOI 10.1021/bi952242v	56	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25145	25151		10.1074/jbc.271.41.25145	http://dx.doi.org/10.1074/jbc.271.41.25145			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810270	hybrid			2022-12-27	WOS:A1996VL69300014
J	Lee, HY; Clair, T; Mulvaney, PT; Woodhouse, EC; Aznavoorian, S; Liotta, LA; Stracke, ML				Lee, HY; Clair, T; Mulvaney, PT; Woodhouse, EC; Aznavoorian, S; Liotta, LA; Stracke, ML			Stimulation of tumor cell motility linked to phosphodiesterase catalytic site of autotaxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE GLYCOPROTEIN PC-1; FIBROBLAST GROWTH-FACTOR; HUMAN-MELANOMA CELLS; AMINO-ACID-SEQUENCE; NUCLEOTIDE PYROPHOSPHATASE; CDNA CLONING; RAT-BRAIN; MOLECULAR-CLONING; SURFACE-ANTIGENS; IV COLLAGENASE	A family of extracellular type I phosphodiesterases has recently been isolated by cDNA cloning, but a physiological function linked to the phosphodiesterase active site has remained unknown, We now present evidence that the phosphodiesterase catalytic site, (201)YMRPVYPTKTFPN(213), is essential for the motility stimulating activity of autotaxin (ATX), one member of the exophosphodiesterase family. Native ATX possesses phosphodiesterase activity at neutral and alkaline pH, binds ATP noncovalently, and undergoes threonine phosphorylation. Homogeneously purified recombinant ATX, based on the teratocarcinoma sequence, retains these same activities, A single amino acid in the phosphodiesterase catalytic site, Thr(210), is found to be necessary for motility stimulation, phosphodiesterase activity, and phosphorylation. Two mutant recombinant proteins, Ala(210)- and Asp(210)-ATX, lack motility stimulation and lack both enzymatic activities; Ser(210)-ATX possesses intermediate activities, Another mutation, with the adjacent lysine (Lys(209)) changed to Leu(209)-ATX, possesses normal motility stimulation with sustained phosphodiesterase activity but exhibits no detectable phosphorylation. This mutation eliminates the phosphorylation reaction and indicates that the dephosphorylated state is an active motility stimulating form of the ATX molecule. By demonstrating that the phosphodiesterase enzymatic site is linked to motility stimulation, these data reveal a novel role for this family of exo/ecto-enzymes and open up the possibility of extracellular enzymatic cascades as a regulatory mechanism for cellular motility.	NCI, PATHOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BELLI SI, 1995, EUR J BIOCHEM, V228, P669, DOI 10.1111/j.1432-1033.1995.tb20308.x; BROWN PD, 1990, CANCER RES, V50, P6184; BUCKLEY MF, 1990, J BIOL CHEM, V265, P17506; CHEN ZP, 1995, J NEUROENDOCRINOL, V7, P83, DOI 10.1111/j.1365-2826.1995.tb00671.x; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; CULP JS, 1985, J BIOL CHEM, V260, P8320; DEISSLER H, 1995, J BIOL CHEM, V270, P9849, DOI 10.1074/jbc.270.17.9849; FUNAKOSHI I, 1992, ARCH BIOCHEM BIOPHYS, V295, P180, DOI 10.1016/0003-9861(92)90504-P; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GRUPE A, 1995, J CLIN INVEST, V94, P560; HALEY BE, 1974, P NATL ACAD SCI USA, V71, P3367, DOI 10.1073/pnas.71.9.3367; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KINDLERROHRBORN A, 1985, DIFFERENTIATION, V30, P53, DOI 10.1111/j.1432-0436.1985.tb00513.x; KINDLERROHRBORN A, 1994, DIFFERENTIATION, V57, P215, DOI 10.1007/s002580050057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HY, 1996, BIOCHEM BIOPH RES CO, V218, P714, DOI 10.1006/bbrc.1996.0127; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0; MARGULIES IMK, 1992, CANCER EPIDEM BIOMAR, V1, P467; MURATA J, 1994, J BIOL CHEM, V269, P30479; NARITA M, 1994, J BIOL CHEM, V269, P28235; ODA Y, 1991, J BIOL CHEM, V266, P16791; ODA Y, 1993, J BIOL CHEM, V268, P27318; RAZZELL WE, 1959, J BIOL CHEM, V234, P2105; REBBE NF, 1991, P NATL ACAD SCI USA, V88, P5192, DOI 10.1073/pnas.88.12.5192; STRACKE ML, 1987, BIOCHEM BIOPH RES CO, V146, P339, DOI 10.1016/0006-291X(87)90730-3; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; TAKAHASHI T, 1970, J EXP MED, V131, P1325, DOI 10.1084/jem.131.6.1325; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0	33	78	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24408	24412		10.1074/jbc.271.40.24408	http://dx.doi.org/10.1074/jbc.271.40.24408			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798697	hybrid			2022-12-27	WOS:A1996VM67400019
J	Rahimi, N; Tremblay, E; Elliott, B				Rahimi, N; Tremblay, E; Elliott, B			Phosphatidylinositol 3-kinase activity is required for hepatocyte growth factor-induced mitogenic signals in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCATTER FACTOR-RECEPTOR; PROTEIN-KINASE-C; TYROSINE KINASE; PHOSPHOINOSITIDE 3-KINASE; HGF-RECEPTOR; ACTIVATION; MET; TRANSFORMATION; PHOSPHORYLATION; ASSOCIATION	Phosphatidylinositol (PI) 3-kinase is an important enzyme implicated in growth factor-stimulated intracellular signaling. In this study we have shown that hepatocyte growth factor (HGF) induces a rapid tyrosine phosphorylation of PI 3-kinase and association with HGF receptor/Met in Mv1Lu epithelial cells. Murine mammary carcinoma (SP1) cells, which co-express HGF and HGF receptor/Met, showed sustained phosphorylation of PI 3-kinase. Wortmannin, a potent inhibitor of PI 3-kinase, inhibited HGF-induced PI 3-kinase activity, proliferation of Mv1Lu cells, and spontaneous growth of SP1 cells in a dose-, and time-dependent manner. Transfection of a dominant negative mutant p85 (Delta p85) subunit of PI 3-kinase into SP1 cells strongly inhibited HGF-stimulated proliferation and PI 3-kinase activity. However, wortmannin did not influence HGF-induced c-Jun expression. Furthermore, HGF stimulated S6 kinase activity, but its activity was not required for HGF-induced proliferation. Overall, these results suggest that HGF-induced PI 3-kinase activity is important for the mitogenic action of HGF in epithelial cells and further demonstrate that expression of c-Jun is not influenced by inhibition of PI 3-kinase activity.	QUEENS UNIV,DEPT PATHOL,CANC RES LAB,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada				Rahimi, Nader/0000-0002-6745-1725				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CARLOW DA, 1985, J NATL CANCER I, V75, P291; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHUNG J, 1992, CELL, V78, P35; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DEFRANCES MC, 1992, DEVELOPMENT, V116, P387; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FIXMAN ED, 1995, ONCOGENE, V10, P237; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GANDINO L, 1990, ONCOGENE, V5, P721; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LEHTOLA L, 1991, J CELL BIOCHEM, V45, P69, DOI 10.1002/jcb.240450114; LONGATI P, 1994, ONCOGENE, V9, P49; LU YL, 1995, EUR J IMMUNOL, V25, P533, DOI 10.1002/eji.1830250234; Matsumoto K, 1993, EXS, V65, P225; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NALDINI L, 1991, ONCOGENE, V6, P501; NOJI S, 1990, BIOCHEM BIOPH RES CO, V173, P42, DOI 10.1016/S0006-291X(05)81018-6; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PETRITSCH C, 1995, EUR J BIOCHEM, V230, P431, DOI 10.1111/j.1432-1033.1995.0431h.x; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; POWIS G, 1994, CANCER RES, V54, P2419; RAHIMI N, 1994, DNA CELL BIOL, V13, P1189, DOI 10.1089/dna.1994.13.1189; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; ROSEN EM, 1993, SYM SOC EXP BIOL, V47, P227; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; SANTOS OFP, 1993, DEV BIOL, V159, P535, DOI 10.1006/dbio.1993.1262; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YANG XM, 1993, DEV BIOL, V157, P308, DOI 10.1006/dbio.1993.1137; YANO H, 1993, J BIOL CHEM, V268, P25846; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zarnegar R, 1993, EXS, V65, P181; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHEN Z, 1994, ONCOGENE, V9, P1691	48	52	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24850	24855		10.1074/jbc.271.40.24850	http://dx.doi.org/10.1074/jbc.271.40.24850			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798760	hybrid			2022-12-27	WOS:A1996VM67400082
J	Touyz, RM; Schiffrin, EL				Touyz, RM; Schiffrin, EL			Angiotensin II and vasopressin modulate intracellular free magnesium in vascular smooth muscle cells through Na+-dependent protein kinase C pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; SALMONELLA-TYPHIMURIUM; PHOSPHOLIPASE-C; MG-2+ EFFLUX; TRANSPORT; CALCIUM; RAT; MG2+; EXCHANGE; LIVER	Vasoactive peptides mobilize cytosolic free Mg2+ in vascular smooth muscle cells, It is unknown whether angiotensin II and arginine vasopressin, potent vaso constrictor agents, influence intracellular Mg2+, The effects of angiotensin II and vasopressin on intracellular free Mg2+ concentrations ([Mg2+](i)) were therefore investigated in primary cultured unpassaged vascular smooth muscle cells (VSMC) from mesenteric arteries of Wistar Kyoto rats, and in an established cell line of rat thoracic aorta cells (A10 cells), Underlying mechanisms of agonist stimulated [Mg2+](i) changes were assessed in A10 cells by pharmacologically manipulating phospholipase C, protein kinase C, and the Na+/H+ exchanger. In addition, the dependence of [Mg2+](i) on intracellular Ca2+ was determined, [Mg2+](i) was measured in single cells by fluorescent digital imaging using mag-fura-2/AM. Basal [Mg2+](i) levels in Wistar Kyoto rat and A10 cells were 0.62 +/- 0.02 mmol/liter and 0.58 +/- 0.01 mmol/ liter, respectively, Angiotensin II and vasopressin induced a dose-dependent biphasic [Mg2+](i) response where [Mg2+](i) increased rapidly and transiently to a peak level and then declined to subbasal levels, which were sustained, Preexposure of cells to neomycin, a nonspecific phospholipase C inhibitor, U-73122, a selective phospholipase C inhibitor, calphostin C, a selective protein kinase C inhibitor, and 5-(N,N-hexamethylene)amiloride, a selective Na+/H+ exchange blocker, attenuated angiotensin II- and vasopressin-induced [Mg2+](i) responses in a concentration-dependent manner, Removal of extracellular Na+ completely inhibited agonist-elicited [Mg2+](i) transients. To determine whether intracellular free Ca2+ concentration ([Ca2+](i)) influences agonist-induced [Mg2+](i) changes, thapsigargin, a selective sarcoplasmic reticular Ca2+-ATPase inhibitor, was used to deplete intracellular Ca2+ stores, In thapsigargin-pretreated cells, angiotensin II-elicited [Ca2+](i) responses were significantly attenuated, whereas agonist-induced [Mg2+](i) responses were unchanged. These data demonstrate that in primary cultured VSMC and in an established VSMC line, angiotensin II and vasopressin modulate [Mg2+](i) through receptor-mediated pathways, which are [Ca2+](i)-independent but which involve phospholipase C, protein kinase C, and the Na+/H+ exchanger, These pathways are linked to a Na+-dependent Mg2+ transporter, which facilitates transmembrane Mg2+ transport.			Touyz, RM (corresponding author), UNIV MONTREAL,CLIN RES INST MONTREAL,MED RES COUNCIL MULTIDISCIPLINARY RES GRP HYPERTENSION,MONTREAL,PQ H2W 1R7,CANADA.		Schiffrin, Ernesto L/AAB-9061-2019; Touyz, Rhian/AAM-3564-2020	Schiffrin, Ernesto L/0000-0002-4502-2823; Touyz, Rhian/0000-0003-0670-0887				Aikawa J K, 1978, World Rev Nutr Diet, V28, P112; ALTURA BM, 1977, FED PROC, V36, P1853; ANDREA JE, 1992, HYPERTENSION, V20, P585, DOI 10.1161/01.HYP.20.5.585; BAKER PF, 1972, J PHYSIOL-LONDON, V227, P855, DOI 10.1113/jphysiol.1972.sp010062; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOND M, 1987, J BIOL CHEM, V262, P15630; ELLIOTT DA, 1974, J BIOL CHEM, V249, P3985; FERAY JC, 1987, J BIOL CHEM, V262, P5763; FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259, DOI 10.1146/annurev.ph.53.030191.001355; GRUBBS RD, 1986, J BIOL CHEM, V261, P2550; GRUBBS RD, 1994, MOL CELL BIOCHEM, V136, P11, DOI 10.1007/BF00931599; GRUBBS RD, 1987, MAGNESIUM, V6, P113; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTHER T, 1985, BIOCHEM BIOPH RES CO, V130, P540, DOI 10.1016/0006-291X(85)90450-4; GUNTHER T, 1992, FEBS LETT, V307, P333, DOI 10.1016/0014-5793(92)80707-N; HARTZELL HC, 1989, J GEN PHYSIOL, V94, P745, DOI 10.1085/jgp.94.4.745; HATHAWAY DR, 1991, CIRCULATION, V83, P382, DOI 10.1161/01.CIR.83.2.382; HENQUIN JC, 1983, NATURE, V301, P73, DOI 10.1038/301073a0; HMIEL SP, 1986, J BACTERIOL, V168, P1444, DOI 10.1128/jb.168.3.1444-1450.1986; HWANG DL, 1993, J CLIN ENDOCR METAB, V76, P549, DOI 10.1210/jc.76.3.549; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LI HY, 1994, BBA-MOL CELL RES, V1222, P164, DOI 10.1016/0167-4889(94)90165-1; LITOSCH I, 1991, J BIOL CHEM, V266, P4764; LOW AM, 1993, EUR J PHARMACOL, V230, P53, DOI 10.1016/0014-2999(93)90409-B; LUDI H, 1987, J PHYSIOL-LONDON, V390, P367; MAGUIRE ME, 1980, J BIOL CHEM, V255, P1030; MURPHY E, 1991, ANNU REV PHYSIOL, V53, P273, DOI 10.1146/annurev.physiol.53.1.273; MURPHY E, 1993, MINER ELECTROL METAB, V19, P250; NG LL, 1992, METABOLISM, V41, P772, DOI 10.1016/0026-0495(92)90319-6; OKADA K, 1992, AM J PHYSIOL, V263, pC873, DOI 10.1152/ajpcell.1992.263.4.C873; PAGE E, 1972, J PHYSIOL-LONDON, V224, P121, DOI 10.1113/jphysiol.1972.sp009884; PICADO MJ, 1994, HYPERTENSION, V23, P987, DOI 10.1161/01.HYP.23.6.987; PUSCH M, 1989, BIOPHYS J, V55, P1267, DOI 10.1016/S0006-3495(89)82922-4; QUAMME GA, 1993, AM J PHYSIOL, V265, P4281; RAJU B, 1989, LIFE SCI, V256, pC540; ROMANI A, 1993, CIRC RES, V72, P1139, DOI 10.1161/01.RES.72.6.1139; ROMANI A, 1990, FEBS LETT, V269, P37, DOI 10.1016/0014-5793(90)81113-3; SCHACHTER M, 1990, BIOCHIM BIOPHYS ACTA, V1035, P378, DOI 10.1016/0304-4165(90)90103-4; SCHIFFRIN EL, 1986, LIFE SCI, V38, P817, DOI 10.1016/0024-3205(86)90598-9; SCHWERTZ DW, 1984, J PHARMACOL EXP THER, V231, P48; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; TOUYZ RM, 1994, J HYPERTENS, V12, P663; TOUYZ RM, 1993, J HYPERTENS, V11, P551, DOI 10.1097/00004872-199305000-00011; VOLPE P, 1990, AM J PHYSIOL, V258, pC1077, DOI 10.1152/ajpcell.1990.258.6.C1077; WALKER GM, 1986, MAGNESIUM, V531, P201; ZHANG A, 1992, BIOCHIM BIOPHYS ACTA, V1134, P25, DOI 10.1016/0167-4889(92)90024-6; ZHENG LX, 1995, ENDOCRINOLOGY, V136, P1079, DOI 10.1210/en.136.3.1079	48	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24353	24358		10.1074/jbc.271.40.24353	http://dx.doi.org/10.1074/jbc.271.40.24353			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798689	hybrid			2022-12-27	WOS:A1996VM67400011
J	Zhou, MY; Wu, XJ; Ginsberg, HN				Zhou, MY; Wu, XJ; Ginsberg, HN			Evidence that a rapidly turning over protein, normally degraded by proteasomes, regulates hsp72 gene transcription in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; DNA-BINDING ACTIVITY; MOLECULAR CHAPERONES; MAMMALIAN-CELLS; APOLIPOPROTEIN-B; STRESS PROTEINS; CYCLIN-B; INDUCTION; DEGRADATION; EXPRESSION	Heat shock protein 72/73 (Hsp70) is a cytosolic molecular chaperone that carries out fundamental roles under both normal and stress situations, There is great interest in delineating the mechanisms whereby Hsp70 levels are regulated. We observed that N-acetyl-leucyl-leucyl-norleucinal (ALLN), a synthetic aldehydic tripeptide that inhibits proteasomes, markedly induced Hsp70 levels (up to 30-fold above base line in HepG2 cells and human endothelial cells). Induction of Hsp70 by ALLN was dose-dependent and not related to cell toxicity. ALLN selectively increased Hsp70 levels without affecting Hsp25, Hsp27, Hsp60, Hsp86, Hsp90, Hsp104, or Bip (immunoglobulin heavy chain binding protein) in HepG2 cells. ALLN induced Hsp70 not only by stabilizing the protein but also by dramatically increasing its synthesis. The modulation of Hsp70 synthesis by ALLN resulted from a rapid and marked increase in transcription of the hsp72 gene, since the induction of hsp72 mRNA was blocked in cells co-treated with actinomycin D. hsp72 mRNA levels were affected in a time-dependent manner by exposure to ALLN; significant elevations occurred within 60 min of treatment, and a decline to background levels was observed by 7 h of recovery. The ALLN-induced increase in hsp72 gene expression was associated with trimerization of the heat shock transcriptional factor (HSF1). ALLN did not affect the steady-state level of HSF1 protein. The effects of ALLN appeared to require de novo protein synthesis, since the induction of both HSF1 trimerization and hsp72 transcription was blocked by co-treatment with cycloheximide. When we tested a series of protease inhibitors, only the related aldehydic tripeptides, N-acetyl-leucyl-leucyl-methioninal and the proteasome inhibitor. Cbz-leucyl-leucyl-leucinal, induced Hsp70 levels. The specific proteasome inhibitor, lactacystin, which has a different structure, also induced Hsp70 levels. Overall, our results suggest that a rapidly turning over protein that is normally degraded by proteasomes may be involved in the regulation of Hsp70 synthesis via effects on the hsp70 transcriptional factor, HSF1.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032	Columbia University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036000] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 21007, HL 36000] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELLA PM, 1979, BIOCHEM BIOPH RES CO, V87, P734, DOI 10.1016/0006-291X(79)92020-5; ANGELIDIS CE, 1991, EUR J BIOCHEM, V199, P35, DOI 10.1111/j.1432-1033.1991.tb16088.x; ASHBURNER M, 1979, CELL, V17, P241, DOI 10.1016/0092-8674(79)90150-8; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; CURRIE RW, 1988, CIRC RES, V63, P543, DOI 10.1161/01.RES.63.3.543; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DIERKS T, 1993, PHILOS T ROY SOC B, V339, P335, DOI 10.1098/rstb.1993.0032; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FREEMAN ML, 1993, RADIAT RES, V135, P387, DOI 10.2307/3578879; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; GOLDBERG AL, 1995, CHEM BIOL, V2, P503, DOI 10.1016/1074-5521(95)90182-5; GOODSON ML, 1995, J BIOL CHEM, V270, P2447, DOI 10.1074/jbc.270.6.2447; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; HEGDE RS, 1995, J CELL PHYSIOL, V165, P186, DOI 10.1002/jcp.1041650122; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; INOUE S, 1991, J BIOL CHEM, V266, P13311; JOHNSON AD, 1995, ARTERIOSCL THROM VAS, V15, P27, DOI 10.1161/01.ATV.15.1.27; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIU AYC, 1989, J BIOL CHEM, V264, P12037; Liu H, 1996, J BIOL CHEM, V271, P4805; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Maniatis T., 1982, MOL CLONING; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MARBER MS, 1993, CIRCULATION, V88, P1264, DOI 10.1161/01.CIR.88.3.1264; MINOWADA G, 1995, J CLIN INVEST, V95, P3, DOI 10.1172/JCI117655; MITANI K, 1993, BIOCHEM J, V290, P819, DOI 10.1042/bj2900819; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; NEUPERT W, 1993, PHILOS T ROY SOC B, V339, P355, DOI 10.1098/rstb.1993.0034; OHTSUKI T, 1992, BRAIN RES, V599, P246, DOI 10.1016/0006-8993(92)90398-S; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PLUMIER JC, 1995, J CLIN INVEST, V94, P1854; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RABINDRAN SK, 1994, MOL CELL BIOL, V14, P6552, DOI 10.1128/MCB.14.10.6552; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RODFORD NB, 1996, P NATL ACAD SCI USA, V93, P2339; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHISSEL SL, 1995, BIOCHEMISTRY-US, V34, P10463, DOI 10.1021/bi00033a019; Schlesinger M. J., 1982, HEAT SHOCK BACTERIA; SHERWOOD SW, 1993, P NATL ACAD SCI USA, V90, P3353, DOI 10.1073/pnas.90.8.3353; SIMON MM, 1995, J CLIN INVEST, V95, P925; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; ZAFARULLAH M, 1993, EXP CELL RES, V208, P371, DOI 10.1006/excr.1993.1258; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220; [No title captured]	60	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24769	24775		10.1074/jbc.271.40.24769	http://dx.doi.org/10.1074/jbc.271.40.24769			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798747	hybrid			2022-12-27	WOS:A1996VM67400069
J	Gillotte, KL; Davidson, WS; LundKatz, S; Rothblat, GH; Phillips, MC				Gillotte, KL; Davidson, WS; LundKatz, S; Rothblat, GH; Phillips, MC			Apolipoprotein A-I structural modification and the functionality of reconstituted high density lipoprotein particles in cellular cholesterol efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; ATHEROSCLEROSIS; TRANSPORT; ACYLTRANSFERASE; QUANTITATION; METABOLISM; MEMBRANE; EPITOPE; DISKS	The role of HDL and its major protein constituent, apolipoprotein (ape) A-I, in promoting the removal of excess cholesterol from cultured cells has been well es tablished; however, the mechanisms by which this occurs are not completely understood, To address the effects of apoA-I modification on cellular unesterified (free) cholesterol (FC) efflux, three recombinant human apoA-I deletion mutants and plasma apoA-I were combined with 1-palmitoyl-2-oleoyl phosphatidylcholine (POPC) and FC to make reconstituted high density lipoprotein (rHDL) discoidal complexes, These particles were characterized structurally and for their efficiency as accepters of mouse L-cell fibroblast cholesterol, The deletion mutant proteins lacked NH2-terminal (apoA-I (Delta 44-126)), central (apoA-I (Delta 139-170)), or COOH-terminal (apoA-I (Delta 190-243)) domains of apoA-I, The three deletion mutants all displayed lipid-binding abilities and formed discoidal complexes that were similar in major diameter (13.2 +/- 1.5 nm) to those formed by human apoA-I when reconstituted at a 100:5:1 (POPC:FC: protein) mole ratio, Gel filtration profiles indicated unreacted protein in the preparation made with apoA-I (Delta 190-243), which is consistent with the COOH terminus portion of apoA-I being an important determinant of lipid binding, Measurements of the percent cu-helix content of the proteins, as well as the number of protein molecules per rHDL particle, gave an indication of the arrangement of the deletion mutant proteins in the discoidal complexes, The rHDL particles containing the deletion mutants had more molecules of protein present than particles containing intact apoA-I, to the extent that a similar number of helical segments was incorporated into each of the discoidal species, Comparison of the experimentally determined number of helical segments with an estimate of the available space indicated that the deletion mutant proteins are probably more loosely arranged than apoA-I around the edge of the rHDL, The abilities of the complexes to remove radiolabeled FC were compared in experiments using cultured mouse L-cell fibroblasts, All four discoidal complexes displayed similar abilities to remove FC from the plasma membrane of L-cells when compared at an acceptor concentration of 50 mu g of phospholipid/ml. Thus, none of the deletions imposed in this study notably altered the ability of the rHDL particles to participate in cellular FC efflux, These results suggest that efficient apoA-I-mediated FC efflux requires the presence of amphipathic alpha-helical segments but is not dependent on specific helical segments.	ALLEGHENY UNIV HLTH SCI,DEPT BIOCHEM,PHILADELPHIA,PA 19129; UNIV ILLINOIS,DEPT BIOCHEM,COLL MED,URBANA,IL 61801	Drexel University; University of Illinois System; University of Illinois Urbana-Champaign				Davidson, William/0000-0003-2756-2989; Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANKA CL, 1994, J BIOL CHEM, V269, P10288; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BRESLOW JL, 1993, P NATL ACAD SCI USA, V90, P8314, DOI 10.1073/pnas.90.18.8314; BRUCE C, 1995, CURR OPIN LIPIDOL, V6, P306, DOI 10.1097/00041433-199510000-00010; DAVIDSON WS, 1994, J BIOL CHEM, V269, P22975; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; DAVIDSON WS, 1995, J BIOL CHEM, V270, P5882, DOI 10.1074/jbc.270.11.5882; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING PE, 1994, BIOCHEMISTRY-US, V33, P6981, DOI 10.1021/bi00188a030; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; GLOMSET JA, 1968, J LIPID RES, V9, P155; HARA H, 1991, J BIOL CHEM, V266, P3080; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; JI Y, 1995, J BIOL CHEM, V270, P11290, DOI 10.1074/jbc.270.19.11290; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; JONAS A, 1989, J BIOL CHEM, V264, P4818; KLANSEK JJ, 1995, J LIPID RES, V36, P2261; LUCHOOMUN J, 1994, BBA-LIPID LIPID MET, V1212, P319, DOI 10.1016/0005-2760(94)90206-2; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NICHOLS AV, 1983, BIOCHIM BIOPHYS ACTA, V750, P353, DOI 10.1016/0005-2760(83)90040-1; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; ROSSENEU M, 1992, HIGH DENSITY LIPOPRO, V3, P105; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; ROTHBLAT GH, 1991, CURR OPIN LIPIDOL, V2, P288; SCANU AM, 1971, ANAL BIOCHEM, V44, P576, DOI 10.1016/0003-2697(71)90247-8; SCHMIDT HHJ, 1995, J BIOL CHEM, V270, P5469, DOI 10.1074/jbc.270.10.5469; SEGREST JP, 1992, J LIPID RES, V33, P141; SHARRETT AR, 1994, ARTERIOSCLER THROMB, V14, P1098, DOI 10.1161/01.ATV.14.7.1098; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; SPARKS DL, 1995, J BIOL CHEM, V270, P26910, DOI 10.1074/jbc.270.45.26910; SPARKS DL, 1993, J BIOL CHEM, V268, P23250; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; Sviridov D, 1996, BIOCHEMISTRY-US, V35, P189, DOI 10.1021/bi9507544; SWANEY JB, 1986, METHOD ENZYMOL, V128, P613; VONECKARDSTEIN A, 1993, J BIOL CHEM, V268, P2616; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1	41	27	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23792	23798		10.1074/jbc.271.39.23792	http://dx.doi.org/10.1074/jbc.271.39.23792			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798607	hybrid			2022-12-27	WOS:A1996VJ44200036
J	MullerSteffner, HM; Augustin, A; Schuber, F				MullerSteffner, HM; Augustin, A; Schuber, F			Mechanism of cyclization of pyridine nucleotides by bovine spleen NAD(+) glycohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; ADENINE-DINUCLEOTIDE GLYCOHYDROLASE; CALCIUM-MOBILIZING METABOLITE; NAD+-GLYCOHYDROLASE; CYCLASE ACTIVITY; HUMAN CD38; RAT-LIVER; HYDROLYSIS; ENZYME; PURIFICATION	We have shown that bovine spleen NAD(+) glycohydrolase (EC 3.2.2.5), purified to homogeneity, is a multifunctional enzyme, A time-dependent formation of cADPR from NAD(+) that did not exceed 1.5-2% of the reaction products was measurable, The cyclase activity of this enzyme was, however, best evidenced by its transformation of NGD(+) into cyclic GDP-ribose (cGDPR), The formation of the cyclic compound could be monitored spectroscopically (UV and fluorescence) and by highperformance liquid chromatography; the product ratio of cGDPR/GDP-ribose was 2:1. Bovine spleen NAD(+) glycohydrolase is also able to hydrolyze cADPR (Muller-Steffner et al. (1994) Biochem. Biophys. Res, Commun. 204, 1279-1285); the kinetic parameters (V/K-m) measured exclude, however, the possibility that cADPR is a kinetically competent reaction intermediate in the transformation of NAD(+) into ADP ribose. Experimental data indicating that NAD(+) glycohydrolase-catalyzed hydrolysis and methanolysis of NA(GD+ occurred at the expense of the formation of the cyclic compounds are in favor of a reaction mechanism involving the partitioning of a common oxocarbenium reaction intermediate between the different accepters. Thus E . A(G)DP-ribosyl oxocarbenium intermediate can react according to i) intramolecular processes with the positions N-1 of adenine and N-7 of guanine to give cA(G)DPR as reaction products, and ii) intermolecular reactions with water (formation of A(G)DP-ribose) and methanol (formation of methyl A(G)DP-ribose). We attribute the marked difference in yield of cADPR and cGDPR to the intrinsic reactivity (nucleophilicity and positioning) of the purine N-positions that are involved in the cyclization reactions within the E . A(G)DP-ribosyl oxocarbenium complexes.	UNIV STRASBOURG 1,CHIM BIOORGAN LAB,CNRS,LAB 1386,FAC PHARM,F-67400 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								AMARCOSTESEC A, 1985, J CELL BIOL, V100, P189, DOI 10.1083/jcb.100.1.189; Bell CE, 1996, BIOCHEMISTRY-US, V35, P1137, DOI 10.1021/bi9520848; BERANEK DT, 1980, CARCINOGENESIS, V1, P595, DOI 10.1093/carcin/1.7.595; BOCCHINI V, 1988, INT J DEV NEUROSCI, V6, P525, DOI 10.1016/0736-5748(88)90060-3; Brown D. M, 1974, BASIC PRINCIPLES NUC, VII, P1, DOI 10.1016/B978-0-12-701902-4.50007-1; FUNARO A, 1995, FUND CLIN IMMUNOL, V3, P101; Graeff RM, 1996, BIOCHEMISTRY-US, V35, P379, DOI 10.1021/bi952083f; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; GUSE AH, 1995, J IMMUNOL, V155, P3353; HANDLON AL, 1994, J AM CHEM SOC, V116, P12087, DOI 10.1021/ja00105a073; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HIRATA Y, 1994, FEBS LETT, V356, P244, DOI 10.1016/0014-5793(94)01279-2; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JONES JW, 1963, J AM CHEM SOC, V85, P193, DOI 10.1021/ja00885a019; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KIM H, 1993, BIOCHEM BIOPH RES CO, V194, P1143, DOI 10.1006/bbrc.1993.1941; KNOWLES JR, 1965, BIOCHEM J, V95, P180, DOI 10.1042/bj0950180; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LEE HC, 1994, MOL CELL BIOCHEM, V138, P229, DOI 10.1007/BF00928466; LEE HC, 1995, BIOCHIMIE PARIS, V77, P354; LUND F, 1995, IMMUNOL TODAY, V16, P469, DOI 10.1016/0167-5699(95)80029-8; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; MASMOUDI A, 1987, BIOCHEMISTRY-US, V26, P1965, DOI 10.1021/bi00381a027; MULLERSTEFFNER H, 1994, BIOCHEM BIOPH RES CO, V204, P1279, DOI 10.1006/bbrc.1994.2601; MULLERSTEFFNER H, 1993, ARCH BIOCHEM BIOPHYS, V304, P154, DOI 10.1006/abbi.1993.1333; Oppenheimer N. J., 1982, PYRIDINE NUCLEOTIDE, P51, DOI DOI 10.1016/B978-0-12-244750-1.50012-9; Price S.R., 1987, PYRIDINE NUCLEOTIDE, V2B, P513; REISBIG RR, 1978, BIOCHEMISTRY-US, V17, P1974, DOI 10.1021/bi00603a028; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SCHUBER F, 1976, EUR J BIOCHEM, V69, P593, DOI 10.1111/j.1432-1033.1976.tb10945.x; SCHUBER F, 1979, BIOORG CHEM, V8, P83, DOI 10.1016/0045-2068(79)90039-7; Singer B, 1975, Prog Nucleic Acid Res Mol Biol, V15, P219, DOI 10.1016/S0079-6603(08)60121-X; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; TARNUS C, 1987, BIOORG CHEM, V15, P31, DOI 10.1016/0045-2068(87)90004-6; TARNUS C, 1988, BIOORG CHEM, V16, P38, DOI 10.1016/0045-2068(88)90036-3; YOST DA, 1983, J BIOL CHEM, V258, P3075; Zhang FJ, 1995, TETRAHEDRON LETT, V36, P9289, DOI 10.1016/0040-4039(95)02004-9; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416	39	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23967	23972		10.1074/jbc.271.39.23967	http://dx.doi.org/10.1074/jbc.271.39.23967			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798630	hybrid			2022-12-27	WOS:A1996VJ44200059
J	Murthy, KS; Coy, DH; Makhlouf, GM				Murthy, KS; Coy, DH; Makhlouf, GM			Somatostatin receptor-mediated signaling in smooth muscle - Activation of phospholipase C-beta 3 by G(beta gamma) and inhibition of adenylyl cyclase by G(alpha il) G(alpha o)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; CA2+ MOBILIZATION; G-PROTEINS; MOLECULAR-BIOLOGY; INTESTINAL MUSCLE; OPIOID RECEPTORS; ALPHA-SUBUNITS; CELLS; RAT; MEMBRANES	In COS-7 cells, all five cloned somatostatin receptors are coupled via inhibitory G proteins to activation of an unidentified phospholipase C-beta (PLC-beta) isozyme and inhibition of adenylyl cyclase. In the present study, intestinal smooth muscle cells (SMC) that express only one receptor type, sstr3, and possess a full complement of G proteins and PLC-beta isozymes were used to identify the PLC beta isozyme and the G proteins coupled to it and to adenylyl cyclase. Somatostatin-14 bound with high affinity to intestinal SMC; stimulated D-myo-inositol-1,4,5-trisphosphate (IP3) formation, Ca2+ release, and contraction; and inhibited forskolin-stimulated cAMP formation in a pertussis toxin-sensitive fashion. Somatostatin also stimulated phosphoinositide hydrolysis in plasma membranes. Only those somatostatin analogs that shared a high affinity for sstr3 receptors elicited muscle contraction. IP3 formation, Ca2+ release, and contraction in permeabilized SMC and phosphoinositide hydrolysis in plasma membranes were inhibited (similar to 80%) by pretreatment with antibodies to PLC-beta 3 but not other PLC-beta isozymes, and by antibodies to G(beta) but not G(alpha). Inhibition of cAMP formation was partially blocked by antibody to G(alpha i1) or G(alpha o) and additively blocked by a combination of both antibodies. Somatostatin-stimulated [S-35]GTP gamma S-G(alpha) complexes in plasma membranes were bound selectively by G(alpha i1) and G(alpha o) antibodies. We conclude that in smooth muscle sstr3 is coupled to G(i1) and G(o); the alpha subunits of both G proteins mediate inhibition of adenylyl cyclase, while the beta gamma subunits mediate activation of PLC-beta 3.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHYSIOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298; TULANE UNIV,MED CTR,PEPTIDE RES LAB,NEW ORLEANS,LA 70112	Virginia Commonwealth University; Virginia Commonwealth University; Tulane University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015564, R37DK015564] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-15564] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKBAR M, 1994, FEBS LETT, V348, P192, DOI 10.1016/0014-5793(94)00603-2; BELL GI, 1993, TRENDS NEUROSCI, V16, P34, DOI 10.1016/0166-2236(93)90050-V; BITO H, 1994, J BIOL CHEM, V269, P12722; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BRUNO JF, 1993, ENDOCRINOLOGY, V133, P2561, DOI 10.1210/en.133.6.2561; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; GU ZF, 1995, AM J PHYSIOL-GASTR L, V268, pG739, DOI 10.1152/ajpgi.1995.268.5.G739; HADCOCK JR, 1994, MOL PHARMACOL, V45, P410; HOYER D, 1994, N-S ARCH PHARMACOL, V350, P441; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KUBOTA A, 1994, BIOCHEM BIOPH RES CO, V204, P176, DOI 10.1006/bbrc.1994.2442; KUEMMERLE JF, 1992, AM J PHYSIOL, V263, pG269, DOI 10.1152/ajpgi.1992.263.2.G269; KUEMMERLE JF, 1994, AM J PHYSIOL, V266, pC1421, DOI 10.1152/ajpcell.1994.266.5.C1421; LAW SF, 1995, CELL SIGNAL, V7, P1, DOI 10.1016/0898-6568(94)00064-I; LAW SF, 1994, MOL PHARMACOL, V45, P587; LI XJ, 1992, J BIOL CHEM, V267, P21307; LUTHIN DR, 1993, J BIOL CHEM, V268, P5990; MURTHY KS, 1991, AM J PHYSIOL, V261, pG945, DOI 10.1152/ajpgi.1991.261.6.G945; MURTHY KS, 1995, MOL PHARMACOL, V47, P1172; MURTHY KS, 1995, AM J PHYSIOL-CELL PH, V269, pC969, DOI 10.1152/ajpcell.1995.269.4.C969; MURTHY KS, 1991, AM J PHYSIOL, V261, pG937, DOI 10.1152/ajpgi.1991.261.6.G937; MURTHY KS, 1995, AM J PHYSIOL-GASTR L, V269, pG93, DOI 10.1152/ajpgi.1995.269.1.G93; MURTHY KS, 1994, J BIOL CHEM, V269, P15977; MURTHY KS, 1996, IN PRESS MOL PHARM; MURTHY KS, 1985, J PHARMACOL EXP THER, V274, P300; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; OKAMOTO T, 1992, FEBS LETT, V305, P125, DOI 10.1016/0014-5793(92)80878-K; PARK DG, 1993, J BIOL CHEM, V268, P4573; PATEL YC, 1994, BIOCHEM BIOPH RES CO, V198, P605, DOI 10.1006/bbrc.1994.1088; PATEL YC, 1995, LIFE SCI, V57, P1249, DOI 10.1016/0024-3205(95)02082-T; REISINE T, 1993, TRENDS NEUROSCI, V16, P506, DOI 10.1016/0166-2236(93)90194-Q; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; ROSSOWSKI WJ, 1993, BIOCHEM BIOPH RES CO, V197, P366, DOI 10.1006/bbrc.1993.2488; SAKANAKA C, 1994, BIOCHEM BIOPH RES CO, V205, P18, DOI 10.1006/bbrc.1994.2623; SIMS SM, 1991, J PHYSIOL-LONDON, V441, P615, DOI 10.1113/jphysiol.1991.sp018770; TALLENT M, 1992, MOL PHARMACOL, V41, P452; TOMURA H, 1994, BIOCHEM BIOPH RES CO, V200, P986, DOI 10.1006/bbrc.1994.1547; UHING RJ, 1986, J BIOL CHEM, V261, P2140; WANG XB, 1993, BIOCHEM BIOPH RES CO, V193, P483, DOI 10.1006/bbrc.1993.1649; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; YAJIMA Y, 1993, MOL CELL ENDOCRINOL, V92, P143, DOI 10.1016/0303-7207(93)90001-Z; YASUDA K, 1992, J BIOL CHEM, V267, P20422	44	111	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23458	23463		10.1074/jbc.271.38.23458	http://dx.doi.org/10.1074/jbc.271.38.23458			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798553	hybrid			2022-12-27	WOS:A1996VH76800079
J	Rich, CB; Nugent, MA; Stone, P; Foster, JA				Rich, CB; Nugent, MA; Stone, P; Foster, JA			Elastase release of basic fibroblast growth factor in pulmonary fibroblast cultures results of elastin gene transcription - A role for basic fibroblast growth factor in regulating lung repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; FACTOR-I; FUNCTIONAL PROMOTER; 5'-FLANKING REGION; SKIN FIBROBLASTS; FACTOR-BETA; EXPRESSION; EMPHYSEMA; MODULATION; BINDING	We have reported previously that a factor released by elastase treatment of pulmonary fibroblast cultures is capable of down-regulating elastin gene expression. In the present study we have pursued the identification of the factor released by elastase treatment and the characterization of the level of elastin gene expression at which this factor exerts its effect. We have found by immunologic and biochemical procedures that elastase treatment results in the release of basic fibroblast growth factor (bFGF) that is bound within the matrix. Both purified bFGF and bFGF released by elastase from cell matrices decrease the transcriptional level of the elastin gene by 70-80% within 24 h. Transient transfections of pulmonary fibroblasts with a series of elastin promoter deletion constructs show that the region of the elastin gene responsive to bFGF is located within sequences spanning -900 to -200 base pairs. The biological implications of these findings coupled with our previous report are significant, since they demonstrate that elastase digestion of pulmonary fibroblast matrices not only results in the proteolysis of elastin but also results in the release of a potent regulator of elastin gene transcription whose activity can influence repair mechanisms.	BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA	Boston University				Nugent, Matthew/0000-0002-8630-4712	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046100, P01HL046902] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 46100, HL 46902] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBIN RJ, 1987, PULMONARY EMPHYSEM 5, P283; BERK JL, 1991, J BIOL CHEM, V266, P3192; BRETTELL LM, 1994, AM J RESP CELL MOL, V10, P306, DOI 10.1165/ajrcmb.10.3.8117449; DAVIDSON JM, 1993, J CELL PHYSIOL, V155, P149, DOI 10.1002/jcp.1041550119; FAZIO MJ, 1990, J INVEST DERMATOL, V94, P191, DOI 10.1111/1523-1747.ep12874495; FOSTER JA, 1988, LAB INVEST, V58, P667; FOSTER JA, 1990, J BIOL CHEM, V265, P15544; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; KAHARI VM, 1990, J BIOL CHEM, V265, P9485; KAHARI VM, 1992, LAB INVEST, V66, P580; KUHN C, 1976, LAB INVEST, V34, P372; LIU JM, 1988, BIOCHEM BIOPH RES CO, V154, P895, DOI 10.1016/0006-291X(88)90224-0; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; RICH CB, 1989, ARCH BIOCHEM BIOPHYS, V268, P551, DOI 10.1016/0003-9861(89)90322-6; SANDHAUS RA, 1987, PULMONARY EMPHYSEMA, P227; SNIDER GL, 1991, ANN NY ACAD SCI, V624, P45, DOI 10.1111/j.1749-6632.1991.tb17005.x; TOWBIN H, 1982, J BIOL CHEM, V257, P2709; TRINKAUSRANDALL V, 1993, INVEST OPHTH VIS SCI, V34, P3103; WOLFE BL, 1993, J BIOL CHEM, V268, P12418; WU Y, 1992, J BIOL CHEM, V267, P24199	20	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23043	23048		10.1074/jbc.271.38.23043	http://dx.doi.org/10.1074/jbc.271.38.23043			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798493	hybrid			2022-12-27	WOS:A1996VH76800019
J	Watanabe, K; Yamaguchi, Y				Watanabe, K; Yamaguchi, Y			Molecular identification of a putative human hyaluronan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-PYOGENES; GROWTH-FACTOR; PROTEIN; CHITIN; BIOSYNTHESIS; SYNTHETASE; CELLS; GENE; PROTEOGLYCAN; FIBROBLASTS	To identify the putative mammalian hyaluronan synthase, we cloned a human cDNA that is related to the Streptococcus hyaluronan synthase (HasA) and the Xenopus developmental protein DG42 which has been shown to have chitin synthase activity. The cDNA, for which we propose the name Has2, encodes a novel protein with a predicted molecular mass of 63.6 kDa, Has2 shows 55% amino acid identity with Xenopus DG42 and 52% identity with the mouse HAS protein, another putative hyaluronan synthase recently reported by Itano and Kimata (Itano, N., and Kimata, K. (1996) J. Biol. Chem. 271, 9875-9878). The deduced primary structure revealed the presence of several hydrophobic stretches which can form multiple transmembrane domains. It also demonstrated the complete conservation of amino acid residues that are known to be critical for N-acetylglucosaminyltransferase activity of yeast chitin synthase. When the Has2 cDNA was transfected into human 293 and Chinese hamster ovary cells, the production of hyaluronan in the transfected cells increased up to 34- and 9-fold, respectively, Strong expression of Has2 mRNA was observed in exponentially proliferating human IMR-90 fibroblasts but not in growth-arrested IMR-90 cells. These results suggest that the Has2 protein is a crucial component of the human hyaluronan synthase system.	BURNHAM INST,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute			Watanabe, Ken/I-3960-2013	Watanabe, Ken/0000-0003-0664-3915	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD025938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032717] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 25938] Funding Source: Medline; NINDS NIH HHS [NS 32717] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRECHT M, 1986, BIOCHEM J, V239, P445, DOI 10.1042/bj2390445; BULAWA CE, 1993, ANNU REV MICROBIOL, V47, P505, DOI 10.1146/annurev.micro.47.1.505; BULAWA CE, 1991, NATURE, V353, P710, DOI 10.1038/353710b0; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DEANGELIS PL, 1994, BIOCHEM BIOPH RES CO, V199, P1, DOI 10.1006/bbrc.1994.1184; GEREMIA RA, 1994, P NATL ACAD SCI USA, V91, P2669, DOI 10.1073/pnas.91.7.2669; HELDIN P, 1992, BIOCHEM J, V283, P165, DOI 10.1042/bj2830165; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; KITCHEN JR, 1995, BIOCHEM J, V309, P649, DOI 10.1042/bj3090649; MATUOKA K, 1987, J CELL BIOL, V104, P1105, DOI 10.1083/jcb.104.4.1105; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; PREHM P, 1984, BIOCHEM J, V220, P191; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; SEMINO CE, 1995, P NATL ACAD SCI USA, V92, P3498, DOI 10.1073/pnas.92.8.3498; Semino CE, 1996, P NATL ACAD SCI USA, V93, P4548, DOI 10.1073/pnas.93.10.4548; SEMINO CE, 1994, CELL MOL BIOL, V40, P1029; SUZUKI M, 1995, BIOCHEM J, V307, P817, DOI 10.1042/bj3070817; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TAKAYAMA S, 1996, IN PRESS GENOMICS; WATANABE K, 1995, J CELL BIOL, V130, P1207, DOI 10.1083/jcb.130.5.1207; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0	25	177	193	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22945	22948		10.1074/jbc.271.38.22945	http://dx.doi.org/10.1074/jbc.271.38.22945			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798477	hybrid			2022-12-27	WOS:A1996VH76800003
J	DiStefano, PS; Boulton, TG; Stark, JL; Zhu, YA; Adryan, KM; Ryan, TE; Lindsay, RM				DiStefano, PS; Boulton, TG; Stark, JL; Zhu, YA; Adryan, KM; Ryan, TE; Lindsay, RM			Ciliary neurotrophic factor induces down-regulation of its receptor and desensitization of signal transduction pathways in vivo: Non-equivalence with pharmacological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; RETROGRADE AXONAL-TRANSPORT; TRIPARTITE CNTF RECEPTOR; EPIDERMAL GROWTH-FACTOR; FACTOR-BINDING PROTEIN; CRYSTAL-STRUCTURE; RECOMBINANT HUMAN; ALPHA COMPONENT; CELL-SURFACE; SOLUBLE FORM	Despite the widespread use of polypeptide growth factors as pharmacological agents, little is known about the extent to which these molecules regulate their cognate cell surface receptors and signal transduction pathways in vivo. We have addressed this issue with respect to the neurotrophic molecule ciliary neurotrophic factor (CNTF). Administration of CNTF in vivo resulted in modest decreases in levels of CNTFR alpha mRNA and protein in skeletal muscle, CNTF causes the rapid tyrosine phosphorylation of LIFR beta and gp130 and the induction of the immediate-early gene, tis11; injection of CNTF 3-7 h after an initial exposure failed to re-stimulate these immediate early responses, suggesting a biochemical desensitization to CNTF not accounted for by decreased receptor protein. To determine whether the desensitization of immediate-early responses caused by CNTF resulted in a functional desensitization, we compared the efficacy of multiple daily injections versus a single daily dose of CNTF in preventing the denervation-induced atrophy of skeletal muscle. Surprisingly, injections of CNTF every 6 h, which falls within the putative refractory period for biochemical responses, resulted in efficacy equal to or greater than injections once daily. These results suggest that although much of the CNTF signal transduction machinery is down-regulated with frequent CNTF dosing, biological signals continue to be recognized and interpreted by the cell.			DiStefano, PS (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Lindsay, Ronald/GQP-8001-2022					ALDERSON RF, 1994, IN PRESS J NEUROCHEM; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BAMEZAI A, 1992, EUR J IMMUNOL, V22, P15, DOI 10.1002/eji.1830220104; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; CEDARBAUM JM, 1995, CLIN NEUROPHARMACOL, V18, P500; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLATTERBUCK RE, 1993, P NATL ACAD SCI USA, V90, P2222, DOI 10.1073/pnas.90.6.2222; CURTIS R, 1993, NATURE, V365, P253, DOI 10.1038/365253a0; Curtis Rory, 1994, Trends in Cell Biology, V4, P383, DOI 10.1016/0962-8924(94)90045-0; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DECKER SJ, 1989, J BIOL CHEM, V264, P17641; Distefano P. S., 1994, Society for Neuroscience Abstracts, V20, P42; DISTEFANO PS, 1993, J NEUROSCI, V13, P2405, DOI 10.1523/JNEUROSCI.13-06-02405.1993; DITTRICH E, 1994, J BIOL CHEM, V269, P19014; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; Frank L, 1996, EUR J NEUROSCI, V8, P1220, DOI 10.1111/j.1460-9568.1996.tb01290.x; FRIEDMAN B, 1992, NEURON, V9, P295, DOI 10.1016/0896-6273(92)90168-D; HAGG T, 1992, NEURON, V8, P145, DOI 10.1016/0896-6273(92)90116-U; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; HEMAR A, 1995, J CELL BIOL, V129, P55, DOI 10.1083/jcb.129.1.55; Ip Nancy Y., 1992, Progress in Growth Factor Research, V4, P139, DOI 10.1016/0955-2235(92)90028-G; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LIPSON KE, 1989, BIOCHEM J, V261, P333, DOI 10.1042/bj2610333; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MACLENNAN AJ, 1994, MOL BRAIN RES, V25, P251, DOI 10.1016/0169-328X(94)90160-0; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; *NIH, 1985, NIH PUBL, V8623; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PORTEU F, 1991, J BIOL CHEM, V266, P18846; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Rijnboutt S, 1996, J CELL BIOL, V132, P35, DOI 10.1083/jcb.132.1.35; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; WONG VV, 1995, J BIOL CHEM, V270, P313, DOI 10.1074/jbc.270.1.313; ZUPAN AA, 1991, J BIOL CHEM, V266, P15384	52	20	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22839	22846		10.1074/jbc.271.37.22839	http://dx.doi.org/10.1074/jbc.271.37.22839			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798462	hybrid			2022-12-27	WOS:A1996VG67200081
J	Schjerling, CK; Hummel, R; Hansen, JR; Borsting, C; Mikkelsen, JM; Kristiansen, K; Knudsen, J				Schjerling, CK; Hummel, R; Hansen, JR; Borsting, C; Mikkelsen, JM; Kristiansen, K; Knudsen, J			Disruption of the gene encoding the acyl-CoA-binding protein (ACB1) perturbs acyl-CoA metabolism in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR DBI; MOLECULAR-CLONING; YEAST; HOMOLOG; EXPRESSION; RAT	The ACB1 gene encoding the acyl-CoA-binding protein (ACBP) was disrupted in Saccharomyces cerevisiae. The disruption did not affect the growth rate on glucose but reduced the growth rate on ethanol slightly. Although the growth rate of the acb1-disrupted cells was unaffected or only slightly affected, the acb1-disrupted strain was unable to compete with wild type cells when grown in mixed culture. The acyl-CoA level in the disrupted cells was increased from 1.5- to 2.5-fold during exponential growth. The increase in the acyl-CoA level was caused solely by an increase in de novo synthesized stearoyl-CoA. Experiments with purified yeast fatty acid synthetase show that it will synthesize long chain acyl-CoAs in the absence of acyl-CoA-binding protein. The addition of ACBP to the incubation medium resulted in a dramatic decrease in the chain length of the synthesized acyl-CoA esters. Despite the fact that the stearoyl-CoA concentration was increased 7-fold and the Delta 9-desaturase mRNA level was increased 3-fold, the synthesis of oleic acid was unchanged in the acb1-disrupted strain. The results strongly indicate that ACBP in yeast is involved in the transport of newly synthesized acyl-CoA esters from the fatty acid synthetase to acyl-CoA-consuming processes.	ODENSE UNIV,INST BIOCHEM,DK-5230 ODENSE M,DENMARK; ODENSE UNIV,DEPT MOL BIOL,DK-5230 ODENSE M,DENMARK	University of Southern Denmark; University of Southern Denmark			Kristiansen, Karsten/J-5148-2014	Kristiansen, Karsten/0000-0002-6024-0917; Borsting, Claus/0000-0003-0421-7429				Ausubel FM, 1992, CURRENT PROTOCOLS MO; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; BOVOLIN P, 1990, REGUL PEPTIDES, V29, P267, DOI 10.1016/0167-0115(90)90089-F; DAMITYO T, 1976, P NATL ACAD SCI USA, V73, P386; FREINBERG AP, 1983, ANAL BIOCHEM, V132, P6; FYRST H, 1995, BIOCHEM J, V306, P793, DOI 10.1042/bj3060793; HILLS MJ, 1994, PLANT MOL BIOL, V25, P917, DOI 10.1007/BF00028886; KNUDSEN J, 1994, BIOCHEM J, V302, P479, DOI 10.1042/bj3020479; KNUDSEN J, 1993, MOL CELL BIOCHEM, V123, P129, DOI 10.1007/BF01076484; KNUDSEN J, 1981, ANAL BIOCHEM, V112, P190, DOI 10.1016/0003-2697(81)90279-7; MANDRUP S, 1993, BIOCHEM J, V290, P369, DOI 10.1042/bj2900369; MCDONOUGH VM, 1992, J BIOL CHEM, V267, P5931; MOGENSEN IB, 1987, BIOCHEM J, V241, P189, DOI 10.1042/bj2410189; OSTENSON CG, 1994, EUR J ENDOCRINOL, V131, P201, DOI 10.1530/eje.0.1310201; PAPADOPOULOS V, 1991, ENDOCRINOLOGY, V129, P1293; RASMUSSEN JT, 1994, BIOCHEM J, V299, P165, DOI 10.1042/bj2990165; ROSE TM, 1992, P NATL ACAD SCI USA, V89, P11287, DOI 10.1073/pnas.89.23.11287; ROSENDAL J, 1993, BIOCHEM J, V290, P321, DOI 10.1042/bj2900321; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 2002, MOL CLONING LAB MANU; SLABAS AR, 1983, EUR J BIOCHEM, V134, P27, DOI 10.1111/j.1432-1033.1983.tb07526.x; SNYDER MJ, 1993, MOL CELL ENDOCRINOL, V94, pR1, DOI 10.1016/0303-7207(93)90064-Q; SUMPER M, 1969, EUR J BIOCHEM, V10, P377, DOI 10.1111/j.1432-1033.1969.tb00701.x; SUMPER M, 1973, FEBS LETT, V30, P29, DOI 10.1016/0014-5793(73)80612-X	25	96	97	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22514	22521		10.1074/jbc.271.37.22514	http://dx.doi.org/10.1074/jbc.271.37.22514			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798418	hybrid			2022-12-27	WOS:A1996VG67200037
J	Suzuki, Y; Sato, N; Tohyama, M; Wanaka, A; Takagi, T				Suzuki, Y; Sato, N; Tohyama, M; Wanaka, A; Takagi, T			cDNA cloning of a novel membrane glycoprotein that is expressed specifically in glial cells in the mouse brain - LIG-1, a protein with leucine-rich repeats and immunoglobulin-like domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE L1; TRANSMEMBRANE PROTEIN; NEUROTROPHIC FACTOR; GROWTH-FACTOR; NG-CAM; SUPERFAMILY; DROSOPHILA; RECEPTOR; MEMBER; BINDING	A cDNA encoding a protein designated as LIG-1 has been cloned and characterized. A fragment of this cDNA was found previously in a screen for genes up-regulated during neural differentiation in mouse P19 embryonal carcinoma cells. Comparative sequence analysis revealed LIG-1 to be a novel integral membrane glycoprotein (1091 amino acids) containing an extracellular region (794 amino acids) with a potential signal peptide, 15 leucine-rich repeats, 3 immnunoglobulin-like domains, and 7 potential N-glycosylation sites, a transmembrane region of 23 amino acids, and a cytoplasmic region of 274 amino acids. This protein, therefore, is a new member of both the leucine-rich repeat and the immunoglobulin superfamilies. Furthermore, Northern blot and in situ hybridization analyses showed LIG-1 gene expression to be predominantly in the brain, restricted to a small subset of glial cells such as Bergmann glial. cells of the cerebellum and glial cells in the nerve fiber layer of the olfactory bulb. On the basis of its structural features and expression pattern, we propose that LIG-1 functions as a cell type-specific adhesion molecule or receptor at the glial cell surface, and plays a role in the nervous system in for example neuroglial differentiation, development, and/or maintenance of neural functions where it is expressed.	OSAKA UNIV,SCH MED,DEPT ANAT & NEUROSCI,SUITA,OSAKA 565,JAPAN; TANABE SEIYAKU CO LTD,LEAD GENERAT RES LAB,YODOGAWA KU,OSAKA 532,JAPAN	Osaka University; Mitsubishi Tanabe Pharma Corporation	Suzuki, Y (corresponding author), OSAKA UNIV,SCH MED,DEPT MOL NEUROBIOL TANABE,2-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN.		Wanaka, Akio/ABE-4671-2020; Wanaka, Akio/AAC-9754-2019; Wanaka, Akio/GPW-8926-2022	Wanaka, Akio/0000-0001-9951-9862; 				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BURGOON MP, 1991, J CELL BIOL, V112, P1017, DOI 10.1083/jcb.112.5.1017; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GRUMET M, 1992, J NEUROSCI RES, V31, P1, DOI 10.1002/jnr.490310102; GRUMET M, 1988, J CELL BIOL, V106, P487, DOI 10.1083/jcb.106.2.487; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; IMAIZUMI K, 1994, MOL BRAIN RES, V26, P189, DOI 10.1016/0169-328X(94)90090-6; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; NELSON RE, 1994, EMBO J, V13, P3438, DOI 10.1002/j.1460-2075.1994.tb06649.x; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; ORTEGA A, 1991, NEUROSCIENCE, V41, P335, DOI 10.1016/0306-4522(91)90331-H; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SOTELO C, 1994, J NEUROSCI, V14, P124; Suzuki Y, 1996, NUCLEIC ACIDS RES, V24, P797, DOI 10.1093/nar/24.4.797; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	51	70	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22522	22527		10.1074/jbc.271.37.22522	http://dx.doi.org/10.1074/jbc.271.37.22522			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798419	hybrid			2022-12-27	WOS:A1996VG67200038
J	Liu, GY; Hinch, B; Beavis, AD				Liu, GY; Hinch, B; Beavis, AD			Mechanisms for the transport of alpha,omega-dicarboxylates through the mitochondrial inner membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN DICARBOXYLIC-ACIDS; AZELAIC ACID; RAT-LIVER; ANION CHANNEL; STAPHYLOCOCCUS-EPIDERMIDIS; PROPIONIBACTERIUM-ACNES; INTACT MITOCHONDRIA; KIDNEY MITOCHONDRIA; LIGHT-SCATTERING; BETA-OXIDATION	alpha,omega-Dicarboxylates have antibacterial properties, have been used in the treatment of hyperpigmentary disorders, are active against various melanoma cell lines, and can also undergo beta-oxidation. Little, however, is known about their transport. In this paper, we examine the mitochondrial transport of alpha,omega-dicarboxylates ranging from oxalate (DC2) to sebacate (DC10). DC2-DC10 are transported by the inner membrane anion channel (IMAC), DC6-DC10 are also transported by an electroneutral mechanism that appears to reflect transport of the acid through the lipid bilayer. At 37 degrees C and pH 7.0, DC10 is transported very rapidly at 3 mu mol/min . mg, and respiring mitochondria swell in the K+ salts of these acids. This transport mechanism is probably the major pathway by which the longer dicarboxylates enter cells, bacteria, and mitochondria, We also demonstrate that DC5-DC10 can also be transported by an electroneutral mechanism mediated by tributyltin, a potent inhibitor of IMAC, The mechanism appears to involve electroneutral exchange of a TBT-dicarboxylate-H complex for TBT-OH. Finally, we present evidence that of all the dicarboxylates tested only DC2-DC4 can be transported by the classical dicarboxylate carrier.	MED COLL OHIO,DEPT PHARMACOL,TOLEDO,OH 43699						NHLBI NIH HHS [HL47735] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [S15HL047735] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAVIS AD, 1988, J BIOL CHEM, V263, P7574; BEAVIS AD, 1989, EUR J BIOCHEM, V185, P511, DOI 10.1111/j.1432-1033.1989.tb15143.x; Beavis AD, 1996, J BIOENERG BIOMEMBR, V28, P207, DOI 10.1007/BF02110652; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BEAVIS AD, 1993, J BIOL CHEM, V268, P997; BEAVIS AD, 1992, J BIOENERG BIOMEMBR, V24, P77, DOI 10.1007/BF00769534; BERGSETH S, 1990, BIOCHIM BIOPHYS ACTA, V1042, P182, DOI 10.1016/0005-2760(90)90005-I; BOJAR RA, 1988, J APPL BACTERIOL, V64, P497, DOI 10.1111/j.1365-2672.1988.tb02441.x; BOJAR RA, 1994, J ANTIMICROB CHEMOTH, V34, P321, DOI 10.1093/jac/34.3.321; BOJAR RA, 1991, J ANTIMICROB CHEMOTH, V28, P843, DOI 10.1093/jac/28.6.843; Breathnach A S, 1989, Acta Derm Venereol Suppl (Stockh), V143, P62; BREATHNACH AC, 1989, CLIN DERMATOL, V7, P106, DOI 10.1016/0738-081X(89)90061-8; CERDAN S, 1988, J BIOL CHEM, V263, P11664; DRAYE JP, 1988, EUR J BIOCHEM, V178, P183, DOI 10.1111/j.1432-1033.1988.tb14442.x; GARLID KD, 1985, J BIOL CHEM, V260, P3434; GREGO AV, 1995, CLIN NUTR, V14, P143, DOI 10.1016/S0261-5614(95)80011-5; HU F, 1986, BRIT J DERMATOL, V114, P17, DOI 10.1111/j.1365-2133.1986.tb02775.x; JEZEK P, 1990, J BIOL CHEM, V265, P19303; KOLVRAA S, 1986, BIOCHIM BIOPHYS ACTA, V876, P515, DOI 10.1016/0005-2760(86)90039-1; LEIGHTON F, 1989, J BIOL CHEM, V264, P10347; Liu GY, 1996, J BIOL CHEM, V271, P19717, DOI 10.1074/jbc.271.33.19717; MARTIN WH, 1984, J BIOL CHEM, V259, P2062; MORTENSEN PB, 1981, BIOCHIM BIOPHYS ACTA, V666, P394, DOI 10.1016/0005-2760(81)90298-8; MORTENSEN PB, 1981, BIOCHIM BIOPHYS ACTA, V664, P349, DOI 10.1016/0005-2760(81)90057-6; NGUYEN QH, 1995, INT J DERMATOL, V34, P75, DOI 10.1111/j.1365-4362.1995.tb03583.x; PASSI S, 1984, BIOCHEM PHARMACOL, V33, P103, DOI 10.1016/0006-2952(84)90376-9; Passi S, 1989, Acta Derm Venereol Suppl (Stockh), V143, P8; POWERS MF, 1991, J BIOL CHEM, V266, P17250; ROBINS EJ, 1985, BRIT J DERMATOL, V113, P687, DOI 10.1111/j.1365-2133.1985.tb02404.x; SELWYN MJ, 1976, ORGANOTIN COMPOUNDS, P204; SHOLTZ KF, 1993, FEBS LETT, V327, P54, DOI 10.1016/0014-5793(93)81038-2; STEIN WD, 1986, TRANSPORT DIFFUSION, P88; STRZELECKI T, 1986, J BIOL CHEM, V261, P2197; STRZELECKI T, 1989, J UROLOGY, V141, P423, DOI 10.1016/S0022-5347(17)40786-5; SUZUKI H, 1989, BIOCHIM BIOPHYS ACTA, V990, P25, DOI 10.1016/S0304-4165(89)80007-8; Tserng KY, 1996, METABOLISM, V45, P162, DOI 10.1016/S0026-0495(96)90047-5; TSERNG KY, 1991, J BIOL CHEM, V266, P2924; VAMECQ J, 1989, AM J PHYSIOL, V256, pG680, DOI 10.1152/ajpgi.1989.256.4.G680	38	35	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25338	25344		10.1074/jbc.271.41.25338	http://dx.doi.org/10.1074/jbc.271.41.25338			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810298	hybrid			2022-12-27	WOS:A1996VL69300042
J	Pallante, KM; Niu, ZL; Zhao, YF; Cohen, AJ; Nah, HD; Adams, SL				Pallante, KM; Niu, ZL; Zhao, YF; Cohen, AJ; Nah, HD; Adams, SL			The chick alpha 2(I) collagen gene contains two functional promoters, and its expression in chondrocytes is regulated at both transcriptional and post-transcriptional levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I COLLAGEN; MESSENGER-RNAS; NUCLEAR FACTOR; DNA-SEQUENCES; BINDING-SITES; PROCOLLAGEN; ENHANCER; PRO-ALPHA-1(I); IDENTIFICATION; FIBROBLASTS	Embryonic chick cartilages contain transcripts derived from the alpha 2(I) collagen gene, although type I collagen is not normally found in these tissues; most of these RNAs are alternative transcripts initiating within intron 2, Use of the internal start site results in replacement of exons 1 and 2 with a previously undescribed exon and a change in the translational reading frame; thus, the alternative transcript cannot encode alpha 2(I) collagen. We have demonstrated that production of the alternative transcript is due to activation of an internal promoter in chondrocytes and have identified a 179-base pair domain that is required for its activity, Furthermore, we have shown that the alternative transcript resulting from activation of the internal promoter turns over relatively rapidly; thus, the steady-state level of this transcript is less than predicted based on the transcription rate, The upstream promoter is only partially repressed in chondrocytes, suggesting that the lack of authentic alpha 2(I) collagen mRNA may also be due in part to decreased mRNA stability, Thus, repression of alpha 2(I) collagen synthesis in cartilage involves both transcriptional and post-transcriptional mechanisms. In contrast, repression of alpha 1(I) collagen synthesis appears to be mediated primarily at the level of transcription.	UNIV PENN,SCH DENT MED,DEPT BIOCHEM,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007490, R01AR041042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R35GM128840] Funding Source: NIH RePORTER; NIAMS NIH HHS [T32 AR07490, AR41042] Funding Source: Medline; NIGMS NIH HHS [GM28840] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SL, 1982, CELL, V30, P373, DOI 10.1016/0092-8674(82)90235-5; ADAMS SL, 1991, EXP CELL RES, V193, P190, DOI 10.1016/0014-4827(91)90555-9; Akira S, 1995, ANN NY ACAD SCI, V762, P15; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ASKEW GR, 1991, J BIOL CHEM, V266, P16834; BAMHART KM, 1989, MOL CELL BIOL, V9, P2606; BENNETT VD, 1989, J BIOL CHEM, V264, P8402; BENNETT VD, 1987, J BIOL CHEM, V262, P14806; BENNETT VD, 1990, J BIOL CHEM, V265, P2223; BOAST S, 1990, J BIOL CHEM, V265, P13351; BOEDTKER H, 1985, ANN NY ACAD SCI, V460, P85, DOI 10.1111/j.1749-6632.1985.tb51159.x; CARSWELL S, 1989, MOL CELL BIOL, V9, P4248, DOI 10.1128/MCB.9.10.4248; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEWET WJ, 1983, J BIOL CHEM, V258, P4385; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; DOEGE KJ, 1994, J BIOL CHEM, V269, P29232; Emerson CP, 1993, CURR OPIN CELL BIOL, V5, P1057, DOI 10.1016/0955-0674(93)90092-5; ERICKSON JM, 1981, GENE, V16, P1, DOI 10.1016/0378-1119(81)90055-X; FOCHT RJ, 1984, MOL CELL BIOL, V4, P1843, DOI 10.1128/MCB.4.9.1843; GILMAN M, 1987, CURRENT PROTOCOLS MO; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMALAINEN L, 1985, J BIOL CHEM, V260, P720; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; HOUGLUM K, 1994, J CLIN INVEST, V94, P808, DOI 10.1172/JCI117400; KARSENTY G, 1991, BIOCHEM BIOPH RES CO, V177, P538, DOI 10.1016/0006-291X(91)92017-E; Krebsbach PH, 1996, J BIOL CHEM, V271, P4298, DOI 10.1074/jbc.271.8.4298; LEHRACH H, 1978, P NATL ACAD SCI USA, V75, P5417, DOI 10.1073/pnas.75.11.5417; LIM K, 1989, BIOTECHNIQUES, V7, P576; LYONS BL, 1984, NUCLEIC ACIDS RES, V12, P2569, DOI 10.1093/nar/12.5.2569; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; Nah HD, 1996, DEV DYNAM, V206, P146, DOI 10.1002/(SICI)1097-0177(199606)206:2<146::AID-AJA4>3.0.CO;2-I; OHKUBO H, 1980, P NATL ACAD SCI-BIOL, V77, P7059, DOI 10.1073/pnas.77.12.7059; OLSEN AS, 1989, MATRIX, V9, P73, DOI 10.1016/S0934-8832(89)80024-1; PACIFICI M, 1991, EXP CELL RES, V195, P38, DOI 10.1016/0014-4827(91)90497-I; PETERKOFSKY B, 1986, J BIOL CHEM, V261, P6818; RHODES C, 1995, NUCLEIC ACIDS RES, V23, P2305, DOI 10.1093/nar/23.12.2305; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDT A, 1985, NATURE, V314, P286, DOI 10.1038/314286a0; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VOGELI G, 1981, P NATL ACAD SCI-BIOL, V78, P5334, DOI 10.1073/pnas.78.9.5334; VOGELI G, 1980, NUCLEIC ACIDS RES, V8, P1823, DOI 10.1093/nar/8.8.1823; Von der Mark K., 1986, RHEUMATOLOGY, V10; VONDERMARK K, 1980, CURR TOP DEV BIOL, V14, P190; VUUST J, 1985, EUR J BIOCHEM, V151, P449, DOI 10.1111/j.1432-1033.1985.tb09122.x; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WANG LQ, 1991, J BIOL CHEM, V266, P19878; WANG S, 1994, MATRIX BIOL, V14, P313, DOI 10.1016/0945-053X(94)90197-X; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WEISS MJ, 1995, EXP HEMATOL, V23, P99; YAMAMOTO T, 1980, J BIOL CHEM, V255, P2612; YOUNG MF, 1984, NUCLEIC ACIDS RES, V12, P4207, DOI 10.1093/nar/12.10.4207	54	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25233	25239		10.1074/jbc.271.41.25233	http://dx.doi.org/10.1074/jbc.271.41.25233			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810284	hybrid			2022-12-27	WOS:A1996VL69300028
J	De, BP; Gupta, S; Zhao, H; Drazba, JA; Banerjee, AK				De, BP; Gupta, S; Zhao, H; Drazba, JA; Banerjee, AK			Specific interaction in vitro and in vivo of glyceraldehyde-3-phosphate dehydrogenase and LA protein with cis-acting RNAs of human parainfluenza virus type 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR STOMATITIS-VIRUS; LEADER RNA; MESSENGER-RNA; GENE-EXPRESSION; BINDING PROTEIN; POLIOVIRUS RNA; POLYMERASE-III; MEASLES-VIRUS; SEQUENCE; TRANSCRIPTION	Human parainfluenza virus type 3 (HPIV3) genome RNA is transcribed and replicated by the virus-encoded RNA-dependent RNA polymerase, and specific cellular proteins play a regulatory role in these processes. To search for cellular proteins potentially interacting with HPIV3 cis-acting regulatory RNAs, a gel mobility shift assay was used, Two cellular proteins specifically interacted with the viral cis-acting RNAs containing the genomic 3'-noncoding region and the plus sense leader sequence region. Surprisingly, by biochemical and immunological analyses, one of the cellular proteins was identified as the key glycolytic enzyme, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The other protein was characterized as the autoantigen, LA protein. Both GAPDH and LA protein also interacted with the same cis-acting RNA sequences in vivo and were found to be associated with the HPIV3 ribonucleoprotein complex in the infected cells. By double immunofluorescent labeling, GAPDH was found to be co-localized with viral ribonucleoprotein in the perinuclear region. These observations strongly suggest that cellular GAPDH and LA Protein participate in the regulation of HPIV3 gene expression.	CLEVELAND CLIN FDN, DEPT NEUROSCI, RES INST, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation	De, BP (corresponding author), CLEVELAND CLIN FDN, DEPT MOL BIOL, RES INST, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.				NIAID NIH HHS [AI32027] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032027] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE AK, 1991, PHARMACOL THERAPEUT, V51, P47, DOI 10.1016/0163-7258(91)90041-J; BLUMBERG BM, 1991, PARAMYXOVIRUSES, P235; CHANG YN, 1994, J VIROL, V68, P7008, DOI 10.1128/JVI.68.11.7008-7020.1994; Collins P. L., 1996, FIELDS VIROLOGY, P1205; DE BP, 1993, J BIOL CHEM, V268, P5703; DE BP, 1993, VIROLOGY, V196, P344, DOI 10.1006/viro.1993.1486; DE BP, 1995, P NATL ACAD SCI USA, V92, P5204, DOI 10.1073/pnas.92.11.5204; DUGGAL R, 1994, AM SOC VIR 13 ANN M, P277; FRANCOEUR AM, 1982, P NATL ACAD SCI-BIOL, V79, P6772, DOI 10.1073/pnas.79.22.6772; Galinski M.S., 1991, PARAMYXOVIRUSES, P41; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; HABETS WJ, 1983, EMBO J, V2, P1625, DOI 10.1002/j.1460-2075.1983.tb01636.x; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; HORIKAMI SM, 1991, J VIROL, V65, P5342, DOI 10.1128/JVI.65.10.5342-5347.1991; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KURILLA MG, 1982, P NATL ACAD SCI-BIOL, V79, P5240, DOI 10.1073/pnas.79.17.5240; KURILLA MG, 1984, J VIROL, V50, P773, DOI 10.1128/JVI.50.3.773-778.1984; KURILLA MG, 1983, CELL, V34, P837, DOI 10.1016/0092-8674(83)90541-X; LEOPARDI R, 1993, J VIROL, V67, P785, DOI 10.1128/JVI.67.2.785-790.1993; LERNER MR, 1981, P NATL ACAD SCI-BIOL, V78, P805, DOI 10.1073/pnas.78.2.805; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; MATHEWS MB, 1984, MOL CELL BIOL, V4, P1134, DOI 10.1128/MCB.4.6.1134; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MEJEAN C, 1989, BIOCHEM J, V264, P671, DOI 10.1042/bj2640671; MURRAY MF, 1995, BIOCHEM BIOPH RES CO, V212, P126, DOI 10.1006/bbrc.1995.1945; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NISHIYAMA A, 1993, MOL BIOL CELL, V4, P1097, DOI 10.1091/mbc.4.11.1097; Pardigon N, 1996, J VIROL, V70, P1173, DOI 10.1128/JVI.70.2.1173-1181.1996; ROKEACH LA, 1988, P NATL ACAD SCI USA, V85, P4832, DOI 10.1073/pnas.85.13.4832; Rossmann M. G., 1975, ENZYMES, V11, P62; RYAZANOV AG, 1985, FEBS LETT, V192, P131, DOI 10.1016/0014-5793(85)80058-2; RYAZANOV AG, 1988, EUR J BIOCHEM, V171, P301, DOI 10.1111/j.1432-1033.1988.tb13790.x; SINGH NK, 1994, P NATL ACAD SCI USA, V91, P12770, DOI 10.1073/pnas.91.26.12770; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; SVITKIN YV, 1994, J VIROL, V68, P1544, DOI 10.1128/JVI.68.3.1544-1550.1994; SVITKIN YV, 1994, J VIROL, V68, P7001, DOI 10.1128/JVI.68.11.7001-7007.1994; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; TONEGUZZO F, 1976, J VIROL, V17, P477, DOI 10.1128/JVI.17.2.477-491.1976; WILUSZ J, 1983, P NATL ACAD SCI-BIOL, V80, P5827, DOI 10.1073/pnas.80.19.5827; ZAMORE PD, 1990, NATURE, V348, P485, DOI 10.1038/348485a0	41	99	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24728	24735		10.1074/jbc.271.40.24728	http://dx.doi.org/10.1074/jbc.271.40.24728			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798741	hybrid			2022-12-27	WOS:A1996VM67400063
J	Nakajima, T; Morita, K; Ohi, N; Arai, T; Nozaki, N; Kikuchi, A; Osaka, F; Yamao, F; Oda, K				Nakajima, T; Morita, K; Ohi, N; Arai, T; Nozaki, N; Kikuchi, A; Osaka, F; Yamao, F; Oda, K			Degradation of topoisomerase II alpha during adenovirus E1A-induced apoptosis is mediated by the activation of the ubiquitin proteolysis system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; POLY(ADP-RIBOSE) POLYMERASE; CHROMATIN CONDENSATION; MITOTIC CHROMOSOMES; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS; E1A PROTEINS; DNA; GENE; P53	The human epithermoid carcinoma-derived cell line MA1, established by introduction of the adenovirus E1A 12 S cDNA linked to the mouse mammary tumor virus long terminal repeat, elicits apoptosis after induction of E1A(12S) in response to dexamethasone. The level of topoisomerase II alpha begins to decrease steeply within 36 h preceding the onset of DNA fragmentation, whereas its mRNA level is unchanged (Nakajima, T., Ohi, N., Arai, T., Nozaki, N., Kikuchi, A., and Oda, K. (1995) Oncogene 10, 651-662). Topoisomerase II alpha prepared by immunoprecipitation or extraction of the nuclear matrix was degraded much more efficiently in the S10 extract prepared from MA1 cells treated with dexamethasone for 42 h (the 42-h extract) than in the extract from untreated MA1 cells (the 0-h extract) in an ATP- and ubiquitin-dependent manner. The proteolytic activity for degradation of topoisomerase II alpha was suppressed specifically by inhibitors for the proteasome and was much reduced in the 42-h extract prepared from MA1-derivative cell lines expressing E1B19k or Bcl-2. The proteolytic activity was lost after fractionation of the 42-h S10 extract into the S70 and P70 fractions by centrifugation at 70,000 x g for 6 h but partially recovered when these fractions were combined. Polyubiquitinated forms of topoisomerase II alpha could be detected by incubating it in the S70 or S100 extract, which lacks most of the proteasome activity. The ubiquitination activity in S70 prepared from the 42-h extract was 4- to 5-fold higher than that prepared from the 0-h extract. These results suggest that a component(s) in the ubiquitin proteolysis pathway, responsible for ubiquitination and degradation of topoisomerase II alpha, is activated or induced during the latent phase of E1A-induced apoptosis.	SCI UNIV TOKYO,DEPT APPL BIOL SCI,NODA,CHIBA 278,JAPAN; KANAGAWA DENT COLL,DEPT ORAL BIOCHEM,YOKOSUKA,KANAGAWA 238,JAPAN; MITSUBISHI CHEM INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN; NATL INST GENET,MISHIMA,SHIZUOKA 411,JAPAN	Tokyo University of Science; Kanagawa Dental College; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Nakajima, T (corresponding author), SCI UNIV TOKYO,DEPT BIOL SCI & TECHNOL,NODA,CHIBA 278,JAPAN.							ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; GIMENEZABIAN JF, 1995, J CELL BIOL, V131, P7, DOI 10.1083/jcb.131.1.7; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRAHAM FL, 1984, ADENOVIRUSES, P339; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Harlow E., 1988, ANTIBODIES LAB MANUA; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HSIANG YH, 1988, CANCER RES, V48, P3230; IZUMI M, 1991, EXP CELL RES, V197, P229, DOI 10.1016/0014-4827(91)90427-V; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEBKOWSKI JS, 1982, J MOL BIOL, V156, P325, DOI 10.1016/0022-2836(82)90332-1; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; MANSER T, 1984, P NATL ACAD SCI-BIOL, V81, P2470, DOI 10.1073/pnas.81.8.2470; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MORIN N, 1994, EMBO J, V13, P4343, DOI 10.1002/j.1460-2075.1994.tb06754.x; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NAKAJIMA T, 1995, ONCOGENE, V10, P651; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TAKEMORI N, 1984, J VIROL, V52, P793, DOI 10.1128/JVI.52.3.793-805.1984; TANIURA H, 1995, J CELL BIOL, V131, P33, DOI 10.1083/jcb.131.1.33; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UGAI S, 1993, J BIOCHEM, V113, P754, DOI 10.1093/oxfordjournals.jbchem.a124116; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VISNITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	72	51	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24842	24849		10.1074/jbc.271.40.24842	http://dx.doi.org/10.1074/jbc.271.40.24842			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798759	hybrid			2022-12-27	WOS:A1996VM67400081
J	Wang, LP; Lim, C; Kuan, YS; Chen, CL; Chen, HF; King, K				Wang, LP; Lim, C; Kuan, YS; Chen, CL; Chen, HF; King, K			Positive charge at position 549 is essential for phosphatidylinositol 4,5-bisphosphate-hydrolyzing but not phosphatidylinositol-hydrolyzing activities of human phospholipase C delta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETIC-ANALYSIS; ALPHA-SUBUNITS; BETA-GAMMA; ACTIVATION; C-DELTA-1; PROTEIN; BINDING; CELLS; GQ; IDENTIFICATION	Point mutagenesis, phosphatidylinositol (PI), and phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis assays and equilibrium centrifugation PIP2 assays were used to study the functional roles of four highly conserved arginine residues in the Y region of human phospholipase C delta 1 (PLC delta 1) (Arg-527, -549, -556, -701), Most of the mutant enzymes were either partially defective or fully active in their abilities to catalyze the hydrolysis of PI or PIP2. However, upon substitution of Arg-549 by glycine or histidine, the mutant enzyme was defective in its ability to catalyze the hydrolysis of PIP2, but it is still able to hydrolyze PI. Replacing Arg-549 with lysine had little effect on the level of PI and PIP2 hydrolytic activities of the mutant enzyme, The residual PIP2 hydrolyzing activity of R549H is highly dependent on pH, R549H showed 5-10% of the PIP2-hydrolyzing activity of the native enzyme between pH 5 and 7 and nondetectable PIP2-hydrolyzing activity at pH 8. The PIP2-hydrolyzing activity of R549G was not detectable at all pH values, Kinetic analysis of PLC delta 1-catalyzed PIP2 hydrolysis revealed that the micellar dissociation constant K-s and interfacial Michaelis constant K-m were similar in the native, R549K, and R549H enzymes; but the specific activity at the saturated substrate mole fraction and infinite level of substrate (V-max) of the R549H mutant were reduced by a factor of 15, PIP2 competitively inhibits the native enzyme to hydrolyze PI at both pH 7 and 8, However, PIP2 inhibits R549H only at pH 7.0 and does not inhibit R549G at either pH. Taken together, these results suggest that positive charge at position 549 of PLC delta 1 protein is essential for the enzyme to recognize and catalyze the hydrolysis of PIP2 but not PI.	ACAD SINICA, INST BIOMED SCI, TAIPEI 11529, TAIWAN; NATL TSING HUA UNIV, DEPT CHEM, HSINCHU 30043, TAIWAN	Academia Sinica - Taiwan; National Tsing Hua University			Lim, Carmay/N-9648-2015; 鍾, 士芳/A-5645-2008; Lim, Carmay/H-5949-2011	Lim, Carmay/0000-0001-9077-7769; Lim, Carmay/0000-0001-9077-7769				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BRISTOL A, 1988, COLD SPRING HARB SYM, V53, P915, DOI 10.1101/SQB.1988.053.01.105; BRUZIK KS, 1992, BIOCHEMISTRY-US, V31, P5183, DOI 10.1021/bi00137a014; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CHENG HF, 1995, J BIOL CHEM, V270, P5495, DOI 10.1074/jbc.270.10.5495; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; ELLIS MV, 1993, EUR J BIOCHEM, V213, P339, DOI 10.1111/j.1432-1033.1993.tb17767.x; ELLIS MV, 1995, BIOCHEM J, V307, P69, DOI 10.1042/bj3070069; EMILSSON A, 1984, J BIOL CHEM, V259, P3111; EMORI Y, 1989, J BIOL CHEM, V264, P21885; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; IMAI A, 1986, P NATL ACAD SCI USA, V83, P8540, DOI 10.1073/pnas.83.22.8540; JAMES SR, 1995, J BIOL CHEM, V270, P11872, DOI 10.1074/jbc.270.20.11872; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KUPPE A, 1989, J BACTERIOL, V171, P6077, DOI 10.1128/jb.171.11.6077-6083.1989; MUELLER P, 1983, BIOPHYS J, V44, P375, DOI 10.1016/S0006-3495(83)84311-2; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RHEE SG, 1992, CELLULAR MOL MECH IN; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WILSON DB, 1985, J BIOL CHEM, V260, P1046; WILSON DB, 1984, J BIOL CHEM, V259, P1718; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179	36	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24505	24516		10.1074/jbc.271.40.24505	http://dx.doi.org/10.1074/jbc.271.40.24505			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798711	hybrid			2022-12-27	WOS:A1996VM67400033
J	Kelm, RJ; Sun, S; Strauch, AR; Getz, MJ				Kelm, RJ; Sun, S; Strauch, AR; Getz, MJ			Repression of transcriptional enhancer factor-1 and activator protein-1-dependent enhancer activity by vascular actin single-stranded DNA binding factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-STIMULATED FIBROBLASTS; GENE PROMOTER; CODING SEQUENCES; OSTEOCALCIN GENE; MESSENGER-RNA; GAMMA-ACTIN; C-MYC; PROTEINS; IDENTIFICATION; ELEMENT	Transcriptional repression of the murine vascular smooth muscle alpha-actin gene in fibroblasts results from the interaction of two sequence-specific single-stranded DNA binding activities (VACssBF1 and VACssBF2) with opposite strands of an essential transcriptional enhancer factor-1 (TEF-1) element (Sun, S., Stoflet, E. S., Cogan, J. G., Strauch, A. R., and Getz, M. J. (1995) Mol. Cell. Biol. 15, 2429-2436). Here, we identify a sequence element located within a protein-coding exon of the gene that bears structural similarity with the TEF-1 enhancer. This includes a 30-base pair region of purine-pyrimidine asymmetry encompassing a perfect 6-base pair GGAATG TEF-1 recognition motif. Unlike the enhancer, however, the exon sequence exhibits no TEF-1 binding activity nor does the pyrimidine-rich strand bind VACssBF1. However, VACssBF2 interacts equally well with the purine-rich strand of both the enhancer and the exon sequence. To test the ability of VACssBF2 to independently repress transcription, the exon sequence was placed upstream of a deletionally activated promoter containing an intact TEF-1 binding site. The exon sequence repressed promoter activity, whereas a mutant deficient in VACssBF2 binding did not. Moreover, VACssBF2 similarly repressed activator protein-1-dependent transcription of a heterologous tissue factor promoter. These results suggest that VACssBF2 possesses an intrinsic ability to disrupt enhancer function independently of the enhancer-binding proteins involved.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; OHIO STATE UNIV,COLL MED,BIOCHEM PROGRAM,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,DEPT CELL BIOL NEUROBIOL & ANAT,COLUMBUS,OH 43210	Mayo Clinic; Ohio State University; Ohio State University					NHLBI NIH HHS [HL54281] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054281] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ALTIOK S, 1993, MOL CELL BIOL, V13, P7303, DOI 10.1128/MCB.13.12.7303; BAZAR L, 1995, J BIOL CHEM, V270, P8241, DOI 10.1074/jbc.270.14.8241; COGAN JG, 1995, J BIOL CHEM, V270, P11310, DOI 10.1074/jbc.270.19.11310; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; Duncan R, 1996, MOL CELL BIOL, V16, P2274; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; ELDER PK, 1988, MOL CELL BIOL, V8, P480, DOI 10.1128/MCB.8.1.480; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; FELTS SJ, 1995, BIOCHEMISTRY-US, V34, P12355, DOI 10.1021/bi00038a032; FOSTER JM, 1995, J BILL CHEM, V267, P11995; FRENKEL B, 1993, BIOCHEMISTRY-US, V32, P13636, DOI 10.1021/bi00212a031; FRENKEL B, 1994, P NATL ACAD SCI USA, V91, P10923, DOI 10.1073/pnas.91.23.10923; GRAY T A, 1990, Technique (Philadelphia), V2, P147; GROSSMANN ME, 1995, J BIOL CHEM, V270, P10968, DOI 10.1074/jbc.270.18.10968; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; HAAS S, 1995, J BIOL CHEM, V270, P12503, DOI 10.1074/jbc.270.21.12503; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KARIYA K, 1993, J BIOL CHEM, V268, P26658; KARNS LF, 1970, J BIOL CHEM, V270, P410; KIM E, 1989, MOL CELL BIOL, V9, P1875, DOI 10.1128/MCB.9.5.1875; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MARR JH, 1990, MOL CELL BIOL, V10, P4271; MIN BH, 1988, NUCLEIC ACIDS RES, V16, P10374, DOI 10.1093/nar/16.21.10374; MIN BH, 1990, NUCLEIC ACIDS FES, V265, P1667; MINTY AJ, 1982, CELL, V30, P185, DOI 10.1016/0092-8674(82)90024-1; MIWA T, 1991, MOL CELL BIOL, V11, P3296, DOI 10.1128/MCB.11.6.3296; PAN WT, 1990, J BIOL CHEM, V265, P7022; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; STOFLET ES, 1992, MOL BIOL CELL, V3, P1073, DOI 10.1091/mbc.3.10.1073; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; SWFEOOR EP, 1992, ONXOFWNW, V7, P841; TANUMA Y, 1995, MOL CELL BIOL, V15, P517, DOI 10.1128/MCB.15.1.517; TOKUNAGA K, 1988, MOL CELL BIOL, V8, P3929, DOI 10.1128/MCB.8.9.3929; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WILKISON WO, 1990, J BIOL CHEM, V265, P477; WOODRUFF KA, 1995, ONCOGENE, V10, P1335	38	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24278	24285		10.1074/jbc.271.39.24278	http://dx.doi.org/10.1074/jbc.271.39.24278			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798674	hybrid			2022-12-27	WOS:A1996VJ44200103
J	Li, GM; Wang, HX; Romano, LJ				Li, GM; Wang, HX; Romano, LJ			Human MutS alpha specifically binds to DNA containing aminofluorene and acetylaminofluorene adducts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MISMATCH REPAIR DEFICIENCY; NONPOLYPOSIS COLON-CANCER; HUMAN MSH2 PROTEIN; CELL-LINES; MICROSATELLITE INSTABILITY; TUMOR-CELLS; HOMOLOG; MECHANISMS; EXTRACTS; NMR	Defects in mismatch repair are associated with several types of cancer. It is also generally believed that environmental carcinogens are responsible for the initiation of cancers by the induction of mutations in critical genes. Prior genetic studies have suggested that the mismatch repair system can also recognize certain forms of DNA damage such as O-6-methylguanine and UV photoproducts, and, therefore, mismatch repair may play a role in environmental agent-induced carcinogenesis. To examine this hypothesis, hMutS alpha, a heterodimer which consists of hMSH2 and GTBP and participates in strand specific mismatch repair, was tested for its ability to recognize DNA containing a site specific C-8-guanine adduct of aminofluorene (AF) or N-acetyl-2-aminofluorene (AAF). We show here that hMutS alpha specifically binds to both AF and AAF adducts. This binding requires both hMSH2 and GTBP. Results from competition and titration experiments indicate that the binding efficiency of hMutS alpha to AF and AAF is about 60% of that to a G-T mismatch, but is at least 10-fold that to an otherwise identical homoduplex DNA without the chemical modification. The specific binding of AF and AAF adducts by hMutS alpha suggests that strand-specific mismatch repair is involved in processing DNA damage induced by environmental carcinogens.	UNIV KENTUCKY,MED CTR,LUCILLE P MARKEY CANC CTR,LAB MED,LEXINGTON,KY 40536; WAYNE STATE UNIV,DEPT CHEM,DETROIT,MI 48202	University of Kentucky; Wayne State University	Li, GM (corresponding author), UNIV KENTUCKY,MED CTR,LUCILLE P MARKEY CANC CTR,DEPT PATHOL,LEXINGTON,KY 40536, USA.		Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578	NATIONAL CANCER INSTITUTE [R01CA040605] Funding Source: NIH RePORTER; NCI NIH HHS [CA40605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BOYER JC, 1995, CANCER RES, V55, P6063; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Fazakerley GV, 1995, METHOD ENZYMOL, V261, P145; FENG WY, 1991, GENETICS, V129, P1007; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Friedberg ECW GC, 1995, DNA REPAIR MUTAGENES, P19; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HEFLICH RH, 1994, MUTAT RES-REV GENET, V318, P73, DOI 10.1016/0165-1110(94)90025-6; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; MILHE C, 1994, NUCLEIC ACIDS RES, V22, P4646, DOI 10.1093/nar/22.22.4646; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NORMAN D, 1989, BIOCHEMISTRY-US, V28, P7462, DOI 10.1021/bi00444a046; OHANDLEY SF, 1993, BIOCHEMISTRY-US, V32, P2481, DOI 10.1021/bi00061a005; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1914; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; RISINGER JI, 1995, CANCER RES, V55, P5664; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SHIBUTANI S, 1991, CARCINOGENESIS, V12, P813, DOI 10.1093/carcin/12.5.813; THOMAS DC, 1994, P NATL ACAD SCI USA, V91, P7752, DOI 10.1073/pnas.91.16.7752; UMAR A, 1994, J BIOL CHEM, V269, P14367; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; ZHOU YZ, 1993, BIOCHEMISTRY-US, V32, P14043, DOI 10.1021/bi00213a038	41	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24084	24088		10.1074/jbc.271.39.24084	http://dx.doi.org/10.1074/jbc.271.39.24084			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798646	hybrid			2022-12-27	WOS:A1996VJ44200075
J	Simmons, WW; UngureanuLongrois, D; Smith, GK; Smith, TW; Kelly, RA				Simmons, WW; UngureanuLongrois, D; Smith, GK; Smith, TW; Kelly, RA			Glucocorticoids regulate inducible nitric oxide synthase by inhibiting tetrahydrobiopterin synthesis and L-arginine transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; ECOTROPIC RETROVIRUS RECEPTOR; CATIONIC AMINO-ACIDS; HUMAN ENDOTHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; GTP CYCLOHYDROLASE-I; GROWTH-FACTOR-BETA; CARDIAC MYOCYTES; INTERFERON-GAMMA; MESSENGER-RNA	The cytokine-inducible isoform of nitric oxide synthase (iNOS or NOS2) plays an important role in the immune response to some pathogens, Within the heart, increased activity of NOS2 in cardiac microvascular endothelial cells (CMEC) also can diminish the contractile function of adjacent cardiac myocytes, Glucocorticoids, which are known to suppress cytokine induction of NOS2 in many cell types, caused only a moderate (approximately 20%) decline in NOS2 protein content and maximal activity measured in homogenates of cytokine-treated CMEC, but almost completely inhibited synthesis of nitrogen oxides (NOx) by intact cells, To determine whether glucocorticoids were inhibiting cellular NOx production by limiting the availability of NOS co-factors or substrate, the effect of dexamethasone on tetrahydro biopterin (BH4) and L-arginine availability in cytokine-treated CMEC was examined, Dexamethasone prevented the coordinate induction of GTP cyclohydrolase I with NOS2 after exposure to interleukin-1 beta and interferon-gamma and also the increase in intracellular BH4 content in cytokine-treated CMEC. Addition of BH4 overcame dexamethasone-mediated suppression of nitrite production, Dexamethasone also prevented a cytokine-mediated increase in L-arginine uptake into CMEC by suppressing the induction of the high affinity cationic amino acid transporters CAT-1 and CAT-2B and the low affinity CAT-2A transporter, In addition, dexamethasone also inhibited cytokine induction in CMEC of argininosuccinate synthase, the rate-limiting enzyme for the de novo synthesis of arginine from citrulline, Thus, glucocorticoids regulate NOx production following cytokine exposure in cardiac microvascular endothelial cells primarily by limiting BH4 and L-arginine availability.	BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; GLAXO WELLCOME INC,RES & DEV,RES TRIANGLE PK,NC 27709	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; GlaxoSmithKline					NHLBI NIH HHS [HL36141, HL52320] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036141, R01HL036141, P50HL052320] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; ALTMAN P, 1967, BLOOD OTHER BODY FLU, P75; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BALLIGAND JL, 1995, AM J PHYSIOL-HEART C, V268, pH1293, DOI 10.1152/ajpheart.1995.268.3.H1293; BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461; BALLIGAND JL, 1994, J BIOL CHEM, V269, P27580; BAYDOUN AR, 1993, BRIT J PHARMACOL, V110, P1401, DOI 10.1111/j.1476-5381.1993.tb13976.x; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BUNE AJ, 1995, FEBS LETT, V366, P127, DOI 10.1016/0014-5793(95)00495-U; Bune AJ, 1996, BIOCHEM BIOPH RES CO, V220, P13, DOI 10.1006/bbrc.1996.0348; BUSSOLATI O, 1993, AM J PHYSIOL, V265, pC1006, DOI 10.1152/ajpcell.1993.265.4.C1006; CETKOVICCVRLJE M, 1993, ENDOCRINOLOGY, V133, P1739, DOI 10.1210/en.133.4.1739; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CITRON BA, 1990, P NATL ACAD SCI USA, V87, P6436, DOI 10.1073/pnas.87.16.6436; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; EVANS HG, 1993, CARDIOVASC RES, V27, P1486, DOI 10.1093/cvr/27.8.1486; FINLEY KD, 1995, P NATL ACAD SCI USA, V92, P9378, DOI 10.1073/pnas.92.20.9378; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GRANGER DL, 1990, J CLIN INVEST, V85, P264, DOI 10.1172/JCI114422; GREEN LC, 1982, ANAL BIOCHEM, V126, P11; GREENE B, 1993, AM J PHYSIOL, V264, pL351, DOI 10.1152/ajplung.1993.264.4.L351; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HATAKEYAMA K, 1991, J BIOL CHEM, V266, P765; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; HATTORI Y, 1993, BIOCHEM BIOPH RES CO, V195, P435, DOI 10.1006/bbrc.1993.2062; HATTORI Y, 1995, ENDOTHELIUM, V3, pS28; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; Kunz D, 1996, P NATL ACAD SCI USA, V93, P255, DOI 10.1073/pnas.93.1.255; LAMBERT MA, 1986, MOL CELL BIOL, V6, P1722, DOI 10.1128/MCB.6.5.1722; Lewis NP, 1996, CIRCULATION, V93, P720, DOI 10.1161/01.CIR.93.4.720; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P453; MORRIS SM, 1989, ARCH BIOCHEM BIOPHYS, V273, P230, DOI 10.1016/0003-9861(89)90183-5; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; Nagasaki A, 1996, J BIOL CHEM, V271, P2658, DOI 10.1074/jbc.271.5.2658; NATHAN C, 1995, CELL, V82, P873, DOI 10.1016/0092-8674(95)90019-5; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; NISHIDA M, 1993, AM J PHYSIOL, V264, pH639, DOI 10.1152/ajpheart.1993.264.2.H639; NUSSLER AK, 1994, J BIOL CHEM, V269, P1257; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; PINSKY DJ, 1995, J CLIN INVEST, V95, P677, DOI 10.1172/JCI117713; PLUMB JA, 1989, CANCER RES, V49, P4435; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; ROBERTS AB, 1992, MOL ENDOCRINOL, V6, P1921, DOI 10.1210/me.6.11.1921; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; SAKAI N, 1992, MOL PHARMACOL, V43, P6; SATO H, 1992, J LEUKOCYTE BIOL, V52, P161, DOI 10.1002/jlb.52.2.161; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHMIDT K, 1992, BIOCHEM J, V281, P297, DOI 10.1042/bj2810297; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SCOTTBURDEN T, 1993, BIOCHEM BIOPH RES CO, V196, P1261, DOI 10.1006/bbrc.1993.2388; Simmons WW, 1996, J BIOL CHEM, V271, P11694, DOI 10.1074/jbc.271.20.11694; SMITH GK, 1983, ARCH BIOCHEM BIOPHYS, V227, P272, DOI 10.1016/0003-9861(83)90371-5; UNGUREANULONGROIS D, 1995, CIRC RES, V77, P486, DOI 10.1161/01.RES.77.3.486; UNGUREANULONGROIS D, 1995, J MOL CELL CARDIOL, V27, P155, DOI 10.1016/S0022-2828(08)80015-6; UNGUREANULONGROIS D, 1995, CIRC RES, V77, P494, DOI 10.1161/01.RES.77.3.494; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; WERNER ER, 1991, BIOCHEM J, V280, P709, DOI 10.1042/bj2800709; WERNER ER, 1989, BIOCHEM J, V262, P861, DOI 10.1042/bj2620861; WERNERFELMAYER G, 1993, FEBS LETT, V322, P223, DOI 10.1016/0014-5793(93)81574-J; WERNERFELMAYER G, 1989, BIOL CHEM H-S, V370, P1063, DOI 10.1515/bchm3.1989.370.2.1063; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WOODARD MH, 1994, AM J PHYSIOL, V266, pE817, DOI 10.1152/ajpendo.1994.266.5.E817; WU GY, 1992, BIOCHEM J, V281, P45, DOI 10.1042/bj2810045; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; YANG XC, 1994, J CLIN INVEST, V94, P714, DOI 10.1172/JCI117390	86	154	156	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23928	23937		10.1074/jbc.271.39.23928	http://dx.doi.org/10.1074/jbc.271.39.23928			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798625	hybrid			2022-12-27	WOS:A1996VJ44200054
J	Yu, CJ; Kennedy, NJ; Chang, CCY; Rothblatt, JA				Yu, CJ; Kennedy, NJ; Chang, CCY; Rothblatt, JA			Molecular cloning and characterization of two isoforms of Saccharomyces cerevisiae Acyl-CoA:sterol acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-CHOLESTEROL ACYLTRANSFERASE; HAMSTER OVARY CELLS; COENZYME-A; LIPID PARTICLES; LEUCINE ZIPPER; RAT-LIVER; YEAST; EXPRESSION; PROTEINS; DNA	Esterification of cholesterol by acyl-CoA:cholesterol acyltransferase (ACAT) is a key element in maintaining cholesterol homeostasis in cells of higher animals. In the budding yeast, Saccharomyces cerevisiae, accumulation of ergosteryl esters accompanies entry into stationary phase and sporulation. We have determined that two genes in yeast, SAT1 and SAT2, encode isozymes of acylCoA:sterol acyltransferase (ASAT) which are functionally related to ACAT. The SATI isozyme is the major catalytic isoform, accounting for at least 65-75% of total ASAT activity. Targeted deletions of one or both genes do not compromise mitotic cell growth or spore germination, However, diploids that are homozygous for a SATI null mutation exhibit significantly reduced sporulation efficiency. Furthermore, a larger fraction of the sporulating diploids arrest after the first meiotic division, Human ACAT expressed in sat1 sat2 mutant cells can catalyze esterification of cholesterol and, to a lesser extent, ergosterol in vitro, but restores ergosteryl oleate formation in vivo to only similar to 8% of that catalyzed by yeast ASAT in wild-type cells.	DARTMOUTH COLL, DEPT BIOL SCI, GILMAN LAB 6044, HANOVER, NH 03755 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, DEPT BIOCHEM, HANOVER, NH 03755 USA	Dartmouth College; Dartmouth College			Yu, Chunjiang/E-9419-2012		NHLBI NIH HHS [HL36709] Funding Source: Medline; NIDDK NIH HHS [DK42867] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036709, R01HL036709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042867] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAILEY RB, 1975, J BACTERIOL, V124, P606, DOI 10.1128/JB.124.2.606-612.1975; BASSON ME, 1986, P NATL ACAD SCI USA, V83, P5563, DOI 10.1073/pnas.83.15.5563; BILLHEIMER JT, 1990, Patent No. 372445; BUCKLAND R, 1989, NATURE, V338, P547, DOI 10.1038/338547a0; CADIGAN KM, 1988, J LIPID RES, V29, P1683; Cao GQ, 1996, J BIOL CHEM, V271, P14642, DOI 10.1074/jbc.271.24.14642; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1986, BIOCHEMISTRY-US, V25, P1693, DOI 10.1021/bi00355a038; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG TY, 1994, TRENDS CARDIOVAS MED, V4, P223, DOI 10.1016/1050-1738(94)90038-8; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CLAUSEN MK, 1974, FEBS LETT, V43, P176, DOI 10.1016/0014-5793(74)80994-4; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DOOLITTLE GM, 1982, BIOCHEMISTRY-US, V21, P674, DOI 10.1021/bi00533a014; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; Hampton R, 1996, TRENDS BIOCHEM SCI, V21, P140, DOI 10.1016/S0968-0004(96)80168-X; HENRY SA, 1973, J BACTERIOL, V114, P1158, DOI 10.1128/JB.114.3.1158-1163.1973; ILLINGWO.RF, 1973, J BACTERIOL, V113, P373, DOI 10.1128/JB.113.1.373-386.1973; KEESLER GA, 1992, ARCH BIOCHEM BIOPHYS, V296, P474, DOI 10.1016/0003-9861(92)90600-2; KRAUSE BR, 1989, 10 INT S DRUGS AFF L; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEBER R, 1994, YEAST, V10, P1421, DOI 10.1002/yea.320101105; PAPE ME, 1995, J LIPID RES, V36, P823; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PILLAI R, 1993, P NATL ACAD SCI USA, V90, P11970, DOI 10.1073/pnas.90.24.11970; RAMER SW, 1992, P NATL ACAD SCI USA, V89, P11589, DOI 10.1073/pnas.89.23.11589; REINHART MP, 1987, J BIOL CHEM, V262, P9649; ROTHBLATT J, 1989, METHOD CELL BIOL, V32, P3; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SIKORSKI RS, 1989, GENETICS, V122, P19; SLISKOVIC DR, 1991, TRENDS PHARMACOL SCI, V12, P194, DOI 10.1016/0165-6147(91)90546-5; TAYLOR FR, 1981, J BIOL CHEM, V256, P3048; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; ZINSER E, 1993, J BACTERIOL, V175, P2853, DOI 10.1128/JB.175.10.2853-2858.1993	45	107	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24157	24163		10.1074/jbc.271.39.24157	http://dx.doi.org/10.1074/jbc.271.39.24157			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798656	hybrid			2022-12-27	WOS:A1996VJ44200085
J	Berkower, C; Taglicht, D; Michaelis, S				Berkower, C; Taglicht, D; Michaelis, S			Functional and physical interactions between partial molecules of STE6, a yeast ATP-binding cassette protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE TRANSPORT-SYSTEM; A-FACTOR TRANSPORTER; HUMAN P-GLYCOPROTEIN; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; MULTIDRUG-RESISTANCE; MUTATIONAL ANALYSIS; NUCLEOTIDE-BINDING; ABC TRANSPORTERS; CYSTIC-FIBROSIS	The Saccharomyces cerevisiae a-factor transporter, STE6, is a member of the ATP binding cassette (ABC) transporter superfamily, ABC proteins consist of four modular units that comprise two membrane spanning domains (MSDs) and two nucleotide-binding domains (NBDs). Like many ABC proteins, STE6 contains these four domains in a single polypeptide; certain other ABC proteins are encoded as pairs of "half-molecules" or are further subdivided. Our previous studies demonstrated that STE6 can be expressed as two half-molecules that are functional when co-expressed, Here we dissect the interactions between modules of STE6 in greater detail, We show by co-immunoprecipitation that STE6 half-molecules interact physically, supporting the view that they co-assemble in vivo to form a functional transporter, We also demonstrate a physical interaction between a STE6 half-molecule and full-length STE6; such complexes appear to be functional, based on the striking finding that the defective activity of full-length STE6 mutated in one of its NBDs can be corrected by co-expression of the corresponding "wild-type" half-molecule. We also show that a quarter-molecule consisting solely of the N-terminal MSD of STE6 can interact physically and functionally with a C-terminal three-quarter molecule of STE6, indicating that information directing the assembly of STE6 from partial molecules is contained, at least in part, within its membrane spans.	JOHNS HOPKINS SCH MED, DEPT ANAT & CELL BIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051508] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 51508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BERKOWER C, 1994, MOL BIOL CELL, V5, P1185, DOI 10.1091/mbc.5.11.1185; BERKOWER C, 1996, IN PRESS MEMBRANE PR; BERKOWER C, 1993, MOL BIOL FUNCTION CA, P130; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EWART GD, 1994, J BIOL CHEM, V269, P10370; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; GOTTESMAN MM, 1995, ANNU REV GENET, V29, P307; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1994, CELL, V79, P393, DOI 10.1016/0092-8674(94)90248-8; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KORONAKIS V, 1993, MOL MICROBIOL, V8, P1163, DOI 10.1111/j.1365-2958.1993.tb01661.x; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1994, J BIOL CHEM, V269, P28683; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; Michaelis S, 1993, Semin Cell Biol, V4, P17, DOI 10.1006/scel.1993.1003; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; Michaelis S, 1995, COLD SPRING HARB SYM, V60, P291, DOI 10.1101/SQB.1995.060.01.034; MOMBURG F, 1994, CURR OPIN IMMUNOL, V6, P32, DOI 10.1016/0952-7915(94)90030-2; NIKAIDO H, 1994, FEBS LETT, V346, P55, DOI 10.1016/0014-5793(94)00315-7; OSTEDGAARD LS, 1994, MOL BIOL CELL, V5, P191; PANAGIOTIDIS CH, 1993, J BIOL CHEM, V268, P23685; RUSS G, 1995, J BIOL CHEM, V270, P21312, DOI 10.1074/jbc.270.36.21312; SIKORSKI RS, 1989, GENETICS, V122, P19; Townsend A, 1993, Semin Cell Biol, V4, P53, DOI 10.1006/scel.1993.1007; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; WANDERSMAN C, 1990, P NATL ACAD SCI USA, V87, P4776, DOI 10.1073/pnas.87.12.4776; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	34	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22983	22989		10.1074/jbc.271.38.22983	http://dx.doi.org/10.1074/jbc.271.38.22983			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798485	hybrid			2022-12-27	WOS:A1996VH76800011
J	Holtmann, MH; Roettger, BF; Pinon, DI; Miller, LJ				Holtmann, MH; Roettger, BF; Pinon, DI; Miller, LJ			Role of receptor phosphorylation in desensitization and internalization of the secretin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; PROTEIN-COUPLED RECEPTORS; BINDING; SEQUENCE; POLYPEPTIDE; HORMONE; CELLS; SEQUESTRATION; IODINATION; HISTIDINE	The secretin receptor is prototypic of a recently described family of G protein-coupled receptors. We recently demonstrated its phosphorylation in response to agonist stimulation and elimination of this covalent modification by C-terminal truncation (F. Ozcelebi et al, (1995) Mol. Pharmacol. 48, 818-824). Here, we explore the functional impact of receptor phosphorylation and structural determinants for desensitization by comparing receptor behavior after agonist exposure in cell lines expressing wild-type and truncated receptor. To characterize receptor internalization, a novel fluorescent full agonist, [rat secretin-27]-Gly-rhodamine, was developed, which bound specifically and with high affinity. Both receptor constructs bound secretin normally, leading to normal G protein coupling and cAMP accumulation and prompt receptor internalization. Exposure to 10 nM secretin for 5 min or 12 h prior to washing and restimulation with a full range of concentrations demonstrated absent cAMP responses in wild-type receptor-bearing cells and responses 25 to 30% of control and shifted 1 order of magnitude to the right in the truncated receptor-bearing cells. Thus, the major mechanism of desensitization was phosphorylation-independent receptor internalization. Phosphorylation was associated with a distinct process that likely represents interference with G protein coupling, manifest as a reduced rate of cAMP stimulation. Thus, dual distinct mechanisms of desensitization exist in the secretin receptor family that should help protect receptor bearing cells from overstimulation.	MAYO CLIN & MAYO FDN,CTR BASIC RES DIGEST DIS,ROCHESTER,MN 55905	Mayo Clinic					NIDDK NIH HHS [DK46577] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046577, R56DK046577] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARAK LS, 1994, J BIOL CHEM, V269, P2790; BAWAB W, 1991, BIOSCIENCE REP, V11, P33, DOI 10.1007/BF01118603; BOISSARD C, 1986, CANCER RES, V46, P4406; CHAKDER S, 1993, J PHARMACOL EXP THER, V266, P392; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; DONNELLY D, 1989, FEBS LETT, V251, P109, DOI 10.1016/0014-5793(89)81438-3; FOURNIER A, 1993, ANAL BIOCHEM, V211, P305, DOI 10.1006/abio.1993.1274; GAUDIN P, 1995, BIOCHEM BIOPH RES CO, V211, P901, DOI 10.1006/bbrc.1995.1897; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HEFFORD MA, 1989, BIOCHIM BIOPHYS ACTA, V998, P267, DOI 10.1016/0167-4838(89)90283-5; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; IZZO RS, 1984, INT J PEPT PROT RES, V23, P292; IZZO RS, 1989, ENDOCRINOLOGY, V124, P2252, DOI 10.1210/endo-124-5-2252; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; ODONNELL M, 1991, J BIOL CHEM, V266, P6389; OZCELEBI F, 1995, MOL PHARMACOL, V48, P818; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; ROETTGER BF, 1995, J CELL BIOL, V130, P579, DOI 10.1083/jcb.130.3.579; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SLICE LW, 1994, J BIOL CHEM, V269, P21755; STAUNOLSEN P, 1982, J NEUROCHEM, V39, P1242, DOI 10.1111/j.1471-4159.1982.tb12561.x; ULRICH CD, 1993, GASTROENTEROLOGY, V105, P1534, DOI 10.1016/0016-5085(93)90162-6; ZHOU XM, 1995, CELL SIGNAL, V7, P207, DOI 10.1016/0898-6568(94)00091-O	32	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23566	23571		10.1074/jbc.271.38.23566	http://dx.doi.org/10.1074/jbc.271.38.23566			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798566	hybrid			2022-12-27	WOS:A1996VH76800092
J	Price, MP; Ishihara, H; Sheppard, DN; Welsh, MJ				Price, MP; Ishihara, H; Sheppard, DN; Welsh, MJ			Function of Xenopus cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channels and use of human-Xenopus chimeras to investigate the pore properties of CFTR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE CHANNEL; APICAL MEMBRANE; ANION SELECTIVITY; R-DOMAIN; EXPRESSION; GENE; IDENTIFICATION; CLONING; CELLS; LOCALIZATION	To explore the relationship between structure and function in the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel, we studied Xenopus CFTR. We found that the anion permeability sequence of cAMP-activated Cl- currents in the apical membrane of Xenopus A6 epithelia differed from that of cAMP-activated Cl- currents in human epithelia expressing CFTR, To understand the molecular basis for this difference and to learn whether CFTR from another species would have properties similar to human CFTR, we assembled a full-length Xenopus CFTR cDNA from A6 cells. Expression of Xenopus CFTR in HeLa cells generated cAMP-activated whole-cell currents and cAMP-dependent protein kinase-activated single channels that resembled those of human CFTR with the exception that the anion permeability sequence was different (Br- = I- > Cl- in Xenopus CFTR and Br- = Cl- > I- in human), In addition, the single-channel conductance of Xenopus CFTR was increased. To investigate protein regions that account for these differences, we constructed chimeric proteins by replacing either the first or second membrane-spanning domain of human CFTR with the equivalent region of Xenopus CFTR (hX1-6 and hX7-12, respectively) and examined their function in HeLa cells. We found that the anion permeability sequence (Br- = I- > Cl-) and single-channel conductance of hX1-6 resembled that of Xenopus CFTR expressed in HeLa cells, whereas hX7-12 had properties like those of human CFTR. However, the gating of hX1-6 showed a flickery behavior. The altered gating of hX1-6 was attributed to residues in the first extracellular loop of Xenopus CFTR because mutation of residues in that region to the corresponding residues of human CFTR produced gating behavior similar to that of human CFTR. These data suggest that sequence differences in the first membrane-spanning domains are responsible for the differences in the permeation properties of human and Xenopus CFTR and that the extracellular loop influences channel gating.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; University of Iowa			Sheppard, David N/AAV-4187-2021	Sheppard, David N/0000-0001-5533-9130; Welsh, Michael/0000-0002-1646-6206				AKABAS MH, 1994, J BIOL CHEM, V269, P14865; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; Ausubel FM, 1992, CURRENT PROTOCOLS MO; CHANG XB, 1994, J BIOL CHEM, V269, P18572; CHANG XB, 1993, J BIOL CHEM, V268, P11304; COPELLO J, 1993, J GEN PHYSIOL, V102, P177, DOI 10.1085/jgp.102.2.177; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DIAMOND G, 1991, J BIOL CHEM, V266, P22761; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FIEDLER MA, 1992, AM J PHYSIOL, V262, pL779, DOI 10.1152/ajplung.1992.262.6.L779; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; LARSEN EH, 1995, J PHYSL, V489, P18; MARSHALL J, 1991, J BIOL CHEM, V266, P22749; MARUNAKA Y, 1993, BIOCHIM BIOPHYS ACTA, V1153, P105, DOI 10.1016/0005-2736(93)90281-4; MCDONOUGH S, 1994, NEURON, V13, P623, DOI 10.1016/0896-6273(94)90030-2; OVERHOLT JL, 1995, AM J PHYSIOL-CELL PH, V268, pC636; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, RECEPTOR CHANNEL, V1, P221; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; Sheppard DN, 1996, J BIOL CHEM, V271, P14995, DOI 10.1074/jbc.271.25.14995; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; TATA F, 1991, GENOMICS, V10, P301, DOI 10.1016/0888-7543(91)90312-3; TEBBUTT SJ, 1995, P NATL ACAD SCI USA, V92, P2293, DOI 10.1073/pnas.92.6.2293; Tucker Stephen J., 1992, Human Molecular Genetics, V1, P77, DOI 10.1093/hmg/1.2.77; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WRIGHT EM, 1977, PHYSIOL REV, V57, P109, DOI 10.1152/physrev.1977.57.1.109	33	39	39	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25184	25191		10.1074/jbc.271.41.25184	http://dx.doi.org/10.1074/jbc.271.41.25184			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810276	hybrid			2022-12-27	WOS:A1996VL69300020
J	Brostrom, CO; Prostko, CR; Kaufmann, RJ; Brostrom, MA				Brostrom, CO; Prostko, CR; Kaufmann, RJ; Brostrom, MA			Inhibition of translational initiation by activators of the glucose-regulated stress protein and heat shock protein stress response systems - Role of the interferon-inducible double-stranded RNA-activated eukaryotic initiation factor 2 alpha kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC RETICULAR CALCIUM; NUCLEOTIDE EXCHANGE FACTOR; NF-KAPPA-B; FACTOR-II; ASIALOGLYCOPROTEIN RECEPTOR; EIF-2-ALPHA KINASE; MESSENGER-RNA; PHOSPHORYLATION; CELLS; GRP78	Depletion of endoplasmic reticulum (ER) Ca2+ perturbs protein folding and processing within the organelle while inhibiting translational initiation through activation of the double-stranded RNA-activated eukaryotic initiation factor (eIF)-2 alpha kinase (PKR) (Prostko, C. R., Dholakia, J. N., Brostrom, M. A., and Brostrom, C. O. (1995) J. Biol. Chem. 270, 6211-6215). The glucose-regulated stress protein (GRP) chaperones are subsequently induced, We now report that sodium arsenite, a prototype for stressors fostering cytoplasmic protein misfolding, also inhibits translational initiation through activation of PKR while subsequently inducing the heat shock protein (HSP) chaperones, Arsenite neither mobilized ER-associated Ca2+ nor slowed peptide chain elongation, Various HSP-inducing chemicals caused rapid phosphorylation of eIF-2 alpha. When incubated with double-stranded RNA, extracts derived from arsenite-treated cells displayed greater degrees of phosphorylation of PKR and eIF-2 alpha than did control extracts. Cells overexpressing a dominant negative PKR mutation resisted translational inhibition and eIF-2 alpha phosphorylation in response to ER or cytoplasmic stressors, Induction of either the HSP or GRP chaperones was accompanied by development of translational tolerance to either Ca2+-mobilizing agents or arsenite, Following induction of the HSPs by arsenite, cells remained susceptible to induction of the GRPs by Ca2+-mobilizing agents. Conversely, cells possessing induced GRP contents in response to Ca2+-mobilizing agents readily induced the HSPs in response to arsenite, It is concluded that the two chaperone systems function independently except for their mutual suppression of PKR.	UNIV MICHIGAN, MED CTR, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Brostrom, CO (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT PHARMACOL, 675 HOES LANE, PISCATAWAY, NJ 08854 USA.							BROSTROM CO, 1983, J BIOL CHEM, V258, P4390; BROSTROM MA, 1990, J BIOL CHEM, V265, P20539; BROSTROM MA, 1995, J BIOL CHEM, V270, P4127, DOI 10.1074/jbc.270.8.4127; BROSTROM MA, 1993, NUTRITION GENE EXPRE, P117; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHIN KV, 1987, J BIOL CHEM, V262, P16509; CROSBY JS, 1994, MOL CELL BIOL, V14, P3906, DOI 10.1128/MCB.14.6.3906; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P546; DUBOIS MF, 1989, J BIOL CHEM, V264, P12165; DUNCAN RF, 1987, ARCH BIOCHEM BIOPHYS, V256, P651, DOI 10.1016/0003-9861(87)90622-9; Gmitter D, 1996, CELL BIOL TOXICOL, V12, P101, DOI 10.1007/BF00143360; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; KOROMILAS AE, 1995, J BIOL CHEM, V270, P25426, DOI 10.1074/jbc.270.43.25426; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; KUZNETSOV G, 1993, J BIOL CHEM, V268, P2001; LEDFORD BE, 1978, BIOCHIM BIOPHYS ACTA, V519, P204, DOI 10.1016/0005-2787(78)90073-4; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEVINSON W, 1980, BIOCHIM BIOPHYS ACTA, V606, P170, DOI 10.1016/0005-2787(80)90108-2; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MURTHARIEL P, 1993, J BIOL CHEM, V268, P12946; PORUCHYNSKY MS, 1991, J CELL BIOL, V114, P651, DOI 10.1083/jcb.114.4.651; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; PROSTKO CR, 1993, MOL CELL BIOCHEM, V128, P255, DOI 10.1007/BF01076776; PROSTKO CR, 1995, J BIOL CHEM, V270, P6211, DOI 10.1074/jbc.270.11.6211; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; TRAUGH JA, 1986, PROG NUCLEIC ACID RE, V33, P195; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WIKSTROM L, 1993, J BIOL CHEM, V268, P14412; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071	48	89	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24995	25002		10.1074/jbc.271.40.24995	http://dx.doi.org/10.1074/jbc.271.40.24995			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798781	hybrid			2022-12-27	WOS:A1996VM67400104
J	Davis, AJ; Butt, JT; Walker, JH; Moss, SE; Gawler, DJ				Davis, AJ; Butt, JT; Walker, JH; Moss, SE; Gawler, DJ			The Ca2+-dependent lipid binding domain of P120(GAP) mediates protein-protein interactions with Ca2+-dependent membrane-binding proteins - Evidence for a direct interaction between annexin VI and P120(GAP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHOLIPID-BINDING; CARCINOMA-CELLS; RAS P21; GAP; IDENTIFICATION; HOMOLOGY; CLONING; MEMBER; FAMILY	The CaLB domain is a 43-amino acid sequence motif found in a number of functionally diverse signaling proteins including three Ras-specific GTPase activating proteins (GAPs), In the Ras GTPase activating protein, p120(GAP), this domain has the ability to confer membrane association in response to intracellular Ca2+ elevation, Here we have isolated three proteins, p55, p70, and p120, which interact with the p120(GAP) CaLB domain in vitro. We identify p70 as the Ca2+-dependent phospholipid-binding protein annexin VI, Using co-immunoprecipitation studies, we have shown that the interaction between p120(GAP) and annexin VI is also detectable in rat fibroblasts, suggesting that this interaction may have a physiological role in vivo. Thus, the CaLB domain in p120(GAP) appears to have the ability to direct specific protein-protein interactions with Ca2+-dependent membrane-associated proteins, In addition, annexin VI is known to have tumor suppressor activity, Therefore, it is possible that the interaction of annexin VI with p120(GAP) may be important in the subsequent modulation of p21(ras) activity.	UNIV LEEDS,DEPT PHARMACOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV LEEDS,DEPT BIOCHEM & MOL BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; UNIV LONDON UNIV COLL,DEPT PHYSIOL,LONDON WC1E 6BT,ENGLAND	University of Leeds; University of Leeds; University of London; University College London				Delafield-Butt, Jonathan/0000-0002-8881-8821				Barwise JL, 1996, J CELL SCI, V109, P247; BOS JL, 1989, CANCER RES, V49, P4682; BOUSTEAD CM, 1988, FEBS LETT, V233, P233, DOI 10.1016/0014-5793(88)80433-2; BOUSTEAD CM, 1991, CELLULAR CALCIUM PRA, P247; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CROMPTON MR, 1988, EMBO J, V7, P21, DOI 10.1002/j.1460-2075.1988.tb02779.x; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; EDWARDS HC, 1995, MOL CELL BIOCHEM, V149, P293, DOI 10.1007/BF01076591; ELLIS C, 1989, NATURE, V342, P711; GAWLER DJ, 1995, BIOCHEM J, V307, P487, DOI 10.1042/bj3070487; GAWLER DJ, 1995, ONCOGENE, V10, P817; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; TAGOE CE, 1994, BBA-BIOMEMBRANES, V1192, P272, DOI 10.1016/0005-2736(94)90128-7; THEOBALD J, 1995, BRIT J CANCER, V71, P786, DOI 10.1038/bjc.1995.152; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0	28	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24333	24336		10.1074/jbc.271.40.24333	http://dx.doi.org/10.1074/jbc.271.40.24333			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798684	hybrid			2022-12-27	WOS:A1996VM67400006
J	Goodman, TG; Bajt, ML				Goodman, TG; Bajt, ML			Identifying the putative metal ion-dependent adhesion site in the beta(2) (CD18) subunit required for alpha(L)beta(2) and alpha(M)beta(2) ligand interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT RECEPTOR TYPE-3; FUNCTION ASSOCIATED MOLECULE-1; INTEGRIN ALPHA-2-BETA-1 VLA-2; GLYCOPROTEIN-IIB-IIIA; AMINO-ACID SEQUENCE; I-DOMAIN; ALPHA-SUBUNIT; CELL-ADHESION; LEUKOCYTE DIFFERENTIATION; VONWILLEBRAND-FACTOR	We have previously demonstrated that Asp(134) and Ser(136) of the beta(2) subunit are essential for alpha(L) beta(2) and alpha(M) beta(2) ligand recognition. It has been proposed that these residues may be part of a metal ion-dependent adhesion site (MIDAS) within the beta subunit homologous to the alpha(M) I domain MIDAS structure (Lee, J.-0., Rieu, P., Arnaout, M. A., and Liddington, R. (1995) Cell 80, 631-638). In the present study, we evaluated the role of additional candidate metal ion-coordinating residues in the beta(2) subunit in ligand interactions. Cells bearing the recombinant alpha(L) beta(2) or alpha(M) beta(2) mutant(s) were tested for the ability to bind to immobilized ligands, Alanine substitution at Asp(232) in beta(2) produced a complete loss in the capacity of both alpha(L) beta(2) and alpha(M) beta(2) to support cell adhesion and suppressed the expression of a divalent cation-dependent conformation recognized by mAb 24. Alanine substitution at Glu(235) differentially affected receptor function dependent upon the co-transfected alpha subunit. Cells expressing alpha(L) beta(2) with a substitution at Glu(235) failed to adhere to intercellular adhesion molecule 1 (ICAM-1) but did retain the capacity to bind mAb 24. Moreover, cells expressing alpha(M) beta(2) with a substitution at Glu(235) failed to adhere to fibrinogen or ICAM-1 and did not bind mAb 24. However, these cells did retain the capacity to adhere to iC3b following antibody-induced activation, These results implicate Asp(232) and Glu(235), along with Asp(134) and Ser(136), in ligand binding function of alpha(L) beta(2) and alpha(M) beta(2).. These findings provide evidence in support of the existence of a MIDAS structure in beta(2) analogous to that seen in the alpha(M) I domain.	PHARMACIA & UPJOHN INC,CELL BIOL & INFLAMMAT RES,KALAMAZOO,MI 49001	Pfizer								AGRAVES WS, 1987, J CELL BIOL, V105, P1183; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ANDERSON DC, 1994, METABOLIC BASIS INHE; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; BAJT ML, 1992, J BIOL CHEM, V267, P22211; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; EDWARDS CP, 1995, J BIOL CHEM, V270, P12635, DOI 10.1074/jbc.270.21.12635; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; KERN A, 1994, J BIOL CHEM, V269, P22811; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MCGUIRE SL, 1995, J BIOL CHEM, V270, P25866, DOI 10.1074/jbc.270.43.25866; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MILLER LJ, 1986, J IMMUNOL, V137, P2891; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SPRINGER TA, 1984, J EXP MED, V160, P1901, DOI 10.1084/jem.160.6.1901; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Uciechowski P., 1989, LEUCOCYTE TYPING, P543; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699	53	86	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23729	23736		10.1074/jbc.271.39.23729	http://dx.doi.org/10.1074/jbc.271.39.23729			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798597	hybrid			2022-12-27	WOS:A1996VJ44200026
J	Lu, AL; Yuen, DS; Cillo, J				Lu, AL; Yuen, DS; Cillo, J			Catalytic mechanism and DNA substrate recognition of Escherichia coli MutY protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME ENDONUCLEASE-III; BASE-PAIR; NUCLEOTIDE-SEQUENCE; MISMATCH REPAIR; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; DAMAGED BASE; GENE-PRODUCT; CHROMOSOME-I; GLYCOSYLASE	Escherichia coli MutY protein cleaves A/G- or A/7,8-dihydro-8-oxo-guanine (A/GO)-containing DNA on the A-strand by N-glycosylase and apurinic/apyrimidinic endonuclease or lyase activities, In this paper, we show that MutY can be trapped in a stable covalent enzyme-DNA intermediate in the presence of sodium borohydride, a new finding that supports the grouping of MutY in that class of DNA glycosylases that possess concomitant apurinic/apyrimidinic lyase activity. To potentially help determine the substrate recognition site of MutY, mutant proteins were constructed. MutY proteins with a Gly116 --> Ala (G116A) or Asp (G116D) mutation had reduced binding affinities for both A/G- and A/GO-containing DNA substrates. The catalytic parameters, however, were differentially affected. While A/G- and A/GO containing DNA were cleaved by MutY with specificity constants (k(cat)/K-m) of 10 and 3.3 min(-1) mu M(-1), respectively, MutY(G116D) cleaved these DNAs 2,300- and 9-fold less efficiently. The catalytic activities of MutY(G116A) with A/G- and A/GO-containing DNA were about the same as that of wild-type MutY. Both MutY(G116A) and MutY(G116D) could be trapped in covalent intermediates with A/GO containing DNA, but with lower efficiencies than the wild type enzyme in the presence of sodium borohydride. MutY(G116A) also formed a covalent intermediate with A/G-containing DNA, but MutY(G116D) did not. Since Gly116 of MutY lies in a region that is highly conserved among several DNA glycosylases, it is likely this conserved region is in the proximity of the substrate binding and/or catalytic sites.			Lu, AL (corresponding author), UNIV MARYLAND, SCH MED, DEPT BIOCHEM & MOL BIOL, BALTIMORE, MD 21201 USA.		Cillo, Joseph/AAS-4294-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035132] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35132] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; AU KG, 1988, P NATL ACAD SCI USA, V85, P9163, DOI 10.1073/pnas.85.23.9163; AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; BARTON AB, 1994, J BACTERIOL, V176, P1872, DOI 10.1128/jb.176.7.1872-1880.1994; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BROWN T, 1986, P NATL ACAD SCI USA, V83, P2402, DOI 10.1073/pnas.83.8.2402; CARBONNAUX C, 1991, BIOCHEMISTRY-US, V30, P5449, DOI 10.1021/bi00236a018; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHETSANGA CJ, 1979, NUCLEIC ACIDS RES, V6, P3673, DOI 10.1093/nar/6.11.3673; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DESIRAJU V, 1993, J BACTERIOL, V175, P541, DOI 10.1128/JB.175.2.541-543.1993; DODD IB, 1987, J MOL BIOL, V194, P557, DOI 10.1016/0022-2836(87)90681-4; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; GAO XL, 1988, J AM CHEM SOC, V110, P5178, DOI 10.1021/ja00223a045; KAN LS, 1983, P NATL ACAD SCI-BIOL, V80, P4263, DOI 10.1073/pnas.80.14.4263; KASAI H, 1991, OXIDATIVE STRESS OXI, P99; KATCHER HL, 1983, BIOCHEMISTRY-US, V22, P4071, DOI 10.1021/bi00286a013; KENNEDY MC, 1984, J BIOL CHEM, V259, P4463; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; LU AL, 1988, GENETICS, V118, P593; LU AL, 1988, CELL, V54, P805, DOI 10.1016/S0092-8674(88)91109-9; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Maniatis T., 1982, MOL CLONING; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Miller J.H., 1972, EXPT MOL GENETICS; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; NOELLING J, 1992, NUCLEIC ACIDS RES, V20, P6501, DOI 10.1093/NAR/20.24.6501; OUELLETTE BFF, 1993, GENOME, V36, P32, DOI 10.1139/g93-005; PATEL DJ, 1984, BIOCHEMISTRY-US, V23, P3207, DOI 10.1021/bi00309a015; RADICELLA JP, 1988, P NATL ACAD SCI USA, V85, P9674, DOI 10.1073/pnas.85.24.9674; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SU SS, 1988, J BIOL CHEM, V263, P6829; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; TSAIWU JYYJ, 1991, J BACTERIOL, V173, P1902, DOI 10.1128/jb.173.6.1902-1910.1991; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011	57	42	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24138	24143		10.1074/jbc.271.39.24138	http://dx.doi.org/10.1074/jbc.271.39.24138			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798653	hybrid			2022-12-27	WOS:A1996VJ44200082
J	Ambesi, A; Pan, RL; Slayman, CW				Ambesi, A; Pan, RL; Slayman, CW			Alanine-scanning mutagenesis along membrane segment 4 of the yeast plasma membrane H+-ATPase - Effects on structure and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-TRANSPORTING ATPASES; BETA-ASPARTYL PHOSPHATE; SARCOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; DIRECTED MUTAGENESIS; NEUROSPORA-CRASSA; SCHIZOSACCHAROMYCES-POMBE; TRANSLOCATING ATPASE; SECRETORY VESICLES; CONSEQUENCES	Membrane segment 4 of P-type cation pumps has been suggested to play a critical role in the coupling of ATP hydrolysis to ion translocation. In this study, structure-function relationships in M4 of the yeast (Saccharomyces cerevisiae) plasma membrane H+-ATPase have been explored by alanine-scanning mutagenesis. Mutant enzymes were expressed behind an inducible heat-shock promoter in yeast secretory vesicles, as described previously (Nakamoto, R. K., Rao, R., and Slayman, C. W. (1991) J. Biol. Chem. 266, 7940-7949). One substitution (I329A) led to arrest of the enzyme at an early stage of biogenesis, and three others (G333A, L338A, G349A) reduced ATP hydrolysis to near-background levels. The remaining 26 mutants were expressed well enough in secretory vesicles (44-121% of wild type) and had sufficient ATPase activity (16-123% of wild type) to be characterized in detail. When acridine orange fluorescence quenching was used to measure rates of ATP-dependent proton pumping over a range of ATP concentrations, only minor changes were seen. In kinetic studies, however, seven of the mutant enzymes (I331A, I332A, V334A, V336A, V341A, V342A, and M346A) were resistant to vanadate inhibition, and three of them (I332A, V336A, and V341A) also had a decreased K-m and increased pH optimum for ATP hydrolysis. Limited trypsinolysis was used to probe the structure of two different Val-336 substitutions, V336A, described above, and V336R, which displayed little or no ATPase activity. Both were cleaved at a relatively normal rate to give a pattern of fragments essentially identical to that seen with the wild-type enzyme. However, while vanadate, ADP, and ATP were able to protect the wild-type and V336A enzymes against trypsinolysis, the V336R ATPase was protected only by ADP and ATP. Taken together, the data suggest that key residues in the M4 segment may help to communicate the E-1-E-2 conformational change to ion-binding sites in the membrane.	YALE UNIV, SCH MED, DEPT CELLULAR & MOL PHYSIOL, NEW HAVEN, CT 06510 USA	Yale University	Ambesi, A (corresponding author), YALE UNIV, SCH MED, DEPT GENET, 333 CEDAR ST, NEW HAVEN, CT 06510 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015761, R01GM015761] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15761] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMORY A, 1982, J BIOL CHEM, V257, P4723; AMORY A, 1982, J BIOL CHEM, V257, P2509; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; ANDERSEN JP, 1992, J BIOL CHEM, V267, P2767; ANDERSEN JP, 1992, ACTA PHYSIOL SCAND, V146, P151; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1993, J BIOL CHEM, V268, P18359; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CYRKLAFF M, 1995, EMBO J, V14, P1854, DOI 10.1002/j.1460-2075.1995.tb07177.x; DAME JB, 1981, J BIOL CHEM, V256, P724; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FAGAN MJ, 1994, J MOL EVOL, V38, P57; Fiske CH, 1925, J BIOL CHEM, V66, P375; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOSEPHSON L, 1977, BIOCHEMISTRY-US, V16, P4572, DOI 10.1021/bi00640a006; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P2993, DOI 10.1074/jbc.270.7.2993; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDALA SM, 1988, J BIOL CHEM, V263, P15122; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NAKAMOTO RK, 1989, ANN NY ACAD SCI, V574, P165; PERLIN DS, 1987, J BIOL CHEM, V262, P6788; PERLIN DS, 1986, ARCH BIOCHEM BIOPHYS, V248, P53, DOI 10.1016/0003-9861(86)90400-5; PERLIN DS, 1992, ACTA PHYSIOL SCAND, V146, P183; PICK U, 1982, J BIOL CHEM, V257, P6111; RAO R, 1993, J BIOL CHEM, V268, P6708; RAO R, 1996, MYCOTA, V3, P29; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schekman R, 1982, MOL BIOL YEAST SACCH, VII, P361; SERRANO R, 1990, BIOCHIM BIOPHYS ACTA, V1018, P195, DOI 10.1016/0005-2728(90)90247-2; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SLAYMAN CL, 1989, ANN NY ACAD SCI, V574, P233; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163	43	42	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22999	23005		10.1074/jbc.271.38.22999	http://dx.doi.org/10.1074/jbc.271.38.22999			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798487	hybrid			2022-12-27	WOS:A1996VH76800013
J	Thompson, A; Zhang, Y; Kamen, D; Jackson, CW; Cardiff, RD; Ravid, K				Thompson, A; Zhang, Y; Kamen, D; Jackson, CW; Cardiff, RD; Ravid, K			Deregulated expression of c-myc in megakaryocytes of transgenic mice increases megakaryopoiesis and decreases polyploidization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; CELL-CYCLE; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTOR; MONOCLONAL-ANTIBODY; HEMATOPOIETIC-CELLS; SIGNAL-TRANSDUCTION; PLATELET PRODUCTION; PROGENITOR CELLS; BONE-MARROW	Platelets, essential for vascular integrity and hemostasis, fragment from polyploid megakaryocytes, characterized by their endomitotic cell cycle. We studied the influence of overexpression of c-myc oncogene on megakaryopoiesis and endomitosis in vivo, using transgenic mice carrying c-myc fused to the estrogen receptor under the control of the platelet factor 4 (PF4) megakaryocyte-specific promoter. The rationale behind this strategy was to obtain controlled overexpression of an active c-Myc, depending on the estrogen level in the mouse circulation. Analysis of these transgenic mice revealed that the bone marrow of female transgenic mice or of estrogen-injected male transgenic mice, but not of age-matched transgenic males nor nontransgenic females, contained frequent immature myeloid cells and an increased number of megakaryocytes. Deregulated expression of c-Myc shifted the normal ploidy profile of megakaryocytes due to a significant increase in proliferating megakaryocytes and a decrease in the fraction of ploidizing cells. These transgenic mice represent a novel in vivo model for a Myc induced myeloproliferative disorder which can be controlled.	BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02139 USA; ST JUDE CHILDRENS RES HOSP, DIV EXPT HEMATOL, MEMPHIS, TN 38105 USA; UNIV CALIF DAVIS, DEPT MED PATHOL, SACRAMENTO, CA 95817 USA	Boston University; St Jude Children's Research Hospital; University of California System; University of California Davis				Thompson, Alex/0000-0002-9315-5321; Ravid, Katya/0000-0002-9918-3024	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053080] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53080] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ARRIAGA M, 1987, BLOOD, V69, P486; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BURSTEIN SA, 1992, EXP HEMATOL, V20, P1170; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DORN GW, 1994, AM J PHYSIOL, V266, pC1231, DOI 10.1152/ajpcell.1994.266.5.C1231; ECKHARDT SG, 1994, P NATL ACAD SCI USA, V91, P6674, DOI 10.1073/pnas.91.14.6674; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GEWIRTZ AM, 1990, EXP HEMATOL, V18, P945; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Guy CT, 1996, MOL CELL BIOL, V16, P685; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOWARD KJ, 1988, J BIOL CHEM, V263, P3474; JACKSON CW, 1984, BLOOD, V63, P768; JACKSON CW, 1973, BLOOD, V42, P413, DOI 10.1182/blood.V42.3.413.413; JACKSON CW, 1992, BLOOD, V79, P1672; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUTER DJ, 1989, BLOOD, V74, P1952; LEPORE DA, 1984, BRIT J HAEMATOL, V58, P473, DOI 10.1111/j.1365-2141.1984.tb03994.x; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MAZUR EM, 1987, EXP HEMATOL, V15, P340; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MULLERSIEBURG CE, 1991, J EXP MED, V174, P161, DOI 10.1084/jem.174.1.161; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; ODELL TT, 1968, EXP CELL RES, V53, P321, DOI 10.1016/0014-4827(68)90302-9; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; RAVID K, 1991, P NATL ACAD SCI USA, V88, P1521, DOI 10.1073/pnas.88.4.1521; RAVID K, 1993, J CELL BIOL, V123, P1545, DOI 10.1083/jcb.123.6.1545; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VINCI G, 1984, BRIT J HAEMATOL, V56, P589, DOI 10.1111/j.1365-2141.1984.tb02184.x; WANG ZY, 1995, BLOOD, V86, P3783, DOI 10.1182/blood.V86.10.3783.bloodjournal86103783; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; Zhang Y, 1996, J BIOL CHEM, V271, P4266	50	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22976	22982		10.1074/jbc.271.38.22976	http://dx.doi.org/10.1074/jbc.271.38.22976			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798484	hybrid			2022-12-27	WOS:A1996VH76800010
J	Walsh, AA; Tullis, K; Rice, RH; Denison, MS				Walsh, AA; Tullis, K; Rice, RH; Denison, MS			Identification of a novel cis-acting negative regulatory element affecting expression of the CYP1A1 gene in rat epidermal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; DIOXIN-RESPONSIVE ENHANCER; NUCLEAR TRANSLOCATOR PROTEIN; AH-RECEPTOR; DNA RECOGNITION; TRANSCRIPTIONAL REGULATION; AROMATIC-HYDROCARBONS; HEPATOMA-CELLS; BINDING; KERATINOCYTES	Polycyclic aromatic hydrocarbons such as 3-methylcholanthrene are toxic to rat epidermal cells in low passages (3 to 6), but cultures of high passage (greater than or equal to 15) are resistant. Since such compounds can be metabolically activated by cytochrome P4501A1, we have examined the regulation of this gene in low and high passage cells, Consistent with this difference, little or no 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-inducible P4501A1 mRNA or enzyme activity was observed in high passage as compared to low passage cultures. Similarly, transfection of a luciferase reporter construct containing -1317 to +256 base pairs of the 5'-flanking region of the murine CYP1A1 gene was TCDD-inducible in low but not high passage cells. Ligand binding and transfection experiments demonstrated the presence of functional Ah receptor complexes in both high and low passage cells. Deletion analysis identified a 26-base pair negative regulatory DNA (NeRD) element contained within the upstream regulatory region of the CYP1A1 gene responsible for this effect. Nuclear extracts from both low and high passage cells contain a protein which specifically binds to NeRD-containing DNA. Thus, the loss of polycyclic aromatic hydrocarbon sensitivity in high passage rat epidermal cells appears to be due to decreased expression of CYP1A1, and this effect may be mediated by an altered NeRD binding factor(s) present in these cells.	UNIV CALIF DAVIS,DEPT ENVIRONM TOXICOL,DAVIS,CA 95616	University of California System; University of California Davis			Rice, Robert/AAP-7813-2021	Tullis, Kathryn/0000-0003-2517-4886	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007059] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR27130] Funding Source: Medline; NIEHS NIH HHS [ES05707, ES07059] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLENHOFFMANN BL, 1984, P NATL ACAD SCI-BIOL, V81, P7802, DOI 10.1073/pnas.81.24.7802; ASMAN DC, 1993, J BIOL CHEM, V268, P12530; BERGHARD A, 1990, J BIOL CHEM, V265, P21086; BHATTACHARYYA KK, 1995, J BIOL CHEM, V270, P11595, DOI 10.1074/jbc.270.19.11595; BNAK PA, 1995, ARCH BIOCHEM BIOPHYS, V317, P439; BOUCHER PD, 1993, J BIOL CHEM, V268, P17384; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN HS, 1994, J BIOL CHEM, V269, P27554; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANIEL V, 1988, NUCLEIC ACIDS RES, V16, P351, DOI 10.1093/nar/16.1.351; DENISON MS, 1986, J BIOL CHEM, V261, P3987; DENISON MS, 1991, ARCH BIOCHEM BIOPHYS, V284, P158, DOI 10.1016/0003-9861(91)90278-Q; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FISHER JM, 1990, J BIOL CHEM, V265, P9676; FISHER JM, 1989, MOL CARCINOGEN, V1, P216, DOI 10.1002/mc.2940010403; Garrison PM, 1996, FUND APPL TOXICOL, V30, P194, DOI 10.1006/faat.1996.0056; GONZALEZ FJ, 1985, NUCLEIC ACIDS RES, V13, P7269, DOI 10.1093/nar/13.20.7269; GRADIN K, 1993, J BIOL CHEM, V268, P4061; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HEIMANN R, 1983, J CELL PHYSIOL, V117, P362, DOI 10.1002/jcp.1041170311; HEIMANN R, 1983, CANCER RES, V43, P4856; HENRY EC, 1993, BIOCHEM J, V294, P95, DOI 10.1042/bj2940095; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HORD NG, 1994, MOL PHARMACOL, V46, P618; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; JONES CL, 1996, FUND APPL TOXICOL S, V30, P275; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; JONES PBC, 1986, P NATL ACAD SCI USA, V83, P2802, DOI 10.1073/pnas.83.9.2802; KAWAJIRI K, 1986, EUR J BIOCHEM, V159, P219, DOI 10.1111/j.1432-1033.1986.tb09857.x; Ko HSP, 1996, MOL CELL BIOL, V16, P430; LAIMINS L, 1986, P NATL ACAD SCI USA, V83, P3151, DOI 10.1073/pnas.83.10.3151; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; MUHKTAR H, 1989, CLIN DERM, V7, P1; MUMFORD JL, 1987, SCIENCE, V235, P217, DOI 10.1126/science.3798109; NELSON DR, 1991, DNA CELL BIOL, V12, P1; PELKONEN O, 1982, PHARMACOL REV, V34, P189; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PROBST MR, 1993, MOL PHARMACOL, V44, P511; PROKIPCAK RD, 1988, ARCH BIOCHEM BIOPHYS, V267, P811, DOI 10.1016/0003-9861(88)90091-4; Reiners J. J. Jr., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P155; REINERS JJ, 1990, P NATL ACAD SCI USA, V87, P1825, DOI 10.1073/pnas.87.5.1825; RHEINWALD JG, 1975, CELL, V6, P317, DOI 10.1016/0092-8674(75)90183-X; ROBBINS M, 1992, MOL BRAIN RES, V13, P83, DOI 10.1016/0169-328X(92)90047-F; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SOGAWA K, 1986, P NATL ACAD SCI USA, V83, P8044, DOI 10.1073/pnas.83.21.8044; Sterling K, 1996, MOL PHARMACOL, V49, P329; STERLING K, 1993, MOL PHARMACOL, V44, P560; STROM A, 1994, DNA CELL BIOL, V13, P805, DOI 10.1089/dna.1994.13.805; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; TODOROVIC R, 1991, MOL CARCINOGEN, V4, P308, DOI 10.1002/mc.2940040409; VANCANTFORT J, 1977, BIOCHEM BIOPH RES CO, V79, P505, DOI 10.1016/0006-291X(77)90186-3; WATSON AJ, 1992, MOL CELL BIOL, V12, P2115, DOI 10.1128/MCB.12.5.2115; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019	63	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22746	22753		10.1074/jbc.271.37.22746	http://dx.doi.org/10.1074/jbc.271.37.22746			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798449	hybrid			2022-12-27	WOS:A1996VG67200068
J	Mauviel, A; Korang, K; Santra, M; Tewari, D; Uitto, J; Iozzo, RV				Mauviel, A; Korang, K; Santra, M; Tewari, D; Uitto, J; Iozzo, RV			Identification of a bimodal regulatory element encompassing a canonical AP-1 binding site in the proximal promoter region of the human decorin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MESSENGER-RNA LEVELS; GROWTH-FACTOR-BETA; HUMAN RECOMBINANT INTERLEUKIN-1-BETA; PRO-INFLAMMATORY CYTOKINES; FACTOR-ALPHA; TRANSCRIPTIONAL REGULATION; DERMAL FIBROBLASTS; C-JUN; EXPRESSION	We have previously described a tumor necrosis factor alpha (TNF-alpha) response element, located between residues -188 and -140 of the human decorin promoter, that mediates the inhibitory effect of TNF-alpha on decorin gene expression (Mauviel, A., Santra, M., Chen, Y.-Q., Uitto, J., and Iozzo, R. V. (1995) J. Biol. Chem. 270, 11692-11700). In this report, we demonstrate that interleukin 1 (IL-1), a pleiotropic cytokine that shares a wide variety of biological properties with TNF-alpha, uses the same cis element to up-regulate decorin gene expression. Specifically, IL-1 enhances the expression of the human decorin gene, and this effect is mediated by activation of the corresponding promoter, as shown in transient cell transfection experiments using decorin promoter-chloramphenicol acetyl transferase reporter gene constructs. Additional transfection experiments with various 5'-deletion promoter-chloramphenicol acetyltransferase constructs demonstrate that both the inhibitory effect of TNF-alpha and the stimulatory effect of IL-1 are mediated by a 48-base pair segment of the promoter, between residues -188 and -140. This region, which contains a canonical AP-1 binding site. TGAGTCA, allows an antagonistic effect of these two cytokines on the decorin promoter activity. When cloned upstream of the thymidine kinase promoter, this promoter fragment requires the AP-1 sequence to be responsive to IL-1. Supershift assays with various AP-1 antibodies identified c-Jun, Jun-B, and Fra-1 as components of the complex binding to the decorin promoter. Overexpression of c-jun, an oncogene encoding the c-Jun/AP-1 transcription factor, reduces the basal activity of both decorin and -188/-140 thymidine kinase promoter constructs. In contrast, blockage of c-jun expression with an antisense c-jun construct potentiates the stimulatory effect of IL-1 and reverses the response to TNF-alpha. These data indicate that the region between residues -188 and -140 of the human decorin promoter functions as a bimodal regulatory element and allows transcriptional repression by c-Jun/AP-1 complexes.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOL PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,KIMMEL CANC CTR,PHILADELPHIA,PA 19107; TEMPLE UNIV,SCH DENT,DEPT ORTHODONT,PHILADELPHIA,PA 19140	Jefferson University; Jefferson University; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania	Mauviel, A (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL & CUTANEOUS BIOL,233 S 10TH ST,PHILADELPHIA,PA 19107, USA.		Iozzo, Renato/AAS-1980-2020; MAUVIEL, Alain/F-6251-2013	Iozzo, Renato/0000-0002-5908-5112; Mauviel, Alain/0000-0002-0438-2793	NCI NIH HHS [R01-CA39481] Funding Source: Medline; NIAMS NIH HHS [T32-AR07651, R01-AR41439] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041439] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GOLDRING MB, 1987, J BIOL CHEM, V262, P16724; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEINO J, 1988, BIOCHEM J, V252, P309, DOI 10.1042/bj2520309; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; LE JM, 1987, LAB INVEST, V56, P234; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; MAUVIEL A, 1993, WOUNDS, V5, P137; MAUVIEL A, 1993, J BIOL CHEM, V268, P6520; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; MAUVIEL A, 1991, J INVEST DERMATOL, V96, P243, DOI 10.1111/1523-1747.ep12462185; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; PULKKINEN L, 1990, J BIOL CHEM, V265, P17780; SANTRA M, 1994, J BIOL CHEM, V269, P579; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	30	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24824	24829		10.1074/jbc.271.40.24824	http://dx.doi.org/10.1074/jbc.271.40.24824			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798756	hybrid			2022-12-27	WOS:A1996VM67400078
J	Mueller, MJ; Andberg, MB; Samuelsson, B; Haeggstrom, JZ				Mueller, MJ; Andberg, MB; Samuelsson, B; Haeggstrom, JZ			Leukotriene A(4) hydrolase, mutation of tyrosine 378 allows conversion of leukotriene A(4) into an isomer of leukotriene B-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM-BASED INACTIVATION; POLYMORPHONUCLEAR LEUKOCYTES; HUMAN-ERYTHROCYTES; EPOXIDE HYDROLASE; ARACHIDONIC-ACID; AMINOPEPTIDASE; PEPTIDASE	Leukotriene A(4) hydrolase catalyzes the final step in the biosynthesis of the proinflammatory compound leukotriene B-4, a reaction which is accompanied by suicide inactivation of the enzyme by leukotriene A(4). We have recently reported that Tyr-378 is a major structural determinant for suicide inactivation and that mutation of Tyr-378 into Phe or Gln protects leukotriene A(4) hydrolase from this catalytic restriction (Mueller, M. J., Blomster, M., Opperman, U. C. T., Jornvall, H., Samuelsson, B., and Haeggstrom, J. Z. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5931-5935), In the present study, we show that both [Y378F]- and [Y378Q]leukotriene A(4) hydrolase converts leukotriene A(4) not only into leukotriene B-4 but also into a second, previously unknown, product of the enzyme. From biophysical analyses and comparison with a synthetic standard, the structure of this product was determined to 5S,12R-dihydroxy-6,10-trans-8,14-cis-eicosatetraenoic acid, i.e. Delta(6)-trans-Delta(8)-cis-leukotriene B-4. The relative formation of Delta(6)-trans-Delta(8)-cis-leukotriene B-4 versus leukotriene B-4 by [Y378F]- and [Y378Q]leukotriene A(4) hydrolase, was 18% and 32%, respectively. For [Y378F]leukotriene A(4) hydrolase, the turnover of leukotriene A(4) into leukotriene B-4 or Delta(6)-trans-Delta(8)-cis-leukotriene B-4 was calculated to 2.5 s(-1) which is almost three times the k(cat) value of the wild type enzyme, Taken together, these findings indicate that Tyr-378 is located at the active site where it assists in the formation of the correct double-bond geometry in the product leukotriene B-4.	KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,DIV CHEM 2,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet			mueller, martin j/C-7616-2019	Blomster Andberg, Martina/0000-0002-8021-9947				BORGEAT P, 1981, PROSTAG LEUKOTR ESS, V6, P557, DOI 10.1016/0161-4630(81)90117-8; BORGEAT P, 1988, PROSTAGLANDINS, V35, P723, DOI 10.1016/0090-6980(88)90145-1; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P3213, DOI 10.1073/pnas.76.7.3213; COREY EJ, 1980, J AM CHEM SOC, V102, P7986, DOI 10.1021/ja00547a600; EVANS JF, 1985, J BIOL CHEM, V260, P966; FITZPATRICK FA, 1982, J BIOL CHEM, V257, P4680; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V173, P431, DOI 10.1016/S0006-291X(05)81076-9; HAEGGSTROM JZ, 1993, J LIPID MEDIATOR, V6, P1; LINDGREN JA, 1981, FEBS LETT, V128, P329, DOI 10.1016/0014-5793(81)80110-X; MCGEE J, 1985, J BIOL CHEM, V260, P2832; MINAMI M, 1990, BIOCHEM BIOPH RES CO, V173, P620, DOI 10.1016/S0006-291X(05)80080-4; MUELLER MJ, 1995, P NATL ACAD SCI USA, V92, P8383, DOI 10.1073/pnas.92.18.8383; Mueller MJ, 1996, P NATL ACAD SCI USA, V93, P5931, DOI 10.1073/pnas.93.12.5931; ORNING L, 1990, J BIOL CHEM, V265, P14911; ORNING L, 1992, J BIOL CHEM, V267, P22733; Stromberg F, 1996, EUR J BIOCHEM, V238, P599, DOI 10.1111/j.1432-1033.1996.0599w.x; WETTERHOLM A, 1992, BIOCHIM BIOPHYS ACTA, V1123, P275, DOI 10.1016/0005-2760(92)90007-I; WETTERHOLM A, 1991, BIOCHIM BIOPHYS ACTA, V1080, P96, DOI 10.1016/0167-4838(91)90134-L; ZHANG YY, 1994, ANAL BIOCHEM, V220, P28, DOI 10.1006/abio.1994.1294	19	29	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24345	24348		10.1074/jbc.271.40.24345	http://dx.doi.org/10.1074/jbc.271.40.24345			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798687	hybrid			2022-12-27	WOS:A1996VM67400009
J	Sun, ZR; Gantt, E; Cunningham, FX				Sun, ZR; Gantt, E; Cunningham, FX			Cloning and functional analysis of the beta-carotene hydroxylase of Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHETIC-PATHWAY; GENE; CONVERSION	An Arabidopsis thaliana cDNA encoding the enzyme beta-carotene hydroxylase was identified by functional complementation in Escherichia coli. The product of this cDNA adds hydroxyl groups to both beta rings of the symmetrical beta-carotene (beta,beta-carotene) to form zeaxanthin (beta,beta-carotene-3,3'-diol) and converts the monocyclic beta-zeacarotene (7',8'-dihydro-beta,psi-carotene) to hydroxy-beta-zeacarotene (7',8'-dihydro-beta,psi-carotene-3-ol). The epsilon rings of delta-carotene (epsilon,psi-carotene) and alpha-zeacarotene (7',8'-dihydro-epsilon,psi-carotene) are poor substrates for the enzyme, The predicted amino acid sequence of the A. thaliana enzyme resembles the four known bacterial beta-carotene hydroxylase enzymes (31-37% identity) but is much longer, with an N-terminal extension of more than 130 amino acids. Truncation of the cDNA to produce a polypeptide lacking the first 69 amino acids does not impair enzyme activity in E. coli. Truncation to yield a polypeptide of a length comparable with the bacterial enzymes (lacking 129 N-terminal amino acids) resulted in the accumulation of the monohydroxy intermediate beta-cryptoxanthin (beta,beta-carotene-3-ol), predominantly, when beta-carotene was provided as the substrate. It is suggested that amino acid residues 70-129 of the A. thaliana enzyme may play a role in formation of a functional homodimer.	UNIV MARYLAND,DEPT PLANT BIOL,COLLEGE PK,MD 20742; UNIV MARYLAND,AGR EXPT STN,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park								BOUVIER F, 1994, PLANT J, V6, P45, DOI 10.1046/j.1365-313X.1994.6010045.x; Britton G, 1990, CAROTENOIDS CHEM BIO, P167; CUNNINGHAM FX, 1994, PLANT CELL, V6, P1107, DOI 10.1105/tpc.6.8.1107; CUNNINGHAM FX, 1996, IN PRESS PLANT CELL; DELSAL G, 1988, NUCLEIC ACIDS RES, V16, P9878; Demmig-Adams B., 1993, CAROTENOIDS PHOTOSYN, P206, DOI [10.1007/978-94-011-2124-8_7, DOI 10.1007/978-94-011-2124-8_7]; GOOD TW, 1980, BIOCH CAROTENOIDS, V1; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; MISAWA N, 1995, BIOCHEM BIOPH RES CO, V209, P867, DOI 10.1006/bbrc.1995.1579; MISAWA N, 1990, J BACTERIOL, V172, P6704, DOI 10.1128/jb.172.12.6704-6712.1990; MISAWA N, 1995, J BACTERIOL, V177, P6575, DOI 10.1128/jb.177.22.6575-6584.1995; PERRY KL, 1986, J BACTERIOL, V168, P607, DOI 10.1128/jb.168.2.607-612.1986; POGSON B, 1996, IN PRESS PLANT CELL; Sambrook J., 2002, MOL CLONING LAB MANU; Weedon B. C. L., 1995, ISOLATION ANAL, V1A, P27	15	187	212	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24349	24352		10.1074/jbc.271.40.24349	http://dx.doi.org/10.1074/jbc.271.40.24349			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798688	hybrid			2022-12-27	WOS:A1996VM67400010
J	Pascolo, E; Toulme, JJ				Pascolo, E; Toulme, JJ			Double hairpin complexes allow accommodation of all four base pairs in triple helices containing both DNA and RNA strands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC RECOGNITION; TRYPANOSOME MESSENGER-RNAS; PARASITE LEISHMANIA-AMAZONENSIS; TETHERED OLIGONUCLEOTIDE PROBES; ANTISENSE OLIGONUCLEOTIDES; IN-VITRO; COOPERATIVE BINDING; MAJOR GROOVE; OLIGODEOXYNUCLEOTIDES; STABILITY	We investigated the binding of an antisense oligodeoxynucleotide to a stem-loop structure corresponding to the mini-exon sequence of the protozoan parasite Leishmania amazonensis. This oligomer was designed to anneal to the single-stranded region adjacent to the bottom of the hairpin and to fold back on itself, giving rise to a ''double-hairpin'' complex that involved a local triplex. This imposed the recognition, by the third strand, of a ''purine'' strand containing 6 interspersed pyrimidines out of 15 nucleic acid bases. The sequence of the complementary oligonucleotide was derived from the so-called pyrimidine motif; the third strand of the anti-mini-exon oligomer was parallel to the purine strand of the target. Electrophoretic mobility shift assays and footprinting studies demonstrated that such an antisense oligomer was able to bind to both the DNA and RNA versions of the Leishmania hairpin. These double hairpin complexes allowed the formation at pH 6.0 of a triple-stranded structure, despite the presence of 4 A:T*G and 2 G:C*T triplets out of 15.	UNIV BORDEAUX 2,INSERM,U386,IFR PATHOL INFECT,F-33076 BORDEAUX,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux				Toulme, Jean-jacques/0000-0002-8432-5034				BAUMANN U, 1988, BIOCHEM BIOPH RES CO, V157, P986, DOI 10.1016/S0006-291X(88)80971-9; BEAL PA, 1992, J AM CHEM SOC, V114, P4976, DOI 10.1021/ja00039a004; BEST GC, 1995, J AM CHEM SOC, V117, P1187, DOI 10.1021/ja00109a001; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BROSSALINA E, 1993, NUCLEIC ACIDS RES, V21, P5616, DOI 10.1093/nar/21.24.5616; BROSSALINA E, 1993, J AM CHEM SOC, V115, P796, DOI 10.1021/ja00055a065; BROSSALINA E, IN PRESS NUCLEIC ACI; CASSIDY SA, 1994, BIOCHEMISTRY-US, V33, P15338, DOI 10.1021/bi00255a015; CHOMILIER J, 1992, BIOPHYS CHEM, V45, P143, DOI 10.1016/0301-4622(92)87006-5; CLOAD ST, 1991, J AM CHEM SOC, V113, P6324, DOI 10.1021/ja00016a089; CLOAD ST, 1994, J AM CHEM SOC, V116, P437, DOI 10.1021/ja00081a002; CORNELISSEN AWCA, 1986, NUCLEIC ACIDS RES, V14, P5605, DOI 10.1093/nar/14.14.5605; CROUCH R J, 1990, New Biologist, V2, P771; DISTEFANO MD, 1991, J AM CHEM SOC, V113, P5901, DOI 10.1021/ja00015a076; ECKER DJ, 1992, SCIENCE, V257, P958, DOI 10.1126/science.1502560; EDER PS, 1991, J BIOL CHEM, V266, P6472; ESCUDE C, 1993, NUCLEIC ACIDS RES, V21, P5547, DOI 10.1093/nar/21.24.5547; FRANCOIS JC, 1988, NUCLEIC ACIDS RES, V16, P11431, DOI 10.1093/nar/16.24.11431; FROEHLER BC, 1992, BIOCHEMISTRY-US, V31, P1603, DOI 10.1021/bi00121a004; GIOVANNANGELI C, 1991, J AM CHEM SOC, V113, P7775, DOI 10.1021/ja00020a058; GIOVANNANGELI C, 1992, P NATL ACAD SCI USA, V89, P8631, DOI 10.1073/pnas.89.18.8631; GRIFFIN LC, 1989, SCIENCE, V245, P967, DOI 10.1126/science.2549639; HAN HY, 1993, P NATL ACAD SCI USA, V90, P3806, DOI 10.1073/pnas.90.9.3806; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HUANG L, 1994, J BIOL CHEM, V269, P25922; KOH JS, 1992, J AM CHEM SOC, V114, P1470, DOI 10.1021/ja00030a050; MERGNY JL, 1992, SCIENCE, V256, P1681, DOI 10.1126/science.256.5064.1681; MERGNY JL, 1991, BIOCHEMISTRY-US, V30, P9791, DOI 10.1021/bi00104a031; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MISHRA RK, 1994, CR ACAD SCI III-VIE, V317, P977; MISHRA RK, 1995, BBA-GENE STRUCT EXPR, V1264, P229, DOI 10.1016/0167-4781(95)00145-7; MISHRA RK, 1996, IN PRESS P NTL ACAD; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; MOUSCADET JF, 1994, BIOCHEMISTRY-US, V33, P4187, DOI 10.1021/bi00180a011; PASCOLO E, 1993, BIOCHIMIE, V75, P43, DOI 10.1016/0300-9084(93)90023-L; PASCOLO E, 1994, BBA-GENE STRUCT EXPR, V1219, P98, DOI 10.1016/0167-4781(94)90251-8; PILCH DS, 1994, P NATL ACAD SCI USA, V91, P9332, DOI 10.1073/pnas.91.20.9332; RAMAZEILLES C, 1994, P NATL ACAD SCI USA, V91, P7859, DOI 10.1073/pnas.91.17.7859; RICHARDSON PL, 1991, J AM CHEM SOC, V113, P5109, DOI 10.1021/ja00013a083; ROBERTS RW, 1992, SCIENCE, V258, P1463, DOI 10.1126/science.1279808; SEMERAD CL, 1994, NUCLEIC ACIDS RES, V22, P5321, DOI 10.1093/nar/22.24.5321; SONG CZ, 1994, P NATL ACAD SCI USA, V91, P9357, DOI 10.1073/pnas.91.20.9357; SUN JS, 1989, P NATL ACAD SCI USA, V86, P9198, DOI 10.1073/pnas.86.23.9198; SUN JS, 1991, P NATL ACAD SCI USA, V88, P6023, DOI 10.1073/pnas.88.14.6023; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; TOULME JJ, 1996, RIBONUCLEASES; VERSPIEREN P, 1987, GENE, V61, P307, DOI 10.1016/0378-1119(87)90194-6; VERSPIEREN P, 1990, NUCLEIC ACIDS RES, V18, P4711, DOI 10.1093/nar/18.16.4711; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; WALDER JA, 1986, SCIENCE, V233, P569, DOI 10.1126/science.3523758; WANG SH, 1994, J AM CHEM SOC, V116, P8857, DOI 10.1021/ja00098a075; XODO LE, 1991, NUCLEIC ACIDS RES, V19, P5625, DOI 10.1093/nar/19.20.5625; YOON K, 1992, P NATL ACAD SCI USA, V89, P3840, DOI 10.1073/pnas.89.9.3840	53	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24187	24192		10.1074/jbc.271.39.24187	http://dx.doi.org/10.1074/jbc.271.39.24187			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798660	hybrid			2022-12-27	WOS:A1996VJ44200089
J	Pastuszak, I; ODonnell, J; Elbein, AD				Pastuszak, I; ODonnell, J; Elbein, AD			Identification of the GalNAc kinase amino acid sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GALACTOKINASE	A new kinase that forms GalNAc-1-P was purified from pig kidney cytosol and identified on gels by labeling with N-3-[P-32]ATP (Pastuszak, I., Drake, R., and Elbein, A. D. (1996) J. Biol. Chem. 271, in press). A 50-kDa labeled protein was eluted, digested with trypsin, and the sequences of four peptides representing 49 amino acids showed 90% identity to sequence of human galactokinase reported to be on chromosome 15. To resolve this dilema, activities and substrate specificities of galactokinase and GalNAc kinase from human and pig kidney, as well as of galactokinase from the yeast clone transfected with the cDNA from presumptive human galactokinase, were compared, The purified galactokinases phosphorylated galactose, but not GalNAc, whereas GalNAc kinase also phosphorylated galatose when this sugar was present at millimolar concentrations. Extracts of gal 1(-) yeast clone, transfected with presumptive human galactokinase cDNA, had very low galactokinase activity even when yeast were grown on galactose, but good activity with GalNAc. On the other hand, the wild type yeast phosphorylated galactose, but not GalNAc. These data indicate that the sequence reported for galactokinase on chromosome 15 is that of GalNAc kinase, which can phosphorylate galactose when this sugar is present at millimolar concentrations, This transfection thus allows the yeast mutant to grow slowly on galactose-containing media.	UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOL BIOL,LITTLE ROCK,AR 72205; UNIV CALIF SAN FRANCISCO,DEPT OPHTHAMOL,SCH MED,SAN FRANCISCO,CA 94143	University of Arkansas System; University of Arkansas Medical Sciences; University of California System; University of California San Francisco					NHLBI NIH HHS [HL-17783] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017783] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AXELROD B, 1967, METABOLIC PATHWAYS, V1, P272; BLUME KG, 1971, J BIOL CHEM, V246, P6507; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P113; GITZELMANN R, 1965, LANCET, V2, P670; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; ISSELBACHER KJ, 1956, SCIENCE, V123, P635, DOI 10.1126/science.123.3198.635; KALCKAR HM, 1958, PHYSIOL REV, V38, P77, DOI 10.1152/physrev.1958.38.1.77; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LEE RT, 1992, P NATL ACAD SCI USA, V89, P10887, DOI 10.1073/pnas.89.22.10887; NEUFELD EF, 1961, BIOCHIM BIOPHYS ACTA, V53, P589, DOI 10.1016/0006-3002(61)90223-2; PASTUSZAK I, 1996, IN PRESS J BIOL CHEM, V271; PILLER F, 1983, J BIOL CHEM, V258, P774; STAMBOLIAN D, 1985, BIOCHIM BIOPHYS ACTA, V831, P306, DOI 10.1016/0167-4838(85)90112-8; Szumilo T, 1996, J BIOL CHEM, V271, P13147, DOI 10.1074/jbc.271.22.13147	14	16	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23653	23656		10.1074/jbc.271.39.23653	http://dx.doi.org/10.1074/jbc.271.39.23653			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798585	hybrid			2022-12-27	WOS:A1996VJ44200014
J	Taylor, KB; Windsor, LJ; Caterina, NCM; Bodden, MK; Engler, JA				Taylor, KB; Windsor, LJ; Caterina, NCM; Bodden, MK; Engler, JA			The mechanism of inhibition of collagenase by TIMP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT-BINDING INHIBITION; C-TERMINAL DOMAIN; TISSUE INHIBITOR; MATRIX METALLOPROTEINASES; KINETIC-ANALYSIS; FACTOR-XA; FIBROBLAST COLLAGENASE; GELATINASE-A; SLOW-BINDING; PROTEINASES	Tissue inhibitor of metalloproteinase-I (TIMP-1) is a slow, tight-binding inhibitor of fibroblast-type collagenase. Time-course data from inhibition experiments were analyzed by graphic analysis, by nonlinear regression of the analytic integrals of the rate equations and by nonlinear regression with numeric integration of the rate equations, With the same assumptions, approximations and data, all three methods of analysis produced the same model preferences and values for the kinetic parameters. The time course data for the inhibition of fibroblast-type collagenase by TIMP-1 are best described by the equations for a noncompetitive two-step mechanism, in which an inactive, rapidly formed, reversible complex slowly forms an inactive, tight complex. However, from the analysis of data from experiments at concentrations of TIMP-1 comparable to that of collagenase, it is apparent that free TIMP-1 also functions in the breakdown of the tight complex, The rapidly formed complex has a dissociation constant of 8 nM and reacts to the tight complex with a first-order rate constant of 0.003 s(-1). The back reaction of the tight complex to the rapid complex has a second-order rate constant of 5 x 10(4) M(-1) s(-1). The resulting global dissociation constant of the tight complex is 0.1 nM at 3 nM TIMP-1 and collagenase concentration. Collagenase without the carboxyl-terminal domain (mini-collagenase) is inhibited by TIMP-1 according to a mechanism, in which the rapidly formed complex has such a high dissociation constant (247 nM) that it effectively constitutes a one-step mechanism, in which TIMP-1 binds with an apparent second-order rate constant of 9.6 x 10(4) mol(-1) s(-1) and the enzyme-TIMP-1 complex dissociates with a first order rate constant of 0.00026 s(-1). The apparent global dissociation constant for the tight complex (2.7 nM) is higher than that for the fibroblast-type collagenase, Participation of TIMP-1 in the dissociation is not demonstrable, Therefore, the carboxyl-terminal domain of fibroblast type collagenase is important for the initial, rapid binding of TIMP-1 and the initial complex contributes to the overall binding.	UNIV ALABAMA,DEPT ORAL BIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT RESTORAT DENT,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH MED,ORAL BIOL RES CTR,BIRMINGHAM,AL 35294; UNIV ALABAMA,SCH DENT,ORAL BIOL RES CTR,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Taylor, KB (corresponding author), UNIV ALABAMA,DEPT BIOCHEM & MOL GENET,CH-19,RM 509,UNIV STN,BIRMINGHAM,AL 35294, USA.				NIDCR NIH HHS [DE08228, DE10631, DE00283] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010631, P50DE008228] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akaike H., 1976, MATH SCI, V14, P5; BAKKER AV, 1990, BIOCHEM J, V271, P559, DOI 10.1042/bj2710559; BARAGI VM, 1994, J BIOL CHEM, V269, P12692; BIGG HF, 1994, BBA-PROTEIN STRUCT M, V1208, P157, DOI 10.1016/0167-4838(94)90173-2; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODDEN MK, 1994, J BIOL CHEM, V269, P18943; BYRNE G, 1976, UCID30132 LAWR LIV N; CHANDLER JP, 1972, COMPUT BIOMED RES, V5, P515, DOI 10.1016/0010-4809(72)90058-4; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; EMONARD H, 1990, CELL MOL BIOL, V36, P131; GUTHEIL WG, 1993, BIOCHEMISTRY-US, V32, P8723, DOI 10.1021/bi00085a001; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; HUANG ZF, 1993, J BIOL CHEM, V268, P26950; JORDAN SP, 1990, BIOCHEMISTRY-US, V29, P11095, DOI 10.1021/bi00502a012; KLEINER DE, 1992, BIOCHEMISTRY-US, V31, P1665, DOI 10.1021/bi00121a013; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIOTTA LA, 1989, J NATL CANCER I, V81, P556, DOI 10.1093/jnci/81.8.556; MERCER E, 1985, BIOCHEM J, V231, P505, DOI 10.1042/bj2310505; *MICR SCI SOFTW, 1993, SCI HDB, P207; MORGENSTERN KA, 1994, BIOCHEMISTRY-US, V33, P3432, DOI 10.1021/bi00177a037; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; MURPHY G, 1989, BIOCHEM J, V261, P1031, DOI 10.1042/bj2611031; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; WALEY SG, 1993, BIOCHEM J, V294, P195, DOI 10.1042/bj2940195; WELGUS HG, 1985, COLLAGEN REL RES, V5, P167; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Williams J W, 1979, Methods Enzymol, V63, P437; WINDSOR LJ, 1994, J BIOL CHEM, V269, P26201; WINDSOR LJ, 1996, IN PRESS BIOCH BIOPH; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	37	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23938	23945		10.1074/jbc.271.39.23938	http://dx.doi.org/10.1074/jbc.271.39.23938			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798626				2022-12-27	WOS:A1996VJ44200055
J	Fujisawa, K; Fujita, A; Ishizaki, T; Saito, Y; Narumiya, S				Fujisawa, K; Fujita, A; Ishizaki, T; Saito, Y; Narumiya, S			Identification of the Rho-binding domain of p160(ROCK), a Rho-associated coiled-coil containing protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; ADRENERGIC-RECEPTOR KINASE; ACTIN STRESS FIBERS; ADP-RIBOSYLATION; RAS TRANSFORMATION; ACTIVATION; GTPASE; INHIBITION; RAC1; G(BETA-GAMMA)	A protein serine/threonine kinase, p160(ROCK), has been identified as a putative Rho target protein that is activated when bound to the GTP-bound form of the small GTPase Rho (Ishizaki, T., Maekawa, M., Fujisawa, K., Okawa, K., Iwamatu, A., Fujita, A., Watanabe, N. Saito, Y., Kakizuka, A., Morii, N., and Narumiya, S. (1996) EMBO J. 15, 1885-1893). p160(ROCK) has a serine/threonine kinase domain in its NH2-terminal region, followed by an approximately 600-amino acid-long alpha-helix, a cysteine-rich zinc finger-like motif, and a pleckstrin homology region in the COOH terminus. To identify the Rho binding domain of this protein, we divided p160 into five fragments, expressed each as a His-tagged recombinant protein, and performed a ligand overlay assay using [S-35]guanosine-5'-3-O-(thio)triphosphate (GTP gamma S)-bound glutathione S-transferase-RhoA. Specific GTP gamma S-Rho binding was observed only in the fragment M2, which covered most of the carboxyl half of the a helix between amino acids 727 and 1021. This fragment was further subdivided into several fragments, and the ligand overlay assay as well as the yeast two hybrid system was carried out to identify the Rho binding region. These studies localized the minimum Rho binding region to amino acids 934-1015. To identify critical amino acids for Rho binding, we analyzed the Rho binding activity of the subfragment with various point mutations. This analysis revealed that K934M, L941A, and E1008A mutations significantly weakened Rho binding and an I1009A mutation abolished Rho binding. The amino acid sequence in this region had no significant homology with Rho effector motif class 1, which is shared by putative Rho targets, PKN, rhophilin, and rhotekin, (Held, T., Furuyashiki, T., Ishizaki, T., Watanabe, G., Watanabe, N., Fujisawa, K., Morii, N., Madaule, P., and Narumiya, S. (1996) J. Biol. Chem. 271, 13556-13560) and may define a distinct class of Rho effector motif.	KYOTO UNIV, FAC MED, DEPT PHARMACOL, SAKYO KU, KYOTO 606, JAPAN	Kyoto University								DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATA K, 1992, J BIOL CHEM, V267, P8719; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MORII N, 1993, J BIOL CHEM, V268, P27160; MORII N, 1992, J BIOL CHEM, V267, P20921; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	29	114	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23022	23028		10.1074/jbc.271.38.23022	http://dx.doi.org/10.1074/jbc.271.38.23022			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798490				2022-12-27	WOS:A1996VH76800016
J	Izbicka, E; Yoneda, T; Takaoka, Y; Horn, D; Williams, P; Mundy, GR				Izbicka, E; Yoneda, T; Takaoka, Y; Horn, D; Williams, P; Mundy, GR			Identification of a novel bone/calcium metabolism-regulating factor in porcine pancreas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-ALPHA; BONE-RESORPTION; OSTEOCLAST FORMATION; NUDE-MICE; HYPERCALCEMIA; ELASTASE; PROGRESSION; EXPRESSION; CARCINOMA; CACHEXIA	We purified from porcine pancreas a hypocalcemic peptide clearly distinguishable from other pancreatic osteotropic factors such as amylin, calcitonin, and glucagon, Porcine pancreas was processed by acetone extraction, anion exchange chromatography, isoelectric focusing, and reverse-phase high performance liquid chromatography. Fractions were assayed for their inhibitory effects on bone resorption in vitro. Amino acid sequence of a homogeneous 28-kDa protein revealed 92% homology to a human elastase IIIB in the N terminus, Recombinant human elastase IIIB (rhEIIIB) inhibited bone resorption in organ culture stimulated by 1,25-dihydroxyvitamin D-3 at concentrations as low as 75 ng/ml. Antibodies to rhEIIIB recognized purified pancreatic factor in Western blots and blocked its inhibitory effect on bone resorption. This antiresorptive activity was abolished by phenylmethylsulfonyl fluoride, suggesting the importance of elastase proteolytic activity for inhibition of bone resorption, In vivo, rhEIIIB and purified pancreatic factor significantly decreased recombinant human interleukin-1 alpha-induced hypercalcemia. In conclusion, a novel naturally occurring inhibitor of bone resorption and calcium-lowering peptide has been identified in porcine pancreas, Because this pancreatic peptide has systemic effects on bone resorption and blood ionized calcium at low concentrations, it may represent a physiological regulator of normal bone remodeling and calcium homeostasis.			Izbicka, E (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT MED,DIV ENDOCRINOL & METAB,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NCI NIH HHS [CA40035] Funding Source: Medline; NIAMS NIH HHS [AR07464] Funding Source: Medline; NIDCR NIH HHS [DE08569] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE008569] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALAM ASMT, 1993, EXP PHYSIOL, V78, P183, DOI 10.1113/expphysiol.1993.sp003679; BOYCE BF, 1989, ENDOCRINOLOGY, V125, P1142, DOI 10.1210/endo-125-3-1142; BOYDE A, 1984, BRIT DENT J, V156, P216, DOI 10.1038/sj.bdj.4805313; CAPPELLUTI E, 1993, BIOCHEMISTRY-US, V32, P551, DOI 10.1021/bi00053a021; FRIEDMAN J, 1968, ENDOCRINOLOGY, V82, P149, DOI 10.1210/endo-82-1-149; FUJII K, 1993, EXP CELL RES, V208, P94, DOI 10.1006/excr.1993.1226; GOZARIU L, 1971, HORM METAB RES, V3, P225, DOI 10.1055/s-0028-1096778; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MUNDY GR, 1990, CALCIUM HOMEOSTASIS, P196; RAISZ LG, 1965, J CLIN INVEST, V44, P103, DOI 10.1172/JCI105117; RATCLIFFE WA, 1994, CLIN ENDOCRINOL, V40, P679, DOI 10.1111/j.1365-2265.1994.tb03021.x; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; TAKAOKA Y, 1969, ACTA MED NAGASAKI, V13, P28; TANI T, 1988, J BIOL CHEM, V263, P1231; Tomomura A, 1995, J BIOL CHEM, V270, P30315, DOI 10.1074/jbc.270.51.30315; TOMOMURA A, 1992, FEBS LETT, V301, P277, DOI 10.1016/0014-5793(92)80256-G; WIJNGAERT FB, 1986, J HISTOL CYTOL, V34, P1317; YONEDA T, 1993, J CLIN INVEST, V91, P2791, DOI 10.1172/JCI116521; YONEDA T, 1993, MOL ENDOCRINOL, V7, P1313, DOI 10.1210/me.7.10.1313; YONEDA T, 1991, FEBS LETT, V278, P171, DOI 10.1016/0014-5793(91)80109-G; YONEDA T, 1994, CANCER RES, V54, P2509; YONEDA T, 1991, J CLIN ONCOL, V9, P468, DOI 10.1200/JCO.1991.9.3.468; ZHU L, 1994, J CLIN INVEST, V94, P1163, DOI 10.1172/JCI117432	23	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23230	23234		10.1074/jbc.271.38.23230	http://dx.doi.org/10.1074/jbc.271.38.23230			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798519	hybrid			2022-12-27	WOS:A1996VH76800045
J	Katzmann, DJ; Hallstrom, TC; Mahe, Y; MoyeRowley, WS				Katzmann, DJ; Hallstrom, TC; Mahe, Y; MoyeRowley, WS			Multiple Pdr1p/Pdr3p binding sites are essential for normal expression of the ATP binding cassette transporter protein-encoding gene PDR5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE-ASSOCIATED PROTEIN; YEAST MULTIDRUG-RESISTANCE; SACCHAROMYCES-CEREVISIAE; DRUG-RESISTANCE; DEPENDENT TRANSPORT; PLEIOTROPIC DRUG; CELLS; OVEREXPRESSION; HOMOLOGY; PRODUCT	Saccharomyces cerevisiae has large number of genes that can be genetically altered to produce a multiple or pleiotropic drug resistance phenotype. The homologous zinc finger transcription factors Pdr1p and Pdr3p both elevate resistance to many drugs, including cycloheximide, This elevation in cycloheximide tolerance only occurs in the presence of an intact copy of the PDR5 gene that encodes a plasma membrane-localized ATP binding cassette transporter protein. Previously, we have found that a single binding site for Pdr3p present in the PDR5 promoter is sufficient to provide Pdr3p-responsive gene expression. In this study, we have found that there are three sites in the PDR5 5'-noncoding region that are closely related to one another and are bound by both Pdr1p and Pdr3p, These elements have been designated Pdr1p/Pdr3p response elements (PDREs), and their role in the maintenance of normal PDR5 expression has been analyzed, Mutations have been constructed in each PDRE and shown to eliminate Pdr1p/Pdr3p binding in vitro. Analysis of the effect of these mutant PDREs on normal PDR5 promoter function indicates that each element is required for wild-type expression and drug resistance. A single PDRE placed upstream of a yeast gene lacking its normal upstream activation sequence is sufficient to confer Pdr1p responsiveness to this heterologous promoter.	UNIV IOWA, PROGRAM MOL BIOL, IOWA CITY, IA 52242 USA; UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, B-1348 LOUVAIN, BELGIUM	University of Iowa; University of Iowa; Universite Catholique Louvain			Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120	NIGMS NIH HHS [GM49825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P2206; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; DEXTER D, 1994, GENETICS, V136, P505; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; LEONARD PJ, 1994, ANTIMICROB AGENTS CH, V38, P2492, DOI 10.1128/AAC.38.10.2492; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; SHATZMAN AR, 1987, METHOD ENZYMOL, V152, P661; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; WU AL, 1993, J BIOL CHEM, V268, P18850	32	109	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23049	23054		10.1074/jbc.271.38.23049	http://dx.doi.org/10.1074/jbc.271.38.23049			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798494	hybrid			2022-12-27	WOS:A1996VH76800020
J	Roseman, NA; Evans, RK; Mayer, EL; Rossi, MA; Slabaugh, MB				Roseman, NA; Evans, RK; Mayer, EL; Rossi, MA; Slabaugh, MB			Purification and characterization of the vaccinia virus deoxyuridine triphosphatase expressed in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DUTP PYROPHOSPHATASE; URACIL DNA GLYCOSYLASE; SACCHAROMYCES-CEREVISIAE; RNA-POLYMERASE; GENE; REPLICATION; ENCODES; ENZYME; MUTANT; CELLS	The deoxyuridine triphosphatase gene of vaccinia vi rus, encoded by the open reading frame F2L, was cloned into Escherichia coli and expressed under the control of a bacteriophage T7 promoter. After induction of T7 RNA polymerase by isopropyl beta-D-thiogalactopyranoside, a 16.5-kDa peptide accumulated to high levels. This 16.5-kDa protein was purified to homogeneity and characterized. Gel filtration of the purified protein revealed a trimeric native structure. Biochemical analysis revealed the enzyme to be a metalloenzyme; enzymatic activity is inhibited by EDTA. This inhibition was reversed by the addition of Mg2+, Mn2+, or Zn2+. While the enzyme activity was highly specific for dUTP with an apparent K-m of 0.94 mu m, inhibition studies show that 8-azido-ATP acted as a competitive inhibitor of dUTP with a K-i of approximately 173 mu m. Also, protection studies demonstrated that nucleotide competitors inhibit photoincorporation of the photoaffinity analogues [gamma-P-32]5-azido-dUTP and [gamma-P-32]8-azido-ATP. This suggests that while catalytic activity is limited to dUTP, other nucleotides can bind the active site.	WILLIAMS COLL, DEPT CHEM, WILLIAMSTOWN, MA 01267 USA; OREGON STATE UNIV, DEPT BIOCHEM & BIOPHYS, CORVALLIS, OR 97331 USA	Williams College; Oregon State University	Roseman, NA (corresponding author), WILLIAMS COLL, DEPT BIOL, WILLIAMSTOWN, MA 01267 USA.				PHS HHS [A124294] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BROYLES SS, 1993, VIROLOGY, V195, P863, DOI 10.1006/viro.1993.1446; CANMAN CE, 1993, CANCER RES, V53, P5219; CEDERGRENZEPPEZAUER ES, 1992, NATURE, V355, P740, DOI 10.1038/355740a0; CLIMIE S, 1994, PROTEIN EXPRES PURIF, V5, P252, DOI 10.1006/prep.1994.1038; CURTIN NJ, 1991, CANCER RES, V51, P2346; DUNCAN BK, 1981, ENZYMES, V1, P565; ELDER JH, 1992, J VIROL, V66, P1791, DOI 10.1128/JVI.66.3.1791-1794.1992; ELHAJJ HH, 1988, J BACTERIOL, V170, P1069, DOI 10.1128/jb.170.3.1069-1075.1988; EVANS RK, 1987, BIOCHEMISTRY-US, V26, P269, DOI 10.1021/bi00375a037; GADSDEN MH, 1993, EMBO J, V12, P4425, DOI 10.1002/j.1460-2075.1993.tb06127.x; GIROIR IE, 1987, J BIOL CHEM, V262, P130; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; HOKARI S, 1987, ARCH BIOCHEM BIOPHYS, V253, P350, DOI 10.1016/0003-9861(87)90188-3; HRUBY DE, 1982, J VIROL, V43, P403, DOI 10.1128/JVI.43.2.403-409.1982; HUGHES SJ, 1991, J BIOL CHEM, V266, P20103; KOPPE B, 1994, J VIROL, V68, P2313; Kornberg A., 1991, DNA REPLICATION; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LERNER DL, 1995, P NATL ACAD SCI USA, V92, P7480, DOI 10.1073/pnas.92.16.7480; LICHTENSTEIN DL, 1995, J VIROL, V69, P2881, DOI 10.1128/JVI.69.5.2881-2888.1995; LIRETTE R, 1990, J CELL BIOCHEM, V43, P339, DOI 10.1002/jcb.240430406; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; MCINTOSH EM, 1992, P NATL ACAD SCI USA, V89, P8020, DOI 10.1073/pnas.89.17.8020; MCINTOSH EM, 1994, CURR GENET, V26, P415, DOI 10.1007/BF00309928; MILLNS AK, 1994, VIROLOGY, V198, P504, DOI 10.1006/viro.1994.1061; MOSS B, 1996, VIROLOGY, P2637; NATION MD, 1989, BIOCHEM J, V259, P593, DOI 10.1042/bj2590593; PARDO EG, 1990, EXP CELL RES, V186, P90, DOI 10.1016/0014-4827(90)90214-U; PERKUS ME, 1991, VIROLOGY, V180, P406, DOI 10.1016/0042-6822(91)90047-F; PRIHADASH A, 1992, PLANT CELL, V4, P149, DOI 10.1105/tpc.4.2.149; SLABAUGH MB, 1989, P NATL ACAD SCI USA, V86, P4152, DOI 10.1073/pnas.86.11.4152; SLABAUGH MB, 1984, J VIROL, V52, P507, DOI 10.1128/JVI.52.2.507-514.1984; STEAGALL WK, 1995, VIROLOGY, V210, P302, DOI 10.1006/viro.1995.1347; STRAHLER JR, 1993, P NATL ACAD SCI USA, V90, P4991, DOI 10.1073/pnas.90.11.4991; STUART DT, 1993, J VIROL, V67, P2503, DOI 10.1128/JVI.67.5.2503-2512.1993; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THREADGILL DS, 1993, J VIROL, V67, P2592, DOI 10.1128/JVI.67.5.2592-2600.1993; TRAKTMAN P, 1990, CURR TOP MICROBIOL, V163, P93; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; WAGAMAN PC, 1993, VIROLOGY, V196, P451, DOI 10.1006/viro.1993.1501; WARNER HR, 1978, NATURE, V272, P32, DOI 10.1038/272032a0; WILLIAMS MV, 1979, J BIOL CHEM, V254, P2897; WOHLRAB F, 1980, P NATL ACAD SCI-BIOL, V77, P1872, DOI 10.1073/pnas.77.4.1872; ZALUD P, 1995, PURINE PYRIMIDINE ME, V7, P135	45	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23506	23511		10.1074/jbc.271.38.23506	http://dx.doi.org/10.1074/jbc.271.38.23506			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798559	hybrid			2022-12-27	WOS:A1996VH76800085
J	Yamada, H; Denzer, AJ; Hori, H; Tanaka, T; Anderson, LVB; Fujita, S; FukutaOhi, H; Shimizu, T; Ruegg, MA; Matsumura, K				Yamada, H; Denzer, AJ; Hori, H; Tanaka, T; Anderson, LVB; Fujita, S; FukutaOhi, H; Shimizu, T; Ruegg, MA; Matsumura, K			Dystroglycan is a dual receptor for agrin and laminin-2 in Schwann cell membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-ASSOCIATED GLYCOPROTEINS; CONGENITAL MUSCULAR-DYSTROPHY; PERIPHERAL-NERVE; EXTRACELLULAR-MATRIX; CHAIN GENE; COMPLEX; BINDING; MEROSIN; IDENTIFICATION; EXPRESSION	We have shown previously that alpha-dystroglycan with a molecular mass of 120 kDa is a Schwann cell receptor of laminin-2, the endoneurial isoform of laminin comprised of the alpha 2, beta 1, and gamma 1 chains. In this paper, we show that Schwann cell alpha-dystroglycan is also a receptor of agrin, an acetylcholine receptor aggregating molecule having partial homology to laminin alpha chains in the C terminus. Immunochemical analysis demonstrates that the peripheral nerve isoform of agrin is a 400-kDa component of the endoneurial basal lamina and is colocalized with alpha-dystroglycan surrounding the outermost layer of myelin sheath of peripheral nerve fibers. Blot overlay analysis demonstrates that both endogenous peripheral nerve agrin and laminin-2 bind to Schwann cell alpha-dystroglycan. Recombinant C-terminal fragment of the peripheral nerve isoform of agrin also binds to Schwann cell alpha-dystroglycan, confirming that the binding site for Schwann cell alpha-dystroglycan resides in the C terminus of agrin molecule. Furthermore, the binding of recombinant agrin C-terminal fragment to Schwann cell alpha-dystroglycan competes with that of laminin-2. All together, these results indicate that alpha-dystroglycan is a dual receptor for agrin and laminin-2 in the Schwann cell membrane.	TEIKYO UNIV, SCH MED, DEPT NEUROL & NEUROSCI, TOKYO 173, JAPAN; UNIV BASEL, BIOZENTRUM, DEPT PHARMACOL, CH-4056 BASEL, SWITZERLAND; TOKYO MED & DENT UNIV, MED RES INST, DEPT TISSUE PHYSIOL, TOKYO 101, JAPAN; SAITAMA RED CROSS, CTR BLOOD, YONO, SAITAMA 338, JAPAN; UNIV NEWCASTLE UPON TYNE, SCH NEUROSCI, NEWCASTLE UPON TYNE NE4 6BE, TYNE & WEAR, ENGLAND; NEWCASTLE GEN HOSP, REG NEUROSCI CTR, MUSCULAR DYSTROPHY GRP LABS, NEWCASTLE UPON TYNE NE4 6BE, TYNE & WEAR, ENGLAND	Teikyo University; University of Basel; Tokyo Medical & Dental University (TMDU); Newcastle University - UK; Newcastle General Hospital			Ruegg, Markus/X-7256-2019	Ruegg, Markus/0000-0002-4974-9384				ARAHATA K, 1993, P JPN ACAD B-PHYS, V69, P259, DOI 10.2183/pjab.69.259; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BRADLEY WG, 1973, J NEUROL SCI, V18, P227, DOI 10.1016/0022-510X(73)90009-9; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CULLEN MJ, 1994, ACTA NEUROPATHOL, V87, P349; DENZER AJ, 1995, J CELL BIOL, V131, P1547, DOI 10.1083/jcb.131.6.1547; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FALLON JR, 1994, TRENDS NEUROSCI, V17, P469, DOI 10.1016/0166-2236(94)90135-X; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GEE SH, 1993, J BIOL CHEM, V268, P14972; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; Hopf C, 1996, J BIOL CHEM, V271, P5231; HORI H, 1994, J BIOCHEM-TOKYO, V116, P1212, DOI 10.1093/oxfordjournals.jbchem.a124666; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; MADRID RE, 1975, NATURE, V257, P319, DOI 10.1038/257319a0; MATSUMURA K, 1993, FEBS LETT, V334, P281, DOI 10.1016/0014-5793(93)80695-Q; REIST NE, 1987, J CELL BIOL, V105, P2457, DOI 10.1083/jcb.105.6.2457; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; SUNADA Y, 1995, HUM MOL GENET, V4, P1055, DOI 10.1093/hmg/4.6.1055; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711	37	96	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23418	23423		10.1074/jbc.271.38.23418	http://dx.doi.org/10.1074/jbc.271.38.23418			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798547				2022-12-27	WOS:A1996VH76800073
J	Yano, S; Fukunaga, K; Takiguchi, M; Ushio, Y; Mori, M; Miyamoto, E				Yano, S; Fukunaga, K; Takiguchi, M; Ushio, Y; Mori, M; Miyamoto, E			Regulation of CCAAT/enhancer-binding protein family members by stimulation of glutamate receptors in cultured rat cortical astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENES; TRANSCRIPTIONAL ACTIVATOR PROTEIN; GROWTH-FACTOR EXPRESSION; LEUCINE ZIPPER PROTEINS; LONG-TERM POTENTIATION; ACUTE-PHASE RESPONSE; 3 C/EBP ISOFORMS; KINASE-II; C-FOS; HIPPOCAMPAL-NEURONS	Regulation of mRNA levels, DNA binding activities, and phosphorylation of CCAAT/enhancer-binding protein (C/EBP) family members by stimulation of glutamate receptors were studied in cultured rat cortical astrocytes. Indirect immunofluorescence and immunoblot analyses with specific antibodies to C/EBP family members revealed that both C/EBP beta and C/EBP delta but not C/EBP alpha are expressed in the nuclei of astrocytes. After exposure to glutamate, C/EBP beta mRNA levels increased within 10 min, reached the maximal level at about 1 h, and returned to the basal level within 6 h, In contrast, C/EBP delta mRNA levels decreased by 6 h and were recovered within 12 h, These changes in mRNA levels were accompanied by an increase and a decrease in proteins for C/EBP beta and C/EBP delta, respectively. Elevation of C/EBP beta mRNA levels by glutamate treatment required an increase in intracellular Ca2+ concentration and depended on activations of protein kinase C and calmodulin-dependent protein kinases. Gel mobility shift analysis using nuclear extracts from the glutamate-treated cells showed increases in C/EBP site binding activities 2 h after the exposure to glutamate, Moreover, glutamate stimulated phosphorylation of C/EBP beta in P-32-labeled astrocytes in a Ca2+-dependent manner. These results suggest that glutamate regulates functions of C/EBP family members in brain astrocytes through changes in mRNA levels of C/EBP beta and C/EBP delta as well as through phosphorylation of C/EBP beta.	KUMAMOTO UNIV, SCH MED, DEPT PHARMACOL, KUMAMOTO 860, JAPAN; KUMAMOTO UNIV, SCH MED, DEPT NEUROSURG, KUMAMOTO 860, JAPAN; KUMAMOTO UNIV, SCH MED, DEPT MOL GENET, KUMAMOTO 860, JAPAN	Kumamoto University; Kumamoto University; Kumamoto University								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; AN G, 1992, BIOCHEM BIOPH RES CO, V188, P1104, DOI 10.1016/0006-291X(92)91345-Q; ARAUJO DM, 1992, J NEUROSCI, V12, P1668; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BRADFORD MM, 1976, ANAL CHEM, V226, P203; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; CONDORELLI DF, 1993, J NEUROCHEM, V60, P877, DOI 10.1111/j.1471-4159.1993.tb03232.x; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; FUKUNAGA K, 1992, J BIOL CHEM, V267, P22527; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; FUKUNAGA K, 1990, Molecular and Cellular Neuroscience, V1, P133; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; IMAGAWA M, 1991, BIOCHEM BIOPH RES CO, V179, P293, DOI 10.1016/0006-291X(91)91368-M; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KAPILOFF MS, 1991, P NATL ACAD SCI USA, V88, P3710, DOI 10.1073/pnas.88.9.3710; KIESSLING M, 1993, J CEREBR BLOOD F MET, V13, P914, DOI 10.1038/jcbfm.1993.114; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; LADENHEIM RG, 1993, J NEUROCHEM, V60, P260, DOI 10.1111/j.1471-4159.1993.tb05846.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; METZ R, 1991, ONCOGENE, V6, P2165; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NISHIYORI A, 1994, J BIOL CHEM, V269, P1323; NISHIZAWA M, 1991, FEBS LETT, V282, P95, DOI 10.1016/0014-5793(91)80452-9; Osada S, 1996, J BIOL CHEM, V271, P3891; PECHAN PA, 1993, NEUROSCI LETT, V153, P111, DOI 10.1016/0304-3940(93)90089-4; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RAY BK, 1994, EUR J BIOCHEM, V222, P891, DOI 10.1111/j.1432-1033.1994.tb18937.x; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARTZ JP, 1990, CELL MOL NEUROBIOL, V10, P447, DOI 10.1007/BF00711186; SZEKELY AM, 1990, MOL PHARMACOL, V38, P624; TAE HJ, 1995, J BIOL CHEM, V270, P21487, DOI 10.1074/jbc.270.37.21487; TAN SE, 1994, J NEUROSCI, V14, P1123, DOI 10.1523/JNEUROSCI.14-03-01123.1994; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; YANO S, 1994, J BIOL CHEM, V269, P5428; ZAFRA F, 1992, J NEUROSCI, V12, P4793	58	39	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23520	23527		10.1074/jbc.271.38.23520	http://dx.doi.org/10.1074/jbc.271.38.23520			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798561				2022-12-27	WOS:A1996VH76800087
J	DebBurman, SK; Ptasienski, J; Benovic, JL; Hosey, MM				DebBurman, SK; Ptasienski, J; Benovic, JL; Hosey, MM			G protein-coupled receptor kinase GRK2 is a phospholipid-dependent enzyme that can be conditionally activated by G protein beta gamma subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; MUSCARINIC ACETYLCHOLINE-RECEPTOR; HETEROTRIMERIC G-PROTEINS; 3RD INTRACELLULAR LOOP; BRUTON TYROSINE KINASE; RHODOPSIN KINASE; PH DOMAIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; G(BETA-GAMMA) SUBUNITS; CHOLINERGIC RECEPTORS	G protein-coupled receptor kinases (GRKs) mediate agonist;dependent phosphorylation of G protein-coupled receptors (GPRs) and initiate homologous receptor desensitization. Previously, we reported that charged phospholipids directly interacted with the two GRK isoforms, GRK2 and GRK3, via a pleckstrin homology (PH) domain to regulate GRK activity (DebBurman, S. K., Ptasienski, J., Boetticher, E., Lomasney, J. W., Benovic, J. L., and Hosey, M. M. (1995) J. Biol. Chem. 270: 5742-5747). Here, evidence is provided to support the hypothesis that charged phospholipids are required for agonist-dependent phosphorylation of receptors by GRK2. In the absence of charged phospholipids, the purified human m2 muscarinic acetylcholine receptor (hm2mAChR) reconstituted in pure phosphatidylcholine vesicles or in a noninhibitory detergent was not a substrate for GRK2. However, these receptor preparations were stoichiometrically phosphorylated in an agonist-dependent manner upon addition of charged phospholipids. The known ability of G protein beta gamma subunits to stimulate mAChR phosphorylation also was found to be absolutely dependent on the presence of charged phospholipids, including phosphatidylinositol 4,5-bisphosphate (PIP2). Phospholipids also regulated GRK-mediated phosphorylation of casein, a nonreceptor-soluble substrate. Among lipids tested, lipid inositol phosphates, PIP2 and phosphatidylinositol 4-monophosphate, were found to be the most potent activators of GRK2 and were the only lipids that regulated GRK2 in a complex biphasic manner. At low mu M concentrations, PIP2 activated GRK2 via an interaction with the GRK pleckstrin homology domain; however, at high mu M concentrations, PIP2 inhibited GRK2, apparently via another mechanism. PIP2-mediated inhibition could be partly relieved by increasing ATP. The results support the hypothesis that GRK2 is a lipid-dependent protein kinase that requires charged phospholipids for enzyme activation, for regulation by G(beta gamma) subunits, and potentially for membrane association.	NORTHWESTERN UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,INST NEUROSCI,CHICAGO,IL 60611; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107	Northwestern University; Northwestern University; Jefferson University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50121] Funding Source: Medline; NIGMS NIH HHS [GM 44944] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; CHEN CY, 1993, J BIOL CHEM, V268, P7825; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; DEBBURMAN SK, 1995, MOL B INT U, P209; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; GARCIAHIGUERA I, 1994, J BIOL CHEM, V269, P1348; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HAGA K, 1994, J BIOL CHEM, V269, P12594; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HARGRAVE PA, 1994, REGULATION CELLULAR, P25; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KAMEYAMA K, 1994, EUR J BIOCHEM, V226, P267, DOI 10.1111/j.1432-1033.1994.tb20050.x; KIM CM, 1993, J BIOL CHEM, V268, P15412; KIM CM, 1993, RECEPTOR, V3, P39; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KONG GH, 1994, J BIOL CHEM, V269, P13084; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIGGETT SB, 1994, REGULATION CELLULAR, P71; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; Murga C, 1996, J BIOL CHEM, V271, P985, DOI 10.1074/jbc.271.2.985; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; ONORATO JJ, 1995, J BIOL CHEM, V270, P21346, DOI 10.1074/jbc.270.36.21346; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PETERSON GL, 1995, J BIOL CHEM, V270, P17808, DOI 10.1074/jbc.270.30.17808; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; QUINN PJ, 1976, MOL BIOL CELL MEMBRA, P33; REN Q, 1993, J BIOL CHEM, V268, P16483; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; SARASTE M, 1995, CURR OPIN STRUC BIOL, V5, P403, DOI 10.1016/0959-440X(95)80104-9; SHI W, 1995, J BIOL CHEM, V270, P2112, DOI 10.1074/jbc.270.5.2112; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; SIBLEY DR, 1987, CELL, V48, P914; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; TSUGA H, 1994, J BIOL CHEM, V269, P32522; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	79	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22552	22562		10.1074/jbc.271.37.22552	http://dx.doi.org/10.1074/jbc.271.37.22552			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798423	hybrid			2022-12-27	WOS:A1996VG67200042
J	Friedman, TM; Reddy, AP; Wassell, R; Jameson, BA; Korngold, R				Friedman, TM; Reddy, AP; Wassell, R; Jameson, BA; Korngold, R			Identification of a human CD4-CDR3-like surface involved in CD4(+) T cell function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS GP120; TYROSINE-PROTEIN-KINASE; CLASS-II MHC; CROSS-LINKING; MONOCLONAL-ANTIBODY; RECEPTOR COMPLEX; LYMPHOCYTES-T; ANTIGEN; CD8; BINDING	The CD4 molecule is expressed on the surface of helper T cells, This molecule contains four tandem external immunoglobulin-like domains (D1-D4), a transmembrane domain, and a cytoplasmic tail, Through the use of molecular modeling techniques, peptide analogs of the CDR3-like region of the human CD4 molecule, analog hPGP, a cyclized peptide 13 amino acids long, was synthesized and tested for its ability to inhibit proliferation in human mixed lymphocyte reactions. A conservative amino acid substitution was made at position 5 (D --> N) to increase its activity and designated hPGP(N), A series of alanine substitution peptides were synthesized based on the sequence of hPGP(N) to determine the importance of each residue to the peptide's function, The substitutions of amino acids in positions 3, 7, and 8 had essentially no effect on the inhibitory activity of hPGP(N), while substitutions of amino acids in positions 4 and 6 increased its inhibitory effect. Alanine substitutions of amino acids in positions 2, 5, and 9 dramatically decreased the inhibitory effect of analog hPGP(N), Molecular modeling of the native CD4-CDR3-like domain suggested that the residues corresponding to positions 2, 5, and 9 of the peptide formed a contiguous surface representing the active site.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, KIMMEL CANC INST, PHILADELPHIA, PA 19107 USA	Jefferson University			Korngold, Robert/AAF-2686-2020					ANDERSON P, 1987, J IMMUNOL, V139, P678; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EMMRICH F, 1987, EUR J IMMUNOL, V17, P529, DOI 10.1002/eji.1830170415; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HOOD L, 1985, CELL, V40, P225, DOI 10.1016/0092-8674(85)90133-3; JAMESON BA, 1994, NATURE, V368, P744, DOI 10.1038/368744a0; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; LANDAU NR, 1988, NATURE, V334, P159, DOI 10.1038/334159a0; Leitenberg D, 1996, J EXP MED, V183, P249, DOI 10.1084/jem.183.1.249; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MCDONNELL JM, 1992, J IMMUNOL, V149, P1626; MCDONNELL JM, 1992, IMMUNOMETHODS, V1, P33; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; MITTLER RS, 1991, J IMMUNOL, V147, P3434; MOEBIUS U, 1992, P NATL ACAD SCI USA, V89, P12008, DOI 10.1073/pnas.89.24.12008; MOEBIUS U, 1993, P NATL ACAD SCI USA, V90, P8259, DOI 10.1073/pnas.90.17.8259; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; PARNES JR, 1989, ADV IMMUNOL, V44, P265, DOI 10.1016/S0065-2776(08)60644-6; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; RIVAS A, 1988, J IMMUNOL, V140, P2912; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RYU SE, 1994, STRUCTURE, V2, P59, DOI 10.1016/S0969-2126(00)00008-3; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SAKIHAMA T, 1995, P NATL ACAD SCI USA, V92, P6444, DOI 10.1073/pnas.92.14.6444; SAKIHAMA T, 1995, IMMUNOL TODAY, V16, P581, DOI 10.1016/0167-5699(95)80081-6; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WILLIAMS AF, 1985, NATURE, V314, P579, DOI 10.1038/314579a0; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; ZERBIB AC, 1994, J EXP MED, V179, P1973, DOI 10.1084/jem.179.6.1973	36	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22635	22640		10.1074/jbc.271.37.22635	http://dx.doi.org/10.1074/jbc.271.37.22635			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798434	hybrid			2022-12-27	WOS:A1996VG67200053
J	Hill, JS; Davis, RC; Yang, D; Wen, J; Philo, JS; Poon, PH; Phillips, ML; Kempner, ES; Wong, H				Hill, JS; Davis, RC; Yang, D; Wen, J; Philo, JS; Poon, PH; Phillips, ML; Kempner, ES; Wong, H			Human hepatic lipase subunit structure determination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LIPOPROTEIN-LIPASE; HIGH-DENSITY-LIPOPROTEINS; RECEPTOR-RELATED PROTEIN; AMINO-ACID SEQUENCE; TRIGLYCERIDE LIPASE; RADIATION INACTIVATION; PANCREATIC LIPASE; RAT-LIVER; CHIMERIC LIPASE; MOLECULAR-SIZE	Chinese hamster ovary cells were stably transfected with a human hepatic lipase (HL) cDNA. The recombinant enzyme was purified from culture medium in milligram quantities and shown to have a molecular weight, specific activity, and heparin affinity equivalent to HL present in human post-heparin plasma. The techniques of intensity light scattering, sedimentation equilibrium, and radiation inactivation were employed to assess the subunit structure of HL. For intensity light scattering, purified enzyme was subjected to size exclusion chromatography coupled to three detectors in series: an ultraviolet absorbance monitor, a differential refractometer, and a light scattering photometer. The polypeptide molecular weight (without carbohydrate contributions) was calculated using the measurements from the three detectors combined with the extinction coefficient of human HL. A single protein peak containing HL activity was identified and calculated to have a molecular mass of 107,000 in excellent agreement with the expected value for a dimer of HL (106.8 kDa). In addition, sedimentation equilibrium studies revealed that HL had a molecular mass (with carbohydrate contributions) of 121 kDa, Finally, to determine the smallest structural unit required for lipolytic activity, HL was subjected to radiation inactivation, Purified HL was exposed to various doses of high energy electrons at -135 degrees C; lipase activity decreased as a single exponential function of the radiation dose to less than 0.01% remaining activity, The target size of functional HL was calculated to be 109 kDa, whereas the size of the structural unit was determined to be 63 kDa. These data indicate that two HL monomer subunits are required for lipolytic activity, consistent with an HL homodimer. A model for active dimeric hepatic lipase is presented with implications for physiological function.	UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90024; AMGEN INC,THOUSAND OAKS,CA 91320; NIAMS,PHYS BIOL LAB,NIH,BETHESDA,MD 20892	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Amgen; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Hill, JS (corresponding author), W LOS ANGELES VET AFFAIRS MED CTR,LIPID RES LAB,11301 WILSHIRE BLVD,BLDG 113,RM 312,LOS ANGELES,CA 90073, USA.			Philo, John/0000-0003-3418-0356	NHLBI NIH HHS [HL28481] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAKAWA T, 1992, ANAL BIOCHEM, V203, P53, DOI 10.1016/0003-2697(92)90042-6; BARRANS A, 1994, J BIOL CHEM, V269, P11572; BENZEEV O, 1987, BIOCHIM BIOPHYS ACTA, V919, P13, DOI 10.1016/0005-2760(87)90212-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCH SJ, 1994, J BIOL CHEM, V269, P16376; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG CF, 1985, J BIOL CHEM, V260, P720; CLAY MA, 1991, ARTERIOSCLER THROMB, V11, P415, DOI 10.1161/01.ATV.11.2.415; DATTA S, 1988, J BIOL CHEM, V263, P1107; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DAVIS RC, 1990, J BIOL CHEM, V265, P6291; DEREWENDA ZS, 1991, J BIOL CHEM, V266, P23112; DIARD P, 1994, BIOCHEM J, V299, P889, DOI 10.1042/bj2990889; DICHEK HL, 1993, J LIPID RES, V34, P1393; DOOLITTLE MH, 1987, J LIPID RES, V28, P1326; DUGI KA, 1992, J BIOL CHEM, V267, P25086; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; GARFINKEL AS, 1983, J LIPID RES, V24, P775; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HEGELE RA, 1993, ARTERIOSCLER THROMB, V13, P720, DOI 10.1161/01.ATV.13.5.720; HIDE WA, 1992, J LIPID RES, V33, P167; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; HORNICK CA, 1992, J BIOL CHEM, V267, P3396; IKEDA Y, 1989, BIOCHIM BIOPHYS ACTA, V1003, P254, DOI 10.1016/0005-2760(89)90231-2; JENSEN GL, 1981, ANAL BIOCHEM, V113, P246, DOI 10.1016/0003-2697(81)90073-7; JI ZS, 1994, J BIOL CHEM, V269, P13429; KEMPNER ES, 1988, ADV ENZYMOL RAMB, V61, P107; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; KUUSI T, 1979, BIOCHEM J, V181, P245, DOI 10.1042/bj1810245; MARTEAU C, 1988, LIFE SCI, V42, P533, DOI 10.1016/0024-3205(88)90094-X; MARTIN GA, 1988, J BIOL CHEM, V263, P10907; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; Olive C, 1975, Methods Enzymol, V41, P196; OLIVECRONA T, 1985, J BIOL CHEM, V260, P6888; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; ROVERY M, 1978, BIOCHIM BIOPHYS ACTA, V525, P373, DOI 10.1016/0005-2744(78)90232-2; SHAFI S, 1994, J LIPID RES, V35, P709; STAHNKE G, 1987, DIFFERENTIATION, V35, P45, DOI 10.1111/j.1432-0436.1987.tb00150.x; SULTAN F, 1990, BIOCHIM BIOPHYS ACTA, V1042, P150, DOI 10.1016/0005-2760(90)90071-5; TAKAGI T, 1983, J CHROMATOGR, V280, P124; TWU JS, 1984, BIOCHIM BIOPHYS ACTA, V792, P330, DOI 10.1016/0005-2760(84)90201-7; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WONG H, 1994, J BIOL CHEM, V269, P10319; WONG H, 1991, P NATL ACAD SCI USA, V88, P11290, DOI 10.1073/pnas.88.24.11290	48	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22931	22936		10.1074/jbc.271.37.22931	http://dx.doi.org/10.1074/jbc.271.37.22931			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798474	hybrid			2022-12-27	WOS:A1996VG67200093
J	Lefebvre, V; Mechin, MC; Louckx, MP; Rider, MH; Hue, L				Lefebvre, V; Mechin, MC; Louckx, MP; Rider, MH; Hue, L			Signaling pathway involved in the activation of heart 6-phosphofructo-2-kinase by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; FRUCTOSE 2,6-BISPHOSPHATE; PHOSPHATIDYLINOSITOL 3-KINASE; RAT-HEART; FRUCTOSE-2,6-BISPHOSPHATE CONTENT; GLUCOSE-UTILIZATION; MOLECULAR-CLONING; S6 KINASE; 2 FORMS; INHIBITION	Incubation of isolated rat cardiomyocytes with insulin increased 2-deoxyglucose uptake, glycogen synthesis, and fructose 2,6-bisphosphate content. Half-maximal effects were obtained with 1-2 nM insulin. The insulin-induced increase in fructose 2,6-bisphosphate content was preceded by a 2-3-fold activation of 6-phosphofructo-2-kinase, which was independent of glucose transport. Insulin activated phosphatidylinositol 3-kinase and p70 ribosomal S6 kinase (p70 S6 kinase), but had no significant effect on mitogen-activated protein kinase, although phorbol 12-myristate 13-acetate activated the latter, The effect of insulin on fructose 2,6-bisphosphate, 6-phosphofructo-2-kinase, and phosphatidylinositol 3-kinase was blocked by wortmannin. However, rapamycin, which inhibited p70 S6 kinase activation, and PD 98059, an inhibitor of the mitogen-activated protein kinase pathway, had no effect on the insulin-induced activation of 6-phosphofructo-2-kinase. Heart 6-phosphofructo-2-kinase can therefore be regarded as a glycolytic target of insulin. Its activation by insulin might be mediated by phosphatidylinositol 3-kinase.	UNIV LOUVAIN,SCH MED,HORMONE & METAB RES UNIT,B-1200 BRUSSELS,BELGIUM; INT INST CELLULAR & MOL PATHOL,B-1200 BRUSSELS,BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel								ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; DEPRE C, 1993, J BIOL CHEM, V268, P13274; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FISCHER Y, 1991, LIFE SCI, V49, P1679, DOI 10.1016/0024-3205(91)90310-8; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HUE L, 1982, J BIOL CHEM, V257, P4308; HUE L, 1995, BIOCHEM SOC T, V23, P311, DOI 10.1042/bst0230311; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; HUE L, 1975, BIOCHEM J, V152, P105, DOI 10.1042/bj1520105; HUE L, 1988, BIOCHEM J, V251, P541, DOI 10.1042/bj2510541; HUNTER T, 1995, CELL, V89, P1; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; KITAMURA K, 1988, J BIOL CHEM, V263, P16796; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Krause U, 1996, J BIOL CHEM, V271, P16668, DOI 10.1074/jbc.271.28.16668; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LAWSON JWR, 1987, J BIOL CHEM, V262, P3165; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; MOWBRAY J, 1973, EUR J BIOCHEM, V36, P362, DOI 10.1111/j.1432-1033.1973.tb02920.x; OKADA T, 1994, J BIOL CHEM, V269, P3563; RIDER MH, 1984, FEBS LETT, V176, P484, DOI 10.1016/0014-5793(84)81223-5; RIDER MH, 1992, BIOCHEM J, V285, P405, DOI 10.1042/bj2850405; Saltiel AR, 1996, AM J PHYSIOL-ENDOC M, V270, pE375, DOI 10.1152/ajpendo.1996.270.3.E375; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118	36	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22289	22292		10.1074/jbc.271.37.22289	http://dx.doi.org/10.1074/jbc.271.37.22289			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798384	hybrid			2022-12-27	WOS:A1996VG67200003
J	Simonian, PL; Grillot, DAM; Merino, R; Nunez, G				Simonian, PL; Grillot, DAM; Merino, R; Nunez, G			Pax can antagonize Bcl-X(L) during etoposide and cisplatin-induced cell death independently of its heterodimerization with Bcl-X(L)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 HOMOLOG BAK; APOPTOSIS; SURVIVAL; EXPRESSION; GENE; MODULATION; PROTEINS; DISTINCT; CANCER; FAMILY	Bax, a member of the Bcl-2 family of proteins, has been shown to promote apoptosis while other members of the family, including Bcl-X(L) and Bcl-2, inhibit cell death induced by a variety of stimuli. The mechanism by which Bax promotes cell death is poorly understood. In the present report, we assessed the ability of Pax to antagonize the death repressor activity of Bcl-X(L) during chemotherapy-induced apoptosis in the lymphoid cell line, FL5.12. Expression of wild-type Bax countered the repressor activity of Bcl-X(L) against cell death mediated by VP-16 and cisplatin. We performed site-directed mutagenesis of the BH1, BH2, and BH3 homology regions in Bax to determine the ability of wild-type and mutant Bax to heterodimerize with Bcl-X(L) and to antagonize the protective effect of Bcl-X(L) against chemotherapy-induced apoptosis. Bax proteins expressing alanine substitutions of the highly conserved amino acids glycine 108 in BH1, tryptophan 151 and 158 in BH2, and glycine 67 and aspartic acid 68 in BH3 retained their ability to promote chemotherapy-induced cell death that was inhibited by Bcl-X(L) and to form heterodimers with Bcl-X(L). Bax proteins containing deletions of the most highly conserved amino acids in BH1 (Delta 102-112) and BH2 (Delta 151-159) maintained the ability of Pax to antagonize the death repressor activity of Bcl-X(L) and to associate with Bcl-X(L). However, Bax with BH3 deleted did not form heterodimers with Bcl-X(L), but retained its ability to counter the death repressor activity of Bcl-X(L). These results demonstrate that the conserved BH3, but not BH1 or BH2, homology region of Pax is necessary for its interaction with Bcl-X(L) in mammalian cells. Furthermore, our results indicate that Pax does not require BH1, BH2, BH3, or heterodimerization with Bcl-X(L) to counter the death repressor activity of Bcl-X(L). Therefore, Pax can antagonize Bcl-X(L) during VP-16 and, in a lesser degree, during cisplatin-induced cell death independent of its heterodimerization with Bcl-X(L).	UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, CTR COMPREHENS CANC, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Merino, Ramón/L-1310-2014; Nuñez, Gabriel/A-7160-2014	Merino, Ramón/0000-0002-5306-0635; 	NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; HAN Z, 1996, GENE DEV, V10, P461; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; MERINO R, 1995, J IMMUNOL, V155, P3830; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; MIYASHITA T, 1993, BLOOD, V81, P151; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	28	102	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22764	22772		10.1074/jbc.271.37.22764	http://dx.doi.org/10.1074/jbc.271.37.22764			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798452	hybrid			2022-12-27	WOS:A1996VG67200071
J	VanLeeuwen, JEM; Kearse, KP				VanLeeuwen, JEM; Kearse, KP			The related molecular chaperones calnexin and calreticulin differentially associate with nascent T cell antigen receptor proteins within the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMATURE THYMOCYTES; MONOCLONAL-ANTIBODY; INITIAL STEP; DELTA-CHAIN; GLYCOPROTEINS; RECOGNITION; EXPRESSION; MEMBRANE; ALPHA; OLIGOSACCHARIDE	Assembly of the multisubunit T cell antigen receptor (TCR) complex is an intricate process requiring coordinated regulation of at least six different gene products (alpha, beta, gamma, delta, epsilon and xi) and the ordered pairing of partner chains within the endoplasmic reticulum (ER). To date, two proteins have been implicated as functioning as molecular chaperones in the assembly of nascent TCR proteins: calnexin, a resident ER transmembrane protein, which associates with all TCR components except xi, and T cell receptor-associated protein, which selectively associates with CD3 gamma epsilon pairs, In this study, we examined the association of calreticulin, a soluble protein with significant sequence homology to calnexin, with newly synthesized TCR proteins, Analogous to calnexin, processing of glycan chains by glucosidase enzymes was required for initial association of TCR alpha and -beta proteins with calreticulin; however, several major differences were noted regarding interaction of calnexin and calreticulin chaperones with TCR proteins. First, TCR alpha and -beta proteins showed prolonged association with calnexin molecules compared with calreticulin; interaction of TCR alpha proteins with calreticulin was particularly transient, with most calreticulin-TCR alpha protein complexes dissociating within 15 min of their initial assembly, Second, we found that, unlike calnexin, which associated with clonotypic TCR alpha and -beta proteins and invariant CD3 delta and -epsilon polypeptides, calreticulin associated specifically with clonotypic TCR alpha and -beta proteins. These studies identify calreticulin as a molecular chaperone for nascent clonotypic TCR alpha and -beta proteins and demonstrate that calreticulin and calnexin differentially associate with newly synthesized TCR proteins within the ER.	NCI,EXPT IMMUNOL BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			van Leeuwen, Jeroen/G-3555-2010					ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; BALOW JP, 1995, J BIOL CHEM, V270, P29025, DOI 10.1074/jbc.270.48.29025; BECKER MLB, 1989, CELL, V58, P911, DOI 10.1016/0092-8674(89)90943-4; BORN W, 1987, NATURE, V330, P572, DOI 10.1038/330572a0; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; GRUPP SA, 1995, J EXP MED, V181, P161, DOI 10.1084/jem.181.1.161; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HYMAN R, 1974, J NATL CANCER I, V52, P429, DOI 10.1093/jnci/52.2.429; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KEARSE KP, 1995, IMMUNITY, V2, P391; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LOO TW, 1994, J BIOL CHEM, V269, P28683; MELNICK J, 1995, IMMUNOL TODAY, V16, P243, DOI 10.1016/0167-5699(95)80167-7; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; PARODI AJ, 1983, J BIOL CHEM, V258, P8260; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; SAMELSON LE, 1986, J IMMUNOL, V137, P3254; SCOTT JE, 1995, J IMMUNOL, V155, P143; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; WADA I, 1991, J BIOL CHEM, V266, P19599; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WIEST DL, 1995, EMBO J, V14, P3425, DOI 10.1002/j.1460-2075.1995.tb07348.x; WIEST DL, 1994, J EXP MED, V180, P1375, DOI 10.1084/jem.180.4.1375	35	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25345	25349		10.1074/jbc.271.41.25345	http://dx.doi.org/10.1074/jbc.271.41.25345			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810299	hybrid			2022-12-27	WOS:A1996VL69300043
J	Arguello, JM; Peluffo, RD; Feng, JN; Lingrel, JB; Berlin, JR				Arguello, JM; Peluffo, RD; Feng, JN; Lingrel, JB; Berlin, JR			Substitution of glutamic 779 with alanine in the Na,K-ATPase alpha subunit removes voltage dependence of ion transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RAT-KIDNEY NA+,K+-ATPASE; SODIUM-PUMP; CATION-BINDING; CHEMICAL MODIFICATION; POTASSIUM-IONS; ATP HYDROLYSIS; OUTER MEDULLA; NA+/K+ PUMP; NA,K PUMP	The effects of changing Glu-779, located in the fifth transmembrane segment of the Na,K-ATPase a subunit, on the phosphorylation characteristics and ion transport properties of the enzyme were investigated, HeLa cells were transfected with cDNA coding the E779A substitution in an ouabain-resistant sheep al subunit (RD). Steady state phosphorylation stimulated by Na+ concentrations less than 20 mM or by imidazole were similar for RD and E779A enzymes, an indication that phosphorylation and Na+ occlusion were not altered by this mutation, With E779A enzyme, higher Na+ concentrations reduced the level of phosphoenzyme and stimulated Na-ATPase activity in the absence of K+. These effects were a consequence of Na+ increasing the rate of protein dephosphorylation. In voltage-clamped HeLa cells expressing E779A enzyme, a prominent electrogenic Na+-Na+ exchange was observed in the absence of extracellular K+. Thus, increased Na-ATPase activity and Na+-dependent dephosphorylation result from Na+ acting as a K+ congener with low affinity at extracellular binding sites, These data suggest that E779A does not directly participate in ion binding but does affect the connection between extracellular ion binding and intracellular enzyme dephosphorylation, In cells expressing control RD enzyme, Na,K-pump current was dependent on membrane potential and extracellular K+ concentration. However, Na,K-pump current in cells expressing E779A enzyme was voltage independent at all extracellular K+ tested, These results indicate that Glu-779 may be part of the access channel determining the voltage dependence of ion transport by the Na,K-ATPase.	UNIV CINCINNATI,COLL MED,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267; GRAD HOSP PHILADELPHIA,BOCKUS RES INST,PHILADELPHIA,PA 19146	University of Cincinnati; University of Pennsylvania	Arguello, JM (corresponding author), WORCESTER POLYTECH INST,DEPT CHEM & BIOCHEM,100 INST RD,WORCESTER,MA 01609, USA.		Arguello, Jose/D-1997-2012	Arguello, Jose/0000-0003-3940-6297	NHLBI NIH HHS [HL28573, HL 03373, HL43712] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028573, R01HL043712, K14HL003373, R29HL043712] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arguello J. M., 1996, Biophysical Journal, V70, pA326; ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; BAMBERG E, 1994, SODIUM PUMP STRUCTUR; BLOSTEIN R, 1988, METHOD ENZYMOL, V156, P171; BLOSTEIN R, 1983, J BIOL CHEM, V258, P7948; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORNELIUS F, 1991, BIOCHIM BIOPHYS ACTA, V1071, P19, DOI 10.1016/0304-4157(91)90011-K; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; FENG JN, 1995, CELL MOL BIOL RES, V41, P29; GADSBY DC, 1989, J GEN PHYSIOL, V94, P511, DOI 10.1085/jgp.94.3.511; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; GARRAHAN PJ, 1967, J PHYSIOL-LONDON, V192, P175, DOI 10.1113/jphysiol.1967.sp008295; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; HEYSE S, 1994, J GEN PHYSIOL, V104, P197, DOI 10.1085/jgp.104.2.197; HILGEMANN DW, 1994, SCIENCE, V263, P1429, DOI 10.1126/science.8128223; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1992, MOL ASPECTS TRANSPOR, P1; KAPLAN JH, 1994, SODIUM PUMP, P321; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P2993, DOI 10.1074/jbc.270.7.2993; LANE LK, 1973, J BIOL CHEM, V248, P7197; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LESCALEMATYS L, 1990, J BIOL CHEM, V265, P17935; LIANG SM, 1976, BIOCHIM BIOPHYS ACTA, V452, P552, DOI 10.1016/0005-2744(76)90207-2; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; MALIK B, 1993, PROTEIN SCI, V2, P2103, DOI 10.1002/pro.5560021211; NAKAO M, 1986, NATURE, V323, P928; PEDEMONTE CH, 1988, J THEOR BIOL, V134, P165, DOI 10.1016/S0022-5193(88)80200-5; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; Pedersen PA, 1996, J BIOL CHEM, V271, P2514, DOI 10.1074/jbc.271.5.2514; Peluffo R. D., 1996, Biophysical Journal, V70, pA18; PRESSLEY TA, 1988, J MEMBRANE BIOL, V105, P187, DOI 10.1007/BF01870996; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RAKOWSKI RF, 1989, J GEN PHYSIOL, V93, P903, DOI 10.1085/jgp.93.5.903; RAKOWSKI RF, 1991, J MEMBRANE BIOL, V121, P177, DOI 10.1007/BF01870531; SAGAR A, 1994, J GEN PHYSIOL, V103, P869, DOI 10.1085/jgp.103.5.869; SCHWARZ W, 1994, SODIUM PUMP, P482; STEKHOVEN FMAHS, 1985, BIOCHIM BIOPHYS ACTA, V815, P16, DOI 10.1016/0005-2736(85)90468-7; VANHUYSSE JW, 1993, BIOCHEMISTRY-US, V32, P819, DOI 10.1021/bi00054a012; VASILETS LA, 1994, SODIUM PUMP, P557; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041	51	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24610	24616		10.1074/jbc.271.40.24610	http://dx.doi.org/10.1074/jbc.271.40.24610			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798726	hybrid			2022-12-27	WOS:A1996VM67400048
J	Campos, SP; Wang, YP; Baumann, H				Campos, SP; Wang, YP; Baumann, H			Insulin modulates STAT3 protein activation and gene transcription in hepatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; RAT-LIVER NUCLEI; SIGNAL TRANSDUCER; MOLECULAR-CLONING; INTERLEUKIN-6; RECEPTORS; PATHWAY; IRS-1; PHOSPHORYLATION; ASSOCIATION	Treatment of rat hepatoma cells with insulin attenuated the interleukin 6 (IL-6) stimulation of acute phase plasma protein genes, To identify the potential mechanism of this action, the influence of insulin on IL-6 signal transduction was determined, An insulin dose-dependent reduction in signal transducer and activator of transcription 3 (STAT3) gene transcription, mRNA accumulation, protein concentration, and IL-6-inducible DNA binding activity was detected, A reduction in the IL-6-activated sis-inducible element binding of STAT3 was observed within 4 h of insulin treatment, whereas a maximal 3-4-fold lower STAT protein concentration was measured after 8-24 h of insulin treatment. Insulin mediated a similar magnitude reduction in the amount of mRNA encoding the IL-6 receptor alpha subunit and IL-6 binding activity, These effects of insulin appear to contribute to the strongly suppressed transcriptional induction of the IL-6-responsive acute phase plasma protein genes.	ROSWELL PK CANC INST,DEPT MOL & CELLULAR BIOL,BUFFALO,NY 14263; CHILDRENS HOSP,DIV ENDOCRINOL,BUFFALO,NY 14222	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NCI NIH HHS [CA26122] Funding Source: Medline; NIDDK NIH HHS [DK33886] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033886] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BAUMANN H, 1986, J CELL BIOL, V102, P370, DOI 10.1083/jcb.102.2.370; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN M, 1990, J BIOL CHEM, V265, P19853; CAMPOS SP, 1992, MOL CELL BIOL, V267, P19744; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; CHENG J, 1990, NUCLEIC ACIDS RES, V18, P4261, DOI 10.1093/nar/18.14.4261; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IMMENSCHUH S, 1994, J BIOL CHEM, V269, P12654; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LEE I, 1995, AM J PHYSIOL, V266, pC319; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MATSUDA T, 1994, BLOOD, V83, P3457; ORIORDAIN MG, 1995, AM J PHYSIOL-ENDOC M, V269, pE323, DOI 10.1152/ajpendo.1995.269.2.E323; REUBER MD, 1961, J NATL CANCER I, V26, P891; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; THOMPSON D, 1991, CYTOKINE, V3, P619, DOI 10.1016/1043-4666(91)90489-Z; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	30	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24418	24424		10.1074/jbc.271.40.24418	http://dx.doi.org/10.1074/jbc.271.40.24418			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798699	hybrid			2022-12-27	WOS:A1996VM67400021
J	Gertler, A; Grosclaude, J; Strasburger, CJ; Nir, S; Djiane, J				Gertler, A; Grosclaude, J; Strasburger, CJ; Nir, S; Djiane, J			Real-time kinetic measurements of the interactions between lactogenic hormones and prolactin-receptor extracellular domains from several species support the model of hormone-induced transient receptor dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; TYROSINE KINASE JAK2; MAMMARY-GLAND; BIOLOGICAL-ACTIVITIES; ESCHERICHIA-COLI; OVINE PROLACTIN; BINDING; CELLS; SUPERFAMILY; ACTIVATION	Interactions of recombinant soluble prolactin receptors-extracellular domains (PRLR-ECDs) from rabbit, rat, and cow and human growth hormone receptor ECD with immobilized human growth hormone, several prolactins, and bovine placental lactogen were studied utilizing surface plasmon resonance. This method enables real-time kinetic measurements of the interactions and calculations of kinetic constants and of the stoichiometry of interaction, even in cases where only transient interactions occur. In contrast to gel filtration or crystallographic studies, where in most cases the interaction of PRLR-ECDs with various lactogenic hormones indicated formation of 1:1 complexes, our surface plasmon resonance experiments indicated in all cases the transient formation of a 2:1 complex. In most of the interactions the 2:1 complex was very unstable and underwent rapid dissociation to a 1:1 complex. This situation was particularly characteristic of homologous interactions involving hormone and receptor from the same species and was mainly attributed to increased dissociation constants, We suggest that as in the ease of growth hormone PRLR activation occurs via hormone-induced transient homodimerization of the receptor, lasting only a few seconds, and that this may be sufficient to initiate the biological signal. Once the signal is initiated, the receptor dimer is no longer required. Its rapid dissociation to a 1:1 complex or to its components may even be advantageous in that it permits activation of additional receptors.	HEBREW UNIV JERUSALEM,FAC AGR,DEPT SOIL SCI,IL-76100 REHOVOT,ISRAEL; UNIV MUNICH,KLINIKUM INNENSTADT,MED KLIN,D-8000 MUNICH,GERMANY; INRA,UNITE ENDOCRINOL MOL,F-78352 JOUY EN JOSAS,FRANCE	Hebrew University of Jerusalem; University of Munich; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Gertler, A (corresponding author), HEBREW UNIV JERUSALEM,FAC AGR,INST BIOCHEM FOOD SCI & NUTR,POB 12,IL-76100 REHOVOT,ISRAEL.							BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERTHON P, 1987, P SOC EXP BIOL MED, V184, P300, DOI 10.3181/00379727-184-42483; BIGNON C, 1994, J BIOL CHEM, V269, P3318; BOULAY JL, 1993, CURR BIOL, V3, P573, DOI 10.1016/0960-9822(93)90002-6; BRAMLEY TA, 1987, J ENDOCRINOL, V113, P365, DOI 10.1677/joe.0.1130365; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUSANTERFOURT I, 1984, ENDOCRINOLOGY, V114, P1021, DOI 10.1210/endo-114-3-1021; ELBERG G, 1990, J BIOL CHEM, V265, P14770; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GERTLER A, 1984, MOL CELL ENDOCRINOL, V34, P51, DOI 10.1016/0303-7207(84)90158-8; GERTLER A, 1992, J BIOL CHEM, V267, P12655; GERTLER A, 1983, MOL CELL ENDOCRINOL, V33, P169, DOI 10.1016/0303-7207(83)90165-X; GERTLER A, 1993, FEBS LETT, V319, P277, DOI 10.1016/0014-5793(93)80562-9; GERTLER A, 1995, P 77 ANN M END SOC W; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOOPER KP, 1993, J BIOL CHEM, V268, P22347; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JERRY DJ, 1991, J ENDOCRINOL, V130, P43, DOI 10.1677/joe.0.1300043; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; NIR S, 1994, COLLOID SURFACE A, V89, P45, DOI 10.1016/0927-7757(94)02858-3; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; RUI H, 1994, J BIOL CHEM, V269, P5364; SAKAL E, 1995, P 77 ANN M END SOC W; SANDOWSKI Y, 1995, MOL CELL ENDOCRINOL, V115, P1, DOI 10.1016/0303-7207(95)03664-S; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; STATEN NR, 1993, J BIOL CHEM, V268, P18467; Strasburger CJ, 1996, J CLIN ENDOCR METAB, V81, P2613, DOI 10.1210/jc.81.7.2613; TAGA T, 1995, CURR OPIN IMMUNOL, V7, P17, DOI 10.1016/0952-7915(95)80024-7; TCHELET A, 1995, J ENDOCRINOL, V144, P393, DOI 10.1677/joe.0.1440393; TCHELET A, 1993, PEDIAT AD E, V24, P114; WELLS JA, 1993, ANNU REV BIOPH BIOM, V22, P329, DOI 10.1146/annurev.bb.22.060193.001553; WELLS JA, 1994, CURR OPIN CELL BIOL, V6, P163, DOI 10.1016/0955-0674(94)90132-5; WU ZN, 1995, J BIOL CHEM, V270, P16039, DOI 10.1074/jbc.270.27.16039; ZHOU M, 1993, BIOCHEMISTRY-US, V32, P8193, DOI 10.1021/bi00083a020	42	98	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24482	24491		10.1074/jbc.271.40.24482	http://dx.doi.org/10.1074/jbc.271.40.24482			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798708	hybrid			2022-12-27	WOS:A1996VM67400030
J	Harley, CA; Tipper, DJ				Harley, CA; Tipper, DJ			The role of charged residues in determining transmembrane protein insertion orientation in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; BETA-LACTAMASE; TOPOLOGY; RULE; KEX2; TRANSLOCATION; DOMAIN; TAILS	The first 79 residues of the yeast Ste2p G protein-coupled pheromone receptor, including the negatively charged N-terminal domain, the first transmembrane segment, and the following positively charged cytoplasmic loop, has been fused to a Kex2p-cleavable beta-lactamase reporter. Insertion orientation was determined by analysis of cell associated and secreted beta-lactamase activities and independently corroborated by analysis of membrane association and glycosylation patterns, This fusion inserts with exclusively N terminus exofacial (N-exo) topology, serving as a model type III membrane protein. Orientation is unaffected by removal of all three positively charged residues in the cytoplasmic loop or by deletion of all but 12 residues from the N-terminal domain. The residual -2 N-terminal charge apparently provides a signal sufficient to determine N-exo topology. This is entirely consistent with the statistically derived rule in which the charge difference, Delta(C-N), counted for the 15 immediately flanking residues, is the primary topology determinant, Mutations altering Delta(C-N) to zero favors N-exo insertion by 3 to 1, whereas increasingly negative values cause increasing inversion of orientation, All results are consistent with the charge difference rule and indicate that whereas positive charges promote cytoplasmic retention, negative charges promote translocation.	UNIV MASSACHUSETTS,SCH MED,DEPT MOL GENET & MICROBIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester			Harley, Carol/J-5375-2013	Harley, Carol/0000-0003-3610-0604				ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; BELTZER JP, 1991, J BIOL CHEM, V266, P973; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; CARTWRIGHT CP, 1991, MOL CELL BIOL, V11, P2620, DOI 10.1128/MCB.11.5.2620; CARTWRIGHT CP, 1992, YEAST, V8, P261, DOI 10.1002/yea.320080404; CARTWRIGHT CP, 1994, YEAST, V10, P497, DOI 10.1002/yea.320100409; CHAUDHURI B, 1992, FEBS LETT, V304, P41, DOI 10.1016/0014-5793(92)80585-5; DALBEY RE, 1995, TRENDS CELL BIOL, V5, P380, DOI 10.1016/S0962-8924(00)89079-0; Denzer AJ, 1995, EMBO J, V14, P6311, DOI 10.1002/j.1460-2075.1995.tb00321.x; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P10752, DOI 10.1073/pnas.92.23.10752; KRISHTALIK LI, 1995, FEBS LETT, V369, P140, DOI 10.1016/0014-5793(95)00756-Y; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; LANKFORD SP, 1993, J BIOL CHEM, V268, P4814; NAKASHIMA H, 1992, FEBS LETT, V303, P141, DOI 10.1016/0014-5793(92)80506-C; NILSSON I, 1993, J BIOL CHEM, V268, P5798; PARKS GD, 1993, J BIOL CHEM, V268, P19101; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; SCHANDEL KA, 1994, MOL CELL BIOL, V14, P7245, DOI 10.1128/MCB.14.11.7245; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SPIESS M, 1995, FEBS LETT, V369, P76, DOI 10.1016/0014-5793(95)00551-J; von Heijne G, 1994, Subcell Biochem, V22, P1; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693	28	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24625	24633		10.1074/jbc.271.40.24625	http://dx.doi.org/10.1074/jbc.271.40.24625			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798728	hybrid			2022-12-27	WOS:A1996VM67400050
J	Inaba, T; Ishibashi, S; Harada, K; Ohsuga, JI; Ohashi, K; Yagyu, H; Yazaki, Y; Higashiyama, S; Kawata, S; Matsuzawa, Y; Yamada, N				Inaba, T; Ishibashi, S; Harada, K; Ohsuga, JI; Ohashi, K; Yagyu, H; Yazaki, Y; Higashiyama, S; Kawata, S; Matsuzawa, Y; Yamada, N			Induction of macrophage colony-stimulating factor receptor (c-fms) expression in vascular medial smooth muscle cells treated with heparin binding epidermal growth factor-like growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE-DERIVED MACROPHAGES; LOW-DENSITY-LIPOPROTEIN; MESSENGER-RNA; EGF; CHOLESTEROL; PROTEIN	Vascular smooth muscle cells migrate, proliferate, and transform to foam cells during the atherosclerotic process. We have reported that smooth muscle cells derived from the intima of atherosclerotic lesions express the proto-oncogene c-fms and a scavenger receptor, which are not normally expressed in normal medial smooth muscle cells, In the present study, we demonstrated that heparin binding epidermal growth factor-like growth factor (HB-EGF) induced the expression of c-fms and the scavenger receptor in normal human medial smooth muscle cells to the level observed in the intima, The expression of c-fms was partially inhibited by a protein kinase C inhibitor, suggesting that HB-EGF induces c-fms via pathways that are both dependent on and independent of protein kinase C, By contrast, most of the scavenger receptor induction by HB-EGF was suppressed by protein kinase C inhibitors, These results indicate that two characteristic genes of monocyte-derived macrophages were induced by HB-EGF via different mechanisms. The alteration of gene expression in response to HB-EGF may play an important role in the phenotypic change of smooth muscle cells to macrophage-like foam cells during the atherosclerotic process.	UNIV TOKYO,DEPT INTERNAL MED 3,TOKYO 113,JAPAN; OSAKA UNIV,SCH MED,DEPT INTERNAL MED 2,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN	University of Tokyo; Osaka University; Osaka University								ABRAHAM JA, 1993, BIOCHEM BIOPH RES CO, V190, P125, DOI 10.1006/bbrc.1993.1020; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DLUZ SM, 1993, J BIOL CHEM, V268, P18330; FISCHERDZOGA K, 1973, EXP MOL PATHOL, V18, P162; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; INABA T, 1992, J BIOL CHEM, V267, P5693; INABA T, 1992, J BIOL CHEM, V267, P13107; INABA T, 1995, ARTERIOSCL THROM VAS, V15, P522, DOI 10.1161/01.ATV.15.4.522; INABA T, 1995, J CLIN INVEST, V95, P1133, DOI 10.1172/JCI117761; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; LEE LS, 1979, P NATL ACAD SCI USA, V76, P5168, DOI 10.1073/pnas.76.10.5168; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; PITAS RE, 1990, J BIOL CHEM, V265, P12722; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966	21	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24413	24417		10.1074/jbc.271.40.24413	http://dx.doi.org/10.1074/jbc.271.40.24413			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798698	hybrid			2022-12-27	WOS:A1996VM67400020
J	Kim, YH; Park, KH; Rho, HM				Kim, YH; Park, KH; Rho, HM			Transcriptional activation of the Cu,Zn-superoxide dismutase gene through the AP2 site by ginsenoside Rb-2 extracted from a medicinal plant, Panax ginseng	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; FACTOR AP-2; CELLS; EXPRESSION; ELEMENTS; BINDING; COPPER; STRESS; REGION; CANCER	We report here that the ginseng saponins induce the transcription of Cu,Zn-superoxide dismutase gene (SOD1), which is one of the major antioxidant enzymes, Total saponins and panaxatriol did not elevate the level of SOD1, but panaxadiol significantly increased SOD1, Among the panaxadiol fractions, ginsenoside Rb-2 was a more specific and more remarkable inducer of the SOD1 gene than ginsenoside Rb-1. Deletion analyses of the SOD1 promoter revealed that the proximal promoter is responsible for this induction, Mobility shift assays with cis-elements in the proximal promoter region showed that specific binding of the AP2 transcription factor was significantly increased by treatment with ginsenoside Rb-2. Mutations of the AP2 binding sites in the heterologous promoter and natural context systems abolished the transcriptional activation by ginsenoside Rb-2. These results suggest that the SOD1 gene was greatly activated by ginsenoside Rb-2 through transcription factor AP2 binding sites and its induction.	SEOUL NATL UNIV,DEPT BIOL MOL,SEOUL 151742,SOUTH KOREA; SEOUL NATL UNIV,RES CTR CELL DIFFERENTIAT,SEOUL 151742,SOUTH KOREA; KOREA GINSENG & TOBACCO RES INST,TAEJON 305345,SOUTH KOREA	Seoul National University (SNU); Seoul National University (SNU)								BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; BREKHMAN II, 1969, ANNU REV PHARMACOLOG, V9, P419, DOI 10.1146/annurev.pa.09.040169.002223; CARRI MT, 1991, FEBS LETT, V278, P263, DOI 10.1016/0014-5793(91)80131-L; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; FRIDOVICH I, 1983, ANN REV PHARM TOXICO, V23, P238; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HUBER W, 1980, CLIN RHEUM DIS, V6, P465; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KIM HT, 1994, BIOCHEM BIOPH RES CO, V201, P1526, DOI 10.1006/bbrc.1994.1877; KIM HY, 1992, BIOCHEM BIOPH RES CO, V189, P670; KIM YH, 1993, GENE, V133, P267; LALORAYA M, 1988, BIOCHEM BIOPH RES CO, V157, P146, DOI 10.1016/S0006-291X(88)80025-1; LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987; LEE KD, 1971, JPN J PHARMACOL, V21, P299, DOI 10.1254/jjp.21.299; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATSUDA H, 1990, PLANTA MED, V56, P19, DOI 10.1055/s-2006-960875; MCCORD JM, 1971, P NATL ACAD SCI USA, V68, P1024, DOI 10.1073/pnas.68.5.1024; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; NICOTERA TM, 1989, CANCER RES, V49, P5239; NISHIYAMA N, 1994, BIOL PHARM BULL, V17, P509, DOI 10.1248/bpb.17.509; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; PERCIVAL SS, 1991, BIOCHEM J, V274, P153, DOI 10.1042/bj2740153; Sambrook J., 2002, MOL CLONING LAB MANU; SATO K, 1994, BIOL PHARM BULL, V17, P635; TANAKA O, 1966, CHEM PHARM BULL, V14, P1159; TODE T, 1993, J CANCER RES CLIN, V120, P24, DOI 10.1007/BF01200720; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YOKOZAWA T, 1993, PHYTOTHER RES, V7, P68, DOI 10.1002/ptr.2650070116; YOKOZAWA T, 1993, PHYTOTHER RES, V7, P240, DOI 10.1002/ptr.2650070306; YUN TK, 1990, INT J EPIDEMIOL, V19, P871, DOI 10.1093/ije/19.4.871	35	108	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24539	24543						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798715	hybrid			2022-12-27	WOS:A1996VM67400037
J	Roberts, JR; Mitchell, GA; Miziorko, HM				Roberts, JR; Mitchell, GA; Miziorko, HM			Modeling of a mutation responsible for human 3-hydroxy-3-methylglutaryl-CoA lyase deficiency implicates histidine 233 as an active site residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A LYASE; ESCHERICHIA-COLI; PSEUDOMONAS-MEVALONII; ISOCITRATE LYASE; ENZYME; MUTAGENESIS; EXPRESSION; CATALYSIS; SUBSTRATE; PROTEINS	3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase is inactivated by diethyl pyrocarbonate (DEPC); activity can be fully restored by incubation with hydroxylamine, Protection against DEPC inactivation is afforded by a substrate analogue, suggesting an active site location for a DEPC target, Included in the inherited defects that map within the HMG-CoA lyase gene is a point mutation that results in an arginine substitution for histidine 233, one of only two invariant histidines, These observations prompted a functional test of the importance of His-233. The mutant lyases H233R, H233A, and H233D were overexpressed in Escherichia coli, isolated, and kinetically characterized. In H233D, DEPC targets one less histidine than was measured using wild-type lyase, supporting the assignment of wild-type lyase His-233 as one of the DEPC targets, Substitution of His-233 results in diminution of activity by similar to 4 orders of magnitude, K-m values of the mutant lyases for both substrate HMG-CoA and activator divalent cation (Mg2+ or Mn2+) are comparable to the values measured for wild-type enzyme, indicating that these enzymes retain substantial structural integrity, This conclusion is reinforced by the observation that the affinity label, 2-butynoyl-CoA, stoichiometrically modifies the mutant lyases, indicating that they contain a full complement of active sites, In view of these data suggesting that the structures of these mutant lyases closely approximate that of the wild-type enzyme, their observed 10(4)-fold diminution in catalytic efficiency supports assignment to His-233 of a role in the chemistry of HMG-CoA cleavage.	MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226; HOP ST JUSTINE,MED GENET SECT,MONTREAL,PQ H3T 1C5,CANADA	Medical College of Wisconsin; Universite de Montreal					NIDDK NIH HHS [DK09018, DK21491] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009018, R37DK021491, R01DK021491] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON DH, 1989, J BACTERIOL, V171, P6468, DOI 10.1128/jb.171.12.6468-6472.1989; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Coon M. J., 1955, S AMINO ACID METABOL, P431; DIEHL P, 1994, J BACTERIOL, V176, P927, DOI 10.1128/jb.176.3.927-931.1994; FAULL K, 1976, NEW ENGL J MED, V294, P1013; GIBSON KM, 1988, EUR J PEDIATR, V148, P180, DOI 10.1007/BF00441397; GOLDFARB S, 1971, J LIPID RES, V12, P512; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HRUZ PW, 1993, BIOCHIM BIOPHYS ACTA, V1162, P149, DOI 10.1016/0167-4838(93)90141-D; HRUZ PW, 1992, BIOCHEMISTRY-US, V31, P6842, DOI 10.1021/bi00144a026; KO YH, 1991, BIOCHEMISTRY-US, V30, P7451, DOI 10.1021/bi00244a012; KRAMER PR, 1980, J BIOL CHEM, V255, P1023; KRAMER PR, 1983, BIOCHEMISTRY-US, V22, P2353, DOI 10.1021/bi00279a008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWENDON A, 1994, BIOCHEMISTRY-US, V33, P1944, DOI 10.1021/bi00173a043; MATHIEU M, 1994, STRUCTURE, V2, P797, DOI 10.1016/S0969-2126(94)00081-6; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; MITCHELL GA, 1993, J BIOL CHEM, V268, P4376; MITCHELL LW, 1995, J BIOL CHEM, V270, P24054, DOI 10.1074/jbc.270.41.24054; MUHLRAD A., 1967, ACTA BIOCHIM BIOPHYS ACAD SCI HUNG, V2, P19; NARASIMHAN C, 1994, ARCH BIOCHEM BIOPHYS, V312, P467, DOI 10.1006/abbi.1994.1333; NARASIMHAN C, 1992, BIOCHEMISTRY-US, V31, P11224, DOI 10.1021/bi00160a037; OVADI J, 1967, ACTA BIOCHIM BIOPHYS, V2, P445; PERDIGUERO E, 1995, BIOCHEMISTRY-US, V34, P6059, DOI 10.1021/bi00018a008; Robert M.-F., 1994, American Journal of Human Genetics, V55, pA41; ROBERTS JR, 1994, J BIOL CHEM, V269, P17841; ROBERTS JR, 1995, J BIOL CHEM, V270, P17311, DOI 10.1074/jbc.270.29.17311; ROBINSON AM, 1980, PHYSIOL REV, V60, P143, DOI 10.1152/physrev.1980.60.1.143; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STEGINK LD, 1968, J BIOL CHEM, V243, P5272; WANG SP, 1993, MAMM GENOME, V4, P382, DOI 10.1007/BF00360589; Wang SP, 1996, GENOMICS, V33, P99, DOI 10.1006/geno.1996.0164; WILLIAMS SF, 1992, J BIOL CHEM, V267, P16041	34	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24604	24609		10.1074/jbc.271.40.24604	http://dx.doi.org/10.1074/jbc.271.40.24604			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798725	hybrid			2022-12-27	WOS:A1996VM67400047
J	Yu, YT				Yu, YT			Distinct domains of myocyte enhancer binding factor-2A determining nuclear localization and cell type-specific transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; MUSCLE-SPECIFIC GENES; MOUSE EMBRYOGENESIS; FACTOR-II; ACTIVATION DOMAINS; MYOGENIC LINEAGE; SERUM INDUCTION; FACTOR MEF-2; EXPRESSION; PROTEINS	The myocyte enhancer binding factor 2 (MEF2) family of transcription factors plays an important role in the regulation of gene expression in multiple muscle cell types. Four mef2 genes (A, B, C, and D) have been identified in vertebrates. They share the conserved N-terminal MCM1-agamous-deficiens-serum response factor and MEF2 domains that determine DNA binding and dimerization functions. Ln this study, we have identified human IMEF2A domains that control its nuclear localization and transcriptional activation function. Studies of subcellular localization of various truncated MEF2A proteins expressed in HeLa cells demonstrated that MEF2A contains a nuclear localization signal located at its C terminus within the peptide encompassing amino acids (aa) 472-507 Examination of MEF2A mutants with sequential C-terminal deletions indicates that the region encompassing aa 321-472 is essential for transcriptional activity. Analysis of the transcriptional activity of fusion proteins consisting of different domains of MEF2A fused to the DNA binding domain of yeast transcription factor GAL4 revealed a major transcriptional activation domain located between aa 274 and 373. Further studies demonstrated that this domain contains positive and negative regulatory subdomains that cooperate with one another to regulate the transcriptional activity of MEF2A in a cell-type discriminatory manner.			Yu, YT (corresponding author), VANDERBILT UNIV,DIV CARDIOL,DEPT MED & BIOCHEM,NASHVILLE,TN 37232, USA.							Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BASSELDUBY R, 1994, MOL CELL BIOL, V14, P4596, DOI 10.1128/MCB.14.7.4596; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CHAUDHARY S, 1994, MOL CELL BIOL, V14, P5290, DOI 10.1128/MCB.14.8.5290; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JOHNSON PF, 1993, J NUTR BIOCHEM, V4, P386, DOI 10.1016/0955-2863(93)90069-9; Johnson SE, 1996, MOL CELL BIOL, V16, P1604; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KENNELLY PJ, 1991, J BIOL CHEM, V266, P1555; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEIBHAM D, 1994, MOL CELL BIOL, V14, P686, DOI 10.1128/MCB.14.1.686; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; MEIER UT, 1992, CELL, V70, P127; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; MOKENTIN JD, 1995, CELL, V83, P1125; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; NURRISH SJ, 1995, MOL CELL BIOL, V15, P4076; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PARMACEK MS, 1991, CIRCULATION, V84, P991, DOI 10.1161/01.CIR.84.3.991; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RAWLS A, 1995, DEV BIOL, V172, P37, DOI 10.1006/dbio.1995.0004; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 2002, MOL CLONING LAB MANU; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SMITH TH, 1994, J CELL BIOL, V127, P95, DOI 10.1083/jcb.127.1.95; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; SUZUKI E, 1995, MOL CELL BIOL, V15, P3415; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	65	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24675	24683						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798735				2022-12-27	WOS:A1996VM67400057
J	Ding, M; Vitale, N; Tsai, SC; Adamik, R; Moss, J; Vaughan, M				Ding, M; Vitale, N; Tsai, SC; Adamik, R; Moss, J; Vaughan, M			Characterization of a GTPase-activating protein that stimulates GTP hydrolysis by both ADP-ribosylation factor (ARF) and ARF-like proteins - Comparison to the ARD1 GAP-domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEINS; GUANINE-NUCLEOTIDE; CHOLERA-TOXIN; PHOSPHOLIPASE-D; BREFELDIN-A; SELECTIVE AMPLIFICATION; ACID PHOSPHOLIPIDS; BOVINE BRAIN; GOLGI; EXCHANGE	ADP-ribosylation factors (ARFs) are similar to 20-kDa guanine nucleotide-binding proteins that participate in vesicular transport in the Golgi and other intracellular compartments and stimulate cholera toxin ADP-ribosyltransferase activity. Both GTP binding and hydrolysis are necessary for its physiological functions, although purified mammalian ARF lacks detectable GTPa selectivity. An ARF GTPase-activating protein (GAP) was purified >15,000-fold from rat spleen cytosol using (NH4)(2)SO4 precipitation and chromatography on Ultrogel AcA 34, DEAE-Sephacel, heparin-Sepharose, hydroxylapatite, and Ultrogel AcA 44. In fractions (similar to 100-kDa proteins) from Ultrogel AcA 44, a major protein band of similar to 50 kDa on SDS-polyacrylamide gel electrophoresis correlated with GAP activity, consistent with it being a homodimer, thus differing from an ARF GAP purified from rat liver (Makler, V., Cukierman, E., Rotman, M., Admon, A., and Cassel, D. (1995) J. Biol. Chem. 270, 5232-5237). Purified spleen GAP accelerated hydrolysis of GTP bound to recombinant ARF1, ARF3, ARF5, and ARF6; no effect of NH2-terminal myristoylation was observed, ARF GAP also activated GTP hydrolysis by ARL1, which is 56% identical in amino acid sequence to ARF1, but lacks ARF activity, ARD1 is a 64-MDa guanine nucleotide binding protein that contains an 18-kDa ARF domain at its carboxyl terminus; the ARF domain lacks the amino-terminal alpha-helix found in native ARF and hence is similar to the amino-terminal truncated mutant Delta 13ARF1. Both the ARF domain of ARD1 and Delta 13ARF1 were poor substrates for ARF GAP. The non-ARF1 do main of ARD1 enhanced the GTPase activity of the ARF domain, but not that of the ARF proteins and Delta 13ARF1, i.e. it lacks the relatively broad substrate specificity exhibited by ARF GAP.	NHLBI, NATL INST HLTH, PULM CRIT CARE MED BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Vitale, Nicolas/G-5967-2014	Vitale, Nicolas/0000-0002-4752-4907				BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CAVENAGH MM, 1994, J BIOL CHEM, V269, P18937; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HONG JX, 1994, J BIOL CHEM, V269, P9743; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAHN RA, 1986, J BIOL CHEM, V261, P7906; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; MURTAGH JJ, 1992, J BIOL CHEM, V267, P9654; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1992, J BIOL CHEM, V267, P17766; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TERUI T, 1994, J BIOL CHEM, V269, P28130; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1994, P NATL ACAD SCI USA, V91, P3063, DOI 10.1073/pnas.91.8.3063; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; Vitale N, 1996, P NATL ACAD SCI USA, V93, P1941, DOI 10.1073/pnas.93.5.1941; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	32	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24005	24009		10.1074/jbc.271.39.24005	http://dx.doi.org/10.1074/jbc.271.39.24005			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798635	hybrid			2022-12-27	WOS:A1996VJ44200064
J	Palvimo, JJ; Reinikainen, P; Ikonen, T; Kallio, PJ; Moilanen, A; Janne, OA				Palvimo, JJ; Reinikainen, P; Ikonen, T; Kallio, PJ; Moilanen, A; Janne, OA			Mutual transcriptional interference between RelA and androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TATA-BINDING PROTEIN; GLUCOCORTICOID RECEPTORS; P65 SUBUNIT; ACTIVATION; ALPHA; TRANSACTIVATION; INTERLEUKIN-6; ASSOCIATION; GENE	Cross-modulation between androgen receptor (AR) and NF-kappa B/Rel proteins was studied using various androgen- and NF-KB-regulated reporter genes under transient transfection conditions. In COS-1 cells, elevated expression of RelA (p65) repressed AR-mediated transactivation in a dose-dependent manner, whereas NF kappa B1 (p50), another major member of the NF-kappa B family, did not influence transactivation. The repression of AR appeared to involve the N-terminal region of the protein between residue 297 and the DNA-binding domain. ReLA-mediated transrepression could not be over come by increasing the amount of AR. Transcriptional interference between RelA and AR was mutual in that cotransfected AR was able to attenuate transactivation by RelA in a dose- and steroid-dependent fashion. An excess of RelA was able to rescue the repression to some extent. Immunological analyses of RelA and AR protein levels indicated that transrepression was not due to reciprocal decrease in their amounts. Neither did AR increase the concentration of I kappa B alpha, which can sequester and inactivate RelA. Electrophoretic mobility shift assays using extracts from cotransfected cells and purified recombinant proteins showed that AR and RelA did not significantly influence each other's DNA binding activity. Nevertheless, protein-protein interaction experiments demonstrated a weak association between AR and RelA. Collectively, these data suggest that the mutual repression in intact cells is due to formation of AR-RelA complexes that are held together by another partner or to competition for a coactivator required for transcription.	UNIV HELSINKI,INST BIOMED,DEPT PHYSIOL,FIN-00014 HELSINKI,FINLAND	University of Helsinki				Palvimo, Jorma/0000-0003-2373-0578				ADEYEMO O, 1993, HUM MOL GENET, V2, P1809, DOI 10.1093/hmg/2.11.1809; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; HERRLICH P, 1994, TRENDS ENDOCRIN MET, V5, P341, DOI 10.1016/1043-2760(94)90164-3; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; KALLIO PJ, 1994, J BIOL CHEM, V269, P11514; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; LIU W, 1995, MOL CELL BIOL, V15, P1005; MHATRE AN, 1993, NAT GENET, V5, P184, DOI 10.1038/ng1093-184; NAKAJIMA Y, 1995, UROL RES, V23, P205, DOI 10.1007/BF00393299; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; Palvimo JJ, 1996, BIOCHEM J, V316, P993, DOI 10.1042/bj3160993; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SPARACIO SM, 1992, J NEUROIMMUNOL, V39, P231, DOI 10.1016/0165-5728(92)90257-L; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1995, MOL CELL BIOL, V15, P4971; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723	33	184	186	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24151	24156		10.1074/jbc.271.39.24151	http://dx.doi.org/10.1074/jbc.271.39.24151			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798655	hybrid			2022-12-27	WOS:A1996VJ44200084
J	Arystarkhova, E; Sweadner, KJ				Arystarkhova, E; Sweadner, KJ			Isoform-specific monoclonal antibodies to Na,K-ATPase alpha subunits - Evidence for a tissue-specific post-translational modification of the alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; CENTRAL-NERVOUS-SYSTEM; RAT CARDIAC VENTRICLE; NA+-K+-ATPASE; CATALYTIC SUBUNIT; BETA-SUBUNIT; DIFFERENTIAL EXPRESSION; ENZYMATIC-PROPERTIES; GEL-ELECTROPHORESIS; SKELETAL-MUSCLE	Monoclonal antibodies to isoforms of the Na,K-ATPase have become important tools in the study of the enzyme's distribution, physiological roles, and gene regulation, and when their epitopes are defined, they are useful in the study of enzyme structure as well. Evidence is presented that the alpha 3-specific antibody McBX3 recognizes an unusual epitope that is not present on alpha 3 in the heart. The epitope, which is also found in kidney oil from some species, was mapped to a site on the large intracellular loop near the ATP binding site. DNA sequencing of reverse transcribed-PCR products encompassing the corresponding regions from alpha 3 from brain (where McBX3 recognizes alpha 3) and heart demonstrated that the tissue difference in epitope is not due to alternative splicing of the mRNA. Instead, hydroxylamine sensitivity indicated that the antibody recognizes a post-translational modification. The epitope for a new antibody for alpha 3, XVIF9-G10, was mapped to a site near the N terminus, a location analogous to the sites for the well-characterized antibodies McK1 (alpha 1) and McB2 (alpha 2). The antibody XVIF9-G10 reacted with the alpha 3 of the heart as well as that of the brain; however, McBX3 and XVIF9-G10 both stained the same cellular structures in sections of the rat retina. A new alpha 1-specific antibody, 6F, was characterized and mapped to another site near the N terminus; this antibody has broader species specificity than the other well-characterized alpha 1 antibody, McK1.	MASSACHUSETTS GEN HOSP, MEMBRANE BIOL LAB, CHARLESTOWN, MA 02129 USA	Harvard University; Massachusetts General Hospital					NHLBI NIH HHS [HL 36271] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036271] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOTT A, 1992, BIOCHEMISTRY-US, V31, P11236, DOI 10.1021/bi00160a039; ABBOTT A, 1993, BIOCHEMISTRY-US, V32, P3511, DOI 10.1021/bi00064a040; ARYSTARKHOVA EA, 1991, BIOPHYS J, V59, pA340; BALL WJ, 1987, BIOCHIM BIOPHYS ACTA, V916, P100, DOI 10.1016/0167-4838(87)90216-0; BAYER R, 1990, BIOCHEMISTRY-US, V29, P2251, DOI 10.1021/bi00461a007; BENALLAL M, 1994, EXPERIENTIA, V50, P664, DOI 10.1007/BF01952869; BERREBIBERTRAND I, 1994, FEBS LETT, V348, P55, DOI 10.1016/0014-5793(94)00550-8; BLANCO G, 1994, P NATL ACAD SCI USA, V91, P8542, DOI 10.1073/pnas.91.18.8542; BORNSTEIN P, 1970, BIOCHEMISTRY-US, V9, P2408, DOI 10.1021/bi00814a004; BROWN D, 1996, IN PRESS J HISTOCHEM; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DALY SE, 1994, J BIOL CHEM, V269, P23944; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; GHOSH S, 1990, J BIOL CHEM, V265, P2935; HSU YM, 1989, BIOCHEMISTRY-US, V28, P569, DOI 10.1021/bi00428a023; HUNDAL HS, 1994, MOL MEMBR BIOL, V11, P255, DOI 10.3109/09687689409160435; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P291; JUST I, 1995, BIOCHEMISTRY-US, V34, P326, DOI 10.1021/bi00001a040; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; Landon, 1977, Methods Enzymol, V47, P145; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LUCCHESI PA, 1991, J BIOL CHEM, V266, P9327; LYTTON J, 1985, BIOCHEM BIOPH RES CO, V132, P764, DOI 10.1016/0006-291X(85)91198-2; MCGRAIL KM, 1990, EUR J NEUROSCI, V2, P170, DOI 10.1111/j.1460-9568.1990.tb00409.x; MCGRAIL KM, 1991, J NEUROSCI, V11, P381, DOI 10.1523/jneurosci.11-02-00381.1991; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; NAGANO K, 1965, BIOCHEM BIOPH RES CO, V19, P759, DOI 10.1016/0006-291X(65)90324-4; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; OVCHINNIKOV YA, 1987, FEBS LETT, V217, P269, DOI 10.1016/0014-5793(87)80676-2; OVCHINNIKOV YA, 1988, FEBS LETT, V227, P235, DOI 10.1016/0014-5793(88)80905-0; OVCHINNIKOV YA, 1988, FEBS LETT, V233, P87, DOI 10.1016/0014-5793(88)81361-9; PEDEMONTE CH, 1992, BIOCHEMISTRY-US, V31, P10465, DOI 10.1021/bi00158a008; PEDEMONTE CH, 1990, P NATL ACAD SCI USA, V87, P9789, DOI 10.1073/pnas.87.24.9789; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; RUSSO JJ, 1990, AM J PHYSIOL, V259, pC968, DOI 10.1152/ajpcell.1990.259.6.C968; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER BG, 1990, EXP EYE RES, V51, P553, DOI 10.1016/0014-4835(90)90086-A; SHAMRAJ OI, 1991, BIOCHEM BIOPH RES CO, V179, P1434, DOI 10.1016/0006-291X(91)91733-S; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SHYJAN AW, 1990, P NATL ACAD SCI USA, V87, P1178, DOI 10.1073/pnas.87.3.1178; SHYJAN AW, 1989, BIOCHEMISTRY-US, V28, P4531, DOI 10.1021/bi00437a002; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; SUN Y, 1992, AM J PHYSIOL, V262, pC1491, DOI 10.1152/ajpcell.1992.262.6.C1491; SWEADNER KJ, 1987, P NATL ACAD SCI USA, V84, P8404, DOI 10.1073/pnas.84.23.8404; SWEADNER KJ, 1985, J BIOL CHEM, V260, P9016; SWEADNER KJ, 1992, ANN NY ACAD SCI, V671, P217, DOI 10.1111/j.1749-6632.1992.tb43798.x; SWEADNER KJ, 1991, ANAL BIOCHEM, V194, P130, DOI 10.1016/0003-2697(91)90159-Q; SWEADNER KJ, 1985, J BIOL CHEM, V260, P1508; SWEADNER KJ, 1988, METHOD ENZYMOL, V156, P65; SWEADNER KJ, 1994, CIRC RES, V74, P669, DOI 10.1161/01.RES.74.4.669; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TAI MM, 1989, BIOCHEMISTRY-US, V28, P3183, DOI 10.1021/bi00434a011; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; Therien AG, 1996, J BIOL CHEM, V271, P7104, DOI 10.1074/jbc.271.12.7104; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; URAYAMA O, 1988, BIOCHEM BIOPH RES CO, V156, P796, DOI 10.1016/S0006-291X(88)80914-8; WATTS AG, 1991, P NATL ACAD SCI USA, V88, P7425, DOI 10.1073/pnas.88.16.7425	61	82	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23407	23417		10.1074/jbc.271.38.23407	http://dx.doi.org/10.1074/jbc.271.38.23407			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798546	hybrid			2022-12-27	WOS:A1996VH76800072
J	Duncan, JA; Gilman, AG				Duncan, JA; Gilman, AG			Autoacylation of G protein alpha subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; BETA-GAMMA SUBUNITS; LIPID MODIFICATIONS; ESCHERICHIA-COLI; SF9 CELLS; PALMITOYLATION; ACYLATION; MYRISTOYLATION; PURIFICATION; EXPRESSION	The palmitoylation or S-acylation of at least some G protein cu subunits is a dynamic process that is regulated in vivo by the activation of associated receptors. Highly purified, myristoylated G(i alpha 1) and other G protein alpha subunits react spontaneously with palmitoyl-CoA in vitro to form thioesterified proteins. This reaction requires native G(i alpha 1) and occurs exclusively at Cys(3), the same residue that is palmitoylated in vivo. The reaction proceeds to completion, and its rate is roughly equal to the rate of loss of palmitate observed in pulse-chase experiments in vivo. The rate of autoacylation is significantly enhanced by the G protein py subunit complex. Autoacylation may play a role in the dynamic thioesterification of some cellular proteins.			Duncan, JA (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.				NIGMS NIH HHS [GM34497, T32 GM07062] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497, T32GM007062] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTHIAUME L, 1995, J BIOL CHEM, V270, P22399; BHARADWAJ M, 1995, J NEUROCHEM, V65, P1805; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P13550; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CAMP LA, 1993, J BIOL CHEM, V268, P22566; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEGTYAREV MY, 1995, J BIOL CHEM, V269, P30893; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HALLAK H, 1994, J BIOL CHEM, V269, P4713; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JOHNSON DR, 1994, ANN REV BIOCH, P63869; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1994, METHOD ENZYMOL, V237, P254; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NADLER MJS, 1994, BBA-LIPID LIPID MET, V1213, P100, DOI 10.1016/0005-2760(94)90227-5; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; QUESNEL S, 1994, BIOCHEMISTRY-US, V33, P13340, DOI 10.1021/bi00249a021; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667	34	162	164	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23594	23600		10.1074/jbc.271.38.23594	http://dx.doi.org/10.1074/jbc.271.38.23594			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798571	hybrid			2022-12-27	WOS:A1996VH76800097
J	Funk, CD; Keeney, DS; Oliw, EH; Boeglin, WE; Brash, AR				Funk, CD; Keeney, DS; Oliw, EH; Boeglin, WE; Brash, AR			Functional expression and cellular localization of a mouse epidermal lipoxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; CDNA CLONING; MOLECULAR-BIOLOGY; PLATELET-TYPE; SKIN; 12-LIPOXYGENASE; KERATINOCYTES; CELLS; 8-LIPOXYGENASE; 5-LIPOXYGENASE	Three distinct murine lipoxygenase genes have been functionally characterized: 5-lipoxygenase (Chen, X.-S., Naumann, T. A., Kurre, U., Jenkins, N. A., Copeland, N. G., and Funk, C. D. (1995) J. Biol. Chem. 270, 17993-17999), platelet-type 12-lipoxygenase and leukocyte-type 12-lipoxygenase (Chen, X.-S., Kurre, U., Jenkins, N. A., Copeland, N. G., and Funk, C. D. (1994) J. Biol. Chem. 269, 13979-13987). Here, we describe the cloning and functional characterization of a fourth lipoxygenase gene in mice. Using a polymerase chain reaction-based approach together with partial sequence information from a genomic clone, we isolated a novel lipoxygenase cDNA hom the RNA of 3-6-day old mouse epidermis. The open reading frame predicts a 662-amino acid lipoxygenase that displays 60% identity with both murine 12-lipoxygenase isozymes and 40% identity to 5-lipoxygenase; the sequence is identical to a genomic sequence reported recently (van Dijk, K. W., Steketee, K., Havekes, L., Frants, R., and Hofker, M. (1995) Biochim. Biophys. Acta 1259, 4-8). A full-length clone was expressed in human embryonic kidney 293 cells and homogenates from disrupted cells produced 12 hydroxyeicosatetraenoic acid (12-HETE) and minor amounts of 15-HETE from arachidonic acid. Chiral phase analysis indicated that the 12-HETE is exclusively the 12S enantiomer. In situ hybridization revealed highly specific expression of epidermal lipoxygenase in differentiated keratinocytes of the epidermis and in restricted regions of the root sheath and bulb of hair follicles. High expression was also detected in conjunctiva of the eyelid and in cells of Meibomian and preputial (sebaceous) glands. A 2.4-kilobase mRNA was detected in mouse epidermis by Northern blot analysis and its abundance was not affected by phorbol ester treatment. The epidermal lipoxygenase gene (Aloxe) resides on mouse chromosome 11 closely linked with the two 12-lipoxygenase genes (Alox12p and Alox12l).	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT BIOCHEM,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University	Funk, CD (corresponding author), UNIV PENN,CTR EXPT THERAPEUT,STELLAR CHANCE LABS,RM 805,422 CURIE BLVD,PHILADELPHIA,PA 19104, USA.		Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233; Oliw, Ernst/0000-0002-7986-8130	NHLBI NIH HHS [HL53558] Funding Source: Medline; NIAMS NIH HHS [AR41943] Funding Source: Medline; NIGMS NIH HHS [GM49502] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049502] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARENBERGER P, 1992, EUR J IMMUNOL, V22, P2469, DOI 10.1002/eji.1830220944; BICKERS DR, 1982, MOL PHARMACOL, V21, P239; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CAMERON GS, 1990, J INVEST DERMATOL, V94, P292, DOI 10.1111/1523-1747.ep12874434; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; CHEN XS, 1994, J BIOL CHEM, V269, P13979; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOWNING DT, 1992, J LIPID RES, V33, P301; FISCHER SM, 1988, CANCER RES, V48, P658; FREIREMOAR J, 1995, BBA-LIPID LIPID MET, V1254, P112, DOI 10.1016/0005-2760(94)00199-9; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; FUNK CD, 1993, PROG NUCLEIC ACID RE, V45, P67, DOI 10.1016/S0079-6603(08)60867-3; FURSTENBERGER G, 1991, J BIOL CHEM, V266, P15738; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GROSS E, 1990, J INVEST DERMATOL, V94, P446, DOI 10.1111/1523-1747.ep12874543; HAMMARSTROM S, 1979, J INVEST DERMATOL, V73, P180, DOI 10.1111/1523-1747.ep12581645; HENKE D, 1986, BIOCHIM BIOPHYS ACTA, V876, P271, DOI 10.1016/0005-2760(86)90284-5; HOGAN B, 1994, MANIPULATING MOUSE E, P327; HUGHES MA, 1991, BIOCHIM BIOPHYS ACTA, V1081, P347, DOI 10.1016/0005-2760(91)90292-P; HUSSAIN H, 1994, AM J PHYSIOL, V266, pC243, DOI 10.1152/ajpcell.1994.266.1.C243; JANSSENTIMMEN U, 1995, P NATL ACAD SCI USA, V92, P6966, DOI 10.1073/pnas.92.15.6966; KRIEG P, 1995, MOL CARCINOGEN, V14, P118, DOI 10.1002/mc.2940140208; MURRAY AW, 1980, J INVEST DERMATOL, V75, P508, DOI 10.1111/1523-1747.ep12524327; NAKADATE T, 1986, PROSTAG LEUKOTR ESS, V21, P305, DOI 10.1016/0262-1746(86)90051-X; NICOLAIDES N, 1974, SCIENCE, V186, P19, DOI 10.1126/science.186.4158.19; NUGTEREN DH, 1987, BIOCHIM BIOPHYS ACTA, V921, P135, DOI 10.1016/0005-2760(87)90179-2; RUZICKA T, 1983, BIOCHIM BIOPHYS ACTA, V751, P369, DOI 10.1016/0005-2760(83)90295-3; RUZICKA T, 1992, EICOSANOIDS, V5, pS63; SIGAL E, 1991, AM J PHYSIOL, V260, pL13, DOI 10.1152/ajplung.1991.260.2.L13; STEWART ME, 1995, J INVEST DERMATOL, V105, P613, DOI 10.1111/1523-1747.ep12323736; TAKAHASHI Y, 1993, J BIOL CHEM, V268, P16443; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; VANDIJK KW, 1995, BBA-LIPID LIPID MET, V1259, P4, DOI 10.1016/0005-2760(95)00158-9; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9	35	82	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23338	23344		10.1074/jbc.271.38.23338	http://dx.doi.org/10.1074/jbc.271.38.23338			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798535	hybrid			2022-12-27	WOS:A1996VH76800061
J	Milani, D; Mazzoni, M; Borgatti, P; Zauli, G; Cantley, L; Capitani, S				Milani, D; Mazzoni, M; Borgatti, P; Zauli, G; Cantley, L; Capitani, S			Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; HIV-1 TAT; STIMULATES PRODUCTION; KINASE; PROLIFERATION; ADHESION; IDENTIFICATION; INHIBITION; APOPTOSIS; RECEPTORS	We have here investigated the effect of the regulatory Tat protein of the human immunodeficiency virus type 1 (HIV-1) on the PI 3-kinase catalytic activity in PC12 rat pheochromocytoma cells. After as early as 1 min from the beginning of the treatment with recombinant HIV-1 Tat protein, a significant increase in the tyrosine phosphorylation levels of the p85 regulatory subunit of PI 3-kinase was noticed in 48 h serum-starved PC12 cells. Moreover, the addition of Tat to PC12 cells induced a great increase in PI 3-kinase immunoprecipitated with an anti-phosphotyrosine antibody with a peak of activity (19-fold increase with respect to the basal levels) after a 15-min treatment. This increase in PI 3-kinase activity was significantly higher in PC12 cell cultures supplemented with Tat protein than in cultures stimulated by 100 ng/ml nerve growth factor (NGF; 8-fold increase with respect to the basal levels). Further experiments showed that Tat protein was able to specifically activate PI 3-kinase at picomolar concentrations, In fact: (i) maximal activation of PI 3-kinase was observed at concentrations as low as 1 ng/ml and was specifically blocked by anti-Tat neutralizing antibody; (ii) a Tat-dependent activation was also observed in experiments in which PI 3-kinase activity was evaluated in either anti-Tyr(P) or anti-p85 immunoprecipitates; (iii) 100 nM wortmannin completely blocked the Tat-mediated increase in PI 3-kinase activity both in vitro and in vivo. Our data strongly support the concept that extracellular Tat acts as a cell stimulator, inducing intracellular signal transduction in uninfected cells.	UNIV FERRARA,INST HUMAN ANAT,I-44100 FERRARA,ITALY; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02215; BETH ISRAEL HOSP,DIV SIGNAL TRANSDUCT,BOSTON,MA 02215	University of Ferrara; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center			Cantley, Lewis C/D-1800-2014; Zauli, Giorgio/ABE-8001-2020; Milani, Daniela/G-5579-2015	Cantley, Lewis C/0000-0002-1298-7653; Milani, Daniela/0000-0002-9540-7801; Zauli, Giorgio/0000-0002-3750-8698; CAPITANI, Silvano/0000-0003-2795-6814	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R37GM041890] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM041890, GM41890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BRAKE DA, 1990, J CELL BIOL, V111, P1275, DOI 10.1083/jcb.111.3.1275; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; LI CJ, 1995, SCIENCE, V268, P229; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MILANI D, 1993, J GEN VIROL, V74, P2587, DOI 10.1099/0022-1317-74-12-2587; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OKADA T, 1994, J BIOL CHEM, V269, P3563; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WEEKS BS, 1993, J BIOL CHEM, V268, P5279; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZAULI G, 1993, CANCER RES, V53, P4481; ZAULI G, 1995, J ACQ IMMUN DEF SYND, V10, P306; ZAULI G, 1992, BLOOD, V80, P3036	27	62	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22961	22964		10.1074/jbc.271.38.22961	http://dx.doi.org/10.1074/jbc.271.38.22961			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798481	hybrid			2022-12-27	WOS:A1996VH76800007
J	Iwamoto, T; Watano, T; Shigekawa, M				Iwamoto, T; Watano, T; Shigekawa, M			A novel isothiourea derivative selectively inhibits the reverse mode of Na+/Ca2+ exchange in cells expressing NCX1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; SMOOTH-MUSCLE CELLS; CARDIAC SARCOLEMMAL VESICLES; NA+-CA2+ EXCHANGER; AMILORIDE ANALOGS; PRIMARY CULTURE; MECHANISM; MYOCYTES; CLONING; ISOFORMS	No.7943 (2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea methanesulfonate), a selective inhibitor of the Na+/Ca2+ exchanger (NCX1), has been newly synthesized, It dose-dependently inhibited Na-i(+)-dependent Ca-45(2+) uptake and Na-i(+)-dependent [Ca2+](i) increase in cardiomyocytes, smooth muscle cells, and NCX1-transfected fibroblasts (IC50 = 1.2-2.4 mu M). Inhibition was observed without prior incubation with the agent and was completely reversed by washing cells with buffer for 1 min. Interestingly, No.7943 was much less potent in inhibiting Na-o(+)-dependent Ca-45(2+) efflux and Na-o(+)-induced [Ca2+](i) decline (IC50 = >30 mu M), indicating that it selectively blocks the reverse mode of Na+/Ca2+ exchange in intact cells. In cardiac sarcolemmal preparations consisting mostly of inside-out vesicles, the agent inhibited Na-i(+)-dependent Ca-45(2+) uptake and Na-o(+)-dependent Ca-45(2+) efflux with similar, but slightly lower, potencies (IC50 = 5.4-13 mu M). Inhibition was noncompetitive with respect to Ca2+ and Na+ in both cells and sarcolemmal vesicles. These results suggest that No.7943 primarily acts on external exchanger site(s) other than the transport sites in intact cells, although it is able to inhibit the exchanger from both sides of the plasma membrane, No.7943 at up to 10 mu M does not affect many other ion transporters nor several cardiac action potential parameters. This agent at these concentrations also did not influence either diastolic [Ca2+](i) or spontaneous beating in cardiomyocytes. Furthermore, No.7943 markedly inhibited Ca2+ overloading into cardiomyocytes under the Ca2+ paradox conditions. Thus, No.7943 is not only useful as a tool with which to study the transport mechanism and physiological role of the Na+/Ca2+ exchanger but also has therapeutic potential as a selective blocker of excessive Ca2+ influx mediated via the Na+/Ca2+ exchanger under pathological conditions.	NATL CARDIOVASC CTR, RES INST, DEPT MOL PHYSIOL, SUITA, OSAKA 565, JAPAN; KANEBO LTD, NEW DRUG RES LABS, OSAKA 534, JAPAN	National Cerebral & Cardiovascular Center - Japan								BERS DM, 1991, ANN NY ACAD SCI, V639, P375, DOI 10.1111/j.1749-6632.1991.tb17326.x; BLAUSTEIN MP, 1991, ANN NY ACAD SCI, V639, P1; BOUCHARD RA, 1993, J PHYSIOL-LONDON, V469, P583, DOI 10.1113/jphysiol.1993.sp019831; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; CHAMLEY JH, 1977, CELL TISSUE RES, V177, P503; CHAPMAN RA, 1987, PROG BIOPHYS MOL BIO, V50, P67, DOI 10.1016/0079-6107(87)90004-6; CHEN CM, 1971, J PHARMACOL EXP THER, V209, P415; Fiske CH, 1925, J BIOL CHEM, V66, P375; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; GARCIA ML, 1990, J BIOL CHEM, V265, P3763; IMAGAWA T, 1989, J BIOCHEM-TOKYO, V106, P342, DOI 10.1093/oxfordjournals.jbchem.a122855; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; IWAMOTO T, 1995, J BIOL CHEM, V270, P8996, DOI 10.1074/jbc.270.15.8996; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; JONES LR, 1988, METHOD ENZYMOL, V157, P85; KACZOROWSKI GJ, 1989, SODIUM CALCIUM EXCHA, P66; KLEYMAN TR, 1990, METHOD ENZYMOL, V191, P739; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KOHMOTO O, 1994, CIRC RES, V74, P550, DOI 10.1161/01.RES.74.3.550; LI ZP, 1991, J BIOL CHEM, V266, P1014; LI ZP, 1994, J BIOL CHEM, V269, P17434; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; Nakamura Aki, 1996, Japanese Journal of Pharmacology, V71, p310P; NAKASAKI Y, 1993, J BIOCHEM-TOKYO, V114, P528, DOI 10.1093/oxfordjournals.jbchem.a124211; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; OHSHIMA N, 1994, J BIOCHEM, V116, P274, DOI 10.1093/oxfordjournals.jbchem.a124519; Philipson K D, 1993, Int Rev Cytol, V137C, P199; PHILIPSON KD, 1985, BIOCHIM BIOPHYS ACTA, V821, P367, DOI 10.1016/0005-2736(85)90107-5; REYNARD AM, 1961, J BIOL CHEM, V236, P2277; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; SLAUGHTER RS, 1988, BIOCHEMISTRY-US, V27, P2403, DOI 10.1021/bi00407a023; TANI M, 1990, ANNU REV PHYSIOL, V52, P543; VEMURI R, 1988, BIOCHIM BIOPHYS ACTA, V937, P258, DOI 10.1016/0005-2736(88)90248-9; WAKABAYASHI S, 1995, J BIOL CHEM, V270, P26460, DOI 10.1074/jbc.270.44.26460; WIER WG, 1990, ANNU REV PHYSIOL, V52, P467	36	438	450	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22391	22397		10.1074/jbc.271.37.22391	http://dx.doi.org/10.1074/jbc.271.37.22391			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798401	hybrid			2022-12-27	WOS:A1996VG67200020
J	ONeill, TJ; Rose, DW; Pillay, TS; Hotta, K; Olefsky, JM; Gustafson, TA				ONeill, TJ; Rose, DW; Pillay, TS; Hotta, K; Olefsky, JM; Gustafson, TA			Interaction of a GRB-IR splice variant (a human GRB10 homolog) with the insulin and insulin-like growth factor I receptors - Evidence for a role in mitogenic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-DEPENDENT INTERACTION; YEAST HO GENE; SH2 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE AUTOPHOSPHORYLATION; INDUCED ACTIVATION; GLUCOSE-TRANSPORT; INTACT-CELLS; NPEY MOTIF; PROTEIN	We have utilized the yeast two-hybrid system to identify proteins that interact with the cytoplasmic domain of the insulin receptor. We identified a human cDNA that is a splice variant of the human GRB10 homolog GRB-IR, which we term GRB10/IR-SV1 (for GRB10/GRB-IR splice variant 1). The protein encoded by the GRB10/IR-SV1 cDNA contains an SH2 domain and a pleckstrin homology domain. Cloning of a full-length human cDNA revealed a predicted coding sequence that was similar to the mouse GRB10 protein, although GRB10/IR-SV1 contained an 80-amino acid deletion. The GRB10/IR-SV1 cDNA is a splice variant of the GRB-IR cDNA such that GRB10/IR-SV1 contains an intact pleckstrin homology domain and a distinct amino terminus. The interaction of GRB10/IR-SV1 with the insulin receptor and the insulin-like growth factor I (IGF-I) receptor is mediated by the SH2 domain, and we show that glutathione S-transferase-SH2 domain fusion proteins interact specifically in vitro with the insulin receptor derived from mammalian cells. The GRB10/IR-SV1 SH2 domain also interacted with an similar to 135-kDa phosphoprotein from unstimulated cell lysates, an interaction that decreased after insulin stimulation. We present evidence that the GRB10/IR-SV1 protein plays a functional role in insulin and IGF-I signaling by showing that microinjection of an SH2 domain fusion protein inhibited insulin- and IGF-I-stimulated mitogenesis in fibroblasts, yet had no effect on mitogenesis induced by epidermal growth factor. Our findings suggest that GRB10/IR-SV1 may serve to positively link the insulin and IGF-I receptors to an uncharacterized mitogenic signaling pathway.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University System of Maryland; University of Maryland Baltimore; University of California System; University of California San Diego				pillay, tahir/0000-0002-9982-9710; Hotta, Kikuko/0000-0003-2427-6354	NIDDK NIH HHS [DK44093, DK50602, DK33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050602, R29DK044093, R01DK033651, R37DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BERHANU P, 1991, MOL ENDOCRINOL, V5, P1827, DOI 10.1210/mend-5-12-1827; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; GUTHRIE C, 1992, METHOD ENZYMOL, V194, P1; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KOSAKI A, 1995, J BIOL CHEM, V270, P20816, DOI 10.1074/jbc.270.35.20816; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; Miller J.H., 1972, EXPT MOL GENETICS; OKADA T, 1994, J BIOL CHEM, V269, P3568; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; OOI J, 1995, ONCOGENE, V10, P1610; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QUON MJ, 1994, J BIOL CHEM, V269, P27920; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; RUBIN R, 1995, LAB INVEST, V73, P311; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAKATA Y, 1991, J BIOL CHEM, V266, P9135; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, J BIOL CHEM, V263, P2969; XIAO S, 1994, J BIOL CHEM, V269, P21244; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG B, 1991, J BIOL CHEM, V266, P990	53	129	133	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22506	22513		10.1074/jbc.271.37.22506	http://dx.doi.org/10.1074/jbc.271.37.22506			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798417	hybrid			2022-12-27	WOS:A1996VG67200036
J	Ziober, BL; Kramer, RH				Ziober, BL; Kramer, RH			Identification and characterization of the cell type-specific and developmentally regulated alpha 7 integrin gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC TRANSCRIPTION; CREATINE-KINASE ENHANCER; RECEPTOR EPSILON-SUBUNIT; TRANS-ACTING FACTOR; CAT BINDING-FACTOR; TROPONIN-C GENE; SKELETAL-MUSCLE; CARDIAC-MUSCLE; CYTOPLASMIC DOMAINS; CD18 PROMOTER	Expression of alpha 7 is mainly confined to skeletal and cardiac muscle in which it appears to be the major laminin-binding integrin. When myoblasts differentiate to myotubes, alpha 7 mRNA and protein expression is up-regulated. To explore the mechanisms involved in the tissue-specific and developmentally regulated expression of alpha 7, we isolated and characterized a genomic clone containing similar to 2.8 kilobase pairs (kb) of the 5'-flanking region of the murine alpha 7 gene. The 5'-flanking region lacks both TATA and CCAAT boxes but contains five putative Sp1 binding sites located in a CpG island. Two transcription start sites, located near an initiator-like sequence, are 176 and 170 base pairs upstream of the translation start site. There are numerous binding sites for developmental and cell type-specific transcription factors, including AP-1, AP-2, GATA, and several AT-rich sites, There are also eight consensus E-boxes that bind the basic helix-loop-helix family of muscle-specific transcription factors. The similar to 2.8-kb 5'-flanking region was an active promoter in C2C12 skeletal myoblasts and exhibited increased expression upon conversion to myotubes but was inactive in HtLM2 cells, a mouse breast carcinoma epithelial cell line that does not express alpha 7. Deletion analysis identified both positive and negative regulatory elements within the similar to 2.8-kb fragment. In 10T1/2 fibroblasts the similar to 2.8-kb alpha 7 promoter was trans-activated by the myogenic basic helix-loop-helix proteins myogenin and MyoD but not by MRF4 and myf5. These results suggest that muscle-specific transcription factors play a role in regulating the cell-type expression of the alpha 7 gene during development.	UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [CA51884] Funding Source: Medline; NIDCR NIH HHS [DE10564, DE10306] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010306, R01DE010564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGURA ED, 1992, BLOOD, V79, P602; AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; BANERJEEBASU S, 1993, MOL CELL BIOL, V13, P7019, DOI 10.1128/MCB.13.11.7019; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BLACK BL, 1995, J BIOL CHEM, V270, P2889, DOI 10.1074/jbc.270.7.2889; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BOSMAN FT, 1993, HISTOCHEM J, V25, P469, DOI 10.1007/BF00159282; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; BRANN TE, 1990, EMBO J, V9, P821; BRUTLAG DL, 1980, ANNU REV GENET, V14, P121, DOI 10.1146/annurev.ge.14.120180.001005; CERVELLA P, 1993, J BIOL CHEM, V268, P5148; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P1156; CHRISTENSEN TH, 1993, MOL CELL BIOL, V13, P6752, DOI 10.1128/MCB.13.11.6752; COLLO G, 1993, J BIOL CHEM, V268, P19019; CSERJESI P, 1994, J BIOL CHEM, V269, P16740; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DONAHUE JP, 1994, BBA-GENE STRUCT EXPR, V1219, P228, DOI 10.1016/0167-4781(94)90278-X; DURR I, 1994, EUR J BIOCHEM, V224, P353, DOI 10.1111/j.1432-1033.1994.00353.x; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FARRANCE IKG, 1992, J BIOL CHEM, V267, P17234; GEORGEWEINSTEIN M, 1993, DEV BIOL, V156, P209, DOI 10.1006/dbio.1993.1071; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HICKSTEIN DD, 1992, P NATL ACAD SCI USA, V89, P2105, DOI 10.1073/pnas.89.6.2105; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KAUFMAN SJ, 1985, J CELL BIOL, V100, P1977, DOI 10.1083/jcb.100.6.1977; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; KRAMER RH, 1989, J BIOL CHEM, V264, P15642; LEUNG E, 1993, INT IMMUNOL, V5, P551, DOI 10.1093/intimm/5.5.551; LI H, 1993, NUCLEIC ACIDS RES, V21, P335, DOI 10.1093/nar/21.2.335; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; MAK KL, 1992, MOL CELL BIOL, V12, P4334, DOI 10.1128/MCB.12.10.4334; Maniatis T, 1989, DECONTAMINATION DILU; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NUEDA A, 1993, J BIOL CHEM, V268, P19305; Olson EN, 1990, GENE DEV, V4, P1454; OTT MO, 1991, DEVELOPMENT, V111, P1097; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; PRANDINI MH, 1992, J BIOL CHEM, V267, P10370; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROSMARIN AG, 1992, BLOOD, V79, P2598; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SONG WK, 1993, J CELL SCI, V106, P1139; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; SUNYER T, 1993, J NEUROSCI RES, V36, P224, DOI 10.1002/jnr.490360213; SUTHERLAND AE, 1993, DEVELOPMENT, V119, P1175; TAYLOR JM, 1995, J BIOL CHEM, V270, P2535, DOI 10.1074/jbc.270.6.2535; TRASK RV, 1992, NUCLEIC ACIDS RES, V20, P2313, DOI 10.1093/nar/20.9.2313; VILLAGARCIA M, 1994, BLOOD, V83, P668, DOI 10.1182/blood.V83.3.668.bloodjournal833668; VINCENT CK, 1993, MOL CELL BIOL, V13, P1264, DOI 10.1128/MCB.13.2.1264; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1; YANG JT, 1995, DEVELOPMENT, V121, P549; YANG JT, 1993, DEVELOPMENT, V119, P1093; ZIOBER BL, 1993, J BIOL CHEM, V268, P26773; ZUTTER MM, 1994, J BIOL CHEM, V269, P463	67	39	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22915	22922		10.1074/jbc.271.37.22915	http://dx.doi.org/10.1074/jbc.271.37.22915			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798472	hybrid			2022-12-27	WOS:A1996VG67200091
J	Echevarria, M; Windhager, EE; Frindt, G				Echevarria, M; Windhager, EE; Frindt, G			Selectivity of the renal collecting duct water channel aquaporin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL CHIP28 PROTEIN; XENOPUS-OOCYTES; ESCHERICHIA-COLI; GLYCEROL FACILITATOR; MOLECULAR-CLONING; RAT-KIDNEY; EXPRESSION; MEMBRANE; FAMILY	Aquaporin-3 (AQP3) is a water channel found in the basolateral cell membrane of principal cells of the renal collecting tubule as well as in other epithelia. To examine the selectivity of AQP3, the permeability to water (P-f), urea (P-ur), and glycerol (P-gly) of Xenopus oocytes injected with cRNA encoding AQP3 was measured. Oocytes injected with cRNA encoding either human or rat aquaporin-1 (AQP1) were used as controls. Although both aquaporins permit water flow across the cell membrane, only AQP3 was permeable to glycerol and urea (P-gly > P-ur). The uptake of glycerol into oocytes expressing AQP3 was linear up to 165 mM. For AQP3 the Arrhenius energy of activation for P-f was 3 kcal/mol, whereas for P-gly and P-ur it was >12 kcal/mol. The sulfhydryl reagent p-chloromercuriphenylsulfonate (1 mM) abolished P-f of AQP3, whereas it did not affect P-gly. In addition, phloretin (0.1 mM) inhibited P-f of AQP3 by 35%, whereas it did not alter P-gly or P-ur. We conclude that water does not share the same pathway with glycerol or urea in AQP3 and that this aquaporin, therefore, forms a water-selective channel.	CORNELL UNIV,COLL MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10021	Cornell University			Echevarría, Miriam/E-6682-2010; IBIS, TERAPIA CELULA/P-3297-2015	Echevarría, Miriam/0000-0002-4758-9428; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK011489] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK11489] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1993, AM J PHYSIOL, V265, pF463; CALAMITA G, 1995, J BIOL CHEM, V270, P29063, DOI 10.1074/jbc.270.49.29063; CHRISPEELS MJ, 1994, TRENDS BIOCHEM SCI, V19, P421, DOI 10.1016/0968-0004(94)90091-4; ECELBARGER CA, 1995, AM J PHYSIOL-RENAL, V269, pF663, DOI 10.1152/ajprenal.1995.269.5.F663; ECHEVARRIA M, 1993, J GEN PHYSIOL, V101, P827, DOI 10.1085/jgp.101.6.827; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; HELLER KB, 1980, J BACTERIOL, V144, P274, DOI 10.1128/JB.144.1.274-278.1980; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; LI J, 1994, PFLUG ARCH EUR J PHY, V428, P455, DOI 10.1007/BF00374565; MA TH, 1994, J BIOL CHEM, V269, P21845; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; MAUREL C, 1994, J BIOL CHEM, V269, P11869; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; SMITH BL, 1991, J BIOL CHEM, V266, P6407; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	16	109	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25079	25082		10.1074/jbc.271.41.25079	http://dx.doi.org/10.1074/jbc.271.41.25079			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810261	hybrid			2022-12-27	WOS:A1996VL69300005
J	McKenna, E; Smith, JS; Coll, KE; Mazack, EK; Mayer, EJ; Antanavage, J; Wiedmann, RT; Johnson, RG				McKenna, E; Smith, JS; Coll, KE; Mazack, EK; Mayer, EJ; Antanavage, J; Wiedmann, RT; Johnson, RG			Dissociation of phospholamban regulation of cardiac sarcoplasmic reticulum Ca2+ ATPase by quercetin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-UPTAKE; ADENOSINE 5'-TRIPHOSPHATE; FUNCTIONAL ASSOCIATION; BINDING; CA2+-ATPASE; MECHANISM; CA-2+-ATPASE; STIMULATION; MODULATION; PUMP	Quercetin had a biphasic effect on Ca2+ uptake and calcium-stimulated ATP hydrolysis in isolated cardiac sarcoplasmic reticulum (SR). Stimulation of Ca(2+)ATPase was observed at low quercetin concentrations (<25 mu M) followed by inhibition at higher concentrations. The effects were dependent upon the SR protein concentration, the MgATP concentration, and intact phospholamban regulation of cardiac Ca(2+)ATPase. Only the inhibitory effects at higher quercetin concentrations were observed in skeletal muscle SR which lacks phospholamban and in cardiac SR treated to remove phospholamban regulation, Stimulation was additive with monoclonal antibody 1D11 (directed against phospholamban) at submaximal antibody concentrations; however, the maximal antibody and quercetin stimulation were identical. Quercetin increased the calcium sensitivity of the Ca(2+)ATPase like that observed with phosphorylation of phospholamban or treatment with monoclonal antibody 1D11. In addition, low concentrations of quercetin increased the steady-state formation of phosphoenzyme from ATP or P-i, but higher quercetin decreased phosphoenzyme levels. Quercetin, even under stimulatory conditions, was a competitive inhibitor of ATP, but ap pears to relieve the Ca(2+)ATPase from phospholamban inhibition, thereby, producing an activation. The subsequent inhibitory action of higher quercetin concentrations results from competition of quercetin with the nucleotide binding site of the Ca(2+)ATPase. The data suggest that quercetin interacts with the nucleotide binding site to mask phospholamban's inhibition of the SR Ca(2+)ATPase and suggests that phospholamban may interact at or near the nucleotide binding site.			McKenna, E (corresponding author), MERCK RES LABS,DEPT PHARMACOL,WP44-B124,W POINT,PA 19486, USA.							BISHOP JE, 1987, J BIOL CHEM, V262, P4658; CABLE MB, 1985, BIOCHEMISTRY-US, V24, P5612, DOI 10.1021/bi00341a049; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; CHIESI M, 1994, BIOCHEM BIOPH RES CO, V202, P1668, DOI 10.1006/bbrc.1994.2126; CHIESI M, 1989, FEBS LETT, V244, P241, DOI 10.1016/0014-5793(89)81201-3; FISCHER TH, 1987, BIOCHEMISTRY-US, V26, P8024, DOI 10.1021/bi00398a070; INESI G, 1980, J BIOL CHEM, V255, P3025; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; KIM HW, 1990, J BIOL CHEM, V265, P1702; KRANIAS EG, 1985, BIOCHIM BIOPHYS ACTA, V844, P193, DOI 10.1016/0167-4889(85)90090-4; KUPPASAMY UR, 1992, BICH PHARM, V47, P521; KUTCHAI H, 1994, BIOCHEMISTRY-US, V33, P13208, DOI 10.1021/bi00249a007; LACAPERE JJ, 1993, EUR J BIOCHEM, V211, P117, DOI 10.1111/j.1432-1033.1993.tb19877.x; LU YZ, 1994, BIOCHEMISTRY-US, V33, P5056, DOI 10.1021/bi00183a008; LU YZ, 1993, BIOCHEMISTRY-US, V32, P3105, DOI 10.1021/bi00063a023; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; Mayer EJ, 1996, J BIOL CHEM, V271, P1669, DOI 10.1074/jbc.271.3.1669; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; MCINTOSH DB, 1984, BIOCHEMISTRY-US, V23, P1959, DOI 10.1021/bi00304a012; NAKAMURA J, 1995, J BIOL CHEM, V270, P17350, DOI 10.1074/jbc.270.29.17350; Racker E, 1986, Prog Clin Biol Res, V213, P257; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; Shi Yongli, 1996, Biophysical Journal, V70, pA283; SHOSHAN V, 1981, J BIOL CHEM, V256, P887; SQUIER TC, 1988, J BIOL CHEM, V263, P9162; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; STOKES DL, 1994, FEBS LETT, V346, P32, DOI 10.1016/0014-5793(94)00297-5; TADA M, 1974, J BIOL CHEM, V249, P6174; TERAO J, 1994, ARCH BIOCHEM BIOPHYS, V308, P278, DOI 10.1006/abbi.1994.1039; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; VLAHOS CJ, 1993, J CELL BIOCHEM, V52, P404, DOI 10.1002/jcb.240520405; VOSS J, 1994, BIOPHYS J, V67, P190, DOI 10.1016/S0006-3495(94)80469-2; VOSS J, 1991, BIOCHEMISTRY-US, V30, P7498, DOI 10.1021/bi00244a019; XU ZC, 1989, J BIOL CHEM, V264, P16644	37	42	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24517	24525		10.1074/jbc.271.40.24517	http://dx.doi.org/10.1074/jbc.271.40.24517			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798712	hybrid			2022-12-27	WOS:A1996VM67400034
J	Neilson, KM; Friesel, R				Neilson, KM; Friesel, R			Ligand-independent activation of fibroblast growth factor receptors by point mutations in the extracellular, transmembrane, and kinase domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROUZON-SYNDROME; DEVELOPMENTAL EXPRESSION; SIGNAL-TRANSDUCTION; XENOPUS DEVELOPMENT; MOUSE DEVELOPMENT; TYROSINE KINASES; GENE CAUSE; FGF; MESODERM; BINDING	The fibroblast growth factor receptors (FGFRs) are a family of receptor protein tyrosine kinases that have been shown to mediate a variety of cellular processes including angiogenesis, wound healing, tumorigenesis, and embryonic development. Distinct FGFR mutations in individuals with autosomal dominant disorders of bone growth and development provide a unique opportunity to determine the function of FGFRs during embryonic development. To determine the consequences of these mutations on receptor function, we have made mutations in Xenopus FGFR1 (XFGFR1) and FGFR2 (XFGFR2) that correspond to several of the mutations identified in these dysmorphic syndromes. Analysis of mutant receptor proteins expressed in Xenopus oocytes indicates that all but one have elevated tyrosine kinase activity relative to their wild-type counterparts. Those mutations that give an unpaired cysteine residue in the extracellular domain result in intermolecular disulfide bond formation and covalent receptor dimerization. Microinjection of Xenopus embryos with RNA encoding mutant receptors with elevated tyrosine kinase activity results in ligand-independent induction of mesoderm in animal pole explants, Wild-type XFGFR1 and XFGFR2 do not induce mesoderm when injected at similar doses. Co-injection of RNA encoding a dominant negative FGF receptor, lacking the tyrosine kinase domain, together with RNA encoding various activated FGFRs inhibits mesoderm induction by a receptor activated by a transmembrane domain mutation or extracellular mutations that introduce an unpaired cysteine residue into the extracellular domain but does not inhibit mesoderm induction by receptors bearing a tyrosine kinase domain mutation. These results indicate that different point mutations may activate FGFRs by distinct mechanisms and that ligand-independent FGFR activation may be a feature in common to many skeletal disorders.	AMER RED CROSS,JEROME H HOLLAND LAB,DEPT BIOL MOL,ROCKVILLE,MD 20855; GEORGE WASHINGTON UNIV,MED CTR,DEPT ANAT & CELL BIOL,WASHINGTON,DC 20037	American Red Cross; George Washington University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029561] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007698] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL-07698] Funding Source: Medline; NICHD NIH HHS [HD29561] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BELLUS GA, 1995, NAT GENET, V10, P357, DOI 10.1038/ng0795-357; BROWN SAN, 1993, BIOCHEM BIOPH RES CO, V193, P1116, DOI 10.1006/bbrc.1993.1741; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; FRIESEL R, 1986, J BIOL CHEM, V261, P7581; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; FRIESEL R, 1992, DEVELOPMENT, V116, P1051; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GREEN JBA, 1990, DEVELOPMENT, V108, P173; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MCDONALD FJ, 1994, DEV GENET, V15, P148, DOI 10.1002/dvg.1020150205; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Moon R. T., 1989, TECHNIQUE, V1, P76; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PARK WJ, 1995, AM J HUM GENET, V57, P748; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PENG HB, 1991, PRACTICAL USES CELL; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; RUTLAND P, 1995, NAT GENET, V9, P173, DOI 10.1038/ng0295-173; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; WILKIE AOM, 1995, CURR BIOL, V5, P500; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	51	134	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					25049	25057		10.1074/jbc.271.40.25049	http://dx.doi.org/10.1074/jbc.271.40.25049			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798788	hybrid			2022-12-27	WOS:A1996VM67400111
J	Ramsey, AJ; Hillas, PJ; Fitzpatrick, PF				Ramsey, AJ; Hillas, PJ; Fitzpatrick, PF			Characterization of the active site iron in tyrosine hydroxylase - Redox states of the iron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENAL-MEDULLA; ESCHERICHIA-COLI; CLONED ENZYME; PURIFICATION; PHOSPHORYLATION; EXPRESSION; 3-MONOOXYGENASE; MUTAGENESIS; INHIBITORS; SERINE-40	Tyrosine hydroxylase is an iron-containing monooxygenase that uses a tetrahydropterin to catalyze the hydroxylation of tyrosine to dihydroxyphenylalanine in catecholamine biosynthesis. The role of the iron in this enzyme is not understood. Purification of recombinant rat tyrosine hydroxylase containing 0.5-0.7 iron atoms/subunit and lacking bound catecholamine has permitted studies of the redox states of the resting enzyme and the enzyme during catalysis. As isolated, the iron is in the ferric form. Dithionite or 6-methyltetrahydropterin can reduce the iron to the ferrous form. Reduction by 6-methyltetrahydropterin consumes 0.5 nmol/nmol of enzyme-bound iron, producing quinonoid 6-methyldihydropterin as the only detectable product. In the presence of oxygen, reoxidation to ferric iron occurs. During turnover the enzyme is in the ferrous form. However, a fraction is oxidized during turnover; this can be trapped by added catechol or by the dihydroxyphenylalanine formed during turnover.	TEXAS A&M UNIV,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843; TEXAS A&M UNIV,DEPT CHEM,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station					NIGMS NIH HHS [R01 GM 47291, T32 GM 08523] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008523, R01GM047291] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON KK, 1992, BIOCHEM J, V284, P687, DOI 10.1042/bj2840687; ANDERSSON KK, 1988, J BIOL CHEM, V263, P18621; DAUBNER SC, 1993, PROTEIN SCI, V2, P1452, DOI 10.1002/pro.5560020909; DAUBNER SC, 1992, J BIOL CHEM, V267, P12639; FITZPATRICK PF, 1989, BIOCHEM BIOPH RES CO, V161, P211, DOI 10.1016/0006-291X(89)91582-9; FITZPATRICK PF, 1991, BIOCHEMISTRY-US, V30, P3658, DOI 10.1021/bi00229a010; FITZPATRICK PF, 1991, BIOCHEMISTRY-US, V30, P6386, DOI 10.1021/bi00240a006; FITZPATRICK PF, 1990, J BIOL CHEM, V265, P2042; FITZPATRICK PF, 1988, J BIOL CHEM, V263, P16058; HAAVIK J, 1988, BIOCHIM BIOPHYS ACTA, V953, P142, DOI 10.1016/0167-4838(88)90019-2; HAAVIK J, 1992, EUR J BIOCHEM, V210, P23, DOI 10.1111/j.1432-1033.1992.tb17386.x; HAAVIK J, 1991, EUR J BIOCHEM, V199, P371, DOI 10.1111/j.1432-1033.1991.tb16133.x; HOELDTKE R, 1977, J BIOL CHEM, V252, P3160; IKEDA M, 1966, J BIOL CHEM, V241, P4452; KAUFMAN S, 1985, FOLATES PTERINS, V2, P251; MAGER HIX, 1967, RECL TRAV CHIM PAY-B, V86, P833; MARTINEZ A, 1993, BIOCHEMISTRY-US, V32, P6381, DOI 10.1021/bi00076a011; PISTORIUS EK, 1976, J BIOL CHEM, V251, P7144; RAMSEY AJ, 1995, PROTEIN SCI, V4, P2082; SHIMAN R, 1971, J BIOL CHEM, V246, P1330; SLYKHOUSE TO, 1976, J BIOL CHEM, V251, P5472; STORM CB, 1971, J ORG CHEM, V36, P3925; WANG YH, 1991, P NATL ACAD SCI USA, V88, P8779, DOI 10.1073/pnas.88.19.8779; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	24	87	87	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24395	24400		10.1074/jbc.271.40.24395	http://dx.doi.org/10.1074/jbc.271.40.24395			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798695	hybrid			2022-12-27	WOS:A1996VM67400017
J	Wu, TL; Vasavada, RC; Yang, K; Massfelder, T; Ganz, M; Abbas, SK; Care, AD; Stewart, AF				Wu, TL; Vasavada, RC; Yang, K; Massfelder, T; Ganz, M; Abbas, SK; Care, AD; Stewart, AF			Structural and physiologic characterization of the mid-region secretory species of parathyroid hormone-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMORAL HYPERCALCEMIA; BONE-RESORPTION; PEPTIDE; CELLS; IDENTIFICATION; CALCIUM; BINDING; CANCER; PTHRP; BIOSYNTHESIS	Parathyroid hormone-related protein (PTHrP) is initially translated as a preprohormone which is posttranslationally processed to yield a family of mature secretory forms, Most attention has focused on the aminoterminal portion of the molecule which is homologous to parathyroid hormone. It is clear, however, that a midregion species of PTHrP is posttranslationally cleaved from the highly conserved mid-region of PTHrP, and that the amino terminus of this peptide is Ala(38). The purposes of the current study were three: 1) to confirm that Arg(37) immediately preceding Ala(38) serves as a posttranslational processing site in the PTHrP precursor, 2) to determine the carboxyl terminus of the mid-region secretory species of PTHrP, and 3) to synthesize this authentic mid-region secretory form of PTHrP and determine whether it is biologically active. The results indicate that: 1) Arg(37) is indeed a processing site in the PTHrP precursor; 2) three distinct mid-region PTHrP species are generated by posttranslational processing, PTHrP(38-94)amide, PTHrP(38-95), and most likely, PTHrP(38-101); and 3) synthetic mid-region PTHrP(38-94)amide is active in four different biological systems. These studies confirm the finding that PTHrP is a prohormone. More importantly, they define a novel, biologically active highly conserved mid-region secretory form of PTHrP.	VET ADM MED CTR,DIV ENDOCRINOL,W HAVEN,CT 06516; YALE UNIV,SCH MED,ENDOCRINOL SECT,NEW HAVEN,CT 06510; VET ADM MED CTR,DIV NEPHROL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106; UNIV WALES,INST BIOMED SCI,ABERYSTWYTH SY23 3DD,DYFED,WALES	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Aberystwyth University			Massfelder, Thierry/I-1260-2016		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002229, R01DK047168] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47168, DK 02229] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBAS SK, 1989, Q J EXP PHYSIOL CMS, V74, P549, DOI 10.1113/expphysiol.1989.sp003303; BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BENNET HPJ, 1993, MECH INTRACELLULAR T, P251; BOURDAIS J, 1991, J BIOL CHEM, V266, P23386; BROADUS AE, 1988, NEW ENGL J MED, V319, P556; Broadus Arthur E., 1994, P259; BURTIS WJ, 1994, J CLIN ENDOCR METAB, V78, P317, DOI 10.1210/jc.78.2.317; BURTIS WJ, 1990, NEW ENGL J MED, V322, P1106, DOI 10.1056/NEJM199004193221603; BURTIS WJ, 1987, J BIOL CHEM, V262, P7151; CARE AD, 1990, EXP PHYSIOL, V75, P605, DOI 10.1113/expphysiol.1990.sp003437; DICKINSON CJ, 1995, J CLIN INVEST, V96, P2425; DIEFENBACHJAGGE.H, 1995, BONE, V16, pS126; EIPPER BA, 1993, ANN NY ACAD SCI, V680, P147, DOI 10.1111/j.1749-6632.1993.tb19681.x; EIPPER BA, 1983, P NATL ACAD SCI-BIOL, V80, P5144, DOI 10.1073/pnas.80.16.5144; EverhartCaye M, 1996, J CLIN ENDOCR METAB, V81, P199, DOI 10.1210/jc.81.1.199; FENTON AJ, 1991, ENDOCRINOLOGY, V129, P3424, DOI 10.1210/endo-129-6-3424; GAICH G, 1993, ENDOCRINOLOGY, V132, P1402, DOI 10.1210/en.132.3.1402; GANZ MB, 1990, AM J PHYSIOL, V259, pF269, DOI 10.1152/ajprenal.1990.259.2.F269; HATSUZAWA K, 1990, J BIOL CHEM, V265, P11075; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; LUPARELLO C, 1995, MOL CELL ENDOCRINOL, V111, P225, DOI 10.1016/0303-7207(95)03577-T; MAINS RE, 1983, TRENDS NEUROSCI, V6, P229, DOI 10.1016/0166-2236(83)90100-5; MCCAULEY LK, 1992, ENDOCRINOLOGY, V130, P300, DOI 10.1210/en.130.1.300; MERENDINO JJ, 1986, SCIENCE, V231, P388, DOI 10.1126/science.2417317; NISSENSON RA, 1992, PARATHYROID HORMONE; ORLOFF JJ, 1992, AM J PHYSIOL, V262, pE599, DOI 10.1152/ajpendo.1992.262.5.E599; ORLOFF JJ, 1994, ENDOCR REV, V15, P40, DOI 10.1210/er.15.1.40; ORLOFF JJ, 1993, J BONE MINER RES, V8, pS133; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; PLAWNER LL, 1995, J BIOL CHEM, V270, P14078, DOI 10.1074/jbc.270.23.14078; RABBANI SA, 1993, BIOCHEMISTRY-US, V32, P4931, DOI 10.1021/bi00069a030; SEVARINO KA, 1987, J BIOL CHEM, V262, P4987; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SOIFER NE, 1992, J BIOL CHEM, V267, P18236; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STEWART AF, 1989, ENDOCRINOLOGY, V124, P642, DOI 10.1210/endo-124-2-642; STEWART AF, 1988, J CLIN INVEST, V81, P596, DOI 10.1172/JCI113358; Strewler Gordon J., 1993, P61; WEATHERLEY AJ, 1983, PLACENTA, V8, P271; WU SX, 1993, ENDOCRINOLOGY, V133, P2437, DOI 10.1210/en.133.6.2437; YANG KH, 1994, BIOCHEMISTRY-US, V33, P7460, DOI 10.1021/bi00189a054; [No title captured]	43	109	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24371	24381		10.1074/jbc.271.40.24371	http://dx.doi.org/10.1074/jbc.271.40.24371			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798692	hybrid			2022-12-27	WOS:A1996VM67400014
J	Daly, SE; Lane, LK; Blostein, R				Daly, SE; Lane, LK; Blostein, R			Structure/function analysis of the amino-terminal region of the alpha 1 and alpha 2 subunits of Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							(NA+ + K+)-ATPASE; ADENOSINE-TRIPHOSPHATASE; MOLECULAR-CLONING; CATALYTIC SUBUNIT; K+; NA+,K+-ATPASE; TRANSPORT; SODIUM; NA+; SUBSTITUTIONS	The alpha 2 isoform of the Na,K-ATPase exhibits kinetic behavior distinct from that of the alpha 1 isoform. The distinctive behavior is apparent when the reaction is carried out under conditions (micromolar ATP concentration) in which the K+ deocclusion pathway of the reaction cycle is rate-limiting; the alpha 1 activity is inhibited by K+, whereas alpha 2 is stimulated. When 32 NH2-terminal amino acid residues are removed from alpha 1, the kinetic behavior of the mutant enzyme (alpha 1M32) is similar to that of alpha 2 (Daly, S. E., Lane, L. K., and Blostein, R. (1994) J. Biol. Chem. 269, 23944-23948). In the current study, the region of the alpha 1 NH2 terminus involved in modulating this kinetic behavior has been localized to the highly charged sequence comprising residues 24-32. Within this nonapeptide, differences between alpha 1 and alpha 2 are conservative and are confined to residues 25-27. The behavior of two chimeric enzymes: (i) alpha 1 with the first 32 residues identical to the alpha 2 sequence, alpha 1 (1-32 alpha 2), and (ii) alpha 2 with the first 32 residues identical to the alpha 1 sequence, alpha 2(1-32 alpha 1), indicates that the distinctive kinetic behavior of alpha 1 and alpha 2 is not due to the 24-32 NH2-terminal domain, per se, but rather to its interaction with other, isoform-specific region(s) of the alpha 1-protein. We also demonstrate that the distinct K+ activation profiles of either alpha 2 or alpha 1M32, compared to alpha 1 is due to a faster release of K+ from the K+-occluded enzyme, and to a higher affinity for ATP. This was determined in studies using two approaches: (i) kinetic analysis of the reaction modeled according to a branched pathway of K+ deocclusion through low and high affinity ATP pathways and, (ii) measurements of the (rapid) phosphorylation of the enzyme (E(1) conformation) by [gamma-P-32]ATP following the rate-limiting formation of the K+-free enzyme from the K+-occluded state (E(2)(K) --> E(1) + K+). The observed kinetic differences between alpha 2 and alpha 1 suggest that these Na,K-ATPase isoforms differ in the steady-state distribution of E(1) and E(2) conformational states.	MCGILL UNIV, DEPT MED, MONTREAL, PQ, CANADA; UNIV CINCINNATI, COLL MED, DEPT PHARMACOL & CELL BIOPHYS, CINCINNATI, OH 45267 USA	McGill University; University of Cincinnati					NHLBI NIH HHS [HL 49204] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049204] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; BLOSTEIN R, 1988, METHOD ENZYMOL, V156, P171; BURGENERKAIRUZ P, 1991, FEBS LETT, V290, P83, DOI 10.1016/0014-5793(91)81231-V; DALY SE, 1994, J BIOL CHEM, V269, P23944; EISNER DA, 1981, J PHYSIOL-LONDON, V319, P403, DOI 10.1113/jphysiol.1981.sp013917; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; FORBUSH B, 1991, SOC GEN PHY, V46, P211; HEGYVARY C, 1971, J BIOL CHEM, V246, P5234; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1977, BIOCHIM BIOPHYS ACTA, V466, P97, DOI 10.1016/0005-2736(77)90211-5; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANE LK, 1993, J BIOL CHEM, V268, P17930; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Markwell M A, 1981, Methods Enzymol, V72, P296; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; OHTA T, 1991, BIOCHIM BIOPHYS ACTA, V1059, P157, DOI 10.1016/S0005-2728(05)80200-2; POST RL, 1972, J BIOL CHEM, V247, P6530; SHANBAKY NM, 1994, AM J PHYSIOL, V267, pC590, DOI 10.1152/ajpcell.1994.267.2.C590; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; Therien AG, 1996, J BIOL CHEM, V271, P7104, DOI 10.1074/jbc.271.12.7104; VASILETS LA, 1991, J BIOL CHEM, V266, P16285; VASILETS LA, 1993, EUR BIOPHYS J BIOPHY, V21, P433, DOI 10.1007/BF00185871; WIERZBICKI W, 1993, P NATL ACAD SCI USA, V90, P70, DOI 10.1073/pnas.90.1.70	27	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23683	23689		10.1074/jbc.271.39.23683	http://dx.doi.org/10.1074/jbc.271.39.23683			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798590				2022-12-27	WOS:A1996VJ44200019
J	Pandey, P; Raingeaud, J; Kaneki, M; Weichselbaum, R; Davis, RJ; Kufe, D; Kharbanda, S				Pandey, P; Raingeaud, J; Kaneki, M; Weichselbaum, R; Davis, RJ; Kufe, D; Kharbanda, S			Activation of p38 mitogen-activated protein kinase by c-Abl-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; DNA-DAMAGING AGENTS; MAP KINASE; IONIZING-RADIATION; JUN KINASE; CELLS; PHOSPHORYLATION; THREONINE; TYROSINE; 1-BETA-D-ARABINOFURANOSYLCYTOSINE	The p38 mitogen-activated protein (MAP) kinase defines a subgroup of the mammalian MAP kinases that are induced in response to lipopolysaccharide, hyperosmolarity, and interleukin 1. p38 MAP kinase appears to play a role in regulating inflammatory responses, including cytokine secretion and apoptosis, Here we show that diverse classes of DNA-damaging agents such as cisplatinum, 1-beta-D-arabinofuranosylcytosine, UV light, ionizing radiation, and methyl methanesulfonate activate p38 MAP kinase, We also demonstrate that cells deficient in c-Abl fail to activate p38 MAP kinase after treatment with cisplatinum and 1-beta-D-arabinofuranosylcytosine but not after exposure to UV and methyl methanesulfonate, Reconstitution of c-Abl in the Abl(-/-) cells restores that response. Similar results were obtained for induction of the Jun-NH2-kinase/stress-activated protein kinase. These findings indicate that p38 MAP and Jun-NH2-kinase/stress-activated protein kinases are differentially regulated in response to different classes of DNA-damaging agents.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOL BIOL,HOWARD HUGHES MED INST,PROGRAM MOL MED,WORCESTER,MA 01605; UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Chicago					NCI NIH HHS [CA29431, CA55241, CA65861] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065861, R01CA029431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Dhar V, 1996, CELL GROWTH DIFFER, V7, P841; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KUFE DW, 1984, MOL PHARMACOL, V26, P128; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; SALEEM A, 1995, CELL GROWTH DIFFER, V6, P1651; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHWARTZ JL, 1986, CARCINOGENESIS, V7, P159, DOI 10.1093/carcin/7.1.159; SHAFMAN TD, 1995, CANCER RES, V55, P3242; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH GJ, 1986, AM J PATHOL, V122, P488; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	42	122	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23775	23779		10.1074/jbc.271.39.23775	http://dx.doi.org/10.1074/jbc.271.39.23775			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798604	hybrid			2022-12-27	WOS:A1996VJ44200033
J	Tamburrini, M; DAvino, R; Fago, A; Carratore, V; Kunzmann, A; diPrisco, G				Tamburrini, M; DAvino, R; Fago, A; Carratore, V; Kunzmann, A; diPrisco, G			The unique hemoglobin system of Pleuragramma antarcticum, an Antarctic migratory teleost - Structure and function of the three components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOTOTHENIA-CORIICEPS-NEGLECTA; AMINO-ACID-SEQUENCE; FISH; BINDING; PURIFICATION; ADAPTATION	Pleuragramma antarcticum (suborder Notothenioidei, family Nototheniidae) is the most abundant fish in the antarctic shelf. This pelagic species has a circum-antarctiac distribution and is characterized by spawning migration. This species displays the highest multiplicity of major hemoglobins (three); the other notothenioids have a single one (except one species, having two) with relatively low oxygen affinity regulated by pH and organophosphates, The hemoglobins of P. antarcticum display strong Bohr and Root effects; however, they reveal important functional differences in subunit cooperativity and organophosphate regulation and, above all, in the response of oxygenation to temperature, De spite the substitution Val beta E11 --> Ile found in Hb 2, which decreases the affinity in human mutants, the hemoglobins have similar oxygen affinity, higher than that of the other notothenioids. Hb 1 has the alpha chain in common with Hb 2 and the beta in common with Hb 3. The amino acid sequence of all four chains has been established, Thus the hematological features of P. antarcticum differ remarkably from those of antarctic notothenioids, This unique and sophisticated oxygen transport system may adequately meet the requirements of the unusual mode of life of this fish.	AARHUS UNIV,DEPT ZOOPHYSIOL,INST BIOL SCI,DK-8000 AARHUS,DENMARK; INST POLAR ECOL,D-24148 KIEL,GERMANY	Aarhus University	Tamburrini, M (corresponding author), CNR,INST PROT BIOCHEM & ENZYMOL,VIA MARCONI 10,I-80125 NAPLES,ITALY.		Kunzmann, Andreas/O-5459-2019; Fago, Angela/J-5946-2013; Kunzmann, Andreas/O-1345-2013	Kunzmann, Andreas/0000-0002-9500-4332; Fago, Angela/0000-0001-7315-2628; Kunzmann, Andreas/0000-0002-9500-4332; TAMBURRINI, MAURIZIO/0000-0001-5987-0957				ANDERSEN N C, 1984, Steenstrupia, V10, P1; Andriashev A.P., 1987, P357; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; BRITTAIN T, 1987, COMP BIOCHEM PHYS B, V86, P473, DOI 10.1016/0305-0491(87)90434-2; CARUSO C, 1991, BIOCHIM BIOPHYS ACTA, V1078, P273, DOI 10.1016/0167-4838(91)90569-L; COCCA E, 1995, P NATL ACAD SCI USA, V92, P1817, DOI 10.1073/pnas.92.6.1817; DAVINO R, 1989, EUR J BIOCHEM, V179, P707, DOI 10.1111/j.1432-1033.1989.tb14604.x; DAVINO R, 1994, J BIOL CHEM, V269, P9675; DAVINO R, 1989, EUR J BIOCHEM, V179, P699, DOI 10.1111/j.1432-1033.1989.tb14603.x; DAVINO R, 1988, COMP BIOCHEM PHYS B, V90, P579, DOI 10.1016/0305-0491(88)90298-2; di Prisco G., 1991, P263; DIPRISCO G, 1992, COMP BIOCHEM PHYS B, V102, P661, DOI 10.1016/0305-0491(92)90062-V; DIPRISCO G, 1988, COMP BIOCHEM PHYS B, V90, P631, DOI 10.1016/0305-0491(88)90304-5; DIPRISCO G, 1989, ANTARCT SCI, V1, P119; DIPRISCO G, 1990, POLAR BIOL, V10, P269, DOI 10.1007/BF00238425; Eastman J. T, 1993, ANTARCTIC FISH BIOL; Everson I., 1968, Bulletin British Antarctic Survey, VNo. 15, P59; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; Giardina B, 1981, Methods Enzymol, V76, P417; Hubold G., 1985, P445; HUREAU JC, 1977, ADAPTATIONS ANTARCTI, P459; ITO N, 1995, J MOL BIOL, V250, P648, DOI 10.1006/jmbi.1995.0405; KUNZMANN A, 1990, POLAR BIOL, V11, P9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; Mylvaganam SE, 1996, NAT STRUCT BIOL, V3, P275, DOI 10.1038/nsb0396-275; NAGAI K, 1987, NATURE, V329, P858, DOI 10.1038/329858a0; PERUTZ MF, 1982, NATURE, V299, P421, DOI 10.1038/299421a0; Root RW, 1931, BIOL BULL-US, V61, P427, DOI 10.2307/1536959; RUUD JT, 1954, NATURE, V173, P848, DOI 10.1038/173848a0; TAMBURRINI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P295, DOI 10.1016/0003-9861(92)90082-8; WELLS RMG, 1980, J FISH BIOL, V17, P517, DOI 10.1111/j.1095-8649.1980.tb02783.x	32	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23780	23785		10.1074/jbc.271.39.23780	http://dx.doi.org/10.1074/jbc.271.39.23780			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798605	hybrid			2022-12-27	WOS:A1996VJ44200034
J	Hopf, FW; Reddy, P; Hong, J; Steinhard, RA				Hopf, FW; Reddy, P; Hong, J; Steinhard, RA			A capacitative calcium current in cultured skeletal muscle cells is mediated by the calcium-specific leak channel and inhibited by dihydropyridine compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; PROTEIN-TYROSINE PHOSPHORYLATION; NEGATIVE MEMBRANE-POTENTIALS; PANCREATIC ACINAR-CELLS; ELEVATED FREE CALCIUM; MUSCULAR-DYSTROPHY; PERMEABLE CHANNELS; PLASMA-MEMBRANE; HUMAN PLATELETS; T-LYMPHOCYTES	Calcium stores from cultured skeletal muscle cells were depleted using cyclopiazonic acid (CPA), a reversible inhibitor of Ca2+-ATPases at the sarcoplasmic reticulum. Store depletion led to activation of the calcium-specific leak channel, as assayed using single-channel patch clamp analysis and rates of manganese influx and quenching of fura-2 fluorescence. Two novel dihydropyridine compounds inhibited this single-channel leak channel activity, the resting and depletion-induced manganese influx, and refilling of the CPA-depleted intracellular calcium store. These compounds represent the first antagonists for a calcium leak channel and for a channel that mediates a capacitative current. The development of the skeletal muscle capacitative current was inhibited by genistein, a tyrosine kinase inhibitor, but was not affected by okadaic acid, a phosphatase inhibitor, or econazole. Thus, the capacitative current in cultured skeletal muscle cells was mediated by the calcium leak channel and was inhibited by pharmacological antagonists and may provide a model system for uncovering the complete set of signals leading from store depletion to channel activation.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041129] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR41129] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALVAREZ J, 1992, FASEB J, V6, P786, DOI 10.1096/fasebj.6.2.1537469; BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BAKKER AJ, 1993, J PHYSIOL-LONDON, V460, P1; Benham C D, 1987, Soc Gen Physiol Ser, V42, P45; BLINKS JR, 1978, J PHYSIOL-LONDON, V277, P291, DOI 10.1113/jphysiol.1978.sp012273; BRINKMEIER H, 1993, J ANIM SCI, V71, P1154, DOI 10.2527/1993.7151154x; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; BURNAY MM, 1994, ENDOCRINOLOGY, V135, P751, DOI 10.1210/en.135.2.751; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; CHUA M, 1991, BIOPHYS J, V59, P1251, DOI 10.1016/S0006-3495(91)82340-2; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CONSTANTIN B, 1993, CELL CALCIUM, V14, P135, DOI 10.1016/0143-4160(93)90083-I; COULOMBE A, 1989, J MEMBRANE BIOL, V111, P57, DOI 10.1007/BF01869209; COYNE MD, 1987, J MEMBRANE BIOL, V97, P205, DOI 10.1007/BF01869223; DENETCLAW WF, 1994, MOL BIOL CELL, V5, P1159, DOI 10.1091/mbc.5.10.1159; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; FONG P, 1990, SCIENCE, V250, P673, DOI 10.1126/science.2173137; FRANCO A, 1990, J PHYSIOL-LONDON, V427, P361, DOI 10.1113/jphysiol.1990.sp018176; FRANZIUS D, 1994, PFLUG ARCH EUR J PHY, V428, P433, DOI 10.1007/BF00374562; GARCIA J, 1990, PFLUG ARCH EUR J PHY, V416, P210, DOI 10.1007/BF00370245; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAVERSTICK DM, 1993, MOL BIOL CELL, V4, P173, DOI 10.1091/mbc.4.2.173; HAWS CM, 1991, P ROY SOC B-BIOL SCI, V245, P173, DOI 10.1098/rspb.1991.0105; HOPF FW, 1996, IN PRESS AM J PHYS; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU YF, 1995, BIOCHEM J, V305, P605, DOI 10.1042/bj3050605; HUANG CF, 1994, NEURON, V13, P167, DOI 10.1016/0896-6273(94)90467-7; KIMURA M, 1994, J HYPERTENS, V12, P199; KITSUKAWA Y, 1994, AM J PHYSIOL, V266, pG613, DOI 10.1152/ajpgi.1994.266.4.G613; KOIKE Y, 1994, CELL CALCIUM, V15, P381, DOI 10.1016/0143-4160(94)90013-2; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; LEECH CA, 1994, ENDOCRINOLOGY, V135, P365, DOI 10.1210/en.135.1.365; LEIPZIGER J, 1994, PFLUG ARCH EUR J PHY, V426, P427, DOI 10.1007/BF00388306; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; LUCKHOFF A, 1994, BIOPHYS J, V67, P177, DOI 10.1016/S0006-3495(94)80467-9; LUTTGAU HC, 1979, J PHYSIOL-LONDON, V296, P411; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MATHES C, 1994, J GEN PHYSIOL, V104, P107, DOI 10.1085/jgp.104.1.107; MERTZ LM, 1990, J BIOL CHEM, V265, P15010; MONGINI T, 1988, NEUROLOGY, V38, P476, DOI 10.1212/WNL.38.3.476; MONTERO M, 1994, J BIOL CHEM, V269, P3963; NEGULESCU PA, 1990, METHOD ENZYMOL, V192, P38; NEGULESCU PA, 1995, AM J PHYSIOL-GASTR L, V269, pG770, DOI 10.1152/ajpgi.1995.269.5.G770; NEGULESCU PA, 1992, AM J PHYSIOL, V263, pC1310, DOI 10.1152/ajpcell.1992.263.6.C1310; NEHER E, 1992, NATURE, V355, P298, DOI 10.1038/355298a0; PAREKH AB, 1993, J PHYSIOL-LONDON, V469, P653, DOI 10.1113/jphysiol.1993.sp019836; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; PREMACK BA, 1994, J IMMUNOL, V152, P5226; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RAYMOND G, 1987, CAN J PHYSIOL PHARM, V65, P704, DOI 10.1139/y87-116; ROED A, 1991, GEN PHARMACOL-VASC S, V22, P313, DOI 10.1016/0306-3623(91)90455-F; ROSENBERG RL, 1988, J GEN PHYSIOL, V92, P27, DOI 10.1085/jgp.92.1.27; ROTHMAN SM, 1983, ANN NEUROL, V13, P176, DOI 10.1002/ana.410130212; SARGEANT P, 1994, EXP PHYSIOL, V79, P269, DOI 10.1113/expphysiol.1994.sp003762; SARGEANT P, 1993, J BIOL CHEM, V268, P18151; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; TEPEL M, 1994, J BIOL CHEM, V269, P26239; TSIEN RW, 1987, PROTEINS EXCITABLE M, P167; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; TURNER PR, 1993, J MEMBRANE BIOL, V133, P243; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC920, DOI 10.1152/ajpcell.1994.267.4.C920; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; VILLALOBOS C, 1992, FASEB J, V6, P2742, DOI 10.1096/fasebj.6.9.1319362; WILLIAMS JH, 1990, MUSCLE NERVE, V13, P1118, DOI 10.1002/mus.880131206; YELLEN G, 1984, J GEN PHYSIOL, V84, P157, DOI 10.1085/jgp.84.2.157; YULE DI, 1994, BIOCHEM BIOPH RES CO, V202, P1697, DOI 10.1006/bbrc.1994.2130; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	73	81	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22358	22367		10.1074/jbc.271.37.22358	http://dx.doi.org/10.1074/jbc.271.37.22358			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798397	hybrid			2022-12-27	WOS:A1996VG67200016
J	Grotzinger, T; Jensen, K; Will, H				Grotzinger, T; Jensen, K; Will, H			The interferon (IFN)-stimulated gene Sp100 promoter contains an IFN-gamma activation site and an imperfect IFN-stimulated response element which mediate type I IFN inducibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; PRIMARY BILIARY-CIRRHOSIS; GUANYLATE-BINDING PROTEIN; SIGNAL TRANSDUCTION PATHWAYS; PML-RAR-ALPHA; DNA-BINDING; TRANSCRIPTION FACTORS; REGULATORY ELEMENTS; T(15-17) TRANSLOCATION; CYTOPLASMIC ACTIVATION	Expression of the nuclear domain-associated proteins Sp100, PML, and NDP52, is enhanced by interferons (IFNs) on the mRNA and protein level. Increase both of Sp100 and PML mRNA is due to enhanced transcription of the corresponding genes which occurs independently of cellular protein synthesis immediately upon IFN-beta addition, Here, we describe the molecular cloning and functional analysis of the Sp100 promoter. DNA sequence analysis revealed potential binding sites for several constitutive and IFN-inducible transcription factors. Consistent with the absence of a TATA box and an initiator element, several transcription initiation sites were found. Transient expression studies identified an imperfect IFN-stimulated response element within the first 100 nucleotides upstream of the major transcription start site. This element rendered a heterologous promoter IFN-beta-inducible and bound IFN-stimulated gene factor 2 strongly but IFN-stimulated gene factor 3 only weakly. An IFN-gamma activation site approximately 500 base pairs upstream of the IFN-stimulated response element was found to bind three IFN-alpha/beta activation factors upon IFN-beta induction and conferred both type I and type II IFN inducibility upon a heterologous promoter, These data demonstrate a novel arrangement of a nonoverlapping IFN-gamma activation site and an IFN-stimulated response element mediating type I IFN inducibility, previously not reported for other IFN-stimulable promoters.	UNIV HAMBURG,HEINRICH PETTE INST EXPT VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY	Heinrich Pette Institute; University of Hamburg								ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DECKER T, 1996, IN PRESS INTERFERON; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Grotzinger T, 1996, MOL CELL BIOL, V16, P1150; Grotzinger T, 1996, EUR J BIOCHEM, V238, P554, DOI 10.1111/j.1432-1033.1996.0554z.x; GUILLE MJ, 1994, EUR J BIOCHEM, V219, P547, DOI 10.1111/j.1432-1033.1994.tb19970.x; GULDNER HH, 1992, J IMMUNOL, V149, P4067; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARROCH S, 1994, J BIOL CHEM, V269, P26191; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KELLY C, 1995, J GEN VIROL, V76, P2887, DOI 10.1099/0022-1317-76-11-2887; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; LAVAU C, 1995, ONCOGENE, V11, P871; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LIN JH, 1995, J EXP MED, V181, P1965; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller M, 1994, J Viral Hepat, V1, P87, DOI 10.1111/j.1365-2893.1994.tb00109.x; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; PARRINGTON J, 1993, EUR J BIOCHEM, V214, P617, DOI 10.1111/j.1432-1033.1993.tb17961.x; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PLASS C, 1995, HEREDITAS, V122, P245, DOI 10.1111/j.1601-5223.1995.00245.x; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; RAZ R, 1994, J BIOL CHEM, V269, P24391; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; SAMANTA H, 1986, J BIOL CHEM, V261, P1849; SAWMBROOK J, 1989, MOL CLONING LAB MANU; SEEGERT D, 1994, J BIOL CHEM, V269, P8590; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STERNSDORF T, 1995, SCAND J IMMUNOL, V42, P257, DOI 10.1111/j.1365-3083.1995.tb03652.x; SZOSTECKI C, 1992, SCAND J IMMUNOL, V36, P555, DOI 10.1111/j.1365-3083.1992.tb03224.x; SZOSTECKI C, 1987, CLIN EXP IMMUNOL, V68, P108; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TERRIS B, 1995, CANCER RES, V55, P1590; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; XIE KW, 1995, P NATL ACAD SCI USA, V92, P1639, DOI 10.1073/pnas.92.5.1639; XIE KW, 1993, MOL CELL BIOL, V13, P6170, DOI 10.1128/MCB.13.10.6170	70	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25253	25260		10.1074/jbc.271.41.25253	http://dx.doi.org/10.1074/jbc.271.41.25253			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810287	hybrid			2022-12-27	WOS:A1996VL69300031
J	Bubulya, A; Wise, SC; Shen, XQ; Burmeister, LA; Shemshedini, L				Bubulya, A; Wise, SC; Shen, XQ; Burmeister, LA; Shemshedini, L			c-Jun can mediate androgen receptor-induced transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; RETINOIC ACID RECEPTORS; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL REGULATION; PROGESTERONE-RECEPTOR; NEGATIVE REGULATION; GENE; FOS; ACTIVATION	The proto-oncoprotein c-Jun forms as a heterodimer with c-Fos, the transcription factor AP-1. AP-1 regulates transcription through transactivation, a process requiring DNA binding. Here we report an indirect mechanism by which c-Jun can regulate transcription via the androgen receptor. In this process, c-Jun is able to support androgen receptor-mediated transactivation in the absence of an interaction with c-Fos or any apparent DNA binding. This positive effect of c-Jun was dose-dependent. Both exogenously added and endogenously induced c-Jun are able to act on the androgen receptor. Transactivation by the androgen receptor can undergo self-squelching, and this was relieved by transfected c-Jun. Using a time-course experiment, we provide evidence that the c-Jun effect is primary. c-Fos is able to block human androgen receptor activity in both the absence and presence of transfected c-Jun, Using a modified form of the yeast two-hybrid system, we show in Cos cells that c-Jun can interact with the DNA binding domain/hinge region (CD regions) of the androgen receptor, Therefore, we propose that c-Jun functions as a mediator for androgen receptor-induced transactivation.	UNIV TOLEDO,DEPT BIOL,TOLEDO,OH 43606	University System of Ohio; University of Toledo								ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; DERUITER PE, 1995, MOL CELL ENDOCRINOL, V110, pR1, DOI 10.1016/0303-7207(95)03534-E; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; EVANS RM, 1988, SCIENCE, V240, P89; FRANKLIN CC, 1995, BIOCHEM J, V305, P967, DOI 10.1042/bj3050967; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; HARRISON RJ, 1995, MOL ENDOCRINOL, V9, P981, DOI 10.1210/me.9.8.981; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARODER M, 1993, MOL ENDOCRINOL, V7, P570, DOI 10.1210/me.7.4.570; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; ONATE SA, 1995, SCIENCE, V270, P1354; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; TANESE N, 1993, COLD SPRING HARB SYM, V58, P179, DOI 10.1101/SQB.1993.058.01.022; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TZUCKERMAN M, 1991, MOL ENDOCRINOL, V91, P1983; WOLF DA, 1992, MOL ENDOCRINOL, V6, P753, DOI 10.1210/me.6.5.753; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; YOUNG CYF, 1994, PROSTATE, V25, P39, DOI 10.1002/pros.2990250106; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	51	94	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24583	24589		10.1074/jbc.271.40.24583	http://dx.doi.org/10.1074/jbc.271.40.24583			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798722	hybrid			2022-12-27	WOS:A1996VM67400044
J	Ding, JB; Knaus, UG; Lian, JP; Bokoch, GM; Badwey, JA				Ding, JB; Knaus, UG; Lian, JP; Bokoch, GM; Badwey, JA			The renaturable 69- and 63-kDa protein kinases that undergo rapid activation in chemoattractant-stimulated guinea pig neutrophils are p21-activated kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH OXIDASE ACTIVATION; PHOSPHOINOSITIDE 3-KINASE; CHEMOTACTIC FACTORS; MOLECULAR-CLONING; FAMILY MEMBERS; RAC; TRANSLOCATION; AUTOPHOSPHORYLATION; PHOSPHORYLATION; IDENTIFICATION	Neutrophils stimulated with the chemoattractant fMet-Leu-Phe (fMLP) are known to exhibit rapid activation of four protein kinases with molecular masses of similar to 69, similar to 63, similar to 49, and similar to 40-kDa. Activation of these kinases is blocked by antagonists of phosphatidylinositol 3-kinase and type 1 and/or type 2A protein phosphatases. These enzymes can be detected by their ability to undergo renaturation and catalyze the phosphorylation of a peptide substrate that corresponds to amino acid residues 297-331 of the 47-kDa subunit of the NADPH-oxidase complex fixed within a gel. In this report, we demonstrate that an antibody generated to a fusion protein containing amino acid residues 175-306 of p21-activated protein kinase 1 (Pak1) reacts with three proteins in guinea pig neutrophils with molecular masses in the 60-70-kDa range during Western blotting. This antibody immunoprecipitates both the 69- and 63-kDa renaturable kinases from lysates of stimulated cells along with a minor 60-kDa kinase. No activities were observed for any of these enzymes in immunoprecipitates from unstimulated neutrophils. However, addition of ATP and activated Rac 1 or Cdc42 to immunoprecipitates from unstimulated cells resulted in the stimulation of two renaturable kinases with molecular masses in the 69- and 63-kDa range. These immunoprecipitates also contained two novel protein kinases with masses of similar to 49 and 40 kDa that were selectively activated by Cdc42. In contrast, the 69- and 63-kDa kinases were not immunoprecipitated from lysates of stimulated neutrophils with an antibody to Pak2 or with nonimmune serum. These data indicate that the renaturable 69- and 63-kDa kinases are Paks and reveal some of the upstream events that are necessary for the rapid activation of this family of protein kinases in neutrophils.	HARVARD UNIV, SCH MED, BOSTON BIOMED RES INST, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02114 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Boston Biomedical Research Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Scripps Research Institute; Scripps Research Institute					NHLBI NIH HHS [HL48008] Funding Source: Medline; NIAID NIH HHS [AI35947] Funding Source: Medline; NIAMS NIH HHS [P60 AR40770] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR040770] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; Badwey J A, 1986, Methods Enzymol, V132, P365; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BENNER GE, 1995, J BIOL CHEM, V270, P21121, DOI 10.1074/jbc.270.36.21121; BRUMELL JH, 1994, AM J PHYSIOL-CELL PH, V267, pC1574, DOI 10.1152/ajpcell.1994.267.6.C1574; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; DEWALD B, 1988, J BIOL CHEM, V263, P16179; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DING JB, 1993, BLOOD, V82, P940; DING JB, 1993, J BIOL CHEM, V268, P5234; DING JB, 1995, J BIOL CHEM, V270, P11684, DOI 10.1074/jbc.270.19.11684; DING JB, 1993, J BIOL CHEM, V268, P17326; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GRINSTEIN S, 1993, J BIOL CHEM, V268, P20223; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HUANG CK, 1988, J BIOL CHEM, V263, P13144; HUANG CK, 1990, J CELL BIOCHEM, V44, P221, DOI 10.1002/jcb.240440404; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; QUINN MT, 1993, J BIOL CHEM, V268, P20983; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; TOKER A, 1994, J BIOL CHEM, V269, P32358; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WHITE JR, 1983, J BIOL CHEM, V258, P4041; XU XM, 1994, J BIOL CHEM, V269, P23569; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	43	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24869	24873		10.1074/jbc.271.40.24869	http://dx.doi.org/10.1074/jbc.271.40.24869			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798763	hybrid			2022-12-27	WOS:A1996VM67400085
J	Nicoll, DA; Quednau, BD; Qui, ZY; Xia, YR; Lusis, AJ; Philipson, KD				Nicoll, DA; Quednau, BD; Qui, ZY; Xia, YR; Lusis, AJ; Philipson, KD			Cloning of a third mammalian Na+-Ca2+ exchanger, NCX3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; NA+/CA2+ EXCHANGER; CA2+-BINDING DOMAIN; MOLECULAR-CLONING; EXPRESSION; CELLS; GENE; CDNA; IDENTIFICATION; LOCALIZATION	NCX3 is the third isoform of a mammalian Na+-Ca2+ exchanger to be cloned. NCX3 was identified from rat brain cDNA by polymerase chain reaction (PCR) using degenerate primers derived from the sequences of two conserved regions of NCX1 and NCX2. The NCX3 PCR product was used to isolate two overlapping clones totalling 4.8 kilobases (kb) from a rat brain cDNA library. The overlapping clones were sequenced and joined at a unique Bsp106I restriction enzyme site to form a full-length cDNA clone. The NCX3 cDNA clone has an open reading frame of 2.8 kb encoding a protein of 927 amino acids. At the amino acid level, NCX3 shares 73% identity with NCX1 and 75% identity with NCX2 and is predicted to share the same membrane topology as NCX1 and NCX2. Following addition of a poly(A)(+) tail to the NCX3 clone, exchanger activity could be expressed in Xenopus oocytes. NCX3 was also expressed in the mammalian BHK cell line. NCX3 transcripts are 6 kb in size and are highly restricted to brain and skeletal muscle. Linkage analysis in the mouse indicated that the NCX family of genes is dispersed, since the NCX1, NCX2, and NCX3 genes mapped to mouse chromosomes 17, 7, and 12, respectively.	UNIV CALIF LOS ANGELES,DEPT PHYSIOL,SCH MED,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT MED,SCH MED,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Nicoll, DA (corresponding author), UNIV CALIF LOS ANGELES,CARDIOVASC RES LAB,SCH MED,3645 MRL BLDG,675 CIRCLE DR S,LOS ANGELES,CA 90095, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568, R37HL048509, R01HL048509, R01HL049101] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30568, HL49101, HL48509] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen RD, 1996, MAMM GENOME, V7, P557, DOI 10.1007/s003359900167; Condrescu M., 1996, Biophysical Journal, V70, pA206; CONDRESCU M, 1995, J BIOL CHEM, V270, P9137, DOI 10.1074/jbc.270.16.9137; DAHAN D, 1991, J BIOL CHEM, V266, P2067; DIPOLO R, 1994, AM J PHYSIOL, V266, pC1382, DOI 10.1152/ajpcell.1994.266.5.C1382; DURKIN JT, 1991, ARCH BIOCHEM BIOPHYS, V290, P369, DOI 10.1016/0003-9861(91)90553-U; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GABELLINI N, 1995, J BIOL CHEM, V270, P6917, DOI 10.1074/jbc.270.12.6917; GILBERT JR, 1982, J MEMBRANE BIOL, V69, P77, DOI 10.1007/BF01871244; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; He Z., 1996, Biophysical Journal, V70, pA201; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; IWAMOTO T, 1995, J BIOL CHEM, V270, P8996, DOI 10.1074/jbc.270.15.8996; *J HOPK U, 1990, HUM GEN DAT BAS; *JACK LAB, 1995, MOUS GEN DAT BAS; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KOFUJI P, 1992, AM J PHYSIOL, V263, pC1241, DOI 10.1152/ajpcell.1992.263.6.C1241; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; KOZAK M, 1994, BIOCHIMIE, V76, P815, DOI 10.1016/0300-9084(94)90182-1; LEE SL, 1994, J BIOL CHEM, V269, P14849; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LI ZP, 1991, J BIOL CHEM, V266, P1014; LI ZP, 1992, J BIOL CHEM, V267, P7828; LI ZP, 1994, J BIOL CHEM, V269, P17434; LONGONI S, 1988, AM J PHYSIOL, V255, pC870, DOI 10.1152/ajpcell.1988.255.6.C870; Lytton J., 1996, Biophysical Journal, V70, pA7; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; REUTER H, 1995, NEURON, V15, P1077, DOI 10.1016/0896-6273(95)90096-9; Sambrook J., 2002, MOL CLONING LAB MANU; SHIEH BH, 1992, GENOMICS, V12, P616, DOI 10.1016/0888-7543(92)90459-6; STURZL M, 1990, ANAL BIOCHEM, V185, P164, DOI 10.1016/0003-2697(90)90274-D; VALDIVIA C, 1995, IN PRESS BIOCH BIOPH; WARDEN CH, 1993, GENOMICS, V18, P295, DOI 10.1006/geno.1993.1469; Welch CL, 1996, J LIPID RES, V37, P1406	43	295	308	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24914	24921		10.1074/jbc.271.40.24914	http://dx.doi.org/10.1074/jbc.271.40.24914			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798769	hybrid			2022-12-27	WOS:A1996VM67400092
J	Oellers, N; Hafen, E				Oellers, N; Hafen, E			Biochemical characterization of rolled(Sem), an activated form of Drosophila mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; OF-FUNCTION MUTATION; ETS DOMAIN PROTEIN; MAP KINASE; MESODERM INDUCTION; REGULATED KINASE; CELLS; RAF; DIFFERENTIATION; LOCALIZATION	The rolled (rl) gene of Drosophila encodes a homologue of vertebrate mitogen-activated protein kinases. Genetic analyses have shown that the gain-of-function mutation rolled(Sevenmaker) (rl(Sem)) is sufficient to activate developmental pathways controlled by distinct receptor tyrosine kinases, such as Sevenless, Torso, and the Drosophila epidermal growth factor receptor homologue. Here we show that mutant Rl(Sem) protein, immunoprecipitated from transiently transfected COS cells, exhibits a moderate increase in kinase activity compared with wild-type Rl protein. Time course studies revealed that Rl(Sem) is more active than Rl following short term as well as prolonged treatment with epidermal growth factor. Interestingly, a more pronounced difference in kinase activity is observed when the proteins are immunoprecipitated from extracts of Drosophila rl and rl(Sem) larvae. In fact, the kinase activity of Rl(Sem) from larvae extracts is comparable to the kinase activity of larvae expressing either an activated Sevenless receptor or an activated Raf kinase. We also demonstrate that Dsor1, which has been placed upstream of rl genetically, is able to phosphorylate and activate Rl in vitro.	UNIV ZURICH,INST ZOOL,CH-8057 ZURICH,SWITZERLAND	University of Zurich								ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; BOTT CM, 1994, FEBS LETT, V352, P201, DOI 10.1016/0014-5793(94)00958-9; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; HAFEN E, 1993, DEVELOPMENT, P41; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HSU JC, 1994, GENE DEV, V8, P2176, DOI 10.1101/gad.8.18.2176; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KERKHOFF E, 1991, ONCOGENE, V6, P93; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OELLERS N, 1994, MOL GEN GENET, V244, P465, DOI 10.1007/BF00583897; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; ZIPURSKY LS, 1994, ANNU REV NEUROSCI, V17, P373	32	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24939	24944		10.1074/jbc.271.40.24939	http://dx.doi.org/10.1074/jbc.271.40.24939			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798773	hybrid, Green Accepted			2022-12-27	WOS:A1996VM67400096
J	Simon, FR; Fortune, J; Alexander, A; Iwahashi, M; Dahl, R; Sutherland, E				Simon, FR; Fortune, J; Alexander, A; Iwahashi, M; Dahl, R; Sutherland, E			Increased hepatic Na,K-ATPase activity during hepatic regeneration is associated with induction of the beta(1)-subunit and expression on the bile canalicular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE PLASMA-MEMBRANES; SENSITIVE RB-86+ UPTAKE; BETA-SUBUNIT; LIVER-REGENERATION; RAT HEPATOCYTE; ALPHA-SUBUNIT; LIPID FLUIDITY; NA+/K+-ATPASE; ADENOSINE-TRIPHOSPHATASE; (NA++K+)-ATPASE ACTIVITY	Cellular and molecular mechanisms regulating the activity of the sodium pump or Na,K-ATPase during proliferation of hepatocytes following 70% liver resection have not been defined. Na,K-ATPase may be regulated by synthesis of its alpha- and beta-subunits, by sorting to either the sinusoidal or apical plasma membrane domains, or by increasing membrane lipid fluidity. This study investigated the time course of changes during hepatic regeneration for Na,K-ATPase activity, lipid composition and fluidity, and protein content of liver plasma membrane subfractions. As early as 4 h after hepatic resection, Na,K-ATPase activity was increased selectively in the bile canalicular fraction. It reached a new steady state at 12 h and remained elevated for 2 days. Although hepatic regeneration was associated with a reduced cholesterol/phospholipid molar ratio and increased fluidity, measured with two different probes, these changes in lipid metabolism were in the sinusoidal membrane domain. The Na,K-ATPase beta(1)-subunit, but not the alpha(1)-subunit, was increased selectively at the bile canalicular surface as shown by immunoblotting of liver plasma membrane subfractions and the morphological demonstration at both the light and electron microscopic levels. Furthermore, cycloheximide blocked the rise in beta(1)-subunit mRNA levels. Since the time course for beta(1)-subunit accumulation was similar to that for activation of Na,K-ATPase activity, this change implicated the beta(1)-subunit in activating sodium pump activity.	VET AFFAIRS MED CTR, DENVER, CO 80262 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Simon, FR (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT MED, HEPATOBILIARY RES CTR, 4200 E 9TH AVE, DENVER, CO 80262 USA.				NIDDK NIH HHS [DK34914, DK15851] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015851, P30DK034914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES BN, 1960, J BIOL CHEM, V235, P769; BARTLES JR, 1986, DEV BIOL, V118, P286, DOI 10.1016/0012-1606(86)90095-3; BARTLES JR, 1991, DEV BIOL, V143, P258, DOI 10.1016/0012-1606(91)90076-F; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRUSCALUPI G, 1980, BIOCHIM BIOPHYS ACTA, V597, P263, DOI 10.1016/0005-2736(80)90104-2; CAM AL, 1979, AM J PHYSIOL, V236, pE594; CHENG HC, 1993, HEPATOLOGY, V17, P280, DOI 10.1016/0270-9139(93)90089-6; CHENG S, 1979, ARCH BIOCHEM BIOPHYS, V196, P424, DOI 10.1016/0003-9861(79)90293-5; CHONG PLG, 1985, J BIOL CHEM, V260, P4484; DAVIS RA, 1978, P NATL ACAD SCI USA, V75, P4130, DOI 10.1073/pnas.75.9.4130; DELICONSTANTINOS G, 1983, BIOCHEM J, V212, P445, DOI 10.1042/bj2120445; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; EMANUEL JR, 1987, P NATL ACAD SCI USA, V84, P9030, DOI 10.1073/pnas.84.24.9030; FAMBROUGH DM, 1994, CURR TOP MEMBR, V41, P45, DOI 10.1016/S0070-2161(08)60453-0; Fausto N, 1993, Prog Liver Dis, V11, P115; FAUSTO N, 1989, LAB INVEST, V60, P4; GEERING K, 1986, CURR TOP MEMBR TRANS, V27, P221; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; GICK GG, 1988, J BIOL CHEM, V263, P16610; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN, P162; GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; Higgins GM, 1931, ARCH PATHOL, V12, P186; HOPPE CA, 1985, J CELL BIOL, V101, P2113, DOI 10.1083/jcb.101.6.2113; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; HUBERT JJ, 1986, BIOCHEMISTRY-US, V25, P4156, DOI 10.1021/bi00362a025; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; KIMELBERG HK, 1975, BIOCHIM BIOPHYS ACTA, V413, P143, DOI 10.1016/0005-2736(75)90065-6; KIMELBERG HK, 1975, J BIOL CHEM, V250, P100; KIMELBERG HK, 1972, BIOCHIM BIOPHYS ACTA, V282, P277, DOI 10.1016/0005-2736(72)90334-3; KIMELBERG HK, 1976, BIOCHIM BIOPHYS ACTA, V455, P865, DOI 10.1016/0005-2736(76)90056-0; KOCH KS, 1979, CELL, V18, P153, DOI 10.1016/0092-8674(79)90364-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFFERT HL, 1985, HEPATOLOGY, V5, P501, DOI 10.1002/hep.1840050327; LEONI S, 1975, BIOCHIM BIOPHYS ACTA, V394, P317, DOI 10.1016/0005-2736(75)90268-0; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU XP, 1991, J BIOL CHEM, V266, P9276; MAHLER SM, 1988, INT J BIOCHEM, V20, P605, DOI 10.1016/0020-711X(88)90100-0; MARTINEZMAS JV, 1995, FEBS LETT, V362, P85, DOI 10.1016/0014-5793(95)00217-W; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MASUDA Y, 1976, BIOCHIM BIOPHYS ACTA, V426, P335, DOI 10.1016/0005-2736(76)90342-4; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Mercer Robert W., 1993, V137C, P139; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; NOGUCHI S, 1990, J BIOL CHEM, V265, P15991; REUSS L, 1986, CURR TOP MEMBR TRANS, V27, P3; ROMAN LM, 1983, J CELL BIOL, V96, P1548, DOI 10.1083/jcb.96.6.1548; ROSARIO J, 1988, BIOCHEMISTRY-US, V27, P3939, DOI 10.1021/bi00411a008; SCHENK DB, 1984, J BIOL CHEM, V259, P14941; SHYJAN AW, 1989, BIOCHEMISTRY-US, V28, P4531, DOI 10.1021/bi00437a002; SIMON FR, 1995, AM J PHYSIOL-CELL PH, V269, pC69, DOI 10.1152/ajpcell.1995.269.1.C69; Simon Francis R., 1993, P297; SINENSKY M, 1979, P NATL ACAD SCI USA, V76, P4893, DOI 10.1073/pnas.76.10.4893; STORCH J, 1984, BIOCHEMISTRY-US, V23, P1165, DOI 10.1021/bi00301a021; SUN Y, 1992, AM J PHYSIOL, V262, pC1491, DOI 10.1152/ajpcell.1992.262.6.C1491; SUTHERLAND E, 1988, P NATL ACAD SCI USA, V85, P8673, DOI 10.1073/pnas.85.22.8673; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; SZTUL ES, 1985, J CELL BIOL, V100, P1248, DOI 10.1083/jcb.100.4.1248; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VASILETS LA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P201, DOI 10.1016/0304-4157(93)90012-D; WRIGHT GH, 1977, BIOCHIM BIOPHYS ACTA, V470, P368, DOI 10.1016/0005-2736(77)90128-6; YOUNG RM, 1987, BIOCHEM BIOPH RES CO, V145, P52, DOI 10.1016/0006-291X(87)91286-1; ZYSSET T, 1985, HEPATOLOGY, V5, P531, DOI 10.1002/hep.1840050402	69	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24967	24975		10.1074/jbc.271.40.24967	http://dx.doi.org/10.1074/jbc.271.40.24967			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798777	hybrid			2022-12-27	WOS:A1996VM67400100
J	DeAngelis, PL; Achyuthan, AM				DeAngelis, PL; Achyuthan, AM			Yeast-derived recombinant DG42 protein of Xenopus can synthesize hyaluronan in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GLUCOSE DEHYDROGENASE; STREPTOCOCCUS-PYOGENES; SENSITIVE METHOD; GENE; SYNTHASE; IDENTIFICATION; BIOSYNTHESIS; SEQUENCE; PRODUCT; ACID	We demonstrate in this report that the Xenopus DG42 gene product made in the yeast Saccharomyces cerevisiae can synthesize authentic high molecular weight hyaluronan (hyaluronic acid; HA) in vitro. Saccharomyces are eukaryotes that do not naturally produce HA or any other molecules known to contain glucuronic acid, Therefore bakers' yeast is a good model system to determine the enzymatic activity of the DG42 protein, which is the topic of recent debate. Membrane extracts prepared from cells expressing DG42 encoded on a plasmid incorporated [C-14]glucuronic acid and N-[H-3]acetylglucosamine from exogenously supplied UDP-sugar nucleotides into a high molecular mass (10(6) to 10(7) Da) polymer in the presence of magnesium ions. Both sugar precursors were simultaneously required for elongation. Control extracts prepared from cells with the vector plasmid alone or the DG42 cDNA in the antisense orientation did not display this activity. The double-labeled polysaccharide product synthesized in vitro was deemed to be HA by enzymatic analyses; specific HA lyase could degrade the polymer, but it was unaffected by protease or chitinase treatments. The fragments generated by HA lyase were identical to fragments derived from authentic vertebrate HA as compared by high performance liquid chromatography. We conclude that DG42 is a membrane-associated HA synthase capable of transferring both glucuronic acid and N-acetylglucosamine groups.			DeAngelis, PL (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,940 STANTON L YOUNG BLVD,OKLAHOMA CITY,OK 73190, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ATKINSON EM, 1992, MOL PLANT MICROBE IN, V5, P439, DOI 10.1094/MPMI-5-439; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1993, J BIOL CHEM, V268, P14568; DEANGELIS PL, 1994, BIOCHEM BIOPH RES CO, V199, P1, DOI 10.1006/bbrc.1994.1184; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; GHEREZGHIHER T, 1987, J CHROMATOGR-BIOMED, V413, P9, DOI 10.1016/0378-4347(87)80208-6; HEMPEL J, 1994, PROTEIN SCI, V3, P1074, DOI 10.1002/pro.5560030710; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LIND T, 1993, J BIOL CHEM, V268, P20705; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P307; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; SEMINO CE, 1995, P NATL ACAD SCI USA, V92, P3498, DOI 10.1073/pnas.92.8.3498; Semino CE, 1996, P NATL ACAD SCI USA, V93, P4548, DOI 10.1073/pnas.93.10.4548; Varki A, 1996, P NATL ACAD SCI USA, V93, P4523, DOI 10.1073/pnas.93.10.4523	21	44	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23657	23660		10.1074/jbc.271.39.23657	http://dx.doi.org/10.1074/jbc.271.39.23657			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798586				2022-12-27	WOS:A1996VJ44200015
J	Deloche, O; Georgopoulos, C				Deloche, O; Georgopoulos, C			Purification and biochemical properties of Saccharomyces cerevisiae's Mge1p, the mitochondrial cochaperone of Ssc1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI DNAJ; ATPASE ACTIVITY; MOLECULAR CHAPERONES; REACTION CYCLE; GRPE; HSP70; HOMOLOG; REPLICATION; IDENTIFICATION	Previous biochemical and genetic studies have demonstrated the universal conservation of the DnaK (Hsp70) chaperone machine, Its three members, DnaK, DnaJ, and GrpE, in Escherichia coli work synergistically to promote protein protection, disaggregation, and import into the various organelles, In the mitochondria of Saccharomyces cerevisiae the three corresponding members are designated as Ssc1p, Mdj1p, and Mge1p, respectively, The MGE1 gene was previously cloned by us and others, and its product has been shown to be absolutely essential for protein transport into mitochondria and hence cell viability, To better understand its biological role, we have proceeded to overexpress and purify the mature Mge1p in E. coli through the construction of the appropriate vector clone. Mge1p has been shown to functionally substitute for its E. coli GrpE counterpart in a variety of its biological functions, including suppression of the bacterial temperature-sensitive phenotype of the grpE280 nutation, formation of a stable complex with DnaK, stimulation of DnaK's ATPase activity, and the refolding of denatured luciferase by the DnaK/DnaJ chaperone proteins. Thus, the function of the GrpE homologues appears to be highly conserved across the biological kingdoms.			Deloche, O (corresponding author), CTR MED UNIV GENEVA, DEPT BIOCHIM MED, 1, RUE MICHEL SERVET, CH-1211 GENEVA 4, SWITZERLAND.							ANG D, 1989, J BACTERIOL, V171, P2748, DOI 10.1128/jb.171.5.2748-2755.1989; ANG D, 1988, THESIS U UTAH SALT L; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; BORK P, 1992, TRENDS BIOCHEM SCI, V17, P129, DOI 10.1016/0968-0004(92)90319-5; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; DEMACARIO EC, 1994, J MOL BIOL, V240, P95, DOI 10.1006/jmbi.1994.1422; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hendrick JP, 1995, FASEB J, V9, P1559, DOI 10.1096/fasebj.9.15.8529835; HOHFELD J, 1995, CELL, V83, P589; IKEDA E, 1994, FEBS LETT, V339, P265, DOI 10.1016/0014-5793(94)80428-1; JOHNSON RB, 1989, GENE, V84, P295, DOI 10.1016/0378-1119(89)90503-9; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; NAKAI M, 1994, BIOCHEM BIOPH RES CO, V200, P435, DOI 10.1006/bbrc.1994.1468; NAYLOR DJ, 1995, BBA-PROTEIN STRUCT M, V1248, P75, DOI 10.1016/0167-4838(95)00007-H; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SPENCE J, 1990, J BACTERIOL, V172, P7157, DOI 10.1128/jb.172.12.7157-7166.1990; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; VOOS W, 1994, MOL CELL BIOL, V14, P6627, DOI 10.1128/MCB.14.10.6627; WALL D, 1994, J BIOL CHEM, V269, P5446; WESTERMANN B, 1995, EMBO J, V14, P3452, DOI 10.1002/j.1460-2075.1995.tb07351.x; WU B, 1994, J BACTERIOL, V176, P6965, DOI 10.1128/JB.176.22.6965-6973.1994; WU B, 1994, THESIS U UTAH SALT L; ZIEGELHOFFER T, 1995, J BIOL CHEM, V270, P10412, DOI 10.1074/jbc.270.18.10412; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431; [No title captured]	42	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23960	23966		10.1074/jbc.271.39.23960	http://dx.doi.org/10.1074/jbc.271.39.23960			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798629	hybrid			2022-12-27	WOS:A1996VJ44200058
J	Guse, AH; daSilva, CP; Weber, K; Ashamu, GA; Potter, BVL; Mayr, GW				Guse, AH; daSilva, CP; Weber, K; Ashamu, GA; Potter, BVL; Mayr, GW			Regulation of cADP-ribose-induced Ca2+ release by Mg2+ and inorganic phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-ADP-RIBOSE; INDUCED CALCIUM-RELEASE; INOSITOL TRISPHOSPHATE; RYANODINE RECEPTOR; T-LYMPHOCYTES; IDENTIFICATION; ACCUMULATION; CELLS	cADP-ribose (cADPr) has recently been shown to release Ca2+ from an intracellular store of permeabilized T lymphocyte cell lines (Guse, A. H., da Silva, C. P., Emmrich, F., Ashamu, G. A., Potter, B. V. L., and Mayr, G. W. (1995) J. Immunol. 155, 3353-3359). Using permeabilized Jurkat and HPB.ALL T lymphocytes, the effects of varying concentrations of inorganic phosphate and Mg2+ on cADPr-induced Ca2+ release were investigated. cADPr induced Ca2+ release was dependent on the concentration of inorganic phosphate, showing very low Ca2+ release activity between 0.5 and 2 mM inorganic phosphate. At 4 to 5 mM inorganic phosphate, the cADPr-induced Ca2+ release was much more pronounced, reaching maximal values at 10 mM inorganic phosphate. The underlying mechanism for this stimulatory effect was an increased loading of the cADPr-sensitive Ca2+ store, which was demonstrated by enhanced resequestration of Ca2+ selectively into the cADPr-sensitive Ca2+ store. The free Mg2+ concentration also influenced cADPr-induced Ca2+ release in permeabilized cells: at 0 and 8.58 mM the release was nearly completely abolished, whereas at 1.06 mM maximal Ca2+ release by cADPr was observed. High performance liquid chromatographic analysis of exogenously added cADPr revealed that the catabolism of cADPr at varying Mg2+ and P-i concentrations had only minor relevance for the modulatory effects observed. To correlate the effects of inorganic phosphate and Mg2+ on cADPr-induced Ca2+ release observed in the permeabilized cell preparations, measurements of these ions in intact Jurkat T lymphocytes were carried out. Intact Jurkat T cells stimulated via the T cell receptor . CD3 complex did not respond with significant elevation of the free intracellular Mg2+ concentration. In contrast, stimulation via the T cell receptor . CD3 complex resulted in an increase in the intracellular inorganic phosphate concentration. These data indicate a role for the intracellular inorganic phosphate concentration in the regulation of cADPr-mediated Ca2+ release in T lymphocytes.	UNIV BATH,SCH PHARM & PHARMACOL,BATH BA2 7AY,AVON,ENGLAND	University of Bath	Guse, AH (corresponding author), UNIV HAMBURG,INST PHYSIOL CHEM,DEPT ENZYME CHEM,GRINDELALLEE 117,D-20146 HAMBURG,GERMANY.		Potter, Barry/AAX-4781-2020; Potter, Barry VL/A-1845-2012					ASHAMU GA, 1995, J CHEM SOC CHEM COMM, P1929; ASHAMU GA, 1995, J CHEM SOC CHEM COMM, P1359, DOI 10.1039/c39950001359; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; CHINI EN, 1995, AM J PHYSIOL-CELL PH, V269, pC1042, DOI 10.1152/ajpcell.1995.269.4.C1042; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; FABIATO A, 1991, CELLULAR CALCIUM PRA, P159; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Galione Antony, 1994, Trends in Cell Biology, V4, P431, DOI 10.1016/0962-8924(94)90104-X; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GRAEFF RM, 1995, BIOCHEM BIOPH RES CO, V206, P786, DOI 10.1006/bbrc.1995.1111; GUSE AH, 1994, BIOCHEM J, V301, P83, DOI 10.1042/bj3010083; GUSE AH, 1993, J BIOL CHEM, V268, P7129; GUSE AH, 1992, BIOCHEM J, V288, P489, DOI 10.1042/bj2880489; GUSE AH, 1991, J BIOL CHEM, V266, P24498; GUSE AH, 1995, J IMMUNOL, V155, P3353; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1994, CELL SIGNAL, V6, P591, DOI 10.1016/0898-6568(94)90042-6; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LEE HC, 1993, J BIOL CHEM, V268, P293; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; TAKAHASHI K, 1995, FEBS LETT, V371, P204, DOI 10.1016/0014-5793(95)00914-U; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S	30	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23946	23953		10.1074/jbc.271.39.23946	http://dx.doi.org/10.1074/jbc.271.39.23946			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798627				2022-12-27	WOS:A1996VJ44200056
J	Mourao, PAS; Pereira, MS; Pavao, MSG; Mulloy, B; Tollefsen, DM; Mowinckel, MC; Abildgaard, U				Mourao, PAS; Pereira, MS; Pavao, MSG; Mulloy, B; Tollefsen, DM; Mowinckel, MC; Abildgaard, U			Structure and anticoagulant activity of a fucosylated chondroitin sulfate from echinoderm - Sulfated fucose branches on the polysaccharide account for its high anticoagulant action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-COFACTOR-II; MAGNETIC-RESONANCE-SPECTRA; PLICATA CHORDATA-TUNICATA; DERMATAN SULFATE; ANTITHROMBIN-III; SEA-CUCUMBER; PENTOSAN POLYSULFATE; STYELA-PLICATA; L-GALACTANS; ASCIDIANS TUNICATES	A polysaccharide isolated from the body wall of the sea cucumber Ludwigothurea grisea has a backbone like that of mammalian chondroitin sulfate: [4-beta-D-GlcA-1-->3-beta-D-GalNAc-1](n) but substituted at the 3-position of the beta-D-glucuronic acid residues with sulfated alpha-L-fucopyranosyl branches (Vieira, R. P., Mulloy, B., and Mourao, P. A. S. (1991) J. Biol. Chem. 266, 13530-13536). Mild acid hydrolysis removes the sulfated alpha-L-fucose branches, and cleaved residues have been characterized by H-1 NMR spectroscopy; the most abundant species is fucose 4-O-monosulfate, but 2,4- and 3,4-di-O-sulfated residues are also present. Degradation of the remaining polysaccharide with chondroitin ABC lyase shows that the sulfated alpha-L-fucose residues released by mild acid hydrolysis are concentrated toward the non-reducing end of the polysaccharide chains; enzyme-resistant polysaccharide material includes the reducing terminal and carries acid resistant L-fucose substitution. The sulfated alpha-L-fucose branches confer anticoagulant activity on the polysaccharide. The specific activity of fucosylated chondroitin sulfate in the activated partial thromboplastin time assay is greater than that of a linear homopolymeric alpha-L-fucan with about the same level of sulfation; this activity is lost on defucosylation or desulfation but not on carboxyl-reduction of the polymer. Assays with purified reagents show that the fucosylated chondroitin sulfate can potentiate the thrombin inhibition activity of both antithrombin and heparin cofactor II.	NATL INST BIOL STAND & CONTROLS, POTTERS BAR EN6 3QG, HERTS, ENGLAND; WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, DIV HEMATOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT BIOCHEM, DIV HEMATOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOL BIOPHYS, DIV HEMATOL, ST LOUIS, MO 63110 USA; AKER UNIV HOSP, DEPT MED, N-0514 OSLO, NORWAY	National Institute for Biological Standards & Control; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Oslo	Mourao, PAS (corresponding author), UNIV FED RIO DE JANEIRO, INST CIENCIAS BIOMED, DEPT BIOQUIM, CAIXA POSTAL 68041, BR-21941590 RIO DE JANEIRO, BRAZIL.		Mourao, Paulo/AAA-5386-2020; Pavao, Mauro Sergio Goncalves/B-1979-2010; Sá Pereira, Mariana/C-2211-2015; Pereira, Mariana/GSE-3546-2022	Pavao, Mauro Sergio Goncalves/0000-0002-1336-4271; 				ABILDGAARD U, 1984, THROMB RES, V35, P257, DOI 10.1016/0049-3848(84)90357-8; ALBANO RM, 1986, J BIOL CHEM, V261, P758; ASPINALL GO, 1982, POLYSACCHARIDES, V1, P19; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CARDOSO LEM, 1994, ARTERIOSCLER THROMB, V14, P115, DOI 10.1161/01.ATV.14.1.115; CHURCH FC, 1989, J BIOL CHEM, V264, P3618; COLLIEC S, 1991, THROMB RES, V64, P143, DOI 10.1016/0049-3848(91)90114-C; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EGGLETON CA, 1981, THROMB RES, V24, P319, DOI 10.1016/0049-3848(81)90005-0; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FISCHER AM, 1982, THROMB HAEMOSTASIS, V47, P104; HOLME KR, 1989, CARBOHYD RES, V186, P301, DOI 10.1016/0008-6215(89)84044-3; JAQUES LB, 1979, SCIENCE, V206, P528, DOI 10.1126/science.386509; KAKKAR VV, 1989, HEPARIN CHEM BIOL PR, P455; KIRCHER HW, 1960, ANAL CHEM, V32, P1103, DOI 10.1021/ac60165a016; MAGGI A, 1987, HAEMOSTASIS, V17, P329; MARCUM JA, 1987, SEMIN THROMB HEMOST, V13, P464, DOI 10.1055/s-2007-1003523; Mathews MB., 1975, CONNECT TISSUE, P93; MAURAY S, 1995, THROMB HAEMOSTASIS, V74, P1280; MCLELLAN DS, 1992, BLOOD COAGUL FIBRIN, V3, P69, DOI 10.1097/00001721-199202000-00011; MERTON RE, 1987, THROMB HAEMOSTASIS, V58, P839; MOURAO PAS, 1987, EUR J BIOCHEM, V166, P431, DOI 10.1111/j.1432-1033.1987.tb13534.x; MULLOY B, 1994, J BIOL CHEM, V269, P22113; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NAGASE H, 1995, BLOOD, V85, P1527, DOI 10.1182/blood.V85.6.1527.bloodjournal8561527; NISHINO T, 1991, THROMB RES, V62, P765, DOI 10.1016/0049-3848(91)90380-F; Painter T.J., 1983, POLYSACCHARIDES, P196, DOI DOI 10.1016/B978-0-12-065602-8.50009-1; Pavao MSG, 1995, J BIOL CHEM, V270, P31027, DOI 10.1074/jbc.270.52.31027; PAVAO MSG, 1989, J BIOL CHEM, V264, P9972; PAVAO MSG, 1994, BBA-GEN SUBJECTS, V1199, P229, DOI 10.1016/0304-4165(94)90001-9; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; RIBEIRO AC, 1994, CARBOHYD RES, V255, P225, DOI 10.1016/S0008-6215(00)90981-9; RONDLE CJM, 1955, BIOCHEM J, V61, P586, DOI 10.1042/bj0610586; RUGGIERO J, 1994, CARBOHYD RES, V256, P275, DOI 10.1016/0008-6215(94)84213-2; SAITO H, 1968, J BIOL CHEM, V243, P1536; SANTOS JA, 1992, EUR J BIOCHEM, V204, P669, DOI 10.1111/j.1432-1033.1992.tb16680.x; SCULLY MF, 1986, THROMB RES, V41, P489, DOI 10.1016/0049-3848(86)91694-4; SCULLY MF, 1984, BIOCHEM J, V222, P571, DOI 10.1042/bj2220571; SHAKA AJ, 1983, J MAGN RESON, V53, P313, DOI 10.1016/0022-2364(83)90035-5; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SUZUKI N, 1991, THROMB HAEMOSTASIS, V65, P369; Taylor R. L., 1976, METHODS CARBOHYDRATE, V7, P149; TEIEN AN, 1976, THROMB RES, V8, P859, DOI 10.1016/0049-3848(76)90014-1; THOMAS DP, 1982, THROMB RES, V28, P343, DOI 10.1016/0049-3848(82)90116-5; THOMAS DP, 1989, ANN NY ACAD SCI, V556, P313; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; VIEIRA RP, 1988, J BIOL CHEM, V263, P18176; VIEIRA RP, 1991, J BIOL CHEM, V266, P13530; WELTI D, 1979, EUR J BIOCHEM, V94, P505, DOI 10.1111/j.1432-1033.1979.tb12919.x	51	264	292	1	64	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23973	23984		10.1074/jbc.271.39.23973	http://dx.doi.org/10.1074/jbc.271.39.23973			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798631	hybrid			2022-12-27	WOS:A1996VJ44200060
J	AlRabiee, R; Zhang, YP; Grant, GA				AlRabiee, R; Zhang, YP; Grant, GA			The mechanism of velocity modulated allosteric regulation in D-3-phosphoglycerate dehydrogenase - Site-directed mutagenesis of effector binding site residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOGLYCERATE DEHYDROGENASE	D-3-Phosphoglycerate dehydrogenase (EC 1.1.1.95) from Escherichia coli catalyzes the first committed step in serine biosynthesis and is allosterically regulated by L-serine, the end product of the pathway, Each subunit of the homotetramer is made up of three distinct domains with one of the intersubunit contacts being between adjacent regulatory domains, Each regulatory domain interface contains two symmetrical serine binding sites such that serine forms hydrogen bonds to both domains across the interface, Previous work (Al-Rabiee, R., Lee, E. J., and Grant, G. A. (1996) J. Biol. Chem. 271, 13013-13017) demonstrated that when adjacent regula tory domains are covalently linked to one another by engineered disulfide bonds, the enzyme was inactivated, Breaking the disulfide bonds by reduction restored enzymatic activity, This study demonstrates that the complementary situation is also true. Site-directed mutagenesis of three residues at the effector binding site, His(344), Asn(346), and Asn(364'), render the enzyme increasingly less susceptible to inhibition by the effector, When mutations result in a situation where it is no longer possible to establish a stable hydrogen bonding network across the regulatory domain interface, the inhibitory capacity of the effector is lost, Furthermore, mutations that produce as much as 5 orders of magnitude decrease in the ability of L-serine to inhibit the enzyme have no appreciable effect on the K-m or k(cat) of the enzyme. These observations support the model that predicts that catalytic activity in D-3-phosphoglycerate dehydrogenase is regulated by the movement of adjacent regulatory domains about a flexible hinge and that effector binding tethers the regulatory domains together producing a state that results in a stable, open active site cleft that is no longer able to promote catalysis.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								AlRabiee R, 1996, J BIOL CHEM, V271, P13013, DOI 10.1074/jbc.271.22.13013; CORMACK B, 1991, CURRENT PROTOCOLS MO; Grant GA, 1996, PROTEIN SCI, V5, P34; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; ROSENBLO.J, 1968, J BIOL CHEM, V243, P2099; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P69, DOI 10.1038/nsb0195-69; SCHULLER DJ, 1989, J BIOL CHEM, V264, P2645; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2090; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; TOBEY KL, 1986, J BIOL CHEM, V261, P2179; Zhao GS, 1996, J BACTERIOL, V178, P232, DOI 10.1128/jb.178.1.232-239.1996	11	46	51	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23235	23238		10.1074/jbc.271.38.23235	http://dx.doi.org/10.1074/jbc.271.38.23235			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798520				2022-12-27	WOS:A1996VH76800046
J	Costa, C; Moura, JJG; Moura, I; Wang, YN; Huynh, BH				Costa, C; Moura, JJG; Moura, I; Wang, YN; Huynh, BH			Redox properties of cytochrome c nitrite reductase from Desulfovibrio desulfuricans ATCC 27774	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WOLINELLA-SUCCINOGENES; NITRATE REDUCTION; ESCHERICHIA-COLI; PURIFICATION; MOSSBAUER	The dissimilatory nitrite reductase from Desulfovibrio desulfuricans ATCC 27774 catalyzes the reduction of nitrite to ammonia. Previous spectroscopic investigation revealed that it is a hexaheme cytochrome containing one high spin ferric heme and five low spin ferric hemes in the oxidized enzyme. The current study uses the high resolution of Mossbauer spectroscopy to obtain redox properties of the six heme groups. Correlating the Mossbauer findings with the EPR data reveals the pairwise spin-spin coupling among four of the heme groups. The other two hemes are found to be magnetically isolated. Reduction with dithionite and reaction with CO further indicate that only the high spin heme is capable of binding small exogenous ligands. These results confirm our previous finding that Desulfovibrio desulfuricans nitrite reductase contains six heme groups and that the high spin ferric heme is the substrate and inhibitor binding site.	EMORY UNIV,DEPT PHYS,ATLANTA,GA 30322; UNIV NOVA LISBOA,FAC CIENCIAS & TECNOL,DEPT QUIM,P-2825 MONTE DE CAPARICA,PORTUGAL; UNIV NOVA LISBOA,FAC CIENCIAS & TECNOL,CTR QUIM FINA & BIOTECNOL,P-2825 MONTE DE CAPARICA,PORTUGAL	Emory University; Universidade Nova de Lisboa; Universidade Nova de Lisboa			Costa, Cristina/A-9966-2012; Moura, José J G/D-6426-2013; Moura, Isabel/D-6339-2013	Costa, Cristina/0000-0002-8611-9023; Moura, José J G/0000-0002-4726-2388; Moura, Isabel/0000-0003-0971-4977	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039803] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 39803, GM 47295] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ANDERSSON KK, 1986, J BIOL CHEM, V261, P1126; BLACKMORE R, 1986, BIOCHEM J, V233, P553, DOI 10.1042/bj2330553; BLACKMORE R, 1986, BIOCHEM J, V233, P547, DOI 10.1042/bj2330547; BLACKMORE RS, 1990, FEBS LETT, V264, P257, DOI 10.1016/0014-5793(90)80262-H; COSTA C, 1990, J BIOL CHEM, V265, P14382; COSTA C, 1994, THESIS U NOVA LISBOA; DARWIN A, 1993, MOL MICROBIOL, V9, P1255, DOI 10.1111/j.1365-2958.1993.tb01255.x; DEVRIES W, 1980, ARCH MICROBIOL, V124, P221, DOI 10.1007/BF00427730; Dutton P L, 1978, Methods Enzymol, V54, P411; HADJIPETROU LP, 1965, J GEN MICROBIOL, V38, P29, DOI 10.1099/00221287-38-1-29; HASAN SM, 1975, J GEN MICROBIOL, V87, P120, DOI 10.1099/00221287-87-1-120; KAJIE SI, 1986, EUR J BIOCHEM, V154, P457, DOI 10.1111/j.1432-1033.1986.tb09419.x; KEITH SM, 1982, ARCH MICROBIOL, V132, P62, DOI 10.1007/BF00690819; Kretchmar S A, 1988, Biol Met, V1, P26, DOI 10.1007/BF01128014; LANG G, 1966, P PHYS SOC LOND, V87, P3, DOI 10.1088/0370-1328/87/1/302; LIU MC, 1987, FEBS LETT, V218, P227, DOI 10.1016/0014-5793(87)81051-7; LIU MC, 1981, J BIOL CHEM, V256, P3159; LIU MC, 1988, ARCH BIOCHEM BIOPHYS, V262, P259, DOI 10.1016/0003-9861(88)90187-7; LIU MC, 1983, FEMS MICROBIOL LETT, V19, P201, DOI 10.1016/0378-1097(83)90060-5; NASRI H, 1991, J AM CHEM SOC, V113, P717, DOI 10.1021/ja00002a075; REHR B, 1986, FEMS MICROBIOL LETT, V35, P325, DOI 10.1111/j.1574-6968.1986.tb01551.x; SCHUMACHER W, 1994, BIOCHEM BIOPH RES CO, V205, P911, DOI 10.1006/bbrc.1994.2751	23	23	23	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23191	23196		10.1074/jbc.271.38.23191	http://dx.doi.org/10.1074/jbc.271.38.23191			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798514	hybrid			2022-12-27	WOS:A1996VH76800040
J	Panneels, V; Macours, P; VandenBergen, H; Braekman, JC; VanSande, J; Boeynaems, JM				Panneels, V; Macours, P; VandenBergen, H; Braekman, JC; VanSande, J; Boeynaems, JM			Biosynthesis and metabolism of 2-iodohexadecanal in cultured dog thyroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS ALDOSE REDUCTASE; LIPID-PEROXIDATION; ALDEHYDE PRODUCTS; CYCLIC-AMP; INHIBITION; IDENTIFICATION; IODIDE; THYROTROPIN; OXIDATION; CYCLASE	2-Iodohexadecanal (2-IHDA) is a major thyroid iodolipid. It mimics the main regulatory effects of iodide on thyroid metabolism: inhibition of H2O2 production and of adenylyl cyclase, The biosynthesis of 2-IHDA and its metabolism have been investigated in cultured dog thyroid cells maintained in a differentiated state by forskolin, Incubation of these cells with [9,10-H-3]hexadecan-1-ol or [9,10-H-3]palmitic acid labeled several phospholipids, but [9,10-H-3]hexadecan-1-ol was selectively incorporated into plasmenylethanolamine. In the presence of an exogenous H2O2 generating system (glucose oxidase), iodide induced the production of [9,10-H-3]2-IHDA from [9,10-H-3]hexadecan-1-ol-labeled cells but not from [9,10-H-3]palmitic acid-labeled cells, 2-IHDA was also generated during the lactoperoxidase-catalyzed iodination of brain and heart plasmalogens, and of ethyl hexadec-1-enyl ether, a synthetic vinyl ether-containing compound, Taken together, these results show that thyroid 2-IHDA is derived from plasmenylethanolamine via an attack of reactive iodine on the vinyl ether group. 2-Iodohexadecan-1-ol (2-IHDO) was also detected in these studies; it was formed later than 2-IHDA, and thyroid cells converted exogenous 2-IHDA into 2-IHDO in a time-dependent way, The ratio of 2-IHDO/2-IHDA increased with H2O2 production and decreased as a function of iodide concentration, An aldehyde-reducing activity was detected in subcellular fractions of the horse thyroid No formation of 2-iodohexadecanoic acid could be detected, Reduction into the biologically inactive 2-IHDO is thus a major metabolic pathway of 2-IHDA in dog thyrocytes.	FREE UNIV BRUSSELS,FAC SCI,BIOORGAN CHEM LAB,B-1070 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,ERASME HOSP,DEPT MED CHEM,B-1070 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,SCH MED,INST INTERDISCIPLINARY RES,B-1070 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel				Panneels, Valerie/0000-0001-8899-3366				BARLUENGA J, 1986, SYNTHESIS-STUTTGART, V8, P678; BENARD B, 1971, UNION MED CAN, V100, P701; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CANUTO RA, 1994, CARCINOGENESIS, V15, P1359, DOI 10.1093/carcin/15.7.1359; COCHAUX P, 1985, FEBS LETT, V179, P303, DOI 10.1016/0014-5793(85)80539-1; COCHAUX P, 1987, EUR J BIOCHEM, V170, P435, DOI 10.1111/j.1432-1033.1987.tb13718.x; CORVILAIN B, 1988, BIOCHEM BIOPH RES CO, V154, P1287, DOI 10.1016/0006-291X(88)90279-3; DELCORSO A, 1989, ARCH BIOCHEM BIOPHYS, V270, P604, DOI 10.1016/0003-9861(89)90543-2; DELCORSO A, 1987, BIOCHEM BIOPH RES CO, V148, P369, DOI 10.1016/0006-291X(87)91120-X; FERRELL WJ, 1970, ANAL BIOCHEM, V37, P227, DOI 10.1016/0003-2697(70)90042-4; GROSS RW, 1985, BIOCHEMISTRY-US, V24, P1662, DOI 10.1021/bi00328a014; HAJRA AK, 1982, ANN NY ACAD SCI, V386, P170, DOI 10.1111/j.1749-6632.1982.tb21415.x; HOLUB BJ, 1987, METHOD ENZYMOL, V141, P234; KAYGANICH KA, 1992, ANAL CHEM, V64, P2965, DOI 10.1021/ac00047a015; LAGROU A, 1974, LIPIDS, V9, P870, DOI 10.1007/BF02532612; MANCUSO AJ, 1978, J ORG CHEM, V43, P2480, DOI 10.1021/jo00406a041; MARMER WN, 1986, LIPIDS, V21, P648, DOI 10.1007/BF02537215; MCLAFFERTY FW, 1966, J CHEM SOC CHEM COMM, P78; MILLIGAN N, 1982, EPILEPSIA, V23, P323, DOI 10.1111/j.1528-1157.1982.tb06198.x; MIYAUCHI K, 1991, J BIOL CHEM, V266, P19536; MUKHERJEE KD, 1980, EUR J BIOCHEM, V107, P289, DOI 10.1111/j.1432-1033.1980.tb04649.x; OHAYON R, 1994, MOL CELL ENDOCRINOL, V99, P133, DOI 10.1016/0303-7207(94)90156-2; PANNEELS V, 1994, MOL CELL ENDOCRINOL, V106, P41, DOI 10.1016/0303-7207(94)90184-8; PANNEELS V, 1994, MOL CELL ENDOCRINOL, V102, P167, DOI 10.1016/0303-7207(94)90110-4; PANNEELS V, 1995, THYROID S1, V5, P123; PEREIRA A, 1990, J BIOL CHEM, V265, P17018; RABINOWITZ JL, 1976, BIOCHEM J, V160, P463, DOI 10.1042/bj1600463; RAPOPORT B, 1977, ENDOCRINOLOGY, V100, P755, DOI 10.1210/endo-100-3-755; RIZZO WB, 1987, J BIOL CHEM, V262, P17412; ROGER PP, 1985, EUR J BIOCHEM, V152, P239, DOI 10.1111/j.1432-1033.1985.tb09189.x; ROGER PP, 1987, EXP CELL RES, V172, P282, DOI 10.1016/0014-4827(87)90387-9; ROGER PP, 1984, MOL CELL ENDOCRINOL, V36, P79, DOI 10.1016/0303-7207(84)90087-X; Srivastava S, 1995, BIOCHEM BIOPH RES CO, V217, P741, DOI 10.1006/bbrc.1995.2835; TASAYCO ML, 1990, J BIOL CHEM, V265, P3094; THOMAS SE, 1992, BIOCHIM BIOPHYS ACTA, V1126, P125, DOI 10.1016/0005-2760(92)90282-Z; ULLRICH O, 1994, FEBS LETT, V352, P84, DOI 10.1016/0014-5793(94)00922-8; VANSANDE J, 1985, MOL CELL ENDOCRINOL, V40, P181, DOI 10.1016/0303-7207(85)90174-1; WOLFF J, 1989, ADV EXP MED BIOL, V261, P211; YOON NM, 1973, J ORG CHEM, V38, P2786, DOI 10.1021/jo00956a011	40	23	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23006	23014		10.1074/jbc.271.38.23006	http://dx.doi.org/10.1074/jbc.271.38.23006			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798488	hybrid			2022-12-27	WOS:A1996VH76800014
J	Reaume, AG; Howland, DS; Trusko, SP; Savage, MJ; Lang, DM; Greenberg, BD; Siman, R; Scott, RW				Reaume, AG; Howland, DS; Trusko, SP; Savage, MJ; Lang, DM; Greenberg, BD; Siman, R; Scott, RW			Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a ''humanized'' A beta sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL FRAGMENT; TRANSGENIC MICE; MISSENSE MUTATION; SECRETED FORMS; MESSENGER-RNA; STEM-CELLS; PEPTIDE; BRAIN; CLEAVAGE; APP	The processing of the beta-amyloid precursor protein (APP) in vivo has been characterized in a novel animal model that recapitulates, in part, the APP genotype of a familial form of Alzheimer's disease (AD). A gene-targeting strategy was used to introduce the Swedish familial AD mutations and convert mouse A beta to the human sequence. The mutant APP is expressed at normal levels in brain, and cleavage at the mutant beta-secretase site is both accurate and enhanced. Furthermore, human A beta production is significantly increased to levels 9-fold greater than those in normal human brain while nonamyloidogenic processing is depressed. The results on A beta production extend similar findings obtained in cell culture to the brain of an animal and substantiate A beta as a etiological factor in Swedish familial AD. These animals provide several distinguishing features over others created by conventional transgenic methodologies. The spatial and temporal expression patterns of human A beta are expected to be faithfully reproduced because the gene encoding the mutant APP remains in its normal chromosomal context. Thus, the neuropathological consequences of human A beta overproduction can be evaluated longitudinally in the absence of potential mitigating effects of APP overexpression or presence of the mouse A beta peptide.	CEPHALON INC, W CHESTER, PA 19380 USA	Teva Pharmaceutical Industries; Cephalon Inc.								ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; ARAKI E, 1995, AMYLOID, V2, P100, DOI 10.3109/13506129509031894; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; DYRKS T, 1994, FEBS LETT, V349, P210, DOI 10.1016/0014-5793(94)00671-7; DYRKS T, 1993, FEBS LETT, V324, P231, DOI 10.1016/0014-5793(93)81399-K; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1994, J BIOL CHEM, V269, P17741; HIGGINS LS, 1993, ANN NY ACAD SCI, V695, P224, DOI 10.1111/j.1749-6632.1993.tb23056.x; Hogan B, 1986, MANIPULATING MOUSE E, P89; HOWLAND DS, 1995, NEUROBIOL AGING, V16, P685, DOI 10.1016/0197-4580(95)00078-S; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; HUNG AY, 1993, J BIOL CHEM, V268, P22959; KAMMESHEIDT A, 1992, P NATL ACAD SCI USA, V89, P10857, DOI 10.1073/pnas.89.22.10857; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KONIG G, 1992, J BIOL CHEM, V267, P10804; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LAMB BT, 1993, NAT GENET, V5, P22, DOI 10.1038/ng0993-22; MANN DMA, 1988, MECH AGEING DEV, V43, P99, DOI 10.1016/0047-6374(88)90041-3; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NARUSE S, 1991, LANCET, V337, P978, DOI 10.1016/0140-6736(91)91612-X; OTVOS L, 1993, EUR J BIOCHEM, V211, P249, DOI 10.1111/j.1432-1033.1993.tb19893.x; PEARSON BE, 1993, P NATL ACAD SCI USA, V90, P10578, DOI 10.1073/pnas.90.22.10578; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; QUON D, 1991, NATURE, V352, P239, DOI 10.1038/352239a0; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SAUER B, 1990, New Biologist, V2, P441; SAVAGE MJ, 1994, NEUROSCIENCE, V60, P607, DOI 10.1016/0306-4522(94)90490-1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SIMAN R, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P675; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; TAMAOKA A, 1994, J BIOL CHEM, V269, P32721; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; WOOD SA, 1993, P NATL ACAD SCI USA, V90, P4582, DOI 10.1073/pnas.90.10.4582; Wurst W., 1993, Gene targeting: a practical approach., P33; YAMADA T, 1987, BIOCHEM BIOPH RES CO, V149, P665, DOI 10.1016/0006-291X(87)90419-0; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	71	116	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23380	23388		10.1074/jbc.271.38.23380	http://dx.doi.org/10.1074/jbc.271.38.23380			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798542	hybrid			2022-12-27	WOS:A1996VH76800068
J	Bojovic, B; Rodrigues, N; Dehbi, M; Bedard, PA				Bojovic, B; Rodrigues, N; Dehbi, M; Bedard, PA			Multiple signaling pathways control the activation of the CEF-4/9E3 cytokine gene by pp60(v-src)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; VIRUS-TRANSFORMED FIBROBLASTS; NF-KAPPA-B; V-SRC; HA-RAS; PROSTAGLANDIN SYNTHASE; SELECTIVE ACTIVATION; TRANSCRIPTION FACTOR; PHOSPHOLIPASE-C; MAMMALIAN-CELLS	The CEF-4/9E3 cytokine gene is expressed aberrantly in chicken embryo fibroblasts (CEF) transformed by the Rous sarcoma virus. The expression of CEF-4 is dependent on both transcriptional and post-transcriptional mechanisms of regulation. The characterization of the promoter region indicated that three distinct regulatory elements corresponding to an AP-1 binding site (or TRE), a PRDII/kappa B domain, and a CAAT box are involved in the activation by pp60(v-src). In this report we investigate the signaling pathways controlling the expression of the TRE and PRDII domain. The expression of a dominant negative mutant of p21(ras) reduced the activity of both elements. In contrast a similar mutant of c-Raf-1 affected modestly the activation dependent on the TRE but not PRDII. The stress-activated protein kinase (SAPK)/Jun N-terminal kinase (JNK) pathway was important for the activity of PRDII and the TRE but was not markedly stimulated by pp60(v-src). The addition of calphostin C and the inhibition of protein kinase C (PKC) diminished the accumulation of the CEF-4 mRNA and reduced the activity of a TRE-controlled promoter. Likewise, the depletion of PHC by chronic treatment with phorbol esters inhibited the activation of the TRE. Rous sarcoma virus-transformed CEF treated with calphostin C were also flatter, did not display a high degree of criss-crossing, and appeared morphologically normal. Hence PKC was important for the activation of AP-1 and the morphological transformation of CEF. The constitutive expression of CEF-4 was correlated with transformation only when dependent on the TRE. This was not true for PRDII, which was the only element required for the constitutive activation to the CEF-4 promoter in nontransformed cells treated chronically with phorbol esters.	UNIV MONTREAL, DEPT BIOCHIM, MONTREAL, PQ H3C 3J7, CANADA; YORK UNIV, DEPT BIOL, N YORK, ON M3J 1P3, CANADA	Universite de Montreal; York University - Canada								AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CATLING AD, 1993, ONCOGENE, V8, P1875; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEHBI M, 1992, BIOCHEM CELL BIOL, V70, P980, DOI 10.1139/o92-142; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DEHBI M, 1994, ONCOGENE, V9, P2399; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOSTER DA, 1993, CELL SIGNAL, V5, P389, DOI 10.1016/0898-6568(93)90078-Z; GONNEVILLE L, 1991, ONCOGENE, V6, P1825; GOODE N, 1992, J BIOL CHEM, V267, P16878; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARTINS TJ, 1989, J CELL BIOL, V108, P683, DOI 10.1083/jcb.108.2.683; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QURESHI SA, 1992, J BIOL CHEM, V267, P17635; QURESHI SA, 1993, BIOCHEM BIOPH RES CO, V192, P969, DOI 10.1006/bbrc.1993.1510; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOZERI O, 1992, ONCOGENE, V7, P2259; SPRANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WASYLYK C, 1994, ONCOGENE, V9, P3665; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; YAN MH, 1994, NATURE, V372, P798; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367	59	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22528	22537		10.1074/jbc.271.37.22528	http://dx.doi.org/10.1074/jbc.271.37.22528			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798420	hybrid			2022-12-27	WOS:A1996VG67200039
J	Capdevila, JH; Wei, SZ; Helvig, C; Falck, JR; Belosludtsev, Y; Truan, G; GrahamLorence, SE; Peterson, JA				Capdevila, JH; Wei, SZ; Helvig, C; Falck, JR; Belosludtsev, Y; Truan, G; GrahamLorence, SE; Peterson, JA			The highly stereoselective oxidation of polyunsaturated fatty acids by cytochrome P450BM-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; BACILLUS-MEGATERIUM; CRYSTAL-STRUCTURE; 18-HYDROXYEICOSATETRAENOIC ACIDS; OMEGA-HYDROXYLATION; RAT-KIDNEY; EPOXYGENASE; EXPRESSION; MONOOXYGENATION; BIOSYNTHESIS	Cytochrome P450BM-3 catalyzes NADPH-dependent metabolism of arachidonic acid to nearly enantiomerically pure 18(R-hydroxyeicosatetraenoic acid and 14(S),15(R)-epoxyeicosatrienoic acid (80 and 20% of total products, respectively), P450BM-3 oxidizes arachidonic acid with a rate of 3.2 +/- 0.4 mu mol/min/nmol at 30 degrees C, the fastest ever reported for an NADPH dependent, P450-catalyzed reaction, Fatty acid, oxygen, and NADPH are utilized in an approximately 1:1:1 molar ratio, demonstrating efficient coupling of electron transport to monooxygenation. Eicosapentaenoic and eicosatrienoic acids, two arachidonic acid analogs that differ in the properties of the C-15-C-18 carbons, are also actively metabolized by P450BM-3 (1.4 +/- 0.2 and 2.9 +/- 0.1 mu mol/min/nmol at 30 degrees C, respectively). While the 17,18-olefinic bond of eicosapentaenoic acid is epoxidized with nearly absolute regio- and stereochemical selectivity to 17(S),18(R)-epoxyeicosatetraenoic acid (greater than or equal to 99% of total products, 97% optical purity), P450BM-3 is only moderately regioselective during hydroxylation of the eicosatrienoic acid omega-1, omega-2, and omega-3 sp(3) carbons, with 17-, 18-, and 19-hydroxyeicosatrienoic acid formed in a ratio of 2.4:2.2:1, respectively. Based on the above and on a model of arachidonic acid-bound P450BM-3, we propose: 1) the formation by P450BM-3 of a single oxidant species capable of olefinic bond epoxidation and sp(3) carbon hydroxylation and 2) that product chemistry and, thus, catalytic outcome are critically dependent on active site spatial coordinates responsible for substrate binding and productive orientation between heme-bound active oxygen and acceptor carbon bond(s).	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT MOL GENET, DALLAS, TX 75235 USA; VANDERBILT UNIV, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Vanderbilt University; Vanderbilt University			; Truan, Gilles/C-7044-2019	Falck, John/0000-0002-9219-7845; Truan, Gilles/0000-0002-3560-8302	NIGMS NIH HHS [GM37922, GM31278, GM43479] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043479, R01GM031278] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BODDUPALLI SS, 1992, ARCH BIOCHEM BIOPHYS, V292, P20, DOI 10.1016/0003-9861(92)90045-X; BODDUPALLI SS, 1990, J BIOL CHEM, V265, P4233; BODDUPALLI SS, 1992, J BIOL CHEM, V267, P10375; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; CAPDEVILA JH, 1992, J BIOL CHEM, V267, P21720; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CAPDEVILAJH, 1995, CYTOCHROME P450 STRU, P443; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; FALCK JR, 1990, J BIOL CHEM, V265, P10244; FALCK JR, 1992, TETRAHEDRON LETT, V33, P4893, DOI 10.1016/S0040-4039(00)61226-1; Groves John T., 1995, P3; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; HO PP, 1976, BIOCHIM BIOPHYS ACTA, V431, P249, DOI 10.1016/0005-2760(76)90145-4; IMAOKA S, 1989, BIOCHEM INT, V18, P731; KARARA A, 1992, BIOCHEM BIOPH RES CO, V182, P1320, DOI 10.1016/0006-291X(92)91877-S; KARARA A, 1993, J BIOL CHEM, V268, P13565; KATOH T, 1991, AM J PHYSIOL, V261, pF578, DOI 10.1152/ajprenal.1991.261.4.F578; Kuhn H, 1988, Basic Life Sci, V49, P945; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MIURA Y, 1975, BIOCHIM BIOPHYS ACTA, V388, P305, DOI 10.1016/0005-2760(75)90089-2; MIURA Y, 1974, J BIOL CHEM, V249, P1880; NARHI LO, 1986, J BIOL CHEM, V261, P7160; OLIW EH, 1991, ADV PROSTAG THROMB L, V21, P197; OLIW EH, 1994, PROG LIPID RES, V33, P329, DOI 10.1016/0163-7827(94)90029-9; OMURA T, 1964, J BIOL CHEM, V239, P2370; OSTER T, 1991, J BIOL CHEM, V266, P22718; PETERSON JA, 1971, ARCH BIOCHEM BIOPHYS, V144, P678, DOI 10.1016/0003-9861(71)90375-4; PETERSON JA, 1975, CYTOCHROMES P450 B5, P311; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; ROMAN LJ, 1993, ARCH BIOCHEM BIOPHYS, V307, P57, DOI 10.1006/abbi.1993.1560; ROSSITER BE, 1984, J ORG CHEM, V49, P3707, DOI 10.1021/jo00194a007; SEVRIOUKOVA IF, 1995, BIOCHIMIE, V77, P562, DOI 10.1016/0300-9084(96)88172-7; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; WEN LP, 1987, J BIOL CHEM, V262, P6676	38	144	171	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22663	22671		10.1074/jbc.271.37.22663	http://dx.doi.org/10.1074/jbc.271.37.22663			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798438				2022-12-27	WOS:A1996VG67200057
J	Hiraki, Y; Inoue, H; Kondo, J; Kamizono, A; Yoshitake, Y; Shukunami, C; Suzuki, F				Hiraki, Y; Inoue, H; Kondo, J; Kamizono, A; Yoshitake, Y; Shukunami, C; Suzuki, F			A novel growth-promoting factor derived from fetal bovine cartilage, chondromodulin II - Purification and amino acid sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT COSTAL CHONDROCYTES; V-MYB; MIM-1 GENE; FACTOR-BETA; C-MYB; CELLS; EXPRESSION; MUTATIONS; PROTEIN; DIFFERENTIATION	During endochondral bone formation, cartilage cells show increased matrix synthesis and rapid proliferation. We found that cartilage matrix contains at least two types of heparin binding growth-promoting components, One, with a higher affinity to heparin, was identified as chondromodulin I (Hiraki, Y., Tanaka, H., Inoue, H., Kondo, J., Kamizono, A., and Suzuki, F. (1991) Biochem, Biophys, Res, Commun, 175, 871-977), In this study, we isolated a novel growth-promoting component, chondromodulin II, which has a lower heparin affinity, from the dissociative extracts of fetal bovine epiphyseal cartilage. Chondromodulin II stimulated the proteoglycan synthesis in rabbit cultured growth plate chondrocytes, an expression of the differentiated phenotype of chondrocytes. It also stimulated DNA synthesis in chondrocytes in both the absence and the presence of fibroblast growth factor-2. The apparent molecular mass of chondromodulin II on SDS-polyacrylamide gel electrophoresis was 16 kDa, Its complete amino acid sequence was determined by overlapping sequences of the peptides released by endopeptidase digestion and CNBr cleavage, Chondromodulin II consists of 133 amino acids (calculated M(r) = 14,548). The sequence was unique but homologous to the repeats 1 and 2 of the deduced amino acid sequence of the chicken mim-1 gene, which is specifically transactivated by the v-Myb oncogene product in promyelocytes. We also found a minor component with a higher heparin affinity, chondromodulin III, in cartilage extracts, Chondromodulin III stimulated DNA synthesis in chondrocytes in vitro, and its N-terminal sequence was identical with ribosomal protein L31 lacking the N-terminal three amino acids, These findings suggest that the growth and differentiation of chondrocytes are regulated by multiple components in the cartilage matrix.	OSAKA UNIV,FAC DENT,DEPT BIOCHEM & CALCIFIED TISSUE METAB,SUITA,OSAKA 565,JAPAN; MITSUBISHI KAGAKU CORP,RES CTR,KANAGAWA 227,JAPAN; KANAZAWA MED UNIV,DEPT BIOCHEM,KANAZAWA,ISHIKAWA 92002,JAPAN	Osaka University; Kanazawa Medical University			Shukunami, Chisa/G-2887-2019	Shukunami, Chisa/0000-0001-5616-6761				BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CHESTER KA, 1989, BIOCHIM BIOPHYS ACTA, V1009, P297, DOI 10.1016/0167-4781(89)90119-X; ELLINGSWORTH LR, 1986, J BIOL CHEM, V261, P2362; FUJITA Y, 1994, BIOCHEM BIOPH RES CO, V199, P706, DOI 10.1006/bbrc.1994.1286; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; HAWKE DH, 1987, ANAL BIOCHEM, V166, P298, DOI 10.1016/0003-2697(87)90578-1; HIRAKI Y, 1991, BIOCHEM BIOPH RES CO, V175, P971, DOI 10.1016/0006-291X(91)91660-5; HIRAKI Y, 1991, J BONE MINER RES, V6, P1373; HIRAKI Y, 1986, EUR J BIOCHEM, V158, P333, DOI 10.1111/j.1432-1033.1986.tb09755.x; HIRAKI Y, 1988, BIOCHIM BIOPHYS ACTA, V969, P91, DOI 10.1016/0167-4889(88)90092-4; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KATO Y, 1983, EUR J BIOCHEM, V129, P685; KATO Y, 1984, J CELL PHYSIOL, V120, P354, DOI 10.1002/jcp.1041200314; KATO Y, 1985, J CELL BIOL, V100, P486, DOI 10.1083/jcb.100.2.486; KONDO J, 1989, MITUSBISHIKASEI R D, V3, P110; MATSUZAKI K, 1989, P NATL ACAD SCI USA, V86, P9911, DOI 10.1073/pnas.86.24.9911; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; QUEVA C, 1992, DEVELOPMENT, V114, P125; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SHIMBARA N, 1993, FEBS LETT, V322, P235, DOI 10.1016/0014-5793(93)81577-M; SHIMOMURA Y, 1975, CALC TISS RES, V19, P179, DOI 10.1007/BF02564002; SULLIVAN R, 1985, J BIOL CHEM, V260, P2399; SUZUKI F, 1987, METHOD ENZYMOL, V146, P313; TANAKA T, 1987, EUR J BIOCHEM, V162, P45, DOI 10.1111/j.1432-1033.1987.tb10539.x; THOMPSON NL, 1989, J CELL BIOL, V108, P661, DOI 10.1083/jcb.108.2.661; YAMADA K, 1992, CELL STRUCT FUNCT, V17, P9, DOI 10.1247/csf.17.9	29	57	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22657	22662		10.1074/jbc.271.37.22657	http://dx.doi.org/10.1074/jbc.271.37.22657			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798437	hybrid			2022-12-27	WOS:A1996VG67200056
J	Ishibashi, S; Perry, S; Chen, Z; Osuga, J; Shimada, M; Ohashi, K; Harada, K; Yazaki, Y; Yamada, N				Ishibashi, S; Perry, S; Chen, Z; Osuga, J; Shimada, M; Ohashi, K; Harada, K; Yazaki, Y; Yamada, N			Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants - A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; HERITABLE HYPERLIPIDEMIC RABBITS; HEPATIC-UPTAKE; WHHL RABBITS; IN-VIVO; PROTEIN-ALPHA-2-MACROGLOBULIN RECEPTOR; RETINYL PALMITATE; CULTURED-CELLS; E DEFICIENCY; RAT-LIVER	Two receptor pathways are thought to mediate the hepatic clearance of chylomicron remnants, (i) the low density lipoprotein receptor (LDLR) pathway and (ii) non-LDLR pathway. The current study was undertaken to quantitatively assess the contribution of each receptor pathway to hepatic catabolism of chylomicron remnants, by using mice that are deficient in apolipoprotein E (apoE) (apoE(-/-)), the LDLR (LDLR(-/-)), and both (apoE(-/-);LDLR(-/-)). Vitamin A fat tolerance tests showed that the area under the curves of the plasma excursions of retinyl ester in the LDLR(-/-), apoE(-/-), and apoE(-/-);LDLR(-/-) mice were 4, 12, and 12 times larger than those in wild-type mice. The retinyl ester accumulated in the plasma of the LDLR(-/-) mice was distributed in larger subfractions of triglyceride-rich lipoproteins, chylomicrons through very low density lipoprotein-C. These results indicate that the LDLR constitutes the major pathway for the clearance of retinyl ester, In support of this, agarose gel electrophoresis revealed that an oral fat load resulted in retention of chylomicrons in the LDLR(-/-) mice, which was not seen in wild-type mice. The observation that the apoE(-/-) mice showed larger retinyl ester excursion than LDLR(-/-) mice indicates that an apoE-dependent non-LDLR pathway is involved in the rest of the clearance of the retinyl ester. Together, we conclude that the LDLR pathway plays a significant role in the chylomicron remnant metabolism in mice fed a normal chow.			Ishibashi, S (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.							BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEAUMONT JL, 1990, ATHEROSCLEROSIS, V85, P103, DOI 10.1016/0021-9150(90)90102-O; BOWLER A, 1991, BIOCHEM J, V276, P381, DOI 10.1042/bj2760381; CHOI SSY, 1991, J CLIN INVEST, V88, P1173, DOI 10.1172/JCI115419; CHOI SY, 1993, J BIOL CHEM, V268, P15804; DEMACKER PNM, 1992, BIOCHEM J, V285, P641, DOI 10.1042/bj2850641; DIETSCHY JM, 1988, HYPERLIPIDAEMIA ATHE, P17; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HAVEL RJ, 1995, CURR OPIN LIPIDOL, V6, P312, DOI 10.1097/00041433-199510000-00011; HERZ J, 1995, P NATL ACAD SCI USA, V92, P4611, DOI 10.1073/pnas.92.10.4611; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; HUSSAIN MM, 1995, J BIOL CHEM, V270, P8578, DOI 10.1074/jbc.270.15.8578; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; JACKLE S, 1992, J LIPID RES, V33, P419; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; JI ZS, 1995, J LIPID RES, V36, P583; JI ZW, 1995, ARTERIOSCLER THROMB, V14, P2025; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KRISETHERTON PM, 1980, J LIPID RES, V21, P435; MABUCHI H, 1989, METABOLISM, V38, P115, DOI 10.1016/0026-0495(89)90249-7; MAHLEY RW, 1994, METABOLIC BASES INHE, P1953; MATTHEWS CME, 1957, PHYS MED BIOL, V2, P36, DOI 10.1088/0031-9155/2/1/305; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; NAGATA Y, 1988, J BIOL CHEM, V263, P15151; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; REDGRAVE TG, 1979, J LIPID RES, V20, P217; RUBINSZTEIN DC, 1990, J CLIN INVEST, V86, P1306, DOI 10.1172/JCI114839; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SHAFI S, 1994, J LIPID RES, V35, P709; SHIMANO H, 1994, J CLIN INVEST, V93, P2215, DOI 10.1172/JCI117218; SULTAN F, 1990, BIOCHIM BIOPHYS ACTA, V1042, P150, DOI 10.1016/0005-2760(90)90071-5; WADE DP, 1986, EUR J BIOCHEM, V159, P333, DOI 10.1111/j.1432-1033.1986.tb09872.x; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537; WILSON DE, 1987, BIOCHIM BIOPHYS ACTA, V922, P247, DOI 10.1016/0005-2760(87)90047-6; WINDLER EET, 1988, BIOCHEM J, V252, P553, DOI 10.1042/bj2520553; YAMADA N, 1988, J CLIN INVEST, V82, P2106, DOI 10.1172/JCI113832; ZHANG SH, 1992, SCIENCE, V258, P458	47	105	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22422	22427		10.1074/jbc.271.37.22422	http://dx.doi.org/10.1074/jbc.271.37.22422			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798405	hybrid			2022-12-27	WOS:A1996VG67200024
J	Quaggin, SE; VandenHeuvel, GB; Golden, K; Bodmer, R; Igarashi, P				Quaggin, SE; VandenHeuvel, GB; Golden, K; Bodmer, R; Igarashi, P			Primary structure, neural-specific expression, and chromosomal localization of Cux-2, a second murine homeobox gene related to Drosophila cut	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT DISPLACEMENT PROTEIN; SENSORY ORGAN IDENTITY; DNA-BINDING SPECIFICITY; HOMEODOMAIN PROTEIN; MOUSE CHROMOSOME-5; LOCUS; TRANSFORMATION; PATTERNS; PROMOTER; ENHANCER	The cut locus of Drosophila encodes a diverged homeodomain-containing protein that is required for the development of external sensory (es) organs and other tissues. A homologous gene (Cux-1) that encodes a transcriptional repressor has been identified in the mouse and other mammals. We have identified a second murine homeobox-containing gene (designated Cux-2) that is structurally related to Drosophila cut. The murine Cux-2 homeobox was similar to Drosophila cut and encoded a homeodomain that contained a characteristic histidine residue at position 50. The predicted Cux-2 protein contained 1426 amino acids and included three internal 60-amino acid repeats (Cut repeats) that were previously found in Drosophila Cut and murine Cux-1. Unlike Cux-1, expression of Cux-2 was restricted to neural tissue. In the adult brain, Cux-2 was prominently expressed in neurons in the thalamus and limbic system. In embryos, Cux-2 was expressed in the developing central and peripheral nervous systems, including the telencephalon and peripheral ganglia of the trigeminal and glossopharyngeal nerves. A glutathione S-transferase fusion protein containing the carboxyl-terminal Cut repeat and homeodomain of Cux-2 exhibited sequence-specific binding to oligonucleotides derived from the promoter of the Ncam gene. Using an interspecific backcross panel, Cux-1 and Cux-2 were mapped to distinct loci that were genetically linked on distal chromosome 5. These results demonstrate that a family of homeobox genes related to Drosophila cutis located on chromesome 5 in the mouse. Cux-2 is expressed exclusively in the central and peripheral nervous systems, and the Cux-2 gene product binds to DNA in a sequence-specific manner. Cux-2 may encode a transcription factor that is involved in neural specification in mammals.	YALE UNIV, SCH MED, NEPHROL SECT, NEW HAVEN, CT 06520 USA; UNIV MICHIGAN, DEPT BIOL, ANN ARBOR, MI 48109 USA	Yale University; University of Michigan System; University of Michigan				Igarashi, Peter/0000-0001-8698-1185; Vanden Heuvel, Gregory/0000-0003-1477-0236	NIDDK NIH HHS [R01 DK-45678] Funding Source: Medline; NINDS NIH HHS [R01 NS-29119] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029119] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDRES V, 1992, DEVELOPMENT, V116, P321; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; BALLYCUIF L, 1993, DEVELOPMENT, V117, P543; BLOCHLINGER K, 1993, DEVELOPMENT, V117, P441; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; FINKELSTEIN R, 1994, TRENDS GENET, V10, P310, DOI 10.1016/0168-9525(94)90033-7; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; Heuvel GBV, 1996, KIDNEY INT, V50, P453, DOI 10.1038/ki.1996.336; HIRSCH MR, 1990, MOL CELL BIOL, V10, P1959, DOI 10.1128/MCB.10.5.1959; HUNT P, 1991, DEVELOPMENT, P187; IGARASHI P, 1995, AM J PHYSIOL-RENAL, V269, pF405, DOI 10.1152/ajprenal.1995.269.3.F405; KAPPEN C, 1989, P NATL ACAD SCI USA, V86, P5459, DOI 10.1073/pnas.86.14.5459; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOZAK CA, 1994, MAMM GENOME, V5, pS65; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LIU S, 1991, GENETICS, V127, P151; MANAK JR, 1994, DEVELOPMENT, P61; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MUENKE M, 1994, P NATL ACAD SCI USA, V91, P8102, DOI 10.1073/pnas.91.17.8102; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; PETERS LL, 1994, GENOMICS, V22, P490, DOI 10.1006/geno.1994.1418; Quaggin S. E., 1994, Molecular Biology of the Cell, V5, p85A; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SCHERER SW, 1993, GENOMICS, V15, P695, DOI 10.1006/geno.1993.1130; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; VALARCHE I, 1993, DEVELOPMENT, V119, P881; YOON SO, 1994, J BIOL CHEM, V269, P18453	39	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22624	22634		10.1074/jbc.271.37.22624	http://dx.doi.org/10.1074/jbc.271.37.22624			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798433	hybrid			2022-12-27	WOS:A1996VG67200052
J	Hatmi, M; Gavaret, JM; Elalamy, I; Vargaftig, BB; Jacquemin, C				Hatmi, M; Gavaret, JM; Elalamy, I; Vargaftig, BB; Jacquemin, C			Evidence for cAMP-dependent platelet ectoprotein kinase activity that phosphorylates platelet glycoprotein IV (CD36)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MYOSIN PHOSPHORYLATION; ADENYLATE-CYCLASE; INTACT PLATELETS; SURFACE; ACTIVATION; THROMBIN; DEPHOSPHORYLATION; IDENTIFICATION; THROMBOSPONDIN	The dephosphorylating enzyme alkaline phosphatase, by removing phosphate groups from the external platelet membrane proteins, modulates platelet activation (Hatmi, M., Haye, B., Gavaret, J. M., Vargaftig, B. B., and Jacquemin, C. (1991) Br. J. Pharmacol. 104, 554-558). This observation, together with findings reported by others (Ehrlich, Y. H., Davis, T. B., Beck, E., Kornecki, E., and Lenox, R. H. (1986) Nature 320, 67-70; Dusenbery, K. E., Mendiola, J. R., and Skubitz, K. M. (1988) Biochem. Biophys. Res. Commun. 153, 7-13), indicate the existence of ectoprotein kinase activity on the blood platelet surface. In this study, we demonstrate that washed human platelets phosphorylate the synthetic heptapeptide kemptide in a cAMP-dependent mode. The intensity of the phosphorylation was concentration-dependent for kemptide. In addition, incubation of platelets with [gamma-P-32]ATP resulted in a rapid incorporation of [P-32] phosphate into proteins at the outer membrane surface that was sensitive to alkaline phosphatase treatment. When cAMP was added to the medium, major phosphorylation of an 88-kDa ectoprotein occurred. Its isoelectric point determined by isoelectric focusing SDS-polyacrylamide gel electrophoresis was around pH 6.2. Phosphorylations of this 88-kDa polypeptide and of the exogenous kemptide substrate were both prevented by the specific protein kinase A inhibitor peptide. When platelets were preincubated with [P-32]inorganic phosphate to label intracellular proteins, the protein phosphorylation pattern was different from that obtained with [gamma-P-32]ATP, indicating that the latter occurred at the outer surface of the cells. Prostacyclin, which induces the increase of intracellular cAMP levels and, consequently, its liberation into the extracellular medium, increased phosphorylation of both kemptide and platelet 88-kDa polypeptide. The major protein of 88-kDa, which was phosphorylated in the presence of cAMP and external [gamma-P-32]ATP, was identified by immunoprecipitation to GPIV (CD36), one of thrombospondin and collagen binding sites on platelets. The phosphorylation of CD36 also occurred in platelet-rich plasma, suggesting a physiological role for this ectoenzyme. In the present study, we clearly demonstrate the presence of an ectoprotein kinase A activity at the surface of intact human platelets, and we revealed its principal endogenous substrate as being CD36.	HOP KREMLIN BICETRE, INSERM, U96, F-94276 LE KREMLIN BICETRE, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Hatmi, M (corresponding author), INST PASTEUR, UNITE PHARMACOL CELLULAIRE, INSERM, U285, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE.		Vargaftig, Bernardo Boris B.B.J./C-3323-2013					ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; BOOYSE FM, 1976, BIOCHIM BIOPHYS ACTA, V422, P60, DOI 10.1016/0005-2744(76)90008-5; CHENG HC, 1986, J BIOL CHEM, V261, P989; DANIEL JL, 1981, J BIOL CHEM, V256, P7510; DUSENBERY KE, 1988, BIOCHEM BIOPH RES CO, V153, P7, DOI 10.1016/S0006-291X(88)81182-3; EDELMAN P, 1986, BLOOD, V67, P56; EHRLICH YH, 1986, NATURE, V320, P67, DOI 10.1038/320067a0; FEINSTEIN MB, 1983, J BIOL CHEM, V258, P1260; FOX JEB, 1987, J BIOL CHEM, V262, P12627; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GORMAN RR, 1977, PROSTAGLANDINS, V13, P377, DOI 10.1016/0090-6980(77)90018-1; HASLAM RJ, 1979, BIOCHEM J, V178, P397, DOI 10.1042/bj1780397; HASLAM RJ, 1977, BIOCHEM BIOPH RES CO, V77, P714, DOI 10.1016/S0006-291X(77)80037-5; HATMI M, 1991, BRIT J PHARMACOL, V104, P554, DOI 10.1111/j.1476-5381.1991.tb12467.x; IMAOKA T, 1983, J BIOL CHEM, V258, P1404; KORCGRODZICKI B, 1988, BIOCHEM BIOPH RES CO, V157, P1131; KORCGRODZICKI B, 1988, P NATL ACAD SCI USA, V85, P7541, DOI 10.1073/pnas.85.20.7541; KUBLER D, 1992, EUR J BIOCHEM, V206, P179, DOI 10.1111/j.1432-1033.1992.tb16915.x; KUBLER D, 1989, J BIOL CHEM, V264, P14549; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYONS RM, 1975, J CLIN INVEST, V56, P924, DOI 10.1172/JCI108172; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MCGREGOR JL, 1983, EUR J BIOCHEM, V131, P427, DOI 10.1111/j.1432-1033.1983.tb07281.x; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; NAIK UP, 1991, BIOCHIM BIOPHYS ACTA, V1092, P256, DOI 10.1016/0167-4889(91)90165-T; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PRADELLES P, 1989, ANAL CHEM, V61, P447, DOI 10.1021/ac00180a014; SCHAFER AI, 1986, J CLIN INVEST, V78, P73, DOI 10.1172/JCI112576; SOSLAU G, 1989, BLOOD, V74, P984; TAKAYAMA H, 1991, BIOCHEM BIOPH RES CO, V174, P922, DOI 10.1016/0006-291X(91)91506-8; TANDON NN, 1989, J BIOL CHEM, V264, P7576; VILGRAIN I, 1991, MOL ENDOCRINOL, V5, P1003, DOI 10.1210/mend-5-7-1003	35	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24776	24780		10.1074/jbc.271.40.24776	http://dx.doi.org/10.1074/jbc.271.40.24776			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798748	hybrid			2022-12-27	WOS:A1996VM67400070
J	PazElizur, T; Takeshita, M; Goodman, M; ODonnell, M; Livneh, Z				PazElizur, T; Takeshita, M; Goodman, M; ODonnell, M; Livneh, Z			Mechanism of translesion DNA synthesis by DNA polymerase II - Comparison to DNA polymerases I and III core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; EXONUCLEASE ACTIVITY; MUTAGENESIS INVITRO; ACCESSORY PROTEINS; REPLICATIVE BYPASS; ADAPTIVE MUTATION; UV MUTAGENESIS; PHI-X174 DNA; ABASIC SITES	Bypass synthesis by DNA polymerase II was studied using a synthetic 40-nucleotide-long gapped duplex DNA containing a site-specific abasic site analog, as a model system for mutagenesis associated with DNA lesions. Bypass synthesis involved a rapid polymerization step terminating opposite the nucleotide preceding the lesion, followed by a slow bypass step. Bypass was found to be dependent on polymerase and dNTP concentrations, on the DNA sequence context, and on the size of the gap. A side-by-side comparison of DNA polymerases I, II, and III core revealed the following. 1) Each of the three DNA polymerases bypassed the abasic site analog unassisted by other proteins. 2) In the presence of physiological-like salt conditions, only DNA polymerase II bypassed the lesion. 3) Bypass by each of the three DNA polymerases increased dramatically in the absence of proofreading. These results support a model (Tomer, G., Cohen-Fix, O., O'Donnell, M., Goodman, M. and Livneh, Z. (1996) Proc. Natl. Acad. Sci. U. S. A, 93, 1376-1380) by which the RecA, UmuD, and UmuC proteins are accessory factors rather than being absolutely required for the core mutagenic bypass reaction in induced mutagenesis in Escherichia coli.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL; SUNY STONY BROOK,DEPT PHARMACOL SCI,STONY BROOK,NY 11794; UNIV SO CALIF,DEPT MOL BIOL,LOS ANGELES,CA 90089; CORNELL UNIV MED COLL,DEPT MICROBIOL,NEW YORK,NY 10021	Weizmann Institute of Science; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Southern California; Cornell University								BELGUISEVALLADIER P, 1994, J MOL BIOL, V236, P151, DOI 10.1006/jmbi.1994.1125; BONNER CA, 1992, J BIOL CHEM, V267, P11431; BONNER CA, 1990, P NATL ACAD SCI USA, V87, P7663, DOI 10.1073/pnas.87.19.7663; CAI H, 1995, J BIOL CHEM, V270, P15327, DOI 10.1074/jbc.270.25.15327; CHRISTENSEN JR, 1988, J MOL BIOL, V203, P635, DOI 10.1016/0022-2836(88)90198-2; CLARK JM, 1989, BIOCHEMISTRY-US, V28, P775, DOI 10.1021/bi00428a054; COHENFIX O, 1992, P NATL ACAD SCI USA, V89, P3300, DOI 10.1073/pnas.89.8.3300; COHENFIX O, 1994, J BIOL CHEM, V269, P4953; ESCARCELLER M, 1994, J BACTERIOL, V176, P6221, DOI 10.1128/jb.176.20.6221-6228.1994; FOSTER PL, 1995, P NATL ACAD SCI USA, V92, P7951, DOI 10.1073/pnas.92.17.7951; HEVRONI D, 1988, P NATL ACAD SCI USA, V85, P5046, DOI 10.1073/pnas.85.14.5046; IWASAKI H, 1990, J BACTERIOL, V172, P6268, DOI 10.1128/jb.172.11.6268-6273.1990; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kornberg A., 1991, DNA REPLICATION; KUNKEL TA, 1981, NATURE, V291, P349, DOI 10.1038/291349a0; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; LIVNEH Z, 1993, CRIT REV BIOCHEM MOL, V28, P465, DOI 10.3109/10409239309085136; LIVNEH Z, 1986, P NATL ACAD SCI USA, V83, P4599, DOI 10.1073/pnas.83.13.4599; MAKI H, 1985, J BIOL CHEM, V260, P2987; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MICHAELS ML, 1987, J BIOL CHEM, V262, P14648; MOORE P, 1979, NATURE, V278, P664, DOI 10.1038/278664a0; MOORE PD, 1981, P NATL ACAD SCI-BIOL, V78, P110, DOI 10.1073/pnas.78.1.110; RABKIN SD, 1983, P NATL ACAD SCI-BIOL, V80, P1541, DOI 10.1073/pnas.80.6.1541; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; RICHEY B, 1987, J BIOL CHEM, V262, P7157; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SHAVITT O, 1989, J BACTERIOL, V171, P3530, DOI 10.1128/jb.171.6.3530-3538.1989; SHIBUTANI S, 1993, J BIOL CHEM, V268, P11703; SHWARTZ H, 1987, J BIOL CHEM, V262, P10518; SHWARTZ H, 1988, J BIOL CHEM, V263, P18277; SOMMER S, 1993, MOL MICROBIOL, V10, P963, DOI 10.1111/j.1365-2958.1993.tb00968.x; STRAUSS BS, 1990, CARCINOGENESIS, V11, P2103, DOI 10.1093/carcin/11.12.2103; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; TAKESHITA M, 1994, NUCLEIC ACIDS RES, V22, P1897, DOI 10.1093/nar/22.10.1897; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P1624, DOI 10.1021/bi00458a038; TESSMAN I, 1985, P NATL ACAD SCI USA, V82, P6614, DOI 10.1073/pnas.82.19.6614; TESSMAN I, 1993, GENETICS, V136, P439; Tomer G, 1996, P NATL ACAD SCI USA, V93, P1376, DOI 10.1073/pnas.93.4.1376; VILLANI G, 1978, P NATL ACAD SCI USA, V75, P3037, DOI 10.1073/pnas.75.7.3037; WALKER GC, 1995, TRENDS BIOCHEM SCI, V20, P416, DOI 10.1016/S0968-0004(00)89091-X; WICKNER RB, 1972, J BIOL CHEM, V247, P489	45	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24662	24669		10.1074/jbc.271.40.24662	http://dx.doi.org/10.1074/jbc.271.40.24662			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798733	hybrid			2022-12-27	WOS:A1996VM67400055
J	Ishihara, H; Shibasaki, Y; Kizuki, N; Katagiri, H; Yazaki, Y; Asano, T; Oka, Y				Ishihara, H; Shibasaki, Y; Kizuki, N; Katagiri, H; Yazaki, Y; Asano, T; Oka, Y			Cloning of cDNAs encoding two isoforms of 68-kDa type I phosphatidylinositol-4-phosphate 5-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDIC-ACID; PANCREATIC-ISLETS; CA2+-ACTIVATED SECRETION; SIGNAL-TRANSDUCTION; INSULIN-SECRETION; MAMMALIAN-CELLS; GLUCOSE; ATP; PHOSPHOLIPIDS; METABOLISM	Accumulating evidence suggests that phosphatidylinositol metabolism is essential for membrane traffic in the cell, Of particular importance, phosphatidylinositol transfer protein and the type I phosphatidylinositol-4-phosphate 5-kinase (PI4P5K) have been identified as cytosolic components required for ATP-dependent, Ca2+-activated secretion. In order to identify PI4P5K isoforms that may play important roles in regulated insulin secretion from pancreatic beta-cells, we employed the polymerase chain reaction with degenerate primers and screening of a cDNA library of the murine pancreatic beta-cell line MIN6, Two novel cDNAs, designated PI4P5K-I alpha and PI4P5K-I beta, were identified, which contained complete coding sequences encoding 539- or 546-amino acid proteins, respectively. These cDNAs were expressed in mammalian cells with an adenoviral expression vector. Proteins of both isoforms migrated at 68 kDa on SDS-polyacrylamide gel electrophoresis and exhibited phosphatidylinositol-4-phosphate 5-kinase activity, which was activated by phosphatidic acid, indicating that these proteins were type I isoforms, While these isoforms share a marked amino acid sequence homology in their central portion, the amino- and carboxyl-terminal regions differ significantly. Northern blot analysis depicted that tissue distributions differed between the two isoforms. Molecular identification of type I PI4P5K isoforms in insulin-secreting cells should provide insights into the role of phosphatidylinositol metabolism in regulated exocytosis of insulin-containing large dense core vesicles.	YAMAGUCHI UNIV,SCH MED,DEPT INTERNAL MED 3,UBE,YAMAGUCHI 755,JAPAN	Yamaguchi University	Ishihara, H (corresponding author), UNIV TOKYO,DEPT INTERNAL MED 3,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CARVAJAL JJ, 1995, HUM MOL GENET, V4, P1411, DOI 10.1093/hmg/4.8.1411; DIVECHA N, 1995, BIOCHEM J, V309, P715, DOI 10.1042/bj3090715; DUNLOP ME, 1985, BIOCHEM BIOPH RES CO, V132, P467, DOI 10.1016/0006-291X(85)91157-X; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; FARESE RV, 1986, ENDOCRINOLOGY, V118, P1498, DOI 10.1210/endo-118-4-1498; Fukami K, 1996, J BIOL CHEM, V271, P2646, DOI 10.1074/jbc.271.5.2646; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Harlow E., 1988, ANTIBODIES LAB MANUA; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; METZ SA, 1990, ARCH BIOCHEM BIOPHYS, V283, P417, DOI 10.1016/0003-9861(90)90663-J; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MORITZ A, 1992, J BIOL CHEM, V267, P7207; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; SHIBASAKI Y, 1996, DIABETES S1, V45, pA243; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416	32	171	175	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23611	23614		10.1074/jbc.271.39.23611	http://dx.doi.org/10.1074/jbc.271.39.23611			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798574	hybrid			2022-12-27	WOS:A1996VJ44200003
J	Kim, SO; Plow, EF; Miles, LA				Kim, SO; Plow, EF; Miles, LA			Regulation of plasminogen receptor expression on monocytoid cells by beta(1)-integrin-dependent cellular adherence to extracellular matrix proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; MAMMARY EPITHELIAL-CELLS; BINDING-SITES; AFFINITY-CHROMATOGRAPHY; UROKINASE RECEPTORS; GENE-EXPRESSION; HUMAN-PLASMA; ACTIVATION; SURFACE; IDENTIFICATION	Plasminogen binding sites function to arm cell surfaces with the proteolytic activity of plasmin, critical for degradation of extracellular matrices, We have assessed the effects of adhesion of the representative monocytoid cell lines, THP-1 and U937, to purified extracellular matrix proteins on their expression of plasminogen receptors, After adhesion to immobilized fibronectin, adherent and nonadherent subpopulations of cells were separated, Plasminogen binding to the nonadherent population of cells increased 3-fold, whereas binding to the adherent population decreased by 60%. These changes were due to differences in the plasminogen binding capacities of the cells, while the affinities of the cells for plasminogen were unchanged, The up-regulation of receptor expression in the nonadherent cell population was: 1) induced rapidly and reversibly, 2) independent of new protein synthesis, 3) required an interaction between adherent and nonadherent cell populations, and 4) associated with an enhanced ability of the cells to promote plasminogen activation and to degrade fibronectin, Other immobilized adhesive proteins, laminin and vitronectin, also supported up-regulation of plasminogen receptors in the nonadherent cells, Carboxypeptidase B treatment eliminated the increment in the plasminogen binding capacity of the nonadherent cells, suggesting that the increase in binding was due to exposure of new carboxyl-terminal lysyl residues on the cell surfaces, Furthermore, both the adherence of the cells and up regulation of plasminogen binding sites was abolished by beta(1)-integrin monoclonal antibodies, These results suggest that proteins found in extracellular matrices have the capacity to modulate the expression of plasminogen binding sites, thus regulating local proteolysis and cell migration.	Scripps Res Inst, RES INST, DEPT VASC BIOL VB1, LA JOLLA, CA 92037 USA; CLEVELAND CLIN FDN, JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL, DEPT MOL CARDIOL, CLEVELAND, OH 44195 USA	Scripps Research Institute; Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045934, R29HL038272, R01HL038272, R01HL017964] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL17964, HL38272, HL45934] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BURGE SM, 1992, BRIT J DERMATOL, V126, P35, DOI 10.1111/j.1365-2133.1992.tb08400.x; CAMACHO M, 1989, FEBS LETT, V245, P21, DOI 10.1016/0014-5793(89)80183-8; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FELEZ J, 1993, THROMB HAEMOSTASIS, V69, P1232; FELEZ J, 1993, BLOOD, V82, P2433, DOI 10.1182/blood.V82.8.2433.bloodjournal8282433; FELEZ J, 1990, J CELL BIOL, V111, P1673, DOI 10.1083/jcb.111.4.1673; GANZ PR, 1991, BIOCHEM CELL BIOL, V69, P442, DOI 10.1139/o91-067; GONIAS SL, 1989, BLOOD, V74, P729; GONZALEZGRONOW M, 1991, ARCH BIOCHEM BIOPHYS, V286, P625, DOI 10.1016/0003-9861(91)90090-6; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HALL SW, 1991, J BIOL CHEM, V266, P12329; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jones Peter Lloyd, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P137; KUUSELA P, 1992, ACTA OPHTHALMOL, V70, P42; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN CQ, 1995, J CELL BIOL, V129, P1115, DOI 10.1083/jcb.129.4.1115; Lottenberg Richard, 1994, Trends in Microbiology, V2, P20, DOI 10.1016/0966-842X(94)90340-9; LU H, 1989, THROMB HAEMOSTASIS, V62, P91; LU H, 1988, BIOCHEM BIOPH RES CO, V155, P418, DOI 10.1016/S0006-291X(88)81102-1; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MILES L A, 1988, Fibrinolysis, V2, P61, DOI 10.1016/0268-9499(88)90369-4; MILES LA, 1985, J BIOL CHEM, V260, P4303; MILES LA, 1989, BIOCHEMISTRY-US, V28, P9337, DOI 10.1021/bi00450a014; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MILES LA, 1988, BLOOD, V72, P628; MILES LA, 1987, THROMB HAEMOSTASIS, V58, P936; MIYAKE K, 1992, J CELL BIOL, V119, P653, DOI 10.1083/jcb.119.3.653; MORIMOTO C, 1985, J IMMUNOL, V134, P3762; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; POLLANEN J, 1989, J BIOL CHEM, V264, P5628; QUIN CQ, 1993, FASEB J, V7, P737; REINARTZ J, 1993, EXP CELL RES, V208, P197, DOI 10.1006/excr.1993.1238; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Tremble P M, 1992, Matrix Suppl, V1, P212; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; VUENTO M, 1979, BIOCHEM J, V183, P331, DOI 10.1042/bj1830331; WALLEN P, 1972, BIOCHIM BIOPHYS ACTA, V257, P122, DOI 10.1016/0005-2795(72)90261-9; WEI Y, 1994, J BIOL CHEM, V269, P32380; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	46	15	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23761	23767		10.1074/jbc.271.39.23761	http://dx.doi.org/10.1074/jbc.271.39.23761			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798602	hybrid			2022-12-27	WOS:A1996VJ44200031
J	Lupher, ML; Reedquist, KA; Miyake, S; Langdon, WY; Band, H				Lupher, ML; Reedquist, KA; Miyake, S; Langdon, WY; Band, H			A novel phosphotyrosine-binding domain in the N-terminal transforming region of Cbl interacts directly and selectively ZAP-70 in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; C-CBL; V-CBL; ANTIGEN RECEPTORS; JURKAT CELLS; SH3 DOMAINS; PROTOONCOGENE; PRODUCT; PHOSPHORYLATION; ONCOGENE	The protooncogene product Cbl has emerged as a novel signal transduction protein downstream of a number of cell surface receptors coupled to tyrosine kinases. Recently, we and others have reported the activation-dependent association of Cbl with the Syk and ZAP-70 tyrosine kinases through presently undefined mechanisms. Potential Src homology 2 and 3 domain binding sites within the C-terminal half of Cbl mediate in vivo interactions with several signaling proteins; however, the N-terminal transforming region (Cbl-N) lacks recognizable catalytic or protein interaction motifs. Here, we show that in vitro Cbl-N (amino acids 1-357) but not Cbl-C (amino acids 358-906) binds to ZAP-70 in a T cell-activation-dependent manner. A point mutation in Cbl-N, G306E, corresponding to a loss of-function mutation in the Caenorhabditis elegans Cbl homologue, SLI-1, severely compromised Cbl-N/ZAP-70 binding. Cbl-N/ZAP-70 binding was direct and phosphotyrosine-dependent, thus identifying a phosphotyrosine-binding domain within the transforming region of Cbl. In vivo, Cbl-N expressed in T cells selectively associated with the ZAP-70/zeta complex. These results identify a novel mechanism for the direct participation of the N-terminal region of Cbl in ZAP-70 signal transduction, and suggest a biochemical mechanism for the leukemogenicity of the oncogene v-cbl through potential interaction with proliferation-related phosphotyrosyl proteins.	HARVARD UNIV,SCH MED,BRIGHAM & WOMENS HOSP,DEPT MED,DIV RHEUMATOL & IMMUNOL,LYMPHOCYTE BIOL,BOSTON,MA 02115; UNIV WESTERN AUSTRALIA,QUEEN ELIZABETH II MED CTR,DEPT PATHOL,NEDLANDS,WA 6009,AUSTRALIA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Western Australia					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36308] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Gao QS, 1996, CANCER RES, V56, P3129; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SPITS H, 1983, HYBRIDOMA, V2, P423, DOI 10.1089/hyb.1983.2.423; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZHOU MM, 1995, NATURE, V92, P7784	36	162	162	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24063	24068		10.1074/jbc.271.39.24063	http://dx.doi.org/10.1074/jbc.271.39.24063			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798643				2022-12-27	WOS:A1996VJ44200072
J	Newcomb, JR; CarboyNewcomb, C; Cresswell, P				Newcomb, JR; CarboyNewcomb, C; Cresswell, P			Trimeric interactions of the invariant chain and its association with major histocompatibility complex class II alpha beta dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA-DR MOLECULES; ANTIGEN-PROCESSING MUTANT; B-LYMPHOBLASTOID CELLS; PEPTIDE BINDING; ENDOPLASMIC-RETICULUM; ENDOCYTIC COMPARTMENT; SURFACE EXPRESSION; MHC MOLECULES; IN-VIVO; DISSOCIATION	The invariant chain (I chain) associates with major histocompatibility complex class II alpha beta heterodimers upon synthesis, preventing them from binding peptides and unfolded proteins in the endoplasmic reticulum and directing class II transport to post-Golgi endosomal compartments. To assess which regions of the I chain are involved in binding class II molecules, we have studied proteolytic fragments of the I chain generated both by natural proteolytic degradation of alpha beta dimer-invariant chain complexes (alpha beta . I) within human B cells and by in vitro digestion of purified alpha beta . I complexes with proteinase K. The 18-kDa luminal I chain fragment generated by proteinase K, called K3, remains associated with alpha beta dimers and retains the complex (alpha beta . K3) in a high molecular mass nonameric configuration. The N terminus of the K3 fragment was identified as glycine 110. This indicates that the K3 fragment lies outside of the class II-associated invariant chain peptide region (amino acids 81-104) of the I chain, shown to be important for initial alpha beta . I assembly. An N-terminal 12-kDa I chain fragment called p12, generated intracellularly, was also analyzed and was found to remain associated with alpha beta dimers in a high molecular mass form analogous to the nonameric alpha beta . I complex. These results demonstrate that at least two class II contact points exist along the length of the I chain and that different regions of the I chain can stabilize the alpha beta . I nonamer. Additional evidence suggests that the O-linked glycan(s) characteristic of the I chain is added to the short C-terminal region absent from the K3 fragment.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University								AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; ARUNACHALAM B, 1993, INT IMMUNOL, V6, P439; AVVA RR, 1994, IMMUNITY, V1, P763, DOI 10.1016/S1074-7613(94)80018-9; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BANGIA N, 1995, INT IMMUNOL, V7, P1585, DOI 10.1093/intimm/7.10.1585; BERTOLINO P, 1995, J IMMUNOL, V154, P2620; BIJLMAKERS MJE, 1994, J EXP MED, V180, P623, DOI 10.1084/jem.180.2.623; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; Busch R, 1996, EMBO J, V15, P418, DOI 10.1002/j.1460-2075.1996.tb00372.x; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; DEMOTZ S, 1993, EUR J IMMUNOL, V23, P2100, DOI 10.1002/eji.1830230909; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; FREISEWINKEL IM, 1993, P NATL ACAD SCI USA, V90, P9703, DOI 10.1073/pnas.90.20.9703; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; JASANOFF A, 1995, P NATL ACAD SCI USA, V92, P9900, DOI 10.1073/pnas.92.21.9900; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAMPSON LA, 1980, J IMMUNOL, V125, P293; MACHAMER CE, 1982, J IMMUNOL, V129, P2564; MARIC MA, 1994, P NATL ACAD SCI USA, V91, P2171, DOI 10.1073/pnas.91.6.2171; MARKS MS, 1990, J CELL BIOL, V111, P839, DOI 10.1083/jcb.111.3.839; MARKS MS, 1985, J IMMUNOL, V136, P2519; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NEWCOMB JR, 1993, J IMMUNOL, V150, P499; NEWCOMB JR, 1993, J IMMUNOL, V151, P4153; OSULLIVAN DM, 1987, J EXP MED, V166, P444, DOI 10.1084/jem.166.2.444; PARK SJ, 1995, P NATL ACAD SCI USA, V92, P11289, DOI 10.1073/pnas.92.24.11289; PETERSON M, 1992, NATURE, V357, P596, DOI 10.1038/357596a0; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; PLETSCHER M, 1983, EUR J IMMUNOL, V13, P581, DOI 10.1002/eji.1830130713; PORATH J, 1973, J CHROMATOGR, V86, P53, DOI 10.1016/S0021-9673(01)81233-4; REYES VE, 1991, J IMMUNOL, V146, P3877; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; ROCHE PA, 1992, EMBO J, V11, P2841, DOI 10.1002/j.1460-2075.1992.tb05351.x; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SCHREIBER KL, 1994, INT IMMUNOL, V6, P101, DOI 10.1093/intimm/6.1.101; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STRUBIN M, 1986, EMBO J, V5, P3483, DOI 10.1002/j.1460-2075.1986.tb04673.x; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0	54	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24249	24256		10.1074/jbc.271.39.24249	http://dx.doi.org/10.1074/jbc.271.39.24249			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798670	hybrid			2022-12-27	WOS:A1996VJ44200099
J	RamalhoSantos, J; deLima, MCP; Nir, S				RamalhoSantos, J; deLima, MCP; Nir, S			Partial fusion activity of influenza virus toward liposomes and erythrocyte ghosts is distinct from viral inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-ACTION ANALYSIS; SENDAI VIRUS; MEMBRANE-FUSION; PHOSPHOLIPID-VESICLES; HEMOLYTIC-ACTIVITY; HIV-1 FUSION; SIALIC-ACID; LOW PH; KINETICS; EXTENT	Final extents of fusion of influenza virus (A/PR/8/34 strain) with neutral and partially acidic liposomes were monitored with (i) a fluorescence resonance energy-transfer assay in which the liposomes were labeled and (ii) by the dequenching of octadecylrhodamine, initially incorporated in the viral membrane. The latter assay was also employed in the fusion of influenza virus and Sendai virus with erythrocyte ghosts. In all cases, a phenomenon of partial fusion activity of the virus was observed, which is distinct from low pH inactivation. The unfused influenza or Sendai virions, which were separated by sucrose gradient centrifugation from liposomes or erythrocyte ghosts exhibited again partial fusion activity toward freshly added liposomes or ghosts, respectively. The conclusion is that the fraction of initially bound and unfused virions does not consist of defective particles, but rather of particles bound to the target membranes via inactive sites on the virus (or on cellular membranes), or else, partial fusion activity is a manifestation of a certain probability of production of fusion inactive sites by irreversible association of viral glycoproteins or peptides in the target membrane.	HEBREW UNIV JERUSALEM,FAC AGR,SEAGRAM CTR SOIL & WATER SCI,IL-76100 REHOVOT,ISRAEL; UNIV COIMBRA,CTR NEUROSCI,P-3000 COIMBRA,PORTUGAL; UNIV COIMBRA,DEPT ZOOL,P-3000 COIMBRA,PORTUGAL; UNIV COIMBRA,DEPT BIOCHEM,P-3000 COIMBRA,PORTUGAL	Hebrew University of Jerusalem; Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra			de Lima, Maria da Conceição Monteiro/AAS-5602-2021; Ramalho-Santos, João/F-8641-2012; Santos, João/HHZ-5595-2022	de Lima, Maria da Conceição Monteiro/0000-0003-1844-5027; Ramalho-Santos, João/0000-0002-1172-4018; 				ALFORD D, 1994, BIOCHEMISTRY-US, V33, P1977, DOI 10.1021/bi00174a002; AMSELEM S, 1986, BIOCHIM BIOPHYS ACTA, V860, P301, DOI 10.1016/0005-2736(86)90527-4; BENTZ J, 1990, FEBS LETT, V276, P1, DOI 10.1016/0014-5793(90)80492-2; BENTZ J, 1992, BIOPHYS J, V63, P448, DOI 10.1016/S0006-3495(92)81622-3; CHEETHAM JJ, 1994, J BIOL CHEM, V269, P5467; DUZGUNES N, 1992, J GEN VIROL, V73, P27, DOI 10.1099/0022-1317-73-1-27; FONTEIJN TAA, 1992, BIOCHIM BIOPHYS ACTA, V1110, P185, DOI 10.1016/0005-2736(92)90357-R; HAYWOOD AM, 1982, BIOCHEMISTRY-US, V21, P6041, DOI 10.1021/bi00267a003; HOEKSTRA D, 1989, J BIOL CHEM, V264, P6786; HOEKSTRA D, 1985, BIOCHEMISTRY-US, V24, P4739, DOI 10.1021/bi00339a005; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; JUNANKAR PR, 1986, BIOCHIM BIOPHYS ACTA, V854, P198, DOI 10.1016/0005-2736(86)90111-2; LARSEN CE, 1993, BIOCHIM BIOPHYS ACTA, V1147, P223, DOI 10.1016/0005-2736(93)90007-M; LIMA M C P D, 1991, Biochimica et Biophysica Acta, V1070, P446; LIMA MCP, 1992, EUR J BIOCHEM, V205, P181; MIAO L, 1995, BIOCHEMISTRY-US, V34, P4676, DOI 10.1021/bi00014a022; NIEVA JL, 1994, BIOCHEMISTRY-US, V33, P3201, DOI 10.1021/bi00177a009; NIR S, 1986, BIOCHEMISTRY-US, V25, P2155, DOI 10.1021/bi00356a046; NIR S, 1986, BIOCHEMISTRY-US, V25, P257, DOI 10.1021/bi00349a036; NIR S, 1983, PROG SURF SCI, V13, P1, DOI 10.1016/0079-6816(83)90010-2; NIR S, 1990, CELL BIOPHYS, V17, P181, DOI 10.1007/BF02990496; NIR S, 1986, BIOCHEMISTRY-US, V25, P8261, DOI 10.1021/bi00373a020; NIR S, 1988, MOL MECHANISMS MEMBR, P451; RAMALHOSANTOS J, 1993, BIOCHEMISTRY-US, V32, P2771, DOI 10.1021/bi00062a006; SATO SB, 1983, P NATL ACAD SCI-BIOL, V80, P3153, DOI 10.1073/pnas.80.11.3153; STAMATATOS L, 1994, J GEN VIROL, V74, P1043; Steck T L, 1974, Methods Enzymol, V31, P172; STEGMANN T, 1989, BIOCHEMISTRY-US, V28, P1698, DOI 10.1021/bi00430a041; STEGMANN T, 1986, J BIOL CHEM, V261, P966; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; SZOKA F, 1980, ANNU REV BIOPHYS BIO, V9, P467, DOI 10.1146/annurev.bb.09.060180.002343; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0	33	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23902	23906		10.1074/jbc.271.39.23902	http://dx.doi.org/10.1074/jbc.271.39.23902			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798621	Green Published, hybrid			2022-12-27	WOS:A1996VJ44200050
J	Gupta, D; Kirkland, TN; Viriyakosol, S; Dziarski, R				Gupta, D; Kirkland, TN; Viriyakosol, S; Dziarski, R			CD14 is a cell-activating receptor for bacterial peptidoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LPS BINDING-PROTEIN; LIPOPOLYSACCHARIDE (LPS)-BINDING PROTEIN; NECROSIS-FACTOR-ALPHA; LIPID-A; STAPHYLOCOCCUS-AUREUS; SIGNAL-TRANSDUCTION; LIPOTEICHOIC ACID; HUMAN MONOCYTES; MACROPHAGES	The hypothesis that CD14 (an endotoxin receptor present on macrophages and neutrophils) acts as a cell-activating receptor for bacterial peptidoglycan was tested using mouse 70Z/3 cells transfected with human CD14. 70Z/3 cells transfected with an empty vector were unresponsive to insoluble and soluble peptidoglycan, as well as to low concentrations of endotoxin, 70Z/3-CD14 cells were responsive to both insoluble and soluble peptidoglycan, as well as to low concentrations of endotoxin, as measured by the expression of surface IgM, activation of NF-kappa B, and degradation of I kappa B-alpha. Peptidoglycan also induced activation of NF-kappa B and degradation of I kappa B-alpha in macrophage RAW264.7 cells. These peptidoglycan-induced effects (in contrast to endotoxin-induced effects) were not inhibited by polymyxin B. Both peptidoglycan- and endotoxin-induced activation of NF-kappa B were inhibited by anti-CD14 mAb. The N-terminal 151 amino acids of CD14 were sufficient for acquisition of full responsiveness to both peptidoglycan and endotoxin, but CD14 deletion mutants lacking four small regions within the N-terminal 65 amino acids showed differentially diminished responses to peptidoglycan and endotoxin. These results identify CD14 as the functional receptor for peptidoglycan and demonstrate that similar, but not identical sequences in the N-terminal 65-amino acid region of CD14 are critical for the NF-kappa B and IgM responses to both peptidoglycan and endotoxin.	INDIANA UNIV,SCH MED,NW CTR MED EDUC,GARY,IN 46408; UNIV CALIF SAN DIEGO,VET AFFAIRS MED CTR,DEPT MED,SAN DIEGO,CA 92161; UNIV CALIF SAN DIEGO,VET AFFAIRS MED CTR,DEPT PATHOL,SAN DIEGO,CA 92161	Indiana University System; Indiana University Northwest; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Kirkland, Theo/ADK-9674-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28797] Funding Source: Medline; NIGMS NIH HHS [GM37696] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DEKIMPE SJ, 1995, P NATL ACAD SCI USA, V92, P10359, DOI 10.1073/pnas.92.22.10359; DOKTER WHA, 1994, J BIOL CHEM, V269, P4201; DZIARSKI R, 1991, J BIOL CHEM, V266, P4713; DZIARSKI R, 1994, J BIOL CHEM, V269, P20431; DZIARSKI R, 1996, IN PRESS J INFECT DI, V174; DZIARSKI R, 1986, BIOL PROPERTIES PEPT, P229; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; GUPTA D, 1995, J IMMUNOL, V155, P2620; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HEUMANN D, 1994, INFECT IMMUN, V62, P2715, DOI 10.1128/IAI.62.7.2715-2721.1994; Heymer B., 1985, IMMUNOLOGY BACTERIAL, P11; JUAN TSC, 1995, J BIOL CHEM, V270, P1382, DOI 10.1074/jbc.270.3.1382; KIRIKAE T, 1994, FEMS IMMUNOL MED MIC, V8, P13; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; MATHISON JC, 1992, J IMMUNOL, V149, P200; MIRELMAN D, 1974, BIOCHEMISTRY-US, V13, P5045, DOI 10.1021/bi00721a028; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; ROONEY JW, 1990, IMMUNOGENETICS, V31, P73, DOI 10.1007/BF00661216; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; VINCENTI MP, 1992, J CELL PHYSIOL, V150, P204, DOI 10.1002/jcp.1041500127; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361; Viriyakosol S, 1996, INFECT IMMUN, V64, P653, DOI 10.1128/IAI.64.2.653-656.1996; WEIDEMANN B, 1994, INFECT IMMUN, V62, P4709, DOI 10.1128/IAI.62.11.4709-4715.1994; WRIGHT SD, 1995, J IMMUNOL, V155, P6; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; ZEIGER AR, 1982, INFECT IMMUN, V37, P1112, DOI 10.1128/IAI.37.3.1112-1118.1982	38	183	188	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23310	23316		10.1074/jbc.271.38.23310	http://dx.doi.org/10.1074/jbc.271.38.23310			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798531	hybrid			2022-12-27	WOS:A1996VH76800057
J	Kuroda, S; Fukata, M; Kobayashi, K; Nakafuku, M; Nomura, N; Iwamatsu, A; Kaibuchi, K				Kuroda, S; Fukata, M; Kobayashi, K; Nakafuku, M; Nomura, N; Iwamatsu, A; Kaibuchi, K			Identification of IQGAP as a putative target for the small GTPases, Cdc42 and Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN RAC; GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; KB CELLS; RHO P21; KINASE; INSULIN; ACTIVATION; DROSOPHILA; EXPRESSION	Cdc42 and Rac1 have been implicated in the regulation of various cell functions such as cell morphology, polarity, and cell proliferation. We have partially purified a Cdc42- and Rac1-associated protein with molecular mass of about 170 kDa (p170) from bovine brain cytosol. This protein interacted with guanosine 5'-(3-O-thio)triphosphate (GTP gamma S)-glutathione S-transferase (GST)-Cdc42 and GTP gamma-GST-Rac1, or GTP gamma S-GST-RhoA). We identified p170 as an IQGAP, which is originally identified as putative Ras GTPase-activating protein. Recombinant IQGAP specifically interacted with GTP gamma S-Cdc42 and GTP gamma S-Rac1. The C-terminal fragment of IQGAP was specifically immunoprecipitated with dominant-active Cdc42(Val12) or Rac1(Val12) from the COS7 cells expressing Cdc42(Val12) or Rac1(Val12), respectively, Immunofluorescence analysis revealed that IQGAP was accumulated at insulin- or Rac1-induced membrane ruffling areas. This accumulation of IQGAP was blocked by the microinjection of the dominant-negative Rac1(Asn17) or Cdc42(Asn17). Moreover, IQGAP was accumulated at the cell-cell junction in MDCK cells, where alpha-catenin and ZO-1 were localized. These results suggest that IQGAP is a novel target molecule for Cdc42 and Rac1.	NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,IKOMA 63001,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT BIOCHEM,MINAMI KU,HIROSHIMA 734,JAPAN; KAZUSA DNA RES INST,KISARAZU,CHIBA 292,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN	Nara Institute of Science & Technology; Hiroshima University; Kazusa DNA Research Institute; Kirin Brewery Company Limited			KURODA, SHINYA/G-4961-2014; Fukata, Masaki/AAZ-2476-2021; Nakafuku, Masato/J-3068-2013	Fukata, Masaki/0000-0001-5200-9806; Nakafuku, Masato/0000-0001-7783-9005				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BARSAGI D, 1995, METHOD ENZYMOL, V255, P436; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DERRY JMJ, 1994, CELL, V79, P923; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GOSHIMA K, 1984, J CELL BIOL, V98, P801, DOI 10.1083/jcb.98.3.801; HARDEN N, 1995, DEVELOPMENT, V121, P903; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MACKAY D, 1995, TRENDS NEUROSCI, V81, P496; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIURA Y, 1993, J BIOL CHEM, V268, P510; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAKAFUKU M, 1995, J NEUROSCI RES, V41, P153, DOI 10.1002/jnr.490410203; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TAKAISHI K, 1995, ONCOGENE, V11, P39; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	49	261	266	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23363	23367		10.1074/jbc.271.38.23363	http://dx.doi.org/10.1074/jbc.271.38.23363			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798539	hybrid			2022-12-27	WOS:A1996VH76800065
J	Sutton, J; Costa, R; Klug, M; Field, L; Xu, DW; Largaespada, DA; Fletcher, CF; Jenkins, NA; Copeland, NG; Klemsz, M; Hromas, R				Sutton, J; Costa, R; Klug, M; Field, L; Xu, DW; Largaespada, DA; Fletcher, CF; Jenkins, NA; Copeland, NG; Klemsz, M; Hromas, R			Genesis, a winged helix transcriptional repressor with expression restricted to embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORK HEAD DOMAIN; HEPATOCYTE NUCLEAR FACTOR-3-BETA; DNA-BINDING; ALVEOLAR RHABDOMYOSARCOMA; REGULATORY ELEMENTS; MAMMALIAN-CELLS; FUSION PROTEIN; FAMILY; MOUSE; CLONING	A novel member of the winged helix (formerly HNF-3/Forkhead) transcriptional regulatory family, termed Genesis, was isolated and characterized. Putative translation of the complete cDNA revealed the winged helix DNA binding domain to be centrally located within the protein, with regions on either side that contain known transcriptional regulatory motifs. Extensive Northern analysis of Genesis found that the message was exclusively expressed in embryonic stem cells or their malignant equivalent, embryonal carcinoma cells. The Genesis transcript was down-regulated when these cells were stimulated to differentiate. DNA sequences that Genesis protein would interact with were characterized and were found to contain a consensus similar to that found in an embryonic stem cell enhancer sequence, Go-transfection experiments revealed that Genesis is a transcriptional repressor. Genesis mapped to mouse chromosome 4 in a region syntenic with human chromosome 1p31, a site of nonrandom abnormalities in germ cell neoplasia, neuroblastoma, and acute lymphoblastic leukemia, Genesis is a candidate for regulating the phenotype of normal or malignant embryonic stem cells.	INDIANA UNIV,MED CTR,DIV HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,MED CTR,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202; UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,CHICAGO,IL 60612; INDIANA UNIV,MED CTR,KRANNERT INST CARDIOL,INDIANAPOLIS,IN 46202; NCI,MAMMALIAN GENET LAB,ABL BASIC RES PROGRAM,NIH,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; INDIANA UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Indiana University System; Indiana University-Purdue University Indianapolis; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Indiana University System; Indiana University-Purdue University Indianapolis			Largaespada, David/C-9832-2014		NHLBI NIH HHS [HL 48915] Funding Source: Medline; NIGMS NIH HHS [GM43241] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043241] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; Andrews PW, 1983, CANCER SURV, V2, P41; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; BASSELDUBY R, 1994, MOL CELL BIOL, V14, P4596, DOI 10.1128/MCB.14.7.4596; BELL DR, 1993, BIOCHEM J, V294, P173, DOI 10.1042/bj2940173; BHAT K, 1988, MOL CELL BIOL, V8, P3251, DOI 10.1128/MCB.8.8.3251; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DARNELL JE, 1982, NATURE, V297, P365, DOI 10.1038/297365a0; DIPERSIO CM, 1991, MOL CELL BIOL, V11, P4405, DOI 10.1128/MCB.11.9.4405; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1994, NAT GENET, V6, P214, DOI 10.1038/ng0294-214d; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Green EL, 1981, GENETICS PROBABILITY, P77; GROSSNIKLAUS U, 1992, GENE DEV, V6, P1030, DOI 10.1101/gad.6.6.1030; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HATINI V, 1994, J NEUROBIOL, V25, P1293, DOI 10.1002/neu.480251010; HROMAS R, 1986, NUCLEIC ACIDS RES, V14, P4837, DOI 10.1093/nar/14.12.4837; HROMAS R, 1993, BLOOD, V81, P2854; HROMAS R, 1991, J BIOL CHEM, V266, P14183; HROMAS R, 1992, CRIT REV ONCOL HEMAT, V12, P167, DOI 10.1016/1040-8428(92)90088-8; HROMAS R, 1995, CRIT REV ONCOL HEMAT, V20, P129, DOI 10.1016/1040-8428(94)00151-I; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAESTNER KH, 1993, P NATL ACAD SCI USA, V90, P7628, DOI 10.1073/pnas.90.16.7628; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LI C, 1992, GENOMICS, V13, P658, DOI 10.1016/0888-7543(92)90138-I; LI C, 1993, P NATL ACAD SCI USA, V90, P11583, DOI 10.1073/pnas.90.24.11583; LI C, 1991, P NATL ACAD SCI USA, V88, P7739, DOI 10.1073/pnas.88.17.7739; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MITELMAN F, 1994, CATALOG CHROMOSOME A; MIURA N, 1993, FEBS LETT, V326, P171, DOI 10.1016/0014-5793(93)81785-X; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PANI L, 1992, MOL CELL BIOL, V12, P552, DOI 10.1128/MCB.12.2.552; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; REHT M, 1995, CURR BIOL, V5, P18; REID L, 1990, CELL, V63, P875, DOI 10.1016/0092-8674(90)90491-V; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SAMADANI U, 1995, CELL GROWTH DIFFER, V6, P879; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SHIMAZAKI T, 1993, EMBO J, V12, P4489, DOI 10.1002/j.1460-2075.1993.tb06138.x; SUBLETT JE, 1995, ONCOGENE, V11, P545; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WEIGEL D, 1990, EMBO J, V9, P1199, DOI 10.1002/j.1460-2075.1990.tb08227.x; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WHITEHOUSE DB, 1992, P NATL ACAD SCI USA, V89, P411, DOI 10.1073/pnas.89.1.411	65	154	160	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23126	23133		10.1074/jbc.271.38.23126	http://dx.doi.org/10.1074/jbc.271.38.23126			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798505	hybrid			2022-12-27	WOS:A1996VH76800031
J	UshioFukai, M; Zafari, AM; Fukui, T; Ishizaka, N; Griendling, KK				UshioFukai, M; Zafari, AM; Fukui, T; Ishizaka, N; Griendling, KK			p22(phox) is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; GLOMERULAR MESANGIAL CELLS; GTP-BINDING PROTEIN; NADPH-OXIDASE; HYDROGEN-PEROXIDE; HUMAN-FIBROBLASTS; ARACHIDONIC-ACID; CYTOCHROME-B; EXPRESSION; RELEASE	Superoxide anion formation is vital to the microbicidal activity of phagocytes. Recently, however, there is accumulating evidence that it is also involved in cell growth in vascular smooth muscle cells (VSMCs). We have shown that the hypertrophic agent angiotensin II stimulates superoxide production by activating the membrane-bound NADH/NADPH oxidase and that inhibition of this oxidase attenuates vascular hypertrophy. However, the molecular identity of this oxidase in VSMCs is unknown, We have recently cloned the cytochrome b(558) alpha-subunit, p22(phox) (one of the key electron transfer elements of the NADPH oxidase in phagocytes), from a rat VSMC cDNA library, but its role in VSMC oxidase activity remains unclarified. Here we report that the complete inhibition of p22(phox) mRNA expression by stable transfection of antisense p22(phox) cDNA into VSMCs results in a decrease in cytochrome b content, which is accompanied by a significant inhibition of angiotensin II-stimulated NADH/NADPH-dependent superoxide production, subsequent hydrogen peroxide production, and [H-3]leucine incorporation. We provide the first evidence that p22(phox) is a critical component of superoxide-generating vascular NADH/NADPH oxidase and suggest a central role for this oxidase system in vascular hypertrophy.	EMORY UNIV, SCH MED, DIV CARDIOL, DEPT MED, ATLANTA, GA 30322 USA	Emory University			Zafari, Abarmard/GRF-6849-2022	Griendling, Kathy/0000-0002-9456-8582	NHLBI NIH HHS [HL38206] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038206, R01HL038206, R29HL038206] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CURNUTTE JT, 1987, ADV HUM GENET, V16, P229; DINAUER MC, 1990, J CLIN INVEST, V86, P1729, DOI 10.1172/JCI114898; FUKUI T, 1995, BBA-BIOENERGETICS, V1231, P215, DOI 10.1016/0005-2728(95)00098-4; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GRIENDLING KK, 1991, J BIOL CHEM, V266, P15498; JONES OTG, 1993, BIOCHEM SOC T, V21, P343, DOI 10.1042/bst0210343; JONES OTG, 1994, BIOESSAYS, V16, P919, DOI 10.1002/bies.950161211; JONES SA, 1995, J AM SOC NEPHROL, V5, P1483; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; LASSEGUE B, 1995, MOL PHARMACOL, V48, P601; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; MAJANDER A, 1994, J BIOL CHEM, V269, P21037; MALY FE, 1993, J EXP MED, V178, P2047, DOI 10.1084/jem.178.6.2047; MATSUBARA T, 1986, J IMMUNOL, V137, P3295; MEIER B, 1993, BIOCHEM J, V289, P481, DOI 10.1042/bj2890481; MEIER B, 1991, BIOCHEM J, V275, P241, DOI 10.1042/bj2750241; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MOHAZZABH KM, 1994, AM J PHYSIOL-LUNG C, V267, pL823, DOI 10.1152/ajplung.1994.267.6.L823; MOHAZZABH KM, 1994, AM J PHYSIOL, V266, pH2568, DOI 10.1152/ajpheart.1994.266.6.H2568; NEALE TJ, 1993, P NATL ACAD SCI USA, V90, P3645, DOI 10.1073/pnas.90.8.3645; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; RADEKE HH, 1991, J BIOL CHEM, V266, P21025; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; STEINBECK MJ, 1994, J CELL BIOL, V126, P765, DOI 10.1083/jcb.126.3.765; Tsai JC, 1996, J BIOL CHEM, V271, P3667; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318	33	669	697	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23317	23321		10.1074/jbc.271.38.23317	http://dx.doi.org/10.1074/jbc.271.38.23317			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798532	hybrid			2022-12-27	WOS:A1996VH76800058
J	Zhao, H; Eide, D				Zhao, H; Eide, D			The ZRT2 gene encodes the low affinity zinc transporter in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; EXPRESSION; TRANSFORMATION; IDENTIFICATION; OVEREXPRESSION; RESISTANCE; ACTIVATOR	Zinc accumulation in Saccharomyces cerevisiae occurs through either of two uptake systems. A high affinity system is active in zinc-limited cells, and the ZRT1 gene encodes the transporter protein of this system, In this study, we characterized the low affinity system that is active in zinc-replete cells, The low affinity system is time-, temperature-, and concentration-dependent and prefers zinc over other metals as its substrate, Our results suggest that the ZRT2 gene encodes the transporter of this system, The amino acid sequence of Zrt2p is remarkably similar to those of Zrt1p and Irt1p, an Fe2+ transporter from Arabidopsis thaliana. Overexpressing ZRT2 increased low affinity uptake, whereas disrupting this gene eliminated that activity, but had little effect on the high affinity system, Therefore, the high and low affinity systems are separate uptake pathways, Analysis of the zinc levels required for growth of zrt2 mutant strains as well as the effects of the zrt2 mutation on the regulation of the high affinity system demonstrated that the low affinity system is a biologically relevant mechanism of zinc accumulation. Finally, a zrt1zrt2 mutant was viable, indicating the existence of additional zinc uptake pathways.	UNIV MINNESOTA, SCH MED, DEPT BIOCHEM & MOL BIOL, DULUTH, MN 55812 USA	University of Minnesota System; University of Minnesota Duluth					NIGMS NIH HHS [GM-48139] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048139] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Borson N D, 1992, PCR Methods Appl, V2, P144; BUTLER G, 1991, MOL CELL BIOL, V11, P476, DOI 10.1128/MCB.11.1.476; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CONKLIN DS, 1994, MOL GEN GENET, V244, P303, DOI 10.1007/BF00285458; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; EIDE D, 1992, J GEN MICROBIOL, V138, P347, DOI 10.1099/00221287-138-2-347; EIDE D, 1992, J BIOL CHEM, V267, P20774; FUHRMANN GF, 1968, BIOCHIM BIOPHYS ACTA, V163, P325, DOI 10.1016/0005-2736(68)90117-X; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; LIU HP, 1992, GENETICS, V132, P665; MOWLL JL, 1983, J GEN MICROBIOL, V129, P3421; OKOROKOV LA, 1983, BIOCHEM INT, V6, P463; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; PLMITER RD, 1996, EMBO J, V15, P1784; RHODES D, 1993, SCI AM, V268, P56, DOI 10.1038/scientificamerican0293-56; RINE J, 1991, METHOD ENZYMOL, V194, P239; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Sherman F., 1986, METHODS YEAST GENETI; STEARNS T, 1990, METHOD ENZYMOL, V185, P280; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WHITE C, 1987, J GEN MICROBIOL, V133, P727; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	30	301	327	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23203	23210		10.1074/jbc.271.38.23203	http://dx.doi.org/10.1074/jbc.271.38.23203			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798516	hybrid			2022-12-27	WOS:A1996VH76800042
J	Cantu, C; Huang, WZ; Palzkill, T				Cantu, C; Huang, WZ; Palzkill, T			Selection and characterization of amino acid substitutions at residues 237-240 of TEM-1 beta-lactamase with altered substrate specificity for aztreonam and ceftazidime	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ACTIVE-SITE; HYDROLYSIS; CEPHALOSPORINS; MUTAGENESIS; RESISTANCE; CEFOTAXIME; MUTANTS; EFFICIENCY; RESOLUTION	Recently, natural variants of TEM-1 beta-lactamase with amino acid substitutions at residues 237-240 have been identified that have increased hydrolytic activity for extended-spectrum antibiotics such as ceftazidime. To identify the sequence requirements in this region for a given antibiotic, a random library was constructed that contained all possible amino acid combinations for the S-residue region 237-240 (ABL numbering system) of TEM-1 beta-lactamase. An antibiotic disc diffusion method was used to select mutants with wild-type level activity or greater for the extended-spectrum cephalosporin ceftazidime and the monobactam aztreonam. Mutants that were selected for optimal ceftazidime hydrolysis contained a conserved Ala at position 237, a Ser for Gly substitution at position 238, and a Lys for Glu at position 240. Mutants selected for aztreonam hydrolysis exhibited a Gly for Ala substitution at position 237, a Ser for Gly substitution at position 238, and a Lys/Arg for Glu at position 240. The role of the A237G substitution in differentiating between ceftazidime and aztreonam was further investigated by kinetic analysis of the A237G, E240K, G238S:E240K, and A237G:G238S:E240K enzymes. The A237G single mutant and the G238S:E240K, double mutant exhibited increases in catalytic efficiency for both ceftazidime and aztreonam. However, the triple mutant A237G:G238S:E240K, displayed a 12-fold decrease in catalytic efficiency for ceftazidime but a 3-fold increase for aztreonam relative to the G238S:E240K double mutant. Thus, the A237G substitution increases ceftazidime hydrolysis when present alone but antagonizes ceftazidime hydrolysis when it is combined with the G238S:E240K substitutions. In contrast, the A237G substitution acts additively with the G238S:E240K substitutions to increase aztreonam hydrolysis.	BAYLOR COLL MED, STRUCT & COMPUTAT BIOL & MOLEC BIOPHYS PROGRAM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MICROBIOL & IMMUNOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NIAID NIH HHS [AI32956] Funding Source: Medline; NIGMS NIH HHS [GM17581] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI032956, R01AI032956, R37AI032956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM017581] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; APPELBAUM PC, 1994, J ANTIMICROB CHEMOTH, V33, P33, DOI 10.1093/jac/33.1.33; Bevington P. R, 1969, DATA REDUCTION ERROR; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BUSH K, 1982, ANTIMICROB AGENTS CH, V22, P414, DOI 10.1128/AAC.22.3.414; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; DUBOIS SK, 1995, J ANTIMICROB CHEMOTH, V35, P7; Fersht A., 1985, ENZYME STRUCTURE MEC; HEALEY WJ, 1989, PROTEINS, V6, P275, DOI 10.1002/prot.340060310; HULETSKY A, 1993, J BIOL CHEM, V268, P3690; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; KNOTHE H, 1983, INFECTION, V11, P315, DOI 10.1007/BF01641355; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUZIN AP, 1995, BIOCHEMISTRY-US, V34, P9532, DOI 10.1021/bi00029a030; LICATA VJ, 1995, BIOCHEMISTRY-US, V34, P3133, DOI 10.1021/bi00010a001; NEU HC, 1965, J BIOL CHEM, V240, P3685; OEFNER C, 1990, NATURE, V343, P284, DOI 10.1038/343284a0; PALZKILL T, 1992, PROTEINS, V14, P29, DOI 10.1002/prot.340140106; PALZKILL T, 1994, MOL MICROBIOL, V12, P217, DOI 10.1111/j.1365-2958.1994.tb01011.x; PALZKILL T, 1991, METHODS COMPANION ME, V3, P155; Petrosino JF, 1996, J BACTERIOL, V178, P1821, DOI 10.1128/jb.178.7.1821-1828.1996; RAQUET X, 1994, J MOL BIOL, V244, P625, DOI 10.1006/jmbi.1994.1756; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVES I, 1995, BIOCHEMISTRY-US, V34, P11660, DOI 10.1021/bi00037a003; SIEGEL EC, 1982, MUTAT RES, V93, P25, DOI 10.1016/0027-5107(82)90122-1; SOWEK JA, 1991, BIOCHEMISTRY-US, V30, P3179, DOI 10.1021/bi00227a004; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; VENKATACHALAM KV, 1994, J BIOL CHEM, V269, P23444; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001	31	61	61	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22538	22545		10.1074/jbc.271.37.22538	http://dx.doi.org/10.1074/jbc.271.37.22538			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798421	hybrid			2022-12-27	WOS:A1996VG67200040
J	Klein, S; Bikfalvi, A; Birkenmeier, TM; Giancotti, FG; Rifkin, DB				Klein, S; Bikfalvi, A; Birkenmeier, TM; Giancotti, FG; Rifkin, DB			Integrin regulation by endogenous expression of 18-kDa fibroblast growth factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY ENDOTHELIAL-CELLS; MOLECULAR-WEIGHT FORMS; HEPARIN-LIKE MOLECULES; FACTOR RECEPTOR GENES; SIGNAL-TRANSDUCTION; FIBRONECTIN RECEPTOR; ELEVATED LEVELS; BLOOD-VESSELS; FACTOR-II; BINDING	The three high molecular weight (HMW) forms of fibroblast growth factor-2 (FGF-2) have a distinct intracellular localization and differentially affect cell mobility and growth compared with the fourth 18-kDa form. To characterize further the effects of the 18-kDa and HMW forms of FGF-2, we have examined their ability to modulate integrin expression. Transfected NIH 3T3 cells expressing only 18-kDa FGF-2 exhibited increased cell surface levels of alpha 5 beta 1, whereas cells expressing only HMW FGF-2 exhibited cell surface alpha 5 beta 1 levels similar to parental cells. When cells synthesizing 18-kDa FGF-2 were transfected with a cDNA encoding a dominant negative FGF receptor, alpha 5 beta 1 cell surface levels decreased. Immunoprecipitation of biosynthetically labeled cells indicated that expression of 18-kDa FGF-2 increased the biosynthesis and rate of maturation of alpha 5. Northern blot analysis showed that 18-kDa FGF-2 increases the level of the alpha 5 subunit mRNA but does not affect beta 1 subunit transcript levels. Experiments utilizing luciferase reporter gene activity revealed increased alpha 5 promoter activity in cells expressing 18-kDa FGF-S indicating that the enhanced alpha 5 transcript level is due to modulation of the transcription rate. Therefore, interaction of 18-kDa FGF-2 with FGF receptors results in changes in alpha 5 beta 1 biosynthesis and processing. In contrast, endogenous expression of HMW FGF-2 does not mediate this effect.	NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016; NYU,MED CTR,RAYMOND & BEVERLY SACKLER FDN LAB,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; UNIV BORDEAUX 1,LAB GROWTH FACTORS & CELL DIFFERENTIAT,F-33405 TALENCE,FRANCE; WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63110	New York University; New York University; New York University; UDICE-French Research Universities; Universite de Bordeaux; Washington University (WUSTL)	Klein, S (corresponding author), NYU,MED CTR,DEPT CELL BIOL,MSB 650,550 1ST AVE,NEW YORK,NY 10016, USA.				NATIONAL CANCER INSTITUTE [R01CA034282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007238] Funding Source: NIH RePORTER; NCI NIH HHS [CA23753, CA34282] Funding Source: Medline; NIGMS NIH HHS [5T32GM07238-19] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; BEAUVAIS A, 1995, J CELL BIOL, V128, P699, DOI 10.1083/jcb.128.4.699; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BISCHOFF J, 1995, TRENDS CELL BIOL, V5, P69, DOI 10.1016/S0962-8924(00)88949-7; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURDSAL CA, 1993, DEVELOPMENT, V118, P829; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DONO R, 1994, DEV BIOL, V163, P316, DOI 10.1006/dbio.1994.1151; DRAKE CJ, 1992, DEV DYNAM, V193, P83, DOI 10.1002/aja.1001930111; DRAKE CJ, 1995, J CELL SCI, V108, P2655; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GIANCOTTI FG, 1992, J CELL BIOL, V118, P951, DOI 10.1083/jcb.118.4.951; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; GIORDANO S, 1992, DEV BIOL, V152, P293, DOI 10.1016/0012-1606(92)90136-5; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KLEIN S, 1993, MOL BIOL CELL, V4, P973, DOI 10.1091/mbc.4.10.973; LIU L, 1993, DEV BIOL, V157, P507, DOI 10.1006/dbio.1993.1153; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; MOSCATELLI D, 1987, P NATL ACAD SCI USA, V84, P5778, DOI 10.1073/pnas.84.16.5778; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; RIESE J, 1995, MECH DEVELOP, V49, P13, DOI 10.1016/0925-4773(94)00296-Y; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sambrook J., 2002, MOL CLONING LAB MANU; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SMITH JC, 1990, DEVELOPMENT, V108, P229; SOMMER A, 1987, BIOCHEM BIOPH RES CO, V144, P543, DOI 10.1016/S0006-291X(87)80001-3; TSUBOI R, 1990, J CELL BIOL, V110, P511, DOI 10.1083/jcb.110.2.511; UENO H, 1992, J BIOL CHEM, V267, P1470; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	59	53	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22583	22590		10.1074/jbc.271.37.22583	http://dx.doi.org/10.1074/jbc.271.37.22583			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798427	hybrid			2022-12-27	WOS:A1996VG67200046
J	Rosok, MJ; Yelton, DE; Harris, LJ; Bajorath, J; Hellstrom, KE; Hellstrom, I; Cruz, GA; Kristensson, K; Lin, H; Huse, WD; Glaser, SM				Rosok, MJ; Yelton, DE; Harris, LJ; Bajorath, J; Hellstrom, KE; Hellstrom, I; Cruz, GA; Kristensson, K; Lin, H; Huse, WD; Glaser, SM			A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESHAPING HUMAN-ANTIBODIES; MONOCLONAL-ANTIBODY; RECOMBINANT IMMUNOTOXIN; HYPERVARIABLE REGIONS; FRAMEWORK RESIDUES; VARIABLE DOMAINS; MOUSE; MUTAGENESIS; ANTIGEN; CONFORMATION	We have used a combinatorial mutagenesis strategy to humanize BR96, a monoclonal antibody that binds to the Lewis Y class of tumor antigens. This approach allows simultaneous assessment of hundreds of humanized variable regions to identify the molecules that best preserve affinity, thus overcoming the major drawback of current humanization procedures, the requirement to construct and analyze each humanized antibody separately. Murine residues of BR96 were mutated to human if they were solvent-exposed residues that did not participate in the formation of the antigen binding site and were not at the interface of the light and heavy chain. At positions that might be involved in binding to antigen, the choice between the murine and human residue was more difficult. Murine and human alternatives were incorporated into a combinatorial library at positions representing buried residues that might affect the structural integrity of the antigen binding site. By encoding this library of humanized BR96 Fabs in an M13 phage vector, we rapidly identified several candidates with nearly identical antigen binding, within 2-fold, of the chimeric Fab. Additional mutagenesis directed at sites suggested in the literature as potentially important for antigen binding in a similar anti-Lewis Y antibody yielded no further improvements.	IXSYS INC, SAN DIEGO, CA 92121 USA		Rosok, MJ (corresponding author), BRISTOL MYERS SQUIBB CO, PHARMACEUT RES INST, 3005 1ST AVE, SEATTLE, WA 98121 USA.		Bajorath, Jürgen/F-7493-2014					BAJORATH J, 1994, BIOCONJUGATE CHEM, V5, P213, DOI 10.1021/bc00027a006; BENHAR I, 1994, P NATL ACAD SCI USA, V91, P12051, DOI 10.1073/pnas.91.25.12051; BOULIANNE GL, 1984, NATURE, V312, P643, DOI 10.1038/312643a0; BRINKMANN U, 1993, P NATL ACAD SCI USA, V90, P7538, DOI 10.1073/pnas.90.16.7538; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; CO MS, 1992, J IMMUNOL, V148, P1149; COUTO JR, 1995, CANCER RES, V55, P1717; FOOTE J, 1992, J MOL BIOL, V224, P487, DOI 10.1016/0022-2836(92)91010-M; GLASER S, 1995, ANTIBODY ENG; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HALE G, 1988, LANCET, V2, P1394; HARRIS L, 1995, PROTEIN SCI, V4, P306; HELLSTROM I, 1990, CANCER RES, V50, P2183; HSIAO KC, 1994, PROTEIN ENG, V7, P815, DOI 10.1093/protein/7.6.815; JEFFREY PD, 1995, NAT STRUCT BIOL, V2, P466, DOI 10.1038/nsb0695-466; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KETTLEBOROUGH CA, 1991, PROTEIN ENG, V4, P773, DOI 10.1093/protein/4.7.773; KHAZAELI MB, 1994, J IMMUNOTHER, V15, P42, DOI 10.1097/00002371-199401000-00006; KRISTENSSON K, 1995, VACCINES, V95, P39; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; MILLER RA, 1983, BLOOD, V62, P988; MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851; NEAR RI, 1992, BIOTECHNIQUES, V12, P88; NEUBERGER MS, 1985, NATURE, V314, P268, DOI 10.1038/314268a0; PADLAN EA, 1991, MOL IMMUNOL, V28, P489, DOI 10.1016/0161-5890(91)90163-E; PASTAN I, 1991, CANCER RES, V51, P3781; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; ROGUSKA MA, 1994, P NATL ACAD SCI USA, V91, P969, DOI 10.1073/pnas.91.3.969; ROUTLEDGE EG, 1993, PROTEIN ENG ANTIBODY, P14; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHROFF RW, 1985, CANCER RES, V45, P879; SINGER II, 1993, J IMMUNOL, V150, P2844; STUDNICKA GM, 1994, PROTEIN ENG, V7, P805, DOI 10.1093/protein/7.6.805; TESSIER DC, 1993, BIOTECHNIQUES, V15, P498; TRAIL PA, 1993, SCIENCE, V261, P212, DOI 10.1126/science.8327892; VERHOEYEN M, 1988, SCIENCE, V239, P1534, DOI 10.1126/science.2451287; YELTON DE, 1995, J IMMUNOL, V155, P1994	44	50	192	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22611	22618		10.1074/jbc.271.37.22611	http://dx.doi.org/10.1074/jbc.271.37.22611			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798431	hybrid			2022-12-27	WOS:A1996VG67200050
J	Hotta, K; Gustafson, TA; Ortmeyer, HK; Bodkin, NL; Nicolson, MA; Hansen, BC				Hotta, K; Gustafson, TA; Ortmeyer, HK; Bodkin, NL; Nicolson, MA; Hansen, BC			Regulation of obese (ob) mRNA and plasma leptin levels in rhesus monkeys - Effects of insulin, body weight, and non-insulin-dependent diabetes mellitus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ADIPOSE-TISSUE; MESSENGER-RNA; FOOD-INTAKE; MICE; RAT; PROTEIN; MOUSE; CLONING; PRODUCT	We have cloned the rhesus monkey obese cDNA and have analyzed its expression in monkeys with a wide range of body weights (lean to very obese) and with or without non-insulin-dependent diabetes mellitus to examine the relationship of ob gene expression to obesity and non-insulin-dependent diabetes mellitus. The sequence of monkey ob protein, excluding the signal peptide, showed 91% identity with the human protein. We observed a significant correlation between the level of ob mRNA and body weight. We also found a significant relationship between ob mRNA and fasting plasma insulin concentration; however, insulin stimulation during a 100-140-min euglycemie/hyperinsulinemic clamp did not result in any changes in ob mRNA levels. Circulating levels of the ob gene product leptin were also significantly correlated with body weight. These results show that ob gene expression is related to body weight and is not acutely regulated by insulin.	UNIV MARYLAND, SCH MED, DEPT PHYSIOL, OBES & DIABET RES CTR, BALTIMORE, MD 21201 USA; AMGEN INC, THOUSAND OAKS, CA 91320 USA	University System of Maryland; University of Maryland Baltimore; Amgen			Ortmeyer, Heidi K/AAM-9223-2021; Hansen, Barbara C/J-8723-2012	Ortmeyer, Heidi K/0000-0002-9376-7029; Hansen, Barbara C/0000-0001-9646-3525; Hotta, Kikuko/0000-0003-2427-6354	NIA NIH HHS [AG42100, AG10612] Funding Source: Medline; NIDDK NIH HHS [DK37717] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037717] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [N01AG042100, R01AG010612] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BECKER DJ, 1995, FEBS LETT, V371, P324, DOI 10.1016/0014-5793(95)00943-4; BODKIN NL, 1989, AM J PHYSIOL, V256, pE676, DOI 10.1152/ajpendo.1989.256.5.E676; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; CUSIN I, 1995, DIABETES, V44, P1467, DOI 10.2337/diabetes.44.12.1467; DEVOS P, 1995, J BIOL CHEM, V270, P15958, DOI 10.1074/jbc.270.27.15958; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; FUNAHASHI T, 1995, BIOCHEM BIOPH RES CO, V211, P469, DOI 10.1006/bbrc.1995.1837; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HANSEN BC, 1986, DIABETOLOGIA, V29, P713, DOI 10.1007/BF00870281; HAYASHI M, 1977, J CLIN ENDOCR METAB, V44, P681, DOI 10.1210/jcem-44-4-681; HE YF, 1995, J BIOL CHEM, V270, P28887, DOI 10.1074/jbc.270.48.28887; HOTTA K, 1991, EUR J BIOCHEM, V202, P293, DOI 10.1111/j.1432-1033.1991.tb16375.x; Hotta K, 1996, BBA-GEN SUBJECTS, V1289, P131, DOI 10.1016/0304-4165(95)00144-1; ISSE N, 1995, J BIOL CHEM, V270, P27728, DOI 10.1074/jbc.270.46.27728; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; MADEJ T, 1995, FEBS LETT, V373, P13, DOI 10.1016/0014-5793(95)00977-H; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MASUZAKI H, 1995, BIOCHEM BIOPH RES CO, V216, P355, DOI 10.1006/bbrc.1995.2631; MASUZAKI H, 1995, DIABETES, V44, P855, DOI 10.2337/diabetes.44.7.855; MASUZAKI H, 1995, P JPN ACAD B-PHYS, V71, P148, DOI 10.2183/pjab.71.148; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MOINAT M, 1995, FEBS LETT, V373, P131, DOI 10.1016/0014-5793(95)01030-I; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V214, P1260, DOI 10.1006/bbrc.1995.2422; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; *NIH, 1985, PUBL NIH, V8523; OGAWA Y, 1995, J CLIN INVEST, V96, P1647, DOI 10.1172/JCI118204; ORTMEYER HK, 1993, DIABETOLOGIA, V36, P200, DOI 10.1007/BF00399950; PACE N, 1947, J BIOL CHEM, V168, P459; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; RENTSCH J, 1995, BIOCHEM BIOPH RES CO, V214, P131, DOI 10.1006/bbrc.1995.2266; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TRAYHURN P, 1995, FEBS LETT, V368, P488, DOI 10.1016/0014-5793(95)00719-P; VYDELINGUM S, 1995, BIOCHEM BIOPH RES CO, V216, P148, DOI 10.1006/bbrc.1995.2603; WADE R, 1990, DEV BIOL, V142, P270, DOI 10.1016/0012-1606(90)90348-M; WEIGLE DS, 1995, J CLIN INVEST, V96, P2065, DOI 10.1172/JCI118254; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZIMMET PZ, 1992, DIABETES CARE, V15, P232, DOI 10.2337/diacare.15.2.232	44	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25327	25331		10.1074/jbc.271.41.25327	http://dx.doi.org/10.1074/jbc.271.41.25327			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810296	hybrid			2022-12-27	WOS:A1996VL69300040
J	Kim, JH; Suh, YJ; Lee, TG; Kim, Y; Bae, SS; Kim, MJ; Lambeth, JD; Suh, PG; Ryu, SH				Kim, JH; Suh, YJ; Lee, TG; Kim, Y; Bae, SS; Kim, MJ; Lambeth, JD; Suh, PG; Ryu, SH			Inhibition of phospholipase D by a protein factor from bovine brain cytosol - Partial, purification and characterization of the inhibition mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; GROWTH-FACTOR; D ACTIVATION; MEMBRANE; ARF; NEUTROPHILS; RHOA; GRANULOCYTES	A specific protein inhibitor of partially purified bovine brain phospholipase D (PLD) was identified from bovine brain cytosol. The PLD inhibitor has been enriched through several chromatographic steps and characterized with respect to size and mechanism of inhibition, The inhibitor showed an apparent molecular mass of 30 kDa by Superose 12 gel exclusion chromatography and inhibited PLD activity with an IC50 of 7 nM. The inhibitor had neither proteolytic activity nor phospholipid-hydrolyzing activity. Because phosphatidylinositol 4,5-bisphosphate (PIP2), which is included in substrate vesicles, is an essential cofactor for PLD, we examined whether the inhibition might be mediated by sequestration of PIP2. PIP2 hydrolysis by phospholipase C (PLC)-beta 1 was not affected by the inhibitor and the inhibitor did not bind to substrate vesicles containing PIP2. In contrast, a PH domain derived from PLC-delta 1, which could bind to PIP2, showed a nearly identical inhibition of both PLC-beta 1 and PLD activities, Thus, the PLD inhibition by the inhibitor is due to the specific interaction with not PIP2 but PLD. The suppression of PLD activity by the inhibitor was largely eliminated by the addition of ADP-ribosylation factor (ARF) and GTP gamma S. We propose that the inhibitor plays a negative role in regulation of PLD activity by PIP2 and ARF.	POHANG UNIV SCI & TECHNOL, DEPT LIFE SCI, POHANG 790784, SOUTH KOREA; EMORY UNIV, SCH MED, DEPT BIOCHEM, ATLANTA, GA 30322 USA	Pohang University of Science & Technology (POSTECH); Emory University			Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048; Kim, Yong/0000-0002-1387-2962	NCI NIH HHS [CA46508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD PG, 1986, BIOCHEM J, V239, P97, DOI 10.1042/bj2390097; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHENG HF, 1995, J BIOL CHEM, V270, P5495, DOI 10.1074/jbc.270.10.5495; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; GENY B, 1995, EUR J BIOCHEM, V231, P31, DOI 10.1111/j.1432-1033.1995.tb20666.x; KOBAYASHI M, 1991, METHOD ENZYMOL, V197, P575; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; LEE YH, 1994, J BIOL CHEM, V269, P26842; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LISCOVITCH M, 1994, SIGNAL ACTIVATED PHO, P31; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; Takahashi K, 1996, J IMMUNOL, V156, P1229; TAKI T, 1979, J BIOL CHEM, V254, P9761; WANG P, 1991, J BIOL CHEM, V266, P14877; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	38	20	20	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25213	25219		10.1074/jbc.271.41.25213	http://dx.doi.org/10.1074/jbc.271.41.25213			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810281	hybrid			2022-12-27	WOS:A1996VL69300025
J	Dunsmore, SE; Rubin, JS; Kovacs, SO; Chedid, M; Parks, WC; Welgus, HG				Dunsmore, SE; Rubin, JS; Kovacs, SO; Chedid, M; Parks, WC; Welgus, HG			Mechanisms of hepatocyte growth factor stimulation of keratinocyte metalloproteinase production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKIN FIBROBLASTS; C-MET RECEPTOR; HUMAN ALVEOLAR MACROPHAGES; FACTOR SCATTER FACTOR; EPITHELIAL-CELLS; MITOGENIC ACTIVITY; TYROSINE KINASE; INTERSTITIAL COLLAGENASE; PROTOONCOGENE PRODUCT; MOLECULAR-CLONING	Matrix metalloproteinases participate in normal physiologic processes; however, their overproduction has been associated with connective tissue destruction in a variety of pathological states. Migrating basal keratinocytes transiently express collagenase-1 during normal cutaneous reepithelialization. However, the overexpression of both collagenase-1 and stromelysin-1 has been associated with the pathogenesis of chronic nonhealing ulcers, Aberrant expression of metalloproteinases in inflammation is mediated, at least in part, by soluble factors. Since hepatocyte growth factor/scatter factor (HGF/SF) has been reported to promote keratinocyte migration and proliferation, key events in wound repair, and since HGF/SF is produced by dermal fibroblasts and its c-Met receptor is expressed by basal keratinocytes in wounded skin, we have studied the effects of HGF/SF upon keratinocyte metalloproteinase expression. We have found that HGF/SF can stimulate keratinocyte collagenase-1 and stromelysin-1 production in a dose-dependent and matrix dependent manner, Expression of 92-kDa gelatinase was not affected by HGF/SF. We determined that HGF/SF regulation of collagenase-1 expression is transcriptionally mediated and requires tyrosine kinase and protein kinase C activaties. HGF/NK1, a naturally occurring, truncated form of HGF/SF, also stimulates collagenase-1 production, but much less efficiently than does the parent molecule, However, HGF/NK2, another HGF/SF splice variant, as well as heparin, potently inhibit HGF/SF-induced collagenase-1 synthesis, These results indicate that HGF/SF and its naturally occurring splice variants have diverse biological effects on keratinocytes and suggest an additional mechanism whereby HGF/SF may regulate keratinocyte function during wound repair.	WASHINGTON UNIV,SCH MED,DEPT MED DERMATOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; NCI,CELLULAR & MOL BIOL LAB,BETHESDA,MD 20892	Washington University (WUSTL); Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Parks, William C./AAH-6786-2021		NIAMS NIH HHS [5T32AR07284, AR35805] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007284, R01AR035805] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARDELLI A, 1994, J BIOTECHNOL, V37, P109, DOI 10.1016/0168-1656(94)90002-7; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; COOPER TW, 1983, COLLAGEN REL RES, V3, P205; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GOHDA E, 1992, FEBS LETT, V301, P107, DOI 10.1016/0014-5793(92)80220-B; GOHDA E, 1994, CYTOKINE, V6, P633, DOI 10.1016/1043-4666(94)90051-5; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; LOKKER NA, 1994, PROTEIN ENG, V7, P895, DOI 10.1093/protein/7.7.895; MACARTNEY HW, 1983, EUR J BIOCHEM, V130, P71; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V181, P691, DOI 10.1016/0006-291X(91)91246-9; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; NAKA D, 1993, EXP CELL RES, V209, P317, DOI 10.1006/excr.1993.1316; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NICHOLSON R, 1989, BIOCHEMISTRY-US, V28, P5195, DOI 10.1021/bi00438a042; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P9555, DOI 10.1021/bi00155a007; OSADA S, 1992, FEBS LETT, V297, P271, DOI 10.1016/0014-5793(92)80554-T; PENTLAND AP, 1990, J CLIN INVEST, V86, P566, DOI 10.1172/JCI114746; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; RAHIMI N, 1994, DNA CELL BIOL, V13, P1189, DOI 10.1089/dna.1994.13.1189; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P163; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SAARIALHOKERE UK, 1994, J CLIN INVEST, V94, P79, DOI 10.1172/JCI117351; SAARIALHOKERE UK, 1992, J CLIN INVEST, V90, P1952, DOI 10.1172/JCI116073; SAARIALHOKERE UK, 1995, J INVEST DERMATOL, V105, P190, DOI 10.1111/1523-1747.ep12317104; SANTOS OFP, 1993, DEV BIOL, V160, P293, DOI 10.1006/dbio.1993.1308; SATO C, 1995, J INVEST DERMATOL, V104, P958, DOI 10.1111/1523-1747.ep12606221; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; SPONSEL HT, 1994, AM J PHYSIOL, V267, pF257, DOI 10.1152/ajprenal.1994.267.2.F257; STRAIN AJ, 1994, EXP CELL RES, V210, P253, DOI 10.1006/excr.1994.1037; STRICKLIN GP, 1993, AM J PATHOL, V143, P1657; STRICKLIN GP, 1994, J INVEST DERMATOL, V103, P352, DOI 10.1111/1523-1747.ep12394926; STRICKLIN GP, 1978, BIOCHEMISTRY-US, V17, P2331, DOI 10.1021/bi00605a012; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; WATANABE S, 1994, BIOCHEM BIOPH RES CO, V199, P1453, DOI 10.1006/bbrc.1994.1394; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WILSON CL, 1995, MOL BIOL CELL, V6, P851, DOI 10.1091/mbc.6.7.851; ZARNEGAR R, 1990, BIOCHEM BIOPH RES CO, V173, P1179, DOI 10.1016/S0006-291X(05)80910-6; ZARNEGAR R, 1989, CANCER RES, V49, P3314; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	65	97	103	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24576	24582		10.1074/jbc.271.40.24576	http://dx.doi.org/10.1074/jbc.271.40.24576			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798721	hybrid			2022-12-27	WOS:A1996VM67400043
J	Kispal, G; Steiner, H; Court, DA; Rolinski, B; Lill, R				Kispal, G; Steiner, H; Court, DA; Rolinski, B; Lill, R			Mitochondrial and cytosolic branched-chain amino acid transaminases from yeast, homologs of the myc oncogene-regulated Eca39 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; INTERMEMBRANE SPACE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; SHUTTLE VECTORS; IMPORT; GENE; AMINOTRANSFERASE; TRANSFORMATION; TRANSLOCATION	We have isolated a high copy suppressor of a temperature-sensitive mutation in ATM1, which codes for an ABC transporter of Saccharomyces cerevisiae mitochondria. The suppressor, termed BAT1, encodes a protein of 393 amino acid residues with an NH2-terminal extension that directs Bat1p to the mitochondrial matrix, A highly homologous protein, Bat2p, of 376 amino acid residues was found in the cytosol. Both Bat proteins show striking similarity to the mammalian protein Eca39, which is one of the few known targets of the myc oncogene, Deletion of a single BAT gene did not impair growth of yeast cells, In contrast, deletion of both genes resulted in an auxotrophy for branched chain amino acids (Ile, Leu, and Val) and in a severe growth reduction on glucose-containing media, even after supply of these amino acids, Mitochondria and cytosol isolated from bat1 and bat2 deletion mutants, respectively, contained largely reduced activities for the conversion of branched-chain 2-ketoacids to their corresponding amino acids, Thus, the Bat proteins represent the first known isoforms of yeast branched-chain amino acid transaminases. The severe growth defect of the double deletion mutant observed even in the presence of branched-chain amino acids suggests that the Bat proteins, in addition to the supply of these amino acids, perform another important function in the cell.	UNIV MUNICH, INST PHYSIOL CHEM PHYS BIOCHEM & ZELLBIOL, D-80336 MUNICH, GERMANY; UNIV MUNICH, KLIN CHEM HAUNERSCHEN KINDERKLIN, D-80336 MUNICH, GERMANY	University of Munich; University of Munich				Lill, Roland/0000-0002-8345-6518; Court, Deborah A./0000-0003-1919-8339				BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; Brunner M., 1994, SIGNAL PEPTIDASES, P73; DAUM G, 1982, J BIOL CHEM, V257, P3028; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Galibert F, 1996, EMBO J, V15, P2031, DOI 10.1002/j.1460-2075.1996.tb00557.x; GASSER SM, 1982, J BIOL CHEM, V257, P3034; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLASER P, 1993, MOL MICROBIOL, V10, P371, DOI 10.1111/j.1365-2958.1993.tb01963.x; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.micro.48.1.743; HAMILTON PB, 1963, ANAL CHEM, V35, P2055, DOI 10.1021/ac60206a024; HINNEBUSCH AG, 1992, MOL CELLULAR BIOL YE, V2, P319; HUTSON SM, 1993, J BIOL CHEM, V268, P3084; Hutson SM, 1995, J BIOL CHEM, V270, P30344, DOI 10.1074/jbc.270.51.30344; INOUE K, 1988, J BIOCHEM-TOKYO, V104, P777, DOI 10.1093/oxfordjournals.jbchem.a122549; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; Jones E. W., 1982, MOL BIOL YEAST SACCH, P181; Kaplan J, 1996, SCIENCE, V271, P1510, DOI 10.1126/science.271.5255.1510; KURAMITSU S, 1985, J BIOCHEM-TOKYO, V97, P993, DOI 10.1093/oxfordjournals.jbchem.a135176; LEIGHTON J, 1995, EMBO J, V14, P188, DOI 10.1002/j.1460-2075.1995.tb06989.x; LEONGMORGENTHALER P, 1994, BIOCHIMIE, V76, P45, DOI 10.1016/0300-9084(94)90061-2; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; NIWA O, 1990, NUCLEIC ACIDS RES, V18, P6709, DOI 10.1093/nar/18.22.6709; Oliver SG, 1996, NATURE, V379, P597, DOI 10.1038/379597a0; ROSE MD, 1993, METHODS YEAST GENETI; RYAN ED, 1973, J BACTERIOL, V116, P222, DOI 10.1128/JB.116.1.222-225.1973; SADLER I, 1984, EMBO J, V3, P2137, DOI 10.1002/j.1460-2075.1984.tb02103.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHLEYER M, 1982, EUR J BIOCHEM, V125, P109, DOI 10.1111/j.1432-1033.1982.tb06657.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; STEINER H, 1995, J BIOL CHEM, V270, P22842, DOI 10.1074/jbc.270.39.22842; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; VARGAS C, 1993, ANAL BIOCHEM, V209, P323, DOI 10.1006/abio.1993.1127; VASTRIK I, 1994, CRIT REV ONCOGENESIS, V5, P59, DOI 10.1615/CritRevOncog.v5.i1.30; WOONTNER M, 1990, J BIOL CHEM, V265, P8979; ZELENAYATROITSKAYA O, 1995, EMBO J, V14, P3268, DOI 10.1002/j.1460-2075.1995.tb07330.x; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723	45	116	133	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24458	24464		10.1074/jbc.271.40.24458	http://dx.doi.org/10.1074/jbc.271.40.24458			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798704	hybrid			2022-12-27	WOS:A1996VM67400026
J	Pastor, CM; Williams, D; Yoneyama, T; Hatakeyama, K; Singleton, S; Naylor, E; Billiar, TR				Pastor, CM; Williams, D; Yoneyama, T; Hatakeyama, K; Singleton, S; Naylor, E; Billiar, TR			Competition for tetrahydrobiopterin between phenylalanine hydroxylase and nitric oxide synthase in rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT FORMATION; SMOOTH-MUSCLE; CELL-LINE; HEPATOCYTES; SUBSTRATE; ENZYME; ARGININE; SUBUNITS; NITRATE; FLUIDS	Tetrahydrobiopterin (BH4) is an important cofactor for two hepatic enzymes, inducible nitric oxide synthase (iNOS) and phenylalanine hydroxylase (PAH), and competition for BH4 between the two enzymes might limit hepatic iNOS or PAH activity, To test this hypothesis, we determined whether conversion of phenylalanine to tyrosine was modified by changes in NO synthase activity, and conversely whether NO synthesis was limited by the rate of phenylalanine conversion to tyrosine in rat hepatocytes and perfused livers, NO production was decreased only slightly, when flux through PAH was maximized in isolated perfused livers, and in isolated hepatocytes only when BH4 synthesis was inhibited, Increases in NO synthesis did not reduce tyrosine formation from phenylalanine. Phenylalanine markedly increased biopterin synthesis, whereas arginine had no effect, Thus, basal BH4 synthesis appears to be adequate to support iNOS activity, whereas BH4 synthesis is increased to support PAH activity.	UNIV PITTSBURGH,DEPT SURG,PRESBYTERIAN UNIV HOSP A1010,PITTSBURGH,PA 15261; UNIV PITTSBURGH,DEPT BIOCHEM GENET,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Yoneyama, Tohru/ABG-2670-2020	Pastor, Catherine/0000-0002-1551-3824	NIGMS NIH HHS [GM-37753, GM-44100] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037753, R01GM044100, R37GM044100, R29GM044100] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BILLIAR TR, 1990, BIOCHEM BIOPH RES CO, V168, P1034, DOI 10.1016/0006-291X(90)91133-D; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; GELLER DA, 1994, ARCH SURG-CHICAGO, V129, P165; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; KAUFMAN S, 1993, ADV ENZYMOL RAMB, V67, P77; KAUFMAN S, 1959, J BIOL CHEM, V234, P2677; KAUFMAN S, 1993, ANNU REV NUTR, V13, P261, DOI 10.1146/annurev.nu.13.070193.001401; KAUFMAN S, 1959, J BIOL CHEM, V234, P2683; KLATT P, 1994, J BIOL CHEM, V269, P13861; MELLOUK S, 1994, INFECT IMMUN, V62, P4043, DOI 10.1128/IAI.62.9.4043-4046.1994; MITNAUL LJ, 1995, P NATL ACAD SCI USA, V92, P885, DOI 10.1073/pnas.92.3.885; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829, DOI 10.1152/ajpendo.1994.266.6.E829; NAKAYAMA DK, 1994, AM J PHYSIOL, V266, pL455, DOI 10.1152/ajplung.1994.266.4.L455; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Pastor CM, 1995, AM J PHYSIOL-GASTR L, V269, pG861, DOI 10.1152/ajpgi.1995.269.6.G861; SAKAI N, 1993, MOL PHARMACOL, V43, P6; SCHMIDT HHHW, 1992, MOL PHARMACOL, V41, P615; SCHMIDT K, 1992, BIOCHEM J, V281, P297, DOI 10.1042/bj2810297; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SHIMAN R, 1980, J BIOL CHEM, V255, P4793; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STADLER J, 1991, AM J PHYSIOL, V260, pC910, DOI 10.1152/ajpcell.1991.260.5.C910; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; XIA T, 1994, J BIOL CHEM, V269, P24657	29	32	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24534	24538		10.1074/jbc.271.40.24534	http://dx.doi.org/10.1074/jbc.271.40.24534			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798714	hybrid, Green Published			2022-12-27	WOS:A1996VM67400036
J	Pitcher, JA; Fredericks, ZL; Stone, WC; Premont, RT; Stoffel, RH; Koch, WJ; Lefkowitz, RJ				Pitcher, JA; Fredericks, ZL; Stone, WC; Premont, RT; Stoffel, RH; Koch, WJ; Lefkowitz, RJ			Phosphatidylinositol 4,5-bisphosphate (PIP2)-enhanced G protein-coupled receptor kinase (GRK) activity - Location, structure, and regulation of the PIP2 binding site distinguishes the GRK subfamilies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PLECKSTRIN-HOMOLOGY DOMAIN; CRYSTAL-STRUCTURE; RHODOPSIN KINASE; EXPRESSION; MEMBRANES; FAMILY; ISOPRENYLATION; IDENTIFICATION; PURIFICATION	The G protein-coupled receptor kinases (GRKs) phosphorylate agonist occupied G protein-coupled receptors and play an important role in mediating receptor desensitization. The localization of these enzymes to their membrane incorporated substrates is required for their efficient function and appears to be a highly regulated process. In this study we demonstrate that phosphatidylinositol 4,5-bisphosphate (PIP2) enhances GRK5-mediated beta-adrenergic receptor (beta AR) phosphorylation by directly interacting with this enzyme and facilitating its membrane association. GRK5-mediated phosphorylation of a soluble peptide substrate is unaffected by PIP2, suggesting that the PIP2-enhanced receptor kinase activity arises as a consequence of this membrane localization. The lipid binding site of GRK5 exhibits a high degree of specificity and appears to reside in the amino terminus of this enzyme. Mutation of six basic residues at positions 22, 23, 24, 26, 28, and 29 of GRK5 ablates the ability of this kinase to bind PIP2. This region of the GRK5, which has a similar distribution of basic amino acids to the PIP2 binding site of gelsolin, is highly conserved between members of the GRK4 subfamily (GRK4, GRK5, and GRK6). Indeed, all the members of the GRK4 subfamily exhibit PIP2-dependent receptor kinase activity. We have shown previously that the membrane association of beta ARK (beta-adrenergic receptor kinase) (GRK2) is mediated, in vitro, by the simultaneous binding of PIP2 and the beta gamma subunits of heterotrimeric G proteins to the carboxyl-terminal pleckstrin homology domain of this enzyme (Pitcher, J. A., Touhara, K., Payne, E. S., and Lefkowitz, R. J. (1995) J. Biol. Chem. 270, 11707-11710). Thus, five members of the GRK family bind PIP2, beta ARK (GRK2), beta ARK2 (GRK3), GRK4, GRK5, and GRK6. However, the structure, location, and regulation of the PIP2 binding site distinguishes the beta ARK (GRK2 and GRK3) and GRK4 (GRK4, GRK5, and GRK6) subfamilies.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute			Pitcher, Julie/ABH-2078-2020; Lefkowitz, Robert/AAW-2649-2021	Premont, Richard/0000-0002-8053-5026	NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BROCKMAN JL, 1991, J BIOL CHEM, V266, P2508; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CERIONE RA, 1983, NATURE, V306, P562, DOI 10.1038/306562a0; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; CULLEN B, 1987, METHOD ENZYMOL, V152, P687; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FREEDMAN NJ, 1996, 1995 REC PROG HORM R, V51, P319; GARCIAHIGUERA I, 1994, J BIOL CHEM, V269, P1348; HASLAM RJ, 1993, NATURE, V363, P310; INGLESE J, 1992, J BIOL CHEM, V267, P1422; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JANMEY PA, 1995, CHEM BIOL, V2, P61, DOI 10.1016/1074-5521(95)90276-7; KIM CM, 1993, RECEPTOR, V3, P39; KUHN H, 1978, BIOCHEMISTRY-US, V21, P4389; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KURLAND IJ, 1992, J BIOL CHEM, V267, P4416; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Murga C, 1996, J BIOL CHEM, V271, P985, DOI 10.1074/jbc.271.2.985; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; ONORATO JJ, 1995, J BIOL CHEM, V270, P21346, DOI 10.1074/jbc.270.36.21346; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; YU FX, 1992, J BIOL CHEM, V267, P14616	35	146	148	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24907	24913		10.1074/jbc.271.40.24907	http://dx.doi.org/10.1074/jbc.271.40.24907			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798768	hybrid			2022-12-27	WOS:A1996VM67400091
J	Xu, X; Zeng, WH; Diaz, J; Muallem, S				Xu, X; Zeng, WH; Diaz, J; Muallem, S			Spacial compartmentalization of Ca2+ signaling complexes in pancreatic acini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS; SENSITIVE CALCIUM POOL; BETA-GAMMA-SUBUNITS; G-PROTEINS; INOSITOL TRISPHOSPHATE; INTRACELLULAR STORES; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; CELLS; RELEASE	Imaging [Ca2+](i) at high temporal resolution and measuring the properties of Ca2+ signaling in streptolysin O (SLO)-permeabilized cells were used to study the spacial organization of signaling complexes. Sequential stimulation of single cells within pancreatic acini with several Ca2+-mobilizing agonists revealed an agonist-specific pattern and propagation rate of Ca2+ waves in the same cells, with CCK8 stimulating the fastest and bombesin the slowest waves. More importantly, each agonist initiated the wave in a different region of the same cell. On the other hand, repetitive stimulation with the same agonist induced Ca2+ waves of the same pattern that were initiated from the same region of the cell. The agonist-specific Ca2+ signaling does not appear to be the result of coupling to different G proteins as infusion of an anti-G alpha q antibody into the cells through a patch pipette equally inhibited Ca2+ signaling by all agonists. Further evidence for compartmentalization of signaling complexes was developed in permeabilized cells. The time-dependent loss of Ca2+ signaling due to SLO permeabiliation occurred in an agonist specific manner in the sequence cabachol > bombesin > cholecystokinin. Signaling by all agonists could be completely restored with as low as 2 mu M guanosine 5'-3-O-(thio)triphosphate (GTP gamma S). At this low concentration GTP gamma S recoupled inositol 1,4,5-trisphosphate production and Ca2+ release, rather than enhancing phospholipase C activity. Priming of Ca2+ signaling by GTP gamma S was agonist-specific. Guanosine 5'-O-(thio)diphosphate (GDP beta S) uncoupled the ability of signaling complexes to release Ca2+ much better than stimulating inositol 1,4,5-trisphosphate production. The uncoupling of Ca2+ signaling by GDP beta S was also agonist specific. The combined findings of agonist-specific initiation sites of the Ca2+ wave and differential access of guanine nucleotides to signaling complexes suggest spacial compartmentalization of Ca2+ signaling complexes. Each complex must include a receptor, G protein, and phospholipase C that are coupled to a specific portion of the Ca2+ pool.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046591, R01DK038938] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031954] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46591, DK38938] Funding Source: Medline; NIGMS NIH HHS [GM31954] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harden T. Kendall, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P11; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KLUESS C, 1992, NATURE, V358, P424; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LOESSBERG PA, 1991, J BIOL CHEM, V266, P1363; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MUALLEM S, 1988, BIOCHEM J, V255, P301; MUALLEM S, 1988, AM J PHYSIOL, V255, pG229, DOI 10.1152/ajpgi.1988.255.2.G229; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; MUALLEM S, 1989, J BIOL CHEM, V264, P205; Muallem Shmuel, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P351; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; NEER EJ, 1995, CELL, V80, P246; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PANDOL SJ, 1985, J BIOL CHEM, V260, P81; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STAUFFER PL, 1993, J BIOL CHEM, V268, P19769; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Williams John A., 1993, P167; Xu X, 1996, J PHYSIOL-LONDON, V491, P647, DOI 10.1113/jphysiol.1996.sp021246; XU X, 1994, J BIOL CHEM, V269, P12645; XU X, 1996, J BIOL CHEM, V271, P18520; YULE DI, 1991, CELL CALCIUM, V12, P145, DOI 10.1016/0143-4160(91)90016-8; ZHANG BX, 1994, J BIOL CHEM, V269, P17132	43	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24684	24690		10.1074/jbc.271.40.24684	http://dx.doi.org/10.1074/jbc.271.40.24684			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798736	hybrid			2022-12-27	WOS:A1996VM67400058
J	Feller, G; leBussy, O; Houssier, C; Gerday, C				Feller, G; leBussy, O; Houssier, C; Gerday, C			Structural and functional aspects of chloride binding to Alteromonas haloplanctis alpha-amylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-MODEL REFINEMENT; ANGSTROM RESOLUTION; CATALYTIC MECHANISM; SUBSTRATE; ASPERGILLUS; STABILITY; ENZYMES; SITE; SEQUENCE; CRYSTAL	Chloride is the allosteric effector of vertebrate pancreatic and salivary alpha-amylases and of the bacterial alpha-amylase from Alteromonas haloplanctis, Activation experiments of A. haloplanctis alpha-amylase by several monovalent anions show that a negative charge, not restricted to that of Cl-, is essential for the amylolytic reaction, Engineering of the chloride binding site reveals that a basic residue is an essential component of the site, The mutation K337R alters the Cl--binding properties, whereas the mutation K337Q produces an active, chloride-independent enzyme. Comparison of the K-d values for Cl- in three homologous alpha-amylases also indicates that the binding affinity is dependent on the chloride coordination mode by this basic residue. Analysis of substrate and chloride binding according to the allosteric kinetic model shows that the chloride effector is not involved in substrate binding, By contrast, the pH dependence of activity and experiments of chemical modifications and Ca2+ inhibition show that the chloride ion is responsible for the pK(alpha) shift of catalytic groups and interacts with active site carboxyl groups.			Feller, G (corresponding author), UNIV LIEGE,BIOCHEM LAB,INST CHEM B6,B-4000 LIEGE,BELGIUM.							BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; BRADY RL, 1991, ACTA CRYSTALLOGR B, V47, P527, DOI 10.1107/S0108768191001908; BRAKE AJ, 1974, J BIOL CHEM, V249, P5452; BRAYER GD, 1995, PROTEIN SCI, V4, P1730, DOI 10.1002/pro.5560040908; BUSH DS, 1989, J BIOL CHEM, V264, P19392; CEASE KB, 1994, PCR METH APPL, V3, P298; FELLER G, 1994, EUR J BIOCHEM, V222, P441, DOI 10.1111/j.1432-1033.1994.tb18883.x; FELLER G, 1992, J BIOL CHEM, V267, P5217; HENSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545; ISHIKAWA K, 1990, BIOCHEMISTRY-US, V29, P7119, DOI 10.1021/bi00482a025; ISHIKAWA K, 1993, BIOCHEMISTRY-US, V32, P6259, DOI 10.1021/bi00075a020; JANECEK S, 1994, EUR J BIOCHEM, V224, P519, DOI 10.1111/j.1432-1033.1994.00519.x; KADZIOLA A, 1994, J MOL BIOL, V239, P104, DOI 10.1006/jmbi.1994.1354; LARSON SB, 1994, J MOL BIOL, V235, P1560, DOI 10.1006/jmbi.1994.1107; LEVITZKI A, 1974, EUR J BIOCHEM, V41, P171, DOI 10.1111/j.1432-1033.1974.tb03257.x; LEVY HM, 1963, J BIOL CHEM, V238, P3654; LIFSHITZ R, 1976, BIOCHEMISTRY-US, V15, P1987, DOI 10.1021/bi00654a028; MACHIUS M, 1995, J MOL BIOL, V246, P545, DOI 10.1006/jmbi.1994.0106; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; McCarter JD, 1996, J BIOL CHEM, V271, P6889, DOI 10.1074/jbc.271.12.6889; Mooser G., 1992, ENZYMES, P187; PETRA PH, 1971, BIOCHEMISTRY-US, V10, P3163, DOI 10.1021/bi00793a001; QIAN MX, 1993, J MOL BIOL, V231, P785, DOI 10.1006/jmbi.1993.1326; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; Ramasubbu N, 1996, ACTA CRYSTALLOGR D, V52, P435, DOI 10.1107/S0907444995014119; RAUSCHER E, 1985, CLIN CHEM, V31, P14; ROBERTSON SP, 1982, J BIOL CHEM, V257, P1743; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STROKOPYTOV B, 1995, BIOCHEMISTRY-US, V34, P2234, DOI 10.1021/bi00007a018; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P401, DOI 10.1016/0022-2836(91)90021-W; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; SWIFT HJ, 1991, ACTA CRYSTALLOGR B, V47, P535, DOI 10.1107/S0108768191001970; TAO BY, 1989, BIOCHIM BIOPHYS ACTA, V995, P214, DOI 10.1016/0167-4838(89)90038-1; THOMA JA, 1971, ENZYMES, V5, P115; VIHINEN M, 1989, CRIT REV BIOCHEM MOL, V24, P329, DOI 10.3109/10409238909082556; VIOLET M, 1989, BIOCHEM J, V263, P665, DOI 10.1042/bj2630665	37	81	82	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23836	23841		10.1074/jbc.271.39.23836	http://dx.doi.org/10.1074/jbc.271.39.23836			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798613	hybrid			2022-12-27	WOS:A1996VJ44200042
J	Rousseau, JC; Farjanel, J; Boutillon, MM; Hartmann, DJ; vanderRest, M; MoradiAmeli, M				Rousseau, JC; Farjanel, J; Boutillon, MM; Hartmann, DJ; vanderRest, M; MoradiAmeli, M			Processing of type XI collagen - Processing of the matrix forms of the alpha 1(XI) chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL PROPEPTIDE; ARGININE-RICH PROTEIN; SMOOTH-MUSCLE CELLS; V COLLAGEN; PRO-ALPHA-1(XI) COLLAGEN; NH2-TERMINAL DOMAIN; HUMAN CARTILAGE; STRUCTURAL-ANALYSIS; FIBRILLAR COLLAGEN; MOLECULAR-CLONING	Type XI collagen is mainly found as a minor constituent in type II-containing fibrils and presents a alpha 1(XI)alpha 2(XI)alpha 3(XI) stoichiometry. This molecule was shown to be partially processed in its intact tissue form, Moreover, alternative splicing has been demonstrated in the variable region of the N-terminal domain of alpha 1(XI) and alpha 2(XI) chains. In this work, the processing of a major intact form of alpha 1(XI) from matrix laid down by chick chondrocytes in culture was identified using N-terminal sequencing and antibodies to synthetic peptides corresponding to the N-terminal propeptide cDNA-derived sequence, The results show that the fully processed form of alpha 1(XI) beans at Gln(254) Of the N-terminal propeptide, seven residues before the end of the proline/arginine-rich protein region encoded by exon I (Zhidkova, N. I., Justice, S. K., and Mayne, R. (1995) J. Biol, Chem, 270, 9486-9493). This sequence is immediately followed by a sequence encoded by exon III, The processing takes place at an Ala-Gln sequence that corresponds to a consensus sequence for procollagen N-proteinase. The antibody raised against a sequence located within the region corresponding to exon IV (anti-P8) fails to recognize this fully processed form of the alpha 1(XI) chain, It recognizes, however, two minor bands of high molecular mass, These results suggest that a major cartilage form of alpha 1(XI) is the product of alternative splicing in which sequences encoded by both exons II and IV are shipped, The presence of a highly acidic subdomain en coded by exon III at the N terminus of the major form of the alpha 1(XI) chain, as predicted by these data, provides potential sites for interaction of collagen XI with other molecules.	INST PASTEUR LYON,URA1459,CNRS,F-69007 LYON,FRANCE; INST BIOL & CHIM PROT,UPR412,CNRS,F-69367 LYON 7,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS)								BERNARD M, 1988, J BIOL CHEM, V263, P17159; BERNILLON J, 1993, BIOTECHNOL TECH, V7, P603, DOI 10.1007/BF00156337; BIRK DE, 1990, J CELL SCI, V95, P649; BORK P, 1992, FEBS LETT, V307, P49, DOI 10.1016/0014-5793(92)80900-2; BROWN KE, 1991, J BIOL CHEM, V266, P23268; BRUCKNER P, 1989, J CELL BIOL, V109, P2537, DOI 10.1083/jcb.109.5.2537; BURGESON RE, 1982, J BIOL CHEM, V257, P7852; BURGESON RE, 1979, BIOCHEM BIOPH RES CO, V87, P1124, DOI 10.1016/S0006-291X(79)80024-8; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; Eyre D, 1987, STRUCTURE FUNCTION C, P261; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; LAWRENCE R, 1994, J BIOL CHEM, V269, P9603; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MERRIFIELD RB, 1964, BIOCHEMISTRY-US, V3, P1385, DOI 10.1021/bi00897a032; MORADIAMELI M, 1994, MATRIX BIOL, V14, P233, DOI 10.1016/0945-053X(94)90187-2; MORADIAMELI M, 1994, EUR J BIOCHEM, V221, P987, DOI 10.1111/j.1432-1033.1994.tb18815.x; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; NAH HD, 1992, J BIOL CHEM, V267, P22581; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; NIYIBIZI C, 1993, BIOCHIM BIOPHYS ACTA, V1203, P304, DOI 10.1016/0167-4838(93)90099-D; OXFORD JT, 1994, EXP CELL RES, V213, P28, DOI 10.1006/excr.1994.1169; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; Parry DA, 1984, ULTRASTRUCTURE CONNE, P34; PODELL DN, 1978, BIOCHEM BIOPH RES CO, V81, P176, DOI 10.1016/0006-291X(78)91646-7; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; THOM JR, 1991, J BIOL CHEM, V266, P7262; TSUMAKI N, 1995, J BIOL CHEM, V270, P2372, DOI 10.1074/jbc.270.5.2372; VANDERREST M, 1993, CURR OPIN STRUC BIOL, V3, P430, DOI 10.1016/S0959-440X(05)80117-4; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; WALCHLI C, 1993, EUR J BIOCHEM, V212, P483, DOI 10.1111/j.1432-1033.1993.tb17685.x; WOODBURY D, 1989, J BIOL CHEM, V264, P2735; WU JJ, 1995, J BIOL CHEM, V270, P18865, DOI 10.1074/jbc.270.32.18865; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; ZHIDKOVA NI, 1993, FEBS LETT, V326, P25, DOI 10.1016/0014-5793(93)81753-M; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486	41	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23743	23748		10.1074/jbc.271.39.23743	http://dx.doi.org/10.1074/jbc.271.39.23743			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798599	hybrid			2022-12-27	WOS:A1996VJ44200028
J	Aldabe, R; Barco, A; Carrasco, L				Aldabe, R; Barco, A; Carrasco, L			Membrane permeabilization by poliovirus proteins 2B and 2BC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED HELA-CELLS; ANIMAL VIRUSES; PHOSPHOLIPASE-ACTIVITY; ESCHERICHIA-COLI; BREFELDIN-A; REPLICATION; INHIBITION; INDUCTION; PROLIFERATION; EXPRESSION	Poliovirus infection leads to drastic alterations in membrane permeability late during infection. Transient expression of each nonstructural protein of poliovirus by means of recombinant vaccinia virus encoding the T7 RNA polymerase indicates that proteins 2B and 2BC strongly enhance membrane permeability to hygromycin B in HeLa cells, Almost no effect on expression of proteins 2C, 3A, 3AB, and 3C was found. Deletions and point mutations in 2B and 2BC have identified sequences in 2B involved in membrane permeabilization. Regions located at both ends of 2B are necessary to bring about these permeability alterations. A deletion of 11 amino acids of 2BC at the junction between 2B and 2C, as well as long deletions in 2C encompassing the GTPase motifs of this protein, do not impair the capacity of 2BC to modify the permeability of the membrane. The release of compounds such as choline or uridine from preloaded cells is also augmented by 2B and 2BC expression.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOL, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)			Carrasco, Luis/H-3001-2017; Barco, Angel/C-3062-2008; Barco, Angel/ABF-1864-2021; Aldabe, Rafael/F-3112-2015; Carrasco, Luis/E-2435-2012	Carrasco, Luis/0000-0003-3833-8835; Barco, Angel/0000-0002-0653-3751; Barco, Angel/0000-0002-0653-3751; Aldabe, Rafael/0000-0002-9461-020X; 				ALDABE R, 1995, BIOCHEM BIOPH RES CO, V206, P64, DOI 10.1006/bbrc.1995.1010; BARCO A, 1995, EMBO J, V14, P3349, DOI 10.1002/j.1460-2075.1995.tb07341.x; BIENZ K, 1992, J VIROL, V66, P2740, DOI 10.1128/JVI.66.5.2740-2747.1992; BIENZ K, 1983, VIROLOGY, V131, P39, DOI 10.1016/0042-6822(83)90531-7; CARRASCO L, 1978, NATURE, V272, P694, DOI 10.1038/272694a0; CARRASCO L, 1994, FEBS LETT, V350, P151, DOI 10.1016/0014-5793(94)00780-2; CARRASCO L, 1995, ADV VIRUS RES, V45, P61, DOI 10.1016/S0065-3527(08)60058-5; CARRASCO L, 1981, VIROLOGY, V113, P623, DOI 10.1016/0042-6822(81)90190-2; CARRASCO L, 1976, NATURE, V264, P807, DOI 10.1038/264807a0; CARRASCO L, 1989, PHARMACOL THERAPEUT, V40, P171, DOI 10.1016/0163-7258(89)90096-X; CHO MW, 1994, VIROLOGY, V202, P129, DOI 10.1006/viro.1994.1329; CONTRERAS A, 1979, J VIROL, V29, P114, DOI 10.1128/JVI.29.1.114-122.1979; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; EGBERTS E, 1977, J VIROL, V22, P591, DOI 10.1128/JVI.22.3.591-597.1977; Feduchi E, 1995, EUR J BIOCHEM, V234, P849, DOI 10.1111/j.1432-1033.1995.849_a.x; FERNANDEZPUENTES C, 1980, CELL, V20, P769, DOI 10.1016/0092-8674(80)90323-2; GUINEA R, 1989, J BIOL CHEM, V264, P21923; GUINEA R, 1990, EMBO J, V9, P2011, DOI 10.1002/j.1460-2075.1990.tb08329.x; GUINEA R, 1995, J VIROL, V69, P2306, DOI 10.1128/JVI.69.4.2306-2312.1995; IRURZUN A, 1993, J GEN VIROL, V74, P1063, DOI 10.1099/0022-1317-74-6-1063; IRURZUN A, 1992, VIROLOGY, V191, P166, DOI 10.1016/0042-6822(92)90178-R; LACAL JC, 1982, EUR J BIOCHEM, V127, P359, DOI 10.1111/j.1432-1033.1982.tb06880.x; LAMA J, 1992, J BIOL CHEM, V267, P15932; LAMA J, 1992, BIOCHEM BIOPH RES CO, V188, P972, DOI 10.1016/0006-291X(92)91327-M; LOPEZRIVAS A, 1987, J GEN VIROL, V68, P335, DOI 10.1099/0022-1317-68-2-335; MAYNELL LA, 1992, J VIROL, V66, P1985, DOI 10.1128/JVI.66.4.1985-1994.1992; NAIR CN, 1984, J GEN VIROL, V65, P1135, DOI 10.1099/0022-1317-65-6-1135; PEREZ L, 1993, J VIROL, V67, P4543; PEREZ L, 1993, VIROLOGY, V194, P28, DOI 10.1006/viro.1993.1231; SARNOW P, 1990, CURR TOP MICROBIOL, V161, P155; SCHAEFER A, 1982, J VIROL, V44, P444, DOI 10.1128/JVI.44.2.445-449.1982; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033	33	110	111	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23134	23137		10.1074/jbc.271.38.23134	http://dx.doi.org/10.1074/jbc.271.38.23134			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798506				2022-12-27	WOS:A1996VH76800032
J	Meh, DA; Siebenlist, KR; Mosesson, MW				Meh, DA; Siebenlist, KR; Mosesson, MW			Identification and characterization of the thrombin binding sites on fibrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; CLOT-BOUND THROMBIN; AMINO-ACID-SEQUENCES; GAMMA-CHAIN; EQUILIBRIUM BINDING; HIRUDIN; PLATELETS; INHIBITOR; MECHANISM; EXOSITE	Thrombin binds to fibrin at two classes of non-substrate sites, one of high affinity and the other of low affinity, We investigated the location of these thrombin binding sites by assessing the binding of thrombin to fibrin lacking or containing gamma' chains, which are fibrinogen gamma chain variants that contain a highly anionic carboxyl-terminal sequence, We found the high affinity thrombin binding site to be located exclusively in D domains on gamma' chains (K-alpha, 4.9 x 10(6) M(-1); n, 1.05 per gamma' chain), whereas the low affinity thrombin binding site was in the fibrin E domain (K-alpha, 0.29 x 10(6) M(-1); n, 1.69 per molecule), The amino terminal beta 15-42 fibrin sequence is an important constituent of low affinity binding, since thrombin binding at this site is greatly diminished in fibrin molecules lacking this sequence. The tyrosine-sulfated, thrombin exosite-binding hirudin peptide, S-Hir(53-64) (hirugen), inhibited both low and high affinity thrombin binding to fibrin (IC50 1.4 and 3.0 mu M, respectively), The presence of the high affinity gamma' chain site on fibrinogen molecules did not inhibit fibrinogen conversion to fibrin as assessed by thrombin time measurements, and thrombin exosite binding to fibrin at either site did not inhibit its catalytic activity toward a small thrombin substrate, S-2238. We infer from these findings that there are two low affinity non substrate thrombin binding sites, one in each half of the dimeric fibrin E domain, and that they may represent a residual aspect of thrombin binding and cleavage of its substrate fibrinogen, The high affinity thrombin binding site on gamma' chains is a constitutive feature of fibrin as well as fibrinogen.	MARQUETTE UNIV,SCH DENT,DEPT BASIC HLTH SCI,MILWAUKEE,WI 53233	Marquette University	Meh, DA (corresponding author), UNIV WISCONSIN,SCH MED,SINAI SAMARITAN MED CTR,WINTE RES BLDG,836 N 12TH ST,MILWAUKEE,WI 53233, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047000] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47000] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERLINER LJ, 1985, BIOCHEMISTRY-US, V24, P7005, DOI 10.1021/bi00345a038; BINNIE CG, 1993, BLOOD, V81, P3186; BINNIE CG, 1991, THROMB HAEMOSTASIS, V65, P165; BOURDON P, 1990, BIOCHEMISTRY-US, V29, P6379, DOI 10.1021/bi00479a006; CHUNG DW, 1984, BIOCHEMISTRY-US, V23, P4232, DOI 10.1021/bi00313a033; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; CRABTREE GR, 1982, CELL, V31, P159, DOI 10.1016/0092-8674(82)90415-9; DEMARCO L, 1994, J BIOL CHEM, V269, P6478; DIMINNO G, 1991, ARTERIOSCLER THROMB, V11, P785, DOI 10.1161/01.ATV.11.4.785; DODT J, 1984, FEBS LETT, V165, P180, DOI 10.1016/0014-5793(84)80165-9; FARRELL DH, 1994, J BIOL CHEM, V269, P226; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; FINLAYSON JS, 1964, BIOCHIM BIOPHYS ACTA, V82, P415, DOI 10.1016/0304-4165(64)90318-6; FRANCIS CW, 1983, J LAB CLIN MED, V102, P220; HAIDARIS PJ, 1989, BLOOD, V74, P2437; HANNA LS, 1984, BIOCHEMISTRY-US, V23, P4681, DOI 10.1021/bi00315a025; HARFENIST EJ, 1984, BLOOD, V64, P1163; HEENE D L, 1973, Thrombosis Research, V2, P137, DOI 10.1016/0049-3848(73)90025-X; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HERBERT JM, 1994, BIOCHEM J, V303, P227, DOI 10.1042/bj3030227; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; HIROSE S, 1988, J BIOL CHEM, V263, P7426; HOGG DH, 1978, THROMB RES, V12, P953, DOI 10.1016/0049-3848(78)90051-8; HOGG PJ, 1990, J BIOL CHEM, V265, P241; HOMANDBERG GA, 1985, THROMB RES, V39, P263, DOI 10.1016/0049-3848(85)90221-X; HORTIN GL, 1989, BIOCHEM INT, V19, P1355; KACZMAREK E, 1988, J BIOL CHEM, V263, P13896; KAMINSKI M, 1983, J BIOL CHEM, V258, P530; KAMINSKI M, 1987, BIOCHEM J, V242, P881, DOI 10.1042/bj2420881; KANAIDE H, 1975, J LAB CLIN MED, V85, P574; KIRSCHBAUM NE, 1992, BLOOD, V79, P2643; KLOTZ IM, 1971, BIOCHEMISTRY-US, V10, P3065, DOI 10.1021/bi00792a013; KOOPMAN J, 1992, P NATL ACAD SCI USA, V89, P3478, DOI 10.1073/pnas.89.8.3478; KUMAR R, 1994, THROMB HAEMOSTASIS, V72, P713; KUMAR R, 1995, THROMB HAEMOSTASIS, V74, P962; LEGRELE CD, 1982, BIOCHEM BIOPH RES CO, V105, P521, DOI 10.1016/0006-291X(82)91466-8; LIU CY, 1980, J BIOL CHEM, V255, P7627; LIU CY, 1979, J BIOL CHEM, V254, P421; LIU CY, 1986, FIBRINOGEN FIBRIN FO, P79; LOEWY AG, 1961, J BIOL CHEM, V236, P625; Lorand L., 1970, METHOD ENZYMOL, V19, P770; Lord ST, 1996, BIOCHEMISTRY-US, V35, P2342, DOI 10.1021/bi952353u; LORD ST, 1995, J BIOL CHEM, V270, P24790, DOI 10.1074/jbc.270.42.24790; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MARTIN BM, 1976, BIOCHEMISTRY-US, V15, P4886, DOI 10.1021/bi00667a021; MARTINELLI RA, 1980, BIOCHEMISTRY-US, V19, P2343, DOI 10.1021/bi00552a010; MATHUR A, 1993, BIOCHEMISTRY-US, V32, P7568, DOI 10.1021/bi00080a031; MIHALYI E, 1988, BIOCHEMISTRY-US, V27, P976, DOI 10.1021/bi00403a021; MOSESSON MW, 1983, ANN NY ACAD SCI, V408, P97, DOI 10.1111/j.1749-6632.1983.tb23237.x; MOSESSON MW, 1966, BIOCHEMISTRY-US, V5, P2829, DOI 10.1021/bi00873a008; MOSESSON MW, 1972, J BIOL CHEM, V247, P5223; MOSESSON MW, 1963, J LAB CLIN MED, V62, P663; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NOE G, 1988, J BIOL CHEM, V263, P11729; PANDY BV, 1991, BIOCHEMISTRY-US, V30, P162, DOI 10.1021/bi00215a024; PARRY MAA, 1994, BIOCHEMISTRY-US, V33, P14807, DOI 10.1021/bi00253a020; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCOPES RK, 1982, PROTEIN PURIFICATION, P241; Siebenlist KR, 1996, BIOCHEMISTRY-US, V35, P10448, DOI 10.1021/bi9606206; SIEBENLIST KR, 1990, J BIOL CHEM, V265, P18650; STATHAKIS NE, 1978, THROMB RES, V13, P467, DOI 10.1016/0049-3848(78)90132-9; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; SUZUKI K, 1991, J BIOL CHEM, V266, P18498; TSIANG M, 1990, BIOCHEMISTRY-US, V29, P10602, DOI 10.1021/bi00499a005; VALI Z, 1988, BIOCHEMISTRY-US, V27, P1956, DOI 10.1021/bi00406a023; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WOLFENSTEINTODEL C, 1980, P NATL ACAD SCI-BIOL, V77, P5069, DOI 10.1073/pnas.77.9.5069; WOLFENSTEINTODEL C, 1981, BIOCHEMISTRY-US, V20, P6146, DOI 10.1021/bi00524a036	70	113	118	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23121	23125		10.1074/jbc.271.38.23121	http://dx.doi.org/10.1074/jbc.271.38.23121			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798504	Green Published, hybrid			2022-12-27	WOS:A1996VH76800030
J	Mendoza, I; Quintero, FJ; Bressan, RA; Hasegawa, PM; Pardo, JM				Mendoza, I; Quintero, FJ; Bressan, RA; Hasegawa, PM; Pardo, JM			Activated calcineurin confers high tolerance to ion stress and alters the budding pattern and cell morphology of yeast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; BUD-SITE SELECTION; SACCHAROMYCES-CEREVISIAE; PROTEIN PHOSPHATASE; POTASSIUM-TRANSPORT; DIFFERENTIAL EXPRESSION; B-SUBUNIT; GROWTH; CALMODULIN; MUTANTS	The PP2B protein phosphatase, also known as calcineurin, is a regulator of ion homeostasis in yeast cells. We have investigated the physiological consequences of constitutive expression of a recombinant form of calcineurin in which the Ca2+/calmodulin-binding and autoinhibitory domains of the catalytic subunit were deleted. The concomitant expression of the regulatory subunit along with the truncated catalytic subunit re suited in high tolerance to toxic levels of Na+ and Li+. This activated form of calcineurin substituted for the Na+ stress signal to promote the expression of the ENA1 gene, encoding a P-ATPase pump, and to induce the transition of the K+ uptake system to the high affinity mode that restricts influx of Na+ and Li+. In addition, the transcriptional responsiveness of ENA1 to Na+ stress was enhanced. These results demonstrate that calcineurin has a pivotal role in a signaling cascade activated by ion stress in yeast. Moreover, we found that changes in the level of calcineurin activity affected budding pattern and cell morphology. Cells expressing the truncated calcineurin were elongated and budded in an unipolar pattern, whereas calcineurin-deficient mutants budded randomly. These results suggest that calcineurin may also act in the establishment of cell polarity.	PURDUE UNIV, CTR PLANT ENVIRONM STRESS PHYSIOL, W LAFAYETTE, IN 47907 USA; CSIC, INST RECURSOS NAT & AGROBIOL, E-41080 SEVILLE, SPAIN	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS)			Quintero, Francisco J./AAG-2924-2019; Pardo, Jose M/AAB-5866-2022; Quintero, Francisco J/C-3086-2014; Pardo, Jose M./B-4652-2009	Quintero, Francisco J./0000-0001-8718-2975; Pardo, Jose M/0000-0003-4510-8624; Quintero, Francisco J/0000-0001-8718-2975; Pardo, Jose M./0000-0003-4510-8624; Mendoza, Imelda/0000-0002-2673-3961				BANUELOS MA, 1995, BBA-BIOENERGETICS, V1229, P233, DOI 10.1016/0005-2728(95)00006-5; BLACKETER MJ, 1993, MOL CELL BIOL, V13, P5567, DOI 10.1128/MCB.13.9.5567; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKERHOFF SE, 1992, J CELL BIOL, V118, P619, DOI 10.1083/jcb.118.3.619; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; Chant J, 1991, CURR OPIN GENET DEV, V1, P342, DOI 10.1016/S0959-437X(05)80298-9; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; FARCASANU IC, 1995, EUR J BIOCHEM, V232, P712, DOI 10.1111/j.1432-1033.1995.tb20865.x; FERREIRA A, 1993, MOL BIOL CELL, V4, P1225, DOI 10.1091/mbc.4.12.1225; FOOR F, 1992, NATURE, V360, P682; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; GARRETTENGELE P, 1995, MOL CELL BIOL, V15, P4103; GIMENO CJ, 1994, MOL CELL BIOL, V14, P2100, DOI 10.1128/MCB.14.3.2100; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HARO R, 1993, PHYSIOL PLANTARUM, V89, P868, DOI 10.1111/j.1399-3054.1993.tb05298.x; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMENWAY CS, 1995, GENETICS, V141, P833; HU GZ, 1994, J BIOL CHEM, V269, P3429; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; KINCAID R, 1993, ADV SEC MESS PHOSPH, V27, P1; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KRON SJ, 1994, MOL BIOL CELL, V5, P1003, DOI 10.1091/mbc.5.9.1003; LYNCH J, 1989, PLANT PHYSIOL, V90, P1271, DOI 10.1104/pp.90.4.1271; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; MILAN D, 1994, CELL, V79, P437, DOI 10.1016/0092-8674(94)90253-4; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; PARSONS JN, 1994, J BIOL CHEM, V269, P19610; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RAMOS J, 1985, ARCH MICROBIOL, V143, P88, DOI 10.1007/BF00414774; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; RONNE H, 1991, MOL CELL BIOL, V11, P4876, DOI 10.1128/MCB.11.10.4876; ROSE M, 1983, METHOD ENZYMOL, V101, P167; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; STRATFORD M, 1994, YEAST, V10, P1741, DOI 10.1002/yea.320101307; TANIDA I, 1995, J BIOL CHEM, V270, P10113, DOI 10.1074/jbc.270.17.10113; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; YOSHIDA T, 1994, J CELL SCI, V107, P1725; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; ZYL W, 1992, MOL CELL BIOL, V12, P4946	45	94	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23061	23067		10.1074/jbc.271.38.23061	http://dx.doi.org/10.1074/jbc.271.38.23061			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798496	hybrid			2022-12-27	WOS:A1996VH76800022
J	Sudhakar, K; Fay, PJ				Sudhakar, K; Fay, PJ			Exposed hydrophobic sites in factor VIII and isolated subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; FLUORESCENCE ENERGY-TRANSFER; PROCOAGULANT ACTIVITY; TRYPTOPHAN RESIDUES; A1/A3-C1-C2 DIMER; MOLTEN GLOBULE; PROTEIN; THROMBIN; COAGULANT; BINDING	Hydrophobic sites on the surface of factor VIII, factor Villa, and their derived subunits were evaluated using the fluorescent, apolar probe, bisanilinonapthalsulfonic acid (bis-ANS). Two hydrophobic sites, with indicated affinities for the probe, were identified on factor VIII (K-d = 0.2 and 1.22 mu M), the isolated heavy chain (HC; K-d = 0.21 and 1.44 mu M), and light chain (LC; K-d = 0.04 and 0.22 mu M), Comparison of these values and fluorescence emission maxima parameters suggested that the higher affinity site on each isolated subunit contributes to the divalent metal ion-dependent, intersubunit interaction while the two lower affinity sites are retained on the surface of the factor VIII heterodimer, A single bis-ANS site was identified on both the A1/A3-C1-C2 dimer (K-d = 0.19 mu M) and A2 subunit (K-d = 0.11 mu M), whereas two sites, equivalent to the sites of factor VIII, were observed on factor VIIIa. These results suggested the absence of interactive hydrophobic sites between A2 subunit and dimer, a major conformational change around the hydrophobic site in A2 upon dissociation, and the lack of accessible hydrophobic regions on the B domain of HC, Ca2+ reduced the emission intensity of bis-ANS bound to the isolated LC, HC, and A1 subunit; but not the A2 subunit, Reconstitution of factor VIII activity from isolated HC and LC was inhibited by >90% in the presence of 20 mu M bis-ANS, whereas this concentration of probe had no effect on the reconstitution of FVIIIa from the A1/A3-C1-C2 dimer and A2 subunit. These results indicate that intersubunit hydrophobic interactions are important for the metal ion-dependent association between A1 and A3 domains, but are not required for the metal ion-independent interaction between A2 subunit and the A1/A3-C1-C2 dimer in factor VIIIa.	UNIV ROCHESTER, MED CTR, HEMATOL UNIT, SCH MED & DENT, DEPT MED, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester					NHLBI NIH HHS [HL38199, HL30616] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038199, P01HL030616] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CASILLAS G, 1971, COAGULATION, V4, P107; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FOWLER WE, 1990, P NATL ACAD SCI USA, V87, P7648, DOI 10.1073/pnas.87.19.7648; HOROWITZ PM, 1985, BIOCHEMISTRY-US, V24, P2587, DOI 10.1021/bi00332a001; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; NORDFANG O, 1988, J BIOL CHEM, V263, P1115; PAN Y, 1995, NAT STRUCT BIOL, V2, P740, DOI 10.1038/nsb0995-740; PRASAD ARS, 1986, BIOCHEMISTRY-US, V25, P3536, DOI 10.1021/bi00360a010; SAFAR J, 1994, BIOCHEMISTRY-US, V33, P8375, DOI 10.1021/bi00193a027; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SHI L, 1994, BIOCHEMISTRY-US, V33, P7536, DOI 10.1021/bi00190a006; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TURNER DC, 1968, BIOCHEMISTRY-US, V7, P3381, DOI 10.1021/bi00850a011; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WANG JL, 1971, J BIOL CHEM, V246, P1185; WITZ G, 1973, J PHYS CHEM-US, V77, P648, DOI 10.1021/j100624a018; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	34	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23015	23021		10.1074/jbc.271.38.23015	http://dx.doi.org/10.1074/jbc.271.38.23015			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798489	hybrid			2022-12-27	WOS:A1996VH76800015
J	Rani, MRS; Foster, GR; Leung, S; Leaman, D; Stark, GR; Ransohoff, RM				Rani, MRS; Foster, GR; Leung, S; Leaman, D; Stark, GR; Ransohoff, RM			Characterization of beta-R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION PATHWAYS; TRANSCRIPTION FACTOR; GAMMA-INTERFERON; ANTIVIRAL ACTIONS; CELL-LINE; RECEPTOR; SUBUNIT; PHOSPHORYLATION; ACTIVATION	We report preliminary characterization of a gene designated beta-R1, which is selectively expressed in response to interferon beta (IFN-beta) compared with IFN-alpha. In human astrocytoma cells, beta-R1 was induced to an equivalent extent by 10 IU/mL IFN-beta or 2500 IU/mL IFN-alpha 2. To address the mechanism of this differential response, we analyzed induction of the beta-R1 gene in fibrosarcoma cells and derivative mutant cells lacking components required for signaling by type I IFNs. beta-R1 was readily induced by IFN-beta in the parental 2fTGH cell line, but not by recombinant IFN-alpha 2, IFN-alpha Con1, or a mixture of IFN-alpha subtypes. IFN-alpha 8 induced beta-R1 weakly. beta-R1 was not induced by IFN-beta in mutant cell lines U2A, U3A, U4A, and U6A, which lack, respectively, p48, STAT1, JAK1, and STATE. U5A cells, which lack the Ifnar 2.2 component of the IFN-alpha and -beta receptor, also failed to express beta-R1. U1A cells are partially responsive to IFN-beta and IFN-alpha 8 but lacked beta-R1 expression, indicating that TYK2 protein is essential for induction of this gene. Taken together, these results suggest that the expression of beta-R1 in response to type I IFN requires IFN-stimulated gene factor 3 plus an additional component, which is more efficiently formed on induction by IFN-beta compared with IFN-alpha.	CLEVELAND CLIN FDN,RES INST,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,RES INST,DEPT BIOL MOL,CLEVELAND,OH 44195; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,DEPT MED,LONDON W21 NY,ENGLAND	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Imperial College London					NCI NIH HHS [P01CA 62220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P591, DOI 10.1093/nar/19.3.591; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; ESTES ML, 1990, J NEUROSCI RES, V27, P697, DOI 10.1002/jnr.490270430; FAN SX, 1993, AIDS RES HUM RETROV, V9, P1115, DOI 10.1089/aid.1993.9.1115; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GRESSER I, 1990, J INVEST DERMATOL, V95, P665; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; GUYER NB, 1995, J IMMUNOL, V155, P3472; HAQUE SJ, 1994, J BIOL CHEM, V269, P19523; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLEIN SB, 1993, J INTERFERON RES, V13, P341, DOI 10.1089/jir.1993.13.341; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; RALPH D, 1993, P NATL ACAD SCI USA, V90, P10710, DOI 10.1073/pnas.90.22.10710; SAMUEL CE, 1988, PROG NUCLEIC ACID RE, V35, P27, DOI 10.1016/S0079-6603(08)60609-1; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; TAYLOR JL, 1990, VIRUS RES, V15, P1, DOI 10.1016/0168-1702(90)90010-9; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; UZE G, 1995, J INTERF CYTOK RES, V15, P3, DOI 10.1089/jir.1995.15.3; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; WEIL J, 1983, NATURE, V301, P437, DOI 10.1038/301437a0; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965	54	148	152	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22878	22884		10.1074/jbc.271.37.22878	http://dx.doi.org/10.1074/jbc.271.37.22878			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798467	hybrid			2022-12-27	WOS:A1996VG67200086
J	Dahl, SW; Rasmussen, SK; Hejgaard, J				Dahl, SW; Rasmussen, SK; Hejgaard, J			Heterologous expression of three plant serpins with distinct inhibitory specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; AMINO-ACID; CONFORMATIONAL CHANGE; BARLEY ENDOSPERM; STRUCTURAL BASIS; PROTEIN-Z; CHYMOTRYPSIN; GENE; ALPHA-2-ANTIPLASMIN; ANTITHROMBIN	For the first time, inhibitory plant serpins, including WSZ1 from wheat, BSZ4, and the previously unknown protein BSZx from barley, have been expressed in Escherichia coli, and a procedure for fast purification of native plant serpins has been developed, BSZx, BSZ4, and WSZ1 were assayed for inhibitory activity against trypsin, chymotrypsin, and cathepsin G, and cleavage sites in the reactive center loop were identified by sequencing. BSZx proved to be a potent inhibitor with specific, overlapping reactive centers either at P-1 Arg for trypsin or at P-2 Leu for chymotrypsin, At 22 degrees C, the apparent rate constant for chymotrypsin inhibition at P-2 (k(a) = 9.4 x 10(5) M(-1) s(-1)) was only four times lower than for trypsin at P-1 (k(a) = 3.9 X 10(6) M(-1) s(-1)), and the apparent inhibition stoichiometries were close to 1. Furthermore, our data suggest that cathepsin G was inhibited by BSZx (k(a) = 3.9 x 10(6) M(-1) s(-1)) at both the P-1 Arg and P-2 Leu. These results indicate a unique adaptability of the reactive center loop of BSZx. WSZ1 inhibited chymotrypsin (k(a) = 1.1 x 10(5) M(-1) s(-1)) and cathepsin G (k(a) = 7.6 x 10(3) M(-1) s(-1)) at P-2 Gln and not, as for BSZx, at the more favorable P-2 Leu. BSZ4 inhibited cathepsin G (k(a) = 2.7 x 10(4) M(-1) s(-1)) at P-1 Met but was hydrolyzed by trypsin and chymotrypsin. The three plant serpins formed stable SDS-resistant complexes with the proteinases in accordance with the kinetic data.	TECH UNIV DENMARK,DEPT BIOCHEM & NUTR,DK-2800 LYNGBY,DENMARK; RISO NATL LAB,DEPT ENVIRONM SCI & TECHNOL,DK-4000 ROSKILDE,DENMARK	Technical University of Denmark; Technical University of Denmark			Rasmussen, Soren K./F-6728-2014	Rasmussen, Soren K./0000-0001-6169-2504				AULAK KS, 1993, PROTEIN SCI, V2, P727, DOI 10.1002/pro.5560020504; BARKHOLT V, 1989, ANAL BIOCHEM, V177, P318, DOI 10.1016/0003-2697(89)90059-6; BRANDT A, 1990, EUR J BIOCHEM, V194, P499, DOI 10.1111/j.1432-1033.1990.tb15644.x; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; DRAG B, 1994, FIBRINOLYSIS, V8, P192, DOI 10.1016/S0268-9499(05)80019-0; ENGHILD JJ, 1993, BIOCHEM J, V291, P933, DOI 10.1042/bj2910933; FERSHT A, 1977, ENZYME STRUCTURE MEC, P256; GETTINS P, 1989, J BIOL CHEM, V264, P3781; HEJGAARD J, 1985, FEBS LETT, V180, P89, DOI 10.1016/0014-5793(85)80238-6; HEJGAARD J, 1994, BBA-PROTEIN STRUCT M, V1204, P68, DOI 10.1016/0167-4838(94)90034-5; HEJGAARD J, 1982, PHYSIOL PLANTARUM, V54, P174, DOI 10.1111/j.1399-3054.1982.tb06322.x; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JOHANSSON A, 1992, PLANT MOL BIOL, V18, P1151, DOI 10.1007/BF00047718; LENNICK M, 1986, BIOCHEMISTRY-US, V25, P3890, DOI 10.1021/bi00361a023; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LUNDGARD R, 1989, CARLSBERG RES COMMUN, V54, P173, DOI 10.1007/BF02904471; MARSHALL CJ, 1993, PHILOS T ROY SOC B, V342, P101, DOI 10.1098/rstb.1993.0141; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; PATSTON PA, 1995, THROMB HAEMOSTASIS, V20, P410; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; POTEMPA J, 1988, SCIENCE, V241, P699, DOI 10.1126/science.2456616; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RASMUSSEN SK, 1993, BIOCHIM BIOPHYS ACTA, V1172, P151, DOI 10.1016/0167-4781(93)90282-I; Rasmussen SK, 1996, PLANT MOL BIOL, V30, P673, DOI 10.1007/BF00049343; ROSENKRANDS I, 1994, FEBS LETT, V343, P75, DOI 10.1016/0014-5793(94)80610-1; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHONBAUM G, 1961, J BIOL CHEM, V236, P2930; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1994, FEBS LETT, V344, P117, DOI 10.1016/0014-5793(94)00369-6; SHIEH BH, 1987, J BIOL CHEM, V262, P6055; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; WRIGHT HT, 1993, J MOL EVOL, V36, P136, DOI 10.1007/BF00166249	38	62	66	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25083	25088		10.1074/jbc.271.41.25083	http://dx.doi.org/10.1074/jbc.271.41.25083			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810262	hybrid			2022-12-27	WOS:A1996VL69300006
J	Elshourbagy, NA; Adamou, JE; Gagnon, AW; Wu, HL; Pullen, M; Nambi, P				Elshourbagy, NA; Adamou, JE; Gagnon, AW; Wu, HL; Pullen, M; Nambi, P			Molecular characterization of a novel human endothelin receptor splice variant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTORS; SEQUENCE-ANALYSIS; LIGAND-BINDING; 2 ISOFORMS; CLONING; EXPRESSION; CELLS; RAT; CALCIUM; RELEASE	Endothelin receptors are widely distributed throughout a number of tissues. A novel ET(B) receptor splice variant (ET(B)-SVR) was identified from a human placental cDNA library, Sequence analysis indicated that the ET(B)-SVR is 436 amino acids long and shares 91% identity to the human ET(B)-R. Northern blot analysis indicated an mRNA species of 2.7 kilobases, which is expressed in the lung, placenta, kidney, and skeletal muscle. Ligand binding studies of the cloned ET(B)-SVR and ET(B)-R receptors expressed in COS cells showed that ET peptides exhibited similar potency in displacing I-125-ET-1 binding. Functional studies showed that ET-1, ET-3, and sarafotoxin 6c displayed similar potencies for inositol phosphates accumulation in ET(B)-R-transfected COS cells, whereas no increase in inositol phosphate accumulation was observed in ET(B)-SVR-transfected cells. In addition, exposure of ET(B)-R-transfected cells to ET-1 caused an increase in the intracellular acidification rate whereas ET(B)-SVR-transfected cells did not respond to ET-1. These data suggest that the ET(B)-SVR and ET(B)-R are functionally distinct and the difference in the amino acid sequences between the two receptors may determine functional coupling. Availability of cDNA clones for endothelin receptors can facilitate our understanding of the role of ET in the pathophysiology of various diseases.	SMITHKLINE BEECHAM PHARMACEUT, DEPT RENAL PHARMACOL, KING OF PRUSSIA, PA 19406 USA	GlaxoSmithKline	Elshourbagy, NA (corresponding author), SMITHKLINE BEECHAM PHARMACEUT, DEPT MOL GENET, KING OF PRUSSIA, PA 19406 USA.							ADACHI M, 1993, J CARDIOVASC PHARM, V22, pS121, DOI 10.1097/00005344-199322008-00033; AIYAR N, 1986, LIFE SCI, V39, P37, DOI 10.1016/0024-3205(86)90435-2; ARAI H, 1993, J BIOL CHEM, V268, P3463; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; CALVO JJ, 1990, ENDOCRINOLOGY, V126, P2288, DOI 10.1210/endo-126-5-2288; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; DAVENPORT AP, 1989, J CARDIOVASC PHARM, V13, pS166, DOI 10.1097/00005344-198900135-00045; DELAPENA P, 1992, J BIOL CHEM, V267, P25703; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; ELSHOURBAGY NA, 1990, J BIOL CHEM, V265, P1430; ELSHOURBAGY NA, 1993, J BIOL CHEM, V268, P3873; ELSHOURBAGY NA, 1992, MOL PHARMACOL, V41, P465; FRONG TM, 1992, MOL PHARMACOL, V41, P24; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JONES CR, 1989, NEUROSCI LETT, V97, P276, DOI 10.1016/0304-3940(89)90610-1; KARNE S, 1993, J BIOL CHEM, V268, P19126; KLOOG Y, 1988, SCIENCE, V242, P268, DOI 10.1126/science.2845579; KLOOG Y, 1989, TRENDS PHARMACOL SCI, V10, P212, DOI 10.1016/0165-6147(89)90261-7; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOMURO I, 1988, FEBS LETT, V238, P249, DOI 10.1016/0014-5793(88)80489-7; Kuang YN, 1996, J BIOL CHEM, V271, P3975; KUMAR C, 1994, J BIOL CHEM, V269, P13414; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LYSKO PG, 1991, NEUROPEPTIDES, V18, P83, DOI 10.1016/0143-4179(91)90005-4; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; ROSOLOWSKY LJ, 1990, ENDOCRINOLOGY, V126, P1860, DOI 10.1210/endo-126-4-1860; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; SAMPSON WK, 1991, ENDOCRINOLOGY, V128, P1465; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHICHIRI M, 1989, BIOCHEM BIOPH RES CO, V163, P1332, DOI 10.1016/0006-291X(89)91124-8; SHIGENO T, 1990, CEREBROVAS BRAIN MET, V2, P227; SHYAMALA V, 1994, CELL MOL BIOL RES, V40, P285; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STOJIKOVIC SS, 1990, MOL PHARMACOL, V39, P762; STOJILKOVIC SS, 1990, SCIENCE, V248, P1663, DOI 10.1126/science.2163546; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; TAKAYANAGI R, 1991, REGUL PEPTIDES, V32, P23, DOI 10.1016/0167-0115(91)90004-Z; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; WILLIAMS DL, 1991, BIOCHEM BIOPH RES CO, V175, P556, DOI 10.1016/0006-291X(91)91601-8; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIZAWA T, 1989, NEUROSCI LETT, V102, P179, DOI 10.1016/0304-3940(89)90075-X	51	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25300	25307		10.1074/jbc.271.41.25300	http://dx.doi.org/10.1074/jbc.271.41.25300			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810293	hybrid			2022-12-27	WOS:A1996VL69300037
J	Kondejewski, LH; Farmer, SW; Wishart, DS; Kay, CM; Hancock, REW; Hodges, RS				Kondejewski, LH; Farmer, SW; Wishart, DS; Kay, CM; Hancock, REW; Hodges, RS			Modulation of structure and antibacterial and hemolytic activity by ring size in cyclic gramicidin S analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; OUTER-MEMBRANE; ANTIMICROBIAL ACTIVITY; SECONDARY STRUCTURE; MODEL PEPTIDES; ANTIBIOTICS; POLYMYXIN; HYDROPHOBICITY	We have evaluated the effect of ring size of gramicidin S analogs on secondary structure, lipid binding, lipid disruption, antibacterial and hemolytic activity, Cyclic analogs with ring sizes ranging from 4 to 14 residues were designed to maintain the amphipathic character as found in gramicidin S and synthesized by solid phase peptide synthesis. The secondary structure of these peptides showed a definite periodicity in beta-sheet content, with rings containing 6, 10, and 14 residues exhibiting beta-sheet structure, and rings containing 8 or 12 residues being largely disordered, Peptides containing 4 or 6 residues did not bind lipopolysaccharide, whereas longer peptides showed a trend of increasing binding affinity for Lipopolysaccharide with increasing length, Destabilization of Escherichia coli outer membranes was only observed in peptides containing 10 or more residues, Peptides containing fewer than 10 residues were completely inactive and exhibited no hemolytic activity, The 10-residue peptide showed an activity profile similar to that of gramicidin S itself, with activity against Gram-positive and Gram negative microorganisms as well as yeast, but also showed high hemolytic activity, Differential activities were obtained by increasing the size of the ring to either 12 or 14 residues, The 14-residue peptide showed no antibiotic activity but exhibited increased hemolytic activity, The 12-residue peptide lost activity against Gram-positive bacteria, retained activity against Gram-negative microorganisms and yeast, but displayed decreased hemolytic activity, Biological activities in the 12-residue peptide were optimized by a series of substitutions in residues comprising both hydrophobic and basic sites resulting in a peptide that exhibited activities comparable with gramicidin S against Gram-negative microorganisms and yeast but with substantially lower hemolytic activity, Compared with gramicidin S, the best analog showed a 10-fold improvement in antibiotic specificity for Gram-negative microorganisms and a 7-fold improvement in specificity for yeast over human erythrocytes as determined by a therapeutic index. These results indicate that it is possible to modulate structure and activities of cyclic gramicidin S analogs by varying ring sizes and further show the potential for developing clinically useful antibiotics based on gramicidin S.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,PROT ENGN NETWORK CTR EXCELLENCE,EDMONTON,AB T6G 2S2,CANADA; UNIV BRITISH COLUMBIA,DEPT MICROBIOL,VANCOUVER,BC V6T 1Z3,CANADA; UNIV BRITISH COLUMBIA,CANADIAN BACTERIAL DIS NETWORK,VANCOUVER,BC V6T 1Z3,CANADA; UNIV ALBERTA,FAC PHARM,EDMONTON,AB T6G 2N8,CANADA	University of Alberta; University of Alberta; University of British Columbia; University of British Columbia; University of Alberta			Wishart, David Scott/ABI-3181-2020; Hancock, Robert E. W./E-1145-2013	Hancock, Robert E. W./0000-0001-5989-8503; Wishart, David S/0000-0002-3207-2434; Farmer, Susan/0000-0002-6712-7810				ALTMANN KH, 1990, INT J BIOCHEM, V22, P947, DOI 10.1016/0020-711X(90)90200-M; ANDO S, 1993, BIOCHIM BIOPHYS ACTA, V1147, P42, DOI 10.1016/0005-2736(93)90314-P; ANDO S, 1995, INT J PEPT PROT RES, V46, P97; ANGUS BL, 1987, J GEN MICROBIOL, V133, P2905; AOYAGI H, 1988, TETRAHEDRON, V44, P877, DOI 10.1016/S0040-4020(01)86123-8; BOMAN HG, 1989, FEBS LETT, V259, P103, DOI 10.1016/0014-5793(89)81505-4; CLARK D, 1984, FEMS MICROBIOL LETT, V21, P189; CREIGHTON TE, 1984, PROTEINS STRUCTURES, P171; Erickson B. W., 1976, PROTEINS, VII, P255; Gause GF, 1944, NATURE, V154, P703, DOI 10.1038/154703a0; HANCOCK REW, 1984, ANTIMICROB AGENTS CH, V26, P48, DOI 10.1128/AAC.26.1.48; HANCOCK REW, 1981, J ANTIMICROB CHEMOTH, V8, P429, DOI 10.1093/jac/8.6.429; HANCOCK REW, 1993, ANTIMICROB AGENTS CH, V37, P453, DOI 10.1128/AAC.37.3.453; HODGKIN DC, 1957, BIOCHEM J, V65, P752, DOI 10.1042/bj0650752; HULL SE, 1978, NATURE, V275, P206, DOI 10.1038/275206a0; IZUMIYA N, 1979, SYNTHETIC ASPECTS BI, P49; KATAYAMA T, 1994, J PHARM SCI, V83, P1357, DOI 10.1002/jps.2600830930; KATSU T, 1993, BIOL PHARM BULL, V16, P178; KITAGAWA T, 1994, CHEM PHARM BULL, V42, P1655; Kondejewski LH, 1996, INT J PEPT PROT RES, V47, P460; KREISWIRTH BN, 1983, NATURE, V305, P704; LAMBERT HP, 1992, ANTIBIOT CHEMOTHER, P232; LOH B, 1984, ANTIMICROB AGENTS CH, V26, P546, DOI 10.1128/AAC.26.4.546; MAEDA T, 1993, J FERMENT BIOENG, V75, P173, DOI 10.1016/0922-338X(93)90110-T; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P3423, DOI 10.1021/bi00010a034; MOORE RA, 1986, ANTIMICROB AGENTS CH, V29, P496, DOI 10.1128/AAC.29.3.496; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; OVCHINNIKOV YA, 1975, TETRAHEDRON, V31, P2177, DOI 10.1016/0040-4020(75)80216-X; OVCHINNIKOV YA, 1982, PROTEINS, V5, P391; PATHAK N, 1995, PROTEINS, V22, P182, DOI 10.1002/prot.340220210; PETERSON AA, 1987, ANTIMICROB AGENTS CH, V31, P230, DOI 10.1128/AAC.31.2.230; PORTLOCK SH, 1990, BIOCHIM BIOPHYS ACTA, V1030, P1, DOI 10.1016/0005-2736(90)90231-C; RACKOVSKY S, 1980, P NATL ACAD SCI USA, V77, P6965, DOI 10.1073/pnas.77.12.6965; SAWYER JG, 1988, INFECT IMMUN, V56, P693, DOI 10.1128/IAI.56.3.693-698.1988; SCHWYZER R, 1964, HELV CHIM ACTA, V47, P441, DOI 10.1002/hlca.19640470213; SCHWYZER R, 1969, HELV CHIM ACTA, V52, P2033, DOI 10.1002/hlca.19690520726; Schwyzer R., 1958, CHIMIA, V12, P53; SCHWYZER R, 1958, CHIMIA, V12, P90; TAMAKI M, 1987, J CHROMATOGR-BIOMED, V413, P287, DOI 10.1016/0378-4347(87)80241-4; TAMAKI M, 1991, B CHEM SOC JPN, V64, P2569, DOI 10.1246/bcsj.64.2569; TAMAKI M, 1988, B CHEM SOC JPN, V61, P3925, DOI 10.1246/bcsj.61.3925; TAMAKI M, 1995, INT J PEPT PROT RES, V45, P299; THENNARASU S, 1995, INT J PEPT PROT RES, V46, P480; TYTLER EM, 1995, BIOCHEMISTRY-US, V34, P4393, DOI 10.1021/bi00013a031; Wishart DS, 1996, LETT PEPT SCI, V3, P53, DOI 10.1007/BF00131086; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WISHART DS, 1995, TECHNIQUES PROTEIN C, V4, P451; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; YUKIOKA M, 1966, J BIOCHEM, V60, P295, DOI 10.1093/oxfordjournals.jbchem.a128436; ZIDOVETZKI R, 1988, BIOCHEMISTRY-US, V27, P5686, DOI 10.1021/bi00415a044	50	163	165	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25261	25268		10.1074/jbc.271.41.25261	http://dx.doi.org/10.1074/jbc.271.41.25261			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810288	hybrid			2022-12-27	WOS:A1996VL69300032
J	Ansai, T; Dupuy, LC; Barik, S				Ansai, T; Dupuy, LC; Barik, S			Interactions between a minimal protein serine/threonine phosphatase and its phosphopeptide substrate sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; MOLECULAR-CLONING; ACID-PHOSPHATASE; CALCINEURIN; EXPRESSION; PHOSPHORYLATION; IDENTIFICATION	The protein phosphatase encoded by coliphage lambda (PP lambda) was found to be the equivalent of the minimal catalytic core of serine/threonine protein phosphatases (PP) by biochemical and mutational criteria. Bacterially expressed truncated versions of PP1 and PP5 phosphatases, representing the catalytic cores homologous to PP lambda, exhibited potent phosphatase activity. Unlike full-length PP1, but like PP lambda, the recombinant cores could use casein, p-nitrophenyl phosphate, and a wide variety of peptides as substrates and were resistant to okadaic acid, microcystin-LR, and trypsin. Mutations of His(173), Asp(208), or Arg(221) had little effect on the activity of the PP1 core protein, indicating its closer identity with PP lambda than with full-length PP1. Terminal deletions of a few amino acids of the cores destroyed their activity, supporting their minimal nature, Analysis of PP lambda mutants suggested an influence of the substrate on metal ion binding. The minimal length of a phosphopeptide substrate of PP lambda appeared to be a phosphorylated serine/threonine flanked by 1 or 2 amino acid residues on either side, the N-terminal ones being more effective.	UNIV S ALABAMA, DEPT BIOCHEM & MOL BIOL, COLL MED, MOBILE, AL 36688 USA	University of South Alabama			Ansai, Toshihiro/AAM-2203-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI037938] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 37938] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barik S, 1996, Subcell Biochem, V26, P115; BARIK S, 1993, P NATL ACAD SCI USA, V90, P10633, DOI 10.1073/pnas.90.22.10633; BARIK S, 1995, VIROLOGY, V213, P405, DOI 10.1006/viro.1995.0013; BARIK S, 1995, METH NEUROSCI, V26, P309; BARKER HM, 1994, BBA-MOL CELL RES, V1220, P212, DOI 10.1016/0167-4889(94)90138-4; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; BECKER W, 1994, J BIOL CHEM, V269, P22586; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; COHEN PTW, 1989, BIOCHEM J, V260, P931, DOI 10.1042/bj2600931; DEANA AD, 1990, BIOCHIM BIOPHYS ACTA, V1051, P199, DOI 10.1016/0167-4889(90)90194-I; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; Eadie GS, 1942, J BIOL CHEM, V146, P85; FISCHER EH, 1989, BIOCHIM BIOPHYS ACTA, V1000, P297, DOI 10.1016/S0006-3002(89)80024-1; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; HUGHES V, 1993, EUR J BIOCHEM, V216, P269, DOI 10.1111/j.1432-1033.1993.tb18142.x; JENNY TF, 1995, PROTEINS, V21, P1, DOI 10.1002/prot.340210102; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN BL, 1994, BBA-PROTEIN STRUCT M, V1206, P136, DOI 10.1016/0167-4838(94)90082-5; MAZUMDER B, 1994, VIROLOGY, V205, P93, DOI 10.1006/viro.1994.1623; MURAMATSU T, 1993, BIOCHIM BIOPHYS ACTA, V1178, P117, DOI 10.1016/0167-4889(93)90117-8; OSTANIN K, 1992, J BIOL CHEM, V267, P22830; SCHLENDER KK, 1989, BIOCHEM BIOPH RES CO, V159, P72, DOI 10.1016/0006-291X(89)92406-6; SCHWARTZ JH, 1961, P NATL ACAD SCI USA, V47, P1996, DOI 10.1073/pnas.47.12.1996; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; VINCENT JB, 1991, J BIOL CHEM, V266, P17737; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; ZHANG ZJ, 1994, J BIOL CHEM, V269, P16997; ZHANG ZJ, 1994, J BIOL CHEM, V269, P13766; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; ZHANG ZJ, 1993, MOL CELL BIOCHEM, V128, P113, DOI 10.1007/BF01076762; ZHANG ZY, 1992, BIOCHEMISTRY-US, V31, P1701, DOI 10.1021/bi00121a018; ZHUO S, 1993, J BIOL CHEM, V268, P17754; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	41	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24401	24407		10.1074/jbc.271.40.24401	http://dx.doi.org/10.1074/jbc.271.40.24401			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798696	hybrid			2022-12-27	WOS:A1996VM67400018
J	English, JD; Sweatt, JD				English, JD; Sweatt, JD			Activation of p42 mitogen-activated protein kinase in hippocampal long term potentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC TRANSMISSION; MAP KINASE; RECEPTOR ACTIVATION; PHOSPHORYLATION; STIMULATION; MAINTENANCE; INDUCTION; CELLS; CA1; LTP	Although classically studied as regulators of cell proliferation and differentiation, mitogen-activated protein kinases (MAPKs) are highly expressed in post-mitotic neurons of the adult nervous system. We have begun investigating the potential role of MAPKs in the regulation of synaptic plasticity in mature neurons. In particular, we have studied the regulation of two MAPK isoforms, p44 and p42 MAPK, in hippocampal long term potentiation (LTP), a system widely studied as a model for the cellular basis of learning and memory. We have found that p42 MAPK, but not p44 MAPK, is activated in area CA1 following direct stimulation of two required components of the LTP induction cascades: protein kinase C and the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor. Furthermore, we have demonstrated that p42 MAPK, but not p44 MAPK, is activated in area CA1 in response to LTP-inducing high frequency stimulation and that this activation requires NMDA receptor stimulation. These data demonstrate that p42 MAPK can be regulated in an activity-dependent manner in the hippocampus and identify it as a potential component of the LTP induction cascades in area CA1. Such observations suggest that p42 MAPK might be an important regulator of synaptic plasticity in post-mitotic neurons.	BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine				Sweatt, J. David/0000-0003-3567-485X	NIMH NIH HHS [MH48186] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048186] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; FIORE RS, 1993, NEUROSCIENCE, V55, P463, DOI 10.1016/0306-4522(93)90516-I; FIORE RS, 1993, J NEUROCHEM, V61, P1626, DOI 10.1111/j.1471-4159.1993.tb09796.x; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GAUSE KC, 1993, J BIOL CHEM, V268, P16124; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Huang Y Y, 1994, Learn Mem, V1, P74; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; KLANN E, 1991, J BIOL CHEM, V266, P24253; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MATTHIES H, 1993, NEUROREPORT, V4, P712, DOI 10.1097/00001756-199306000-00028; MURPHY TH, 1994, J NEUROSCI, V14, P1320, DOI 10.1523/JNEUROSCI.14-03-01320.1994; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; Roberson ED, 1996, LEARN MEMORY, V3, P1, DOI 10.1101/lm.3.1.1; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STRATTON KR, 1989, P NATL ACAD SCI USA, V86, P2489	29	498	505	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24329	24332		10.1074/jbc.271.40.24329	http://dx.doi.org/10.1074/jbc.271.40.24329			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798683	hybrid			2022-12-27	WOS:A1996VM67400005
J	Godde, JS; Kass, SU; Hirst, MC; Wolffe, AP				Godde, JS; Kass, SU; Hirst, MC; Wolffe, AP			Nucleosome assembly on methylated CGG triplet repeats in the Fragile X Mental Retardation gene 1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE; CPG SEQUENCES; DNA; TRANSCRIPTION; CHROMATIN; FMR-1; INSTABILITY; TEMPLATES; INVITRO; REGION	Expansion and methylation of CGG repeat sequences is associated with Fragile X syndrome in humans. We have examined the consequences of CGG repeat expansion and methylation for nucleosome assembly and positioning on the Fragile X Mental Retardation gene 1 (FMR1) gene. Short unmethylated CGG repeats are not particularly favored in terms of affinity for the histone octamer or for positioning of the reconstituted nucleosome. However, upon methylation their affinity for the histone octamer increases and a highly positioned nucleosome assembles with the repeat sequences found adjacent to the nucleosomal dyad. Expansion of these CGG repeats abolishes the preferential nucleosome assembly due to methylation. Thus, the expansion and methylation of these triplet repeats can alter the functional organization of chromatin, which may contribute to alterations in the expression of the FMR1 gene and the disease phenotype.	NICHHD,LAB MOL EMBRYOL,NIH,BETHESDA,MD 20892; JOHN RADCLIFFE HOSP,INST MOL MED,OXFORD OX3 9D4,ENGLAND	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Hirst, Mark/0000-0003-3851-9740				BALL DJ, 1983, P NATL ACAD SCI-BIOL, V80, P5490, DOI 10.1073/pnas.80.18.5490; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BURKHOFF AM, 1987, CELL, V48, P935, DOI 10.1016/0092-8674(87)90702-1; BURKHOFF AM, 1988, NATURE, V331, P455, DOI 10.1038/331455a0; CAMERINIOTERO RD, 1976, CELL, V8, P333, DOI 10.1016/0092-8674(76)90145-8; CAMPOY FJ, 1995, J BIOL CHEM, V270, P26473, DOI 10.1074/jbc.270.44.26473; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; DREW HR, 1987, J MOL BIOL, V197, P485, DOI 10.1016/0022-2836(87)90560-2; ENGLANDER EW, 1993, J BIOL CHEM, V268, P19565; Felsenfeld G, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 2, P577; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GACY AM, 1995, CELL, V81, P533; Godde JS, 1996, J BIOL CHEM, V271, P15222, DOI 10.1074/jbc.271.25.15222; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HIRST M, 1995, AM J HUM GENET, V56, P67; HIRST MC, 1991, NUCLEIC ACIDS RES, V19, P3283, DOI 10.1093/nar/19.12.3283; HIRST MC, 1991, J MED GENET, V28, P824, DOI 10.1136/jmg.28.12.824; HWU WL, 1993, BIOCHEM BIOPH RES CO, V193, P324, DOI 10.1006/bbrc.1993.1627; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LEVINE A, 1993, J BIOL CHEM, V268, P21754; LUBS HA, 1969, AM J HUM GENET, V21, P231; McArthur M, 1996, EMBO J, V15, P1705, DOI 10.1002/j.1460-2075.1996.tb00516.x; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; NAKAHORI Y, 1991, NUCLEIC ACIDS RES, V19, P4355, DOI 10.1093/nar/19.16.4355; NIGHTINGALE K, 1995, J BIOL CHEM, V270, P4197, DOI 10.1074/jbc.270.9.4197; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; OOSTRA BA, 1995, BIOESSAYS, V17, P941, DOI 10.1002/bies.950171107; OTTEN AD, 1995, P NATL ACAD SCI USA, V92, P5465, DOI 10.1073/pnas.92.12.5465; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SUTHERLAND GR, 1977, SCIENCE, V197, P256; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VINCENT A, 1991, NATURE, V349, P624, DOI 10.1038/349624a0; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WOLFFE AP, 1995, AM SCI MED, V2, P68; WOLFFE AP, 1993, METH MOL G, V2, P314; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	50	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24325	24328		10.1074/jbc.271.40.24325	http://dx.doi.org/10.1074/jbc.271.40.24325			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology	VM674	8798682	hybrid			2022-12-27	WOS:A1996VM67400004
J	Temsamani, J; Pederson, T				Temsamani, J; Pederson, T			The C-group heterogeneous nuclear ribonucleoprotein proteins bind to the 5' stem-loop of the U2 small nuclear ribonucleoprotein particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; HNRNP CORE PROTEINS; HELA-CELLS; 3' END; U1 RNA; TRANSCRIPTION; COMPLEXES; OLIGODEOXYNUCLEOTIDES; IDENTIFICATION; RECONSTITUTION	The C group heterogeneous nuclear ribonucleoprotein (hnRNP) proteins bind to nascent pre-messenger RNA. In vitro studies have indicated that the C hnRNP proteins bind particularly strongly to the intron polypyrimidine tract of pre-mRNA and may be important for pre-mRNA splicing. In addition, there is evidence that the interaction of the C hnRNP proteins with pre-mRNA is facilitated by the U1 and U2 small nuclear RNPs (snRNPs). In the present study, we have uncovered another feature of the C hnRNP proteins that may provide a unifying framework for these previous observations; the C hnRNP proteins bind to the 5' stem-loop of the U2 snRNP. This was detected by incubating human P-32-labeled U2 snRNP in micrococcal nuclease-treated HeLa nuclear extracts, followed by UV-mediated protein-RNA cross-linking, which revealed that C hnRNP proteins were cross-linked to P-32-nucleotides in the U2 snRNP. In similar experiments, no cross-linking of C hnRNP proteins to P-32-labeled U1 or U4 snRNPs was observed. The observed cross-linking of C hnRNP proteins to U2 snRNP was efficiently competed by excess U2 RNA and by poly(U) but not by poly(A). No competition was observed with an RNA molecule comprising U2 nucleotides 105-189, indicating that the C hnRNP protein interactive regions of U2 RNA reside solely in the 5' half of the molecule. Oligodeoxynucleotide-mediated RNase H cleavage experiments revealed that a 5' region of U2 RNA including nucleotides 15-28 is essential for the observed C hnRNP protein cross-linking. C hnRNP protein cross-linking to U2 snRNP was efficiently competed by a mini-RNA corresponding to the first 29 nucleotides of U2 RNA, whereas no competition was observed with a variant of this mini-RNA in which the UUUU loop of stem-loop I was mutationally configured into a single-stranded RNA by replacing the stem with non-pairing nucleotides. Competition experiments with another mutant mini-U2 RNA in which the UUUU loop was replaced by AAAA indicated that both the UUUU loop and the stem are important for C hnRNP protein cross-linking, a finding consistent with other recent data on the RNA sequence specificity of C hnRNP protein binding.	WORCESTER FDN BIOMED RES, CELL BIOL GRP, SHREWSBURY, MA 01545 USA	Worcester Foundation for Biomedical Research					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021595] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21595-21] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRAWAL S, 1990, P NATL ACAD SCI USA, V87, P1401, DOI 10.1073/pnas.87.4.1401; AMERO SA, 1992, P NATL ACAD SCI USA, V89, P8409, DOI 10.1073/pnas.89.18.8409; AMRUTE SB, 1994, BIOCHEMISTRY-US, V33, P8282, DOI 10.1021/bi00193a015; BEHRENS SE, 1993, MOL CELL BIOL, V13, P307, DOI 10.1128/MCB.13.1.307; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; BHORJEE JS, 1972, P NATL ACAD SCI USA, V69, P3345, DOI 10.1073/pnas.69.11.3345; BLACK AC, 1995, J VIROL, V69, P6852, DOI 10.1128/JVI.69.11.6852-6858.1995; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; DAVIES DR, 1968, STRUCTURAL CHEM MOL, P422; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; ECONOMIDIS IV, 1983, P NATL ACAD SCI-BIOL, V80, P1599, DOI 10.1073/pnas.80.6.1599; ECONOMIDIS IV, 1982, P NATL ACAD SCI-BIOL, V79, P1469, DOI 10.1073/pnas.79.5.1469; FAKAN S, 1986, J CELL BIOL, V103, P1153, DOI 10.1083/jcb.103.4.1153; FIRTEL RA, 1975, P NATL ACAD SCI USA, V72, P301, DOI 10.1073/pnas.72.1.301; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GORLACH M, 1994, J BIOL CHEM, V269, P23074; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HAMMARSTROM K, 1982, EMBO J, V1, P737, DOI 10.1002/j.1460-2075.1982.tb01239.x; JACOBSON MR, 1993, MOL CELL BIOL, V13, P1119, DOI 10.1128/MCB.13.2.1119; KARN J, 1977, J BIOL CHEM, V252, P7307; KISH VM, 1975, J MOL BIOL, V95, P227, DOI 10.1016/0022-2836(75)90392-7; KLEINSCHMIDT AM, 1989, NUCLEIC ACIDS RES, V17, P4817, DOI 10.1093/nar/17.12.4817; KLEINSCHMIDT AM, 1987, MOL CELL BIOL, V7, P3131, DOI 10.1128/MCB.7.9.3131; LESER GP, 1984, J BIOL CHEM, V259, P1827; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MADORE SJ, 1984, J CELL BIOL, V99, P1140, DOI 10.1083/jcb.99.3.1140; MAYRAND S, 1981, J CELL BIOL, V90, P380, DOI 10.1083/jcb.90.2.380; MAYRAND S, 1981, P NATL ACAD SCI-BIOL, V78, P2208, DOI 10.1073/pnas.78.4.2208; MAYRAND SH, 1993, P NATL ACAD SCI USA, V90, P7764, DOI 10.1073/pnas.90.16.7764; MAYRAND SH, 1990, NUCLEIC ACIDS RES, V18, P3307, DOI 10.1093/nar/18.11.3307; Mayrand SH, 1996, MOL CELL BIOL, V16, P1241; McAfee JG, 1996, BIOCHEMISTRY-US, V35, P1212, DOI 10.1021/bi951974k; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MIMORI T, 1984, J BIOL CHEM, V259, P560; Moore M., 1993, RNA WORLD, P303; PATTON JR, 1987, MOL CELL BIOL, V7, P4030, DOI 10.1128/MCB.7.11.4030; PATTON JR, 1988, P NATL ACAD SCI USA, V85, P747, DOI 10.1073/pnas.85.3.747; PATTON JR, 1994, P NATL ACAD SCI USA, V91, P3324, DOI 10.1073/pnas.91.8.3324; PATTON JR, 1989, MOL CELL BIOL, V9, P3360, DOI 10.1128/MCB.9.8.3360; PEDERSON T, 1974, P NATL ACAD SCI USA, V71, P617, DOI 10.1073/pnas.71.3.617; PEDERSON T, 1974, J MOL BIOL, V83, P163, DOI 10.1016/0022-2836(74)90386-6; PEDERSON T, 1983, J CELL BIOL, V97, P1321, DOI 10.1083/jcb.97.5.1321; PULLMAN JM, 1983, J CELL BIOL, V97, P99, DOI 10.1083/jcb.97.1.99; QUINLAN TJ, 1974, P NATL ACAD SCI USA, V71, P2632, DOI 10.1073/pnas.71.7.2632; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; SAMARINA OP, 1968, J MOL BIOL, V33, P251, DOI 10.1016/0022-2836(68)90292-1; SAMARINA OP, 1965, DOKL AKAD NAUK SSSR+, V163, P1510; SASS H, 1984, J MOL BIOL, V180, P911, DOI 10.1016/0022-2836(84)90263-8; SIERAKOWSKA H, 1986, NUCLEIC ACIDS RES, V14, P5241, DOI 10.1093/nar/14.13.5241; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TEMSAMANI J, 1991, J BIOL CHEM, V266, P468; TEMSAMANI J, 1991, J BIOL CHEM, V266, P20356; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; WU JA, 1992, MOL CELL BIOL, V12, P5464, DOI 10.1128/MCB.12.12.5464	56	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24922	24926		10.1074/jbc.271.40.24922	http://dx.doi.org/10.1074/jbc.271.40.24922			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798770	hybrid			2022-12-27	WOS:A1996VM67400093
J	Agarwala, KL; Kawabata, SI; Miura, Y; Kuroki, Y; Iwanaga, S				Agarwala, KL; Kawabata, SI; Miura, Y; Kuroki, Y; Iwanaga, S			Limulus intracellular coagulation inhibitor type 3 - Purification, characterization, cDNA cloning, and tissue localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TACHYPLEUS-TRIDENTATUS HEMOCYTES; SERINE-PROTEASE ZYMOGEN; AMINO-ACID-SEQUENCE; PLASMINOGEN-ACTIVATOR INHIBITOR; SERPIN SUPERFAMILY; FACTOR-C; ANTIBACTERIAL ACTIVITY; BINDING-SITE; PROTEINS; DEGRADATION	We reported that limulus intracellular coagulation inhibitor type-1 (LICI-1) (Miura, Y., Kawabata, S., and Iwanaga, S. (1994) J. Biol. Chem. 269, 542-547) and LICI type-a (LICI-2) (Miura, Y., Kawabata, S., Wakamiya, Y., Nakamura, T., and Iwanaga, S. (1995) J. Biol. Chem. 270, 558-565) found in the hemocyte lysate belong to the serpin family. The LICI-1 specifically inhibits limulus lipopolysaccharide-sensitive serine protease, factor C (k(1) = 2.5 x 10(6) M(-1) S-1), whereas LICI-2 inhibits preferentially limulus clotting enzyme (k(1) = 4.3 x 10(5) M(-1) S-1). In our ongoing studies on limulus serpin, we found another inhibitor, named LICI type-3 (LICI-3), which strongly inhibits (1,3)-beta-D-glucan-sensitive serine protease, factor G (k(1) = 3.9 x 10(5) M(-1) S-1). Thus, the limulus hemolymph coagulation cascade is effectively regulated by at least the three endogenous serpins. LICI-3, newly identified in hemocytes, is a single chain glycoprotein with an apparent M(r) = 53,000, the largest one among known limulus serpins. A cDNA sequence for LICI-3 coded a mature protein of 392 amino acids, of which 68 residues were confirmed by peptide sequencing. LICI-3 showed significant sequence similarity to LICI-1 (45.8% identity) and LICI-2 (33.7% identity). LICI-3 contained a putative reactive site, -Arg-Ser-, distinct from that of LICI-2 (Lys-Ser-) but the same as that of LICI-1. Expression of LICI-3 mRNA was detected only in hemocytes, and not in heart, brain, stomach, intestine, coral gland, and skeletal muscle. Immunoblotting of the hemocyte-derived large and small granules with antiserum against LICI-3 suggested that it is stored specifically in large granules, as in the case of LICI-1 and LICI-2, and is released in response to external stimuli.	KYUSHU UNIV 33,FAC SCI,DEPT BIOL,HIGASHI KU,FUKUOKA 81281,JAPAN; KYUSHU UNIV 33,GRAD SCH MED SCI,DEPT MOL BIOL,FUKUOKA 81281,JAPAN	Kyushu University; Kyushu University			Miura, Yoshiki/U-8875-2019	Miura, Yoshiki/0000-0002-7596-0482				AKETAGAWA J, 1986, J BIOL CHEM, V261, P7357; ARMSTRONG PB, 1990, BIOL BULL, V178, P137, DOI 10.2307/1541972; BJORK I, 1986, PROTEINASE INHIBITOR, P489; CHASE T, 1970, METHOD ENZYMOL, V19, P20; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; HARLOW E, 1989, ANTIBODIES LABORATOR, P471; HEUSSEN C, 1984, J BIOL CHEM, V259, P1635; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; KANOST MR, 1989, J BIOL CHEM, V264, P965; KATO H, 1987, J BIOCHEM, V102, P1389, DOI 10.1093/oxfordjournals.jbchem.a122185; KATO H, 1980, J BIOCHEM-TOKYO, V88, P183; KAWABATA S, 1985, J BIOCHEM, V97, P1073, DOI 10.1093/oxfordjournals.jbchem.a135150; Kawabata Shun-ichiro, 1996, P255; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; MEGA T, 1980, J BIOL CHEM, V255, P4057; MILETICH JP, 1978, J BIOL CHEM, V253, P6908; MINETTI CASA, 1991, J BIOL CHEM, V266, P20773; MIURA Y, 1995, J BIOL CHEM, V270, P558, DOI 10.1074/jbc.270.2.558; MIURA Y, 1992, J BIOCHEM-TOKYO, V112, P476, DOI 10.1093/oxfordjournals.jbchem.a123924; MIURA Y, 1994, J BIOL CHEM, V269, P542; MIYATA T, 1984, J BIOL CHEM, V259, P8924; MORITA T, 1981, FEBS LETT, V129, P318, DOI 10.1016/0014-5793(81)80192-5; Muta T., 1996, Progress in Molecular and Subcellular Biology, V15, P154; MUTA T, 1991, J BIOL CHEM, V266, P6554; MUTA T, 1995, J BIOL CHEM, V270, P892, DOI 10.1074/jbc.270.2.892; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; NAKAMURA T, 1986, J BIOCHEM, V99, P847, DOI 10.1093/oxfordjournals.jbchem.a135545; NAKAMURA T, 1985, J BIOCHEM, V97, P1561, DOI 10.1093/oxfordjournals.jbchem.a135213; NARUMI H, 1993, EUR J BIOCHEM, V214, P181, DOI 10.1111/j.1432-1033.1993.tb17911.x; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; Okino N, 1995, J BIOL CHEM, V270, P31008, DOI 10.1074/jbc.270.52.31008; PANYUTICH AV, 1995, AM J RESP CELL MOL, V12, P351, DOI 10.1165/ajrcmb.12.3.7873202; PATTERSON SD, 1990, BIOCHEM INT, V20, P429; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; RUBIN H, 1990, J BIOL CHEM, V265, P1199; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; SAITO T, 1995, J BIOL CHEM, V270, P14493, DOI 10.1074/jbc.270.24.14493; Sambrook J., 2002, MOL CLONING LAB MANU; SEKI N, 1994, J BIOL CHEM, V269, P1370; SHIGENAGA T, 1993, J BIOCHEM-TOKYO, V114, P307, DOI 10.1093/oxfordjournals.jbchem.a124173; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; TAKAGI H, 1990, J BIOCHEM, V108, P372, DOI 10.1093/oxfordjournals.jbchem.a123208; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; TRAVIS J, 1990, BIOL CHEM H-S, V371, P3; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; YE RD, 1987, J BIOL CHEM, V262, P3718	48	34	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23768	23774		10.1074/jbc.271.39.23768	http://dx.doi.org/10.1074/jbc.271.39.23768			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798603				2022-12-27	WOS:A1996VJ44200032
J	Pang, YP; Quiram, P; Jelacic, T; Hong, F; Brimijoin, S				Pang, YP; Quiram, P; Jelacic, T; Hong, F; Brimijoin, S			Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase - Steps toward novel drugs for treating Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUPERZINE-A; BUTYRYLCHOLINESTERASE; TETRAHYDROAMINOACRIDINE; DYNAMICS; BINDING; TORPEDO; ANALOGS; INVITRO; CHANNEL	We report highly potent, selective, and low cost bifunctional acetylcholinesterase (AChE) inhibitors developed by our two-step prototype optimization strategy utilizing computer modeling of ligand docking with target proteins: 1) identify low affinity sites normally missed by x-ray crystallography; and 2) design bifunctional analogs capable of simultaneous binding at the computer-determined low affinity site and the x-ray-identified high affinity site. Applying this strategy to 9-amino-1,2,3,4-tetrahydroacridine (THA), a drug for Alzheimer's disease, we obtained alkylene linked bis-THA analogs. These analogs were up to 10,000-fold more selective and 1,000-fold more potent than THA in inhibiting rat AChE and yet required one simple reaction to synthesize. Additionally, alkylene linked benzyl-THA analogs were developed to examine the specificity of the docking-derived low affinity THA peripheral site in AChE. The present work and our previous computational studies strongly suggest that a low affinity THA peripheral site exists in AChE. This peripheral site provides a structural basis for design of improved cholinesterase ligands for treating Alzheimer's disease and for other health-related purposes.	MAYO FDN MED EDUC & RES,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic	Pang, YP (corresponding author), MAYO FDN MED EDUC & RES,4500 SAN PABLO RD,JACKSONVILLE,FL 32224, USA.		Jelacic, Tanya/S-3173-2019	Jelacic, Tanya/0000-0002-1584-5300; Pang, Yuan-Ping/0000-0003-0838-2560	NINDS NIH HHS [NS29646] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029646] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERMAN HA, 1992, MOL PHARMACOL, V41, P412; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; DAVIS KL, 1995, LANCET, V345, P625, DOI 10.1016/S0140-6736(95)90526-X; DELAHOZ D, 1986, LIFE SCI, V39, P195, DOI 10.1016/0024-3205(86)90530-8; EICHLER J, 1994, MOL PHARMACOL, V45, P335; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FLYNN DD, 1989, J PHARMACOL EXP THER, V250, P573; GALANAKIS D, 1995, J MED CHEM, V38, P595, DOI 10.1021/jm00004a005; GAO J, 1989, SCIENCE, V244, P1069, DOI 10.1126/science.2727695; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; Inestrosa NC, 1996, NEURON, V16, P881, DOI 10.1016/S0896-6273(00)80108-7; KOSHLAND DE, 1962, J THEOR BIOL, V2, P75, DOI 10.1016/0022-5193(62)90037-1; LIU JS, 1986, CAN J CHEM, V64, P837, DOI 10.1139/v86-137; MESULAM MM, 1994, ANN NEUROL, V36, P722, DOI 10.1002/ana.410360506; NELSON ME, 1994, MOL PHARMACOL, V46, P151; OSTERRIEDER W, 1987, BRIT J PHARMACOL, V92, P521, DOI 10.1111/j.1476-5381.1987.tb11352.x; PANG YP, 1994, J COMPUT AID MOL DES, V8, P669, DOI 10.1007/BF00124014; PANG YP, 1995, PESEPCT DRUG DISCOVE, V6, P106; PATOCKA J, 1976, COLLECT CZECH CHEM C, V41, P816, DOI 10.1135/cccc19760816; POMPONI M, 1992, MED CHEM RES, V2, P306; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; Segel I.H., 1975, ENZYME KINETICS; SHUTSKE GM, 1989, J MED CHEM, V32, P1805, DOI 10.1021/jm00128a024; Steinberg G M, 1975, J Med Chem, V18, P1057; SUGIMOTO H, 1992, BIOORG MED CHEM LETT, V8, P871; SUSSMAN JL, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P95; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR JL, 1994, MOL PHARMACOL, V45, P74; VILLALOBOS A, 1995, J MED CHEM, V38, P2802, DOI 10.1021/jm00015a002; WILSON IB, 1955, BIOCHIM BIOPHYS ACTA, V18, P168, DOI 10.1016/0006-3002(55)90040-8	32	388	403	1	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23646	23649		10.1074/jbc.271.39.23646	http://dx.doi.org/10.1074/jbc.271.39.23646			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798583	hybrid			2022-12-27	WOS:A1996VJ44200012
J	Platanias, LC; Uddin, S; Domanski, P; Colamonici, OR				Platanias, LC; Uddin, S; Domanski, P; Colamonici, OR			Differences in interferon alpha and beta signaling - Interferon beta selectively induces the interaction of the alpha and beta(L) subunits of the Type I interferon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID TYROSINE PHOSPHORYLATION; IFN-ALPHA; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; PROTEIN; KINASE; EXPRESSION; CLONING; ASSOCIATION; P135(TYK2)	All Type I interferons (IFN alpha, IFN beta, IFN omega) bind to the Type I IFN receptor (IFNR) and elicit a common set of signaling events, including activation of the Jak/Stat and IRS pathways. However, IFN beta selectively induces the association of the alpha subunit of the Type I IFNR with p100, a tyrosyl phosphoprotein, to transduce IFN beta-specific signals. Using antibodies raised against the different components of the Type I IFNR, we identified p100 as the long form of the beta subunit (beta(L) subunit) of the Type I IFNR, This was also confirmed in experiments with mouse L-929 cells transfected with truncated forms of beta(L). Thus, IFN beta stimulation of human cells or mouse L-929 transfectants expressing the human alpha and beta(L) subunits, selectively induces the formation of a signaling complex containing the alpha and beta(L) subunits of the receptor, The IFN beta-regulated interaction of the alpha and beta(L) chains is rapid and transient and follows a similar time course with the tyrosine phosphorylation of these receptor components, These data demonstrate that the signaling specificity for different Type I IFNs is established early in the signaling cascade, at the receptor level, and results from distinct interactions between components of the Type I IFNR.	UNIV ILLINOIS,HEMATOL ONCOL SECT,MBRB,DEPT MED,CHICAGO,IL 60607; W SIDE VET AFFAIRS HOSP,CHICAGO,IL 60607; LOYOLA UNIV,DIV HEMATOL ONCOL,MAYWOOD,IL 60153; VET AFFAIRS EDWARD HINES JR HOSP,DIV HEMATOL ONCOL,MAYWOOD,IL 60153; UNIV TENNESSEE,DEPT PATHOL,MEMPHIS,TN 38163	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; University of Tennessee System; University of Tennessee Health Science Center				Uddin, Shahab/0000-0003-1886-6710	NCI NIH HHS [CA73381, CA55079] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055079, R29CA073381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1993, J BIOL CHEM, V268, P10895; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLAMONICI OR, 1994, J BIOL CHEM, V269, P5660; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; CONSTANTINESCU SN, 1995, P NATL ACAD SCI USA, V92, P10487, DOI 10.1073/pnas.92.23.10487; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PETSKA S, 1987, ANNU REV BIOCHEM, V56, P727; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; PLATANIAS LC, 1993, J IMMUNOL, V150, P3382; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; Platanias Leonidas C., 1995, Current Opinion in Oncology, V7, P560, DOI 10.1097/00001622-199511000-00015; RANI MRS, 1995, J INTERFERON CYTO S1, V15, pS107; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; UDDIN S, 1995, J BIOL CHEM, V270, P24627, DOI 10.1074/jbc.270.42.24627; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179	29	95	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23630	23633		10.1074/jbc.271.39.23630	http://dx.doi.org/10.1074/jbc.271.39.23630			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798579	hybrid			2022-12-27	WOS:A1996VJ44200008
J	Schmidt, PP; Andersson, KK; Barra, AL; Thelander, L; Graslund, A				Schmidt, PP; Andersson, KK; Barra, AL; Thelander, L; Graslund, A			High field EPR studies of mouse ribonucleotide reductase indicate hydrogen bonding of the tyrosyl radical	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PHOTOSYSTEM-II; RECOVERY EPR; SPECTROSCOPY; PROTEIN; RESONANCE; SATURATION; R2	Ribonucleotide reductase catalyzes by free radical chemistry the reduction of ribonucleotides to deoxyribonucleotides. The R2 protein of a class 1 ribonucleotide reductase contains a stable tyrosyl radical of neutral phenoxy character, which is necessary for normal enzymatic activity, Here we present the EPR spectra from the tyrosyl free radical in the R2 protein from mouse at 9.62, 115, and 245 GHz. We show that the g-value anisotropy of the mouse R2 radical, when precisely determined from high field EPR spectra, is similar to that of the hydrogen bonded dark stable Y-D(.) tyrosyl radical of photosystem II and different from that of the Escherichia coli R2 radical. Because the g-value anisotropy is an important indicator of the hydrogen bonding status of the tyrosyl radical, this result suggests that the mouse R2 radical has its tyrosylate oxygen hydrogen bonded with a D2O exchangeable proton, whereas this hydrogen bond is absent in the E. coli enzyme. It is suggested that the observed proton may be derived from the tyrosine that will become a tyrosyl radical.	UNIV OSLO,DEPT BIOCHEM,N-0316 OSLO,NORWAY; STOCKHOLM UNIV,ARRHENIUS LABS,DEPT BIOPHYS,S-10691 STOCKHOLM,SWEDEN; CNRS,MPI,HIGH FIELD MAGNET LAB,F-38042 GRENOBLE,FRANCE; UMEA UNIV,DEPT MED BIOCHEM & BIOPHYS,S-90187 UMEA,SWEDEN	University of Oslo; Stockholm University; Centre National de la Recherche Scientifique (CNRS); Umea University			Andersson, K Kristoffer/F-9624-2010					Allard P, 1996, J AM CHEM SOC, V118, P895, DOI 10.1021/ja9529192; Andersson K. K., 1995, ADV INORG CHEM, V43, P359; Atta M, 1996, J BIOL INORG CHEM, V1, P210, DOI 10.1007/s007750050045; BARRA AL, 1990, CHEM PHYS LETT, V165, P107, DOI 10.1016/0009-2614(90)87019-N; BENDER CJ, 1989, J AM CHEM SOC, V111, P8076, DOI 10.1021/ja00203a002; BERNHARD WA, 1989, J MAGN RESON, V82, P156, DOI 10.1016/0022-2364(89)90176-5; BURGHAUS O, 1993, J PHYS CHEM-US, V97, P7639, DOI 10.1021/j100131a037; EHRENBERG A, 1988, CHEM SCRIPTA, V28A, P27; GALLI C, 1995, J AM CHEM SOC, V117, P740, DOI 10.1021/ja00107a017; GERFEN GJ, 1993, J AM CHEM SOC, V115, P6420, DOI 10.1021/ja00067a071; Graslund A, 1996, ANNU REV BIOPH BIOM, V25, P259; HIRSH DJ, 1992, J AM CHEM SOC, V114, P7475, DOI 10.1021/ja00045a021; Hoganson CW, 1996, J AM CHEM SOC, V118, P4672, DOI 10.1021/ja953979a; HOGANSON CW, 1992, BIOCHEMISTRY-US, V31, P11874, DOI 10.1021/bi00162a028; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MULLER F, 1989, REV SCI INSTRUM, V60, P3681, DOI 10.1063/1.1140474; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; PRINCE RC, 1988, TRENDS BIOCHEM SCI, V13, P286, DOI 10.1016/0968-0004(88)90119-3; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; Sjoberg B. M., 1995, NUCLEIC ACIDS MOL BI, V9, P192; Stubbe JA, 1995, CHEM BIOL, V2, P793, DOI 10.1016/1074-5521(95)90084-5; THELANDER L, 1993, MET IONS BIOL SYST, V30, P109; TOMMOS C, 1995, J AM CHEM SOC, V117, P10325, DOI 10.1021/ja00146a017; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; UN S, 1994, P NATL ACAD SCI USA, V91, P5262, DOI 10.1073/pnas.91.12.5262; UN S, 1995, J AM CHEM SOC, V117, P10713, DOI 10.1021/ja00148a013; VANDERDONK WA, 1995, J AM CHEM SOC, V117, P8908, DOI 10.1021/ja00140a003; WARNCKE K, 1994, J AM CHEM SOC, V116, P7332, DOI 10.1021/ja00095a042	31	66	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23615	23618		10.1074/jbc.271.39.23615	http://dx.doi.org/10.1074/jbc.271.39.23615			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798575	hybrid			2022-12-27	WOS:A1996VJ44200004
J	Batiza, AF; Schulz, T; Masson, PH				Batiza, AF; Schulz, T; Masson, PH			Yeast respond to hypotonic shock with a calcium pulse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION PATHWAY; ACTIVATED ION CHANNELS; SACCHAROMYCES-CEREVISIAE; VOLUME REGULATION; CATION CHANNELS; MAMMALIAN-CELLS; PKC1; MECHANISMS; MEMBRANE	We have used the transgenic AEQUORIN calcium reporter system to monitor the cytosolic calcium ([Ca2+](cyt)) response of Saccharomyces cerevisiae to hypotonic shock. Such a shock generates an almost immediate and transient rise in [Ca2+](cyt) which is eliminated by gadolinium, a blocker of stretch-activated channels. In addition, this transient rise in [Ca2+](cyt) which is initially insensitive to 1,2-bis-(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), an extracellular calcium chelator. However, BAPTA abruptly attenuates the maintenance of that transient rise. These data show that hypotonic shock generates a stretch-activated channel-dependent calcium pulse in yeast. They also suggest that the immediate calcium influx is primarily generated from intracellular stores, and that a sustained increase in [Ca2+](cyt) depends upon extracellular calcium.	UNIV WISCONSIN,GENET LAB,MADISON,WI 53706; UNIV WISCONSIN,CELL & MOL BIOL PROGRAM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM48053] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048053] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; BAGNASCO SM, 1993, AM J PHYSIOL, V264, pC1165, DOI 10.1152/ajpcell.1993.264.5.C1165; BARGMANN CI, 1994, CELL, V78, P729; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHRISTENSEN O, 1987, NATURE, V330, P66, DOI 10.1038/330066a0; CHRISTENSEN O, 1992, J MEMBRANE BIOL, V129, P13; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; COBBOLD PH, 1991, CELLULAR CALCIUM PRA, P51; CORNET M, 1993, J MEMBRANE BIOL, V133, P161; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; DAVIDSON RM, 1993, J MEMBRANE BIOL, V131, P81, DOI 10.1007/BF02258536; DING JP, 1991, HEARING RES, V56, P19, DOI 10.1016/0378-5955(91)90149-4; DING JP, 1993, PLANT J, V3, P83, DOI 10.1111/j.1365-313X.1993.tb00013.x; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; KNIGHT MR, 1992, P NATL ACAD SCI USA, V89, P4967, DOI 10.1073/pnas.89.11.4967; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEE KS, 1992, MOL CELL BIOL, V12, P172, DOI 10.1128/MCB.12.1.172; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; Moore DD, 1995, GLOB MOB SURV; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; OIKE M, 1994, P NATL ACAD SCI USA, V91, P2940, DOI 10.1073/pnas.91.8.2940; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; PIERCE SK, 1990, ANNU REV PHYSIOL, V52, P27, DOI 10.1146/annurev.ph.52.030190.000331; ROTHSTEIN A, 1990, AM J PHYSIOL, V258, pC827, DOI 10.1152/ajpcell.1990.258.5.C827; RUSSELL P, 1986, CELL, V45, P781, DOI 10.1016/0092-8674(86)90550-7; SIKORSKI RS, 1989, GENETICS, V122, P19; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; SUZUKI M, 1990, AM J PHYSIOL, V258, pF690, DOI 10.1152/ajprenal.1990.258.3.F690; TILLY BC, 1993, J BIOL CHEM, V268, P19919; WATANABE M, 1994, J BIOL CHEM, V269, P16829; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333	42	139	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23357	23362		10.1074/jbc.271.38.23357	http://dx.doi.org/10.1074/jbc.271.38.23357			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798538	hybrid			2022-12-27	WOS:A1996VH76800064
J	FernandezBusquets, X; Kammerer, RA; Burger, MM				FernandezBusquets, X; Kammerer, RA; Burger, MM			A 35-kDa protein is the basic unit of the core from the 2 x 10(4)-kDa aggregation factor responsible for species-specific cell adhesion in the marine sponge Microciona prolifera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; HUMAN-LUNG FIBROBLASTS; MOLECULAR-CLONING; CARTILAGE PROTEOGLYCAN; SEXUAL AGGLUTINATION; POLYACRYLAMIDE GELS; HANSENULA-WINGEI; BINDING; GLYCOSAMINOGLYCANS; IDENTIFICATION	Dissociated sponge cells quickly reaggregate in a species-specific manner, differentiate, and reconstruct tissue, providing a very handy system to investigate the molecular basis of more complex intercellular recognition processes. Species specific cell adhesion in the marine sponge Microciona prolifera is mediated by a supramolecular complex with a M-r = 2 x 10(7), termed aggregation factor, Guanidinium hydrochloride/cesium chloride dissociative gradients and rhodamine B isothiocyanate staining indicated the presence of several proteins with different degrees of glycosylation. Hyaluronate has been found to be associated with the aggregation factor. Chemical deglycosylation revealed a main component accounting for nearly 90% of the total protein. The cDNA-deduced amino acid sequence predicts a 35-kDa protein (MAFp3), the first sponge aggregation factor core protein ever described, The open reading frame is uninterrupted upstream from the amino terminus of the mature protein, and the deduced amino acid sequence for this region has been found to contain a long stretch sharing homology with the Na+-Ca2+ exchanger protein. A putative hyaluronic acid binding domain and several putative N- and O-glycosylation signals are present in MAFp3, as well as eight cysteines, some of them involved in intermolecular disulfide bridges. Northern blot data suggest variable expression, and Southern blot analysis reveals the presence of other related gene sequences. According to the respective molecular masses, one aggregation factor molecule would contain about 300 MAFp3 units, suggesting that sponge cell adhesion might be based on the assembly of multiple small glycosylated protein subunits.	MARINE BIOL LAB, WOODS HOLE, MA 02543 USA	Marine Biological Laboratory - Woods Hole	FernandezBusquets, X (corresponding author), FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND.		Fernàndez-Busquets, Xavier/K-1323-2014	Fernàndez-Busquets, Xavier/0000-0002-4622-9631; Kammerer, Richard/0000-0003-4570-5197				ANTONSSON P, 1989, J BIOL CHEM, V264, P16170; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BOURDON MA, 1986, J BIOL CHEM, V261, P2534; CAULDWELL CB, 1973, BIOCHEMISTRY-US, V12, P3051, DOI 10.1021/bi00740a017; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAMMER U, 1995, SCIENCE, V267, P1173, DOI 10.1126/science.7855599; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; ENGHILD JJ, 1993, J BIOL CHEM, V268, P8711; FERNANDEZBUSQUETS X, 1995, ANAL BIOCHEM, V227, P394, DOI 10.1006/abio.1995.1299; GRAMZOW M, 1988, EXP CELL RES, V179, P243, DOI 10.1016/0014-4827(88)90363-1; GRAMZOW M, 1988, J HISTOCHEM CYTOCHEM, V36, P205, DOI 10.1177/36.2.3335775; GRAMZOW M, 1986, J CELL BIOL, V102, P1344, DOI 10.1083/jcb.102.4.1344; HANSON AN, 1983, ANAL BIOCHEM, V130, P32, DOI 10.1016/0003-2697(83)90646-2; HARDINGHAM TE, 1976, BIOCHEM J, V157, P127, DOI 10.1042/bj1570127; HENKART P, 1973, BIOCHEMISTRY-US, V12, P3045, DOI 10.1021/bi00740a016; HEREMANS A, 1990, J BIOL CHEM, V265, P8716; HUMPHREYS S, 1977, J SUPRAMOL STR CELL, V7, P339, DOI 10.1002/jss.400070307; HUMPHREYS T, 1963, DEV BIOL, V8, P27, DOI 10.1016/0012-1606(63)90024-1; JUMBLATT JE, 1980, BIOCHEMISTRY-US, V19, P1038, DOI 10.1021/bi00546a032; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KNECHT R, 1986, ANAL CHEM, V58, P2375, DOI 10.1021/ac00125a006; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; KREIS T, 1993, GUIDEBOOK EXTRACELLU; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landon, 1977, Methods Enzymol, V47, P145; LI ZP, 1994, J BIOL CHEM, V269, P17434; LIPKE PN, 1992, MICROBIOL REV, V56, P180, DOI 10.1128/MMBR.56.1.180-194.1992; LYON M, 1986, BIOCHIM BIOPHYS ACTA, V881, P22, DOI 10.1016/0304-4165(86)90092-9; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; MCDEVITT CA, 1971, ANAL BIOCHEM, V44, P612, DOI 10.1016/0003-2697(71)90250-8; MIN H, 1986, ANAL BIOCHEM, V155, P275, DOI 10.1016/0003-2697(86)90437-9; MISEVIC GN, 1990, J BIOL CHEM, V265, P20577; MISEVIC GN, 1987, J BIOL CHEM, V262, P5870; MISEVIC GN, 1982, J BIOL CHEM, V257, P6931; MISEVIC GN, 1993, J BIOL CHEM, V268, P4922; MISEVIC GN, 1986, J BIOL CHEM, V261, P2853; MISEVIC GN, 1989, METHOD ENZYMOL, V179, P95; MORT AJ, 1977, ANAL BIOCHEM, V82, P289, DOI 10.1016/0003-2697(77)90165-8; MULLER WEG, 1977, J BIOL CHEM, V252, P3836; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PFEIFER K, 1993, GLYCOBIOLOGY, V3, P179, DOI 10.1093/glycob/3.2.179; ROBITZKI A, 1990, BIOCHEM J, V271, P415, DOI 10.1042/bj2710415; ROTHBARD JB, 1982, J BIOL CHEM, V257, P1064; ROUGHLEY PJ, 1993, BIOCHEM J, V295, P421, DOI 10.1042/bj2950421; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAJDERA S, 1969, J BIOL CHEM, V244, P77; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; Showalter AM, 1990, ORG ASSEMBLY PLANT A, P247; SPILLMANN D, 1993, J BIOL CHEM, V268, P13378; TAYLOR NW, 1971, BIOCHEMISTRY-US, V10, P2043, DOI 10.1021/bi00787a012; TEMPLETON DM, 1992, CRIT REV CL LAB SCI, V29, P141, DOI 10.3109/10408369209114599; TREVELYAN WE, 1952, BIOCHEM J, V50, P298, DOI 10.1042/bj0500298; TURNER RS, 1973, NATURE, V244, P509, DOI 10.1038/244509a0; VARNER JA, 1995, J CELL SCI, V108, P3119; VARNER JA, 1988, J BIOL CHEM, V263, P8498; VILIM V, 1991, ANAL BIOCHEM, V197, P34, DOI 10.1016/0003-2697(91)90351-S; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YEN PH, 1974, BIOCHEMISTRY-US, V13, P2428, DOI 10.1021/bi00708a030	66	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23558	23565		10.1074/jbc.271.38.23558	http://dx.doi.org/10.1074/jbc.271.38.23558			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798565	hybrid			2022-12-27	WOS:A1996VH76800091
J	Luo, W; Skalnik, DG				Luo, W; Skalnik, DG			Interferon regulatory factor-2 directs transcription from the gp91(phox) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; CCAAT DISPLACEMENT PROTEIN; BETA GENE-EXPRESSION; LEUKEMIA CELL-LINE; FC-GAMMA RECEPTOR; FACTOR-I; GP91-PHOX PROMOTER; CYTOCHROME B(558); FACTOR IRF-2; ACTIVATION	Repressor elements in the gp91(phox) promoter are necessary to restrict tissue-specific transcription to mature phagocytes. Deletion of these elements leads to significant promoter activity in cell lines such as HEL and K562 that do not normally express gp91(phox). The -100 to +12 base pair gp91(phox) promoter region is sufficient to direct maximal de repressed transcription in these cells. However, promoter activity is dramatically decreased following a 16-base pair truncation that deletes an interferon-stimulated response element. This element interacts with IRF-1 and IRF-2, members of the interferon regulatory factor family of transcription factors. In addition, this promoter region is bound by a factor with properties similar to BID, a DNA-binding protein that also interacts with three upstream sites within the gp91(phox) promoter. Transient transfection studies using mutated promoters indicate that both the IRF and BID binding sites are required for maximal gp91(phox) promoter activity. Overexpression of IRF-1 or IRF-2 in K562 cells leads to transactivation of gp91(phox) promoter constructs, which is dependent on the presence of an intact IRF binding site. IRF-2 predominates in macrophages that express the gp91(phox) gene as well as in HEL and K562 cells. We conclude that IRF-2 and BID activate gp91(phox) promoter activity in the absence of transcriptional repression.	JAMES WHITCOMB RILEY HOSP CHILDREN,HERMAN B WELLS CTR PEDIAT RES,SECT PEDIAT HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT PEDIAT,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL CANCER INSTITUTE [R01CA058947, R29CA058947] Funding Source: NIH RePORTER; NCI NIH HHS [CA58947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Babior B M, 1995, Curr Opin Hematol, V2, P55; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; EILERS A, 1994, MOL CELL BIOL, V14, P1364, DOI 10.1128/MCB.14.2.1364; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; EKLUND EA, 1995, J BIOL CHEM, V270, P8267, DOI 10.1074/jbc.270.14.8267; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GEY GO, 1952, CANCER RES, V12, P264; GOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KURIBAYASHI F, 1995, BIOCHEM BIOPH RES CO, V209, P146, DOI 10.1006/bbrc.1995.1482; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEE TC, 1994, ONCOGENE, V9, P1047; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; LIN RT, 1994, J BIOL CHEM, V269, P17542; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NEWBURGER PE, 1988, P NATL ACAD SCI USA, V85, P5215, DOI 10.1073/pnas.85.14.5215; NEWBURGER PE, 1994, J CLIN INVEST, V94, P1205, DOI 10.1172/JCI117437; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Sambrook J., 1989, MOL CLONING; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SKALNIK DG, 1991, P NATL ACAD SCI USA, V88, P8505, DOI 10.1073/pnas.88.19.8505; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TUCKER KA, 1987, BLOOD, V70, P372; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WHITESIDE ST, 1994, J BIOL CHEM, V269, P27059; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WOODMAN RC, 1995, BLOOD, V85, P231, DOI 10.1182/blood.V85.1.231.bloodjournal851231; YAMAMOTO H, 1994, ONCOGENE, V9, P1423	50	63	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23445	23451		10.1074/jbc.271.38.23445	http://dx.doi.org/10.1074/jbc.271.38.23445			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798551	hybrid			2022-12-27	WOS:A1996VH76800077
J	MacLeod, RJ; Hamilton, JR				MacLeod, RJ; Hamilton, JR			Activation of Na+/H+ exchange is required for regulatory volume decrease after modest ''physiological'' volume increases in jejunal villus epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NA/H EXCHANGER; HAMSTER OVARY CELLS; PROTEIN-KINASE-C; MOLECULAR-CLONING; INTRACELLULAR PH; FUNCTIONAL EXPRESSION; CYTOPLASMIC PH; H+ EXCHANGER; NHE-1; COTRANSPORT	Epithelial cell volume increases that occur because of the uptake of Na+-cotransported solutes or hypotonic dilution are followed by a regulatory volume decrease (RVD) due to the activation of K+ and Cl- channels, We studied the relationship of Na+/H+ exchange (NHE) to this RVD in suspended guinea pig jejunal villus cells, using electronic sizing to measure cell volume changes and fluorescent spectroscopy of cells loaded with 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein to monitor intracellular pH (pH(i)). When the volume increase achieved by these cells during Na+ solute absorption was duplicated by a modest 5-7% hypotonic dilution, their pH(i) first acidified and then alkalinized. This alkalinization was blocked by 5-(N-methyl-N-isobutyl) amiloride (MIA; 1 mu M), an inhibitor of NHE, The RVD subsequent to 5-7% hypotonic dilution was prevented by Na+-free medium and by amiloride and non-amiloride derivatives, The order of potency of these inhibitors was as follows: MIA > 5-(N,N-dimethyl) amiloride > cimetidine > clonidine, in keeping with the pattern attributable to NHE-1 as the isoform of NHE responsible for increase in pH(i) after modest volume increases. A substantial 30% hypotonic dilution caused acidification, and RM) following this larger volume increase was not affected by MIA. To assess the effect of hypotonicity on the activity of NHE, we measured the rate of MIA-sensitive pH(i) recovery from an acid load (dpH(i)/dt) in 5 and 30% hypotonic media, pH(i) recovery was faster in 5% hypotonic medium compared with isotonic medium and slowest in 30% hypotonic medium, which suggested that the activity of NHE was stimulated in the slightly hypotonic medium, but inhibited in the 30% hypotonic medium, To determine the role of activated NHE in RVD after a modest volume increase, cells were hypotonically diluted 7% in MIA to prevent RVD and then alkalinized by NH4Cl or acidified by propionic acid addition. Only after alkalinization was there complete volume regulation, We conclude that in Na+-absorbing enterocytes, the NHE-1 isoform of Na+/H+ exchange is stimulated by volume increases that duplicate the "physiological" volume increase occurring when these cells absorb Na+-cotransported solutes, The subsequent alkalinization of pH(i) is a required determinant of the osmolyte loss that underlies this distinct volume regulatory mechanism.			MacLeod, RJ (corresponding author), MCGILL UNIV, MONTREAL CHILDRENS HOSP, RES INST, DEPT PEDIAT, 2300 TUPPER ST, MONTREAL, PQ H3H 1P3, CANADA.							ALAUQATI O, 1986, ANN REV CELL BIOL, V2, P179; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; BIDANI A, 1994, AM J PHYSIOL, V266, pL681, DOI 10.1152/ajplung.1994.266.6.L681; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; BORON WF, 1976, J GEN PHYSIOL, V67, P911; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CASAVOLA V, 1992, J MEMBRANE BIOL, V130, P105; CHANG D, 1991, J GEN PHYSIOL, V98, P183, DOI 10.1085/jgp.98.1.183; COLLINS JF, 1993, P NATL ACAD SCI USA, V90, P3938, DOI 10.1073/pnas.90.9.3938; DEMAUREX N, 1993, J PHYSIOL-LONDON, V466, P329; DEMAUREX N, 1995, J GEN PHYSIOL, V106, P85, DOI 10.1085/jgp.106.1.85; GREEN J, 1988, J BIOL CHEM, V263, P5012; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GRINSTEIN S, 1989, METHOD ENZYMOL, V173, P777; GUERRA L, 1993, J MEMBRANE BIOL, V135, P209; HALLOWS KR, 1994, AM J PHYSIOL-CELL PH, V267, pC1057, DOI 10.1152/ajpcell.1994.267.4.C1057; Hoogerwerf WA, 1996, AM J PHYSIOL-GASTR L, V270, pG29, DOI 10.1152/ajpgi.1996.270.1.G29; KAPUS A, 1994, J BIOL CHEM, V269, P23544; LIVNE A, 1987, J CELL PHYSIOL, V131, P354, DOI 10.1002/jcp.1041310307; LIVNE A, 1990, J MEMBRANE BIOL, V114, P153, DOI 10.1007/BF01869096; MACLEOD RJ, 1991, AM J PHYSIOL, V260, pG405, DOI 10.1152/ajpgi.1991.260.3.G405; MACLEOD RJ, 1992, J MEMBRANE BIOL, V130, P23; MACLEOD RJ, 1990, AM J PHYSIOL, V258, pG665, DOI 10.1152/ajpgi.1990.258.5.G665; MACLEOD RJ, 1991, AM J PHYSIOL, V260, pG26, DOI 10.1152/ajpgi.1991.260.1.G26; MACLEOD RJ, 1992, AM J PHYSIOL, V262, pC950, DOI 10.1152/ajpcell.1992.262.4.C950; MacLeod RJ, 1994, CELLULAR MOL PHYSL C, P191; MAHOUTSMITH MP, 1989, J EXP BIOL, V145, P455; NANDA A, 1992, J BIOL CHEM, V267, P22740; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; STAR RA, 1992, J BIOL CHEM, V267, P17665; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P210; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1993, J BIOL CHEM, V268, P11917; WANG Z, 1993, J BIOL CHEM, V268, P11925; YU FH, 1993, J BIOL CHEM, V268, P25536	40	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23138	23145		10.1074/jbc.271.38.23138	http://dx.doi.org/10.1074/jbc.271.38.23138			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798507	hybrid			2022-12-27	WOS:A1996VH76800033
J	Parent, JL; LeGouill, C; Escher, E; RolaPleszczynski, M; Stankova, J				Parent, JL; LeGouill, C; Escher, E; RolaPleszczynski, M; Stankova, J			Identification of transmembrane domain residues determinant in the structure-function relationship of the human platelet-activating factor receptor by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MOLECULAR-CLONING; PHOSPHOLIPASE-C; EXPRESSION; PHOSPHORYLATION; CDNA; PAF; HYDROLYSIS; ANALOG; KINASE	Platelet-activating factor (PAF) is a potent phospholipid mediator that produces a wide range of biological responses. The PAF receptor is a member of the seven-transmembrane GTP binding regulatory protein-coupled receptor superfamily. This receptor binds PAF with high affinity and couples to multiple signaling pathways, leading to physiological responses that can be inhibited by various structurally distinct PAF antagonists. We have used site-directed mutagenesis and functional expression studies to examine the role of the Phe(97) and Phe(98) residues located in the third transmembrane helix and Asn(285) and Asp(289) of the seventh transmembrane helix in ligand binding and activation of the human PAF receptor in transiently transfected COS-7 cells. The double mutant FFGG (Phe(97) and Phe(98) mutated into Gly residues) showed a 3-4-fold decrease in affinity for PAF, but not for the specific antagonist WEB2086, when compared with the wild-type (WT) receptor. The FFGG mutant receptor, however, displayed normal agonist activation, suggesting that these two adjacent Phe residues maintain the native PAF receptor conformation rather than interacting with the ligand. On the other hand, substitution of Ala for Asp(289) increased the receptor affinity for PAF but abolished PAF-dependent inositol phosphate accumulation; it did not affect WEB2086 binding. Substitution of Asn for Asp(289), however, resulted in a mutant receptor with normal binding and activation characteristics. When Asn(285) was mutated to Ala, the resulting receptor was undistinguishable from the WT receptor. Surprisingly, substitution of Ile for Asn(285) led to a loss of ligand binding despite normal cell surface expression levels of this mutant, as verified by flow cytometric analysis. Our data suggest that residues 285 and 289 are determinant in the structure and activation of the PAF receptor but not in direct ligand binding, as had been recently proposed in a PAF receptor molecular model.	UNIV SHERBROOKE,FAC MED,DEPT PEDIAT,DIV IMMUNOL,SHERBROOKE,PQ J1H 5N4,CANADA; UNIV SHERBROOKE,FAC MED,DEPT PHARMACOL,SHERBROOKE,PQ J1H 5N4,CANADA	University of Sherbrooke; University of Sherbrooke				Escher, Emanuel/0000-0001-6601-987X				ALI H, 1994, J BIOL CHEM, V269, P24557; BENVENISTE J, 1979, CR ACAD SCI D NAT, V289, P1037; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BITO H, 1994, EUR J BIOCHEM, V221, P211, DOI 10.1111/j.1432-1033.1994.tb18731.x; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BRAQUET P, 1987, PROSTAGLANDINS, V34, P143, DOI 10.1016/0090-6980(87)90190-0; CHASE PB, 1993, AM J RESP CELL MOL, V8, P240, DOI 10.1165/ajrcmb/8.3.240; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; FRANKLIN RA, 1993, J IMMUNOL, V151, P1802; FRANKLIN RA, 1995, BIOCHEM BIOPH RES CO, V209, P1111, DOI 10.1006/bbrc.1995.1612; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HWANG SB, 1990, J LIPID MEDIATOR, V2, P123; KAJIHARA A, 1994, J LIPID MEDIAT CELL, V9, P185; KUNZ D, 1992, J BIOL CHEM, V267, P9101; KURUVILLA A, 1993, J IMMUNOL, V151, P637; LIU B, 1994, J BIOCHEM-TOKYO, V116, P882, DOI 10.1093/oxfordjournals.jbchem.a124611; MARTIN TFJ, 1983, J BIOL CHEM, V258, P4816; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; Parent JL, 1996, J BIOL CHEM, V271, P7949, DOI 10.1074/jbc.271.14.7949; Parent JL, 1996, BIOCHEM BIOPH RES CO, V219, P968, DOI 10.1006/bbrc.1996.0341; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; RODRIGUEZ CG, 1995, J BIOL CHEM, V270, P25178, DOI 10.1074/jbc.270.42.25178; SAWYER DB, 1989, BIOCHIM BIOPHYS ACTA, V987, P129, DOI 10.1016/0005-2736(89)90464-1; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; SUGIMOTO T, 1992, BIOCHEM BIOPH RES CO, V189, P617, DOI 10.1016/0006-291X(92)92245-S; SVARESE T, 1992, BIOCHEM J, V283, P1; TAKANO T, 1994, J BIOL CHEM, V269, P22453; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6; ZHOU W, 1994, MOL PHARMACOL, V45, P165	35	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23298	23303		10.1074/jbc.271.38.23298	http://dx.doi.org/10.1074/jbc.271.38.23298			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798529	hybrid			2022-12-27	WOS:A1996VH76800055
J	Takatsuji, H; Matsumoto, T				Takatsuji, H; Matsumoto, T			Target sequence recognition by separate type Cys(2)/His(2) zinc finger proteins in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIIA; DNA-BINDING; CRYSTAL-STRUCTURE; ARABIDOPSIS; DOMAINS; FAMILY; SPECIFICITY; RECEPTORS; ELEMENTS; SUPERMAN	The EPF family is a group of transcription factors containing canonical Cys(2)/His(2)-type zinc finger motifs that were first discovered in plants. These zinc finger proteins are characterized by two zinc fingers that are separated by spacers of various lengths, which are much longer than typical spacers (HC-link) in cluster-type zinc finger proteins. We describe here direct evidence that the two zinc fingers make contact with two tandemly repeated AGT core sequences that are separated by about 13 base pairs, by contrast to the cluster-type zinc finger proteins that bind to contiguous triplet sequences. DNA binding affinities were sensitive to the spaces between the core sequences, and the sensitivity to the spacing was greatly affected by the DNA sequence between the core sequences, with GC-rich sequences endowing much higher specificity than AT-rich sequences. Among the members of the EPF family, EPF1 was less sensitive to the spacing than EPF2-5. These results suggest that EPFs recognize their cognate target DNAs not only by the sequence of the core sites but also by the spacing between the core sites and, moreover, that different members in the EPF family distinguish their specific target genes by reference to these two parameters. This represents a unique type of target-sequence recognition among Cys(2)/His(2)-type zinc finger transcription factors. In addition, site-directed mutagenesis studies demonstrated that the two zinc fingers contribute synergistically to the binding to DNA, indicating that both fingers are necessary for the high affinity DNA binding.	NATL INST AGROBIOL RESOURCES,LAB PROT ENGN,TSUKUBA,IBARAKI 305,JAPAN	National Institute of Agrobiological Sciences - Japan	Takatsuji, H (corresponding author), NATL INST AGROBIOL RESOURCES,DEV BIOL LAB,2-1-2 KANNONDAI,TSUKUBA,IBARAKI 305,JAPAN.							BOWMAN JL, 1992, DEVELOPMENT, V114, P599; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; FAIRALL L, 1992, J MOL BIOL, V226, P349, DOI 10.1016/0022-2836(92)90952-G; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAKASEKO Y, 1992, J MOL BIOL, V228, P619, DOI 10.1016/0022-2836(92)90845-B; NARDELLI J, 1992, NUCLEIC ACIDS RES, V20, P4137, DOI 10.1093/nar/20.16.4137; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SAKAI H, 1995, NATURE, V378, P199, DOI 10.1038/378199a0; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; TAGUE BW, 1995, PLANT MOL BIOL, V28, P267, DOI 10.1007/BF00020246; TAKATSUJI H, 1992, EMBO J, V11, P241, DOI 10.1002/j.1460-2075.1992.tb05047.x; TAKATSUJI H, 1994, PLANT CELL, V6, P947, DOI 10.1105/tpc.6.7.947; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y	24	51	62	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23368	23373		10.1074/jbc.271.38.23368	http://dx.doi.org/10.1074/jbc.271.38.23368			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798540	hybrid			2022-12-27	WOS:A1996VH76800066
J	Feron, O; Belhassen, L; Kobzik, L; Smith, TW; Kelly, RA; Michel, T				Feron, O; Belhassen, L; Kobzik, L; Smith, TW; Kelly, RA; Michel, T			Endothelial nitric oxide synthase targeting to caveolae - Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE; PALMITOYLATION; PARTICULATE; CULTURE	The endothelial isoform of nitric oxide synthase (eNOS) modulates cardiac myocyte function and is expressed in the particulate subcellular fraction. We have previously shown that eNOS is targeted to plasmalemmal caveolae in endothelial cells, Caveolae, specialized domains of the plasma membrane, may serve to sequester signaling proteins; a family of transmembrane proteins, the caveolins, form a key structural component of these microdomains, Caveolae in cardiac tissues contain the muscle-specific isoform caveolin-3, and caveolae in endothelial cells contain the widely expressed isoform caveolin-1, which shares limited sequence identity with caveolin-3. Our immunohistochemical analyses of rat cardiac muscle used isoform-specific caveolin antibodies to reveal prominent caveolin-3 staining in myocyte sarcolemmal membranes and at intercalated discs, whereas caveolin-1 staining was prominent in the vascular endothelium. Caveolin or eNOS antibodies were utilized to immunoprecipitate cardiac myocyte or cultured aortic endothelial cell lysates, which then were analyzed in immunoblots, In endothelial cells, we found that eNOS is quantitatively immunoprecipitated by antibodies to caveolin-1. In cardiac myocyte lysates, nearly all the eNOS is immunoprecipitated instead by antibodies to caveolin-3 and, conversely, eNOS antiserum immunoprecipitated primarily caveolin-3, These studies establish expression of eNOS in cardiac myocyte caveolae and document tissue-specific and quantitative associations of eNOS with caveolin, These findings may have important implications for the regulation of eNOS by caveolin isoforms and by other signaling proteins targeted to caveolae.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT RESP BIOL,BOSTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health			FERON, Olivier/AAM-6395-2020	FERON, Olivier/0000-0001-5360-0286	NHLBI NIH HHS [HL52320, HL46457] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046457, R29HL046457, P50HL052320] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; BERGER HJ, 1994, AM J PHYSIOL, V266, pH341, DOI 10.1152/ajpheart.1994.266.1.H341; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; KELLY RA, 1996, IN PRESS CIRC RES; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LISANTI MP, 1995, MOL MEMBR BIOL, V12, P121, DOI 10.3109/09687689509038506; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; ROBINSON LJ, 1995, P NATL ACAD SCI USA, V92, P11776, DOI 10.1073/pnas.92.25.11776; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SASE K, 1996, IN PRESS TRENDS CARD; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SHAUL PW, 1996, J BIOL CHEM, V271, P618; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255	26	580	595	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22810	22814		10.1074/jbc.271.37.22810	http://dx.doi.org/10.1074/jbc.271.37.22810			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798458	hybrid			2022-12-27	WOS:A1996VG67200077
J	Gaymard, F; Cerutti, M; Horeau, C; Lemaillet, G; Urbach, S; Ravallec, M; Devauchelle, G; Sentenac, H; Thibaud, JB				Gaymard, F; Cerutti, M; Horeau, C; Lemaillet, G; Urbach, S; Ravallec, M; Devauchelle, G; Sentenac, H; Thibaud, JB			The baculovirus/insect cell system as an alternative to Xenopus oocytes - First characterization of the AKT1 K+ channel from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; SACCHAROMYCES-CEREVISIAE; POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; ION CHANNELS; INSECT CELLS; GUARD-CELLS; VOLTAGE; PURIFICATION; CLONING	Two plant (Arabidopsis thaliana) K+ transport systems, KAT1 and AKT1, have been expressed in insect cells (Sf9 cell line) using recombinant baculoviruses. Microscopic observation after immunogold staining revealed that the expressed AKT1 and KAT1 polypeptides were mainly associated with internal membranes, but that a minute fraction was targeted to the cell membrane, KAT1 was known, from earlier electrophysiological characterization in Xenopus oocytes, to be an inwardly rectifying voltage-gated channel highly selective for K+, while similar experiments had failed to characterize AKT1. Insect cells expressing KAT1 displayed an exogenous inwardly rectifying K+ conductance reminiscent of that described previously in Xenopus oocytes expressing KAT1. Under similar conditions, cells expressing AKT1 showed a disturbed cell membrane electrical stability that precluded electrophysiological analysis. Use of a baculovirus transfer vector designed so as to decrease the expression level allowed the first electrophysiological characterization of AKT1. The baculovirus system can thus be used as an alternative method when expression in Xenopus oocytes is unsuccessful for electrophysiological characterization of the ion channel of interest. The plant AKT1 protein has been shown in this way to be an inwardly rectifying voltage gated channel highly selective for K+ ions and sensitive to cGMP.	INRA, LAB PATHOL COMPAREE, CNRS, URA 1184, F-30380 ST CHRISTOL LES ALES, FRANCE	Centre National de la Recherche Scientifique (CNRS); INRAE	Gaymard, F (corresponding author), ECOLE NATL SUPER AGRON MONTPELLIER, INRA, LAB BIOCHIM & PHYSIOL MOL PLANTES, CNRS, URA 2133, F-34060 MONTPELLIER 1, FRANCE.			Sentenac, Herve/0000-0003-3641-4822; THIBAUD, Jean-Baptiste/0000-0002-0824-6465				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Basset M, 1995, PLANT MOL BIOL, V29, P947, DOI 10.1007/BF00014968; BERTL A, 1995, P NATL ACAD SCI USA, V92, P2701, DOI 10.1073/pnas.92.7.2701; BROWN AM, 1993, ANNU REV BIOPH BIOM, V22, P173, DOI 10.1146/annurev.bb.22.060193.001133; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; CAO YW, 1995, PLANT PHYSIOL, V109, P1093, DOI 10.1104/pp.109.3.1093; DAVRINCHE C, 1993, BIOCHEM BIOPH RES CO, V195, P469, DOI 10.1006/bbrc.1993.2067; GARNIER L, 1995, J VIROL, V69, P4060, DOI 10.1128/JVI.69.7.4060-4068.1995; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEDRICH R, 1995, EUR BIOPHYS J, V24, P107, DOI 10.1007/BF00211406; HEUSTERSPREUTE M, 1985, GENE, V39, P299, DOI 10.1016/0378-1119(85)90327-0; HONORE E, 1992, EMBO J, V11, P2465, DOI 10.1002/j.1460-2075.1992.tb05311.x; HOSHI T, 1995, J GEN PHYSIOL, V105, P309, DOI 10.1085/jgp.105.3.309; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; Ketchum KA, 1996, FEBS LETT, V378, P19, DOI 10.1016/0014-5793(95)01417-9; KLAIBER K, 1990, NEURON, V5, P221, DOI 10.1016/0896-6273(90)90311-3; Kochian Y.G., 1988, ADV BOT RES, V15, P93; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagarde D, 1996, PLANT J, V9, P195, DOI 10.1046/j.1365-313X.1996.09020195.x; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LI WW, 1994, PLANT PHYSIOL, V106, P957, DOI 10.1104/pp.106.3.957; LUCKOW VA, 1988, VIROLOGY, V167, P56, DOI 10.1016/0042-6822(88)90054-2; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; Luttge U., 1989, Progress in Botany, V50, P51; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MINET M, 1992, PLANT J, V2, P417; MULLERROBER B, 1995, EMBO J, V14, P2409, DOI 10.1002/j.1460-2075.1995.tb07238.x; NAKAMURA RL, 1995, PLANT PHYSIOL, V109, P371, DOI 10.1104/pp.109.2.371; PAJOTAUGY E, 1995, J MOL ENDOCRINOL, V14, P51, DOI 10.1677/jme.0.0140051; SANTACRUZTOLOZA L, 1994, BIOCHEMISTRY-US, V33, P1295, DOI 10.1021/bi00172a002; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schertler G. F. X., 1992, CURR OPIN STRUC BIOL, V2, P534, DOI DOI 10.1016/0959-440X(92)90083-J; SCHROEDER JI, 1994, ANNU REV BIOPH BIOM, V23, P441, DOI 10.1146/annurev.bb.23.060194.002301; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; STAUFFER KA, 1991, J CELL BIOL, V115, P141, DOI 10.1083/jcb.115.1.141; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VERY AA, 1994, PFLUG ARCH EUR J PHY, V428, P422, DOI 10.1007/BF00724528; VERY AA, 1995, PLANT J, V7, P321, DOI 10.1046/j.1365-313X.1995.7020321.x; ZITTLAU KE, 1991, PFLUG ARCH EUR J PHY, V418, P190, DOI 10.1007/BF00370470	41	131	138	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22863	22870		10.1074/jbc.271.37.22863	http://dx.doi.org/10.1074/jbc.271.37.22863			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798465	Green Published, hybrid			2022-12-27	WOS:A1996VG67200084
J	Gibbs, E; Pan, ZQ; Niu, HW; Hurwitz, J				Gibbs, E; Pan, ZQ; Niu, HW; Hurwitz, J			Studies on the in vitro phosphorylation of HSSB-p34 and -p107 by cyclin-dependent kinases - Cyclin-substrate interactions dictate the efficiency of phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; DNA-BINDING PROTEIN; NUCLEOTIDE EXCISION-REPAIR; TRANSCRIPTION FACTOR E2F; CELL-CYCLE; RETINOBLASTOMA PROTEIN; COMPLEX-FORMATION; P107 PROTEIN; CDK2 KINASE; T-ANTIGEN	Cyclin-dependent kinases (Cdks) are required for cell cycle progression. Two potentially significant Cdk substrates in human cells are the human single-stranded binding protein (HSSB or RPA), which plays an essential role in DNA replication, repair, and recombination, and the tumor suppressor p107 which acts to negatively regulate cell growth. In this report we describe the in vitro phosphorylation of these two proteins by Cdks in an attempt to understand how cyclin-substrate interactions direct phosphorylation efficiencies. We show that cyclin A-Cdk2 efficiently phosphorylates the p34 subunit of HSSB (HSSB-p34) alone or as a part of the heterotrimeric complex. In contrast, cyclin E-Cdk2 that is active in phosphorylating histone H1, does not support the phosphorylation of the p34 subunit of HSSB. We provide evidence that this differential phosphorylation results from a specific interaction between HSSB-p34 and cyclin Abut not cyclin E. Thus the observed cell cycle-dependent phosphorylation of HSSB-p34 at the G(1) to S transition is most likely catalyzed by cyclin A-Cdk2 initiated by the direct interaction between cyclin A and the HSSB-p34 subunit. These studies are consistent with our previous observation that p107, which directly binds cyclin A, is efficiently phosphorylated by cyclin A-Cdk2 but not cyclin B-associated kinases. Here we further demonstrate that cyclin A only complexes with p107 in its unphosphorylated form. These data suggest a catalytic mechanism by which Cdk acts: substrate targeting by a cyclin-substrate interaction followed by dissociation of the Cdk upon phosphate incorporation allowing the Cdk to become available for the next cycle of phosphorylation.	MEM SLOAN KETTERING CANC CTR, GRAD PROGRAM MOL BIOL, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center					NIGMS NIH HHS [GM38559] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIN AA, 1994, J BIOL CHEM, V269, P7735; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P24203; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KATO J, 1993, GENE DEV, V7, P331; KENNY MK, 1990, J BIOL CHEM, V265, P769; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI L, 1995, MOL CELL BIOL, V15, P5396; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; LONGHESE MP, 1994, MOL CELL BIOL, V14, P7884, DOI 10.1128/MCB.14.12.7884; LUCHE RM, 1993, MOL CELL BIOL, V13, P5749, DOI 10.1128/MCB.13.9.5749; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; OCONNELL MJ, 1994, CURR OPIN CELL BIOL, V6, P867, DOI 10.1016/0955-0674(94)90058-2; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAN ZQ, 1993, J BIOL CHEM, V268, P20443; PAN ZQ, 1994, P NATL ACAD SCI USA, V91, P8343, DOI 10.1073/pnas.91.18.8343; PAN ZQ, 1993, J BIOL CHEM, V268, P20433; PAN ZQ, 1995, P NATL ACAD SCI USA, V92, P4636, DOI 10.1073/pnas.92.10.4636; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; UMBRICHT CB, 1993, J BIOL CHEM, V268, P6131; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	47	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22847	22854		10.1074/jbc.271.37.22847	http://dx.doi.org/10.1074/jbc.271.37.22847			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798463	hybrid			2022-12-27	WOS:A1996VG67200082
J	Sheu, FS; Mahoney, CW; Seki, K; Huang, KP				Sheu, FS; Mahoney, CW; Seki, K; Huang, KP			Nitric oxide modification of rat brain neurogranin affects its phosphorylation by protein kinase C and affinity for calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; BINDING DOMAIN; SUBSTRATE RC3; SUBCELLULAR-FRACTIONS; DEPENDENT TARGET; NMDA RECEPTORS; NEUROMODULIN; IDENTIFICATION; SITE; PEROXYNITRITE	Neurogranin (Ng) is a prominent protein kinase C (PKC) substrate which binds calmodulin (CaM) in the absence of Ca2+. Rat brain Ng contains four cysteine residues that were readily oxidized by nitric oxide (NO) donors, 1,1-diethyl-2-hydroxy-2-nitrosohydrazine (DEANO) and sodium nitroprusside, and by oxidants, H2O2 and o-iodosobenzoic acid, NO oxidation of Ng resulted in a conformational change detectable by increased electrophoretic mobility upon SDS-polyacrylamide gel electrophoresis. The NO-mediated mobility shift was reversed by treatment with dithiothreitol and was blocked by modification of Ng sulfhydryl groups with 4-vinylpyridine. Both the nonphosphorylated and PKC-phosphorylated Ng were susceptible to NO oxidation. Modification of Ng by DEANO was blocked by CaM in the absence of Ca2+; while in the presence of Ca2+, CaM did not protect Ng from oxidation by DEANO. CaM also failed to protect DEANO-mediated oxidation of PKC-phosphorylated Ng with or without Ca2+. Oxidation of Ng by the various oxidants apparently resulted in the formation of intramolecular disulfide bond(s) as judged by a reduction of apparent M(r) on SDS-polyacrylamide gel electrophoresis; this oxidized form, unlike the reduced form, did not bind to CaM-affinity column. The oxidized Ng was also a poorer substrate for PKC; both the reduced and oxidized forms had similar K-m values, but the V-max of the oxidized form was about one fourth of the reduced one. When comparing the rate of DEANO-mediated nitrosation of Ng with other sulfhydryl-containing compounds, it became evident that Ng ranked as one of the best NO accepters among those tested, including serum albumin, glutathione, and dithiothreitol. Ng present in the rat brain synaptosomal preparations was also oxidized by DEANO in a dose-dependent manner when analyzed by immunoblot with a polyclonal antibody against this protein. These results suggest that Ng is a likely target of NO and other oxidants and that oxidation/reduction may serve as a mechanism for controlling both the PKC phosphorylation and the CaM-binding affinity of this protein.	NICHHD, METAB REGULAT SECT, ENDOCRINOL & REPROD RES BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			SHEU, Fwu-Shan/G-6435-2011	SHEU, Fwu-Shan/0000-0002-2784-2529				ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; COGGINS PJ, 1989, J NEUROCHEM, V53, P1895, DOI 10.1111/j.1471-4159.1989.tb09259.x; COGGINS PJ, 1991, NEUROSCI RES COMMUN, V8, P49; COHEN RW, 1993, BRAIN RES, V627, P147, DOI 10.1016/0006-8993(93)90758-F; COLLEY PA, 1993, BRAIN RES REV, V18, P115, DOI 10.1016/0165-0173(93)90009-O; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CONN PJ, 1994, PROTEIN KINASE C, P199; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; DUNKLEY PR, 1988, BRAIN RES, V441, P59, DOI 10.1016/0006-8993(88)91383-2; FEELISCH M, 1991, J CARDIOVASC PHARM, V17, pS25, DOI 10.1097/00005344-199117003-00006; FEROROV NB, 1995, EUR J NEUROSCI, V7, P819; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GERENDASY DD, 1994, J BIOL CHEM, V269, P22420; GERENDASY DD, 1995, J BIOL CHEM, V270, P6741, DOI 10.1074/jbc.270.12.6741; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; HUANG KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P570, DOI 10.1006/abbi.1993.1463; HUANG KP, 1991, METHOD ENZYMOL, V200, P241; HUANG KP, 1986, J BIOL CHEM, V261, P4781; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; KIM DS, 1987, J BIOL CHEM, V262, P14250; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; KLANN E, 1992, J NEUROCHEM, V58, P1576, DOI 10.1111/j.1471-4159.1992.tb11382.x; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MARTZEN MR, 1995, J NEUROCHEM, V64, P92; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; MONCADA S, 1991, PHARMACOL REV, V43, P109; NOACK E, 1991, OXIDATIVE STRESS OXI, P445; PERKEL DJ, 1993, NEURON, V11, P817, DOI 10.1016/0896-6273(93)90111-4; RADI R, 1991, J BIOL CHEM, V266, P4244; RAMAKERS GMJ, 1995, J BIOL CHEM, V270, P13892, DOI 10.1074/jbc.270.23.13892; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; SATO T, 1995, J BIOL CHEM, V270, P10314, DOI 10.1074/jbc.270.17.10314; SLEMMON JR, 1994, BIOCHEMISTRY-US, V33, P5653, DOI 10.1021/bi00184a039; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; WATSON JB, 1994, MOL BRAIN RES, V27, P323, DOI 10.1016/0169-328X(94)90017-5; WATSON JB, 1990, J NEUROSCI RES, V26, P397, DOI 10.1002/jnr.490260402; WINTERBOURN CC, 1995, METHOD ENZYMOL, V251, P81, DOI 10.1016/0076-6879(95)51112-1	50	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22407	22413		10.1074/jbc.271.37.22407	http://dx.doi.org/10.1074/jbc.271.37.22407			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798403	hybrid			2022-12-27	WOS:A1996VG67200022
J	vandenBorn, J; Jann, K; Assmann, KJM; Lindahl, U; Berden, JHM				vandenBorn, J; Jann, K; Assmann, KJM; Lindahl, U; Berden, JHM			N-acetylated domains in heparan sulfates revealed by a monoclonal antibody against the Escherichia coli K5 capsular polysaccharide - Distribution of the cognate epitope in normal human kidney and transplant kidney with chronic vascular rejection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; SUBENDOTHELIAL EXTRACELLULAR-MATRIX; GLOMERULAR-BASEMENT-MEMBRANE; MOLECULAR-ORGANIZATION; PROTEIN INTERACTIONS; ENDOTHELIAL-CELLS; BINDING SEQUENCE; LYMPHOCYTES-T; PROTEOGLYCANS; CHAINS	The Escherichia coli K5 capsular polysaccharide has the same (GlcUA-->GlcNAc)(n) structure as the nonsulfated heparan sulfate/heparin precursor polysaccharide. A monoclonal antibody (mAb 865) against the K5 polysaccharide has been described (Peters, H., Jurs, M., Jann, B., Jann, K., Timmis, K. N., and Bitter-Sauermann, D. (1985) Infect. Immun. 50, 459-466). In this report, we demonstrate the binding of anti-K5 mAb 865 to N-acetylated sequences in heparan sulfates and heparan sulfate proteoglycans but not to heparin. This is shown by direct binding and fluid phase inhibition of mAb 865 in an enzyme-linked immunosorbent assay. In this system we found that the binding of the mAb decreased with increasing sulfate content of the polysaccharide. By testing chemically modified K5 and heparin polysaccharides, we found that each of the modifications that occur during heparan sulfate (HS) synthesis (N-sulfation, C-5 epimerization, and O-sulfation) prevents recognition by mAb 865. Samples of heparan sulfate from human aorta (HS-II) were selectively degraded so as to allow the separate isolation of N-sulfated and N-acetylated block structures. N-Sulfated oligosaccharides (obtained after N-deacetylation by hydrazinolysis followed by nitrous acid deamination at pH 3.9) were not recognized by mAb 865, in contrast to N-acetylated oligosaccharides (obtained after nitrous acid deamination at pH 1.5), although the reactivity was lower than for intact HS-II. Analysis of the latter's pH 1.5 deamination products by gel filtration indicated that a minimal size of 18 saccharide units was necessary for antibody binding. These results lead us to propose bivalent antibody-heparan sulfate interaction, in which both F(ab) domains of the mAb interact with their epitopes, both of which are present in a single large (greater than or equal to 18 saccharide units) N-acetylated domain and additionally with single epitopes present in two N-acetylated sequences (each < 18 saccharide units) bridged by a short N-sulfated domain. Immunohistochemistry with mAb 865 on cryostat sections of normal human kidney tissue, revealed its binding to most but not all renal basement membranes. However, all renal basement membranes contain heparan sulfate, as shown by a mAb against heparitinase-digested heparan sulfate stubs (mAb 3G10). This finding indicates that not all heparan sulfate chains present in basement membranes express the mAb 865 epitopes. Besides the normal distribution, mAb 865 staining was found in fibrotic and sclerotic lesions in vessels, interstitium, and mesangium in transplant kidneys with chronic vascular rejection. Occasionally, a decrease of staining was observed within tubulo-interstitium and glomeruli. These findings show that N-acetylated sequences in heparan sulfates can be demonstrated by anti-K5 mAb 865 in normal and diseased kidneys.	UNIV NIJMEGEN ST RADBOUD HOSP,DEPT PATHOL,NL-6500 HB NIJMEGEN,NETHERLANDS; MAX PLANCK INST IMMUNBIOL,D-79011 FREIBURG,GERMANY; UNIV UPPSALA,DEPT MED & PHYSIOL CHEM,S-75123 UPPSALA,SWEDEN	Radboud University Nijmegen; Max Planck Society; Uppsala University	vandenBorn, J (corresponding author), UNIV NIJMEGEN ST RADBOUD HOSP,DIV NEPHROL,POB 9101,NL-6500 HB NIJMEGEN,NETHERLANDS.		Berden, J.H.M./H-8009-2014					BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; DANISHEFSKY I., 1965, BIOCHIM BIOPHYS ACTA, V101, P37, DOI 10.1016/0926-6534(65)90028-X; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; GORDON PB, 1989, J CELL PHYSIOL, V140, P584, DOI 10.1002/jcp.1041400325; GROGGEL GC, 1990, AM J PHYSIOL, V258, pF259, DOI 10.1152/ajprenal.1990.258.2.F259; HAHNENBERGER R, 1993, GLYCOBIOLOGY, V3, P567, DOI 10.1093/glycob/3.6.567; HISCOCK DRR, 1995, BBA-GEN SUBJECTS, V1244, P104, DOI 10.1016/0304-4165(94)00206-D; IOZZO RV, 1989, J BIOL CHEM, V264, P2690; IVERIUS PH, 1971, BIOCHEM J, V124, P677, DOI 10.1042/bj1240677; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; KATO M, 1994, J BIOL CHEM, V269, P18881; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLEIN J, 1982, IMMUNOLOGY SCI SELF, P156; LIDER O, 1995, P NATL ACAD SCI USA, V92, P5037, DOI 10.1073/pnas.92.11.5037; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; LINDBLOM A, 1991, BIOCHEM J, V279, P821, DOI 10.1042/bj2790821; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, J BIOL CHEM, V269, P11208; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; MATZNER Y, 1985, J CLIN INVEST, V76, P1306, DOI 10.1172/JCI112104; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAPARSTEK Y, 1984, NATURE, V310, P241, DOI 10.1038/310241a0; OLDBERG A, 1980, BIOCHEMISTRY-US, V19, P5755, DOI 10.1021/bi00566a014; OOSTA GM, 1982, J BIOL CHEM, V257, P1249; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; PEJLER G, 1988, J BIOL CHEM, V263, P5197; PEJLER G, 1987, J BIOL CHEM, V262, P5036; PEJLER G, 1994, J BIOL CHEM, V269, P14451; PETERS H, 1985, INFECT IMMUN, V50, P459, DOI 10.1128/IAI.50.2.459-466.1985; SAVION N, 1984, J CELL PHYSIOL, V118, P169, DOI 10.1002/jcp.1041180209; SCHMIDT A, 1990, EUR J CELL BIOL, V52, P229; SCHMIDT A, 1992, EUR J CELL BIOL, V59, P322; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; SHARMA AK, 1993, KIDNEY INT, V44, P774, DOI 10.1038/ki.1993.312; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; THUNBERG L, 1982, J BIOL CHEM, V257, P278; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; VANDENBORN J, 1993, KIDNEY INT, V43, P454, DOI 10.1038/ki.1993.67; VANDENBORN J, 1995, DIABETOLOGIA, V38, P161, DOI 10.1007/s001250050266; VANDENHEUVEL LPWJ, 1989, BIOCHEM J, V264, P457, DOI 10.1042/bj2640457; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2	52	19	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22802	22809		10.1074/jbc.271.37.22802	http://dx.doi.org/10.1074/jbc.271.37.22802			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798457	Green Published, hybrid			2022-12-27	WOS:A1996VG67200076
J	Creemers, JWM; Usac, EF; Bright, NA; VandeLoo, JW; Jansen, E; VandeVen, WJM; Hutton, JC				Creemers, JWM; Usac, EF; Bright, NA; VandeLoo, JW; Jansen, E; VandeVen, WJM; Hutton, JC			Identification of a transferable sorting domain for the regulated pathway in the prohormone convertase PC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; PROPROTEIN PROCESSING ENZYME; SECRETORY PROTEINS; FURIN; CELLS; PRECURSOR; CLEAVAGE; PROTEASE; LOCALIZATION; PROPEPTIDE	The mammalian subtilisin-like endoproteases furin and PC2 catalyze similar reactions but in different parts of the cell: furin in the trans-Golgi network and PC2 in dense-core granules. To map targeting domains within PC2, chimeras were constructed of the pro-, catalytic, and middle domains of furin with the carboxyl-terminal domain of PC2 (F-S-P) or of the pro- and catalytic domains of furin with the middle and carboxyl-terminal domains of PC2 (F-N-P). Their behavior in stable transfected AtT-20 cells was compared to a furin mutant truncated after the middle domain (F-S), wild-type furin, and with wild-type PC2. F-S-P, F-N-P, and F-S were catalytically active and underwent post-translational proteolysis and N-glycosylation with similar kinetics to wild-type furin. The truncated furin mutant was not stored intracellularly, whereas both chimeras, like PC2, showed inh acellular retention and regulated release. Immunofluorescence and immune-electron microscopy showed the presence of the chimeras and PC2 in dense-cored secretory granules together with proopiomelanocortin immunoreactivity. PC2 was sorted more efficiently than F-S-P, and the inclusion of the middle domain (F-N-P) further enhanced intracellular retention. It is concluded that sorting of PC2 into the regulated pathway depends on its carboxyl terminus. The middle domain may provide additional sorting determinants or a conformational framework for expression of the sorting signal.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND; FLANDERS INTERUNIV INST BIOTECHNOL,B-3000 LOUVAIN,BELGIUM	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Creemers, JWM (corresponding author), CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,MOL ONCOL LAB,HERESTR 49,B-3000 LOUVAIN,BELGIUM.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAILYES EM, 1995, BIOCHEM J, V309, P587, DOI 10.1042/bj3090587; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHUNG KN, 1989, SCIENCE, V243, P192, DOI 10.1126/science.2911732; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; DESTROOPER B, 1995, BBA-PROTEIN STRUCT M, V1246, P185, DOI 10.1016/0167-4838(94)00194-L; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; GUEST PC, 1992, J BIOL CHEM, V267, P22401; HALBAN PA, 1994, BIOCHEM J, V299, P1; HASHIMOTO S, 1987, J CELL BIOL, V105, P1579, DOI 10.1083/jcb.105.4.1579; HATSUZAWA K, 1992, J BIOCHEM-TOKYO, V111, P296, DOI 10.1093/oxfordjournals.jbchem.a123753; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; KIZER JS, 1991, BIOCHEM BIOPH RES CO, V174, P586, DOI 10.1016/0006-291X(91)91457-N; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MAINS RE, 1995, MOL ENDOCRINOL, V9, P3, DOI 10.1210/me.9.1.3; MALIDE D, 1995, J HISTOCHEM CYTOCHEM, V43, P11, DOI 10.1177/43.1.7822759; MITRA A, 1994, J BIOL CHEM, V269, P19876; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOORE HPH, 1986, NATURE, V321, P443, DOI 10.1038/321443a0; MROZ EA, 1986, SCIENCE, V232, P871, DOI 10.1126/science.2422756; NAPIER RM, 1988, PLANTA, V176, P519, DOI 10.1007/BF00397659; OUIMET T, 1993, FEBS LETT, V330, P343, DOI 10.1016/0014-5793(93)80901-6; PARKINSON D, 1990, J BIOL CHEM, V265, P17101; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V32, P11586; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROEBROEK AJM, 1992, J BIOL CHEM, V267, P17208; SCHAFER W, 1995, EMBO J, V14, P242; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHENNAN KIJ, 1994, J BIOL CHEM, V269, P18646; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMIT AB, 1992, FEBS LETT, V312, P213, DOI 10.1016/0014-5793(92)80938-D; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STOLLER TJ, 1989, J CELL BIOL, V108, P1647, DOI 10.1083/jcb.108.5.1647; TOKUYASU KT, 1978, J ULTRA MOL STRUCT R, V63, P287, DOI 10.1016/S0022-5320(78)80053-7; TOOZE SA, 1994, BIOCHIMIE, V76, P271, DOI 10.1016/0300-9084(94)90157-0; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VANDEVEN WJM, 1993, CRIT REV ONCOGENESIS, V4, P115; VANDUIJNHOVEN HLP, 1992, HYBRIDOMA, V11, P71, DOI 10.1089/hyb.1992.11.71; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509; ZHOU Y, 1995, J BIOL CHEM, V270, P24702, DOI 10.1074/jbc.270.42.24702; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641; [No title captured]	55	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25284	25291		10.1074/jbc.271.41.25284	http://dx.doi.org/10.1074/jbc.271.41.25284			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810291	hybrid			2022-12-27	WOS:A1996VL69300035
J	Puppe, W; Zimmann, P; Jung, K; Lucassen, M; Altendorf, K				Puppe, W; Zimmann, P; Jung, K; Lucassen, M; Altendorf, K			Characterization of truncated forms of the KdpD protein, the sensor kinase of the K+-translocating Kdp system of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM-TRANSPORT; SIGNAL TRANSDUCTION; CONTROL EXPRESSION; OPERON EXPRESSION; ATPASE; PHOSPHORYLATION; REGULATOR; AUTOPHOSPHORYLATION; OSMOREGULATION; IDENTIFICATION	The expression of the kdpFABC operon, coding for the K+-translocating Kdp system, is controlled by the two regulatory proteins, KdpD and KdpE, which belong to the group of sensor kinase/response regulator systems. This study describes the construction and analysis of KdpD sensor kinases, in which different deletions in the N-terminal part of the protein were introduced. Truncated KdpD proteins, in which the membrane-spanning segments were deleted, had lost their phosphorylation capacity. Truncated KdpD proteins, in which the four membrane-spanning helices were untouched, were still phosphorylated, and the phosphoryl group could be transferred to the response regulator KdpE in vitro. Furthermore, these truncated KdpD proteins cause dephosphorylation of KdpE(P), which is comparable with that of the wild-type protein. To investigate the effect of the deletions on signal transduction in vivo the corresponding kdp genes were transferred to the chromosome, Growth studies with the mutant strains are in accord with the data obtained from the in vitro studies. Furthermore, kdp expression was investigated using a KdpA-LacZ fusion. The data obtained support the notion that the extent of hdp expression is modulated by the N-terminal part of KdpD.	UNIV OSNABRUCK, FACHBEREICH BIOL CHEM, D-49069 OSNABRUCK, GERMANY	University Osnabruck			Lucassen, Magnus/ABA-8396-2021; Lucassen, Magnus/E-8433-2011	Lucassen, Magnus/0000-0003-4276-4781; Lucassen, Magnus/0000-0003-4276-4781				ALTENDORF K, 1994, RES MICROBIOL, V145, P374, DOI 10.1016/0923-2508(94)90084-1; ALTENDORF K, 1992, ANN NY ACAD SCI, V671, P228, DOI 10.1111/j.1749-6632.1992.tb43799.x; ARBER W, 1960, VIROLOGY, V11, P273, DOI 10.1016/0042-6822(60)90066-0; ASHA H, 1993, J BACTERIOL, V175, P4528, DOI 10.1128/JB.175.14.4528-4537.1993; Ausubel FM, 1991, CURRENT PROTOCOLS MO; BAKKER EP, 1993, ALKALI CATION TRANSP, P00205; BOSSEMEYER D, 1989, J BACTERIOL, V171, P2219, DOI 10.1128/jb.171.4.2219-2221.1989; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; DOSCH DC, 1991, J BACTERIOL, V173, P687, DOI 10.1128/jb.173.2.687-696.1991; EPSTEIN W, 1986, FEMS MICROBIOL LETT, V39, P73; EPSTEIN W, 1992, ACTA PHYSIOL SCAND, V146, P193; EPSTEIN W, 1985, CURR TOP MEMBR TRANS, V23, P153; Epstein W, 1970, J BACTERIOL, V101, P836, DOI 10.1128/JB.101.3.836-843.1970; GUTTERSON NI, 1983, P NATL ACAD SCI-BIOL, V80, P4894, DOI 10.1073/pnas.80.16.4894; HAARDT M, 1993, THESIS U KONSTANZ; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HENGGEARONIS R, 1993, J BACTERIOL, V175, P259, DOI 10.1128/JB.175.1.259-265.1993; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; LAIMINS LA, 1978, P NATL ACAD SCI USA, V75, P3216, DOI 10.1073/pnas.75.7.3216; LAIMINS LA, 1981, P NATL ACAD SCI-BIOL, V78, P464, DOI 10.1073/pnas.78.1.464; LOIS AF, 1993, J BIOL CHEM, V268, P4370; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; Miller J. H, 1972, EXPT MOL GENETICS; NAKASHIMA K, 1993, MOL MICROBIOL, V7, P109, DOI 10.1111/j.1365-2958.1993.tb01102.x; NAKASHIMA K, 1992, MOL MICROBIOL, V6, P1777, DOI 10.1111/j.1365-2958.1992.tb01350.x; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NINFA EG, 1993, J BACTERIOL, V175, P7024, DOI 10.1128/jb.175.21.7024-7032.1993; Parkinson J.S., 1995, 2 COMPONENT SIGNAL T, P9; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; POLAREK JW, 1988, METHOD ENZYMOL, V157, P655; POLAREK JW, 1992, J BACTERIOL, V174, P2145, DOI 10.1128/JB.174.7.2145-2151.1992; PUPPE W, 1992, MOL MICROBIOL, V6, P3511, DOI 10.1111/j.1365-2958.1992.tb01786.x; RHOADS DB, 1976, J GEN PHYSIOL, V67, P325, DOI 10.1085/jgp.67.3.325; ROBERTS DL, 1994, J BIOL CHEM, V269, P8728; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEBERS A, 1988, EUR J BIOCHEM, V178, P131, DOI 10.1111/j.1432-1033.1988.tb14438.x; SIEBERS A, 1993, ALKALI CATION TRANSP, P225; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; STUMPE S, 1996, HDB BIOL PHYS, V2, P473; SUGIURA A, 1994, MOL MICROBIOL, V14, P929, DOI 10.1111/j.1365-2958.1994.tb01328.x; VOELKNER P, 1993, EUR J BIOCHEM, V217, P1019, DOI 10.1111/j.1432-1033.1993.tb18333.x; WALDERHAUG MO, 1992, J BACTERIOL, V174, P2152, DOI 10.1128/JB.174.7.2152-2159.1992; WEBER K, 1969, J BIOL CHEM, V244, P4406; ZIMMANN P, 1995, J BIOL CHEM, V270, P28282	46	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					25027	25034		10.1074/jbc.271.40.25027	http://dx.doi.org/10.1074/jbc.271.40.25027			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798785	hybrid			2022-12-27	WOS:A1996VM67400108
J	Filatov, D; Bjorklund, S; Johansson, E; Thelander, L				Filatov, D; Bjorklund, S; Johansson, E; Thelander, L			Induction of the mouse ribonucleotide reductase R1 and R2 genes in response to DNA damage by UV light	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE-SPECIFIC EXPRESSION; EXCISION-REPAIR; PROMOTER; HYDROXYUREA; SUBUNIT; BINDING; CELLS; ELEMENT; BREAKS; ACID	Ribonucleotide reductase is responsible for the production of deoxyribonucleotides required for DNA synthesis and consists of two nonidentical subunits, proteins R1 and R2. Here we show that the R1 promoter can be induced up to 3-fold, and the R2 promoter is induced up to 10-fold by UV light in a dose-dependent manner. This was demonstrated using serum-starved, synchronized G(0)/G(1) mouse fibroblast 3T3 cells stably transformed with different R1 and R2 promoter-luciferase reporter gene constructs, R2 promoter activation requires a minimal promoter, containing a TTTAAA element plus the transcription start, and either three upstream DNA-protein binding regions or one proximal, NF-Y binding region. This is different from proliferation-specific activation of the R2 promoter. Using Northern blotting we show a preferential accumulation of the minor, 1.6-kilobase R2 transcript in irradiated cells, whereas the levels of the major 2.1-kilobase transcript are unchanged. No R2 promoter activation was observed after treatment of mouse cells with agents reported to induce the ribonucleotide reductase genes in Saccharomyces cerevisiae such as hydroxyurea or methylmethane sulfonate. This indicates that activation of ribonucleotide reductase gene expression is specific for nucleotide excision repair in mammalian cells and not part of a general response to DNA damage.	UMEA UNIV,DEPT MED BIOCHEM & BIOPHYS,S-90187 UMEA,SWEDEN	Umea University				Johansson, Erik/0000-0002-8526-6224				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BJORKLUND S, 1992, EMBO J, V11, P4953, DOI 10.1002/j.1460-2075.1992.tb05602.x; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; BJORKLUND S, 1993, P NATL ACAD SCI USA, V90, P11322, DOI 10.1073/pnas.90.23.11322; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARAS IW, 1985, J BIOL CHEM, V260, P7015; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ELLEDGE SJ, 1989, MOL CELL BIOL, V9, P4932, DOI 10.1128/MCB.9.11.4932; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; ERIXON K, 1979, MUTAT RES, V59, P257, DOI 10.1016/0027-5107(79)90164-7; FILATOV D, 1995, J BIOL CHEM, V270, P25239, DOI 10.1074/jbc.270.42.25239; FRIEDBERG EC, 1995, DNA REPAIR; HOLMBERG M, 1989, MUTAT RES, V218, P33, DOI 10.1016/0921-8777(89)90044-X; HURTA RAR, 1992, J BIOL CHEM, V267, P7066; JOHANSSON E, 1995, J BIOL CHEM, V270, P30162, DOI 10.1074/jbc.270.50.30162; KUSEWITT DF, 1991, MUTAT RES, V255, P1, DOI 10.1016/0921-8777(91)90012-E; LASSMANN G, 1992, BIOCHEM BIOPH RES CO, V188, P879, DOI 10.1016/0006-291X(92)91138-G; MANN GJ, 1988, CANCER RES, V48, P5151; NYHOLM S, 1993, BIOCHEMISTRY-US, V32, P11569, DOI 10.1021/bi00094a013; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; ROSEN CF, 1992, AM J PHYSIOL, V263, pC1103, DOI 10.1152/ajpcell.1992.263.5.C1103; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; Sambrook J., 2002, MOL CLONING LAB MANU; SLAMENOVA D, 1990, MUTAT RES, V242, P127, DOI 10.1016/0165-1218(90)90038-4; SNYDER RD, 1984, MUTAT RES, V131, P163, DOI 10.1016/0167-8817(84)90057-9; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; THELANDER L, 1994, MET IONS BIOL SYST, V30, P109; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; THELANDER M, 1989, EMBO J, V8, P2475, DOI 10.1002/j.1460-2075.1989.tb08383.x; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; YEW FFH, 1979, BIOCHIM BIOPHYS ACTA, V562, P240, DOI 10.1016/0005-2787(79)90170-9	33	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23698	23704		10.1074/jbc.271.39.23698	http://dx.doi.org/10.1074/jbc.271.39.23698			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798592	hybrid			2022-12-27	WOS:A1996VJ44200021
J	Kuwayama, H; VanHaastert, PJM				Kuwayama, H; VanHaastert, PJM			Regulation of guanylyl cyclase by a cGMP-binding protein during chemotaxis in Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN PHOSPHORYLATION; CYCLIC-GMP; MYOSIN-II; MUTANTS; PHOSPHODIESTERASE; CYTOSKELETON; CLONING; CELLS	Chemoattractants transiently activate guanylyl cyclase in Dictyostelium discoideum cells. Mutant analysis demonstrates that the produced cGMP plays an essential role in chemotactic signal transduction, controlling the actomyosin-dependent motive force. Guanylyl cyclase activity is associated with the particulate fraction of a cell homogenate. The addition of the cytosol stimulates guanylyl cyclase activity, whereas the cytosol plus ATP/Mg2+ inhibits enzyme activity, We have analyzed the regulation of guanylyl cyclase in chemotactic mutants and present evidence that a cGMP-binding protein mediates both stimulation and ATP-dependent inhibition of guanylyl cyclase. Upon chromatography of cytosolic proteins, cGMP binding activity co-elutes with both guanylyl cyclase-stimulating and ATP-dependent-inhibiting activities. In addition, ATP-dependent inhibition of guanylyl cyclase activity is enhanced by the cGMP analogue 8-Br-cGMP, suggesting that a cGMP-binding protein regulates guanylyl cyclase activity, Mutant KI-4 has an aberrant cGMP binding activity with very low K-d and shows a very small chemoattractant-mediated cGMP response; the cytosol from this mutant does not stimulate guanylyl cyclase, In contrast to KI-4, the aberrant cGMP binding activity of mutant KI-7 has a very high K-d and chemoattractants induce a prolonged cGMP response. The cytosol of this mutant stimulates guanylyl cyclase activity, but ATP does not inhibit the enzyme. Thus, two previously isolated chemotactic mutants are defective in the activation and inhibition of guanylyl cyclase, respectively. The positive and negative regulation of guanylyl cyclase by its product cGMP may well explain how cells process the temporospatial information of chemotactic signals, which is necessary for sensing the direction of the chemoattractant.	UNIV GRONINGEN, DEPT BIOCHEM, NL-9747 AG GRONINGEN, NETHERLANDS	University of Groningen								BOMINAAR AA, 1993, EMBO J, V12, P2275, DOI 10.1002/j.1460-2075.1993.tb05881.x; COUKELL MB, 1986, DEV GENET, V6, P163; DELOZANNE A, 1985, P NATL ACAD SCI USA, V82, P6807, DOI 10.1073/pnas.82.20.6807; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; FORTE LR, 1995, FASEB J, V9, P643, DOI 10.1096/fasebj.9.8.7768356; JANSSENS PMW, 1989, J BIOL CHEM, V264, P4329; JANSSENS PMW, 1988, BIOCHEM BIOPH RES CO, V150, P405, DOI 10.1016/0006-291X(88)90535-9; KUCZMARSKI ER, 1980, P NATL ACAD SCI-BIOL, V77, P7292, DOI 10.1073/pnas.77.12.7292; Kuwayama H, 1996, SCIENCE, V271, P207, DOI 10.1126/science.271.5246.207; KUWAYAMA H, 1993, J CELL BIOL, V123, P1453, DOI 10.1083/jcb.123.6.1453; KUWAYAMA H, 1995, BBA-MOL CELL RES, V1268, P214, DOI 10.1016/0167-4889(95)00082-4; LIU G, 1993, J CELL SCI, V106, P591; LIU G, 1991, J CELL SCI, V98, P483; Mato J., 1977, DEV DIFFERENTIATION, P93; MATO JM, 1977, FEBS LETT, V79, P331, DOI 10.1016/0014-5793(77)80814-4; MATO JM, 1978, FEBS LETT, V90, P261, DOI 10.1016/0014-5793(78)80381-0; MATO JM, 1975, P NATL ACAD SCI USA, V72, P4991, DOI 10.1073/pnas.72.12.4991; PARISSENTI AM, 1989, J CELL SCI, V92, P291; PASTERNAK C, 1989, J CELL BIOL, V109, P203, DOI 10.1083/jcb.109.1.203; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; ROOS W, 1977, NATURE, V266, P259, DOI 10.1038/266259a0; ROSS FM, 1981, J GEN MICROBIOL, V127, P339; SCHOEN CD, 1992, THESIS U AMSTERDAM; SCHULKES CCGM, 1992, BIOCHIM BIOPHYS ACTA, V1135, P73, DOI 10.1016/0167-4889(92)90168-B; SPUDICH JA, 1989, CELL REGUL, V1, P1; TRUONG T, 1992, J BIOL CHEM, V267, P9767; VALKEMA R, 1992, BIOCHEM BIOPH RES CO, V186, P263, DOI 10.1016/S0006-291X(05)80802-2; VANHAASTERT PJM, 1982, MOL CELL ENDOCRINOL, V25, P171, DOI 10.1016/0303-7207(82)90050-8; VANHAASTERT PJM, 1982, J CELL BIOL, V94, P271, DOI 10.1083/jcb.94.2.271; VANHAASTERT PJM, 1982, FEBS LETT, V147, P149, DOI 10.1016/0014-5793(82)81029-6; VANHAASTERT PJM, 1983, J CELL BIOL, V96, P347, DOI 10.1083/jcb.96.2.347; VANHAASTERT PJM, 1993, SENSORY TRANSDUCTION, P359; YUMURA S, 1992, J CELL BIOL, V117, P1231, DOI 10.1083/jcb.117.6.1231	36	21	21	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23718	23724		10.1074/jbc.271.39.23718	http://dx.doi.org/10.1074/jbc.271.39.23718			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798595	Green Published, hybrid			2022-12-27	WOS:A1996VJ44200024
J	Neufer, PD; Benjamin, IJ				Neufer, PD; Benjamin, IJ			Differential expression of alpha B-crystallin and Hsp27 in skeletal muscle during continuous contractile activity - Relationship to myogenic regulatory factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; STRESS PROTEINS; LENS CRYSTALLINS; MESSENGER-RNA; GENE; MOUSE; RAT; INDUCTION; CELLS; IDENTIFICATION	alpha B-crystallin (alpha BC) is a major structural protein (22 kDa) of the ocular lens as well as a bona fide heat shock protein in non-lens tissue. The alpha BC gene is abundantly expressed in tissues with high oxidative capacity, including the heart and type I skeletal muscle fibers, and is regulated by the MyoD family of basic helix-loop-helix transcription factors during myogenesis. To test the hypothesis that alpha BC expression may be directly regulated by the demand for oxidative metabolism, we examined the expression of alpha BC and the ancestral-related Hsp27 in rabbit tibialis anterior muscle subjected to continuous low frequency motor nerve stimulation (3 V, 10 Hz). alpha BC mRNA and protein increased within the 1st day of continuous contractile activity (5- and 2.5-fold, respectively) and achieved maximum levels (>20- and 4-fold, respectively) after 21 d of stimulation, Hsp27 mRNA and protein levels also increased with stimulation, but with a less specific and dramatic induction pattern. In agreement with the Northern analysis, in situ hybridization performed on cross sections from tibialis anterior muscle revealed progressively increasing alpha BC transcript signal, localized in a ringlet pattern, from 1 through 21 days of stimulation, Serial sections subjected to myosin immunohistochemistry revealed that alpha BC expression was confined to slow-twitch type I and a subpopulation of fast twitch type II fibers after 1 day but present in nearly all fibers after 21 days of stimulation. Transcript levels of all four myogenic regulatory factors (MyoD, myogenin, myf-5, and MRF4) also increased with stimulation in a pattern temporally similar with alpha BC, suggesting that expression of alpha BC in response to stimulation may, in part, be regulated through myogenic regulatory factor(s) interaction with the canonical E-box element located within the alpha BC promotor. These data demonstrate that expression of the small heat shock protein, alpha BC, is rapidly induced independent of the ancestrally related Hsp27 in a fiber type specific pattern in skeletal muscle subjected to the oxidative stress imposed by continuous contractile activity.	UNIV TEXAS,SW MED CTR,MOL CARDIOL RES LABS,DEPT INTERNAL MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007360, P50HL055988] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07360, P50-HL55988-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANNEX BH, 1991, AM J PHYSIOL, V260, pC266, DOI 10.1152/ajpcell.1991.260.2.C266; ATOMI Y, 1991, J BIOCHEM-TOKYO, V110, P812, DOI 10.1093/oxfordjournals.jbchem.a123665; ATOMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P1323, DOI 10.1016/0006-291X(91)92083-V; BENJAMIN IJ, 1992, J CLIN INVEST, V89, P1685, DOI 10.1172/JCI115768; BENNARDINI F, 1992, CIRC RES, V71, P288, DOI 10.1161/01.RES.71.2.288; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; CADEFAU JA, 1993, PFLUG ARCH EUR J PHY, V424, P529, DOI 10.1007/BF00374918; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DUBIN RA, 1991, MOL CELL BIOL, V11, P4340, DOI 10.1128/MCB.11.9.4340; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; EISENBERG BR, 1981, CELL TISSUE RES, V220, P449, DOI 10.1007/BF00216750; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GOEBEL HH, 1995, MUSCLE NERVE, V18, P1306, DOI 10.1002/mus.880181114; GOPALSRIVASTAVA R, 1993, MOL CELL BIOL, V13, P7144, DOI 10.1128/MCB.13.11.7144; HAMALAINEN N, 1993, J HISTOCHEM CYTOCHEM, V41, P733, DOI 10.1177/41.5.8468455; HEAD MW, 1994, J CELL PHYSIOL, V159, P41, DOI 10.1002/jcp.1041590107; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; INAGUMA Y, 1992, BIOCHEM BIOPH RES CO, V182, P844, DOI 10.1016/0006-291X(92)91809-5; INAGUMA Y, 1993, J BIOCHEM-TOKYO, V114, P378, DOI 10.1093/oxfordjournals.jbchem.a124184; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1993, ACTA NEUROPATHOL, V85, P475; IWAKI T, 1990, J HISTOCHEM CYTOCHEM, V38, P31, DOI 10.1177/38.1.2294148; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; KATO K, 1993, J BIOCHEM-TOKYO, V114, P640, DOI 10.1093/oxfordjournals.jbchem.a124230; KATO K, 1992, J BIOL CHEM, V267, P7718; KIM K, 1995, BIOCHEM J, V306, P353, DOI 10.1042/bj3060353; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KRAUS WE, 1989, AM J PHYSIOL, V256, pC506, DOI 10.1152/ajpcell.1989.256.3.C506; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LOCKE M, 1990, AM J PHYSIOL, V258, pC723, DOI 10.1152/ajpcell.1990.258.4.C723; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; NEUFER PD, 1996, IN PRESS AM J PHYSL; ORNATSKY OI, 1995, BIOCHEM J, V311, P119, DOI 10.1042/bj3110119; PETTE D, 1992, REV PHYSIOL BIOCH P, V120, P115, DOI 10.1007/BFb0036123; PIATIGORSKY J, 1994, EXS, V71, P241; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PIATIGORSKY J, 1992, J BIOL CHEM, V267, P4277; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; WILLIAMS RS, 1993, HDB PHYSL, P1124; WISTOW G, 1993, TRENDS BIOCHEM SCI, V18, P301, DOI 10.1016/0968-0004(93)90041-K; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936; ZHANG W, 1995, GENE DEV, V9, P1388, DOI 10.1101/gad.9.11.1388	49	93	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24089	24095		10.1074/jbc.271.39.24089	http://dx.doi.org/10.1074/jbc.271.39.24089			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798647	hybrid			2022-12-27	WOS:A1996VJ44200076
J	Rehrauer, WM; Lavery, PE; Palmer, EL; Singh, RN; Kowalczykowski, SC				Rehrauer, WM; Lavery, PE; Palmer, EL; Singh, RN; Kowalczykowski, SC			Interaction of Escherichia coli RecA protein with LexA repressor .1. LexA repressor cleavage is competitive with binding of a secondary DNA molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; PHAGE-LAMBDA-REPRESSOR; HOMOLOGOUS RECOMBINATION; SOS INDUCTION; NUCLEOSIDE TRIPHOSPHATE; DEPENDENT PROTEOLYSIS; ENZYMATIC-PROPERTIES; DIRECTED CLEAVAGE; STABLE COMPLEXES; ATP HYDROLYSIS	Essential to the two distinct cellular events of genetic recombination and SOS induction in Escherichia coli, RecA protein promotes the homologous pairing and exchange of DNA strands and the proteolytic cleavage of the LexA repressor, respectively, Since both of these activities require single-stranded DNA (ssDNA) and ATP, the inter-relationship between these reactions was investigated and found to display many parallels, The extent of active complex formed between RecA protein and M13 ssDNA, as measured by both ATP hydrolysis and LexA proteolysis, is stimulated in a similar manner by either a reduction in magnesium ion concentration or the presence of single-stranded DNA binding (SSB) protein. However, unexpectedly, SSB protein inhibits both LexA proteolysis and ATP hydrolysis (in assays containing repressor) at concentrations of RecA protein that are substoichiometric to the ssDNA, arguing that LexA repressor affects the competition between RecA and SSB proteins for limited ssDNA binding sites. Additionally, attenuation of LexA repressor cleavage in the presence of double-stranded DNA or by an excess of ssDNA suggests that interaction of the RecA nucleoprotein filament with either LexA repressor or a secondary DNA molecule is mutually exclusive. The significance of these results is discussed in the context of both the regulation of inducible responses to DNA damage, and the competitive relationship between the processes of SOS induction and genetic recombination.	UNIV CALIF DAVIS,MICROBIOL SECT,DIV BIOL SCI,DAVIS,CA 95616; NORTHWESTERN UNIV,SCH MED,DEPT BIOL MOL,CHICAGO,IL 60611; UNIV CALIF DAVIS,SECT MOL & CELLULAR BIOL,DIV BIOL SCI,DAVIS,CA 95616	University of California System; University of California Davis; Northwestern University; University of California System; University of California Davis					NIAID NIH HHS [AI-18987] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018987] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAGDASARIAN M, 1986, P NATL ACAD SCI USA, V83, P5723, DOI 10.1073/pnas.83.15.5723; BAGDASARIAN M, 1992, MOL MICROBIOL, V6, P885, DOI 10.1111/j.1365-2958.1992.tb01539.x; BAILONE A, 1988, MOL GEN GENET, V214, P389, DOI 10.1007/BF00330471; BRANDSMA JA, 1982, GENE, V18, P77, DOI 10.1016/0378-1119(82)90058-0; BRYANT FR, 1985, P NATL ACAD SCI USA, V82, P297, DOI 10.1073/pnas.82.2.297; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P7799, DOI 10.1021/bi00372a003; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; CELERIER J, 1988, MECH CONSEQUENCES DN, P445; CHASE JW, 1984, J BIOL CHEM, V259, P805; CHAUDHURY AM, 1985, MOL GEN GENET, V201, P525, DOI 10.1007/BF00331350; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1982, J BIOL CHEM, V257, P8523; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; CRAIG NL, 1980, NATURE, V283, P26, DOI 10.1038/283026a0; DICAPUA E, 1992, J MOL BIOL, V226, P707, DOI 10.1016/0022-2836(92)90627-V; DICAPUA E, 1990, J MOL BIOL, V214, P557, DOI 10.1016/0022-2836(90)90198-U; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; Harmon FG, 1996, J BIOL CHEM, V271, P23874, DOI 10.1074/jbc.271.39.23874; HEUSER J, 1989, J MOL BIOL, V210, P473, DOI 10.1016/0022-2836(89)90124-1; HIGASHITANI N, 1992, J BACTERIOL, V174, P1612, DOI 10.1128/jb.174.5.1612-1618.1992; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P5872, DOI 10.1021/bi00368a006; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; LAVERY PE, 1988, J MOL BIOL, V203, P861, DOI 10.1016/0022-2836(88)90112-X; LEBOWITZ J, 1985, THESIS J HOPKINS U B; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1991, BIOCHIMIE, V73, P411, DOI 10.1016/0300-9084(91)90108-D; LITTLE JW, 1980, P NATL ACAD SCI-BIOL, V77, P3225, DOI 10.1073/pnas.77.6.3225; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MENETSKI JP, 1992, J BIOL CHEM, V267, P10400; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1987, J BIOL CHEM, V262, P2085; MENETSKI JP, 1988, BIOCHEMISTRY-US, V27, P1205, DOI 10.1021/bi00404a021; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MEYER RR, 1982, MUTAT RES, V94, P299, DOI 10.1016/0027-5107(82)90293-7; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MOREAU PL, 1987, J MOL BIOL, V194, P621, DOI 10.1016/0022-2836(87)90239-7; MOREAU PL, 1989, J BIOL CHEM, V264, P2302; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; PHIZICKY EM, 1981, CELL, V25, P259, DOI 10.1016/0092-8674(81)90251-8; PHIZICKY EM, 1980, J MOL BIOL, V139, P319, DOI 10.1016/0022-2836(80)90133-3; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RESNICK J, 1982, P NATL ACAD SCI-BIOL, V79, P2832, DOI 10.1073/pnas.79.9.2832; ROBERTS JW, 1978, P NATL ACAD SCI USA, V75, P4714, DOI 10.1073/pnas.75.10.4714; ROMAN LJ, 1986, BIOCHEMISTRY-US, V25, P7375, DOI 10.1021/bi00371a020; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SCHNARR M, 1984, FEBS LETT, V171, P207, DOI 10.1016/0014-5793(84)80489-5; SCHNARR M, 1985, BIOCHEMISTRY-US, V24, P2812, DOI 10.1021/bi00332a032; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHINAGAWA H, 1988, P NATL ACAD SCI USA, V85, P1806, DOI 10.1073/pnas.85.6.1806; SOMMER S, 1993, MOL MICROBIOL, V10, P963, DOI 10.1111/j.1365-2958.1993.tb00968.x; Stasiak A, 1988, GENETIC RECOMBINATIO, P265; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; SWEASY JB, 1990, J BACTERIOL, V172, P3030, DOI 10.1128/jb.172.6.3030-3036.1990; TAKAHASHI M, 1986, FEBS LETT, V196, P215, DOI 10.1016/0014-5793(86)80249-6; TAKAHASHI M, 1989, EUR J BIOCHEM, V183, P617, DOI 10.1111/j.1432-1033.1989.tb21091.x; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P883; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P2100, DOI 10.1073/pnas.78.4.2100; WILLIAMS KR, 1984, J BIOL CHEM, V259, P1804; WITKIN EM, 1991, BIOCHIMIE, V73, P133, DOI 10.1016/0300-9084(91)90196-8; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976; YU X, 1993, J MOL BIOL, V231, P29, DOI 10.1006/jmbi.1993.1254	72	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23865	23873		10.1074/jbc.271.39.23865	http://dx.doi.org/10.1074/jbc.271.39.23865			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798617	hybrid			2022-12-27	WOS:A1996VJ44200046
J	Rother, RP; Zhao, J; Zhou, QS; Sims, PJ				Rother, RP; Zhao, J; Zhou, QS; Sims, PJ			Elimination of potential sites of glycosylation fails to abrogate complement regulatory function of cell surface CD59	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPESVIRUS SAIMIRI; INHIBITORY ACTIVITY; PROTEIN CD59; 2ND LIGAND; C9; C5B-8; EXPRESSION; BINDING; LYSIS; CD2	CD59 is a glycosylphosphatidylinositol-anchored membrane glycoprotein that serves as the principle cellular inhibitor of the C5b-9 membrane attack complex (MAC) of human complement, Approximately 50% of the total apparent mass of CD59 is attributable to glycosylation of a single Asn (Asn(18)), The deduced amino acid sequences of CD59 homologues identified in Old and New World primates as well as in rat reveal that the motif for N-linked glycosylation at the residue corresponding to Asn(18) of human CD59 is invariably conserved, despite considerable sequence divergence elsewhere in the protein, Such conservation suggests that the post translational modification at Asn(18) has importance for either expression or normal function of CD59 at the cell surface, In this study, we specifically examined how deletion or transposition of the site of N-linked glycosylation in the CD59 polypeptide affects its MAC inhibitory function. Our data demonstrate that the inhibitory potency of CD59 is unaffected when glycosylation is transposed from Asn(18) to another site in the polypeptide. Furthermore, we show that CD59 retains normal MAC regulatory function when mutated to eliminate all potential sites for N-linked glycosylation, These data suggest that the MAC inhibitory function of CD59 is entirely provided by residues exposed at the surface of the core polypeptide and that this core structure is not influenced by glycosylation at Asn(18).	BLOOD CTR SE WISCONSIN INC,MILWAUKEE,WI 53201; ALEXION PHARMACEUT INC,NEW HAVEN,CT 06511	Versiti Blood Center of Wisconsin					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036061] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL36061] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKAMI T, 1994, TRANSPL P, V26, P1256; ALBRECHT JC, 1992, VIROLOGY, V190, P527, DOI 10.1016/0042-6822(92)91247-R; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHENG KH, 1985, J IMMUNOL, V135, P459; DAVIES A, 1993, IMMUNOL RES, V12, P258, DOI 10.1007/BF02918257; DECKERT M, 1992, EUR J IMMUNOL, V22, P2943, DOI 10.1002/eji.1830221128; FLETCHER CM, 1994, STRUCTURE, V2, P185, DOI 10.1016/S0969-2126(00)00020-4; FLETCHER CM, 1993, PROTEIN SCI, V2, P2015, DOI 10.1002/pro.5560021203; FODOR WL, 1995, IMMUNOGENETICS, V41, P51, DOI 10.1007/BF00188435; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HAHN WC, 1992, SCIENCE, V256, P1805, DOI 10.1126/science.1377404; KIEFFER B, 1994, BIOCHEMISTRY-US, V33, P4471, DOI 10.1021/bi00181a006; MENU E, 1994, J IMMUNOL, V153, P2444; MERI S, 1990, IMMUNOLOGY, V71, P1; Nakano Yasuko, 1993, Molecular Immunology, V30, P37, DOI 10.1016/0161-5890(93)90307-W; NINOMIYA H, 1992, J BIOL CHEM, V267, P8404; OKADA H, 1989, BIOCHEM BIOPH RES CO, V162, P1553, DOI 10.1016/0006-291X(89)90852-8; Okada N, 1989, Int Immunol, V1, P205, DOI 10.1093/intimm/1.2.205; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; ROLLINS SA, 1991, J IMMUNOL, V146, P2345; ROTHER RP, 1994, J VIROL, V68, P730, DOI 10.1128/JVI.68.2.730-737.1994; RUSHMERE NK, 1994, BIOCHEM J, V304, P595, DOI 10.1042/bj3040595; SIMS PJ, 1984, BIOCHEMISTRY-US, V23, P3248, DOI 10.1021/bi00309a020; SUZUKI H, 1994, CLIN EXP IMMUNOL S2, V97, P46; ZHAO J, 1991, J BIOL CHEM, V266, P13418	26	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23842	23845		10.1074/jbc.271.39.23842	http://dx.doi.org/10.1074/jbc.271.39.23842			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798614	hybrid			2022-12-27	WOS:A1996VJ44200043
J	Xu, XF; Colombini, M				Xu, XF; Colombini, M			Self-catalyzed insertion of proteins into phospholipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; NEUROSPORA-CRASSA; YEAST MITOCHONDRIA; PRECURSOR PROTEINS; RECEPTOR COMPLEX; ION CHANNEL; IMPORT; TRANSLOCATION; PORIN; VDAC	We present evidence that the mitochondrial channel, VDAC, when reconstituted into a phospholipid membrane, can catalyze the insertion of other VDAC channels. This property called ''auto-directed insertion'' was first proposed by Ziti et al. (1995) to explain observations on asymmetric VDAC channels, We found that 2 M urea or guanidinium chloride (GdmCl) caused a burst of insertions of VDAC channels when added to the same side as VDAC addition. More strikingly, when added to the opposite side they caused a 10-60-fold sustained yet reversible increase in insertion rate. Protein stabilization by sarcosine eliminated the effect of urea and GdmCl on VDAC insertion, Control experiments showed that water flow, ionic strength, osmotic force, phospholipid type, and membrane potential were not involved. Therefore, although both urea and GdmCl affect the properties of phospholipid membranes, it is more likely that these agents act either by changing the structure of the pre-inserted channels, allowing them to be more effective catalysts for VDAC insertion, or by flowing through the channels and acting on nearby VDAC channels inducing them to insert, Either way, insertion must be occurring next to pre-inserted channels, Urea and GdmCl may mimic chaperones by partially unfolding VDAC and keeping it in an insertion-competent state, ''Auto-directed insertion'' may ensure both correct targeting and orientation of nascent proteins in vivo.	UNIV MARYLAND,DEPT ZOOL,CELL BIOL LAB,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park			Colombini, Marco/A-1540-2014					ANCHORDOGUY TJ, 1990, ARCH BIOCHEM BIOPHYS, V283, P356, DOI 10.1016/0003-9861(90)90654-H; ARAKAWA T, 1985, BIOPHYS J, V47, P411, DOI 10.1016/S0006-3495(85)83932-1; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; COLOMBINI M, 1987, METHOD ENZYMOL, V148, P465; COLOMBINI M, 1994, CURR TOP MEMBR, V42, P73, DOI 10.1016/S0070-2161(08)60819-9; COLOMBINI M, 1980, J MEMBRANE BIOL, V53, P79, DOI 10.1007/BF01870576; COLOMBINI M, 1987, BIOCHIM BIOPHYS ACTA, V905, P279, DOI 10.1016/0005-2736(87)90456-1; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; EILERS M, 1988, CELL, V52, P481, DOI 10.1016/0092-8674(88)90458-8; FREITAG H, 1983, METHOD ENZYMOL, V97, P286; GARTNER F, 1995, J BIOL CHEM, V270, P3788; GASSER SM, 1983, J BIOL CHEM, V258, P3427; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; HILLE B, 1992, IONIC CHANNELS EXCIT, P296; HINES V, 1993, J BIOL CHEM, V268, P449; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; MAKHATADZE GI, 1992, J MOL BIOL, V226, P491, DOI 10.1016/0022-2836(92)90963-K; MANNELLA CA, 1984, BIOCHIM BIOPHYS ACTA, V774, P206, DOI 10.1016/0005-2736(84)90293-1; MANNELLA CA, 1990, BIOPHYS J, V57, P23, DOI 10.1016/S0006-3495(90)82503-0; MANNELLA CA, 1982, J CELL BIOL, V94, P680, DOI 10.1083/jcb.94.3.680; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P8529, DOI 10.1021/bi00489a004; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; NARGANG FE, 1995, EMBO J, V14, P1099, DOI 10.1002/j.1460-2075.1995.tb07093.x; ORBACH E, 1980, J GEN PHYSIOL, V75, P427, DOI 10.1085/jgp.75.4.427; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1987, EMBO J, V6, P2635, DOI 10.1002/j.1460-2075.1987.tb02554.x; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFALLER R, 1985, J BIOL CHEM, V260, P8188; PFANNER N, 1988, J BIOL CHEM, V263, P4049; SANTORO MM, 1992, BIOCHEMISTRY-US, V31, P5278, DOI 10.1021/bi00138a006; SANYAL A, 1995, J BIOL CHEM, V270, P11970, DOI 10.1074/jbc.270.20.11970; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; SCHLOSSMANN J, 1994, J BIOL CHEM, V269, P11893; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; VERNER K, 1987, EMBO J, V6, P2449, DOI 10.1002/j.1460-2075.1987.tb02524.x; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; YEAGLE PL, 1986, BIOCHEMISTRY-US, V25, P7518, DOI 10.1021/bi00371a039; ZHAN HJ, 1994, BIOCHEMISTRY-US, V33, P11254, DOI 10.1021/bi00203a022; ZIZI M, 1995, J MEMBRANE BIOL, V144, P121	45	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23675	23682		10.1074/jbc.271.39.23675	http://dx.doi.org/10.1074/jbc.271.39.23675			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798589	hybrid			2022-12-27	WOS:A1996VJ44200018
J	Driscoll, JE; Seachord, CL; Lupisella, JA; Darveau, RP; Reczek, PR				Driscoll, JE; Seachord, CL; Lupisella, JA; Darveau, RP; Reczek, PR			Ligand-induced conformational changes in the human retinoic acid receptor gamma detected using monoclonal antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; BINDING DOMAIN; THYROID-HORMONE; CO-REPRESSOR; CRYSTAL-STRUCTURE; X-RECEPTORS; ALPHA; BETA; IMMUNODETECTION; PHOSPHORYLATION	The mechanism by which the naturally occurring ligand for a nuclear hormone receptor regulates transcription remains largely unknown, One approach combines the specificity of monoclonal antibodies, which recognize a three-dimensional epitope, with ligand binding. Using purified retinoic acid receptor gamma D and E domains, a panel of six unique monoclonal antibodies were isolated and characterized using solid-state receptor binding and retinoic acid receptor (RAR)-RXR heterodimer supershift formation. Three antibodies are specific for RAR gamma (mAbI, mAbII, and mAbV) and four recognize a three dimensional epitope (mAbI, mAbIV, mAbV, and mAbVI). Three antibodies (mAbIII, mAbV, and mAbVI) dissociate from the receptor in electrophoretic mobility shift assays upon the addition of retinoic acid. In particular, the binding characteristics of mAbIII, whose epitope was mapped to a region identified as an Omega-loop (amino acids 207-222), suggest a model for ligand binding to the receptor, In this model, ligand binding causes a positioning of helix 12 into a favorable conformation for interaction with the transcriptional machinery. The Omega-loop then closes in order to stabilize this "active" position. The results reported here also suggest that a region of the hinge or D domain of the receptor (amino acids 156-188), an area that can play a role in protein-protein interactions, may also be important in ligand-induced functional changes.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOL BIOL, BUFFALO, NY 14213 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT IMMUNOL, SEATTLE, WA 98121 USA	Bristol-Myers Squibb; Bristol-Myers Squibb				Lupisella, John/0000-0003-1343-6412				ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DE LUCA LM, 1991, FASEB J, V5, P2924; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GAUB MP, 1989, P NATL ACAD SCI USA, V86, P3089, DOI 10.1073/pnas.86.9.3089; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEID M, 1994, J BIOL CHEM, V269, P14175; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LUPISELLA JA, 1995, J BIOL CHEM, V270, P24884, DOI 10.1074/jbc.270.42.24884; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; OSTROWSKI J, 1995, P NATL ACAD SCI USA, V92, P1812, DOI 10.1073/pnas.92.6.1812; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; TAIRIS N, 1994, J BIOL CHEM, V269, P19516; TAM MR, 1982, INFECT IMMUN, V36, P1042, DOI 10.1128/IAI.36.3.1042-1053.1982; TATE BF, 1995, J BIOL CHEM, V270, P20258, DOI 10.1074/jbc.270.35.20258; TONEY JH, 1993, BIOCHEMISTRY-US, V32, P2, DOI 10.1021/bi00052a001; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x	35	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22969	22975		10.1074/jbc.271.38.22969	http://dx.doi.org/10.1074/jbc.271.38.22969			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798483	hybrid			2022-12-27	WOS:A1996VH76800009
J	Guillon, JM; Heiss, S; Soutourina, J; Mechulam, Y; Laalami, S; GrunbergManago, M; Blanquet, S				Guillon, JM; Heiss, S; Soutourina, J; Mechulam, Y; Laalami, S; GrunbergManago, M; Blanquet, S			Interplay of methionine tRNAs with translation elongation factor Tu and translation initiation factor 2 in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYLMETHIONINE TRANSFER-RNA; PROTEIN-SYNTHESIS; FACTOR-II; RIBOSOMAL-SUBUNIT; ANTICODON STEM; ACCEPTOR STEM; SEQUENCE; MUTANTS; GENE; INVIVO	According to their role in translation, tRNAs specifically interact either with elongation factor Tu (EFTu) or with initiation factor 2 (IF2). We here describe the effects of overproducing EFTu and IF2 on the elongator versus initiator activities of various mutant tRNA(Met) species in vivo, The data obtained indicate that the selection of a tRNA through one or the other pathway of translation depends on the relative amounts of the translational factors. A moderate overexpression of EFTu is enough to lead to a misappropriation of initiator tRNA in the elongation process, whereas overproduced IF2 allows the initiation of translation to occur with unformylated tRNA species. In addition, we report that a strain devoid of formylase activity can be cured by the overproduction of tRNA(f)(Met). The present study brings additional evidence for the importance of formylation in defining tRNA(f)(Met) initiator identity, as well as a possible explanation for the residual growth of bacterial strains lacking a functional formylase gene such as observed in Guillon, J. M., Mechulam, Y., Schmitter, J.-M., Blanquet, S., and Fayat, G. (1992) J. Bacteriol. 174, 4294-4301.	ECOLE POLYTECH,BIOCHIM LAB,CNRS,URA 1970,F-91128 PALAISEAU,FRANCE; INST BIOL PHYSICOCHIM,CNR,URA 1139,F-75005 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS)			Soutourina, Julie/F-8305-2014; Guillon, Jean-Michel/N-7892-2018; Mechulam, Yves/F-3313-2019	Soutourina, Julie/0000-0001-5218-2350; Guillon, Jean-Michel/0000-0002-0178-2521; Mechulam, Yves/0000-0003-3586-3554				Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527, DOI [10.1046/j.1365-2486.2000.06017.x, DOI 10.1046/J.1365-2486.2000.06017.X]; BREVET A, 1995, J BIOL CHEM, V270, P14439, DOI 10.1074/jbc.270.24.14439; CANONACO MA, 1986, FEBS LETT, V207, P198, DOI 10.1016/0014-5793(86)81488-0; CLARK BFC, 1966, J MOL BIOL, V17, P394, DOI 10.1016/S0022-2836(66)80150-X; EISENSTADT J, 1966, SCIENCE, V154, P524; GUALERZI CO, 1986, FEBS LETT, V202, P1, DOI 10.1016/0014-5793(86)80637-8; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; GUILLON JM, 1993, J BACTERIOL, V175, P4507, DOI 10.1128/JB.175.14.4507-4514.1993; GUILLON JM, 1992, J BACTERIOL, V174, P4294, DOI 10.1128/JB.174.13.4294-4301.1992; GUILLON JM, 1992, J MOL BIOL, V224, P359, DOI 10.1016/0022-2836(92)91000-F; HARTZ D, 1990, GENE DEV, V4, P1790, DOI 10.1101/gad.4.10.1790; HARVEY RJ, 1973, J BACTERIOL, V114, P309, DOI 10.1128/JB.114.1.309-322.1973; Hershey JW., 1987, ESCHERICHIA COLI SAL, P613; HOHN B, 1980, GENE, V11, P291, DOI 10.1016/0378-1119(80)90069-4; LAALAMI S, 1991, J MOL BIOL, V220, P335, DOI 10.1016/0022-2836(91)90017-Z; LEE CP, 1991, J BIOL CHEM, V266, P18012; MAJUMDAR A, 1976, J BIOL CHEM, V251, P137; MANGROO D, 1995, J BIOL CHEM, V270, P12203, DOI 10.1074/jbc.270.20.12203; MARCKER K, 1964, J MOL BIOL, V8, P835, DOI 10.1016/S0022-2836(64)80164-9; MECHULAM Y, 1985, J BACTERIOL, V164, P63, DOI 10.1128/JB.164.1.63-69.1985; MEINNEL T, 1993, J MOL BIOL, V229, P26, DOI 10.1006/jmbi.1993.1005; MEINNEL T, 1988, NUCLEIC ACIDS RES, V16, P8095, DOI 10.1093/nar/16.16.8095; MEINNEL T, 1991, P NATL ACAD SCI USA, V88, P291, DOI 10.1073/pnas.88.1.291; MEINNEL T, 1995, J BIOL CHEM, V270, P15908, DOI 10.1074/jbc.270.26.15908; Miller J.H., 1972, EXPT MOL GENETICS; MILLER JH, 1983, J MOL BIOL, V164, P59, DOI 10.1016/0022-2836(83)90087-6; MIYAJIMA A, 1980, FEBS LETT, V119, P215, DOI 10.1016/0014-5793(80)80255-9; PAK M, 1992, BIOCHEMISTRY-US, V31, P3303, DOI 10.1021/bi00128a001; PETERSEN HU, 1979, BIOCHEM BIOPH RES CO, V91, P1068, DOI 10.1016/0006-291X(79)91989-2; PETERSEN HU, 1981, FEBS LETT, V128, P161, DOI 10.1016/0014-5793(81)81105-2; PLUMBRIDGE JA, 1983, J MOL BIOL, V167, P227, DOI 10.1016/S0022-2836(83)80333-7; SCHULMAN LH, 1974, J BIOL CHEM, V249, P7102; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P8859, DOI 10.1073/pnas.84.24.8859; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P334, DOI 10.1073/pnas.84.2.334; SEONG BL, 1989, J BIOL CHEM, V246, P6504; SPRINGER M, 1989, EMBO J, V8, P2417, DOI 10.1002/j.1460-2075.1989.tb08372.x; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; SUNDARI RM, 1976, J BIOL CHEM, V251, P3338; VARSHNEY U, 1992, J BACTERIOL, V174, P7819, DOI 10.1128/JB.174.23.7819-7826.1992; VARSHNEY U, 1991, J BIOL CHEM, V266, P18018; VARSHNEY U, 1993, P NATL ACAD SCI USA, V90, P2305, DOI 10.1073/pnas.90.6.2305; WEIEL J, 1982, J BIOL CHEM, V257, P1215; WREDE P, 1979, P NATL ACAD SCI USA, V76, P3289, DOI 10.1073/pnas.76.7.3289	43	40	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22321	22325		10.1074/jbc.271.37.22321	http://dx.doi.org/10.1074/jbc.271.37.22321			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798391	hybrid			2022-12-27	WOS:A1996VG67200010
J	Miglarese, MR; Richardson, AF; Aziz, N; Bender, TP				Miglarese, MR; Richardson, AF; Aziz, N; Bender, TP			Differential regulation of c-Myb-induced transcription activation by a phosphorylation site in the negative regulatory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; NORMAL HUMAN-LYMPHOCYTES; CELL-CYCLE REGULATION; CASEIN KINASE-II; V-MYB; LEUCINE-ZIPPER; TYROSINE PHOSPHORYLATION; ERYTHROLEUKEMIA-CELLS; FUNCTIONAL DOMAINS; ONCOGENE PRODUCT	The c-myb protooncogene encodes a highly conserved 75-89-kDa transcription factor that contains three functional domains, an amino-terminal DNA binding domain (DBD), a central acidic transactivation domain, and a carboxyl-terminal negative regulatory domain (NRD), Two acute transforming retroviruses, avian myeloblastosis virus and the E26 leukemia virus, transduced portions of c-myb and encode Myb proteins that are truncated in both the DBD and the NRD, Several conserved potential sites for phosphorylation by proline-directed serine/threonine protein kinases reside in or near the NRD, suggesting that phosphorylation might play a role in regulating c-Myb. We have previously demonstrated that serine 528, located in the NRD, is a target for p42(mapk) in vitro. Serine 528 is phosphorylated in vivo in several cell lines, and substitution of serine 528 to alanine (S528A) resulted in an increased ability of Myb to transactivate a synthetic promoter containing five copies of the mim-1A Myb-responsive element and a minimal herpes th promoter, We have tested the ability of S528A Myb to transactivate a series of cellular target promoters and report that the serine to alanine substitution increased the ability of Myb to activate transcription from the CD34 promoter but not the c-myc or mim-1 promoters, This suggests that phosphorylation of serine 528 may differentially regulate c-Myb activity at different promoters, The DNA binding and multimerization activities of c-Myb appear to be unaffected by the 5528A substitution, suggesting that phosphorylation of serine 528 may mediate its effect on the transcription transactivating activity of c-Myb by regulating interactions with other proteins.	UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia				Aziz, Natasha/0000-0001-8195-1446	NCI NIH HHS [CA-09109, CA-40042] Funding Source: Medline; NIGMS NIH HHS [GM-07055] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; AZIZ N, 1993, ONCOGENE, V8, P2259; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BADING H, 1989, ONCOGENE, V4, P33; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BROWN KE, 1992, J BIOL CHEM, V267, P4625; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CATRON KM, 1992, J IMMUNOL, V148, P934; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CIVIN CI, 1990, EXP HEMATOL, V18, P461; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; ESS KC, 1995, MOL CELL BIOL, V15, P5707; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FAVIER D, 1994, ONCOGENE, V9, P305; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GRIFFIN CA, 1985, CANCER RES, V45, P272; GUERIN M, 1990, ONCOGENE, V5, P131; HE XY, 1994, BLOOD, V83, P1822, DOI 10.1182/blood.V83.7.1822.bloodjournal8371822; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA T, 1993, J BIOL CHEM, V268, P21914; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; OKUDA K, 1992, BLOOD, V79, P2880; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; PRESS RD, 1994, MOL CELL BIOL, V14, P2278, DOI 10.1128/MCB.14.4.2278; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TORELLI G, 1985, MOL CELL BIOL, V5, P2874, DOI 10.1128/MCB.5.10.2874; VANDENELSEN P, 1983, VIROLOGY, V128, P377; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	74	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22697	22705		10.1074/jbc.271.37.22697	http://dx.doi.org/10.1074/jbc.271.37.22697			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798443	hybrid			2022-12-27	WOS:A1996VG67200062
J	Palaniappan, C; Wisniewski, M; Wu, WM; Fay, PJ; Bambara, RA				Palaniappan, C; Wisniewski, M; Wu, WM; Fay, PJ; Bambara, RA			Misincorporation by HIV-1 reverse transcriptase promotes recombination via strand transfer synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MISPAIR EXTENSION KINETICS; RETROVIRAL SHUTTLE VECTOR; SITE-SPECIFIC MUTAGENESIS; SINGLE REPLICATION CYCLE; DNA POLYMERASE-ALPHA; GENETIC-VARIATION; CLEAVAGE SPECIFICITY; PHENOTYPIC SELECTION; ANGSTROM RESOLUTION	Genome heterogeneity in retroviruses derives from poor fidelity of the reverse transcriptase (RT) and recombination via RT-catalyzed strand transfer synthesis, RTs lack proofreading ability, and they proficiently extend primers with mismatched termini. Recombination reactions carried out in vitro are accompanied by a high frequency of base substitution errors, suggesting a relationship. Here we provide evidence that misincorporation during RNA-directed DNA synthesis promotes strand transfer recombination. Experiments involved measurement of DNA synthesis, RNase H-directed cleavage, and strand transfer synthesis from preformed mismatched primers on RNA templates by human immunodeficiency virus (HIV) RT in, vitro. A significant pause in synthesis occurred from a G(primer). rA(template) mismatch compared to the synthesis from a correctly paired (T . rA) primer. The misincorporation-induced pause allowed an unusually large area of RT-RNase H-directed cleavage of the template RNA beneath the primer. Strand transfer to an acceptor molecule with sequence identical to the template RNA was about 50% more efficient than if the primer had had a correctly paired terminus. Overall transfer was measured over a large region of homology. Assuming that enhanced transfer occurs primarily at the site of the mismatch, the actual increase in transfer at that site must have been 1-2 orders of magnitude. Inclusion of a different acceptor molecule with complete complementarity to the originally mismatched 3' primer terminus resulted in an additional 2-fold increase in strand transfer efficiency. Overall, these results suggest the mechanism by which misincorporation during minus strand DNA synthesis in retroviral replication would promote high frequency recombination.	UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester					NCI NIH HHS [CA 11198] Funding Source: Medline; NIGMS NIH HHS [GM 49573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKHANASHVILI M, 1993, FEBS LETT, V319, P201, DOI 10.1016/0014-5793(93)80067-5; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; Bebenek K, 1993, REVERSE TRANSCRIPTAS, P85; COFFIN JM, 1986, CELL, V46, P1, DOI 10.1016/0092-8674(86)90851-2; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DESTEFANO JJ, 1994, BBA-GENE STRUCT EXPR, V1219, P380, DOI 10.1016/0167-4781(94)90062-0; FRY M, 1992, P NATL ACAD SCI USA, V89, P763, DOI 10.1073/pnas.89.2.763; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; HU WS, 1993, REVERSE TRANSCRIPTAS, P251; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JI JP, 1994, VIROLOGY, V199, P323, DOI 10.1006/viro.1994.1130; JI JP, 1994, NUCLEIC ACIDS RES, V22, P47, DOI 10.1093/nar/22.1.47; KATZ RA, 1990, ANNU REV GENET, V24, P409, DOI 10.1146/annurev.ge.24.120190.002205; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; PALANIAPPAN C, 1995, J BIOL CHEM, V270, P4861, DOI 10.1074/jbc.270.9.4861; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6024, DOI 10.1073/pnas.87.16.6024; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P3890, DOI 10.1021/bi00179a014; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; PULSINELLI GA, 1994, P NATL ACAD SCI USA, V91, P9490, DOI 10.1073/pnas.91.20.9490; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; Sambrook J., 2002, MOL CLONING LAB MANU; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; Wu WM, 1996, NUCLEIC ACIDS RES, V24, P1710, DOI 10.1093/nar/24.9.1710; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; YU H, 1992, J BIOL CHEM, V267, P10888; ZINNEN S, 1994, J BIOL CHEM, V269, P24195	45	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22331	22338		10.1074/jbc.271.37.22331	http://dx.doi.org/10.1074/jbc.271.37.22331			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798393	hybrid			2022-12-27	WOS:A1996VG67200012
J	Gunz, D; Hess, MT; Naegeli, H				Gunz, D; Hess, MT; Naegeli, H			Recognition of DNA adducts by human nucleotide excision repair - Evidence for a thermodynamic probing mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; HUMAN CELL-EXTRACTS; XERODERMA-PIGMENTOSUM; DEOXYRIBONUCLEIC-ACID; MOLECULAR-DYNAMICS; 6-4 PHOTOPRODUCTS; ESCHERICHIA-COLI; MAMMALIAN-CELLS; UVRABC NUCLEASE; ABASIC SITES	The mechanism by which mammalian nucleotide excision repair (NER) detects a wide range of base lesions is poorly understood, Here, we tested the ability of human NER to recognize bulky modifications that either destabilize the DNA double helix (acetylaminofluorene (AAF) and benzo[a]pyrene diol-epoxide (BPDE) adducts, UV radiation products) or induce opposite effects by stabilizing the double helix (8-methoxypsoralen (8-MOP), anthramycin, and CC-1065 adducts). We constructed plasmid DNA carrying a defined number of each of these adducts and determined their potential to sequester NER factors contained in a human cell-free extract. For that purpose, we measured the capacity of damaged plasmids to compete with excision repair of a site-directed NER substrate. This novel approach showed differences of more than 3 orders of magnitude in the efficiency by which helix-destabilizing and helix-stabilizing adducts sequester NER factors. For example, AAF modifications were able to compete with the NER substrate similar to 1740 times more effectively than 8-MOP adducts, The sequestration potency decreased with the following order of adducts, AAF > UV greater than or equal to BPDE > 8-MOP > anthramycin, CC-1065. A strong preference for helix-destabilizing lesions was confirmed by monitoring the formation of NER patches at site specific adducts with either AAF or CC-1065. This comparison based on factor sequestration and repair synthesis indicates that human NER is primarily targeted to sites at which the secondary structure of DNA is destabilized. Thus, an early step of DNA damage recognition involves thermodynamic probing of the duplex.	UNIV ZURICH,TIERSPITAL,INST PHARMACOL & TOXICOL,CH-8057 ZURICH,SWITZERLAND	University of Zurich								ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BIGGERSTAFF M, 1991, MUTAT RES, V254, P217, DOI 10.1016/0921-8777(91)90059-X; BOLES TC, 1984, P NATL ACAD SCI-BIOL, V81, P5623, DOI 10.1073/pnas.81.18.5623; CADET J, 1992, J PHOTOCH PHOTOBIO B, V15, P277, DOI 10.1016/1011-1344(92)85135-H; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; COSMAN M, 1993, BIOCHEMISTRY-US, V32, P4145, DOI 10.1021/bi00067a001; DELOSSANTOS C, 1992, BIOCHEMISTRY-US, V31, P5245, DOI 10.1021/bi00138a002; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P283; GARCIA A, 1993, P NATL ACAD SCI USA, V90, P5989, DOI 10.1073/pnas.90.13.5989; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HANSSON J, 1989, J BIOL CHEM, V264, P21788; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HEARST JE, 1984, Q REV BIOPHYS, V17, P1, DOI 10.1017/S0033583500005242; Hess MT, 1996, NUCLEIC ACIDS RES, V24, P824, DOI 10.1093/nar/24.5.824; Hess MT, 1996, CHEM BIOL, V3, P121, DOI 10.1016/S1074-5521(96)90288-4; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P12213, DOI 10.1073/pnas.91.25.12213; HURLEY LH, 1984, PHARMACEUT RES, V1, P53; KALNIK MW, 1989, BIOCHEMISTRY-US, V28, P3373, DOI 10.1021/bi00434a037; KIM JK, 1995, EUR J BIOCHEM, V228, P849, DOI 10.1111/j.1432-1033.1995.0849m.x; KOHN KW, 1970, J MOL BIOL, V51, P551, DOI 10.1016/0022-2836(70)90008-2; KRUGH TR, 1989, BIOCHEMISTRY-US, V28, P9988, DOI 10.1021/bi00452a017; LEE CS, 1991, CHEM RES TOXICOL, V4, P203, DOI 10.1021/tx00020a013; LEE SH, 1995, J BIOL CHEM, V270, P21800, DOI 10.1074/jbc.270.37.21800; LI L, 1995, MOL CELL BIOL, V15, P5396; LIN JJ, 1992, MOL MICROBIOL, V6, P2219, DOI 10.1111/j.1365-2958.1992.tb01398.x; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MATSUMOTO Y, 1989, MOL CELL BIOL, V9, P3750, DOI 10.1128/MCB.9.9.3750; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NAZIMIEC M, 1992, J BIOL CHEM, V267, P24716; OHANDLEY SF, 1993, BIOCHEMISTRY-US, V32, P2481, DOI 10.1021/bi00061a005; PIERCE JR, 1989, BIOCHEMISTRY-US, V28, P5821, DOI 10.1021/bi00440a018; Rahn R.O., 1976, PHOTOCHEM PHOTOBIOL, V2, P97; REYNOLDS VL, 1986, J ANTIBIOT, V39, P319, DOI 10.7164/antibiotics.39.319; Sambrook J., 2002, MOL CLONING LAB MANU; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SCHWARTZ A, 1989, J MOL BIOL, V207, P445, DOI 10.1016/0022-2836(89)90266-0; SHI YB, 1988, NUCLEIC ACIDS RES, V16, P8945, DOI 10.1093/nar/16.18.8945; SHI YB, 1986, BIOCHEMISTRY-US, V25, P5895, DOI 10.1021/bi00368a009; SPIELMANN HP, 1995, BIOCHEMISTRY-US, V34, P12937, DOI 10.1021/bi00040a004; SUH M, 1995, CARCINOGENESIS, V16, P2561, DOI 10.1093/carcin/16.10.2561; SUN DY, 1992, J MED CHEM, V35, P1773, DOI 10.1021/jm00088a012; SUQUET C, 1995, J BIOL CHEM, V270, P16507, DOI 10.1074/jbc.270.28.16507; SWENSON DH, 1982, CANCER RES, V42, P2821; SZYMKOWSKI DE, 1993, P NATL ACAD SCI USA, V90, P9823, DOI 10.1073/pnas.90.21.9823; TANAKA K, 1994, TRENDS BIOCHEM SCI, V19, P83, DOI 10.1016/0968-0004(94)90040-X; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; WOOD RD, 1991, BIOESSAYS, V13, P447, DOI 10.1002/bies.950130904; XU R, 1992, NUCLEIC ACIDS RES, V20, P6167, DOI 10.1093/nar/20.23.6167; ZOU Y, 1995, BIOCHEMISTRY-US, V34, P13582, DOI 10.1021/bi00041a038	56	167	169	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25089	25098		10.1074/jbc.271.41.25089	http://dx.doi.org/10.1074/jbc.271.41.25089			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810263	hybrid			2022-12-27	WOS:A1996VL69300007
J	Colwill, K; Feng, LL; Yeakley, JM; Gish, GD; Caceres, JF; Pawson, T; Fu, XD				Colwill, K; Feng, LL; Yeakley, JM; Gish, GD; Caceres, JF; Pawson, T; Fu, XD			SRPK1 and Clk/Sty protein kinases show distinct substrate specificities for serine/arginine-rich splicing factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEINS; SR PROTEINS; SERINE-RICH; CONSERVED FAMILY; SITE SELECTION; CELL-CYCLE; SPLICEOSOME; IDENTIFICATION; REGULATORS; DOMAINS	Serine/arginine-rich (SR) proteins are essential for pre-mRNA splicing, and modify the choice of splice site during alternative splicing in a process apparently regulated by protein phosphorylation, Two protein kinases have been cloned that can phosphorylate SR proteins in vitro: SRPK1 and Clk/Sty. Here, we show that these two kinases phosphorylate the same SR proteins in. vitro, but that SRPK1 has the higher specific activity toward ASF/SF2. SRPK1, like Clk/Sty, phosphorylates ASF/SF2 in vitro on sites that are also phosphorylated in vivo. Tryptic peptide mapping of ASF/SF2 revealed that three of the phosphopeptides from full-length ASF/SF2 phosphorylated in vitro contain consecutive phosphoserine-arginine residues or phosphoserine-proline residues. In vitro, the Clk/Sty kinase phosphorylated Ser-Arg, Ser-Lys, or Ser-Pro sites, whereas SRPK1 had a strong preference for Ser-Arg sites. These results suggest that SRPK1 and Clk/Sty may play different roles in regulating SR splicing factors, and suggest that Clk/Sty has a broader substrate specificity than SRPK1.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAMME MOL BIOL & CANC, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON M5S 1A8, CANADA; UNIV CALIF SAN DIEGO, DIV CELLULAR & MOL MED, SAN DIEGO, CA 92093 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of California System; University of California San Diego; Cold Spring Harbor Laboratory			Caceres, Javier F/D-5260-2013; Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013; Colwill, Karen/K-5101-2012	Caceres, Javier F/0000-0001-8025-6169; Colwill, Karen/0000-0002-8979-1659				AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; AYANE M, 1991, NUCLEIC ACIDS RES, V19, P1273, DOI 10.1093/nar/19.6.1273; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CARDINALI B, 1994, FEBS LETT, V352, P276, DOI 10.1016/0014-5793(94)00973-2; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; CHAUDHARY N, 1991, P NATL ACAD SCI USA, V88, P8189, DOI 10.1073/pnas.88.18.8189; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DIAMOND RH, 1993, J BIOL CHEM, V268, P15185; DUNCAN PI, 1995, J BIOL CHEM, V270, P21524, DOI 10.1074/jbc.270.37.21524; FU XD, 1995, RNA, V1, P663; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; MERMOUD JE, 1992, NUCLEIC ACIDS RES, V20, P5263, DOI 10.1093/nar/20.20.5263; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; ROSCIGNO RF, 1995, RNA, V1, P692; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; TAZI J, 1992, J BIOL CHEM, V267, P4322; VANDERGEER P, 1993, CELL BIOL LAB HDB, P422; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	41	161	165	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24569	24575		10.1074/jbc.271.40.24569	http://dx.doi.org/10.1074/jbc.271.40.24569			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798720	hybrid			2022-12-27	WOS:A1996VM67400042
J	Craig, AWB; Cosentino, GP; Donze, O; Sonenberg, N				Craig, AWB; Cosentino, GP; Donze, O; Sonenberg, N			The kinase insert domain of interferon-induced protein kinase PKR is required for activity but not for interaction with the pseudosubstrate K3L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; FACTOR-2-ALPHA EIF-2-ALPHA KINASE; TRANSLATIONAL CONTROL MECHANISM; INITIATION FACTOR-2-ALPHA; MALIGNANT TRANSFORMATION; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; YEAST; CLONING	Interferon-induced protein kinase (PKR) is a member of a family of kinases that regulate translation initiation through phosphorylation of eukaryotic initiation factor 2 alpha. In addition to the conserved catalytic subdomains that are present in all serine/threonine kinases, the eukaryotic initiation factor 2 alpha kinases possess an insert region between catalytic subdomains IV and V that has been termed the kinase insert domain. To investigate the importance of the kinase insert domain of PKR, several deletions and point mutations were introduced within this domain and analyzed for kinase activity both in vitro and in vivo, Here we show that deletion of the kinase insert sequence or mutation of serine 355, which lies within this region, abrogates kinase activity. In addition, the kinase insert domain of PKR and adjacent amino acids (LFIQME) in catalytic subdomain V are not required for binding of the pseudosubstrate inhibitor K3L from vaccinia virus. A portion of the catalytic domain of PKR between amino acids 366 and 415 confers K3L binding in vivo, suggesting a possible role for this region of PKR in substrate interaction.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, CTR CANC, MONTREAL, PQ H3G 1Y6, CANADA; BIOMEGA BOEHRINGER INGELHEIM RES INC, LAVAL, PQ H7S 2G5, CANADA	McGill University; McGill University; Boehringer Ingelheim			Craig, Andrew/G-2312-2017; Craig, Andrew/AAC-6923-2019	Craig, Andrew/0000-0002-2039-2393; Craig, Andrew/0000-0002-2039-2393				BARBER GN, 1993, P NATL ACAD SCI USA, V90, P4621, DOI 10.1073/pnas.90.10.4621; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; BLACK TL, 1989, J VIROL, V63, P2244, DOI 10.1128/JVI.63.5.2244-2251.1989; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CARROLL K, 1993, J BIOL CHEM, V268, P12837; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHEN JJ, 1994, BIOCHIMIE, V76, P761, DOI 10.1016/0300-9084(94)90080-9; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P945; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DONZE O, 1995, NUCLEIC ACIDS RES, V23, P861, DOI 10.1093/nar/23.5.861; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; EDERY I, 1989, CELL, V56, P303, DOI 10.1016/0092-8674(89)90904-5; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GALABRU J, 1987, J BIOL CHEM, V262, P15538; Gale M, 1996, MOL CELL BIOL, V16, P4172; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; ICELY PL, 1991, J BIOL CHEM, V266, P16073; JAGUS R, 1994, BIOCHIMIE, V76, P779, DOI 10.1016/0300-9084(94)90082-5; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KATZE MG, 1987, EMBO J, V6, P689, DOI 10.1002/j.1460-2075.1987.tb04809.x; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOROMILAS AE, 1955, J BIOL CHEM, V270, P25426; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; MELLOR H, 1994, J BIOL CHEM, V269, P10201; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, J SAMBROOK MOL CLONI; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; THOMIS DC, 1992, P NATL ACAD SCI USA, V89, P10837, DOI 10.1073/pnas.89.22.10837; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985	50	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24526	24533		10.1074/jbc.271.40.24526	http://dx.doi.org/10.1074/jbc.271.40.24526			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798713	hybrid			2022-12-27	WOS:A1996VM67400035
J	Han, ZY; Malik, N; Carter, T; Reeves, WH; Wyche, JH; Hendrickson, EA				Han, ZY; Malik, N; Carter, T; Reeves, WH; Wyche, JH; Hendrickson, EA			DNA-dependent protein kinase is a target for a CPP32-like apoptotic protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; KU P70/P80 AUTOANTIGEN; STRAND BREAK REPAIR; BCL-2 HOMOLOG BAK; POLY(ADP-RIBOSE) POLYMERASE; HL-60 CELLS; ANTIGENIC DETERMINANTS; V(D)J RECOMBINATION; SCID MUTATION; INHIBITION	We demonstrate that the catalytic subunit of the DNA-dependent protein kinase (DNA-PKcs) is specifically, proteolytically cleaved in HL-60 cells treated with staurosporine (STS), a potent inducer of apoptosis. The proteolysis of DNA-PKcs correlated with or preceded apoptotic chromosomal DNA degradation. Cell free extracts prepared from STS-treated HL-60 cells recapitulated the proteolysis of DNA-PKcs in an in vitro assay using purified DNA-PK as the substrate. Western blot analyses of the apoptotic cell extract showed that the 32-kDa precursor of CPP32 is expressed in HL-60 cells and processed following STS treatment. In addition, whereas the DNA-PKcs protease activity was not inhibitable by many conventional protease inhibitors, it was inhibitable by a highly selective peptide-derived inhibitor of CPP32. These data strongly suggest that CPP32, or a CPP32-like protease, is responsible for DNA-PKcs proteolysis. Finally, our results demonstrated that the cleavage of DNA-PKcs in vitro proceeded in the presence of Bcl-2, indicating that the function provided by Bcl-2 lies upstream the proteolysis of DNA-PKcs.	BROWN UNIV, DEPT BIOCHEM MOL BIOL & CELL BIOL, PROVIDENCE, RI 02912 USA; ST JOHNS UNIV, DEPT BIOL SCI, JAMAICA, NY 11439 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT IMMUNOL & MED MICROBIOL, THURSTON ARTHRIT RES CTR, CHAPEL HILL, NC 27599 USA	Brown University; Saint John's University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040391] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35763] Funding Source: Medline; NIAMS NIH HHS [AR40391] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AJMANI AK, 1995, J EXP MED, V181, P2049, DOI 10.1084/jem.181.6.2049; ANDERSON CW, 1996, IN PRESS CURRENT TOP; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Errami A, 1996, MOL CELL BIOL, V16, P1519; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GONG JP, 1993, J CELL PHYSIOL, V157, P263; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; HAN ZY, 1994, AM J PATHOL, V145, P423; Han ZY, 1996, CANCER RES, V56, P1621; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HOCKENBERY DM, 1995, BIOESSAYS, V17, P631, DOI 10.1002/bies.950170709; HOWARD AD, 1991, J IMMUNOL, V147, P2964; Jackson SP, 1996, CURR OPIN GENET DEV, V6, P19, DOI 10.1016/S0959-437X(96)90005-2; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; POLTORATSKY VP, 1995, J IMMUNOL, V155, P4529; PORGES AJ, 1990, J IMMUNOL, V145, P4222; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707; WANG JS, 1993, MOL BIOL REP, V18, P15, DOI 10.1007/BF01006891; WANG JS, 1994, J CELL SCI, V107, P3223; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHYTE M, 1995, NATURE, V376, P17, DOI 10.1038/376017a0; WYLLIE AH, 1987, INT REV CYTOL, P755; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	51	123	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					25035	25040		10.1074/jbc.271.40.25035	http://dx.doi.org/10.1074/jbc.271.40.25035			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798786	hybrid			2022-12-27	WOS:A1996VM67400109
J	Cassard, S; Choquet, D; Fridman, WH; Bonnerot, C				Cassard, S; Choquet, D; Fridman, WH; Bonnerot, C			Regulation of ITAM signaling by specific sequences in Ig-beta B cell antigen receptor subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; CROSS-LINKING; MEMBRANE IMMUNOGLOBULIN; SURFACE-IMMUNOGLOBULIN; CYTOPLASMIC DOMAIN; LYMPHOCYTES-B; FC-RECEPTORS; SRC FAMILY; ALPHA; ASSOCIATION	B cell antigen receptors (BCR) are composed of an antigen binding subunit, the membrane Ig, and Ig-alpha/Ig-beta heterodimers, that contain a transducing motif named ITAM for ''immuno-receptor tyrosine-based activation motif.'' Ig-alpha and Ig-beta ITAMs only differ by four amino acids located before the second conserved tyrosine (DCSM in Ig-alpha and QTAT in Ig-beta), which determine the in vitro association of Ig-alpha with the src kinase fyn. We have previously shown that Ig-alpha and Ig-beta BCR subunits activate different signaling pathways by expressing, in B cells, Fc gamma RII chimeras containing the cytoplasmic tails of Ig-alpha or Ig-beta. We report here that the signaling capacity of Ig-beta ITAM is regulated by peptide sequences located inside (QTAT region) or outside the ITAM (flanking sequences), Furthermore, when isolated, Ig-alpha and Ig-beta ITAM have similar abilities as the entire Ig-alpha tail and the whole BCR in triggering tyrosine kinase activation, an increase of intracellular calcium concentration as well as late events of cell activation as assessed by cytokine secretion, These data show that alterations that modify the ability of Ig-alpha and Ig-beta to interact in vitro with the src kinase fyn (switch between QTAT and DCSM) also determine signal transduction capabilities of these molecules expressed in B cells.	INST CURIE,INSERM,U255,F-75231 PARIS 05,FRANCE; INST PASTEUR,INSERM,U261,F-75724 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Cassard, S (corresponding author), INST CURIE,CJF 9501,INSERM,12 RUE LHOMOND,F-75231 PARIS 05,FRANCE.		Choquet, Daniel/K-7893-2018; Choquet, Daniel/E-4203-2013; Choquet, Daniel/GOJ-8825-2022	Choquet, Daniel/0000-0003-4726-9763; Choquet, Daniel/0000-0003-4726-9763; fridman, wolf herman/0000-0002-1332-0973				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; BAIXERAS E, 1993, IMMUNOL REV, V132, P5, DOI 10.1111/j.1600-065X.1993.tb00836.x; BURKHARDT AL, 1994, MOL CELL BIOL, V14, P1095, DOI 10.1128/MCB.14.2.1095; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; CHOQUET D, 1994, J BIOL CHEM, V269, P6491; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DENNIS GJ, 1987, J IMMUNOL, V138, P4307; DIEGEL ML, 1994, J BIOL CHEM, V269, P11409; FLASWINKEL H, 1994, EMBO J, V13, P83, DOI 10.1002/j.1460-2075.1994.tb06237.x; FRIEDRICH RJ, 1993, J IMMUNOL, V150, P2814; GELFAND EW, 1988, EUR J IMMUNOL, V18, P917, DOI 10.1002/eji.1830180613; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; ISHIHARA K, 1993, J IMMUNOL, V150, P2253; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LIN JJ, 1992, J IMMUNOL, V149, P1548; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; TADDIE JA, 1994, J BIOL CHEM, V269, P13529; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; WILLIAMS GT, 1994, P NATL ACAD SCI USA, V91, P474, DOI 10.1073/pnas.91.2.474; WILSON HA, 1987, J EXP MED, V166, P601, DOI 10.1084/jem.166.2.601; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	31	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23786	23791		10.1074/jbc.271.39.23786	http://dx.doi.org/10.1074/jbc.271.39.23786			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798606	hybrid			2022-12-27	WOS:A1996VJ44200035
J	Deed, RW; Armitage, S; Norton, JD				Deed, RW; Armitage, S; Norton, JD			Nuclear localization and regulation of Id protein through an E protein-mediated chaperone mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; DNA-BINDING; MUSCLE DIFFERENTIATION; GENE; E2A; MYOD; SITE; IDENTIFICATION; EXPRESSION; COMPLEXES	Members of the Id family of helix-loop-helix proteins function as negative regulators of DNA binding, E protein, helix-loop-helix transcription factors in the control of cell growth, differentiation, and development. By using transient transfection analysis of COS cells, we show that in the absence of its E protein target, the Id3 protein is localized exclusively to the cytoplasm/perinuclear region. Co-transfection with E protein (E47) results in nuclear translocation of the Id3 protein, a process requiring both a functional Id helix-loop-helix dimerization domain and an E protein nuclear localization signal. Id3 that is associated with E protein displays an extended half-life, while the E protein itself is more rapidly turned over. These observations demonstrate that E protein, by nuclear chaperoning Id, can regulate the available cellular pool of its own inhibitory partner.	CHRISTIE HOSP NATL HLTH SERV TRUST,DEPT GENE REGULAT,PATERSON INST CANC RES,CANC RES CAMPAIGN,MANCHESTER M20 9BX,LANCS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research								BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; CLINE TW, 1993, TRENDS GENET, V9, P385, DOI 10.1016/0168-9525(93)90138-8; CONDORELLI G, 1995, BLOOD, V86, P164, DOI 10.1182/blood.V86.1.164.bloodjournal861164; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DEED RW, 1994, BBA-GENE STRUCT EXPR, V1219, P160, DOI 10.1016/0167-4781(94)90261-5; DEED RW, 1993, ONCOGENE, V8, P599; DEED RW, 1994, GENE, V151, P309, DOI 10.1016/0378-1119(94)90676-9; DORSHKIND K, 1994, CELL, V79, P751, DOI 10.1016/0092-8674(94)90065-5; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LAVERONE A, 1994, GENE DEV, V8, P1270; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; MEYER KB, 1995, EUR J IMMUNOL, V25, P1770, DOI 10.1002/eji.1830250643; MURPHY JJ, 1990, BIOCHIM BIOPHYS ACTA, V1049, P261; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; VASTRIK I, 1995, ONCOGENE, V11, P553; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WATERS CM, 1990, ONCOGENE, V5, P669; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WIBLEY J, 1996, BIOCHIM BIOPHYS ACTA, V1924, P138	27	77	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23603	23606		10.1074/jbc.271.39.23603	http://dx.doi.org/10.1074/jbc.271.39.23603			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798572	hybrid			2022-12-27	WOS:A1996VJ44200001
J	Kammer, W; Lischke, A; Moriggl, R; Groner, B; Ziemiecki, A; Gurniak, CB; Berg, LJ; Friedrich, K				Kammer, W; Lischke, A; Moriggl, R; Groner, B; Ziemiecki, A; Gurniak, CB; Berg, LJ; Friedrich, K			Homodimerization of interleukin-4 receptor alpha chain can induce intracellular signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON GAMMA-CHAIN; TRANSCRIPTION FACTOR; KINASE; DOMAIN; IL-4; PHOSPHORYLATION; LYMPHOCYTES; PROTEIN; SURFACE; BINDING	The possible role of homodimerization events in intracellular signal transduction triggered by the bipartite human interleukin-4 receptor was addressed, We generated cell lines functionally expressing derivatives of the two receptor subunits alpha and gamma, which allow for a specific and background-free experimental induction of intracellular homo- and heterodimers, A heterodimer of alpha and gamma released an intracellular signal, whereas a gamma-gamma homodimer did not, Unexpectedly, we found the intracellular domain of interleukin-4 receptor alpha chain to evoke cell proliferation and activation of tyrosine kinase Jak1 as well as of transcription factor State upon homodimerization. Both recruitment of the common gamma chain and activation of kinase Jak3 were shown to be dispensible for these processes.	THEODOR BOVERI INST BIOWISSENSCH BIOZENTRUM,D-97074 WURZBURG,GERMANY; INST EXPT CANC RES,TUMOR BIOL CTR,D-79106 FREIBURG,GERMANY; LAB CLIN & EXPT CANC RES,CH-3004 BERN,SWITZERLAND; HARVARD UNIV,DEPT MOL & CELL BIOL,CAMBRIDGE,MA 02138	Harvard University			Moriggl, Richard/H-8118-2019	Moriggl, Richard/0000-0003-0918-9463				BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BONSCH D, 1995, J BIOL CHEM, V270, P8452, DOI 10.1074/jbc.270.15.8452; DUSCHL A, 1995, EUR J BIOCHEM, V228, P305; Gurniak CB, 1996, BLOOD, V87, P3151, DOI 10.1182/blood.V87.8.3151.bloodjournal8783151; HARADA N, 1992, J BIOL CHEM, V267, P22752; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KOETTNITZ K, 1993, EUR J IMMUNOL, V23, P988, DOI 10.1002/eji.1830230437; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; Lai SY, 1996, P NATL ACAD SCI USA, V93, P231, DOI 10.1073/pnas.93.1.231; LISCHKE A, 1995, EUR J BIOCHEM, V234, P100, DOI 10.1111/j.1432-1033.1995.100_c.x; Lischke A, 1996, ANAL BIOCHEM, V236, P322, DOI 10.1006/abio.1996.0173; Nelson BH, 1996, MOL CELL BIOL, V16, P309; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PAUL WE, 1991, BLOOD, V77, P1859; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Sambrook J., 2002, MOL CLONING LAB MANU; SELDIN DC, 1994, P NATL ACAD SCI USA, V91, P2140, DOI 10.1073/pnas.91.6.2140; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; SUGAMURA K, 1995, ADV IMMUNOL, V59, P225, DOI 10.1016/S0065-2776(08)60632-X; WAKAO H, 1992, J BIOL CHEM, V267, P16365; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YIN TG, 1994, J BIOL CHEM, V269, P26614	29	66	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23634	23637		10.1074/jbc.271.39.23634	http://dx.doi.org/10.1074/jbc.271.39.23634			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798580				2022-12-27	WOS:A1996VJ44200009
J	Robins, P; Lindahl, T				Robins, P; Lindahl, T			DNA ligase IV from HeLa cell nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; MAMMALIAN-CELLS; REPAIR; RECOMBINATION; LOCALIZATION; REPLICATION; EXPRESSION; ENZYME; PURIFICATION; DOMAIN	A human cDNA encoding a previously unrecognized DNA ligase IV has been identified (Wei, Y.-F., Robins, P., Carter, K., Caldecott, K., Pappin, D. J. C., Yu, G.-L., Wang, R.-P., Shell, B. K., Nash, R. A., Schar, P., Barnes, D. E., Haseltine, W. A., and Lindahl, T. (1995) Mol. Cell. Biol. 15, 3206-3216). Antibodies have been raised against predicted peptide sequences of DNA ligase IV and used to identify the enzyme during purification from HeLa cell nuclei. The 96-kDa DNA ligase IV and the 103-kDa DNA ligase III co-migrate during SDS-polyacrylamide gel electrophoresis and have similar column fractionation properties, which complicates the distinction between the two enzymes, but they have been separated by Mono S liquid chromatography. During initial size fractionation by gel chromatography in 1 M NaCl, DNA ligase IV elutes in the same position as the DNA ligase III-XRCC1 protein complex, indicating that DNA ligase IV is also bound to another protein or occurs as a dimer. DNA ligase IV has been purified free from other DNA ligases, and its enzymatic properties have been examined. The purified protein effectively joins single-strand breaks in a double-stranded polydeoxynucleotide in an ATP-dependent reaction. The substrate specificity of DNA ligase IV differs from those of the other two cloned human DNA ligases, I and III, with regard to their ability to join the hybrid substrates oligo(dT). poly(rA) and oligo(rA). poly(dT). DNA ligase IV occurs in part as an enzyme-adenylate complex in HeLa cell nuclear extracts.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND									ARRAND JE, 1986, J BIOL CHEM, V261, P9079; BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; Bentley DJ, 1996, NAT GENET, V13, P489, DOI 10.1038/ng0896-489; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; CHEN JW, 1995, MOL CELL BIOL, V15, P5412; ELDER RH, 1990, BIOCHEMISTRY-US, V29, P6009, DOI 10.1021/bi00477a019; HARLOW E, 1988, ANTIBODIES; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; LASKO DD, 1990, J BIOL CHEM, V265, P12618; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MONTECUCCO A, 1995, EMBO J, V14, P5379, DOI 10.1002/j.1460-2075.1995.tb00222.x; PETRINI JHJ, 1995, MOL CELL BIOL, V15, P4303; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; ROBERTS E, 1994, J BIOL CHEM, V269, P3789; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; TOMKINSON AE, 1991, J BIOL CHEM, V266, P21728; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TOMKINSON AE, 1991, P NATL ACAD SCI USA, V88, P400, DOI 10.1073/pnas.88.2.400; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; WEI YF, 1995, MOL CELL BIOL, V15, P3206	23	112	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24257	24261		10.1074/jbc.271.39.24257	http://dx.doi.org/10.1074/jbc.271.39.24257			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798671	hybrid			2022-12-27	WOS:A1996VJ44200100
J	Stella, N; Magistretti, PJ				Stella, N; Magistretti, PJ			Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) potentiate the glutamate-evoked release of arachidonic acid from mouse cortical neurons - Evidence for a cAMP-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA-RECEPTOR ACTIVATION; CEREBELLAR GRANULE CELLS; C-DEPENDENT PROCESSES; SPINAL-CORD NEURONS; RAT VISUAL-CORTEX; PRIMARY CULTURES; SYNAPTIC TRANSMISSION; SIGNAL-TRANSDUCTION; CEREBRAL-CORTEX; PHOSPHOLIPASE-C	Glutamatergic neurotransmission is associated with release of arachidonic acid (AA) from membrane phospholipids of both neurons and astrocytes. Since free AA has been shown to enhance glutamate mediated synaptic transmission, it can be postulated that glutamate release and AA formation constitute a positive feed-back mechanism for sustained excitatory neurotransmission. In the present study, we examined whether the glutamate-evoked release of AA could be modulated by peptides. Using mouse cortical neurons in primary cultures, we show that the release of AA evoked by glutamate is potentiated by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide (PACAP). This effect is mediated through the activation of PACAP I receptors. However, several arguments show that this potentiating mechanism does not involve the cAMP/PKA pathway. 1) Increasing intracellular cAMP by either cholera toxin, forskolin, or 8-Br-cAMP treatments does not affect the glutamate evoked release of AA; 2) potentiation of the glutamate response by PACAP is not prevented by the PKA inhibitor 8-Br-R(p)-cAMPS. Also, an involvement of the phospholipase C protein kinase C pathways is unlikely since inhibitors of both phospholipase C (i.e. U-73122) and protein kinase C (i.e. Ro 31-8220) do not affect the potentiation of the glutamate response by PACAP. These observations indicate an effect mediated by PACAP I receptors, which does not involve the second messenger pathways classically associated with activation of this type of receptors. Furthermore, results indicate that this potentiating mechanism mediated by PACAP I receptor acts at a level downstream of the glutamate receptor-mediated calcium influx.	UNIV LAUSANNE,FAC MED,CHUV,SERV NEUROL,CH-1005 LAUSANNE,SWITZERLAND	University of Geneva; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Stella, N (corresponding author), UNIV LAUSANNE,FAC MED,INST PHYSIOL,LAB RECH NEUROL,7 RUE BUGNON,CH-1005 LAUSANNE,SWITZERLAND.			Magistretti, Pierre Julius/0000-0002-6678-320X				ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHNEIWEISS H, 1985, J NEUROCHEM, V44, P779, DOI 10.1111/j.1471-4159.1985.tb12883.x; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DRAPEAU C, 1990, NEUROSCI LETT, V115, P286, DOI 10.1016/0304-3940(90)90470-T; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; DUMUIS A, 1993, MOL PHARMACOL, V43, P976; ELETR M, 1992, J NEUROSCI, V12, P1363; GIRAULT JA, 1988, P NATL ACAD SCI USA, V85, P7790, DOI 10.1073/pnas.85.20.7790; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAJOS F, 1988, ANAT EMBRYOL, V178, P207, DOI 10.1007/BF00318224; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; LAZAREWICZ JW, 1990, J NEUROCHEM, V55, P1875, DOI 10.1111/j.1471-4159.1990.tb05771.x; LAZAREWICZ JW, 1988, NEUROPHARMACOLOGY, V27, P765, DOI 10.1016/0028-3908(88)90088-3; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; LYNCH MA, 1990, J NEUROCHEM, V55, P215, DOI 10.1111/j.1471-4159.1990.tb08841.x; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAGISTRETTI PJ, 1984, NATURE, V308, P280, DOI 10.1038/308280a0; MAGISTRETTI PJ, 1990, TRENDS PHARMACOL SCI, V11, P250, DOI 10.1016/0165-6147(90)90253-5; MAGISTRETTI PJ, 1988, NEUROSCIENCE, V24, P367, DOI 10.1016/0306-4522(88)90338-7; MARTIN JL, 1992, BRAIN RES, V587, P1, DOI 10.1016/0006-8993(92)91423-C; MARTIN JL, 1995, J NEUROCHEM, V65, P1; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; MORRISON JH, 1984, BRAIN RES, V292, P269, DOI 10.1016/0006-8993(84)90763-7; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PELLERIN L, 1991, NEUROCHEM RES, V16, P983, DOI 10.1007/BF00965841; PETERS A, 1988, J COMP NEUROL, V267, P409, DOI 10.1002/cne.902670310; PETROU S, 1993, TRENDS BIOCHEM SCI, V18, P41, DOI 10.1016/0968-0004(93)90050-W; PIOMELLI D, 1991, P NATL ACAD SCI USA, V88, P6770, DOI 10.1073/pnas.88.15.6770; PIOMELLI D, 1991, NATURE, V353, P164, DOI 10.1038/353164a0; PIOMELLI D, 1994, CRIT REV NEUROBIOL, V8, P65; PREZEAU L, 1994, MOL PHARMACOL, V45, P570; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STELLA N, 1995, J NEUROSCI, V15, P3307; STELLA N, 1994, J NEUROSCI, V14, P568; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; YU ACH, 1986, J NEUROCHEM, V47, P1181; ZHONG Y, 1995, NATURE, V375, P588, DOI 10.1038/375588a0	49	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23705	23710		10.1074/jbc.271.39.23705	http://dx.doi.org/10.1074/jbc.271.39.23705			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798593	hybrid			2022-12-27	WOS:A1996VJ44200022
J	Carlson, SA; Chatterjee, TK; Fisher, RA				Carlson, SA; Chatterjee, TK; Fisher, RA			The third intracellular domain of the platelet-activating factor receptor is a critical determinant in receptor coupling to phosphoinositide phospholipase C activating G proteins - Studies using intracellular domain minigenes and receptor chimeras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUTURE CLINICAL IMPLICATIONS; BETA-ADRENERGIC RECEPTORS; FORMYL PEPTIDE RECEPTOR; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAINS; BETA-2-ADRENERGIC RECEPTOR; CELLULAR EXPRESSION; INHIBITION; CLONING; LOOP	Platelet activating factor (PAF) is a potent phospholipid mediator which elicits a diverse array of biological actions by interacting with G protein-coupled PAF receptors (PAFR). Binding of PAF to PAFRs leads to activation of G protein(s) that stimulate phosphoinositide phospholipase C and subsequent intracellular signaling responses. To identify the potential role of intracellular domains of the rat PAFR (rPAFR) in signaling, we examined effects of transfecting minigenes encompassing rPAFR intracellular domains 1 (1i), 2 (2i), and 3 (3i) on inositol phosphate (IP) production mediated by the cotransfected rPAFR cDNA. Although transfection of the rPAFR1i and rPAFR2i minigenes had no effects on PAF-stimulated signaling, transfection of the rPAFR3i minigene inhibited PAF-stimulated IP production by approximately 50% compared to controls. The rPAFR3i domain did not inhibit IP production mediated by the multifunctional rat pituitary adenylate cyclase-activating polypeptide receptor (rPACAPR), demonstrating the specificity of the competition by the rPAFR3i domain, In further experiments, the rPAFR3i domain was engineered onto the homologous domain of a monofunctional transmembrane variant of the rPACAPR (rPACAPR(2)) that activates only adenylyl cyclase. The rPACAPR(2)/rPAFR3i chimera responded to PACAP with increases in IP production which were attenuated nearly completely in cells cotransfected with the rPAFR3i domain. In contrast, PACAP had no effects on IP production in a receptor chimera expressing a mutated form of the rPAFR3i domain (rPACAPR(2)/rPAFR3i(mut)). These results demonstrate the ability of the rPAFR3i domain to confer a phospholipase C-signaling phenotype to a receptor deficient in this activity and show that this activity is specific for the engineered rPAFR3i domain. These results suggest that the third intracellular loop of the rPAFR is a primary determinant in its coupling to phosphoinositide phospholipase C-activating G proteins, providing the first insight into the molecular basis of interaction of PAFRs with signal transducing G proteins.	UNIV IOWA,COLL MED,DEPT PHARMACOL,IOWA CITY,IA 52242	University of Iowa			Chatterjee, Rima/J-8066-2017	Fisher, Rory/0000-0003-3108-4836	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041071, R29HL041071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41071] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMATRUDA TT, 1995, J BIOL CHEM, V270, P28010; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BALSINDE J, 1991, J BIOL CHEM, V266, P18726; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BITO H, 1994, EUR J BIOCHEM, V221, P211, DOI 10.1111/j.1432-1033.1994.tb18731.x; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BROWN E, 1984, J NEUROCHEM, V42, P1379, DOI 10.1111/j.1471-4159.1984.tb02798.x; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; CHATTERJEE TK, 1995, METHODS NEUROSCIENCE; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; DELCERRO S, 1990, BEHAV NEURAL BIOL, V54, P213, DOI 10.1016/0163-1047(90)90595-W; DHAR A, 1991, J BIOL CHEM, V266, P18797; EASON MG, 1995, J BIOL CHEM, V270, P24753, DOI 10.1074/jbc.270.42.24753; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HASLAM RJ, 1982, J BIOL CHEM, V257, P6879; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HWANG SB, 1990, J LIPID MEDIATOR, V2, P123; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOLTAI M, 1991, DRUGS, V42, P174, DOI 10.2165/00003495-199142020-00002; KOLTAI M, 1991, DRUGS, V42, P9, DOI 10.2165/00003495-199142010-00002; KOZELL LB, 1994, J BIOL CHEM, V269, P30299; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NAKASHIMA S, 1989, J IMMUNOL, V143, P1295; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NUSSENZVEIG DR, 1994, J BIOL CHEM, V269, P28123; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; REN Q, 1993, J BIOL CHEM, V268, P16483; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; SHIMIZU T, 1992, BIOCHEM PHARMACOL, V44, P1001; SIRGANIAN RP, 1971, J IMMUNOL, V106, P1244; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TAKAGI Y, 1995, J BIOL CHEM, V270, P10072, DOI 10.1074/jbc.270.17.10072; TAKANO T, 1994, J BIOL CHEM, V269, P22453; WANG CL, 1995, J BIOL CHEM, V270, P16677, DOI 10.1074/jbc.270.28.16677; WANG Z, 1993, MOL ENDOCRINOL, V7, P85, DOI 10.1210/me.7.1.85; WONG SKF, 1994, J BIOL CHEM, V269, P18968; WONG SKF, 1990, J BIOL CHEM, V265, P6219	48	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23146	23153		10.1074/jbc.271.38.23146	http://dx.doi.org/10.1074/jbc.271.38.23146			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798508	hybrid			2022-12-27	WOS:A1996VH76800034
J	Davletov, BA; Shamotienko, OG; Lelianova, VG; Grishin, EV; Ushkaryov, YA				Davletov, BA; Shamotienko, OG; Lelianova, VG; Grishin, EV; Ushkaryov, YA			Isolation and biochemical characterization of a Ca2+-independent alpha-latrotoxin-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WIDOW SPIDER VENOM; FROG NEUROMUSCULAR-JUNCTION; HIGH-AFFINITY BINDING; TRANSMITTER RELEASE; RAT-BRAIN; NEUROTRANSMITTER RELEASE; SYNAPTIC VESICLES; TOXIN BINDING; RECEPTOR; MEMBRANE	alpha-Latrotoxin, a black widow spider neurotoxin, can bind to high affinity receptors on the presynaptic plasma membrane and stimulate massive neurotransmitter release in the absence of Ca2+. Neurexins, previously isolated as Lu-latrotoxin receptors, require Ca2+ for their interaction with the toxin and, thus, may not participate in the Ca2+-independent cu-latrotoxin activity, We now report the isolation of a novel protein that binds alpha-latrotoxin with high affinity in the presence of various divalent cations (Ca2+, Mg2+, Ba2+, and Sr2+) as well as in EDTA. This protein, termed here latrophilin, has been purified from detergent-solubilized bovine brain membranes by affinity chromatography on immobilized alpha-latrotoxin and concentrated on a wheat germ agglutinin affinity column. The single polypeptide chain of latrophilin is N-glycosylated and has an apparent molecular weight of 120,000. Sucrose gradient centrifugations demonstrated that latrophilin and alpha-latrotoxin form a stable equimolar complex, In the presence of the toxin, anti-alpha-latrotoxin antibodies precipitated iodinated latrophilin, whose binding to immobilized toxin was characterized by a dissociation constant of 0.5-0.7 nM. This presumably membrane-bound protein is localized to and differentially distributed among neuronal tissues, with about four times more latrophilin expressed in the cerebral cortex than in the cerebellum; subcellular fractionation showed that the protein is highly enriched in synaptosomal plasma membranes, Our data suggest that latrophilin may represent the Ca2+-independent receptor and/or molecular target for alpha-latrotoxin.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AY,ENGLAND; SHEMYAKIN & OVCHINNIKOV INST BIOORGAN CHEM,MOSCOW 117871,RUSSIA	Imperial College London; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences			Ushkaryov, Yuri/AAQ-2985-2020; Davletov, Bazbek/ABA-8569-2021	Ushkaryov, Yuri/0000-0002-5712-8297; Davletov, Bazbek/0000-0003-4658-3275	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BORDIER C, 1981, J BIOL CHEM, V256, P1604; DAVLETOV BA, 1995, J BIOL CHEM, V270, P23903, DOI 10.1074/jbc.270.41.23903; FRONTALI N, 1976, J CELL BIOL, V68, P462, DOI 10.1083/jcb.68.3.462; GORDONWEEKS PR, 1987, NEUROCHEMISTRY PRACT; GRASSO A, 1980, NATURE, V283, P774, DOI 10.1038/283774a0; HURLBUT WP, 1990, J PHYSIOL-LONDON, V425, P501, DOI 10.1113/jphysiol.1990.sp018115; HURLBUT WP, 1994, J MEMBRANE BIOL, V138, P91, DOI 10.1007/BF00211072; HURLBUT WP, 1979, NEUROTOXINS TOOLS NE; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALGAROLI A, 1989, NEUROSCIENCE, V32, P393, DOI 10.1016/0306-4522(89)90088-2; MATTEOLI M, 1988, P NATL ACAD SCI USA, V85, P7366, DOI 10.1073/pnas.85.19.7366; MELDOLESI J, 1983, NEUROSCIENCE, V10, P997, DOI 10.1016/0306-4522(83)90238-5; MELDOLESI J, 1982, J NEUROCHEM, V38, P1559, DOI 10.1111/j.1471-4159.1982.tb06633.x; MELDOLESI J, 1984, P NATL ACAD SCI-BIOL, V81, P620, DOI 10.1073/pnas.81.2.620; MISLER S, 1979, P NATL ACAD SCI USA, V76, P991, DOI 10.1073/pnas.76.2.991; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; PASHKOV V, 1993, NEUROSCIENCE, V56, P695, DOI 10.1016/0306-4522(93)90366-N; PETRENKO AG, 1993, J BIOL CHEM, V268, P1860; PETRENKO AG, 1990, EMBO J, V9, P2023, DOI 10.1002/j.1460-2075.1990.tb08331.x; ROSENTHAL L, 1990, MOL PHARMACOL, V38, P917; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; SCHEER H, 1985, EMBO J, V4, P323, DOI 10.1002/j.1460-2075.1985.tb03632.x; SCHEER H, 1986, EMBO J, V5, P2643, DOI 10.1002/j.1460-2075.1986.tb04546.x; STORCHAK LG, 1994, FEBS LETT, V351, P267, DOI 10.1016/0014-5793(94)00790-X; TZENG MC, 1979, J NEUROCHEM, V33, P263, DOI 10.1111/j.1471-4159.1979.tb11728.x; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1986, BIOORG KHIM+, V12, P71; VALTORTA F, 1984, J CELL BIOL, V99, P124, DOI 10.1083/jcb.99.1.124; VICENTINI LM, 1984, BIOCHEM BIOPH RES CO, V121, P538, DOI 10.1016/0006-291X(84)90215-8	30	125	134	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23239	23245		10.1074/jbc.271.38.23239	http://dx.doi.org/10.1074/jbc.271.38.23239			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798521	hybrid			2022-12-27	WOS:A1996VH76800047
J	Lewis, DL; Farr, CL; Wang, YX; Lagina, AT; Kaguni, LS				Lewis, DL; Farr, CL; Wang, YX; Lagina, AT; Kaguni, LS			Catalytic subunit of mitochondrial DNA polymerase from Drosophila embryos - Cloning, bacterial overexpression, and biochemical characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I KLENOW FRAGMENT; ESCHERICHIA-COLI; 3'->5' EXONUCLEASE; SUBSTRATE-SPECIFICITY; XENOPUS-LAEVIS; GAMMA; IDENTIFICATION; FIDELITY; POLYMERIZATION; MELANOGASTER	A full-length cDNA of the catalytic subunit of mitochondrial DNA polymerase from Drosophila embryos has been obtained, and its nucleotide sequence was determined. The cDNA clone encodes a polypeptide with a deduced amino acid sequence of 1145 residues and a predicted molecular mass of 129.9 kDa. Amino-terminal sequence analysis of the mature catalytic subunit of the heterodimeric mitochondrial enzyme from Drosophila embryos identified the amino-terminal amino acid at position +10 in the deduced amino acid sequence, indicating a mitochondrial presequence peptide of only nine amino acids. Alignment of the catalytic subunit sequence with that of Escherichia coli DNA polymerase I Klenow fragment indicated a high degree of amino acid sequence conservation in each of the three DNA polymerase and three 3' --> 5' exonuclease domains identified by biochemical studies in the latter enzyme. Bacterial overexpression, purification, and biochemical analysis demonstrated both 5' --> 3' DNA polymerase and 3' --> 5' exonuclease in the recombinant polypeptide. This rep resents the first demonstration of 3' --> 5' exonuclease activity in the polymerase catalytic subunit of animal mitochondrial DNA polymerase.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University			Lagina, Anthony/AAO-2806-2020	Lagina, Anthony/0000-0002-9121-8712	NIGMS NIH HHS [GM45295] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045295] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x; FOURY F, 1989, J BIOL CHEM, V11, P2717; GRAY H, 1992, J BIOL CHEM, V267, P5835; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HU JP, 1995, GENE, V160, P105, DOI 10.1016/0378-1119(95)00215-R; HUBSCHER U, 1979, P NATL ACAD SCI USA, V76, P2316, DOI 10.1073/pnas.76.5.2316; INSDORF NF, 1989, J BIOL CHEM, V264, P21498; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; ITO J, 1990, NUCLEIC ACIDS RES, V18, P6716, DOI 10.1093/nar/18.22.6716; KAGUNI LS, 1989, P NATL ACAD SCI USA, V86, P6469, DOI 10.1073/pnas.86.17.6469; KAGUNI LS, 1988, CANC CELLS EUKARYOTI, P425; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; KUNKEL TA, 1989, BIOCHEMISTRY-US, V28, P988, DOI 10.1021/bi00429a011; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDOUX SP, 1992, CARCINOGENESIS, V13, P1967, DOI 10.1093/carcin/13.11.1967; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; OLSON MW, 1995, J BIOL CHEM, V270, P28932, DOI 10.1074/jbc.270.48.28932; OLSON MW, 1992, J BIOL CHEM, V267, P23136; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; ROPP PA, 1995, GENE, V165, P103, DOI 10.1016/0378-1119(95)00412-Y; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; WERNETTE CM, 1988, BIOCHEMISTRY-US, V27, P6046, DOI 10.1021/bi00416a033; WERNETTE CM, 1986, J BIOL CHEM, V261, P4764; WOLSTENHOLME DR, 1992, INT REV CYTOL, V141, P173, DOI 10.1016/S0074-7696(08)62066-5; XIAO H, 1993, J BIOL CHEM, V268, P11773; Ye F, 1996, NUCLEIC ACIDS RES, V24, P1481, DOI 10.1093/nar/24.8.1481	34	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23389	23394		10.1074/jbc.271.38.23389	http://dx.doi.org/10.1074/jbc.271.38.23389			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798543	hybrid			2022-12-27	WOS:A1996VH76800069
J	Lim, R; Zaheer, A				Lim, R; Zaheer, A			In vitro enhancement of p38 mitogen-activated protein kinase activity by phosphorylated glia maturation factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; FACTOR-BETA; CELLS; EXPRESSION; ENDOTOXIN; CASCADE; GTPASES; RHO; RAC	We previously demonstrated that glia maturation factor (GMF), a 17-kDa brain protein, can be phosphorylated in test tube by several protein kinases, and that endogenous GMF is rapidly phosphorylated upon stimulation of astrocytes by phorbol 12-myristate 13-acetate. We further observed that protein kinase A (PKA)-phosphorylated GMF is a potent inhibitor (IC50 = 3 nM) of the ERK1/ERK2 (p44/p42) subfamily of mitogen-activated protein (MAP) kinase. We now report that, by contrast, PKA-phosphorylated GMF strongly enhances the activity of a related but distinct subfamily of MAP kinase, the p38 MAP kinase, showing an increase of 60-fold over baseline and an EC(50) of 7 nM. Non-phosphorylated GMF or GMF phosphorylated by other kinases exhibits only minimal effect, The intracellular interaction of PKA, GMF, and p38 is supported by the phosphorylation of GMF upon cellular stimulation by forskolin (blocked by PKA inhibitor) and by the co-immunoprecipitation of p38 with GMF from cell lysates, Withdrawal of nerve growth factor from PC12 leads to increased GMF phosphorylation with a time course similar to that reported for p38 activation. The results correlate well with a previous report that ERK and p38 carry out opposing functions and implicate GMF as a regulator of major cellular events.	VET AFFAIRS MED CTR,IOWA CITY,IA 52242	US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Lim, R (corresponding author), UNIV IOWA,COLL MED,DEPT NEUROL,DIV NEUROCHEM & NEUROBIOL,IOWA CITY,IA 52242, USA.				NIDDK NIH HHS [DK-25295] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN JH, 1993, J BIOL CHEM, V268, P25009; KAPLAN R, 1991, J NEUROCHEM, V57, P483, DOI 10.1111/j.1471-4159.1991.tb03777.x; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; LIM R, 1995, BIOCHEM BIOPH RES CO, V211, P928, DOI 10.1006/bbrc.1995.1901; LIM R, 1989, P NATL ACAD SCI USA, V86, P3901, DOI 10.1073/pnas.86.10.3901; LIM R, 1990, P NATL ACAD SCI USA, V87, P5233, DOI 10.1073/pnas.87.14.5233; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZAHEER A, 1993, J NEUROCHEM, V60, P914, DOI 10.1111/j.1471-4159.1993.tb03237.x; Zaheer A, 1996, BIOCHEMISTRY-US, V35, P6283, DOI 10.1021/bi960034c	24	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22953	22956		10.1074/jbc.271.38.22953	http://dx.doi.org/10.1074/jbc.271.38.22953			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798479	hybrid			2022-12-27	WOS:A1996VH76800005
J	Yan, SR; Berton, G				Yan, SR; Berton, G			Regulation of Src family tyrosine kinase activities in adherent human neutrophils - Evidence that reactive oxygen intermediates produced by adherent neutrophils increase the activity of the p58(c-fgr) and p53/56(lyn) tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; HYDROGEN-PEROXIDE; RESPIRATORY BURST; PHOSPHATASE INHIBITOR; BIOLOGICAL SURFACES; PROTEIN-KINASE; NADPH OXIDASE; CELL-SURFACE; FACTOR-ALPHA	Src family tyrosine kinases have been implicated in the adhesion-dependent activation of neutrophil functions (Yan, S. R., Fumagalli, L., and Berton, G. (1995) J. Inflamm. 45, 297-312; Lowell, C. A., Fumagalli, L., and Berton, G. (1996) J. Cell Biol, 133, 895-910). Because the activity of tyrosine kinases can be affected by oxidants, we investigated whether reactive oxygen intermediates (ROI) produced by adherent neutrophils regulate Src family kinase activities. Inhibition of ROI production by diphenylene iodonium, an inhibitor of NADPH oxidase, or degradation of H2O2 by exogenously added catalase inhibited the adhesion-stimulated activities of p58(c-fgr) and p53/56(lyn). In addition, adhesion-stimulated p58(c-fgr) and p53/56(lyn) activities were greatly reduced in neutrophils from patients with chronic granulomatous disease (CGD) that are deficient in the production of ROI. Exogenously added H2O2 increased p58(c-fgr) and p53/56(lyn) activities in nonadherent neutrophils. Although ROI regulated the activities of p58(c-frg) and p53/56(lyn), they did not affect the redistribution of the two kinases to a Triton X-100-insoluble, cytoskeletal fraction that occurs in adherent neutrophils. Tyrosine phosphorylation of proteins in adherent, CGD neutrophils was only partially inhibited, suggesting that the full activation of p58(c-fgr) and p53/56(lyn), which depends on endogenously produced ROI, does not represent an absolute requirement for protein tyrosine phosphorylation. The adhesion stimulated activity of the tyrosine kinase p72(syk) was not affected by catalase in normal neutrophils, and it was comparable in normal and CGD neutrophils. These findings suggest that ROI endogenously produced by adherent neutrophils regulate Src family kinases activity selectively and establish the existence of a cross-talk between reorganization of the cytoskeleton, production of ROI, and Src family tyrosine kinase activities in signaling by adhesion.	UNIV VERONA,IST PATOL GEN,I-37134 VERONA,ITALY	University of Verona								BELLAVITE P, 1992, J LEUKOCYTE BIOL, V51, P329, DOI 10.1002/jlb.51.4.329; BENNETT PA, 1993, J CELL SCI, V106, P891; BERTON G, 1992, J CELL BIOL, V116, P1007, DOI 10.1083/jcb.116.4.1007; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BERTON G, 1996, IN PRESS INT J CLIN; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; Brumelll JH, 1996, J BIOL CHEM, V271, P1455, DOI 10.1074/jbc.271.3.1455; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRI P, 1991, INT J TISSUE REACT, V13, P193; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; EVANS GA, 1994, J BIOL CHEM, V269, P23407; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FUORTES M, 1993, J CELL BIOL, V120, P777, DOI 10.1083/jcb.120.3.777; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; LAUDANNA C, 1990, BIOCHEM BIOPH RES CO, V166, P308, DOI 10.1016/0006-291X(90)91946-P; LAUDANNA C, 1993, BIOCHEM BIOPH RES CO, V190, P935, DOI 10.1006/bbrc.1993.1139; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NAKAMURA K, 1993, ONCOGENE, V8, P3133; NATHAN C, 1990, J CELL BIOL, V111, P2171, DOI 10.1083/jcb.111.5.2171; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; PAVALKO FM, 1993, J IMMUNOL, V151, P3795; QIN S, 1955, BIOCHEM J, V308, P347; RICHTER J, 1989, J IMMUNOL, V142, P3199; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SCHULTE RJ, 1994, J IMMUNOL, V153, P5465; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SMITH RM, 1991, BLOOD, V77, P673; SUCHARD SJ, 1994, J IMMUNOL, V152, P290; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; TRUDEL S, 1991, BIOCHEM J, V276, P611, DOI 10.1042/bj2760611; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YAN SR, 1995, J LEUKOCYTE BIOL, V58, P595, DOI 10.1002/jlb.58.5.595; Yan SR, 1995, J INFLAMM, V45, P297; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165; ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879	59	89	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23464	23471		10.1074/jbc.271.38.23464	http://dx.doi.org/10.1074/jbc.271.38.23464			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798554	hybrid			2022-12-27	WOS:A1996VH76800080
J	Bhat, GJ; Abraham, ST; Baker, KM				Bhat, GJ; Abraham, ST; Baker, KM			Angiotensin II interferes with interleukin 6-induced Stat3 signaling by a pathway involving mitogen-activated protein kinase kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; EPIDERMAL GROWTH-FACTOR; RAT CARDIAC FIBROBLASTS; DNA-BINDING ACTIVITY; PC12 CELLS; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; GENE-EXPRESSION; AT(1A) RECEPTOR; IN-VITRO	We reported recently that angiotensin II (AII) and phorbol 12-myristate 13-acetate (PMA) transiently inhibit interleukin 6 (IL-6)-stimulated tyrosine phosphorylation of signal transducers and activators of transcription 3 (Stat3) and subsequent formation of sis-inducing factor-A (SIF-A), However, the AII-mediated inhibition was independent of PMA-sensitive isoforms of protein kinase C (Bhat, G. J., Thekkumkara, T. J. Thomas, W. G., Conrad, K. M., and Baker, K. M. (1995) J, Biol, Chem. 270, 19059-19065), In this study, we demonstrate that the inhibition of IL-6-induced Stat3/SIF-A by AII is concentration-dependent and does not involve degradation of Stat3 protein, We hypothesized that the activation profile of the AII- and PMA-induced mitogen-activated protein (MAP) kinase cascade may be different from that of IL-6 and could contribute to the inhibitory effect; therefore, blocking the MAP kinase pathway at the level of MAPK kinase (MAPKK) would attenuate this inhibitory effect, AII and PMA rapidly induced high levels of MAP kinase activity (8-fold), which contrasted with the delayed and weak activation by IL-6 (1.7-fold), Treatment of cells with PD98059, a specific inhibitor of MAPKK1, attenuated the inhibitory effects of AII and PMA on IL-6-induced Stat3 tyrosine phosphorylation and SIF-A formation, These data suggest that differences in magnitude and/or duration of activation of the MAP kinase cascade differentially affects the status of Stat3 tyrosine phosphorylation, and that MAPKK1 or a downstream intermediate is involved in the inhibition of IL-6-induced Stat3 by AII and PMA, Modulatory cross-talk between AII and IL-6 may have relevance in pathophysiological conditions such as cardiac hypertrophy and in acute phase and inflammatory responses.			Bhat, GJ (corresponding author), WEIS CTR RES, GEISINGER CLIN, DANVILLE, PA 17822 USA.							ACETO JF, 1990, AM J PHYSIOL, V258, pH806, DOI 10.1152/ajpheart.1990.258.3.H806; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BHAT GJ, 1995, J BIOL CHEM, V270, P19059, DOI 10.1074/jbc.270.32.19059; BOOZ GW, 1995, CARDIOVASC RES, V30, P537, DOI 10.1016/S0008-6363(96)88507-5; BOOZ GW, 1994, AM J PHYSIOL-CELL PH, V267, pC1308, DOI 10.1152/ajpcell.1994.267.5.C1308; CASTELL JV, 1989, ANN NY ACAD SCI, V557, P87; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KUSHNER I, 1989, ANN NY ACAD SCI, V557, P19; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; SCHORB W, 1995, J MOL CELL CARDIOL, V27, P1151, DOI 10.1016/0022-2828(95)90051-9; THEKKUMKARA TJ, 1995, MOL CELL BIOCHEM, V146, P79, DOI 10.1007/BF00926885; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YAO A, 1995, J CLIN INVEST, V96, P69, DOI 10.1172/JCI118081; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	39	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22447	22452		10.1074/jbc.271.37.22447	http://dx.doi.org/10.1074/jbc.271.37.22447			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798409	hybrid			2022-12-27	WOS:A1996VG67200028
J	Lin, X; VoynoYasenetskaya, TA; Hooley, R; Lin, CY; Orlowski, J; Barber, DL				Lin, X; VoynoYasenetskaya, TA; Hooley, R; Lin, CY; Orlowski, J; Barber, DL			G alpha 12 differentially regulates Na+-H+ exchanger isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NA/H EXCHANGER; SOMATOSTATIN RECEPTORS; MOLECULAR-CLONING; INTRACELLULAR PH; ALPHA-SUBUNITS; INDEPENDENT MECHANISM; CELLS; EXPRESSION; ANTIPORTER; PROTEINS	Activation of several GTPases stimulates Na+-H+ exchange, resulting in an increased efflux of intracellular H+. These GTPases include alpha subunits of the heterotrimeric G proteins G(q) and G13, as well as the low molecular weight GTP-binding proteins Ras, Cdc42, and Rho (Hooley, R., Yu, C.-Y., Simon, M., and Barber, D. L. (1996) J. Biol. Chem. 271, 6152-6158). GTPases coupled to the inhibition of Na+-H+ exchange, however, have not been identified. Several neurotransmitters, including somatostatin and dopamine, inhibit Na+-H+ exchange through a guanine-nueleotide dependent mechanism, suggesting the involvement of a GTPase. In this study we determined that mutational activation of the alpha subunit of G12 inhibits the ubiquitously expressed Na+-H+ exchanger isoform, NBE1. Transient expression of mutationally activated Glu12 inhibited serum- and G alpha 13-stimulated NHE1 activity in HEK293 cells and CCL39 fibroblasts. In addition, in NHE-deficient AP1 cells stably expressing specific NHE isoforms, mutationally activated G alpha 12 inhibited NHE1 activity but stimulated activities of the Na+-H+ exchanger (NHE) isoforms NHE2 and NHE3. In contrast, mutationally activated G alpha 13, another member of the G alpha 12/13 family. stimulated all three NHE isoforms. Although previous studies have identified a parallel action of G alpha 12 and G alpha 13 in regulating MAP (mitogen-activated protein) kinases and cell growth, these GTPases have opposing effects on NHE1 activity.	UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MOL & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143; MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; McGill University				Orlowski, John/0000-0001-7371-175X	NIDDK NIH HHS [DK 40259] Funding Source: Medline; NIGMS NIH HHS [GM 47413] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040259, R01DK040259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047413] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; AZARANI A, 1995, J BIOL CHEM, V270, P23166, DOI 10.1074/jbc.270.39.23166; BARBER DL, 1989, J BIOL CHEM, V264, P21038; BARBER DL, 1992, J BIOL CHEM, V267, P20607; BARBER DL, 1991, CELL SIGNAL, V3, P387, DOI 10.1016/0898-6568(91)90069-7; BORGESE F, 1994, P NATL ACAD SCI USA, V91, P5431, DOI 10.1073/pnas.91.12.5431; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; Fukushima T, 1996, J CELL BIOL, V132, P1037, DOI 10.1083/jcb.132.6.1037; GANZ MB, 1990, J BIOL CHEM, V265, P8989; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; HOU CF, 1994, J BIOL CHEM, V269, P10357; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KITAMURA K, 1995, AM J PHYSIOL-CELL PH, V268, pC101, DOI 10.1152/ajpcell.1995.268.1.C101; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LAW SF, 1991, J BIOL CHEM, V266, P17885; MALY K, 1989, J BIOL CHEM, V264, P11839; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; ROTIN D, 1989, AM J PHYSIOL, V257, pC1148; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SOLEIMANI M, 1994, J BIOL CHEM, V269, P27973; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, J BIOL CHEM, V268, P11917; VARIO G, 1992, J BIOL CHEM, V267, P19043; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WANG Z, 1993, J BIOL CHEM, V268, P11925; WEINMAN EJ, 1993, ANNU REV PHYSIOL, V55, P289, DOI 10.1146/annurev.ph.55.030193.001445; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; YUN CHC, 1993, J BIOL CHEM, V268, P206; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1	46	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22604	22610		10.1074/jbc.271.37.22604	http://dx.doi.org/10.1074/jbc.271.37.22604			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798430	hybrid			2022-12-27	WOS:A1996VG67200049
J	Watanabe, G; Lee, RJ; Albanese, C; Rainey, WE; Batlle, D; Pestell, RG				Watanabe, G; Lee, RJ; Albanese, C; Rainey, WE; Batlle, D; Pestell, RG			Angiotensin II activation of cyclin D1-dependent kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SIDE-CHAIN CLEAVAGE; FASCICULATA-RETICULARIS CELLS; BOVINE ADRENOCORTICAL-CELLS; EPIDERMAL GROWTH-FACTOR; NIH 3T3 CELLS; C-JUN; PROTEIN-KINASE; TRANSCRIPTION FACTOR; MAP KINASE	Angiotensin II (AII) binds to specific G protein-coupled receptors and is mitogenic in adrenal, liver epithelial, and vascular smooth muscle cells. Since the cyclin D1 gene encodes the regulatory subunit of the cyclin D1-dependent kinase (CD1K) required for phosphorylation of the retinoblastoma protein (pRB), an essential and rate-limiting step in G(1) phase progression of the cell cycle, we examined the effect of AII. on cyclin D1 expression and CD1K activity in the human adrenal cell line H295R. AII (10(-6) M) stimulated G(1) phase progression within 12 h, with a maximal effect after 72 h. This action was antedated by the induction of cyclin D1 mRNA (3-fold), cyclin D1 nuclear protein abundance (4-fold), and CD1K activity (4-fold). AT(1) induced cyclin D1 promoter activity 4-fold, via the AT(1) receptor through an enhancer sequence at -954 base pairs. c-Fos and c-Jun bound the cyclin D1 -954 enhancer sequence, and the abundance of c-Fos within this complex was increased by All treatment, AII induced extracellular signal-regulated kinase (ERK) activity 7-fold, and dominant-negative mutants of either p21(ras) or ERK reduced AII stimulated cyclin D1 promoter activity. These findings suggest that AII may stimulate mitogenesis by increasing CD1K activity through a p21(ras)/ERK/activator protein 1 pathway.	NORTHWESTERN UNIV, SCH MED, DIV ENDOCRINOL METAB & MOL MED, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT MED, DIV NEPHROL & HYPERTENS, CHICAGO, IL 60611 USA; UNIV TEXAS, SW MED CTR, DEPT OBSTET GYNECOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	Northwestern University; Northwestern University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BARRETT PQ, 1989, ENDOCR REV, V10, P496, DOI 10.1210/edrv-10-4-496; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BIRD IM, 1993, ENDOCRINOLOGY, V133, P1555, DOI 10.1210/en.133.4.1555; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; CAMPBELLBOSWELL M, 1981, EXP MOL PATHOL, V35, P265, DOI 10.1016/0014-4800(81)90066-6; CAPPONI AM, 1989, ADRENAL HYPERTENSION, P45; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLYNE CD, 1993, ENDOCRINOLOGY, V132, P2206, DOI 10.1210/en.132.5.2206; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; INDOLFI C, 1995, NAT MED, V1, P541, DOI 10.1038/nm0695-541; JIANG W, 1993, ONCOGENE, V8, P3447; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KAUFFMAN RF, 1991, LIFE SCI, V49, pPL223, DOI 10.1016/0024-3205(91)90298-P; KHOCHBIN S, 1988, CYTOMETRY, V9, P499, DOI 10.1002/cyto.990090516; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KUMABE T, 1992, NUCLEIC ACIDS RES, V20, P2598, DOI 10.1093/nar/20.10.2598; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEBRETHON MC, 1994, J CLIN ENDOCR METAB, V78, P1212, DOI 10.1210/jc.78.5.1212; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NATARAJAN R, 1992, ENDOCRINOLOGY, V131, P1174, DOI 10.1210/en.131.3.1174; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; PESTELL RG, 1993, J MOL ENDOCRINOL, V10, P297, DOI 10.1677/jme.0.0100297; PESTELL RG, 1995, J BIOL CHEM, V270, P18301, DOI 10.1074/jbc.270.31.18301; Pestell Richard G., 1995, P59; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SETH A, 1992, J BIOL CHEM, V267, P24796; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; VIARD I, 1992, ENDOCRINOLOGY, V130, P1193, DOI 10.1210/en.130.3.1193; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	73	127	127	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22570	22577		10.1074/jbc.271.37.22570	http://dx.doi.org/10.1074/jbc.271.37.22570			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798425	hybrid			2022-12-27	WOS:A1996VG67200044
J	Feliciello, A; Giuliano, P; Porcellini, A; Garbi, C; Obici, S; Mele, E; Angotti, E; Grieco, D; Amabile, G; Cassano, S; Li, Y; Musti, AM; Rubin, CS; Gottesman, ME; Avvedimento, EV				Feliciello, A; Giuliano, P; Porcellini, A; Garbi, C; Obici, S; Mele, E; Angotti, E; Grieco, D; Amabile, G; Cassano, S; Li, Y; Musti, AM; Rubin, CS; Gottesman, ME; Avvedimento, EV			The v-Ki-Ras oncogene alters cAMP nuclear signaling by regulating the location and the expression of cAMP-dependent protein kinase II beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-PROTEIN; MESSENGER RIBONUCLEIC-ACID; THYROID EPITHELIAL-CELLS; CATALYTIC SUBUNIT; MOLECULAR-CLONING; GENE-EXPRESSION; INTRACELLULAR-LOCALIZATION; HORMONAL-REGULATION; SKELETAL-MUSCLE; CDNA STRUCTURE	The v-Ki-Ras oncoprotein dedifferentiates thyroid cells and inhibits nuclear accumulation of the catalytic subunit of cAMP-dependent protein kinase, After activation of v-Ras or protein kinase C, the regulatory subunit of type II protein kinase A, RII beta, translocates from the membranes to the cytosol. RII beta mRNA and protein were eventually depleted. These effects were mimicked by expressing AKAP45, a truncated version of the RII anchor protein, AKAP75. Because AKAP45 lacks membrane targeting domains, it induces the translocation of PKAII to the cytoplasm. Expression of AKAP45 markedly decreased thyroglobulin mRNA levels and inhibited accumulation of C-PKA in the nucleus. Our results suggest that: 1) The localization of PKAII influences cAMP signaling to the nucleus; 2) Ras alters the localization and the expression of PKAII; 3) Translocation of PKAII to the cytoplasm reduces nuclear C-PKA accumulation, resulting in decreased expression of cAMP-dependent genes, including RII beta, TSH receptor, and thyroglobulin. The loss of RII beta permanently down-regulates thyroid-specific gene expression.	UNIV NAPLES FEDERICO II,FAC MED,CONSIGLIO NAZL RIC,DIPARTIMENTO BIOL & PATOL MOL & CELLULARE,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,FAC MED CATANZARO,I-88100 CATANZARO,ITALY; COLUMBIA UNIV,INST CANC RES,NEW YORK,NY 10032; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOL PHARMACOL,BRONX,NY 10461	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; Columbia University; Yeshiva University; Albert Einstein College of Medicine			Porcellini, Antonio/E-1900-2011; Musti, Anna Maria/M-2520-2019; Porcellini, Antonio/AAC-6097-2019	Porcellini, Antonio/0000-0001-6882-9518; CASSANO, SILVANA/0000-0001-9868-7936; MUSTI, Anna Maria/0000-0003-1443-2739; GRIECO, Domenico/0000-0002-7131-5742; Feliciello, Antonio/0000-0002-7932-2170	NCI NIH HHS [2 PO1 CA23767] Funding Source: Medline; NIDDK NIH HHS [DK41146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK041146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; AVVEDIMENTO EV, 1989, CELL, V58, P1135, DOI 10.1016/0092-8674(89)90511-4; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BACHSKAI BJ, 1993, SCIENCE, V260, P222; BEEBE SJ, 1986, ENZYMES, V17, P43; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BERLINGIERI MT, 1990, BIOCHEM BIOPH RES CO, V173, P172, DOI 10.1016/S0006-291X(05)81037-X; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; COLLETTA G, 1988, FEBS LETT, V228, P37, DOI 10.1016/0014-5793(88)80579-9; CONRAD KE, 1992, ONCOGENE, V7, P1279; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ERLICHMAN J, 1980, J BIOL CHEM, V255, P8179; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FANTOZZI DA, 1992, J BIOL CHEM, V267, P16824; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GALLO A, 1995, CELL GROWTH DIFFER, V6, P91; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Hall A, 1993, CURR OPIN CELL BIOL, V5, P265, DOI 10.1016/0955-0674(93)90114-6; HARDY S, 1993, MOL CELL BIOL, V13, P5943, DOI 10.1128/MCB.13.10.5943; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; HEDIN L, 1987, ENDOCRINOLOGY, V120, P1928, DOI 10.1210/endo-120-5-1928; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; KERYER G, 1993, P NATL ACAD SCI USA, V90, P5418, DOI 10.1073/pnas.90.12.5418; KUNO T, 1987, BIOCHEM BIOPH RES CO, V146, P878, DOI 10.1016/0006-291X(87)90612-7; LANDMARK BF, 1991, ENDOCRINOLOGY, V129, P2345, DOI 10.1210/endo-129-5-2345; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARX J, 1993, SCIENCE, V262, P988, DOI 10.1126/science.8257559; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OLSON EN, 1993, MOL ENDOCRINOL, V7, P1369, DOI 10.1210/me.7.11.1369; OTTEN AD, 1989, J BIOL CHEM, V264, P20255; OYEN O, 1988, MOL ENDOCRINOL, V2, P1070, DOI 10.1210/mend-2-11-1070; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; RUSSELL M, 1994, MOL CELL BIOL, V14, P2343, DOI 10.1128/MCB.14.4.2343; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SPINA A, 1988, BIOCHEM BIOPH RES CO, V157, P1093, DOI 10.1016/S0006-291X(88)80986-0; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; WEBER W, 1986, BIOCHEMISTRY-US, V25, P5661, DOI 10.1021/bi00367a047; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	59	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25350	25359		10.1074/jbc.271.41.25350	http://dx.doi.org/10.1074/jbc.271.41.25350			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810300	hybrid			2022-12-27	WOS:A1996VL69300044
J	Fischer, R; Wei, Y; Anagli, J; Berchtold, MW				Fischer, R; Wei, Y; Anagli, J; Berchtold, MW			Calmodulin binds to and inhibits GTP binding of the Ras-like GTPase Kir/Gem	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM; TRANSCRIPTION; RECOGNITION; ACTIVATION; PROTEINS; KINASES; FAMILY; MUSCLE	Recently, a new subfamily of Ras-related GTP-binding proteins consisting of Rad (Ras associated with diabetes), Gem (immediate early gene expressed in mitogen-stimulated T-cells), and Kir (tyrosine kinase-inducible Ras-like) was discovered. The C terminus of these proteins contains an extension of approximately 30 amino acids not present in other members of the Ras family and which exhibits all the hallmarks typical for calmodulin (CaM)-binding domains. A peptide corresponding to the putative CaM-binding domain of the Kir/Gem protein was synthesized, and its affinity for CaM was determined by fluorescence spectrometry, Titration of dansyl-CaM with the Kir/Gem peptide gave an affinity constant of 1 nM. Furthermore, a single point mutation of the peptide, W269G, abolished this high affinity interaction. Gel-shift analysis showed that the complex formation between CaM and the Kir/Gem peptide is strictly calcium-dependent. We also demonstrate with a newly developed [P-32]CaM overlay technique that full-length Kir/Gem and Rad proteins bind CaM in a Ca2+-dependent fashion. The binding of CaM to glutathione S-transferase-Kir and GST-Gem inhibited the binding of GTP to Kir/Gem significantly. These results suggest the existence of a direct link between Ca2+/CaM and growth factor signal transduction pathways at the level of small Ras-like GTPases.	UNIV ZURICH IRCHEL,DEPT VET BIOCHEM,CH-8057 ZURICH,SWITZERLAND; ETH ZURICH,INST BIOCHEM,CH-8092 ZURICH,SWITZERLAND	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich			Berchtold, Martin/L-1695-2014	Berchtold, Martin/0000-0001-8995-9047				ANAGLI J, 1995, EUR J BIOCHEM, V233, P701, DOI 10.1111/j.1432-1033.1995.701_3.x; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; Dorin D, 1995, ONCOGENE, V11, P2267; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Fischer R, 1996, BIOTECHNIQUES, V21, P292; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Sambrook J., 2002, MOL CLONING LAB MANU; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; STINSON RA, 1973, BIOCHEM J, V131, P719, DOI 10.1042/bj1310719; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; Zhu JH, 1996, J BIOL CHEM, V271, P768, DOI 10.1074/jbc.271.2.768; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	22	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25067	25070		10.1074/jbc.271.41.25067	http://dx.doi.org/10.1074/jbc.271.41.25067			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810259	hybrid			2022-12-27	WOS:A1996VL69300003
J	Xu, LZ; Sanchez, R; Sali, A; Heintz, N				Xu, LZ; Sanchez, R; Sali, A; Heintz, N			Ligand specificity of brain lipid-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; RETINOIC ACID; RAT-LIVER; GENE; EXPRESSION; PROGRAM; TRANSCRIPTION; RESOLUTION; SEQUENCE; ELEMENT	Brain lipid-binding protein (BLBP) is a member of the fatty acid-binding protein (FABP) family, Although BLBP expression in the developing central nervous system is complex, a close correlation between its expression and radial glial differentiation has been observed. Furthermore, antibodies to BLBP can block glial cell differentiation in mixed primary cell cultures. Here we describe the ligand binding properties of BLBP, The binding affinities of BLBP for oleic acid (K-d similar to 0.44 mu M) and arachidonic acid (K-d similar to 0.25 mu M) are similar to those reported for other FABPs, but BLBP does not bind to palmitic acid or arachidinic acid. These and other experiments establish that BLBP has a strong preference for binding long chain polyunsaturated fatty acids. A probable in vivo ligand for BLBP is docosahexaenoic acid (DHA), since its binding affinity (K-d similar to 10 nM) is the highest yet reported for an FABP/ligand interaction, exceeding even the affinity of retinoic acid for its binding proteins. Furthermore, the requirement of DHA for nervous system development and the coincident expression of BLBP during these developmental stages suggest that the physiologic role of BLBP may involve DHA utilization. Finally, we present a structural model of BLBP/DHA interaction that provides insight into both the structural characteristics important for ligand binding and the effects of specific mutations upon BLBP/ligand interactions.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,MOL BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOL BIOPHYS LAB,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University; Rockefeller University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS030532] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 30532] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; ASTROM A, 1994, J BIOL CHEM, V269, P22334; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CANNON JR, 1991, BIOCHEM J, V280, P387, DOI 10.1042/bj2800387; CHEN LX, 1995, J BIOL CHEM, V270, P4518, DOI 10.1074/jbc.270.9.4518; CHENG L, 1991, J BIOL CHEM, V266, P24404; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; FENG L, 1995, DEVELOPMENT, V121, P1719; GLATZ JFC, 1984, J BIOL CHEM, V259, P4295; INNIS SM, 1994, CAN J PHYSIOL PHARM, V72, P1483, DOI 10.1139/y94-214; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHAR SG, 1993, DEVELOPMENT, V117, P97; KURTZ A, 1994, DEVELOPMENT, V120, P2637; LALONDE JM, 1994, J BIOL CHEM, V269, P25339; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE J, 1995, INVEST OPHTH VIS SCI, V36, P2032; MAKRIDES M, 1995, LANCET, V345, P1463, DOI 10.1016/S0140-6736(95)91035-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; PAULUSSEN RJA, 1988, ARCH BIOCHEM BIOPHYS, V264, P533, DOI 10.1016/0003-9861(88)90319-0; Rich MR, 1996, BIOCHEMISTRY-US, V35, P1506, DOI 10.1021/bi951574x; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SAKI RK, 1988, SCIENCE, V239, P487; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; SCHOENTGEN F, 1990, MOL CELL BIOCHEM, V98, P35; SCHULENBERGSCHELL H, 1988, EUR J BIOCHEM, V170, P565, DOI 10.1111/j.1432-1033.1988.tb13735.x; SHA RS, 1993, J BIOL CHEM, V268, P7885; SIMOPOULOS AP, 1989, J NUTR, V119, P521, DOI 10.1093/jn/119.4.521; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WAINWRIGHT PE, 1989, LIPIDS, V24, P989, DOI 10.1007/BF02544067; WANG N, 1992, EXP EYE RES, V54, P933, DOI 10.1016/0014-4835(92)90157-N; XU ZH, 1993, J BIOL CHEM, V268, P7874; YOUNG ACM, 1994, STRUCTURE, V2, P523, DOI 10.1016/S0969-2126(00)00052-6	36	137	152	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24711	24719						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798739				2022-12-27	WOS:A1996VM67400061
J	Bertoldi, M; Moore, PS; Maras, B; Dominici, P; Voltattorni, CB				Bertoldi, M; Moore, PS; Maras, B; Dominici, P; Voltattorni, CB			Mechanism-based inactivation of dopa decarboxylase by serotonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSAMINASE; PIG-KIDNEY; ASSAY; COFACTOR	Pig kidney dopa decarboxylase (DDC) expressed in Escherichia coli is a homodimeric enzyme containing one catalytically active pyridoxal 5'-phosphate active site per subunit. In addition to catalyzing the decarboxylation of L-aromatic amino acids, DDC also reacts with 5-hydroxytryptamine (5-HT), converting it to 5-hydroxyindolacetaldehyde and ammonia. These products have been identified by means of the enzymes alcohol dehydrogenase and glutamate dehydrogenase, together with high performance liquid chromatographic and mass spectroscopic analysis. The K-cat and K-m values of this reaction were determined to be 0.48 min(-1) and 0.47 mM, respectively. The NaBH4-reduced enzyme does not catalyze this reaction. Concurrent with this reaction, 5-HT inactivates DDC in both a time- and concentration-dependent manner and exhibits saturation of the rate of inactivation at high concentrations, with K-i and K-inact values of 0.40 mM and 0.023 min(-1), respectively. Protection from inactivation by 5-HT was observed in the presence of the active site-directed inhibitor 3,4-dihydroxy-D-phenylalanine. inactivation with [2-C-14]5-HT results in the incorporation of 1 mol of label/enzyme subunit. Taken together, these findings indicate that 5-HT is both a substrate and a mechanism-based inactivator with a partition ratio for product formation versus inactivation of 21. The absorbance, CD, and fluorometric features of 5-HT-inactivated DDC have also been characterized. A speculative mechanism for the reaction and inactivation consistent with the experimental findings is presented.	UNIV VERONA,FAC MED & CHIRURG,IST CHIM BIOL,I-37134 VERONA,ITALY; UNIV ROMA LA SAPIENZA,DIPARTIMENTO SCI BIOCHIM,I-00100 ROME,ITALY; UNIV VERONA,FAC SCI MATEMAT FIS & NAT,I-37134 VERONA,ITALY; UNIV ROMA LA SAPIENZA,CNR,CTR MOL BIOL,I-00100 ROME,ITALY	University of Verona; Sapienza University Rome; University of Verona; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome			Moore, Patrick/GVR-8294-2022; Bertoldi, Mariarita/F-1154-2010; Maras, Bruno/A-2020-2010	Bertoldi, Mariarita/0000-0002-2337-9928; 				AKHTAR M, 1990, BIOCHEMISTRY-US, V29, P7648, DOI 10.1021/bi00485a014; BAILEY GB, 1967, BIOCHEMISTRY-US, V6, P1526, DOI 10.1021/bi00857a039; BARBONI E, 1981, BIOCHEM BIOPH RES CO, V99, P576, DOI 10.1016/0006-291X(81)91784-8; BHATIA MB, 1993, J BIOL CHEM, V268, P17687; BOSSA F, 1968, ITAL J BIOCHEM, V17, P285; CHARTERIS A, 1975, ANAL BIOCHEM, V66, P365, DOI 10.1016/0003-2697(75)90604-1; DELPOZO AM, 1992, BIOCHEMISTRY-US, V31, P6018, DOI 10.1021/bi00141a009; DOMINICI P, 1993, BIOCHEM J, V295, P493, DOI 10.1042/bj2950493; DUINE JA, 1991, EUR J BIOCHEM, V200, P271, DOI 10.1111/j.1432-1033.1991.tb16183.x; GROEN BW, 1988, FEBS LETT, V237, P98, DOI 10.1016/0014-5793(88)80179-0; HUNTLEY TE, 1968, S PYRIDOXAL ENZYMES, P81; LIKOS JJ, 1982, BIOCHEMISTRY-US, V21, P4377, DOI 10.1021/bi00261a029; MARAS B, 1991, EUR J BIOCHEM, V201, P385, DOI 10.1111/j.1432-1033.1991.tb16295.x; Moore PS, 1996, BIOCHEM J, V315, P249, DOI 10.1042/bj3150249; OLEARY MH, 1978, BIOCHEMISTRY-US, V17, P1010, DOI 10.1021/bi00599a011; OLEARY MH, 1977, J BIOL CHEM, V252, P7168; OLEARY MH, 1975, NATURE, V253, P52, DOI 10.1038/253052a0; SHERALD AF, 1973, ANAL BIOCHEM, V56, P300, DOI 10.1016/0003-2697(73)90194-2; SZUTOWICZ A, 1984, ANAL BIOCHEM, V138, P86, DOI 10.1016/0003-2697(84)90773-5; VOLTATTO.CB, 1971, FEBS LETT, V17, P231, DOI 10.1016/0014-5793(71)80153-9; Voltattorni C B, 1979, Eur J Biochem, V93, P181; VOLTATTORNI CB, 1983, BIOCHEMISTRY-US, V22, P2249, DOI 10.1021/bi00278a030; VOLTATTORNI CB, 1980, B MOL BIOL MED, V5, P52	23	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23954	23959		10.1074/jbc.271.39.23954	http://dx.doi.org/10.1074/jbc.271.39.23954			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798628	hybrid			2022-12-27	WOS:A1996VJ44200057
J	Geimonen, E; Jiang, W; Ali, M; Fishman, GI; Garfield, RE; Andersen, J				Geimonen, E; Jiang, W; Ali, M; Fishman, GI; Garfield, RE; Andersen, J			Activation of protein kinase C in human uterine smooth muscle induces connexin-43 gene transcription through an AP-1 site in the promoter sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							U937 LEUKEMIC-CELLS; DNA-BINDING; GLUCOCORTICOID RECEPTOR; FUNCTIONAL ANTAGONISM; REGULATORY ELEMENTS; INDUCIBLE ENHANCER; ESTROGEN-RECEPTOR; HUMAN MYOMETRIUM; PRETERM LABOR; GAP-JUNCTIONS	Myometrial connexin-43 gap junctions are scarce throughout gestation but appear in large numbers at term to facilitate contractions during labor, The mechanisms that regulate this process are incompletely characterized. This report investigates the effects of protein kinase C activation on the regulation of connexin-43 gene transcription in human uterine smooth muscle cells. In primary myometrial cells treated with phorbol ester, transient increases in c-Fos and c-Jun protein levels were observed at 2-4 h, followed by significant increases in connexin-43 protein levels at 6-8 h. Nuclear run on transcription analysis showed an increase in connexin-43 transcription 3 h after phorbol ester treatment. AP-1 sites were identified in the sequence of the 5'-flanking promoter region of the human connexin-43 gene at 44 and 1000 base pairs upstream of transcription start. Transcription from a reporter plasmid containing the proximal human connexin-43 promoter was increased in transfected primary cultures treated with phorbol ester. Mutation of the proximal AP-1 site in the promoter abolished the phorbol ester dependent transactivation. This work provides evidence that transcription of the human connexin-43 gene is induced through protein kinase C activation in uterine smooth muscle cells, and that the induction involves up-regulation and activation of c-Jun and c-Fos.	SUNY STONY BROOK,SCH MED,DEPT OBSTET GYNECOL & REPROD MED,STONY BROOK,NY 11794; UNIV TEXAS,MED BRANCH,DEPT OBSTET & GYNECOL,GALVESTON,TX 77555; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MED,SECT MOL CARDIOL,BRONX,NY 10461	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Texas System; University of Texas Medical Branch Galveston; Yeshiva University; Albert Einstein College of Medicine				Fishman, Glenn/0000-0002-2366-8527	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030482] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K11HL002391] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02391] Funding Source: Medline; NICHD NIH HHS [HD 30482] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMBROSINO C, 1993, MOL ENDOCRINOL, V7, P1472, DOI 10.1210/me.7.11.1472; ANDERSEN J, 1995, J SOC GYNECOL INVEST, V2, P663, DOI 10.1016/1071-5576(95)00021-6; ANDERSEN J, 1993, AM J OBSTET GYNECOL, V169, P1266, DOI 10.1016/0002-9378(93)90293-R; ANDERSEN J, 1995, J SOC GYNECOL INVEST, V2, P542, DOI 10.1016/1071-5576(94)00053-4; AUSUBEL FM, 1992, SHORT PROTOCOLS MOL, P8; BALDUCCI J, 1993, AM J OBSTET GYNECOL, V168, P1609, DOI 10.1016/S0002-9378(11)90806-0; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; CHEN ZQ, 1995, J BIOL CHEM, V270, P3863, DOI 10.1074/jbc.270.8.4088; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAIREWATHES DC, 1982, J REPROD FERTIL, V65, P497; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAHL E, 1995, ANAT EMBRYOL, V191, P267; DELEON JR, 1994, J MOL CELL CARDIOL, V26, P379, DOI 10.1006/jmcc.1994.1047; DONAHUE HJ, 1995, J BONE MINER RES, V10, P881; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FISHMAN GI, 1990, J CELL BIOL, V111, P589, DOI 10.1083/jcb.111.2.589; FISHMAN GI, 1991, GENOMICS, V10, P250, DOI 10.1016/0888-7543(91)90507-B; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Garfield R.E., 1985, P143; GARFIELD RE, 1982, AM J OBSTET GYNECOL, V142, P21; GARFIELD RE, 1977, SCIENCE, V198, P958, DOI 10.1126/science.929182; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GOODENOUGH DA, 1975, COLD SPRING HARB SYM, V40, P37, DOI 10.1101/SQB.1976.040.01.006; HENDRIX EM, 1992, MOL REPROD DEV, V33, P27, DOI 10.1002/mrd.1080330105; HYDER SM, 1995, J BIOL CHEM, V270, P8506, DOI 10.1074/jbc.270.15.8506; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHAN SA, 1994, PROTOONCOGENES GROWT, P105; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; MACKENZIE LW, 1986, CAN J PHYSIOL PHARM, V64, P462, DOI 10.1139/y86-074; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; NEPHEW KP, 1995, ENDOCRINOLOGY, V136, P3007, DOI 10.1210/en.136.7.3007; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RISEK B, 1990, J CELL BIOL, V110, P269, DOI 10.1083/jcb.110.2.269; Salmi A, 1996, MOL CELL ENDOCRINOL, V117, P233, DOI 10.1016/0303-7207(95)03759-4; Sambrook J., 1989, MOL CLONING LAB MANU, P15; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SPELSBERG TC, 1994, PROTOONCOGENES GROWT, P69; STANCEL GM, 1994, PROTOONCOGENES GROWT, P87; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; UNLAP T, 1992, NUCLEIC ACIDS RES, V20, P897, DOI 10.1093/nar/20.4.897; WEISZ A, 1990, MOL ENDOCRINOL, V4, P1041, DOI 10.1210/mend-4-7-1041; WILLECKE K, 1991, EUR J CELL BIOL, V56, P1; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WINNING RS, 1991, NUCLEIC ACIDS RES, V19, P3709, DOI 10.1093/nar/19.13.3709; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YU W, 1994, P ROY SOC B-BIOL SCI, V255, P125, DOI 10.1098/rspb.1994.0018; Zhao K, 1996, BIOL REPROD, V54, P607, DOI 10.1095/biolreprod54.3.607	55	120	125	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23667	23674		10.1074/jbc.271.39.23667	http://dx.doi.org/10.1074/jbc.271.39.23667			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798588	hybrid			2022-12-27	WOS:A1996VJ44200017
J	Kim, HY; LaVaute, T; Iwai, K; Klausner, RD; Rouault, TA				Kim, HY; LaVaute, T; Iwai, K; Klausner, RD; Rouault, TA			Identification of a conserved and functional iron-responsive element in the 5'-untranslated region of mammalian mitochondrial aconitase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; RNA-BINDING; REGULATORY FACTOR; SULFUR CLUSTER; MESSENGER-RNA; TRANSLATIONAL REPRESSOR; SUCCINATE-DEHYDROGENASE; CYTOSOLIC ACONITASE; SUBUNIT; GENE	Iron responsive elements (IREs) are RNA stem-loop motifs found in genes of iron metabolism. When cells are iron depleted, iron regulatory proteins (IRPs) bind to IREs in the transcripts of ferritin, transferrin receptor, and erythroid amino-levulinic acid synthetase. Binding of IRPs to IRE motifs near the 5' end of the transcript results in attenuation of translation while binding to IREs in the 3'-untranslated region of the transferrin receptor results in protection from endonucleolytic cleavage. Iron deprivation results in activation of IRE binding activity, whereas iron replete cells lose IRE binding activation. Here, we report the identification of a conserved IRE in the 5'-untranslated region of the transcript of the citric acid cycle enzyme mitochondrial aconitase from four different mammalian species. The IRE in the transcript of mitochondrial aconitase can mediate in vitro translational repression of mitochondrial aconitase by IRPs. Furthermore, levels of mitochondrial aconitase are decreased in mice maintained on a low iron diet, whereas levels of mRNA remain unchanged. The decrease in levels of mitochondrial aconitase is likely due to activation of IRP binding and consequent attenuation of translation. Thus, expression of the iron-sulfur protein mitochondrial aconitase and function of the citric acid cycle may be regulated by iron levels in cells.			Kim, HY (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,NATL INST HLTH,BETHESDA,MD 20892, USA.		IWAI, KAZUHIRO/GSN-7385-2022	Iwai, Kazuhiro/0000-0001-5620-5951				AU HC, 1995, GENE, V159, P249, DOI 10.1016/0378-1119(95)00162-Y; AU HC, 1994, GENE, V149, P261, DOI 10.1016/0378-1119(94)90158-9; BASILION JP, 1994, ARCH BIOCHEM BIOPHYS, V311, P517, DOI 10.1006/abbi.1994.1270; BEAUMONT C, 1994, J BIOL CHEM, V269, P20281; COCCIA EM, 1995, BLOOD, V86, P1570, DOI 10.1182/blood.V86.4.1570.bloodjournal8641570; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; EMERYGOODMAN A, 1993, NUCLEIC ACIDS RES, V21, P1457, DOI 10.1093/nar/21.6.1457; GRAY NK, 1993, EUR J BIOCHEM, V218, P657, DOI 10.1111/j.1432-1033.1993.tb18420.x; GUO B, 1994, J BIOL CHEM, V269, P24252; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HENDERSON BR, 1995, J BIOL CHEM, V270, P20509, DOI 10.1074/jbc.270.35.20509; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KIM HY, 1995, J BIOL CHEM, V270, P4983, DOI 10.1074/jbc.270.10.4983; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Kohler SA, 1995, J BIOL CHEM, V270, P30781, DOI 10.1074/jbc.270.51.30781; KUHNLC, 1994, BAILLIERE CLIN HAEM, V7, P763; MELEFORS O, 1993, BLOOD REV, V7, P251, DOI 10.1016/0268-960X(93)90012-S; ROUAULT TA, 1992, BIOMETALS, V5, P131, DOI 10.1007/BF01061319; ROUAULT TA, 1996, IN PRESS CURR TOP CE, V35; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TANG CK, 1992, J BIOL CHEM, V267, P24466; ZHENG LM, 1992, ARCH BIOCHEM BIOPHYS, V299, P356, DOI 10.1016/0003-9861(92)90287-7; ZHENG LM, 1990, J BIOL CHEM, V265, P2814; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	27	112	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24226	24230		10.1074/jbc.271.39.24226	http://dx.doi.org/10.1074/jbc.271.39.24226			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798666	hybrid			2022-12-27	WOS:A1996VJ44200095
J	Roy, R; Kumar, A; Lee, JC; Mitra, S				Roy, R; Kumar, A; Lee, JC; Mitra, S			The domains of mammalian base excision repair enzyme N-methylpurine-DNA glycosylase - Interaction, conformational change, and role in DNA binding and damage recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL FRAGMENT; ESCHERICHIA-COLI; VINYL-CHLORIDE; 3-METHYLADENINE-DNA GLYCOSYLASE; LIMITED PROTEOLYSIS; ALKYLATING-AGENTS; ADAPTIVE RESPONSE; STRUCTURAL BASIS; POLYMERASE-BETA; GENE MAPS	Repair of a variety of alkylated base adducts in DNA is initiated by their removal by N-methylpurine-DNA glycosylase. The 31-kDa mouse N-methylpurine-DNA glycosylase, derived by deletion of 48 amino acid residues from the 333-residue wild type protein without loss of activity, was analyzed for the presence of protease-resistant domains with specific roles in substrate binding and catalysis. Increasing proteolysis with trypsin generated first a 29-kDa polypeptide by removal of 42 amino-terminal residues, followed by production of 8-, 6-, and 13-kDa fragments with defined, nonoverlapping boundaries. The 8- and 13-kDa domains include the amino and carboxyl termini, respectively. Based on DNA-affinity chromatography and the protease protection assay, it appears that the 6- and 13-kDa domains are necessary for nontarget DNA binding and that the 8-kDa domain, in cooperation with the other two domains, participates in recognition of damaged bases. Furthermore, chemical cross-linking studies indicated that, in the presence of substrate DNA, the 8- and 6-kDa domains undergo conformational changes reflected by both protection from proteolysis and reduced availability of cysteine residues for the thiol-exchange reaction.	UNIV TEXAS, MED BRANCH, SEALY CTR MOL SCI, GALVESTON, TX 77555 USA; UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston			Lee, James C/A-7849-2009		NATIONAL CANCER INSTITUTE [R01CA053791] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NCI NIH HHS [CA53791] Funding Source: Medline; NIEHS NIH HHS [ES06676] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BASU AK, 1993, BIOCHEMISTRY-US, V32, P12793, DOI 10.1021/bi00210a031; BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; BESSHO T, 1993, P NATL ACAD SCI USA, V90, P8901, DOI 10.1073/pnas.90.19.8901; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; BOITEUX S, 1984, EMBO J, V3, P2569, DOI 10.1002/j.1460-2075.1984.tb02175.x; BRASIER AR, 1994, J BIOL CHEM, V269, P10341; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; CHENG KC, 1991, P NATL ACAD SCI USA, V88, P9974, DOI 10.1073/pnas.88.22.9974; CHENG KC, 1992, J BIOL CHEM, V267, P166; COOPER LP, 1994, J MOL BIOL, V236, P1011, DOI 10.1016/0022-2836(94)90008-6; DOSANJH MK, 1994, BIOCHEMISTRY-US, V33, P1624, DOI 10.1021/bi00173a002; DOSANJH MK, 1994, P NATL ACAD SCI USA, V91, P1024, DOI 10.1073/pnas.91.3.1024; ENGELWARD BP, 1993, CARCINOGENESIS, V14, P175; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; FRIEDBERG FC, 1995, DNA REPAIR MUTAGENES; GAJEWSKI E, 1990, BIOCHEMISTRY-US, V29, P7876, DOI 10.1021/bi00486a014; GEISLER N, 1977, BIOCHEMISTRY-US, V16, P938, DOI 10.1021/bi00624a020; GILBERT W, 1993, GENE, V135, P137, DOI 10.1016/0378-1119(93)90058-B; GIULIAN GG, 1983, ANAL BIOCHEM, V129, P277, DOI 10.1016/0003-2697(83)90551-1; JANIN J, 1985, METHOD ENZYMOL, V115, P420; JOVIN TM, 1977, NATURE, V269, P668, DOI 10.1038/269668a0; KASAI H, 1991, OXIDATIVE STRESS OXI; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; LARSON K, 1985, MUTAT RES, V150, P77, DOI 10.1016/0027-5107(85)90103-4; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; OCONNOR TR, 1990, EMBO J, V9, P3337, DOI 10.1002/j.1460-2075.1990.tb07534.x; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; OGATA RT, 1978, P NATL ACAD SCI USA, V75, P5851, DOI 10.1073/pnas.75.12.5851; PABO CO, 1979, P NATL ACAD SCI USA, V76, P1608, DOI 10.1073/pnas.76.4.1608; PORTER RR, 1973, SCIENCE, V180, P713, DOI 10.1126/science.180.4087.713; PURCHASE IFH, 1987, FOOD CHEM TOXICOL, V25, P187, DOI 10.1016/0278-6915(87)90153-0; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2940, DOI 10.1021/bi00225a030; ROY R, 1994, BIOCHEMISTRY-US, V33, P15131, DOI 10.1021/bi00254a024; ROY R, 1996, IN PRESS CARCINOGENE; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; Schulz G. E., 1979, PRINCIPLES PROTEIN S; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VITA C, 1989, EUR J BIOCHEM, V183, P513, DOI 10.1111/j.1432-1033.1989.tb21079.x; VOLKERT MR, 1988, ENVIRON MOL MUTAGEN, V11, P241, DOI 10.1002/em.2850110210; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; WILSON JE, 1991, METHOD BIOCHEM ANAL, V35, P207; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011	53	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23690	23697		10.1074/jbc.271.39.23690	http://dx.doi.org/10.1074/jbc.271.39.23690			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798591	hybrid			2022-12-27	WOS:A1996VJ44200020
J	Shainoff, JR; Smejkal, GB; DiBello, PM; Mitkevich, OV; Levy, PJ; Dempfle, CE; Lill, H				Shainoff, JR; Smejkal, GB; DiBello, PM; Mitkevich, OV; Levy, PJ; Dempfle, CE; Lill, H			Isolation and characterization of the fibrin intermediate arising from cleavage of one fibrinopeptide A from fibrinogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-XIIIA; ALPHA-CHAIN; POLYMERIZATION SITES; ELECTRON-MICROSCOPY; PLASMIC DEGRADATION; CROSS-LINKING; AMINO-ACIDS; THROMBIN; DERIVATIVES; RELEASE	The thrombin-catalyzed cleavage of N-terminal fibrinopeptide A (FPA) from the two A alpha-chains of fibrinogen exposes aggregation sites with the critical sequence GPR located just behind FPA. It is well known that exposure of both GPR sites transforms fibrinogen into self-aggregating, fully coagulable alpha-fibrin monomers, but the fibrin precursor with one site exposed and one FPA intact has eluded description. The formation of this ''alpha-profibrin'' in the course of thrombin reactions and its distribution among both the aggregating and non-aggregating components of the reactions are characterized here by immunoprobing electrophoretic and gel chromatographic separations using monoclonal antibodies specific for FPA and for exposed GPR sites. These analyses show alpha-profibrin to be a non-aggregating derivative indistinguishable from fibrinogen in solutions that are rich in fibrinogen relative to dissolved fibrin. But alpha-profibrin forms soluble complexes with alpha-fibrin monomer under conditions in which it and fibrin predominate over fibrinogen. It was isolated as a complex with fibrin by gel chromatography of cryoprecipitates and then separated from the fibrin either by electrophoretic gel shifts induced with a peptide analog of the GPR aggregation site or by chromatographic gel shifts induced with monoclonal anti-FPA antibody. The weak aggregation of alpha-profibrin with itself and with fibrinogen conforms with prior indications that coupled interactions through the paired GPR sites on fibrin monomers are pivotal to their aggregation. It is suggested that alpha-profibrin may be a hypercoagulable fibrin precursor because it is converted to alpha-fibrin monomer faster than fibrinogen converts to monomer.	CARDIOL RES CTR,INST EXPT CARDIOL,MOSCOW 121552,RUSSIA; KLINIKUM STADT MANNHEIM,D-8167 MANNHEIM,GERMANY; BOEHRINGER MANNHEIM GMBH,NEW DIAGNOST DIV,D-8132 TUTZING,GERMANY	National Medical Research Center of Cardiology; Ruprecht Karls University Heidelberg	Shainoff, JR (corresponding author), CLEVELAND CLIN FDN,RES INST FF40,DEPT CELL BIOL,CLEVELAND,OH 44195, USA.				NHLBI NIH HHS [HL-16361] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016361] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABILDGAARD U, 1964, SCAND J CLIN LAB INV, V16, P531, DOI 10.3109/00365516409060551; BAILEY K, 1951, NATURE, V167, P233, DOI 10.1038/167233a0; BALE MD, 1982, BIOPOLYMERS, V21, P2265, DOI 10.1002/bip.360211113; BANG NU, 1974, SEM THROMB HEMOSTASI, V1, P91; BLOMBACK B, 1968, NATURE, V218, P130, DOI 10.1038/218130a0; BLOMBACK B, 1972, J BIOL CHEM, V247, P1496; BLOMBACK B, 1958, ACTA PHYSIOL SCAND, V43, P1; BLOMBACK B, 1958, ARK KEMI, V12, P299; BUDZYNSK.AZ, 1974, J BIOL CHEM, V249, P2294; DARDIK BN, 1979, THROMB HAEMOSTASIS, V42, P864; DARDIK BN, 1985, BLOOD, V65, P680; DEMPFLE CE, 1993, BLOOD COAGUL FIBRIN, V4, P79, DOI 10.1097/00001721-199304010-00013; DONNELLY JW, 1955, ARCH BIOCHEM BIOPHYS, V56, P369; EBERT RF, 1985, ANAL BIOCHEM, V148, P70, DOI 10.1016/0003-2697(85)90629-3; FERRY JD, 1954, PHYSIOL REV, V34, P753, DOI 10.1152/physrev.1954.34.4.753; FRANCIS CW, 1982, SEMIN THROMB HEMOST, V8, P25, DOI 10.1055/s-2007-1005040; GLADNER JA, 1959, J BIOL CHEM, V234, P62; HENSCHEN A, 1990, ADV EXP MED BIOL, V281, P49; HUNZIKER EB, 1990, J BIOL CHEM, V265, P7455; HURLETJENSEN A, 1982, THROMB RES, V27, P419, DOI 10.1016/0049-3848(82)90059-7; IKEGAKI N, 1989, J IMMUNOL METHODS, V124, P205, DOI 10.1016/0022-1759(89)90354-2; JANMEY PA, 1983, BIOCHEMISTRY-US, V22, P4336, DOI 10.1021/bi00287a026; JANMEY PA, 1983, BIOPOLYMERS, V22, P2017, DOI 10.1002/bip.360220902; JANMEY PA, 1982, BIOPOLYMERS, V21, P2253, DOI 10.1002/bip.360211112; KANAIDE H, 1975, J LAB CLIN MED, V85, P574; KAWASAKI K, 1992, CHEM PHARM BULL, V40, P3253, DOI 10.1248/cpb.40.3253; KAWASAKI K, 1993, CHEM PHARM BULL, V41, P975; KUDRYK BJ, 1974, J BIOL CHEM, V249, P3322; LANDIS WJ, 1975, ARCH BIOCHEM BIOPHYS, V168, P498, DOI 10.1016/0003-9861(75)90280-5; LAUDANO AP, 1978, P NATL ACAD SCI USA, V75, P3085, DOI 10.1073/pnas.75.7.3085; LAUDANO AP, 1983, ANN NY ACAD SCI, V408, P315, DOI 10.1111/j.1749-6632.1983.tb23254.x; LORAND L, 1951, NATURE, V167, P992, DOI 10.1038/167992a0; MARDER VJ, 1969, J BIOL CHEM, V244, P2111; MARSHALL AG, 1978, BIOPHYSICAL CHEM PRI; MCFARLANE AS, 1963, J CLIN INVEST, V42, P346, DOI 10.1172/JCI104721; MEH DA, 1995, J LAB CLIN MED, V125, P384; MEH DA, 1993, BLOOD COAGUL FIBRIN, V4, P107; NASKI MC, 1991, J BIOL CHEM, V266, P13003; NASKI MC, 1990, J BIOL CHEM, V265, P1401; OLEXA SA, 1980, P NATL ACAD SCI-BIOL, V77, P1374, DOI 10.1073/pnas.77.3.1374; PAPP AC, 1989, THROMB HAEMOSTASIS, V61, P15; PATESTOS NP, 1988, ELECTROPHORESIS, V9, P488, DOI 10.1002/elps.1150090908; PRENTICE CRM, 1970, BRIT J HAEMATOL, V13, P898; SANCHEZMADRID F, 1982, CELL IMMUNOL, V73, P1, DOI 10.1016/0008-8749(82)90431-2; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SELMAYR E, 1988, BIOPOLYMERS, V27, P1733, DOI 10.1002/bip.360271104; SHAINOFF J R, 1986, Biotechniques, V4, P120; SHAINOFF JR, 1991, J BIOL CHEM, V266, P6429; SHAINOFF JR, 1983, ANN NY ACAD SCI, V408, P254, DOI 10.1111/j.1749-6632.1983.tb23249.x; SHAINOFF JR, 1962, J EXP MED, V116, P687, DOI 10.1084/jem.116.5.687; SHAINOFF JR, 1979, SCIENCE, V204, P200, DOI 10.1126/science.155308; SHAINOFF JR, 1960, CIRC RES, V8, P1013, DOI 10.1161/01.RES.8.5.1013; SHAINOFF JR, 1993, BLOOD COAGUL FIBRIN, V4, P87, DOI 10.1097/00001721-199304010-00014; SHAINOFF JR, 1994, J THORAC CARDIOV SUR, V108, P437, DOI 10.1016/S0022-5223(94)70253-5; SHAINOFF JR, 1985, FIBRINOGEN STRUCTURA, P91; SHAINOFF JR, 1993, AD ELECTROP, V6, P61; SHAINOFF JR, 1970, THROMB DIATH HAEMO, V39, P203; SHULMAN S, 1951, J PHYS COLLOID CHEM, V55, P135, DOI 10.1021/j150484a015; SIEBENLIST KR, 1990, J BIOL CHEM, V265, P18650; SMITH GF, 1980, BIOCHEM J, V185, P1; STURTEVANT JM, 1955, J AM CHEM SOC, V77, P6168, DOI 10.1021/ja01628a021; VALENZUELA R, 1992, AM J PATHOL, V141, P861; WEISEL JW, 1993, J BIOL CHEM, V268, P26618; WEISEL JW, 1986, BIOPHYS J, V50, P1079, DOI 10.1016/S0006-3495(86)83552-4; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; WILF J, 1986, BIOCHEMISTRY-US, V25, P3124, DOI 10.1021/bi00359a009	66	25	29	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24129	24137		10.1074/jbc.271.39.24129	http://dx.doi.org/10.1074/jbc.271.39.24129			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798652	hybrid			2022-12-27	WOS:A1996VJ44200081
J	Behrens, TW; Kearns, GM; Rivard, JJ; Bernstein, HD; Yewdell, JW; Staudt, LM				Behrens, TW; Kearns, GM; Rivard, JJ; Bernstein, HD; Yewdell, JW; Staudt, LM			Carboxyl-terminal targeting and novel post-translational processing of JAW1, a lymphoid protein of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; TRANSMEMBRANE PROTEINS; MEMBRANE-PROTEINS; MICROSOMAL-MEMBRANES; MAMMALIAN-CELLS; TRANSLOCATION; SEQUENCE; TRANSPORT; RETENTION; RESIDUES	Jaw1 is a lymphoid-restricted protein localized to the cytoplasmic face of the endoplasmic reticulum (ER) and is a member of a recently recognized class of integral membrane proteins that contain carboxyl-terminal membrane anchors. The carboxyl-terminal 71 amino acids of the Jaw1 protein, which contain a hydrophobic membrane spanning region, are sufficient to target a heterologous protein to the ER. By discontinuous sucrose gradient ultracentrifugation, differential sedimentation was noted for the four major Jaw1 protein isoforms, with two of the forms predominantly soluble and two microsome-bound. Pulse-chase immunoprecipitations suggest a post translational modification of two major isoforms of the protein resulting in an increase in mobility on SDS-polyacrylamide gel electrophoresis. In. vitro translation studies are compatible with a posttranslational processing event that results in cleavage of a short 36 amino acid lumenal domain. These findings define a carboxyl-terminal domain of the Jaw1 protein that is both necessary and sufficient for ER localization. In addition, the processing of the small lumenal domain of Jaw1 represents a novel post-translational protein modification performed by the endoplasmic reticulum.	NCI,METAB BRANCH,BETHESDA,MD 20892; NIDDK,GENET & BIOCHEM BRANCH,BETHESDA,MD 20892; NIH,VIRAL DIS LAB,NIAID,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Behrens, TW (corresponding author), UNIV MINNESOTA,SCH MED,UMHC,DEPT MED,BOX 108,515 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.		Staudt, Louis/AAC-5324-2019; yewdell, jyewdell@nih.gov jonathan/A-1702-2012		NIAMS NIH HHS [AR01959] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001959] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P7249, DOI 10.1073/pnas.80.23.7249; BEHRENS TW, 1994, J IMMUNOL, V153, P682; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORREAROTTER R, 1992, BIOTECHNIQUES, V12, P154; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, J CELL SCI, V105, P481; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JANTTI J, 1994, J CELL SCI, V107, P3623; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MITOMA JY, 1992, EMBO J, V11, P4197, DOI 10.1002/j.1460-2075.1992.tb05513.x; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RAPOPORT TA, 1991, FASEB J, V5, P2792, DOI 10.1096/fasebj.5.13.1916103; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; Simon S, 1993, CURR OPIN CELL BIOL, V5, P581, DOI 10.1016/0955-0674(93)90126-B; SITIA R, 1992, MOL BIOL CELL, V3, P1067, DOI 10.1091/mbc.3.10.1067; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; SWEET DJ, 1992, EMBO J, V11, P423, DOI 10.1002/j.1460-2075.1992.tb05071.x; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735; ZOPF D, 1993, J CELL BIOL, V120, P1113, DOI 10.1083/jcb.120.5.1113	37	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23528	23534		10.1074/jbc.271.38.23528	http://dx.doi.org/10.1074/jbc.271.38.23528			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798562	hybrid			2022-12-27	WOS:A1996VH76800088
J	Borden, P; Solymar, D; Sucharczuk, A; Lindman, B; Cannon, P; Heller, RA				Borden, P; Solymar, D; Sucharczuk, A; Lindman, B; Cannon, P; Heller, RA			Cytokine control of interstitial collagenase and collagenase-3 gene expression in human chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOPROTEINASES; ACTIVATOR; FOS; BINDING; CELLS; AP-1; TPA; JUN	Human collagenase-3 expression, previously seen only in a breast tumor tissue, is here shown to be expressed in primary human chondrocytes derived from the joint tissue and in transformed human chondrocytes. Its mRNA is inducible by the inflammatory cytokines interleukin-1 beta plus tumor necrosis factor-alpha, but not by phorbol 12-myristate 13-acetate and only slightly by the growth factors platelet-derived growth factor and epidermal growth factor. Human synovial fibroblasts, another prominent cell type in the joint tissue, do not produce collagenase-3 message, Expression of the murine collagenase, which is possibly the counterpart of human collagenase-3, is induced by interleukin-1 beta plus tumor necrosis factor-alpha, and its full induction requires the presence of the transcription factor, c-FOS, This family of transcription factors also plays a role in induction of human collagenase-3, since it binds to the AP-1 site of this matrix metalloproteinase.	ROCHE BIOSCI,PALO ALTO,CA 94304	Roche Holding				Lindman, Brian/0000-0002-6879-5343				Alexander CM, 1991, CELL BIOL EXTRACELLU, P255; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GADHER SJ, 1987, RHEUMATOL INT, V7, P13, DOI 10.1007/BF00267337; HELLER RA, 1992, CELL, V70, P47; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MEATS JE, 1980, NATURE, V286, P891, DOI 10.1038/286891a0; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; PENDAS AM, 1995, GENOMICS, V26, P615, DOI 10.1016/0888-7543(95)80186-P; QUINONES S, 1989, J BIOL CHEM, V264, P8339; RYSECK RP, 1991, ONCOGENE, V6, P533; SCIAVOLINO PJ, 1994, J BIOL CHEM, V269, P21627; SHYY YJ, 1990, BIOCHEM BIOPH RES CO, V169, P346, DOI 10.1016/0006-291X(90)90338-N; ZVAIFLER NJ, 1994, ARTHRITIS RHEUM, V37, P783, DOI 10.1002/art.1780370601	25	159	163	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23577	23581		10.1074/jbc.271.38.23577	http://dx.doi.org/10.1074/jbc.271.38.23577			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798568	hybrid			2022-12-27	WOS:A1996VH76800094
J	Buse, MG; Robinson, KA; Marshall, BA; Mueckler, M				Buse, MG; Robinson, KA; Marshall, BA; Mueckler, M			Differential effects of GLUT1 or GLUT4 overexpression on hexosamine biosynthesis by muscles of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT SYSTEM; RAT SKELETAL-MUSCLES; INSULIN-RESISTANCE; METABOLIC-REGULATION; EXPRESSION; PATHWAY; MECHANISMS	Transgenic mice that overexpress GLUT1 or GLUT4 in skeletal muscle were studied; the former but not the latter develop insulin resistance. Because increased glucose flux via the hexosamine biosynthesis pathway has been implicated in glucose-induced insulin resistance, we measured the activity of glutamine:fructose-6-phosphate amidotransferase (GFAT; rate-limiting enzyme) and the concentrations of UDP-N-acetyl hexosamines (major products of the pathway) as well as UDP-hexoses and GDP-mannose in hind limb muscles and liver in both transgenic models and controls. GFAT activity was increased 60-70% in muscles of GLUT1 but not in GLUT4 transgenics. GFAT mRNA abundance was unchanged. The concentrations of all nucleotide-linked sugars were increased 2-3-fold in GLUT1 and were unchanged in GLUT4-overexpressing muscles. Similar results were obtained in fed and fasted mice. GFAT and nucleotide sugars were unchanged in liver, where the transgene is not expressed. We concluded that 1) glucose transport appears to be rate limiting for synthesis of nucleotide sugars; 2) chronically increased glucose flux increases muscle GFAT activity posttranscriptionally; 3) increased UDP-glucose likely accounts for the marked glycogen accumulation in muscles of GLUT1-overexpressing mice; and 4) glucose flux via the hexosamine biosynthetic pathway is increased in muscles of GLUT1-overexpressing but not GLUT4-overexpressing mice; products of the pathway may contribute to insulin resistance in GLUT1 transgenics.	MED UNIV S CAROLINA,DEPT DIABET & MED GENET,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT BIOCHEM MOL BIOL,CHARLESTON,SC 29425; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Medical University of South Carolina; Medical University of South Carolina; Washington University (WUSTL); Washington University (WUSTL)	Buse, MG (corresponding author), MED UNIV S CAROLINA,DEPT MED,DIV ENDOCRINOL,171 ASHLEY AVE,CHARLESTON,SC 29425, USA.		Mueckler, Mike M/F-6115-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK002001, R01DK038495, R01DK050332, R01DK002001] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38495, DK-02001, DK 50332] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; BELL GI, 1993, J BIOL CHEM, V268, P19161; BUSE MG, 1996, DIABETES S2, V45, pA250; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Daniels MC, 1996, J CLIN INVEST, V97, P1235, DOI 10.1172/JCI118538; DANIELS MC, 1993, MOL ENDOCRINOL, V7, P1041, DOI 10.1210/me.7.8.1041; ETCHEBEHERE LC, 1993, J BACTERIOL, V175, P5022, DOI 10.1128/JB.175.16.5022-5027.1993; FRISA PS, 1982, P NATL ACAD SCI USA, V179, P6289; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GULVE EA, 1994, J BIOL CHEM, V269, P18366; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KERN M, 1990, BIOCHEM J, V270, P397, DOI 10.1042/bj2700397; KLIP A, 1990, DIABETES CARE, V13, P228, DOI 10.2337/diacare.13.3.228; KORNFELD S, 1964, P NATL ACAD SCI USA, V52, P371, DOI 10.1073/pnas.52.2.371; LIU ML, 1993, P NATL ACAD SCI USA, V90, P11346, DOI 10.1073/pnas.90.23.11346; MARSHALL BA, 1993, J BIOL CHEM, V268, P18442; MARSHALL BA, 1994, AM J PHYSIOL-ENDOC M, V267, pE738, DOI 10.1152/ajpendo.1994.267.5.E738; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P25208; OLSON AL, 1993, J BIOL CHEM, V268, P9839; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; POGALOTTI AL, 1982, ANAL BIOCHEM, V126, P335; REN JM, 1993, J BIOL CHEM, V268, P16113; ROBINSON KA, 1995, DIABETES, V44, P1438, DOI 10.2337/diabetes.44.12.1438; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; SPIRO MJ, 1984, DIABETOLOGIA, V26, P70; STARON RS, 1993, COMP BIOCHEM PHYS B, V106, P463, DOI 10.1016/0305-0491(93)90120-T; YKIYARVINEN H, 1996, DIABETES, V45, P302; ZHOU JX, 1995, DIABETES, V44, pA165	33	56	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23197	23202		10.1074/jbc.271.38.23197	http://dx.doi.org/10.1074/jbc.271.38.23197			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798515	hybrid			2022-12-27	WOS:A1996VH76800041
J	Samkurashvili, I; Luse, DS				Samkurashvili, I; Luse, DS			Translocation and transcriptional arrest during transcript elongation by RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEXES; FACTOR-SII; TERMINATION; CLEAVAGE; INVITRO; DNA; TEMPLATES; TFIIS	RNA polymerase II may stop transcription, or arrest, while transcribing certain DNA sequences. The molecular basis for arrest is not well understood, but a connection has been suggested between arrest and a transient failure of the polymerase to translocate along the template. We have investigated this question by monitoring the movement of RNA polymerase II along a number of templates, using exonuclease III protection as our assay. We found that normal transcription is accompanied by essentially coordinate movement of the active site and both the leading and trailing edges of the polymerase. However, as polymerase approaches an arrest site, translocation of the body of the polymerase stops while transcription continues, leading to an arrested complex in which the 3' end of the transcript is located much closer than normal to the front edge of the polymerase. Surprisingly, mutated arrest sites that no longer block transcription continue to direct the transient failure of polymerase translocation. As transcription proceeds through these sequences, the initially stationary polymerase moves forward 10-15 bases along the template in response to the addition of only 3 bases to the nascent RNA. Mutagenesis studies indicate that the sequences responsible for the transient block to polymerase movement are located downstream of the T-rich motif required for arrest, Our results indicate that blocking translocation is not sufficient to cause arrest.	CLEVELAND CLIN FDN,DEPT MOL BIOL,RES INST,CLEVELAND,OH 44195; UNIV CINCINNATI,COLL MED,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	Cleveland Clinic Foundation; University System of Ohio; University of Cincinnati					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029487] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29487] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; GU WG, 1993, J BIOL CHEM, V268, P25604; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1989, J BIOL CHEM, V264, P10799; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SPENCER CA, 1990, ONCOGENE, V5, P777; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	26	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23495	23505		10.1074/jbc.271.38.23495	http://dx.doi.org/10.1074/jbc.271.38.23495			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798558	hybrid			2022-12-27	WOS:A1996VH76800084
J	ONeill, MA; Warrenfeltz, D; Kates, K; Pellerin, P; Doco, T; Darvill, AG; Albersheim, P				ONeill, MA; Warrenfeltz, D; Kates, K; Pellerin, P; Doco, T; Darvill, AG; Albersheim, P			Rhamnogalacturonan-II, a pectic polysaccharide in the walls of growing plant cell, forms a dimer that is covalently cross-linked by a borate ester - In vitro conditions for the formation and hydrolysis of the dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL CHARACTERIZATION; MAGNETIC-RESONANCE; TOBACCO CELLS; GROWTH; BORON; ACID; LOCALIZATION; SPECTROSCOPY; ELONGATION; STABILITY	Rhamnogalacturonan II (RG-II) is a structurally complex pectic polysaccharide present in the walls of growing plant cells. We now report that RG-II, released by endopolygalacturonase treatment of the walls of suspension-cultured sycamore cells and etiolated pea stems, exists mainly as a dimer that is cross-linked by a borate ester. The borate ester is completely hydrolyzed at room temperature within 30 min at pH 1, partially hydrolyzed between pH 2 and 4, and stable above pH 4. The dimer is formed in vitro between pH 2.4 and 6.2 by treating monomeric RG-II (0.5 mM) with boric acid (1.2 mM); the dimer formed after 24 h at pH 3.4 and 5.0 accounts for similar to 30 and similar to 5%, respectively, of the RG-II. In contrast, the dimer accounts for similar to 80 and similar to 54% of the RG-II when the monomer is treated for 24 h at pH 3.4 and 5.0, respectively, with boric acid and 0.5 mM Sr2+, Pb2+, or Ba2+, The amount of dimer formed at pH 3.4 or 5.0 is not increased by addition of 0.5 mM Ca2+, Cd2+, Cu2+, Mg2+, Ni2+, and Zn2+. Steric considerations appear to regulate dimer formation since those divalent cations that enhance dimer formation have an ionic radius >1.1 Angstrom. Our data suggest that the borate ester is located on C-2 and C-3 of two of the four 3'-linked apiosyl residues of dimeric RG-II, Our results, taken together with the results of two previous studies (Kobayashi, M., Matoh, T., and Azuma, J.-I. (1996) Plant Physiol. 110, 1017-1020; Ishii, T., and Matsunaga, T. (1996) Carbohydr. Res. 284, 1-9) provide substantial evidence that this plant cell wall pectic polysaccharide is covalently cross-linked.	UNIV GEORGIA, DEPT BIOCHEM & MOL BIOL, ATHENS, GA 30602 USA; INRA, INST PROD VIGNE, LAB POLYMERES & TECH PHYSICOCHIM, F-34060 MONTPELLIER, FRANCE	University System of Georgia; University of Georgia; INRAE	ONeill, MA (corresponding author), UNIV GEORGIA, COMPLEX CARBOHYDRATE RES CTR, 220 RIVERBEND RD, ATHENS, GA 30602 USA.			Doco, Thierry/0000-0002-1453-8683				ALBERSHEIM P, 1975, SCI AM, V232, P81; BARONEPEL O, 1988, PLANTA, V175, P389, DOI 10.1007/BF00396345; BROWN JA, 1993, PLANT PHYSIOL, V103, P993, DOI 10.1104/pp.103.3.993; BROWN PH, 1994, PHYSIOL PLANTARUM, V91, P435, DOI 10.1111/j.1399-3054.1994.tb02971.x; CALDEIRA MM, 1994, INORG CHIM ACTA, V221, P69; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; COSGROVE DJ, 1993, PLANT PHYSIOL, V102, P1, DOI 10.1104/pp.102.1.1; COSGROVE DJ, 1993, NEW PHYTOL, V124, P1, DOI 10.1111/j.1469-8137.1993.tb03795.x; DARVILL AG, 1978, PLANT PHYSIOL, V62, P418, DOI 10.1104/pp.62.3.418; Deuel H., 1954, NATURAL PLANT HYDROC, P51, DOI [10.1021/ba-1954-0011.ch009, DOI 10.1021/BA-1954-0011.CH009]; DOCO T, 1993, CARBOHYD RES, V243, P333, DOI 10.1016/0008-6215(93)87037-S; DRAKE LR, 1996, ANAL CHEM, V69, pA22; HU HI, 1994, PLANT PHYSIOL, V105, P681, DOI 10.1104/pp.105.2.681; Hu HN, 1996, J EXP BOT, V47, P227, DOI 10.1093/jxb/47.2.227; Ishii T, 1996, CARBOHYD RES, V284, P1, DOI 10.1016/0008-6215(96)00010-9; JACKSON PJ, 1990, J ENVIRON QUAL, V19, P644, DOI 10.2134/jeq1990.00472425001900040003x; KEEGSTRA K, 1973, PLANT PHYSIOL, V51, P188, DOI 10.1104/pp.51.1.188; KIM JB, 1992, PLANT PHYSIOL, V98, P646, DOI 10.1104/pp.98.2.646; Kobayashi M, 1996, PLANT PHYSIOL, V110, P1017, DOI 10.1104/pp.110.3.1017; KUTSCHERA U, 1994, NEW PHYTOL, V126, P549, DOI 10.1111/j.1469-8137.1994.tb02951.x; LOOMIS WD, 1992, BIOFACTORS, V3, P229; MAKKEE M, 1985, RECL TRAV CHIM PAY B, V104, P230; MARFA V, 1991, PLANT J, V1, P217, DOI 10.1111/j.1365-313X.1991.00217.x; MATOH T, 1993, PLANT CELL PHYSIOL, V34, P639; MCCANN MC, 1994, PLANT J, V5, P773, DOI 10.1046/j.1365-313X.1994.5060773.x; McCann MC, 1991, CYTOSKELETAL BASIS P, P109; MOHR MD, 1995, RAPID COMMUN MASS SP, V9, P809, DOI 10.1002/rcm.1290090919; ONEILL MA, 1991, METHODS PLANT BIOCH, V2, P415; PELLERIN P, 1996, IN PRESS CARBOHYDR R; PETERS JA, 1983, RECL TRAV CHIM PAY B, V102, P381; RAYLE DL, 1992, PLANT PHYSIOL, V99, P1271, DOI 10.1104/pp.99.4.1271; REDGWELL RJ, 1991, CARBOHYD RES, V209, P191, DOI 10.1016/0008-6215(91)80156-H; SALT DE, 1995, BIO-TECHNOL, V13, P468, DOI 10.1038/nbt0595-468; SHELP BJ, 1995, PHYSIOL PLANTARUM, V94, P356, DOI 10.1111/j.1399-3054.1995.tb05323.x; SPELLMAN MW, 1983, CARBOHYD RES, V122, P131, DOI 10.1016/0008-6215(83)88413-4; STEVENSON TT, 1988, CARBOHYD RES, V182, P207, DOI 10.1016/0008-6215(88)84004-7; THOMAS JR, 1987, PLANT PHYSIOL, V83, P659, DOI 10.1104/pp.83.3.659; THOMAS JR, 1989, CARBOHYD RES, V185, P261, DOI 10.1016/0008-6215(89)80041-2; VANDENBERG R, 1994, CARBOHYD RES, V253, P1, DOI 10.1016/0008-6215(94)80050-2; VANDUIN M, 1984, TETRAHEDRON, V40, P2901, DOI 10.1016/S0040-4020(01)91300-6; Weast R. C., 1983, HDB CHEM PHYS, pF; WELCH RM, 1995, CRIT REV PLANT SCI, V14, P49, DOI 10.1080/713608066; WHITCOMBE AJ, 1995, CARBOHYD RES, V271, P15, DOI 10.1016/0008-6215(94)00002-W; York WS, 1985, METHOD ENZYMOL, P3, DOI DOI 10.1016/0076-6879(86)18062-1	44	402	424	3	54	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22923	22930		10.1074/jbc.271.37.22923	http://dx.doi.org/10.1074/jbc.271.37.22923			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798473	hybrid, Green Published			2022-12-27	WOS:A1996VG67200092
J	Petrovic, N; Black, TA; Fabian, JR; Kane, C; Jones, CA; Loudon, JA; Abonia, JP; Sigmund, CD; Gross, KW				Petrovic, N; Black, TA; Fabian, JR; Kane, C; Jones, CA; Loudon, JA; Abonia, JP; Sigmund, CD; Gross, KW			Role of proximal promoter elements in regulation of renin gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; TRANSGENIC MICE; MAMMALIAN-CELLS; CULTURED-CELLS; FACTOR PIT-1; REN-2 GENE; MOUSE; DNA; IDENTIFICATION; PROTEIN	Mouse As4.1 cells, obtained after transgene-targeted oncogenesis to induce neoplasia in renal renin-expressing cells, express high levels of renin mRNA from the endogenous Ren-1(c) gene. We have used these cells to characterize the role of the Ren-lc proximal promoter (+6 to -117) in the regulation of renin gene transcription. It was found that 4.1 kilobases (kb) of Ren-1(c) 5'-flanking sequence, in combination with the proximal promoter, are required for strong activation (similar to 2 orders of magnitude over the basal level of the promoter alone) of the chloramphenicol acetyltransferase reporter in transfection assays. Within the 4.1-kb fragment, a 241-base pair region was identified that retains full activity in an orientation-independent manner in combination with the promoter. The resulting transcripts initiate at the normal renin start site. Electrophoretic mobility shift assays identified a sequence at approximately position -60 in the promoter region that binds nuclear proteins specific for renin-expressing As4.1 cells. Mutations in this sequence, which disrupt binding of nuclear protein(s), completely abolish activation of transcription by the 4.1-kb fragment. Activation of transcription by the 241-base pair enhancer was still observed, although it was diminished in magnitude (60-fold over the mutated promoter alone). We present a model derived from the current data that suggests that regulation of renin expression is achieved through cooperation of transcription factors binding at the proximal promoter element and a distal enhancer element to abrogate or override the effects of an intervening negative regulatory region.	ROSWELL PK CANC INST, DEPT MOL & CELLULAR BIOL, BUFFALO, NY 14263 USA; UNIV IOWA, COLL MED, DEPT INTERNAL MED, DIV CARDIOVASC DIS, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	Roswell Park Cancer Institute; University of Iowa; University of Iowa			Sigmund, Curt D./W-1611-2019	Sigmund, Curt D./0000-0002-1453-0921	NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048459, R01HL035792] Funding Source: NIH RePORTER; NCI NIH HHS [CA16056] Funding Source: Medline; NHLBI NIH HHS [HL35792, HL48459] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM, 1988, MOL REPROD DEV; BARRETT G, 1992, P NATL ACAD SCI USA, V89, P885, DOI 10.1073/pnas.89.3.885; BORENSZTEIN P, 1994, CIRC RES, V74, P764, DOI 10.1161/01.RES.74.5.764; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURT DW, 1989, J BIOL CHEM, V264, P7357; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; EKKER M, 1989, P NATL ACAD SCI USA, V86, P5155, DOI 10.1073/pnas.86.13.5155; FABIAN JR, 1989, J BIOL CHEM, V264, P17589; FIELD LJ, 1984, HYPERTENSION, V6, P597, DOI 10.1161/01.HYP.6.4.597; FIELD LJ, 1985, P NATL ACAD SCI USA, V82, P6196, DOI 10.1073/pnas.82.18.6196; FIELD LJ, 1984, MOL CELL BIOL, V4, P2321, DOI 10.1128/MCB.4.11.2321; GILBERT MT, 1994, J BIOL CHEM, V269, P28049; GOMEZ RA, 1988, AM J PHYSIOL, V254, pF900, DOI 10.1152/ajprenal.1988.254.6.F900; GOMEZ RA, 1989, AM J PHYSIOL, V257, pF850, DOI 10.1152/ajprenal.1989.257.5.F850; GOMEZ RA, 1988, AM J PHYSIOL, V254, pF582, DOI 10.1152/ajprenal.1988.254.4.F582; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HACKENTHAL E, 1990, PHYSIOL REV, V70, P1067, DOI 10.1152/physrev.1990.70.4.1067; HARTROFT PM, 1963, CIRC RES, V12, P525, DOI 10.1161/01.RES.12.5.525; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; HORIUCHI M, 1993, J CLIN INVEST, V92, P1805, DOI 10.1172/JCI116770; JONES CA, 1990, MOL ENDOCRINOL, V4, P375, DOI 10.1210/mend-4-3-375; KIT S, 1963, EXP CELL RES, V31, P297, DOI 10.1016/0014-4827(63)90007-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURTZ A, 1989, REV PHYSIOL BIOCH P, V113, P1; LINDOP GBM, 1986, HISTOPATHOLOGY, V10, P335, DOI 10.1111/j.1365-2559.1986.tb02489.x; MILLER CCJ, 1989, NUCLEIC ACIDS RES, V17, P3117, DOI 10.1093/nar/17.8.3117; MULLINS JJ, 1982, EMBO J, V1, P1461, DOI 10.1002/j.1460-2075.1982.tb01338.x; MULLINS JJ, 1989, EMBO J, V8, P4065, DOI 10.1002/j.1460-2075.1989.tb08590.x; NAKAMURA N, 1989, P NATL ACAD SCI USA, V86, P56, DOI 10.1073/pnas.86.1.56; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; PANTHIER JJ, 1982, EMBO J, V1, P1417, DOI 10.1002/j.1460-2075.1982.tb01332.x; PHILBRICK WM, 1989, LIFE SCI ADV MOL GEN, V8, P21; PICCINI N, 1982, CELL, V30, P205, DOI 10.1016/0092-8674(82)90026-5; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SIGMUND CD, 1991, HYPERTENSION, V18, P446, DOI 10.1161/01.HYP.18.4.446; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; SIGMUND CD, 1990, BIOCHEM BIOPH RES CO, V170, P344, DOI 10.1016/0006-291X(90)91280-6; SIGMUND CD, 1990, P NATL ACAD SCI USA, V87, P7993, DOI 10.1073/pnas.87.20.7993; SIGMUND CD, 1991, AM J PHYSIOL, V260, pF249, DOI 10.1152/ajprenal.1991.260.2.F249; SMITH DL, 1991, MOL CELL ENDOCRINOL, V80, P139, DOI 10.1016/0303-7207(91)90150-Q; SOLA C, 1989, ONCOGENE RES, V5, P149; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; SOUBRIER F, 1986, GENE, V41, P85, DOI 10.1016/0378-1119(86)90270-2; SUGIYAMA F, 1993, J VET MED SCI, V55, P537, DOI 10.1292/jvms.55.537; SUN JD, 1993, J BIOL CHEM, V268, P1505; SUN JD, 1994, CIRC RES, V75, P624, DOI 10.1161/01.RES.75.4.624; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P3617, DOI 10.1093/nar/20.14.3617; TAMURA K, 1994, J CLIN INVEST, V94, P1959, DOI 10.1172/JCI117547; TRONIK D, 1987, EMBO J, V6, P983, DOI 10.1002/j.1460-2075.1987.tb04848.x; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; YAMADA T, 1995, J CLIN INVEST, V96, P1230, DOI 10.1172/JCI118156	54	91	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22499	22505		10.1074/jbc.271.37.22499	http://dx.doi.org/10.1074/jbc.271.37.22499			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798416	hybrid			2022-12-27	WOS:A1996VG67200035
J	Silve, S; Dupuy, PH; LabitLebouteiller, C; Kaghad, M; Chalon, P; Rahier, A; Taton, M; Lupker, J; Shire, D; Loison, G				Silve, S; Dupuy, PH; LabitLebouteiller, C; Kaghad, M; Chalon, P; Rahier, A; Taton, M; Lupker, J; Shire, D; Loison, G			Emopamil-binding protein, a mammalian protein that binds a series of structurally diverse neuroprotective agents, exhibits Delta 8-Delta 7 sterol isomerase activity in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOGEN USTILAGO-MAYDIS; SIGMA-RECEPTOR LIGAND; GUINEA-PIG LIVER; CHOLESTEROL-BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; ERG2 GENE; INHIBITION; FENPROPIMORPH	Delta 8-Delta 7 sterol isomerase is an essential enzyme on the sterol biosynthesis pathway in eukaryotes. This endoplasmic reticulum-resident membrane protein catalyzes the conversion of Delta 8-sterols to their corresponding Delta 7-isomers, No sequence data for high eukaryote sterol isomerase being available so far, we have cloned a murine sterol isomerase-encoding cDNA by functional complementation of the corresponding deficiency in the yeast. Saccharomyces cerevisiae. The amino acid sequence deduced from the cDNA open reading frame is highly similar to human emopamil-binding protein (EBP), a protein of unknown function that constitutes a molecular target for neuroprotective drugs. A yeast strain in which the sterol isomerase coding sequence has been replaced by that of human EBP or its murine homologue recovers the ability to convert Delta 8-sterol into Delta 7-sterol, both in vivo and in vitro. In these recombinant strains, both cell proliferation and the sterol isomerization reaction are inhibited by the high affinity EBP ligand trifluoperazine, as is the case in mammalian cells but not in wild type yeast cell. In contrast, the recombinant strains are much less susceptible to the sterol inhibition effect of haloperidol and fenpropimorph, as compared with wild type yeast strains, Our results strongly suggest that EBP and Delta 8-Delta 7 sterol isomerase are identical proteins in mammals.	SANOFI RECH,DEPT MICROBIOL,F-31676 LABEGE,FRANCE; SANOFI RECH,DEPT ANIM CELL TECHNOL,F-31676 LABEGE,FRANCE; SANOFI RECH,DEPT GENE MOL BIOL,F-31676 LABEGE,FRANCE; SANOFI RECH,DEPT ORGAN CHEM,F-31676 LABEGE,FRANCE; INST BOT,DEPT CELLULAR & MOL ENZYMOL,F-67083 STRASBOURG,FRANCE	Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France								ARTHINGTON BA, 1991, GENE, V107, P173, DOI 10.1016/0378-1119(91)90314-2; ASHMAN WH, 1991, LIPIDS, V26, P628, DOI 10.1007/BF02536427; BAILEY AM, 1994, EXP MYCOL, V18, P87, DOI 10.1006/emyc.1994.1009; BAKER CH, 1995, BIOCHEM BIOPH RES CO, V213, P154, DOI 10.1006/bbrc.1995.2110; BALOCH RI, 1987, PHYTOCHEMISTRY, V26, P663, DOI 10.1016/S0031-9422(00)84762-7; Bergeron R, 1996, J NEUROSCI, V16, P1193; CIGAN AM, 1987, GENE, V59, P1; CORIOCOSTET MF, 1988, BIOCHEM J, V256, P829, DOI 10.1042/bj2560829; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P317; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HANNER M, 1995, J BIOL CHEM, V270, P7551, DOI 10.1074/jbc.270.13.7551; HAYASGU T, 1993, J PHARMACOL EXP THER, V267, P1423; KANG MK, 1995, J BIOCHEM-TOKYO, V117, P819, DOI 10.1093/oxfordjournals.jbchem.a124781; KAY G, 1983, BIOCHEM BIOPH RES CO, V110, P82, DOI 10.1016/0006-291X(83)91263-9; KEON JPR, 1994, CURR GENET, V25, P531, DOI 10.1007/BF00351674; Klette KL, 1995, BRAIN RES, V704, P31, DOI 10.1016/0006-8993(95)01103-X; LESAGE AS, 1995, SYNAPSE, V20, P156, DOI 10.1002/syn.890200210; MARCIREAU C, 1992, CURR GENET, V22, P267, DOI 10.1007/BF00317919; MARCIREAU C, 1990, ANTIMICROB AGENTS CH, V34, P989, DOI 10.1128/AAC.34.6.989; MOEBIUS FF, 1994, J BIOL CHEM, V269, P29314; MOEBIUS FF, 1993, MOL PHARMACOL, V44, P966; MOEBIUS FF, 1993, MOL PHARMACOL, V43, P139; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; OGORODNIKA TE, 1988, GENETIKA, V24, P1367; ONEILL M, 1995, EUR J PHARMACOL, V283, P217, DOI 10.1016/0014-2999(95)00356-P; PAIK YK, 1986, J BIOL CHEM, V261, P6470; POPJAK G, 1989, J BIOL CHEM, V264, P6230; SAKAKIBARA J, 1995, J BIOL CHEM, V270, P17, DOI 10.1074/jbc.270.1.17; Sambrook J., 2002, MOL CLONING LAB MANU; Silve S, 1996, MOL CELL BIOL, V16, P2719; SU TP, 1991, EUR J BIOCHEM, V200, P633, DOI 10.1111/j.1432-1033.1991.tb16226.x; TAKAHASHI H, 1995, STROKE, V26, P1676, DOI 10.1161/01.STR.26.9.1676; VANSICKLE WA, 1993, J PHARMACOL EXP THER, V267, P1243; YAMAGA N, 1978, J LIPID RES, V19, P375	36	108	115	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22434	22440		10.1074/jbc.271.37.22434	http://dx.doi.org/10.1074/jbc.271.37.22434			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798407				2022-12-27	WOS:A1996VG67200026
J	Cairns, W; Smith, CAD; McLaren, AW; Wolf, CR				Cairns, W; Smith, CAD; McLaren, AW; Wolf, CR			Characterization of the human cytochrome P4502D6 promoter - A potential role for antagonistic interactions between members of the nuclear receptor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; RNA POLYMERASE-II; TRANSCRIPTION FACTOR; DNA-BINDING; SUPERFAMILY; HNF-4; EXPRESSION; LIVER; ORPHAN; RAT	The functional mapping of the human cytochrome P4502D6 (CYP2D6) promoter in HepG2 cells revealed the presence of both positive and negative regulatory elements. One of these regulatory elements overlapped a sequence that is highly conserved in most members of the CYP2 family, This element, which consists of a degenerate AGGTCA direct repeat spaced by 1 base pair (DR1) and is known to be a target for members of the steroid receptor superfamily, was found to bind in vitro translated hepatocyte nuclear factor 4 (HNF4) in gel retardation analysis. Using HepG2 nuclear extracts, three protein-DNA complexes were formed on the DR1 element, one of which was confirmed to be dependent on the binding of HNF4. The other DR1 complexes were shown to be due to the interaction of the orphan receptor chicken ovalbumin upstream promoter transcription factor I (COUP-TFI). Experiments in COS-7 cells showed that HNF4 could activate the CYP2D6 promoter 30-fold. Surprisingly, mutation of the DR1 element produced a relatively minor 23% decrease in activity in HepG2 cells. Additionally, COUP-TFI was shown to inhibit HNF4 stimulation of the CYP2D6 promoter in COS-7 cells, suggesting that COUP-TFI could attenuate the effect of HNF4 in HepG2 cells, However, when HNF4 levels were increased in HepG2 cells by co-transfection, it resulted in the enhancement of CYP2D6 promoter activity, indicating that HNF4 could overcome the repressive effect of COUP-TFI. Therefore, the contribution of the DR1 element in controlling the transcription of the CYP2D6 gene depends on the balance between positively and negatively acting transcription factors.	NINEWELLS HOSP, MOL PHARMACOL UNIT, IMPERIAL CANC RES FUND, CTR BIOMED RES, DUNDEE DD1 9SY, SCOTLAND	University of Dundee								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG CB, 1994, MOL CELL BIOL, V14, P5175, DOI 10.1128/MCB.14.8.5175; CHEN D, 1994, J BIOL CHEM, V269, P5420; DALY AK, 1991, PHARMACOGENETICS, V1, P33, DOI 10.1097/00008571-199110000-00006; DALY AK, 1993, PHARMACOL THERAPEUT, V57, P129, DOI 10.1016/0163-7258(93)90053-G; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERDMANN D, 1995, J BIOL CHEM, V270, P22988, DOI 10.1074/jbc.270.39.22988; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P1, DOI 10.1016/0163-7258(90)90006-N; GORMAN C, 1986, DNA CLONING, V3, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUGH AC, 1990, NATURE, V347, P773, DOI 10.1038/347773a0; HAHN CN, 1991, J BIOL CHEM, V266, P17031; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; HENDERSON CJ, 1992, PROGR DRUG METABOLIS, V13, P73; IBEANU GC, 1995, BIOCHEMISTRY-US, V34, P8028, DOI 10.1021/bi00025a008; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JAISWAL AK, 1990, NUCLEIC ACIDS RES, V18, P4237, DOI 10.1093/nar/18.14.4237; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KOOP DR, 1990, BIOESSAYS, V12, P429, DOI 10.1002/bies.950120906; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; Leng X, 1996, MOL CELL BIOL, V16, P2332; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MODE A, 1993, J REPROD FERTIL, P77; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P207; SMITH CAD, 1992, LANCET, V339, P1375, DOI 10.1016/0140-6736(92)91196-F; STROM A, 1995, J BIOL CHEM, V270, P11276, DOI 10.1074/jbc.270.19.11276; STUMPF H, 1995, CARCINOGENESIS, V16, P143, DOI 10.1093/carcin/16.1.143; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; TRAUTWEIN C, 1995, J HEPATOL, V22, P50, DOI 10.1016/0168-8278(95)80259-2; TRELUYER JM, 1991, EUR J BIOCHEM, V202, P583, DOI 10.1111/j.1432-1033.1991.tb16411.x; UENO T, 1990, MOL CELL BIOL, V10, P4495, DOI 10.1128/MCB.10.9.4495; WANG LH, 1987, J BIOL CHEM, V262, P16080; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WOLF CR, 1992, CARCINOGENESIS, V13, P1035, DOI 10.1093/carcin/13.6.1035; YANO M, 1992, MOL CELL BIOL, V12, P2847, DOI 10.1128/MCB.12.6.2847; YOKOMORI N, 1995, MOL CELL BIOL, V15, P5355; YOSHIOKA H, 1990, J BIOL CHEM, V265, P14612	50	76	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25269	25276		10.1074/jbc.271.41.25269	http://dx.doi.org/10.1074/jbc.271.41.25269			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810289	hybrid			2022-12-27	WOS:A1996VL69300033
J	Selzer, J; Hofmann, F; Rex, G; Wilm, M; Mann, M; Just, I; Aktories, K				Selzer, J; Hofmann, F; Rex, G; Wilm, M; Mann, M; Just, I; Aktories, K			Clostridium novyi alpha-toxin-catalyzed incorporation of GlcNAc into Rho subfamily proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM ADP-RIBOSYLTRANSFERASE; ACTIN STRESS FIBERS; MASS-SPECTROMETRY; CDC42 GTPASES; GENE-PRODUCT; DIFFICILE; RAC; PURIFICATION; ELECTROSPRAY; SORDELLII	The lethal and edema-inducing alpha-toxin from Clostridium novyi causes rounding up of cultured cell lines by redistribution of the actin cytoskeleton. alpha-Toxin belongs to the family of large clostridial cytotoxins that encompasses Clostridium difficile toxin A and B and the lethal toxin from Clostridium sordellii. Toxin A and toxin B have been recently identified as monoglucosyltransferases to modify the low molecular mass GTPases of the Rho subfamily (Just, I., Selzer, J., Wilm, M., Von Eichel-Streiber, C., Mann, M., and Aktories, K. (1995) Nature 375, 500-503 and Just, I., Wilm, M., Selzer, J., Rex, G., Von Eichel-Streiber, C., Mann, M., and Aktories, K. (1995) J. Biol. Chem. 270, 13932-13936). We report here the identification of the alpha-toxin-catalyzed modification of Rho. Using electrospray mass spectrometry, the mass of the modification was determined as 203 Da, consistent with a N-acetyl-hexosamine moiety. UDP-N-acetyl-glucosamine selectively served as cosubstrate for alpha-toxin-catalyzed modification into the Rho subfamily proteins Rho, Rac, Cdc42, and RhoG. The acceptor amino acid of N-acetyl-glucosaminylation was identified by mutagenesis as Thr-37 in Rho (equivalent to Thr-35 in Rac/Cdc42), which is located in the effector domain of the GTPases. C. novyi alpha-toxin seems to mediate its cytotoxic effects on cells by mimicking endogenous post-translational modification of cellular proteins.	UNIV FREIBURG, INST PHARMAKOL & TOXIKOL, D-79104 FREIBURG, GERMANY; EUROPEAN MOL BIOL LAB, D-69012 HEIDELBERG, GERMANY	University of Freiburg; European Molecular Biology Laboratory (EMBL)			Mann, Matthias/A-3454-2013; Aktories, Klaus/CAJ-5682-2022	Mann, Matthias/0000-0003-1292-4799; Aktories, Klaus/0000-0002-5397-0436; Wilm, Matthias/0000-0002-5461-6834				AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; BAIROCH A, 1988, NATURE, V331, P22, DOI 10.1038/331022a0; BETTE P, 1989, INFECT IMMUN, V57, P2507, DOI 10.1128/IAI.57.8.2507-2513.1989; BETTE P, 1991, TOXICON, V29, P877, DOI 10.1016/0041-0101(91)90224-F; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Eichel-Streiber C. von, 1990, Gene, V96, P107, DOI 10.1016/0378-1119(90)90348-U; EICHELSTREIBER C, 1993, GENETICS MOL BIOL AN, P264; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; GREEN GA, 1995, GENE, V161, P57, DOI 10.1016/0378-1119(95)00263-6; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOFMANN F, 1995, MOL GEN GENET, V247, P670, DOI 10.1007/BF00290398; IGLEWSKI WJ, 1990, ADP RIBOSYLATING TOX, P511; JACQUEMIN C, 1986, NATURE, V323, P182, DOI 10.1038/323182a0; JUST I, 1995, J CLIN INVEST, V95, P1026, DOI 10.1172/JCI117747; JUST I, 1992, J BIOL CHEM, V267, P10274; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYERLY D M, 1988, Clinical Microbiology Reviews, V1, P1; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; MCGREGOR JA, 1989, AM J OBSTET GYNECOL, V161, P987, DOI 10.1016/0002-9378(89)90768-0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MULLER H, 1992, INFECT IMMUN, V60, P3007; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OKSCHE A, 1992, INFECT IMMUN, V60, P3002, DOI 10.1128/IAI.60.7.3002-3006.1992; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; SEKINE A, 1989, J BIOL CHEM, V264, P8602; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9	44	116	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25173	25177		10.1074/jbc.271.41.25173	http://dx.doi.org/10.1074/jbc.271.41.25173			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810274	hybrid			2022-12-27	WOS:A1996VL69300018
J	Bohme, B; Vandenbos, T; Cerretti, DP; Park, LS; Holtrich, U; RubsamenWaigmann, H; Strebhardt, K				Bohme, B; Vandenbos, T; Cerretti, DP; Park, LS; Holtrich, U; RubsamenWaigmann, H; Strebhardt, K			Cell-cell adhesion mediated by binding of membrane-anchored ligand LERK-2 to the EPH-related receptor human embryonal kinase 2 promotes tyrosine kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; MOLECULAR CHARACTERIZATION; CDNA CLONING; FAMILY; GENE; IDENTIFICATION; ECK; ELK; HEK; HTK	Human embryonal kinase 2 (HEK2) is a protein-tyrosine kinase that is a member of the EPH family of receptors. Transcripts for HEK2 have a wide tissue distribution. Recently, a still growing family of ligands, which we have named LERKs, for ligands of the ephrelated kinases, has been isolated. In order to analyze functional effects between the LERKs and the HEK2 receptor, we expressed HEK2 cDNA in an interleukin-3-dependent progenitor cell line 32D that grows as single cells in culture. Within the group of LERKs, LERK-2 and -5 were shown to bind to HEK2. Membrane-bound and soluble forms of LERK-2 were demonstrated to signal through HEK2 as judged by receptor phosphorylation. Coincubation of HEK2 and LERK-2 expressing cells induced cell-cell adhesion and formation of cell aggregates. This interaction could be inhibited by preincubation of HEK2 expressing cells with soluble LERK-2. Coexpression of HEK2 and LERK-2 in 32D cells showed reduced kinase activity and autophosphorylation of HEK2 compared with the juxtacrine stimulation, which seems to be due to a reduced sensitivity of the receptor.	GEORG SPEYER HAUS,CHEMOTHERAPEUT FORSCHUNGSINST,D-60596 FRANKFURT,GERMANY; IMMUNEX RES & DEV CORP,SEATTLE,WA 98101; BAYER AG,INST VIROL,D-42096 WUPPERTAL,GERMANY	Octapharma; Bayer AG			Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BOHME B, 1993, ONCOGENE, V8, P2857; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; Cerretti DP, 1995, MOL IMMUNOL, V32, P1197, DOI 10.1016/0161-5890(95)00108-5; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; FOX GM, 1995, ONCOGENE, V10, P897; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; IWASE T, 1993, BIOCHEM BIOPH RES CO, V194, P698, DOI 10.1006/bbrc.1993.1878; KATO H, 1993, J BIOL CHEM, V268, P2655; KIYOKAWA E, 1994, CANCER RES, V54, P3645; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	31	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24747	24752		10.1074/jbc.271.40.24747	http://dx.doi.org/10.1074/jbc.271.40.24747			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798744	hybrid			2022-12-27	WOS:A1996VM67400066
J	Johnson, JA; Gray, MO; Chen, CH; MochlyRosen, D				Johnson, JA; Gray, MO; Chen, CH; MochlyRosen, D			A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; SUBCELLULAR-LOCALIZATION; INTRACELLULAR RECEPTORS; RAT-HEART; ACTIVATION; MYOCYTES; CELLS; EPSILON; DOMAIN; PHOSPHORYLATION	Protein kinase C (PKC) isozymes translocate to unique subcellular sites following activation. We previously suggested that translocation of activated isozymes is required for their function and that in addition to binding to lipids, translocation involves binding of the activated isozymes to specific anchoring proteins (receptors for activated protein kinase C. Using cultured cardiomyocytes we identified inhibitors, the V1 fragment of epsilon PKC (epsilon V1), and an 8-amino acid peptide derived from it that selectively inhibited the translocation of epsilon PKC. Inhibition of epsilon PKC translocation but not inhibition of delta or beta PKC translocation specifically blocked phorbol ester- or norepinephrine-mediated regulation of contraction. These isozyme-selective translocation inhibitors provide novel tools to determine the function of individual PKC isozymes in intact cells.	STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305	Stanford University				Mochly-Rosen, Daria/0000-0002-6691-8733	NHLBI NIH HHS [HL52141] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DISATNIK MH, 1995, J MOL CELL CARDIOL, V27, P2473, DOI 10.1006/jmcc.1995.0235; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P6438; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; JOHNSON JA, 1995, CIRC RES, V76, P654, DOI 10.1161/01.RES.76.4.654; KARIYA K, 1991, J BIOL CHEM, V266, P10023; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; LACERDA AE, 1988, NATURE, V335, P249, DOI 10.1038/335249a0; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LEHEL C, 1995, J BIOL CHEM, V270, P19651, DOI 10.1074/jbc.270.33.19651; LIU JD, 1989, BIOCHEM BIOPH RES CO, V162, P1105, DOI 10.1016/0006-291X(89)90787-0; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SMITH BL, 1992, BIOCHEM BIOPH RES CO, V188, P1235, DOI 10.1016/0006-291X(92)91363-U; SOSSIN WS, 1993, TRENDS BIOCHEM SCI, V18, P207, DOI 10.1016/0968-0004(93)90189-T; TREJO J, 1991, J BIOL CHEM, V266, P7876; WILKINSON SE, 1994, TRENDS PHARMACOL SCI, V15, P53, DOI 10.1016/0165-6147(94)90110-4; WOLF M, 1986, J BIOL CHEM, V261, P3327; ZHANG Z, 1996, BIOPHYS J, V70, P391	34	338	363	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24962	24966		10.1074/jbc.271.40.24962	http://dx.doi.org/10.1074/jbc.271.40.24962			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798776	hybrid			2022-12-27	WOS:A1996VM67400099
J	Joos, H; Trouliaris, S; Helftenbein, G; Niemann, H; Tamura, T				Joos, H; Trouliaris, S; Helftenbein, G; Niemann, H; Tamura, T			Tyrosine phosphorylation of the juxtamembrane domain of the v-Fms oncogene product is required for its association with a 55-kDa protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; STIMULATING FACTOR-I; FELINE SARCOMA-VIRUS; FACTOR BETA-RECEPTOR; CSF-1 RECEPTOR; KINASE-ACTIVITY; BINDING-SITE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS	Tyrosine autophosphorylation of the v-Fms oncogene product results in the formation of high affinity binding sites for cellular proteins with Src homology 2 (SH2) domains that are involved in various signal cascades, Tryptic digestion of the autophosphorylated v-Fms and of its cellular counterpart, the feline c-Fms polypeptide, gave rise to at least six common major phosphopeptides, four of which have been characterized previously. Employing site-directed mutagenesis and phosphopeptide mapping of in vitro phosphorylated glutathione S-transferase v-Fms fusion proteins as well as full-length v-Fms molecules expressed in various cells, we show here that Tyr(543) Of the juxtamembrane domain and Tyr(696) of the kinase insert domain constitute major autophosphorylation sites. Recombinant fusion proteins containing the tyrosine-phosphorylated kinase insert domain bind the growth factor receptor bound protein 2 and the p85 and p110 subunits of phosphatidylinositol 3'-kinase. In contrast, fusion proteins containing the juxtamembrane domain phosphorylated on Tyr(543) fail to bind any of the known SH2 domain-containing cellular proteins but associate specifically with an as yet undefined 55-kDa cellular protein that by itself is phosphorylated on tyrosine.	UNIV GIESSEN,INST VIROL,D-35392 GIESSEN,GERMANY; HANNOVER MED SCH,INST BIOCHEM,D-30625 HANNOVER,GERMANY	Justus Liebig University Giessen; Hannover Medical School								ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PLUTZKY L, 1992, P NATL ACAD SCI USA, V89, P11239; PONS S, 1995, MOL CELL BIOL, V15, P4453; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SMOLA U, 1991, J VIROL, V65, P6181, DOI 10.1128/JVI.65.11.6181-6187.1991; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; TAMURA T, 1990, ONCOGENE, V5, P1259; TAMURA T, 1986, MOL CELL BIOL, V6, P4745, DOI 10.1128/MCB.6.12.4745; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; TROULIARIS S, 1995, ARCH VIROL, V140, P179, DOI 10.1007/BF01309733; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; TWAMLEY GM, 1993, ADV SEC MESS PHOSPH, V28, P187; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	43	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24476	24481		10.1074/jbc.271.40.24476	http://dx.doi.org/10.1074/jbc.271.40.24476			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798707	hybrid			2022-12-27	WOS:A1996VM67400029
J	Marcheselli, VL; Bazan, NG				Marcheselli, VL; Bazan, NG			Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus - Inhibition by a platelet-activating factor antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; INDUCIBLE CYCLOOXYGENASE; ELECTROCONVULSIVE SHOCK; CEREBRAL-CORTEX; GENE DISRUPTION; C-FOS; EXPRESSION; INFLAMMATION; MESSENGER; AVOIDANCE	Prostaglandin G/H synthase-2 and zif-268 mRNA expression is transiently induced in rat brain by kainic acid (KA)-induced seizures and by a single electroconvulsive shock. Induction of both genes by KA shows neuroanatomical specificity in the order hippocampus > cerebral cortex > striatum > brain stem > cerebellum. Nuclear run-on and Western blotting shows that both genes are transcriptionally activated, and that kainic acid up-regulation of prostaglandin G/H synthase-2 mRNA expression in hippocampus matches increased protein levels. Whereas the magnitude of hippocampal zif-268 mRNA induction is similar in both seizure models, peak induction of prostaglandin G/H synthase-2 mRNA is 7-fold greater in the kainic acid model than in the electroconvulsive shock model and is much more prolonged. Pretreatment of animals by intracerebroventricular injection with the intracellular platelet-activating factor receptor antagonist BN 50730 strongly attenuates kainic acid and electroconvulsive shock induction of prostaglandin G/H synthase-2 expression. The drug partially inhibits electroconvulsive shock induction of zif-268, but is relatively ineffective against kainic acid-induced zif-268 expression. Seizure-induced expression of both genes involves platelet-activating factor, but the mechanisms of induction must be otherwise distinct. The selectively elevated induction of hippocampal prostaglandin G/H synthase-2 by kainic acid correlates with a neuroanatomical region in which the agonist induces neuronal damage.	LOUISIANA STATE UNIV, CTR MED, CTR NEUROSCI, SCH MED, NEW ORLEANS, LA 70112 USA	Louisiana State University System			Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023002] Funding Source: NIH RePORTER; NINDS NIH HHS [NS23002] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams J, 1996, J NEUROCHEM, V66, P6; BAZAN NG, 1995, NATURE, V374, P501, DOI 10.1038/374501a0; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BAZAN NG, 1994, P NATL ACAD SCI USA, V91, P5252, DOI 10.1073/pnas.91.12.5252; BIRKLE DL, 1987, J NEUROCHEM, V48, P1768, DOI 10.1111/j.1471-4159.1987.tb05735.x; BREDER CD, 1995, J COMP NEUROL, V355, P296, DOI 10.1002/cne.903550208; CHEN J, 1995, NEUROREPORT, V6, P245; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK GD, 1992, NEURON, V9, P1211, DOI 10.1016/0896-6273(92)90078-R; DEWITT D, 1995, CELL, V83, P345, DOI 10.1016/0092-8674(95)90109-4; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; HATTORI M, 1993, J BIOL CHEM, V268, P18748; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HERTTING G, 1989, ANN NY ACAD SCI, V559, P84; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; IZQUIERDO I, 1995, P NATL ACAD SCI USA, V92, P5047, DOI 10.1073/pnas.92.11.5047; JERUSALINSKY D, 1994, BEHAV NEURAL BIOL, V62, P1, DOI 10.1016/S0163-1047(05)80052-4; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; KUMAR R, 1988, BIOCHIM BIOPHYS ACTA, V963, P375, DOI 10.1016/0005-2760(88)90304-9; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Marcheselli V. L., 1994, Society for Neuroscience Abstracts, V20, P1053; MARCHESELLI VL, 1990, J BIOL CHEM, V265, P9140; MARCHESELLI VL, 1994, J NEUROSCI RES, V37, P54, DOI 10.1002/jnr.490370108; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Mori M, 1996, J NEUROSCI, V16, P3590; NAFFAHMAZZACORATTI MG, 1995, NEUROCHEM INT, V27, P461, DOI 10.1016/0197-0186(95)00053-B; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; SQUINTO SP, 1989, J NEUROSCI RES, V24, P558, DOI 10.1002/jnr.490240414; STEPHENSON DT, 1994, BRAIN RES, V637, P97, DOI 10.1016/0006-8993(94)91221-1; Sun GY, 1995, PROG BRAIN RES, V105, P231; Takechi H, 1996, J BIOL CHEM, V271, P5901, DOI 10.1074/jbc.271.10.5901; THOMPSON RJ, 1973, J NEUROCHEM, V21, P19, DOI 10.1111/j.1471-4159.1973.tb04222.x; WIERASZKO A, 1993, NEURON, V10, P553, DOI 10.1016/0896-6273(93)90342-O; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	40	146	149	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24794	24799		10.1074/jbc.271.40.24794	http://dx.doi.org/10.1074/jbc.271.40.24794			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798751	hybrid			2022-12-27	WOS:A1996VM67400073
J	Umbach, AL; Siedow, JN				Umbach, AL; Siedow, JN			The reaction of the soybean cotyledon mitochondrial cyanide-resistant oxidase with sulfhydryl reagents suggests that alpha-keto acid activation involves the formation of a thiohemiacetal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-PLANT MITOCHONDRIA; ALTERNATIVE OXIDASE; ACTIVE-SITE; SUCCINATE-DEHYDROGENASE; MOLECULAR-BIOLOGY; CYTOCHROME; PYRUVATE; RESPIRATION; PROTEIN; TOBACCO	The cyanide-resistant alternative oxidase of plant mitochondria is known to be activated by alpha-keto acids, such as pyruvate, and by the reduction of a disulfide bond that bridges the two subunits of the enzyme homodimer. When the regulatory cysteines are oxidized, the inactivated enzyme is much less responsive to pyruvate than when these groups are reduced. When soybean cotyledon mitochondria were isolated in the presence of iodoacetate or N-ethylmaleimide, the intermolecular disulfide bond did not form and the alternative oxidase was present only as a noncovalently associated dimer. N-Ethylmaleimide inhibited alternative oxidase activity, but iodoacetate was found to stimulate activity much like pyruvate, including enhancing the enzyme's apparent affinity for reduced ubiquinone. The presence of pyruvate or iodoacetate blocked inhibition of the enzyme by N-ethylmaleimide, indicating that all three compounds acted at the same sulfhydryl group on the alternative oxidase protein, The site of pyruvate and iodoacetate action was shown to be a different sulfhydryl than that involved in the redox-active regulatory disulfide bond, because iodoacetate bound to the alternative oxidase at the activating site even when the redox-active regulatory sulfhydryls were oxidized. Given the nature of the covalent adduct formed by the reaction of iodoacetate with sulfhydryls, the activation of the alternative oxidase by alpha-keto acids appears to involve the formation of a thiohemiacetal.	DUKE UNIV,DEPT BOT,DEV CELL & MOL BIOL GRP,DURHAM,NC 27708	Duke University								ADAMS MJ, 1987, ENZYME MECHANISMS, P477; CRUZHERNANDEZ A, 1995, PLANTA, V197, P569, DOI 10.1007/BF00191562; DAY DA, 1994, PLANT PHYSIOL, V106, P1421, DOI 10.1104/pp.106.4.1421; DAY DA, 1995, AUST J PLANT PHYSIOL, V22, P497, DOI 10.1071/PP9950497; DRY IB, 1989, ARCH BIOCHEM BIOPHYS, V273, P148, DOI 10.1016/0003-9861(89)90173-2; ELTHON TE, 1986, PLANT PHYSIOL, V82, P1, DOI 10.1104/pp.82.1.1; ELTHON TE, 1989, PLANT PHYSIOL, V89, P1311, DOI 10.1104/pp.89.4.1311; ELTHON TE, 1987, P NATL ACAD SCI USA, V84, P8399, DOI 10.1073/pnas.84.23.8399; FINK AL, 1987, ENZYME MECHANISMS, P159; FRIDOVICH I, 1962, J AM CHEM SOC, V84, P3208, DOI 10.1021/ja00875a050; GRAZI E, 1973, BIOCHEMISTRY-US, V12, P2583, DOI 10.1021/bi00738a006; Hiser C, 1996, PLANT PHYSIOL, V110, P277, DOI 10.1104/pp.110.1.277; Hoefnagel MHN, 1996, PLANT PHYSIOL, V110, P1329, DOI 10.1104/pp.110.4.1329; HOEFNAGEL MHN, 1995, ARCH BIOCHEM BIOPHYS, V318, P394, DOI 10.1006/abbi.1995.1245; HOEFNAGELMHN, 1995, EUR J BIOCHEM, V233, P531; KANCHUGER MS, 1979, J AM CHEM SOC, V101, P3005, DOI 10.1021/ja00505a030; KENNEY WC, 1976, J BIOL CHEM, V251, P2369; KENNEY WC, 1975, J BIOL CHEM, V250, P3089; KYTE J, 1995, STRUCTURE PROTEIN CH, P357; LEACH GR, 1994, BIOCHEM SOC T, V22, pS406, DOI 10.1042/bst022406s; LI D, 1994, BIOPHYS J, V67, P29, DOI 10.1016/S0006-3495(94)80484-9; Li QH, 1996, GENETICS, V142, P129; LIENHARD GE, 1966, J AM CHEM SOC, V88, P3982, DOI 10.1021/ja00969a017; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCINTOSH L, 1994, PLANT PHYSIOL, V105, P781, DOI 10.1104/pp.105.3.781; Means GE, 1971, CHEM MODIFICATION PR, P105; Millar AH, 1996, PLANT PHYSIOL, V111, P613, DOI 10.1104/pp.111.2.613; MILLAR AH, 1993, FEBS LETT, V329, P259, DOI 10.1016/0014-5793(93)80233-K; MOORE AL, 1988, FEBS LETT, V235, P76, DOI 10.1016/0014-5793(88)81237-7; MOORE AL, 1995, J BIOENERG BIOMEMBR, V27, P367, DOI 10.1007/BF02109999; RHOADS DM, 1991, P NATL ACAD SCI USA, V88, P2122, DOI 10.1073/pnas.88.6.2122; RHOADS DM, 1993, PLANT PHYSIOL, V103, P877, DOI 10.1104/pp.103.3.877; RIBAS-CARBO M, 1995, PLANT PHYSIOL, V109, P829, DOI 10.1104/pp.109.3.829; RIBAS-CARBO M, 1995, ARCH BIOCHEM BIOPHYS, V317, P156, DOI 10.1006/abbi.1995.1148; RICH PR, 1980, BIOCHIM BIOPHYS ACTA, V592, P506, DOI 10.1016/0005-2728(80)90095-X; ROBINSON SA, 1995, AUST J PLANT PHYSIOL, V22, P487, DOI 10.1071/PP9950487; SAKAJO S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P102; SCHNACKERZ KD, 1970, J BIOL CHEM, V245, P6417; SIEDOW JN, 1995, FEBS LETT, V362, P10, DOI 10.1016/0014-5793(95)00196-G; SIEDOW JN, 1995, PLANT CELL, V7, P821, DOI 10.1105/tpc.7.7.821; UMBACH AL, 1993, PLANT PHYSIOL, V103, P845, DOI 10.1104/pp.103.3.845; UMBACH AL, 1994, FEBS LETT, V348, P181, DOI 10.1016/0014-5793(94)00600-8; VANLERBERGHE GC, 1992, PLANT PHYSIOL, V100, P115, DOI 10.1104/pp.100.1.115; VANLERBERGHE GC, 1995, PLANT PHYSIOL, V109, P353, DOI 10.1104/pp.109.2.353; VINOGRAD.AD, 1972, BIOCHEM BIOPH RES CO, V49, P441, DOI 10.1016/0006-291X(72)90430-5; Whelan J, 1996, PLANTA, V198, P197, DOI 10.1007/BF00206244; Zhang QS, 1996, PHYSIOL PLANTARUM, V96, P551, DOI 10.1111/j.1399-3054.1996.tb00226.x	47	82	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					25019	25026		10.1074/jbc.271.40.25019	http://dx.doi.org/10.1074/jbc.271.40.25019			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798784	hybrid			2022-12-27	WOS:A1996VM67400107
J	Harmon, FG; Rehrauer, WM; Kowalczykowski, SC				Harmon, FG; Rehrauer, WM; Kowalczykowski, SC			Interaction of Escherichia coli RecA protein with LexA repressor .2. Inhibition of DNA strand exchange by the uncleavable LexA S119A repressor argues that recombination and SOS induction are competitive processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE-LAMBDA-REPRESSOR; BINDING-PROTEIN; HOMOLOGOUS RECOMBINATION; SSB PROTEIN; GENETIC-RECOMBINATION; PARTIAL SUPPRESSOR; DIRECTED CLEAVAGE; BIOCHEMICAL BASIS; ACTIVATED RECA; POLYNUCLEOTIDE	The Escherichia coli RecA protein is involved in SOS induction, DNA repair, and homologous recombination. In vitro, RecA protein serves as a co-protease to cleave LexA repressor, the repressor of the SOS regulon; in addition, RecA protein promotes homologous pairing and DNA strand exchange, steps important to homologous recombination and DNA repair. To determine if these two functions of RecA protein are competing or parallel, the effect of uncleavable LexA S119A repressor on RecA protein-dependent activities was examined, LexA S119A repressor inhibits both the single-stranded DNA (ssDNA)-dependent ATP hydrolysis and DNA strand exchange activities of RecA protein, As for wildtype LexA repressor (Rehrauer, W. M., Lavery, P. E., Palmer, E. L., Singh, R. N., and Kowalczykowski, S. C. (1996) J. Biol. Chem. 271, 23865-23873), inhibition of ATP hydrolysis is dependent upon the presence of E. coli single-stranded DNA binding (SSB) protein, arguing that LexA repressor affects the competition between RecA protein and SSB protein for ssDNA binding sites. In contrast, inhibition of DNA strand exchange activity is SSB protein-independent, suggesting that LexA S119A repressor blocks a site required for DNA strand exchange. These results imply that there is a common site on the RecA protein filament for secondary DNA and LexA repressor binding and raise the possibility that the recombination and co-protease activities of the RecA protein filament are competitive.	UNIV CALIF DAVIS,MICROBIOL SECT,DIV BIOL SCI,DAVIS,CA 95616; UNIV CALIF DAVIS,SECT MOL & CELLULAR BIOL,DIV BIOL SCI,DAVIS,CA 95616; UNIV CALIF DAVIS,GRAD GRP MICROBIOL,DAVIS,CA 95616	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018987] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-18987] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIANCHI M, 1983, CELL, V34, P931, DOI 10.1016/0092-8674(83)90550-0; CHAUDHURY AM, 1985, MOL GEN GENET, V201, P525, DOI 10.1007/BF00331350; CHOW SA, 1988, J BIOL CHEM, V263, P200; CLARK AJ, 1973, ANNU REV GENET, V7, P67, DOI 10.1146/annurev.ge.07.120173.000435; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; CRAIG NL, 1980, NATURE, V283, P26, DOI 10.1038/283026a0; DICAPUA E, 1992, J MOL BIOL, V226, P707, DOI 10.1016/0022-2836(92)90627-V; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; HSIEH P, 1992, P NATL ACAD SCI USA, V89, P6492, DOI 10.1073/pnas.89.14.6492; KIM B, 1992, SCIENCE, V255, P203, DOI 10.1126/science.1553548; KIM B, 1993, CELL, V73, P1165, DOI 10.1016/0092-8674(93)90645-7; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LAVERY PE, 1992, J BIOL CHEM, V267, P20648; LAVERY PE, 1988, J MOL BIOL, V203, P861, DOI 10.1016/0022-2836(88)90112-X; LAVERY PE, 1992, J BIOL CHEM, V267, P9307; LAVERY PE, 1990, J BIOL CHEM, V265, P4004; LEBOWITZ J, 1985, THESIS J HOPKINS U B; LITTLE JW, 1991, BIOCHIMIE, V73, P411, DOI 10.1016/0300-9084(91)90108-D; LITTLE JW, 1980, P NATL ACAD SCI-BIOL, V77, P3225, DOI 10.1073/pnas.77.6.3225; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MADIRAJU MVVS, 1988, P NATL ACAD SCI USA, V85, P6592, DOI 10.1073/pnas.85.18.6592; MADIRAJU MVVS, 1990, MOL GEN GENET, V224, P129, DOI 10.1007/BF00259459; MADIRAJU MVVS, 1992, BIOCHEMISTRY-US, V31, P10529, DOI 10.1021/bi00158a016; MAGEE TR, 1990, J BACTERIOL, V172, P1834, DOI 10.1128/jb.172.4.1834-1839.1990; MCENTEE K, 1977, J BACTERIOL, V132, P904, DOI 10.1128/JB.132.3.904-911.1977; MENETSKI JP, 1989, BIOCHEMISTRY-US, V28, P5871, DOI 10.1021/bi00440a025; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MENETSKI JP, 1990, J MOL BIOL, V211, P845, DOI 10.1016/0022-2836(90)90078-Z; MENETSKI JP, 1988, BIOCHEMISTRY-US, V27, P1205, DOI 10.1021/bi00404a021; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; PUGH BF, 1988, J BIOL CHEM, V263, P76; RADDING CM, 1991, J BIOL CHEM, V266, P5355; Rehrauer WM, 1996, J BIOL CHEM, V271, P23865, DOI 10.1074/jbc.271.39.23865; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; RUYECHAN WT, 1976, BIOCHEMISTRY-US, V15, P5057, DOI 10.1021/bi00668a017; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SCHNARR M, 1984, FEBS LETT, V171, P207, DOI 10.1016/0014-5793(84)80489-5; SCHNARR M, 1985, BIOCHEMISTRY-US, V24, P2812, DOI 10.1021/bi00332a032; SLILATY SN, 1986, BIOCHEMISTRY-US, V25, P6866, DOI 10.1021/bi00370a020; SLILATY SN, 1987, P NATL ACAD SCI USA, V84, P3987, DOI 10.1073/pnas.84.12.3987; SOMMER S, 1993, MOL MICROBIOL, V10, P963, DOI 10.1111/j.1365-2958.1993.tb00968.x; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TAKAHASHI M, 1989, EUR J BIOCHEM, V183, P617, DOI 10.1111/j.1432-1033.1989.tb21091.x; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; UMEZU K, 1994, J BIOL CHEM, V269, P30005; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P883; WITKIN EM, 1991, BIOCHIMIE, V73, P133, DOI 10.1016/0300-9084(91)90196-8; YU X, 1993, J MOL BIOL, V231, P29, DOI 10.1006/jmbi.1993.1254	53	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23874	23883		10.1074/jbc.271.39.23874	http://dx.doi.org/10.1074/jbc.271.39.23874			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798618	Green Submitted			2022-12-27	WOS:A1996VJ44200047
J	Hatada, Y; Igarashi, K; Ozaki, K; Ara, K; Hitomi, J; Kobayashi, T; Kawai, S; Watabe, T; Ito, S				Hatada, Y; Igarashi, K; Ozaki, K; Ara, K; Hitomi, J; Kobayashi, T; Kawai, S; Watabe, T; Ito, S			Amino acid sequence and molecular structure of an alkaline amylopullulanase from Bacillus that hydrolyzes alpha-1,4 and alpha-1,6 linkages in polysaccharides at different active sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOANAEROBACTERIUM-SACCHAROLYTICUM B6A-RI; CLOSTRIDIUM-THERMOSULFUROGENES EM1; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; ALKALOPHILIC BACILLUS; THERMOSTABLE PULLULANASE; DNA FRAGMENTS; PLASMID DNA; SP KSM-1378; APU GENE	An amylopullulanase from alkalophilic Bacillus sp. KSM-1378 hydrolyzes both alpha-1,6 linkages in pullulan and (alpha-1,4 linkages in other polysaccharides, with maximum activity in each case at an alkaline pH, to generate oligosaccharides (Ara, K., Saeki, K., Igarashi, K., Takaiwa, M., Uemura, T., Hagihara, H., Kawai, S., and Ito, S. (1995) Biochim. Biophys. Acta 1243, 315-324). Here, we report the molecular cloning and sequencing of the gene for and the structure of this enzyme and show that its dual hydrolytic activities are associated with two independent active sites. The structural gene contained a single, long open reading frame of 5,814 base pairs, corresponding to 1,938 amino acids that included a signal peptide of 32 amino acids. The molecular mass of the extracellular mature enzyme (Glu(33) through Leu(1938)) was calculated to be 211,450 Da, a value close to the 210 kDa determined for the amylopullulanase produced by Bacillus sp. KSM-1378. The amylase and the pullulanase domains were located in the amino-terminal half and in the carboxyl-terminal half of the enzyme, respectively, being separated by a tandem repeat of a sequence of 35 amino acids. Four regions, designated I, II, III, and IV, were highly conserved in each catalytic domain, and they included a putative catalytic triad Asp(550)-Glu(579)-Asp(645) for the amylase activity and Asp(1464)-Glu(1493)-Asp(1581) for the pullulanase activity. The purified enzyme was rotary shadowed at a low angle and observed by transmission electron microscopy; it appeared to be a ''castanet-like'' or ''bent dumbbell-like'' molecule with a diameter of approximately 25 nm.	KAO CORP,TOCHIGI RES LABS,HAGA,TOCHIGI 32134,JAPAN; JEOL DATUM LTD,ELECT OPT INSTRUMENTS TRAINING & APPL CTR,AKISHIMA,TOKYO 196,JAPAN	KAO Corporation; Jeol Ltd; JEOL Japan								ARA K, 1995, BIOSCI BIOTECH BIOCH, V59, P662, DOI 10.1271/bbb.59.662; Ara K, 1996, BIOSCI BIOTECH BIOCH, V60, P634, DOI 10.1271/bbb.60.634; ARA K, 1992, BIOSCI BIOTECH BIOCH, V56, P62, DOI 10.1271/bbb.56.62; ARA K, 1995, BBA-GEN SUBJECTS, V1243, P315, DOI 10.1016/0304-4165(94)00148-Q; ARA K, 1994, J GEN MICROBIOL, V139, P781; BAHL H, 1991, APPL ENVIRON MICROB, V57, P1554, DOI 10.1128/AEM.57.5.1554-1559.1991; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN SH, 1993, APPL ENVIRON MICROB, V59, P2614, DOI 10.1128/AEM.59.8.2614-2621.1993; BUISSON G, 1987, EMBO J, V6, P3909, DOI 10.1002/j.1460-2075.1987.tb02731.x; CHANG S, 1979, MOL GEN GENET, V168, P111, DOI 10.1007/BF00267940; COLEMAN RD, 1993, GENETICS MOL BIOL AN, P640; COLLINS FS, 1984, P NATL ACAD SCI-BIOL, V81, P6812, DOI 10.1073/pnas.81.21.6812; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FARALDO MM, 1992, J BACTERIOL, V174, P7458, DOI 10.1128/jb.174.22.7458-7462.1992; FLINT HJ, 1993, J BACTERIOL, V175, P2943, DOI 10.1128/JB.175.10.2943-2951.1993; HALDENWANG WG, 1995, MICROBIOL REV, V59, P1; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOLM L, 1990, PROTEIN ENG, V3, P181, DOI 10.1093/protein/3.3.181; IGARASHI K, 1992, BIOSCI BIOTECH BIOCH, V56, P514, DOI 10.1271/bbb.56.514; ISHIWA H, 1986, JPN J GENET, V61, P515, DOI 10.1266/jjg.61.515; KATSURAGI N, 1987, J BACTERIOL, V169, P2301, DOI 10.1128/jb.169.5.2301-2306.1987; KIMURA T, 1990, FEMS MICROBIOL LETT, V71, P35; KURIKI T, 1990, J FERMENT BIOENG, V69, P204, DOI 10.1016/0922-338X(90)90213-G; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SP, 1994, APPL ENVIRON MICROB, V60, P3764, DOI 10.1128/AEM.60.10.3764-3773.1994; LEE YE, 1993, J BACTERIOL, V175, P5890, DOI 10.1128/JB.175.18.5890-5898.1993; LEE YE, 1993, INT J SYST BACTERIOL, V43, P41, DOI 10.1099/00207713-43-1-41; MATHUPALA SP, 1993, J BIOL CHEM, V268, P16332; MATSUURA Y, 1984, J BIOL CHEM, V95, P679; MATUSCHEK M, 1994, J BACTERIOL, V176, P3295, DOI 10.1128/jb.176.11.3295-3302.1994; MELASNIEMI H, 1990, J GEN MICROBIOL, V136, P447, DOI 10.1099/00221287-136-3-447; MELASNIEMI H, 1988, BIOCHEM J, V250, P813, DOI 10.1042/bj2500813; MEZES PSF, 1985, MOL BIOL BACILLI, V2, P151; MILLER GL, 1960, ANAL BIOCHEM, V2, P127, DOI DOI 10.1016/0003-2697(60)90004-X; MORAN CP, 1982, MOL GEN GENET, V186, P339, DOI 10.1007/BF00729452; MURPHY N, 1984, NUCLEIC ACIDS RES, V12, P5355, DOI 10.1093/nar/12.13.5355; NAKAJIMA R, 1985, J BACTERIOL, V163, P401, DOI 10.1128/JB.163.1.401-406.1985; NAKAMURA N, 1989, STARCH-STARKE, V41, P112, DOI 10.1002/star.19890410310; NORMAN BE, 1982, STARKE, V34, P340, DOI 10.1002/star.19820341005; OCHMAN H, 1988, GENETICS, V120, P621; OHNISHI H, 1992, EUR J BIOCHEM, V207, P413, DOI 10.1111/j.1432-1033.1992.tb17064.x; OZAKI K, 1995, BIOSCI BIOTECH BIOCH, V59, P1613, DOI 10.1271/bbb.59.1613; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PETERS J, 1989, J BACTERIOL, V171, P6307, DOI 10.1128/jb.171.11.6307-6315.1989; RAMESH MV, 1994, APPL ENVIRON MICROB, V60, P94, DOI 10.1128/AEM.60.1.94-101.1994; SAHA BC, 1988, BIOCHEM J, V252, P343, DOI 10.1042/bj2520343; SAHA BC, 1989, ENZYME MICROB TECH, V11, P760, DOI 10.1016/0141-0229(89)90126-9; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; SAKANO Y, 1982, AGR BIOL CHEM TOKYO, V46, P1121, DOI 10.1080/00021369.1982.10865223; SAUL DJ, 1990, APPL ENVIRON MICROB, V56, P3117, DOI 10.1128/AEM.56.10.3117-3124.1990; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPREINAT A, 1990, APPL MICROBIOL BIOT, V33, P511; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; TAKATA H, 1992, J BIOL CHEM, V267, P18447; TAKEKAWA S, 1991, J BACTERIOL, V173, P6820, DOI 10.1128/jb.173.21.6820-6825.1991; TANIGUCHI H, 1982, AGR BIOL CHEM TOKYO, V46, P2107, DOI 10.1080/00021369.1982.10865394; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; YAMAZAKI H, 1983, J BACTERIOL, V156, P327, DOI 10.1128/JB.156.1.327-337.1983	64	59	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24075	24083		10.1074/jbc.271.39.24075	http://dx.doi.org/10.1074/jbc.271.39.24075			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798645	hybrid			2022-12-27	WOS:A1996VJ44200074
J	Wei, J; Wayman, G; Storm, DR				Wei, J; Wayman, G; Storm, DR			Phosphorylation and inhibition of type III adenylyl cyclase by calmodulin-dependent protein kinase II in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; CALCIUM; CELLS; CA2+; STIMULATION; EXPRESSION; ACCUMULATION; MOBILIZATION; NUCLEOTIDE; MECHANISM	Inhibition of type III adenylyl cyclase (III-AC) by intracellular Ca2+ in vivo provides a mechanism for attenuation of hormone-stimulated cAMP signals in olfactory epithelium, heart, and other tissues (Wayman, G. A., Impey, S., and Storm, D. R. (1995) J. Biol. Chem. 270, 21480-21486). Although the mechanism for Ca2+ inhibition of III-AC in vivo has not been defined, inhibition is not mediated by G(i), cAMP-dependent protein kinase, or protein kinase C. However, Ca2+-inhibition of III-AC is antagonized by KN-62, a CaM-dependent kinase inhibitor. In addition, constitutively activated CaM kinase II inhibits the enzyme. These data suggest that CaM kinase II regulates the activity of III-AC by direct phosphorylation or by an indirect mechanism involving phosphorylation of a protein that inhibits III-AC. Here we report that III-AC is phosphorylated in vivo when intracellular Ca2+ is increased and that phosphorylation is prevented by CaM-dependent kinase inhibitors. Site-directed mutagenesis of a CaM kinase II consensus site (Ser-1076 to Ala-1076) in III-AC greatly reduced Ca2+-stimulated phosphorylation and inhibition of III-AC in vivo. These data support the hypothesis that Ca2+ inhibition of III-AC is due to direct phosphorylation of the enzyme by CaM kinase II in vivo.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL 44948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BIRNBAUMER L, 1973, BIOCHIM BIOPHYS ACTA, V300, P129, DOI 10.1016/0304-4157(73)90002-6; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; BOYAJIAN CL, 1990, CELL CALCIUM, V11, P299, DOI 10.1016/0143-4160(90)90007-H; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDWELL KK, 1992, CELL CALCIUM, V13, P107, DOI 10.1016/0143-4160(92)90004-C; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; COLVIN RA, 1991, CELL CALCIUM, V12, P19, DOI 10.1016/0143-4160(91)90081-O; COOPER DMF, 1994, BIOCHEM J, V297, P437, DOI 10.1042/bj2970437; DEBERNARDI MA, 1991, P NATL ACAD SCI USA, V88, P9257, DOI 10.1073/pnas.88.20.9257; DITTMAN AH, 1994, BIOCHEMISTRY-US, V33, P943, DOI 10.1021/bi00170a013; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; GIANNATTASIO G, 1987, ENDOCRINOLOGY, V120, P2611, DOI 10.1210/endo-120-6-2611; HIRONO J, 1992, J NEUROSCI METH, V42, P185, DOI 10.1016/0165-0270(92)90098-X; JAWORSKY DE, 1995, J NEUROSCI, V15, P310; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARK MD, 1995, J CELL BIOL, V130, P701, DOI 10.1083/jcb.130.3.701; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MONS N, 1994, MOL BRAIN RES, V22, P236, DOI 10.1016/0169-328X(94)90052-3; NARAYANAN N, 1989, ENDOCRINOLOGY, V124, P484, DOI 10.1210/endo-124-1-484; Potter J D, 1980, Ann N Y Acad Sci, V356, P220, DOI 10.1111/j.1749-6632.1980.tb29613.x; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; SAKAGAMI H, 1993, MOL BRAIN RES, V20, P51, DOI 10.1016/0169-328X(93)90109-3; SUGIMOTO M, 1989, ANAL BIOCHEM, V179, P309, DOI 10.1016/0003-2697(89)90134-6; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; WAYMAN GA, 1995, J BIOL CHEM, V270, P24108, DOI 10.1074/jbc.270.41.24108; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; Xia Z., 1996, REGULATORY PROPERTIE; YU HJ, 1993, MOL PHARMACOL, V44, P689	31	130	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24231	24235		10.1074/jbc.271.39.24231	http://dx.doi.org/10.1074/jbc.271.39.24231			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798667	hybrid			2022-12-27	WOS:A1996VJ44200096
J	Daas, PJH; Wassenaar, RW; Willemsen, P; Theunissen, RJ; Keltjens, JT; vanderDrift, C; Vogels, GD				Daas, PJH; Wassenaar, RW; Willemsen, P; Theunissen, RJ; Keltjens, JT; vanderDrift, C; Vogels, GD			Purification and properties of an enzyme involved in the ATP-dependent activation of the methanol:2-mercaptoethanesulfonic acid methyltransferase reaction in Methanosarcina barkeri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCTIVE ACTIVATION; METHIONINE SYNTHASE; METHANOL; 5-HYDROXYBENZIMIDAZOLYLCOBAMIDE; PROTEINS	In Methanosarcina barkeri the transfer of the methyl group from methanol to 2-mercaptoethanesulfonic acid is catalyzed by the concerted action of two methyltransferases. The first one is the corrinoid-containing methanol:5-hydroxybenzimidazolylcobamide methyltransferase (MT(1)), which binds the methyl group of methanol to its corrinoid prosthetic group. MT(1) is only catalytically active when the cobalt atom of the corrinoid is present in the highly reduced Co(I) state, In the course of its purification and even during catalysis, MT(1) becomes oxidatively inactivated. The enzyme, however, may be reductively reactivated by a suitable reducing system (hydrogen and hydrogenase), ATP, and an enzyme called methyltransferase activation protein (MAP). In order to elucidate its role in the reactivation process, MAP was purified to apparent homogeneity. The protein had an M(r) = 60,000. Preincubation of the enzymic components involved with 8-azido-ATP or with ATP demonstrated MAP to be the primary site of action of ATP. In agreement herewith, the protein was auto phosphorylated by [gamma-P-32]ATP in a 1:1 stoichiometry, Phosphorylated MAP substituted for ATP in the activation of MT(1), and the addition of increasing amounts of MAP phosphate resulted in a corresponding increase of active MT(1). However, in the presence of limiting amounts of MAP, maximal activation of MT(1) could be achieved during a lag phase provided ATP was present, indicating that MAP acts as a catalyst. This paper is the first to report on the presence, isolation, and function of a phosphorylated protein in a methanogenic archaeon.	UNIV NIJMEGEN,FAC SCI,DEPT MICROBIOL,NL-6525 ED NIJMEGEN,NETHERLANDS	Radboud University Nijmegen			Keltjens, Jan/M-3002-2013					BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; BANERJEE RV, 1990, FASEB J, V4, P1450, DOI 10.1096/fasebj.4.5.2407589; CHUAN H, 1989, J BIOL CHEM, V264, P7981; COZZONE AJ, 1993, J CELL BIOCHEM, V51, P7, DOI 10.1002/jcb.240510103; Daas PJH, 1996, J BIOL CHEM, V271, P22346, DOI 10.1074/jbc.271.37.22346; DAAS PJH, 1995, ARCH BIOCHEM BIOPHYS, V319, P244, DOI 10.1006/abbi.1995.1288; DAAS PJH, 1993, J BACTERIOL, V175, P1278, DOI 10.1128/JB.175.5.1278-1283.1993; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HUTTEN TJ, 1981, J BACTERIOL, V145, P27, DOI 10.1128/JB.145.1.27-34.1981; KELTJENS JT, 1986, FEMS MICROBIOL LETT, V39, P259, DOI 10.1111/j.1574-6968.1986.tb01862.x; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MATTHEWS R G, 1990, Biofactors, V2, P147; STAHL E, 1967, DUNNSCHICHT CHROMATO; STUPPERICH E, 1993, FEMS MICROBIOL REV, V12, P349, DOI 10.1016/0168-6445(93)90012-X; VANDERMEIJDEN P, 1984, BIOCHEM BIOPH RES CO, V118, P760, DOI 10.1016/0006-291X(84)91460-8; VANDERMEIJDEN P, 1984, J BACTERIOL, V160, P629, DOI 10.1128/JB.160.2.629-635.1984; VANDERMEIJDEN P, 1983, ARCH MICROBIOL, V134, P238, DOI 10.1007/BF00407765; VANDERMEIJDEN P, 1983, J BACTERIOL, V153, P6, DOI 10.1128/JB.153.1.6-11.1983	19	41	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22339	22345		10.1074/jbc.271.37.22339	http://dx.doi.org/10.1074/jbc.271.37.22339			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798394	Green Published			2022-12-27	WOS:A1996VG67200013
J	Kudo, M; Osuga, Y; Kobilka, BK; Hsueh, AJW				Kudo, M; Osuga, Y; Kobilka, BK; Hsueh, AJW			Transmembrane regions V and VI of the human luteinizing hormone receptor are required for constitutive activation by a mutation in the third intracellular loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMITED PRECOCIOUS PUBERTY; PROTEIN-COUPLED RECEPTORS; PHOSPHATIDYLINOSITOL HYDROLYSIS; ALPHA-1B-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; CYTOPLASMIC DOMAINS; REGULATORY PROTEINS; ACTIVE MUTANTS; POINT MUTATION; LIGAND-BINDING	Gonadotropin receptors are members of the seven-transmembrane (TR-I) receptor family. Several point mutations in TM V and VI and the intracellular loop 3 (i3) have been identified in the luteinizing hormone (LH) receptor gene, leading to constitutive activation of the receptor. Because gonadotropin receptors are highly conserved, we mutated the follicle stimulating hormone (FSH) receptor at the corresponding amino acids. However, the FSH receptor mutants showed minimal increases in basal cAMP production. Taking advantage of this difference between the two receptors, we designed chimeric receptors with or without a point mutation in the i3 to identify the region in the LH receptor important for its constitutive activation, Introduction of the point mutation into chimeric receptors containing only TM V to VI from the LH receptor led to major increases in ligand-independent-cAMP production. Furthermore, a chimeric receptor with only TM V and VI derived from the LH receptor can be rendered constitutively active by the mutation in the i3 from the FSH receptor. These results suggest that interactions between TM V and VI of the FSH receptor are essential for maintaining the receptor in the more constrained state, whereas interactions between these domains of the LH receptor are permissive for constitutively activating mutations in the i3.	STANFORD UNIV,SCH MED,DEPT OBSTET & GYNECOL,DIV REPROD BIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University				Kobilka, Brian/0000-0001-5958-3990	NICHD NIH HHS [HD-23273] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023273, R37HD023273] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BARKER EL, 1994, J BIOL CHEM, V269, P11687; BIRNBAUMER M, 1995, J RECEPT SIGNAL TR R, V15, P131, DOI 10.3109/10799899509045213; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Cetani F, 1996, FEBS LETT, V378, P27, DOI 10.1016/0014-5793(95)01384-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DAVOREN JB, 1985, BIOL REPROD, V33, P37, DOI 10.1095/biolreprod33.1.37; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gromoll J, 1996, J CLIN ENDOCR METAB, V81, P1367, DOI 10.1210/jc.81.4.1367; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HSUEH AJW, 1992, TRENDS ENDOCRIN MET, V3, P164, DOI 10.1016/1043-2760(92)90166-X; Hwa J, 1996, J BIOL CHEM, V271, P7956, DOI 10.1074/jbc.271.14.7956; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; KEENE JL, 1989, J BIOL CHEM, V264, P4769; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOSUGI S, 1995, HUM MOL GENET, V4, P183, DOI 10.1093/hmg/4.2.183; KRAAIJ R, 1995, J CLIN ENDOCR METAB, V80, P3168, DOI 10.1210/jc.80.11.3168; KREMER H, 1993, HUM MOL GENET, V2, P1779, DOI 10.1093/hmg/2.11.1779; LATRONICO AC, 1995, J CLIN ENDOCR METAB, V80, P2490, DOI 10.1210/jc.80.8.2490; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; LAUE LL, 1996, IN PRESS BIOCH MOL M; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; LIU J, 1995, J BIOL CHEM, V270, P19532, DOI 10.1074/jbc.270.33.19532; LUTTRELL LM, 1993, SCIENCE, V259, P1453, DOI 10.1126/science.8383880; MIYACHI Y, 1972, J CLIN ENDOCR METAB, V34, P23, DOI 10.1210/jcem-34-1-23; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PARMA J, 1994, MOL CELL ENDOCRINOL, V100, P159, DOI 10.1016/0303-7207(94)90296-8; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; RAYMOND JR, 1994, AM J PHYSIOL, V266, pF163, DOI 10.1152/ajprenal.1994.266.2.F163; REN Q, 1993, J BIOL CHEM, V268, P16483; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SANDE JV, 1995, J CLIN ENDOCR METAB, V80, P2577; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SU JGJ, 1992, BIOCHEM BIOPH RES CO, V186, P293, DOI 10.1016/S0006-291X(05)80806-X; TIBERI M, 1994, J BIOL CHEM, V269, P27925; TILLY JL, 1992, ENDOCRINOLOGY, V131, P799, DOI 10.1210/en.131.2.799; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YANO K, 1995, J CLIN ENDOCR METAB, V80, P1162, DOI 10.1210/jc.80.4.1162; YANO K, 1994, J CLIN ENDOCR METAB, V79, P1818, DOI 10.1210/jc.79.6.1818	61	104	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22470	22478		10.1074/jbc.271.37.22470	http://dx.doi.org/10.1074/jbc.271.37.22470			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798412	hybrid			2022-12-27	WOS:A1996VG67200031
J	Lankester, AC; Rood, PML; vanSchijndel, GMW; Hooibrink, B; Verhoeven, AJ; vanLier, RAW				Lankester, AC; Rood, PML; vanSchijndel, GMW; Hooibrink, B; Verhoeven, AJ; vanLier, RAW			Alteration of B-cell antigen receptor signaling by CD19 co-ligation - A study with bispecific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED PROTEINS; LYMPHOCYTES-B; TRANSDUCTION COMPLEX; CYTOPLASMIC DOMAIN; PHOSPHOLIPASE-C; ACTIVATION; KINASE; LYN; PHOSPHATASE; CD22	The activation of B cell antigen receptor-associated protein tyrosine kinases is an early and crucial event in B-cell signaling. Apart from the B-cell antigen receptor (BCR), the B cell-specific transmembrane glycoprotein CD19 has also been shown to directly activate intracellular signaling cascades. In addition, because CD19 and the BCR are associated on the surface of activated B-cells, it has been proposed that close approximation between these two entities is crucial for optimal B-cell triggering. To test this hypothesis, bispecific antibodies were generated that bind membrane IgM and CD19 simultaneously, Although CD19 bispecific antibodies strongly induced tyrosine phosphorylation, they were, in contrast to mu F(ab)(2) fragments, unable to induce a proliferative response. Detailed analysis of the early signaling events showed that compared with mu F(ab)(2) fragments CD19 bispecific antibodies potently raised the intracellular [Ca2+], which was correlated with an efficient tyrosine phosphorylation of syk. Strikingly, the assembly of Grb2 complexes that may couple the BCR to p21(ras) was clearly altered by the CD19 bispecific antibody. In addition to the reported She and 145-kDa phosphoproteins, a prominent 90-95-kDa phosphoprotein resembling CD19 was detected in the Grb2 complexes. Thus, studies with CD19 bispecific antibodies show that CD19 co-ligation both quantitatively and qualitatively alters BCR signaling.	UNIV AMSTERDAM,EXPT & CLIN IMMUNOL LAB,NL-1066 CX AMSTERDAM,NETHERLANDS	University of Amsterdam	Lankester, AC (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,PLESMANLAAN 125,NL-1066 CX AMSTERDAM,NETHERLANDS.			van Lier, Rene/0000-0002-3201-7144				BRADBURY LE, 1992, J IMMUNOL, V149, P2841; BRADBURY LE, 1993, J IMMUNOL, V151, P2915; CALLARD RE, 1992, J IMMUNOL, V148, P2983; CAMPBELL MA, 1995, EUR J IMMUNOL, V25, P1573, DOI 10.1002/eji.1830250616; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; CARTER RH, 1991, J IMMUNOL, V147, P3663; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P3745; CHALUPNY NJ, 1993, EMBO J, V12, P2691, DOI 10.1002/j.1460-2075.1993.tb05930.x; DERIE MA, 1989, CELL IMMUNOL, V118, P368, DOI 10.1016/0008-8749(89)90385-7; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FEARON DT, 1993, CURR OPIN IMMUNOL, V5, P341, DOI 10.1016/0952-7915(93)90051-S; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; GOLD MR, 1994, ADV IMMUNOL, V55, P221; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Krop I, 1996, EUR J IMMUNOL, V26, P238, DOI 10.1002/eji.1830260137; LANE PJL, 1991, J IMMUNOL, V146, P715; LANKESTER AC, 1995, BLOOD, V86, P1090; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; LANKESTER AC, 1993, IMMUNOLOGY, V80, P45; LANKESTER AC, 1995, J BIOL CHEM, V270, P20305, DOI 10.1074/jbc.270.35.20305; MATSUMOTO AK, 1991, J EXP MED, V173, P55, DOI 10.1084/jem.173.1.55; MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; PESANDO JM, 1989, J EXP MED, V170, P2159, DOI 10.1084/jem.170.6.2159; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; ROIFMAN CM, 1993, BIOCHEM BIOPH RES CO, V194, P222, DOI 10.1006/bbrc.1993.1807; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCHEUERMANN RH, 1994, P NATL ACAD SCI USA, V91, P4048, DOI 10.1073/pnas.91.9.4048; SHANAFELT MC, 1995, J IMMUNOL, V154, P1684; SMIT L, 1994, J BIOL CHEM, V269, P20209; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; VANLIER R, 1989, IMMUNOLOGY, V67, P333; VANNOESEL CJM, 1993, IMMUNOL TODAY, V14, P8, DOI 10.1016/0167-5699(93)90316-D; VANNOESEL CJM, 1993, INT IMMUNOL, V5, P699; VOSSEBELD PJM, 1995, J BIOL CHEM, V270, P10671, DOI 10.1074/jbc.270.18.10671; ZHOU LJ, 1991, J IMMUNOL, V147, P1424; ZHOU LJ, 1994, MOL CELL BIOL, V14, P3884, DOI 10.1128/MCB.14.6.3884	41	11	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22326	22330		10.1074/jbc.271.37.22326	http://dx.doi.org/10.1074/jbc.271.37.22326			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798392				2022-12-27	WOS:A1996VG67200011
J	Qu, DF; Teckman, JH; Omura, S; Perlmutter, DH				Qu, DF; Teckman, JH; Omura, S; Perlmutter, DH			Degradation of a mutant secretory protein, alpha(1)-antitrypsin Z, in the endoplasmic reticulum requires proteasome activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE; T-CELL; CALNEXIN; TRANSPORT; SUBUNIT; CFTR; OLIGOSACCHARIDE; GLYCOPROTEINS; LACTACYSTIN; ASSOCIATION	Degradation of proteins that are retained in the quality control apparatus of the endoplasmic reticulum (ER) has been attributed to a third proteolytic system, distinct from the lysosomal and the cytoplasmic ubiquitin-dependent proteosomal proteolytic pathways. However, several recent studies have shown that ER degradation of a mutant membrane protein, CFTR Delta F508, is at least in part mediated from the cytoplasmic side by the 26 S proteasome. In this study, we examined the possibility that ER degradation of mutant secretory protein alpha(1)-antitrypsin (alpha(1)-AT) Z, the mutant protein associated with infantile liver disease and adult-onset emphysema of alpha(1)-AT deficiency, is mediated by the proteasome. The results show that a specific proteasome inhibitor, lactacystin, inhibits ER degradation of alpha 1-ATZ in transfected human fibroblast cell lines and in a cell-free microsomal translocation system, Although it is relatively easy to conceptualize how a transmembrane protein like CFTR Delta F508 might be accessible on the cytoplasmic aspect of the ER membrane for ubiquitination and degradation by the proteasome, it is more difficult to conceptualize how this might occur for a luminal polypeptide, The results show that, once within the lumen of the ER, alpha(1)-ATZ interacts with the transmembrane molecular chaperone calnexin and specifically induces the polyubiquitination of calnexin, The results, therefore, provide evidence that the proteasome, from its cytoplasmic localization, induces the degradation of the luminal alpha(1)-ATZ molecule by first attacking the cytoplasmic tail of calnexin molecules that are associated with alpha(1)-ATZ.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL,ST LOUIS,MO 63110; CHILDRENS HOSP,DIV GASTROENTEROL & NUTR,ST LOUIS,MO 63110; KITASATO INST,TOKYO 108,JAPAN	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Kitasato University				Teckman, Jeffrey/0000-0002-4870-2621	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001379] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37784-DP] Funding Source: Medline; NIDDK NIH HHS [DK 01379-JT] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; CARRELL RW, 1986, J CLIN INVEST, V78, P1427, DOI 10.1172/JCI112731; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; INOUE S, 1992, J BIOL CHEM, V267, P9080; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; Perlmutter D H, 1993, Prog Liver Dis, V11, P139; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; Teckman JH, 1996, J BIOL CHEM, V271, P13215, DOI 10.1074/jbc.271.22.13215; TECTOR M, 1995, J BIOL CHEM, V270, P19638, DOI 10.1074/jbc.270.33.19638; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014	27	279	284	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22791	22795		10.1074/jbc.271.37.22791	http://dx.doi.org/10.1074/jbc.271.37.22791			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798455	hybrid			2022-12-27	WOS:A1996VG67200074
J	Zorzato, F; Menegazzi, P; Treves, S; Ronjat, M				Zorzato, F; Menegazzi, P; Treves, S; Ronjat, M			Role of malignant hyperthermia domain in the regulation of Ca2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE; CA-2+ RELEASE; IDENTIFICATION; EXPRESSION; CALMODULIN; MUTATION; PROTEINS; CLONING; COMPLEX; SITES	A fusion protein encompassing Gly(341) of the skeletal muscle ryanodine receptor was used to raise monoclonal antibodies; epitope mapping demonstrates that monoclonal antibody 419 (mAb419) reacts with a sequence a few residues upstream from Gly(341). The mAb419 was then used to probe ryanodine receptor (EYE) functions. Our results show that upon incubation of triads vesicles with mAb419 the Ca2+-induced Ca2+ release rate at pCa 8 was increased. Equilibrium evaluation of [H-3]ryanodine binding at different [Ca2+] indicates that mAb419 shifted the half-maximal [Ca2+] for stimulation of ryanodine binding to lower value (0.1 versus 1.2 mu M). Such functional effects may be due to a direct action of the Ab on the Ca2+ binding domain of the RYR or to the perturbation by the Ab of the intramolecular interaction between the immunopositive region and regulatory domain of the RYR. The latter hypothesis was tested directly using the optical biosensor BIA-core (Pharmacia Biotech Inc.): we show that the immunopositive EYE polypeptide is able to interact with the native RYR complex. Ligand overlays with immunopositive digoxigenin-RYR fusion protein indicate that such an interaction might occur with a calmodulin binding domain (defined by residues 3010-3225) and with a polypeptide defined by residues 799-1172. In conclusion our results suggest that the stimulation by the mAb419 of the RYR channel activity is due to the perturbation of an intramolecular interaction between the immunopositive polypeptide and a Ca2+ regulatory site probably corresponding to a calmodulin binding domain.	UNIV FERRARA, INST GEN PATHOL, I-44100 FERRARA, ITALY; CEA, CENG,DEPT BIOL MOL & STRUCT,CNRS,URA 520, LAB BIOPHYS MOL & CELLULAIRE, F-38054 GRENOBLE 9, FRANCE	University of Ferrara; CEA; Centre National de la Recherche Scientifique (CNRS)				Treves, Susan/0000-0002-0007-9631; Ronjat, Michel/0000-0002-9728-6425	Telethon [655, 617] Funding Source: Medline	Telethon(Fondazione Telethon)		BURATTI R, 1995, BIOCHEM BIOPH RES CO, V213, P1082, DOI 10.1006/bbrc.1995.2238; ENDO M, 1985, CURR TOP MEMBR TRANS, V25, P181; FILL M, 1990, BIOPHYS J, V57, P471, DOI 10.1016/S0006-3495(90)82563-7; FILL M, 1991, BIOPHYS J, V59, P1085, DOI 10.1016/S0006-3495(91)82323-2; FRANZINIARMSTRONG C, 1980, FED PROC, V39, P2403; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; GERSHONI JM, 1985, ANAL BIOCHEM, V144, P32, DOI 10.1016/0003-2697(85)90080-6; HRLOW E, 1988, ANTIBODIES LAB MANUA, P305; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Maniatis T, 1989, MOL CLONING; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MENEGAZZI P, 1994, BIOCHEMISTRY-US, V33, P9078, DOI 10.1021/bi00197a008; MICKELSON JR, 1988, J BIOL CHEM, V263, P9310; MOUTIN MJ, 1988, J BIOL CHEM, V263, P4228; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; QUANE KA, 1994, HUM MOL GENET, V3, P471, DOI 10.1093/hmg/3.3.471; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; SAITO A, 1984, J CELL BIOL, V99, P975; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SOMLYO AV, 1985, J BIOL CHEM, V260, P6801; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TREVES S, 1993, BIOCHEM J, V291, P757, DOI 10.1042/bj2910757; TRIPATHY A, 1995, BIOPHYS J, V69, P103; YOUNG RA, 1985, P NATL ACAD SCI USA, V82, P2583, DOI 10.1073/pnas.82.9.2583; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	29	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22759	22763		10.1074/jbc.271.37.22759	http://dx.doi.org/10.1074/jbc.271.37.22759			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798451	hybrid			2022-12-27	WOS:A1996VG67200070
J	Ptasznik, A; Prossnitz, ER; Yoshikawa, D; Smrcka, A; TraynorKaplan, AE; Bokoch, GM				Ptasznik, A; Prossnitz, ER; Yoshikawa, D; Smrcka, A; TraynorKaplan, AE; Bokoch, GM			A tyrosine kinase signaling pathway accounts for the majority of phosphatidylinositol 3,4,5-trisphosphate formation in chemoattractant-stimulated human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PHOSPHOINOSITIDE 3-KINASE ACTIVITY; MYELOID-DERIVED CELLS; PHOSPHOLIPASE-C; SH2 DOMAINS; ACTIVATED NEUTROPHILS; PROTEIN-KINASES; BINDING; TRANSDUCTION; INHIBITOR	The signaling pathway leading from G protein-coupled chemoattractant receptors to the generation of oxidants by NADPH oxidase in human neutrophils requires the formation of the lipid mediator phosphatidylinositol 3,4,5-trisphosphate (PIP3). Two mechanisms through which PIP3 can be generated have been described in human leukocytes. One pathway involves the coupling of the src-related tyrosine kinase Lyn to the ''classical'' p85/p110 form of phosphatidylinositol 3-kinase. The second paradigm utilizes a novel form of phosphatidylinositol 3-kinase whose activity is directly regulated by G protein beta gamma subunits. In this paper, we show that formation of PIP3 in chemoattractant-stimulated neutrophils is substantially attenuated by inhibitors that specifically block tyrosine kinase activity. These data suggest that the Lyn activation pathway plays a major role in the formation of this important lipid messenger during chemoattractant stimulation of human neutrophils.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV ROCHESTER, MED CTR, DEPT PHYSIOL & PHARMACOL, ROCHESTER, NY 14642 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92037 USA	Scripps Research Institute; University of Rochester; University of California System; University of California San Diego	Ptasznik, A (corresponding author), Scripps Res Inst, DEPT IMMUNOL IMM14, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Prossnitz, Eric R./B-4543-2008	Prossnitz, Eric/0000-0001-9190-8302	NIDDK NIH HHS [DK47240] Funding Source: Medline; NIGMS NIH HHS [GM39434, GM44428] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044428, R01GM039434] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; BOKOCH GM, 1991, CURRENT TOPICS MEMBR, P65; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHANMUGAM P, 1995, J BIOL CHEM, V270, P5418, DOI 10.1074/jbc.270.10.5418; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DOBOS GJ, 1992, J IMMUNOL, V149, P609; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KWON HJ, 1992, CANCER RES, V52, P6926; KWON HJ, 1992, BIOSCI BIOTECH BIOCH, V56, P538; LEW DP, 1993, CURRENT OPINION HEMA, P106; MATTER WF, 1992, BIOCHEM BIOPH RES CO, V186, P624, DOI 10.1016/0006-291X(92)90792-J; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THELEN M, 1994, CURR OPIN IMMUNOL, V6, P106, DOI 10.1016/0952-7915(94)90041-8; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; VLAHOS CJ, 1992, FEBS LETT, V309, P242, DOI 10.1016/0014-5793(92)80781-B; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	45	103	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25204	25207		10.1074/jbc.271.41.25204	http://dx.doi.org/10.1074/jbc.271.41.25204			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810279	hybrid			2022-12-27	WOS:A1996VL69300023
J	Kataoka, K; Mizushima, T; Ogata, Y; Miki, T; Sekimizu, K				Kataoka, K; Mizushima, T; Ogata, Y; Miki, T; Sekimizu, K			Heat shock-induced DNA relaxation in vitro by DNA gyrase of Escherichia coli in the presence of ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICKING-CLOSING ENZYME; TOPOISOMERASE-IV; NALIDIXIC-ACID; NALA-GENE; PURIFICATION; PROTEINS; MUTATIONS; INDUCTION; MUTANTS; INVITRO	Genetic studies revealed that DNA gyrase seems to catalyze immediate and transient DNA relaxation after Escherichia coli cells are exposed to heat shock (Ogata, Y., Mizushima, T., Kataoka, K., Miki, T., and Sekimizu, K. (1994) Mol. Gen. Genet. 244, 451-455). We have now obtained biochemical evidence to support this hypothesis. DNA gyrase catalyzed an increase in the linking number of DNA and relaxation of negatively supercoiled DNA, under physiological concentrations of ATP. Analyses by gel filtration chromatography of each subunit revealed that DNA relaxation activity co-migrated with each subunit. The linking number of DNA increased as the temperature increased. Further, the reaction was inhibited by nalidixic acid or by oxolinic acid. Based on these results, we propose that DNA gyrase participates in a concerted reaction with DNA topoisomerases in the immediate relaxation of DNA in cells exposed to heat shock.	KYUSHU UNIV, FAC PHARMACEUT SCI, DEPT MICROBIOL, FUKUOKA 81282, JAPAN; TOKAI UNIV, INST MED SCI, DEPT PARASITOL, TOKYO 108, JAPAN	Kyushu University; Tokai University				Ogata, Yasuyuki/0000-0003-0316-0109				BALKE VL, 1987, J BACTERIOL, V169, P4499, DOI 10.1128/jb.169.10.4499-4506.1987; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; COZZARELLI NR, 1980, SCIENCE, V207, P953, DOI 10.1126/science.6243420; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; DRLICA K, 1984, MICROBIOL REV, V48, P273, DOI 10.1128/MMBR.48.4.273-289.1984; ESPOSITO F, 1987, NUCLEIC ACIDS RES, V15, P5105, DOI 10.1093/nar/15.13.5105; GELLERT M, 1979, P NATL ACAD SCI USA, V76, P6289, DOI 10.1073/pnas.76.12.6289; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; GELLERT M, 1980, COLD SPRING HARB SYM, V45, P391; GELLERT M, 1981, ENZYMES, V14, P345; HAQ S, 1993, J BIOCHEM, V113, P620, DOI 10.1093/oxfordjournals.jbchem.a124092; Kaneko T, 1996, MOL GEN GENET, V250, P593; KATO J, 1992, J BIOL CHEM, V267, P25676; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; KREUZER KN, 1978, MOL GEN GENET, V167, P129, DOI 10.1007/BF00266906; LIU LF, 1978, CELL, V15, P979, DOI 10.1016/0092-8674(78)90281-7; MAKI S, 1992, J BIOL CHEM, V267, P12244; MIZUSHIMA T, 1993, MOL GEN GENET, V238, P1; MIZUSHIMA T, 1994, FEMS MICROBIOL LETT, V121, P333, DOI 10.1016/0378-1097(94)90313-1; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; OGATA Y, 1994, MOL GEN GENET, V244, P451, DOI 10.1007/BF00583895; PENG H, 1993, J BIOL CHEM, V268, P24481; PULLEYBLANK DE, 1975, P NATL ACAD SCI USA, V72, P4280, DOI 10.1073/pnas.72.11.4280; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHURE M, 1977, NUCLEIC ACIDS RES, V4, P1183, DOI 10.1093/nar/4.5.1183; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1969, J MOL BIOL, V43, P25, DOI 10.1016/0022-2836(69)90076-X; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JY, 1992, MOL MICROBIOL, V6, P1861, DOI 10.1111/j.1365-2958.1992.tb01358.x	32	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24806	24810		10.1074/jbc.271.40.24806	http://dx.doi.org/10.1074/jbc.271.40.24806			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798753	hybrid			2022-12-27	WOS:A1996VM67400075
J	Krohn, M; Wagner, R				Krohn, M; Wagner, R			Transcriptional pausing of RNA polymerase in the presence of guanosine tetraphosphate depends on the promoter and gene sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL STRINGENT CONTROL; STARVED ESCHERICHIA-COLI; AMINO-ACID STARVATION; GROWTH-RATE CONTROL; RIBOSOMAL-RNA; PLASMID PBR322; INVITRO TRANSCRIPTION; TERNARY COMPLEXES; HISTIDINE OPERON; CHAIN ELONGATION	We have studied the response of the effector molecule guanosine 3',5'-bisdiphosphate (ppGpp) on RNA polymerase pausing during in vitro transcription elongation. Pausing was followed during single round extension of stalled ternary complexes excluding possible ppGpp effects on initiation. The ppGpp dependences of early pausing sites within different transcription systems controlled by promoters with known response to enhanced ppGpp levels in vivo were quantitatively characterized. Transcription of stable RNAs and mRNA genes were analyzed. In addition, the in vitro pausing behavior of two promoter variants directing the same sequence but differing in their in vivo ppGpp sensitivity were compared. In the presence of ppGpp we noted a slight general enhancement of specific pauses in all transcription systems. However, genes known to be un der stringent or growth rate control in vivo revealed a notably stronger pausing enhancement. The sites of pausing are not changed by the presence of ppGpp but appear to be sequence-specific. The effect of ppGpp on the extent of pausing depends on the particular promoter and closely adjacent sequences that the RNA polymerase has passed during initiation. Pausing enhancement requires the presence of ppGpp during elongation but not during initiation. The results underline the importance of pausing for transcription regulation and offer a plausible explanation for inhibition of stable RNA expression under conditions of elevated concentrations of ppGpp.	UNIV DUSSELDORF,INST PHYS BIOL,D-40225 DUSSELDORF,GERMANY	Heinrich Heine University Dusseldorf								ADHYA S, 1982, CELL, V29, P939, DOI 10.1016/0092-8674(82)90456-1; AXELROD VD, 1978, NUCLEIC ACIDS RES, V5, P3549, DOI 10.1093/nar/5.10.3549; BARACCHINI E, 1988, J BIOL CHEM, V263, P2597; BREMER H, 1995, BBA-GENE STRUCT EXPR, V1262, P15, DOI 10.1016/0167-4781(95)00042-F; BROSIUS J, 1984, GENE, V27, P151, DOI 10.1016/0378-1119(84)90136-7; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4636; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; CHAN CL, 1989, J BIOL CHEM, V264, P20796; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; CONDON C, 1993, EMBO J, V12, P4305, DOI 10.1002/j.1460-2075.1993.tb06115.x; DAS A, 1992, J BACTERIOL, V174, P6711, DOI 10.1128/JB.174.21.6711-6716.1992; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; GAFNY R, 1994, J MOL BIOL, V243, P152, DOI 10.1006/jmbi.1994.1641; GALLANT JA, 1979, ANNU REV GENET, V13, P393, DOI 10.1146/annurev.ge.13.120179.002141; GAUSING K, 1977, J MOL BIOL, V115, P335, DOI 10.1016/0022-2836(77)90158-9; GENTRY DR, 1993, J BACTERIOL, V175, P7982, DOI 10.1128/JB.175.24.7982-7989.1993; GLASER G, 1983, NATURE, V302, P74, DOI 10.1038/302074a0; GLASS RE, 1986, MOL GEN GENET, V203, P265, DOI 10.1007/BF00333964; GOLIGER JA, 1989, J MOL BIOL, V205, P331, DOI 10.1016/0022-2836(89)90344-6; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; HECKER M, 1983, MOL GEN GENET, V190, P355, DOI 10.1007/BF00330665; HERMAN A, 1994, MOL GEN GENET, V243, P374, DOI 10.1007/BF00280467; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; KAJITANI M, 1984, J BIOL CHEM, V259, P1951; KINGSTON RE, 1983, BIOCHEMISTRY-US, V22, P5249, DOI 10.1021/bi00292a002; KINGSTON RE, 1981, CELL, V27, P523, DOI 10.1016/0092-8674(81)90394-9; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; KLOTSKY RA, 1987, GENE, V55, P141, DOI 10.1016/0378-1119(87)90257-5; KROHN M, 1992, MOL MICROBIOL, V6, P581, DOI 10.1111/j.1365-2958.1992.tb01504.x; KROHN M, 1995, ANAL BIOCHEM, V225, P188, DOI 10.1006/abio.1995.1138; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; LIEBIG B, 1995, MOL GEN GENET, V249, P328, DOI 10.1007/BF00290534; LINCHAO S, 1986, MOL GEN GENET, V203, P150, DOI 10.1007/BF00330396; LINCHAO S, 1986, MOL GEN GENET, V203, P143, DOI 10.1007/BF00330395; LITTLE R, 1983, J BACTERIOL, V154, P787, DOI 10.1128/JB.154.2.787-792.1983; MIZUSHIMASUGANO J, 1985, EMBO J, V4, P1053, DOI 10.1002/j.1460-2075.1985.tb03738.x; NODWELL JR, 1991, GENE DEV, V5, P2141, DOI 10.1101/gad.5.11.2141; OHLSEN KL, 1992, J BACTERIOL, V174, P6071, DOI 10.1128/JB.174.19.6071-6075.1992; OWENS JR, 1987, BIOCHEM BIOPH RES CO, V142, P964, DOI 10.1016/0006-291X(87)91508-7; PARDON B, 1994, BIOL CHEM H-S, V375, P11, DOI 10.1515/bchm3.1994.375.1.11; PARDON B, 1995, NUCLEIC ACIDS RES, V23, P932, DOI 10.1093/nar/23.6.932; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; REDDY PS, 1995, MOL MICROBIOL, V15, P255, DOI 10.1111/j.1365-2958.1995.tb02240.x; RIGGS DL, 1986, P NATL ACAD SCI USA, V83, P9333, DOI 10.1073/pnas.83.24.9333; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SCHETTERS H, 1972, BIOCHIM BIOPHYS ACTA, V272, P549, DOI 10.1016/0005-2787(72)90510-2; SCHROETER A, 1988, J BASIC MICROB, V28, P553, DOI 10.1002/jobm.3620280818; SORENSEN MA, 1994, J MOL BIOL, V236, P441, DOI 10.1006/jmbi.1994.1156; STEPHENS JC, 1975, P NATL ACAD SCI USA, V72, P4389, DOI 10.1073/pnas.72.11.4389; TEDIN K, 1992, J BIOL CHEM, V267, P2337; TELESNITSKY APW, 1989, J MOL BIOL, V205, P315, DOI 10.1016/0022-2836(89)90343-4; THEISSEN G, 1990, ANAL BIOCHEM, V189, P254, DOI 10.1016/0003-2697(90)90117-R; TIPPNER D, 1994, MOL MICROBIOL, V11, P589, DOI 10.1111/j.1365-2958.1994.tb00339.x; TOMIZAWA J, 1981, P NATL ACAD SCI-BIOL, V78, P1421, DOI 10.1073/pnas.78.3.1421; TRAVERS AA, 1980, J BACTERIOL, V141, P973, DOI 10.1128/JB.141.2.973-976.1980; TRAVERS AA, 1986, J MOL BIOL, V189, P251, DOI 10.1016/0022-2836(86)90397-9; TRAVERS AA, 1984, NUCLEIC ACIDS RES, V12, P2605, DOI 10.1093/nar/12.6.2605; VINCENTE M, 1991, MOL MICROBIOL, V5, P2085; VOGEL U, 1995, J BIOL CHEM, V270, P18335, DOI 10.1074/jbc.270.31.18335; VOGEL U, 1994, J BACTERIOL, V176, P2807, DOI 10.1128/JB.176.10.2807-2813.1994; VOGEL U, 1994, J BIOL CHEM, V269, P16236; VOGEL U, 1992, MOL MICROBIOL, V6, P2191, DOI 10.1111/j.1365-2958.1992.tb01393.x; WOODY AYM, 1987, BIOCHIM BIOPHYS ACTA, V909, P115, DOI 10.1016/0167-4781(87)90033-9; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; ZACHARIAS M, 1990, NUCLEIC ACIDS RES, V18, P6271, DOI 10.1093/nar/18.21.6271; ZACHARIAS M, 1989, EMBO J, V8, P3357, DOI 10.1002/j.1460-2075.1989.tb08498.x	71	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23884	23894		10.1074/jbc.271.39.23884	http://dx.doi.org/10.1074/jbc.271.39.23884			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798619	hybrid			2022-12-27	WOS:A1996VJ44200048
J	Miller, MJ; Martinez, A; Unsworth, EJ; Thiele, CJ; Moody, TW; Elsasser, T; Cuttitta, F				Miller, MJ; Martinez, A; Unsworth, EJ; Thiele, CJ; Moody, TW; Elsasser, T; Cuttitta, F			Adrenomedullin expression in human tumor cell lines - Its potential role as an autocrine growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GASTRIN-RELEASING PEPTIDE; GENE-ASSOCIATED PEPTIDES; PULMONARY VASCULAR BED; LUNG-CANCER; HYPOTENSIVE PEPTIDE; RAT ADRENOMEDULLIN; COLORIMETRIC ASSAY; NECROSIS-FACTOR; CLONING	Although adrenomedullin (AM) previously has been identified in human tumors, its role has remained elusive. Analysis by reverse transcriptase-polymerase chain reaction (RT-PCR) revealed AM mRNA in 18 of 20 human normal tissues representing major organs, and 55 of 58 (95%) malignant cell lines. Western blot and high performance liquid chromatography analysis showed immunoreactive AM species of 18, 14, and 6 kDa that are consistent with the precursor, intermediate product, and active peptide, respectively. Immunohistochemistry and in situ RT-PCR performed on paraffin-embedded tumor cell lines of various tissue origins exhibited AM cytoplasmic staining. Neutralizing monoclonal antibody to AM inhibits tumor cell growth in a concentration-dependent manner, an effect that was reversed with the addition of exogenous AM. Responding tumor cells were shown to have approximately 50,000 AM receptors per cell by Scatchard analysis with I-125-AM and expressed AM receptor mRNA by RT-PCR. Our data showed 36 of 48 (75%) tumor cell lines expressed AM receptor mRNA by RT-PCR assessment, all of them also expressed AM. In the presence of AM, cAMP levels were shown to increase in tumor cells. Our collective data demonstrate that AM and AM receptor are expressed in numerous human cancer cell lines of diverse origin and constitute a potential autocrine growth mechanism that could drive neoplastic proliferation.	NCI, PEDIAT BRANCH, DIV CANC TREATMENT, NIH, BETHESDA, MD 20892 USA; ARS, USDA, BELTSVILLE, MD 20705 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Agriculture (USDA)	Miller, MJ (corresponding author), NCI, BIOMARKERS & PREVET RES BRANCH, DIV CLIN SCI, ROCKVILLE, MD 20850 USA.		Martinez, Alfredo/ABH-8659-2020; Martinez, Alfredo/GQH-5998-2022	Martinez, Alfredo/0000-0003-4882-4044				AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; BUDILLON A, 1995, P NATL ACAD SCI USA, V92, P10634, DOI 10.1073/pnas.92.23.10634; CARMICHAEL J, 1987, CANCER RES, V47, P943; CHENG DY, 1994, LIFE SCI, V55, pPL251, DOI 10.1016/0024-3205(94)00246-0; CHINI EN, 1995, BIOCHEM BIOPH RES CO, V215, P868, DOI 10.1006/bbrc.1995.2544; CUTTITTA F, 1988, J CLIN ENDOCR METAB, V67, P576, DOI 10.1210/jcem-67-3-576; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; EBARA T, 1994, EUR J PHARMACOL, V263, P69, DOI 10.1016/0014-2999(94)90524-X; HOOSEIN NM, 1989, REGUL PEPTIDES, V24, P15, DOI 10.1016/0167-0115(89)90207-3; ISHIYAMA Y, 1993, EUR J PHARMACOL, V241, P271, DOI 10.1016/0014-2999(93)90214-3; ISHIZAKA Y, 1994, BIOCHEM BIOPH RES CO, V200, P642, DOI 10.1006/bbrc.1994.1496; ISHIZUKA J, 1994, CANCER RES, V54, P2129; JOUGASAKI M, 1995, AM J PHYSIOL-RENAL, V268, pF657, DOI 10.1152/ajprenal.1995.268.4.F657; KANAZAWA H, 1994, BIOCHEM BIOPH RES CO, V205, P251, DOI 10.1006/bbrc.1994.2657; KAPAS S, 1995, J BIOL CHEM, V270, P25344, DOI 10.1074/jbc.270.43.25344; KITAMURA K, 1994, FEBS LETT, V338, P306, DOI 10.1016/0014-5793(94)80289-0; KITAMURA K, 1994, FEBS LETT, V351, P35, DOI 10.1016/0014-5793(94)00810-8; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V194, P720, DOI 10.1006/bbrc.1993.1881; Lalli E, 1996, EMBO J, V15, P528, DOI 10.1002/j.1460-2075.1996.tb00385.x; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; LIPPTON H, 1994, J APPL PHYSIOL, V76, P2154, DOI 10.1152/jappl.1994.76.5.2154; LOHMANN SM, 1984, ADV CYCLIC NUCL PROT, V18, P63; MAHMOUD S, 1991, CANCER RES, V51, P1798; MARTINEZ A, 1995, J HISTOCHEM CYTOCHEM, V43, P739, DOI 10.1177/43.8.7542678; Martinez A, 1996, ENDOCRINOLOGY, V137, P2626, DOI 10.1210/en.137.6.2626; MARTINEZ A, 1995, ENDOCRINOLOGY, V136, P4099, DOI 10.1210/en.136.9.4099; MINAMINO N, 1995, BIOCHEM BIOPH RES CO, V211, P686, DOI 10.1006/bbrc.1995.1866; MOODY TW, 1993, P NATL ACAD SCI USA, V90, P4345, DOI 10.1073/pnas.90.10.4345; MURPHY TC, 1995, ENDOCRINOLOGY, V136, P2459, DOI 10.1210/en.136.6.2459; NAKANISHI Y, 1988, J CLIN INVEST, V82, P354, DOI 10.1172/JCI113594; NAKANISHI Y, 1988, EXP CELL BIOL, V56, P74; NAKATA T, 1995, CIRCULATION, V92, P3794; Quinn KA, 1996, J BIOL CHEM, V271, P11477, DOI 10.1074/jbc.271.19.11477; REEVE JR, 1989, J BIOL CHEM, V264, P1928; SAKATA J, 1993, BIOCHEM BIOPH RES CO, V195, P921, DOI 10.1006/bbrc.1993.2132; SAMSON WK, 1995, ENDOCRINOLOGY, V136, P2349, DOI 10.1210/en.136.5.2349; SANTIAGO JA, 1994, LIFE SCI, V55, pPL85, DOI 10.1016/0024-3205(94)00652-0; SATO A, 1995, BIOCHEM BIOPH RES CO, V217, P211, DOI 10.1006/bbrc.1995.2765; SATOH F, 1995, J CLIN ENDOCR METAB, V80, P1750, DOI 10.1210/jc.80.5.1750; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHIMEKAKE Y, 1995, J BIOL CHEM, V270, P4412, DOI 10.1074/jbc.270.9.4412; SHIMOSAWA T, 1995, J CLIN INVEST, V96, P1672, DOI 10.1172/JCI118208; SIEGFRIED JM, 1994, J BIOL CHEM, V269, P8596; Steller MA, 1995, P NATL ACAD SCI USA, V92, P11970, DOI 10.1073/pnas.92.26.11970; SUGO S, 1995, BIOCHEM BIOPH RES CO, V207, P25, DOI 10.1006/bbrc.1995.1148; SUGO S, 1995, FEBS LETT, V369, P311, DOI 10.1016/0014-5793(95)00769-6; SUGO S, 1994, BIOCHEM BIOPH RES CO, V203, P719, DOI 10.1006/bbrc.1994.2241; TAKAHASHI H, 1994, AM J HYPERTENS, V7, P478, DOI 10.1093/ajh/7.5.478; TORTORA G, 1994, CELL GROWTH DIFFER, V5, P753; Withers DJ, 1996, FEBS LETT, V378, P83, DOI 10.1016/0014-5793(95)01427-6; YAMAGUCHI T, 1994, LIFE SCI, V56, P379, DOI 10.1016/0024-3205(94)00903-1	52	293	304	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23345	23351						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798536				2022-12-27	WOS:A1996VH76800062
J	Saltman, LH; Lu, Y; Zaharias, EM; Isberg, RR				Saltman, LH; Lu, Y; Zaharias, EM; Isberg, RR			A region of the Yersinia pseudotuberculosis invasin protein that contributes to high affinity binding to integrin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; ENTEROPATHOGENIC ESCHERICHIA-COLI; SITE-DIRECTED MUTAGENESIS; TISSUE-CULTURE CELLS; MAMMALIAN-CELLS; FIBROBLAST ADHESION; SYNTHETIC PEPTIDES; DIVALENT-CATIONS; GENETIC-LOCUS; FIBRONECTIN	The entry of Yersinia pseudotuberculosis into cultured mammalian cells is mediated by the bacterial protein invasin. The mammalian receptors for invasin are five beta(1) chain integrins. Site directed mutagenesis of the aspartate and lysine residues in the 192-amino acid integrin binding domain of invasin was performed to identify regions, in addition to the previously characterized 903-913 region, that are important for integrin binding. One mutation, D811A, resulted in depressed ability of invasin to bind purified alpha(5) beta(1) and to promote bacterial entry. Further mutational analysis of Asp-811 indicated that an oxygen-containing side chain is required at this position, A second nearby residue, Phe-808, was also shown to be important for integrin binding, as an alanine substitution at this site had properties similar to the Asp-811 mutation. This mutational analysis has therefore identified a second region that, in conjunction with residues 903-913, is required for wild type levels of integrin binding. The contribution to binding by two noncontiguous sites in the primary sequence parallels results that indicate two domains of fibronectin are involved in integrin binding.	TUFTS UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT MOL BIOL & MICROBIOL, BOSTON, MA 02111 USA	Howard Hughes Medical Institute; Tufts University; Tufts University					NIAID NIH HHS [R01-AI23538] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023538] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; AKIYAMA SK, 1985, J BIOL CHEM, V260, P402; AOTA S, 1991, J BIOL CHEM, V266, P15938; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; BRASAEMLE DL, 1988, BIOTECHNIQUES, V6, P418; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; DONNENBERG MS, 1990, INFECT IMMUN, V58, P1565, DOI 10.1128/IAI.58.6.1565-1571.1990; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; FALKOW S, 1992, ANNU REV CELL BIOL, V8, P333, DOI 10.1146/annurev.cb.08.110192.002001; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GOUGH JA, 1983, J MOL BIOL, V166, P1, DOI 10.1016/S0022-2836(83)80047-3; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; GRUTZKAU A, 1990, GUT, V31, P1011, DOI 10.1136/gut.31.9.1011; HANSKI C, 1989, INFECT IMMUN, V57, P673, DOI 10.1128/IAI.57.3.673-678.1989; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISBERG RR, 1994, ANNU REV GENET, V28, P395, DOI 10.1146/annurev.ge.28.120194.002143; ISBERG RR, 1990, MOL BIOL MED, V7, P73; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; KRAMER B, 1984, CELL, V38, P879, DOI 10.1016/0092-8674(84)90283-6; KUMAMOTO CA, 1983, J BACTERIOL, V154, P253, DOI 10.1128/JB.154.1.253-260.1983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LEE KK, 1989, MOL MICROBIOL, V3, P1493, DOI 10.1111/j.1365-2958.1989.tb00135.x; LEONG JM, 1991, INFECT IMMUN, V59, P3424, DOI 10.1128/IAI.59.10.3424-3433.1991; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; LEONG JM, 1995, EMBO J, V14, P422, DOI 10.1002/j.1460-2075.1995.tb07018.x; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LUND B, 1988, MOL MICROBIOL, V2, P255, DOI 10.1111/j.1365-2958.1988.tb00027.x; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; Maniatis T., 1982, MOL CLONING; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; NHIEU GTV, 1993, EMBO J, V12, P1887; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; PAGLIARO L, 1988, J CELL BIOL, V107, P981, DOI 10.1083/jcb.107.3.981; PEPE JC, 1993, P NATL ACAD SCI USA, V90, P6473, DOI 10.1073/pnas.90.14.6473; PHILLIPS DR, 1983, J BIOL CHEM, V258, P240; PIERSCHBACHER M, 1983, P NATL ACAD SCI-BIOL, V80, P1224, DOI 10.1073/pnas.80.5.1224; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; RANKIN S, 1992, INFECT IMMUN, V60, P3909, DOI 10.1128/IAI.60.9.3909-3912.1992; RANKIN S, 1994, METHOD ENZYMOL, V236, P566; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANSONETTI PJ, 1986, INFECT IMMUN, V51, P461, DOI 10.1128/IAI.51.2.461-469.1986; STEINER B, 1989, J BIOL CHEM, V264, P13102; STREETER HB, 1987, J CELL BIOL, V105, P507, DOI 10.1083/jcb.105.1.507; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SWANSON J, 1973, J EXP MED, V137, P571, DOI 10.1084/jem.137.3.571; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325	62	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23438	23444		10.1074/jbc.271.38.23438	http://dx.doi.org/10.1074/jbc.271.38.23438			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798550	hybrid			2022-12-27	WOS:A1996VH76800076
J	Stein, E; Cerretti, DP; Daniel, TO				Stein, E; Cerretti, DP; Daniel, TO			Ligand activation of ELK receptor tyrosine kinase promotes its association with Grb10 and Grb2 in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN; MOLECULAR CHARACTERIZATION; FAMILY; CLONING; TRANSFORMATION; YEAST; VECTORS; SIGNAL; BRAIN	ELK is a member of the Eph related tyrosine kinase family that includes receptors signaling axonal guidance, neuronal bundling, and angiogenesis. We recently identified ELK expression in human renal microvascular endothelial cells and sought to identify intracellular proteins through which it signals responses. The cytoplasmic domain of ELK was used as "bait" in a yeast two-hybrid screen to identify interactive proteins expressed from a randomly primed embryonic murine library (E9.5-10.5). Among interactive products of 76 cDNAs characterized, 10 nonidentical, overlapping clones encoded the SH2 domain of the recently reported Grb10 adapter protein, and an additional 3 encoded Grb2. A self-phosphorylated recombinant, baculovirus-expressed GST-ELKcy fusion protein bound Grb10 and Grb2 from human renal microvascular endothelial cell extracts, while the unphosphorylated fusion form did not. Site-directed mutation identified Tyr-929 as a putative phosphorylation site required for Grb10, but not Grb2, interaction in yeast and recombinant protein assays. The ELK ligand, LERK-2/Fc, stimulated tyrosine phosphorylation of ELK, and recruitment of Grb10 and Grb2 to endothelial ELK receptors recovered by wheat germ agglutinin lectin and immunoprecipitation. These findings define ligand-activated interaction between ELK and the SH2 domains of Grb2 and the newly identified Grb10 protein that shares homology with a Caenorhabditis elegans gene product implicated in neural cell migration.	VANDERBILT UNIV, SCH MED, DIV NEPHROL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT PHARMACOL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA; IMMUNEX RES & DEV CORP, SEATTLE, WA 98101 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University			Stein, Elke/E-8107-2013	Stein, Elke/0000-0001-8965-5692	NIDDK NIH HHS [DK47078, DK38517] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038517, R01DK047078] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; *BIOR LAB INC, 1994, E COL PULS TRANSF AP; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARPENTER MK, 1995, J NEUROSCI RES, V42, P199, DOI 10.1002/jnr.490420207; Cerretti DP, 1995, MOL IMMUNOL, V32, P1197, DOI 10.1016/0161-5890(95)00108-5; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; GRUENWALD S, 1995, PHARMINGEN RES PRODU; GRUENWALD S, 1995, BACULOVIRUS EXPRESSI; HAUN RS, 1992, BIOTECHNIQUES, V13, P515; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OOI J, 1995, ONCOGENE, V10, P1621; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Rose MD., 1990, METHODS YEAST GENETI; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; TANG XX, 1995, GENOMICS, V29, P426, DOI 10.1006/geno.1995.9985; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; WOJTA J, 1989, J BIOL CHEM, V264, P2846; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	136	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23588	23593		10.1074/jbc.271.38.23588	http://dx.doi.org/10.1074/jbc.271.38.23588			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798570	hybrid			2022-12-27	WOS:A1996VH76800096
J	Wang, YH; Griffith, J				Wang, YH; Griffith, J			Methylation of expanded CCG triplet repeat DNA from fragile X syndrome patients enhances nucleosome exclusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY GENE; CPG BINDING-PROTEIN; DIHYDROFOLATE-REDUCTASE; CHROMATIN STRUCTURE; RNA-BINDING; TRANSCRIPTION; PROMOTER; SITE; EXPRESSION; SEQUENCE	Long tracts of CCG trinucleotide or CCGNN pentanucleotide repeats in DNA have previously been shown to resist assembly into nucleosomes. This may provide a molecular explanation for the nature of certain rare, folate-sensitive fragile sites in human chromosomes that contain expanded CCG triplet tracts, Further, it is known that methylation of CpG dinucleotides at or near these fragile sites enhances the fragile phenotype, Here DNAs containing 76 tandem CCG triplets or 48 CCGNN pentanucleotide repeats were methylated with SssI methylase at three different levels of methylation. Using competitive nucleosome reconstitution/gel shift assays, the ability of these DNAs and a mixed sequence DNA from the pUC19 plasmid were compared in their ability to assemble into nucleosomes, DNA methylation had no significant effect on nucleosome formation over the pUC 19 fragment. However, the highly methylated DNAs containing 76 CCG triplets or 48 CCGNN pentanucleotide repeats were 2.0 +/- 0.2-fold and 2.1 +/- 0.3-fold less efficient in nucleosome assembly than the respective unmethylated forms, and 4.4 +/- 0.4-fold and 12.6 +/- 1.6-fold less efficient than a pUC19 fragment of similar length.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill								ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; DREW HR, 1987, J MOL BIOL, V197, P485, DOI 10.1016/0022-2836(87)90560-2; ENGLANDER EW, 1993, J BIOL CHEM, V268, P19565; FELSENFELD G, 1982, COLD SPRING HARB SYM, V47, P577; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; HOMSTRA IK, 1993, HUM MOL GENET, V2, P1659; HSIEH CH, 1988, CELL, V52, P535, DOI 10.1016/0092-8674(88)90466-7; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MATSUO K, 1994, NUCLEIC ACIDS RES, V22, P5354, DOI 10.1093/nar/22.24.5354; MAVROTHALASSITIS GJ, 1990, ONCOGENE, V5, P1337; MCCONKIEROSELL A, 1993, AM J HUM GENET, V53, P800; NANCARROW JK, 1994, SCIENCE, V264, P1938, DOI 10.1126/science.8009225; NUR I, 1985, J BACTERIOL, V164, P19, DOI 10.1128/JB.164.1.19-24.1985; PARRISH JE, 1994, NAT GENET, V8, P229, DOI 10.1038/ng1194-229; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; SHIMADA T, 1986, J BIOL CHEM, V261, P1445; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SHRADER TE, 1990, J MOL BIOL, V216, P69, DOI 10.1016/S0022-2836(05)80061-0; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WANG Y, 1996, UNPUB; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; WANG YH, 1996, IN PRESS P NATL ACAD	37	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					22937	22940		10.1074/jbc.271.38.22937	http://dx.doi.org/10.1074/jbc.271.38.22937			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798475	hybrid			2022-12-27	WOS:A1996VH76800001
J	delaCruz, IP; Nillni, EA				delaCruz, IP; Nillni, EA			Intracellular sites of prothyrotropin-releasing hormone processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREFELDIN-A; RAT-BRAIN; PROHORMONE CONVERTASES; SECRETORY GRANULES; MAMMALIAN-CELLS; TRH PROHORMONE; ATT20 CELLS; PRO-TRH; PEPTIDES; MEMBRANE	Post-translational processing of proteins plays a key role in regulating their subcellular localization, enzymatic activity, and protein-protein interactions by such diverse mechanisms as phosphorylation, glycosylation, and proteolytic cleavage, The prothyrotropin-releasing hormone (pro-TRH) precursor (26 kDa) undergoes proteolytic cleavage at either of two sites, generating a 15/10-kDa or a 9.5/16.5-kDa N/C-terminal pair of intermediates, Using transfected AtT20 cells encoding a prepro-TRH cDNA, we have previously reported that this initial set of cleavages occurs prior to entry into the secretory granules (Nillni, E. A., Sevarino, K. A., and Jackson, I. M. D. (1993) Endocrinology 132, 1271-1277). In this study, we set out to identify the subcellular compartment where this initial cleavage takes place as well as to determine the sites of processing of the intermediates produced, Our strategy was to block the transport of pro-TRH or its intermediates from one subcellular compartment to the next and to assay for the accumulation of intermediates, presumably because their processing occurs in a post-blockade compartment. Radiolabeling experiments in AtT20 cells in the presence of the drug brefeldin A, which blocks transport from the endoplasmic reticulum to the Golgi complex, led to an accumulation of the 26-kDa precursor, suggesting a post-endoplasmic reticulum site of processing, When Golgi complex-to-secretory granule transport was blocked at 20 degrees C, the processing of the 26-kDa precursor was not affected, suggesting a Golgi complex site of processing, At this temperature, the 15-kDa N-terminal intermediate accumulated, suggesting a post-Golgi complex processing site, while the 16.5-kDa C-terminal intermediate was processed in the Golgi complex to produce a 5.4-kDa peptide.	BROWN UNIV,RHODE ISL HOSP,SCH MED,DEPT MED,DIV ENDOCRINOL,PROVIDENCE,RI 02903	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital								BOWERS CY, 1971, BIOCHEM BIOPH RES CO, V45, P1033, DOI 10.1016/0006-291X(71)90441-4; BULANT M, 1990, ENDOCRINOLOGY, V127, P1978, DOI 10.1210/endo-127-4-1978; BULANT M, 1988, J BIOL CHEM, V263, P17189; COCKLE SM, 1990, FEBS LETT, V264, P253, DOI 10.1016/0014-5793(90)80261-G; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; Eipper B A, 1980, Endocr Rev, V1, P1; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; FRIEDMAN TC, 1995, ENDOCRINOLOGY, V136, P4462, DOI 10.1210/en.136.10.4462; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; GUEST PC, 1992, J BIOL CHEM, V267, P22401; HALL ME, 1983, PEPTIDES, V4, P763, DOI 10.1016/0196-9781(83)90033-5; HEDNER J, 1981, NEUROSCI LETT, V24, P317; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOOK VYH, 1984, P NATL ACAD SCI-BIOL, V81, P2776, DOI 10.1073/pnas.81.9.2776; JACKSON IMD, 1994, REGULATION THYROTROP; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; Lechan R.M., 1993, THYROID TODAY, V16, P1; LECHAN RM, 1986, SCIENCE, V231, P159, DOI 10.1126/science.3079917; LECHAN RM, 1987, ENDOCRINOLOGY, V121, P1879, DOI 10.1210/endo-121-5-1879; LEGRADI G, 1996, IN PRESS BRAIN RES; LISTON D, 1984, SCIENCE, V225, P734, DOI 10.1126/science.6547780; METCALF G, 1974, NATURE, V252, P310, DOI 10.1038/252310a0; MILGRAM SL, 1994, J CELL SCI, V107, P737; Nicholson WE, 1996, ENDOCRINOLOGY, V137, P2171, DOI 10.1210/en.137.5.2171; Nillni E. A., 1995, Molecular Biology of the Cell, V6, p331A; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1260, DOI 10.1210/en.132.3.1260; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1271, DOI 10.1210/en.132.3.1271; NILLNI EA, 1995, J NEUROCHEM, V65, P2462; NILLNI EA, 1996, IN PRESS ENDOCRINOLO; NILLNI EA, 1991, NEUROPEPTIDE TECHNOL, P51; REDEI E, 1995, ENDOCRINOLOGY, V136, P3557, DOI 10.1210/en.136.8.3557; ROUSSEL JP, 1991, NEUROENDOCRINOLOGY, V54, P559, DOI 10.1159/000125960; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCOTT REM, 1993, MOL ENDOCRINOL, V7, P585, DOI 10.1210/me.7.4.585; SEGERSON TP, 1987, ENDOCRINOLOGY, V121, P98, DOI 10.1210/endo-121-1-98; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEVARINO KA, 1989, J BIOL CHEM, V264, P21529; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; TAKAHARA J, 1974, P SOC EXP BIOL MED, V146, P831, DOI 10.3181/00379727-146-38200; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; WILBER JF, 1967, P SOC EXP BIOL MED, V127, P488; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; ZHOU A, 1994, J BIOL CHEM, V269, P17440	46	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22736	22745		10.1074/jbc.271.37.22736	http://dx.doi.org/10.1074/jbc.271.37.22736			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798448	hybrid			2022-12-27	WOS:A1996VG67200067
J	Ding, Y; Kobayashi, S; Kopito, R				Ding, Y; Kobayashi, S; Kopito, R			Mapping of ankyrin binding determinants on the erythroid anion exchanger, AE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CYTOPLASMIC DOMAIN; MAJOR ANKYRIN; REPEAT DOMAIN; CELL-LINE; MEMBRANE; BAND-3; BRAIN; PROTEIN; KIDNEY	The association of ankryrin with the AE1 anion exchanger contributes an essential function to the mechanical and viscoelastic properties of the erythrocyte and constitutes the best understood link between the plasma membrane and the underlying membrane skeleton. The AE1 binding domain of ankyrin consists of 24 tandem repeats of a 33-amino acid motif that is present on a wide variety of otherwise unrelated proteins. The experiments described in this paper are aimed at identifying the specific amino acid sequences in AE1 that comprise the ankyrin binding site. We have exploited a cell-free binding assay to quantify the binding affinity of anion exchangers and a recombinant fragment of ANK1, R13-H. Our previous study (Ding, Y., Casey, J. R and Kopito, R. R. (1995) J. Biol. Chem. 269, 32201-32208) identified an essential role of the amino-terminal 79 AE1 residues in ankyrin binding. The present study extends these findings to show that these 79 amino acids, although necessary, are not sufficient for ankyrin binding. Using chimeras between AE1 and the closely related anion exchanger AE2, which does not bind ankyrin, we have defined a 40-residue region of AE1 between positions 155 and 195 that is also essential for ankyrin binding.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038543] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM38543] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER SL, 1988, J BIOL CHEM, V263, P17092; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1979, NATURE, V280, P468, DOI 10.1038/280468a0; BENNETT V, 1992, J BIOL CHEM, V267, P8703; DAVIS JQ, 1993, J CELL BIOL, V121, P121, DOI 10.1083/jcb.121.1.121; DAVIS L, 1989, J BIOL CHEM, V264, P9665; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DING Y, 1994, J BIOL CHEM, V269, P32201; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KOBAYASHI S, 1994, J NEUROSCI, V14, P6266; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; KUNIMOTO M, 1991, J CELL BIOL, V115, P1319, DOI 10.1083/jcb.115.5.1319; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEE BS, 1991, J BIOL CHEM, V266, P11448; LI ZP, 1993, J BIOL CHEM, V268, P11489; LINN SC, 1992, J BIOL CHEM, V267, P7927; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LOW PS, 1984, J BIOL CHEM, V259, P3070; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; Michaely P, 1995, J BIOL CHEM, V270, P31298, DOI 10.1074/jbc.270.52.31298; MORGANS CW, 1993, J CELL SCI, V105, P1137; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SMITH PR, 1993, AM J PHYSIOL, V264, pC63, DOI 10.1152/ajpcell.1993.264.1.C63; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; THOMAS HA, 1989, AM J PHYSIOL, V257, pC537, DOI 10.1152/ajpcell.1989.257.3.C537; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893	34	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22494	22498		10.1074/jbc.271.37.22494	http://dx.doi.org/10.1074/jbc.271.37.22494			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798415	hybrid			2022-12-27	WOS:A1996VG67200034
J	Ji, L; Mochon, E; Arcinas, M; Boxer, LM				Ji, L; Mochon, E; Arcinas, M; Boxer, LM			CREB proteins function as positive regulators of the translocated bcl-2 allele in t(14;18) lymphomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; LIGATION-MEDIATED PCR; CHRONIC LYMPHOCYTIC-LEUKEMIA; RESPONSE ELEMENT; MALIGNANT-LYMPHOMA; BURKITTS-LYMPHOMA; EXPRESSION; GENE; TRANSCRIPTION; CELLS	The translocated and normal bcl-2 alleles in the DHL-4 cell line with the t(14;18) translocation were separated by pulsed field electrophoresis, An in vivo footprint over a cAMP response element (CRE) in the bcl-2 5'-flanking sequence was identified on the translocated allele, Electrophoretic mobility shift assays with the bcl-2 CRE demonstrated complexes with mobilities identical to those with a consensus CRE. UV cross-linking experiments revealed that proteins with molecular masses of 34, 43, and 67 kDa bound to the bcl-2 CRE site, Electrophoretic mobility shift assay with an antibody specific to the phosphorylated cAMP response-binding protein (CREB) demonstrated that phosphorylated CREB was present in DHL-4 cells. Treatment with phorbol 12-myristate 13-acetate (PMA) led to an increase in both the amount of phosphorylated CREB and the bcl-2 promoter activity, The response to PMA was dependent on an intact CRE site. The activity of the bcl-2 promoter was increased 20-fold in a construct with the immunoglobulin heavy chain enhancers, and mutation of the CRE site abolished most of the induction, The addition of PMA increased the activity of the bcl-2-immunoglobulin enhancer construct by 3.5-fold. Access to the CRE site is blocked in the silent normal bcl-2 allele, while CREB proteins bind to the site on the translocated allele. We conclude that the CRE site functions as a positive regulatory site for the translocated bcl-2 allele in t(14;18) lymphomas.	STANFORD UNIV,SCH MED,DIV HEMATOL,DEPT MED,STANFORD,CA 94305; PALO ALTO VET AFFAIRS MED CTR,CTR MOL BIOL & MED,STANFORD,CA 94305	Stanford University					NATIONAL CANCER INSTITUTE [R01CA056764, R56CA056764] Funding Source: NIH RePORTER; NCI NIH HHS [CA56764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCINAS M, 1994, ONCOGENE, V9, P2699; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DARIAVACH P, 1991, EUR J IMMUNOL, V21, P1499, DOI 10.1002/eji.1830210625; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; FRANKFURT OS, 1993, ONCOL RES, V5, P37; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; HANADA M, 1993, BLOOD, V82, P1820; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; LALLI E, 1994, J BIOL CHEM, V269, P17359; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Maxam A M, 1980, Methods Enzymol, V65, P499; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MIYASHITA T, 1994, CANCER RES, V54, P3131; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; QUINN PG, 1993, J BIOL CHEM, V268, P16999; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; XING LP, 1994, J BIOL CHEM, V269, P28732; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; ZELENETZ AD, 1991, BLOOD, V78, P1552	31	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22687	22691		10.1074/jbc.271.37.22687	http://dx.doi.org/10.1074/jbc.271.37.22687			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798441	hybrid			2022-12-27	WOS:A1996VG67200060
J	Matsumoto, K; Meric, F; Wolffe, AP				Matsumoto, K; Meric, F; Wolffe, AP			Translational repression dependent on the interaction of the Xenopus Y-box protein FRGY2 with mRNA - Role of the cold shock domain, tail domain, and selective RNA sequence recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEOPROTEIN PARTICLES; OOCYTE-SPECIFIC PROTEINS; ACID BINDING-PROTEINS; DEVELOPMENTAL REGULATION; TRANSCRIPTION FACTOR; BACILLUS-SUBTILIS; MASKING PROTEINS; SOMATIC-CELLS; DNA-BINDING; IN-VIVO	We have examined the determinants of the translational repression of mRNA by the Xenopus oocyte-specific Y-box protein FRGY2 using in vitro and in vivo assays. In vitro reconstitution of messenger ribonucleoprotein (mRNP) complexes demonstrates that the sequence-specific RNA-binding cold shock domain is not required for translational repression, whereas the RNA-binding C-terminal tail domain is essential. However, microinjection of reconstituted mRNPs into Xenopus oocytes demonstrates that although translational repression occurs in the absence of consensus RNA binding sequences for FRGY2, the presence of FRGY2 recognition elements within mRNA potentiates translational repression. Analysis of the in vivo assembly of mRNP shows that the cold shock domain alone is not stably incorporated into mRNP, whereas the C-terminal tail domain is sufficient for stable incorporation. We suggest that translational repression of mRNA by FRGY2 is favored by sequence-selective recognition of RNA sequences by the cold shock domain. However, translational repression in vitro and the assembly of mRNP in vivo requires the relatively nonspecific interaction of the C-terminal tail domain with mRNA. Thus two distinct domains of FRGY2 are likely to contribute to translational control.	NICHHD,MOL EMBRYOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Matsumoto, Ken/F-9083-2013	Matsumoto, Ken/0000-0002-7864-3394				ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BOUVET P, 1995, J BIOL CHEM, V270, P28297; BRADDOCK M, 1994, NUCLEIC ACIDS RES, V22, P5255, DOI 10.1093/nar/22.24.5255; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CHO HS, 1994, GENE, V143, P233; DARNBROUGH CH, 1981, EUR J BIOCHEM, V113, P415, DOI 10.1111/j.1432-1033.1981.tb05081.x; Davidson E. H., 1986, GENE ACTIVITY EARLY; DINGWALL C, 1984, EMBO J, V3, P1933, DOI 10.1002/j.1460-2075.1984.tb02072.x; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; GUNKEL N, 1995, NUCLEIC ACIDS RES, V23, P405, DOI 10.1093/nar/23.3.405; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KICK D, 1987, NUCLEIC ACIDS RES, V15, P4099, DOI 10.1093/nar/15.10.4099; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LANDSBERGER N, 1995, MOL CELL BIOL, V15, P6013; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; MARELLO K, 1992, NUCLEIC ACIDS RES, V20, P5593, DOI 10.1093/nar/20.21.5593; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; MURRAY MT, 1994, BIOCHEMISTRY-US, V33, P13910, DOI 10.1021/bi00250a046; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; SOMMERVILLE J, 1992, BIOESSAYS, V14, P337, DOI 10.1002/bies.950140509; Spirin A. S., 1966, Current Topics in Developmental Biology, V1, P1; SPIRIN AS, 1994, MOL REPROD DEV, V38, P107, DOI 10.1002/mrd.1080380117; STANDART N, 1994, CURR BIOL, V4, P939, DOI 10.1016/S0960-9822(00)00212-8; STANDART N, 1992, SEMIN DEV BIOL, V3, P369; TAFURI SR, 1993, J BIOL CHEM, V268, P24255; TAFURI SR, 1992, NEW BIOL, V4, P349; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TOYODA T, 1992, DEV BIOL, V153, P150, DOI 10.1016/0012-1606(92)90099-3; WICKENS M, 1992, SEM DEV BIOL, V3, P399; Wolffe A., 1995, CHROMATIN STRUCTURE; Wolffe AP, 1996, INT J BIOCHEM CELL B, V28, P247, DOI 10.1016/1357-2725(95)00141-7; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; WORMINGTON M, 1994, BIOESSAYS, V16, P533, DOI 10.1002/bies.950160804	43	107	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22706	22712		10.1074/jbc.271.37.22706	http://dx.doi.org/10.1074/jbc.271.37.22706			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798444	hybrid			2022-12-27	WOS:A1996VG67200063
J	Miao, YJ; Wang, JYJ				Miao, YJ; Wang, JYJ			Binding of A/T-rich DNA by three high mobility group-like domains in c-Abl tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN FUNCTION; SEX-DETERMINING REGION; CELL-CYCLE; TRANSCRIPTION FACTOR; ALPHA-ENHANCER; HMG DOMAIN; PHOSPHORYLATION; COMPLEX; SITE; GENE	The c-Abl tyrosine kinase has been shown previously to bind DNA, Using polymerase chain reaction-based binding site-selection methods, no consensus high affinity binding site for c-Abl was found, Instead, oligonucleotides with runs of A/T sequences were isolated, and purified c-Abl was shown to bind A/T-containing oligo nucleotides better than those without A/T sequences, DNA binding of c-Abl was dependent on three high mobility group 1-like boxes (HLBs), which bound cooperatively to the A/T-rich oligonucleotides. To distinguish binding to A/T sequences per se from binding to nonspecific DNA with a bend at the A/T-rich region, two oligonucleotides were compared for binding to c-Abl, Both oligonucleotides contained A/T sequences, In one, the A/T motif was part of an 80-mer duplex DNA. In another, the A/T motif was in the duplex arm of an 80-mer ''bubble DNA'' containing an internal unpaired 20-mer region to provide a flexible hinge. Interestingly, the HLBs of c-Abl bound better to the oligonucleotide containing the bubble, suggesting a higher affinity for bent DNA rather than A/T sequences per se. Taken together, these observations define a new class of DNA binding domains, the HLBs, which do not bind DNA with a high degree of sequence specificity, but may selectively bind to bent DNA or to sequences that are easier to distort.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R37CA043054, R01CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA043054, CA 43054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1996, MOL CELL BIOL, V16, P3361; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BIRCHENALLROBERTS MC, 1995, MOL CELL BIOL, V15, P6088; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; JANTZEN HM, 1992, GENE DEV, V6, P1950, DOI 10.1101/gad.6.10.1950; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; WANG JYJ, 1994, TRENDS BIOCHEM SCI, V19, P373, DOI 10.1016/0968-0004(94)90114-7; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104	34	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22823	22830		10.1074/jbc.271.37.22823	http://dx.doi.org/10.1074/jbc.271.37.22823			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798460	hybrid			2022-12-27	WOS:A1996VG67200079
J	Isomoto, S; Kondo, C; Yamada, M; Matsumoto, S; Higashiguchi, O; Horio, Y; Matsuzawa, Y; Kurachi, Y				Isomoto, S; Kondo, C; Yamada, M; Matsumoto, S; Higashiguchi, O; Horio, Y; Matsuzawa, Y; Kurachi, Y			A novel sulfonylurea receptor forms with BIR (Kir6.2) a smooth muscle type ATP-sensitive K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INWARD RECTIFIER; CARDIAC-MUSCLE; GLIBENCLAMIDE; CELLS; INHIBITION	We have isolated a cDNA encoding a novel isoform of the sulfonylurea receptor from a mouse heart cDNA library. Coexpression of this isoform and BIR (Kir6.2) in a mammalian cell line elicited ATP-sensitive K+ (K-ATP) channel currents. The channel was effectively activated by both diazoxide and pinacidil, which is the feature of smooth muscle K-ATP channels. Sequence analysis indicated that this clone is a variant of cardiac type sulfonylurea receptor (SUR2), The 42 amino acid residues located in the carboxyl-terminal end of this novel sulfonylurea receptor is, however, divergent from that of SURE but highly homologous to that of the pancreatic one (SUR1). Therefore, this short part of the carboxyl terminus may be important for diazoxide activation of K-ATP channels, The reverse transcription-polymerase chain reaction analysis showed that mRNA of this clone was ubiquitously expressed in diverse tissues, including brain, heart, liver, urinary bladder, and skeletal muscle. These results suggest that this novel isoform of sulfonylurea receptor is a subunit reconstituting the smooth muscle K-ATP channel.	OSAKA UNIV,FAC MED,DEPT PHARMACOL 2,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,FAC MED,DEPT INTERNAL MED 2,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,FAC MED,DEPT OBSTET & GYNECOL,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University; Osaka University				Horio, Yoshiyuki/0000-0002-5021-5929				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ammala C, 1996, NATURE, V379, P545, DOI 10.1038/379545a0; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BEECH DJ, 1993, BRIT J PHARMACOL, V110, P573, DOI 10.1111/j.1476-5381.1993.tb13849.x; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; FAIVRE JF, 1989, BIOCHIM BIOPHYS ACTA, V984, P1, DOI 10.1016/0005-2736(89)90334-9; FINDLAY I, 1992, J PHARMACOL EXP THER, V261, P540; FINDLAY I, 1985, J MEMBRANE BIOL, V88, P165, DOI 10.1007/BF01868430; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, BIOCHEM BIOPH RES CO, V218, P286, DOI 10.1006/bbrc.1996.0050; KAJIOKA S, 1991, J PHYSIOL-LONDON, V444, P397, DOI 10.1113/jphysiol.1991.sp018885; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; SPRUCE AE, 1987, J PHYSIOL-LONDON, V382, P213, DOI 10.1113/jphysiol.1987.sp016364; STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869; TERZIC A, 1995, AM J PHYSIOL-CELL PH, V269, pC525, DOI 10.1152/ajpcell.1995.269.3.C525	18	470	491	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24321	24324		10.1074/jbc.271.40.24321	http://dx.doi.org/10.1074/jbc.271.40.24321			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798681	hybrid			2022-12-27	WOS:A1996VM67400003
J	Lee, JW; Romeo, A; Kosman, DJ				Lee, JW; Romeo, A; Kosman, DJ			Transcriptional remodeling and G(1) arrest in dioxygen stress in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; CELL-CYCLE BLOCKAGE; OXIDATIVE STRESS; POLYUBIQUITIN GENE; SIGNALING PATHWAY; HYDROGEN-PEROXIDE; MESSENGER-RNAS; YEAST; EXPRESSION; PROTEIN	Saccharomyces cerevisiae, which lack a functional SOD1 gene, encoding the cytosolic Cu,Zn-superoxide dismutase (SOD1), exhibit a variety of metabolic defects in aerobic but not in anaerobic growth. We test here the hypothesis that some of these defects may be due to specific transcriptional changes programmed for cell survival under dioxygen stress. Analysis of the budding pattern and generation time showed that the slower proliferation of an sod1 Delta mutant strain under air was due to an increase from 42 to 89 min spent in the G(1) phase of the cell cycle. This delay in G(1) was not due to an overall decline in biosynthetic activity since total protein and mRNA synthesis was not reduced even under 100% O-2. However, rRNA synthesis was strongly decreased, e.g. by 80% in the mutant under 100% O-2 (in comparison to N-2). Under these conditions, the mutant permanently arrested in G(1); this arrest was due to an inhibition of the Start function that prepares yeast for S phase. This Start arrest was due to an inhibition of transcription of the autoregulated G(1) cyclins, CLN1 and CLN2; the transcription of the constitutive G(1) cyclin, CLN3, was unaffected by the stress. Expression of a hyperstable Cln3 prevented the G(1) arrest, indicating that it was due solely to the inhibition of cell cycle-dependent cyclin expression. This remodeling of transcription in oxidative stress was seen also in the inhibition of glucose derepression of SUC2 expression. In contrast, the signaling and activation of mating pheromone (FUS1) and copper-responsive (CUP1) promoter activity were not affected by dioxygen stress, while genes encoding other anti-oxidant enzymes (SOD2, CTT1 and CTA1) were strongly induced. The UBI loci, encoding ubiquitin, were particularly good examples of this pattern of negative and positive transcriptional response to the stress. UBI1-UBI3 expression was repressed in the mutant under 100% O-2, while expression of UBI4 was strongly induced. The data demonstrate that extensive remodeling of transcription occurs in yeast under a strong dioxygen stress. This remodeling results in a pattern of expression of gene products needed for defense and repair, and suppression of activities associated with normal proliferative growth.	SUNY BUFFALO,DEPT BIOCHEM,SCH MED & BIOMED SCI,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046787] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46787] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS BJ, 1993, SCIENCE, V261, P1543, DOI 10.1126/science.8372349; BARNES CA, 1990, J BACTERIOL, V172, P4352, DOI 10.1128/jb.172.8.4352-4358.1990; BELAZZI T, 1991, EMBO J, V10, P585, DOI 10.1002/j.1460-2075.1991.tb07985.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHANG EC, 1990, J BACTERIOL, V172, P1840, DOI 10.1128/jb.172.4.1840-1845.1990; CHANG EC, 1991, J BIOL CHEM, V266, P4417; CHENG L, 1994, MOL GEN GENET, V243, P358, DOI 10.1007/BF00301072; COLLINSON LP, 1992, J GEN MICROBIOL, V138, P329, DOI 10.1099/00221287-138-2-329; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DAVIES JMS, 1995, ARCH BIOCHEM BIOPHYS, V317, P1, DOI 10.1006/abbi.1995.1128; ENRIGHT HU, 1992, NUCLEIC ACIDS RES, V20, P3341, DOI 10.1093/nar/20.13.3341; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FLATTERYOBRIEN J, 1993, J GEN MICROBIOL, V139, P501, DOI 10.1099/00221287-139-3-501; GALIAZZO F, 1993, FEBS LETT, V315, P197, DOI 10.1016/0014-5793(93)81162-S; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; GRALLA EB, 1991, J BACTERIOL, V173, P5918, DOI 10.1128/jb.173.18.5918-5920.1991; GRALLA EB, 1992, ADV GENET, V30, P251, DOI 10.1016/S0065-2660(08)60322-3; GRECO MA, 1990, J BACTERIOL, V172, P317, DOI 10.1128/JB.172.1.317-325.1990; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JAMIESON DJ, 1994, MICROBIOL-UK, V140, P3277, DOI 10.1099/13500872-140-12-3277; JAMIESON DJ, 1992, J BACTERIOL, V174, P6678, DOI 10.1128/JB.174.20.6678-6681.1992; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KRAAKMAN LS, 1993, MOL GEN GENET, V239, P196, DOI 10.1007/BF00281618; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; MAGER WH, 1995, MICROBIOL REV, V59, P506, DOI 10.1128/MMBR.59.3.506-531.1995; MAGER WH, 1993, BIOCHEM J, V290, P1; Maniatis T., 1982, MOL CLONING; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; MILLER J H, 1972, P466; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; ROSE MD, 1990, METHODS YEAST GENETI, P179; ROWLEY A, 1993, MOL CELL BIOL, V13, P1034, DOI 10.1128/MCB.13.2.1034; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; THEVELEIN JM, 1991, MOL MICROBIOL, V5, P1301, DOI 10.1111/j.1365-2958.1991.tb00776.x; TIPPER DJ, 1973, J BACTERIOL, V116, P245, DOI 10.1128/JB.116.1.245-256.1973; TREGER JM, 1988, MOL CELL BIOL, V8, P1132, DOI 10.1128/MCB.8.3.1132; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; VEINOTDREBOT LM, 1989, J BIOL CHEM, V264, P19528; VEINOTDREBOT LM, 1989, J BIOL CHEM, V264, P19473; WERNER D, 1984, ANAL BIOCHEM, V141, P329, DOI 10.1016/0003-2697(84)90050-2; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832	53	43	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24885	24893		10.1074/jbc.271.40.24885	http://dx.doi.org/10.1074/jbc.271.40.24885			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798765	hybrid			2022-12-27	WOS:A1996VM67400088
J	Teusink, B; Larsson, C; Diderich, J; Richard, P; vanDam, K; Gustafsson, L; Westerhoff, HV				Teusink, B; Larsson, C; Diderich, J; Richard, P; vanDam, K; Gustafsson, L; Westerhoff, HV			Synchronized heat flux oscillations in yeast cell populations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOLYTIC OSCILLATIONS; SACCHAROMYCES-CEREVISIAE; SUGAR PHOSPHATES; ENERGY BALANCES; MAKE-UP; THERMODYNAMICS; GROWTH; METABOLITES; CALORIMETRY; PATHWAY	Microcalorimetry was adapted to the study of glycolytic oscillations in suspensions of intact yeast cells. A correction procedure was developed for the distortion of the amplitude and phase of the heat signal, caused by the slow response of the calorimeter. This made it possible to observe oscillations in the heat production rate with a period of less than 1 min, and a relative amplitude of 5-10%. By simultaneously measuring the heat flux and concentrations of glycolytic metabolites, and by comparing acetaldehyde-induced phase shifts of the heat flux oscillations with those of NADH oscillations, the heat flux was found to be 100 degrees out of phase with glucose 6-phosphate, 80 degrees out of phase with fructose 1,6-bisphosphate, and in phase with NADH. The flux measurement made possible by microcalorimetry allowed the recognition of (i) changes in metabolic capacity that may affect glycolytic dynamics, (ii) implications of glucose carrier kinetics for glycolytic dynamics and (iii) the continued requirement for an acetaldehyde trapping agent for the oscillations.	UNIV AMSTERDAM,EC SLATER INST BIOCHEM RES,BIOCENTRUM,NL-1018 TV AMSTERDAM,NETHERLANDS; UNIV GOTHENBURG,DEPT GEN & MARINE MICROBIOL,S-41319 GOTHENBURG,SWEDEN; FREE UNIV AMSTERDAM,FAC BIOL,DEPT MICROBIAL PHYSIOL,NL-1081 HV AMSTERDAM,NETHERLANDS	University of Amsterdam; University of Gothenburg; Vrije Universiteit Amsterdam			Diderich, Jasper/AAH-3373-2019; Westerhoff, Hans V/I-5762-2012; Richard, Peter/A-4229-2009	Westerhoff, Hans V/0000-0002-0443-6114; Richard, Peter/0000-0003-0922-6092; Teusink, Bas/0000-0003-3929-0423; Diderich, Jasper/0000-0003-2675-9712; Larsson, Christer/0000-0002-0721-5405				ALBERTY RA, 1994, BBA-PROTEIN STRUCT M, V1207, P1, DOI 10.1016/0167-4838(94)90045-0; ALBERTY RA, 1992, BIOCHEMISTRY-US, V31, P10610, DOI 10.1021/bi00158a025; AON MA, 1991, J CELL SCI, V99, P325; AON MA, 1992, J GEN MICROBIOL, V138, P2219, DOI 10.1099/00221287-138-10-2219; BETZ A, 1978, CHRONOBIOLOGIA, V5, P45; BETZ A, 1965, ARCH BIOCHEM BIOPHYS, V109, P585, DOI 10.1016/0003-9861(65)90404-2; BETZ A, 1965, ARCH BIOCHEM BIOPHYS, V109, P579, DOI 10.1016/0003-9861(65)90403-0; BETZ A, 1975, J INTERDISCIPL CYCLE, V6, P167, DOI 10.1080/09291017509359480; BETZ A, 1966, PHYSIOL PLANTARUM, V19, P1049, DOI 10.1111/j.1399-3054.1966.tb07095.x; BURTON K, 1974, BIOCHEM J, V143, P365, DOI 10.1042/bj1430365; CHEN AT, 1982, J BIOCHEM BIOPH METH, V6, P297, DOI 10.1016/0165-022X(82)90011-2; COLLATZ KG, 1990, COMP BIOCHEM PHYS B, V96, P771, DOI 10.1016/0305-0491(90)90229-M; DEKONING W, 1992, ANAL BIOCHEM, V204, P118, DOI 10.1016/0003-2697(92)90149-2; DORAN PM, 1987, BIOTECHNOL BIOENG, V29, P892, DOI 10.1002/bit.260290711; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; GHOSH AK, 1971, ARCH BIOCHEM BIOPHYS, V145, P319, DOI 10.1016/0003-9861(71)90042-7; GIERSCH C, 1975, BIOSYSTEMS, V7, P147, DOI 10.1016/0303-2647(75)90052-0; GNAIGER E, 1994, MOD TR BIOTHERMOKIN, V3, P207; GROSPIETSCH T, 1995, EXPERIENTIA, V51, P117, DOI 10.1007/BF01929352; GUSTAFSSON L, 1991, THERMOCHIM ACTA, V193, P145, DOI 10.1016/0040-6031(91)80181-H; HESS B, 1979, J EXP BIOL, V81, P7; HESS B, 1968, H-S Z PHYSIOL CHEM, V349, P1567, DOI 10.1515/bchm2.1968.349.2.1567; HESS B, 1973, BIOL BIOCH OSCILLATO, P229; LAMPRECHT I, 1992, INDIAN J TECHNOL, V30, P578; LARSSON C, 1991, BIOTECHNOL BIOENG, V38, P447, DOI 10.1002/bit.260380503; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MULLER KH, 1987, THERMOCHIM ACTA, V119, P189, DOI 10.1016/0040-6031(87)88020-6; PLESSER T, 1985, FEBS LETT, V189, P42, DOI 10.1016/0014-5793(85)80838-3; PYE EK, 1969, CAN J BOTANY, V47, P271, DOI 10.1139/b69-040; RANDZIO SL, 1980, BIOL MICROCALORIMETR, P311; Richard P, 1996, YEAST, V12, P731; Richard P, 1996, EUR J BIOCHEM, V235, P238, DOI 10.1111/j.1432-1033.1996.00238.x; RICHARD P, 1994, FEBS LETT, V341, P223, DOI 10.1016/0014-5793(94)80461-3; RICHARD P, 1993, FEBS LETT, V318, P80, DOI 10.1016/0014-5793(93)81332-T; RICHTER PH, 1981, SCIENCE, V211, P715, DOI 10.1126/science.6450447; Spink C, 1976, Methods Biochem Anal, V23, P1, DOI 10.1002/9780470110430.ch1; SUURKUUSK J, 1982, CHEM SCRIPTA, V20, P155; TEWARI YB, 1988, J BIOL CHEM, V263, P3670; TEWARI YB, 1988, J BIOL CHEM, V263, P3664; TORNHEIM K, 1979, J THEOR BIOL, V79, P491, DOI 10.1016/0022-5193(79)90240-6; VONSTOCKAR U, 1993, BIOCHIM BIOPHYS ACTA, V1183, P221, DOI 10.1016/0005-2728(93)90225-5; WALSH MC, 1994, J BACTERIOL, V176, P953, DOI 10.1128/JB.176.4.953-958.1994; WESTERHOFF HV, 1995, TRENDS BIOTECHNOL, V13, P242, DOI 10.1016/S0167-7799(00)88955-6; YATES WF, 1952, J AM CHEM SOC, V74, P4153, DOI 10.1021/ja01136a058; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	49	21	22	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24442	24448		10.1074/jbc.271.40.24442	http://dx.doi.org/10.1074/jbc.271.40.24442			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798702	Green Published, hybrid			2022-12-27	WOS:A1996VM67400024
J	Larsson, G; Nyman, PO; Kvassman, JO				Larsson, G; Nyman, PO; Kvassman, JO			Kinetic characterization of dUTPase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYURIDINE TRIPHOSPHATASE; URACIL INCORPORATION; PURIFICATION; PYROPHOSPHATASE; PROTEIN; ENZYME; VIRUS; DNA	The enzyme dUTPase catalyzes the hydrolysis of dUTP to dUMP and pyrophosphate, thereby preventing a deleterious incorporation of uracil into DNA. The best known dUTPase is that from Escherichia coli, which, like the human enzyme, consists of three identical subunits. In the present work, the catalytic properties of the E. coli dUTPase were investigated in the pH range 5-11. The enzyme was found to be highly specific for dUTP and discriminated both base and sugar as well as the phosphate moiety (bound dUDP was not hydrolyzed). The second best substrate among the nucleotides serving as building blocks for DNA was dCTP, which was hydrolyzed an astonishing 10(5) times less efficiently than dUTP, a decline largely accounted for by a higher K-m for dCTP. With dUTP Mg as substrate, k(cat) was found to vary little with pH and to range from 6 to 9 s(-1). K-m passed through a broad minimum in the neutral pH range with values approaching 10(-7) M. It increased with deprotonation of the uracil moiety of dUTP and showed dependence on two ionizations in the enzyme, exhibiting pK(a) values of 5.8 and 10.3. When excess dUTPase was reacted with dUTP Mg at pH 8, the two protons transferred to the reaction medium were released in a concerted mode after the rate-limiting step, The Mg2+ ion enhances binding to dUTPase of dUTP by a factor of 100 and dUDP by a factor of 10. Only one enantiomer of the substrate analog 2'-deoxyuridine-5'-(alpha-thio)-triphosphate was hydrolyzed by the enzyme. These results are interpreted to favor a catalytic mechanism involving magnesium binding to the cy-phosphate, rate-limiting hydrolysis by a shielded and activated water molecule and a fast ordered desorption of the products. The results are discussed with reference to recent data on the structure of the E. coli dUTPase dUDP complex.	LUND UNIV,CTR CHEM & CHEM ENGN,DEPT BIOCHEM,LUND,SWEDEN; HENRY FORD HLTH SCI CTR,DIV BIOCHEM RES,HENRY FORD HLTH SYST,DETROIT,MI 48202	Lund University; Henry Ford Health System; Henry Ford Hospital								ALBERTY RA, 1969, J BIOL CHEM, V244, P3290; BERGMAN AC, 1994, VIROLOGY, V204, P420, DOI 10.1006/viro.1994.1547; BERTANI LE, 1961, J BIOL CHEM, V236, P67; BJORNBERG O, 1993, PROTEIN EXPRES PURIF, V4, P149, DOI 10.1006/prep.1993.1021; CEDERGRENZEPPEZAUER ES, 1992, NATURE, V355, P740, DOI 10.1038/355740a0; CEDERGRENZEPPEZAUER ES, 1988, PROTEINS, V4, P71, DOI 10.1002/prot.340040110; CLARK AM, 1951, BIOCHEM J, V48, P495, DOI 10.1042/bj0480495; CLIMIE S, 1994, PROTEIN EXPRES PURIF, V5, P252, DOI 10.1006/prep.1994.1038; COHN M, 1990, ANN NY ACAD SCI, V103, P151; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; ELHAJJ HH, 1988, J BACTERIOL, V170, P1069, DOI 10.1128/jb.170.3.1069-1075.1988; FERSHT A, 1984, ENZYME STRUCTURE MEC, P152; GADSDEN MH, 1993, EMBO J, V12, P4425, DOI 10.1002/j.1460-2075.1993.tb06127.x; HOFFMANN I, 1987, EUR J BIOCHEM, V164, P45, DOI 10.1111/j.1432-1033.1987.tb10990.x; HOFFMANN I, 1987, THESIS U SAARBRUCKEN; HUANG SL, 1982, BIOCHEMISTRY-US, V21, P951, DOI 10.1021/bi00534a021; KAHN MM, 1966, J AM CHEM SOC, V88, P668; Kornberg A., 1991, DNA REPLICATION; Larsson G, 1996, NAT STRUCT BIOL, V3, P532, DOI 10.1038/nsb0696-532; Lohmann K, 1932, BIOCHEM Z, V254, P381; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; MCINTOSH EM, 1994, CURR GENET, V26, P415, DOI 10.1007/BF00309928; Mildvan A.S., 1970, ENZYMES, P445; SHLOMAI J, 1978, J BIOL CHEM, V253, P3305; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; VILLAFRANCA JJ, 1980, ANNU REV BIOPHYS BIO, V9, P363, DOI 10.1146/annurev.bb.09.060180.002051; Walker A. C, 1944, ARCH BIOCHEM, V5, P445; ZALUD P, 1995, PURINE PYRIMIDINE ME, V8, P135	28	84	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24010	24016		10.1074/jbc.271.39.24010	http://dx.doi.org/10.1074/jbc.271.39.24010			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798636	hybrid			2022-12-27	WOS:A1996VJ44200065
J	Latimer, MT; Painter, MH; Ferry, JG				Latimer, MT; Painter, MH; Ferry, JG			Characterization of an iron-sulfur flavoprotein from Methanosarcina thermophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHANOBACTERIUM-THERMOAUTOTROPHICUM; TRANSCRIPTIONAL REGULATION; ELECTRON-TRANSPORT; ACETATE KINASE; RNA-POLYMERASE; GENES; PURIFICATION; PROTEINS; PHOSPHOTRANSACETYLASE; METHANOGENESIS	A gene (isf) encoding an iron sulfur flavoprotein (Isf) from Methanosarcina thermophila was cloned and sequenced. The gene was located directly upstream of the genes (pta and ach) encoding phosphotransacetylase and acetate kinase and is transcribed in the opposite direction. The amino acid sequence deduced from isf contained a cluster of cysteine residues reminiscent of proteins that accommodate either a [4Fe-4S] or [3Fe-4S] center. The protein was heterologously produced in Escherichia coli and purified to apparent homogeneity. The 29-kDa subunit molecular mass of heterologously produced Isf (determined by SDS-polyacrylamide gel electrophoresis) corresponded to the molecular mass of 30,451 Da calculated from the amino acid composition deduced from isf. Gel filtration estimated a molecular mass of 65 kDa for the native Isf-indicating an alpha(2) homodimer. The UV-visible absorption spectrum was characteristic of iron-sulfur flavoproteins with maxima at 484, 452, 430, 378, and 280 nm. Analyses identified 2 FMN, 7-8 non-heme iron atoms, and 6-7 acid-labile sulfur atoms per alpha(2) homodimer. Comparisons of the deduced Isf sequence with sequences in available protein data bases suggested Isf is a novel iron-sulfur flavoprotein. Western blot analysis indicated the presence of Isf in extracts of acetate-grown M. thermophila. Ferredoxin stimulated the GO-dependant reduction of Isf by the CO dehydrogenase-acetyl-CoA synthase complex that suggested ferredoxin is a physiological electron donor to Isf.	PENN STATE UNIV, DEPT BIOCHEM & MOL BIOL, UNIVERSITY PK, PA 16802 USA; VIRGINIA POLYTECH INST & STATE UNIV, DEPT BIOCHEM & ANAEROB MICROBIOL, BLACKSBURG, VA 24061 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Virginia Polytechnic Institute & State University								ALBER BE, 1994, P NATL ACAD SCI USA, V91, P6909, DOI 10.1073/pnas.91.15.6909; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARON SF, 1989, J BACTERIOL, V171, P3846, DOI 10.1128/jb.171.7.3846-3853.1989; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMMACK R, 1983, CHEM SCRIPTA, V21, P87; CLEMENTS AP, 1992, J BACTERIOL, V174, P5244, DOI 10.1128/JB.174.16.5244-5250.1992; DAWSON RMC, 1989, DATA BIOCH RES, P126; Ferry James G., 1993, P304; FERRY JG, 1992, CRIT REV BIOCHEM MOL, V27, P473, DOI 10.3109/10409239209082570; FERRY JG, 1995, ANNU REV MICROBIOL, V49, P305, DOI 10.1146/annurev.mi.49.100195.001513; Ferry JG, 1996, MICROBIAL GROWTH ON C(1) COMPOUNDS, P64; Fortune WB, 1938, IND ENG CHEM, V10, P0060, DOI 10.1021/ac50118a004; GORNALL AG, 1949, J BIOL CHEM, V177, P751; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATIMER MT, 1993, J BACTERIOL, V175, P6822, DOI 10.1128/jb.175.21.6822-6829.1993; LIGHT DR, 1980, ANAL BIOCHEM, V109, P87, DOI 10.1016/0003-2697(80)90014-7; MaupinFurlow J, 1996, J BACTERIOL, V178, P340, DOI 10.1128/jb.178.2.340-346.1996; MAUPINFURLOW JA, 1995, J BIOL CHEM, V270, P28617, DOI 10.1074/jbc.270.48.28617; NOLLING J, 1995, EUR J BIOCHEM, V231, P628, DOI 10.1111/j.1432-1033.1995.0628d.x; PEER CW, 1994, J BACTERIOL, V176, P6974, DOI 10.1128/JB.176.22.6974-6979.1994; Reeve John N., 1993, P493; SANTANGELO JD, 1991, J BACTERIOL, V173, P1088, DOI 10.1128/jb.173.3.1088-1095.1991; SIEGEL LM, 1965, ANAL BIOCHEM, V11, P126, DOI 10.1016/0003-2697(65)90051-5; SINGHWISSMANN K, 1995, J BACTERIOL, V177, P1699, DOI 10.1128/jb.177.7.1699-1702.1995; SOWERS KR, 1984, CURR MICROBIOL, V11, P227, DOI 10.1007/BF01567165; SOWERS KR, 1993, J BIOL CHEM, V268, P23172; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TERLESKY KC, 1988, J BIOL CHEM, V263, P4080; TIMMONS TM, 1990, METHOD ENZYMOL, V182, P679; WASSERFALLEN A, 1995, J BACTERIOL, V177, P2436, DOI 10.1128/jb.177.9.2436-2441.1995; ZINDER SH, 1985, INT J SYST BACTERIOL, V35, P522, DOI 10.1099/00207713-35-4-522	32	24	25	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24023	24028		10.1074/jbc.271.39.24023	http://dx.doi.org/10.1074/jbc.271.39.24023			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798638	hybrid			2022-12-27	WOS:A1996VJ44200067
J	Lukowski, S; Lecomte, MC; Mira, JP; Marin, P; Gautero, H; RussoMarie, F; Geny, B				Lukowski, S; Lecomte, MC; Mira, JP; Marin, P; Gautero, H; RussoMarie, F; Geny, B			Inhibition of phospholipase D activity by fodrin - An active role for the cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ADP-RIBOSYLATION FACTOR; PERMEABILIZED CHROMAFFIN CELLS; PHOSPHATIDIC-ACID; STREPTOLYSIN-O; BRAIN SPECTRIN; HL-60 CELLS; PARTIAL-PURIFICATION; ADENYLATE-CYCLASE; D ACTIVATION	Phospholipase D (PLD) is a major enzyme implicated in important cellular processes such as secretion and proliferation. The knowledge of its regulation is essential to understand the control of these phenomena. Several proteins activating PLD have been described in the last years. In this report, we chromatographed bovine brain cytosolic proteins to identify fodrin, the nonerythroid spectrin, as the first described inhibitor of PLD. A cytosolic fraction with an inhibitory effect on PLD activity loses its capacity after immunoprecipitation of fodrin. Moreover, at 1 nM, purified fodrin blocks fully and quickly PLD activity, whatever the stimuli used. In contrast, fodrin has no effect on adenylate cyclase activity. Fodrin-analogous proteins like dimeric or tetrameric erythroid spectrin have the same inhibitory effect on PLD, at higher concentrations. Other cytoskeletal proteins, actin and vimentin, are inefficient on PLD inhibition. The mechanisms implicated in PLD modulation such as post-translational modifications of fodrin and the role of small G-proteins on the cytoskeleton regulation are discussed. In conclusion, this study reveals that fodrin is involved in the control of PLD activity, suggesting that the cytoskeleton could have an active role in control of secretion and proliferation.	INST COCHIN GENET MOL,INSERM,U332,F-75014 PARIS,FRANCE; FAC MED BICHAT,INSERM,U409,F-75018 PARIS,FRANCE; COLL FRANCE,INSERM,U114,F-75231 PARIS 05,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France								BENDER JL, 1983, J BIOL CHEM, V258, P2432; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BOARDER MR, 1994, TRENDS PHARMACOL SCI, V15, P57, DOI 10.1016/0165-6147(94)90111-2; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BROWN HA, 1995, METHOD ENZYMOL, V257, P313; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARNERO A, 1994, J CELL BIOCHEM, V54, P478, DOI 10.1002/jcb.240540415; CHNEIWEISS H, 1988, J NEUROSCI, V8, P3376; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DAWSON RMC, 1967, BIOCHEM J, V102, P76, DOI 10.1042/bj1020076; GALLIARD T, 1965, BIOCHIM BIOPHYS ACTA, V106, P551, DOI 10.1016/0005-2760(65)90071-8; GENY B, 1995, EUR J BIOCHEM, V231, P31, DOI 10.1111/j.1432-1033.1995.tb20666.x; GENY B, 1993, EUR J BIOCHEM, V215, P389, DOI 10.1111/j.1432-1033.1993.tb18045.x; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GENY B, 1989, CELL SIGNAL, V1, P165, DOI 10.1016/0898-6568(89)90006-5; GLENNEY JR, 1982, CELL, V28, P843, DOI 10.1016/0092-8674(82)90063-0; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HARRIS AS, 1989, J BIOL CHEM, V264, P17401; HASHIZUME T, 1994, BBA-MOL CELL RES, V1221, P179, DOI 10.1016/0167-4889(94)90011-6; HU RJ, 1991, J BIOL CHEM, V266, P18200; JIANG H, 1995, J BIOL CHEM, V270, P6006, DOI 10.1074/jbc.270.11.6006; KANAHO Y, 1991, J IMMUNOL, V146, P3536; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LISCOVITCH M, 1994, SIGNAL ACTIVATED PHO, P31; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; MESKINI N, 1995, EUR J BIOCHEM, V233, P907, DOI 10.1111/j.1432-1033.1995.907_3.x; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; Morrow JS, 1989, CURR OPIN CELL BIOL, V1, P23, DOI 10.1016/S0955-0674(89)80032-8; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; OHGUCHI K, 1995, BIOCHEM BIOPH RES CO, V211, P306, DOI 10.1006/bbrc.1995.1811; OKAMURA S, 1994, J BIOL CHEM, V269, P31207; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERRIN D, 1987, NATURE, V326, P498, DOI 10.1038/326498a0; PERRIN D, 1985, NATURE, V315, P589, DOI 10.1038/315589a0; PRICE LS, 1995, CURR BIOL, V5, P68, DOI 10.1016/S0960-9822(95)00018-2; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SIMMONDS AC, 1985, BIOCHIM BIOPHYS ACTA, V813, P331, DOI 10.1016/0005-2736(85)90249-4; Singer WD, 1996, J BIOL CHEM, V271, P4504; SONTAG JM, 1988, EUR J CELL BIOL, V46, P316; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Thompson N T, 1993, Adv Pharmacol, V24, P199, DOI 10.1016/S1054-3589(08)60938-2; XING MZ, 1992, J BIOL CHEM, V267, P6602; Yamamoto H, 1995, PROSTAGLANDINS, V50, P201, DOI 10.1016/0090-6980(95)00121-2; ZHANG H, 1990, J BIOL CHEM, V265, P21309	55	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24164	24171		10.1074/jbc.271.39.24164	http://dx.doi.org/10.1074/jbc.271.39.24164			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798657	hybrid			2022-12-27	WOS:A1996VJ44200086
J	Rouslin, W; Broge, CW				Rouslin, W; Broge, CW			IF1 function in situ in uncoupler-challenged ischemic rabbit, rat, and pigeon hearts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE 5'-TRIPHOSPHATASE; ATPASE INHIBITOR PROTEIN; CARDIAC-MUSCLE; LUFTS DISEASE; SLOW; BINDING; TRIPHOSPHATASE; AUTOLYSIS; TISSUES; INTACT	Rabbit, rat, and pigeon are species representative of three cardiac muscle mitochondrial ATPase regulatory classes, a, b and c, respectively, Class a species contain a full complement of higher affinity ATPase inhibitor subunit, IF1, in their cardiac muscle mitochondria and show marked IF1-mediated mitochondrial ATPase inhibition during myocardial ischemia. Class b species contain low levels of higher affinity IF1 and show very little IF1-mediated ATPase inhibition during ischemia. Class c species contain a full complement of a lower affinity form of IF1 and show a low-to-moderate level of IF1-mediated ATPase inhibition during ischemia, In the present study we perfused hearts of a member of each regulatory class through the coronary arteries with the uncoupler, carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP), before making them ischemic, We then compared net rates of cell ATP depletion during ischemia in the FCCP-treated hearts to identically treated FCCP-free hearts, Thus, we tested the relative capacities of cardiac muscle mitochondria of the three species to avert a potentially greatly increased net rate of cell ATP depletion due to ATP hydrolysis by the fully uncoupled mitochondrial ATPase, We found that FCCP-uncoupling in situ had a relatively small effect on ATP depletion during ischemia in rabbit hearts, that it dramatically accelerated ATP depletion in ischemic rat hearts, and that it had an intermediate effect on GTP depletion in ischemic pigeon hearts. These results demonstrate for the first time the relative extents to which IF1-mediated mitochondrial ATPase inhibition can slow cell ATP depletion due to the fully uncoupled mitochondrial ATPase in these three classes of hearts. They show that, in contrast to the situation in rabbit hearts, the low level of higher affinity IF1 present in the cardiac muscle mitochondria of the rat is, under these conditions, essentially nonfunctional, while the full complement of the lower affinity form of IF1 present in the cardiac muscle mitochondria of the pigeon is partially functional in that it appeared to provide an intermediate level of protection against rapid cell ATP depletion.			Rouslin, W (corresponding author), UNIV CINCINNATI,COLL MED,DEPT PHARMACOL & CELL BIOPHYS,CINCINNATI,OH 45267, USA.				NHLBI NIH HHS [HL30926] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030926] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON BS, 1987, AM J PHYSIOL, V252, pC349, DOI 10.1152/ajpcell.1987.252.4.C349; AW TY, 1987, AM J PHYSIOL, V252, pC356, DOI 10.1152/ajpcell.1987.252.4.C356; DIMAURO S, 1976, J NEUROL SCI, V27, P217, DOI 10.1016/0022-510X(76)90063-0; FRANGIONE B, 1981, P NATL ACAD SCI-BIOL, V78, P7403, DOI 10.1073/pnas.78.12.7403; ISHIKAWA N, 1990, J BIOL CHEM, V265, P6274; LI WH, 1990, P NATL ACAD SCI USA, V87, P6703, DOI 10.1073/pnas.87.17.6703; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; ROUSLIN W, 1986, J MOL CELL CARDIOL, V18, P1187, DOI 10.1016/S0022-2828(86)80044-X; ROUSLIN W, 1987, J MOL CELL CARDIOL, V19, P661, DOI 10.1016/S0022-2828(87)80374-7; ROUSLIN W, 1983, J BIOL CHEM, V258, P9657; ROUSLIN W, 1983, AM J PHYSIOL, V244, pH743, DOI 10.1152/ajpheart.1983.244.6.H743; ROUSLIN W, 1987, J BIOL CHEM, V262, P3472; ROUSLIN W, 1989, J BIOL CHEM, V264, P15224; ROUSLIN W, 1988, J MOL CELL CARDIOL, V20, P999, DOI 10.1016/0022-2828(88)90577-9; ROUSLIN W, 1993, ARCH BIOCHEM BIOPHYS, V303, P443, DOI 10.1006/abbi.1993.1307; ROUSLIN W, 1987, AM J PHYSIOL, V252, pH622, DOI 10.1152/ajpheart.1987.252.3.H622; ROUSLIN W, 1994, ANAL BIOCHEM, V222, P68, DOI 10.1006/abio.1994.1455; ROUSLIN W, 1990, AM J PHYSIOL, V259, pH1759, DOI 10.1152/ajpheart.1990.259.6.H1759; ROUSLIN W, 1995, J BIOENERG BIOMEMBR, V27, P117, DOI 10.1007/BF02110339; ROUSLIN W, 1990, ARCH BIOCHEM BIOPHYS, V280, P103, DOI 10.1016/0003-9861(90)90524-3; ROUSLIN W, 1993, AM J PHYSIOL, V264, pC209, DOI 10.1152/ajpcell.1993.264.1.C209; TZAGOLOF.A, 1968, J BIOL CHEM, V243, P2405; VANDESTADT RJ, 1974, BIOCHIM BIOPHYS ACTA, V347, P240, DOI 10.1016/0005-2728(74)90048-6; YAMADA EW, 1992, BIOCHIM BIOPHYS ACTA, V1139, P143, DOI 10.1016/0925-4439(92)90093-3; YOSHIDA Y, 1990, EUR J BIOCHEM, V192, P49, DOI 10.1111/j.1432-1033.1990.tb19193.x	26	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23638	23641		10.1074/jbc.271.39.23638	http://dx.doi.org/10.1074/jbc.271.39.23638			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798581	hybrid			2022-12-27	WOS:A1996VJ44200010
J	Wang, XK; Yue, TL; Ohlstein, EH; Sung, CP; Feuerstein, GZ				Wang, XK; Yue, TL; Ohlstein, EH; Sung, CP; Feuerstein, GZ			Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC MESSENGER-RNA; RAT ISCHEMIC CORTEX; ADHESION MOLECULE-1; EARLY GENE; EXPRESSION; ATHEROSCLEROSIS; CHEMOATTRACTANT; CYTOKINES; IP-10; INTERLEUKIN-8	Interferon-inducible protein-10 (IP-10) is a member of the C-X-C chemokine family. Using mRNA differential display, we isolated a rat homologue to murine and human IP-10 from lipopolysaccharide-stimulated carotid arteries. Our studies demonstrated that IP-10 is a potent mitogenic and chemotactic factor for vascular smooth muscle cells, the critical features of smooth muscle cells for their contribution to the pathogenesis of atherosclerosis and restenosis. IP-10 induced a concentration-dependent stimulation of DNA synthesis, cell proliferation, and cell migration of rat aortic smooth muscle cells. A concentration- and time-dependent IP-10 mRNA induction was observed in lipopolysaccharide- or interferon-gamma-stimulated, but not interleukin-1 beta- or tumor necrosis factor-alpha-stimulated smooth muscle cells. A marked synergistic effect on IP-10 mRNA expression was observed when smooth muscle cells were challenged with interferon-gamma together with interleukin-1 beta or tumor necrosis factor-alpha. Furthermore, IP-10 mRNA expression was induced in the rat carotid artery after balloon angioplasty. The mitogenic and chemotactic features of IP-10 for smooth muscle cells, along with its discrete induction in cultured vascular smooth muscle cells and in carotid arteries after balloon angioplasty (neointima formation) suggest that IP-10 may play an active and distinct role in vascular remodeling processes.			Wang, XK (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT CARDIOVASC PHARMACOL,709 SWEDELAND RD,POB 1539,UW 2511,KING OF PRUSSIA,PA 19406, USA.							BEDARD PA, 1993, J CELL PHYSIOL, V154, P433, DOI 10.1002/jcp.1041540227; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLINTON SK, 1992, ARCH PATHOL LAB MED, V116, P1292; DAVIES MJ, 1993, J PATHOL, V171, P223, DOI 10.1002/path.1711710311; DEWALD B, 1992, IMMUNOL LETT, V32, P81, DOI 10.1016/0165-2478(92)90203-Z; GomezChiarri M, 1996, AM J PATHOL, V148, P301; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; HIDAKA Y, 1992, ATHEROSCLEROSIS, V95, P87, DOI 10.1016/0021-9150(92)90179-K; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1994, P NATL ACAD SCI USA, V91, P12515, DOI 10.1073/pnas.91.26.12515; LUSTER AD, 1993, J EXP MED, V178, P1057, DOI 10.1084/jem.178.3.1057; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; LUSTER AD, 1987, J EXP MED, V166, P1084, DOI 10.1084/jem.166.4.1084; MARMUR JD, 1992, CIRCULATION, V86, P53; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MUKAIDA N, 1992, MICROBIOL IMMUNOL, V36, P773, DOI 10.1111/j.1348-0421.1992.tb02080.x; NILSSON J, 1993, CARDIOVASC RES, V27, P1184, DOI 10.1093/cvr/27.7.1184; OHLSTEIN EH, 1993, DRUG DEVELOP RES, V29, P108, DOI 10.1002/ddr.430290207; OHMORI Y, 1990, BIOCHEM BIOPH RES CO, V168, P1261, DOI 10.1016/0006-291X(90)91164-N; OHMORI Y, 1994, BIOCHEM BIOPH RES CO, V198, P590, DOI 10.1006/bbrc.1994.1086; POSTON RN, 1992, AM J PATHOL, V140, P665; PRINTSEVA OY, 1992, AM J PATHOL, V140, P889; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RAJCHEL A, 1988, NUCLEIC ACIDS RES, V16, P2347, DOI 10.1093/nar/16.5.2347; ROSS R, 1993, AM J PATHOL, V143, P987; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; SUNG CP, 1993, J CARDIOVASC PHARM, V21, P221, DOI 10.1097/00005344-199302000-00006; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; VANGURI P, 1994, J IMMUNOL, V152, P1411; VANGURI P, 1990, J BIOL CHEM, V265, P15049; WANG XK, 1995, STROKE, V26, P1665, DOI 10.1161/01.STR.26.9.1665; WANG XK, 1995, STROKE, V26, P661, DOI 10.1161/01.STR.26.4.661; Wang XK, 1996, CIRC RES, V78, P322, DOI 10.1161/01.RES.78.2.322; WANG XK, 1992, J BIOL CHEM, V267, P9176; WANG XK, 1996, IN PRESS ATERIOSCLER; WANG XK, 1995, BIOTECHNIQUES, V18, P192; YOSHIMURA T, 1991, BIOCHEM BIOPH RES CO, V174, P504, DOI 10.1016/0006-291X(91)91445-I; YUE TL, 1994, CIRC RES, V75, P1, DOI 10.1161/01.RES.75.1.1; YUE TL, 1994, EXP CELL RES, V214, P459, DOI 10.1006/excr.1994.1282	40	129	138	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24286	24293		10.1074/jbc.271.39.24286	http://dx.doi.org/10.1074/jbc.271.39.24286			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798675				2022-12-27	WOS:A1996VJ44200104
J	Zahedi, R; Aulak, KS; Eldering, E; Davis, AE				Zahedi, R; Aulak, KS; Eldering, E; Davis, AE			Characterization of C1 inhibitor-Ta - A dysfunctional C1INH with deletion of lysine 251	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA KALLIKREIN; REACTIVE CENTER; C1-INHIBITOR; MUTATION; REGION; QUANTIFICATION; COMPLEXES; CONTAINS; SERPINS; DISEASE	Dysfunctional C1 inhibitor (C1INH)-Ta is a naturally occurring mutant from a patient with type II hereditary angioedema. This mutant has a deletion of the codon for Lys-251, which is located in the connecting strand between helix F and strand 3A, overlying beta sheet A. Deletion of this Lys modifies the amino acid sequence at this position from Asn-Lys-Ile-Ser to Asn-Ile-Ser and creates a new glycosylation site. To further characterize the mechanism of dysfunction, we have analyzed the recombinant normal and Ta proteins expressed by COS cells in addition to the proteins in serum and isolated from serum. Recombinant C1INH-Ta revealed an intermediate thermal stability in comparison with the intact and reactive center cleaved normal proteins. Analysis of the reactivity of this recombinant protein with target proteases demonstrated no complex formation with C1s, C1r, or kallikrein. Inefficient complex formation was, however, clearly detectable with beta-factor XIIa. Each protease produced partial cleavage of the recombinant mutant inhibitor. Recombinant C1INH-Ta, on 7.5% SDS-polyacrylamide gel electrophoresis and by size fractionation on Superose 12, showed a higher molecular weight fraction that was compatible in size with dimer formation. However, no multimerization of C1INH-Ta isolated from serum or of C1INH-Ta in serum, was observed. The C1INH-Ta dimer expressed the epitopes that normally are expressed only on the protease complexed or the cleaved inhibitor. These epitopes were not expressed on the monomeric inhibitor. The data suggest that the mutation in C1INH-Ta results in a folding abnormality that behaves as if it consists of two populations of molecules, one of which is susceptible to multimerization and one of which is converted to a substrate, but which retains residual inhibitory activity.	CHILDRENS HOSP RES FDN,DIV NEPHROL,CINCINNATI,OH 45229; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT AUTOIMMUNE DIS,NL-1006 AD AMSTERDAM,NETHERLANDS	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation					NICHD NIH HHS [HD22082] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022082, R37HD022082] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AULAK K S, 1989, Complement and Inflammation, V6, P310; AULAK KS, 1988, BIOCHEM J, V253, P615, DOI 10.1042/bj2530615; AULAK KS, 1993, J BIOL CHEM, V268, P18088; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; DAVIS AE, 1992, NAT GENET, V1, P354, DOI 10.1038/ng0892-354; DEAGOSTINI A, 1988, J CLIN INVEST, V82, P700, DOI 10.1172/JCI113650; DESMET BJGL, 1993, BLOOD, V81, P56, DOI 10.1182/blood.V81.1.56.bloodjournal81156; DEVRAJKIZUK R, 1988, BLOOD, V72, P1518; ELDERING E, 1995, J BIOL CHEM, V270, P2579, DOI 10.1074/jbc.270.6.2579; ELDERING E, 1992, J BIOL CHEM, V267, P7013; LEWIN MF, 1983, J BIOL CHEM, V258, P6415; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; Malek R, 1996, CLIN EXP IMMUNOL, V105, P191, DOI 10.1046/j.1365-2249.1996.d01-714.x; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; NUIJENS JH, 1989, J CLIN INVEST, V84, P443, DOI 10.1172/JCI114185; NUIJENS JH, 1988, BLOOD, V72, P1841; PARAD RB, 1990, P NATL ACAD SCI USA, V88, P6786; PEMBERTON PA, 1989, BIOCHEM J, V58, P193; PERRY DJ, 1989, FEBS LETT, V254, P174, DOI 10.1016/0014-5793(89)81033-6; SCHAPIRA M, 1985, Complement, V2, P111; SCHAPIRA M, 1985, J CLIN INVEST, V76, P635; SIDDIQUE ZM, 1992, HUM HERED, V2, P231; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; YORK JD, 1991, J BIOL CHEM, V266, P8495; ZAHEDI R, 1985, J CLIN INVEST, V95, P1299	29	18	19	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24307	24312		10.1074/jbc.271.39.24307	http://dx.doi.org/10.1074/jbc.271.39.24307			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798678	hybrid			2022-12-27	WOS:A1996VJ44200107
J	Zheng, Y; Glaven, JA; Wu, WJ; Cerione, RA				Zheng, Y; Glaven, JA; Wu, WJ; Cerione, RA			Phosphatidylinositol 4,5-bisphosphate provides an alternative to guanine nucleotide exchange factors by stimulating the dissociation of GDP from Cdc42Hs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; DBL ONCOGENE PRODUCT; ACTIN STRESS FIBERS; PHOSPHOINOSITIDE 3-KINASE; MOLECULAR-CLONING; PHOSPHOLIPASE-D; RHO; RAC; ACTIVATION; GTPASES	Members of the Rho subfamily of Ras-related GTP-binding proteins play important roles in the organization of the actin cytoskeleton and in the regulation of cell growth. We have shown previously that the dbl oncogene product, which represents a prototype for a family of growth regulatory proteins, activates Rho subfamily GTP-binding proteins by catalyzing the dissociation of GDP from their nucleotide binding site. In the present study, we demonstrate that the acidic phospholipid, phosphatidylinositol 4,5-bisphosphate (PIP2), provides an alternative mechanism for the activation of Cdc42Hs. Among a variety of lipids tested, only PIP2 was able to stimulate GDP release from Cdc42Hs in a dose dependent manner, with a half-maximum effect at similar to 50 mu M. Unlike the Dbl oncoprotein, which requires the presence of (free) guanine nucleotide in the medium to replace the GDP bound to Cdc42Hs, PIP2 stimulates GDP release from Cdc42Hs in the absence of free guanine nucleotide. PIP2, when incorporated into phosphatidylcholine carrier vesicles, binds tightly to the guanine nucleotide-depleted form of Cdc42Hs and weakly to the GDP-bound form of the GTP-binding protein but does not bind to GTP-bound Cdc42Hs, similar to what was observed for the Dbl oncoprotein. However, mutational analysis of Cdc42Hs indicates that the site that Is essential for the functional interaction between PIP2 and Cdc42Hs is distinct from the Dbl binding site and is located at the positively charged carboxyl-terminal end of the GTP-binding protein. The GDP-releasing activity of PIP2 is highly effective toward Cdc42Hs and Rho (and is similar to the reported effects of PIP2 on Arf (Terui, T., Kahn, R. A., and Randazzo, P. A., (1994) J. Biol. Chem. 269, 28130-28135)), is less effective with Rac, and is not observed with Ras, Rap1a, or Ran. The ability of PIP2 to activate Cdc42Hs (or Rho) and Arf provides a possible point of convergence for the biological pathways regulated by these different GTP-binding proteins and may be related to the synergism observed between Arf and Rho-subtype proteins in the stimulation of phospholipase D activity (Singer, W. D., Brown, H. A., Bokoch, G. M., and Sternweis, P. C. (1995) J. Biol. Chem. 270, 14944-14950).	CORNELL UNIV,COLL VET MED,DEPT PHARMACOL,ITHACA,NY 14853	Cornell University			Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NIGMS NIH HHS [GM47458, GM40654] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654, R01GM047458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHOU MM, 1996, CELL, V85, P575; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; TERUI T, 1994, J BIOL CHEM, V269, P28130; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	47	76	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23815	23819		10.1074/jbc.271.39.23815	http://dx.doi.org/10.1074/jbc.271.39.23815			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798610	hybrid			2022-12-27	WOS:A1996VJ44200039
J	Hensold, JO; BarthBaus, D; Stratton, CA				Hensold, JO; BarthBaus, D; Stratton, CA			Inducers of erythroleukemic differentiation cause messenger RNAs that lack poly(A)-binding protein to accumulate in translationally inactive, salt-labile 80 S ribosomal complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) BINDING-PROTEIN; MALIGNANT TRANSFORMATION; INITIATION; EXPRESSION; CELLS; MATURATION; CAP; RAT; ELONGATION; SEQUENCES	Translation has an established role in the regulation of cell growth, Posttranslational modification of translation initiation and elongation factors or regulation of mRNA polyadenylation represent common means of regulating translation in response to mitogenic or developmental signals. Induced differentiation of Friend virus-transformed erythroleukemia cells is accompanied by a rapid decrease in the translation rate of these cells. Although inducers do not alter initiation factor modifications, characterization of their effect on mRNA translation provides evidence that this is mediated by the poly(A)-binding protein (PABP). Inducer exposure results in an increase in the amount of mRNA that sediments at 80 S and a decrease in the amount in polysomes, Although these 80 S ribosomes have characteristics previously attributed to "vacant ribosomal couples," including lability in 500 mM KCl and an inability to incorporate amino acids into protein, we provide evidence that these 80 S complexes are not vacant but contain mRNA that is stably bound to the 40 S subunit, whereas the 60 S subunit is dissociated from the complex by high salt. The absence of eukaryotic initiation factor 2 from these complexes suggests that translation has proceeded through subunit joining, Immunoblotting demonstrates that the mRNAs in these 80 S ribosomal complexes do not contain bound PABP and that this protein is found to be almost exclusively associated with translating polysomes. These data suggest that the PABP plays a role in the accumulation of these 80 S ribosomal mRNA complexes and may facilitate the formation of translationally active salt-stable ribosomes.	DEPT VET AFFAIRS MED CTR, CLEVELAND, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Hensold, JO (corresponding author), CASE WESTERN RESERVE UNIV, UNIV IRELAND CANC CTR, DEPT MED, 10900 EUCLID AVE, BRB ROOM 333, CLEVELAND, OH 44106 USA.				NIDDK NIH HHS [DK43414] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; DE SA MFG, 1988, EUR J BIOCHEM, V176, P521; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; FAGAN RJ, 1991, J BIOL CHEM, V266, P16518; FEINBERG AP, 1983, ANAL BIOCHEM, V12, P6; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; GALLIE DR, 1994, J BIOL CHEM, V269, P17166; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GIEBEL LB, 1988, DEV BIOL, V125, P200, DOI 10.1016/0012-1606(88)90073-5; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; Hensold JO, 1996, J BIOL CHEM, V271, P3385; HENSOLD JO, 1991, BLOOD, V77, P1362; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOGAN BLM, 1968, BIOCHIM BIOPHYS ACTA, V169, P129, DOI 10.1016/0005-2787(68)90014-2; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LIN A, 1987, J BIOL CHEM, V262, P14343; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MARTIN TE, 1973, EXP CELL RES, V80, P496, DOI 10.1016/0014-4827(73)90333-9; MARTIN TE, 1969, J MOL BIOL, V43, P135, DOI 10.1016/0022-2836(69)90084-9; MARTIN TE, 1970, J BIOL CHEM, V245, P1504; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; PALATNIK CM, 1984, CELL, V36, P1017, DOI 10.1016/0092-8674(84)90051-5; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PAZ V, 1989, FEBS LETT, V251, P89, DOI 10.1016/0014-5793(89)81434-6; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; SHERTON CC, 1976, DEV BIOL, V48, P118, DOI 10.1016/0012-1606(76)90051-8; SIEKIERKA J, 1982, P NATL ACAD SCI USA, V81, P352; Sonenberg N, 1993, CURR OPIN CELL BIOL, V5, P955, DOI 10.1016/0955-0674(93)90076-3; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; Spirin A, 1986, RIBOSOME STRUCTURE P; STAEHELI.T, 1967, BIOCHIM BIOPHYS ACTA, V145, P105, DOI 10.1016/0005-2787(67)90659-4; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; WARNER JR, 1963, P NATL ACAD SCI USA, V49, P122, DOI 10.1073/pnas.49.1.122; Wickens Marvin, 1992, Seminars in Developmental Biology, V3, P363; Wormington M, 1996, EMBO J, V15, P900, DOI 10.1002/j.1460-2075.1996.tb00424.x; Wormington M, 1993, CURR OPIN CELL BIOL, V5, P950, DOI 10.1016/0955-0674(93)90075-2; ZELUS BD, 1989, MOL CELL BIOL, V9, P2756, DOI 10.1128/MCB.9.6.2756; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8; ZYLBER EA, 1970, BIOCHIM BIOPHYS ACTA, V204, P221, DOI 10.1016/0005-2787(70)90505-8	52	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23246	23254		10.1074/jbc.271.38.23246	http://dx.doi.org/10.1074/jbc.271.38.23246			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798522	hybrid			2022-12-27	WOS:A1996VH76800048
J	Pauly, RP; Rosche, F; Wermann, M; McIntosh, CHS; Pederson, RA; Demuth, HU				Pauly, RP; Rosche, F; Wermann, M; McIntosh, CHS; Pederson, RA; Demuth, HU			Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization time of flight mass spectrometry - A novel kinetic approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESORPTION IONIZATION; QUANTITATIVE-ANALYSIS; HUMAN SERUM; IN-VITRO; IMPROVEMENT; INHIBITORS; RESOLUTION; PROTEINS; VIVO	The incretins glucose-dependent insulinotropic polypeptide (GIP1-42) and glucagon-like peptide-1-(7-36)-amide (GLP-1(7-36)), hormones that potentiate glucose induced insulin secretion from the endocrine pancreas, are substrates of the circulating exopeptidase dipeptidyl peptidase IV and are rendered biologically inactive upon cleavage of their N-terminal dipeptides. This study was designed to determine if matrix-assisted laser desorption/ionization-time of flight mass spectrometry is a useful analytical tool to study the hydrolysis of these hormones by dipeptidyl peptidase IV, including kinetic analysis. Spectra indicated that serum-incubated peptides were cleaved by this enzyme with only minor secondary degradation due to other serum protease activity. Quantification of the mass spectrometric signals allowed kinetic constants for both porcine kidney- and human serum dipeptidyl peptidase IV-catalyzed incretin hydrolysis to be calculated. The binding constants (K-m) of these incretins to purified porcine kidney-derived enzyme were 1.8 +/- 0.3 and 3.8 +/- 0.3 mu M, whereas the binding constants observed in human serum were 39 +/- 29 and 13 +/- 9 mu M for glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1-(7-36)-amide respectively. The large range of K-m values found in human serum suggests a heterogeneous pool of enzyme. The close correlation between the reported kinetic constants and those previously described validates this novel approach to kinetic analysis.	UNIV BRITISH COLUMBIA,DEPT PHYSIOL,VANCOUVER,BC V6T 1Z3,CANADA; HANS KNOLL INST NAT PROD RES JENA,D-06120 HALLE,GERMANY	University of British Columbia; Hans Knoll Institute (HKI)								BROWN JC, 1981, PEPTIDES, V2, P241, DOI 10.1016/0196-9781(81)90038-3; BROWN JC, 1994, GUT PEPTIDES BIOCH P, P765; BROWN RS, 1995, ANAL CHEM, V67, P1998, DOI 10.1021/ac00109a015; CRAIG AG, 1994, BIOL MASS SPECTROM, V23, P519, DOI 10.1002/bms.1200230810; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; DEACON CF, 1995, J CLIN ENDOCR METAB, V80, P952, DOI 10.1210/jc.80.3.952; Demuth H U, 1990, J Enzyme Inhib, V3, P249, DOI 10.3109/14756369009030375; DEMUTH HU, 1995, DIPEPTIDYL PEPTIDASE, P1; Dockray JH., 1994, GUT PEPTIDES BIOCH P, P217; DUKECOHAN JS, 1995, J BIOL CHEM, V270, P14107, DOI 10.1074/jbc.270.23.14107; DukeCohan JS, 1996, J IMMUNOL, V156, P1714; DUNCAN MW, 1993, RAPID COMMUN MASS SP, V7, P1090, DOI 10.1002/rcm.1290071207; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; GUSEV AI, 1995, ANAL CHEM, V67, P1034, DOI 10.1021/ac00102a003; HARVEY DJ, 1993, RAPID COMMUN MASS SP, V7, P614, DOI 10.1002/rcm.1290070712; HSIEH FYL, 1995, ANAL BIOCHEM, V229, P20, DOI 10.1006/abio.1995.1373; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; KIEFFER TJ, 1995, ENDOCRINOLOGY, V136, P3585, DOI 10.1210/en.136.8.3585; MENTLEIN R, 1993, EUR J BIOCHEM, V214, P829, DOI 10.1111/j.1432-1033.1993.tb17986.x; NELSON RW, 1994, ANAL CHEM, V66, P1408, DOI 10.1021/ac00081a008; SCHMIDT W E, 1986, European Journal of Clinical Investigation, V16, pA9; SCHON E, 1991, BIOL CHEM H-S, V372, P305, DOI 10.1515/bchm3.1991.372.1.305; SCHUERCH S, 1994, BIOL MASS SPECTROM, V23, P695, DOI 10.1002/bms.1200231108; SIUZDAK G, 1994, P NATL ACAD SCI USA, V91, P11290, DOI 10.1073/pnas.91.24.11290; Tanaka K, 1988, RAPID COMMUN MASS SP, V2, P151, DOI [10.1002/RCM.1290020802, DOI 10.1002/RCM.1290020802, 10.1002/rcm.1290020802]; TANG K, 1993, ANAL CHEM, V65, P2164, DOI 10.1021/ac00063a041; WOLF B, 1978, ACTA BIOL MED GER, V37, P409; YAMASHITA M, 1984, J PHYS CHEM-US, V88, P4451, DOI 10.1021/j150664a002; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572; ZALUZEC EJ, 1995, PROTEIN EXPRES PURIF, V6, P109, DOI 10.1006/prep.1995.1014	30	141	144	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23222	23229		10.1074/jbc.271.38.23222	http://dx.doi.org/10.1074/jbc.271.38.23222			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798518	hybrid			2022-12-27	WOS:A1996VH76800044
J	Tsytsikov, VN; Yurovsky, VV; Atamas, SP; Alms, WJ; White, B				Tsytsikov, VN; Yurovsky, VV; Atamas, SP; Alms, WJ; White, B			Identification and characterization of two alternative splice variants of human interleukin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GAMMA-CHAIN; T-CELL LEUKEMIA; BLOOD MONONUCLEAR-CELLS; AFFINITY IL-2 RECEPTOR; ALPHA-CHAIN; BETA-CHAIN; CYTOKINE SECRETION; TAC ANTIGEN; BINDING; EXPRESSION	Our previous work showed that alternative splicing is used to make an inhibitory variant of human interleukin (IL)-4. Because of homology between IL-4 and IL-2 proteins and receptors, we tested whether alternative splicing is used to generate similar inhibitory variants of human IL-2, Messenger RNA from peripheral blood mononuclear cells was subjected to reverse transcription-polymerase chain reaction using IL-2 exon 1- and exon 4-specific primers. Two amplification products, named IL-2 delta 2 and IL-2 delta 3, were found in addition to the native IL-2 product. The IL-2 delta 2 cDNA sequence was identical to IL-2 cDNA throughout the entire coding region, except exon 2 was omitted by alternative splicing. In IL-2 delta 3 cDNA, the third exon of IL-2 was omitted by alternative splicing, Unlike IL-2, IL-2 delta 2 and IL-2 delta 3 did not stimulate T cell proliferation. However, both inhibited IL-2 costimulation of T cell proliferation, and both inhibited cellular binding of rhIL-2 to high affinity IL-2 receptors. Thus, IL-2 is the second cytokine that uses alternative splicing to generate variants that are competitive inhibitors.	VET AFFAIRS MED CTR,MED SERV,BALTIMORE,MD 21201; VET AFFAIRS MED CTR,RES SERV,BALTIMORE,MD 21201	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)	Tsytsikov, VN (corresponding author), UNIV MARYLAND,DEPT MED,DIV CLIN IMMUNOL & RHEUMATOL,MSTF ROOM 8-23,10 S PINE ST,BALTIMORE,MD 21201, USA.							Alms WJ, 1996, MOL IMMUNOL, V33, P361, DOI 10.1016/0161-5890(95)00154-9; ANASETTI C, 1994, BLOOD, V84, P1320; ANDREUSANCHEZ JL, 1991, J EXP MED, V173, P1323, DOI 10.1084/jem.173.6.1323; Atamas SP, 1996, J IMMUNOL, V156, P435; BAZAN JF, 1992, SCIENCE, V257, P410, DOI 10.1126/science.1631562; BERNDT WG, 1994, BIOCHEMISTRY-US, V33, P6571, DOI 10.1021/bi00187a026; BOULAY JL, 1992, J BIOL CHEM, V267, P20525; BRANDHUBER BJ, 1987, SCIENCE, V238, P1707, DOI 10.1126/science.3500515; BUCHLI P, 1993, ARCH BIOCHEM BIOPHYS, V307, P411, DOI 10.1006/abbi.1993.1608; CANTRELL DA, 1983, J EXP MED, V158, P1895, DOI 10.1084/jem.158.6.1895; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS MKL, 1990, EUR J IMMUNOL, V20, P573, DOI 10.1002/eji.1830200317; FLEMMING CL, 1993, EUR J IMMUNOL, V23, P917, DOI 10.1002/eji.1830230423; FUJITA T, 1983, P NATL ACAD SCI-BIOL, V80, P7437, DOI 10.1073/pnas.80.24.7437; GILLIS S, 1978, J IMMUNOL, V120, P2027; GOLDSMITH MA, 1994, CYTOKINE HDB, P14; GRANT AJ, 1992, P NATL ACAD SCI USA, V89, P2165, DOI 10.1073/pnas.89.6.2165; HEATH WR, 1992, NATURE, V359, P547, DOI 10.1038/359547a0; HEATON KM, 1993, CANCER RES, V53, P2597; HEATON KM, 1993, CELL IMMUNOL, V147, P167, DOI 10.1006/cimm.1993.1057; HEATON KM, 1995, HUM IMMUNOL, V42, P274, DOI 10.1016/0198-8859(94)00106-Z; Hopkins SA, 1992, PHARM ENG, V12, P48; HOWARD MC, 1993, FUNDAMENTAL IMMUNOLO, P766; JU G, 1987, J BIOL CHEM, V262, P5723; KJELDSENKRAGH J, 1993, EUR J IMMUNOL, V23, P2092, DOI 10.1002/eji.1830230908; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KORSMEYER SJ, 1983, P NATL ACAD SCI USA, V80, P4255; KUZIEL WA, 1993, J IMMUNOL, V150, P3357; LOWENTHAL JW, 1987, J EXP MED, V166, P1156, DOI 10.1084/jem.166.4.1156; LOWENTHAL JW, 1991, CURRENT PROTOCOLS IM; MAEDA M, 1987, BLOOD, V70, P1407; MCKAY DB, 1992, SCIENCE, V257, P412, DOI 10.1126/science.257.5068.412; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; MOTT HR, 1992, BIOCHEMISTRY-US, V31, P7741, DOI 10.1021/bi00148a040; NEMOTO T, 1995, EUR J IMMUNOL, V25, P3001, DOI 10.1002/eji.1830251102; RINGHEIM GE, 1991, LYMPHOKINE CYTOK RES, V10, P219; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; RONG Y, 1992, BIOCHEM BIOPH RES CO, V188, P949, DOI 10.1016/0006-291X(92)91147-I; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SAUVE K, 1991, P NATL ACAD SCI USA, V88, P4636, DOI 10.1073/pnas.88.11.4636; SCHWARTING R, 1985, J CLIN PATHOL, V38, P1196, DOI 10.1136/jcp.38.10.1196-b; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANAKA J, 1995, LEUKEMIA LYMPHOMA, V16, P413, DOI 10.3109/10428199509054427; TANIGUCHI T, 1983, NATURE, V302, P305, DOI 10.1038/302305a0; TINUBU SA, 1994, J IMMUNOL, V153, P4330; UCHIYAMA T, 1985, J CLIN INVEST, V76, P446, DOI 10.1172/JCI111992; VOSS SD, 1993, P NATL ACAD SCI USA, V90, P2428, DOI 10.1073/pnas.90.6.2428; WALDMANN TA, 1992, ANN INTERN MED, V116, P148, DOI 10.7326/0003-4819-116-2-148; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WALDMANN TA, 1984, J CLIN INVEST, V73, P1711, DOI 10.1172/JCI111379; WANG ZY, 1995, EUR J IMMUNOL, V25, P1212, DOI 10.1002/eji.1830250512; WEIDMANN E, 1992, CANCER RES, V52, P5963; WEIGEL U, 1989, EUR J BIOCHEM, V180, P295, DOI 10.1111/j.1432-1033.1989.tb14647.x; WILKINSON PC, 1994, IMMUNOLOGY, V82, P134; YAMAMURA M, 1992, J IMMUNOL, V149, P1470	57	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23055	23060		10.1074/jbc.271.38.23055	http://dx.doi.org/10.1074/jbc.271.38.23055			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798495	hybrid			2022-12-27	WOS:A1996VH76800021
J	Freeman, JL; Lambeth, JD				Freeman, JL; Lambeth, JD			NADPH oxidase activity is independent of p47(phox) in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; CELL-FREE SYSTEM; NEUTROPHIL FLAVOCYTOCHROME B(558); SRC HOMOLOGY-3 DOMAINS; RECOMBINANT P47-PHOX; ANIONIC AMPHIPHILE; PLASMA-MEMBRANE; BINDING; PROTEIN	The neutrophil superoxide generating NADPH oxidase is activated by the assembly of cytosolic protein components with a membrane-associated flavocytochrome. The activity can be reconstituted in vitro using purified cytosolic factors p47(phox), p67(phox), and Rac plus the phospholipid-reconstituted flavocytochrome b(558). Here, we demonstrate that activity is reconstituted in the absence of p47(phox) when high concentrations of p67(phox) and Rac are used. V-max values were the same in the presence or absence of p47(phox), yet p47(phox) increases the affinity of both p67(phox) and Rac for the oxidase complex by nearly 2 orders of magnitude, p67(phox)-(1-246), a truncated form of the protein which eliminates SH3 domains involved in binding to p47(phox), also supports superoxide generation, both in the presence and absence of p47(phox), providing further evidence for p47(phox) independent activity. In the absence of p47(phox), p67(phox)-(1-246) binds to the NADPH oxidase complex 3-fold more tightly than does native p67(phox) indicating that the C terminus contains a region which masks binding to the oxidase complex. Results indicate that p47(phox) does not play a direct role in regulating electron transfer. Rather, ifs function is to serve as an adaptor protein to enhance the assembly of the other cytosolic components with the flavocytochrome and possibly to unmask a binding region in the N terminus of p67(phox) by binding to its C-terminal domains. p67(phox) and/or Rac play a more direct role in regulating electron transfer.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University					NIAID NIH HHS [AI22809] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022809] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BABIOR BM, 1988, ARCH BIOCHEM BIOPHYS, V264, P361, DOI 10.1016/0003-9861(88)90300-1; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOWMAN E, 1995, METHODS ENZYMOLOGY S, P246; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNHAM DN, 1990, J BIOL CHEM, V265, P17550; CHANOCK SJ, 1992, P NATL ACAD SCI USA, V89, P10174, DOI 10.1073/pnas.89.21.10174; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CROSS AR, 1995, J BIOL CHEM, V270, P6543, DOI 10.1074/jbc.270.12.6543; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; FINAN P, 1994, J BIOL CHEM, V269, P13752; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; FREEMAN JLR, 1994, BIOCHEMISTRY-US, V33, P13431, DOI 10.1021/bi00249a031; FUJIMOTO S, 1989, J BIOL CHEM, V264, P21629; HENDERSON LM, 1995, J BIOL CHEM, V270, P5909, DOI 10.1074/jbc.270.11.5909; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KRECK ML, 1994, J BIOL CHEM, V269, P4161; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; LAMBETH JD, 1988, J BIOL CHEM, V263, P3818; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; NISIMOTO Y, 1995, J BIOL CHEM, V270, P16428, DOI 10.1074/jbc.270.27.16428; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; OKAMURA N, 1988, BLOOD, V72, P811; OKAMURA N, 1990, J CLIN INVEST, V85, P1583, DOI 10.1172/JCI114608; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SMITH RM, 1991, BLOOD, V77, P673; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; TEAHAN CG, 1990, BIOCHEM J, V267, P485, DOI 10.1042/bj2670485; TYAGI SR, 1992, BIOCHEMISTRY-US, V31, P2765, DOI 10.1021/bi00125a017; UHLINGER DJ, 1992, BIOCHEM BIOPH RES CO, V186, P509, DOI 10.1016/S0006-291X(05)80837-X; UHLINGER DJ, 1994, J BIOL CHEM, V269, P22095; UHLINGER DJ, 1993, J BIOL CHEM, V268, P8624; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; XU XM, 1994, J BIOL CHEM, V269, P23569	45	152	153	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22578	22582		10.1074/jbc.271.37.22578	http://dx.doi.org/10.1074/jbc.271.37.22578			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798426	hybrid			2022-12-27	WOS:A1996VG67200045
J	Ida, N; Hartmann, T; Pantel, J; Schroder, J; Zerfass, R; Forstl, H; Sandbrink, R; Masters, CL; Beyreuther, K				Ida, N; Hartmann, T; Pantel, J; Schroder, J; Zerfass, R; Forstl, H; Sandbrink, R; Masters, CL; Beyreuther, K			Analysis of heterogeneous beta A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE BRAIN; AMYLOID-BETA; A-BETA; PROTEIN-PRECURSOR; APOLIPOPROTEIN-E; SENILE PLAQUES; CORE PROTEIN; DEPOSITS; CELLS; A-BETA-42(43)	The beta A4 peptide, a major component of senile plaques in Alzheimer's disease (AD) brain, has been found in cerebrospinal fluid (CSF) and blood of both AD patients and normal subjects, Although beta A4 1-40 is the major form produced by cell metabolism and found in CSF, recent observations suggest that the long-tailed beta A4 1-42 plays a more crucial role in AD pathogenesis. Here, we established new monoclonal antibodies against the C-terminal end of beta A4 1-40 and 1-42, and used them for the specific Western blot detection. After optimizing the assay conditions, these antibodies detected low picogram amount of beta A4, and both beta A4 1-40 and 1-42 levels in CSF could be determined by direct loading of the samples. flood levels of beta A4 1-40 and 1-42 were also determined by specific immunoprecipitation followed by Western blot detection. We found that CSF beta A4 1-42 level is lower in AD patients compared with non-demented controls, although there was a significant overlap between the groups. The level of beta A4 1-40 in CSF, and of beta A4 1-40 as well as beta A4 1-42 in plasma, were not different between AD patients and controls. Besides the 4-kDa full-length beta A4 band, we could also detect several N-terminal variants of beta A4 in CSF and plasma of both AD patients and controls. Two N-terminally truncated beta A4 species migrating at the position of 3.3 and 3.7 kDa were found in CSF, while 3.7- and 5-kDa forms were found in plasma. The relative abundance of these various species were considerably different in the CSF and plasma, suggesting that the cellular source and/or clearance of beta A4 is different in these two compartments.	UNIV HEIDELBERG, CTR MOL BIOL HEIDELBERG, D-69120 HEIDELBERG, GERMANY; UNIV HEIDELBERG, PSYCHIAT CLIN, D-69115 HEIDELBERG, GERMANY; CENT INST MENTAL HLTH, D-69159 MANNHEIM, GERMANY; UNIV MELBOURNE, DEPT PATHOL, PARKVILLE, VIC 3052, AUSTRALIA	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Central Institute of Mental Health; University of Melbourne			Hartmann, Tobias/AAB-8297-2022; Pantel, Johannes/ABC-6341-2020; förstl, hans/B-5869-2008	Forstl, Hans/0000-0002-6188-6883; Hartmann, Tobias/0000-0001-7481-6430				ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLABEK A, 1995, NEUROSCI LETT, V191, P79, DOI 10.1016/0304-3940(95)11565-7; GOWING E, 1994, J BIOL CHEM, V269, P10987; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1995, J BIOL CHEM, V270, P6186, DOI 10.1074/jbc.270.11.6186; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jensen M., 1995, Society for Neuroscience Abstracts, V21, P1501; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIDA E, 1995, NEUROSCI LETT, V193, P105, DOI 10.1016/0304-3940(95)11678-P; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MOTTER R, 1995, ANN NEUROL, V38, P643, DOI 10.1002/ana.410380413; NAKAMURA T, 1994, ANN NEUROL, V36, P903, DOI 10.1002/ana.410360616; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; NITSCH RM, 1995, ANN NEUROL, V37, P512, DOI 10.1002/ana.410370414; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SCHWARZMAN AL, 1994, P NATL ACAD SCI USA, V91, P8368, DOI 10.1073/pnas.91.18.8368; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHAPIRA R, 1988, J NEUROCHEM, V50, P69, DOI 10.1111/j.1471-4159.1988.tb13231.x; SHINKAI Y, 1995, ANN NEUROL, V38, P421, DOI 10.1002/ana.410380312; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Simons M, 1996, J NEUROSCI, V16, P899; Song X.-H., 1995, Society for Neuroscience Abstracts, V21, P1501; SOTO C, 1995, NEUROSCI LETT, V186, P115, DOI 10.1016/0304-3940(95)11299-C; Southwick PC, 1996, J NEUROCHEM, V66, P259; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; SWERDLOW PS, 1986, ANAL BIOCHEM, V156, P147, DOI 10.1016/0003-2697(86)90166-1; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; TAMAOKA A, 1994, BIOCHEM BIOPH RES CO, V205, P834, DOI 10.1006/bbrc.1994.2740; TAMAOKA A, 1994, J BIOL CHEM, V269, P32721; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANGOOL WA, 1995, ANN NEUROL, V37, P277, DOI 10.1002/ana.410370221; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423; YAMAGUCHI H, 1992, AM J PATHOL, V141, P249	46	465	503	3	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22908	22914		10.1074/jbc.271.37.22908	http://dx.doi.org/10.1074/jbc.271.37.22908			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798471				2022-12-27	WOS:A1996VG67200090
J	Malik, N; Canfield, VA; Beckers, MC; Gros, P; Levenson, R				Malik, N; Canfield, VA; Beckers, MC; Gros, P; Levenson, R			Identification of the mammalian Na,K-ATPase beta 3 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+,K+-ATPASE ALPHA-SUBUNIT; TISSUE-SPECIFIC EXPRESSION; RAT-BRAIN; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; NERVOUS-SYSTEM; GENE; BETA-2-SUBUNIT; ASSIGNMENT	We have isolated and characterized cDNA clones encoding the human and rat Na,K-ATPase beta 3 subunit isoform, The human cDNA encodes a polypeptide of 279 amino acids that exhibits primary sequence and secondary structure similarities to Na,K-ATPase beta subunit isoforms. Sequence comparisons showed that the human beta 3 subunit closely resembles the beta 3 subunit of Xenopus laevis (59% amino acid identity) and is less similar to the human Na,K-ATPase beta 1 and beta 2 subunits (38% and 48% amino acid identity, respectively). By analyzing the segregation of restriction fragment length polymorphisms among recombinant inbred strains of mice, we localized the beta 3 subunit gene to murine chromosome 7. Northern blot analysis revealed that the beta 3 subunit gene encodes two transcripts that are expressed in a variety of rat tissues including testis, brain, kidney, lung, stomach, small intestine, colon, spleen, and liver. Identification of the mammalian beta 3 subunit suggests an even greater potential for Na,K-ATPase isoenzyme diversity than previously realized.	PENN STATE COLL MED,MILTON S HERSHEY MED CTR,DEPT PHARMACOL,HERSHEY,PA 17033; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; McGill University				Levenson, Robert/0000-0002-0936-8421	NHLBI NIH HHS [HL-39263] Funding Source: Medline; NIGMS NIH HHS [GM-49023] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049023] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CAMERON R, 1994, MOL BRAIN RES, V21, P338; CANFIELD VA, 1990, J BIOL CHEM, V265, P19878; CANTLEY LC, 1981, CURR TOP BIOENERG, V11, P201; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVISSON M, 1991, MOUSE GENOME, V89, P5; DEVREUX J, 1984, NUCLEIC ACIDS RES, V12, P387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GLYNN IM, 1985, ENZYMES BIOL MEMBR, P35; GOOD PJ, 1990, P NATL ACAD SCI USA, V87, P9088, DOI 10.1073/pnas.87.23.9088; GRENE MC, 1989, GENETIC VARIANTS STR, P773; HERRERA VL, 1987, J CELL BIOL, V105, P1055; HUNDAL HS, 1992, J BIOL CHEM, V267, P5040; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1993, PFLUG ARCH EUR J PHY, V425, P446, DOI 10.1007/BF00374871; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; KAWAKAMI K, 1986, NUCLEIC ACIDS RES, V14, P2833, DOI 10.1093/nar/14.7.2833; KENT RB, 1987, P NATL ACAD SCI USA, V84, P5369, DOI 10.1073/pnas.84.15.5369; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEMAS MV, 1993, BIOCHIM BIOPHYS ACTA, V1149, P339; MALO D, 1990, GENOMICS, V6, P697, DOI 10.1016/0888-7543(90)90507-Q; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; NESBITT M, 1990, MOUSE GENOME, V88, P113; SCHNEIDER BG, 1991, J HISTOCHEM CYTOCHEM, V39, P507, DOI 10.1177/39.4.1848572; SHAMRAJ OI, 1994, P NATL ACAD SCI USA, V91, P12952, DOI 10.1073/pnas.91.26.12952; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SHYJAN AW, 1990, J BIOL CHEM, V265, P5166; SHYJAN AW, 1990, P NATL ACAD SCI USA, V87, P1178, DOI 10.1073/pnas.87.3.1178; SHYJAN AW, 1989, BIOCHEMISTRY-US, V28, P4531, DOI 10.1021/bi00437a002; SILVER J, 1985, J HERED, V76, P436, DOI 10.1093/oxfordjournals.jhered.a110140; URAYAMA O, 1989, J BIOL CHEM, V264, P8271; WATTS AG, 1991, P NATL ACAD SCI USA, V88, P7425, DOI 10.1073/pnas.88.16.7425	33	140	142	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22754	22758		10.1074/jbc.271.37.22754	http://dx.doi.org/10.1074/jbc.271.37.22754			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798450	hybrid			2022-12-27	WOS:A1996VG67200069
J	Tao, NB; Wagner, SJ; Lublin, DM				Tao, NB; Wagner, SJ; Lublin, DM			CD36 is palmitoylated on both N- and C-terminal cytoplasmic tails	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IV CD36; MEMBRANE-PROTEIN; SIGNAL-TRANSDUCTION; LIMP-II; SR-BI; THROMBOSPONDIN; PLATELET; RECEPTOR; IDENTIFICATION; ADHESION	The membrane protein CD36 has been reported to carry out a wide range of potential functions, including serving as a receptor for thrombospondin, collagen, oxidized low density lipoprotein, fatty acids, anionic phospholipids, and Plasmodium falciparum malaria parasitized erythrocytes, This implicates CD36 in cellular adhesion, human atherosclerotic lesion formation, lipid metabolism, and malaria. A presumed rat homolog of CD36 was previously reported to be palmitoylated, We confirmed that human CD36 is palmitoylated and identified cysteines 3, 7, 464, and 466 as the palmitoylation sites using a mutagenesis approach, This result suggests that both the N- and C-terminal tails of CD36 are cyto plasmic. Published models for the topology of CD36 have the C terminus located in the cytoplasm but differ as to whether the N terminus is cytoplasmic or extracellular. To address this question, a C terminal truncation mutant of CD36 was made by introducing a stop codon just upstream of the C-terminal transmembrane domain. This mutant was found membrane-bound when expressed in human embryonic kidney 293 cells, indicating that the N-terminal hydrophobic domain serves as a transmembrane anchor, and thus supporting a CD36 topology with two transmembrane domains.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV LAB MED,ST LOUIS,MO 63110	Washington University (WUSTL)					NHLBI NIH HHS [T32 HL07038] Funding Source: Medline; NIGMS NIH HHS [GM 41297] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM041297, R01GM041297] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Alessio M, 1996, J BIOL CHEM, V271, P1770, DOI 10.1074/jbc.271.3.1770; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; CALVO D, 1993, J BIOL CHEM, V268, P18929; DAVIET L, 1995, BIOCHEM J, V305, P221, DOI 10.1042/bj3050221; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; GREENWALT DE, 1990, BIOCHEMISTRY-US, V29, P7054, DOI 10.1021/bi00482a015; GREENWALT DE, 1992, BLOOD, V80, P1105; HART K, 1993, J MOL BIOL, V234, P249, DOI 10.1006/jmbi.1993.1580; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; JOCHEN A, 1993, J LIPID RES, V34, P1783; KASHIWAGI H, 1995, J CLIN INVEST, V95, P1040, DOI 10.1172/JCI117749; KNOWLES DM, 1984, J IMMUNOL, V132, P2170; KULCZYCKI A, 1980, J IMMUNOL METHODS, V37, P133, DOI 10.1016/0022-1759(80)90198-2; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PEARCE SFA, 1994, BLOOD, V84, P384; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SCHLESINGER MJ, 1994, LIPID MODIFICATIONS; SCHUEPP BJ, 1991, BIOCHEM BIOPH RES CO, V175, P263, DOI 10.1016/S0006-291X(05)81229-X; SCHWEIZER A, 1995, J BIOL CHEM, V270, P9638, DOI 10.1074/jbc.270.16.9638; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TANDON NN, 1989, J BIOL CHEM, V264, P7576; VEGA MA, 1991, J BIOL CHEM, V266, P16818; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	31	132	141	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22315	22320		10.1074/jbc.271.37.22315	http://dx.doi.org/10.1074/jbc.271.37.22315			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798390	hybrid			2022-12-27	WOS:A1996VG67200009
J	Chen, T; Repetto, B; Chizzonite, R; Pullar, C; Burghardt, C; Dharm, E; Zhao, AC; Carroll, R; Nunes, P; Basu, M; Danho, W; Visnick, M; Kochan, J; Waugh, D; Gilfillan, AM				Chen, T; Repetto, B; Chizzonite, R; Pullar, C; Burghardt, C; Dharm, E; Zhao, AC; Carroll, R; Nunes, P; Basu, M; Danho, W; Visnick, M; Kochan, J; Waugh, D; Gilfillan, AM			Interaction of phosphorylated Fc epsilon RI gamma immunoglobulin receptor tyrosine activation motif-based peptides with dual and single SH2 domains of p72(syk) - Assessment of binding parameters and real, time binding kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; AFFINITY PHOSPHOTYROSYL PEPTIDE; SRC HOMOLOGY-2 DOMAIN; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN; KINASES; ZAP-70; SYK	To examine the characteristics of the interaction of the Fc epsilon RI gamma ITAM with the SH2 domains of p72(syk), the binding of an I-125-labeled dual phosphorylated Fc epsilon RI gamma ITEM-based peptide to the p72(syk) SH2 domains was monitored utilizing a novel scintillation proximity based assay. The K-d for this interaction, determined from the saturation binding isotherm, was 1.4 nM. This high affinity binding was reflected in the rapid rate of association for the peptide binding to the SH2 domains. Competition studies utilizing a soluble C-terminal SH2 domain knockout and N-terminal SH2 domain knockouts revealed that both domains contribute cooperatively to the high affinity binding. I-125-labeled dual phosphorylated peptide competed with the I-125-labeled peptide for binding to the dual p72(syk) SH2 domains with an IC50 value of 4.8 nM. Monophosphorylated 24-mer Fc epsilon RI gamma ITAM peptides, and phosphotyrosine also competed for binding, but with substantially higher IC50 values. This, and other data discussed, suggest that high affinity binding requires both tyrosine residues to be phosphorylated and that the preferred binding orientation of the ITAM is such that the N-terminal phosphotyrosine occupies the C-terminal SH2 domain and the C-terminal phosphotyrosine occupies the N-terminal SH2 domain.	HOFFMANN LA ROCHE INC, DEPT INFLAMMAT & AUTOIMMUNE DIS, NUTLEY, NJ 07110 USA; HOFFMANN LA ROCHE INC, DEPT METAB DIS, NUTLEY, NJ 07110 USA; HOFFMANN LA ROCHE INC, DEPT ANTISENSE RES, NUTLEY, NJ 07110 USA; HOFFMANN LA ROCHE INC, DEPT CHEM PHYS, NUTLEY, NJ 07110 USA	Roche Holding; Roche Holding; Roche Holding; Roche Holding								BANNWARTH W, 1992, HELV CHIM ACTA, V75, P707, DOI 10.1002/hlca.19920750305; BERNATOWICZ MS, 1989, TETRAHEDRON LETT, V30, P4645, DOI 10.1016/S0040-4039(01)80764-4; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EISEMAN E, 1992, NATURE, V355, P78; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; GILMER T, 1994, J BIOL CHEM, V269, P31711; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KIHARA H, 1994, J BIOL CHEM, V269, P22427; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW CL, 1994, J BIOL CHEM, V269, P12310; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LEMMON MA, 1994, BIOCHEMISTRY-US, V33, P5070, DOI 10.1021/bi00183a010; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; NAKAMURA K, 1994, BBA-MOL CELL RES, V1224, P495, DOI 10.1016/0167-4889(94)90287-9; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; PULLAR CE, 1996, FASEB J, V10, pA1215; REPH M, 1989, NATURE, V338, P383; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1992, COLD SPRING HARB SYM, V57, P67, DOI 10.1101/SQB.1992.057.01.009; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SIERKE SL, 1993, BIOCHEMISTRY-US, V32, P10102, DOI 10.1021/bi00089a028; SWIETER M, 1995, J IMMUNOL, V155, P5330; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TSAO KL, 1996, GENE AMST, V149, P59; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WEIL R, 1995, J BIOL CHEM, V270, P2791, DOI 10.1074/jbc.270.6.2791; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6; WILCHEK M, 1990, METHOD ENZYMOL, V184, P123; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	59	58	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25308	25315		10.1074/jbc.271.41.25308	http://dx.doi.org/10.1074/jbc.271.41.25308			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810294	hybrid			2022-12-27	WOS:A1996VL69300038
J	Chambers, RS; Kane, CM				Chambers, RS; Kane, CM			Purification and characterization of an RNA polymerase II phosphatase from yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; TATA-BINDING PROTEIN; MAJOR LATE PROMOTER; TRANSCRIPTION FACTOR; POLYACRYLAMIDE GELS; SUBUNIT-IIA; PHOSPHORYLATION; CTD; INITIATION; CELLS	RNA polymerase (RNAP) II is subject to extensive phosphorylation on the heptapeptide repeats of the C-terminal domain (CTD) of the largest subunit, An activity that is required for the dephosphorylation of yeast RNAP II in vitro has been purified from a yeast whole cell extract by >30,000-fold, The yeast CTD phosphatase activity copurified with two bands with apparent molecular masses of 100 and 103 kDa, The properties of the yeast CTD phosphatase are similar to those of a previously characterized CTD phosphatase from HeLa cells, These properties include stimulation by the general transcription factor IIF (TFIIF), competitive inhibition by RNAP II, magnesium dependence, and resistance to okadaic acid. Both the HeLa and yeast CTD phosphatases are highly specific for their cognate polymerases. Neither phosphatase functions upon the polymerase molecule from the other species, even though the heptapeptide repeats of the CTDs in yeast RNAP II and mammalian RNAP II are essentially identical. The activity of the highly purified CTD phosphatase is stimulated >300-fold by a partially purified fraction of TFIIF. Recombinant TFIIF did not substitute for the TFIIF fraction, indicating that an additional factor present in the TFIIF fraction is required for CTD phosphatase activity, These results show that yeast contains a CTD phosphatase activity similar to that of mammalian cells that is likely composed of at least two components, one of which is 100 and/or 103 kDa.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,DIV BIOCHEM & MOL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NIGMS NIH HHS [GM 34963] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUERMEYER AB, 1995, J BIOL CHEM, V270, P6798, DOI 10.1074/jbc.270.12.6798; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, FEBS LETT, V250, P601, DOI 10.1016/0014-5793(89)80804-X; CONAWAY JW, 1987, J BIOL CHEM, V262, P8293; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; DEMORENO MR, 1985, ANAL BIOCHEM, V151, P466, DOI 10.1016/0003-2697(85)90206-4; DUBOIS MF, 1994, EMBO J, V13, P4787, DOI 10.1002/j.1460-2075.1994.tb06804.x; DUBOIS MF, 1994, J CELL PHYSIOL, V158, P417, DOI 10.1002/jcp.1041580305; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; KANG ME, 1993, J BIOL CHEM, V268, P25033; KANG ME, 1995, J BIOL CHEM, V270, P23390, DOI 10.1074/jbc.270.40.23390; KEPHART DD, 1994, J BIOL CHEM, V269, P13536; KIM WY, 1989, J BIOL CHEM, V264, P3169; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JE, 1993, BIOCHEMISTRY-US, V32, P8987, DOI 10.1021/bi00086a002; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LI Y, 1994, SCIENCE, V263, P805, DOI 10.1126/science.8303296; PAYNE JM, 1993, J BIOL CHEM, V268, P80; POON D, 1993, J BIOL CHEM, V268, P15325; RICE SA, 1994, J VIROL, V68, P988, DOI 10.1128/JVI.68.2.988-1001.1994; SHENOLIKAR S, 1995, CURRENT PROTOCOLS MO, V3; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; WANG YX, 1995, J BIOL CHEM, V270, P25607, DOI 10.1074/jbc.270.43.25607; WEST ML, 1995, GENETICS, V140, P1223; WOYCHIK NA, 1991, J BIOL CHEM, V266, P19053; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	38	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24498	24504		10.1074/jbc.271.40.24498	http://dx.doi.org/10.1074/jbc.271.40.24498			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798710	hybrid			2022-12-27	WOS:A1996VM67400032
J	Crabeel, M; Soetens, O; DeRijcke, M; Pratiwi, R; Pankiewicz, R				Crabeel, M; Soetens, O; DeRijcke, M; Pratiwi, R; Pankiewicz, R			The ARG11 gene of Saccharomyces cerevisiae encodes a mitochondrial integral membrane protein required for arginine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; YEAST; SEQUENCE; CARRIER; EXPRESSION; MUTATIONS; RECEPTOR; VECTORS; CLONING; PLASMID	Prototype strain MG409 (arg11-1) is a severe arginine bradytroph with greatly reduced ornithine and arginine pools, although all known enzymes required for arginine biosynthesis are functional. To identify the function required for normal arginine production impaired in MG409, we have cloned, sequenced, and performed a first molecular characterization of ARG11. We show that the ARG11 open reading frame encodes a putative 292-residue protein with a predicted molecular mass of 31.5 kDa. Sequence similarities, a tripartite organization, and six potential hydrophobic transmembrane spans suggest that Arg11p belongs to the mitochondrial integral inner membrane carrier family. We have used immune-Western blotting and hemagglutinin epitope-tagged derivatives of Arg11p, Arg8p (a mitochondrial matrix marker), and Arg3p (a cytosolic marker) to demonstrate that Arg11p is confined to the mitochondria and behaves like an integral membrane protein. A deletion created in ARG11 causes the same arginine-leaky behavior as the original arg11-1 mutation, which yields a premature stop codon at residue 266. Arg11p thus appears to fulfill a partially redundant function requiring its 27 carboxyl-terminal amino acids. As a working hypothesis, we propose that Arg11p participates in the export of matrix-made ornithine into the cytosol.	FREE UNIV BRUSSELS, DEPT GENET & MICROBIOL, B-1050 BRUSSELS, BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Crabeel, M (corresponding author), COOVI, RES INST, VLAAMS INTERUNIV INST BIOTECHNOL, 1 E GRYSONLAAN, B-1070 BRUSSELS, BELGIUM.		Pratiwi, Rarastoeti/AAK-1315-2021	Pratiwi, Rarastoeti/0000-0002-8421-2056; De Rycke, Martine/0000-0001-7861-9426				BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; BOONCHIRD C, 1991, EUR J BIOCHEM, V199, P325, DOI 10.1111/j.1432-1033.1991.tb16128.x; CHEVALLIER MR, 1980, GENE, V11, P11, DOI 10.1016/0378-1119(80)90082-7; CRABEEL M, 1981, P NATL ACAD SCI-BIOL, V78, P5026, DOI 10.1073/pnas.78.8.5026; CRABEEL M, 1983, EMBO J, V2, P205, DOI 10.1002/j.1460-2075.1983.tb01406.x; CRABEEL M, 1988, CURR GENET, V13, P113, DOI 10.1007/BF00365645; CULLIN C, 1994, YEAST, V10, P105, DOI 10.1002/yea.320100110; DEGRIJSE E, 1947, FEBS LETT, V43, P285; DELFORGE J, 1975, EUR J BIOCHEM, V57, P231, DOI 10.1111/j.1432-1033.1975.tb02295.x; EMMERMANN M, 1991, CURR GENET, V20, P405, DOI 10.1007/BF00317069; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GRAF R, 1993, YEAST, V9, P301, DOI 10.1002/yea.320090310; HEIMBERG H, 1990, GENE, V90, P69, DOI 10.1016/0378-1119(90)90440-3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAUNIAUX JC, 1978, J BACTERIOL, V133, P1096, DOI 10.1128/JB.133.3.1096-1107.1978; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; MESSENGUY F, 1980, EUR J BIOCHEM, V108, P439, DOI 10.1111/j.1432-1033.1980.tb04740.x; MINET M, 1971, THESIS U LIBRE BRUXE; MURAKAMI H, 1990, NATURE, V347, P488, DOI 10.1038/347488a0; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; RAMOS F, 1979, EUR J BIOCHEM, V94, P409, DOI 10.1111/j.1432-1033.1979.tb12908.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; WIAME JM, 1971, RECENT ADV MICROBIOL, P243; Wiemann S, 1996, YEAST, V12, P281; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; ZARA V, 1991, EUR J BIOCHEM, V198, P405, DOI 10.1111/j.1432-1033.1991.tb16029.x	32	50	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					25011	25018		10.1074/jbc.271.40.25011	http://dx.doi.org/10.1074/jbc.271.40.25011			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798783	hybrid			2022-12-27	WOS:A1996VM67400106
J	Desmarais, D; Royal, A				Desmarais, D; Royal, A			The TATA motif is a target for efficient transcriptional activation and nerve growth factor induction of the peripherin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEIN; NEGATIVE REGULATORY ELEMENT; NEURON-SPECIFIC EXPRESSION; RNA POLYMERASE-II; BINDING PROTEIN; CORE PROMOTER; CELL-LINES; PC12 CELLS; DIFFERENTIAL EXPRESSION; MESSENGER-RNAS	Three proximal elements, PERI, PER2, and PER3, have been implicated in the regulation of peripherin gene expression. PER1 contains the TATA motif and was identified as the principal mediator of neuronal specificity. Here, we demonstrate by transfection of constructs mutated in PER1 that the in vitro protein binding activity of PER1 is irrelevant to its function. However, mutations or substitutions in the TATA box decreased promoter activity by up to 80%. We have investigated this unusual preference for a particular TATA sequence in PC12 cells. In these cells, nerve growth factor induces neuronal differentiation, increasing peripherin gene expression 3-4-fold, while dexamethasone elicits chromaffin differentiation and a 3-fold decrease in peripherin mRNA. Experiments with stably transfected PC12 cells revealed that the specific TATA box of the peripherin gene was crucial for nerve growth factor response. However, it did not affect dexamethasone down-regulation. Therefore, nerve growth factor acts through an element essential for neuronal peripherin gene expression. The results predict that proteins interacting in the vicinity of the TATA box, by inference factors associated with the preinitiation complex, are important for peripherin gene regulation and provide new insights into the mechanisms underlying neuronal differentiation.	UNIV MONTREAL, DEPT PATHOL, GRP RECH ONCOGENET, MONTREAL, PQ H3C 3J7, CANADA	Universite de Montreal								ADAMS AD, 1995, J BIOL CHEM, V270, P6975, DOI 10.1074/jbc.270.12.6975; ANDERSON DJ, 1986, CELL, V47, P1079, DOI 10.1016/0092-8674(86)90823-8; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BELECKYADAMS T, 1993, J NEUROSCI, V13, P5056, DOI 10.1523/JNEUROSCI.13-12-05056.1993; BRODY BA, 1989, J NEUROSCI, V9, P2391; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIN LS, 1994, J BIOL CHEM, V269, P18507; DESMARAIS D, 1992, EMBO J, V11, P2971, DOI 10.1002/j.1460-2075.1992.tb05367.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; ESCURAT M, 1990, J NEUROSCI, V10, P764; FEDEROFF HJ, 1988, J BIOL CHEM, V263, P19290; FERRARI N, 1995, GENE, V159, P159, DOI 10.1016/0378-1119(95)00140-2; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; GORHAM JD, 1990, DEV BRAIN RES, V57, P235, DOI 10.1016/0165-3806(90)90049-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HERNANDEZ MC, 1995, J BIOL CHEM, V270, P3224, DOI 10.1074/jbc.270.7.3224; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HUANG DH, 1988, J BIOL CHEM, V263, P12596; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; LEDOUARIN NM, 1986, SCIENCE, V231, P1515, DOI 10.1126/science.3952494; LEITMAN DC, 1992, MOL CELL BIOL, V12, P1352, DOI 10.1128/MCB.12.3.1352; LEONARD DGB, 1988, J CELL BIOL, V106, P181, DOI 10.1083/jcb.106.1.181; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MINNA J, 1972, NATURE-NEW BIOL, V235, P225, DOI 10.1038/newbio235225a0; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OBLINGER MM, 1989, J NEUROSCI, V9, P3766; PARYSEK LM, 1987, J NEUROSCI, V7, P781; PARYSEK LM, 1988, J NEUROSCI, V8, P555; Portier Marie-Madeleine, 1993, Comptes Rendus de l'Academie des Sciences Serie III Sciences de la Vie, V316, P1124; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P215, DOI 10.1159/000112348; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHWORAK NW, 1993, J BIOL CHEM, V268, P24460; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SIMON MC, 1990, P NATL ACAD SCI USA, V87, P513, DOI 10.1073/pnas.87.2.513; STARR DB, 1995, J MOL BIOL, V250, P434; STEIN R, 1988, DEV BIOL, V127, P316, DOI 10.1016/0012-1606(88)90318-1; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THEILL LE, 1987, MOL CELL BIOL, V7, P4329, DOI 10.1128/MCB.7.12.4329; THOMPSON MA, 1992, MOL CELL BIOL, V12, P2501, DOI 10.1128/MCB.12.6.2501; TIMMERS HTM, 1992, P NATL ACAD SCI USA, V89, P8140, DOI 10.1073/pnas.89.17.8140; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; TROY CM, 1990, NEUROSCIENCE, V36, P217, DOI 10.1016/0306-4522(90)90364-A; VANDEKLUNDERT FAJM, 1993, EUR J BIOCHEM, V214, P351; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WILKINSON M, 1991, NUCLEIC ACIDS RES, V19, P679, DOI 10.1093/nar/19.3.679; WONG J, 1990, J NEUROSCI RES, V27, P332, DOI 10.1002/jnr.490270312; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	63	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24976	24981		10.1074/jbc.271.40.24976	http://dx.doi.org/10.1074/jbc.271.40.24976			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798778	hybrid			2022-12-27	WOS:A1996VM67400101
J	Webb, DJ; Wen, J; Lysiak, JJ; Umans, L; VanLeuvenn, F; Gonias, SL				Webb, DJ; Wen, J; Lysiak, JJ; Umans, L; VanLeuvenn, F; Gonias, SL			Murine alpha-macroglobulins demonstrate divergent activities as neutralizers of transforming growth factor-beta and as inducers of nitric oxide synthesis - A possible mechanism for the endotoxin insensitivity of the alpha(2)-macroglobulin gene knock-out mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APPARENT EQUILIBRIUM CONDITIONS; MACROPHAGE CELL-LINE; CARCINOMA FET CELLS; HUMAN ALPHA-2-MACROGLOBULIN; SEPTIC SHOCK; DIFFERENTIAL INDUCTION; INTERFERON-GAMMA; SYNTHASE; BINDING; EXPRESSION	alpha(2)-Macroglobulin null mice demonstrate increased resistance to endotoxin challenge (Umans, L., Serneels, L., Overbergh, L., Van Leuven, F., and Van den Berghe, H. (1995) J. Biol. Chem. 270, 19778-19785). We hypothesized that this phenotype might reflect the function of murine alpha(2)M (m alpha(2)M) as a neutralizer of transforming growth factor-beta (TGF-beta) and inducer of nitric oxide synthesis in vivo. When incubated with wild-type mouse plasma, TGF-beta 1 and TGF-beta 2 bound only to m alpha(2)M. Alternative TGF-beta-binding proteins were not detected in plasma from alpha(2)M(-/-) mice. Wild-type mouse plasma, but not plasma from alpha(2)M(-/-) mice, inhibited TGF-beta 1 binding to TGF-beta receptors on fibroblasts. Purified alpha(2)M bound TGF-beta 1 and TGF-beta 2 with similar affinity; the K-D values were 28 +/- 4 and 33 +/- 4 nm, respectively. Murinoglobulin, the second murine cu-macroglobulin, bound both TGF-beta isoforms with 30-fold lower affinity, M alpha(2)M counteracted the activities of TGF-beta 1 and TGF-beta 2 in an endothelial cell growth assay. M alpha(2)M also induced NO synthesis when incubated with RAW 264.7 cells, an activity which probably results from the neutralization of autocrine TGF-beta activity. Human alpha(2)M induced NO synthesis comparably to m alpha(2)M; however, MUG had no effect. These studies demonstrate that the ability to neutralize TGF-beta is a property of m alpha(2)M, which is not redundant in the murine alpha-macroglobulin family or in murine plasma, M alpha(2)M is the only murine alpha-macroglobulin that promotes NO synthesis. The absence of m alpha(2)M, in alpha(2)M(-/-) mice, may allow TGF-beta to more efficiently suppress excessive iNOS expression following endotoxin challenge.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908; KATHOLIEKE UNIV LEUVEN,DEPT HUMAN GENET,EXPT GENET GRP,B-3000 LOUVAIN,BELGIUM	University of Virginia; University of Virginia; KU Leuven					NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE K, 1989, J BIOCHEM-TOKYO, V106, P564; ANONICK PK, 1989, BIOCHEM J, V264, P745, DOI 10.1042/bj2640745; ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BERMUDEZ LE, 1993, J IMMUNOL, V150, P1838; BURMESTER JK, 1993, P NATL ACAD SCI USA, V90, P8628, DOI 10.1073/pnas.90.18.8628; BURRELL R, 1994, CIRC SHOCK, V43, P137; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; CROOKSTON KP, 1994, BIOCHEM BIOPH RES CO, V200, P1578, DOI 10.1006/bbrc.1994.1631; CROOKSTON KP, 1994, J BIOL CHEM, V269, P1533; CUNHA FQ, 1994, IMMUNOLOGY, V81, P211; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DENHOLM EM, 1993, AM J PHYSIOL, V264, pL36, DOI 10.1152/ajplung.1993.264.1.L36; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; GIRI SN, 1993, THORAX, V48, P6959; GONIAS SL, 1983, BIOCHEM J, V209, P99, DOI 10.1042/bj2090099; GONIAS SL, 1994, ANN NY ACAD SCI, V737, P273, DOI 10.1111/j.1749-6632.1994.tb44318.x; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HAAKFRENDSCHO M, 1990, CLIN EXP IMMUNOL, V82, P404; HUANG SS, 1988, J BIOL CHEM, V263, P1535; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAMARRE J, 1994, BIOCHEM J, V302, P199, DOI 10.1042/bj3020199; LAMBERT LE, 1989, CELL IMMUNOL, V120, P401, DOI 10.1016/0008-8749(89)90208-6; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LYSIAK JJ, 1995, J BIOL CHEM, V270, P21919, DOI 10.1074/jbc.270.37.21919; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1994, J BIOL CHEM, V269, P13725; OCONNORMCCURT M, 1987, J BIOL CHEM, V262, P1400; OVERBERGH L, 1994, GENOMICS, V22, P530, DOI 10.1006/geno.1994.1426; OVERBERGH L, 1991, J BIOL CHEM, V266, P16903; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; PETROS A, 1994, CARDIOVASC RES, V28, P34, DOI 10.1093/cvr/28.1.34; PIZZO SV, 1984, RECEPTORS, V1, P177; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SAITO A, 1985, J BIOL CHEM, V260, P775; SZABO C, 1993, BRIT J PHARMACOL, V108, P786, DOI 10.1111/j.1476-5381.1993.tb12879.x; UMANS L, 1995, J BIOL CHEM, V270, P19778, DOI 10.1074/jbc.270.34.19778; VANLEUVEN F, 1992, EUR J BIOCHEM, V210, P319; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WANG DH, 1995, J BIOL CHEM, V270, P14154, DOI 10.1074/jbc.270.23.14154; Weaver AM, 1995, J BIOL CHEM, V270, P30741, DOI 10.1074/jbc.270.51.30741; WEBB DJ, 1995, BIOCHEM J, V312, P579, DOI 10.1042/bj3120579; WEBB DJ, 1994, J BIOL CHEM, V269, P30402; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; WOLF BB, 1994, BIOCHEMISTRY-US, V33, P11270, DOI 10.1021/bi00203a024; WOLFE TA, 1995, ANN PHARMACOTHER, V29, P36, DOI 10.1177/106002809502900108; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	58	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24982	24988		10.1074/jbc.271.40.24982	http://dx.doi.org/10.1074/jbc.271.40.24982			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798779	hybrid			2022-12-27	WOS:A1996VM67400102
J	Jang, SI; Steinert, PM; Markova, NG				Jang, SI; Steinert, PM; Markova, NG			Activator protein 1 activity is involved in the regulation of the cell type-specific expression from the proximal promoter of the human profilaggrin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-18; DIFFERENTIATION-SPECIFIC EXPRESSION; KERATINOCYTE-SPECIFIC TRANSCRIPTION; EPIDERMAL DIFFERENTIATION; TRANSGENIC MICE; DNA-BINDING; HUMAN LORICRIN; RETINOIC ACID; AP-1 ELEMENT; AP1 SITES	The human profilaggrin gene is expressed in the granular layer during the late stages of terminal differentiation of the epidermis. In in vitro transcription experiments we show that the abundance of the mRNA and the specificity of the expression are regulated primarily at the level of transcription. We found that the 5'-flanking sequences control the transcription in a keratinocyte-specific mode and that as little as 116 base pairs preceding the mRNA initiation site is sufficient to restrict the transcription to epidermal cells in vitro. This specificity depends critically on the presence of an activator protein 1 (AP1) motif at position -77. Binding of c-jun/c-fos heterodimers to this sequence confers high levels of expression to the reporter constructs in cultured epidermal keratinocytes, while having little effect in HeLa cells. The transactivating properties of c-jun are essential in this process. On the other hand, junB and junD, which are involved in transactivating the transcription of earlier epidermal differentiation markers, control profilaggrin expression through a pathway which does not depend on a direct binding at the AP1 site and is not cell-type specific. These data indicate that AP1 factors are involved in a complex, multipathway regulation of the profilaggrin gene expression.	NIAMS,NATL INST HLTH,SKIN BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)								ANDDERSON B, 1992, SCIENCE, V260, P78; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BASSETSEGUIN N, 1994, ONCOGENE, V9, P765; Bernerd Francoise, 1993, Gene Expression, V3, P187; BLESSING M, 1989, EMBO J, V8, P117, DOI 10.1002/j.1460-2075.1989.tb03355.x; Blumenberg Miroslav, 1993, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIATA P, 1993, EXP CELL RES, V204, P136, DOI 10.1006/excr.1993.1018; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COULOMBE PA, 1989, J CELL BIOL, V109, P2295, DOI 10.1083/jcb.109.5.2295; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; FISCHER C, 1987, J INVEST DERMATOL, V88, P661; FISHER C, 1991, DEVELOPMENT, V111, P253; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HOHL D, 1991, J BIOL CHEM, V266, P6626; HOPPESEYLER F, 1991, J VIROL, V65, P5613, DOI 10.1128/JVI.65.10.5613-5618.1991; HU L, 1994, J BIOL CHEM, V269, P183; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LERSCH R, 1989, MOL CELL BIOL, V9, P3685, DOI 10.1128/MCB.9.9.3685; LIEW FM, 1992, EXP CELL RES, V202, P310, DOI 10.1016/0014-4827(92)90080-R; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; LU B, 1994, J BIOL CHEM, V269, P7443; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MARKOVA NG, 1993, MOL CELL BIOL, V13, P613, DOI 10.1128/MCB.13.1.613; MCKINLEYGRANT L, 1990, P NATL ACAD SCI USA, V86, P4848; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; NAVARRO JM, 1995, J BIOL CHEM, V270, P21362, DOI 10.1074/jbc.270.36.21362; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Ohtsuki Mamitaro, 1993, Gene Expression, V3, P201; OSHIMA R G, 1992, Current Opinion in Cell Biology, V4, P110, DOI 10.1016/0955-0674(92)90067-M; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PARRY DAD, 1995, INTRMEDIATE FILAMENT; PFEUFFER I, 1994, J IMMUNOL, V153, P5572; Polakowska R. R., 1991, PHYSL BIOCH MOL BIOL, P168; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; PRESLAND RB, 1992, J BIOL CHEM, V267, P23772; Resing K.A., 1991, PHYSL BIOCH MOL BIOL, V1, P148; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROOP DR, 1988, CANCER RES, V48, P3245; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEMAT A, 1988, DIFFERENTIATION, V37, P40, DOI 10.1111/j.1432-0436.1988.tb00794.x; SNAPE AM, 1991, DEVELOPMENT, V113, P283; STEINERT PM, 1991, PHYSL BIOCH MOL BIOL, P113; STELLMACH V, 1991, P NATL ACAD SCI USA, V88, P4582, DOI 10.1073/pnas.88.11.4582; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; TAKAHASHI H, 1992, J INVEST DERMATOL, V100, P10; TAMAI K, 1994, J BIOL CHEM, V269, P493; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; THOREY IS, 1992, DEV DYNAM, V195, P100, DOI 10.1002/aja.1001950204; Watt FM, 1989, CURR OPIN CELL BIOL, V1, P1107, DOI 10.1016/S0955-0674(89)80058-4; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WU RL, 1994, J BIOL CHEM, V269, P28450; YAMADA K, 1994, BIOCHEM MOL BIOL INT, V34, P827; YANG-YEN H-F, 1990, New Biologist, V2, P351; YUKAWA K, 1993, GENE, V133, P163; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	71	86	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24105	24114		10.1074/jbc.271.39.24105	http://dx.doi.org/10.1074/jbc.271.39.24105			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798649	hybrid			2022-12-27	WOS:A1996VJ44200078
J	McInerney, EM; Katzenellenbogen, BS				McInerney, EM; Katzenellenbogen, BS			Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RECEPTORS; PROMOTER-CONTEXT; DISTINCT CLASSES; BINDING DOMAINS; HORMONE; CELLS; TRANSACTIVATION; IDENTIFICATION; LIGAND; YEAST	The human estrogen receptor (ER) is a ligand-inducible transcription factor that contains two transcriptional activation functions, one located in the NH2-terminal region of the protein (AF-1) and the second in the COOH-terminal region (AF-2). Antiestrogens, such as trans-hydroxytamoxifen (TOT), have partial agonistic activity in certain cell types, and studies have implied that this agonism is AF-1-dependent. We have made progressive NH2-terminal and other segment deletions and ligations in the A/B domain, and studied the transcriptional activity of these mutant ERs in ER-negative MDA-MB-231 human breast cancer and HEC-1 human endometrial cancer cells. Using several estrogens and several partial agonist/antagonist antiestrogens, we find that estrogens and antiestrogens require different regions of AF-1 for transcriptional activation. Deletion of the first 40 amino acids has no effect on receptor activity. Antiestrogen agonism is lost upon deletion to amino acid 87, while estrogen agonism is not lost until deletions progress to amino acid 109. Antiestrogen agonism has been further defined to require amino acids 41-64, as deletion of only these amino acids results in an ER that exhibits 100% activity with E(2), but no longer shows an agonist response to TOT. With A/B-modified receptors in which antiestrogens lose their agonistic activity, the antiestrogens then function as pure estrogen antagonists. Our studies show that in these cellular contexts, hormone-dependent transcription utilizes a range of the amino acid sequence within the A/B domain. Furthermore, the agonist/antagonist balance and activity of antiestrogens such as TOT are determined by specific sequences within the A/B domain and thus may be influenced by differences in levels of specific factors that interact with these regions of the ER.	UNIV ILLINOIS,DEPT MOL & INTEGRAT PHYSIOL,URBANA,IL 61801; UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL CANCER INSTITUTE [R37CA018119, R01CA060514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007238] Funding Source: NIH RePORTER; NCI NIH HHS [2R37CA18119, CA60514] Funding Source: Medline; NIGMS NIH HHS [T32GM07238] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN GF, 1992, J BIOL CHEM, V267, P19513; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; CHEN C, 1987, MOL CELL BIOL, V8, P5323; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; KATZENELLENBOGEN BS, 1979, ENDOCRINOLOGY, V105, P33, DOI 10.1210/endo-105-1-33; KATZENELLENBOGEN BS, 1995, J STEROID BIOCHEM, V53, P387, DOI 10.1016/0960-0760(95)00084-D; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; MONTANO MM, 1995, MOL ENDOCRINOL, V9, P814, DOI 10.1210/me.9.7.814; PHAM TA, 1992, MOL ENDOCRINOL, V6, P1043, DOI 10.1210/me.6.7.1043; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; VONANGERER E, 1995, ANN NY ACAD SCI, V761, P176; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WHITE R, 1987, MOL ENDOCRINOL, V1, P735, DOI 10.1210/mend-1-10-735; WRENN CK, 1990, MOL ENDOCRINOL, V4, P1647, DOI 10.1210/mend-4-11-1647	33	171	176	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24172	24178		10.1074/jbc.271.39.24172	http://dx.doi.org/10.1074/jbc.271.39.24172			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798658	hybrid			2022-12-27	WOS:A1996VJ44200087
J	Reverey, H; Veit, M; Ponimaskin, E; Schmidt, MFG				Reverey, H; Veit, M; Ponimaskin, E; Schmidt, MFG			Differential fatty acid selection during biosynthetic S-acylation of a transmembrane protein (HEF) and other proteins in insect cells (Sf9) and in mammalian cells (CV1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-C-VIRUS; COA-BINDING PROTEIN; BACULOVIRUS VECTOR; GLYCOPROTEIN; FUSION; EXPRESSION; OLIGOSACCHARIDES; HEMAGGLUTININ; GENE; DNA	The transmembrane glycoprotein HEF and its acylation deficient mutant M1 were expressed in Sf9 insect cells infected with recombinant baculovirus and in CV1 mammalian cells using the vaccinia T7 system, In insect cells (Sf9), both wild type HEF and HEF(M1) are synthesized in their precursor form HEF(0), which appears as a double band in SDS gels, Digestion with glycopeptidase F and endoglycosidase H reveals that the larger 84-kDa form is modified by the attachment of unprocessed carbohydrates of the high mannose type whereas the smaller 76-kDa form is non-glycosylated. As revealed by in vitro labeling experiments with palmitic acid another modification of HEF is the attachment of a long chain fatty acid to cysteine residue Cys-652 which is located at the internal border of the cytoplasmic membrane, After labeling with [H-3]palmitic acid in both systems only HEF(WT) is acylated, whereas HEF(M1) is not, High performance liquid chromatography analysis of the fatty acids bound to HEF(WT) expressed in Sf9 insect cells reveals nearly 80% of palmitic acid. In contrast to this finding, the acylation pattern of HEF expressed in CV1 cells shows nearly the same amounts of stearic and palmitic acid (40%), Since the interconversion of the input [H-3]palmitic acid to stearic acid is even lower in CV1 cells than in insect cells, it follows that only HEF expressed in mammalian, but not in insect cells selects for stearic acid during its biosynthetic acylation, We extended our study to acylation of endogenous proteins in Sf9 cells. In finding only palmitate linked to protein we present evidence that, in contrast to mammalian cells, insect cells (Sf9) cannot transfer stearic acid to polypeptide, This finding favors the hypothesis of enzymatic acylation over non-enzymatic mechanisms of acyl transfer to protein.	FREE UNIV BERLIN, INST IMMUNOL & MOL BIOL, FACHBEREICH VET MED, D-10117 BERLIN, GERMANY	Free University of Berlin			Veit, Michael/G-6492-2010	Veit, Michael/0000-0002-7638-1829; Ponimaskin, evgeni/0000-0002-4570-5130				BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6167, DOI 10.1021/bi00239a013; FORMANOWSKI F, 1988, VIRUS RES, V10, P177, DOI 10.1016/0168-1702(88)90014-7; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HERRLER G, 1988, J GEN VIROL, V69, P839, DOI 10.1099/0022-1317-69-4-839; HERRLER G, 1979, VIROLOGY, V99, P49, DOI 10.1016/0042-6822(79)90035-7; HEWAT EA, 1984, J MOL BIOL, V175, P175, DOI 10.1016/0022-2836(84)90473-X; KITAME F, 1982, ARCH VIROL, V73, P357, DOI 10.1007/BF01318090; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCILHINNEY RAJ, 1987, BIOCHEM J, V244, P109, DOI 10.1042/bj2440109; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NAGELE A, 1983, THESIS TU MUNICH; NAKADA S, 1984, J VIROL, V50, P118, DOI 10.1128/JVI.50.1.118-124.1984; OHUCHI M, 1982, J VIROL, V42, P1076, DOI 10.1128/JVI.42.3.1076-1079.1982; PFEIFER JB, 1984, VIRUS RES, V1, P281, DOI 10.1016/0168-1702(84)90017-0; PONIMASKIN E, 1994, J GEN VIROL, V75, P1163, DOI 10.1099/0022-1317-75-5-1163; Possee RD., 1992, BACULOVIRUS EXPRESSI; QUESNEL S, 1994, BIOCHEMISTRY-US, V33, P13340, DOI 10.1021/bi00249a021; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; ROSENDAL J, 1993, BIOCHEM J, V290, P321, DOI 10.1042/bj2900321; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SZEPANSKI S, 1994, J GEN VIROL, V75, P1023, DOI 10.1099/0022-1317-75-5-1023; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TOWLER D, 1986, BIOCHEMISTRY-US, V25, P878, DOI 10.1021/bi00352a021; VEIT M, 1990, VIROLOGY, V177, P807, DOI 10.1016/0042-6822(90)90554-5; Veit M, 1996, BIOCHEM J, V318, P163, DOI 10.1042/bj3180163	27	23	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23607	23610		10.1074/jbc.271.39.23607	http://dx.doi.org/10.1074/jbc.271.39.23607			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798573	hybrid			2022-12-27	WOS:A1996VJ44200002
J	Richardson, RT; ORand, MG				Richardson, RT; ORand, MG			Site-directed mutagenesis of rabbit proacrosin - Identification of residues involved in zona pellucida binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOAR SPERM PROACROSIN; ACROSOME REACTION; GLYCOPROTEINS; PROTEINS; POLYSACCHARIDES; LOCALIZATION; ACTIVATION; POLYMERS; PORCINE; MATRIX	The mammalian acrosomal sperm protease proacrosin plays a role in fertilization by proteolysis of the oocyte's outer investments, In addition to its serine protease activity, acrosin from several species is known to have binding activity for the zona pellucida, and this action may serve to anchor sperm during zona penetration. In this study, proacrosin was purified from acid extracts of rabbit sperm and shown to bind to homologous zona pellucida using an in vitro assay. Measurement of this binding activity indicated a high affinity saturable interaction with a K-D = 1.4 x 10(-8) M. Using cDNAs obtained from previously cloned and sequenced rabbit proacrosin and a splice variant that encodes a shorter form of acrosin (Richardson, R. T., and O'Rand, M. G. (1994) Biochim. Biophys. Acta 1219, 215-218), constructs of various sizes were produced using polymerase chain reaction and expressed as recombinant proteins. In the same in vitro zona binding assay, a construct representing residues 1-279 of rabbit proacrosin was found to bind to zona with a high affinity similar to that of native proacrosin, K-D = 2.1 x 10(-8) M. By making smaller recombinant fragments and assaying them for zona binding activity, the location of the binding site was mapped to residues 47-94. Protein modeling of rabbit proacrosin using chymotrypsinogen A as a three-dimensional model indicated that an exposed loop Asp(35) to His(40) in chymotrypsinogen A is extended with an additional five amino acid residues in rabbit proacrosin from Ile(43) to His(53) containing arginine residues Arg(47), Arg(50) and Arg(51). Site-directed mutagenesis of arginine residues Arg(50) and Arg(51) to alanine produced a recombinant without significant zona binding activity. These results are consistent with the hypothesis that rabbit proacrosin contains a specific zona pellucida binding site and that the loop containing arginine residues 50 and 51 is critical for zona binding activity.			Richardson, RT (corresponding author), UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CB 7090,CHAPEL HILL,NC 27599, USA.				NICHD NIH HHS [P30HD18968, HD 14232] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD018968, R01HD014232] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BABA T, 1989, J BIOL CHEM, V264, P11920; DUNBAR BS, 1980, BIOCHEMISTRY-US, V19, P356, DOI 10.1021/bi00543a017; DUNBAR BS, 1981, BIOL REPROD, V24, P1111; EBERSPAECHER U, 1991, MOL REPROD DEV, V30, P164, DOI 10.1002/mrd.1080300214; HARDY DM, 1994, J BIOL CHEM, V269, P19000; HEDRICK JL, 1989, BIOCATALYSIS AGR BIO, P215; JANSEN S, 1993, BIOCHEM SOC T, V21, P470; JONES R, 1991, DEVELOPMENT, V111, P1155; KLEMM U, 1991, HUM GENET, V87, P635; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGGIO LL, 1994, J REPROD FERTIL, V100, P177, DOI 10.1530/jrf.0.1000177; MUKERJI SK, 1979, J BIOL CHEM, V254, P1721; ORAND MG, 1988, DEV BIOL, V129, P231, DOI 10.1016/0012-1606(88)90177-7; ORAND MG, 1986, MOL CELLULAR ASPECTS, P131; PEITSCH MC, 1993, INT IMMUNOL, V5, P233, DOI 10.1093/intimm/5.2.233; RICHARDSON DC, 1992, PROTEIN SCI, V1, P3; RICHARDSON RT, 1991, BIOL REPROD, V45, P20, DOI 10.1095/biolreprod45.1.20; RICHARDSON RT, 1994, BBA-GENE STRUCT EXPR, V1219, P215, DOI 10.1016/0167-4781(94)90275-5; RICHARDSON RT, 1994, DEV BIOL, V165, P688, DOI 10.1006/dbio.1994.1285; Schleuning W D, 1976, Methods Enzymol, V45, P330; TOPFERPETERSEN E, 1987, FEBS LETT, V226, P38, DOI 10.1016/0014-5793(87)80546-X; TOPFERPETERSEN E, 1990, FEBS LETT, V265, P51, DOI 10.1016/0014-5793(90)80881-I; TOPFERPETERSEN E, 1990, INT J ANDROL, V13, P190, DOI 10.1111/j.1365-2605.1990.tb00976.x; URCH UA, 1991, DEVELOPMENT, V111, P1165; WILLIAMS RM, 1993, J EXP ZOOL, V266, P65, DOI 10.1002/jez.1402660110; Zaneveld L. J. D., 1991, A comparative overview of mammalian fertilization., P63	26	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24069	24074		10.1074/jbc.271.39.24069	http://dx.doi.org/10.1074/jbc.271.39.24069			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798644				2022-12-27	WOS:A1996VJ44200073
J	Sorgenfrei, O; Duin, EC; Klein, A; Albracht, SPJ				Sorgenfrei, O; Duin, EC; Klein, A; Albracht, SPJ			Interactions of Se-77 and (CO)-C-13 with nickel in the active site of active F-420-nonreducing hydrogenase from Methanococcus voltae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-GIGAS HYDROGENASE; ELECTRON-PARAMAGNETIC-RES; IRON-SULFUR CENTERS; CHROMATIUM-VINOSUM; VULGARIS HILDENBOROUGH; METHANOBACTERIUM-THERMOAUTOTROPHICUM; REDOX PROPERTIES; EPR; ACTIVATION; IDENTIFICATION	The selenium-containing F-420-nonreducing hydrogenase from Methanococcus voltae was prepared in the Ni-a(I). CO state. The effect of illumination on this light-sensitive species was studied. EPR studies were carried out with enzyme containing natural selenium or with enzyme enriched in Se-77. Samples were prepared with either CO or (CO)-C-13. In the Ni-a(I). CO state, the nuclear spins of both Se-77 (I = 1/2) and C-13 (I = 1/2) interacted with the nickel based unpaired electron, suggesting that they are positioned on opposite sites of the nickel ion, In the light-induced signal, the interaction with (CO)-C-13 was lost. The Se-77 nuclear spin introduced an anisotropic hyperfine splitting in both the dark and light-induced EPR signals, The data on the active enzyme of M. voltae are difficult to reconcile with the crystal structure of the inactive hydrogenase of Desulfovibrio gigas (Volbeda, A., Charon, M. H., Piras, C, Hatchikian, E. C., Frey, M., and Fontecilla Camps, J. C. (1995) Nature 373, 580-587) and suggest a structural change in the active site upon activation of the enzyme.	BIOCENTRUM AMSTERDAM,EC SLATER INST,NL-1018 TV AMSTERDAM,NETHERLANDS	University of Amsterdam	Sorgenfrei, O (corresponding author), UNIV MARBURG,DEPT BIOL,KARL VON FRISCH STR,D-35032 MARBURG,GERMANY.							ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5; ALBRACHT SPJ, 1983, BIOCHIM BIOPHYS ACTA, V724, P309, DOI 10.1016/0005-2728(83)90089-0; ALBRACHT SPJ, 1994, BBA-BIOENERGETICS, V1188, P167, DOI 10.1016/0005-2728(94)90036-1; ALBRACHT SPJ, 1982, FEBS LETT, V140, P311, DOI 10.1016/0014-5793(82)80921-6; BEINERT H, 1982, BIOCHIM BIOPHYS ACTA, V683, P245, DOI 10.1016/0304-4173(82)90003-9; CAMMACK R, 1987, BIOCHIM BIOPHYS ACTA, V912, P98, DOI 10.1016/0167-4838(87)90252-4; COREMANS JMC, 1991, THESIS U AMSTERDAM N; COREMANS JMCC, 1992, BIOCHIM BIOPHYS ACTA, V1119, P148, DOI 10.1016/0167-4838(92)90385-Q; FAN CL, 1991, J AM CHEM SOC, V113, P20, DOI 10.1021/ja00001a003; FERNANDEZ VM, 1985, BIOCHIM BIOPHYS ACTA, V832, P69, DOI 10.1016/0167-4838(85)90175-X; FERNANDEZ VM, 1986, BIOCHIM BIOPHYS ACTA, V883, P145, DOI 10.1016/0304-4165(86)90145-5; FRIEDRICH B, 1981, J BACTERIOL, V145, P1144, DOI 10.1128/JB.145.3.1144-1149.1981; GRAF EG, 1981, FEBS LETT, V136, P165, DOI 10.1016/0014-5793(81)81238-0; HAGEN WR, 1986, FEBS LETT, V201, P158, DOI 10.1016/0014-5793(86)80590-7; HAGEN WR, 1986, FEBS LETT, V203, P59, DOI 10.1016/0014-5793(86)81436-3; HALBOTH S, 1992, MOL GEN GENET, V233, P217, DOI 10.1007/BF00587582; HE SH, 1989, J BIOL CHEM, V264, P2678; KOJIMA N, 1983, P NATL ACAD SCI-BIOL, V80, P378, DOI 10.1073/pnas.80.2.378; KRASNA AI, 1954, J AM CHEM SOC, V76, P3015, DOI 10.1021/ja01640a045; MARGANIAN CA, 1995, J AM CHEM SOC, V117, P1584, DOI 10.1021/ja00110a013; MARGANIANGOLDMA.C, 1995, COMMENTS INORG CHEM, V18, P1; MEDINA M, 1994, J CHEM SOC FARADAY T, V90, P2921, DOI 10.1039/ft9949002921; MEYER J, 1991, BIOCHEMISTRY-US, V30, P9697, DOI 10.1021/bi00104a018; MOURA JJG, 1982, BIOCHEM BIOPH RES CO, V108, P1388, DOI 10.1016/S0006-291X(82)80060-0; NEESE F, 1995, 136 QCMP; PIERIK AJ, 1992, EUR J BIOCHEM, V206, P697, DOI 10.1111/j.1432-1033.1992.tb16976.x; RITTENBERG D, 1955, DISCUSS FARADAY SOC, V20, P185; SORGENFREI O, 1993, FEBS LETT, V332, P291, DOI 10.1016/0014-5793(93)80652-B; SORGENFREI O, 1993, EUR J BIOCHEM, V213, P1355, DOI 10.1111/j.1432-1033.1993.tb17888.x; SURERUS KK, 1994, BIOCHEMISTRY-US, V33, P4980, DOI 10.1021/bi00182a029; TEIXEIRA M, 1983, EUR J BIOCHEM, V130, P481, DOI 10.1111/j.1432-1033.1983.tb07175.x; TEIXEIRA M, 1985, J BIOL CHEM, V260, P8942; VANDERZWAAN JW, 1985, FEBS LETT, V179, P271, DOI 10.1016/0014-5793(85)80533-0; VANDERZWAAN JW, 1990, BIOCHIM BIOPHYS ACTA, V1041, P101, DOI 10.1016/0167-4838(90)90051-G; VANDERZWAAN JW, 1986, BIOCHIM BIOPHYS ACTA, V872, P208, DOI 10.1016/0167-4838(86)90273-6; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; VOORDOUW G, 1992, ADV INORG CHEM, V38, P397, DOI 10.1016/S0898-8838(08)60069-0; VOORDOUW G, 1985, EUR J BIOCHEM, V148, P515, DOI 10.1111/j.1432-1033.1985.tb08869.x; Wertz J. E., 1972, ELECTRON SPIN RESONA; WHITEHEAD JP, 1993, J AM CHEM SOC, V115, P5629, DOI 10.1021/ja00066a032; WHITMAN WB, 1982, J BACTERIOL, V149, P852, DOI 10.1128/JB.149.3.852-863.1982; YAMAZAKI S, 1982, J BIOL CHEM, V257, P7926	42	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23799	23806		10.1074/jbc.271.39.23799	http://dx.doi.org/10.1074/jbc.271.39.23799			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798608	Green Published, hybrid			2022-12-27	WOS:A1996VJ44200037
J	Ayala, A; Parrado, J; Bougria, M; Machado, A				Ayala, A; Parrado, J; Bougria, M; Machado, A			Effect of oxidative stress, produced by cumene hydroperoxide, on the various steps of protein synthesis - Modifications of elongation factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE AMINO-ACIDS; FACTOR-II; LIPID-PEROXIDATION; RAT-LIVER; GLUTAMINE-SYNTHETASE; ADP-RIBOSYLATION; OXYGEN RADICALS; HYDROLYSIS PRODUCTS; HISTIDINE RESIDUE; DIPHTHERIA-TOXIN	We have studied the effect of oxidative stress on protein synthesis in rat liver. Cumene hydroperoxide (CH) was used as an oxidant agent, The approach used was to determine the ribosomal state of aggregation and the time for assembly and release of polypeptide chains in the process of protein synthesis in rat liver in vivo. The results suggest that the elongation step is the most sensitive to CH treatment. The measurement of both carbonyl groups content and ADP-ribosylatable elongation factor 2 (EF-2), the main protein involved in the elongation step, indicates that under CH treatment EF-2 is oxidatively modified and a lower amount of active EF-2 is present. These results are corroborated by in vitro oxidation of EF-2 and could explain for the decline in the elongation step.	UNIV SEVILLA,FAC FARM,DEPT BIOQUIM BROMATOL & TOXICOL,E-41012 SEVILLE,SPAIN	University of Sevilla			Parrado, Juan/E-6637-2010; IBIS, ENVEJECIMIENTO/O-9381-2015; Ayala, Antonio/N-7591-2019	Parrado, Juan/0000-0002-1462-408X; Ayala, Antonio/0000-0001-9711-3711				AIRHART J, 1974, BIOCHEMISTRY-US, V140, P539, DOI 10.1042/bj1400539; AYUSOPARRILLA M, 1973, J BIOL CHEM, V248, P4394; CHEN JYC, 1988, J BIOL CHEM, V263, P11692; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; FENDRICK JL, 1989, P NATL ACAD SCI USA, V86, P554, DOI 10.1073/pnas.86.2.554; FERN EB, 1974, BIOCHEM J, V142, P413, DOI 10.1042/bj1420413; GIULIVI C, 1994, METHOD ENZYMOL, V233, P363; GORDILLO E, 1988, J BIOL CHEM, V263, P8053; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HALLIWELL B, 1986, FREE RADICAL BIO MED, P139; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HENSHAW EC, 1971, J BIOL CHEM, V246, P436; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; IGLEWSKI WJ, 1991, FEBS LETT, V283, P235, DOI 10.1016/0014-5793(91)80596-U; IGLEWSKI WJ, 1994, MOL CELL BIOCHEM, V138, P131, DOI 10.1007/BF00928454; IGLEWSKI WJ, 1984, FEBS LETT, V173, P113, DOI 10.1016/0014-5793(84)81028-5; JANERO DR, 1993, AM J PHYSIOL, V264, pC1401, DOI 10.1152/ajpcell.1993.264.6.C1401; KODAMAN PH, 1994, ENDOCRINOLOGY, V135, P27; KRAMER K, 1986, FEBS LETT, V198, P80, DOI 10.1016/0014-5793(86)81188-7; LAJTHA A, 1981, LIFE SCI, V29, P755, DOI 10.1016/0024-3205(81)90030-8; LEE H, 1984, P NATL ACAD SCI USA, V81, P2704; LENZ AG, 1989, ANAL BIOCHEM, V177, P419, DOI 10.1016/0003-2697(89)90077-8; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1983, J BIOL CHEM, V258, P1828; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; MARZOUKI A, 1989, FEBS LETT, V255, P72, DOI 10.1016/0014-5793(89)81063-4; MORTIMOR.GE, 1970, J BIOL CHEM, V245, P2375; MORTIMORE GE, 1972, J BIOL CHEM, V247, P2776; NILSSON A, 1995, BBA-GENE STRUCT EXPR, V1260, P200, DOI 10.1016/0167-4781(94)00198-C; NYGARD O, 1990, EUR J BIOCHEM, V191, P1, DOI 10.1111/j.1432-1033.1990.tb19087.x; OMURA F, 1989, EUR J BIOCHEM, V180, P1, DOI 10.1111/j.1432-1033.1989.tb14607.x; PACIFICI RE, 1990, METHOD ENZYMOL, V186, P485; PERENTESIS JP, 1992, BIOFACTORS, V3, P173; POOT M, 1988, MECH AGEING DEV, V43, P1, DOI 10.1016/0047-6374(88)90093-0; POOT M, 1988, J CELL PHYSIOL, V137, P421, DOI 10.1002/jcp.1041370305; RATTAN SIS, 1991, MUTAT RES, V256, P115, DOI 10.1016/0921-8734(91)90005-V; Richardson A, 1983, REV BIOL RES AGING, V1, P255; RIIS B, 1989, BIOCHEM BIOPH RES CO, V159, P1141, DOI 10.1016/0006-291X(89)92228-6; RIIS B, 1989, J BIOCHEM BIOPH METH, V19, P319, DOI 10.1016/0165-022X(89)90063-8; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; SAHAKIAN JA, 1995, ARCH BIOCHEM BIOPHYS, V318, P411, DOI 10.1006/abbi.1995.1248; SCORNIK OA, 1974, J BIOL CHEM, V249, P3876; SHIMURA J, 1985, BIOCHIM BIOPHYS ACTA, V845, P43, DOI 10.1016/0167-4889(85)90052-7; SIES H, 1975, EUR J BIOCHEM, V57, P503, DOI 10.1111/j.1432-1033.1975.tb02325.x; STADTMAN ER, 1986, TRENDS BIOCHEM SCI, V11, P11, DOI 10.1016/0968-0004(86)90221-5; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; TAFFE BG, 1987, J BIOL CHEM, V262, P12143; VANNESS BG, 1980, J BIOL CHEM, V255, P710; VANNESS BG, 1980, J BIOL CHEM, V255, P717; WEISS RH, 1986, ARCH BIOCHEM BIOPHYS, V251, P336, DOI 10.1016/0003-9861(86)90081-0; WENDEL A, 1981, BIOCHEM PHARMACOL, V30, P2513, DOI 10.1016/0006-2952(81)90576-1	56	84	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23105	23110		10.1074/jbc.271.38.23105	http://dx.doi.org/10.1074/jbc.271.38.23105			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798501	hybrid			2022-12-27	WOS:A1996VH76800027
J	Hartman, JL; Northup, JK				Hartman, JL; Northup, JK			Functional reconstitution in situ of 5-hydroxytryptamine(2c) (5HT(2c)) receptors with alpha(q) and inverse agonism of 5HT(2c) receptor antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; PHOSPHOLIPASE-C ISOZYMES; BETA-GAMMA-SUBUNITS; GTP-BINDING PROTEIN; SF9 CELLS; SIGNAL-TRANSDUCTION; GUANINE-NUCLEOTIDES; INTRINSIC ACTIVITY; ADENYLATE-CYCLASE; CHOROID-PLEXUS	Membranes prepared after infection of Sf9 cells with recombinant baculovirus containing the rat 5HT(2c) receptor DNA, but not after infection with wild-type virus, expressed high affinity binding sites for I-125-lysergic acid diethylamide and [H-3]mesulergine. The receptor site density reached an optimum of 50-70 pmol/mg membrane protein at 60 h postinfection. Extraction of peripheral membrane proteins from the postnuclear membrane fraction with 6 M urea depleted GTP gamma S-binding 4-fold without decreasing 5HT(2c) receptor binding activity. Urea-extracted Sf9 membranes expressing the 5HT(2c) receptor catalyzed the activation of squid retinal alpha(q) but not bovine retinal alpha(t) or bovine alpha(o) alpha(i). Productive interaction of 5HT(2c), receptors with squid alpha(q) was enhanced by the addition of beta gamma dimers prepared from either bovine brain or bovine rod outer segment discs. While the addition of serotonin increased 5HT(2c) receptor-catalyzed GTP gamma S binding to alpha(q), the unoccupied receptor was also catalytically active. The 5HT(2c) receptor antagonists, mesulergine, mianserin, and ketanserin competitively inhibited 5HT activation of the receptor with predicted rank-order affinities; and mianserin and ketanserin markedly inhibited basal 5HT(2c) receptor activity. Interestingly, this ''inverse agonist'' efficacy did not correlate with antagonist affinity for the 5HT(2c) receptor. Baculoviral expression of the 5HT(2c) receptor and urea extraction of postnuclear Sf9 cell membranes have provided a high density of in situ, uncoupled, G-protein-linked receptor useful for reconstitution with purified G-protein subunits. This has allowed for independent manipulation of receptor and G protein chemical concentrations and has revealed that a G-protein-linked receptor can possess a significant basal catalytic activity and that antagonist compounds can act as inverse agonists of this basal activity at the level of receptor activation of G-proteins.			Hartman, JL (corresponding author), NIMH, CELL BIOL LAB, BLDG 36, BETHESDA, MD 20892 USA.			Hartman, John/0000-0003-1176-6469				BARKER EL, 1994, J BIOL CHEM, V269, P11687; BERTIN B, 1992, J BIOL CHEM, V267, P8200; CERIONE RA, 1991, METHOD ENZYMOL, V195, P329; CERIONE RA, 1991, BIOCHIM BIOPHYS ACTA, V1071, P473, DOI 10.1016/0304-4157(91)90007-J; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; CONN PJ, 1986, P NATL ACAD SCI USA, V83, P4086, DOI 10.1073/pnas.83.11.4086; CONN PJ, 1986, J NEUROCHEM, V47, P1754, DOI 10.1111/j.1471-4159.1986.tb13085.x; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HARGRAVE PA, 1993, BIOESSAYS, V15, P43, DOI 10.1002/bies.950150107; Hargrave PA, 1991, CURR OPIN STRUC BIOL, V1, P575, DOI 10.1016/S0959-440X(05)80080-6; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HILF G, 1992, EUR J PHARM-MOLEC PH, V225, P245, DOI 10.1016/0922-4106(92)90026-R; HOYER D, 1988, TRENDS PHARMACOL SCI, V9, P89, DOI 10.1016/0165-6147(88)90174-5; HUMPHREY PPA, 1993, TRENDS PHARMACOL SCI, V14, P233, DOI 10.1016/0165-6147(93)90016-D; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JASPER JR, 1992, BIOCHEM PHARMACOL, V43, P119, DOI 10.1016/0006-2952(92)90268-N; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KENAKIN T, 1987, TRENDS PHARMACOL SCI, V8, P423, DOI 10.1016/0165-6147(87)90229-X; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PARK DG, 1993, J BIOL CHEM, V268, P4573; PARKER EM, 1991, J BIOL CHEM, V266, P519; PEDERSEN SE, 1982, P NATL ACAD SCI-BIOL, V79, P7228, DOI 10.1073/pnas.79.23.7228; PEROUTKA SJ, 1988, ANNU REV NEUROSCI, V11, P45, DOI 10.1146/annurev.ne.11.030188.000401; POTTINGER JDD, 1991, BIOCHEM J, V279, P323, DOI 10.1042/bj2790323; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RYBA NJ, 1993, BIOCHEM J, V292, P333, DOI 10.1042/bj2920333; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SJOERDSMA A, 1990, ANN NY ACAD SCI, V600, P1, DOI 10.1111/j.1749-6632.1990.tb16869.x; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEPHENSON RP, 1956, BRIT J PHARM CHEMOTH, V11, P379, DOI 10.1111/j.1476-5381.1956.tb00006.x; STERNWEIS PC, 1979, J BIOL CHEM, V254, P3333; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; TAYLOR P, 1990, P1; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794	47	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22591	22597		10.1074/jbc.271.37.22591	http://dx.doi.org/10.1074/jbc.271.37.22591			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798428	hybrid			2022-12-27	WOS:A1996VG67200047
J	Leng, XH; Manolson, MF; Liu, Q; Forgac, M				Leng, XH; Manolson, MF; Liu, Q; Forgac, M			Site-directed mutagenesis of the 100-kDa subunit (Vph1p) of the yeast vacuolar (H+)-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; MEMBRANE H+-ATPASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GENE ENCODES; TRANSLOCATING ATPASE; CDNA SEQUENCE; ADENOSINE-TRIPHOSPHATASE; CHROMAFFIN GRANULES; 116-KDA POLYPEPTIDE	Vacuolar (H+) ATPases (V-ATPases) are multisubunit complexes responsible for acidification of intracellular compartments in eukaryotic cells. V-ATPases possess a subunit of approximate molecular mass 100 kDa of unknown function that is composed of an amino-terminal hydrophilic domain and a carboxyl-terminal hydrophobic domain. To test whether the 100-kDa subunit plays a role in proton transport, site-directed mutagenesis of the VPH1 gene, which is one of two genes that encodes this subunit in yeast, has been carried out in a strain lacking both endogenous genes. Ten charged and twelve polar residues located in the seven putative transmembrane helices in the COOH-terminal domain of the molecule were individually changed, and the effects on pro ton transport, ATPase activity, and assembly of the yeast V-ATPase were measured. Two mutations (R735L and Q634L) in transmembrane helix 6 and at the border of transmembrane helix 5, respectively, showed greatly reduced levels of the 100 kDa subunit in the vacuolar membrane, suggesting that these mutations affected stability of the 100-kDa subunit. Two mutations, D425N and K538A, in transmembrane helix 1 and at the border of transmembrane helix 3, respectively, showed reduced assembly of the V-ATPase, with the D425N mutation also reducing the activity of V-ATPase complexes that did assemble. Two mutations, H743A and K593A, in transmembrane helix 6 and at the border of transmembrane helix 4, respectively, have significantly greater effects on activity than on assembly, with proton transport and ATPase activity inhibited 40-60%. One mutation, E789Q, in transmembrane helix 7, virtually completely abolished proton transport and ATPase activity while having no effect on assembly. These results suggest that the 100-kDa subunit may be required for activity as well as assembly of the V-ATPase complex and that several charged residues in the last four putative transmembrane helices of this subunit may play a role in proton transport.	TUFTS UNIV, SCH MED, DEPT CELLULAR & MOL PHYSIOL, BOSTON, MA 02111 USA; HOSP SICK CHILDREN, DIV CELL BIOL, TORONTO, ON M5G 1X8, CANADA	Tufts University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Manolson, Morris/0000-0001-8755-5460	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34928] Funding Source: Medline; NIGMS NIH HHS [R01 GM034478, GM 34478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; [Anonymous], 1991, Methods Enzymol, V194, P1; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1987, J BIOL CHEM, V262, P11006; ARAI H, 1988, J BIOL CHEM, V263, P8796; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1986, J BIOL CHEM, V261, P43; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; FENG Y, 1992, J BIOL CHEM, V267, P5817; FILLINGAME RH, 1992, J BIOENERG BIOMEMBR, V24, P485, DOI 10.1007/BF00762366; FORGAC M, 1992, J BIOENERG BIOMEMBR, V24, P341, DOI 10.1007/BF00762527; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; FOURY F, 1990, J BIOL CHEM, V265, P18554; FUTAI M, 1994, BBA-BIOENERGETICS, V1187, P165, DOI 10.1016/0005-2728(94)90104-X; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KIBAK H, 1992, J BIOENERG BIOMEMBR, V24, P415, DOI 10.1007/BF00762534; KIM EJ, 1994, P NATL ACAD SCI USA, V91, P6128, DOI 10.1073/pnas.91.13.6128; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CK, 1990, MOL IMMUNOL, V27, P1137; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PENG SB, 1994, J BIOL CHEM, V269, P17262; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; SCHNEIDER E, 1987, MICROBIOL REV, V51, P477, DOI 10.1128/MMBR.51.4.477-497.1987; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SUN SZ, 1987, J BIOL CHEM, V262, P14790; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; UMEMOTO N, 1990, J BIOL CHEM, V265, P18447; WANG SY, 1988, J BIOL CHEM, V263, P17638; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZHANG JM, 1994, J BIOL CHEM, V269, P23518; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102; [No title captured]	70	108	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22487	22493		10.1074/jbc.271.37.22487	http://dx.doi.org/10.1074/jbc.271.37.22487			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798414				2022-12-27	WOS:A1996VG67200033
J	Tabas, I; Marathe, S; Keesler, GA; Beatini, N; Shiratori, Y				Tabas, I; Marathe, S; Keesler, GA; Beatini, N; Shiratori, Y			Evidence that the initial up-regulation of phosphatidylcholine biosynthesis in free cholesterol-loaded macrophages is an adaptive response that prevents cholesterol-induced cellular necrosis - Proposed role of an eventual failure of this response in foam cell necrosis in advanced atherosclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; ACYL-COENZYME-A; UNESTERIFIED CHOLESTEROL; ATHEROGENIC LIPOPROTEINS; HUMAN-MONOCYTES; LYSOPHOSPHATIDYLCHOLINE; INHIBITION; ACYLTRANSFERASE; ACCUMULATION	Macrophages in atherosclerotic lesions accumulate free cholesterol (FC) as well as cholesteryl ester and appear to have high rates of phospholipid (PL) synthesis and increased PL mass, Previous short term (i.e. less than or equal to 24 h) studies with cultured macrophages have shown that these cells respond to FC loading by up-regulating phosphatidylcholine biosynthesis, We propose that this response is adaptive by keeping the FC:PL ratio in the macrophages from reaching toxic levels. We further propose that one cause of macrophage necrosis, a prominent and important event in atherosclerosis, is an eventual decrease of this adaptive response, To explore these ideas, cultured macrophages were loaded with FC for up to 4 days and assayed for phosphatidylcholine biosynthesis, FC and PL mass, and cytotoxicity. For the first 24 h, cellular phosphatidylcholine biosynthesis and FC and PL mass increased 3-4-fold, and thus the FC:PL molar ratio was prevented from reaching very high levels; at this point, there were no overt signs of cytotoxicity. Over the next 24-48 h, however, phosphatidylcholine biosynthesis, and then phosphatidylcholine mass, began to decrease. Initially, the macrophages remained healthy and continued to accumulate FC, but eventually these macrophages, but not unloaded macrophages, became necrotic (swollen organelles and disrupted membranes), Lipoprotein dose studies indicated a close relationship between the onset of macrophage necrosis and the FC:PL ratio, To test further the causal nature of these relationships, cellular FC and PL mass were independently manipulated by using high density lipoprotein, (HDL,) to decrease cellular FC and choline depletion to decrease cellular PC. As predicted by our hypotheses, HDL, protected FC-loaded macrophages from necrosis, whereas choline depletion accelerated cytotoxic changes, These findings support the idea that the initial increase in phosphatidylcholine biosynthesis in FC-loaded macrophages is an adaptive response that prevents cholesterol-induced macrophage necrosis, We propose that an eventual failure of the PL response in foam cells may represent one cause of macrophage necrosis in advanced atherosclerotic lesions.	COLUMBIA UNIV, COLL PHYS & SURG, DEPT ANAT & CELL BIOL, NEW YORK, NY 10032 USA	Columbia University	Tabas, I (corresponding author), COLUMBIA UNIV, COLL PHYS & SURG, DEPT MED, 630 W 168TH ST, NEW YORK, NY 10032 USA.		Shiratori, Yoshimune/I-6206-2014		NHLBI NIH HHS [HL-39703, HL-21006, HL-54591] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591, P50HL021006, R01HL039703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ARIASDIAZ J, 1994, J CLIN INVEST, V94, P244, DOI 10.1172/JCI117313; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BRASITUS TA, 1988, J BIOL CHEM, V263, P8592; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUCK RC, 1951, AMA ARCH PATHOL, V51, P224; COFFEY MD, 1995, J CLIN INVEST, V96, P1866, DOI 10.1172/JCI118232; CORNELL R, 1985, J BIOL CHEM, V260, P1290; CRAIN RC, 1980, BIOCHEMISTRY-US, V19, P1433, DOI 10.1021/bi00548a026; DAY AJ, 1969, EXP MOL PATHOL, V11, P263, DOI 10.1016/0014-4800(69)90014-8; FOWLER S, 1980, ACTA MED SCAND, P151; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GERRITY RG, 1981, AM J PATHOL, V103, P181; Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4; GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408; HABERLAND ME, 1973, P NATL ACAD SCI USA, V70, P2313, DOI 10.1073/pnas.70.8.2313; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEINLE H, 1987, EXP MOL PATHOL, V46, P312, DOI 10.1016/0014-4800(87)90052-9; JACKSON RL, 1976, ATHEROSCLER REV, V1, P1; JEROME WG, 1985, AM J PATHOL, V119, P210; KASHFI K, 1991, BIOCHEM BIOPH RES CO, V177, P1121, DOI 10.1016/0006-291X(91)90655-Q; KATZ S S, 1976, Journal of Clinical Investigation, V58, P200; KHOO JC, 1989, BIOCHIM BIOPHYS ACTA, V1012, P215, DOI 10.1016/0167-4889(89)90099-2; KORZENIEWSKI C, 1983, J IMMUNOL METHODS, V64, P313, DOI 10.1016/0022-1759(83)90438-6; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG B, 1985, ATHEROSCLEROSIS, V56, P93, DOI 10.1016/0021-9150(85)90087-5; MAOR I, 1995, ARTERIOSCL THROM VAS, V15, P1378, DOI 10.1161/01.ATV.15.9.1378; NAKANO T, 1994, P NATL ACAD SCI USA, V91, P1069, DOI 10.1073/pnas.91.3.1069; NIEWOEHNER DE, 1989, J APPL PHYSIOL, V66, P261, DOI 10.1152/jappl.1989.66.1.261; OKWU AK, 1994, J LIPID RES, V35, P644; ORTEGA A, 1986, BIOCHEM BIOPH RES CO, V139, P868, DOI 10.1016/S0006-291X(86)80258-3; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; RAPP JH, 1983, J LIPID RES, V24, P1329; RENIER G, 1994, J LIPID RES, V35, P271; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; RUSSELL DW, 1992, CARDIOVASC DRUG THER, V6, P103, DOI 10.1007/BF00054556; SALMON WD, 1962, ARCH PATHOL, V73, P190; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; SHECHTER I, 1981, J LIPID RES, V22, P63; SHIO H, 1979, LAB INVEST, V41, P160; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; SHIRATORI Y, 1995, J BIOL CHEM, V270, P29894; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; SMITH CW, 1972, EXP CELL RES, V73, P394, DOI 10.1016/0014-4827(72)90063-8; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; TABAS I, 1993, J BIOL CHEM, V268, P20419; TANGIRALA RK, 1994, J LIPID RES, V35, P93; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WAHLQVIST ML, 1969, EXP MOL PATHOL, V11, P275, DOI 10.1016/0014-4800(69)90015-X; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; YAO ZM, 1990, J BIOL CHEM, V265, P4326; YEAGLE PL, 1983, BIOCHIM BIOPHYS ACTA, V727, P39, DOI 10.1016/0005-2736(83)90366-8; ZILVERSMIT DB, 1954, CIRCULATION, V9, P581, DOI 10.1161/01.CIR.9.4.581	62	95	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22773	22781		10.1074/jbc.271.37.22773	http://dx.doi.org/10.1074/jbc.271.37.22773			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798453	hybrid			2022-12-27	WOS:A1996VG67200072
J	Holmes, JK; Solomon, MJ				Holmes, JK; Solomon, MJ			A predictive scale for evaluating cyclin-dependent kinase substrates - A comparison of p34(cdc2) and p33(cdk2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY LIGHT-CHAIN; PROTEIN-KINASE; CDC2 KINASE; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; CELL-CYCLE; MYOSIN-II; A-TYPE; PHOSPHORYLATION; P34CDC2	Protein phosphorylation by members of the Cdk (cyclin dependent kinase) family of protein kinases is necessary for progression through the cell cycle. However, the primary sequence determinants of Cdk substrate specificity have get to be examined quantitatively. We have used a panel of glutathione S-transferase peptide fusions to investigate the fine-structure specificity of p33(cdk2) and p34(cdc2). Our data indicate that the generally held consensus sequences for p34(cdc2) represent a significant oversimplification of its true specificity and that this specificity is conserved between species. p33(cdk2) and p34(cdc2) have similar but distinct substrate specificities that are affected modestly by the associated cyclin subunit, We derive specific values of phosphorylation efficiencies by these enzymes that can be used to estimate the phosphorylation potential of proposed Cdk substrates.	YALE UNIV, SCH MED, DEPT MOL BIOPHYS & BIOCHEM, NEW HAVEN, CT 06520 USA	Yale University					NIGMS NIH HHS [GM47830] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047830] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESSEV G, 1991, J CELL BIOL, V112, P523, DOI 10.1083/jcb.112.4.523; ERIKSON E, 1989, J BIOL CHEM, V264, P19577; HARPER JW, 1993, CELL, V75, P805; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KATO J, 1993, GENE DEV, V7, P331; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; MARIN O, 1992, FEBS LETT, V301, P111, DOI 10.1016/0014-5793(92)80221-2; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; Nigg E A, 1991, Semin Cell Biol, V2, P261; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; THOMAS L, 1992, J BIOL CHEM, V267, P6183; YAMAKITA Y, 1994, J CELL BIOL, V124, P129, DOI 10.1083/jcb.124.1.129; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	28	129	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25240	25246		10.1074/jbc.271.41.25240	http://dx.doi.org/10.1074/jbc.271.41.25240			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810285	hybrid			2022-12-27	WOS:A1996VL69300029
J	Lomasney, JW; Cheng, HF; Wang, LP; Kuan, YS; Liu, SM; Fesik, SW; King, K				Lomasney, JW; Cheng, HF; Wang, LP; Kuan, YS; Liu, SM; Fesik, SW; King, K			Phosphatidylinositol 4,5-bisphosphate binding to the pleckstrin homology domain of phospholipase C-delta 1 enhances enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BETA-GAMMA-SUBUNITS; ADRENERGIC-RECEPTOR KINASE; HETEROTRIMERIC G-PROTEINS; ADP-RIBOSYLATION FACTOR; PH DOMAIN; INOSITOL PHOSPHATES; HIGH-AFFINITY; SIGNALING PROTEINS; ACID PHOSPHOLIPIDS	The pleckstrin homology (PH) domain is a newly recognized protein module believed to play an important role in signal transduction. While the tertiary structures of several PH domains have been determined, some co-complexed with ligands, the function of this domain remains elusive. In this report, the PH domain located in the N terminus of human phospholipase C-delta 1 (PLC delta 1) was found to regulate enzyme activity, The hydrolysis of phosphatidylinositol (PI) was stimulated by phosphatidylinositol 4,5-bisphosphate (PIP2) in a dose dependent manner with an EC(50) = 1 mu M (0.3 mol%), up to 9-fold higher when 5 mu M (1.5 mol%) of PIP2 was incorporated into the PI/phosphatidylserine (PS)/phosphatidylcholine (PC) vesicles (30 mu M of PI with a molar ratio of PI:PS:PC = 1:5:5). Stimulation was specific for PIP2, since other anionic phospholipids including phosphatidylinositol 4-phosphate had no stimulatory effect. PIP2-mediated stimulation was, however, inhibited by inositol 1,4,5-triphosphate (IP3) in a dose-dependent manner, suggesting a modulatory role for this inositol, When a nested set of PH domain deletions up to 70 amino acids from the N terminus of PLC delta 1 were constructed, the deletion mutant enzymes all catalyzed the hydrolysis of the micelle forms of PI and PIP2 with specific activities comparable with those of the wild type enzyme. However, the stimulatory effect of PIP2 was greatly diminished when more than 20 amino acid residues were deleted from the N terminus. To identify the specific residues involved in PIP2-mediated enzyme activation, amino acids with functional side chains between residues 20 and 40 were individually changed to glycine, While all these mutations had little effect on the ability of the enzyme to catalyze the hydrolysis of PI or PIP2 micelles, the catalytic activity of mutants K24G, K30G, K32G, R38G, or W36G was markedly unresponsive to PIP2. Analysis of PIP2-stimulated PI hydrolysis by a dual substrate binding model of catalysis revealed that the micellar dissociation constant (K-s) of PLC delta 1 for the PI/PS/PC vesicles was reduced from 558 mu M to 53 mu M, and the interfacial Michaelis constant (K-m) was reduced from 0.21 to 0.06 by PIP2. The maximum rate of PI hydrolysis (V-max) was not affected by PIP2. These results demonstrate that a major function of the PH domain of PLC delta 1 is to modulate enzyme activity, Further, our results identify PIP2 as a functional ligand for a PH domain and suggest a general mechanism for the regulation of other proteins by PIP2.	ACAD SINICA,INST BIOMED SCI,TAIPEI 115,TAIWAN; NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,FEINBERG CARDIOVASC RES INST,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,FEINBERG CARDIOVASC RES INST,DEPT PHARMACOL,CHICAGO,IL 60611; ABBOTT LABS,DIV PHARMACEUT DISCOVERY,ABBOTT PK,IL 60064	Academia Sinica - Taiwan; Northwestern University; Northwestern University; Abbott Laboratories								BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHENG HF, 1995, J BIOL CHEM, V270, P5495, DOI 10.1074/jbc.270.10.5495; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5712; DOWNING AK, 1994, CURR BIOL, V4, P884, DOI 10.1016/S0960-9822(00)00197-4; ELLIS MV, 1993, EUR J BIOCHEM, V213, P339, DOI 10.1111/j.1432-1033.1993.tb17767.x; ELLIS MV, 1995, BIOCHEM J, V307, P69, DOI 10.1042/bj3070069; EMORI Y, 1989, J BIOL CHEM, V264, P21885; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; JAMES SR, 1995, J BIOL CHEM, V270, P11872, DOI 10.1074/jbc.270.20.11872; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LEE MH, 1989, J BIOL CHEM, V264, P14797; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; OGEL ZB, 1992, PROTEIN ENG, V5, P467, DOI 10.1093/protein/5.5.467; ORR JW, 1992, J BIOL CHEM, V267, P15263; PARKER PJ, 1994, TRENDS BIOCHEM SCI, V19, P54, DOI 10.1016/0968-0004(94)90031-0; PAWELCZYK T, 1993, BIOCHEM J, V291, P693, DOI 10.1042/bj2910693; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SULPICE JC, 1994, J BIOL CHEM, V269, P6347; TERUI T, 1994, J BIOL CHEM, V269, P28130; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TUMA PL, 1993, J BIOL CHEM, V268, P17240; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; YU FX, 1992, J BIOL CHEM, V267, P14616; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	60	99	100	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25316	25326		10.1074/jbc.271.41.25316	http://dx.doi.org/10.1074/jbc.271.41.25316			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810295	hybrid			2022-12-27	WOS:A1996VL69300039
J	Preugschat, F; Averett, DR; Clarke, BE; Porter, DJT				Preugschat, F; Averett, DR; Clarke, BE; Porter, DJT			A steady-state and pre-steady-state kinetic analysis of the NTPase activity associated with the hepatitis C virus NS3 helicase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI REP HELICASE; ADENINE-NUCLEOTIDE BINDING; DNA-INDUCED DIMERIZATION; RNA HELICASE; NUCLEIC-ACID; P80 PROTEIN; HELA-CELLS; PESTIVIRUS; MECHANISM; HYDROLYSIS	The helicase domain of hepatitis C virus NS3 (genotype 1b) was expressed in Escherichia coli and purified to homogeneity. The purified protein catalyzed the hydrolysis of nucleoside triphosphates (NTP) and the unwinding of duplex RNA in the presence of divalent metal ion. The enzyme was not selective for the NTP substrate. For example, UTP and acyclovir triphosphate were hydrolyzed efficiently by the enzyme. The rate of NTP hydrolysis was stimulated up to 27-fold by oligomeric nucleic acids (NA). Furthermore, NA bound to the enzyme with concomitant quenching of the intrinsic protein fluorescence. The dissociation constants of the enzyme for selected NA in the absence of NTP were between 10 and 35 mu M at pH 7.0 and 25 degrees C. The enzyme had maximal affinity for NA with 12 or more nucleotides. A detailed steady-state and pre-steady-state kinetic analysis of ATP hydrolysis was made with (dU)(18) as the effector. The k(cat) values for ATP hydrolysis in the presence and absence of (dU)(18) were 80 s(-1) and 2.7 s(-1), respectively. The association (dissociation) rate constants for the enzyme and (dU),, in the presence and absence of ATP were 5.7 mu M(-1) s(-1) (3.9 s(-1)) and 290 mu M(-1) s(-1) (2.27 s(-1)), respectively. The association (dissociation) rate constants for the enzyme and ATP in the presence and absence of (dU)(18) were 0.4 mu M(-1) s(-1) (<0.5 s(-1)) and 0.9 mu M(-1) s(-1) (<10(-1) s(-1)), respectively. These data were consistent with a random kinetic mechanism.	GLAXO WELLCOME INC,DIV BIOCHEM,RES TRIANGLE PK,NC 27709; GLAXO WELLCOME INC,MED RES CTR,DIV CELLULAR SCI,STEVENAGE,HERTS,ENGLAND	GlaxoSmithKline; GlaxoSmithKline					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; BUKH J, 1994, P NATL ACAD SCI USA, V91, P8239, DOI 10.1073/pnas.91.17.8239; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CLARKE BE, 1990, J GEN VIROL, V71, P1109, DOI 10.1099/0022-1317-71-5-1109; CLAUDE A, 1991, J BIOL CHEM, V266, P10358; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; KANAI A, 1995, FEBS LETT, V376, P221, DOI 10.1016/0014-5793(95)01283-X; Kayne FJ, 1973, ENZYMES, V8, P353, DOI 10.1016/S1874-6047(08)60071-2; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; LAIN S, 1991, J VIROL, V65, P1, DOI 10.1016/0042-6822(91)90641-N; LEE CG, 1992, J BIOL CHEM, V267, P4398; Lohman T. M., 1995, BIOPHYS J, V68, p180S; LOHMAN TM, 1992, METHOD ENZYMOL, V212, P400; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MAGRIN S, 1994, HEPATOLOGY, V19, P273; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14565, DOI 10.1021/bi00252a024; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14550, DOI 10.1021/bi00252a023; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; PAUSE A, 1992, EMBO J, V11, P2654; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SEGAL IH, 1993, ENZYME KINETICS, P54; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; TAMURA JK, 1993, VIROLOGY, V193, P1, DOI 10.1006/viro.1993.1097; TANAKA T, 1995, BIOCHEM BIOPH RES CO, V215, P744, DOI 10.1006/bbrc.1995.2526; WARRENER P, 1993, J VIROL, V67, P989, DOI 10.1128/JVI.67.2.989-996.1993; WARRENER P, 1995, J VIROL, V69, P1720, DOI 10.1128/JVI.69.3.1720-1726.1995; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; WONG I, 1992, J BIOL CHEM, V267, P7596; ZHANG SS, 1994, BIOCHEMISTRY-US, V33, P3906, DOI 10.1021/bi00179a016	32	130	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24449	24457		10.1074/jbc.271.40.24449	http://dx.doi.org/10.1074/jbc.271.40.24449			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798703	hybrid			2022-12-27	WOS:A1996VM67400025
J	Woo, SB; Neet, KE				Woo, SB; Neet, KE			Characterization of histidine residues essential for receptor binding and activity of nerve growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRK PROTOONCOGENE PRODUCT; HUMAN NEUROTROPHIC FACTOR; MOLECULAR-CLONING; FACTOR FAMILY; BIOLOGICAL-ACTIVITY; LOW-AFFINITY; SIGNAL-TRANSDUCTION; NGF RECEPTOR; PC12 CELLS; TYROSINE	The role of the four histidine residues in receptor binding and activity of mouse nerve growth factor (NGF) was investigated using both site directed mutagenesis and chemical modification with diethyl pyrocarbonate, Replacement of His-75 or His-84 with alanine resulted in decreased biological activity and decreased affinity for p140(trkA); however, with H75A only, a 5-fold increased affinity toward p75(LANR) was observed, The effect of simultaneous replacement of both His-75 and His-84 was neither additive nor synergistic. Slight perturbations in circular dichroism spectra and weakened self-association of the mutants indicated that His-75 and His-84 may be involved in stability, dimerization, and/or folding of NGF, Diethyl pyrocarbonate modification of His-4 and His-8 in the H75A/H84Q double mutant abolished neuritogenesis, binding to both receptors, and phosphorylation of p140(trkA) in PC12 cells, These chemi cal and mutational results confirm and clarify previous evidence for the involvement of His-75 and His-84 (Dunbar, J. C., Tregear, G. W., and Bradshaw, R. A. (1984) J. Protein Chem, 3, 349-356) or His-4 and His-8 (Shih, A., Laramee, G. R., Schmelzer, C. H., Burton, L. E., and Winslow, J. W. (1994) J. Biol. Chem. 269, 27679-27686) in receptor binding of NGF. At least three and possibly all four histidines, which are located in three spatially distinct regions, contribute to maintenance of functional sites that are essential for receptor binding and activity of NGF.	FINCH UNIV HLTH SCI CHICAGO MED SCH,DEPT BIOL CHEM,N CHICAGO,IL 60064	Chicago Medical School					NINDS NIH HHS [NS24380] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024380] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARBACID M, 1993, ONCOGENE, V8, P2033; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; DRINKWATER CC, 1993, J BIOL CHEM, V268, P23202; DRINKWATER CC, 1991, P ROY SOC B-BIOL SCI, V246, P307, DOI 10.1098/rspb.1991.0159; DUNBAR JC, 1984, J PROTEIN CHEM, V3, P349, DOI 10.1007/BF01025171; EBENDAL T, 1992, J NEUROSCI RES, V32, P461, DOI 10.1002/jnr.490320402; EDWARDS RH, 1988, J BIOL CHEM, V263, P6810; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; FRAZIER WA, 1973, BIOCHEMISTRY-US, V12, P3281, DOI 10.1021/bi00741a021; GODFREY EW, 1986, J NEUROSCI, V6, P2543; GOTZ R, 1994, NATURE, V372, P266, DOI 10.1038/372266a0; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOLLAND DR, 1994, J MOL BIOL, V239, P385, DOI 10.1006/jmbi.1994.1380; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IBANEZ CF, 1994, J NEUROBIOL, V25, P1349, DOI 10.1002/neu.480251104; IBANEZ CF, 1990, EMBO J, V9, P1477, DOI 10.1002/j.1460-2075.1990.tb08265.x; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAHLE P, 1992, J BIOL CHEM, V267, P22707; KAISHO Y, 1990, FEBS LETT, V266, P187, DOI 10.1016/0014-5793(90)81536-W; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LANDRETH GE, 1980, P NATL ACAD SCI-BIOL, V77, P4751, DOI 10.1073/pnas.77.8.4751; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LONGO FM, 1989, NERVE GROWTH FACTORS, P3; LUO Y, 1992, J BIOL CHEM, V267, P12275; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; NANDURI J, 1994, J NEUROSCI RES, V37, P433, DOI 10.1002/jnr.490370402; NEET KE, 1987, METHOD ENZYMOL, V147, P186; PETTMANN B, 1988, J NEUROSCI, V8, P3624; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; REINHOLD DS, 1989, J BIOL CHEM, V264, P3538; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SHIH A, 1994, J BIOL CHEM, V269, P27679; SMITH AP, 1968, BIOCHEMISTRY-US, V7, P3259, DOI 10.1021/bi00849a032; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SUTER U, 1992, J NEUROSCI, V12, P306; THOENEN H, 1987, REV PHYSIOL BIOCH P, V109, P145, DOI 10.1007/BFb0031026; VALE RD, 1985, METHOD ENZYMOL, V109, P21; WOO SB, 1995, J BIOL CHEM, V270, P6278, DOI 10.1074/jbc.270.11.6278; WOODRUFF NR, 1986, BIOCHEMISTRY-US, V25, P7956, DOI 10.1021/bi00372a026	56	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24433	24441		10.1074/jbc.271.40.24433	http://dx.doi.org/10.1074/jbc.271.40.24433			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798701	hybrid			2022-12-27	WOS:A1996VM67400023
J	DiasKadambi, BL; Combs, KA; Drum, CL; Hanck, DA; Blumenthal, KM				DiasKadambi, BL; Combs, KA; Drum, CL; Hanck, DA; Blumenthal, KM			The role of exposed tryptophan residues in the activity of the cardiotonic polypeptide anthopleurin B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROCTONUS-AUSTRALIS HECTOR; NUCLEAR-MAGNETIC-RESONANCE; RESISTANT NA+ CHANNELS; SEA-ANEMONE TOXIN; SODIUM-CHANNEL; 3-DIMENSIONAL STRUCTURE; SCORPION NEUROTOXINS; CATIONIC RESIDUES; EXCITABLE CELLS; RECEPTOR-SITE	Scorpion and sea anemone venoms contain several polypeptides that delay inactivation of voltage-sensitive sodium channels via interaction with a common site. In this report, we target exposed hydrophobic residues at positions 33 and 45 of anthopleurin B (ApB) by polymerase chain reaction mutagenesis to ascertain their contribution to toxin activity. Nonconservative replacements are not permitted at position 33, indicating that Trp-33 may play an important structural role. Strikingly, the relatively conservative substitution of Trp-33 by phenylalanine results in major reductions in binding affinity for both the cardiac and neuronal channel isoforms as measured by ion flux, whereas substitution with tyrosine is tolerated and exhibits near wild type affinities, suggesting that either the ability to form a hydrogen bond or the amphiphilic nature of the side chain are important at this position. Electrophysiological analysis of W33F indicates that its diminished affinity is primarily due to a decreased association rate. Analysis of a panel of mutants at Trp-45 shows only modest changes in apparent binding affinity for both channel isoforms but significant effects on V-max. In neuronal channels, the maximal levels of uptake for W45A/S/F are about 50% those seen with ApB. This effect is also observed for W45A and W45S in the cardiac model, wherein W45F is normal, These results suggest that a hydrophobic contact is involved in toxin-induced stabilization of the open conformation of the cardiac sodium channel. We conclude that Trp-33 contributes significantly to apparent affinity, whereas Trp-45 does not appear to affect binding per se, Furthermore, W33F is the first ApB mutant that displays a significantly altered association rate and may prove to be a useful probe of the channel binding site.	UNIV CINCINNATI,COLL MED,DEPT MOL GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637	University of Cincinnati; University of Chicago; University of Chicago			Drum, Chester/A-6089-2015	Drum, Chester/0000-0001-6327-4584	NHLBI NIH HHS [HL-41543, HL-PO1-20592] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041543, P01HL020592] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKER S, 1992, BIOCHEMISTRY-US, V31, P8229, DOI 10.1021/bi00150a016; CATTERALL WA, 1978, J BIOL CHEM, V253, P7393; CATTERALL WA, 1977, J BIOL CHEM, V252, P8660; Cleland W W, 1979, Methods Enzymol, V63, P103; DARBON H, 1991, BIOCHEMISTRY-US, V30, P1836, DOI 10.1021/bi00221a016; DiasKadambi BL, 1996, J BIOL CHEM, V271, P9422, DOI 10.1074/jbc.271.16.9422; DOGGRELL S, 1994, CLIN EXP PHARMACOL P, V21, P833, DOI 10.1111/j.1440-1681.1994.tb02454.x; DONAHUE LM, 1991, DEV BIOL, V147, P415, DOI 10.1016/0012-1606(91)90299-I; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; ELAYEB M, 1986, EUR J BIOCHEM, V155, P289; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FONTECILLACAMPS JC, 1988, P NATL ACAD SCI USA, V85, P7443, DOI 10.1073/pnas.85.20.7443; FONTECILLACAMPS JC, 1981, TRENDS BIOCHEM SCI, V6, P291, DOI 10.1016/0968-0004(81)90105-5; FONTECILLACAMPS JC, 1982, TOXICON, V20, P1, DOI 10.1016/0041-0101(82)90137-4; FRELIN C, 1981, EUR J BIOCHEM, V119, P437, DOI 10.1111/j.1432-1033.1981.tb05627.x; FRELIN C, 1984, MOL PHARMACOL, V26, P70; GALLAGHER MJ, 1994, J BIOL CHEM, V269, P254; GALLAGHER MJ, 1992, J BIOL CHEM, V267, P13958; GOOLEY PR, 1986, J BIOL CHEM, V261, P1536; GROSS GJ, 1985, EUR J PHARMACOL, V110, P271, DOI 10.1016/0014-2999(85)90223-7; KHERA PK, 1995, BIOCHEMISTRY-US, V34, P8533, DOI 10.1021/bi00027a003; KHERA PK, 1994, J BIOL CHEM, V269, P921; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; Maniatis T., 1982, MOL CLONING; MONKS SA, 1995, STRUCTURE, V3, P791, DOI 10.1016/S0969-2126(01)00214-3; NEWCOMB R, 1980, FRONTIERS PROTEIN CH, P539; NORTON RS, 1986, EUR J BIOCHEM, V157, P343, DOI 10.1111/j.1432-1033.1986.tb09674.x; NORTON RS, 1991, TOXICON, V29, P1051, DOI 10.1016/0041-0101(91)90205-6; NORTON TR, 1976, J PHARM SCI, V65, P1368, DOI 10.1002/jps.2600650927; NORTON TR, 1981, FED PROC, V40, P21; PALLAGHY PK, 1995, BIOCHEMISTRY-US, V34, P3782, DOI 10.1021/bi00011a036; RENAUD JF, 1986, EUR J PHARMACOL, V120, P161, DOI 10.1016/0014-2999(86)90536-4; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SCHWEITZ H, 1981, BIOCHEMISTRY-US, V20, P5245, DOI 10.1021/bi00521a023; SCRIABINE A, 1979, J CARDIOVASC PHARM, V1, P571, DOI 10.1097/00005344-197909000-00009; STRICHARTZ G, 1987, ANNU REV NEUROSCI, V10, P237; TANAKA JC, 1983, J BIOL CHEM, V258, P7519; TEJEDOR FJ, 1988, P NATL ACAD SCI USA, V85, P8742, DOI 10.1073/pnas.85.22.8742; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VINCENT JP, 1980, P NATL ACAD SCI-BIOL, V77, P1646, DOI 10.1073/pnas.77.3.1646; Zeng DW, 1996, AM J PHYSIOL-CELL PH, V270, pC1522, DOI 10.1152/ajpcell.1996.270.5.C1522	43	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23828	23835		10.1074/jbc.271.39.23828	http://dx.doi.org/10.1074/jbc.271.39.23828			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798612	hybrid			2022-12-27	WOS:A1996VJ44200041
J	Klickstein, LB; York, MR; deFougerolles, AR; Springer, TA				Klickstein, LB; York, MR; deFougerolles, AR; Springer, TA			Localization of the binding site on intercellular adhesion molecule-3 (ICAM-3) for lymphocyte function-associated antigen 1 (LFA-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; COUNTER-RECEPTOR; CRYSTAL-STRUCTURE; IMMUNOGLOBULIN; CLONING; DOMAINS; PEPTIDE; LIGAND; INVOLVEMENT; ARRANGEMENT	Intercellular adhesion molecule 3 (ICAM-3; CD50) is the predominant counter receptor on resting T cells and monocytes for the leukocyte integrin, lymphocyte function associated antigen 1 (LFA-1; CD11a/CD18), and may play an important role in the initial stages of the T cell-dependent immune response, Deletion of individual immunoglobulin superfamily (IgSF) domains of ICAM-3 and ICAM-3 IgSF domain chimeras with CD21 showed there is a single LFA-1 binding site in ICAM-3 and that IgSF domain 1 is necessary and sufficient for LFA-1 binding. Epitope mapping and functional studies performed with 17 anti-ICAM-3 monoclonal antibodies demonstrated that only some monoclonal antibodies, with epitopes wholly within domain 1 of ICAM-3, were able to block binding of ICAM-3 bearing cells to purified LFA-1, in agreement with the data obtained from the domain deletion mutants and CD21 chimeras. Analysis of a panel of 45 point mutants of domain 1 of ICAM-3 identified five residues that may contact LFA-1 as part of the binding site, Asn(23), Ser(25), Glu(37), Phe(54), and Gln(75). These five residues are predicted by molecular modeling, based on the structure of vascular cell adhesion molecule 1 (VCAM-1), to cluster in two distinct locations on domain 1 of ICAM-3 on the BED face (Asn(23) and Ser(25)) and on the C strand or CD loop (E37), the E strand (F54), and the FG loop (Q75). The residues, Asn(23) and Ser(25), comprise a consensus N-linked glycosylation site.	CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School				York, Michael/0000-0002-2507-3834	NATIONAL CANCER INSTITUTE [R37CA031798, R01CA031798] Funding Source: NIH RePORTER; NCI NIH HHS [CA 31798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; CAMPANERO MR, 1993, J CELL BIOL, V123, P1007, DOI 10.1083/jcb.123.4.1007; CORDELL JL, 1994, J CLIN PATHOL, V47, P143, DOI 10.1136/jcp.47.2.143; DEFOUGEROLLES AR, 1994, J EXP MED, V179, P619, DOI 10.1084/jem.179.2.619; DEFOUGEROLLES AR, 1993, J EXP MED, V177, P1187, DOI 10.1084/jem.177.4.1187; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; FECONDO JV, 1991, P NATL ACAD SCI USA, V88, P2879, DOI 10.1073/pnas.88.7.2879; GARRETT TPJ, 1993, J MOL BIOL, V234, P763, DOI 10.1006/jmbi.1993.1625; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HERNANDEZCASELLES T, 1993, EUR J IMMUNOL, V23, P2799, DOI 10.1002/eji.1830231112; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; JUAN M, 1993, EUR J IMMUNOL, V23, P1508, DOI 10.1002/eji.1830230717; Klickstein L. B., 1993, Tissue Antigens, V42, P270; KLICKSTEIN LB, 1995, LEUCOCYTE TYPING, V5, P1546; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDIS RC, 1994, J CELL BIOL, V126, P529, DOI 10.1083/jcb.126.2.529; LI R, 1993, J BIOL CHEM, V268, P17513; LOWELL CA, 1989, J EXP MED, V170, P1931, DOI 10.1084/jem.170.6.1931; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; ROSS L, 1992, J BIOL CHEM, V267, P8537; SADHU C, 1994, CELL ADHES COMMUN, V2, P429, DOI 10.3109/15419069409004453; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SETH R, 1991, FEBS LETT, V282, P193, DOI 10.1016/0014-5793(91)80475-I; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SLATKO B, 1991, CURRENT PROTOCOLS MO; STARLING GC, 1995, LEUKOCYTE TYPING, V5, P1578; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; VILELLA R, 1990, TISSUE ANTIGENS, V36, P203, DOI 10.1111/j.1399-0039.1990.tb01830.x; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714	43	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23920	23927		10.1074/jbc.271.39.23920	http://dx.doi.org/10.1074/jbc.271.39.23920			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798624	hybrid			2022-12-27	WOS:A1996VJ44200053
J	Monaghan, A; Hay, RT				Monaghan, A; Hay, RT			Pyridoxal 5'-phosphate inhibition of adenovirus DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; VIRUS REVERSE-TRANSCRIPTASE; SUBSTRATE-BINDING DOMAIN; AMINO-ACID-SEQUENCE; CRYSTAL-STRUCTURE; ACTIVE-SITE; ESCHERICHIA-COLI; FUNCTIONAL DOMAINS; PREINITIATION COMPLEX; ANGSTROM RESOLUTION	Pyridoxal phosphate modification of adenovirus DNA polymerase results in loss of DNA polymerase activity, whereas the 3' --> 5' exonuclease activity is unaffected. Inhibition by pyridoxal phosphate is time-dependent, displays saturation kinetics, and is reversible in the presence of excess primary amine unless the pyridoxal phosphate-enzyme adduct is first reduced with NaBH4. Thus, inhibition is the consequence of Schiff base formation between the aldehyde moiety of pyridoxal phosphate and primary amino groups on the enzyme. In addition to inhibiting DNA polymerase activity, pyridoxal phosphate also inhibited the ability of the enzyme to initiate viral DNA replication, by transfer of dCMP onto the preterminal protein. Neither template-primer nor dNTP protect against pyridoxal phosphate inhibition, but the combination of template-primer and complementary substrate dNTP protected both initiation and DNA polymerase activities. Thus, it is likely that both the dCMP transfer activity required for initiation and DNA polymerase activity are carried out at the same site of the enzyme.	UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS KY16 9AL,FIFE,SCOTLAND	University of St Andrews			Hay, Ronald T/F-9338-2011; Hay, Ronald/S-3233-2019	Hay, Ronald T/0000-0001-7113-9024; Hay, Ronald/0000-0001-7113-9024				BASU A, 1988, J BIOL CHEM, V263, P1648; BASU A, 1987, BIOCHEMISTRY-US, V26, P1704, DOI 10.1021/bi00380a032; BASU A, 1989, J BIOL CHEM, V264, P8746; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BESSE LS, 1993, BIOCHEMISTRY-US, V32, P14095; BLASCO MA, 1992, J BIOL CHEM, V267, P19427; BLASCO MA, 1993, J BIOL CHEM, V268, P16763; BLASCO MA, 1993, J BIOL CHEM, V268, P24106; BLASCO MA, 1992, CHROMOSOMA, V102, P32; BOSHER J, 1990, New Biologist, V2, P1083; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; BULL P, 1975, BIOCHEM BIOPH RES CO, V64, P1152, DOI 10.1016/0006-291X(75)90814-1; CHEN M, 1990, J BIOL CHEM, V265, P18634; CHEN M, 1989, P NATL ACAD SCI USA, V86, P6116, DOI 10.1073/pnas.86.16.6116; DIFFLEY JFX, 1988, J BIOL CHEM, V263, P14669; DIFFLEY JX, 1988, J BIOL CHEM, V263, P19156; DONG Q, 1994, J BIOL CHEM, V270, P21563; FANSLER BS, 1974, METHOD ENZYMOL, V29, P52; FIELD J, 1984, J BIOL CHEM, V259, P9487; GODING CR, 1983, EMBO J, V2, P339, DOI 10.1002/j.1460-2075.1983.tb01428.x; HARZA AK, 1984, BIOCHEMISTRY-US, V23, P2073; HAY RT, 1984, J MOL BIOL, V175, P493, DOI 10.1016/0022-2836(84)90181-5; HAY RT, 1989, BIOCHEM J, V258, P3, DOI 10.1042/bj2580003; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOUNG I, 1992, J VIROL, V66, P5788, DOI 10.1128/JVI.66.10.5788-5796.1992; JUNG G, 1990, BIOCHEM BIOPH RES CO, V170, P12294; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; LARDER BA, 1987, EMBO J, V6, P169, DOI 10.1002/j.1460-2075.1987.tb04735.x; LICHY JH, 1982, P NATL ACAD SCI-BIOL, V79, P5225, DOI 10.1073/pnas.79.17.5225; LINDENBAUM JO, 1986, J BIOL CHEM, V261, P218; MARTIAL J, 1975, BIOCHEMISTRY-US, V14, P4907, DOI 10.1021/bi00693a020; MODAK MJ, 1976, BIOCHEMISTRY-US, V15, P3620, DOI 10.1021/bi00661a033; MONAGHAN A, 1994, NUC ACIDS RES, V5, P742; MUL YM, 1990, J VIROL, V64, P5510, DOI 10.1128/JVI.64.11.5510-5518.1990; MUL YM, 1992, EMBO J, V11, P751, DOI 10.1002/j.1460-2075.1992.tb05108.x; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STOW ND, 1982, NUCLEIC ACIDS RES, V10, P5105, DOI 10.1093/nar/10.17.5105; TEMPERLEY SM, 1992, EMBO J, V11, P761, DOI 10.1002/j.1460-2075.1992.tb05109.x; VANDERVLIET PC, 1991, SEMINARS VIROLOGY, V2, P271; VENEGAS A, 1973, BIOCHEM BIOPH RES CO, V55, P1053, DOI 10.1016/S0006-291X(73)80001-4; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; ZIJDERVELD DC, 1993, NUCLEIC ACIDS RES, V21, P641	52	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24242	24248		10.1074/jbc.271.39.24242	http://dx.doi.org/10.1074/jbc.271.39.24242			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798669	hybrid			2022-12-27	WOS:A1996VJ44200098
J	Wu, DF; Cederbaum, AI				Wu, DF; Cederbaum, AI			Ethanol cytotoxicity to a transfected HepG2 cell line expressing human cytochrome P4502E1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOLIC LIVER-DISEASE; LIPID-PEROXIDATION; SUPEROXIDE-DISMUTASE; CYTO-TOXICITY; MICROSOMAL OXIDATION; RADICAL GENERATION; COLORIMETRIC ASSAY; HYDROGEN-PEROXIDE; FED RATS; METABOLISM	The effect of ethanol on the viability of a HepG2 cell model which was developed to constitutively express human CYP2E1 was studied in an attempt to establish a linkage between CYP2E1, reactive oxygen intermediates, and ethanol toxicity, Assays of toxicity included leakage of lactate dehydrogenase, trypan blue uptake, morphology, and formazan production, Ethanol was toxic to HepG2 E9 cells, which express CYP2E1, but not to HepG2 MV5 cells, which do not express CYP2E1. The ethanol toxicity was dependent on the concentration of ethanol, starting with 10 mM ethanol, and on the time of incubation with ethanol, Phorbol 12-myristate 13-acetate, which increases the expression of CYP2E1 in this model, increased the toxicity by ethanol, Ethanol toxicity was prevented by 4-methylpyrazole and by diallyl sulfide, inhibitors of CYP2E1, The ethanol toxicity was also prevented by radical trapping agents such as N-acetylcysteine and N-t-butyl-alpha-phenylnitrone, antioxidative agents such as catalase, superoxide dismutase, thiourea, and uric acid, and inhibitors of lipid peroxidation, such as vitamin E phosphate, Trolox, and diphenylphenylenediamine. Besides ethanol, other substrates such as Me(2)SO, CCl4, isoniazid, and N,N-dimethylnitrosamine were cytotoxic to cells expressing CYP2E1 but not to control cells, These results indicate that ethanol was toxic to HepG2 cells which express human CYP2E1 by a pathway sensitive to inhibitors of CYP2E1 and to a variety of antioxidative agents, This model appears to be useful in efforts to establish a CYP2E1-dependent ethanol hepatotoxicity system and to evaluate the role of oxidative stress and reactive radical species in the toxicity by ethanol.	MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai					NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006610, R56AA003312, R01AA003312, R37AA006610] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-03312, AA-06610] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALBANO E, 1991, BIOCHEM PHARMACOL, V41, P1895, DOI 10.1016/0006-2952(91)90129-S; Albano E, 1987, Free Radic Res Commun, V3, P243, DOI 10.3109/10715768709069789; AOYAMA T, 1990, ENDOCRINOLOGY, V126, P3101, DOI 10.1210/endo-126-6-3101; BRADY JF, 1991, CHEM RES TOXICOL, V4, P642, DOI 10.1021/tx00024a008; CARMICHAEL J, 1987, CANCER RES, V47, P936; CARROCCIO A, 1994, BIOCHEM BIOPH RES CO, V203, P727, DOI 10.1006/bbrc.1994.2242; CASTILLO T, 1992, HEPATOLOGY, V16, P992, DOI 10.1002/hep.1840160423; CEDERBAUM AI, 1989, FREE RADICAL BIO MED, V7, P537, DOI 10.1016/0891-5849(89)90029-4; CEDERBAUM AI, 1989, FREE RADICAL BIO MED, V7, P559, DOI 10.1016/0891-5849(89)90033-6; CLAY KL, 1977, TOXICOL APPL PHARM, V39, P39, DOI 10.1016/0041-008X(77)90175-2; DAI Y, 1993, BIOCHEMISTRY-US, V32, P6928, DOI 10.1021/bi00078a017; Dai Y, 1995, J PHARMACOL EXP THER, V275, P1614; DAI Y, 1995, J PHARMACOL EXP THER, V273, P1497; DIANZANI MU, 1985, ALCOHOL ALCOHOLISM, V20, P161; DICKER E, 1988, FASEB J, V2, P2901, DOI 10.1096/fasebj.2.13.3169467; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; FEIERMAN DE, 1985, ALCOHOL CLIN EXP RES, V9, P421, DOI 10.1111/j.1530-0277.1985.tb05576.x; FEIERMAN DE, 1986, BIOCHEM J, V239, P671, DOI 10.1042/bj2390671; FRENCH SW, 1993, EXP MOL PATHOL, V58, P61, DOI 10.1006/exmp.1993.1006; FRENCH SW, 1992, CRIT REV CL LAB SCI, V29, P83, DOI 10.3109/10408369209114597; GERGEL D, 1995, J BIOL CHEM, V270, P20922, DOI 10.1074/jbc.270.36.20922; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; KNECHT KT, 1993, ARCH BIOCHEM BIOPHYS, V303, P339, DOI 10.1006/abbi.1993.1293; KOOP DR, 1992, FASEB J, V6, P724, DOI 10.1096/fasebj.6.2.1537462; KOOP DR, 1982, J BIOL CHEM, V257, P8472; KUKIELKA E, 1994, BIOCHEM J, V302, P773, DOI 10.1042/bj3020773; KYLE ME, 1988, J BIOL CHEM, V263, P3784; KYLE ME, 1987, BIOCHEM BIOPH RES CO, V149, P889, DOI 10.1016/0006-291X(87)90491-8; MAGNUSSON G, 1972, EXPERIENTIA, V28, P1198, DOI 10.1007/BF01946169; MALORNI W, 1995, CHEM-BIOL INTERACT, V96, P113, DOI 10.1016/0009-2797(94)03576-T; MCMARTIN KE, 1980, ARCH BIOCHEM BIOPHYS, V199, P606, DOI 10.1016/0003-9861(80)90318-5; MORIMOTO M, 1993, ALCOHOL, V10, P459, DOI 10.1016/0741-8329(93)90065-V; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NANJI AA, 1993, ALCOHOL CLIN EXP RES, V17, P598, DOI 10.1111/j.1530-0277.1993.tb00806.x; NANJI AA, 1989, LIFE SCI, V44, P223, DOI 10.1016/0024-3205(89)90599-7; NEUMAN MG, 1995, GASTROENTEROLOGY, V109, P555, DOI 10.1016/0016-5085(95)90345-3; NEUMAN MG, 1993, BIOCHEM BIOPH RES CO, V197, P932, DOI 10.1006/bbrc.1993.2569; NIEMELA O, 1995, HEPATOLOGY, V22, P1208, DOI 10.1016/0270-9139(95)90630-4; NORDMANN R, 1992, FREE RADICAL BIO MED, V12, P219, DOI 10.1016/0891-5849(92)90030-K; PALAKODETY RB, 1988, J BIOL CHEM, V263, P878; PARACCHINI L, 1993, ANTICANCER RES, V13, P1607; PATTEN CJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P163, DOI 10.1016/0003-9861(92)90258-X; PUNTARULO S, 1988, ARCH BIOCHEM BIOPHYS, V266, P435, DOI 10.1016/0003-9861(88)90275-5; RASHBASTEP J, 1993, ARCH BIOCHEM BIOPHYS, V300, P401, DOI 10.1006/abbi.1993.1054; REINKE LA, 1987, P NATL ACAD SCI USA, V84, P9223, DOI 10.1073/pnas.84.24.9223; REINKE LA, 1994, FREE RADICAL RES, V21, P213, DOI 10.3109/10715769409056573; SADRZADEH SMH, 1994, J PHARMACOL EXP THER, V269, P632; SASSA S, 1987, BIOCHEM BIOPH RES CO, V143, P52, DOI 10.1016/0006-291X(87)90628-0; TAKAHASHI H, 1992, PHARMACOL TOXICOL, V70, P347, DOI 10.1111/j.1600-0773.1992.tb00485.x; TSUKAMOTO H, 1986, HEPATOLOGY, V6, P814, DOI 10.1002/hep.1840060503; TSUKAMOTO H, 1995, J CLIN INVEST, V96, P620, DOI 10.1172/JCI118077; TSUKAMOTO H, 1993, ALCOHOL, V10, P439, DOI 10.1016/0741-8329(93)90061-R; WAXMAN DJ, 1991, ARCH BIOCHEM BIOPHYS, V290, P160, DOI 10.1016/0003-9861(91)90602-F; YANG CS, 1991, METHOD ENZYMOL, V206, P595	57	163	167	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23914	23919		10.1074/jbc.271.39.23914	http://dx.doi.org/10.1074/jbc.271.39.23914			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798623	hybrid			2022-12-27	WOS:A1996VJ44200052
J	Foster, JL; Higgins, GC; Jackson, FR				Foster, JL; Higgins, GC; Jackson, FR			Biochemical properties and cellular localization of the Drosophila DG1 cGMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING SITES; CATALYTIC DOMAIN; I-BETA; EXPRESSION; CLONING; SEQUENCE; MUSCLE; BRAIN; RAT; PHOSPHORYLATION	The protein encoded by the Drosophila cGMP-dependent protein kinase gene, DG1, was expressed in Sf9 cells. cGMP (10 mu M) stimulated histone H2B phosphorylation by the DG1 protein kinase 20-fold. Maximal activity was observed at 40-50 mM Mg2+. The concentrations of cGMP, cAMP, cIMP, 8-bromo-cGMP, and 8-bromo-cAMP that gave 50% activation were 0.19 +/- 0.06, 11.7 +/- 2.8, 5.3 +/- 1.5, 0.04 +/- 0.01, and 0.62 +/- 0.06 mu M, respectively. cGMP activation was cooperative with a Hill coefficient (n(H)) of 1.28 +/- 0.10, whereas activation by cAMP was not cooperative. DG1 kinase expressed in Sf9 cells was found to be a dimer with an amino-terminal dimerization domain. It also autophosphorylated in a reaction stimulated by cGMP and cAMP. Immunoadsorbed DG1 protein from fly extracts was also capable of autophosphorylation, and this assay was used to quantitate the DG1 kinase in extracts from heads and bodies of adults and whole embryos. Activity was highest in heads of either sex and male bodies, intermediate in female bodies, and lowest in embryos. These results were in accord with DG1 mRNA abundance. Tissue distribution of the DG1 kinase was investigated by immunohistochemistry. In embryos, specific immunoreactivity was observed in large cells scattered along the anterior-posterior axis at stage 13. Prominent staining of adult heads was restricted to the proximal level of the lamina cortex.	UNIV TENNESSEE,COLL MED,LEBONHEUR CHILDRENS MED CTR,DEPT BIOCHEM,MEMPHIS,TN 38163; UNIV TENNESSEE,COLL MED,LEBONHEUR CHILDRENS MED CTR,DEPT PEDIAT,MEMPHIS,TN 38163; UNIV TENNESSEE,COLL MED,LEBONHEUR CHILDRENS MED CTR,CRIPPLED CHILDREN FDN RES CTR,MEMPHIS,TN 38163; WORCESTER FDN BIOMED RES,SHREWSBURY,MA 01545	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Worcester Foundation for Biomedical Research					NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009767] Funding Source: NIH RePORTER; NCRR NIH HHS [R01 RR09767] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BOERTH NJ, 1994, FEBS LETT, V342, P255, DOI 10.1016/0014-5793(94)80512-1; CORBIN JD, 1983, J BIOL CHEM, V258, P1391; ELHUSSEINI AED, 1995, J NEUROCHEM, V64, P2814; FEIL R, 1995, BIOCHEMISTRY-US, V34, P13152, DOI 10.1021/bi00040a029; FLOCKERZI V, 1978, J BIOL CHEM, V253, P3395; FOSTER JL, 1981, J BIOL CHEM, V256, P5029; FOSTER JL, 1988, J BIOL CHEM, V263, P1676; Francis S H, 1994, Adv Pharmacol, V26, P115, DOI 10.1016/S1054-3589(08)60053-8; FRENCH PJ, 1995, J BIOL CHEM, V270, P26626, DOI 10.1074/jbc.270.44.26626; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; HEIL WG, 1987, EUR J BIOCHEM, V168, P117, DOI 10.1111/j.1432-1033.1987.tb13395.x; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; ITOH N, 1985, DROS INF SERVICE, V61, P89; JACKSON FR, 1990, J NEUROCHEM, V54, P1068, DOI 10.1111/j.1471-4159.1990.tb02359.x; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; JARRETT HW, 1995, J BIOL CHEM, V270, P5578, DOI 10.1074/jbc.270.10.5578; JOYCE NC, 1984, MICROVASC RES, V28, P206, DOI 10.1016/0026-2862(84)90018-9; KALDERON D, 1989, J BIOL CHEM, V264, P10738; LINCOLN TM, 1994, HYPERTENSION, V23, P1141, DOI 10.1161/01.HYP.23.6.1141; LOHMANN SM, 1981, P NATL ACAD SCI-BIOL, V78, P653, DOI 10.1073/pnas.78.1.653; MACKENZIE CW, 1982, J BIOL CHEM, V257, P5589; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; MERINEY SD, 1994, NATURE, V369, P336, DOI 10.1038/369336a0; PRYZWANSKY KB, 1995, J LEUKOCYTE BIOL, V57, P670, DOI 10.1002/jlb.57.4.670; PRYZWANSKY KB, 1995, BLOOD, V85, P222, DOI 10.1182/blood.V85.1.222.bloodjournal851222; RUTH P, 1991, EUR J BIOCHEM, V202, P1339, DOI 10.1111/j.1432-1033.1991.tb16509.x; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; SMITH JA, 1993, BIOCHEMISTRY-US, V127, P51; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; TEPASS U, 1994, DEVELOPMENT, V120, P1829; UHLER MD, 1993, J BIOL CHEM, V268, P13586; WALDMANN R, 1986, EUR J BIOCHEM, V158, P203, DOI 10.1111/j.1432-1033.1986.tb09739.x; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	37	12	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23322	23328		10.1074/jbc.271.38.23322	http://dx.doi.org/10.1074/jbc.271.38.23322			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798533	hybrid			2022-12-27	WOS:A1996VH76800059
J	Hazen, SL; Hsu, FF; Duffin, K; Heinecke, JW				Hazen, SL; Hsu, FF; Duffin, K; Heinecke, JW			Molecular chlorine generated by the myeloperoxidase hydrogen peroxide chloride system of phagocytes converts low density lipoprotein cholesterol into a family of chlorinated sterols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; HYPOCHLOROUS ACID; HUMAN-NEUTROPHILS; OXIDATIVE MODIFICATION; BIOLOGICAL-ACTIVITIES; LIPID-PEROXIDATION; SCAVENGER RECEPTOR; OXYGENATED STEROLS; MACROPHAGES; PROTEINS	Oxidation of low density lipoprotein (LDL) may be of critical importance in triggering the pathological events of atherosclerosis. Myeloperoxidase, a heme protein secreted by phagocytes, is a potent catalyst for LDL oxidation in vitro, and active enzyme is present in human atherosclerotic lesions, We have explored the possibility that reactive intermediates generated by myeloperoxidase target LDL cholesterol for oxidation, LDL exposed to the myeloperoxidase-H2O2-Cl- system at acidic pH yielded a family of chlorinated sterols, The products were identified by mass spectrometry as a novel dichlorinated sterol, cholesterol alpha-chlorohydrin (6 beta-chlorocholestane-(3 beta,5 alpha)-diol), cholesterol beta-chlorohydrin (5 alpha-chlorocholestane-(3 beta,6 beta)-diol), and a structurally related cholesterol chlorohydrin, Oxidation of LDL cholesterol by myeloperoxidase required H2O2 and Cl-, suggesting that hypochlorous acid (HOCl) was an intermediate in the reaction. However, HOCl failed to generate chlorinated sterols under chloride-free conditions. Since HOCl is in equilibrium with molecular chlorine (Cl-2) through a reaction which requires Cl- and H+, this raised the possibility that Cl-2 was the actual chlorinating intermediate. Consonant with this hypothesis, HOCl oxidized LDL cholesterol in the presence of Cl- and at acidic pH. Moreover, in the absence of Cl- and at neutral pH, Cl-2 generated the same family of chlorinated sterols as the myeloperoxidase-H2O2-Cl- system. Finally, direct addition of Cl-2 to the double bond of cholesterol accounts for dichlorinated sterol formation by myeloperoxidase, Collectively, these results indicate that Cl-2 derived from HOCl is the chlorinating intermediate in the oxidation of cholesterol by myeloperoxidase. Our observations suggest that Cl-2 generation in acidic compartments may constitute one pathway for oxidation of LDL cholesterol in the artery wall.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; MONSANTO CO,ST LOUIS,MO 63198	Washington University (WUSTL); Washington University (WUSTL); Monsanto			Hazen, Stanley L/ABD-5845-2021	Hsu, Fong-Fu/0000-0001-5368-0183	NIA NIH HHS [AG12293] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012293] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agner K., 1972, STRUCTURE FUNCTION O, P329; ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; ARNHOLD J, 1991, BIOMED BIOCHIM ACTA, V50, P967; BARTON DHR, 1950, J AM CHEM SOC, V72, P370, DOI 10.1021/ja01157a100; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHISOLM GM, 1994, P NATL ACAD SCI USA, V91, P11452, DOI 10.1073/pnas.91.24.11452; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DELAMARE PBD, 1954, J CHEM SOC, P1290, DOI 10.1039/jr9540001290; DELAMARE PBD, 1959, AROMATIC SUBSTITUTIO, P105; DOUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768; ELSAADANI M, 1989, J LIPID RES, V30, P627; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; FRANK JS, 1989, J LIPID RES, V30, P967; HAJJAR DP, 1988, ARCH BIOCHEM BIOPHYS, V262, P375, DOI 10.1016/0003-9861(88)90201-9; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; HAZELL LJ, 1994, BIOCHEM J, V302, P297, DOI 10.1042/bj3020297; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1996, J BIOL CHEM, V271, P1861, DOI 10.1074/jbc.271.4.1861; HAZEN SL, 1996, IN PRESS J CLIN INVE; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; HEINECKE JW, 1994, CORONARY ARTERY DIS, V5, P205, DOI 10.1097/00019501-199403000-00004; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HODIS HN, 1992, ATHEROSCLEROSIS, V96, P125, DOI 10.1016/0021-9150(92)90059-P; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; HWANG PL, 1991, BIOESSAYS, V13, P583, DOI 10.1002/bies.950131108; JENSEN MS, 1973, J CELL BIOL, V56, P379, DOI 10.1083/jcb.56.2.379; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTION, P447; KNOX WE, 1948, J BACTERIOL, V55, P451, DOI 10.1128/JB.55.4.451-458.1948; LEHRER RI, 1984, BLOOD, V63, P88; MAERKER G, 1988, LIPIDS, V23, P761, DOI 10.1007/BF02536218; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Orton KJP, 1927, J CHEM SOC, P986, DOI 10.1039/jr9270000986; RAKITA RM, 1990, BIOCHEMISTRY-US, V29, P1075, DOI 10.1021/bi00456a033; RASMUSSEN J, 1995, CIRCULATION S1, V92, P162; RIVETT DEA, 1950, J ORG CHEM, V15, P35; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; SEPE SM, 1985, J IMMUNOL, V134, P1888; SEVANIAN A, 1994, FREE RADICAL BIO MED, V17, P397, DOI 10.1016/0891-5849(94)90166-X; SEVANIAN A, 1986, FOOD CHEM TOXICOL, V24, P1103, DOI 10.1016/0278-6915(86)90295-4; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; SMITH LL, 1989, FREE RADICAL BIO MED, V7, P285, DOI 10.1016/0891-5849(89)90136-6; STEINBRECHER UP, 1992, ARTERIOSCLER THROMB, V12, P608, DOI 10.1161/01.ATV.12.5.608; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TEST ST, 1986, ADV FREE RADICAL BIO, V2, P91, DOI 10.1016/S8755-9668(86)80025-4; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1982, BIOCHEMISTRY-US, V21, P6299, DOI 10.1021/bi00267a040; TURK J, 1983, BIOCHIM BIOPHYS ACTA, V751, P189, DOI 10.1016/0005-2760(83)90173-X; WEIL I, 1949, J AM CHEM SOC, V71, P1664, DOI 10.1021/ja01173a033; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WHITE GC, 1972, HDB CHLORINATION, P182; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WRIGHT SD, 1984, NATURE, V309, P359, DOI 10.1038/309359a0; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZHANG HF, 1993, J BIOL CHEM, V268, P5535	67	189	194	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23080	23088		10.1074/jbc.271.38.23080	http://dx.doi.org/10.1074/jbc.271.38.23080			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798498	hybrid			2022-12-27	WOS:A1996VH76800024
J	Ikeda, M; Wilcox, EC; Chin, WW				Ikeda, M; Wilcox, EC; Chin, WW			Different DNA elements can modulate the conformation of thyroid hormone receptor heterodimer and its transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X RECEPTOR; RESPONSE ELEMENTS; DEOXYRIBONUCLEIC-ACID; INVERTED PALINDROMES; LIGAND SENSITIVITY; DIRECT REPEATS; HALF-SITES; C-ERBA; BINDING; BETA	Thyroid-hormone receptors (TRs) form heterodimers with retinoid-X receptors (RXRs) on thyroid-hormone-response elements (TREs). However, it is not known whether the formation of liganded TR/RXR heterodimer on a TRE alone is sufficient to dictate transcriptional activity. We designed several mutated DR4s (half-sites arranged as direct repeats with a nucleotide gap of 4) that bound TR/RXR heterodimers preferentially, and employed them to characterize functional and biochemical properties of the heterodimers on DNA. Although TR/RXR heterodimer binding was similar on some of the mutated DR4s, transient transfection assays showed that TR alpha failed to support triiodothyronine (T-3)-stimulated transcription on "inactive" DR4s but mediated basal repression on both "active" and inactive mutated DR4. T-3 binding assays showed that the mutated DR4s did not affect T-3 binding to the heterodimer. Finally, partial proteolysis studies revealed that binding of active DR4 elements and T-3 to the heterodimer synergistically enhanced heterodimerization-induced protease resistance of TR, but not RXR, in the heterodimer. These results suggest that: 1) liganded TR/RXR heterodimer binding to a DR4 is not sufficient for transcriptional activation of the target gene, and 2) DNA sequences in specific TREs may modify T-3-mediated transcription by affecting the conformation of the liganded heterodimer.	UNIV YAMANASHI, SCH MED, DEPT INTERNAL MED 3, TAMAHO, YAMANASHI 40938, JAPAN; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	University of Yamanashi; Harvard University; Harvard Medical School								ALLAN GF, 1992, J BIOL CHEM, V267, P19513; ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; BARTA A, 1981, P NATL ACAD SCI-BIOL, V78, P4867, DOI 10.1073/pnas.78.8.4867; BENDIK I, 1995, J BIOL CHEM, V270, P3107, DOI 10.1074/jbc.270.7.3107; BHAT MK, 1993, BIOCHEM BIOPH RES CO, V195, P385, DOI 10.1006/bbrc.1993.2055; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CHEN CS, 1995, ENDOCRINOLOGY, V136, P2776; DARLING DS, 1993, J BIOL CHEM, V268, P10221; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORCE WR, 1994, J BIOL CHEM, V269, P8863; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; IKEDA M, 1994, ENDOCRINOLOGY, V135, P1628, DOI 10.1210/en.135.4.1628; KATZ RW, 1994, J BIOL CHEM, V269, P18915; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KING IN, 1993, J BIOL CHEM, V268, P495; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEE IJ, 1994, P NATL ACAD SCI USA, V91, P1647, DOI 10.1073/pnas.91.5.1647; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEHMANN JM, 1993, MOL CELL BIOL, V13, P7698, DOI 10.1128/MCB.13.12.7698; LEIDIG F, 1992, J BIOL CHEM, V267, P913; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; LENG XH, 1994, J BIOL CHEM, V269, P31436; LU XP, 1993, MOL CELL BIOL, V13, P6509, DOI 10.1128/MCB.13.10.6509; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PETTY KJ, 1995, MOL CELL ENDOCRINOL, V108, P131, DOI 10.1016/0303-7207(94)03466-7; RHEE M, 1995, ENDOCRINOLOGY, V136, P2697, DOI 10.1210/en.136.6.2697; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SCHRADER M, 1994, DNA CELL BIOL, V13, P333, DOI 10.1089/dna.1994.13.333; SCHRADER M, 1995, MOL CELL BIOL, V15, P1154; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; TANGUAY RL, 1990, NUCLEIC ACIDS RES, V18, P5902, DOI 10.1093/nar/18.19.5902; TONE Y, 1994, J BIOL CHEM, V269, P31157; TONEY JH, 1993, BIOCHEMISTRY-US, V32, P2, DOI 10.1021/bi00052a001; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; WILLMANN T, 1986, NATURE, V324, P688, DOI 10.1038/324688a0; YEN PM, 1993, MOL CELL ENDOCRINOL, V97, P93, DOI 10.1016/0303-7207(93)90214-5; YEN PM, 1994, J BIOL CHEM, V269, P12704; YEN PM, 1995, ENDOCRINOLOGY, V136, P2845, DOI 10.1210/en.136.7.2845; YEN PM, 1994, TRENDS ENDOCRIN MET, V5, P65, DOI 10.1016/1043-2760(94)90004-3; YEN PM, 1994, ENDOCRINOLOGY, V134, P1075, DOI 10.1210/en.134.3.1075; YEN PM, 1992, J BIOL CHEM, V267, P23248; YEN PM, 1993, ENDOCR J, V1, P461; ZHANG XK, 1993, TRENDS ENDOCRIN MET, V4, P156, DOI 10.1016/1043-2760(93)90105-N	59	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23096	23104		10.1074/jbc.271.38.23096	http://dx.doi.org/10.1074/jbc.271.38.23096			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798500	hybrid			2022-12-27	WOS:A1996VH76800026
J	Melen, K; Keskinen, P; Ronni, T; Sareneva, T; Lounatmaa, K; Julkunen, I				Melen, K; Keskinen, P; Ronni, T; Sareneva, T; Lounatmaa, K; Julkunen, I			Human MxB protein, an interferon-alpha-inducible GTPase, contains a nuclear targeting signal and is localized in the heterochromatin region beneath the nuclear envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS; BINDING PROTEINS; DYNAMIN GTPASE; LEUCINE ZIPPER; MURINE MX1; EXPRESSION; RESISTANCE; MECHANISM; SEQUENCE; DOMAIN	Interferon-inducible Mx proteins belong to the family of large GTPases and are highly homologous with dynamins within their GTP-binding domain. Cytoplasmically localized human MxA protein mediates resistance to influenza and several other viruses, whereas human MxB protein has not been found to have any antiviral activity. Here we show that MxB protein is found both in the cytoplasm and in the nucleus, where it is localized in a granular pattern in the heterochromatin region beneath the nuclear envelope. Transfection experiments in COS cells of N-terminally deleted MxB constructs revealed a functional nuclear localization signal within the first 24 N-terminal amino acids. Nuclear 78-kDa and cytoplasmic 76-kDa forms of MxB protein were found in all of the cell lines studied and in human peripheral blood mononuclear cells. MxB protein proved to be a functional GTPase with activity comparable to that of MxA protein. N-terminally truncated (Delta 1-82) MxB protein lacking both the nuclear localization signal and a proline-rich domain had almost completely lost its GTPase activity. Analysis of peripheral blood mononuclear cells suggested that MxB protein expression is strictly regulated by interferon-alpha. This is the first documentation that human Mx protein resides in the nucleus. It also emphasizes that there are considerable differences in the localization and structure of functional domains within Mx proteins.	NATL PUBL HLTH INST,DEPT VIROL,FIN-00300 HELSINKI,FINLAND; UNIV HELSINKI,INST BIOTECHNOL,FIN-00014 HELSINKI,FINLAND	Finland National Institute for Health & Welfare; University of Helsinki								AEBI M, 1989, MOL CELL BIOL, V9, P5062, DOI 10.1128/MCB.9.11.5062; Arnheiter H, 1996, CURR TOP MICROBIOL, V206, P119; BAZZIGHER L, 1993, VIROLOGY, V195, P100, DOI 10.1006/viro.1993.1350; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CANTELL K, 1986, METHOD ENZYMOL, V119, P54; Cantell K, 1981, Methods Enzymol, V78, P29; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Harlow E, 1988, ANTIBODIES LAB MANUA, P418; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HORISBERGER MA, 1992, J VIROL, V66, P4705, DOI 10.1128/JVI.66.8.4705-4709.1992; HORISBERGER MA, 1990, J VIROL, V64, P1171, DOI 10.1128/JVI.64.3.1171-1181.1990; JANS DA, 1995, BIOCHEM J, V311, P705, DOI 10.1042/bj3110705; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; KELLY RB, 1995, NATURE, V374, P116, DOI 10.1038/374116a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MELEN K, 1992, J BIOL CHEM, V267, P25898; MELEN K, 1994, VIROLOGY, V205, P269, DOI 10.1006/viro.1994.1643; MELEN K, 1994, J BIOL CHEM, V269, P2009; NAKAYAMA M, 1991, J BIOL CHEM, V266, P21404; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; Newman GR, 1989, COLLOIDAL GOLD PRINC, V2; NOTEBORN M, 1987, J INTERFERON RES, V7, P657, DOI 10.1089/jir.1987.7.657; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; PITOSSI F, 1993, J VIROL, V67, P6726, DOI 10.1128/JVI.67.11.6726-6732.1993; RICHTER MF, 1995, J BIOL CHEM, V270, P13512, DOI 10.1074/jbc.270.22.13512; RONNI T, 1995, J IMMUNOL, V154, P2764; RONNI T, 1993, J IMMUNOL, V150, P1715; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHMALJOHN CS, 1985, SCIENCE, V227, P1041, DOI 10.1126/science.2858126; SCHWEMMLE M, 1995, J BIOL CHEM, V270, P13518, DOI 10.1074/jbc.270.22.13518; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; Summers M., 1986, TEX AGR EXP STN B, V1555, P1; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; VALLEE RB, 1993, NATURE, V365, P107, DOI 10.1038/365107a0; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WILSBACH K, 1993, EMBO J, V12, P3049, DOI 10.1002/j.1460-2075.1993.tb05974.x; XIANGJU G, 1996, EMBO J, V15, P695	49	112	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23478	23486		10.1074/jbc.271.38.23478	http://dx.doi.org/10.1074/jbc.271.38.23478			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798556	hybrid			2022-12-27	WOS:A1996VH76800082
J	Moyers, JS; Bilan, PJ; Reynet, C; Kahn, CR				Moyers, JS; Bilan, PJ; Reynet, C; Kahn, CR			Overexpression of rad inhibits glucose uptake in cultured muscle and fat cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; GROWTH-FACTOR-I; PROTEIN-PHOSPHORYLATION; GUANINE-NUCLEOTIDES; 3T3-L1 ADIPOCYTES; BINDING PROTEINS; PLASMA-MEMBRANE; TRANSPORT; STIMULATION; GENE	Rad is a Ras-like GTPase that was isolated by subtraction cloning of human muscle and shown to have increased expression in some individuals with Type II diabetes, To ascertain the potential role of Rad in insulin-mediated signaling, we have overexpressed Rad in myocyte and adipocyte cell lines, Expression of Rad resulted in a 50-90% reduction in insulin-stimulated 2-deoxyglucose glucose uptake in C2C12 murine myotubes, L6 rat myotubes, and 3T3-L1 adipocytes and a 25% reduction in 3-O-methylglucose uptake in 3T3-L1 adipocytes, This occurred despite unaltered levels of glucose transporter expression, with no detectable change in Glut4 translocation and with no alteration in insulin receptor or substrate phosphorylation or phosphatidylinositol 3-kinase activity, These data indicate that Rad is a negative regulator of glucose uptake and that this effect may be due to a decrease in the intrinsic activity of the transporter molecules, rather than an effect on the translocation of Glut4.	HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02216; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02216	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045935, T32DK007260, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 36836, DK 07260, DK 45935] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BERRIDGE MV, 1995, BIOCHEM J, V305, P843, DOI 10.1042/bj3050843; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLTENSPERGER K, 1993, SCIENCE, V260, P1950; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CHEATHAM BC, 1993, P NATL ACAD SCI USA, V90, P7366; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; CORMONT M, 1991, ENDOCRINOLOGY, V129, P3343, DOI 10.1210/endo-129-6-3343; CORMONT M, 1993, J BIOL CHEM, V268, P19491; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; FARESE RV, 1993, J BIOL CHEM, V268, P19949; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FOLLI F, 1992, J BIOL CHEM, V267, P22171; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; HARRISON SA, 1991, J BIOL CHEM, V266, P19438; KARNIELI E, 1990, HORM RES, V33, P99, DOI 10.1159/000181491; KUZNETSOV SA, 1992, NATURE, V356, P722, DOI 10.1038/356722a0; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; REIZMAN H, 1993, TRENDS CELL BIOL, V3, P273; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; SARGEANT R, 1993, J ENDOCRINOL INVEST, V16, P147, DOI 10.1007/BF03347669; SATOH S, 1993, J BIOL CHEM, V268, P17820; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHURMANN A, 1989, FEBS LETT, V255, P259, DOI 10.1016/0014-5793(89)81102-0; SHIBATA H, 1995, J BIOL CHEM, V270, P11489, DOI 10.1074/jbc.270.19.11489; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUZUKI Y, 1992, BIOCHEM BIOPH RES CO, V189, P572, DOI 10.1016/0006-291X(92)91596-I; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; YANO Y, 1993, BIOCHIM BIOPHYS ACTA, V1176, P327, DOI 10.1016/0167-4889(93)90062-T; Zhu JH, 1996, J BIOL CHEM, V271, P768, DOI 10.1074/jbc.271.2.768; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	43	109	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23111	23116		10.1074/jbc.271.38.23111	http://dx.doi.org/10.1074/jbc.271.38.23111			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798502	hybrid			2022-12-27	WOS:A1996VH76800028
J	Saks, ME; Sampson, JR; Nowak, MW; Kearney, PC; Du, FY; Abelson, JN; Lester, HA; Dougherty, DA				Saks, ME; Sampson, JR; Nowak, MW; Kearney, PC; Du, FY; Abelson, JN; Lester, HA; Dougherty, DA			An engineered Tetrahymena tRNA(Gln) for in vivo incorporation of unnatural amino acids into proteins by nonsense suppression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASE; NICOTINIC ACETYLCHOLINE-RECEPTOR; GATED ION CHANNELS; M2 DOMAIN; RECOGNITION; ANTICODON; MUTATIONS; IDENTITY; GENES; ISOPENTENYLATION	A new tRNA, THG73, has been designed and evaluated as a vehicle for incorporating unnatural amino acids site-specifically into proteins expressed in vivo using the stop codon suppression technique, The construct is a modification of tRNA(Gln)(CUA) from Tetrahymena thermophila, which naturally recognizes the stop codon UAG. Using electrophysiological studies of mutations at several sites of the nicotinic acetylcholine receptor, it is established that THG73 represents a major improvement over previous nonsense suppressors both in terms of efficiency and fidelity of unnatural amino acid incorporation, Compared with a previous tRNA used for in vivo suppression, THG73 is as much as 100-fold less likely to be acylated by endogenous synthetases of the Xenopus oocyte. This effectively eliminates a major concern of the in vivo suppression methodology, the undesirable incorporation of natural amino acids at the suppression site. In addition, THG73 is 4-10-fold more efficient at incorporating unnatural amino acids in the oocyte system, Taken together, these two advances should greatly expand the range of applicability of the in vivo nonsense suppression methodology.	CALTECH, DIV CHEM & CHEM ENGN 16430, PASADENA, CA 91125 USA; CALTECH, DIV BIOL, PASADENA, CA 91125 USA	California Institute of Technology; California Institute of Technology					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034407, R01NS011756, R37NS034407] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48560] Funding Source: Medline; NINDS NIH HHS [NS34407, NS11756] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AYLWIN ML, 1994, FEBS LETT, V349, P99, DOI 10.1016/0014-5793(94)00649-0; BIENZ M, 1980, NUCLEIC ACIDS RES, V8, P5169, DOI 10.1093/nar/8.22.5169; BJORK GR, 1995, PROG NUCLEIC ACID RE, V50, P263, DOI 10.1016/S0079-6603(08)60817-X; CORNISH VW, 1995, ANGEW CHEM INT EDIT, V34, P621, DOI 10.1002/anie.199506211; COULONDRE C, 1977, J MOL BIOL, V117, P525, DOI 10.1016/0022-2836(77)90056-0; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; DIHANICH ME, 1987, MOL CELL BIOL, V7, P177, DOI 10.1128/MCB.7.1.177; England T E, 1980, Methods Enzymol, V65, P65; ENGLAND TE, 1978, BIOCHEMISTRY-US, V17, P2069, DOI 10.1021/bi00604a008; FILATOV GN, 1995, MOL PHARMACOL, V48, P379; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; GUREVITZ M, 1983, BIOCHEMISTRY-US, V22, P4000, DOI 10.1021/bi00286a002; HANYU N, 1986, EMBO J, V5, P1307, DOI 10.1002/j.1460-2075.1986.tb04360.x; HATFIELD DL, 1990, CRIT REV BIOCHEM MOL, V25, P71, DOI 10.3109/10409239009090606; HAYASE Y, 1992, EMBO J, V11, P4159, DOI 10.1002/j.1460-2075.1992.tb05509.x; HIRSH, 1971, J MOL BIOL, V58, P439, DOI 10.1016/0022-2836(71)90362-7; HUDZIAK RM, 1982, CELL, V31, P137, DOI 10.1016/0092-8674(82)90413-5; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; LASKI FA, 1982, P NATL ACAD SCI-BIOL, V79, P5813, DOI 10.1073/pnas.79.19.5813; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; MARTIN NC, 1982, J BIOL CHEM, V257, P562; MATTAJ IW, 1987, EMBO J, V6, P2409, DOI 10.1002/j.1460-2075.1987.tb02519.x; MCCLAIN WH, 1993, J MOL BIOL, V234, P257, DOI 10.1006/jmbi.1993.1582; MILLER JH, 1979, NONSENSE MUTATIONS T, P127; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; NOWAK MW, 1995, SCIENCE, V268, P439, DOI 10.1126/science.7716551; Nowak MW, 1996, BIOPHYS J, V70, pSU253; NOWAK NW, 1996, BIOPHYS J, V70, P76; PICARD B, 1980, EUR J BIOCHEM, V109, P359, DOI 10.1111/j.1432-1033.1980.tb04802.x; QUICK MW, 1994, ION CHANNELS EXCITAB, P261; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; ROBERTSON SA, 1991, J AM CHEM SOC, V113, P2722, DOI 10.1021/ja00007a055; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; SAKS ME, 1994, SCIENCE, V263, P191, DOI 10.1126/science.7506844; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHULL C, 1994, NUCLEIC ACIDS RES, V22, P1974, DOI 10.1093/nar/22.11.1974; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; STEEGE DA, 1979, BIOL REGUL DEV, P433; YARUS M, 1982, SCIENCE, V218, P646, DOI 10.1126/science.6753149; YOUNG JF, 1983, SCIENCE, V221, P873, DOI 10.1126/science.6308765	47	95	122	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23169	23175		10.1074/jbc.271.38.23169	http://dx.doi.org/10.1074/jbc.271.38.23169			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798511	hybrid, Green Accepted			2022-12-27	WOS:A1996VH76800037
J	Cowen, DS; Sowers, RS; Manning, DR				Cowen, DS; Sowers, RS; Manning, DR			Activation of a mitogen-activated protein kinase (ERK2) by the 5-hydroxytryptamine(1A) receptor is sensitive not only to inhibitors of phosphatidylinositol 3-kinase, but to an inhibitor of phosphatidylcholine hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; MAP KINASE; SIGNAL-TRANSDUCTION; 5-HT1A RECEPTOR; CELLS; RAS; INVOLVEMENT; WORTMANNIN; SUBUNITS; PATHWAYS	A variety of receptors coupled to GTP binding regulatory proteins (G proteins) initiate signals that culminate in activation of the mitogen-activated protein kinases ERK1 and ERK2. We demonstrate here that the human 5-HT1A receptor expressed in Chinese hamster ovary cells similarly promotes activation of ERK1 and ERK2, but that the pathway used does not conform entirely to those proposed previously for G protein-coupled receptors. Activation of ERK2 by the 5-HT1A receptor-selective agonist 8-hydroxy-N,N-dipropyl-2-aminotetralin hydrobromide (8-OH-DPAT) was inhibited completely by pertussis toxin and substantially by prolonged treatment of cells with phorbol 12-myristate 13-acetate, The implied requirement for protein kinase C, however, was negated in studies with bisindolylmaleimide and Ro-31-8220, which, although completely inhibiting activation of ERK2 by phorbol ester, had no impact on activation by 8-OH-DPAT, The anticipated inhibition by the tyrosine kinase inhibitors genistein and herbimycin A, moreover, was marginal at best, As expected for a G(i)-coupled receptor, the inhibitors of phosphatidylinositol 3-kinase wortmannin and LY294002 inhibited activation of ERK2, albeit only partly (70%), Of significance, an inhibitor of a phosphatidylcholine-specific phospholipase C, tricyclodecan-9-yl-xanthogenate (D609), caused a similar degree of inhibition, When the two types of inhibitors were combined, an almost complete inhibition was achieved, Our data suggest that phosphatidylinositol 3-kinase and phosphatidylcholine-specific phospholipase C represent components of different, but partly overlapping pathways that can account almost entirely for the activation of ERK2 by the 5-HT1A receptor.	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PSYCHIAT,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH048125, T32MH014654] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51196] Funding Source: Medline; NIMH NIH HHS [MH14654, MH48125] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BUSCHER D, 1995, MOL CELL BIOL, V15, P466; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; COWEN DS, 1990, J BIOL CHEM, V265, P1618; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DELLACQUA M, 1993, J BIOL CHEM, V269, P5678; DEVIVO M, 1986, J PHARMACOL EXP THER, V238, P248; EXTON JH, 1990, J BIOL CHEM, V265, P1; FARGIN A, 1988, NATURE, V335, P358, DOI 10.1038/335358a0; FARGIN A, 1989, J BIOL CHEM, V264, P14848; FLORDELLIS CS, 1995, J BIOL CHEM, V270, P3491, DOI 10.1074/jbc.270.8.3491; HALSTEAD J, 1995, J BIOL CHEM, V270, P13600, DOI 10.1074/jbc.270.23.13600; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; KAHAN C, 1992, J BIOL CHEM, V267, P13369; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; MULLERDECKER K, 1989, BIOCHEM BIOPH RES CO, V162, P198, DOI 10.1016/0006-291X(89)91981-5; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; RAYMOND JR, 1993, BIOCHEMISTRY-US, V32, P11064, DOI 10.1021/bi00092a016; SAKANAKA C, 1994, BIOCHEM BIOPH RES CO, V205, P18, DOI 10.1006/bbrc.1994.2623; SHUTZE S, 1992, CELL, V71, P765; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WINITZ S, 1993, J BIOL CHEM, V268, P19196; ZHANG WY, 1995, J CELL PHYSIOL, V162, P348, DOI 10.1002/jcp.1041620307	32	97	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22297	22300		10.1074/jbc.271.37.22297	http://dx.doi.org/10.1074/jbc.271.37.22297			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798386				2022-12-27	WOS:A1996VG67200005
J	Daas, PJH; Hagen, WR; Keltjens, JT; vanderDrift, C; Vogels, GD				Daas, PJH; Hagen, WR; Keltjens, JT; vanderDrift, C; Vogels, GD			Activation mechanism of Methanol:5-hydroxybenzimidazolylcobamide methyltransferase from Methanosarcina barkeri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISSIMILATORY SULFITE REDUCTASE; DEPENDENT METHIONINE SYNTHASE; 2-MERCAPTOETHANESULFONIC ACID; METHANOL; IRON; CORRINOIDS; 5-HYDROXYBENZIMIDAZOLYLCOBAMIDE; DEHYDROGENASE; INVOLVEMENT; COMPONENT	Methanol:5-hydroxybenzimidazolylcobamide methyltransferase (MT(1)) is the first of two enzymes involved in the transmethylation reaction from methanol to 2-mercaptoethanesulfonic acid in Methanosarcina barkeri. MT(1) only binds the methyl group of methanol when the cobalt atom of its corrinoid prosthetic groups is present in the highly reduced Co(I) state. Formation of this redox state requires H-2, hydrogenase, methyltransferase activation protein, and ATP. Optical and electron paramagnetic resonance spectroscopy studies were employed to determine the oxidation states and coordinating ligands of the corrinoids of MT(1) during the activation process. Purified MT(1) contained 1.7 corrinoids per enzyme with cobalt in the fully oxidized Co(III) state. Water and N-3 of the 5-hydroxybenzimidazolyl base served as the upper and lower ligands, respectively. Reduction to the Co(II) level was accomplished by H-2 and hydrogenase. The Co(II)amide of MT(1) had the base coordinated at this stage. Subsequent addition of methyltransferase activation protein and ATP resulted in the formation of base-uncoordinated Co(II) MT(1). The activation mechanism is discussed within the context of a proposed model and compared to those described for other corrinoid-containing methyl group transferring proteins.	UNIV NIJMEGEN,FAC SCI,DEPT MICROBIOL,NL-6525 ED NIJMEGEN,NETHERLANDS; AGR UNIV WAGENINGEN,DEPT BIOCHEM,NL-6703 HA WAGENINGEN,NETHERLANDS	Radboud University Nijmegen; Wageningen University & Research			Keltjens, Jan/M-3002-2013; Hagen, Wilfred R./H-8918-2017	Hagen, Wilfred R./0000-0002-1609-6671				ARENDSEN AF, 1993, BIOCHEMISTRY-US, V32, P10323, DOI 10.1021/bi00090a007; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; BANERJEE RV, 1990, FASEB J, V4, P1450, DOI 10.1096/fasebj.4.5.2407589; BARTLEY W, 1957, BIOCHEM J, V67, P291, DOI 10.1042/bj0670291; DAAS PJH, 1995, ARCH BIOCHEM BIOPHYS, V319, P244, DOI 10.1006/abbi.1995.1288; DAAS PJH, 1993, J BACTERIOL, V175, P1278, DOI 10.1128/JB.175.5.1278-1283.1993; DAAS PJH, 1996, J BIOL CHEM, V172, P22339; DIEKERT G, 1994, ANTON LEEUW INT J G, V66, P209, DOI 10.1007/BF00871640; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FRIEDRICH W, 1975, FERMENTE HORMONE VIT, V3, P46; Gianotti C., 1982, B12, V1, P393; HARDER SR, 1989, BIOCHEMISTRY-US, V28, P9080, DOI 10.1021/bi00449a019; HOLLIGER C, 1993, J AM CHEM SOC, V115, P5651, DOI 10.1021/ja00066a034; HUTTEN TJ, 1981, J BACTERIOL, V145, P27, DOI 10.1128/JB.145.1.27-34.1981; JABLONSKI PE, 1993, J BIOL CHEM, V268, P325; JETTEN MSM, 1991, EUR J BIOCHEM, V202, P1291, DOI 10.1111/j.1432-1033.1991.tb16502.x; KELTJENS JT, 1986, FEMS MICROBIOL LETT, V39, P259, DOI 10.1111/j.1574-6968.1986.tb01862.x; LJUNGDAHL LG, 1973, J BIOL CHEM, V12, P1802; LU WP, 1995, J BACTERIOL, V177, P2245, DOI 10.1128/jb.177.9.2245-2250.1995; MATTHEWS R G, 1990, Biofactors, V2, P147; PIERIK AJ, 1991, EUR J BIOCHEM, V195, P505, DOI 10.1111/j.1432-1033.1991.tb15731.x; Pilbrow J. R., 1982, B12, V1, P431; POL A, 1982, BIOCHEM BIOPH RES CO, V108, P731, DOI 10.1016/0006-291X(82)90890-7; POL A, 1984, BIOCHIM BIOPHYS ACTA, V797, P83, DOI 10.1016/0304-4165(84)90385-4; RAGSDALE SW, 1991, CRIT REV BIOCHEM MOL, V26, P261, DOI 10.3109/10409239109114070; ROUVIERE PE, 1989, J BACTERIOL, V171, P4556, DOI 10.1128/jb.171.9.4556-4562.1989; VANDERMEIJDEN P, 1983, FEMS MICROBIOL LETT, V19, P247, DOI 10.1016/0378-1097(83)90069-1; VANDERMEIJDEN P, 1984, BIOCHEM BIOPH RES CO, V118, P760, DOI 10.1016/0006-291X(84)91460-8; VANDERMEIJDEN P, 1984, J BACTERIOL, V160, P629, DOI 10.1128/JB.160.2.629-635.1984; VANDERMEIJDEN P, 1983, ARCH MICROBIOL, V134, P238, DOI 10.1007/BF00407765; VANDERMEIJDEN P, 1983, J BACTERIOL, V153, P6, DOI 10.1128/JB.153.1.6-11.1983	32	36	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22346	22351		10.1074/jbc.271.37.22346	http://dx.doi.org/10.1074/jbc.271.37.22346			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798395	Green Submitted, hybrid			2022-12-27	WOS:A1996VG67200014
J	Klein, ES; Pino, ME; Johnson, AT; Davies, PJA; Nagpal, S; Thacher, SM; Krasinski, G; Chandraratna, AS				Klein, ES; Pino, ME; Johnson, AT; Davies, PJA; Nagpal, S; Thacher, SM; Krasinski, G; Chandraratna, AS			Identification and functional separation of retinoic acid receptor neutral antagonists and inverse agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; THYROID-HORMONE; CO-REPRESSOR; NUCLEAR RECEPTOR; BINDING-PROTEINS; EXPRESSION; LIGAND; ESTROGEN; GENE; TRANSCRIPTION	Inverse agonists are ligands that are capable of repressing basal receptor activity in the absence of an agonist. We have designed a series of C-1-substituted acetylenic retinoids that exhibit potent antagonism of retinoic acid receptor (RAR)-mediated transactivation. Comparison of these related retinoid antagonists for their ability 60 repress basal RAR transcriptional activity demonstrates that the identity of the C-1 substituent differentiates these ligands into two groups: RAR inverse agonists and neutral antagonists, We show that treatment of cultured human keratinocytes with a RAR inverse agonist, but not a RAR neutral antagonist, leads to the repression of the serum-induced differentiation marker MRP-8. While RAR-selective agonists also repress expression of MRP-8, cotreatment with a RAR inverse agonist and a RAR agonist results in a mutual repression of their individual inhibitory activities, indicating the distinct modes of action of these two disparate retinoids in modulating MRP-8 expression, Our data indicate that RARs, like beta(2)-adrenoreceptors, are sensitive to inverse agonists and that this new class of retinoids will provide insight into the molecular mechanisms of RAR function in skin and other responsive tissues.	ALLERGAN PHARMACEUT INC, RETINOID RES, DEPT BIOL, IRVINE, CA 92715 USA; ALLERGAN PHARMACEUT INC, RETINOID RES, DEPT CHEM, IRVINE, CA 92715 USA; UNIV TEXAS, SCH MED, DEPT PHARMACOL, HOUSTON, TX 77225 USA; UNIV TEXAS, SCH MED, DEPT MED, HOUSTON, TX 77225 USA	AbbVie; Allergan; AbbVie; Allergan; University of Texas System; University of Texas System			Nagpal, Sunil/A-8007-2009					ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BYGDEMAN M, 1994, HUM REPROD, V9, P121, DOI 10.1093/humrep/9.suppl_1.121; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; COSTA T, 1992, MOL PHARMACOL, V41, P549; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JOHNSON AT, 1995, J MED CHEM, V38, P4764, DOI 10.1021/jm00024a003; JORDAN VC, 1992, CANCER, V70, P977; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KELLY SE, 1989, J PATHOL, V159, P17, DOI 10.1002/path.1711590107; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; MADSEN P, 1992, J INVEST DERMATOL, V99, P299, DOI 10.1111/1523-1747.ep12616641; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; PARKER MG, 1993, ANN NY ACAD SCI, V684, P119, DOI 10.1111/j.1749-6632.1993.tb32276.x; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; Standeven AM, 1996, TOXICOL APPL PHARM, V138, P169, DOI 10.1006/taap.1996.0110; THACHER SM, 1991, EXP CELL RES, V194, P238, DOI 10.1016/0014-4827(91)90360-7; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WILKINSON MM, 1988, J CELL SCI, V91, P221	34	94	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22692	22696		10.1074/jbc.271.37.22692	http://dx.doi.org/10.1074/jbc.271.37.22692			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798442	hybrid			2022-12-27	WOS:A1996VG67200061
J	Tanti, JF; Gremeaux, T; Grillo, S; Calleja, V; Klippel, A; Williams, LT; VanObberghen, E; LeMarchandBrustel, Y				Tanti, JF; Gremeaux, T; Grillo, S; Calleja, V; Klippel, A; Williams, LT; VanObberghen, E; LeMarchandBrustel, Y			Overexpression of a constitutively active form of phosphatidylinositol 3-kinase is sufficient to promote glut 4 translocation in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; STIMULATED GLUCOSE-TRANSPORT; INSULIN-RECEPTOR SUBSTRATE-1; PROTEIN-KINASE-B; 3T3-L1 ADIPOCYTES; 1-PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; GLYCOGEN-SYNTHASE; OKADAIC ACID; MAP KINASE	Insulin stimulates glucose transport in its target cells by recruiting the glucose transporter Glut 4 from an intracellular compartment to the cell surface. Previous studies have indicated that phosphatidylinositol 3-kinase (PI 3-kinase) is a necessary step in this insulin action. We have investigated whether PI 3-kinase activation is sufficient to promote Glut 4 translocation in transiently transfected adipocytes. Rat adipose cells were cotransfected with expression vectors that allowed transient expression of epitope-tagged Glut 4 and a constitutively active form of PI 3-kinase (p110*). The expression of p110* induced the appearance of epitope-tagged Glut 4 at the cell surface at a level similar to that obtained after insulin treatment, whereas a kinase-dead version of p110* had no effect. The p110* effect was observed over a wide range of the transfected cDNA. When subcellular fractionation of adipocytes was performed, p110* was found, similar to the endogenous PI 3-kinase, enriched in the low density microsomal compartment, which also contains the Glut 4 vesicles. This could suggest that a specific localization of PI 3-kinase in this compartment is required for the action on Glut 4, The observations made with PI 3-kinase are in contrast with those seen with the MAP kinase cascade. Indeed, a constitutively active form of MAP kinase kinase had no effect on Glut 4 translocation in basal conditions. At the highest degree of expression, the constitutively active form of MAP kinase kinase slightly inhibited the insulin stimulation of Glut 4 translocation. Taken together, our results indicate that Glut 4 translocation can be efficiently promoted by an active form of PI 3-kinase but not by the activation of the MAP kinase pathway.	CHIRON CORP,EMERYVILLE,CA 94143	Novartis	Tanti, JF (corresponding author), FAC MED NICE,INSERM,U145,AVE VALOMBROSE,F-06107 NICE,FRANCE.			Tanti, Jean-Francois/0000-0003-1782-1318				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CORMONT M, 1993, J BIOL CHEM, V268, P19491; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; GOULD GW, 1994, CELL SIGNAL, V6, P313, DOI 10.1016/0898-6568(94)90036-1; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LEMARCHANDBRUSTEL Y, 1990, ENDOCRINOLOGY, V127, P2687; LEMARCHANDBRUSTEL Y, 1995, ENDOCRINOLOGY, V136, P3564, DOI 10.1210/en.136.8.3564; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARCUSOHN J, 1995, CURR BIOL, V5, P1296, DOI 10.1016/S0960-9822(95)00256-9; OKADA T, 1994, J BIOL CHEM, V269, P3568; QUON MJ, 1994, J BIOL CHEM, V269, P27920; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; Tozzo E, 1996, J BIOL CHEM, V271, P10490, DOI 10.1074/jbc.271.18.10490; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125	39	143	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25227	25232		10.1074/jbc.271.41.25227	http://dx.doi.org/10.1074/jbc.271.41.25227			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810283	hybrid			2022-12-27	WOS:A1996VL69300027
J	Ybarra, J; Horowitz, PM				Ybarra, J; Horowitz, PM			Nucleotides reveal polynucleotide phosphorylase activity from conventionally purified GroEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RNASE-E; PROTEIN; DEGRADATION; IDENTIFICATION; PURIFICATION; COMPLEX	GroEL, as conventionally purified, can be incubated with nucleotides to produce high molecular weight material with an absorption maximum at 260 nm. This material is most clearly demonstrated when samples are subjected to gel filtration under conditions where GroEL is monomeric. There is a time-dependent increase in the high molecular weight material that occurs on incubation with ADP or, more slowly, with ATP, This material is generated during incubation, and none is present in the initial samples. Experiments with nucleases, proteases, radiolabeled nucleotides, and chemical cleavage reagents demonstrate that the high molecular weight material is polyadenylic acid whose formation is inhibited by phosphate. These results are consistent with the GroEL samples containing polynucleotide phosphorylase activity. Nondenaturing gels stained with acridine orange, after incubation in ADP, reveal that the activity producing the poly(A) coelectrophoreses with authentic polynucleotide phosphorylase. Conditions that remove the tryptophan-like fluorescence from preparations of GroEL also remove the PNPase activity, Thus, this activity is not associated with GroEL itself, The results are consistent with reports that GroEL can associate with RNase E and with other studies showing that RNase E and PNPase can form complexes, Thus, the present experiments support suggestions that GroEL can participate in multiprotein complexes that are involved in mRNA processing and degradation.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; DESSAUER CW, 1994, J BIOL CHEM, V269, P19766; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GEORGELLIS D, 1995, MOL MICROBIOL, V16, P1259, DOI 10.1111/j.1365-2958.1995.tb02347.x; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; KANDROR O, 1994, J BIOL CHEM, V269, P23575; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; NEUHOFF V, 1986, ELECTROPHORESIS, V7, P56, DOI 10.1002/elps.1150070110; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; THANG MN, 1967, BIOCHEM BIOPH RES CO, V28, P374, DOI 10.1016/0006-291X(67)90320-8; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; YBARRA J, 1995, J BIOL CHEM, V270, P22962, DOI 10.1074/jbc.270.39.22962	16	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25063	25066		10.1074/jbc.271.41.25063	http://dx.doi.org/10.1074/jbc.271.41.25063			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810258	hybrid			2022-12-27	WOS:A1996VL69300002
J	Desdouits, F; Buxbaum, JD; DesdouitsMagnen, J; Nairn, AC; Greengard, P				Desdouits, F; Buxbaum, JD; DesdouitsMagnen, J; Nairn, AC; Greengard, P			Amyloid beta peptide formation in cell-free preparations - Regulation by protein kinase C, calmodulin, and calcineurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; MUTATION; SECRETION; INHIBITION; ACTIVATION; RELEASE; CALCIUM; GENE	Amyloid beta peptide (A beta) is a short peptide that is the major constituent of the amyloid plaques and cerebrovascular amyloid deposits found in Alzheimer's disease. The lack of availability of a cell-free system in which to study A beta formation has limited our understanding of the molecular mechanisms involved in its production, We report here the reconstitution of such a cell-free system. The reconstituted A beta formation was temperature-dependent and required ATP, Preincubation with purified protein kinase C (PKC) induced a pronounced inhibition of A beta formation, similar to that observed in intact cells upon stimulation of PKC. The calmodulin antagonists W-7 and trifluoperazine inhibited A beta formation and enhanced the action of PKC in both the cell-free system and intact cells. A role for the calcium/calmodulin-activated protein phosphatase calcineurin in the regulation of A beta formation was demonstrated using a specific peptide inhibitor of calcineurin in vitro as well as cyclosporin A, a cell-permeant inhibitor of calcineurin, in intact cells. Our results suggest that a single substrate might mediate opposing actions of PKC and calcineurin in the regulation of A beta formation.	ROCKEFELLER UNIV, MOL & CELLULAR NEUROSCI LAB, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, ELIZABETH M FISHER CTR RES ALZHEIMER DIS, NEW YORK, NY 10021 USA	Rockefeller University; Rockefeller University			Buxbaum, Joseph D/G-6001-2010	Buxbaum, Joseph/0000-0001-8898-8313; Nairn, Angus/0000-0002-7075-0195	NIA NIH HHS [AG 09464, AG 08051] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG008051, P01AG009464] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BUXBAUM JD, 1994, P NATL ACAD SCI USA, V91, P4489, DOI 10.1073/pnas.91.10.4489; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CHECLER F, 1995, J NEUROCHEM, V65, P1431; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDELL B, 1994, ANNU REV PHARMACOL, V34, P69; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HUNG AY, 1993, J BIOL CHEM, V268, P22959; JACOBSEN JS, 1994, J BIOL CHEM, V269, P8376; KHACHATURIAN ZS, 1989, ANN NY ACAD SCI, V568, P1, DOI 10.1111/j.1749-6632.1989.tb12485.x; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; Klafki HW, 1995, NEUROSCI LETT, V201, P29, DOI 10.1016/0304-3940(95)12122-K; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARTIN TFJ, 1989, J BIOL CHEM, V264, P10299; McConlogue L, 1996, J BIOL CHEM, V271, P1343, DOI 10.1074/jbc.271.3.1343; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SILVA EFDE, 1995, MOL MED, V1, P535, DOI 10.1007/BF03401590; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	30	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24670	24674		10.1074/jbc.271.40.24670	http://dx.doi.org/10.1074/jbc.271.40.24670			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798734	hybrid			2022-12-27	WOS:A1996VM67400056
J	Economides, AN; Everdeen, D; Panayotatos, N				Economides, AN; Everdeen, D; Panayotatos, N			A shared, non-canonical DNA conformation detected at DNA/protein contact sites and bent DNA in the absence of supercoiling or cognate protein binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 ENDONUCLEASE-I; HOLLIDAY JUNCTIONS; ESCHERICHIA-COLI; KINETOPLAST DNA; PROMOTER; CLEAVAGE; INVITRO; REPLICATION; SPECIFICITY; RESOLUTION	A hybrid protein (H144), consisting of Lac repressor and T7 endonuclease I, binds at the lac operator and cleaves relaxed double stranded DNA at distal but distinct sites. These sites are shown here to coincide with a bacterial promoter, a phage T7 promoter, a site for gyrase and intrinsically bent DNA. The targets do not seem to share a particular DNA sequence, and in bent DNA, cleavage occurs at the physical center rather than at the common A-tracts. These results indicate that protein contact sites and intrinsic bends assume a non-canonical conformation in the absence of supercoiling or cognate protein binding. This feature may serve as a recognition signal or facilitate protein binding to initiate transcription and recombination.	REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591	Regeneron				Economides, Aris/0000-0002-6508-8942				BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BROSIUS J, 1982, J BIOL CHEM, V257, P9205; CADDLE MS, 1990, J MOL BIOL, V211, P19, DOI 10.1016/0022-2836(90)90008-A; CAMILLONI G, 1991, BIOCHIM BIOPHYS ACTA, V1129, P73, DOI 10.1016/0167-4781(91)90214-7; CASERTA M, 1989, NUCLEIC ACIDS RES, V17, P8463, DOI 10.1093/nar/17.21.8463; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DEMASSY B, 1987, J MOL BIOL, V193, P359, DOI 10.1016/0022-2836(87)90224-5; DICKERSON RE, 1994, P NATL ACAD SCI USA, V91, P3579, DOI 10.1073/pnas.91.9.3579; DICKIE P, 1988, J MOL BIOL, V201, P19, DOI 10.1016/0022-2836(88)90435-4; DICKIE P, 1987, J BIOL CHEM, V262, P14826; ECONOMIDES AN, 1993, THESIS MICHIGAN STAT; ELBOROUGH KM, 1990, EMBO J, V9, P2931, DOI 10.1002/j.1460-2075.1990.tb07484.x; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GRZESKOWIAK K, 1993, BIOCHEMISTRY-US, V32, P8923, DOI 10.1021/bi00085a025; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; HUBNER P, 1989, J MOL BIOL, P493; JENSCH F, 1989, EMBO J, V8, P4325, DOI 10.1002/j.1460-2075.1989.tb08619.x; JEYASEELAN R, 1988, BIOCHEM BIOPH RES CO, V156, P1054, DOI 10.1016/S0006-291X(88)80951-3; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; KIRKEGAARD K, 1981, CELL, V23, P721, DOI 10.1016/0092-8674(81)90435-9; KITCHIN PA, 1986, J BIOL CHEM, V261, P1302; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; LILLEY DMJ, 1984, CELL, V36, P413, DOI 10.1016/0092-8674(84)90234-4; LU M, 1991, J BIOL CHEM, V266, P2531; MARINI JC, 1984, J BIOL CHEM, V259, P8974; MASHAL RD, 1995, NAT GENET, V9, P177, DOI 10.1038/ng0295-177; MULLER B, 1990, NUCLEIC ACIDS RES, V18, P5633, DOI 10.1093/nar/18.19.5633; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; PANAYOTATOS N, 1989, J BIOL CHEM, V264, P15070; PANAYOTATOS N, 1989, J BIOL CHEM, V264, P15066; PARSONS CA, 1990, NUCLEIC ACIDS RES, V18, P4377, DOI 10.1093/nar/18.15.4377; PARVIN JD, 1995, NATURE, V373, P724, DOI 10.1038/373724a0; PEREZMARTIN J, 1994, J MOL BIOL, V241, P7, DOI 10.1006/jmbi.1994.1468; PICKSLEY SM, 1990, J MOL BIOL, V212, P723, DOI 10.1016/0022-2836(90)90233-C; RAMSTEIN J, 1988, P NATL ACAD SCI USA, V85, P7231, DOI 10.1073/pnas.85.19.7231; SIEBENLIST U, 1979, NATURE, V279, P651, DOI 10.1038/279651a0; STROTHKAMP RE, 1980, BIOCHEMISTRY-US, V19, P1074, DOI 10.1021/bi00547a005; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YOUNG MA, 1995, BIOPHYS J, V68, P2454, DOI 10.1016/S0006-3495(95)80427-3; ZAHN K, 1987, SCIENCE, V236, P416, DOI 10.1126/science.2951850; ZAHN K, 1985, NATURE, V317, P451, DOI 10.1038/317451a0	43	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24836	24841		10.1074/jbc.271.40.24836	http://dx.doi.org/10.1074/jbc.271.40.24836			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798758	hybrid			2022-12-27	WOS:A1996VM67400080
J	Medina, R; Grishina, G; Meloni, EG; Muth, TR; Berlot, CH				Medina, R; Grishina, G; Meloni, EG; Muth, TR; Berlot, CH			Localization of the effector-specifying regions of G(i2 alpha) and G(q alpha)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNIT; RECOMBINANT-GQ-ALPHA; ADENYLYL-CYCLASE; PHOSPHOLIPASE-C; SIGNAL TRANSDUCTION; GTP HYDROLYSIS; GS-ALPHA; ACTIVATION; CHIMERAS; BINDING	Heterotrimeric G proteins transmit hormonal and sensory signals received by cell surface receptors to effector proteins that regulate cellular processes. Members of the highly conserved family of cu subunits specifically modulate the activities of a diverse array of effector proteins. To investigate the determinants of alpha subunit-effector specificity, we localized the effector-specifying regions of alpha(i2), which inhibits adenylyl cyclase, and alpha(q), which stimulates phosphoinositide phospholipase C using chimeric alpha subunits. The chimeras were generated using an in vivo recombination method in Escherichia coli. The effector-specifying regions of both alpha(i2) and alpha(q) were localized within the GTPase domain. An alpha(q) alpha(i2)alpha(q) chimera containing only 78 alpha(i2) residues within the GTPase domain robustly inhibited adenylyl cyclase. This alpha(i2) segment includes regions corresponding to two of the three regions of alpha(s) that activate adenylyl cyclase, but does not include any of the alpha subunit regions that switch conformation upon binding GTP. Replacement of the alpha(q) residues that comprise the helical domain with the homologous alpha(i2) residues resulted in a chimeric alpha subunit that activated phospholipase C. Combined with previous studies of the effector-specifying residues of alpha(s) and alpha(t) our results suggest that the effector specificity of alpha subunits is generally determined by the GTPase and not the helical domain.	YALE UNIV, SCH MED, DEPT CELLULAR & MOL PHYSIOL, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, INTERDEPARTMENTAL NEUROSCI PROGRAM, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06520 USA	Yale University; Yale University; Yale University				Muth, Theodore/0000-0002-6882-1193				ANTONELLI M, 1994, FEBS LETT, V340, P249, DOI 10.1016/0014-5793(94)80148-7; ARKINSTALL S, 1995, FEBS LETT, V364, P45, DOI 10.1016/0014-5793(95)00351-9; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CHUNG CT, 1988, NUCLEIC ACIDS RES, V16, P3580, DOI 10.1093/nar/16.8.3580; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; DEBERNARDI MA, 1993, MOL PHARMACOL, V43, P451; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAY GL, 1986, J BACTERIOL, V166, P635, DOI 10.1128/jb.166.2.635-643.1986; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; JONES DT, 1987, J BIOL CHEM, V262, P14241; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEVIN LR, 1995, J BIOL CHEM, V270, P7573, DOI 10.1074/jbc.270.13.7573; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; MOORE KR, 1994, BIOTECHNIQUES, V17, P130; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; PARIS S, 1987, J BIOL CHEM, V262, P1970; QUAN F, 1991, P NATL ACAD SCI USA, V88, P1898, DOI 10.1073/pnas.88.5.1898; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SPICKOFSKY N, 1994, NAT STRUCT BIOL, V1, P771, DOI 10.1038/nsb1194-771; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	57	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24720	24727		10.1074/jbc.271.40.24720	http://dx.doi.org/10.1074/jbc.271.40.24720			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798740	hybrid			2022-12-27	WOS:A1996VM67400062
J	Venable, ME; Bielawska, A; Obeid, LM				Venable, ME; Bielawska, A; Obeid, LM			Ceramide inhibits phospholipase D in a cell-free system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; HUMAN-NEUTROPHILS; HL-60 CELLS; PLASMA-MEMBRANE; D ACTIVATION; GRANULOCYTES; FAMILY; ARF	Recent evidence in whole cells has implicated ceramide in the regulation of phospholipase D (PLD). In intact HL-60 cells, phorbol myristate acetate (PMA) activated PLD as measured by [H-3]palmitate-labeled phosphatidylcholine conversion to phosphatidylethanol in the presence of 2% ethanol. C-6-Ceramide completely inhibited PLD activation after 4 h of treatment and was maximally active at 10 mu m. The activity was structurally specific in that the structural analogs 4,5-dihydro-C-6-ceramide and dioctanoylglycerol were inactive. Although ceramide inhibited PMA-induced activation of PLD, it did not inhibit translocation of protein kinase C (PKC) to the membrane in response to PMA. In a cell-free system, we confirmed that PLD is activated by guanosine 5'-O-(3-thiotriphosphate (GTP gamma S); however, ceramide had no effect on this activity under a variety of conditions. Activation of PLD by GTP gamma S was synergistically enhanced by the addition of PKC activators. This upstream effect was inhibited rapidly and specifically by ceramide (30 mu m). Recombinant ARF plus PKC alpha substituted for crude cytosol in the activation of PLD, and this activity was inhibited by C-6-ceramide. Taken together, these data show that ceramide interferes with PKC-mediated activation of PLD.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,DURHAM,NC 27710	Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Venable, ME (corresponding author), DUKE UNIV,MED CTR,DEPT MED,BOX 3345,DURHAM,NC 27710, USA.			obeid, lina/0000-0002-0734-0847; Venable, Mark/0000-0003-1708-9163	NIA NIH HHS [1R29-AG-12467] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R29AG012467] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KISS Z, 1992, BIOCHIM BIOPHYS ACTA, V1124, P300, DOI 10.1016/0005-2760(92)90143-J; KUSNER DJ, 1993, J BIOL CHEM, V268, P19973; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; MARTINSON EA, 1994, CELL MOL BIOL, V40, P627; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; NAKAMURA T, 1994, J BIOL CHEM, V269, P18384; Nakamura Y, 1996, J IMMUNOL, V156, P256; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OHGUCHI K, 1995, BIOCHEM BIOPH RES CO, V211, P306, DOI 10.1006/bbrc.1995.1811; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PAI JK, 1988, J BIOL CHEM, V263, P12472; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; SONG JG, 1993, BIOCHEM J, V294, P711, DOI 10.1042/bj2940711; TYAGI SR, 1989, J BIOL CHEM, V264, P12977; VANDERMEULEN J, 1990, BIOCHEM J, V271, P693, DOI 10.1042/bj2710693; VENABLE ME, 1994, J BIOL CHEM, V269, P26040; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121	41	89	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24800	24805		10.1074/jbc.271.40.24800	http://dx.doi.org/10.1074/jbc.271.40.24800			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798752	hybrid			2022-12-27	WOS:A1996VM67400074
J	Lee, DY; Clayton, D				Lee, DY; Clayton, D			Properties of a primer RNA-DNA hybrid at the mouse mitochondrial DNA leading-strand origin of replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED PROTEINS; TELOMERIC DNA; SWITCH REGION; G-QUARTET; INITIATION; TRANSCRIPTION; SITE; BACTERIOPHAGE-T7; POLYMERASE; MODEL	Primers for vertebrate mitochondrial leading-strand DNA replication are products of transcription synthesized by mitochondrial RNA polymerase. The precursor primer RNA exists as a persistent RNA-DNA hybrid, known as an R-loop, formed during transcription through the replication origin (Xu, B., and Clayton, D. A. (1996) EMBO J. 15, 3135-3143). In an effort to examine the precise structure of this primer RNA intermediate, we have used two methods to reconstitute model R-loops containing the mouse mitochondrial DNA origin sequence. First, we demonstrate that bacteriophage SP6 RNA polymerase can efficiently catalyze the formation of an R-loop at the mouse mtDNA origin sequence. Second, the R-loop can be assembled by annealing presynthesized RNA and supercoiled DNA template in the presence of formamide. R-loop formation by either method is dependent on specific template sequences. The reconstituted R-loop is exceptionally stable and exhibits an unexpected structure. Structural studies indicate that the RNA strand is organized within the RNA-DNA base-paired region, suggesting that the heteroduplex interaction occurs through a specific conformation. We propose that the organized structure of the R-loop is critical for primer RNA function in vivo with important implications for the RNA processing and DNA replication machinery.	STANFORD UNIV,DEPT DEV BIOL,BECKMAN CTR MOL & GENET MED,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033088, T32GM007365, R01GM033088] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33088-25, GM07365-18] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BENNETT JL, 1990, MOL CELL BIOL, V10, P2191, DOI 10.1128/MCB.10.5.2191; BOGENHAGEN D, 1978, J MOL BIOL, V119, P69, DOI 10.1016/0022-2836(78)90270-X; CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHEONG CJ, 1992, BIOCHEMISTRY-US, V31, P8406, DOI 10.1021/bi00151a003; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; Daniels GA, 1995, NUCLEIC ACIDS RES, V23, P5006, DOI 10.1093/nar/23.24.5006; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; FULLER CW, 1985, J BIOL CHEM, V260, P3185; GAMPER HB, 1982, CELL, V29, P81, DOI 10.1016/0092-8674(82)90092-7; GILLUM AM, 1979, J MOL BIOL, V135, P353, DOI 10.1016/0022-2836(79)90441-8; GRABCZYK E, 1995, J BIOL CHEM, V270, P1791, DOI 10.1074/jbc.270.4.1791; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; KORNBERG A, 1992, DNA REPLICATION, P209; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MASUKATA H, 1990, CELL, V62, P331, DOI 10.1016/0092-8674(90)90370-T; REABAN ME, 1994, J BIOL CHEM, V269, P21850; REABAN ME, 1990, NATURE, V348, P342, DOI 10.1038/348342a0; ROMANO LJ, 1981, P NATL ACAD SCI-BIOL, V78, P4107, DOI 10.1073/pnas.78.7.4107; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; THOMAS M, 1976, P NATL ACAD SCI USA, V73, P2294, DOI 10.1073/pnas.73.7.2294; VINOGRAD J, 1968, J MOL BIOL, V33, P173, DOI 10.1016/0022-2836(68)90287-8; WALBERG MW, 1981, NUCLEIC ACIDS RES, V9, P5411, DOI 10.1093/nar/9.20.5411; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; XU BJ, 1995, MOL CELL BIOL, V15, P580, DOI 10.1128/MCB.15.1.580; Xu BJ, 1996, EMBO J, V15, P3135, DOI 10.1002/j.1460-2075.1996.tb00676.x; ZIMMERMAN SB, 1975, J MOL BIOL, V92, P181, DOI 10.1016/0022-2836(75)90222-3	31	63	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24262	24269		10.1074/jbc.271.39.24262	http://dx.doi.org/10.1074/jbc.271.39.24262			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798672	hybrid			2022-12-27	WOS:A1996VJ44200101
J	Rezaie, AR				Rezaie, AR			Role of residue 99 at the S2 subsite of factor Xa and activated protein C in enzyme specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-THROMBOMODULIN COMPLEX; HUMAN ALPHA-THROMBIN; COAGULATION FACTOR-V; PRO-TRP INSERTION; BLOOD-COAGULATION; ANTITHROMBIN-III; KUNITZ INHIBITORS; DOMAIN; SITE; RECONSTITUTION	It is thought that only a limited number of residues in the extended binding pocket of coagulation proteases are critical for substrate and inhibitor specificity, A candidate residue from the crystal structures of thrombin and factor Xa (FXa) that may be critical for specificity at the S2 subsite is residue 99, Residue 99 is Tyr in FXa and Thr in activated protein C (APC), To determine the role of residue 99 in S2 specificity, a Gla-domainless mutant of protein C (GDPC) was prepared in which Thr(99) was replaced with Tyr of FXa, GDPC T99Y bound Ca2+ and was activated by the thrombin-thrombomodulin complex normally, The T99Y mutant, similar to FXa, hydrolyzed the chromogenic substrates with a Gly at the P2 positions, This mutant was also inhibited by antithrombin (AT) (k(2) = 4.2 +/- 0.2 x 10(1) M(-1) s(-1)), and heparin accelerated the reaction >350-fold (k(2) = 1.5 +/- 0.1 x 10(4) M(-1) s(-1)). The T99Y mutant, however, did not activate prothrombin but inactivated factor Va approximate to 2-fold better than wild type, To try to switch the specificity of FXa, both Tyr(99) and Gln(192) of FXa were replaced with those of APC in the Gla-domainless factor X (GDFX Y99T/Q192E), This mutant was folded correctly as it bound Ca2+ with a similar affinity as GDFX and was also activated by the Russell's viper venom at similar rate, but it cleaved the chromogenic substrates with a Gly at the P2 positions poorly, The mutant, instead, cleaved the APC-specific chromogenic substrates efficiently, The Y99T/Q192E mutant became resistant to inhibition by AT in the absence of heparin but was inhibited by AT almost normally in the presence of heparin (k(2) = 3.4 +/- 0.5 x 10(5) M(-1) s(-1)). The Y99T/Q192E mutant did not inactivate factor Va, and prothrombin activation by this mutant was impaired, These results indicate that 1) residue 99 is critical for enzyme specificity at the S2 subsite, 2) a role for heparin in acceleration of FXa inhibition by AT may involve the S2-P2 modulation, and 3) the exchange of residues 99 and 192 in FXa and APC may switch the enzyme specificity with the chromogenic substrates and inhibitors but not with the natural substrates.			Rezaie, AR (corresponding author), OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104, USA.				NHLBI NIH HHS [P01 HL54804] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DANGELO SV, 1986, J CLIN INVEST, V77, P416, DOI 10.1172/JCI112319; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1982, J BIOL CHEM, V257, P7944; ESMON CT, 1989, J BIOL CHEM, V264, P4743; ESMON CT, 1977, CHEM BIOL THROMBIN, P403; ESMON CT, 1973, THESIS WASHINGTON U; FISHER CL, 1994, PROTEIN SCI, V3, P588; Furie B.C., 1976, Methods Enzymol, V45, P191; GALVIN JB, 1987, J BIOL CHEM, V262, P2199; GRIFFITH MJ, 1982, THROMB RES, V25, P245, DOI 10.1016/0049-3848(82)90244-4; GUINTO ER, 1994, J BIOL CHEM, V269, P18395; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOPKINS PCR, 1995, J BIOL CHEM, V270, P11866, DOI 10.1074/jbc.270.20.11866; JAKUBOWSKI HV, 1986, J BIOL CHEM, V261, P3876; KANE WH, 1988, BLOOD, V71, P539; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LEBONNIEC BF, 1993, J BIOL CHEM, V268, P19055; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; MANN KG, 1984, PROG HEMOST THROMB, V7, P1; MANN KG, 1990, BLOOD, V76, P1; MESTERS RM, 1993, PROTEIN SCI, V2, P1482, DOI 10.1002/pro.5560020912; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; REZAIE AR, 1993, J BIOL CHEM, V268, P19943; REZAIE AR, 1995, J BIOL CHEM, V270, P25336, DOI 10.1074/jbc.270.43.25336; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; REZAIE AR, 1995, J BIOL CHEM, V270, P16176, DOI 10.1074/jbc.270.27.16176; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; Rezaie AR, 1996, BIOCHEMISTRY-US, V35, P1918, DOI 10.1021/bi952065y; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEEHAN JP, 1993, THROMB HAEMOSTASIS, V69, P1044; SKOGEN WF, 1983, BIOCHEM BIOPH RES CO, V111, P14, DOI 10.1016/S0006-291X(83)80110-7; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; YE J, 1994, J BIOL CHEM, V269, P17965	41	43	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23807	23814		10.1074/jbc.271.39.23807	http://dx.doi.org/10.1074/jbc.271.39.23807			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798609				2022-12-27	WOS:A1996VJ44200038
J	Sun, DX; Funk, CD				Sun, DX; Funk, CD			Disruption of 12/15-lipoxygenase expression in peritoneal macrophages - Enhanced utilization of the 5-lipoxygenase pathway and diminished oxidation of low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONATE 12-LIPOXYGENASE; MESSENGER-RNA; TARGETED DISRUPTION; ATHEROSCLEROTIC LESIONS; HUMAN 15-LIPOXYGENASE; PORCINE LEUKOCYTES; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; PLATELET-TYPE; LIPOXYGENASE	Previously, we isolated the murine ''leukocyte-type'' 12-lipoxygenase (L-12LO) cDNA from RNA of peritoneal-elicited cells that consisted predominantly of leukocytes (Chen, X.-S., Kurre, U., Jenkins, N. A., Copeland, N. G., and Funk, C. D. (1994) J. Biol. Chem. 269, 13979-13987). By in situ hybridization we show that the L-12LO gene is expressed abundantly in a subset of peritoneal macrophages but not in elicited leukocytes, alveolar macrophages, or bone marrow-derived macrophages. L-12LO is highly related to human and rabbit 15-lipoxygenases, enzymes that have been implicated in the maturation process of red blood cells, and the oxidative modification of low density lipoproteins that is implicated in atherogenesis. Accordingly, these enzymes have been referred to as 12/15-lipoxygenases. We have inactivated the L-12LO gene in mice using homologous recombination in embryonic stem cells. Macrophage expression of L-12LO was abolished in homozygous deficient mice as was formation of 12-hydroxyeicosatetraenoic acid (12-HETE). In zymosan-stimulated cells, there was significant diversion of metabolism to the 5-lipoxygenase products leukotriene C-4 and 5-HETE and in A23187-treated cells to 5-HETE only. The enhanced formation of 5-lipoxygenase metabolites was not due to compensatory changes of 5-lipoxygenase or 5-lipoxygenase activating protein but rather an apparent substrate diversion. L-12LO-deficient mice have no obvious abnormalities in reticulocyte or mature red blood cells, which suggest that in mice this pathway is not functionally important for erythrocytic development. Indices for oxidation of low density lipoprotein (measured as either thiobarbituric acid-reactive substances or the oxidant stress marker isoprostane 8-epi-prostaglandin F-2 alpha) were identical in incubations with unstimulated wild type and L-12LO deficient macrophages, but the zymosan-induced increase observed with wild-type macrophages was abolished in L-12LO-deficient cells, Thus, 12/15-lipoxygenase-deficient mice will be useful for the study of interaction between lipoxygenase pathways and determination of the in vivo role of 12/15-lipoxygenase-catalyzed oxidation of LDL in atherogenesis.	UNIV PENN, STELLAR CHANCE LAB, CTR EXPT THERAPEUT, PHILADELPHIA, PA 19104 USA	University of Pennsylvania			Sun, Duxin/AAA-1774-2022; Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053558, R01HL046017, K04HL002710] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS DO, 1984, ANNU REV IMMUNOL, V2, P283, DOI 10.1146/annurev.immunol.2.1.283; BENZ DJ, 1995, J BIOL CHEM, V270, P5191, DOI 10.1074/jbc.270.10.5191; BOLTZNITULESCU G, 1981, CELL IMMUNOL, V59, P106, DOI 10.1016/0008-8749(81)90438-X; CARLSON RP, 1985, AGENTS ACTIONS, V17, P197, DOI 10.1007/BF01966592; CATHCART MK, 1988, IN VITRO CELL DEV B, V24, P1001; CHANG WC, 1993, J BIOL CHEM, V268, P18734; CHEN XS, 1994, J BIOL CHEM, V269, P13979; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; CHEN XS, 1993, FASEB J, V7, P694, DOI 10.1096/fasebj.7.8.8500694; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; COWAN HB, 1992, ARCH BIOCHEM BIOPHYS, V296, P314, DOI 10.1016/0003-9861(92)90578-K; DELANEROLLE P, 1993, J BIOL CHEM, V268, P16883; DEMARZO N, 1992, AM J PHYSIOL, V262, pL198; DING AH, 1988, J IMMUNOL, V141, P2407; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; FUNK CD, 1993, PROG NUCLEIC ACID RE, V45, P67, DOI 10.1016/S0079-6603(08)60867-3; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HARATS D, 1995, TRENDS CARDIOVAS MED, V5, P29, DOI 10.1016/1050-1738(94)00029-U; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HUSSAIN H, 1994, AM J PHYSIOL, V266, pC243, DOI 10.1152/ajpcell.1994.266.1.C243; JESSUP W, 1991, BIOCHEM J, V278, P163, DOI 10.1042/bj2780163; KUHN H, 1990, J BIOL CHEM, V265, P1454; LEVY BD, 1993, J CLIN INVEST, V92, P1572, DOI 10.1172/JCI116738; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; NADEL JA, 1991, J CLIN INVEST, V87, P1139, DOI 10.1172/JCI115110; NASSAR GM, 1994, J BIOL CHEM, V269, P27631; NISHIYAMA M, 1993, J HISTOCHEM CYTOCHEM, V41, P111, DOI 10.1177/41.1.8417106; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; PRATICO D, 1995, J BIOL CHEM, V270, P9800, DOI 10.1074/jbc.270.17.9800; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; RAPOPORT SM, 1986, BIOCHIM BIOPHYS ACTA, V864, P471, DOI 10.1016/0304-4157(86)90006-7; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHUH J, 1978, P NATL ACAD SCI USA, V75, P3173, DOI 10.1073/pnas.75.7.3173; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; SHINJO F, 1986, J BIOL CHEM, V261, P3377; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPARROW CP, 1992, P NATL ACAD SCI USA, V89, P128, DOI 10.1073/pnas.89.1.128; SPARROW CP, 1988, J LIPID RES, V29, P745; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TAKAHASHI Y, 1993, J BIOL CHEM, V268, P16443; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; WALKER WS, 1974, IMMUNOLOGY, V26, P1025; WALSTRA P, 1987, BIOCHIM BIOPHYS ACTA, V921, P312, DOI 10.1016/0005-2760(87)90032-4; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; YOKOYAMA C, 1986, J BIOL CHEM, V261, P6714; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142	54	214	215	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24055	24062		10.1074/jbc.271.39.24055	http://dx.doi.org/10.1074/jbc.271.39.24055			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798642	hybrid			2022-12-27	WOS:A1996VJ44200071
J	vanEs, S; Virdy, KJ; Pitt, GS; Meima, M; Sands, TW; Devreotes, PN; Cotter, DA; Schaap, P				vanEs, S; Virdy, KJ; Pitt, GS; Meima, M; Sands, TW; Devreotes, PN; Cotter, DA; Schaap, P			Adenylyl cyclase G, an osmosensor controlling germination of Dictyostelium spores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; REGULATORY SUBUNIT; GENE-EXPRESSION; CAMP; DIFFERENTIATION; DISCOIDEUM; PRESPORE; SUFFICIENT; CELLS; YEAST	Dictyostelium cells express a G-protein-coupled adenylyl cyclase, ACA, during aggregation and an atypical adenylyl cyclase, ACG, in mature spores, The ACG gene was disrupted by homologous recombination. acg(-) cells developed into normal fruiting bodies with viable spores, but spore germination was no longer inhibited by high osmolarity, a fairly universal constraint for spore and seed germination, ACG activity, measured in aca(-)/ACG cells, was strongly stimulated by high osmolarity with optimal stimulation occurring at 200 milliosmolar. RdeC mutants, which display unrestrained protein kinase A (PKA) activity and a cell line, which overexpresses PKA under a prespore specific promoter, germinate very poorly, both at high and low osmolarity, These data indicate that ACG is an osmosensor controlling spore germination through activation of protein kinase A.	LEIDEN UNIV,CELL BIOL SECT,INST MOL PLANT SCI,NL-2333 AL LEIDEN,NETHERLANDS; UNIV WINDSOR,DEPT BIOL SCI,WINDSOR,ON N9B 3P4,CANADA; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Leiden University; Leiden University - Excl LUMC; University of Windsor; Johns Hopkins University			Pitt, Geoffrey/L-4927-2019; Schaap, Pauline/A-3682-2009; Schaap, Pauline/M-5355-2019	Schaap, Pauline/0000-0003-4500-2555; Schaap, Pauline/0000-0003-4500-2555				ABE H, 1976, Tetrahedron Letters, V42, P3807; BURKI E, 1991, GENE, V102, P57, DOI 10.1016/0378-1119(91)90538-M; COTTER DA, 1977, CAN J MICROBIOL, V23, P1170, DOI 10.1139/m77-176; COTTER DA, 1981, FUNGAL SPORE MORPHOG, P385; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; HARWOOD AJ, 1992, CELL, V69, P615, DOI 10.1016/0092-8674(92)90225-2; HOPPER NA, 1993, EMBO J, V12, P2459, DOI 10.1002/j.1460-2075.1993.tb05900.x; KAHN A, 1960, PLANT PHYSIOL, V35, P1, DOI 10.1104/pp.35.1.1; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MANN SKO, 1993, DEVELOPMENT, V119, P135; MANN SKO, 1994, P NATL ACAD SCI USA, V91, P10561, DOI 10.1073/pnas.91.22.10561; MANN SKO, 1991, MECH DEVELOP, V35, P89, DOI 10.1016/0925-4773(91)90060-J; MIZUNO T, 1990, MOL MICROBIOL, V4, P1077, DOI 10.1111/j.1365-2958.1990.tb00681.x; MUTZEL R, 1987, P NATL ACAD SCI USA, V84, P6, DOI 10.1073/pnas.84.1.6; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PITT GS, 1993, GENE DEV, V7, P2172, DOI 10.1101/gad.7.11.2172; SCHULKES C, 1995, FEBS LETT, V368, P381, DOI 10.1016/0014-5793(95)00676-Z; SIMON MN, 1992, NATURE, V356, P171, DOI 10.1038/356171a0; SIMON MN, 1989, EMBO J, V8, P2039, DOI 10.1002/j.1460-2075.1989.tb03612.x; WELBAUM GE, 1990, PLANT PHYSIOL, V92, P1029, DOI 10.1104/pp.92.4.1029; WERNER JE, 1995, PHYSIOL PLANTARUM, V93, P659, DOI 10.1111/j.1399-3054.1995.tb05114.x	23	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23623	23625		10.1074/jbc.271.39.23623	http://dx.doi.org/10.1074/jbc.271.39.23623			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798577				2022-12-27	WOS:A1996VJ44200006
J	Yokosaki, Y; Monis, H; Chen, J; Sheppard, D				Yokosaki, Y; Monis, H; Chen, J; Sheppard, D			Differential effects of the integrins alpha 9 beta 1, alpha v beta 3, and alpha v beta 6 on cell proliferative responses to tenascin - Roles of the beta subunit extracellular and cytoplasmic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; FIBRONECTIN; ADHESION; GROWTH; EXPRESSION; PROTEIN; MATRIX; ANGIOGENESIS; ATTACHMENT; BINDING	Members of the integrin family manifest considerable overlap in ligand specificity, and many cells have the capacity to express multiple integrin receptors for the same ligand. For example, at least 5 different integrins recognize tenascin as a ligand, and 4 of these bind to the same region of the protein, the third fibronectin type III repeat (TNfn3). We utilized colon carcinoma cells (SW480) that do not normally attach to TNfn3 to examine the possibility that ligation of different integrin receptors for this ligand would induce different effects on cell behavior and intracellular signaling. Heterologous expression of the tenascin receptors alpha v beta 3 and alpha 9 beta 1 produced comparable effects on cell adhesion and spreading on TNfn3, but alpha v beta 3-transfectants proliferated considerably better on each concentration examined, alpha v beta 6-transfectants attached (although less avidly), but completely failed to spread or proliferate. Expression of a chimeric beta subunit composed of the beta 3 extracellular domain fused to the beta 6 transmembrane and cytoplasmic domains resulted in adhesion and spreading similar to that seen with beta 3-transfectants, but considerably less proliferation. When the same cell lines were plated on fibronectin, alpha v beta 6-transfectants spread and proliferated as well as cells transfected with the chimeric beta 3/beta 6 subunit, but, again, neither cell line proliferated as well as cells expressing alpha v beta 3. Cell proliferation was always associated with spreading and with phosphorylation of the focal adhesion kinase, paxillin, and the mitogen-activated kinase, Erk2, but cell attachment in the absence of spreading or proliferation was not associated with phosphorylation of any of these proteins. These data suggest that different integrin receptors for a single ligand can produce markedly different effects on cell proliferation, and that both the extracellular and cyto plasmic domains of integrin beta subunits contribute to these differences.	UNIV CALIF SAN FRANCISCO,LUNG BIOL CTR,CTR ENVIRONM & OCCUPAT HLTH,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NHLBI NIH HHS [HL/A133259, HL53949, HL47412] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047412, R01HL053949, R37HL053949] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGREZ M, 1994, J CELL BIOL, V127, P547, DOI 10.1083/jcb.127.2.547; BREUSS JM, 1995, J CELL SCI, V108, P2241; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BUSK M, 1992, J BIOL CHEM, V267, P5790; CHEN QM, 1994, J BIOL CHEM, V269, P26602; DITTEL BN, 1993, BLOOD, V81, P2272; END P, 1992, EUR J BIOCHEM, V209, P1041, DOI 10.1111/j.1432-1033.1992.tb17380.x; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GRINNELL F, 1977, EXP CELL RES, V110, P175, DOI 10.1016/0014-4827(77)90284-1; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HANSEN LK, 1994, MOL BIOL CELL, V5, P967, DOI 10.1091/mbc.5.9.967; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; KANNO S, 1994, PATHOL INT, V44, P96, DOI 10.1111/j.1440-1827.1994.tb01693.x; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; MOONEY D, 1992, J CELL PHYSIOL, V151, P497, DOI 10.1002/jcp.1041510308; NEWMAN PJ, 1985, BLOOD, V65, P227; NISHIMURA SL, 1994, J BIOL CHEM, V269, P28708; PRIETO AL, 1992, J CELL BIOL, V119, P663, DOI 10.1083/jcb.119.3.663; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; Rulo H. F. C., 1993, Journal of Dermatological Science, V5, P54, DOI 10.1016/0923-1811(93)90106-Y; SAMBROOK J, 1989, TRANSFECTION COPRECI; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; WNG A, 1996, IN PRESS AM J RESPIR; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691; YOUNG SL, 1994, DEV BIOL, V161, P615, DOI 10.1006/dbio.1994.1057; ZAGZAG D, 1995, CANCER RES, V55, P907; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	35	130	144	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24144	24150		10.1074/jbc.271.39.24144	http://dx.doi.org/10.1074/jbc.271.39.24144			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798654	hybrid			2022-12-27	WOS:A1996VJ44200083
J	Sawaya, BE; Rohr, O; Aunis, D; Schaeffer, E				Sawaya, BE; Rohr, O; Aunis, D; Schaeffer, E			Chicken ovalbumin upstream promoter transcription factor, a transcriptional activator of HIV-1 gene expression in human brain cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CENTRAL-NERVOUS-SYSTEM; LONG TERMINAL REPEAT; NF-KAPPA-B; STEROID-RECEPTOR SUPERFAMILY; HUMAN TRANSFERRIN GENE; TRANSGENIC MICE; THYROID-HORMONE; NEURONAL CELLS; FACTOR TFIIB	Viral infection of the central nervous system by the human immunodeficiency virus type 1 leads to a wide range of neuropathological disorders. However, the molecular mechanisms governing transcription of the human immunodeficiency virus type 1 genome in brain remain unclear.We have recently established that in brain cells, proteins belonging to the steroid/thyroid/ retinoic acid receptor family bind to the -352 to -320 region of the long terminal repeat (LTR). Here, by supershift experiments, we have identified chicken ovalbumin upstream promoter transcription factor (COUP-TF), an orphan member of this nuclear receptor family, as one of the major proteins interacting with this LTR site. Cotransfection studies revealed that COUP-TF is able to dramatically activate LTR-directed gene transcription in human oligodendroglioma but not in astrocytoma cells. This activation occurs through two mechanisms, depending on the LTR sequence. Moreover, in neuronal cells COUP-TF and dopamine, a catecholamine neurotransmitter, enhance LTR directed transcription by acting on the proximal LTR region. These results reveal the importance of COUP-TF and the dopamine signaling pathway as activators of human immunodeficiency virus type 1 gene expression in brain.	INSERM,UITE 338,F-67084 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Dominique, Aunis/W-1419-2019	ROHR, Olivier/0000-0001-8992-2025				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; BUSY JM, 1995, VIROLOGY, V210, P361; CANONNEHERGAUX F, 1995, J VIROL, V69, P6634, DOI 10.1128/JVI.69.11.6634-6642.1995; COONEY AJ, 1991, J VIROL, V65, P2853, DOI 10.1128/JVI.65.6.2853-2860.1991; CORBOY JR, 1992, SCIENCE, V258, P1804, DOI 10.1126/science.1465618; DESAIYAJNIK V, 1993, MOL CELL BIOL, V13, P5057, DOI 10.1128/MCB.13.8.5057; GARCIA JA, 1994, PROG NUCLEIC ACID RE, V49, P157; GAYNOR R, 1992, AIDS, V6, P3761; GELEZIUNAS R, 1992, AIDS, V6, P1411, DOI 10.1097/00002030-199212000-00001; GUILLOU F, 1991, J BIOL CHEM, V266, P9876; GYORKEY F, 1987, J INFECT DIS, V155, P870, DOI 10.1093/infdis/155.5.870; ING NH, 1992, J BIOL CHEM, V267, P17617; KADOWAKI Y, 1995, P NATL ACAD SCI USA, V92, P4432, DOI 10.1073/pnas.92.10.4432; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; LADIAS JAA, 1994, J BIOL CHEM, V269, P5944; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LEE MO, 1994, P NATL ACAD SCI USA, V91, P5632, DOI 10.1073/pnas.91.12.5632; LEONARD JM, 1988, SCIENCE, V242, P1665, DOI 10.1126/science.3201255; MASDONALD PN, 1995, J BIOL CHEM, V270, P4748; MERRILL JE, 1988, AGENTS, V2, P77; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; NUOVO GJ, 1994, AM J PATHOL, V144, P659; PORTEGIE SP, 1991, AIDS S2, V5, pS211; POWER C, 1994, J VIROL, V68, P4643, DOI 10.1128/JVI.68.7.4643-4649.1994; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; Rahman A, 1995, J BIOL CHEM, V270, P31059, DOI 10.1074/jbc.270.52.31059; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; SAWAYA BE, 1995, NUCLEIC ACIDS RES, V23, P2206, DOI 10.1093/nar/23.12.2206; SCHAEFFER E, 1993, J BIOL CHEM, V268, P23399; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; TAYLOR JP, 1994, J VIROL, V68, P3971, DOI 10.1128/JVI.68.6.3971-3981.1994; TAYLOR JP, 1994, ADV NEUROIMMUNOL, V4, P291, DOI 10.1016/S0960-5428(06)80270-6; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WANG LH, 1987, J BIOL CHEM, V262, P16080; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089	41	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23572	23576		10.1074/jbc.271.38.23572	http://dx.doi.org/10.1074/jbc.271.38.23572			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798567	Green Published, hybrid			2022-12-27	WOS:A1996VH76800093
J	Kwon, J; Lee, SJ; Benveniste, EN				Kwon, J; Lee, SJ; Benveniste, EN			A 3' cis-acting element is involved in tumor necrosis factor-alpha gene expression in astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROMOTER REGION; HYPERSENSITIVE SITES; ENHANCER ELEMENTS; CELL LINES; T-CELL; ACTIVATION; LIPOPOLYSACCHARIDE; TRANSCRIPTION; PROTEIN	Tumor necrosis factor-alpha (TNF-alpha) contributes to demyelinating diseases in the central nervous system. Astrocytes, the major glial cells in the CNS, do not constitutively express TNF-alpha, but the TNF-alpha gene is transcriptionally activated in response to a variety of stimuli, including TNF-alpha itself. Because of the importance of TNF-alpha in the CNS, we examined the mechanisms underlying transcriptional regulation of the TNF-alpha gene in astrocytes, In transient transfection assays, a plasmid construct containing 1.3 kilobase pairs (kb) of 5' flanking sequence of the rat TNF-alpha gene showed high basal activity that could not be further enhanced by TNF-alpha stimulation. A ''marked'' 10-kb TNF-alpha gene construct, which contains the whole TNF-beta gene with 1.2 kb of 5' flanking sequence, 1.1 kb of intergenic sequence, and the whole TNF-alpha gene with 3 kb of 3' flanking sequence, was able to respond to TNF-alpha stimulation, Analysis of a series of 5' and 3' deletion constructs of the marked TNF-alpha genes demonstrated that upstream sequence elements such as NF-kappa B are not required for TNF-alpha induction and that TNF-alpha responsive elements are located in the 3' flanking region of the TNF-alpha gene, We also found that a TNF-alpha-inducible DNase I-hypersensitive (DH) site is present in this 3' region whose deletion abolishes TNF-alpha inducibility of the marked TNF-alpha gene. Electrophoresis mobility shift assays showed that TNF-alpha-inducible nuclear proteins, consisting of p50 and p65 NF-kappa B proteins, specifically bind to two consecutive NF-kappa B binding sites within the 3' DH site, These results indicate that TNF-alpha-induced TNF-alpha gene expression in astrocytes involves p50 and p65 NF-kappa B proteins binding to downstream NF-kappa B sites and concomitant modulation of the chromatin structure.	UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NIMH NIH HHS [MH-50421] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH050421] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BENVENISTE EN, 1994, J IMMUNOL, V153, P5210; BENVENISTE EN, 1995, HUMAN CYTOKINES THEI, P195; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CEREGHINI S, 1984, EMBO J, V3, P1243, DOI 10.1002/j.1460-2075.1984.tb01959.x; CHUNG IY, 1992, J IMMUNOL, V149, P3894; CHUNG IY, 1990, J IMMUNOL, V144, P2999; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; ECONOMOU JS, 1989, J EXP MED, V170, P321, DOI 10.1084/jem.170.1.321; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HENSEL G, 1987, LYMPHOKINE RES, V6, P119; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KRAMER B, 1995, J BIOL CHEM, V270, P6577; KUPRASH DV, 1995, ONCOGENE, V11, P97; KWON JB, 1993, GENE, V132, P227, DOI 10.1016/0378-1119(93)90200-M; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEITMAN DC, 1992, MOL CELL BIOL, V12, P1352, DOI 10.1128/MCB.12.3.1352; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PANEK RB, 1992, P NATL ACAD SCI USA, V89, P11518, DOI 10.1073/pnas.89.23.11518; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; PESSARA U, 1990, MOL CELL BIOL, V10, P4146, DOI 10.1128/MCB.10.8.4146; POPE RM, 1994, J CLIN INVEST, V94, P1449, DOI 10.1172/JCI117482; PROBERT L, 1995, P NATL ACAD SCI USA, V92, P11294, DOI 10.1073/pnas.92.24.11294; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; ROBBINS DS, 1987, J IMMUNOL, V139, P2593; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SPARACIO SM, 1992, J NEUROIMMUNOL, V39, P231, DOI 10.1016/0165-5728(92)90257-L	40	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22383	22390		10.1074/jbc.271.37.22383	http://dx.doi.org/10.1074/jbc.271.37.22383			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798400	hybrid			2022-12-27	WOS:A1996VG67200019
J	Sawaya, BE; Rohr, O; Aunis, D; Schaeffer, E				Sawaya, BE; Rohr, O; Aunis, D; Schaeffer, E			Regulation of human immunodeficiency virus type 1 gene transcription by nuclear receptors in human brain cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; RETINOIC ACID RECEPTORS; CENTRAL-NERVOUS-SYSTEM; THYROID-HORMONE RECEPTOR; HUMAN TRANSFERRIN GENE; NF-KAPPA-B; PHORBOL ESTER; CO-REPRESSOR; X-RECEPTOR; EXPRESSION	Infection of cells of the central nervous system by the human immunodeficiency virus type-1 (HIV-1) leads to HIV-1-associated neuropathology. Recent studies have demonstrated the importance of long terminal repeat (LTR) binding sites in determining the pathogenicity of HIV. Here we have investigated the presence and the functional role of transcription factors that have the potential to interact, directly or indirectly, with the nuclear receptor-responsive element in the LTR of HIV-1, in different human cell lines of the brain. Cotransfection experiments showed that in oligodendroglioma TC-620 cells, the retinoic acid receptor and the retinoid X receptor activate LTR-driven transcription in the absence of ligand. Addition of all trans- or 9-cis-retinoic acid reverses this effect. In contrast, in astrocytoma, neuronal, and microglial cells, no significant effect of the retinoid acid pathway was detected. This retinoid response is mediated by distinct molecular interactions in the lymphotropic LAI and the neurotropic JR-CSF HIV-1 strains. Moreover, retinoid receptors were found to antagonize the chicken ovalbumin upstream promoter transcription factor- as well as the c-JUN-mediated LTR transactivation, Our findings demonstrate the importance of the retinoic acid signaling pathway and of cross coupling interactions in the repression of HIV-1 LTR gene expression.	INSERM,UNITE 338,F-67084 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Dominique, Aunis/W-1419-2019	ROHR, Olivier/0000-0001-8992-2025				BERRODIN TJ, 1992, MOL ENDOCRINOL, V6, P1468, DOI 10.1210/me.6.9.1468; CANONNEHERGAUX F, 1995, J VIROL, V69, P6634, DOI 10.1128/JVI.69.11.6634-6642.1995; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CORBOY JR, 1992, SCIENCE, V258, P1804, DOI 10.1126/science.1465618; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; DESAIYAJNIK V, 1993, MOL CELL BIOL, V13, P5057, DOI 10.1128/MCB.13.8.5057; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GAYNOR R, 1992, AIDS, V6, P3761; GUILLOU F, 1991, J BIOL CHEM, V266, P9876; GYORKEY F, 1987, J INFECT DIS, V155, P870, DOI 10.1093/infdis/155.5.870; HATCH WC, 1994, AIDS RES HUM RETROV, V10, P1597, DOI 10.1089/aid.1994.10.1597; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JANABI N, 1995, NEUROSCI LETT, V195, P105, DOI 10.1016/0304-3940(94)11792-H; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LADIAS JAA, 1994, J BIOL CHEM, V269, P5944; LEE MO, 1994, P NATL ACAD SCI USA, V91, P5632, DOI 10.1073/pnas.91.12.5632; LINNEY E, 1992, CURR TOP DEV BIOL, V27, P309, DOI 10.1016/S0070-2153(08)60538-4; MACIASZEK JW, 1994, J VIROL, V68, P6598, DOI 10.1128/JVI.68.10.6598-6604.1994; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MERRILL JE, 1988, AGENTS, V2, P77; NUOVO GJ, 1994, AM J PATHOL, V144, P659; ORCHARD K, 1993, J ACQ IMMUN DEF SYND, V6, P440; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; POLI G, 1992, P NATL ACAD SCI USA, V89, P2689, DOI 10.1073/pnas.89.7.2689; Rahman A, 1995, J BIOL CHEM, V270, P31059, DOI 10.1074/jbc.270.52.31059; RANKI A, 1995, AIDS, V9, P1001, DOI 10.1097/00002030-199509000-00004; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SCHAEFFER E, 1989, J BIOL CHEM, V264, P7153; TOWERS G, 1995, AIDS, V9, P129, DOI 10.1097/00002030-199509020-00003; TURPIN JA, 1992, J IMMUNOL, V148, P2539; WANG LH, 1987, J BIOL CHEM, V262, P16080; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; YAMAGUCHI K, 1994, AIDS, V8, P1675, DOI 10.1097/00002030-199412000-00006	38	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22895	22900		10.1074/jbc.271.37.22895	http://dx.doi.org/10.1074/jbc.271.37.22895			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798469	Green Published, hybrid			2022-12-27	WOS:A1996VG67200088
J	Schulz, K; Danner, S; Bauer, P; Schroder, S; Lohse, MJ				Schulz, K; Danner, S; Bauer, P; Schroder, S; Lohse, MJ			Expression of phosducin in a phosducin-negative cell line reveals functions of a G(beta gamma)-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENERGIC-RECEPTOR KINASE; BETA-GAMMA-SUBUNITS; MUSCARINIC ACETYLCHOLINE-RECEPTORS; PLECKSTRIN-HOMOLOGY DOMAIN; HETEROTRIMERIC G-PROTEINS; DEPENDENT PHOSPHORYLATION; BETA-2-ADRENERGIC RECEPTORS; ADENOSINE RECEPTORS; CYCLIC-AMP; DESENSITIZATION	Phosducin is a member of the large group of proteins that bind to G-protein beta gamma-subunits (G(beta gamma)) and whose biological functions are often unknown. Human A431 cells do not contain detectable amounts of phosducin. We generated A431 cells expressing phosducin at a level of approximate to 1 pmol/mg of cytosolic protein, which is approximate to 10% of the phosducin level in brain, cAMP accumulation in response to beta(2)-adrenergic receptor agonists was enhanced at early times in phosducin-expressing cells, but reached a lower plateau than in control cells. Permeabilization of the cells with digitonin did not change this pattern, but allowed the introduction of specific inhibitors: antibodies to phosducin abolished all differences between the two cell lines. Inhibitors of the beta-adrenergic receptor kinase abolished the differences at early time points. An almost complete loss of beta(2)-adrenergic receptor desensitization in the phosducin-expressing cells was also observed when intact cells were desensitized and receptor function was then determined in membrane preparations. Inhibition of protein kinase A accentuated the effects of phosducin, suggesting that also in vivo phosducin is regulated by this kinase. These data indicate that phosducin affects G-protein-mediated signaling in at least two ways: it dampens the overall responsiveness, and it impairs the rapid desensitization mediated by the beta-adrenergic receptor kinase.			Schulz, K (corresponding author), UNIV WURZBURG,INST PHARMACOL,VERSBACHER STR 9,D-97078 WURZBURG,GERMANY.		Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510				BAUER PH, 1992, NATURE, V358, P73, DOI 10.1038/358073a0; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BLACK JW, 1983, PROC R SOC SER B-BIO, V220, P141, DOI 10.1098/rspb.1983.0093; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CLARK RB, 1987, FASEB J, V1, P289, DOI 10.1096/fasebj.1.4.2820824; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; Harlow E., 1988, ANTIBODIES LAB MANUA; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HEKMAN M, 1994, FEBS LETT, V343, P120, DOI 10.1016/0014-5793(94)80302-1; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LEE RH, 1992, J BIOL CHEM, V267, P25104; LOHSE MJ, 1991, MOL PHARMACOL, V39, P517; LOHSE MJ, 1984, MOL PHARMACOL, V26, P1; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1992, N-S ARCH PHARMACOL, V345, P444; LOHSE MJ, 1990, J BIOL CHEM, V265, P3210; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MULLER S, 1995, BIOCHEM SOC T, V23, P141; Muller S, 1996, J BIOL CHEM, V271, P11781, DOI 10.1074/jbc.271.20.11781; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFFERMANNS S, 1994, N-S ARCH PHARMACOL, V350, P329; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; REIG JA, 1990, J BIOL CHEM, V265, P5816; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SOHLEMANN P, 1993, FEBS LETT, V324, P59, DOI 10.1016/0014-5793(93)81532-5; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WINSTEL R, 1995, N-S ARCH PHARMACOL, V351, pR139; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050	43	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22546	22551		10.1074/jbc.271.37.22546	http://dx.doi.org/10.1074/jbc.271.37.22546			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798422	hybrid			2022-12-27	WOS:A1996VG67200041
J	Lee, SH; Minowa, MT; Mouradian, MM				Lee, SH; Minowa, MT; Mouradian, MM			Two distinct promoters drive transcription of the human D-1A dopamine receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; MESSENGER-RNA; MOLECULAR-CLONING; GROWTH-HORMONE; ALTERNATIVE PROMOTER; MULTIPLE PROMOTERS; PREFRONTAL CORTEX; RAT-BRAIN; EXPRESSION; D1	The human D-1A dopamine receptor gene has a GC-rich, TATA-less promoter located upstream of a small, noncoding exon 1, which is separated from the coding exon 2 by a 116-base pair (bp)-long intron. Serial 3'-deletions of the 5'-noncoding region of this gene, including the intron and 5'-end of exon 2, resulted in 80 and 40% decrease in transcriptional activity of the upstream promoter in two D-1A-expressing neuroblastoma cell lines, SK-N-MC and NS20Y, respectively. To investigate the function of this region, the intron and 245 bp at the 5'-end of exon 2 were investigated, Transient expression analyses using various chloramphenicol acetyltransferase constructs showed that the transcriptional activity of the intron is higher than that of the upstream promoter by 12-fold in SK-N-MC cells and by 5.5-fold in NS20Y cells in an orientation-dependent manner, indicating that the D-1A intron is a strong promoter. Primer extension and ribonuclease protection assays revealed that transcription driven by the intron promoter is initiated at the junction of intron and exon 2 and at a cluster of nucleotides located 50 bp downstream from this junction. The same transcription start sites are utilized by the chloramphenicol acetyltransferase constructs employed in transfections as well as by the D-1A gene expressed within the human caudate. The relative abundance of D-1A transcripts originating from the upstream promoter compared with those transcribed from the intron promoter is 1.5-2.9 times in SK-N-MC cells and 2 times in the human caudate. Transcript stability studies in SK-N-MC cells revealed that longer D-1A mRNA molecules containing exon 1 are degraded 1.8 times faster than shorter transcripts lacking exon 1, Although gel mobility shift assay could not detect DNA-protein interaction at the D-1A intron, competitive co-transfection using the intron as competitor confirmed the presence of trans-acting factors at the intron, These data taken together indicate that the human D-1A gene has two functional TATA-less promoters, both in D-1A expressing cultured neuroblastoma cells and in the human striatum.	NINCDS,NIH,EXPT THERAPEUT BRANCH,GENET PHARMACOL UNIT,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)				Mouradian, M. Maral/0000-0002-9937-412X				ARAKI E, 1987, J BIOL CHEM, V262, P16186; Ausubel FM, 1988, MOL REPROD DEV; BISHOP JF, 1994, MOL BRAIN RES, V26, P225, DOI 10.1016/0169-328X(94)90094-9; BOYCE FM, 1991, P NATL ACAD SCI USA, V88, P1276, DOI 10.1073/pnas.88.4.1276; BOYSON SJ, 1986, J NEUROSCI, V6, P3177; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CERVELLA P, 1993, J BIOL CHEM, V268, P5148; CHELLY J, 1990, NATURE, V344, P64, DOI 10.1038/344064a0; CHIPKIN RE, 1988, J PHARMACOL EXP THER, V247, P1093; COURTOIS SJ, 1992, J BIOL CHEM, V267, P19736; COX LA, 1995, BIOCHEM BIOPH RES CO, V212, P925, DOI 10.1006/bbrc.1995.2058; CREESE I, 1987, RECEPTOR BIOCH METHO, V8; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; FOYT HL, 1991, J BIOL CHEM, V266, P7300; FOYT HL, 1992, MOL ENDOCRINOL, V6, P1881, DOI 10.1210/me.6.11.1881; GONZALEZCRESPO S, 1991, P NATL ACAD SCI USA, V88, P8749, DOI 10.1073/pnas.88.19.8749; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRENADER AC, 1995, AM J PHYSIOL-RENAL, V268, pF423, DOI 10.1152/ajprenal.1995.268.3.F423; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HOSHIKO S, 1990, P NATL ACAD SCI USA, V87, P9073, DOI 10.1073/pnas.87.23.9073; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KIKINIS Z, 1995, NUCLEIC ACIDS RES, V23, P4190, DOI 10.1093/nar/23.20.4190; LEE T, 1978, NATURE, V273, P59, DOI 10.1038/273059a0; LI Y, 1993, J BIOL CHEM, V268, P3563; LIDOW MS, 1991, NEUROSCIENCE, V40, P657, DOI 10.1016/0306-4522(91)90003-7; LIN YH, 1995, J BIOL CHEM, V270, P26968; MINOWA MT, 1993, J BIOL CHEM, V268, P23544; MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045; MONSMA FJ, 1990, P NATL ACAD SCI USA, V87, P6723, DOI 10.1073/pnas.87.17.6723; NUDEL U, 1989, NATURE, V337, P76, DOI 10.1038/337076a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Ren HZ, 1995, MOL PHARMACOL, V48, P975; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; SEEMAN P, 1984, SCIENCE, V225, P728, DOI 10.1126/science.6147018; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; SUZUKI H, 1995, J BIOL CHEM, V270, P9676, DOI 10.1074/jbc.270.16.9676; TAYLOR LA, 1991, LIFE SCI, V49, P1505, DOI 10.1016/0024-3205(91)90051-C; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; WILLIAMS GV, 1995, NATURE, V376, P572, DOI 10.1038/376572a0; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140; ZHOU QY, 1992, J NEUROCHEM, V59, P1875, DOI 10.1111/j.1471-4159.1992.tb11023.x; ZHOU QY, 1990, NATURE, V347, P76, DOI 10.1038/347076a0	55	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25292	25299		10.1074/jbc.271.41.25292	http://dx.doi.org/10.1074/jbc.271.41.25292			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810292	hybrid			2022-12-27	WOS:A1996VL69300036
J	Adachi, K; Pang, JA; Reddy, LR; Bradley, LE; Chen, QK; Trifillis, P; Schwartz, E; Surrey, S				Adachi, K; Pang, JA; Reddy, LR; Bradley, LE; Chen, QK; Trifillis, P; Schwartz, E; Surrey, S			Polymerization of three hemoglobin A(2) variants containing Val(delta 6) and inhibition of hemoglobin S polymerization by hemoglobin A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL DISEASE; DELTA-GLOBIN GENE; DEOXYHEMOGLOBIN; GELATION; SEQUENCE; YEAST	To understand determinants for hemoglobin (Hb) stability and Hb A(2) inhibition of Hb S polymerization, three Val(delta 6) Hb A(2) variants (Hb A(2) delta E6V, Hb A(2) delta E6V, delta Q87T, and Hb A(2) delta E6V, delta A22E, delta Q87T) were expressed in yeast, and stability to mechanical agitation and polymerization properties were assessed. Oxy forms of Hb A(2) delta E6V and Hb A(2) delta E6V, delta Q87T were 2- and 1.6-fold, respectively, less stable than oxy-Hb S, while the stability of Hb A(2) delta E6V, delta A22E, delta Q87T was similar to that of Hb S, suggesting that Ala(delta 22) and Gln(delta 87) contribute to the surface hydrophobicity of Rb A(2). Deoxy Hb A(2) delta E6V polymerized without a delay time, like deoxy Hb F gamma EGV, while deoxy Hb A(2) delta E6V, delta Q87T and deoxy Hb A(2) delta E6V, delta A22E, delta Q87T polymerized after a delay time, like deoxy Hb S, suggesting that beta 87 Thr is required for the formation of nuclei. Deoxy Hb F gamma E6V, gamma Q87T showed no delay time and required a 3.5-fold higher concentration than deoxy Hb S for polymerization, suggesting that Thr effects on Val(delta 6) Hb A(2) and Val(gamma 6) Hb F variants are different. Mixtures of deoxy Hb S/Hb A(2) delta E6V, delta Q87T polymerized, like deoxy Hb S, while polymerization of Hb S/Hb A(2) delta E6V mixtures was inhibited, like Hb S/Hb F gamma E6V mixtures. These results suggest alpha(2) beta(S) delta(6 Val, 87 Thr) hybrids and Hb A(2) delta E6V, delta 87T participate in Hb S nucleation, while only 50% of alpha(2) beta(S) delta(6Val) hybrids and none of the Hb A(2) delta E6V participate. These findings are in contrast to those of mixtures of Hb S with Hb F gamma E6V or Hb F gamma E6V, Q87T, which both inhibit Hb S polymerization. Our results also suggest participation in nucleation of some alpha(2) beta(S) delta hybrids in A(2)S mixtures but not alpha(2) beta(S) gamma hybrids in FS mixtures.			Adachi, K (corresponding author), UNIV PENN,SCH MED,CHILDRENS HOSP PHILADELPHIA,DIV HEMATOL,ABRAMSON CTR,34TH ST & CIV CTR BLVD,PHILADELPHIA,PA 19104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016691] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38632] Funding Source: Medline; NIDDK NIH HHS [DK16691] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI K, 1990, BLOOD, V75, P2070; ADACHI K, 1993, J BIOL CHEM, V268, P21650; ADACHI K, 1979, J BIOL CHEM, V254, P7765; ADACHI K, 1980, J BIOL CHEM, V255, P7595; Adachi K, 1996, BLOOD, V87, P1617, DOI 10.1182/blood.V87.4.1617.bloodjournal8741617; ADACHI K, 1978, J BIOL CHEM, V253, P382; ADACHI K, 1994, J BIOL CHEM, V269, P9562; ADACHI K, 1992, PROTEIN ENG, V5, P807, DOI 10.1093/protein/5.8.807; ADACHI K, 1994, J BIOL CHEM, V269, P17477; ADACHI K, 1992, FEBS LETT, V315, P47; Antonini E., 1971, FRONT BIOL, V21, P19; ASAKURA T, 1974, P NATL ACAD SCI USA, V71, P1594, DOI 10.1073/pnas.71.5.1594; BENESCH RE, 1980, P NATL ACAD SCI-BIOL, V77, P5130, DOI 10.1073/pnas.77.9.5130; BOOKCHIN RM, 1975, NATURE, V256, P667, DOI 10.1038/256667a0; BUNN HF, 1983, NATURE, V306, P498, DOI 10.1038/306498a0; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P452; CHEETHAM RC, 1979, J MOL BIOL, V129, P45, DOI 10.1016/0022-2836(79)90058-5; EMBURY SH, 1994, SICKLE HEMOGLOBINS S; GOLDBERG MA, 1977, J BIOL CHEM, V252, P3414; HEBBEL RP, 1991, BLOOD, V77, P214; ITANO HA, 1953, ARCH BIOCHEM BIOPHYS, V47, P148, DOI 10.1016/0003-9861(53)90444-5; KINDERLE.J, 1970, BIOCHEM J, V119, pP66; MCCUNE SL, 1994, P NATL ACAD SCI USA, V91, P9852, DOI 10.1073/pnas.91.21.9852; Nagel R. L., 1995, Blood, V86, p251A; NAGEL RL, 1979, P NATL ACAD SCI USA, V76, P670, DOI 10.1073/pnas.76.2.670; Oosawa F., 1975, THERMODYNAMICS POLYM; OU CN, 1983, J CHROMATOGR, V266, P197, DOI 10.1016/S0021-9673(01)90893-3; PALDAN EA, 1985, J BIOL CHEM, V260, P8280; Shackleton CHL, 1994, MASS SPECTROMETRY CL, V2, P135; SPRITZ RA, 1980, CELL, V21, P639, DOI 10.1016/0092-8674(80)90427-4; SUNSHINE HR, 1979, J MOL BIOL, V133, P435, DOI 10.1016/0022-2836(79)90402-9; TRIFILLIS P, 1991, BLOOD, V78, P3298; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; Wang Z. P., 1996, Biophysical Journal, V70, pA435; WATERMAN MR, 1979, J MOL BIOL, V128, P337; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; WITKOWSKA HE, 1991, NEW ENGL J MED, V325, P1150, DOI 10.1056/NEJM199110173251607; YAMASHIRO DJ, 1994, J BIOL CHEM, V269, P23996	38	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24557	24563		10.1074/jbc.271.40.24557	http://dx.doi.org/10.1074/jbc.271.40.24557			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798718	hybrid			2022-12-27	WOS:A1996VM67400040
J	Bhattacharjee, H; Rosen, BP				Bhattacharjee, H; Rosen, BP			Spatial proximity of Cys(113), Cys(172), and Cys(422) in the metalloactivation domain of the ArsA ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING ATPASE; ANION PUMP	ArsA ATPase activity is allosterically activated by salts of the semimetal arsenic or antimony. Activation is associated with the presence of three cysteine residues in ArsA: Cys(113), Cys(172), and Cys(422). To determine the distance between cysteine residues, wild type ArsA and ArsA proteins with cysteine to serine substitutions were treated with the bifunctional alkylating agent dibromobimane, which reacts with thiol pairs within 3-6 Angstrom of each other to form a fluorescent adduct. ArsA proteins in which single cysteine residues were altered by site-directed mutagenesis still formed fluorescent adducts. Proteins in which two of the three cysteine residues were substituted did not form fluorescent adducts, These results demonstrate that Cys(113), Cys(172), and Cys(422) are in close proximity of each other. We propose a model in which As(III) or Sb(III) interacts with these three cysteines in a trigonal pyramidal geometry, forming a novel soft metal-thiol cage.	WAYNE STATE UNIV,DEPT BIOCHEM & MOL BIOL,SCH MED,DETROIT,MI 48201	Wayne State University				Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019793] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19793] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BHATTACHARJEE H, 1995, J BIOL CHEM, V270, P11245, DOI 10.1074/jbc.270.19.11245; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; DEY S, 1994, ARCH BIOCHEM BIOPHYS, V311, P418, DOI 10.1006/abbi.1994.1256; HAUGLAND RP, 1994, HDB FLUORESCENT PROB, P56; HSU CM, 1989, J BIOL CHEM, V264, P17349; HSU CM, 1991, J BIOL CHEM, V266, P2327; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORNET D, 1985, P NATL ACAD SCI USA, V82, P1658, DOI 10.1073/pnas.82.6.1658; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; ROSEN BP, 1995, J BIOENERG BIOMEMBR, V27, P85, DOI 10.1007/BF02110335; ROSEN BP, 1988, J BIOL CHEM, V263, P3067; Sambrook J., 2002, MOL CLONING LAB MANU; Shi WP, 1996, J BIOL CHEM, V271, P9291, DOI 10.1074/jbc.271.16.9291; SOWERBY DB, 1994, CHEM ORGANIC ARSENIC, P25; VOGEL G, 1976, BIOCHEMISTRY-US, V16, P208	17	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24465	24470		10.1074/jbc.271.40.24465	http://dx.doi.org/10.1074/jbc.271.40.24465			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798705	hybrid			2022-12-27	WOS:A1996VM67400027
J	Coqueret, O; Berube, G; Nepveu, A				Coqueret, O; Berube, G; Nepveu, A			Dna binding by cut homeodomain proteins is down-modulated by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT DISPLACEMENT PROTEIN; CELL TYPE SPECIFICATION; SENSORY ORGAN IDENTITY; RAT FIBROBLASTS; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; ZETA-ISOFORM; DROSOPHILA; ISOZYMES	The Drosophila and mammalian Cut homeodomain proteins contain, in addition to the homeodomain, three other DNA binding regions called Cut repeats. Cut-related proteins thus belong to a distinct class of homeodomain proteins with multiple DNA binding domains. Using nuclear extracts from mammalian cells, Cut-specific DNA binding was increased following phosphatase treatment, suggesting that endogenous Cut proteins are phosphorylated in vivo. Sequence analysis of Cut repeats revealed the presence of sequences that match the consensus phosphorylation site for protein kinase C (PKC). Therefore, we investigated whether PKC can modulate the activity of mammalian Cut proteins. In vitro, a purified preparation of PKC efficiently phosphorylated Cut repeats, which inhibited DNA binding. In vivo, a brief treatment of cells with calphostin C, a specific inhibitor of PKC, led to an increase in Cut-specific DNA binding, whereas phorbol 12-myristate 13-acetate, a specific activator of PKC, caused a decrease in DNA binding. The PKC phosphorylation sites within the murine Cut (mCut) protein were identified by in vitro mutagenesis as residues Thr(415), Thr(804), and Ser(987) within Cut repeats 1-3, respectively. Cut homeodomain proteins were previously shown to function as transcriptional repressors. Activation of PKC by phorbol 12-myristate 13-acetate reduced transcriptional repression by mCut, whereas a mutant mCut protein containing alanine substitutions at these sites was not affected. Altogether, our results indicate that the transcriptional activity of Cut proteins is modulated by PKC.	MCGILL UNIV,MOL ONCOL GRP,DEPT MED,ROYAL VICTORIA HOSP,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,MOL ONCOL GRP,DEPT ONCOL,ROYAL VICTORIA HOSP,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,MOL ONCOL GRP,DEPT BIOCHEM,ROYAL VICTORIA HOSP,MONTREAL,PQ H3A 1A1,CANADA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital			Coqueret, Olivier/K-9660-2015; /AAB-8315-2020	Coqueret, Olivier/0000-0002-2843-7867; 				ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; ANDRES V, 1992, DEVELOPMENT, V116, P321; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CACACE AM, 1993, ONCOGENE, V8, P2095; CHIDA K, 1994, MOL CELL BIOL, V14, P3782, DOI 10.1128/MCB.14.6.3782; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HA KS, 1993, J BIOL CHEM, V268, P10534; HALSEY DL, 1987, J BIOL CHEM, V262, P2234; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; HARADA R, 1994, J BIOL CHEM, V269, P2062; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; JACK J, 1991, DEVELOPMENT, V113, P735; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIU S, 1992, DEV BIOL, V150, P133, DOI 10.1016/0012-1606(92)90013-7; LIU S, 1991, GENETICS, V127, P151; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; NAKAMURA S, 1994, J BIOCHEM, V115, P1029, DOI 10.1093/oxfordjournals.jbchem.a124451; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUPERTIFURGA G, 1989, BIOCHIM BIOPHYS ACTA, V1007, P237, DOI 10.1016/0167-4781(89)90046-8; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; VALARCHE I, 1993, DEVELOPMENT, V119, P881; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YOON SO, 1994, J BIOL CHEM, V269, P18453	56	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24862	24868		10.1074/jbc.271.40.24862	http://dx.doi.org/10.1074/jbc.271.40.24862			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798762	hybrid			2022-12-27	WOS:A1996VM67400084
J	Ericsson, J; Jackson, SM; Edwards, PA				Ericsson, J; Jackson, SM; Edwards, PA			Synergistic binding of sterol regulatory element-binding protein and NF-Y to the farnesyl diphosphate synthase promoter is critical for sterol-regulated expression of the gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN RECEPTOR PROMOTER; LEUCINE ZIPPER PROTEIN; MOLECULAR-CLONING; TRANSCRIPTION; DNA; IDENTIFICATION; ACTIVATION; SREBP-1; DOMAIN; PRENYLTRANSFERASE	Sterol-regulated transcription of the farnesyl diphosphate (FPP) synthase gene is dependent on two cis elements in the proximal promoter. These elements, an inverted CCAAT box and sterol regulatory element 3 (SRE-3), bind NF-Y and sterol regulatory element-binding protein 1 (SREBP-1), respectively. We now demonstrate that the binding of recombinant SREBP-1 to its cognate site (SRE-3) within the FPP synthase promoter in vitro is enhanced by binding of NF-Y to the upstream inverted CCAAT box, Using an FPP synthase promoter fragment containing the binding sites for both NF-Y and SREBP-1 in gel mobility shift assays, we demonstrate that the addition of NF-Y increases the binding of SREBP-1 to SRE-3 over 20-fold. In contrast, NF-Y does not stimulate the binding of SREBP-1 to SRE-3 when the inverted CCAAT box is either mutated or 4 base pairs (bp) are inserted between the inverted CCAAT box and SRE-3. Promoter-reporter genes, containing either the wildtype FPP synthase promoter sequence or containing the 4-bp insertion between the inverted CCAAT box and SRE-3, were transiently transfected into cells. The activity of the wild-type promoter-reporter gene increased when the cells were either incubated in sterol-depleted medium or were co-transfected with an expression vector encoding transcriptionally active SREBP-1. This increase in activity was attenuated when the promoter contained the 4-bp insert, consistent with defective binding of SREBP to the promoter in vivo. These studies suggest that the binding of SREBP-1 to SRE-3 in the FPP synthase promoter, and subsequent stimulation of transcription, is dependent on synergistic binding and a functional interaction between SREBP-1 and NF-Y.	UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Ericsson, Johan/AAA-6664-2020	Ericsson, Johan/0000-0003-1186-6574	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; EDWARDS PA, 1996, BIOCH LIPIDS LIPOPRO; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRAY JC, 1987, ADV BOT RES, V14, P25; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; KIM JB, 1995, MOL CELL BIOL, V15, P2582; KRISANS SK, 1994, J BIOL CHEM, V269, P14165; LI XY, 1992, J BIOL CHEM, V267, P8984; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SATO R, 1994, J BIOL CHEM, V269, P17267; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; SPEAR DH, 1994, J BIOL CHEM, V269, P25212; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; TJIAN R, 1995, CELL, V77, P5; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	36	97	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24359	24364		10.1074/jbc.271.40.24359	http://dx.doi.org/10.1074/jbc.271.40.24359			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798690	hybrid			2022-12-27	WOS:A1996VM67400012
J	Frank, S; Werner, S				Frank, S; Werner, S			The human homologue of the yeast CHL1 gene is a novel keratinocyte growth factor-regulated gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CHROMOSOME TRANSMISSION; MORPHOGENESIS; CELLS; KGF	Keratinocyte growth factor (KGF) is a potent and specific mitogen for different types of epithelial cells, including keratinocytes of the skin. To gain insight into the mechanisms of KGF action in this tissue, we attempted to identify genes that are regulated by KGF in keratinocytes. Using the differential display reverse transcription polymerase chain reaction technology, a gene was identified which was strongly induced in these cells by treatment with KGF but not with serum growth factors or pro-inflammatory cytokines. This gene seems to be part of a multigene family as assessed by Southern blot analysis. Molecular cloning and sequencing of the full-length cDNA revealed a strong homology with the yeast CHL1 gene. The latter encodes a putative helicase, which is involved in correct chromosome transmission and cell cycle progression. Furthermore, the CHL1 gene product and the protein encoded by the novel KGF-regulated gene were identical in size, indicating that we had cloned the human CHL1 homologue. This finding suggests a novel and specific role of KGF in correct chromosome segregation and/or cell cycle progression.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Max Planck Society								ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; Amann J, 1996, GENOMICS, V32, P260, DOI 10.1006/geno.1996.0113; BAUER D, 1994, PCR METH APPL, V4, P97; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BURATOWSKI S, 1993, SCIENCE, V260, P37, DOI 10.1126/science.8465198; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNHA GR, 1994, INT CONGR SER, V1064, P45; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; Hines MD, 1996, J BIOL CHEM, V271, P6245, DOI 10.1074/jbc.271.11.6245; Maniatis T., 1982, MOL CLONING; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PANOS RJ, 1995, J CLIN INVEST, V96, P2026, DOI 10.1172/JCI118250; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; SPENCER F, 1990, GENETICS, V124, P237; WERNER S, 1989, INT J CANCER, V43, P1137, DOI 10.1002/ijc.2910430629; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639	22	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24337	24340		10.1074/jbc.271.40.24337	http://dx.doi.org/10.1074/jbc.271.40.24337			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798685	hybrid			2022-12-27	WOS:A1996VM67400007
J	Inoue, S; Kitajima, K; Inoue, Y				Inoue, S; Kitajima, K; Inoue, Y			Identification of 2-keto-3-deoxy-D-glycero-D-galactonononic acid (KDN, deaminoneuraminic acid) residues in mammalian tissues and human lung carcinoma cells - Chemical evidence of the occurrence of KDN glycoconjugates in mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAMINATED NEURAMINIC ACID; PERFORMANCE LIQUID-CHROMATOGRAPHY; TROUT EGG POLYSIALOGLYCOPROTEINS; RICH GLYCOPROTEIN; 3-DEOXY-D-GLYCERO-D-GALACTO-NONULOSONIC ACID; VITELLINE ENVELOPE; JELLY COAT; CHAINS; SEQUENCES; SERA	Since the discovery of KDN glycoprotein in 1986, the occurrence of KDN (= 2-keto-3-deoxy-D-glycero-D-galactonononic acid) glycan chains has been reported for different organisms ranging from bacteria to lower vertebrates, including amphibians and fish. Recently, the presence of alpha 2-->8-linked oligo/polyKDN groups in mammalian tissues was shown by immunohistochemical and immunoblotting methods. In this communication we report the detection and quantitation of the KDN residues in glycoprotein and glycolipid fractions of rat tissues and human lung cancer cell lines by a highly sensitive fluorometric highperformance liquid chromatography (HPLC) method. We now provide unequivocal chemical proof of the occurrence of KDN in mammals by isolation of KDN from pig submaxillary gland and by structural assignment using chemical methods including fast atom bombardment-mass spectrometry, fluorescence-assisted HPLC analysis, gas-liquid chromatography, and H-1 NMR spectroscopy.	UNIV TOKYO,DEPT BIOCHEM & BIOPHYS,GRAD SCH SCI,TOKYO 113,JAPAN	University of Tokyo	Inoue, S (corresponding author), ACAD SINICA,INST BIOL CHEM,NANKANG,TAIPEI 115,TAIWAN.							AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; ANGATA T, 1994, GLYCOCONJUGATE J, V11, P493, DOI 10.1007/BF00731286; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HARA S, 1987, ANAL BIOCHEM, V164, P138, DOI 10.1016/0003-2697(87)90377-0; INOUE S, 1988, BIOCHEM BIOPH RES CO, V153, P172, DOI 10.1016/S0006-291X(88)81204-X; INOUE S, 1979, CARBOHYD RES, V74, P361, DOI 10.1016/S0008-6215(00)84795-3; IWASAKI M, 1987, BIOCHEMISTRY-US, V26, P1452, DOI 10.1021/bi00379a036; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; KANAMORI A, 1994, HISTOCHEMISTRY, V101, P333, DOI 10.1007/BF00268994; KANAMORI A, 1989, BIOCHEM BIOPH RES CO, V164, P744, DOI 10.1016/0006-291X(89)91522-2; KANAMORI A, 1990, J BIOL CHEM, V265, P21811; KANAMORI A, 1990, THESIS U TOKYO; KIMURA M, 1994, J BIOL CHEM, V269, P32138; KITAJIMA K, 1994, J BIOL CHEM, V269, P21415; KNIREL YA, 1989, CARBOHYD RES, V188, P145, DOI 10.1016/0008-6215(89)84067-4; NADANO D, 1986, J BIOL CHEM, V261, P1550; Nishino S, 1996, J BIOL CHEM, V271, P2909, DOI 10.1074/jbc.271.6.2909; NOMOTO H, 1982, ARCH BIOCHEM BIOPHYS, V218, P335, DOI 10.1016/0003-9861(82)90352-6; QU B, 1996, IN PRESS P NATL ACAD; SATO C, 1995, J BIOL CHEM, V270, P18923, DOI 10.1074/jbc.270.32.18923; SHAUER R, 1978, METHOD ENZYMOL, V50, P64; SONG Y, 1991, J BIOL CHEM, V266, P21929; STRECKER G, 1992, BIOCHEM J, V287, P905, DOI 10.1042/bj2870905; STRECKER G, 1992, EUR J BIOCHEM, V207, P995, DOI 10.1111/j.1432-1033.1992.tb17135.x; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; TERADA T, 1993, J BIOL CHEM, V268, P2640; TEZUKA T, 1993, BIOCHEMISTRY-US, V33, P6495; UCHIDA Y, 1977, J BIOCHEM-TOKYO, V82, P1425, DOI 10.1093/oxfordjournals.jbchem.a131830; YU S, 1993, BIOCHEMISTRY-US, V32, P9221; Ziak M, 1996, P NATL ACAD SCI USA, V93, P2759, DOI 10.1073/pnas.93.7.2759	30	69	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24341	24344		10.1074/jbc.271.40.24341	http://dx.doi.org/10.1074/jbc.271.40.24341			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798686	hybrid			2022-12-27	WOS:A1996VM67400008
J	Valenti, G; Frigeri, A; Ronco, PM; DEttorre, C; Svelto, M				Valenti, G; Frigeri, A; Ronco, PM; DEttorre, C; Svelto, M			Expression and functional analysis of water channels in a stably AQP2-transfected human collecting duct cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY; MOLECULAR-CLONING; MEMBRANE; PERMEABILITY; PROTEIN; IMMUNOLOCALIZATION; LOCALIZATION; GLYCEROL; HOMOLOGS; NEPHRON	In this study, we describe the establishment of a stably transfected epithelial cell line with the cDNA for the rat aquaporin 2 (AQP2). To this end, we used a human cell line (HCD) derived from the cortical collecting duct and having characteristics of principal cells (Prie, D., Friedlander, G., Coureau, C., Vandewalle, A., Cassigena, R., and Ronco, P. M. (1995) Kidney Int. 47, 1310-1318). The HCD cells were first screened for the constitutive expression of AQPs. By Western blot analysis, we found a low expression of immunoreactive AQP2 and AQP4 proteins. In contrast, transfected cells (clone CD8) probed with AQP2 antiserum expressed an intense 29-kDa protein on immunoblot in addition to a broad band between 35-45 kDa corresponding to the glycosylated form of the protein, indicating that full maturity of the protein is attained in transfected cells. Immunofluorescence demonstrated that AQP2 was located in intracellular vesicles. After vasopressin stimulation, the staining redistributed from an intracellular site to the apical pole of the cells, an effect similar to that described on collecting duct principal cells in vivo (Sabolic, I., Katsura, T., Verbavatz, J. M., and Brown, D. (1995) J. Membr. Biol. 143, 165-175) and in perfused tubules (Nielsen, S., Chou, C. L., Marples, D., Christensen, E. I., Kishore, B. K., and Knepper, M. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 1013-1017). The redistribution of AQP2 in CD8 cells was accompanied by an approximately B-fold increase in osmotic water permeability coefficient (P-f), which was inhibited by 0.3 mM HgCl2. These data indicate that functional vasopressin-sensitive water channels are expressed in transfected cells. The stably transfected cells represent a suitable model to unravel by direct experimental approach the intracellular signals involved in the translocation of AQP2 to the apical plasma membrane in the presence of vasopressin.	DOMPE SPA, LAQUILA, ITALY; HOP TENON, INSERM, U64, F-75970 PARIS, FRANCE	Dompe; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Valenti, G (corresponding author), UNIV BARI, IST FIS GEN, VIA AMENDOLA 165A, I-70126 BARI, ITALY.		Svelto, Maria/P-6186-2014; Ronco, Pierre/AAC-8390-2022; frigeri, Antonio/AAC-6336-2022	Svelto, Maria/0000-0002-5584-9541; Frigeri, Antonio/0000-0002-5284-2934; VALENTI, GIOVANNA/0000-0003-0233-0778				AGRE P, 1995, CURR OPIN CELL BIOL, V7, P472, DOI 10.1016/0955-0674(95)80003-4; BENEDETTI PA, 1995, P SOC PHOTO-OPT INS, V2412, P56, DOI 10.1117/12.205348; BENEDETTI PA, 1995, ZOOL STUD, V34, P186; CHABARDES D, 1980, J CLIN INVEST, V65, P439, DOI 10.1172/JCI109687; DILLINGHAM MA, 1985, J MEMBRANE BIOL, V88, P277, DOI 10.1007/BF01871091; ECELBARGER CA, 1995, AM J PHYSIOL-RENAL, V269, pF663, DOI 10.1152/ajprenal.1995.269.5.F663; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; FARINAS J, 1995, BIOPHYS J, V68, P1613, DOI 10.1016/S0006-3495(95)80335-8; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; FRIGERI A, 1995, J CELL SCI, V108, P2993; FUSHIMI K, 1994, AM J PHYSIOL-RENAL, V267, pF573, DOI 10.1152/ajprenal.1994.267.4.F573; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; PRIE D, 1995, KIDNEY INT, V47, P1310, DOI 10.1038/ki.1995.186; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; SABOLIC I, 1995, J MEMBRANE BIOL, V143, P165, DOI 10.1007/BF00233445; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Terris J, 1995, AM J PHYSIOL-RENAL, V269, pF775, DOI 10.1152/ajprenal.1995.269.6.F775; VALENTI G, 1994, AM J PHYSIOL, V267, pC812, DOI 10.1152/ajpcell.1994.267.3.C812; VERKMAN AS, 1989, AM J PHYSIOL, V257, pC837, DOI 10.1152/ajpcell.1989.257.5.C837; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	29	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	1996	271	40					24365	24370		10.1074/jbc.271.40.24365	http://dx.doi.org/10.1074/jbc.271.40.24365			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VM674	8798691	hybrid			2022-12-27	WOS:A1996VM67400013
J	Grammer, TC; Blenis, J				Grammer, TC; Blenis, J			The serine protease inhibitors, tosylphenylalanine chloromethyl ketone and tosyllysine chloromethyl ketone, potently inhibit pp70(s6k) activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; P70 S6 KINASE; INDUCED PHOSPHORYLATION; RAPAMYCIN; DISSOCIATION; SUFFICIENT; SIGNAL	pp70(s6k) is a mitogen-regulated serine/threonine kinase involved in the G(1) to S phase transition of the cell cycle. We have analyzed its regulation in several cell lines by a variety of agonists and have found that pp70(s6k) activation by all. stimuli tested is completely blocked by the serine protease inhibitors tosylphenylalanine chloromethyl ketone (TPCK) and tosyllysine chloromethyl ketone (TLCK). TPCK inhibition of the pp70(s6k) signaling pathway resembles that of the immunosuppressant rapamycin; however, we demonstrate that their methods of inhibition differ. We find that TPCK and TLCK are not general signaling inhibitors since the activation of the mitogen-activated protein kinase pathway is not abrogated. The demonstration that these protease inhibitors prevent signaling via the pp70(s6k) pathway will help in understanding the variety of physiological processes that TPCK and TLCK have been shown to effect.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; BARNA JB, 1995, INFLAMMATION, V19, P561, DOI 10.1007/BF01539136; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DUMONT FJ, 1994, J IMMUNOL, V152, P992; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GRISCAVAGE JM, 1995, BIOCHEM BIOPH RES CO, V215, P721, DOI 10.1006/bbrc.1995.2523; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Rodriguez J, 1996, LIFE SCI, V58, P607, DOI 10.1016/0024-3205(95)02330-5; Yoshida A, 1996, LEUKEMIA, V10, P821	16	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23650	23652		10.1074/jbc.271.39.23650	http://dx.doi.org/10.1074/jbc.271.39.23650			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798584				2022-12-27	WOS:A1996VJ44200013
J	Konrad, RJ; Dean, RM; Young, RA; Billings, PC; Wolf, BA				Konrad, RJ; Dean, RM; Young, RA; Billings, PC; Wolf, BA			Glucose-induced tyrosine phosphorylation of p125 in beta cells and pancreatic islets - A novel proximal signal in insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE DOMAIN AUTOPHOSPHORYLATION; GROWTH-FACTOR RECEPTOR; ACYL-COA ESTERS; ARACHIDONIC-ACID; PHOSPHATIDYLINOSITOL 3'-KINASE; ION CHANNELS; MALONYL-COA; PROTEIN; RELEASE; IRS-1	In this study, we demonstrate that stimulation of beta cells with carbachol and glucose causes increased tyrosine phosphorylation of a 125-kDa protein concurrently with increased insulin secretion. The effect was observed in two different insulin-secreting cell lines and in rat pancreatic islets. Tyrosine phosphorylation was largely calcium independent and occurred within 2 min after stimulation of beta cells with glucose and the muscarinic agonist carbachol. In islets, the effect of glucose was greatly diminished by the addition of mannoheptulose, a seven-carbon sugar that inhibits glucokinase, suggesting that glucose metabolism is required for tyrosine phosphorylation of the protein to occur. Neither insulin nor insulin-like growth factor I significantly increased tyrosine phosphorylation of the 125-kDa protein, suggesting that it was not an autocrine effect. Depolarization of beta cells with glyburide or 50 mM potassium dramatically increased insulin secretion but had no significant effect on tyrosine phosphorylation. Addition of phorbol ester caused a less than 2-fold increase in tyrosine phosphorylation, whereas the calcium ionophore A23187 had no effect. Among the various fuel secretagogues tested, only D-glucose stimulated tyrosine phosphorylation, both alone and in combination with carbachol. Finally, the tyrosine kinase inhibitor AG879 inhibited both tyrosine phosphorylation and insulin secretion in a dose-dependent manner. Taken together, these data demonstrate the presence of a novel signaling pathway in glucose-induced insulin secretion: tyrosine phosphorylation of beta cell p125, which is a proximal step in insulin secretion. Our current working hypothesis is that glucose stimulation of beta cell p125 tyrosine phosphorylation is an essential step for insulin secretion.	UNIV PENN,DEPT PATHOL & LAB MED,SCH MED,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043354, K04DK002217] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK43354, K04 DK02217] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; COLCA JR, 1985, BIOCHEM J, V228, P529, DOI 10.1042/bj2280529; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; CORBETT JA, 1994, AM J PHYSIOL, V267, pC48, DOI 10.1152/ajpcell.1994.267.1.C48; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; DEENEY JT, 1992, J BIOL CHEM, V267, P19840; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; EASOM RA, 1990, J BIOL CHEM, V265, P14938; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JOLLY YC, 1993, BIOCHEMISTRY-US, V32, P12209, DOI 10.1021/bi00096a034; KAVANAUGH WM, 1994, BIOCHEMISTRY-US, V33, P11046, DOI 10.1021/bi00202a026; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; KONRAD RJ, 1992, BIOCHEM J, V287, P283, DOI 10.1042/bj2870283; KONRAD RJ, 1994, BIOCHEMISTRY-US, V33, P13284, DOI 10.1021/bi00249a015; KONRAD RJ, 1993, MOL CELL ENDOCRINOL, V92, P135, DOI 10.1016/0303-7207(93)90084-W; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MALAISSE WJ, 1979, METABOLISM, V28, P373, DOI 10.1016/0026-0495(79)90111-2; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OHMICHI M, 1992, J BIOL CHEM, V267, P21601; OLSZEWSKI S, 1994, J BIOL CHEM, V269, P27987; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RADVANYI F, 1993, MOL CELL BIOL, V13, P423; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TURK J, 1987, PROG LIPID RES, V26, P125, DOI 10.1016/0163-7827(87)90010-5; WENHAM RM, 1994, J BIOL CHEM, V269, P4947; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; WOLLHEIM CB, 1990, FEBS LETT, V268, P376, DOI 10.1016/0014-5793(90)81289-Z; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914	44	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24179	24186		10.1074/jbc.271.39.24179	http://dx.doi.org/10.1074/jbc.271.39.24179			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798659	hybrid			2022-12-27	WOS:A1996VJ44200088
J	McArdle, CA; Willars, GB; Fowkes, RC; Nahorski, SR; Davidson, JS; ForrestOwen, W				McArdle, CA; Willars, GB; Fowkes, RC; Nahorski, SR; Davidson, JS; ForrestOwen, W			Desensitization of gonadotropin-releasing hormone action in alpha T3-1 cells due to uncoupling of inositol 1,4,5-trisphosphate generation and Ca2+ mobilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH-SY5Y NEUROBLASTOMA-CELLS; ANTERIOR-PITUITARY CELLS; PROTEIN KINASE-C; RAPID DESENSITIZATION; RECEPTOR; GNRH; SIGNAL; CA-2+; INTERNALIZATION; REFRACTORINESS	Gonadotropin-releasing hormone (GnRH) acts via a G-protein coupled receptor on gonadotropes to increase cytosolic Ca2+ and stimulate gonadotropin secretion, Sustained exposure causes desensitization of these effects, but the GnRH receptor has no C-terminal tail and does not undergo rapid (<5 min) desensitization. Nevertheless, pretreatment of alpha T3-1 cells with GnRH reduced the spike Ca2+ response to GnRH and decreased the GnRH effect on inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) by 30-50%. Ca2+-free medium with or without thapsigargin also decreased GnRH-stimulated Ins(1,4,5)P-3 generation, implying that attenuation of the Ca2+ response underlies the Ins(1,4,5)P-3 reduction rather than vice versa. Intracellular Ca2+ pool depletion cannot explain desensitization of the Ca2+ response because pool depletion and repletion were faster (half-times, <1 min) than the onset of and recovery from desensitization (half-times 10-20 min and 4-6 h). Moreover, 1-h GnRH pretreatment attenuated the spike Ca2+ response to GnRH but not that to ionomycin, and brief GnRH exposure in Ca2+-free medium reduced the response to ionomycin more effectively in controls than in desensitized cells, GnRH pretreatment also attenuated the Ca2+ response to PACAP38. This novel form of desensitization does not reflect uncoupling of GnRH receptors from their immediate effector system but rather a reduced efficiency of mobilization by Ins(1,4,5)P-3 of Ca2+ from an intact intracellular pool.	UNIV LEICESTER,DEPT CELL PHYSIOL & PHARMACOL,LEICESTER LE1 9HN,LEICS,ENGLAND; UNIV CAPE TOWN,DEPT CHEM PATHOL,ZA-7925 CAPE TOWN,SOUTH AFRICA	University of Leicester; University of Cape Town	McArdle, CA (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,MARLBOROUGH ST,BRISTOL BS2 8HW,AVON,ENGLAND.		Fowkes, Robert/AAI-4756-2020; Fowkes, Robert/HHT-0664-2022; McArdle, Craig/AAQ-5660-2021	Fowkes, Robert/0000-0002-2222-2056; McArdle, Craig/0000-0003-4836-5351	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKERMAN SN, 1991, ENDOCRINOLOGY, V129, P475, DOI 10.1210/endo-129-1-475; ANDERSON L, 1993, J ENDOCRINOL, V136, P51, DOI 10.1677/joe.0.1360051; BARBIERI RL, 1992, TRENDS ENDOCRIN MET, V3, P30, DOI 10.1016/1043-2760(92)90089-J; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; CONN PM, 1991, NEW ENGL J MED, V324, P93; CONN PM, 1995, REPROD ENDOCRINOLOGY, V1, P163; DAVIDSON J, 1991, MOL CELL ENDOCRINOL, V76, P33; DAVIDSON JS, 1994, BIOCHEM J, V300, P299, DOI 10.1042/bj3000299; DEKONING J, 1978, J ENDOCRINOL, V79, P311, DOI 10.1677/joe.0.0790311; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HILLE B, 1995, RECENT PROG HORM RES, V50, P75; JINNAH HA, 1986, ENDOCRINOLOGY, V118, P2599, DOI 10.1210/endo-118-6-2599; JINNAH HA, 1985, AM J PHYSIOL, V249, pE619, DOI 10.1152/ajpendo.1985.249.6.E619; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V189, P289, DOI 10.1016/0006-291X(92)91556-6; Knobil E, 1980, Recent Prog Horm Res, V36, P53; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MCARDLE CA, 1988, ENDOCRINOLOGY, V122, P1905, DOI 10.1210/endo-122-5-1905; MCARDLE CA, 1995, ENDOCRINOLOGY, V136, P4864, DOI 10.1210/en.136.11.4864; McArdle CA, 1996, J ENDOCRINOL, V149, P155, DOI 10.1677/joe.0.1490155; MCARDLE CA, 1992, MOL CELL NEUROSCI, V3, P124, DOI 10.1016/1044-7431(92)90016-U; MCARDLE CA, 1992, ENDOCRINOLOGY, V130, P3567, DOI 10.1210/en.130.6.3567; MCARDLE CA, 1987, MOL ENDOCRINOL, V1, P420, DOI 10.1210/mend-1-6-420; MCDONOUGH PM, 1988, BIOCHEM J, V249, P135, DOI 10.1042/bj2490135; MERELLI F, 1992, ENDOCRINOLOGY, V131, P925, DOI 10.1210/en.131.2.925; NAOR Z, 1990, ENDOCR REV, V11, P326, DOI 10.1210/edrv-11-2-326; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; Rawlings SR, 1996, ENDOCR REV, V17, P4, DOI 10.1210/er.17.1.4; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; SCHOMERUS E, 1994, ENDOCRINOLOGY, V134, P615; STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462; STOJILKOVIC SS, 1989, J BIOL CHEM, V264, P10939; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TOBIN AB, 1992, MOL PHARMACOL, V42, P1042; TSUTSUMI M, 1992, MOL ENDOCRINOL, V6, P1163, DOI 10.1210/me.6.7.1163; WILLARS GB, 1995, MOL PHARMACOL, V47, P509; WILLARS GB, 1995, BRIT J PHARMACOL, V114, P1133, DOI 10.1111/j.1476-5381.1995.tb13325.x; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; WOJCIKIEWICZ RJH, 1994, J NEUROCHEM, V63, P177; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3	44	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					23711	23717		10.1074/jbc.271.39.23711	http://dx.doi.org/10.1074/jbc.271.39.23711			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798594	Green Published, hybrid			2022-12-27	WOS:A1996VJ44200023
J	Yang, XM; Richardson, CC				Yang, XM; Richardson, CC			Structural and functional organization of the DNA polymerase of bacteriophage T7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; ACID REPLICATION INVITRO; DEOXYRIBONUCLEIC-ACID; EXONUCLEASE ACTIVITY; LIMITED PROTEOLYSIS; GENE-5 PROTEIN; PROCESSIVITY; SUBUNITS; DOMAIN; MUTANT	The 80-kDa gene 5 protein encoded by bacteriophage T7 shares significant amino acid homology with the large fragment of Escherichia coli DNA polymerase I (Klenow fragment). Like the Klenow fragment, T7 gene 5 protein has both DNA polymerase and 3' to 5' exonuclease activities. However, unlike the Klenow fragment, T7 gene 5 protein binds tightly to E. coli thioredoxin to form a complex that has a high processivity of nucleotide polymerization. In order to identify the domains of gene 5 protein responsible for polymerization, hydrolysis, and binding of thioredoxin, we have analyzed proteolytic fragments of gene 5 protein. Cleavage of the protein within one protease-sensitive region (residue 250-300) yields two molecular weight species of peptides of 32-37 and 43-51 kDa derived from the N-terminal and C-terminal region, respectively. DNA polymerase activity is found within the C-terminal fragments and exonuclease activity within the N-terminal fragments. Thioredoxin stimulates the DNA polymerase activity of the C-terminal fragments. All fragments bind to DNA. In addition to delineating the polymerase and exonuclease domains, the protease-sensitive region appears to interact with E. coli thioredoxin. Thioredoxin protects this region from proteolysis, and alteration of this region reduces the ability of thioredoxin to stimulate polymerase activity.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI006045, R37AI006045] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-06045] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADLER S, 1979, J BIOL CHEM, V254, P1605; ARNOLD E, 1995, CURR OPIN STRUC BIOL, V5, P27, DOI 10.1016/0959-440X(95)80006-M; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BERNARD A, 1991, GENE AMST, V100, P27; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; BRUTLAG D, 1969, BIOCHEM BIOPH RES CO, V37, P982, DOI 10.1016/0006-291X(69)90228-9; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; FRANK P, 1993, BIOCHEM BIOPH RES CO, V196, P1552, DOI 10.1006/bbrc.1993.2428; FREEMONT P S, 1986, Proteins Structure Function and Genetics, V1, P66, DOI 10.1002/prot.340010111; HIMAWAN JS, 1992, P NATL ACAD SCI USA, V89, P9774, DOI 10.1073/pnas.89.20.9774; HORI K, 1979, J BIOL CHEM, V254, P1598; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HUBER HE, 1987, J BIOL CHEM, V262, P16224; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KARAWYA E, 1983, ANAL BIOCHEM, V135, P318, DOI 10.1016/0003-2697(83)90689-9; KIM YT, 1992, J BIOL CHEM, V267, P15032; KLENOW H, 1970, P NATL ACAD SCI USA, V65, P168, DOI 10.1073/pnas.65.1.168; Kornberg A., 1992, DNA REPLICATION, VSecond, P113; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN TC, 1994, J BIOL CHEM, V269, P19286; MARK DF, 1976, P NATL ACAD SCI USA, V73, P780, DOI 10.1073/pnas.73.3.780; MODRICH P, 1975, J BIOL CHEM, V250, P5508; MODRICH P, 1975, J BIOL CHEM, V250, P5515; NAKAI H, 1986, J BIOL CHEM, V261, P5208; OLLIS DL, 1985, NATURE, V313, P818, DOI 10.1038/313818a0; OLLIS DL, 1985, NATURE, V313, P726; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PISANI FM, 1994, J BIOL CHEM, V269, P7887; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; RICHARDSON CC, 1994, CELL, V77, P157; SCARLATO V, 1992, GENE, V118, P109, DOI 10.1016/0378-1119(92)90256-O; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P438; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1987, J BIOL CHEM, V262, P15330; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; TABOR S, 1989, J BIOL CHEM, V264, P6447; Weber K, 1972, Methods Enzymol, V26, P3; WEISSHART K, 1994, J BIOL CHEM, V269, P22788	42	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	1996	271	39					24207	24212		10.1074/jbc.271.39.24207	http://dx.doi.org/10.1074/jbc.271.39.24207			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VJ442	8798663	Green Published, hybrid			2022-12-27	WOS:A1996VJ44200092
J	LaPres, JJ; Hudson, LG				LaPres, JJ; Hudson, LG			Identification of a functional determinant of differentiation-dependent expression in the involucrin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; TRANSCRIPTION FACTOR; BETA-GALACTOSIDASE; HUMAN KERATINOCYTE; PROMOTER; CELLS; ACTIVATION; EPIDERMIS; ELEMENT; PROLIFERATION	Involucrin is an integral component of the cornified envelope which is a characteristic feature of the differentiated keratinocyte. Involucrin expression is tightly linked to the onset of differentiation and first expressed in the immediate suprabasal layers of the epidermis. We have identified a transcriptional response element within the distal 5'-flanking region of the involucrin gene which contributes to differentiation dependent expression, Deletion of this site impairs differentiation-dependent promoter activity in transient transfection analysis, and conversely, this region imparts differentiation-dependent expression to a heterologous promoter. The identified site bears sequence similarity to several AP2-like response elements identified in keratinocyte-specific genes and binds a protein complex (keratinocyte differentiation factor, KDF-1) which is distinct from AP2 by several criteria. The migration of KDF-1 is distinct from AP2 in electrophoretic mobility shift assays, KDF-1 is antigenically unrelated to AP2 since AP2 specific antibodies do not supershift the KDF-1-DNA complex and KDF-1 is poorly competed by oligonucleotides representing consensus AP2 recognition sequences. In addition, the KDF-1 complex is not detected in nuclear extracts derived from human dermal fibroblasts or an enriched population of basal keratinocytes. These findings provide insights to the underlying basis of differentiation-dependent expression of a keratinocyte specific gene.	NORTHWESTERN UNIV, DEPT MOL PHARMACOL & BIOL CHEM, CHICAGO, IL 60611 USA	Northwestern University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008061] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM08061] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Bernerd Francoise, 1993, Gene Expression, V3, P187; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BRENNAN JK, 1975, IN VITRO CELL DEV B, V11, P354, DOI 10.1007/BF02616371; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; CARROLL JM, 1992, J CELL SCI, V103, P925; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; ECKERT RL, 1989, ENVIRON HEALTH PERSP, V80, P109, DOI 10.2307/3430736; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; FAUS I, 1994, MOL CELL BIOL, V14, P3263, DOI 10.1128/MCB.14.5.3263; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; HU L, 1994, J BIOL CHEM, V269, P183; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; Leigh I.M., 1994, KERATINOCYTE METHODS; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; LOTAN R, 1993, J CELL BIOCHEM, P167; LU B, 1994, J BIOL CHEM, V269, P7443; MAGNALDO T, 1993, DNA CELL BIOL, V12, P911, DOI 10.1089/dna.1993.12.911; Mariniello L, 1995, J BIOL CHEM, V270, P31358, DOI 10.1074/jbc.270.52.31358; MOSER M, 1995, DEVELOPMENT, V121, P2779; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; OFFORD EA, 1993, CARCINOGENESIS, V14, P2447, DOI 10.1093/carcin/14.12.2447; Ohtsuki Mamitaro, 1993, Gene Expression, V3, P201; PRUSSAK CE, 1989, J BIOL CHEM, V264, P4957; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SNAPE AM, 1990, DEVELOPMENT, V109, P157; STAEDEL C, 1994, J INVEST DERMATOL, V102, P768, DOI 10.1111/1523-1747.ep12377673; TAMAI K, 1994, J BIOL CHEM, V269, P493; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WILKE MS, 1988, AM J PATHOL, V131, P171	39	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23154	23160		10.1074/jbc.271.38.23154	http://dx.doi.org/10.1074/jbc.271.38.23154			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798509	hybrid			2022-12-27	WOS:A1996VH76800035
J	Liu, L; Dudler, T; Gelb, MH				Liu, L; Dudler, T; Gelb, MH			Purification of a protein palmitoyltransferase that acts on H-Ras protein and on a C-terminal N-Ras peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID ACYLATION; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; TUBE FORMATION; SARCOMA-VIRUS; FARNESYL; P21RAS; ACYLTRANSFERASE; PALMITOYLATION; CYSTEINE	Mammalian H-Ras and N-Ras are GTP-binding proteins that must be post-translationally lipidated to function as molecular switches in signal transduction cascades controlling cell growth and differentiation. These proteins contain a C-terminal farnesyl-cysteine cu-methyl ester and palmitoyl groups attached to nearby cysteines. Data is presented showing that rat liver microsomes contain an enzyme that transfers the palmitoyl group from palmitoyl-coenzyme A to cysteine residues of H-Ras protein and of a synthetic peptide having the structure of the C terminus of N-Ras, This protein palmitoyltransferase (PPT) was solubilized from membranes and purified 10,500-fold to apparent homogeneity with an overall yield of 10%. On an SDS gel, PPT appears as two proteins of molecular masses of approximate to 30 and approximate to 33 kDa. If the palmitoylation sites of the N-Ras peptide (the non-farnesylated cysteine) or H-Ras protein (cysteines 181 and 184) are changed to serine, palmitoylation by PPT does not occur. Non-farnesylated H-Ras produced in bacteria as well as in vitro farnesylated bacterial H-Ras are not substrates for PPT nor is the non farnesylated, methylated N-Ras peptide, These results suggest, but do not prove, that farnesylation and possibly C-terminal methylation are prerequisites for Ras palmitoylation, PPT shows a large preference for palmitoyl-coenzyme A over myristoyl-coenzyme as the acyl donor, Values of K-m for palmitoyl-CoA and H-Ras are 4.3 +/- 1.2 and 0.8 +/- 0.3 mu M, respectively. PPT is the first protein palmitoyltransferase to be purified, and the availability of pure enzyme should contribute to our understanding of the function and regulation of Ras palmitoylation in cells.	UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				gelb, michael/0000-0001-7000-5219	NCI NIH HHS [CA52874] Funding Source: Medline; NIGMS NIH HHS [GM562] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; BERGER M, 1984, J BIOL CHEM, V259, P7245; BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; BHARADWAJ M, 1995, J NEUROCHEM, V65, P1805; BHATTACHARYA S, 1995, P NATL ACAD SCI USA, V92, P2984, DOI 10.1073/pnas.92.7.2984; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN ZQ, 1985, J VIROL, V56, P607, DOI 10.1128/JVI.56.2.607-612.1985; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; Dudler T, 1996, J BIOL CHEM, V271, P11541, DOI 10.1074/jbc.271.19.11541; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FUJIYAMA A, 1986, P NATL ACAD SCI USA, V83, P1266, DOI 10.1073/pnas.83.5.1266; GHOMASHCHI F, 1995, BIOCHEMISTRY-US, V34, P11910, DOI 10.1021/bi00037a032; GRAND RJA, 1987, ONCOGENE, V1, P305; GUTIERREZ L, 1991, BIOCHIM BIOPHYS ACTA, V1078, P147, DOI 10.1016/0167-4838(91)99003-B; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; JANG GF, 1993, BIOCHEMISTRY-US, V32, P9500, DOI 10.1021/bi00087a031; KAJRA AK, 1986, METHOD ENZYMOL, V122, P50; KAMIYA Y, 1978, BIOCHEM BIOPH RES CO, V83, P1077, DOI 10.1016/0006-291X(78)91505-X; LIU L, 1994, METHOD ENZYMOL, V250, P189; MA YT, 1992, P NATL ACAD SCI USA, V89, P6275, DOI 10.1073/pnas.89.14.6275; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MCGEADY P, 1995, J BIOL CHEM, V270, P26347, DOI 10.1074/jbc.270.44.26347; PORFIRI E, 1995, METHOD ENZYMOL, V255, P13; QUESNEL S, 1994, BIOCHEMISTRY-US, V33, P13340, DOI 10.1021/bi00249a021; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; SAKAGAMI Y, 1978, AGR BIOL CHEM TOKYO, V42, P1093, DOI 10.1080/00021369.1978.10863118; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHMIDT MFG, 1989, BIOCHEM SOC T, V17, P859, DOI 10.1042/bst0170859; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SHIH TY, 1982, J VIROL, V42, P253, DOI 10.1128/JVI.42.1.253-261.1982; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0	43	80	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23269	23276		10.1074/jbc.271.38.23269	http://dx.doi.org/10.1074/jbc.271.38.23269			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798525	hybrid			2022-12-27	WOS:A1996VH76800051
J	Morrow, JD; Awad, JA; Wu, AP; Zackert, WE; Daniel, VC; Roberts, LJ				Morrow, JD; Awad, JA; Wu, AP; Zackert, WE; Daniel, VC; Roberts, LJ			Nonenzymatic free radical-catalyzed generation of thromboxane-like compounds (isothromboxanes) in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTANOIDS F2-ISOPROSTANES; HUMAN-DISEASE; RAT; NONCYCLOOXYGENASE; PROSTAGLANDINS; MECHANISM; RECEPTORS; SERIES	The isoprostanes (IsoPs) are novel bioactive prostaglandin-like compounds produced in vivo by free radical catalyzed peroxidation of arachidonyl-containing lip ids, Previously, we have identified IsoPs containing F-type and D- and E-type prostane rings that are formed by reduction and rearrangement of IsoP endoperoxide intermediates, respectively, We now explore whether thromboxane B-2 (TxB(2))-like compounds, termed B-2-isothromboxanes (B-2-IsoTxs), are formed by rearrangement of IsoP endoperoxides. Detection of these compounds was carried out using a stable isotope dilution mass spectrometric assay originally developed for quantification of cyclooxygenase-derived TxB(2). Incubations of arachidonic acid with Fe/ADP/ascorbate for 30 min in vitro generated a series of peaks representing putative B-2-IsoTx at levels of 62.4 +/- 21.0 ng/mg arachidonate. Using various chemical modification and derivatization approaches, it was determined that these compounds contained hemiacetal ring structures and two double bonds, as would be expected for B-2-IsoTx. Analysis of the compounds by electron ionization mass spectrometry yielded multiple mass spectra similar to those of TxB(2). B-2-IsoTxs are also formed esterified to phospholipids; oxidation of arachidonyl containing phosphatidylcholine in vitro followed by hydrolysis resulted in the release of large amounts of these compounds. To explore whether B-2-IsoTxs are also formed in vivo, a well characterized animal model of lipid peroxidation consisting of orogastric administration of CCl4 to rats was used, Levels of B-2-IsoTx esterified in lipids in the liver increased 41-fold from 2.5 +/- 0.5 to 102 +/- 30 ng/g of liver. In addition, circulating levels of free compounds increased from undetectable (<5 pg/ml) to 185 +/- 30 pg/ml after CCl4, a 37-fold increase. Thus, we have provided evidence that IsoTxs constitute another novel class of eicosanoids produced in vivo nonenzymatically by free radical-catalyzed lipid peroxidation. These studies thus expand our understanding of products of lipid peroxidation formed in vivo from the free radical-catalyzed peroxidation of arachidonic acid.	VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM042056, P50GM015431, P01GM015431, R01GM042056] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIGMS NIH HHS [GM42056, GM15431] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; BANERJEE M, 1992, AM J PHYSIOL, V263, pH660, DOI 10.1152/ajpheart.1992.263.3.H660; BURK RF, 1979, TOXICOL APPL PHARM, V50, P467, DOI 10.1016/0041-008X(79)90400-9; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619, DOI 10.1152/ajpcell.1993.264.6.C1619; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HECKER M, 1989, J BIOL CHEM, V264, P141; JACKSON EK, 1989, J PHARMACOL EXP THER, V250, P9; LONGMIRE AW, 1994, BIOCHEM PHARMACOL, V47, P1173, DOI 10.1016/0006-2952(94)90389-1; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1994, J BIOL CHEM, V269, P4317; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; PARSONS WG, 1988, J IMMUNOL, V141, P2413; RADIN NS, 1969, METHOD ENZYMOL, V14, P245; ROBERTS LJ, 1981, J BIOL CHEM, V256, P8384; SEVANIAN A, 1985, Journal of Free Radicals in Biology and Medicine, V1, P263, DOI 10.1016/0748-5514(85)90130-8; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P390, DOI 10.1016/S0025-6196(12)64862-9; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826; WAUGH RJ, 1996, J AM SOC MASS SPECTR, V1, P490	21	99	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23185	23190		10.1074/jbc.271.38.23185	http://dx.doi.org/10.1074/jbc.271.38.23185			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798513	hybrid			2022-12-27	WOS:A1996VH76800039
J	Spicer, AP; Augustine, ML; McDonald, JA				Spicer, AP; Augustine, ML; McDonald, JA			Molecular cloning and characterization of a putative mouse hyaluronan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATED TERATOCARCINOMA CELLS; SACCHAROMYCES-CEREVISIAE; STREPTOCOCCUS-PYOGENES; EXTRACELLULAR-MATRIX; NUCLEOTIDE-SEQUENCE; DEGENERATE PRIMERS; BINDING PROTEINS; MESSENGER-RNAS; GENE; LOCALIZATION	We report the isolation of a novel mouse gene which encodes a putative hyaluronan synthase. The cDNA was identified using degenerate reverse transcriptase polymerase chain reaction. Degenerate primers were designed based upon an alignment of the amino acid sequences of Streptococcus pyogenes HasA, Xenopus laevis DG42, and Rhizobium meliloti NodC. A mouse embryo cDNA library was screened with the resultant polymerase chain reaction product, and multiple cDNA clones spanning 3 kilobase pairs (kb) were isolated. The open reading frame predicted a 63-kDa protein with several transmembrane sequences, multiple consensus phosphorylation sites, and four putative hyaluronan binding motifs. The amino acid sequence displayed 55% identity to mouse HAS, 56% identity to Xenopus DG42, and 21% identity to Streptococcus HasA. Northern analysis identified transcripts of 4.8 kb and 3.2 kb, which were expressed highly in the developing mouse embryo and at lower levels in adult mouse heart, brain, spleen, lung, and skeletal muscle. Transfection experiments demonstrated that mouse Has2 could direct hyaluronan coat biosynthesis in transfected COS cells, as evidenced by a classical particle exclusion assay. These results suggest that mammalian HA synthase activity is regulated by at least two related genes. Accordingly, we propose the name Has2 for this gene.			Spicer, AP (corresponding author), MAYO CLIN SCOTTSDALE,DEPT BIOCHEM & MOL BIOL,SAMUEL C JOHNSON MED RES BLDG,SCOTTSDALE,AZ 85259, USA.							BALBAS JAM, 1993, TERATOLOGY, V48, P197, DOI 10.1002/tera.1420480303; BALDWIN HS, 1994, CIRC RES, V74, P244, DOI 10.1161/01.RES.74.2.244; BERTHEIM U, 1994, BRIT J PLAST SURG, V47, P483, DOI 10.1016/0007-1226(94)90031-0; BIGNAMI A, 1993, ANAT EMBRYOL, V188, P419; BRAY BA, 1994, EXP LUNG RES, V20, P317, DOI 10.3109/01902149409064390; BROWN JJG, 1993, DEVELOPMENT, V117, P483; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; CLARRIS BJ, 1968, EXP CELL RES, V49, P181, DOI 10.1016/0014-4827(68)90530-2; COLLINSEMERSON JM, 1990, NUCLEIC ACIDS RES, V18, P6690, DOI 10.1093/nar/18.22.6690; COPP AJ, 1988, DEV BIOL, V130, P583, DOI 10.1016/0012-1606(88)90353-3; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1994, BIOCHEM BIOPH RES CO, V199, P1, DOI 10.1006/bbrc.1994.1184; EGGLI PS, 1992, NEUROSCIENCE, V48, P737, DOI 10.1016/0306-4522(92)90417-Z; FENDERSON BA, 1993, DIFFERENTIATION, V54, P85; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HADDON CM, 1991, DEVELOPMENT, V112, P541; HELDIN P, 1993, EXP CELL RES, V208, P422, DOI 10.1006/excr.1993.1264; HERSCOVICS A, 1994, J BIOL CHEM, V269, P9864; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; JACOBS TW, 1985, J BACTERIOL, V162, P469, DOI 10.1128/JB.162.2.469-476.1985; KLEWES L, 1994, J CELL PHYSIOL, V160, P539, DOI 10.1002/jcp.1041600317; KLEWES L, 1993, BIOCHEM J, V290, P791, DOI 10.1042/bj2900791; KNUDSON CB, 1988, BIOCHEM INT, V17, P735; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KNUDSON CB, 1987, DEV BIOL, V124, P82, DOI 10.1016/0012-1606(87)90462-3; KNUDSON W, 1993, P NATL ACAD SCI USA, V90, P4003, DOI 10.1073/pnas.90.9.4003; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANSING M, 1993, BIOCHEM J, V289, P179, DOI 10.1042/bj2890179; LAURENT C, 1991, CELL TISSUE RES, V263, P201, DOI 10.1007/BF00318761; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LEE GM, 1993, J CELL BIOL, V123, P1899, DOI 10.1083/jcb.123.6.1899; MAIER J, 1995, BIOCHEM BIOPH RES CO, V212, P705, DOI 10.1006/bbrc.1995.2026; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MARKWALD RR, 1978, DEV BIOL, V62, P292, DOI 10.1016/0012-1606(78)90218-X; Meyer K, 1934, J BIOL CHEM, V107, P629; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; NAKAMURA A, 1981, J EMBRYOL EXP MORPH, V65, P235; OREGAN M, 1994, INT J BIOL MACROMOL, V16, P283, DOI 10.1016/0141-8130(94)90056-6; PEARSON RB, 1993, PROTEIN PHOSPHORYLAT; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; PHILIPSON LH, 1985, BIOCHEMISTRY-US, V24, P7899, DOI 10.1021/bi00348a008; PREHM P, 1984, BIOCHEM J, V220, P597, DOI 10.1042/bj2200597; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; PREHM P, 1983, BIOCHEM J, V211, P191, DOI 10.1042/bj2110191; PREHM P, 1990, BIOCHEM J, V267, P185, DOI 10.1042/bj2670185; PREHM P, 1986, ARTICULAR CARTILAGE, P81; PYTELA R, 1994, METHOD ENZYMOL, V245, P420; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; Sambrook J., 2002, MOL CLONING LAB MANU; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SEMINO CE, 1995, P NATL ACAD SCI USA, V92, P3498, DOI 10.1073/pnas.92.8.3498; Semino CE, 1996, P NATL ACAD SCI USA, V93, P4548, DOI 10.1073/pnas.93.10.4548; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; SINGH GD, 1994, ARCH ORAL BIOL, V39, P401, DOI 10.1016/0003-9969(94)90170-8; SUZUKI M, 1995, BIOCHEM J, V307, P817, DOI 10.1042/bj3070817; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; WESSELS MR, 1994, INFECT IMMUN, V62, P433, DOI 10.1128/IAI.62.2.433-441.1994; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YASUHARA O, 1994, BRAIN RES, V635, P269, DOI 10.1016/0006-8993(94)91448-6; [No title captured]	65	144	161	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23400	23406		10.1074/jbc.271.38.23400	http://dx.doi.org/10.1074/jbc.271.38.23400			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798545	hybrid			2022-12-27	WOS:A1996VH76800071
J	Vogel, BS; Wildung, MR; Vogel, G; Croteau, R				Vogel, BS; Wildung, MR; Vogel, G; Croteau, R			Abietadiene synthase from grand fir (Abies grandis) - cDNA isolation, characterization, and bacterial expression of a bifunctional diterpene cyclase involved in resin acid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL-DIPHOSPHATE SYNTHASE; CHLOROPLAST TRANSIT PEPTIDES; SITE-DIRECTED MUTAGENESIS; SESQUITERPENE CYCLASE; GIBBERELLIN BIOSYNTHESIS; ENZYMATIC CYCLIZATION; OXIDOSQUALENE CYCLASE; 4S-LIMONENE SYNTHASE; MONOTERPENE CYCLASE; TERPENE CYCLASES	(-)-Abietic acid, the principal diterpenoid resin acid of the wound-induced oleoresin secreted by grand fir (Abies grandis), is synthesized by the cyclization of geranylgeranyl diphosphate to (-)-abieta-7(8),13(14)-diene, followed by sequential three-step oxidation of the C-18 methyl group of the olefin to a carboxyl function, The enzyme catalyzing the cyclization reaction, abietadiene synthase, was purified from stems of wounded grand fir saplings and was digested with trypsin, Amino acid sequence information from the resulting peptides allowed construction of degenerate oligonucleotide primers, which amplified a 551-base pair fragment from a wound-induced stem cDNA library, This hybridization probe was then utilized to screen the wound-induced stern cDNA library, from which three cDNA clones were isolated that were functionally expressed in Escherichia coli, thereby confirming that a single protein catalyzes the complex, multistep cyclization of geranylgeranyl diphosphate tea abietadiene, cDNA isolate Ac22.1, which yielded the highest expressed level of cyclase activity, was 2861 base pairs in length and encoded an 868-amino acid open reading frame that included a putative plastidial transit peptide, Deduced amino acid sequence comparison to other terpene cyclases revealed an amino-terminal region of the abietadiene synthase, which resembles those of enzymes that employ substrate double bond protonation to initiate the carbocationic reaction cascade, and a carboxyl-terminal region of the synthase, which resembles those of enzymes that employ ionization of the substrate allylic diphosphate ester function to initiate the cyclization reaction. This apparent fusion of segments of the two distinct terpenoid cyclase types is consistent with the novel mechanism of the bifunctional abietadiene synthase in catalyzing both protonation-initiated and ionization-initiated cyclization steps.	WASHINGTON STATE UNIV, INST BIOL CHEM, PULLMAN, WA 99164 USA; WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA	Washington State University; Washington State University								ABE I, 1995, LIPIDS, V30, P231, DOI 10.1007/BF02537826; ABE I, 1994, J BIOL CHEM, V269, P802; ABE I, 1993, CHEM REV, V93, P2189, DOI 10.1021/cr00022a009; ASHBY MN, 1992, J BIOL CHEM, V267, P4128; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BACK K, 1995, J BIOL CHEM, V270, P7375, DOI 10.1074/jbc.270.13.7375; BENSEN RJ, 1995, PLANT CELL, V7, P75, DOI 10.1105/tpc.7.1.75; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANE DE, 1994, BIOCHEMISTRY-US, V33, P5846, DOI 10.1021/bi00185a024; CHEN AJ, 1994, PROTEIN SCI, V3, P600; Chen XY, 1995, ARCH BIOCHEM BIOPHYS, V324, P255, DOI 10.1006/abbi.1995.0038; CHENICLET C, 1987, J EXP BOT, V38, P1557, DOI 10.1093/jxb/38.9.1557; COLBY SM, 1993, J BIOL CHEM, V268, P23016; COOLBAUGH RC, 1983, BIOCH PHYSL GIBBEREL, V1, P53; COREY EJ, 1993, P NATL ACAD SCI USA, V90, P11628, DOI 10.1073/pnas.90.24.11628; Croteau R., 1985, BIOSYNTHESIS BIODEGR, P379; DENNIS DT, 1967, J BIOL CHEM, V242, P3293; DOGBO O, 1988, P NATL ACAD SCI USA, V85, P7054, DOI 10.1073/pnas.85.19.7054; DUNCAN JD, 1981, PLANT PHYSIOL, V68, P1128, DOI 10.1104/pp.68.5.1128; FACCHINI PJ, 1992, P NATL ACAD SCI USA, V89, P11088, DOI 10.1073/pnas.89.22.11088; FAHN A, 1979, SECRETORY TISSUES PL, P185; FUNK C, 1994, PLANT PHYSIOL, V106, P999, DOI 10.1104/pp.106.3.999; FUNK C, 1994, ARCH BIOCHEM BIOPHYS, V308, P258, DOI 10.1006/abbi.1994.1036; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GIJZEN M, 1991, ARCH BIOCHEM BIOPHYS, V289, P267, DOI 10.1016/0003-9861(91)90471-T; Graebe J. E., 1980, Plant growth substances 1979 [Skoog, F. (Editor)]., P180; GRAEBE JE, 1987, ANNU REV PLANT PHYS, V38, P419, DOI 10.1146/annurev.pp.38.060187.002223; HOHN TM, 1989, GENE, V79, P131, DOI 10.1016/0378-1119(89)90098-X; JOHNSON MA, 1987, ACS SYM SER, V325, P76; JOLY A, 1993, J BIOL CHEM, V268, P26983; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KLEINIG H, 1989, ANNU REV PLANT PHYS, V40, P39, DOI 10.1146/annurev.pp.40.060189.000351; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFEVER RE, 1994, ARCH BIOCHEM BIOPHYS, V313, P139, DOI 10.1006/abbi.1994.1370; LEWINSOHN E, 1991, PLANT PHYSIOL, V96, P38, DOI 10.1104/pp.96.1.38; Lewinsohn E., 1994, Plant Molecular Biology Reporter, V12, P20, DOI 10.1007/BF02668660; LEWINSOHN E, 1993, PHYTOCHEM ANALYSIS, V4, P220, DOI 10.1002/pca.2800040506; LEWINSOHN E, 1993, PLANT PHYSIOL, V101, P1021, DOI 10.1104/pp.101.3.1021; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; MATH SK, 1992, P NATL ACAD SCI USA, V89, P6761, DOI 10.1073/pnas.89.15.6761; MAU CJD, 1994, P NATL ACAD SCI USA, V91, P8497, DOI 10.1073/pnas.91.18.8497; MURPHY PJ, 1969, ARCH BIOCHEM BIOPHYS, V133, P395, DOI 10.1016/0003-9861(69)90468-8; NEBEKER TE, 1993, BEETLE PATHOGEN INTE, P158; OCHS D, 1992, J BACTERIOL, V174, P298, DOI 10.1128/jb.174.1.298-302.1992; PORALLA K, 1994, TRENDS BIOCHEM SCI, V19, P157, DOI 10.1016/0968-0004(94)90276-3; POULTER CD, 1990, ACCOUNTS CHEM RES, V23, P70, DOI 10.1021/ar00171a003; PROCTOR RH, 1993, J BIOL CHEM, V268, P4543; Raffa K.F., 1991, P245; RAFFA KF, 1985, ENVIRON ENTOMOL, V14, P552, DOI 10.1093/ee/14.5.552; RAJAONARIVONY JIM, 1992, ARCH BIOCHEM BIOPHYS, V299, P77, DOI 10.1016/0003-9861(92)90246-S; SAITO T, 1995, PLANT PHYSIOL, V109, P1239, DOI 10.1104/pp.109.4.1239; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAVAGE TJ, 1995, ARCH BIOCHEM BIOPHYS, V320, P257, DOI 10.1016/0003-9861(95)90008-X; SHI Z, 1994, P NATL ACAD SCI USA, V91, P7370, DOI 10.1073/pnas.91.15.7370; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; STEELE CL, 1995, P NATL ACAD SCI USA, V92, P4164, DOI 10.1073/pnas.92.10.4164; STONE KL, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P31; SUN TP, 1994, PLANT CELL, V6, P1509, DOI 10.1105/tpc.6.10.1509; TABOR S, 1991, CURRENT PROTOCOLS MO; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; West C. A., 1981, BIOSYNTHESIS ISOPREN, V1, P375; WEST CA, 1979, RECENT ADV PHYTOCHEM, V13, P163; Wildung MR, 1996, J BIOL CHEM, V271, P9201, DOI 10.1074/jbc.271.16.9201; YAMADA T, 1992, DEFENSE MECHANISMS W, P147; YAMAGUCHI S, 1996, IN PRESS PLANT J	71	157	168	2	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	1996	271	38					23262	23268						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VH768	8798524	hybrid			2022-12-27	WOS:A1996VH76800050
J	Buchbinder, JL; Fletterick, RJ				Buchbinder, JL; Fletterick, RJ			Role of the active site gate of glycogen phosphorylase in allosteric inhibition and substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BISUBSTRATE ANALOG N-(PHOSPHONACETYL)-L-ASPARTATE; ASPARTATE CARBAMOYLTRANSFERASE; CATALYTIC SITE; STRUCTURAL-CHANGES; ESCHERICHIA-COLI; RABBIT MUSCLE; T-STATE; ACTIVATION; GLUCOSE; ALPHA	The functional role in allosteric regulation of a flexible loop (residues 280-288) located near the active site of muscle glycogen phosphorylase was investigated. Mutations were made in residues 283-285 based on crystallographic studies that indicate that the loop functions as a gate controlling access of substrates to the active site and that these specific residues play distinct roles in mimicking the substrate and binding inhibitors when the enzyme is in an inactive conformation, Substitution of Ala or Asn for Asp-283, the putative substrate mimic, results in a 15-fold decrease in V-max, a 10-fold decrease in the S-0.5 for glucose 1-phosphate, a 10-fold increase in the K-alpha for AMP, and a 10-20-fold increase in the K-i for glucose, Substitution of Ala for Asn-284, which normally forms a hydrogen bond with the inhibitor glucose, re duces V-max 3-fold, increases the K-i for glucose 2-fold, but has little effect on AMP or glucose 1-phosphate binding or cooperativity, Substitution of Asp at 284, on the other hand, reduces V-max 10-fold, elevates the K-i for glucose 10-fold, decreases AMP cooperativity, but has little effect on the affinity of AMP or the cooperativity and binding of glucose 1-phosphate. Substitution of Leu for Phe-285, which forms aromatic stacking interactions with purine inhibitors, reduces V-max 2-fold, decreases the affinity for caffeine at least 10-fold, raises the K-alpha for AMP 3-fold, and decreases AMP cooperativity but has little effect on glucose 1-phosphate binding or cooperativity. The results of the mutagenesis studies show the importance of the 280's loop for inhibitor binding and modulation of substrate affinity and suggest a role for the loop in allosteric activation, The propagation of allosteric effects across the domain interface may depend upon specific contacts between residues of the 280's loop and the C-terminal domain.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco			Buchbinder, Ioseph/K-9306-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032822] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015371] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32822] Funding Source: Medline; NIGMS NIH HHS [GM15371] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BROWNER MF, 1994, NAT STRUCT BIOL, V1, P327, DOI 10.1038/nsb0594-327; BROWNER MF, 1992, BIOCHEMISTRY-US, V31, P11297, DOI 10.1021/bi00161a006; BROWNER MF, 1991, PROTEIN ENG, V4, P351, DOI 10.1093/protein/4.3.351; BROWNER MF, 1992, TRENDS BIOCHEM SCI, V17, P66, DOI 10.1016/0968-0004(92)90504-3; BROWNER MF, 1992, BIOCHEMISTRY-US, V31, P11291, DOI 10.1021/bi00161a005; BUC MH, 1971, BIOCHIMIE, V53, P283, DOI 10.1016/S0300-9084(71)80094-9; BUCHBINDER JL, 1995, BIOCHEMISTRY-US, V34, P6423, DOI 10.1021/bi00019a023; CARNEY IT, 1978, ANAL BIOCHEM, V85, P321, DOI 10.1016/0003-2697(78)90309-3; Cori CF, 1936, P SOC EXP BIOL MED, V34, P702; Cori GT, 1940, J BIOL CHEM, V135, P733; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; FISCHER EH, 1955, J BIOL CHEM, V216, P121; FISCHER EH, 1959, J BIOL CHEM, V234, P1698; FLETTERICK RJ, 1980, ANNU REV BIOCHEM, V49, P31, DOI 10.1146/annurev.bi.49.070180.000335; FLETTERICK RJ, 1982, ACCOUNTS CHEM RES, V15, P361, DOI 10.1021/ar00083a004; GOLDSMITH EJ, 1989, SCIENCE, V245, P528, DOI 10.1126/science.2756432; GOLDSMITH EJ, 1987, J BIOL CHEM, V262, P1449; HELMREICH E, 1967, BIOCHEMISTRY-US, V6, P3695, DOI 10.1021/bi00864a012; HUANG CY, 1970, BIOCHEMISTRY-US, V9, P660, DOI 10.1021/bi00805a028; HUDSON JW, 1993, BIOCHIM BIOPHYS ACTA, V1164, P197, DOI 10.1016/0167-4838(93)90248-P; HUDSON JW, 1993, J MOL BIOL, V234, P700, DOI 10.1006/jmbi.1993.1621; Johnson L. N., 1989, ALLOSTERIC ENZYMES, P81; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; KASVINSKY PJ, 1978, J BIOL CHEM, V253, P9102; KIHLMAN B, 1955, EXP CELL RES, V8, P252, DOI 10.1016/0014-4827(55)90066-5; KIM KH, 1987, J MOL BIOL, V196, P853, DOI 10.1016/0022-2836(87)90410-4; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; KRAUSE KL, 1985, P NATL ACAD SCI USA, V82, P1643, DOI 10.1073/pnas.82.6.1643; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUONG CBH, 1992, J CHROMATOGR-BIOMED, V584, P77, DOI 10.1016/0378-4347(92)80011-E; MADSEN NB, 1976, MOL CELL BIOCHEM, V11, P35, DOI 10.1007/BF01792832; MADSEN NB, 1967, J BIOL CHEM, V242, P3301; Madsen NB, 1986, ENZYMES, V17, P365; MARTIN JL, 1990, BIOCHEMISTRY-US, V29, P10745, DOI 10.1021/bi00500a005; MEYER F, 1970, J BIOL CHEM, V245, P6642; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MORGAN HE, 1964, J BIOL CHEM, V239, P2440; PARMEGGIANI A, 1962, BIOCHEM BIOPH RES CO, V9, P252, DOI 10.1016/0006-291X(62)90068-2; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; Segel I.H., 1975, ENZYME KINETICS; SOMAN G, 1972, INDIAN J BIOCHEM BIO, V9, P304; SPRANG S, 1979, J MOL BIOL, V131, P523, DOI 10.1016/0022-2836(79)90006-8; SPRANG S, 1982, BIOCHEMISTRY-US, V21, P2036, DOI 10.1021/bi00538a010; SPRANG S, 1987, SCIENCE, V237, P1012, DOI 10.1126/science.3616621; SPRANG SR, 1982, BIOCHEMISTRY-US, V21, P5364, DOI 10.1021/bi00264a038; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; SPRANG SR, 1992, PROTEIN SCI, V1, P1100, DOI 10.1002/pro.5560010904; Wang J. H, 1972, ENZYMES, V7, P435; WANG JH, 1970, J BIOL CHEM, V245, P3115; WITHERS SG, 1982, BIOCHEMISTRY-US, V21, P5372, DOI 10.1021/bi00264a039	53	21	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22305	22309		10.1074/jbc.271.37.22305	http://dx.doi.org/10.1074/jbc.271.37.22305			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798388	hybrid			2022-12-27	WOS:A1996VG67200007
J	Keller, SH; Lindstrom, J; Taylor, P				Keller, SH; Lindstrom, J; Taylor, P			Involvement of the chaperone protein calnexin and the acetylcholine receptor beta-subunit in the assembly and cell surface expression of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFECTED COS CELLS; ENDOPLASMIC-RETICULUM; BREFELDIN-A; XENOPUS OOCYTES; N-GLYCOSYLATION; LIGAND-BINDING; RETENTION; ER; IDENTIFICATION; DETERMINANTS	The nicotinic acetylcholine receptor at the neuromuscular junction is a ligand-gated ion channel assembled in the endoplasmic reticulum from four distinct glycoprotein subunits into the pentameric configuration of alpha(2) beta gamma delta. The individual homologous subunits form specific contacts at interfaces with neighboring subunits to achieve the appropriate orientation and order of each subunit in surrounding the ion channel. Assembly is thought to proceed through the formation of intermediates composed of dimers of the alpha delta and alpha gamma subunits which are eventually joined by the beta-subunit to achieve a circular structure enclosing the gated ion channel. In this study, we transfect cDNAs encoding receptor subunits in various combinations into HEK-293 cells to identify intracellular factors that influence the assembly and cell surface expression of the receptor. Our data derived from brefeldin A-treated cells indicate that intracellular association of the receptor subunits with the beta-subunit increases the pool of fully assembled receptors available for transport to the cell surface, presumably by protection from degradation, In addition, we determined that the chaperone protein calnexin is associated with the isolated alpha-, beta-, and delta-subunits of the receptor, but calnexin is not detected in association with assembled alpha delta subunit dimers. Calnexin is also detected in association with maturely folded, unassembled a-subunits, as ob served by the recognition of this complex by the monoclonal antibody mAb 35, believed to be specific for correctly folded alpha-subunits. Thus, calnexin appears to associate with the individual nascent subunits, thereby facilitating their assembly into the mature pentameric receptor.	UNIV PENN,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT NEUROSCI,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	Keller, SH (corresponding author), UNIV CALIF SAN DIEGO,DEPT PHARMACOL 0636,LA JOLLA,CA 92093, USA.				NIGMS NIH HHS [GM 18360] Funding Source: Medline; NINDS NIH HHS [NS 09715, NS 11323] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009715, R01NS011323] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BULLER AL, 1990, J MEMBRANE BIOL, V115, P179, DOI 10.1007/BF01869456; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; FORSAYETH JR, 1992, J CELL BIOL, V117, P841, DOI 10.1083/jcb.117.4.841; GEHLE VM, 1991, MOL BRAIN RES, V11, P17, DOI 10.1016/0169-328X(91)90016-Q; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KELLER SH, 1995, J BIOL CHEM, V270, P4165, DOI 10.1074/jbc.270.8.4165; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KREIENKAMP HJ, 1995, NEURON, V14, P636; LETOURNEUR F, 1995, J CELL BIOL, V129, P971, DOI 10.1083/jcb.129.4.971; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MACHOLD J, 1995, EUR J BIOCHEM, V234, P427, DOI 10.1111/j.1432-1033.1995.427_b.x; MERLIE JP, 1986, J MEMBRANE BIOL, V91, P1, DOI 10.1007/BF01870209; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; MILES K, 1988, MOL NEUROBIOL, V91, P1; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NODA M, 1983, NATURE, V305, P818, DOI 10.1038/305818a0; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; PAULSON HL, 1991, J CELL BIOL, V113, P1371, DOI 10.1083/jcb.113.6.1371; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SINE SM, 1991, J BIOL CHEM, V266, P19369; SMITH MM, 1987, J BIOL CHEM, V262, P4367; SMITH MM, 1986, J BIOL CHEM, V261, P4825; SUMIKAWA K, 1989, MOL BRAIN RES, V5, P183, DOI 10.1016/0169-328X(89)90034-X; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WILEMAN T, 1993, J CELL BIOL, V122, P67, DOI 10.1083/jcb.122.1.67	42	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22871	22877		10.1074/jbc.271.37.22871	http://dx.doi.org/10.1074/jbc.271.37.22871			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798466				2022-12-27	WOS:A1996VG67200085
J	Ruan, J; Xie, QW; Hutchinson, N; Cho, H; Wolfe, GC; Nathan, C				Ruan, J; Xie, QW; Hutchinson, N; Cho, H; Wolfe, GC; Nathan, C			Inducible nitric oxide synthase requires both the canonical calmodulin-binding domain and additional sequences in order to bind calmodulin and produce nitric oxide in the absence of free Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MACROPHAGES; MOLECULAR-CLONING; PEPTIDE COMPLEX; IDENTIFICATION; EXPRESSION; ENZYME; PURIFICATION; FLAVOPROTEIN; RECOGNITION; SUBUNIT	All three mammalian isoforms of nitric oxide synthase (NOS) must bind calmodulin (CaM) for enzymatic activity, Only NOS2 (the inducible isoform, iNOS) does so at the low levels of free Ca2+ in resting cells and when almost all Ca2+ is chelated in cell-free preparations, To test directly whether the predicted CaM-binding region of mouse NOS2 accounts for its Ca2+ independence, we prepared chimeric NOS's in which mouse NOS2 residues 503-532 were reciprocally exchanged with the corresponding residues 725-754 of rat NOS1 (neuronal NOS). Unlike either parent, both chimeras required an intermediate level of free Ca2+ to bind CaM and generate NO. In cell lysates, the concentration of Ca2+ necessary for half-maximal activity (EC(50)) was similar to 0 for NOS2, 200-300 nM for NOS1, and 7-10 nM for the chimeras, Results were similar when the region exchanged was enlarged by 7-8 residues toward the amino terminus, In contrast, when the carboxyl-terminal half of NOS2 (residues 454-1144) was replaced with that of NOS1 (residues 675-1429), the resulting chimera resembled NOS1 (EC(50), 200-300 nM free Ca2+). Truncation analysis suggested that NOS2 residues within the sequence 484-726 were required for Ca2+-independent CaM-binding. Thus, both the canonical CaM-binding domain and additional residues within the region 484-726 are necessary for NOS2's ability to bind CaM and produce NO when Ca2+ levels approach zero.	MERCK RES LABS, DEPT IMMUNOL & INFLAMMAT, RAHWAY, NJ 07065 USA; CORNELL UNIV, COLL MED, DEPT MED, BEATRICE & SAMUEL A SEAVER LAB, NEW YORK, NY 10021 USA	Merck & Company; Cornell University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI034543, R01AI034543] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34543] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; Anderson JT, 1996, J BIOL CHEM, V271, P6605, DOI 10.1074/jbc.271.12.6605; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSCHMEIER B, 1987, J BIOL CHEM, V262, P9454; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CHO HJ, 1995, P NATL ACAD SCI USA, V92, P11514, DOI 10.1073/pnas.92.25.11514; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GENG YJ, 1994, BBA-GENE STRUCT EXPR, V1218, P421, DOI 10.1016/0167-4781(94)90196-1; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; LADANT D, 1988, J BIOL CHEM, V263, P2612; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHARMA RK, 1986, J BIOL CHEM, V261, P14160; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; STEVENSTRUSS R, 1995, BIOCHEMISTRY-US, V34, P15638, DOI 10.1021/bi00048a006; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; VODOVOTZ Y, 1994, J IMMUNOL, V152, P4110; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; Xie QW, 1996, P NATL ACAD SCI USA, V93, P4891, DOI 10.1073/pnas.93.10.4891; XIE QW, 1994, J BIOL CHEM, V269, P28500; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; ZHANG MJ, 1994, J BIOL CHEM, V269, P981; ZHUANG SB, 1995, J BIOL CHEM, V270, P19964, DOI 10.1074/jbc.270.34.19964	42	91	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	1996	271	37					22679	22686		10.1074/jbc.271.37.22679	http://dx.doi.org/10.1074/jbc.271.37.22679			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VG672	8798440	hybrid			2022-12-27	WOS:A1996VG67200059
